62	O
year	O
old	O
male	O
with	O
chest	O
pain	O
.	O
BACKGROUND	O
Family	O
Father	O
with	O
revascularised	O
ischaemic	O
heart	O
disease	O
,	O
debut	O
at	O
64	O
years	O
of	O
age	O
.	O
Personal	O
history	O
No	O
known	O
drug	O
allergies	O
.	O
No	O
toxic	O
habits	O
.	O
Diabetes	O
mellitus	O
type	O
2	O
with	O
good	O
metabolic	O
control	O
.	O
Hypercholesterolemia	O
type	O
dyslipidaemia	O
treated	O
so	O
far	O
with	O
hygienic	O
dietary	O
measures	O
.	O
HIV	O
positive	O
,	O
diagnosed	O
in	O
1998	O
.	O
Clinical	O
stage	O
C3	O
Pneumocystis	O
carinii	O
pneumonia	O
and	O
CD4	O
lymphocyte	O
nadir	O
of	O
79	O
cells	O
mm3	O
.	O
Under	O
treatment	O
with	O
highly	O
active	O
antiretroviral	O
therapy	O
HAART	O
,	O
with	O
immuno	O
virological	O
efficacy	O
criteria	O
.	O
HIV	O
RNA	O
negative	O
,	O
which	O
he	O
has	O
maintained	O
since	O
2005	O
.	O
Baseline	O
situation	O
retired	O
.	O
Independent	O
for	O
basic	O
activities	O
of	O
daily	O
living	O
.	O
Active	O
life	O
.	O
Surgical	O
interventions	O
right	O
inguinal	O
herniorrhaphy	O
.	O
Previous	O
medication	O
abacavir	B-FARMACO
lamivudine	I-FARMACO
600	O
300	O
mg	O
0	O
0	O
1	O
,	O
atazanavir	B-FARMACO
200	O
mg	O
0	O
0	O
1	O
,	O
ritonavir	B-FARMACO
100	O
mg	O
0	O
0	O
1	O
,	O
metformin	B-FARMACO
850	O
mg	O
1	O
0	O
1	O
.	O
CURRENT	O
ILLNESS	O
Onset	O
suddenly	O
and	O
while	O
at	O
rest	O
with	O
oppressive	O
central	O
thoracic	O
pain	O
,	O
radiating	O
to	O
the	O
left	O
upper	O
limb	O
,	O
accompanied	O
by	O
nausea	O
and	O
profuse	O
sweating	O
.	O
Suspecting	O
that	O
the	O
pain	O
was	O
muscular	O
in	O
origin	O
,	O
she	O
took	O
an	O
analgesic	O
,	O
but	O
without	O
improvement	O
.	O
Given	O
the	O
persistence	O
of	O
the	O
pain	O
and	O
its	O
progressive	O
nature	O
,	O
she	O
went	O
to	O
her	O
health	O
centre	O
where	O
electrocardiographic	O
alterations	O
compatible	O
with	O
ST	O
segment	O
elevation	O
acute	O
coronary	O
syndrome	O
STEMI	O
were	O
observed	O
and	O
she	O
was	O
transferred	O
urgently	O
to	O
our	O
hospital	O
for	O
cardiac	O
catheterisation	O
.	O
PHYSICAL	O
EXAMINATION	O
Afebrile	O
.	O
Blood	O
pressure	O
BP	O
133	O
74	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
60	O
bpm	O
.	O
Oxygen	O
saturation	O
SatO2	O
with	O
room	O
air	O
98	O
.	O
Reference	O
weight	O
70	O
kg	O
.	O
Conscious	O
,	O
oriented	O
and	O
cooperative	O
.	O
Well	O
hydrated	O
and	O
perfused	O
.	O
Regular	O
general	O
condition	O
,	O
affected	O
by	O
pain	O
.	O
Eupneic	O
at	O
rest	O
.	O
Jugular	O
venous	O
pressure	O
normal	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
respiratory	O
sounds	O
preserved	O
without	O
over	O
additions	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
and	O
non	O
painful	O
.	O
Peristalsis	O
present	O
.	O
Lower	O
extremities	O
no	O
oedema	O
.	O
Radial	O
and	O
femoral	O
pulses	O
present	O
and	O
symmetrical	O
.	O
COMPLEMENTARY	O
TESTS	O
ELECTROCARDIOGRAM	O
ECG	O
at	O
the	O
health	O
centre	O
sinus	O
bradycardia	O
at	O
50	O
bpm	O
.	O
Normal	O
PR	O
.	O
Narrow	O
QRS	O
.	O
ST	O
segment	O
elevation	O
in	O
DII	O
,	O
DIII	O
and	O
aVF	O
with	O
ST	O
segment	O
depression	O
in	O
aVL	O
,	O
V1	O
and	O
V2	O
.	O
ANALYTICS	O
haemoglobin	O
13	O
.	O
4	O
g	O
dl	O
,	O
platelets	O
218	O
,	O
000	O
uL	O
,	O
leucocytes	O
10	O
,	O
980	O
ul	O
,	O
glucose	O
176	O
mg	O
dl	O
,	O
urea	O
50	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
83	O
mg	O
dl	O
,	O
sodium	O
140	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
5	O
mEq	O
l	O
.	O
Triglycerides	O
222	O
mg	O
dl	O
,	O
total	O
cholesterol	O
202	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
31	O
mg	O
dl	O
,	O
LDL	O
cholesterol	O
127	O
mg	O
dl	O
,	O
.	O
Uric	O
acid	O
4	O
.	O
3	O
mg	O
dl	O
,	O
ALT	O
54	O
U	O
l	O
,	O
AST	O
120	O
U	O
l	O
,	O
GGT	O
27	O
U	O
l	O
,	O
alkaline	O
phosphatase	O
70	O
U	O
l	O
,	O
total	O
bilirubin	O
2	O
.	O
4	O
mg	O
dl	O
,	O
TSH	O
1	O
.	O
32	O
,	O
HbA1C	O
6	O
.	O
2	O
,	O
peak	O
troponin	O
I	O
89	O
.	O
39	O
.	O
THORAX	O
RADIOGRAPHY	O
normal	O
cardio	O
thoracic	O
index	O
.	O
No	O
acute	O
pleuroparenchymal	O
lesions	O
.	O
Urgent	O
CARDIAC	O
CATHETERISM	O
single	O
vessel	O
coronary	O
artery	O
disease	O
.	O
Thrombotic	O
occlusion	O
in	O
proximal	O
right	O
coronary	O
artery	O
.	O
Moderate	O
lesions	O
in	O
proximal	O
anterior	O
descending	O
,	O
middle	O
anterior	O
descending	O
and	O
marginal	O
branch	O
.	O
Primary	O
percutaneous	O
coronary	O
intervention	O
PCI	O
was	O
performed	O
with	O
thrombus	O
aspiration	O
and	O
implantation	O
of	O
a	O
zotarolimus	B-FARMACO
eluting	O
stent	O
in	O
the	O
proximal	O
right	O
coronary	O
artery	O
with	O
good	O
results	O
.	O
Pre	O
discharge	O
echocardiogram	O
non	O
dilated	O
left	O
ventricle	O
with	O
moderate	O
concentric	O
hypertrophy	O
.	O
Hypokinesia	O
of	O
the	O
basal	O
and	O
middle	O
segments	O
of	O
the	O
inferior	O
face	O
.	O
Global	O
left	O
ventricular	O
systolic	O
function	O
preserved	O
EF	O
58	O
.	O
Prolonged	O
relaxation	O
in	O
transmitral	O
flow	O
pattern	O
.	O
Normal	O
right	O
ventricle	O
.	O
Normal	O
mitral	O
valve	O
in	O
structure	O
and	O
function	O
,	O
with	O
mild	O
insufficiency	O
.	O
Normal	O
aortic	O
valve	O
,	O
without	O
insufficiency	O
or	O
stenosis	O
.	O
Normal	O
tricuspid	O
valve	O
,	O
without	O
insufficiency	O
.	O
No	O
pericardial	O
effusion	O
.	O
CLINICAL	O
EVOLUTION	O
After	O
primary	O
angioplasty	O
,	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
coronary	O
unit	O
without	O
pain	O
and	O
haemodynamically	O
stable	O
.	O
Good	O
subsequent	O
evolution	O
,	O
without	O
arrhythmias	O
or	O
heart	O
failure	O
.	O
High	O
blood	O
pressure	O
with	O
low	O
doses	O
of	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
ACE	O
inhibitor	O
and	O
beta	O
blocker	O
;	O
hypertension	O
was	O
diagnosed	O
.	O
He	O
was	O
transferred	O
to	O
the	O
hospital	O
ward	O
,	O
from	O
where	O
he	O
was	O
discharged	O
without	O
incident	O
.	O
ECG	O
at	O
discharge	O
in	O
sinus	O
bradycardia	O
at	O
58	O
bpm	O
,	O
with	O
Q	O
wave	O
and	O
negative	O
T	O
wave	O
in	O
inferior	O
leads	O
.	O
Treatment	O
on	O
discharge	O
adiro	B-FARMACO
100	O
mg	O
0	O
1	O
0	O
,	O
clopidogrel	B-FARMACO
75	O
mg	O
0	O
1	O
0	O
,	O
ranitidine	B-FARMACO
150	O
mg	O
1	O
0	O
0	O
,	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
1	O
0	O
0	O
,	O
ramipril	B-FARMACO
2	O
.	O
5	O
mg	O
0	O
0	O
1	O
,	O
nitroglycerin	B-FARMACO
1	O
mg	O
sl	O
if	O
necessary	O
,	O
rosuvastatin	B-FARMACO
5	O
mg	O
0	O
0	O
1	O
,	O
in	O
addition	O
to	O
the	O
antiretroviral	O
drugs	O
and	O
metformin	B-FARMACO
that	O
he	O
had	O
been	O
taking	O
at	O
home	O
.	O
At	O
6	O
weeks	O
,	O
he	O
came	O
to	O
the	O
outpatient	O
clinic	O
asymptomatic	O
,	O
in	O
functional	O
class	O
I	O
of	O
the	O
New	O
York	O
Heart	O
Association	O
NYHA	O
.	O
Control	O
laboratory	O
tests	O
showed	O
LDL	O
cholesterol	O
of	O
80	O
mg	O
dl	O
,	O
with	O
normal	O
CPK	O
and	O
liver	O
function	O
tests	O
.	O
Rosuvastatin	B-FARMACO
dose	O
increased	O
to	O
10	O
mg	O
0	O
0	O
1	O
.	O
The	O
rest	O
of	O
the	O
medication	O
remained	O
unchanged	O
.	O
She	O
underwent	O
a	O
blood	O
test	O
at	O
6	O
weeks	O
at	O
her	O
health	O
centre	O
with	O
LDL	O
cholesterol	O
of	O
65	O
mg	O
dl	O
.	O
DIAGNOSIS	O
Ischaemic	O
heart	O
disease	O
.	O
Lower	O
STEMI	O
.	O
Coronary	O
artery	O
disease	O
of	O
one	O
vessel	O
.	O
Primary	O
angioplasty	O
on	O
proximal	O
right	O
coronary	O
artery	O
.	O
Electrocardiographic	O
evolution	O
to	O
inferior	O
infarction	O
.	O
Preserved	O
global	O
left	O
ventricular	O
LV	O
systolic	O
function	O
.	O
Killip	O
I	O
.	O
Arterial	O
hypertension	O
.	O
Secondary	O
moderate	O
LV	O
hypertrophy	O
.	O
Dyslipidaemia	O
.	O
Diabetes	O
mellitus	O
with	O
good	O
metabolic	O
control	O
.	O
HIV	O
infection	O
in	O
treatment	O
with	O
negative	O
viral	O
load	O
.	O

Male	O
,	O
70	O
years	O
old	O
.	O
BACKGROUND	O
No	O
known	O
allergic	O
drug	O
reactions	O
.	O
Toxic	O
habits	O
ex	O
smoker	O
.	O
Hypertension	O
.	O
No	O
known	O
diabetes	O
mellitus	O
or	O
dyslipidaemia	O
.	O
Aortic	O
valve	O
replacement	O
due	O
to	O
double	O
lesion	O
Carbomedics	O
mechanical	O
prosthesis	O
no21	O
on	O
24	O
September	O
1993	O
.	O
Multiple	O
subsequent	O
complications	O
9	O
November	O
1993	O
aortic	O
pseudoaneurysm	O
with	O
compression	O
of	O
the	O
right	O
ventricle	O
RV	O
and	O
aorto	O
cutaneous	O
fistula	O
with	O
sternal	O
osteolysis	O
.	O
The	O
fistula	O
was	O
closed	O
at	O
the	O
aortic	O
level	O
and	O
a	O
sternal	O
exeresis	O
and	O
plasty	O
of	O
both	O
pectoral	O
muscles	O
with	O
disinsertion	O
of	O
the	O
humerus	O
muscles	O
pectoralis	O
major	O
myoplasty	O
was	O
performed	O
.	O
During	O
this	O
admission	O
he	O
required	O
several	O
reoperations	O
due	O
to	O
bleeding	O
in	O
the	O
context	O
of	O
coagulopathy	O
,	O
both	O
in	O
cardiac	O
surgery	O
and	O
plastic	O
surgery	O
.	O
During	O
his	O
two	O
months	O
in	O
intensive	O
care	O
ICU	O
he	O
developed	O
multi	O
organ	O
failure	O
.	O
23	O
February	O
1995	O
reoperation	O
for	O
dehiscence	O
of	O
the	O
prosthesis	O
periprosthetic	O
leak	O
and	O
implantation	O
of	O
a	O
St	O
.	O
Jude	O
prosthesis	O
no	O
.	O
21	O
.	O
Femoral	O
pseudoaneurysm	O
after	O
preoperative	O
coronary	O
angiography	O
.	O
Duodenal	O
ulcer	O
with	O
gastrointestinal	O
bleeding	O
in	O
1999	O
.	O
Spontaneous	O
retroperitoneal	O
haematoma	O
in	O
the	O
context	O
of	O
anticoagulation	O
.	O
Admission	O
to	O
cardiology	O
in	O
September	O
2017	O
for	O
syncope	O
with	O
cardiogenic	O
profile	O
and	O
no	O
clear	O
cause	O
.	O
Electrocardiogram	O
ECG	O
in	O
sinus	O
rhythm	O
with	O
left	O
anterior	O
hemiblock	O
of	O
the	O
His	O
bundle	O
HARIHH	O
,	O
absence	O
of	O
findings	O
in	O
telemetry	O
monitoring	O
and	O
echocardiogram	O
without	O
relevant	O
findings	O
with	O
mild	O
moderate	O
left	O
ventricular	O
hypertrophy	O
,	O
normal	O
biventricular	O
function	O
and	O
normofunctioning	O
aortic	O
prosthesis	O
.	O
For	O
all	O
these	O
reasons	O
,	O
it	O
was	O
decided	O
to	O
implant	O
a	O
subcutaneous	O
Holter	O
.	O
Other	O
repeated	O
acute	O
otitis	O
media	O
in	O
both	O
ears	O
,	O
predominantly	O
in	O
the	O
left	O
ear	O
.	O
Benign	O
prostatic	O
hyperplasia	O
.	O
Usual	O
treatment	O
acenocoumarol	B-FARMACO
,	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
24	O
hours	O
,	O
simvastatin	B-FARMACO
40	O
mg	O
24	O
hours	O
,	O
valsartan	B-FARMACO
160	O
mg	O
24	O
hours	O
,	O
dutasteride	B-FARMACO
tamsulosin	I-FARMACO
0	O
.	O
5	O
0	O
.	O
4	O
mg	O
24	O
hours	O
.	O
CURRENT	O
ILLNESS	O
Admitted	O
on	O
7	O
12	O
2017	O
to	O
the	O
multipurpose	O
ICU	O
after	O
presenting	O
with	O
traumatic	O
brain	O
injury	O
TBI	O
in	O
the	O
context	O
of	O
a	O
new	O
syncopal	O
episode	O
with	O
amnesia	O
of	O
the	O
episode	O
,	O
with	O
witnesses	O
referring	O
trauma	O
to	O
the	O
frontal	O
region	O
and	O
objectifying	O
hypotension	O
and	O
bradycardia	O
.	O
On	O
arrival	O
at	O
the	O
ED	O
,	O
the	O
patient	O
was	O
haemodynamically	O
and	O
respiratory	O
stable	O
with	O
blood	O
pressure	O
BP	O
120	O
70	O
mmHg	O
,	O
INR	O
4	O
.	O
65	O
and	O
sinus	O
rhythm	O
at	O
60	O
bpm	O
.	O
A	O
cranial	O
CT	O
scan	O
was	O
performed	O
showing	O
subdural	O
haematoma	O
in	O
the	O
cerebral	O
sickle	O
without	O
midline	O
displacement	O
.	O
The	O
subcutaneous	O
Holter	O
monitor	O
also	O
showed	O
sinus	O
bradycardia	O
during	O
the	O
episode	O
at	O
50	O
bpm	O
without	O
pauses	O
,	O
so	O
pacemaker	O
implantation	O
was	O
not	O
recommended	O
.	O
During	O
his	O
stay	O
in	O
the	O
ED	O
,	O
the	O
patient	O
began	O
to	O
have	O
paresis	O
of	O
the	O
right	O
lower	O
limb	O
,	O
so	O
a	O
repeat	O
CT	O
scan	O
was	O
performed	O
,	O
which	O
showed	O
an	O
increase	O
in	O
subdural	O
haematoma	O
and	O
foci	O
of	O
subarachnoid	O
haemorrhage	O
,	O
and	O
it	O
was	O
decided	O
to	O
admit	O
him	O
to	O
the	O
ICU	O
.	O
Initially	O
,	O
the	O
patient	O
presented	O
with	O
right	O
hemiparesis	O
and	O
comical	O
crises	O
that	O
required	O
orotracheal	O
intubation	O
and	O
surgical	O
tracheostomy	O
.	O
Conservative	O
management	O
was	O
decided	O
with	O
good	O
subsequent	O
evolution	O
,	O
and	O
the	O
patient	O
was	O
transferred	O
to	O
neurosurgery	O
,	O
who	O
requested	O
a	O
cardiology	O
consultation	O
due	O
to	O
syncope	O
and	O
a	O
tendency	O
to	O
bradycardia	O
without	O
beta	O
blocker	O
treatment	O
,	O
and	O
on	O
review	O
of	O
the	O
subcutaneous	O
Holter	O
,	O
multiple	O
episodes	O
of	O
bradycardia	O
and	O
spells	O
of	O
complete	O
atrioventricular	O
block	O
AVB	O
were	O
observed	O
.	O
Given	O
the	O
presence	O
of	O
these	O
episodes	O
,	O
the	O
patient	O
was	O
transferred	O
to	O
cardiology	O
for	O
monitoring	O
and	O
to	O
evaluate	O
the	O
implantation	O
of	O
a	O
permanent	O
pacemaker	O
.	O
PHYSICAL	O
EXPLORATION	O
on	O
admission	O
to	O
the	O
ICU	O
Head	O
and	O
face	O
soft	O
tissue	O
wound	O
in	O
the	O
right	O
frontal	O
region	O
,	O
without	O
active	O
bleeding	O
.	O
No	O
other	O
injuries	O
.	O
Neck	O
no	O
wounds	O
,	O
haematomas	O
or	O
deformities	O
were	O
identified	O
.	O
Chest	O
Inspection	O
no	O
bruises	O
,	O
good	O
respiratory	O
mechanics	O
.	O
No	O
crepitus	O
on	O
palpation	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
,	O
no	O
pathological	O
sounds	O
.	O
Cardiac	O
auscultation	O
muffled	O
,	O
rhythmic	O
tones	O
,	O
prosthetic	O
opening	O
click	O
,	O
no	O
murmurs	O
or	O
extratones	O
.	O
Abdomen	O
inspection	O
abdomen	O
not	O
distended	O
,	O
not	O
painful	O
.	O
Perineum	O
no	O
signs	O
of	O
haematoma	O
,	O
no	O
rectorrhagia	O
.	O
Back	O
no	O
painful	O
stitches	O
or	O
deformities	O
.	O
Extremities	O
no	O
excoriations	O
.	O
No	O
deformities	O
.	O
No	O
joint	O
instability	O
.	O
Neurological	O
examination	O
GSC	O
15	O
M6	O
,	O
O4	O
,	O
V5	O
.	O
Pupils	O
isochoric	O
,	O
normoreactive	O
.	O
Motor	O
right	O
lower	O
limb	O
paralysis	O
.	O
Muscle	O
strength	O
right	O
upper	O
limb	O
5	O
5	O
,	O
right	O
upper	O
limb	O
5	O
5	O
,	O
left	O
lower	O
limb	O
5	O
5	O
,	O
right	O
lower	O
limb	O
0	O
5	O
.	O
COMPLEMENTARY	O
TESTS	O
MICROBIOLOGY	O
blood	O
cultures	O
08	O
01	O
18	O
in	O
two	O
sets	O
Enterococcus	O
faecalis	O
with	O
antibiogram	O
ampicillin	O
amoxicillin	O
S	O
1	O
,	O
gentamicin	O
500	O
S	O
500	O
,	O
strepto	O
1000	O
S	O
1	O
.	O
000	O
,	O
vancomycin	O
S	O
1	O
,	O
teicoplanin	O
S	O
1	O
.	O
Subsequent	O
blood	O
cultures	O
negative	O
.	O
ANALYSIS	O
On	O
admission	O
normocytic	O
normochromic	O
anaemia	O
with	O
Hb	O
9	O
.	O
7g	O
dl	O
,	O
normal	O
platelets	O
,	O
normal	O
leukocytes	O
,	O
with	O
elevated	O
C	O
reactive	O
protein	O
CRP	O
10	O
.	O
39	O
mg	O
dl	O
,	O
INR	O
5	O
.	O
22	O
.	O
Biochemistry	O
with	O
renal	O
profile	O
without	O
alterations	O
,	O
including	O
creatinine	O
0	O
.	O
45	O
mg	O
dl	O
which	O
means	O
a	O
glomerular	O
filtration	O
rate	O
CKD	O
EPI	O
90	O
ml	O
min	O
,	O
normal	O
liver	O
profile	O
and	O
thyroid	O
profile	O
.	O
On	O
discharge	O
06	O
03	O
CRP	O
0	O
.	O
73	O
mg	O
dl	O
,	O
without	O
leukocytosis	O
or	O
neutrophilia	O
,	O
with	O
Hb	O
10	O
.	O
2g	O
dl	O
.	O
Emergency	O
ECG	O
sinus	O
rhythm	O
at	O
60	O
bpm	O
.	O
Left	O
axis	O
,	O
narrow	O
QRS	O
,	O
HARIHH	O
similar	O
to	O
previous	O
ones	O
,	O
without	O
repolarisation	O
alterations	O
.	O
CRANIAL	O
CT	O
07	O
12	O
18	O
subdural	O
haematoma	O
in	O
cerebral	O
sickle	O
with	O
haematocrit	O
levels	O
.	O
There	O
is	O
no	O
midline	O
displacement	O
.	O
Inflammatory	O
changes	O
in	O
the	O
left	O
middle	O
ear	O
and	O
maxillary	O
sinuses	O
.	O
ECHOCARDIOGRAPHIC	O
STUDY	O
11	O
1	O
18	O
TRANSTORACIC	O
TTE	O
left	O
ventricle	O
not	O
dilated	O
,	O
with	O
preserved	O
systolic	O
function	O
.	O
Normal	O
right	O
ventricle	O
.	O
Bidisc	O
mechanical	O
prosthesis	O
in	O
aortic	O
position	O
movement	O
of	O
both	O
occluders	O
with	O
increased	O
transvalvular	O
gradients	O
maximum	O
average	O
40	O
19	O
mmHg	O
without	O
suspicion	O
of	O
obstruction	O
triangular	O
jet	O
morphology	O
,	O
acceleration	O
time	O
of	O
70	O
ms	O
,	O
AT	O
ET	O
0	O
.	O
3	O
,	O
DVI	O
0	O
.	O
57	O
.	O
Mitral	O
valve	O
thickened	O
leaflets	O
,	O
mild	O
insufficiency	O
.	O
Tricuspid	O
valve	O
poor	O
visualisation	O
,	O
no	O
significant	O
insufficiency	O
by	O
colour	O
Doppler	O
.	O
No	O
indirect	O
signs	O
of	O
pulmonary	O
hypertension	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
with	O
physiological	O
inspiratory	O
collapse	O
estimated	O
DBP	O
5	O
mmHg	O
.	O
Aortic	O
root	O
,	O
ascending	O
aorta	O
and	O
aortic	O
arch	O
not	O
visualised	O
.	O
Atrial	O
septum	O
intact	O
,	O
without	O
suspicion	O
of	O
intracardiac	O
shunt	O
by	O
colour	O
Doppler	O
.	O
Pericardium	O
of	O
normal	O
thickness	O
and	O
refractoriness	O
,	O
without	O
effusion	O
.	O
Conclusions	O
increased	O
aortic	O
transprosthetic	O
gradients	O
without	O
suspicion	O
of	O
obstruction	O
.	O
Transesophageal	O
echocardiography	O
TEE	O
bidisc	O
mechanical	O
prosthesis	O
in	O
aortic	O
position	O
with	O
movement	O
of	O
both	O
occluders	O
.	O
Intraprosthetic	O
lavage	O
insufficiency	O
is	O
visualised	O
with	O
three	O
trivial	O
regurgitation	O
jets	O
.	O
Rounded	O
image	O
of	O
4	O
mm	O
x	O
3	O
mm	O
visualised	O
on	O
the	O
aortic	O
side	O
of	O
the	O
prosthesis	O
suggestive	O
of	O
a	O
wart	O
.	O
Thickening	O
of	O
the	O
posterior	O
area	O
of	O
the	O
prosthetic	O
ring	O
,	O
with	O
extension	O
towards	O
mitroaortic	O
fibrosis	O
,	O
thickened	O
anterior	O
mitral	O
leaflet	O
at	O
the	O
level	O
of	O
A1	O
A2	O
and	O
towards	O
the	O
interatrial	O
septum	O
,	O
no	O
fistulous	O
tracts	O
are	O
visualised	O
.	O
Mitral	O
valve	O
with	O
thickening	O
of	O
the	O
anterior	O
leaflet	O
,	O
no	O
images	O
compatible	O
with	O
vegetation	O
.	O
No	O
mitral	O
insufficiency	O
.	O
Rest	O
of	O
valves	O
with	O
no	O
images	O
compatible	O
with	O
vegetation	O
.	O
Conclusions	O
signs	O
of	O
IE	O
thickening	O
at	O
the	O
posterior	O
level	O
of	O
the	O
aortic	O
annulus	O
,	O
mitroaortic	O
fibrosis	O
and	O
at	O
the	O
base	O
of	O
the	O
anterior	O
mitral	O
leaflet	O
suggestive	O
of	O
phlegmon	O
.	O
Small	O
endocardial	O
wart	O
,	O
visualised	O
on	O
the	O
aortic	O
side	O
of	O
the	O
aortic	O
prosthesis	O
.	O
Normal	O
functioning	O
aortic	O
prosthesis	O
.	O
Control	O
TEE	O
23	O
1	O
18	O
signs	O
suggestive	O
of	O
IE	O
with	O
slight	O
progression	O
with	O
respect	O
to	O
the	O
previous	O
study	O
at	O
the	O
level	O
of	O
the	O
aortic	O
annulus	O
,	O
but	O
above	O
all	O
progression	O
at	O
the	O
level	O
of	O
the	O
anterior	O
mitral	O
leaflet	O
with	O
an	O
image	O
of	O
an	O
endocardial	O
wart	O
.	O
Normally	O
functioning	O
aortic	O
prosthesis	O
.	O
Mild	O
mitral	O
insufficiency	O
.	O
CRANIAL	O
MRI	O
15	O
01	O
18	O
multiple	O
acute	O
cortical	O
microinfarcts	O
of	O
supra	O
and	O
infratentorial	O
location	O
.	O
Given	O
the	O
multi	O
territorial	O
involvement	O
,	O
they	O
suggest	O
embolic	O
origin	O
.	O
Decreased	O
size	O
of	O
the	O
left	O
frontal	O
parenchymal	O
parenchymal	O
contusions	O
and	O
subdural	O
haematoma	O
.	O
Abdominal	O
CT	O
scan	O
with	O
intravenous	O
contrast	O
07	O
02	O
2018	O
appearance	O
of	O
focal	O
infarcts	O
in	O
the	O
left	O
kidney	O
,	O
of	O
probable	O
embolic	O
aetiology	O
.	O
TEE	O
16	O
02	O
2018	O
signs	O
suggestive	O
of	O
IE	O
with	O
abscessation	O
at	O
the	O
level	O
of	O
the	O
aortic	O
ring	O
fibrous	O
mitroaortic	O
ring	O
,	O
aortic	O
prosthesis	O
with	O
normal	O
gradients	O
,	O
posterior	O
periprosthetic	O
leak	O
related	O
to	O
the	O
abscessed	O
area	O
of	O
moderate	O
degree	O
.	O
CLINICAL	O
EVOLUTION	O
On	O
arrival	O
at	O
the	O
cardiology	O
department	O
,	O
fever	O
peaks	O
were	O
observed	O
,	O
with	O
Enterococcus	O
faecalis	O
growing	O
in	O
blood	O
cultures	O
.	O
He	O
also	O
had	O
a	O
positive	O
urine	O
culture	O
for	O
Citrobacter	O
freundii	O
sensitive	O
to	O
fosfomycin	B-FARMACO
and	O
was	O
treated	O
.	O
In	O
view	O
of	O
the	O
blood	O
culture	O
findings	O
,	O
treatment	O
was	O
started	O
with	O
ampicillin	B-FARMACO
and	O
ceftriaxone	B-FARMACO
and	O
an	O
echocardiogram	O
was	O
requested	O
to	O
screen	O
for	O
endocarditis	O
,	O
which	O
showed	O
thickening	O
at	O
the	O
posterior	O
level	O
of	O
the	O
aortic	O
ring	O
,	O
mitroaortic	O
fibrosis	O
and	O
the	O
base	O
of	O
the	O
anterior	O
mitral	O
leaflet	O
suggestive	O
of	O
abscess	O
,	O
while	O
at	O
the	O
same	O
time	O
a	O
small	O
wart	O
was	O
seen	O
on	O
the	O
aortic	O
prosthesis	O
,	O
all	O
of	O
which	O
was	O
compatible	O
with	O
endocarditis	O
.	O
As	O
part	O
of	O
the	O
protocol	O
to	O
search	O
for	O
septic	O
embolisms	O
,	O
a	O
cerebral	O
MRI	O
angiography	O
showed	O
multiple	O
acute	O
cortical	O
micro	O
infarctions	O
of	O
supra	O
and	O
infratentorial	O
location	O
suggesting	O
embolic	O
origin	O
and	O
a	O
CT	O
scan	O
with	O
no	O
evidence	O
of	O
other	O
peripheral	O
embolisms	O
.	O
Given	O
the	O
presence	O
of	O
advanced	O
local	O
involvement	O
,	O
the	O
case	O
was	O
presented	O
at	O
a	O
medical	O
surgical	O
session	O
and	O
surgery	O
was	O
ruled	O
out	O
,	O
given	O
the	O
previous	O
surgical	O
history	O
and	O
the	O
high	O
technical	O
complexity	O
.	O
A	O
control	O
echocardiogram	O
was	O
performed	O
after	O
2	O
weeks	O
of	O
antibiotic	O
therapy	O
which	O
showed	O
progression	O
with	O
respect	O
to	O
the	O
previous	O
study	O
with	O
the	O
appearance	O
of	O
an	O
aortic	O
perivalvular	O
leak	O
leading	O
to	O
mild	O
aortic	O
insufficiency	O
,	O
disappearance	O
of	O
the	O
aortic	O
wart	O
and	O
the	O
appearance	O
of	O
a	O
wart	O
at	O
mitral	O
level	O
.	O
In	O
this	O
context	O
,	O
it	O
was	O
decided	O
to	O
add	O
tigecycline	B-FARMACO
to	O
the	O
antibiotic	O
treatment	O
due	O
to	O
its	O
better	O
penetration	O
into	O
soft	O
tissues	O
.	O
Subsequently	O
,	O
in	O
the	O
fourth	O
week	O
of	O
antibiotic	O
therapy	O
,	O
he	O
developed	O
sudden	O
pain	O
in	O
the	O
left	O
flank	O
with	O
elevated	O
LDH	O
and	O
CRP	O
,	O
so	O
a	O
new	O
abdominal	O
CT	O
scan	O
was	O
performed	O
which	O
showed	O
the	O
appearance	O
of	O
left	O
renal	O
infarcts	O
.	O
During	O
the	O
sixth	O
week	O
of	O
antibiotic	O
therapy	O
,	O
a	O
new	O
transesophageal	O
echocardiogram	O
was	O
performed	O
showing	O
progression	O
of	O
the	O
valvular	O
lesions	O
with	O
abscessation	O
at	O
the	O
level	O
of	O
the	O
aortic	O
annulus	O
mitroaortic	O
fibrosis	O
,	O
which	O
had	O
previously	O
been	O
phlegmonous	O
,	O
with	O
disappearance	O
of	O
the	O
mitral	O
wart	O
and	O
progression	O
of	O
the	O
amount	O
of	O
leak	O
,	O
which	O
was	O
moderate	O
.	O
However	O
,	O
the	O
patient	O
was	O
stable	O
,	O
with	O
no	O
evidence	O
of	O
heart	O
failure	O
,	O
syncope	O
or	O
new	O
relevant	O
alterations	O
in	O
the	O
electrocardiogram	O
or	O
telemetry	O
,	O
remaining	O
afebrile	O
with	O
three	O
rounds	O
of	O
sterile	O
control	O
blood	O
cultures	O
after	O
1	O
,	O
2	O
and	O
6	O
weeks	O
of	O
antibiotic	O
treatment	O
,	O
completing	O
a	O
6	O
week	O
intravenous	O
antibiotic	O
cycle	O
of	O
ampicillin	B-FARMACO
and	O
ceftriaxone	B-FARMACO
and	O
4	O
weeks	O
of	O
tigecycline	B-FARMACO
with	O
good	O
tolerance	O
.	O
From	O
the	O
neurological	O
point	O
of	O
view	O
,	O
she	O
showed	O
clear	O
improvement	O
with	O
rehabilitation	O
,	O
being	O
able	O
to	O
perform	O
gross	O
and	O
fine	O
motor	O
exercises	O
with	O
the	O
affected	O
upper	O
limb	O
and	O
to	O
ambulate	O
with	O
the	O
help	O
of	O
a	O
support	O
.	O
Given	O
the	O
good	O
clinical	O
evolution	O
and	O
the	O
echocardiographic	O
worsening	O
,	O
outpatient	O
antibiotherapy	O
with	O
dalbavancin	B-FARMACO
1	O
,	O
500	O
mg	O
intravenous	O
every	O
15	O
days	O
was	O
decided	O
,	O
once	O
adequate	O
tolerance	O
had	O
been	O
verified	O
,	O
after	O
administering	O
the	O
first	O
two	O
doses	O
in	O
hospital	O
without	O
complications	O
,	O
fever	O
or	O
positive	O
control	O
blood	O
cultures	O
.	O
With	O
respect	O
to	O
paroxysmal	O
complete	O
AVB	O
,	O
beta	O
blocker	O
treatment	O
was	O
withdrawn	O
.	O
Given	O
the	O
presence	O
of	O
endocarditis	O
,	O
it	O
was	O
decided	O
not	O
to	O
implant	O
a	O
pacemaker	O
for	O
the	O
time	O
being	O
,	O
maintaining	O
subcutaneous	O
Holter	O
monitoring	O
and	O
outpatient	O
follow	O
up	O
by	O
both	O
cardiology	O
and	O
the	O
infectious	O
diseases	O
unit	O
,	O
with	O
the	O
patient	O
remaining	O
clinically	O
stable	O
until	O
the	O
present	O
day	O
.	O
DIAGNOSIS	O
Main	O
diagnosis	O
IE	O
due	O
to	O
Enterococcus	O
faecalis	O
on	O
mechanical	O
aortic	O
prosthesis	O
with	O
undetermined	O
entry	O
point	O
bacteraemia	O
,	O
rejected	O
for	O
surgical	O
treatment	O
.	O
Other	O
diagnoses	O
mitroaortic	O
abscess	O
with	O
secondary	O
mild	O
moderate	O
aortic	O
insufficiency	O
.	O
Multiple	O
cortical	O
cerebral	O
microinfarcts	O
and	O
left	O
renal	O
infarction	O
secondary	O
to	O
IE	O
.	O
Anaemia	O
in	O
the	O
context	O
of	O
IE	O
.	O
Traumatic	O
subdural	O
haematoma	O
and	O
left	O
frontal	O
parenchymal	O
parenchymal	O
contusions	O
in	O
the	O
context	O
of	O
traumatic	O
brain	O
injury	O
after	O
syncopal	O
episode	O
,	O
with	O
hemiparesis	O
and	O
comical	O
crises	O
in	O
the	O
acute	O
phase	O
.	O
Paroxysmal	O
AVB	O
.	O
Urinary	O
tract	O
infection	O
by	O
Citrobacter	O
freundii	O
.	O

BACKGROUND	O
No	O
known	O
drug	O
allergies	O
.	O
No	O
known	O
cardiovascular	O
risk	O
factors	O
.	O
No	O
toxic	O
habits	O
.	O
Non	O
ischaemic	O
dilated	O
cardiomyopathy	O
with	O
severe	O
biventricular	O
dysfunction	O
LVEF	O
15	O
20	O
of	O
debut	O
in	O
October	O
2010	O
evolving	O
to	O
advanced	O
heart	O
failure	O
ergospirometry	O
with	O
peak	O
oxygen	O
consumption	O
of	O
12	O
ml	O
min	O
kg	O
.	O
AF	O
of	O
uncertain	O
chronology	O
diagnosed	O
in	O
2010	O
.	O
CHA2DS2	O
VASc	O
1	O
point	O
anticoagulated	O
with	O
dabigatran	B-FARMACO
150	O
mg	O
every	O
12	O
hours	O
.	O
Implantation	O
of	O
an	O
implantable	O
cardioverter	O
defibrillator	O
ICD	O
in	O
primary	O
prevention	O
in	O
January	O
2011	O
,	O
with	O
subsequent	O
inappropriate	O
shocks	O
due	O
to	O
episodes	O
of	O
AF	O
with	O
rapid	O
ventricular	O
response	O
.	O
Usual	O
treatment	O
dabigatran	B-FARMACO
150	O
mg	O
every	O
12	O
hours	O
,	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
every	O
12	O
hours	O
,	O
spironolactone	B-FARMACO
25	O
mg	O
every	O
24	O
hours	O
,	O
furosemide	B-FARMACO
40	O
mg	O
every	O
12	O
hours	O
,	O
digoxin	B-FARMACO
0	O
.	O
25	O
mg	O
half	O
tablet	O
every	O
24	O
hours	O
,	O
sildenafil	B-FARMACO
20	O
mg	O
every	O
12	O
hours	O
,	O
periodic	O
cycles	O
of	O
levosimendan	B-FARMACO
and	O
ferric	B-FARMACO
carboxymaltose	I-FARMACO
.	O
CURRENT	O
DISEASE	O
After	O
completing	O
the	O
pre	O
transplant	O
work	O
up	O
see	O
complementary	O
tests	O
,	O
the	O
patient	O
is	O
electively	O
listed	O
for	O
heart	O
transplantation	O
in	O
March	O
2017	O
,	O
being	O
then	O
in	O
New	O
Yor	O
Heart	O
Association	O
NYHA	O
functional	O
class	O
II	O
III	O
.	O
One	O
month	O
later	O
,	O
on	O
18	O
April	O
2017	O
,	O
he	O
was	O
telephoned	O
for	O
scheduled	O
admission	O
due	O
to	O
the	O
appearance	O
of	O
an	O
optimal	O
donor	O
for	O
heart	O
transplantation	O
.	O
He	O
was	O
admitted	O
to	O
the	O
cardiology	O
ward	O
and	O
on	O
arrival	O
an	O
electrocardiogram	O
ECG	O
,	O
complete	O
blood	O
tests	O
with	O
coagulation	O
study	O
,	O
chest	O
X	O
ray	O
and	O
blood	O
product	O
reserve	O
was	O
requested	O
.	O
The	O
patient	O
was	O
anticoagulated	O
with	O
dabigatran	B-FARMACO
150	O
mg	O
every	O
12	O
hours	O
,	O
having	O
taken	O
the	O
last	O
dose	O
on	O
the	O
morning	O
of	O
admission	O
8	O
hours	O
.	O
PHYSICAL	O
EXAMINATION	O
Good	O
general	O
condition	O
.	O
Conscious	O
,	O
oriented	O
and	O
cooperative	O
.	O
Afebrile	O
on	O
admission	O
.	O
Haemodynamically	O
stable	O
with	O
blood	O
pressure	O
BP	O
107	O
65	O
mmHg	O
and	O
heart	O
rate	O
HR	O
65	O
bpm	O
.	O
Eupneic	O
at	O
rest	O
and	O
speech	O
with	O
headrest	O
at	O
30o	O
.	O
Slight	O
jugular	O
ingurgitation	O
.	O
On	O
auscultation	O
,	O
arrhythmic	O
cardiac	O
tones	O
without	O
audible	O
murmurs	O
.	O
Bladder	O
murmur	O
preserved	O
with	O
no	O
added	O
pathological	O
sounds	O
.	O
Lower	O
limbs	O
with	O
slight	O
perimalleolar	O
oedema	O
,	O
no	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
No	O
other	O
noteworthy	O
findings	O
on	O
examination	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
AF	O
at	O
53	O
bpm	O
.	O
Narrow	O
QRS	O
with	O
left	O
anterior	O
hemiblock	O
morphology	O
.	O
Chest	O
X	O
ray	O
significant	O
cardiomegaly	O
at	O
the	O
expense	O
of	O
left	O
cavities	O
with	O
opening	O
of	O
the	O
carinal	O
angle	O
above	O
90o	O
,	O
double	O
right	O
atrial	O
contour	O
and	O
marked	O
growth	O
of	O
left	O
ventricular	O
shadow	O
showing	O
a	O
peculiar	O
morphology	O
of	O
the	O
cardiac	O
tip	O
in	O
"	O
hump	O
"	O
reminiscent	O
of	O
ventricular	O
aneurysm	O
.	O
Normopositioned	O
LAD	O
.	O
Transthoracic	O
echocardiography	O
severely	O
dilated	O
left	O
atrium	O
.	O
Globular	O
left	O
ventricle	O
with	O
end	O
diastolic	O
diameter	O
of	O
64	O
mm	O
,	O
end	O
diastolic	O
volume	O
of	O
256	O
ml	O
and	O
thinned	O
walls	O
with	O
non	O
compaction	O
in	O
septo	O
apical	O
segments	O
,	O
without	O
systolic	O
thickening	O
and	O
with	O
an	O
overall	O
ejection	O
fraction	O
of	O
15	O
20	O
.	O
Thin	O
mitral	O
valve	O
with	O
good	O
mobility	O
and	O
with	O
grade	O
II	O
IV	O
regurgitation	O
directed	O
to	O
the	O
posterolateral	O
wall	O
.	O
Thin	O
trivalve	O
aortic	O
valve	O
with	O
mild	O
regurgitation	O
directed	O
to	O
the	O
anterior	O
mitral	O
leaflet	O
.	O
Dilated	O
right	O
ventricle	O
with	O
end	O
diastolic	O
diameter	O
of	O
40	O
mm	O
and	O
TAPSE	O
of	O
17	O
mm	O
.	O
Hypocontractility	O
in	O
lateral	O
segments	O
.	O
Electrocatheter	O
in	O
the	O
right	O
ventricle	O
.	O
Moderate	O
tricuspid	O
regurgitation	O
with	O
right	O
atrium	O
right	O
ventricle	O
gradient	O
of	O
37	O
mmHg	O
.	O
CORONARYGRAPHY	O
normal	O
coronary	O
arteries	O
.	O
RIGHT	O
CATHETERISM	O
right	O
atrium	O
18	O
mmHg	O
,	O
right	O
ventricle	O
59	O
18	O
mmHg	O
,	O
pulmonary	O
artery	O
trunk	O
59	O
35	O
43	O
mmHg	O
,	O
pulmonary	O
capillary	O
pressure	O
35	O
mmHg	O
,	O
transpulmonary	O
gradient	O
8	O
mmHg	O
,	O
cardiac	O
output	O
3	O
.	O
7	O
l	O
min	O
.	O
Peripheral	O
vascular	O
resistance	O
2	O
.	O
16	O
Wood	O
units	O
.	O
Thoracic	O
abdominal	O
CT	O
scan	O
Noteworthy	O
is	O
the	O
presence	O
of	O
pseudonodular	O
hypodense	O
areas	O
in	O
the	O
liver	O
,	O
at	O
the	O
level	O
of	O
segment	O
II	O
and	O
between	O
segments	O
V	O
and	O
VI	O
,	O
with	O
unspecific	O
characteristics	O
that	O
could	O
correspond	O
to	O
fibrotic	O
areas	O
,	O
less	O
likely	O
patchy	O
steatosis	O
.	O
DOPLER	O
ultrasound	O
of	O
the	O
supra	O
aortic	O
trunks	O
and	O
lower	O
limbs	O
no	O
significant	O
lesions	O
.	O
BLOOD	O
GROUP	O
A	O
.	O
Anti	O
HLA	O
I	O
II	O
antibodies	O
negative	O
.	O
SEROLOGY	O
hepatitis	O
C	O
IgG	O
negative	O
,	O
hepatitis	O
A	O
IgG	O
positive	O
,	O
hepatitis	O
B	O
S	O
antigen	O
negative	O
,	O
anti	O
HBs	O
IgG	O
negative	O
,	O
anti	O
HBc	O
IgG	O
negative	O
.	O
Positive	O
IgG	O
antibodies	O
against	O
mumps	O
virus	O
,	O
rubella	O
,	O
measles	O
,	O
herpes	O
virus	O
type	O
1	O
,	O
varicella	O
zoster	O
and	O
cytomegalovirus	O
.	O
IgG	O
toxoplasma	O
positive	O
,	O
IgM	O
toxoplasma	O
negative	O
.	O
IgG	O
tetanus	O
positive	O
.	O
HIV	O
1	O
2	O
negative	O
.	O
IgG	O
Epstein	O
Bar	O
virus	O
negative	O
,	O
IgM	O
negative	O
.	O
Syphilis	O
screening	O
negative	O
.	O
TUMOUR	O
MARKERS	O
negative	O
.	O
ANALYTICS	O
pretransplant	O
glucose	O
,	O
renal	O
function	O
,	O
abdominal	O
profile	O
and	O
ions	O
normal	O
.	O
Haemoglobin	O
11	O
.	O
3	O
g	O
dl	O
.	O
HbA1c	O
5	O
.	O
5	O
.	O
NT	O
proBNP	O
1297	O
pg	O
ml	O
.	O
Coagulation	O
with	O
INR	O
1	O
.	O
31	O
,	O
PT	O
14	O
.	O
5	O
seconds	O
,	O
TPTA	O
57	O
.	O
1	O
seconds	O
,	O
TPTA	O
ratio	O
1	O
.	O
78	O
.	O
Lipid	O
profile	O
total	O
cholesterol	O
185	O
mg	O
dl	O
,	O
LDL	O
95	O
mg	O
dl	O
,	O
HDL	O
65	O
mg	O
dl	O
.	O
Normal	O
thyroid	O
profile	O
.	O
COAGULATION	O
TEST	O
after	O
idarucizumab	B-FARMACO
IV	O
infusion	O
INR	O
1	O
.	O
13	O
,	O
PT	O
12	O
.	O
4	O
seconds	O
,	O
TPTA	O
30	O
.	O
3	O
seconds	O
,	O
TPTA	O
ratio	O
0	O
.	O
95	O
.	O
CLINICAL	O
EVOLUTION	O
On	O
receiving	O
the	O
analytical	O
results	O
requested	O
on	O
admission	O
,	O
the	O
effect	O
of	O
dabigatran	B-FARMACO
on	O
the	O
patient	O
's	O
coagulation	O
was	O
confirmed	O
by	O
means	O
of	O
the	O
TPTA	O
57	O
.	O
1	O
seconds	O
and	O
TPTA	O
ratio	O
1	O
.	O
78	O
.	O
At	O
this	O
point	O
,	O
haematology	O
was	O
contacted	O
to	O
reverse	O
the	O
anticoagulation	O
,	O
who	O
indicated	O
the	O
administration	O
of	O
5	O
g	O
of	O
idarucizumab	B-FARMACO
IV	O
by	O
means	O
of	O
two	O
consecutive	O
infusions	O
of	O
2	O
.	O
5	O
g	O
50	O
ml	O
in	O
5	O
10	O
minutes	O
each	O
,	O
with	O
a	O
new	O
control	O
15	O
minutes	O
after	O
administration	O
,	O
normalising	O
the	O
coagulation	O
times	O
TPTA	O
30	O
.	O
3	O
seconds	O
and	O
TPTA	O
ratio	O
0	O
.	O
97	O
.	O
Once	O
the	O
anticoagulant	O
effect	O
of	O
dabigatran	B-FARMACO
had	O
been	O
reversed	O
,	O
surgery	O
was	O
performed	O
and	O
orthotopic	O
heart	O
transplantation	O
was	O
performed	O
using	O
the	O
bicava	O
technique	O
.	O
The	O
extracorporeal	O
surgery	O
time	O
is	O
78	O
minutes	O
and	O
the	O
anoxia	O
time	O
is	O
60	O
minutes	O
.	O
During	O
surgery	O
,	O
3	O
g	O
of	O
fibrinogen	B-FARMACO
was	O
administered	O
and	O
the	O
patient	O
did	O
not	O
require	O
transfusions	O
of	O
blood	O
products	O
.	O
Heparinisation	O
is	O
reversed	O
with	O
protamine	B-FARMACO
.	O
Finally	O
,	O
two	O
mediastinal	O
drains	O
were	O
left	O
in	O
place	O
and	O
were	O
removed	O
48	O
hours	O
after	O
surgery	O
without	O
incident	O
.	O
In	O
the	O
immediate	O
postoperative	O
period	O
,	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
.	O
He	O
was	O
extubated	O
in	O
the	O
first	O
6	O
hours	O
,	O
with	O
a	O
favourable	O
evolution	O
at	O
all	O
times	O
,	O
with	O
no	O
bleeding	O
complications	O
.	O
The	O
usual	O
immunosuppression	O
protocol	O
was	O
started	O
tacrolimus	B-FARMACO
mycophenolate	I-FARMACO
mofetil	I-FARMACO
prednisone	I-FARMACO
.	O
He	O
was	O
transferred	O
to	O
the	O
cardiac	O
transplant	O
hospitalisation	O
unit	O
72	O
hours	O
after	O
surgery	O
and	O
was	O
discharged	O
home	O
early	O
.	O
DIAGNOSIS	O
Scheduled	O
admission	O
for	O
orthotopic	O
heart	O
transplant	O
with	O
bicava	O
technique	O
in	O
a	O
patient	O
on	O
the	O
elective	O
waiting	O
list	O
for	O
non	O
ischaemic	O
dilated	O
cardiomyopathy	O
with	O
severe	O
biventricular	O
dysfunction	O
LVEF	O
15	O
20	O
.	O
Persistent	O
anticoagulated	O
AF	O
CHA2DS2	O
VASc	O
1	O
point	O
,	O
HAS	O
BLED	O
0	O
points	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
The	O
patient	O
is	O
a	O
45	O
year	O
old	O
woman	O
with	O
no	O
known	O
drug	O
allergies	O
.	O
As	O
cardiovascular	O
risk	O
factors	O
,	O
she	O
has	O
recently	O
diagnosed	O
type	O
2	O
diabetes	O
mellitus	O
under	O
dietary	O
treatment	O
and	O
smokes	O
half	O
a	O
pack	O
a	O
day	O
.	O
She	O
had	O
no	O
previous	O
cardiological	O
history	O
and	O
had	O
undergone	O
parathyroidectomy	O
.	O
The	O
patient	O
was	O
referred	O
to	O
the	O
emergency	O
department	O
of	O
our	O
centre	O
from	O
her	O
health	O
centre	O
due	O
to	O
headache	O
,	O
pulsating	O
frontal	O
headache	O
related	O
to	O
hypertensive	O
emergency	O
,	O
as	O
well	O
as	O
dyspnoea	O
on	O
moderate	O
exertion	O
in	O
the	O
last	O
few	O
weeks	O
.	O
She	O
denied	O
chest	O
pain	O
,	O
dizziness	O
or	O
other	O
cardiovascular	O
symptoms	O
.	O
Physical	O
examination	O
on	O
arrival	O
at	O
the	O
ED	O
showed	O
blood	O
pressure	O
BP	O
180	O
100	O
,	O
heart	O
rate	O
HR	O
74	O
bpm	O
.	O
Conscious	O
,	O
oriented	O
,	O
cooperative	O
.	O
Neurological	O
examination	O
within	O
normal	O
limits	O
.	O
Normal	O
jugular	O
venous	O
pulse	O
.	O
Rhythmic	O
heart	O
sounds	O
with	O
systolic	O
murmur	O
II	O
VI	O
predominantly	O
in	O
the	O
mesocardium	O
and	O
with	O
preserved	O
S2	O
.	O
Pulmonary	O
,	O
abdominal	O
and	O
lower	O
limb	O
auscultation	O
without	O
relevant	O
alterations	O
.	O
COMPLEMENTARY	O
TESTS	O
ELECTROCARDIOGRAM	O
ECG	O
sinus	O
rhythm	O
at	O
86	O
bpm	O
.	O
Poor	O
progression	O
of	O
R	O
in	O
precordial	O
leads	O
with	O
biphasic	O
T	O
in	O
V2	O
.	O
Negative	O
in	O
lateral	O
leads	O
.	O
BIOCHEMISTRY	O
glucose	O
160	O
.	O
Urea	O
38	O
mg	O
dl	O
.	O
Creatinine	O
0	O
.	O
81	O
mg	O
dl	O
.	O
Estimated	O
glomerular	O
filtration	O
rate	O
60	O
.	O
Urate	O
5	O
.	O
3	O
mg	O
dl	O
.	O
Sodium	O
ion	O
139	O
mmol	O
l	O
,	O
potassium	O
ion	O
5	O
.	O
1	O
mmol	O
l	O
.	O
Creatine	O
kinase	O
81	O
.	O
Total	O
bilirubin	O
1	O
.	O
0	O
.	O
Total	O
cholesterol	O
217	O
,	O
HDL	O
cholesterol	O
54	O
mg	O
dl	O
,	O
triglycerides	O
111	O
mg	O
dl	O
,	O
calculated	O
LDL	O
cholesterol	O
141	O
mg	O
dl	O
.	O
HbA1c	O
7	O
.	O
Troponin	O
T	O
69	O
ng	O
dl	O
maximum	O
166	O
ng	O
dl	O
.	O
Haemogram	O
red	O
blood	O
cells	O
4410	O
.	O
Haemoglobin	O
12	O
.	O
3	O
.	O
Haematocrit	O
38	O
.	O
2	O
.	O
MCV	O
86	O
.	O
6	O
fl	O
.	O
MCH	O
27	O
.	O
9	O
pg	O
,	O
MCHC	O
32	O
.	O
2	O
g	O
dl	O
.	O
Leukocytes	O
14050	O
.	O
Neutrophils	O
blood	O
62	O
.	O
1	O
.	O
Neutrophils	O
8730	O
.	O
Lymphocytes	O
28	O
.	O
2	O
.	O
Lymphocytes	O
3960	O
.	O
Monocytes	O
blood	O
7	O
,	O
7	O
.	O
Monocytes	O
1080	O
.	O
Eosinophils	O
blood	O
1	O
.	O
6	O
.	O
Eosinophils	O
220	O
.	O
Basophils	O
blood	O
0	O
.	O
4	O
.	O
Basophils	O
60	O
.	O
Platelets	O
769000	O
fl	O
.	O
SEROLOGY	O
Mycoplasma	O
pneumoniae	O
IgM	O
negative	O
,	O
Legionella	O
pneumophila	O
IgM	O
negative	O
,	O
Legionella	O
pneumophila	O
IgG	O
negative	O
,	O
Influenza	O
B	O
IgM	O
negative	O
,	O
Influenza	O
A	O
IgM	O
negative	O
,	O
CMV	O
IgM	O
negative	O
,	O
CMV	O
IgG	O
positive	O
,	O
Borrelia	O
burgdorferi	O
IgM	O
Lyme	O
negative	O
,	O
Borrelia	O
burgdorferi	O
IgG	O
Lyme	O
negative	O
.	O
COAGULATION	O
Prothrombin	O
T	O
.	O
13	O
,	O
30	O
.	O
Prothrombin	O
T	O
.	O
76	O
,	O
0	O
,	O
Prothrombin	O
T	O
.	O
ratio	O
1	O
,	O
23	O
.	O
T	O
.	O
partial	O
thromboplastin	O
34	O
.	O
60	O
,	O
T	O
.	O
partial	O
thromboplastin	O
R	O
1	O
.	O
15	O
.	O
Fibrinogen	O
derivative	O
1436	O
.	O
DDimer	O
750	O
.	O
00	O
.	O
INR	O
1	O
.	O
23	O
.	O
ECOCARDIOGRAM	O
admission	O
videos	O
1	O
3	O
Left	O
atrium	O
LA	O
slightly	O
dilated	O
.	O
Left	O
ventricle	O
LV	O
with	O
severe	O
concentric	O
hypertrophy	O
21	O
mm	O
approximately	O
at	O
septal	O
level	O
,	O
15	O
mm	O
in	O
relation	O
to	O
PP	O
,	O
without	O
asynergies	O
and	O
with	O
preserved	O
systolic	O
function	O
.	O
Prolonged	O
diastolic	O
relaxation	O
pattern	O
type	O
1	O
diastolic	O
dysfunction	O
.	O
A	O
subvalvular	O
gradient	O
of	O
approx	O
.	O
22	O
mmHg	O
is	O
obtained	O
in	O
relation	O
to	O
prominent	O
septal	O
knee	O
,	O
due	O
to	O
flow	O
acceleration	O
at	O
this	O
level	O
no	O
SAM	O
and	O
no	O
subaortic	O
membrane	O
.	O
Normofunctioning	O
mitral	O
valve	O
.	O
Trivalve	O
aortic	O
valve	O
with	O
good	O
opening	O
without	O
significant	O
stenosis	O
or	O
insufficiency	O
.	O
Right	O
ventricle	O
RV	O
with	O
preserved	O
function	O
,	O
without	O
adequate	O
signal	O
for	O
calculation	O
of	O
pulmonary	O
arterial	O
systolic	O
pressure	O
PSAP	O
.	O
No	O
pericardial	O
effusion	O
.	O
No	O
significant	O
gradient	O
at	O
the	O
level	O
of	O
the	O
descending	O
aorta	O
.	O
Normal	O
vena	O
cava	O
.	O
CORONARYGRAPHY	O
right	O
dominance	O
.	O
Coronary	O
arteries	O
without	O
significant	O
angiographic	O
lesions	O
.	O
ECOCARDIOGRAM	O
outpatient	O
,	O
5	O
months	O
after	O
discharge	O
video	O
4	O
LV	O
of	O
normal	O
size	O
and	O
thickness	O
,	O
without	O
alterations	O
of	O
segmental	O
contractility	O
and	O
preserved	O
systolic	O
function	O
.	O
Normal	O
diastolic	O
pattern	O
for	O
age	O
.	O
RV	O
of	O
normal	O
size	O
and	O
function	O
.	O
Mild	O
mitral	O
insufficiency	O
.	O
Mild	O
moderate	O
tricuspid	O
insufficiency	O
that	O
allows	O
estimating	O
a	O
PSAP	O
of	O
24	O
mmHg	O
PVC	O
.	O
Laboratory	O
tests	O
at	O
the	O
clinic	O
LDL	O
cholesterol	O
100	O
mg	O
dl	O
,	O
HbA1c	O
6	O
.	O
5	O
.	O
Cardiac	O
NUCLEAR	O
MAGNETIC	O
RESONANCE	O
MRI	O
outpatient	O
after	O
control	O
echocardiography	O
LV	O
and	O
RV	O
images	O
were	O
obtained	O
in	O
cine	O
sequences	O
,	O
Stir	O
and	O
late	O
enhancement	O
after	O
gadolinium	O
administration	O
.	O
LV	O
normal	O
size	O
,	O
with	O
VTD	O
of	O
64	O
ml	O
m2	O
range	O
41	O
81	O
ml	O
m2	O
and	O
STV	O
of	O
18	O
ml	O
m2	O
range	O
12	O
21	O
ml	O
m2	O
.	O
EF	O
71	O
,	O
cardiac	O
output	O
5	O
.	O
4	O
l	O
min	O
and	O
stroke	O
volume	O
88	O
ml	O
.	O
Normal	O
segmental	O
contractility	O
.	O
Normal	O
myocardial	O
mass	O
of	O
65	O
g	O
m2	O
range	O
63	O
95	O
g	O
m2	O
.	O
Maximum	O
septal	O
thickness	O
of	O
12	O
mm	O
.	O
No	O
myocardial	O
oedema	O
on	O
STIR	O
sequence	O
.	O
No	O
pathological	O
contrast	O
uptake	O
suggesting	O
areas	O
of	O
fibrosis	O
,	O
signs	O
of	O
infiltrative	O
cardiomyopathy	O
or	O
other	O
findings	O
.	O
RV	O
normal	O
size	O
,	O
without	O
morphological	O
alterations	O
,	O
with	O
TVD	O
of	O
62	O
ml	O
m2	O
range	O
48	O
87	O
ml	O
m2	O
and	O
STV	O
of	O
24	O
ml	O
m2	O
range	O
11	O
28	O
ml	O
m2	O
.	O
EF	O
61	O
,	O
cardiac	O
output	O
4	O
.	O
5	O
l	O
min	O
and	O
stroke	O
volume	O
72	O
.	O
5	O
ml	O
.	O
Contractility	O
normal	O
.	O
Left	O
atrium	O
LA	O
area	O
19	O
cm2	O
,	O
normal	O
size	O
.	O
Right	O
atrium	O
RA	O
area	O
19	O
cm2	O
,	O
normal	O
size	O
.	O
Aortic	O
root	O
flow	O
quantification	O
phase	O
contrast	O
velocity	O
coding	O
.	O
Anterograde	O
volume	O
78	O
ml	O
and	O
retrograde	O
volume	O
2	O
.	O
35	O
ml	O
.	O
Regurgitation	O
fraction	O
3	O
.	O
Peak	O
velocity	O
155	O
cm	O
s	O
.	O
Pressure	O
gradient	O
9	O
.	O
6	O
mmHg	O
.	O
Quantification	O
of	O
main	O
pulmonary	O
artery	O
flow	O
phase	O
contrast	O
velocity	O
coding	O
.	O
Antegrade	O
volume	O
83	O
ml	O
and	O
retrograde	O
volume	O
1	O
.	O
6	O
ml	O
.	O
Regurgitation	O
fraction	O
1	O
.	O
9	O
.	O
Peak	O
velocity	O
107	O
cm	O
s	O
.	O
Pressure	O
gradient	O
4	O
.	O
5	O
mmHg	O
.	O
Pericardium	O
no	O
significant	O
pericardial	O
thickening	O
or	O
effusion	O
.	O
Conclusions	O
LV	O
of	O
normal	O
size	O
and	O
function	O
.	O
No	O
significant	O
hypertrophy	O
maximum	O
thickness	O
12	O
mm	O
and	O
no	O
evidence	O
of	O
infiltrative	O
cardiomyopathy	O
.	O
CLINICAL	O
EVOLUTION	O
Electrocardiogram	O
and	O
laboratory	O
tests	O
were	O
performed	O
with	O
markers	O
of	O
myocardial	O
damage	O
creatine	O
kinase	O
and	O
ultrasensitive	O
troponin	O
T	O
with	O
elevation	O
of	O
these	O
markers	O
.	O
In	O
view	O
of	O
these	O
findings	O
and	O
with	O
the	O
diagnosis	O
of	O
acute	O
myocardial	O
infarction	O
AMI	O
type	O
2	O
in	O
the	O
context	O
of	O
hypertensive	O
emergency	O
,	O
admission	O
was	O
decided	O
for	O
adjustment	O
of	O
treatment	O
and	O
completion	O
of	O
studies	O
.	O
An	O
echocardiogram	O
was	O
performed	O
showing	O
severe	O
concentric	O
hypertrophy	O
causing	O
a	O
dynamic	O
gradient	O
at	O
the	O
LV	O
outflow	O
tract	O
and	O
a	O
complete	O
serological	O
study	O
,	O
given	O
the	O
recent	O
onset	O
of	O
symptoms	O
,	O
in	O
order	O
to	O
try	O
to	O
exclude	O
a	O
possible	O
infectious	O
origin	O
,	O
which	O
was	O
negative	O
,	O
as	O
well	O
as	O
coronary	O
angiography	O
,	O
given	O
the	O
mobilisation	O
of	O
markers	O
of	O
myocardial	O
damage	O
without	O
evidence	O
of	O
significant	O
angiographic	O
lesions	O
.	O
The	O
patient	O
progressed	O
favourably	O
after	O
starting	O
antihypertensive	O
treatment	O
with	O
a	O
combination	O
of	O
olmesartan	B-FARMACO
,	O
amlodipine	B-FARMACO
and	O
hydrochlorothiazide	B-FARMACO
40	O
5	O
12	O
.	O
5mg	O
and	O
beta	O
blocker	O
bisoprolol	B-FARMACO
2	O
,	O
5mg	O
,	O
so	O
in	O
view	O
of	O
the	O
results	O
it	O
was	O
decided	O
to	O
discharge	O
him	O
home	O
and	O
a	O
possible	O
diagnosis	O
of	O
hypertrophic	O
cardiomyopathy	O
or	O
hypertensive	O
heart	O
disease	O
with	O
severe	O
left	O
ventricular	O
hypertrophy	O
was	O
established	O
,	O
and	O
to	O
try	O
to	O
establish	O
the	O
differential	O
diagnosis	O
,	O
an	O
outpatient	O
cardiac	O
MRI	O
was	O
requested	O
.	O
Simultaneously	O
,	O
treatment	O
was	O
started	O
with	O
metformin	B-FARMACO
850	O
mg	O
12	O
hours	O
and	O
rosuvastatin	B-FARMACO
20	O
mg	O
every	O
24	O
hours	O
,	O
based	O
on	O
the	O
results	O
of	O
the	O
analytical	O
controls	O
.	O
Three	O
months	O
after	O
discharge	O
,	O
she	O
visited	O
the	O
cardiology	O
outpatient	O
clinic	O
for	O
a	O
check	O
up	O
.	O
She	O
required	O
a	O
progressive	O
decrease	O
in	O
antihypertensive	O
medication	O
and	O
at	O
the	O
time	O
of	O
consultation	O
was	O
treated	O
with	O
amlodipine	B-FARMACO
5	O
mg	O
and	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
with	O
optimal	O
control	O
of	O
BP	O
and	O
ambulatory	O
values	O
maintained	O
at	O
around	O
120	O
60	O
mmHg	O
.	O
The	O
physical	O
examination	O
revealed	O
that	O
the	O
systolic	O
murmur	O
that	O
had	O
been	O
present	O
on	O
admission	O
had	O
disappeared	O
,	O
so	O
it	O
was	O
decided	O
to	O
request	O
an	O
ABPM	O
that	O
confirmed	O
optimal	O
control	O
of	O
BP	O
and	O
an	O
echocardiogram	O
with	O
normalisation	O
of	O
wall	O
thicknesses	O
and	O
no	O
other	O
relevant	O
alterations	O
.	O
Finally	O
,	O
cardiac	O
MRI	O
was	O
performed	O
,	O
showing	O
a	O
LV	O
of	O
normal	O
size	O
and	O
thickness	O
with	O
no	O
evidence	O
of	O
pathological	O
gadolinium	O
uptake	O
,	O
either	O
early	O
or	O
late	O
,	O
so	O
structural	O
heart	O
disease	O
was	O
ruled	O
out	O
and	O
a	O
definitive	O
diagnosis	O
of	O
resolved	O
myocarditis	O
was	O
established	O
.	O
DIAGNOSIS	O
Acute	O
myocarditis	O
in	O
resolution	O
.	O
Type	O
2	O
diabetes	O
mellitus	O
.	O
Hypercholesterolemia	O
type	O
dyslipidaemia	O
.	O
Newly	O
diagnosed	O
arterial	O
hypertension	O
AHT	O
.	O

BACKGROUND	O
74	O
year	O
old	O
woman	O
.	O
Arterial	O
hypertension	O
.	O
Rheumatic	O
heart	O
disease	O
with	O
predominantly	O
mitral	O
insufficiency	O
.	O
Mitral	O
valve	O
replacement	O
by	O
mechanical	O
prosthesis	O
Bjork	O
no	O
.	O
31	O
in	O
1976	O
.	O
31	O
in	O
1976	O
.	O
Pacemaker	O
implantation	O
due	O
to	O
symptomatic	O
slow	O
atrial	O
fibrillation	O
in	O
1996	O
with	O
last	O
generator	O
replacement	O
in	O
2015	O
,	O
presenting	O
on	O
that	O
occasion	O
with	O
spontaneously	O
draining	O
bursa	O
haematoma	O
with	O
negative	O
blood	O
cultures	O
and	O
normal	O
TTE	O
,	O
which	O
was	O
covered	O
empirically	O
with	O
ampicillin	B-FARMACO
intravenous	O
gentamicin	B-FARMACO
with	O
good	O
subsequent	O
evolution	O
.	O
Chronic	O
treatment	O
acenocoumarol	B-FARMACO
according	O
to	O
schedule	O
,	O
olmesartan	B-FARMACO
hydrochlorothiazide	I-FARMACO
20	O
12	O
.	O
5	O
mg	O
c	O
24	O
hours	O
,	O
verapamil	B-FARMACO
120	O
mg	O
c	O
24	O
hours	O
,	O
zolpidem	B-FARMACO
10	O
mg	O
c	O
24	O
hours	O
,	O
formoterol	B-FARMACO
budesodin	I-FARMACO
160	O
4	O
.	O
5	O
mcg	O
inh	O
c	O
24	O
hours	O
.	O
CURRENT	O
ILLNESS	O
She	O
attended	O
the	O
emergency	O
department	O
on	O
10	O
3	O
2016	O
for	O
general	O
malaise	O
,	O
headache	O
,	O
arthomyalgia	O
,	O
anorexia	O
,	O
fever	O
and	O
weight	O
loss	O
of	O
2	O
weeks	O
'	O
evolution	O
.	O
Initial	O
suspicion	O
of	O
pneumonia	O
in	O
the	O
left	O
upper	O
lobe	O
led	O
to	O
empirical	O
antibiotic	O
treatment	O
with	O
levofloxacin	B-FARMACO
,	O
escalating	O
to	O
imipenem	B-FARMACO
due	O
to	O
persistent	O
febrile	O
syndrome	O
and	O
general	O
deterioration	O
,	O
in	O
addition	O
to	O
finding	O
growth	O
of	O
Streptococcus	O
gordinii	O
in	O
blood	O
cultures	O
.	O
PHYSICAL	O
EXAMINATION	O
Temperature	O
36	O
oC	O
.	O
Blood	O
pressure	O
126	O
63	O
mmHg	O
,	O
heart	O
rate	O
66	O
bpm	O
,	O
oxygen	O
saturation	O
97	O
with	O
nasal	O
goggles	O
at	O
2	O
l	O
min	O
,	O
RR	O
16	O
rpm	O
.	O
Conscious	O
,	O
oriented	O
and	O
cooperative	O
.	O
Good	O
general	O
condition	O
.	O
Eupneic	O
at	O
rest	O
.	O
Good	O
distal	O
perfusion	O
,	O
adequate	O
hydric	O
status	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
with	O
prosthetic	O
click	O
without	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
rhonchi	O
,	O
minimal	O
crackles	O
in	O
the	O
left	O
base	O
.	O
Lower	O
extremities	O
no	O
oedema	O
,	O
no	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
ventricular	O
rhythm	O
stimulated	O
by	O
pacemaker	O
at	O
60	O
bpm	O
.	O
THORAX	O
X	O
RAY	O
condensation	O
at	O
the	O
level	O
of	O
the	O
left	O
upper	O
lobe	O
.	O
ANALYSIS	O
Haemogram	O
Hb	O
10	O
g	O
dl	O
.	O
Leukocytes	O
24	O
,	O
300	O
u	O
l	O
neutrophils	O
85	O
,	O
lymphocytes	O
8	O
,	O
platelets	O
201	O
,	O
000	O
u	O
l	O
.	O
Biochemistry	O
glucose	O
135	O
mg	O
dl	O
.	O
Urea	O
54	O
mg	O
dl	O
.	O
Creatinine	O
1	O
.	O
28	O
mg	O
dl	O
.	O
GFR	O
41	O
ml	O
min	O
.	O
Sodium	O
132	O
mmol	O
l	O
.	O
Potassium	O
4	O
.	O
4	O
mmol	O
l	O
.	O
C	O
reactive	O
protein	O
211	O
mg	O
l	O
.	O
CPK	O
119	O
U	O
l	O
.	O
Troponin	O
T	O
19	O
ng	O
l	O
normal	O
.	O
Coagulation	O
PT	O
16	O
s	O
.	O
INR	O
4	O
.	O
2	O
.	O
Fibrinogen	O
905	O
mg	O
dl	O
.	O
Blood	O
gases	O
pH	O
7	O
.	O
47	O
,	O
pO2	O
68	O
mmHg	O
,	O
pCO2	O
29	O
mmHg	O
,	O
SatO2	O
97	O
.	O
Transthoracic	O
echocardiography	O
TTE	O
and	O
transesophageal	O
echocardiography	O
TEE	O
endocarditis	O
on	O
mitral	O
prosthetic	O
valve	O
.	O
Bjork	O
mechanical	O
prosthesis	O
in	O
mitral	O
position	O
with	O
no	O
signs	O
of	O
dysfunction	O
.	O
In	O
the	O
posterior	O
portion	O
of	O
the	O
annulus	O
close	O
to	O
the	O
atrial	O
appendage	O
there	O
is	O
an	O
anechoic	O
cavity	O
of	O
pulsatile	O
appearance	O
of	O
approximately	O
2	O
.	O
6	O
cm	O
x	O
1	O
.	O
6	O
cm	O
with	O
images	O
of	O
greater	O
density	O
in	O
its	O
interior	O
,	O
suggesting	O
an	O
abscess	O
in	O
the	O
clinical	O
context	O
of	O
the	O
patient	O
.	O
Left	O
ventricle	O
LV	O
neither	O
dilated	O
nor	O
hypertrophic	O
LVEF	O
58	O
.	O
Right	O
ventricle	O
RV	O
not	O
dilated	O
,	O
normal	O
global	O
contractility	O
.	O
Both	O
atria	O
moderately	O
dilated	O
.	O
Normofunctioning	O
aortic	O
valve	O
.	O
Tricuspid	O
normal	O
,	O
mild	O
insufficiency	O
.	O
Pulmonary	O
arterial	O
systolic	O
pressure	O
PSAP	O
50	O
mmHg	O
15	O
20	O
mmHg	O
severe	O
pulmonary	O
hypertension	O
.	O
Pericardium	O
without	O
effusion	O
.	O
Right	O
pleural	O
effusion	O
.	O
Inferior	O
vena	O
cava	O
slightly	O
dilated	O
with	O
respiratory	O
variation	O
present	O
.	O
Pacemaker	O
electrode	O
in	O
right	O
ventricle	O
without	O
apparent	O
alterations	O
.	O
Chest	O
PET	O
CT	O
scan	O
hypermetabolism	O
in	O
the	O
mitral	O
region	O
suggesting	O
an	O
infectious	O
process	O
,	O
with	O
no	O
evidence	O
of	O
hypermetabolic	O
foci	O
in	O
the	O
path	O
of	O
the	O
pacemaker	O
lead	O
.	O
Uptake	O
at	O
the	O
generator	O
site	O
residual	O
of	O
recent	O
replacement	O
versus	O
very	O
low	O
activity	O
infection	O
.	O
Post	O
surgical	O
changes	O
in	O
mitral	O
valve	O
with	O
replacement	O
by	O
mechanical	O
prosthesis	O
.	O
Collection	O
with	O
contrast	O
in	O
its	O
interior	O
of	O
28	O
x	O
17	O
x	O
15	O
mm	O
depending	O
on	O
the	O
anterior	O
portion	O
of	O
the	O
mitral	O
annulus	O
,	O
suggestive	O
of	O
pseudoaneurysm	O
.	O
CLINICAL	O
EVOLUTION	O
Due	O
to	O
persistent	O
febrile	O
syndrome	O
and	O
positive	O
cultures	O
for	O
multisensitive	O
Streptococcus	O
gordinii	O
,	O
it	O
was	O
decided	O
to	O
perform	O
the	O
aforementioned	O
studies	O
.	O
TTE	O
showed	O
an	O
image	O
on	O
the	O
atrial	O
side	O
in	O
the	O
lateral	O
region	O
of	O
the	O
mitral	O
annulus	O
suggestive	O
of	O
an	O
abscess	O
compatible	O
with	O
the	O
diagnosis	O
of	O
endocarditis	O
on	O
the	O
prosthetic	O
valve	O
.	O
This	O
finding	O
was	O
corroborated	O
by	O
PET	O
CT	O
,	O
which	O
showed	O
a	O
collection	O
in	O
the	O
anterior	O
portion	O
of	O
the	O
mitral	O
annulus	O
suggestive	O
of	O
pseudoaneurysm	O
with	O
hypercaptation	O
at	O
this	O
level	O
.	O
Urgent	O
surgical	O
intervention	O
was	O
decided	O
in	O
June	O
2016	O
and	O
an	O
open	O
abscess	O
was	O
found	O
towards	O
the	O
left	O
atrium	O
at	O
the	O
level	O
of	O
leaflets	O
A1	O
P1	O
.	O
In	O
addition	O
,	O
on	O
examining	O
the	O
mechanical	O
prosthesis	O
,	O
there	O
was	O
evidence	O
of	O
restriction	O
of	O
the	O
movement	O
of	O
the	O
disc	O
due	O
to	O
pannus	O
with	O
calcified	O
mitral	O
annulus	O
,	O
as	O
well	O
as	O
part	O
of	O
the	O
atrial	O
wall	O
.	O
The	O
abscess	O
was	O
closed	O
with	O
two	O
stitches	O
and	O
a	O
Perimount	O
Edwards	O
No	O
27	O
biological	O
mitral	O
prosthesis	O
was	O
implanted	O
,	O
as	O
well	O
as	O
a	O
generator	O
replacement	O
due	O
to	O
minimal	O
hypercaptation	O
,	O
as	O
seen	O
on	O
PET	O
CT	O
.	O
During	O
her	O
stay	O
in	O
hospital	O
she	O
evolved	O
favourably	O
,	O
de	O
escalating	O
antibiotic	O
treatment	O
and	O
prescribing	O
benzylpenicillin	B-FARMACO
,	O
with	O
negative	O
blood	O
cultures	O
for	O
control	O
and	O
prosthetic	O
material	O
.	O
She	O
was	O
asymptomatic	O
and	O
progressed	O
well	O
in	O
hospital	O
,	O
so	O
it	O
was	O
decided	O
to	O
discharge	O
her	O
and	O
continue	O
outpatient	O
follow	O
up	O
,	O
completing	O
antibiotic	O
treatment	O
with	O
amoxicillin	B-FARMACO
for	O
two	O
months	O
.	O
DIAGNOSIS	O
Infectious	O
endocarditis	O
due	O
to	O
multisensitive	O
Streptococcus	O
gordinii	O
on	O
mechanical	O
mitral	O
prosthesis	O
complicated	O
by	O
mitral	O
periannular	O
abscess	O
.	O
Replacement	O
of	O
mechanical	O
mitral	O
prosthesis	O
with	O
Perimount	O
Edwards	O
No	O
27	O
biological	O
mitral	O
prosthesis	O
.	O
Replacement	O
of	O
pacemaker	O
generator	O
due	O
to	O
suspected	O
pacemaker	O
pocket	O
infection	O
.	O

ANAMNESIS	O
Female	O
,	O
58	O
years	O
old	O
.	O
Non	O
smoker	O
.	O
Moderate	O
drinker	O
.	O
High	O
blood	O
pressure	O
on	O
treatment	O
.	O
Insomnia	O
on	O
treatment	O
with	O
BDZ	O
.	O
Lumbociatalgia	O
.	O
Usual	O
treatment	O
Omeprazole	B-FARMACO
,	O
ASA	B-FARMACO
,	O
Calcium	B-FARMACO
,	O
Celecoxib	B-FARMACO
,	O
Mometasone	B-FARMACO
,	O
Flunitrazepam	B-FARMACO
and	O
Lormetazepam	B-FARMACO
.	O
Current	O
illness	O
She	O
attended	O
the	O
emergency	O
department	O
on	O
17	O
09	O
2012	O
due	O
to	O
febrile	O
symptoms	O
with	O
shivering	O
associated	O
with	O
drowsiness	O
and	O
marked	O
disorientation	O
.	O
In	O
the	O
anamnesis	O
she	O
reported	O
clinical	O
symptoms	O
of	O
two	O
weeks	O
'	O
evolution	O
,	O
consisting	O
of	O
asthenia	O
and	O
anorexia	O
,	O
with	O
fever	O
since	O
14	O
09	O
2012	O
associated	O
with	O
odynophagia	O
,	O
with	O
partial	O
improvement	O
with	O
clarithromycin	B-FARMACO
.	O
Physical	O
examination	O
BP	O
85	O
55	O
Fc	O
95x	O
"	O
Ta	O
37	O
.	O
3oC	O
Conscious	O
,	O
disoriented	O
in	O
time	O
and	O
space	O
.	O
Eupneic	O
at	O
rest	O
.	O
Mucocutaneous	O
pallor	O
.	O
No	O
adenopathies	O
,	O
no	O
neck	O
rigidity	O
.	O
PCA	O
Tachycardic	O
,	O
no	O
murmurs	O
.	O
Global	O
hypoventilation	O
without	O
pathological	O
sounds	O
.	O
Rest	O
anodyne	O
.	O
Complementary	O
tests	O
in	O
the	O
Emergency	O
Department	O
ECG	O
Sinus	O
rhythm	O
at	O
90x	O
"	O
.	O
Chest	O
X	O
ray	O
No	O
cardiomegaly	O
or	O
pathological	O
findings	O
.	O
Laboratory	O
tests	O
Blood	O
Lactate	O
35	O
mg	O
dL	O
,	O
Procalcitonin	O
89	O
.	O
8ng	O
mL	O
,	O
Urea	O
62	O
mg	O
dL	O
,	O
Creatinine	O
1	O
.	O
36	O
mg	O
dL	O
,	O
Na	O
131	O
mEq	O
L	O
,	O
CRP	O
7	O
mg	O
dL	O
,	O
Hb	O
10	O
.	O
9	O
g	O
dL	O
,	O
Hto	O
31	O
.	O
6	O
,	O
MCV	O
100	O
.	O
8	O
fL	O
,	O
Platelets	O
126000	O
L	O
,	O
Leukocytes	O
27300	O
L	O
,	O
IP	O
48	O
,	O
INR	O
1	O
.	O
67	O
.	O
Arterial	O
blood	O
gas	O
pH	O
7	O
.	O
43	O
,	O
pCO2	O
33	O
,	O
pO2	O
49	O
,	O
HCO3	O
22	O
,	O
EB	O
1	O
.	O
8	O
,	O
Sat02	O
85	O
Urine	O
sediment	O
Blood	O
,	O
Leukocytes	O
Cranial	O
CT	O
No	O
acute	O
intracranial	O
pathology	O
.	O
Cerebrospinal	O
fluid	O
Clear	O
,	O
transparent	O
.	O
Proteins	O
63	O
mg	O
dL	O
,	O
Glucose	O
66mg	O
dL	O
,	O
Hematies	O
110	O
cells	O
mm3	O
,	O
Others	O
7	O
cells	O
mm3	O
Lymphocytes	O
18	O
,	O
Segmented	O
74	O
,	O
Monocytes	O
8	O
Abdominal	O
ultrasound	O
Homogeneous	O
splenomegaly	O
of	O
14	O
.	O
4	O
cm	O
.	O
Rest	O
within	O
normality	O
.	O
Evolution	O
Admitted	O
to	O
ICU	O
on	O
18	O
09	O
2012	O
with	O
the	O
diagnosis	O
of	O
septic	O
shock	O
of	O
unidentified	O
aetiology	O
,	O
with	O
urinary	O
focus	O
as	O
the	O
most	O
likely	O
,	O
requiring	O
low	O
doses	O
of	O
inotropics	O
and	O
vasopressors	O
.	O
Five	O
hours	O
later	O
,	O
the	O
patient	O
is	O
haemodynamically	O
stable	O
,	O
and	O
inotropes	O
and	O
vasopressors	O
can	O
be	O
withdrawn	O
.	O
However	O
,	O
disorientation	O
and	O
somnolence	O
persisted	O
,	O
with	O
aphasia	O
and	O
new	O
onset	O
right	O
hemiplegia	O
.	O
An	O
urgent	O
cranial	O
CT	O
scan	O
was	O
performed	O
She	O
was	O
assessed	O
by	O
Neurology	O
,	O
without	O
an	O
invasive	O
intravascular	O
procedure	O
due	O
to	O
a	O
history	O
of	O
lumbar	O
puncture	O
in	O
the	O
previous	O
24	O
hours	O
,	O
and	O
antiplatelet	O
therapy	O
with	O
ASA	B-FARMACO
was	O
administered	O
.	O
Urgent	O
TTE	O
was	O
performed	O
,	O
which	O
revealed	O
a	O
non	O
dilated	O
LV	O
with	O
severe	O
MI	O
.	O
On	O
19	O
09	O
2012	O
,	O
in	O
the	O
morning	O
,	O
he	O
presented	O
with	O
a	O
deterioration	O
in	O
the	O
level	O
of	O
consciousness	O
,	O
with	O
clear	O
pupillary	O
asymmetry	O
and	O
decortication	O
posture	O
.	O
OTI	O
and	O
connection	O
to	O
mechanical	O
ventilation	O
and	O
a	O
new	O
cranial	O
CT	O
scan	O
were	O
required	O
.	O
Despite	O
treatment	O
,	O
neurological	O
deterioration	O
progressed	O
,	O
and	O
she	O
remained	O
intubated	O
with	O
only	O
some	O
trunk	O
reflexes	O
.	O
There	O
was	O
no	O
fever	O
peak	O
at	O
any	O
time	O
.	O
In	O
the	O
anamnesis	O
of	O
the	O
relatives	O
,	O
there	O
was	O
no	O
evidence	O
of	O
endocarditis	O
.	O
TEE	O
19	O
09	O
2012	O
Lowly	O
mobile	O
vegetation	O
and	O
homogeneous	O
density	O
of	O
15x14	O
mm	O
,	O
with	O
associated	O
perforated	O
aneurysm	O
on	O
the	O
anterior	O
mitral	O
leaflet	O
.	O
Severe	O
mitral	O
insufficiency	O
with	O
2	O
jets	O
,	O
one	O
originating	O
through	O
the	O
perforation	O
of	O
the	O
aneurysm	O
and	O
directed	O
towards	O
the	O
posterior	O
wall	O
of	O
the	O
left	O
atrium	O
with	O
coanda	O
effect	O
,	O
with	O
another	O
smaller	O
one	O
at	O
the	O
central	O
level	O
.	O
Severe	O
tricuspid	O
regurgitation	O
due	O
to	O
prolapse	O
.	O
Mild	O
degenerative	O
aortic	O
regurgitation	O
.	O
Cultures	O
Blood	O
cultures	O
Collected	O
on	O
admission	O
.	O
Positive	O
for	O
Streptococcus	O
mitis	O
Sensitive	O
to	O
Penicillin	O
,	O
Amoxicillin	B-FARMACO
,	O
Ceftriaxone	B-FARMACO
,	O
Cotrimoxazole	B-FARMACO
Resistant	O
to	O
Clindamycin	B-FARMACO
and	O
Erythromycin	B-FARMACO
.	O
The	O
clinical	O
course	O
progressed	O
to	O
brain	O
death	O
on	O
21	O
09	O
2012	O
,	O
96	O
hours	O
after	O
admission	O
to	O
the	O
ICU	O
.	O
A	O
cervico	O
thoracic	O
abdomino	O
pelvic	O
CT	O
scan	O
was	O
requested	O
,	O
in	O
case	O
he	O
could	O
be	O
considered	O
a	O
donor	O
.	O
Body	O
CT	O
scan	O
lesions	O
in	O
the	O
spleen	O
and	O
right	O
kidney	O
compatible	O
with	O
small	O
embolic	O
infarcts	O
.	O
DIAGNOSTIC	O
IMPRESSION	O
INFECTIVE	O
ENDOCARDITIS	O
ON	O
NATIVE	O
MITRAL	O
VALVE	O
DUE	O
TO	O
STREPTOCOCCUS	O
MITIS	O
.	O
SEVERE	O
MITRAL	O
INSUFFICIENCY	O
DUE	O
TO	O
PERFORATION	O
AT	O
THE	O
LEVEL	O
OF	O
THE	O
ANTERIOR	O
MITRAL	O
LEAFLET	O
VEGETATION	O
.	O
SEPTIC	O
SHOCK	O
.	O
SEPTIC	O
EMBOLISM	O
AT	O
CEREBRAL	O
LEVEL	O
WITH	O
HAEMORRHAGIC	O
TRANSFORMATION	O
AND	O
ENCEPHALIC	O
DEATH	O
.	O

A	O
30	O
year	O
old	O
man	O
with	O
a	O
smoking	O
rate	O
of	O
10	O
packs	O
year	O
;	O
he	O
began	O
his	O
illness	O
3	O
months	O
previously	O
with	O
the	O
presence	O
of	O
asthenia	O
,	O
adynamia	O
,	O
general	O
malaise	O
,	O
diaphoresis	O
,	O
predominantly	O
at	O
night	O
,	O
and	O
weight	O
loss	O
of	O
12	O
kg	O
;	O
subsequently	O
,	O
indurated	O
,	O
erythematous	O
,	O
slightly	O
painful	O
lesions	O
appeared	O
on	O
the	O
middle	O
finger	O
and	O
first	O
left	O
eye	O
,	O
and	O
fever	O
.	O
Physical	O
examination	O
revealed	O
fever	O
,	O
caries	O
in	O
the	O
upper	O
second	O
molar	O
and	O
presence	O
of	O
lower	O
dental	O
plaque	O
,	O
systolic	O
I	O
IV	O
murmur	O
radiating	O
to	O
the	O
neck	O
vessels	O
and	O
diastolic	O
II	O
IV	O
in	O
the	O
aortic	O
focus	O
,	O
bounding	O
pulse	O
,	O
Lyan	O
's	O
sign	O
and	O
femoral	O
shot	O
,	O
increased	O
volume	O
and	O
redness	O
on	O
the	O
second	O
phalange	O
of	O
the	O
right	O
hand	O
finger	O
;	O
labs	O
showed	O
haemoglobin	O
13	O
g	O
dL	O
,	O
leukocytes	O
9	O
,	O
200	O
mm3	O
,	O
neutrophils	O
83	O
,	O
lymphocytes	O
13	O
,	O
platelets	O
320	O
,	O
000	O
mm3	O
,	O
glucose	O
121	O
mg	O
dL	O
,	O
ESR	O
46	O
mm	O
h	O
and	O
Creactive	O
protein	O
5	O
.	O
1	O
mg	O
dL	O
.	O
The	O
chest	O
X	O
ray	O
showed	O
grade	O
I	O
cardiomegaly	O
and	O
the	O
echocardiogram	O
showed	O
a	O
calcified	O
aorta	O
with	O
a	O
slightly	O
reduced	O
valve	O
opening	O
2	O
.	O
3	O
cm2	O
,	O
with	O
masses	O
on	O
the	O
leaflets	O
of	O
very	O
mobile	O
low	O
reflectance	O
,	O
suggesting	O
vegetations	O
that	O
condition	O
moderate	O
to	O
severe	O
insufficiency	O
.	O
Blood	O
culture	O
isolated	O
streptococcus	O
viridans	O
on	O
3	O
occasions	O
.	O

Personal	O
history	O
81	O
year	O
old	O
male	O
patient	O
.	O
Moderate	O
chronic	O
obstructive	O
pulmonary	O
disease	O
COPD	O
,	O
ex	O
smoker	O
since	O
1998	O
,	O
hypertension	O
,	O
dyslipidaemia	O
and	O
insulin	O
dependent	O
type	O
II	O
diabetes	O
mellitus	O
DM	O
.	O
In	O
2010	O
,	O
severe	O
aortic	O
stenosis	O
treated	O
by	O
bioprosthesis	O
,	O
whose	O
postoperative	O
period	O
was	O
complicated	O
by	O
respiratory	O
infection	O
,	O
surgical	O
wound	O
infection	O
and	O
sternal	O
dehiscence	O
,	O
reintervened	O
15	O
days	O
after	O
surgery	O
.	O
Moderate	O
heart	O
failure	O
,	O
Barthel	O
index	O
50	O
moderate	O
.	O
In	O
2012	O
,	O
the	O
patient	O
had	O
numerous	O
episodes	O
of	O
enterococcal	O
bacteraemia	O
and	O
was	O
admitted	O
to	O
hospital	O
on	O
four	O
occasions	O
.	O
Given	O
the	O
recurrence	O
of	O
the	O
infection	O
,	O
an	O
exhaustive	O
study	O
was	O
carried	O
out	O
in	O
search	O
of	O
possible	O
foci	O
of	O
infection	O
,	O
with	O
particular	O
interest	O
in	O
the	O
prosthetic	O
valve	O
,	O
with	O
only	O
a	O
gallium	O
67	O
scan	O
performed	O
in	O
February	O
2013	O
showing	O
hypercaptation	O
in	O
the	O
right	O
sternoclavicular	O
joint	O
,	O
leading	O
to	O
a	O
diagnosis	O
of	O
enterococcal	O
sternal	O
osteomyelitis	O
and	O
antibiotic	O
treatment	O
was	O
completed	O
with	O
ampicillin	B-FARMACO
for	O
4	O
weeks	O
.	O
Three	O
days	O
after	O
returning	O
home	O
,	O
the	O
patient	O
developed	O
fever	O
,	O
general	O
malaise	O
,	O
dyspnoea	O
,	O
increased	O
cough	O
and	O
secretions	O
and	O
returned	O
to	O
the	O
hospital	O
.	O
CLINICAL	O
OBSERVATION	O
At	O
the	O
last	O
admission	O
before	O
the	O
current	O
illness	O
,	O
he	O
was	O
diagnosed	O
with	O
sternal	O
osteomyelitis	O
due	O
to	O
enterococci	O
.	O
Initially	O
,	O
third	O
generation	O
cephalosporin	O
was	O
administered	O
,	O
which	O
was	O
changed	O
to	O
ampicillin	B-FARMACO
and	O
finally	O
to	O
amoxicillin	B-FARMACO
clavulanic	I-FARMACO
acid	I-FARMACO
.	O
During	O
this	O
admission	O
,	O
up	O
to	O
4	O
red	O
blood	O
cell	O
concentrates	O
were	O
administered	O
due	O
to	O
significant	O
anaemisation	O
and	O
also	O
due	O
to	O
extravasation	O
coinciding	O
with	O
the	O
administration	O
of	O
a	O
blood	O
transfusion	O
.	O
Physical	O
examination	O
conscious	O
and	O
oriented	O
,	O
nourished	O
and	O
hydrated	O
,	O
chest	O
pain	O
,	O
general	O
malaise	O
,	O
pallor	O
,	O
sweating	O
,	O
dyspnoea	O
,	O
jugular	O
ingurgitation	O
and	O
malleolar	O
oedema	O
.	O
Vital	O
signs	O
blood	O
pressure	O
120	O
60	O
mmHg	O
,	O
heart	O
rate	O
70	O
bpm	O
,	O
temperature	O
39	O
C	O
.	O
CBC	O
20	O
,	O
700	O
mil	O
mm3	O
leukocytes	O
,	O
8	O
.	O
5	O
g	O
dl	O
haemoglobin	O
,	O
199	O
,	O
000	O
mm3	O
platelets	O
.	O
Glucose	O
207	O
mg	O
dl	O
,	O
urea	O
109	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
6	O
mg	O
dl	O
,	O
sodium	O
135	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
7	O
mEq	O
l	O
,	O
CRP	O
56	O
mg	O
L	O
.	O
Electrocardiogram	O
atrial	O
fibrillation	O
at	O
70	O
bpm	O
.	O
Chest	O
X	O
ray	O
cardiomegaly	O
.	O
Auscultation	O
arrhythmic	O
heart	O
with	O
aortic	O
systolic	O
murmur	O
.	O
Bilateral	O
pulmonary	O
rhonchi	O
.	O
Blood	O
gases	O
pO2	O
167	O
,	O
pCO2	O
133	O
,	O
pH	O
7	O
.	O
40	O
,	O
HCO3	O
20	O
.	O
Blood	O
cultures	O
Enterococcus	O
faecalis	O
was	O
isolated	O
.	O
Transthoracic	O
and	O
transesophageal	O
echocardiogram	O
In	O
the	O
posterior	O
annulus	O
of	O
the	O
mitral	O
valve	O
a	O
mass	O
image	O
of	O
16	O
x	O
12	O
mm	O
is	O
observed	O
.	O
With	O
echogenic	O
borders	O
that	O
was	O
not	O
seen	O
in	O
the	O
previous	O
transesophageal	O
echocardiogram	O
in	O
December	O
2012	O
.	O
Provisional	O
diagnosis	O
subacute	O
enterococcal	O
mitral	O
endocarditis	O
complicated	O
by	O
anaemia	O
due	O
to	O
chronic	O
disease	O
,	O
acute	O
renal	O
failure	O
due	O
to	O
aminoglycosides	O
,	O
exacerbation	O
of	O
COPD	O
due	O
to	O
nosocomial	O
respiratory	O
infection	O
with	O
Stenotrophomona	O
maltophilia	O
and	O
organic	O
brain	O
syndrome	O
.	O
Initial	O
treatment	O
low	B-FARMACO
molecular	I-FARMACO
weight	I-FARMACO
heparin	I-FARMACO
LMWH	I-FARMACO
,	O
furosemide	B-FARMACO
,	O
ampicillin	B-FARMACO
,	O
inhalers	O
,	O
oxygen	O
therapy	O
,	O
rest	O
,	O
vital	O
signs	O
monitoring	O
and	O
oxygen	O
saturation	O
.	O
Evolution	O
After	O
being	O
diagnosed	O
with	O
mitral	O
endocarditis	O
,	O
the	O
patient	O
was	O
treated	O
for	O
6	O
weeks	O
with	O
ampicillin	B-FARMACO
and	O
2	O
weeks	O
with	O
gentamicin	B-FARMACO
;	O
in	O
the	O
fourth	O
week	O
of	O
admission	O
,	O
the	O
patient	O
suffered	O
an	O
exacerbation	O
of	O
his	O
COPD	O
due	O
to	O
a	O
respiratory	O
infection	O
by	O
Strenotrophomonas	O
maltophilia	O
,	O
receiving	O
treatment	O
with	O
cotrimoxazole	B-FARMACO
for	O
2	O
weeks	O
,	O
achieving	O
clinical	O
and	O
microbiological	O
resolution	O
of	O
the	O
episode	O
.	O
Due	O
to	O
the	O
administration	O
of	O
this	O
whole	O
battery	O
of	O
antibiotics	O
,	O
he	O
suffered	O
acute	O
renal	O
failure	O
due	O
to	O
aminoglycosides	O
,	O
but	O
after	O
discontinuation	O
of	O
treatment	O
in	O
the	O
sixth	O
week	O
of	O
treatment	O
,	O
this	O
resolved	O
.	O
During	O
admission	O
,	O
there	O
was	O
a	O
progressive	O
worsening	O
of	O
the	O
patient	O
's	O
chronic	O
anaemia	O
associated	O
with	O
the	O
subacute	O
infectious	O
disease	O
and	O
the	O
prolonged	O
administration	O
of	O
antibiotics	O
,	O
which	O
led	O
to	O
the	O
administration	O
of	O
three	O
red	O
blood	O
cell	O
concentrates	O
.	O
Between	O
the	O
third	O
and	O
fourth	O
week	O
,	O
the	O
patient	O
's	O
general	O
condition	O
worsened	O
significantly	O
,	O
and	O
the	O
nursing	O
team	O
focused	O
on	O
addressing	O
collaboration	O
problems	O
and	O
diagnosing	O
activity	O
intolerance	O
related	O
to	O
an	O
imbalance	O
between	O
oxygen	O
intake	O
and	O
demand	O
,	O
and	O
on	O
self	O
care	O
diagnoses	O
.	O
The	O
patient	O
's	O
haematocrit	O
and	O
haemoglobin	O
figures	O
improved	O
markedly	O
after	O
resolution	O
of	O
the	O
infectious	O
process	O
and	O
administration	O
of	O
plasma	O
derivatives	O
.	O
From	O
the	O
fifth	O
week	O
of	O
treatment	O
,	O
the	O
patient	O
gradually	O
recovers	O
,	O
and	O
it	O
is	O
possible	O
to	O
work	O
with	O
him	O
on	O
the	O
diagnoses	O
of	O
anxiety	O
and	O
deficient	O
knowledge	O
as	O
well	O
as	O
to	O
progressively	O
increase	O
the	O
number	O
of	O
activities	O
aimed	O
at	O
self	O
care	O
.	O
During	O
his	O
prolonged	O
illness	O
and	O
numerous	O
hospitalisations	O
,	O
in	O
the	O
last	O
months	O
of	O
his	O
hospital	O
stay	O
,	O
the	O
patient	O
suffers	O
a	O
serious	O
functional	O
deterioration	O
,	O
being	O
unable	O
to	O
ambulate	O
and	O
carry	O
out	O
basic	O
activities	O
of	O
daily	O
living	O
;	O
current	O
Barthel	O
index	O
15	O
Total	O
.	O
Medical	O
discharge	O
Following	O
resolution	O
of	O
the	O
infectious	O
process	O
,	O
he	O
was	O
discharged	O
from	O
hospital	O
on	O
28	O
May	O
2013	O
and	O
transferred	O
to	O
a	O
medium	O
stay	O
hospital	O
for	O
the	O
purpose	O
of	O
rehabilitation	O
.	O
A	O
half	O
stay	O
hospital	O
is	O
a	O
level	O
of	O
care	O
used	O
to	O
complete	O
the	O
rehabilitation	O
of	O
patients	O
with	O
real	O
possibilities	O
of	O
recovery	O
,	O
who	O
require	O
longer	O
stays	O
than	O
those	O
traditionally	O
accepted	O
in	O
the	O
hospital	O
environment	O
.	O
The	O
average	O
stay	O
in	O
this	O
centre	O
is	O
between	O
25	O
and	O
30	O
days	O
,	O
and	O
the	O
maximum	O
stay	O
should	O
not	O
exceed	O
3	O
months	O
.	O
The	O
medical	O
treatment	O
received	O
at	O
discharge	O
consisted	O
of	O
rehabilitation	O
,	O
heparin	B-FARMACO
,	O
diuretics	O
,	O
inhalers	O
salbutamol	B-FARMACO
and	O
Seretide	B-FARMACO
50	O
100	O
mcg	O
,	O
iron	B-FARMACO
and	O
vitamin	B-FARMACO
B9	I-FARMACO
.	O
For	O
several	O
weeks	O
prior	O
to	O
discharge	O
,	O
the	O
patient	O
did	O
not	O
require	O
hypoglycaemic	O
or	O
antihypertensive	O
treatment	O
.	O

Male	O
,	O
2	O
years	O
and	O
6	O
months	O
old	O
.	O
Previously	O
healthy	O
.	O
Well	O
fed	O
.	O
Good	O
growth	O
.	O
Good	O
neuropsychic	O
development	O
.	O
Schooled	O
.	O
Received	O
the	O
corresponding	O
vaccinations	O
according	O
to	O
the	O
country	O
's	O
Scheme	O
Certificate	O
.	O
He	O
has	O
presented	O
repeated	O
skin	O
infections	O
diagnosed	O
as	O
impetigo	O
secondary	O
to	O
insect	O
bites	O
and	O
scratching	O
,	O
these	O
infections	O
were	O
treated	O
with	O
antibiotic	O
therapy	O
.	O
His	O
current	O
illness	O
began	O
3	O
days	O
prior	O
to	O
admission	O
with	O
fever	O
up	O
to	O
39	O
.	O
7oC	O
,	O
partial	O
refusal	O
of	O
food	O
,	O
weakness	O
and	O
tendency	O
to	O
sleep	O
.	O
Partial	O
seizure	O
with	O
secondary	O
generalisation	O
.	O
Consultation	O
and	O
admission	O
with	O
diagnosis	O
of	O
probable	O
central	O
nervous	O
system	O
CNS	O
infection	O
.	O
On	O
examination	O
soporous	O
,	O
febrile	O
,	O
haemoglobin	O
O2	O
saturation	O
SatO2	O
measured	O
with	O
pulse	O
oximeter	O
of	O
98	O
with	O
free	O
flow	O
mask	O
.	O
No	O
polypnoea	O
,	O
no	O
respiratory	O
function	O
.	O
Good	O
bilateral	O
air	O
entry	O
,	O
no	O
rales	O
.	O
Heart	O
rate	O
130cpm	O
,	O
well	O
beat	O
sounds	O
without	O
murmurs	O
.	O
Pulses	O
present	O
.	O
Normotensive	O
.	O
Well	O
perfused	O
.	O
Numerous	O
impetiginised	O
lesions	O
on	O
lower	O
limbs	O
predominantly	O
on	O
legs	O
,	O
some	O
in	O
crusted	O
stage	O
,	O
others	O
melisseria	O
and	O
scars	O
of	O
previous	O
ones	O
.	O
Psychoneuromucular	O
,	O
no	O
meningeal	O
signs	O
,	O
tone	O
and	O
strength	O
preserved	O
,	O
no	O
motor	O
deficits	O
.	O
Osteotendinous	O
reflexes	O
present	O
and	O
symmetrical	O
in	O
all	O
four	O
limbs	O
.	O
Initial	O
laboratory	O
tests	O
haemoglobin	O
Hb	O
12	O
.	O
7	O
g	O
dL	O
,	O
leukocytosis	O
WBC	O
14	O
,	O
100	O
elements	O
mm3	O
,	O
78	O
polymorphonuclear	O
PMN	O
,	O
platelets	O
257	O
,	O
000	O
elements	O
mm3	O
.	O
C	O
reactive	O
protein	O
CRP	O
51	O
.	O
3	O
mg	O
l	O
.	O
Cerebrospinal	O
fluid	O
CSF	O
WBC	O
50	O
mm3	O
mostly	O
PMN	O
,	O
normal	O
protein	O
and	O
glucuroraxia	O
.	O
A	O
bacteriological	O
study	O
of	O
CSF	O
was	O
performed	O
and	O
an	O
investigation	O
of	O
viral	O
agents	O
of	O
meningoencephalitis	O
by	O
polymerase	O
chain	O
reaction	O
PCR	O
was	O
requested	O
,	O
and	O
an	O
electroencephalogram	O
EEG	O
was	O
performed	O
within	O
48	O
hours	O
of	O
the	O
onset	O
of	O
the	O
disease	O
,	O
which	O
was	O
reported	O
as	O
normal	O
.	O
Hospitalised	O
in	O
the	O
paediatric	O
ward	O
,	O
treatment	O
was	O
started	O
with	O
ceftriaxone	B-FARMACO
and	O
acyclovir	B-FARMACO
at	O
the	O
usual	O
doses	O
.	O
He	O
continued	O
to	O
be	O
sleepy	O
,	O
irritable	O
,	O
tachycardia	O
and	O
dereprosy	O
.	O
New	O
lesions	O
on	O
palms	O
and	O
soles	O
were	O
added	O
and	O
due	O
to	O
neurological	O
compromise	O
he	O
was	O
admitted	O
to	O
intermediate	O
care	O
CIP	O
.	O
Examination	O
on	O
admission	O
Glasgow	O
Scale	O
GSC	O
15	O
,	O
irritable	O
,	O
SatO297	O
on	O
air	O
.	O
Apiric	O
,	O
pustular	O
indurated	O
lesion	O
on	O
the	O
anterior	O
aspect	O
of	O
the	O
right	O
hemithorax	O
,	O
rest	O
of	O
the	O
lesions	O
already	O
mentioned	O
.	O
Sinus	O
tachycardia	O
167	O
bpm	O
,	O
no	O
murmurs	O
,	O
normotensive	O
,	O
full	O
pulses	O
,	O
recovery	O
time	O
RT	O
less	O
than	O
2	O
seconds	O
.	O
Good	O
air	O
entry	O
,	O
no	O
rales	O
.	O
No	O
neck	O
or	O
trunk	O
rigidity	O
.	O
No	O
motor	O
deficit	O
.	O
The	O
treatment	O
started	O
was	O
maintained	O
with	O
the	O
addition	O
of	O
vancomycin	B-FARMACO
.	O
Repeat	O
blood	O
tests	O
showed	O
an	O
increase	O
in	O
CRP264	O
mg	O
dl	O
,	O
leukocytosis	O
4	O
,	O
600	O
elements	O
mm3	O
,	O
platelets	O
103	O
,	O
000	O
elements	O
mm3	O
,	O
mobilisation	O
of	O
liver	O
enzymes	O
TGO	O
87	O
U	O
L	O
,	O
TGP	O
88	O
U	O
L	O
.	O
Normal	O
glomerular	O
renal	O
function	O
.	O
Skin	O
lesion	O
and	O
blood	O
cultures	O
showed	O
sensitive	O
Staphylococcus	O
aureusmeticillinus	O
SAMS	O
,	O
CSF	O
culture	O
and	O
PCR	O
for	O
Herpes	O
virus	O
were	O
negative	O
.	O
A	O
few	O
hours	O
after	O
admission	O
,	O
an	O
intense	O
systolic	O
murmur	O
was	O
noted	O
in	O
the	O
mesocardium	O
.	O
In	O
view	O
of	O
the	O
diagnosis	O
of	O
probable	O
infective	O
endocarditis	O
with	O
encephalic	O
embolisation	O
,	O
a	O
Doppler	O
echocardiogram	O
was	O
performed	O
,	O
which	O
showed	O
"	O
thickening	O
of	O
both	O
leaflets	O
in	O
the	O
mitral	O
valve	O
with	O
a	O
small	O
image	O
adhering	O
to	O
the	O
septal	O
leaflet	O
compatible	O
with	O
vegetation	O
.	O
Mild	O
to	O
moderate	O
mitral	O
insufficiency	O
.	O
Good	O
systolic	O
function	O
"	O
.	O
Encephalic	O
magnetic	O
resonance	O
imaging	O
MRI	O
shows	O
"	O
lesions	O
compatible	O
with	O
septic	O
embolism	O
with	O
moderate	O
perilesional	O
oedema	O
"	O
.	O
Other	O
emboligenic	O
foci	O
were	O
ruled	O
out	O
.	O
Treatment	O
was	O
maintained	O
with	O
vancomycin	B-FARMACO
and	O
gentamicin	B-FARMACO
in	O
therapeutic	O
range	O
.	O
The	O
paediatric	O
cardiac	O
surgery	O
team	O
was	O
consulted	O
and	O
initially	O
maintained	O
a	O
wait	O
and	O
see	O
attitude	O
regarding	O
the	O
surgical	O
approach	O
,	O
with	O
serial	O
controls	O
with	O
echocardiography	O
.	O
The	O
patient	O
was	O
placed	O
on	O
apyrexia	O
on	O
the	O
17th	O
day	O
of	O
treatment	O
.	O
Echocardiograms	O
showed	O
worsening	O
mitral	O
regurgitation	O
and	O
persistent	O
vegetations	O
.	O
He	O
repeated	O
encephalic	O
embolisation	O
with	O
left	O
hemiplegia	O
and	O
a	O
new	O
MRI	O
was	O
performed	O
which	O
confirmed	O
ischaemic	O
infarction	O
in	O
the	O
putamen	O
area	O
.	O
After	O
a	O
joint	O
assessment	O
with	O
the	O
neuropaediatrician	O
and	O
heart	O
surgeons	O
,	O
cardiac	O
surgery	O
was	O
performed	O
to	O
clean	O
the	O
valve	O
,	O
attempting	O
to	O
repair	O
it	O
with	O
pericardium	O
,	O
which	O
failed	O
,	O
leaving	O
the	O
patient	O
with	O
a	O
mechanical	O
valve	O
and	O
hypocoagulation	O
.	O
Atrioventricular	O
block	O
requiring	O
corticoids	O
and	O
external	O
pacemaker	O
for	O
15	O
days	O
,	O
later	O
returning	O
to	O
sinus	O
rhythm	O
.	O
Good	O
evolution	O
,	O
with	O
improvement	O
of	O
haemiparesis	O
with	O
physiotherapy	O
.	O

55	O
year	O
old	O
man	O
with	O
mitral	O
and	O
aortic	O
biological	O
valve	O
prostheses	O
Bioimplant	O
since	O
1989	O
.	O
He	O
was	O
admitted	O
in	O
May	O
1996	O
for	O
back	O
pain	O
,	O
fever	O
and	O
general	O
malaise	O
of	O
4	O
weeks	O
'	O
duration	O
,	O
with	O
clinical	O
suspicion	O
of	O
infective	O
endocarditis	O
.	O
Physical	O
examination	O
revealed	O
fever	O
of	O
38	O
C	O
,	O
apical	O
impulse	O
displaced	O
laterally	O
and	O
inferiorly	O
towards	O
the	O
anterior	O
axillary	O
line	O
,	O
rhythmic	O
heart	O
sounds	O
of	O
normal	O
intensity	O
with	O
aortic	O
systolic	O
ejection	O
murmur	O
grade	O
II	O
VI	O
and	O
mild	O
splenomegaly	O
.	O
The	O
admission	O
blood	O
test	O
showed	O
a	O
white	O
blood	O
cell	O
count	O
of	O
11	O
,	O
300	O
l	O
91	O
neutrophils	O
and	O
the	O
erythrocyte	O
sedimentation	O
rate	O
ESR	O
was	O
12	O
mm	O
at	O
one	O
hour	O
.	O
The	O
rest	O
of	O
the	O
analytical	O
parameters	O
were	O
within	O
normal	O
limits	O
.	O
The	O
electrocardiogram	O
showed	O
sinus	O
rhythm	O
at	O
70	O
beats	O
min	O
,	O
PR	O
spacing	O
0	O
.	O
16	O
.	O
QRS	O
axis	O
at	O
60	O
and	O
non	O
specific	O
ventricular	O
repolarisation	O
disturbance	O
from	O
V4	O
to	O
V6	O
.	O
Chest	O
X	O
ray	O
showed	O
radiological	O
grade	O
I	O
cardiomegaly	O
with	O
cardiothoracic	O
index	O
of	O
0	O
.	O
55	O
.	O
Transthoracic	O
echocardiography	O
revealed	O
mitral	O
prosthetic	O
valve	O
dysfunction	O
with	O
prolapse	O
of	O
one	O
of	O
its	O
leaflets	O
and	O
mild	O
moderate	O
regurgitation	O
;	O
aortic	O
prosthetic	O
valve	O
dysfunction	O
with	O
mild	O
prolapse	O
and	O
regurgitation	O
;	O
there	O
was	O
no	O
definite	O
evidence	O
of	O
endocardial	O
vegetation	O
.	O
Six	O
serial	O
blood	O
cultures	O
were	O
performed	O
,	O
and	O
Staphylococcus	O
capitis	O
growth	O
was	O
detected	O
in	O
all	O
of	O
them	O
.	O
Specific	O
antibiotic	O
therapy	O
was	O
started	O
,	O
according	O
to	O
the	O
antibiogram	O
and	O
in	O
accordance	O
with	O
the	O
therapeutic	O
regimen	O
recommended	O
in	O
the	O
literature	O
with	O
vancomycin	B-FARMACO
30	O
mg	O
kg	O
body	O
weight	O
i	O
.	O
v	O
.	O
every	O
24	O
h	O
in	O
four	O
daily	O
doses	O
,	O
rifampicin	B-FARMACO
300	O
mg	O
v	O
.	O
o	O
.	O
every	O
8	O
h	O
both	O
for	O
six	O
weeks	O
and	O
gentamicin	B-FARMACO
1	O
mg	O
kg	O
body	O
weight	O
i	O
.	O
v	O
.	O
every	O
8	O
h	O
for	O
two	O
weeks	O
7	O
,	O
with	O
fever	O
remitting	O
on	O
the	O
third	O
day	O
of	O
treatment	O
.	O
Six	O
days	O
after	O
admission	O
,	O
the	O
patient	O
suffered	O
a	O
fleeting	O
episode	O
of	O
dizziness	O
,	O
dysarthria	O
,	O
paraesthesia	O
in	O
the	O
left	O
hand	O
,	O
headache	O
and	O
generalised	O
tremor	O
.	O
Cranial	O
CT	O
scan	O
showed	O
an	O
image	O
of	O
cerebral	O
infarction	O
in	O
the	O
right	O
temporoparietal	O
region	O
.	O
Transesophageal	O
echocardiography	O
showed	O
aortic	O
and	O
mitral	O
valve	O
vegetations	O
,	O
severe	O
mitral	O
regurgitation	O
and	O
moderate	O
aortic	O
regurgitation	O
.	O
Fifteen	O
days	O
after	O
admission	O
,	O
the	O
patient	O
presented	O
pain	O
in	O
the	O
left	O
hypochondrium	O
and	O
increased	O
splenomegaly	O
.	O
An	O
abdominal	O
ultrasound	O
and	O
gallium	O
67	O
scintigraphy	O
revealed	O
the	O
existence	O
of	O
a	O
splenic	O
infarction	O
.	O
Twenty	O
one	O
days	O
after	O
admission	O
,	O
fever	O
recurred	O
,	O
and	O
a	O
new	O
blood	O
test	O
showed	O
an	O
elevated	O
ESR	O
up	O
to	O
84	O
mm	O
in	O
the	O
first	O
hour	O
and	O
anaemia	O
not	O
present	O
on	O
admission	O
with	O
a	O
haemoglobin	O
of	O
9	O
.	O
8	O
mg	O
dl	O
and	O
a	O
haematocrit	O
of	O
28	O
.	O
7	O
.	O
Given	O
the	O
patient	O
's	O
clinical	O
evolution	O
,	O
surgery	O
was	O
decided	O
,	O
and	O
the	O
biological	O
valve	O
prostheses	O
were	O
replaced	O
twice	O
with	O
new	O
mechanical	O
valve	O
prostheses	O
on	O
day	O
30	O
of	O
admission	O
.	O
The	O
same	O
antibiotherapy	O
treatment	O
regimen	O
was	O
continued	O
for	O
a	O
further	O
two	O
weeks	O
.	O
Subsequent	O
blood	O
cultures	O
showed	O
no	O
growth	O
of	O
microorganisms	O
.	O
The	O
patient	O
's	O
clinical	O
evolution	O
was	O
favourable	O
and	O
he	O
was	O
discharged	O
from	O
hospital	O
57	O
days	O
after	O
admission	O
.	O
It	O
was	O
not	O
possible	O
to	O
identify	O
the	O
entry	O
point	O
of	O
the	O
germ	O
.	O

A	O
58	O
year	O
old	O
man	O
was	O
admitted	O
to	O
the	O
Cayetano	O
Heredia	O
Hospital	O
with	O
a	O
2	O
month	O
history	O
of	O
vomiting	O
,	O
fever	O
of	O
38	O
C	O
and	O
severe	O
disabling	O
back	O
pain	O
.	O
Clinical	O
examination	O
revealed	O
a	O
multifocal	O
holosystolic	O
murmur	O
,	O
predominantly	O
in	O
the	O
mitral	O
focus	O
of	O
intensity	O
III	O
VI	O
,	O
radiating	O
to	O
the	O
axilla	O
and	O
neck	O
.	O
Positive	O
Lasegue	O
and	O
Psoas	O
sign	O
,	O
as	O
well	O
as	O
positive	O
Dandy	O
sign	O
at	O
L3	O
,	O
L4	O
and	O
L5	O
.	O
Laboratory	O
data	O
obtained	O
on	O
admission	O
were	O
haemoglobin	O
12	O
.	O
2	O
g	O
dl	O
,	O
haematocrit	O
38	O
,	O
white	O
blood	O
cell	O
count	O
14	O
.	O
01	O
l	O
neutrophils	O
64	O
.	O
5	O
,	O
erythrocyte	O
sedimentation	O
rate	O
ESR	O
116	O
mm	O
h	O
and	O
C	O
reactive	O
protein	O
CRP	O
1	O
16	O
mg	O
l	O
.	O
Chest	O
X	O
ray	O
showed	O
no	O
signs	O
of	O
condensation	O
.	O
Similarly	O
,	O
the	O
electrocardiographic	O
tracing	O
at	O
rest	O
showed	O
no	O
relevant	O
alterations	O
.	O
Transesophageal	O
echocardiography	O
revealed	O
mitral	O
and	O
aortic	O
valve	O
involvement	O
characterised	O
by	O
vegetations	O
on	O
the	O
anterior	O
leaflet	O
of	O
the	O
mitral	O
valve	O
atrial	O
and	O
ventricular	O
surface	O
of	O
segment	O
A2	O
and	O
a	O
1	O
.	O
6	O
x	O
1	O
.	O
3	O
cm	O
perforated	O
aneurysm	O
0	O
.	O
7	O
cm	O
with	O
severe	O
regurgitation	O
.	O
Also	O
,	O
in	O
the	O
aortic	O
valve	O
,	O
multiple	O
vegetations	O
were	O
found	O
in	O
the	O
three	O
leaflets	O
;	O
the	O
largest	O
measuring	O
0	O
.	O
9	O
cm	O
,	O
with	O
severe	O
regurgitation	O
and	O
flow	O
compatible	O
with	O
perforation	O
of	O
the	O
posterior	O
semilunar	O
leaflet	O
.	O
Streptococcus	O
gordonnii	O
was	O
isolated	O
in	O
blood	O
cultures	O
.	O
Additionally	O
the	O
lumbosacral	O
MRI	O
showed	O
vertebral	O
osteomyelitis	O
of	O
L4	O
L5	O
.	O
During	O
the	O
surgical	O
procedure	O
,	O
the	O
aforementioned	O
findings	O
were	O
confirmed	O
and	O
the	O
aortic	O
and	O
mitral	O
bivalvular	O
replacement	O
was	O
performed	O
with	O
the	O
implantation	O
of	O
mechanical	O
prostheses	O
.	O

A	O
43	O
year	O
old	O
man	O
,	O
with	O
no	O
clinical	O
history	O
of	O
interest	O
,	O
who	O
2	O
months	O
prior	O
to	O
his	O
diagnosis	O
began	O
a	O
subacute	O
episode	O
of	O
a	O
peak	O
fever	O
of	O
39	O
C	O
,	O
predominantly	O
in	O
the	O
evening	O
,	O
and	O
pain	O
,	O
swelling	O
and	O
functional	O
impotence	O
in	O
the	O
right	O
hand	O
and	O
left	O
ankle	O
.	O
Physical	O
examination	O
revealed	O
pain	O
on	O
palpation	O
and	O
inflammatory	O
signs	O
at	O
the	O
level	O
of	O
the	O
carpus	O
,	O
second	O
,	O
third	O
,	O
fourth	O
and	O
fifth	O
right	O
metacarpophalangeal	O
joints	O
and	O
left	O
ankle	O
with	O
painful	O
limitation	O
of	O
mobility	O
in	O
the	O
first	O
degrees	O
in	O
all	O
arcs	O
of	O
movement	O
,	O
as	O
well	O
as	O
auscultation	O
of	O
a	O
diastolic	O
murmur	O
in	O
the	O
aortic	O
focus	O
.	O
The	O
rest	O
of	O
the	O
examination	O
was	O
normal	O
.	O
Laboratory	O
tests	O
showed	O
leukocytosis	O
16	O
,	O
000	O
with	O
neutrophilia	O
85	O
;	O
ESR	O
,	O
52	O
mm	O
h	O
,	O
and	O
CRP	O
,	O
4	O
.	O
6	O
mg	O
dl	O
.	O
Haemostasis	O
and	O
biochemistry	O
were	O
normal	O
.	O
In	O
the	O
immunological	O
study	O
,	O
rheumatoid	O
factor	O
,	O
antinuclear	O
antibodies	O
,	O
anti	O
DNA	O
antibodies	O
,	O
immunoglobulins	O
and	O
complement	O
were	O
negative	O
,	O
as	O
was	O
serology	O
for	O
viruses	O
and	O
bacteria	O
.	O
Blood	O
cultures	O
were	O
performed	O
after	O
the	O
first	O
febrile	O
peak	O
and	O
before	O
initiation	O
of	O
antibiotic	O
therapy	O
and	O
were	O
positive	O
for	O
Enterococcus	O
faecalis	O
.	O
Chest	O
X	O
ray	O
showed	O
a	O
discrete	O
bilateral	O
pleural	O
effusion	O
and	O
echocardiography	O
showed	O
severe	O
aortic	O
insufficiency	O
with	O
thickening	O
of	O
the	O
valvular	O
leaflets	O
.	O
With	O
the	O
diagnosis	O
of	O
bacterial	O
endocarditis	O
due	O
to	O
E	O
.	O
faecalis	O
,	O
intravenous	O
antibiotherapy	O
with	O
ampicillin	B-FARMACO
and	O
gentamicin	B-FARMACO
was	O
started	O
,	O
with	O
progressive	O
improvement	O
of	O
joint	O
symptoms	O
and	O
fever	O
and	O
imaging	O
findings	O
,	O
until	O
the	O
patient	O
became	O
asymptomatic	O
.	O

Female	O
patient	O
,	O
aged	O
60	O
years	O
,	O
resident	O
of	O
Mexico	O
City	O
.	O
She	O
was	O
admitted	O
to	O
the	O
Hospital	O
de	O
Cardiologa	O
del	O
Instituto	O
Mexicano	O
del	O
Seguro	O
Social	O
in	O
Mexico	O
City	O
in	O
February	O
2017	O
,	O
referred	O
from	O
another	O
hospital	O
with	O
a	O
diagnosis	O
of	O
probable	O
IE	O
.	O
The	O
patient	O
presented	O
with	O
fever	O
of	O
unknown	O
origin	O
,	O
intermittent	O
,	O
up	O
to	O
39	O
.	O
7	O
C	O
,	O
accompanied	O
by	O
diaphoresis	O
and	O
chills	O
for	O
24	O
months	O
of	O
evolution	O
,	O
as	O
well	O
as	O
vegetations	O
on	O
the	O
aortic	O
valve	O
demonstrated	O
by	O
echocardiography	O
.	O
According	O
to	O
Duke	O
's	O
criteria	O
,	O
it	O
was	O
concluded	O
that	O
he	O
had	O
IE	O
of	O
aetiology	O
to	O
be	O
determined	O
.	O
He	O
had	O
a	O
smoking	O
rate	O
of	O
1	O
.	O
5	O
packs	O
year	O
,	O
occasional	O
alcoholism	O
without	O
becoming	O
intoxicated	O
and	O
rheumatoid	O
arthritis	O
diagnosed	O
in	O
2012	O
,	O
treated	O
with	O
chloroquine	B-FARMACO
150	O
mg	O
24	O
hours	O
,	O
prednisone	B-FARMACO
2	O
.	O
5	O
mg	O
24	O
hours	O
and	O
cyclosporine	B-FARMACO
100	O
mg	O
24	O
hours	O
.	O
The	O
following	O
studies	O
were	O
performed	O
at	O
the	O
Cardiology	O
Hospital	O
transthoracic	O
echocardiography	O
TTEE	O
and	O
transesophageal	O
echocardiography	O
TTEE	O
,	O
corroborating	O
the	O
existence	O
of	O
two	O
vegetations	O
on	O
the	O
aortic	O
valve	O
smaller	O
than	O
10	O
mm	O
in	O
diameter	O
;	O
scintigraphy	O
and	O
scintigraphy	O
studies	O
demonstrated	O
the	O
presence	O
of	O
hepato	O
splenomegaly	O
.	O
Laboratory	O
tests	O
including	O
blood	O
biometry	O
,	O
blood	O
chemistry	O
,	O
coagulation	O
times	O
,	O
blood	O
grouping	O
,	O
immunology	O
and	O
blood	O
cultures	O
showed	O
the	O
following	O
results	O
normocytic	O
normochromic	O
anaemia	O
ranging	O
from	O
8	O
to	O
11	O
.	O
3	O
g	O
dL	O
,	O
persistent	O
thrombocytopenia	O
48	O
and	O
122	O
x	O
103	O
L	O
,	O
leukopenia	O
ranging	O
from	O
2	O
to	O
3	O
.	O
8	O
x	O
103	O
L	O
,	O
prothrombin	O
time	O
prolongation	O
ranging	O
from	O
7	O
to	O
28	O
.	O
7	O
seconds	O
,	O
partial	O
thromboplastin	O
time	O
prolongation	O
ranging	O
from	O
9	O
to	O
118	O
.	O
2	O
seconds	O
,	O
positive	O
anti	O
toxoplasma	O
IgG	O
and	O
anti	O
cytomegalovirus	O
IgG	O
.	O
The	O
rest	O
of	O
the	O
studies	O
were	O
within	O
normal	O
reference	O
ranges	O
.	O
Three	O
blood	O
cultures	O
processed	O
by	O
the	O
BacT	O
ALERT	O
3D	O
system	O
were	O
performed	O
and	O
showed	O
no	O
microbiological	O
growth	O
.	O
Although	O
the	O
blood	O
cultures	O
processed	O
by	O
the	O
automated	O
method	O
were	O
negative	O
,	O
and	O
given	O
the	O
clinical	O
and	O
imaging	O
suspicion	O
of	O
IE	O
,	O
according	O
to	O
the	O
treatment	O
criteria	O
for	O
intracardiac	O
vegetations	O
10	O
mm	O
,	O
the	O
patient	O
was	O
managed	O
with	O
ceftriaxone	B-FARMACO
,	O
vancomycin	B-FARMACO
and	O
amikacin	B-FARMACO
for	O
14	O
days	O
.	O
At	O
the	O
control	O
ECTT	O
performed	O
at	O
the	O
end	O
of	O
February	O
,	O
it	O
was	O
observed	O
that	O
the	O
vegetations	O
had	O
increased	O
in	O
diameter	O
one	O
measured	O
14	O
x	O
8	O
mm	O
and	O
the	O
other	O
4	O
x	O
5	O
mm	O
,	O
so	O
in	O
March	O
2017	O
she	O
underwent	O
vegectomy	O
and	O
biological	O
aortic	O
valve	O
implantation	O
.	O
The	O
patient	O
was	O
discharged	O
from	O
the	O
Cardiology	O
Hospital	O
in	O
April	O
2017	O
,	O
with	O
treatment	O
for	O
rheumatoid	O
arthritis	O
,	O
as	O
well	O
as	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
and	O
metoprolol	B-FARMACO
.	O
During	O
his	O
in	O
hospital	O
stay	O
,	O
as	O
part	O
of	O
a	O
research	O
protocol	O
,	O
a	O
manual	O
blood	O
culture	O
was	O
performed	O
using	O
the	O
lysis	O
centrifugation	O
method	O
,	O
which	O
,	O
according	O
to	O
previous	O
publications	O
,	O
increases	O
the	O
isolation	O
of	O
fungi	O
.	O
From	O
the	O
sediment	O
obtained	O
with	O
this	O
technique	O
,	O
a	O
white	O
,	O
filamentous	O
,	O
cottony	O
colony	O
developed	O
,	O
whose	O
direct	O
examination	O
with	O
cotton	O
blue	O
showed	O
septate	O
hyaline	O
filaments	O
,	O
with	O
vesicular	O
cells	O
in	O
chains	O
,	O
without	O
conidia	O
;	O
microscopic	O
examination	O
of	O
the	O
subculture	O
showed	O
the	O
same	O
structures	O
.	O
In	O
the	O
absence	O
of	O
morphological	O
structures	O
to	O
guide	O
identification	O
,	O
molecular	O
biology	O
procedures	O
were	O
used	O
.	O
DNA	O
was	O
extracted	O
using	O
a	O
commercial	O
kit	O
ExgeneTM	O
Plant	O
SV	O
,	O
Gene	O
All	O
,	O
Biotechnology	O
CO	O
,	O
Korea	O
,	O
following	O
the	O
manufacturer	O
's	O
instructions	O
.	O
By	O
PCR	O
,	O
the	O
ITS	O
D1D2	O
region	O
was	O
amplified	O
with	O
primers	O
ITS1	O
5	O
"	O
TCCGTAGGTGAACCTGCGG	O
3	O
"	O
and	O
ITS4	O
5	O
"	O
TCCTCCGCTTATTGATATATGC	O
3	O
"	O
.	O
PCR	O
was	O
performed	O
with	O
100	O
ng	O
of	O
DNA	O
;	O
denaturation	O
temperature	O
of	O
96	O
C	O
for	O
5	O
minutes	O
;	O
40	O
cycles	O
of	O
94	O
C	O
for	O
30	O
seconds	O
,	O
58	O
C	O
for	O
30	O
seconds	O
and	O
72	O
C	O
for	O
30	O
seconds	O
;	O
final	O
extension	O
at	O
72	O
C	O
for	O
5	O
minutes	O
.	O
The	O
amplification	O
product	O
was	O
620	O
base	O
pairs	O
bp	O
,	O
which	O
was	O
purified	O
and	O
sequenced	O
.	O
The	O
sequence	O
received	O
was	O
compared	O
in	O
the	O
Genebank	O
database	O
,	O
resulting	O
in	O
100	O
identity	O
with	O
Histoplasma	O
capsulatum	O
Sequence	O
ID	O
KX646015	O
.	O
1	O
.	O
It	O
is	O
important	O
to	O
mention	O
that	O
the	O
fungal	O
development	O
of	O
the	O
blood	O
culture	O
with	O
the	O
lysis	O
centrifugation	O
technique	O
occurred	O
after	O
the	O
patient	O
's	O
discharge	O
.	O
Histopathological	O
study	O
of	O
the	O
vegetations	O
,	O
with	O
PAS	O
and	O
Grocott	O
stains	O
,	O
performed	O
by	O
the	O
Department	O
of	O
Pathological	O
Anatomy	O
of	O
the	O
Cardiology	O
Hospital	O
,	O
showed	O
the	O
presence	O
of	O
two	O
types	O
of	O
fungal	O
structures	O
yeasts	O
of	O
2	O
to	O
3	O
m	O
in	O
diameter	O
and	O
septate	O
,	O
tortuous	O
filaments	O
of	O
approximately	O
5	O
m	O
in	O
diameter	O
and	O
variable	O
length	O
.	O
Given	O
the	O
evidence	O
of	O
H	O
.	O
capsulatum	O
IE	O
,	O
the	O
patient	O
was	O
treated	O
with	O
itraconazole	B-FARMACO
,	O
300	O
mg	O
day	O
.	O
To	O
date	O
,	O
quarterly	O
check	O
ups	O
have	O
shown	O
no	O
alterations	O
suggesting	O
persistence	O
of	O
the	O
infection	O
.	O

A	O
9	O
year	O
old	O
girl	O
was	O
hospitalised	O
with	O
fever	O
and	O
headache	O
for	O
two	O
days	O
.	O
She	O
was	O
being	O
followed	O
up	O
for	O
a	O
small	O
congenital	O
VSD	O
diameter	O
3	O
mm	O
.	O
She	O
had	O
no	O
history	O
of	O
dental	O
or	O
surgical	O
procedures	O
.	O
On	O
physical	O
examination	O
,	O
body	O
temperature	O
38	O
.	O
5	O
C	O
,	O
respiratory	O
rate	O
20	O
min	O
,	O
pulse	O
110	O
min	O
,	O
blood	O
pressure	O
100	O
60	O
mmHg	O
.	O
An	O
intense	O
holosystolic	O
murmur	O
at	O
the	O
left	O
lower	O
sternal	O
border	O
and	O
signs	O
of	O
nuchal	O
rigidity	O
and	O
positive	O
Kernig	O
's	O
signs	O
were	O
also	O
noted	O
.	O
The	O
child	O
had	O
no	O
other	O
relevant	O
features	O
.	O
She	O
had	O
no	O
subungual	O
haemorrhages	O
,	O
no	O
splenomegaly	O
and	O
no	O
obvious	O
focal	O
neurological	O
impairment	O
.	O
Laboratory	O
data	O
were	O
as	O
follows	O
leucocyte	O
count	O
17	O
000	O
mm3	O
;	O
neutrophils	O
93	O
;	O
lymphocytes	O
5	O
;	O
haemoglobin	O
12	O
.	O
7	O
g	O
dl	O
;	O
thrombocytes	O
225	O
000	O
mm3	O
;	O
erythrocyte	O
sedimentation	O
rate	O
ESR	O
40	O
mm	O
h	O
and	O
C	O
reactive	O
protein	O
10	O
mg	O
dl	O
.	O
Cerebrospinal	O
fluid	O
CSF	O
count	O
was	O
22	O
neutrophils	O
mm3	O
,	O
66	O
lymphocytes	O
mm3	O
,	O
protein	O
content	O
26	O
mg	O
dl	O
and	O
glucose	O
61	O
mg	O
dl	O
.	O
MRI	O
was	O
unremarkable	O
.	O
Ceftriaxone	B-FARMACO
was	O
started	O
due	O
to	O
suspicion	O
of	O
meningitis	O
after	O
a	O
lumbar	O
puncture	O
.	O
By	O
day	O
3	O
of	O
hospitalisation	O
,	O
symptoms	O
had	O
completely	O
resolved	O
.	O
Once	O
negative	O
results	O
were	O
obtained	O
on	O
CSF	O
Gram	O
stain	O
,	O
PCR	O
panel	O
for	O
bacterial	O
viral	O
meningitis	O
,	O
blood	O
culture	O
and	O
urine	O
culture	O
,	O
ceftriaxone	B-FARMACO
was	O
discontinued	O
and	O
the	O
patient	O
was	O
discharged	O
on	O
day	O
7	O
.	O
Two	O
days	O
later	O
,	O
she	O
was	O
readmitted	O
with	O
fever	O
39	O
.	O
5	O
C	O
and	O
stiff	O
neck	O
.	O
Laboratory	O
tests	O
showed	O
the	O
following	O
leukocytes	O
25	O
000	O
mm3	O
92	O
neutrophils	O
with	O
toxic	O
granulations	O
,	O
haemoglobin	O
11	O
g	O
dl	O
,	O
thrombocytes	O
216	O
000	O
mm3	O
,	O
ESR	O
55	O
mm	O
h	O
and	O
C	O
reactive	O
protein	O
16	O
mg	O
dl	O
.	O
On	O
physical	O
examination	O
,	O
no	O
obvious	O
source	O
of	O
fever	O
was	O
found	O
.	O
The	O
family	O
refused	O
CSF	O
examination	O
.	O
An	O
echocardiogram	O
was	O
performed	O
to	O
detect	O
the	O
origin	O
of	O
the	O
fever	O
and	O
found	O
tricuspid	O
valve	O
endocarditis	O
with	O
vegetation	O
10	O
.	O
7	O
mm	O
x	O
6	O
.	O
6	O
mm	O
and	O
VSD	O
diameter	O
3	O
mm	O
with	O
left	O
to	O
right	O
shunt	O
.	O
Cranial	O
CT	O
scan	O
was	O
normal	O
.	O
On	O
follow	O
up	O
,	O
the	O
nuchal	O
rigidity	O
resolved	O
within	O
24	O
hours	O
.	O
Two	O
consecutive	O
blood	O
cultures	O
were	O
positive	O
for	O
methicillin	O
sensitive	O
Staphylococcus	O
aureus	O
and	O
teicoplanin	B-FARMACO
and	O
gentamicin	B-FARMACO
were	O
started	O
.	O
Vegetation	O
on	O
the	O
tricuspid	O
valve	O
caused	O
valvular	O
insufficiency	O
and	O
was	O
removed	O
by	O
heart	O
surgery	O
with	O
cardiopulmonary	O
bypass	O
,	O
including	O
tricuspid	O
valvuloplasty	O
four	O
weeks	O
later	O
.	O
Antibiotics	O
were	O
discontinued	O
after	O
six	O
weeks	O
,	O
after	O
blood	O
cultures	O
were	O
negative	O
for	O
two	O
weeks	O
.	O
The	O
patient	O
was	O
discharged	O
with	O
residual	O
mild	O
tricuspid	O
regurgitation	O
.	O
During	O
the	O
one	O
year	O
follow	O
up	O
,	O
she	O
was	O
symptom	O
free	O
.	O

An	O
8	O
year	O
old	O
boy	O
,	O
with	O
no	O
clinical	O
history	O
of	O
interest	O
,	O
consulted	O
the	O
emergency	O
department	O
for	O
a	O
clinical	O
picture	O
of	O
fever	O
up	O
to	O
39	O
.	O
5	O
oC	O
of	O
14	O
days	O
'	O
evolution	O
,	O
associated	O
with	O
chills	O
,	O
pale	O
skin	O
,	O
bilateral	O
cervical	O
lymphadenopathy	O
,	O
weakness	O
and	O
lack	O
of	O
appetite	O
.	O
He	O
had	O
been	O
treated	O
with	O
azithromycin	B-FARMACO
500	O
mg	O
daily	O
for	O
five	O
days	O
.	O
Physical	O
examination	O
revealed	O
the	O
presence	O
of	O
a	O
grade	O
II	O
III	O
systolic	O
murmur	O
in	O
the	O
auscultatory	O
focus	O
corresponding	O
to	O
the	O
left	O
ventricle	O
.	O
The	O
electroencephalogram	O
and	O
chest	O
X	O
ray	O
showed	O
no	O
pathological	O
findings	O
.	O
Laboratory	O
tests	O
showed	O
the	O
presence	O
of	O
inflammatory	O
markers	O
leukocytes	O
of	O
10	O
,	O
500	O
cells	O
ml	O
,	O
a	O
neutrophilia	O
of	O
70	O
and	O
an	O
elevated	O
CRP	O
119	O
mg	O
L	O
.	O
Treatment	O
was	O
started	O
with	O
cefotaxime	B-FARMACO
i	O
.	O
v	O
.	O
200	O
mg	O
kg	O
day	O
after	O
serial	O
blood	O
cultures	O
on	O
two	O
consecutive	O
days	O
.	O
After	O
24	O
h	O
of	O
incubation	O
,	O
both	O
blood	O
cultures	O
were	O
positive	O
.	O
Gram	O
stain	O
showed	O
pleomorphic	O
gram	O
positive	O
bacilli	O
in	O
a	O
"	O
V	O
"	O
shape	O
.	O
Direct	O
identification	O
of	O
the	O
organism	O
from	O
the	O
positive	O
blood	O
cultures	O
by	O
MALDI	O
TOF	O
mass	O
spectrometry	O
was	O
C	O
.	O
pseudodiphtheriticum	O
.	O
In	O
this	O
context	O
,	O
echocardiography	O
was	O
performed	O
,	O
showing	O
a	O
10	O
mm	O
vegetative	O
formation	O
Figure	O
1	O
on	O
the	O
left	O
ventricular	O
side	O
,	O
causing	O
moderate	O
insufficiency	O
,	O
without	O
repercussions	O
on	O
haemodynamics	O
and	O
cardiac	O
function	O
.	O
The	O
presence	O
of	O
bicuspid	O
aortic	O
valve	O
disease	O
was	O
also	O
noted	O
.	O
With	O
the	O
diagnosis	O
of	O
infective	O
endocarditis	O
,	O
gentamicin	B-FARMACO
6	O
mg	O
kg	O
day	O
was	O
added	O
to	O
therapy	O
pending	O
definitive	O
identification	O
of	O
the	O
microorganism	O
and	O
its	O
antimicrobial	O
susceptibility	O
profile	O
.	O
After	O
24	O
h	O
of	O
incubation	O
on	O
solid	O
culture	O
media	O
,	O
the	O
growth	O
of	O
grey	O
colonies	O
on	O
blood	O
agar	O
plates	O
,	O
catalase	O
positive	O
,	O
was	O
observed	O
.	O
Identification	O
by	O
16S	O
RNA	O
gene	O
sequencing	O
confirmed	O
the	O
isolation	O
of	O
Corynebacterium	O
pseudodiphtheriticum	O
.	O
Epsilometric	O
antibiogram	O
E	O
test	O
showed	O
resistance	O
to	O
azithromycin	B-FARMACO
MIC	O
256	O
g	O
ml	O
and	O
sensitivity	O
MIC	O
to	O
amoxicillin	B-FARMACO
ac	I-FARMACO
.	I-FARMACO
clavulanic	I-FARMACO
acid	I-FARMACO
0	O
.	O
016	O
g	O
ml	O
,	O
cefotaxime	B-FARMACO
0	O
.	O
38	O
g	O
ml	O
,	O
ciprofloxacin	B-FARMACO
0	O
.	O
5	O
g	O
ml	O
,	O
linezolid	B-FARMACO
0	O
.	O
016	O
g	O
ml	O
,	O
penicillin	B-FARMACO
G	I-FARMACO
0	O
.	O
25	O
g	O
ml	O
and	O
vancomycin	B-FARMACO
0	O
.	O
38	O
g	O
ml	O
.	O
The	O
patient	O
's	O
clinical	O
course	O
was	O
favourable	O
,	O
with	O
remission	O
of	O
his	O
febrile	O
symptoms	O
within	O
48	O
h	O
of	O
initiation	O
of	O
combined	O
antimicrobial	O
therapy	O
.	O
Given	O
his	O
good	O
evolution	O
,	O
with	O
negative	O
blood	O
cultures	O
and	O
no	O
imaging	O
changes	O
,	O
cardiac	O
surgery	O
was	O
not	O
considered	O
at	O
that	O
time	O
,	O
unless	O
there	O
was	O
any	O
clinical	O
deterioration	O
.	O
Sixteen	O
days	O
after	O
hospitalisation	O
,	O
the	O
patient	O
again	O
presented	O
fever	O
associated	O
with	O
frontal	O
headache	O
,	O
disorientation	O
and	O
poor	O
motor	O
tone	O
that	O
evolved	O
into	O
right	O
brachial	O
paresis	O
,	O
right	O
hemicara	O
and	O
aphasia	O
.	O
The	O
picture	O
was	O
interpreted	O
as	O
a	O
cerebral	O
septic	O
embolism	O
.	O
Linezolid	B-FARMACO
was	O
added	O
to	O
the	O
antimicrobial	O
treatment	O
for	O
possible	O
superinfection	O
by	O
resistant	O
microorganisms	O
in	O
another	O
focus	O
.	O
Given	O
the	O
risk	O
of	O
a	O
new	O
embolism	O
,	O
cardiac	O
surgery	O
was	O
performed	O
on	O
the	O
aortic	O
valve	O
territory	O
Ross	O
procedure	O
,	O
which	O
was	O
successfully	O
completed	O
.	O
On	O
the	O
third	O
post	O
operative	O
day	O
,	O
the	O
patient	O
developed	O
intracranial	O
hypertension	O
.	O
A	O
brain	O
MRI	O
was	O
performed	O
which	O
revealed	O
an	O
ischaemic	O
infarction	O
due	O
to	O
occlusion	O
at	O
the	O
origin	O
of	O
the	O
left	O
middle	O
cerebral	O
artery	O
.	O
Due	O
to	O
its	O
severity	O
,	O
the	O
patient	O
died	O
in	O
the	O
following	O
days	O
.	O
The	O
final	O
microbiological	O
results	O
again	O
confirmed	O
the	O
isolation	O
of	O
C	O
.	O
pseudodiphtheriticum	O
in	O
blood	O
cultures	O
.	O

89	O
year	O
old	O
woman	O
,	O
with	O
no	O
known	O
history	O
,	O
consulted	O
for	O
a	O
15	O
day	O
history	O
of	O
fever	O
of	O
39	O
degrees	O
,	O
asthenia	O
,	O
adynamia	O
,	O
urinary	O
symptoms	O
in	O
the	O
last	O
week	O
,	O
medicated	O
with	O
ciprofloxacin	B-FARMACO
500mg	O
every	O
12	O
hours	O
until	O
the	O
day	O
before	O
hospitalisation	O
,	O
who	O
,	O
due	O
to	O
persistent	O
thermal	O
rises	O
,	O
went	O
to	O
the	O
emergency	O
room	O
.	O
Physical	O
examination	O
findings	O
pale	O
conjunctivae	O
,	O
tachycardic	O
,	O
rhythmic	O
,	O
normo	O
phonemic	O
heart	O
sounds	O
,	O
regurgitant	O
murmur	O
in	O
mitral	O
focus	O
II	O
VI	O
,	O
non	O
radiated	O
,	O
with	O
abdominal	O
distention	O
,	O
fighting	O
sounds	O
,	O
palpable	O
mass	O
of	O
4	O
x	O
4	O
cm	O
in	O
the	O
left	O
iliac	O
fossa	O
.	O
Laboratory	O
on	O
admission	O
leukocytes	O
13	O
,	O
300mm3	O
,	O
neutrophils	O
77	O
,	O
haemoglobin	O
6	O
.	O
8mg	O
dl	O
,	O
haematocrit	O
21	O
.	O
6mg	O
dl	O
,	O
ESR	O
109MM	O
,	O
CRP	O
.	O
Urine	O
culture	O
and	O
blood	O
cultures	O
were	O
performed	O
,	O
and	O
a	O
CT	O
scan	O
of	O
the	O
abdomen	O
was	O
requested	O
,	O
which	O
revealed	O
the	O
presence	O
of	O
a	O
bilobulated	O
formation	O
of	O
apparent	O
gynaecological	O
origin	O
,	O
which	O
to	O
the	O
left	O
showed	O
an	O
image	O
suggestive	O
of	O
a	O
fistula	O
with	O
a	O
loop	O
of	O
small	O
intestine	O
,	O
with	O
oral	O
contrast	O
substance	O
inside	O
the	O
lesion	O
.	O
With	O
a	O
presumptive	O
diagnosis	O
of	O
perforated	O
tumour	O
with	O
intestinal	O
fistula	O
,	O
the	O
patient	O
was	O
taken	O
to	O
the	O
operating	O
theatre	O
and	O
antibiotic	O
treatment	O
was	O
started	O
,	O
covering	O
the	O
abdominal	O
focus	O
.	O
Since	O
the	O
patient	O
continued	O
to	O
be	O
febrile	O
,	O
together	O
with	O
positive	O
blood	O
culture	O
results	O
for	O
Escherichia	O
coli	O
,	O
an	O
echocardiogram	O
was	O
requested	O
,	O
which	O
revealed	O
a	O
rounded	O
image	O
measuring	O
1	O
.	O
5x0	O
.	O
8	O
millimetres	O
that	O
could	O
correspond	O
to	O
vegetation	O
,	O
so	O
treatment	O
was	O
started	O
with	O
ceftriaxone	B-FARMACO
plus	O
gentamicin	B-FARMACO
,	O
with	O
good	O
clinical	O
evolution	O
,	O
and	O
the	O
patient	O
was	O
subsequently	O
discharged	O
.	O

A	O
76	O
year	O
old	O
man	O
with	O
a	O
history	O
of	O
type	O
II	O
diabetes	O
mellitus	O
,	O
hypertension	O
,	O
hypercholesterolemia	O
and	O
chronic	O
renal	O
failure	O
.	O
The	O
patient	O
came	O
to	O
the	O
emergency	O
department	O
of	O
our	O
centre	O
with	O
general	O
malaise	O
,	O
nausea	O
,	O
vomiting	O
and	O
episodes	O
of	O
profuse	O
sweating	O
without	O
chest	O
pain	O
.	O
Five	O
days	O
earlier	O
he	O
had	O
been	O
discharged	O
from	O
hospital	O
after	O
two	O
stents	O
had	O
been	O
placed	O
for	O
ischaemic	O
heart	O
disease	O
.	O
She	O
was	O
admitted	O
with	O
leukocytosis	O
with	O
left	O
shift	O
,	O
acute	O
renal	O
failure	O
,	O
normochromic	O
normocytic	O
anaemia	O
and	O
a	O
CRP	O
of	O
112mg	O
L	O
.	O
The	O
electrocardiogram	O
showed	O
complete	O
right	O
bundle	O
branch	O
block	O
and	O
second	O
degree	O
atrioventricular	O
block	O
.	O
During	O
the	O
first	O
days	O
of	O
admission	O
to	O
the	O
ICU	O
he	O
was	O
afebrile	O
,	O
with	O
rising	O
leukocytosis	O
without	O
clear	O
focus	O
,	O
and	O
showing	O
some	O
episodes	O
of	O
temporospatial	O
disorientation	O
with	O
psychomotor	O
agitation	O
.	O
Treatment	O
with	O
piperacillin	B-FARMACO
tazobactam	I-FARMACO
was	O
started	O
and	O
a	O
cranial	O
CT	O
scan	O
was	O
performed	O
showing	O
a	O
small	O
occipital	O
subarachnoid	O
haemorrhage	O
.	O
On	O
the	O
sixth	O
day	O
of	O
admission	O
,	O
the	O
patient	O
presented	O
fever	O
over	O
38oC	O
,	O
with	O
tachypnoea	O
and	O
increased	O
respiratory	O
work	O
with	O
severe	O
metabolic	O
acidosis	O
,	O
accompanied	O
by	O
a	O
deterioration	O
in	O
the	O
level	O
of	O
consciousness	O
.	O
A	O
chest	O
CT	O
scan	O
showed	O
bilateral	O
pleural	O
effusion	O
.	O
Urine	O
,	O
bronchial	O
aspirate	O
and	O
blood	O
samples	O
were	O
collected	O
for	O
culture	O
.	O
The	O
following	O
day	O
the	O
microbiology	O
laboratory	O
reported	O
that	O
two	O
blood	O
cultures	O
grew	O
gram	O
positive	O
cocci	O
in	O
clusters	O
which	O
were	O
later	O
identified	O
as	O
Staphylococcus	O
lugdunensis	O
not	O
producing	O
beta	O
lactamase	O
.	O
Following	O
this	O
result	O
,	O
antibiotic	O
treatment	O
was	O
adjusted	O
according	O
to	O
the	O
antibiogram	O
to	O
cloxacillin	B-FARMACO
and	O
gentamicin	B-FARMACO
.	O
A	O
transesophageal	O
echocardiogram	O
was	O
performed	O
,	O
showing	O
two	O
vegetations	O
on	O
the	O
atrial	O
side	O
of	O
the	O
mitral	O
valve	O
,	O
one	O
in	O
the	O
septal	O
leaflet	O
measuring	O
12	O
x	O
12	O
mm	O
and	O
the	O
other	O
in	O
the	O
posterior	O
leaflet	O
measuring	O
13	O
x	O
12	O
mm	O
,	O
indicating	O
moderate	O
mitral	O
insufficiency	O
.	O
Surgery	O
for	O
valve	O
replacement	O
was	O
considered	O
,	O
but	O
the	O
patient	O
died	O
before	O
surgery	O
could	O
be	O
performed	O
.	O
The	O
patient	O
was	O
diagnosed	O
with	O
mitral	O
endocarditis	O
on	O
native	O
valve	O
.	O

In	O
June	O
2010	O
,	O
a	O
61	O
year	O
old	O
man	O
came	O
to	O
the	O
internal	O
medicine	O
department	O
for	O
the	O
study	O
of	O
an	O
almost	O
daily	O
febrile	O
fever	O
and	O
occasionally	O
a	O
fever	O
of	O
over	O
38oC	O
.	O
His	O
personal	O
history	O
included	O
hypertension	O
,	O
hypercholesterolaemia	O
,	O
haemochromatosis	O
under	O
treatment	O
with	O
periodic	O
bleeding	O
up	O
to	O
a	O
year	O
earlier	O
,	O
ex	O
smoker	O
,	O
and	O
a	O
patient	O
with	O
a	O
prosthetic	O
mitral	O
valve	O
and	O
stent	O
since	O
2008	O
due	O
to	O
ischaemic	O
heart	O
disease	O
with	O
biventricular	O
involvement	O
.	O
Six	O
months	O
earlier	O
,	O
the	O
patient	O
had	O
started	O
to	O
experience	O
a	O
progressive	O
onset	O
of	O
fever	O
,	O
asthenia	O
,	O
hyporexia	O
and	O
cough	O
.	O
In	O
March	O
of	O
the	O
same	O
year	O
,	O
he	O
was	O
referred	O
by	O
his	O
primary	O
care	O
physician	O
for	O
the	O
finding	O
of	O
three	O
peripheral	O
pulmonary	O
micronodules	O
measuring	O
5	O
mm	O
.	O
Complementary	O
examinations	O
revealed	O
moderate	O
normochromic	O
anaemia	O
,	O
elevated	O
ESR	O
and	O
CRP	O
together	O
with	O
significant	O
homogeneous	O
splenomegaly	O
.	O
No	O
fever	O
was	O
noted	O
and	O
he	O
was	O
discharged	O
to	O
continue	O
the	O
study	O
in	O
the	O
outpatient	O
department	O
.	O
In	O
April	O
he	O
returned	O
to	O
the	O
ED	O
with	O
fever	O
of	O
38	O
.	O
7oC	O
and	O
pleuritic	O
pain	O
in	O
the	O
left	O
hemithorax	O
.	O
Two	O
blood	O
cultures	O
were	O
taken	O
and	O
were	O
negative	O
after	O
5	O
days	O
of	O
incubation	O
.	O
He	O
started	O
empirical	O
antibiotic	O
treatment	O
with	O
amoxicillin	B-FARMACO
clavulanic	I-FARMACO
acid	I-FARMACO
with	O
partial	O
improvement	O
of	O
symptoms	O
.	O
From	O
the	O
Internal	O
Medicine	O
department	O
and	O
due	O
to	O
a	O
further	O
worsening	O
of	O
symptoms	O
,	O
it	O
was	O
decided	O
to	O
admit	O
him	O
.	O
At	O
that	O
time	O
he	O
was	O
anaemic	O
,	O
with	O
iron	O
levels	O
of	O
34	O
mcg	O
dl	O
,	O
a	O
blood	O
rate	O
of	O
56	O
mm	O
h	O
and	O
CRP	O
of	O
3	O
.	O
6	O
mg	O
dl	O
.	O
Thoracic	O
abdominal	O
CT	O
showed	O
splenomegaly	O
with	O
an	O
image	O
compatible	O
with	O
splenic	O
infarcts	O
and	O
persistence	O
of	O
the	O
aforementioned	O
unchanged	O
pulmonary	O
micronodules	O
.	O
A	O
transesophageal	O
echocardiogram	O
showed	O
a	O
mechanical	O
mitral	O
prosthesis	O
with	O
two	O
vegetation	O
images	O
,	O
a	O
medial	O
one	O
measuring	O
14	O
x	O
5	O
mm	O
and	O
a	O
lateral	O
one	O
measuring	O
13	O
x	O
4	O
mm	O
on	O
the	O
atrial	O
side	O
.	O
There	O
was	O
no	O
prosthetic	O
dysfunction	O
.	O
Three	O
blood	O
cultures	O
were	O
taken	O
aerobic	O
and	O
anaerobic	O
flasks	O
.	O
All	O
three	O
anaerobic	O
flasks	O
grew	O
a	O
non	O
spore	O
forming	O
,	O
pleomorphic	O
gram	O
positive	O
bacillus	O
at	O
7	O
,	O
8	O
and	O
10	O
days	O
.	O
The	O
isolate	O
was	O
sent	O
to	O
the	O
Centro	O
Nacional	O
de	O
Microbiologa	O
in	O
Majadahonda	O
where	O
it	O
was	O
identified	O
as	O
Propionibacterium	O
acnes	O
by	O
amplification	O
and	O
sequencing	O
of	O
the	O
16S	O
rRNA	O
gene	O
.	O
When	O
initially	O
reporting	O
the	O
growth	O
of	O
an	O
anaerobic	O
gram	O
positive	O
bacillus	O
in	O
blood	O
cultures	O
,	O
the	O
patient	O
was	O
treated	O
with	O
vancomycin	B-FARMACO
,	O
ceftriaxone	B-FARMACO
and	O
gentamicin	B-FARMACO
.	O
Subsequently	O
,	O
ceftriaxone	B-FARMACO
and	O
gentamicin	B-FARMACO
were	O
replaced	O
by	O
clindamycin	B-FARMACO
.	O
After	O
suspecting	O
that	O
the	O
microorganism	O
was	O
P	O
.	O
acnes	O
,	O
it	O
was	O
decided	O
to	O
change	O
antibiotherapy	O
to	O
penicillin	B-FARMACO
G	I-FARMACO
sodium	I-FARMACO
,	O
4	O
,	O
000	O
,	O
000	O
IU	O
every	O
4	O
hours	O
.	O
The	O
patient	O
's	O
evolution	O
at	O
the	O
start	O
of	O
treatment	O
was	O
favourable	O
,	O
but	O
the	O
reappearance	O
of	O
fever	O
with	O
peaks	O
above	O
38oC	O
after	O
ten	O
days	O
,	O
together	O
with	O
the	O
results	O
of	O
a	O
second	O
transesophageal	O
echocardiogram	O
unchanged	O
from	O
the	O
previous	O
one	O
,	O
made	O
it	O
advisable	O
to	O
perform	O
surgery	O
to	O
replace	O
the	O
prosthesis	O
.	O

The	O
patient	O
was	O
a	O
64	O
year	O
old	O
woman	O
who	O
presented	O
to	O
the	O
emergency	O
department	O
of	O
a	O
tertiary	O
hospital	O
with	O
erythematous	O
lesions	O
on	O
both	O
hands	O
and	O
swelling	O
,	O
pain	O
and	O
functional	O
impotence	O
of	O
the	O
right	O
wrist	O
joint	O
.	O
She	O
had	O
a	O
biological	O
aortic	O
valve	O
prosthesis	O
,	O
implanted	O
fifteen	O
months	O
before	O
the	O
current	O
consultation	O
.	O
Examination	O
of	O
the	O
patient	O
revealed	O
that	O
she	O
was	O
febrile	O
38oC	O
and	O
Osler	O
nodules	O
were	O
observed	O
on	O
the	O
hands	O
and	O
feet	O
,	O
as	O
well	O
as	O
nail	O
haemorrhages	O
.	O
Blood	O
tests	O
showed	O
leukocytosis	O
12	O
.	O
8	O
x	O
106	O
L	O
.	O
Blood	O
cultures	O
were	O
taken	O
and	O
a	O
chest	O
ultrasound	O
showed	O
a	O
large	O
vegetation	O
on	O
the	O
prosthetic	O
valve	O
annulus	O
.	O
She	O
was	O
diagnosed	O
with	O
prosthetic	O
valve	O
endocarditis	O
and	O
treatment	O
was	O
started	O
with	O
vancomycin	B-FARMACO
,	O
gentamicin	B-FARMACO
and	O
rifampicin	B-FARMACO
at	O
appropriate	O
doses	O
.	O
After	O
two	O
days	O
of	O
evolution	O
,	O
the	O
patient	O
showed	O
decreased	O
level	O
of	O
consciousness	O
and	O
right	O
hemiparesis	O
.	O
A	O
normal	O
head	O
CT	O
scan	O
and	O
lumbar	O
puncture	O
were	O
performed	O
.	O
CSF	O
biochemistry	O
showed	O
no	O
alterations	O
and	O
a	O
sample	O
was	O
sent	O
to	O
the	O
Microbiology	O
Department	O
.	O
It	O
was	O
decided	O
to	O
perform	O
surgery	O
for	O
a	O
new	O
valve	O
replacement	O
,	O
but	O
the	O
patient	O
died	O
eight	O
hours	O
later	O
due	O
to	O
cardiorespiratory	O
arrest	O
,	O
before	O
she	O
could	O
be	O
operated	O
on	O
.	O
No	O
autopsy	O
was	O
performed	O
.	O
Blood	O
cultures	O
and	O
cerebrospinal	O
fluid	O
were	O
negative	O
after	O
seven	O
days	O
of	O
incubation	O
.	O
Blind	O
passages	O
of	O
blood	O
cultures	O
were	O
given	O
and	O
all	O
culture	O
media	O
sown	O
showed	O
whitish	O
cream	O
coloured	O
colonies	O
with	O
a	O
membranous	O
appearance	O
after	O
three	O
days	O
of	O
incubation	O
.	O
Microscopic	O
examination	O
revealed	O
yeasts	O
,	O
short	O
filaments	O
and	O
arthroconidia	O
.	O
The	O
micro	O
organism	O
grew	O
in	O
the	O
subculture	O
after	O
72	O
h	O
of	O
incubation	O
on	O
standard	O
culture	O
media	O
.	O
The	O
vast	O
majority	O
of	O
yeasts	O
that	O
cause	O
infections	O
in	O
humans	O
can	O
have	O
these	O
characteristics	O
.	O
However	O
,	O
Candida	O
species	O
usually	O
grow	O
within	O
24	O
h	O
on	O
standard	O
media	O
,	O
so	O
the	O
yeast	O
may	O
be	O
thought	O
to	O
belong	O
to	O
a	O
slow	O
growing	O
species	O
Cryptococcus	O
,	O
Trichosporon	O
,	O
Rhodotorula	O
,	O
Geotrichum	O
,	O
Galactomyces	O
.	O
The	O
macroscopic	O
appearance	O
of	O
the	O
colonies	O
cream	O
coloured	O
and	O
membranous	O
appearance	O
helps	O
to	O
rule	O
out	O
pigmented	O
yeasts	O
such	O
as	O
Rhodotorula	O
and	O
Sporobolomyces	O
,	O
which	O
are	O
red	O
and	O
orange	O
,	O
respectively	O
.	O
However	O
,	O
the	O
most	O
significant	O
data	O
is	O
the	O
microscopic	O
morphology	O
yeast	O
like	O
organisms	O
,	O
with	O
hyphae	O
and	O
arthroconidia	O
.	O
The	O
presence	O
of	O
hyphae	O
helps	O
to	O
rule	O
out	O
a	O
genus	O
such	O
as	O
Cryptococcus	O
which	O
does	O
not	O
usually	O
produce	O
filaments	O
.	O
The	O
presence	O
of	O
arthroconidia	O
helps	O
to	O
make	O
a	O
presumptive	O
identification	O
.	O
Arthroconidia	O
are	O
a	O
type	O
of	O
asexual	O
reproduction	O
,	O
consisting	O
of	O
the	O
generation	O
of	O
conidia	O
by	O
simple	O
fragmentation	O
of	O
the	O
hyphae	O
in	O
the	O
area	O
where	O
the	O
septa	O
are	O
located	O
.	O
It	O
is	O
typical	O
of	O
several	O
species	O
belonging	O
to	O
the	O
genera	O
Trichosporon	O
,	O
Galactomyces	O
and	O
Geotrichum	O
.	O
Within	O
the	O
arthroconidial	O
group	O
,	O
three	O
species	O
cause	O
the	O
vast	O
majority	O
of	O
infections	O
in	O
humans	O
Galactomyces	O
geotrichum	O
Geotrichum	O
candidum	O
,	O
Dipodascus	O
capitatus	O
Geotrichumcapitatum	O
and	O
Trichosporon	O
beigelii	O
.	O
The	O
latter	O
can	O
be	O
considered	O
as	O
a	O
genospecies	O
and	O
in	O
recent	O
taxonomic	O
classifications	O
has	O
been	O
divided	O
into	O
multiple	O
species	O
,	O
of	O
which	O
at	O
least	O
6	O
are	O
pathogenic	O
to	O
humans	O
T	O
.	O
asahii	O
,	O
T	O
.	O
cutaneum	O
,	O
T	O
.	O
inkin	O
,	O
T	O
.	O
mucoides	O
,	O
T	O
.	O
ovoides	O
and	O
T	O
.	O
asteroides	O
.	O
Of	O
these	O
,	O
T	O
.	O
asahii	O
is	O
the	O
most	O
important	O
from	O
a	O
pathogenic	O
point	O
of	O
view	O
,	O
as	O
it	O
is	O
the	O
one	O
that	O
causes	O
almost	O
all	O
cases	O
of	O
deep	O
Trichosporon	O
infections	O
.	O
To	O
distinguish	O
between	O
the	O
three	O
arthroconidial	O
species	O
requires	O
morphological	O
study	O
,	O
biochemical	O
tests	O
and	O
complementary	O
techniques	O
.	O
Macroscopic	O
morphology	O
does	O
not	O
help	O
to	O
differentiate	O
between	O
the	O
three	O
species	O
,	O
as	O
the	O
colonies	O
of	O
all	O
species	O
are	O
white	O
or	O
cream	O
coloured	O
and	O
membranous	O
in	O
appearance	O
.	O
Microscopic	O
morphology	O
is	O
somewhat	O
more	O
specific	O
,	O
although	O
not	O
definitive	O
,	O
as	O
sometimes	O
only	O
hyphae	O
and	O
arthroconidia	O
are	O
observed	O
.	O
The	O
microscopic	O
morphology	O
of	O
D	O
.	O
capitatus	O
is	O
characterised	O
by	O
narrow	O
hyphae	O
branching	O
at	O
acute	O
angles	O
,	O
with	O
anelloconidia	O
and	O
endospores	O
.	O
G	O
.	O
geotrichum	O
usually	O
has	O
thicker	O
hyphae	O
branching	O
at	O
right	O
angles	O
.	O
T	O
.	O
beigelii	O
has	O
a	O
variable	O
morphology	O
as	O
it	O
is	O
a	O
genospecies	O
.	O
Generally	O
speaking	O
,	O
it	O
usually	O
has	O
fine	O
disarticulated	O
hyphae	O
,	O
with	O
abundant	O
formacubic	O
and	O
sometimes	O
appressoria	O
narrow	O
filamentous	O
structures	O
,	O
attached	O
to	O
the	O
hyphae	O
and	O
branching	O
very	O
irregularly	O
and	O
giant	O
spindle	O
cells	O
.	O
Both	O
biochemical	O
tests	O
and	O
complementary	O
techniques	O
are	O
used	O
as	O
confirmatory	O
methods	O
of	O
identification	O
.	O
Trichosporon	O
species	O
are	O
easily	O
distinguished	O
from	O
Galactomyces	O
and	O
Dipodascus	O
as	O
they	O
assimilate	O
a	O
large	O
number	O
of	O
carbohydrates	O
and	O
produce	O
urea	O
hydrolysis	O
.	O
G	O
.	O
geotrichum	O
and	O
D	O
.	O
capitatus	O
assimilate	O
fewer	O
carbohydrates	O
glucose	O
,	O
galactose	O
and	O
some	O
others	O
depending	O
on	O
the	O
strain	O
and	O
do	O
not	O
hydrolyse	O
urea	O
.	O
These	O
two	O
species	O
can	O
be	O
distinguished	O
because	O
Galactomyces	O
does	O
not	O
usually	O
grow	O
well	O
at	O
37oC	O
and	O
because	O
many	O
strains	O
also	O
assimilate	O
xylose	O
.	O
None	O
of	O
the	O
three	O
species	O
ferment	O
carbohydrates	O
.	O

A	O
55	O
year	O
old	O
man	O
with	O
a	O
history	O
of	O
ischaemic	O
heart	O
disease	O
attended	O
the	O
emergency	O
department	O
for	O
fever	O
of	O
6	O
months	O
of	O
intermittent	O
evolution	O
,	O
accompanied	O
by	O
chills	O
,	O
sweating	O
,	O
asthenia	O
and	O
anorexia	O
.	O
On	O
examination	O
he	O
presented	O
a	O
temperature	O
of	O
39oC	O
,	O
septic	O
mouth	O
and	O
rhythmic	O
cardiac	O
auscultation	O
at	O
90	O
bpm	O
with	O
a	O
multifocal	O
systolic	O
murmur	O
III	O
VI	O
.	O
Laboratory	O
tests	O
showed	O
haemoglobin	O
12	O
.	O
5	O
g	O
dL	O
,	O
haematocrit	O
37	O
,	O
MCV	O
91	O
fL	O
,	O
white	O
and	O
platelet	O
series	O
normal	O
,	O
and	O
CRP	O
9	O
.	O
0	O
mg	O
dL	O
.	O
Chest	O
X	O
ray	O
was	O
normal	O
.	O
Serial	O
blood	O
cultures	O
were	O
taken	O
and	O
the	O
patient	O
was	O
admitted	O
.	O
A	O
transesophageal	O
echocardiogram	O
showed	O
two	O
warts	O
in	O
the	O
anteroseptal	O
mitral	O
leaflet	O
with	O
mild	O
mitral	O
insufficiency	O
.	O
Empirical	O
antibiotic	O
treatment	O
for	O
infective	O
endocarditis	O
was	O
started	O
with	O
amoxicillin	B-FARMACO
clavulanic	I-FARMACO
acid	I-FARMACO
2	O
g	O
4	O
h	O
,	O
iv	O
and	O
gentamicin	B-FARMACO
80	O
mg	O
8	O
h	O
,	O
iv	O
.	O
Seven	O
days	O
after	O
admission	O
,	O
bacterial	O
growth	O
was	O
detected	O
in	O
3	O
of	O
the	O
4	O
blood	O
culture	O
bottles	O
.	O
No	O
microorganisms	O
were	O
observed	O
in	O
the	O
direct	O
Gram	O
stain	O
.	O
At	O
48	O
hours	O
,	O
in	O
the	O
subculture	O
performed	O
on	O
chocolate	O
agar	O
in	O
a	O
CO2	O
atmosphere	O
,	O
greyish	O
coloured	O
punctate	O
colonies	O
grew	O
,	O
which	O
corresponded	O
to	O
gram	O
negative	O
coccobacilli	O
in	O
the	O
Gram	O
stain	O
.	O
Biochemical	O
tests	O
were	O
as	O
follows	O
catalase	O
positive	O
,	O
oxidase	O
negative	O
,	O
urea	O
negative	O
,	O
indolnegative	O
and	O
non	O
fermenting	O
of	O
glucose	O
,	O
galactose	O
and	O
lactose	O
.	O
The	O
micro	O
organism	O
did	O
not	O
grow	O
in	O
aerobic	O
atmosphere	O
at	O
37oC	O
or	O
on	O
EMB	O
agar	O
,	O
but	O
did	O
grow	O
on	O
Brucella	O
enanaerobiosis	O
agar	O
.	O
A	O
subculture	O
was	O
performed	O
in	O
thioglycollate	O
broth	O
and	O
after	O
7	O
days	O
of	O
incubation	O
,	O
growth	O
was	O
observed	O
in	O
the	O
form	O
of	O
clumps	O
adhering	O
to	O
the	O
wall	O
of	O
the	O
tube	O
and	O
then	O
becoming	O
diffuse	O
throughout	O
the	O
broth	O
.	O
Serological	O
tests	O
for	O
Brucella	O
were	O
negative	O
.	O
Due	O
to	O
the	O
microbiological	O
results	O
obtained	O
and	O
the	O
appearance	O
of	O
new	O
febrile	O
episodes	O
,	O
it	O
was	O
decided	O
to	O
change	O
the	O
antibiotic	O
treatment	O
to	O
ceftriaxone	B-FARMACO
2g	O
24	O
h	O
,	O
iv	O
.	O
The	O
original	O
culture	O
was	O
incubated	O
for	O
a	O
prolonged	O
period	O
of	O
time	O
in	O
a	O
CO2	O
atmosphere	O
and	O
after	O
25	O
days	O
rough	O
colonies	O
with	O
a	O
stellate	O
appearance	O
in	O
the	O
centre	O
were	O
observed	O
by	O
low	O
magnification	O
light	O
microscopy	O
.	O
The	O
sensitivity	O
study	O
was	O
performed	O
by	O
the	O
disc	O
plate	O
method	O
after	O
prolonged	O
incubation	O
,	O
resulting	O
sensitive	O
to	O
penicillin	O
,	O
cephalosporins	O
,	O
aminoglycosides	O
,	O
quinolones	O
,	O
cotrimoxazole	O
,	O
rifampicin	O
and	O
tetracycline	O
,	O
and	O
resistant	O
to	O
glycopeptides	O
and	O
clindamycin	O
,	O
being	O
the	O
determination	O
of	O
beta	O
lactamase	O
negative	O
.	O
The	O
patient	O
's	O
clinical	O
evolution	O
was	O
satisfactory	O
,	O
with	O
no	O
complications	O
.	O
He	O
was	O
discharged	O
and	O
continued	O
with	O
outpatient	O
antibiotic	O
treatment	O
,	O
completing	O
5	O
weeks	O
of	O
treatment	O
with	O
ceftriaxone	B-FARMACO
.	O
The	O
existence	O
of	O
endocarditis	O
with	O
a	O
subacute	O
course	O
and	O
the	O
late	O
growth	O
of	O
gram	O
negative	O
microorganisms	O
in	O
the	O
blood	O
culture	O
should	O
lead	O
us	O
to	O
suspect	O
the	O
participation	O
of	O
microorganisms	O
belonging	O
to	O
the	O
HACEK	O
group	O
,	O
which	O
includes	O
bacteria	O
that	O
are	O
difficult	O
to	O
grow	O
and	O
have	O
special	O
nutritional	O
and	O
incubation	O
requirements	O
.	O
This	O
group	O
includes	O
the	O
following	O
microorganisms	O
Haemophilus	O
H	O
.	O
aphrophilus	O
,	O
H	O
.	O
paraphrophilus	O
,	O
etc	O
.	O
,	O
Actinobacillus	O
actinomycetemcomitans	O
,	O
Cardiobacterium	O
hominis	O
,	O
Eikenella	O
corrodens	O
and	O
Kingella	O
kingae	O
.	O
The	O
common	O
characteristics	O
of	O
all	O
of	O
them	O
are	O
the	O
following	O
they	O
are	O
part	O
of	O
the	O
normal	O
flora	O
of	O
the	O
oropharyngeal	O
cavity	O
and	O
upper	O
respiratory	O
tract	O
,	O
they	O
are	O
small	O
gram	O
negative	O
coccobacilli	O
,	O
they	O
are	O
demanding	O
microorganisms	O
,	O
very	O
slow	O
growing	O
,	O
requiring	O
prolonged	O
incubation	O
in	O
a	O
CO2	O
atmosphere	O
and	O
producing	O
similar	O
clinical	O
pictures	O
of	O
insidious	O
course	O
,	O
endocarditis	O
being	O
the	O
most	O
frequent	O
pathology	O
.	O
According	O
to	O
the	O
microbiological	O
results	O
,	O
A	O
.	O
actinomycetemcomitans	O
was	O
identified	O
as	O
the	O
causative	O
organism	O
of	O
this	O
infection	O
.	O
It	O
is	O
a	O
gram	O
negative	O
,	O
capnophilic	O
,	O
facultative	O
anaerobic	O
,	O
very	O
slow	O
growing	O
coccobacillus	O
,	O
which	O
is	O
part	O
of	O
the	O
normal	O
bacterial	O
flora	O
of	O
the	O
oral	O
cavity	O
.	O
It	O
requires	O
blood	O
enriched	O
culture	O
media	O
and	O
does	O
not	O
grow	O
on	O
selective	O
media	O
such	O
as	O
MacConkey	O
agar	O
or	O
EMB	O
.	O
Endocarditis	O
due	O
to	O
A	O
.	O
actinomycetemcomitans	O
is	O
very	O
rare	O
on	O
both	O
native	O
and	O
prosthetic	O
valves	O
,	O
with	O
102	O
cases	O
reported	O
in	O
the	O
literature	O
so	O
far	O
.	O
It	O
is	O
the	O
microorganism	O
of	O
the	O
HACEK	O
group	O
that	O
most	O
frequently	O
causes	O
endocarditis	O
,	O
especially	O
in	O
patients	O
with	O
underlying	O
cardiac	O
pathologies	O
.	O
The	O
entry	O
point	O
is	O
usually	O
an	O
oropharyngeal	O
infection	O
,	O
but	O
it	O
can	O
also	O
be	O
secondary	O
to	O
instrumentation	O
in	O
the	O
oral	O
cavity	O
.	O
On	O
other	O
occasions	O
,	O
as	O
in	O
our	O
case	O
,	O
the	O
origin	O
is	O
related	O
to	O
a	O
septic	O
mouth	O
with	O
teeth	O
in	O
poor	O
condition	O
.	O
A	O
.	O
actinomycetemcomitans	O
is	O
sensitive	O
to	O
cephalosporins	O
,	O
aztreonam	O
,	O
rifampicin	O
,	O
aminoglycosides	O
,	O
aminoglycosides	O
,	O
cotrimoxazole	O
,	O
tetracycline	O
,	O
chloramphenicol	O
and	O
quinolones	O
,	O
with	O
variable	O
sensitivity	O
to	O
penicillin	O
.	O
In	O
endocarditis	O
caused	O
by	O
this	O
microorganism	O
,	O
the	O
most	O
commonly	O
used	O
treatment	O
regimen	O
has	O
been	O
the	O
combination	O
of	O
penicillin	O
or	O
ampicillin	O
with	O
an	O
intravenous	O
aminoglycoside	O
,	O
although	O
penicillinase	O
producing	O
strains	O
have	O
been	O
described	O
.	O
For	O
this	O
reason	O
,	O
third	O
generation	O
cephalosporins	O
,	O
associated	O
with	O
either	O
rifampicin	O
or	O
an	O
aminoglycoside	O
,	O
are	O
an	O
option	O
to	O
consider	O
due	O
to	O
their	O
excellent	O
in	O
vitro	O
activity	O
.	O
The	O
recommended	O
duration	O
of	O
treatment	O
is	O
4	O
weeks	O
in	O
endocarditis	O
on	O
native	O
valves	O
and	O
6	O
weeks	O
when	O
prosthetic	O
valves	O
are	O
affected	O
.	O
The	O
use	O
of	O
fluoroquinolones	O
,	O
as	O
well	O
as	O
cotrimoxazole	O
or	O
aztreonam	O
,	O
should	O
be	O
considered	O
as	O
an	O
alternative	O
in	O
patients	O
who	O
are	O
intolerant	O
or	O
allergic	O
to	O
beta	O
lactams	O
,	O
given	O
their	O
high	O
sensitivity	O
rates	O
and	O
the	O
in	O
vitro	O
demonstration	O
of	O
synergy	O
with	O
rifampicin	O
.	O
Isolated	O
cases	O
of	O
complete	O
cure	O
have	O
been	O
reported	O
after	O
treatment	O
with	O
oral	O
ciprofloxacin	O
,	O
alone	O
or	O
in	O
association	O
with	O
rifampicin	O
or	O
doxycycline	O
,	O
for	O
a	O
longer	O
period	O
of	O
time	O
than	O
with	O
parenteral	O
treatments	O
8	O
weeks	O
.	O
These	O
data	O
suggest	O
that	O
oral	O
fluoroquinolones	O
may	O
be	O
a	O
valid	O
option	O
,	O
as	O
monotherapy	O
or	O
in	O
combination	O
with	O
other	O
antimicrobials	O
,	O
in	O
episodes	O
of	O
A	O
.	O
actinomycetemcomitans	O
endocarditis	O
without	O
serious	O
complications	O
.	O
Valve	O
replacement	O
is	O
necessary	O
in	O
24	O
of	O
cases	O
.	O

A	O
70	O
year	O
old	O
male	O
patient	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
fever	O
of	O
two	O
weeks	O
'	O
duration	O
,	O
with	O
chills	O
,	O
shivering	O
,	O
up	O
to	O
39oC	O
,	O
predominantly	O
in	O
the	O
evening	O
,	O
which	O
resolved	O
well	O
with	O
paracetamol	B-FARMACO
but	O
reappeared	O
a	O
few	O
hours	O
later	O
.	O
The	O
fever	O
is	O
accompanied	O
by	O
asthenia	O
and	O
generalised	O
osteoarticular	O
pain	O
.	O
No	O
cough	O
,	O
no	O
expectoration	O
,	O
no	O
dyspnoea	O
,	O
no	O
chest	O
pain	O
.	O
No	O
nausea	O
or	O
vomiting	O
.	O
Soft	O
stools	O
,	O
without	O
pathological	O
products	O
in	O
the	O
last	O
weeks	O
.	O
No	O
micturition	O
symptoms	O
.	O
Since	O
coming	O
to	O
the	O
emergency	O
department	O
,	O
on	O
treatment	O
with	O
levofloxacin	B-FARMACO
for	O
5	O
days	O
with	O
clinical	O
improvement	O
,	O
but	O
relapse	O
of	O
fever	O
and	O
general	O
malaise	O
48	O
hours	O
after	O
finishing	O
the	O
antibiotic	O
.	O
No	O
trips	O
abroad	O
.	O
No	O
skin	O
lesions	O
or	O
dental	O
interventions	O
.	O
The	O
family	O
reports	O
that	O
the	O
patient	O
has	O
been	O
more	O
depressed	O
for	O
the	O
last	O
6	O
months	O
,	O
coinciding	O
with	O
the	O
last	O
pacemaker	O
replacement	O
.	O
Since	O
then	O
,	O
his	O
activity	O
has	O
been	O
progressively	O
decreasing	O
,	O
with	O
the	O
appearance	O
of	O
joint	O
pain	O
.	O
Weight	O
loss	O
,	O
but	O
no	O
loss	O
of	O
appetite	O
.	O
BACKGROUND	O
ADR	O
Hypersensitivity	O
to	O
beta	O
lactams	O
.	O
Toxic	O
habits	O
Non	O
smoker	O
.	O
Drinker	O
of	O
2	O
glasses	O
of	O
wine	O
a	O
day	O
for	O
3	O
4	O
months	O
.	O
Personal	O
history	O
AHT	O
,	O
IIDM	O
,	O
dyslipidaemia	O
,	O
hyperuricaemia	O
with	O
gout	O
,	O
permanent	O
AF	O
since	O
2013	O
anticoagulated	O
with	O
Acenocoumarol	B-FARMACO
,	O
chronic	O
ischaemic	O
heart	O
disease	O
since	O
2004	O
,	O
AOTHETIC	O
PROSTHESIS	O
J	O
21	O
,	O
carotid	O
sinus	O
hypersensitivity	O
of	O
unknown	O
aetiology	O
.	O
DDDR	O
pacemaker	O
wearer	O
since	O
December	O
2004	O
and	O
since	O
2013	O
in	O
VVIR	O
mode	O
due	O
to	O
AF	O
.	O
Last	O
pacemaker	O
replacement	O
in	O
July	O
2016	O
,	O
without	O
complications	O
.	O
Vertebral	O
ankylosing	O
hyperostosis	O
and	O
gout	O
,	O
seen	O
in	O
rheumatology	O
in	O
November	O
2016	O
and	O
in	O
follow	O
up	O
by	O
general	O
practitioner	O
.	O
Community	O
acquired	O
pneumonia	O
in	O
2015	O
Surgical	O
history	O
appendectomy	O
,	O
prosthesisaortic	O
.	O
Retired	O
,	O
former	O
car	O
body	O
repairer	O
,	O
lives	O
in	O
El	O
Palmar	O
.	O
Self	O
employed	O
for	O
all	O
ABVD	O
,	O
drives	O
his	O
car	O
,	O
has	O
a	O
small	O
vegetable	O
garden	O
PHYSICAL	O
EXAMINATION	O
BP	O
120	O
40mmHG	O
HR	O
70lpm	O
T	O
37	O
"	O
2	O
oC	O
.	O
Eupneic	O
at	O
rest	O
No	O
adenopathies	O
in	O
the	O
main	O
lymph	O
node	O
groups	O
.	O
Normal	O
colour	O
.	O
Not	O
hydrated	O
.	O
No	O
jaundice	O
Septic	O
mouth	O
.	O
Normal	O
pharynx	O
without	O
exudate	O
.	O
No	O
crepitus	O
,	O
no	O
signs	O
of	O
inflammation	O
over	O
the	O
pacemaker	O
stack	O
.	O
AC	O
Rhythmic	O
.	O
Mitral	O
regurgitation	O
murmur	O
and	O
valvular	O
click	O
in	O
aortic	O
murmur	O
.	O
AP	O
Normal	O
respiratory	O
sounds	O
.	O
Abdomen	O
soft	O
,	O
tender	O
,	O
non	O
painful	O
,	O
no	O
palpable	O
masses	O
or	O
visceromegaly	O
.	O
Extremities	O
without	O
oedema	O
,	O
with	O
palpable	O
pulses	O
,	O
no	O
signs	O
of	O
DVT	O
.	O
No	O
skin	O
lesions	O
or	O
loss	O
of	O
skin	O
continuity	O
.	O
Conscious	O
,	O
oriented	O
,	O
cooperative	O
,	O
normal	O
speech	O
,	O
mobilises	O
all	O
4	O
limbs	O
,	O
normal	O
cranial	O
nerves	O
.	O
Negative	O
meningeal	O
signs	O
.	O
COMPLEMENTARY	O
EXPLORATIONS	O
ECG	O
pacemaker	O
rhythm	O
at	O
70lpm	O
,	O
with	O
ventricular	O
stimulation	O
,	O
left	O
bundle	O
branch	O
block	O
.	O
Chest	O
X	O
ray	O
global	O
cardiomegaly	O
,	O
signs	O
of	O
LVI	O
.	O
Pacemaker	O
with	O
electrodes	O
in	O
AD	O
and	O
VD	O
.	O
Biochemistry	O
glucose	O
168	O
mg	O
dl	O
Urea	O
78	O
mg	O
dl	O
Creatinine	O
1	O
.	O
65	O
mg	O
dl	O
Ck	O
48	O
ui	O
l	O
Sodium	O
131	O
CRP	O
134	O
FG	O
41	O
Fibrinogen	O
667	O
Blood	O
gases	O
Haematology	O
Leucocytes	O
15	O
"	O
2x10e9	O
l	O
neutrfilos	O
11	O
"	O
9x10e9	O
l	O
Brucellamelitensisrosa	O
de	O
bengala	O
negative	O
Abnormal	O
and	O
sediment	O
normal	O
.	O
DIAGNOSTIC	O
SUSPICION	O
BACTERIAL	O
ENDOCARDITIS	O
PLAN	O
Blood	O
cultures	O
Complete	O
blood	O
test	O
Echocardiogram	O
Allergology	O
consultation	O
HAEMOCULTURES	O
Anaerobic	O
flask	O
Enterococcus	O
faecalis	O
Sensitive	O
to	O
penicillin	B-FARMACO
Resistant	O
to	O
Quinupristin	B-FARMACO
dalfopristin	I-FARMACO
Cefuroxime	I-FARMACO
axetil	I-FARMACO
Cefuroxime	I-FARMACO
Trimethoprim	O
sulfamethoxazole	O
Clindamycin	B-FARMACO
Erythromycin	I-FARMACO
ECHOCARDIOGRAM	O
Impossibility	O
of	O
performing	O
a	O
TE	O
echocardiogram	O
due	O
to	O
lack	O
of	O
collaboration	O
Performance	O
of	O
TT	O
echocardiogram	O
Slight	O
left	O
atrial	O
dilatation	O
,	O
the	O
rest	O
of	O
the	O
chambers	O
being	O
of	O
normal	O
size	O
,	O
with	O
preserved	O
EF	O
.	O
Presence	O
of	O
concentric	O
LV	O
hypertrophy	O
.	O
Vegetation	O
of	O
12x7mm	O
at	O
the	O
level	O
of	O
the	O
atrial	O
segment	O
of	O
the	O
posterior	O
mitral	O
leaflet	O
without	O
haemodynamic	O
repercussions	O
.	O
Biological	O
aortic	O
prosthesis	O
,	O
normal	O
function	O
,	O
with	O
no	O
signs	O
suggestive	O
of	O
endocarditic	O
involvement	O
.	O
CONCLUSIONS	O
Endocarditismitral	O
.	O
Positive	O
blood	O
cultures	O
echocardiographic	O
confirmation	O
PET	O
CT	O
Due	O
to	O
limited	O
TTE	O
RESULT	O
focal	O
increase	O
of	O
activity	O
on	O
mitral	O
valve	O
.	O
While	O
in	O
biological	O
aortic	O
valve	O
prosthesis	O
no	O
focal	O
metabolic	O
uptake	O
is	O
observed	O
,	O
suggesting	O
infection	O
in	O
the	O
current	O
study	O
.	O
ALLERGOLOGY	O
INTERCONSULTATION	O
Initially	O
allergy	O
to	O
beta	B-FARMACO
lactams	I-FARMACO
,	O
treatment	O
with	O
VANCOMICIN	B-FARMACO
GENTAMYCIN	I-FARMACO
After	O
consultation	O
no	O
allergy	O
AMPICYLINE	B-FARMACO
2G	O
4H	O
CEFTRIAXONE	B-FARMACO
2G	O
12H	O
TREATMENT	O
Infection	O
on	O
native	O
valve	O
4	O
weeks	O
of	O
treatment	O
Infection	O
in	O
complex	O
patient	O
,	O
with	O
prosthetic	O
valve	O
and	O
pacemaker	O
we	O
extend	O
treatment	O
to	O
6	O
weeks	O
.	O

69	O
year	O
old	O
man	O
.	O
History	O
of	O
biological	O
AVR	O
9	O
months	O
earlier	O
.	O
Native	O
of	O
CABA	O
,	O
with	O
no	O
relevant	O
epidemiological	O
history	O
.	O
Evaluated	O
for	O
fever	O
and	O
intermittent	O
chills	O
of	O
2	O
months	O
of	O
evolution	O
.	O
Samples	O
were	O
taken	O
for	O
HC	O
which	O
were	O
repeatedly	O
negative	O
;	O
TEE	O
anechoic	O
image	O
compatible	O
with	O
drained	O
abscess	O
in	O
mitroaortic	O
fibrosa	O
territory	O
;	O
PET	O
CT	O
hypercaptation	O
at	O
perivalvular	O
level	O
.	O
He	O
underwent	O
empirical	O
antibiotic	O
treatment	O
with	O
Daptomycin	B-FARMACO
10	O
mg	O
kg	O
day	O
Ceftriaxone	B-FARMACO
2	O
g	O
day	O
for	O
6	O
weeks	O
with	O
a	O
diagnosis	O
of	O
probable	O
early	O
Ao	O
IVPVD	O
with	O
negative	O
HC	O
.	O
As	O
the	O
patient	O
progressed	O
favourably	O
,	O
it	O
was	O
decided	O
not	O
to	O
perform	O
surgery	O
during	O
the	O
hospitalisation	O
.	O
Two	O
months	O
after	O
completion	O
of	O
ATB	O
treatment	O
,	O
she	O
returned	O
with	O
fever	O
and	O
chills	O
.	O
HC	O
again	O
negative	O
and	O
TEE	O
with	O
progression	O
of	O
the	O
perivalvular	O
lesion	O
,	O
it	O
was	O
decided	O
to	O
perform	O
surgery	O
.	O
Perivalvular	O
sample	O
was	O
sent	O
for	O
culture	O
,	O
AP	O
and	O
PCR	O
in	O
which	O
C	O
.	O
burnetti	O
was	O
detected	O
by	O
16S	O
DNA	O
sequencing	O
.	O
Serology	O
by	O
IFA	O
for	O
Coxiella	O
IgG	O
1	O
256	O
.	O
Treatment	O
with	O
Doxycycline	B-FARMACO
200	O
mg	O
day	O
Hydroxychloroquine	B-FARMACO
400	O
mg	O
day	O
was	O
started	O
.	O
During	O
his	O
evolution	O
and	O
without	O
ever	O
being	O
able	O
to	O
go	O
outside	O
,	O
he	O
suffers	O
multiple	O
complications	O
associated	O
with	O
health	O
care	O
,	O
which	O
lead	O
to	O
his	O
death	O
5	O
months	O
after	O
surgery	O
.	O
Coxiella	O
burnetti	O
is	O
a	O
rare	O
cause	O
of	O
IE	O
.	O
It	O
should	O
be	O
suspected	O
especially	O
in	O
patients	O
with	O
negative	O
HC	O
and	O
specific	O
epidemiological	O
factors	O
such	O
as	O
contact	O
with	O
cattle	O
,	O
sheep	O
and	O
goats	O
.	O

A	O
59	O
year	O
old	O
male	O
with	O
a	O
high	O
fever	O
39o	O
of	O
2	O
days	O
'	O
evolution	O
and	O
an	O
episode	O
of	O
convulsive	O
crisis	O
.	O
He	O
appears	O
stuporous	O
.	O
BP	O
97	O
80	O
mmHg	O
.	O
Fc	O
132	O
bpm	O
.	O
SatO2	O
95	O
.	O
Fr	O
22	O
rpm	O
.	O
Ta	O
34	O
,	O
2oC	O
.	O
Fulfils	O
criteria	O
of	O
SEPSIS	O
SERIOUS	O
Ta34	O
,	O
2o	O
.	O
Acute	O
renal	O
failure	O
Creatinine	O
2	O
,	O
2	O
;	O
elevated	O
PCT	O
and	O
CRP	O
bacterial	O
infection	O
;	O
Hypotension	O
97	O
80	O
with	O
signs	O
of	O
poor	O
perfusion	O
cold	O
and	O
sweaty	O
,	O
Metabolic	O
acidosis	O
low	O
bicarbonate	O
,	O
elevated	O
lactate	O
hypoperfusion	O
;	O
Oligoanuria	O
;	O
very	O
striking	O
Plateletopenia	O
16	O
.	O
000	O
;	O
Tachycardia	O
AF	O
at	O
132	O
x	O
,	O
Tachypnoea	O
at	O
26	O
x	O
low	O
pCO2	O
.	O
The	O
FOCO	O
is	O
unknown	O
.	O
Let	O
's	O
go	O
by	O
parts	O
1	O
Sepsis	O
induced	O
hypotension	O
2	O
,	O
000	O
cc	O
of	O
Physiological	B-FARMACO
Serum	I-FARMACO
is	O
administered	O
and	O
later	O
in	O
ICU	O
1	O
,	O
500	O
cc	O
SF	B-FARMACO
.	O
maintains	O
BP	O
105	O
75	O
2	O
Atrial	O
fibrillation	O
at	O
130	O
x	O
AMIODARONE	B-FARMACO
IV	O
.	O
.	O
.	O
.	O
Sinus	O
rhythm	O
.	O
3	O
Antibiotic	O
?	O
After	O
2	O
blood	O
cultures	O
MEROPENEM	B-FARMACO
IV	O
,	O
CLOXACILLIN	B-FARMACO
CEFOTAXIME	I-FARMACO
CYPROFLOXACIN	I-FARMACO
was	O
chosen	O
in	O
ICU	O
.	O
and	O
subsequently	O
CLOXACILLIN	B-FARMACO
DAPTOMYCIN	I-FARMACO
currently	O
CLOXACILLIN	B-FARMACO
GENTAMYCIN	O
.	O
4	O
Convulsive	O
crisis	O
that	O
recurred	O
after	O
a	O
few	O
hours	O
.	O
CT	O
scan	O
SUBARACHNOID	O
HEMORRHAGE	O
,	O
probably	O
related	O
to	O
plateletopenia	O
or	O
mycotic	O
infectious	O
aneurysm	O
start	O
treatment	O
with	O
IV	O
LEVETIRACETAM	B-FARMACO
.	O
5	O
Plateletopenia	O
.	O
Consultation	O
with	O
haematology	O
"	O
does	O
not	O
meet	O
criteria	O
for	O
TTP	O
,	O
HIT	O
or	O
haemophagocytic	O
syndrome	O
;	O
ITP	O
versus	O
vasculitis	O
is	O
not	O
ruled	O
out	O
in	O
addition	O
to	O
the	O
septic	O
picture	O
"	O
.	O
Treatment	O
was	O
started	O
with	O
corticoids	O
platelet	O
perfusion	O
a	O
daily	O
pool	O
.	O
6	O
Search	O
for	O
FOCO	O
transthoracic	O
echocardiogram	O
was	O
performed	O
NO	O
warts	O
were	O
visualised	O
.	O
7	O
Blood	O
cultures	O
positive	O
for	O
STAPHILOCOCCUS	O
AUREUS	O
sensitive	O
to	O
methicillin	O
8	O
Transesophageal	O
echocardiogram	O
was	O
carried	O
out	O
an	O
image	O
of	O
VERRUGE	O
in	O
the	O
anterior	O
leaflet	O
of	O
the	O
mitral	O
valve	O
was	O
visualised	O
.	O
9	O
Consultation	O
with	O
Cardiovascular	O
Surgery	O
surgical	O
treatment	O
was	O
ruled	O
out	O
at	O
the	O
present	O
time	O
due	O
to	O
SAH	O
.	O
Reassessment	O
after	O
6	O
weeks	O
.	O
10	O
Appearance	O
of	O
purpuric	O
lesions	O
ecchymotic	O
of	O
probable	O
embolic	O
origin	O
on	O
the	O
tips	O
of	O
the	O
fingers	O
and	O
soles	O
of	O
the	O
feet	O
.	O
After	O
a	O
week	O
in	O
ICU	O
,	O
she	O
remained	O
stable	O
.	O
She	O
was	O
transferred	O
to	O
the	O
ward	O
.	O
DIAGNOSTIC	O
JUDGEMENT	O
Myxomatous	O
myxomatous	O
degeneration	O
due	O
to	O
S	O
.	O
AUREUS	O
.	O
SEVERE	O
SEPSIS	O
with	O
RENAL	O
FAILURE	O
corrected	O
at	O
discharge	O
.	O
SEVERE	O
PLATELETOPENIA	O
.	O
SUBARACHNOID	O
HAEMORRHAGE	O
.	O
Generalised	O
EPILEPTIC	O
CRISIS	O
ACxFA	O
reverted	O
to	O
sinus	O
rhythm	O
Commentary	O
Staphylococcus	O
aureus	O
S	O
.	O
Aureus	O
lives	O
on	O
human	O
skin	O
causes	O
skin	O
infections	O
folliculitis	O
,	O
impetigo	O
,	O
skin	O
abscesses	O
,	O
furunculosis	O
,	O
mastitis	O
,	O
cellulitis	O
,	O
wound	O
infection	O
.	O
.	O
.	O
also	O
surgical	O
wounds	O
.	O
.	O
.	O
.	O

Personal	O
history	O
Male	O
,	O
56	O
years	O
old	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
No	O
known	O
cardiological	O
history	O
.	O
Behet	O
's	O
disease	O
pulmonary	O
aneurysms	O
in	O
the	O
right	O
lung	O
,	O
surgery	O
in	O
1995	O
.	O
Chronic	O
hepatitis	O
B	O
.	O
Home	O
treatment	O
ASA	B-FARMACO
300	O
mg	O
,	O
peginterferon	B-FARMACO
alfa	I-FARMACO
2a	I-FARMACO
,	O
entecavir	B-FARMACO
.	O
Present	O
illness	O
She	O
has	O
been	O
suffering	O
from	O
generalised	O
asthenia	O
for	O
about	O
15	O
days	O
,	O
with	O
chest	O
pain	O
on	O
exertion	O
that	O
subsides	O
immediately	O
when	O
she	O
stops	O
.	O
No	O
orthopnoea	O
,	O
no	O
paroxysmal	O
nocturnal	O
dyspnoea	O
.	O
No	O
pre	O
syncope	O
.	O
No	O
fever	O
or	O
dysthymic	O
sensation	O
in	O
the	O
previous	O
days	O
.	O
Physical	O
examination	O
BP	O
123	O
79	O
mmHg	O
.	O
HR	O
41	O
bpm	O
.	O
Ta	O
35	O
.	O
2	O
C	O
.	O
Conscious	O
,	O
oriented	O
,	O
cooperative	O
.	O
Good	O
general	O
condition	O
.	O
Eupneic	O
on	O
ambient	O
air	O
.	O
Head	O
and	O
neck	O
no	O
IVY	O
at	O
45o	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
,	O
no	O
extra	O
sounds	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
non	O
painful	O
.	O
No	O
organomegaly	O
.	O
Extremities	O
no	O
oedema	O
.	O
No	O
evidence	O
of	O
deep	O
vein	O
thrombosis	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
high	O
degree	O
AV	O
block	O
with	O
2	O
1	O
conduction	O
.	O
QRS	O
130	O
ms	O
.	O
QRS	O
axis	O
at	O
60o	O
.	O
Bifascicular	O
block	O
BRDHH	O
HAI	O
with	O
ventriculophasic	O
sinus	O
arrhythmia	O
.	O
Chest	O
X	O
ray	O
no	O
evidence	O
of	O
acute	O
pleuropulmonary	O
pathology	O
.	O
Loss	O
of	O
right	O
lung	O
volume	O
and	O
metallic	O
density	O
material	O
in	O
the	O
lower	O
portion	O
of	O
the	O
ipsilateral	O
hemithorax	O
in	O
relation	O
to	O
surgical	O
history	O
.	O
Cardiopericardial	O
silhouette	O
of	O
normal	O
size	O
.	O
Annular	O
calcifications	O
projecting	O
on	O
the	O
cardiac	O
silhouette	O
,	O
already	O
present	O
in	O
the	O
previous	O
study	O
.	O
CBC	O
leukocytes	O
2	O
,	O
890	O
uL	O
N	O
50	O
.	O
2	O
,	O
L	O
34	O
.	O
9	O
.	O
Hb	O
12	O
.	O
9	O
g	O
dl	O
.	O
Platelets	O
93	O
,	O
000	O
uL	O
.	O
INR	O
1	O
.	O
12	O
.	O
TPPA	O
Ratio	O
1	O
.	O
12	O
.	O
Glucose	O
83	O
mg	O
dl	O
.	O
Urea	O
65	O
mg	O
dl	O
.	O
Creat	O
0	O
.	O
74	O
mg	O
dl	O
.	O
Na	O
143	O
.	O
K	O
4	O
.	O
5	O
.	O
Troponin	O
I	O
0	O
.	O
017	O
ng	O
dl	O
.	O
Echocardiogram	O
left	O
ventricle	O
not	O
dilated	O
,	O
with	O
preserved	O
ejection	O
fraction	O
.	O
Trivalve	O
aortic	O
valve	O
,	O
with	O
good	O
opening	O
and	O
slight	O
central	O
insufficiency	O
.	O
Left	O
atrium	O
not	O
dilated	O
.	O
Mitral	O
valve	O
with	O
good	O
opening	O
,	O
diastolic	O
mitral	O
regurgitation	O
.	O
Aortic	O
root	O
not	O
dilated	O
.	O
Right	O
chambers	O
not	O
dilated	O
,	O
good	O
right	O
ventricular	O
contractility	O
.	O
Mild	O
tricuspid	O
insufficiency	O
.	O
No	O
pericardial	O
effusion	O
.	O
Coronary	O
angiography	O
left	O
coronary	O
trunk	O
without	O
lesions	O
.	O
Anterior	O
descending	O
calcified	O
aneurysmal	O
dilatation	O
of	O
the	O
proximal	O
wall	O
with	O
slowing	O
of	O
distal	O
flow	O
.	O
Circumflex	O
large	O
aneurysmal	O
dilatation	O
at	O
proximal	O
level	O
,	O
calcified	O
,	O
with	O
partial	O
thrombosis	O
of	O
the	O
lumen	O
,	O
which	O
conditions	O
flow	O
slowing	O
at	O
distal	O
level	O
.	O
Right	O
coronary	O
artery	O
no	O
lesions	O
.	O
Aortography	O
no	O
aneurysmal	O
dilatation	O
.	O
Coronary	O
CT	O
coronary	O
saccular	O
aneurysms	O
in	O
circumflex	O
partially	O
thrombosed	O
and	O
with	O
a	O
3	O
4	O
mm	O
neck	O
and	O
in	O
the	O
anterior	O
descending	O
artery	O
not	O
thrombosed	O
and	O
seated	O
on	O
a	O
15	O
mm	O
long	O
dysplastic	O
artery	O
segment	O
.	O
EVOLUTION	O
A	O
56	O
year	O
old	O
patient	O
was	O
admitted	O
to	O
the	O
Coronary	O
Care	O
Unit	O
for	O
2	O
1	O
AV	O
block	O
with	O
wide	O
QRS	O
and	O
symptoms	O
compatible	O
with	O
recent	O
onset	O
exertional	O
angina	O
.	O
Coronary	O
angiography	O
was	O
performed	O
,	O
showing	O
evidence	O
of	O
anterior	O
descending	O
artery	O
with	O
calcified	O
aneurysmal	O
dilatation	O
of	O
the	O
proximal	O
wall	O
with	O
slowing	O
of	O
distal	O
flow	O
,	O
proximal	O
circumflex	O
artery	O
with	O
large	O
aneurysmal	O
dilatation	O
,	O
calcified	O
,	O
with	O
partial	O
thrombosis	O
of	O
the	O
lumen	O
,	O
leading	O
to	O
slowing	O
of	O
distal	O
flow	O
.	O
The	O
case	O
was	O
discussed	O
in	O
a	O
medical	O
surgical	O
session	O
and	O
coronary	O
surgery	O
was	O
decided	O
upon	O
,	O
prior	O
to	O
the	O
implantation	O
of	O
a	O
permanent	O
pacemaker	O
.	O
The	O
convenience	O
of	O
temporarily	O
suspending	O
treatment	O
with	O
peginterferon	B-FARMACO
alfa	I-FARMACO
in	O
order	O
to	O
improve	O
the	O
leukocyte	O
and	O
platelet	O
count	O
figures	O
as	O
much	O
as	O
possible	O
in	O
preparation	O
for	O
surgery	O
was	O
discussed	O
at	O
the	O
session	O
.	O
In	O
this	O
regard	O
,	O
he	O
was	O
assessed	O
by	O
Hepatology	O
and	O
they	O
recommended	O
suspending	O
peginterferon	B-FARMACO
prior	O
to	O
surgery	O
and	O
resuming	O
it	O
as	O
soon	O
as	O
possible	O
after	O
the	O
operation	O
.	O
On	O
21	O
October	O
2016	O
,	O
an	O
EPS	O
was	O
performed	O
,	O
which	O
revealed	O
infra	O
Hisian	O
AV	O
block	O
,	O
and	O
a	O
definitive	O
bicameral	O
pacemaker	O
was	O
subsequently	O
implanted	O
without	O
complications	O
.	O
Post	O
implantation	O
controls	O
of	O
the	O
pacemaker	O
showed	O
adequate	O
functioning	O
of	O
the	O
device	O
.	O
He	O
was	O
stable	O
cardiovascular	O
and	O
asymptomatic	O
,	O
with	O
no	O
evidence	O
of	O
HF	O
,	O
and	O
was	O
discharged	O
from	O
hospital	O
for	O
admission	O
the	O
following	O
week	O
for	O
cardiac	O
surgery	O
.	O
On	O
4	O
November	O
2016	O
,	O
coronary	O
revascularisation	O
surgery	O
with	O
a	O
double	O
"	O
Y	O
"	O
mammary	O
artery	O
under	O
ECC	O
was	O
scheduled	O
.	O
Bypass	O
of	O
the	O
left	O
mammary	O
artery	O
to	O
the	O
anterior	O
descending	O
artery	O
and	O
of	O
the	O
right	O
mammary	O
artery	O
to	O
the	O
obtuse	O
marginal	O
artery	O
was	O
performed	O
.	O
Distal	O
and	O
proximal	O
ligation	O
of	O
the	O
anterior	O
descending	O
aneurysm	O
was	O
also	O
performed	O
.	O
Intervention	O
without	O
complications	O
.	O
Postoperative	O
resuscitation	O
without	O
incident	O
.	O
DIAGNOSIS	O
Behet	O
's	O
disease	O
.	O
Infra	O
Hisian	O
atrioventricular	O
2	O
1	O
block	O
.	O
Implantation	O
of	O
a	O
definitive	O
bicameral	O
pacemaker	O
.	O
Ischaemic	O
heart	O
disease	O
due	O
to	O
coronary	O
aneurysms	O
.	O
Coronary	O
revascularisation	O
with	O
double	O
mammary	O
artery	O
to	O
anterior	O
descending	O
and	O
obtuse	O
marginal	O
.	O
Ligation	O
of	O
anterior	O
descending	O
aneurysm	O
.	O

HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
We	O
present	O
the	O
case	O
of	O
a	O
72	O
year	O
old	O
patient	O
,	O
operated	O
on	O
for	O
symptomatic	O
severe	O
aortic	O
stenosis	O
with	O
implantation	O
of	O
a	O
biological	O
aortic	O
prosthesis	O
Mitroflow	O
no21	O
,	O
who	O
was	O
admitted	O
for	O
febrile	O
syndrome	O
.	O
The	O
patient	O
had	O
a	O
personal	O
history	O
of	O
hypertension	O
and	O
dyslipidaemia	O
,	O
and	O
was	O
being	O
treated	O
with	O
enalapril	B-FARMACO
10mg	O
,	O
one	O
tablet	O
every	O
12	O
hours	O
,	O
and	O
simvastatin	B-FARMACO
40	O
mg	O
,	O
one	O
tablet	O
per	O
day	O
.	O
Three	O
months	O
after	O
the	O
operation	O
,	O
the	O
patient	O
consulted	O
the	O
emergency	O
department	O
for	O
two	O
weeks	O
of	O
fever	O
38	O
C	O
,	O
asthenia	O
,	O
anorexia	O
and	O
deterioration	O
of	O
general	O
condition	O
.	O
On	O
physical	O
examination	O
he	O
was	O
haemodynamically	O
stable	O
BP	O
140	O
80	O
mmHg	O
;	O
HR	O
75	O
bpm	O
,	O
SatO2	O
97	O
breathing	O
room	O
air	O
.	O
Cardiopulmonary	O
auscultation	O
revealed	O
rhythmic	O
,	O
tachycardic	O
sounds	O
,	O
with	O
systolic	O
murmur	O
II	O
VI	O
in	O
the	O
aortic	O
focus	O
,	O
with	O
no	O
clinical	O
signs	O
of	O
heart	O
failure	O
.	O
The	O
rest	O
of	O
the	O
examination	O
was	O
unremarkable	O
,	O
with	O
no	O
cutaneous	O
stigmata	O
of	O
endocarditis	O
.	O
COMPLEMENTARY	O
TESTS	O
The	O
admission	O
blood	O
test	O
showed	O
a	O
high	O
white	O
blood	O
cell	O
count	O
16	O
,	O
000	O
L	O
at	O
the	O
expense	O
of	O
neutrophils	O
87	O
with	O
elevated	O
acute	O
phase	O
reactants	O
CRP	O
267	O
mg	O
l	O
,	O
the	O
rest	O
of	O
the	O
analytical	O
parameters	O
being	O
normal	O
.	O
The	O
electrocardiogram	O
showed	O
sinus	O
tachycardia	O
and	O
signs	O
of	O
left	O
chamber	O
enlargement	O
with	O
an	O
overload	O
pattern	O
.	O
On	O
admission	O
,	O
4	O
batches	O
of	O
serial	O
blood	O
cultures	O
were	O
taken	O
and	O
Staphylococcus	O
epidermidis	O
was	O
isolated	O
in	O
all	O
the	O
bottles	O
,	O
so	O
antibiotherapy	O
with	O
vancomycin	B-FARMACO
,	O
gentamicin	B-FARMACO
and	O
rifampicin	B-FARMACO
was	O
started	O
,	O
in	O
accordance	O
with	O
the	O
regimen	O
recommended	O
by	O
the	O
clinical	O
practice	O
guidelines	O
.	O
As	O
a	O
first	O
approach	O
,	O
transthoracic	O
echocardiography	O
TTE	O
was	O
performed	O
,	O
which	O
showed	O
a	O
biological	O
prosthesis	O
in	O
the	O
aortic	O
position	O
,	O
with	O
adequate	O
opening	O
of	O
its	O
leaflets	O
,	O
without	O
the	O
presence	O
of	O
periprosthetic	O
regurgitation	O
.	O
Transesophageal	O
echocardiography	O
TEE	O
showed	O
no	O
evidence	O
of	O
prosthetic	O
dysfunction	O
or	O
conclusive	O
signs	O
of	O
endocarditis	O
.	O
Given	O
the	O
high	O
clinical	O
suspicion	O
of	O
infective	O
endocarditis	O
,	O
it	O
was	O
decided	O
to	O
extend	O
the	O
study	O
with	O
positron	O
emission	O
tomography	O
with	O
18F	O
fluorodeoxyglucose	O
18F	O
FDG	O
PET	O
CT	O
,	O
which	O
showed	O
increased	O
FDG	O
uptake	O
at	O
the	O
level	O
of	O
the	O
aortic	O
root	O
,	O
periprosthetic	O
,	O
of	O
annular	O
morphology	O
and	O
with	O
a	O
SUVmax	O
Standard	O
Uptake	O
Value	O
of	O
5	O
,	O
compatible	O
with	O
endocarditis	O
.	O
It	O
was	O
decided	O
to	O
perform	O
a	O
new	O
TEE	O
,	O
2	O
weeks	O
after	O
the	O
first	O
study	O
,	O
where	O
signs	O
of	O
endocarditis	O
with	O
significant	O
periprosthetic	O
involvement	O
were	O
observed	O
presence	O
of	O
periannular	O
pseudoaneurysm	O
with	O
fistulisation	O
towards	O
the	O
right	O
atrium	O
,	O
vegetations	O
and	O
signs	O
of	O
periprosthetic	O
dehiscence	O
.	O
EVOLUTION	O
After	O
two	O
weeks	O
of	O
antibiotic	O
therapy	O
with	O
negative	O
blood	O
cultures	O
,	O
valve	O
replacement	O
surgery	O
and	O
repair	O
of	O
the	O
aorto	O
atrial	O
fistula	O
with	O
pericardial	O
patch	O
was	O
performed	O
.	O
Microbiological	O
analysis	O
of	O
the	O
excised	O
surgical	O
tissue	O
showed	O
abundant	O
polymorphonuclear	O
cells	O
without	O
microorganisms	O
in	O
the	O
Gram	O
stain	O
,	O
and	O
the	O
culture	O
was	O
finally	O
negative	O
.	O
DIAGNOSIS	O
Early	O
infective	O
endocarditis	O
on	O
aortic	O
biological	O
prosthesis	O
due	O
to	O
Staphylococcus	O
epidermidis	O
.	O
Periprosthetic	O
pseudoaneurysm	O
,	O
fistulised	O
to	O
right	O
chambers	O
.	O
Antibiotic	O
and	O
surgical	O
treatment	O
with	O
good	O
evolution	O
.	O

Male	O
,	O
72	O
years	O
old	O
.	O
History	O
Arterial	O
hypertension	O
,	O
non	O
insulin	O
dependent	O
diabetes	O
mellitus	O
,	O
ex	O
smoker	O
and	O
dyslipidaemia	O
as	O
main	O
cardiovascular	O
risk	O
factors	O
.	O
Cardiological	O
history	O
implantation	O
of	O
a	O
mechanical	O
aortic	O
prosthesis	O
in	O
2005	O
due	O
to	O
severe	O
aortic	O
stenosis	O
in	O
bicuspid	O
valve	O
.	O
Home	O
treatment	O
lorazepam	B-FARMACO
1	O
day	O
,	O
acenocoumarol	B-FARMACO
,	O
torasemide	B-FARMACO
5	O
mg	O
1	O
day	O
,	O
telmisartan	B-FARMACO
80	O
mg	O
1	O
day	O
,	O
metformin	B-FARMACO
850	O
mg	O
1	O
12	O
h	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
1	O
day	O
.	O
Previously	O
well	O
,	O
the	O
patient	O
presented	O
with	O
absence	O
of	O
language	O
and	O
loss	O
of	O
strength	O
and	O
sensitivity	O
in	O
the	O
entire	O
right	O
hemisphere	O
.	O
The	O
SAMU	O
was	O
notified	O
and	O
activated	O
the	O
Stroke	O
Code	O
,	O
arriving	O
at	O
the	O
emergency	O
department	O
in	O
a	O
conventional	O
ambulance	O
with	O
an	O
estimated	O
NIHSS	O
of	O
16	O
.	O
In	O
previous	O
days	O
she	O
had	O
referred	O
mild	O
catarrhal	O
symptoms	O
associated	O
with	O
a	O
feeling	O
of	O
dystrophy	O
.	O
Physical	O
examination	O
Neurological	O
NIHSS	O
score	O
alert	O
0	O
.	O
Does	O
not	O
answer	O
questions	O
or	O
obey	O
orders	O
2	O
2	O
.	O
Gaze	O
deviation	O
to	O
the	O
left	O
1	O
.	O
Central	O
facial	O
paresis	O
D	O
2	O
.	O
Paresis	O
4	O
5	O
in	O
right	O
upper	O
limb	O
1	O
.	O
Paresis	O
2	O
5	O
in	O
right	O
lower	O
limb	O
3	O
.	O
Not	O
assessable	O
sensitivity	O
although	O
to	O
painful	O
manoeuvre	O
,	O
slight	O
withdrawal	O
1	O
.	O
Ataxia	O
not	O
assessable	O
0	O
.	O
Mutism	O
3	O
1	O
.	O
Not	O
assessable	O
extinction	O
.	O
BP	O
120	O
75	O
mmHg	O
,	O
Sat	O
99	O
with	O
nasal	O
goggles	O
at	O
3	O
bpm	O
,	O
HR	O
70	O
.	O
Temperature	O
not	O
recorded	O
AC	O
RsCsRs	O
without	O
audible	O
murmurs	O
,	O
prosthetic	O
click	O
.	O
AP	O
mvc	O
,	O
no	O
added	O
sounds	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
.	O
MMII	O
without	O
oedema	O
or	O
signs	O
of	O
DVT	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
sinus	O
rhythm	O
at	O
66	O
bpm	O
.	O
Left	O
anterior	O
hemiblock	O
.	O
Chest	O
X	O
ray	O
no	O
condensation	O
or	O
signs	O
of	O
HF	O
.	O
Laboratory	O
tests	O
biochemistry	O
Glc	O
187	O
mg	O
dl	O
.	O
Urea	O
45	O
mg	O
dl	O
.	O
Creatinine	O
0	O
.	O
95	O
mg	O
dl	O
.	O
Na	O
133	O
mmol	O
l	O
.	O
K	O
4	O
.	O
8	O
mmol	O
L	O
.	O
TnT	O
16	O
ng	O
l	O
normal	O
35	O
ng	O
l	O
.	O
CPK	O
66	O
U	O
l	O
normal	O
200	O
U	O
l	O
.	O
Haemogram	O
Hb	O
12	O
.	O
8	O
g	O
dl	O
.	O
Ht	O
34	O
.	O
9	O
.	O
Leukocytes	O
14	O
,	O
300	O
uL	O
with	O
78	O
neutrophils	O
.	O
Platelets	O
199	O
.	O
000	O
uL	O
.	O
Coagulation	O
PT	O
45	O
;	O
INR	O
1	O
.	O
86	O
.	O
Cranial	O
CT	O
discrete	O
hypodensity	O
with	O
loss	O
of	O
differentiation	O
between	O
grey	O
matter	O
and	O
white	O
matter	O
at	O
the	O
level	O
of	O
the	O
left	O
frontal	O
insula	O
and	O
operculum	O
,	O
compatible	O
with	O
acute	O
ischaemic	O
lesion	O
ASPECTS	O
8	O
.	O
No	O
intra	O
or	O
extra	O
axial	O
haemorrhages	O
are	O
observed	O
.	O
Morphology	O
of	O
sulci	O
and	O
ventricles	O
within	O
normal	O
limits	O
for	O
the	O
patient	O
's	O
age	O
.	O
Discrete	O
bilateral	O
periventricular	O
hypodensity	O
compatible	O
with	O
chronic	O
small	O
vessel	O
disease	O
.	O
Centred	O
midline	O
.	O
Permeable	O
base	O
cisterns	O
.	O
Cerebral	O
perfusion	O
CT	O
in	O
the	O
superficial	O
territory	O
of	O
the	O
left	O
MCA	O
there	O
is	O
an	O
increase	O
in	O
time	O
to	O
peak	O
,	O
mean	O
transit	O
time	O
and	O
drainage	O
time	O
,	O
with	O
a	O
decrease	O
in	O
cerebral	O
blood	O
flow	O
.	O
At	O
the	O
level	O
of	O
the	O
insula	O
and	O
the	O
left	O
frontal	O
operculum	O
there	O
is	O
a	O
decrease	O
in	O
volume	O
,	O
compatible	O
with	O
established	O
infarction	O
,	O
while	O
in	O
the	O
rest	O
of	O
the	O
superficial	O
territory	O
of	O
the	O
left	O
MCA	O
the	O
volume	O
is	O
preserved	O
,	O
compatible	O
with	O
a	O
penumbra	O
area	O
.	O
Angio	O
CT	O
of	O
supra	O
aortic	O
trunks	O
and	O
Willis	O
polygon	O
repletion	O
defect	O
at	O
the	O
level	O
of	O
the	O
distal	O
M1	O
segment	O
of	O
the	O
left	O
MCA	O
,	O
with	O
poor	O
distal	O
collateral	O
circulation	O
.	O
No	O
other	O
repletion	O
defects	O
,	O
aneurysmal	O
formations	O
or	O
other	O
alterations	O
at	O
the	O
level	O
of	O
the	O
intra	O
or	O
extracranial	O
circulation	O
.	O
Absence	O
of	O
both	O
posterior	O
communicating	O
arteries	O
.	O
Carotid	O
shafts	O
slightly	O
elongated	O
.	O
Patent	O
vertebral	O
arteries	O
with	O
right	O
dominance	O
.	O
Basilar	O
artery	O
dependent	O
exclusively	O
on	O
the	O
right	O
vertebral	O
artery	O
,	O
with	O
left	O
vertebral	O
artery	O
leading	O
directly	O
into	O
the	O
PICA	O
.	O
Cerebral	O
angiography	O
under	O
sedation	O
,	O
cerebral	O
arteriography	O
was	O
performed	O
via	O
the	O
right	O
femoral	O
approach	O
,	O
without	O
groin	O
complications	O
.	O
Occlusion	O
of	O
the	O
distal	O
M1	O
segment	O
of	O
the	O
left	O
MCA	O
was	O
confirmed	O
,	O
with	O
the	O
existence	O
of	O
a	O
proximal	O
loop	O
in	O
the	O
internal	O
carotid	O
artery	O
.	O
We	O
proceeded	O
to	O
perform	O
mechanical	O
thrombectomy	O
with	O
an	O
extractor	O
device	O
,	O
achieving	O
complete	O
recanalisation	O
of	O
this	O
artery	O
,	O
although	O
with	O
migration	O
of	O
two	O
small	O
emboli	O
one	O
in	O
the	O
distal	O
posterior	O
parietal	O
region	O
non	O
occlusive	O
embolus	O
and	O
the	O
other	O
in	O
the	O
sylvian	O
region	O
.	O
Blood	O
cultures	O
positive	O
for	O
Enterococcus	O
faecalis	O
.	O
TTE	O
and	O
TEE	O
endocarditis	O
on	O
prosthetic	O
aortic	O
valve	O
.	O
Ascending	O
aortic	O
aneurysm	O
of	O
49	O
mm	O
.	O
Mechanical	O
aortic	O
prosthesis	O
with	O
good	O
disc	O
mobility	O
,	O
maximum	O
gradient	O
of	O
35	O
mmHg	O
,	O
washout	O
insufficiency	O
.	O
Two	O
vibrational	O
images	O
compatible	O
with	O
vegetation	O
visualised	O
in	O
LVOT	O
are	O
observed	O
.	O
Thickening	O
of	O
the	O
aortic	O
root	O
and	O
mitro	O
aortic	O
junction	O
suggestive	O
of	O
abscess	O
at	O
this	O
level	O
.	O
MV	O
with	O
mild	O
insufficiency	O
.	O
LV	O
of	O
normal	O
dimensions	O
with	O
preserved	O
systolic	O
function	O
.	O
RV	O
of	O
normal	O
dimensions	O
with	O
normal	O
function	O
.	O
Moderate	O
TR	O
,	O
with	O
estimated	O
PSAP	O
of	O
30	O
mmHg	O
plus	O
PVC	O
.	O
Normal	O
vena	O
cava	O
.	O
No	O
pericardial	O
effusion	O
.	O
EVOLUTION	O
On	O
arrival	O
at	O
the	O
emergency	O
department	O
,	O
on	O
suspicion	O
of	O
acute	O
stroke	O
,	O
the	O
above	O
mentioned	O
complementary	O
tests	O
were	O
performed	O
and	O
cerebral	O
angiography	O
confirmed	O
the	O
presence	O
of	O
occlusion	O
of	O
the	O
distal	O
M1	O
segment	O
of	O
the	O
middle	O
cerebral	O
artery	O
.	O
As	O
a	O
result	O
,	O
mechanical	O
thrombectomy	O
was	O
performed	O
,	O
achieving	O
complete	O
recanalisation	O
of	O
the	O
artery	O
.	O
The	O
patient	O
was	O
then	O
admitted	O
to	O
the	O
Intensive	O
Care	O
Unit	O
for	O
neurological	O
and	O
haemodynamic	O
monitoring	O
and	O
surveillance	O
.	O
The	O
patient	O
progressed	O
satisfactorily	O
in	O
the	O
ICU	O
,	O
where	O
a	O
transthoracic	O
echocardiogram	O
was	O
performed	O
with	O
suspicion	O
of	O
endocarditis	O
.	O
Isolation	O
of	O
Enterococcus	O
faecalis	O
in	O
blood	O
cultures	O
.	O
A	O
transesophageal	O
study	O
was	O
performed	O
with	O
the	O
results	O
described	O
.	O
Once	O
stable	O
,	O
in	O
the	O
light	O
of	O
the	O
echocardiographic	O
findings	O
,	O
discharge	O
from	O
the	O
ICU	O
to	O
the	O
Cardiology	O
ward	O
was	O
decided	O
in	O
order	O
to	O
assess	O
valve	O
surgery	O
.	O
During	O
his	O
admission	O
to	O
Cardiology	O
,	O
he	O
was	O
assessed	O
by	O
the	O
Rehabilitation	O
Service	O
and	O
Neurology	O
,	O
who	O
began	O
motor	O
and	O
phoniatric	O
recovery	O
exercises	O
.	O
Cardiologically	O
,	O
he	O
remained	O
stable	O
,	O
with	O
prolonged	O
PR	O
.	O
Two	O
days	O
later	O
,	O
the	O
patient	O
had	O
two	O
episodes	O
of	O
sudden	O
loss	O
of	O
consciousness	O
,	O
and	O
telemetry	O
showed	O
complete	O
atrioventricular	O
block	O
,	O
so	O
he	O
was	O
transferred	O
to	O
the	O
Coronary	O
Unit	O
for	O
implantation	O
of	O
a	O
provisional	O
pacemaker	O
via	O
the	O
right	O
jugular	O
vein	O
.	O
The	O
case	O
was	O
discussed	O
with	O
Cardiac	O
Surgery	O
who	O
,	O
given	O
the	O
electrical	O
worsening	O
and	O
the	O
need	O
for	O
a	O
temporary	O
pacemaker	O
on	O
command	O
to	O
maintain	O
stability	O
,	O
decided	O
to	O
perform	O
surgery	O
within	O
48	O
hours	O
.	O
The	O
patient	O
underwent	O
surgery	O
two	O
days	O
later	O
and	O
a	O
metallic	O
valve	O
prosthesis	O
was	O
extracted	O
with	O
abscess	O
cleaning	O
and	O
a	O
biological	O
prosthesis	O
was	O
implanted	O
in	O
the	O
aortic	O
position	O
,	O
as	O
well	O
as	O
a	O
supracoronary	O
tube	O
due	O
to	O
the	O
discovery	O
of	O
an	O
aneurysm	O
of	O
the	O
ascending	O
aorta	O
.	O
Immediate	O
and	O
late	O
postoperative	O
evolution	O
was	O
favourable	O
,	O
except	O
for	O
the	O
persistence	O
of	O
advanced	O
AVB	O
in	O
ECG	O
despite	O
the	O
absence	O
of	O
images	O
compatible	O
with	O
abscesses	O
in	O
echocardiography	O
,	O
so	O
it	O
was	O
decided	O
to	O
implant	O
a	O
definitive	O
DDD	O
pacemaker	O
.	O
Hospital	O
discharge	O
was	O
decided	O
in	O
view	O
of	O
the	O
good	O
clinical	O
evolution	O
in	O
the	O
postoperative	O
period	O
40	O
days	O
after	O
the	O
neurological	O
ischaemic	O
event	O
.	O
DIAGNOSIS	O
Late	O
prosthetic	O
endocarditis	O
due	O
to	O
Enterococcus	O
faecalis	O
.	O
Ischaemic	O
stroke	O
due	O
to	O
thrombotic	O
occlusion	O
in	O
left	O
middle	O
cerebral	O
artery	O
.	O
Thrombectomy	O
performed	O
successfully	O
.	O
Complete	O
atrioventricular	O
block	O
with	O
definitive	O
DDDR	O
pacemaker	O
implantation	O
MCP	O
.	O
Aortic	O
valve	O
replacement	O
with	O
Perimount	O
biological	O
aortic	O
prosthesis	O
no23	O
.	O
	O
Ascending	O
aortic	O
aneurysm	O
.	O
Supracoronary	O
tube	O
implantation	O
.	O

Sam	O
is	O
a	O
52	O
year	O
old	O
male	O
ex	O
smoker	O
who	O
denies	O
any	O
other	O
cardiovascular	O
risk	O
factors	O
.	O
He	O
has	O
developed	O
an	O
unresectable	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
tonsil	O
T4bN2bM0	O
as	O
a	O
result	O
of	O
his	O
past	O
tobacco	O
use	O
.	O
Currently	O
undergoing	O
radical	O
treatment	O
with	O
cetuximab	B-FARMACO
and	O
radiotherapy	O
.	O
Asymptomatic	O
from	O
the	O
cardiological	O
point	O
of	O
view	O
until	O
the	O
night	O
of	O
the	O
day	O
before	O
the	O
consultation	O
,	O
when	O
he	O
presented	O
with	O
central	O
thoracic	O
pain	O
,	O
oppressive	O
and	O
radiating	O
to	O
the	O
back	O
and	O
neck	O
,	O
lasting	O
a	O
few	O
hours	O
.	O
He	O
denies	O
having	O
had	O
fever	O
or	O
infectious	O
symptoms	O
.	O
He	O
consulted	O
his	O
primary	O
care	O
doctor	O
who	O
performed	O
an	O
electrocardiogram	O
ECG	O
in	O
which	O
they	O
described	O
an	O
increase	O
in	O
the	O
lower	O
ST	O
and	O
high	O
and	O
low	O
lateral	O
ST	O
,	O
and	O
was	O
assessed	O
by	O
members	O
of	O
the	O
Canary	O
Islands	O
Emergency	O
Service	O
SUC	O
who	O
informed	O
the	O
hospital	O
of	O
the	O
diagnosis	O
of	O
inferolateral	O
acute	O
myocardial	O
infarction	O
AMI	O
with	O
a	O
view	O
to	O
carrying	O
out	O
primary	O
angioplasty	O
.	O
On	O
arrival	O
at	O
the	O
Emergency	O
Department	O
he	O
was	O
found	O
to	O
be	O
hypotensive	O
,	O
so	O
dopamine	B-FARMACO
was	O
started	O
at	O
a	O
dose	O
of	O
15	O
mcg	O
kg	O
min	O
,	O
and	O
the	O
Haemodynamics	O
section	O
was	O
contacted	O
for	O
urgent	O
catheterisation	O
,	O
so	O
the	O
cardiologist	O
on	O
duty	O
went	O
down	O
to	O
assess	O
the	O
patient	O
.	O
The	O
ECG	O
was	O
repeated	O
.	O
Physical	O
examination	O
revealed	O
a	O
poor	O
general	O
condition	O
,	O
with	O
significant	O
tachypnoea	O
and	O
arterial	O
hypotension	O
of	O
85	O
55	O
mmHg	O
despite	O
catecholamines	B-FARMACO
and	O
mild	O
jugular	O
venous	O
insufficiency	O
.	O
Cardiac	O
sounds	O
are	O
very	O
diminished	O
with	O
no	O
murmurs	O
or	O
friction	O
rub	O
.	O
There	O
is	O
an	O
erythematous	O
lump	O
on	O
the	O
neck	O
,	O
warm	O
and	O
painful	O
on	O
palpation	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
tests	O
no	O
leukocytosis	O
,	O
normocytic	O
normochromic	O
anaemia	O
of	O
9	O
.	O
7	O
mg	O
dL	O
and	O
acute	O
renal	O
failure	O
with	O
creatinine	O
of	O
2	O
.	O
4	O
mg	O
dL	O
.	O
Hb	O
13	O
.	O
3	O
g	O
dL	O
,	O
leukocytes	O
64	O
,	O
000	O
,	O
platelets	O
77x10	O
3	O
mcL	O
.	O
Echocardiography	O
global	O
and	O
segmental	O
left	O
ventricular	O
function	O
was	O
preserved	O
and	O
severe	O
pericardial	O
effusion	O
was	O
detected	O
with	O
a	O
maximum	O
of	O
36	O
mm	O
at	O
the	O
anterior	O
level	O
.	O
Its	O
appearance	O
is	O
dense	O
,	O
hyperechogenic	O
and	O
mottled	O
.	O
There	O
were	O
signs	O
of	O
haemodynamic	O
compromise	O
,	O
with	O
collapse	O
of	O
the	O
left	O
atrium	O
and	O
a	O
slight	O
collapse	O
of	O
the	O
right	O
ventricle	O
.	O
Other	O
complementary	O
tests	O
during	O
admission	O
ECG	O
sinus	O
rhythm	O
at	O
100	O
bpm	O
,	O
normal	O
PR	O
,	O
normal	O
electrical	O
axis	O
,	O
narrow	O
QRS	O
with	O
generalised	O
concave	O
ST	O
elevation	O
I	O
,	O
II	O
,	O
III	O
,	O
aVF	O
,	O
V3	O
V6	O
Pericardial	O
fluid	O
culture	O
and	O
blood	O
cultures	O
Streptococcus	O
constellatum	O
.	O
Chest	O
CT	O
with	O
contrast	O
bibasal	O
lung	O
consolidations	O
.	O
To	O
evaluate	O
possible	O
bronchoaspiration	O
.	O
Minimal	O
right	O
pleural	O
effusion	O
.	O
Pneumopericardium	O
with	O
drainage	O
catheter	O
inside	O
.	O
Multiple	O
hepatic	O
abscesses	O
in	O
LHI	O
.	O
LOE	O
in	O
LHI	O
in	O
relation	O
to	O
abscess	O
versus	O
metastatic	O
disease	O
not	O
present	O
in	O
previous	O
study	O
.	O
Rest	O
normal	O
,	O
no	O
mesenteric	O
or	O
retroperitoneal	O
adenopathy	O
.	O
Neck	O
CT	O
favourable	O
response	O
of	O
left	O
tonsillar	O
neoplasm	O
and	O
adenopathic	O
conglomerates	O
.	O
Significant	O
response	O
with	O
a	O
decrease	O
in	O
the	O
overall	O
tumour	O
volume	O
of	O
the	O
neoplasm	O
originating	O
in	O
the	O
left	O
lingual	O
tonsil	O
,	O
with	O
a	O
residual	O
necrotic	O
lesion	O
persisting	O
at	O
this	O
level	O
with	O
a	O
diameter	O
of	O
24	O
.	O
8	O
30	O
mm	O
,	O
which	O
protrudes	O
towards	O
the	O
left	O
lateral	O
margin	O
of	O
the	O
floor	O
of	O
the	O
mouth	O
.	O
EVOLUTION	O
It	O
was	O
decided	O
to	O
perform	O
an	O
urgent	O
therapeutic	O
pericardiocentesis	O
in	O
the	O
haemodynamics	O
room	O
.	O
Initially	O
,	O
600	O
cc	O
of	O
foul	O
smelling	O
,	O
purulent	O
fluid	O
was	O
extracted	O
.	O
After	O
analysing	O
the	O
emergency	O
fluid	O
,	O
it	O
was	O
found	O
to	O
be	O
purulent	O
and	O
S	O
.	O
constellatum	O
,	O
which	O
was	O
also	O
isolated	O
from	O
blood	O
,	O
was	O
isolated	O
.	O
An	O
aetiological	O
study	O
was	O
completed	O
with	O
a	O
CT	O
scan	O
of	O
the	O
chest	O
and	O
abdomen	O
to	O
identify	O
the	O
possible	O
origin	O
of	O
the	O
purulent	O
collection	O
,	O
finding	O
multiple	O
large	O
liver	O
abscesses	O
,	O
in	O
whose	O
culture	O
different	O
microorganisms	O
grew	O
,	O
although	O
they	O
were	O
also	O
present	O
in	O
the	O
oral	O
microbiota	O
Gemella	O
morbillorum	O
and	O
Parvimonas	O
micra	O
.	O
In	O
the	O
first	O
few	O
days	O
after	O
drainage	O
,	O
the	O
patient	O
continued	O
to	O
require	O
catecholaminergic	O
support	O
due	O
to	O
septic	O
shock	O
,	O
so	O
he	O
was	O
admitted	O
to	O
the	O
ICU	O
,	O
where	O
empirical	O
intravenous	O
antibiotic	O
treatment	O
was	O
initially	O
established	O
,	O
and	O
subsequently	O
adjusted	O
to	O
the	O
antibiogram	O
.	O
Within	O
a	O
week	O
of	O
complete	O
drainage	O
of	O
the	O
fluid	O
and	O
despite	O
optimal	O
antibiotic	O
treatment	O
,	O
the	O
patient	O
developed	O
severe	O
pericardial	O
effusion	O
again	O
.	O
Urgent	O
pericardiocentesis	O
and	O
pericardial	O
window	O
were	O
performed	O
the	O
following	O
morning	O
surgically	O
by	O
thoracoscopy	O
.	O
DIAGNOSIS	O
Purulent	O
pericarditis	O
complicated	O
by	O
pericardial	O
tamponade	O
.	O
Polymicrobial	O
septic	O
shock	O
with	O
liver	O
abscesses	O
.	O
T4N2bM0	O
tonsil	O
carcinoma	O
.	O

Background	O
A	O
63	O
year	O
old	O
patient	O
with	O
no	O
known	O
drug	O
allergies	O
,	O
with	O
cardiovascular	O
risk	O
factors	O
hypertension	O
,	O
dyslipidaemia	O
,	O
obesity	O
and	O
a	O
history	O
of	O
epilepsy	O
,	O
hypothyroidism	O
secondary	O
to	O
thyroiditis	O
and	O
chronic	O
renal	O
failure	O
with	O
baseline	O
creatinine	O
levels	O
of	O
around	O
1	O
.	O
91	O
.	O
In	O
December	O
2012	O
,	O
he	O
presented	O
with	O
a	O
first	O
episode	O
of	O
congestive	O
heart	O
failure	O
and	O
was	O
diagnosed	O
with	O
a	O
bicuspid	O
aortic	O
valve	O
with	O
severe	O
insufficiency	O
and	O
moderate	O
LV	O
dysfunction	O
,	O
and	O
the	O
medical	O
surgical	O
committee	O
decided	O
to	O
perform	O
surgery	O
.	O
Preoperative	O
coronary	O
angiography	O
ruled	O
out	O
significant	O
coronary	O
lesions	O
.	O
The	O
operation	O
was	O
successfully	O
performed	O
on	O
08	O
04	O
2013	O
and	O
a	O
St	O
Jude	O
No	O
.	O
25	O
mechanical	O
prosthesis	O
was	O
placed	O
.	O
During	O
the	O
postoperative	O
period	O
,	O
the	O
patient	O
had	O
a	O
torpid	O
evolution	O
with	O
atrial	O
flutter	O
with	O
a	O
high	O
ventricular	O
response	O
that	O
was	O
difficult	O
to	O
control	O
,	O
oliguric	O
renal	O
failure	O
with	O
an	O
increase	O
in	O
creatinine	O
levels	O
to	O
a	O
maximum	O
of	O
4	O
mg	O
dl	O
,	O
a	O
generalised	O
tonic	O
clonic	O
seizure	O
episode	O
with	O
a	O
good	O
pharmacological	O
response	O
to	O
valproate	B-FARMACO
and	O
levetiracetam	B-FARMACO
and	O
retroperitoneal	O
haematoma	O
in	O
the	O
head	O
and	O
body	O
of	O
the	O
pancreas	O
.	O
After	O
progressive	O
improvement	O
with	O
favourable	O
evolution	O
,	O
the	O
patient	O
was	O
discharged	O
from	O
hospital	O
.	O
Pre	O
discharge	O
echocardiography	O
aortic	O
prosthesis	O
with	O
normofunction	O
criteria	O
.	O
LV	O
slightly	O
dilated	O
LVED	O
56	O
mm	O
and	O
LVEF	O
approximately	O
50	O
.	O
Central	O
mild	O
MI	O
.	O
ECG	O
prior	O
to	O
discharge	O
sinus	O
rhythm	O
with	O
HRBBB	O
at	O
60	O
bpm	O
.	O
Subsequently	O
,	O
correct	O
follow	O
up	O
by	O
Cardiology	O
outpatients	O
without	O
new	O
cardiological	O
events	O
of	O
interest	O
and	O
with	O
normal	O
echocardiographic	O
controls	O
.	O
Regular	O
treatment	O
with	O
synthrom	B-FARMACO
,	O
omeprazole	B-FARMACO
40	O
mg	O
,	O
ezetimibe	B-FARMACO
simvastatin	I-FARMACO
10	O
40	O
mg	O
,	O
fenofibrate	B-FARMACO
200	O
mg	O
,	O
eutirox	B-FARMACO
100	O
mcg	O
,	O
allopurinol	B-FARMACO
300	O
mg	O
and	O
levetiracetam	B-FARMACO
1	O
,	O
000	O
mg	O
every	O
12	O
hours	O
.	O
Current	O
history	O
on	O
5	O
01	O
2017	O
he	O
attended	O
the	O
Emergency	O
Department	O
of	O
our	O
hospital	O
due	O
to	O
initially	O
diffuse	O
and	O
episodic	O
abdominal	O
pain	O
that	O
later	O
became	O
localised	O
in	O
the	O
right	O
hypochondrium	O
for	O
six	O
hours	O
,	O
with	O
no	O
accompanying	O
vegetative	O
cortex	O
.	O
There	O
was	O
no	O
thermometric	O
fever	O
,	O
although	O
there	O
was	O
a	O
feeling	O
of	O
dystrophy	O
.	O
The	O
patient	O
also	O
presented	O
an	O
increase	O
in	O
his	O
usual	O
dyspnoea	O
to	O
the	O
point	O
of	O
minimal	O
effort	O
and	O
orthopnoea	O
.	O
No	O
syncope	O
or	O
presyncope	O
.	O
No	O
palpitations	O
or	O
chest	O
pain	O
.	O
Physical	O
examination	O
BP	O
120	O
57	O
,	O
HR	O
63	O
bpm	O
,	O
Temperature	O
37	O
.	O
7	O
C	O
,	O
Baseline	O
O2	O
Sat	O
97	O
Patient	O
conscious	O
and	O
temporospatially	O
oriented	O
,	O
well	O
perfused	O
and	O
hydrated	O
.	O
Colour	O
slightly	O
jaundiced	O
,	O
eupneic	O
at	O
rest	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
without	O
audible	O
murmurs	O
.	O
Aortic	O
valve	O
click	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
in	O
all	O
fields	O
without	O
added	O
pathological	O
sounds	O
.	O
Abdomen	O
globular	O
but	O
depressible	O
,	O
pain	O
on	O
palpation	O
in	O
the	O
right	O
hypochondrium	O
.	O
Murphy	O
.	O
Hydro	O
aerial	O
sounds	O
present	O
.	O
No	O
signs	O
of	O
peritoneal	O
irritation	O
.	O
Lower	O
extremities	O
without	O
oedema	O
or	O
signs	O
of	O
DVT	O
.	O
COMPLEMENTARY	O
TESTS	O
Blood	O
tests	O
on	O
arrival	O
at	O
the	O
ED	O
glucose	O
341	O
,	O
urea	O
84	O
,	O
creatinine	O
2	O
.	O
59	O
,	O
Na	O
131	O
,	O
Cl	O
101	O
,	O
K	O
4	O
.	O
8	O
,	O
liver	O
profile	O
and	O
bilirubin	O
without	O
alterations	O
.	O
Myocardial	O
necrosis	O
markers	O
troponin	O
I	O
0	O
.	O
06	O
,	O
myoglobin	O
97	O
.	O
ProBNP	O
3	O
.	O
984	O
.	O
Haemogram	O
Leukocytes	O
8	O
,	O
700	O
75	O
.	O
4	O
neutrophils	O
,	O
Hb	O
10	O
.	O
6	O
,	O
Hto	O
33	O
.	O
2	O
,	O
platelets	O
19	O
,	O
600	O
.	O
INR	O
3	O
.	O
33	O
,	O
prothrombin	O
activity	O
25	O
.	O
ECG	O
complete	O
AV	O
block	O
with	O
escape	O
rhythm	O
at	O
56	O
bpm	O
.	O
BRDHH	O
.	O
No	O
acute	O
repolarisation	O
abnormalities	O
.	O
Chest	O
X	O
ray	O
06	O
01	O
2017	O
atheromatosis	O
and	O
aortic	O
elongation	O
.	O
Aortic	O
prosthesis	O
,	O
cardiomegaly	O
.	O
Hilar	O
thickening	O
with	O
vascular	O
appearance	O
.	O
Ultrasound	O
of	O
the	O
abdomen	O
07	O
01	O
2017	O
distended	O
gallbladder	O
125	O
x	O
44	O
mm	O
with	O
thickening	O
and	O
parietal	O
oedema	O
4	O
mm	O
,	O
perivesicular	O
oedema	O
,	O
perivesicular	O
perihepatic	O
free	O
fluid	O
and	O
maximum	O
pain	O
at	O
the	O
gallbladder	O
site	O
.	O
Inside	O
,	O
there	O
are	O
few	O
small	O
hyperechogenic	O
images	O
,	O
one	O
of	O
them	O
with	O
posterior	O
shadowing	O
.	O
Overall	O
,	O
the	O
patient	O
fulfils	O
the	O
criteria	O
for	O
acute	O
cholecystitis	O
as	O
the	O
first	O
diagnostic	O
possibility	O
.	O
It	O
could	O
be	O
,	O
although	O
less	O
likely	O
,	O
a	O
stress	O
gallbladder	O
in	O
the	O
context	O
of	O
heart	O
failure	O
or	O
alliasic	O
cholecystitis	O
diabetic	O
debut	O
.	O
Liver	O
with	O
a	O
marked	O
diffuse	O
increase	O
in	O
steatotic	O
echorefringence	O
.	O
No	O
bile	O
duct	O
ectasia	O
.	O
Pancreatic	O
area	O
is	O
not	O
visible	O
due	O
to	O
abundant	O
abdominal	O
weathering	O
.	O
Spleen	O
of	O
normal	O
size	O
and	O
morphology	O
.	O
Kidneys	O
of	O
normal	O
morphology	O
and	O
symmetrical	O
.	O
Abdominal	O
aorta	O
not	O
approachable	O
.	O
Bladder	O
without	O
alterations	O
.	O
EVOLUTION	O
Given	O
the	O
ultrasound	O
findings	O
of	O
acute	O
cholecystitis	O
,	O
antibiotherapy	O
was	O
started	O
as	O
conservative	O
management	O
without	O
improvement	O
of	O
the	O
picture	O
,	O
persisting	O
fever	O
and	O
worsening	O
analytical	O
control	O
analysis	O
procalcitonin	O
6	O
.	O
84	O
,	O
creatinine	O
4	O
.	O
13	O
,	O
chlorine	O
108	O
,	O
sodium	O
135	O
,	O
potassium	O
5	O
.	O
4	O
,	O
amylase	O
95	O
,	O
lipase	O
258	O
,	O
normal	O
liver	O
profile	O
,	O
leucocytes	O
13	O
.	O
500	O
N87	O
.	O
3	O
,	O
Hb	O
9	O
.	O
5	O
,	O
haematocrit	O
30	O
.	O
7	O
,	O
INR	O
18	O
.	O
84	O
,	O
prothrombin	O
activity	O
4	O
.	O
In	O
view	O
of	O
this	O
situation	O
,	O
it	O
was	O
decided	O
to	O
perform	O
an	O
urgent	O
cholecystectomy	O
.	O
Prior	O
to	O
surgery	O
,	O
the	O
Anaesthesia	O
Service	O
requested	O
our	O
assessment	O
.	O
Given	O
the	O
finding	O
of	O
complete	O
AVB	O
and	O
fever	O
,	O
it	O
was	O
decided	O
to	O
perform	O
echocardiography	O
with	O
the	O
following	O
result	O
Echocardiography	O
09	O
01	O
2017	O
non	O
dilated	O
LV	O
LVEDD	O
55	O
mm	O
,	O
preserved	O
LVEF	O
estimated	O
by	O
Teicholz	O
65	O
.	O
Septa	O
with	O
flattened	O
motion	O
.	O
MV	O
slightly	O
fibrous	O
leaflets	O
with	O
calcium	O
in	O
the	O
mitral	O
annulus	O
,	O
mild	O
central	O
MI	O
,	O
no	O
images	O
suggestive	O
of	O
endocarditis	O
on	O
the	O
mitral	O
valve	O
.	O
St	O
Jude	O
mechanical	O
aortic	O
prosthesis	O
no	O
.	O
25	O
,	O
slightly	O
elevated	O
gradients	O
for	O
model	O
and	O
number	O
of	O
prosthesis	O
maximum	O
gradient	O
of	O
45	O
mmHg	O
,	O
mean	O
gradient	O
of	O
24	O
mmHg	O
.	O
At	O
the	O
level	O
of	O
the	O
mitro	O
aortic	O
junction	O
,	O
a	O
filiform	O
image	O
of	O
anarchic	O
movement	O
suggestive	O
of	O
an	O
endocarditic	O
process	O
can	O
be	O
seen	O
.	O
At	O
apical	O
level	O
5C	O
there	O
is	O
flow	O
from	O
VAo	O
to	O
LA	O
suggestive	O
of	O
aorto	O
auricular	O
fistula	O
.	O
Right	O
chambers	O
not	O
dilated	O
.	O
Preserved	O
RVEF	O
TAPSE	O
23	O
mmHg	O
,	O
mild	O
TR	O
.	O
Non	O
dilated	O
IVC	O
with	O
normal	O
inspiratory	O
collapse	O
.	O
PAPs	O
35	O
mmHg	O
.	O
No	O
pericardial	O
effusion	O
,	O
perihepatic	O
free	O
fluid	O
.	O
In	O
view	O
of	O
the	O
new	O
evidence	O
,	O
blood	O
cultures	O
were	O
taken	O
and	O
empirical	O
antibiotic	O
treatment	O
was	O
started	O
with	O
cloxacillin	B-FARMACO
,	O
ampicillin	B-FARMACO
and	O
gentamicin	B-FARMACO
,	O
adjusted	O
according	O
to	O
renal	O
function	O
.	O
He	O
was	O
admitted	O
to	O
the	O
coronary	O
ICU	O
of	O
our	O
hospital	O
pending	O
transesophageal	O
echocardiography	O
and	O
assessment	O
by	O
Cardiac	O
Surgery	O
.	O
On	O
admission	O
to	O
the	O
ICU	O
,	O
he	O
presented	O
disconnection	O
from	O
the	O
environment	O
,	O
right	O
hemiplegia	O
and	O
complete	O
aphasia	O
.	O
An	O
urgent	O
cranial	O
CT	O
scan	O
was	O
performed	O
which	O
showed	O
an	O
acute	O
cerebral	O
haematoma	O
in	O
the	O
right	O
parieto	O
temporal	O
region	O
measuring	O
29	O
x	O
25	O
x	O
32	O
mm	O
with	O
an	O
estimated	O
volume	O
of	O
12	O
cc	O
,	O
subarachnoid	O
discharge	O
and	O
minimal	O
intraventricular	O
blood	O
.	O
After	O
acute	O
haemorrhagic	O
stroke	O
,	O
action	O
by	O
Cardiac	O
Surgery	O
was	O
postponed	O
.	O
Subsequent	O
poor	O
evolution	O
with	O
persistent	O
fever	O
,	O
septic	O
symptoms	O
and	O
haemodynamic	O
deterioration	O
despite	O
targeted	O
antibiotic	O
therapy	O
.	O
Blood	O
cultures	O
isolated	O
Streptococcus	O
gallolyticus	O
sensitive	O
to	O
beta	O
lactams	O
.	O
The	O
patient	O
died	O
on	O
17	O
01	O
2017	O
after	O
progressive	O
worsening	O
and	O
multiorgan	O
failure	O
.	O
DIAGNOSIS	O
Acute	O
cholecystitis	O
with	O
torpid	O
evolution	O
,	O
persistent	O
fever	O
and	O
complete	O
AV	O
block	O
.	O
Streptococcus	O
gallolyticus	O
endocarditis	O
on	O
prosthetic	O
AV	O
complicated	O
by	O
aorto	O
cavitary	O
fistula	O
to	O
the	O
left	O
atrium	O
.	O
Acute	O
haemorrhagic	O
stroke	O
of	O
possible	O
cardioembolic	O
origin	O
Septic	O
shock	O
refractory	O
to	O
intensive	O
medical	O
treatment	O
and	O
multi	O
organ	O
failure	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
19	O
year	O
old	O
female	O
patient	O
with	O
a	O
personal	O
history	O
of	O
anorexia	O
bulimia	O
for	O
2	O
years	O
undergoing	O
psychological	O
treatment	O
,	O
with	O
no	O
toxic	O
habits	O
.	O
Diagnosed	O
in	O
January	O
2016	O
with	O
severe	O
bone	O
marrow	O
aplasia	O
,	O
with	O
no	O
response	O
to	O
immunosuppressive	O
treatment	O
,	O
on	O
the	O
waiting	O
list	O
for	O
a	O
bone	O
marrow	O
transplant	O
.	O
Carrier	O
of	O
subcutaneous	O
venous	O
reservoir	O
.	O
Current	O
history	O
fever	O
up	O
to	O
39	O
C	O
,	O
vomiting	O
and	O
dizziness	O
of	O
less	O
than	O
24	O
hours	O
of	O
evolution	O
.	O
She	O
also	O
reports	O
a	O
dry	O
,	O
irritative	O
cough	O
of	O
about	O
15	O
days	O
'	O
duration	O
.	O
No	O
rhinorrhoea	O
,	O
no	O
otalgia	O
.	O
No	O
micturition	O
symptoms	O
.	O
No	O
alterations	O
in	O
stool	O
habits	O
.	O
Last	O
transfusion	O
last	O
Thursday	O
.	O
She	O
reported	O
pain	O
and	O
discomfort	O
in	O
the	O
area	O
of	O
the	O
reservoir	O
for	O
a	O
week	O
,	O
with	O
erythematous	O
area	O
and	O
increased	O
local	O
heat	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
108	O
68	O
.	O
Heart	O
rate	O
123	O
pm	O
.	O
Temperature	O
38	O
.	O
50	O
oC	O
.	O
Oxygen	O
saturation	O
99	O
basal	O
.	O
Conscious	O
,	O
oriented	O
,	O
reactive	O
.	O
Glasgow	O
15	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
,	O
tachycardic	O
.	O
No	O
murmurs	O
were	O
heard	O
.	O
Pulmonary	O
auscultation	O
normal	O
ventilation	O
in	O
all	O
fields	O
.	O
Bilateral	O
PPR	O
negative	O
.	O
Lower	O
extremities	O
no	O
oedema	O
,	O
no	O
signs	O
of	O
DVT	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
painful	O
on	O
palpation	O
of	O
the	O
epigastrium	O
.	O
No	O
masses	O
or	O
visceromegaly	O
palpable	O
.	O
Peristalsis	O
preserved	O
,	O
no	O
signs	O
of	O
peritonism	O
.	O
Blumberg	O
and	O
Murphy	O
negative	O
.	O
COMPLEMENTARY	O
TESTS	O
CBC	O
900	O
leukocytes	O
with	O
400	O
neutrophils	O
per	O
dl	O
,	O
Hb	O
9	O
.	O
8	O
g	O
dl	O
,	O
Hto	O
28	O
.	O
5	O
,	O
platelets	O
8	O
,	O
000	O
.	O
Glucose	O
103	O
mg	O
dl	O
,	O
urea	O
42	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
67	O
mg	O
dl	O
,	O
total	O
bilirubin	O
2	O
.	O
11	O
mg	O
dl	O
,	O
Na	O
136	O
mEq	O
l	O
,	O
K	O
3	O
.	O
8	O
mEq	O
l	O
.	O
FA	O
71	O
mg	O
dl	O
,	O
GGT	O
15	O
mg	O
dl	O
,	O
GOT	O
89	O
mg	O
dl	O
,	O
GPT	O
106	O
mg	O
dl	O
,	O
LDH	O
144	O
mg	O
dl	O
.	O
Blood	O
cultures	O
positive	O
for	O
Staphylococcus	O
epidermidis	O
,	O
resistant	O
to	O
cloxacillin	B-FARMACO
.	O
Chest	O
X	O
ray	O
possible	O
consolidating	O
focus	O
in	O
LID	O
.	O
Echocardiogram	O
normal	O
LVEF	O
and	O
no	O
contractile	O
asymmetries	O
.	O
Normal	O
diastole	O
.	O
LA	O
not	O
dilated	O
.	O
MV	O
of	O
fine	O
veils	O
,	O
preserved	O
kinetics	O
,	O
no	O
MI	O
.	O
VAo	O
trivalva	O
,	O
fine	O
veils	O
,	O
normal	O
flow	O
.	O
Dilated	O
right	O
chambers	O
RV	O
inflow	O
tract	O
50	O
mm	O
and	O
AD	O
area	O
23	O
cm2	O
,	O
with	O
preserved	O
function	O
.	O
TV	O
thickening	O
11	O
mm	O
of	O
the	O
posterior	O
and	O
proximal	O
subvalvular	O
annulus	O
as	O
well	O
as	O
the	O
entire	O
posterior	O
leaflet	O
.	O
At	O
least	O
two	O
thick	O
,	O
echodense	O
,	O
anarchically	O
moving	O
masses	O
,	O
almost	O
2	O
cm	O
long	O
,	O
originating	O
in	O
the	O
atrial	O
side	O
of	O
the	O
posterior	O
annulus	O
and	O
posterior	O
leaflet	O
,	O
suggestive	O
of	O
endocardial	O
involvement	O
.	O
Smaller	O
mobile	O
images	O
can	O
be	O
seen	O
on	O
the	O
other	O
two	O
leaflets	O
.	O
In	O
addition	O
,	O
a	O
rounded	O
,	O
echodense	O
image	O
on	O
distal	O
subvalvular	O
,	O
very	O
mobile	O
,	O
which	O
usually	O
corresponds	O
to	O
fibrosis	O
of	O
the	O
subvalvular	O
,	O
but	O
endocardial	O
involvement	O
at	O
that	O
level	O
cannot	O
be	O
ruled	O
out	O
given	O
the	O
clinical	O
context	O
.	O
Severe	O
TR	O
without	O
appreciating	O
clear	O
perforation	O
of	O
the	O
leaflets	O
.	O
No	O
apparent	O
mobile	O
images	O
on	O
the	O
tip	O
of	O
the	O
central	O
catheter	O
of	O
the	O
RA	O
.	O
PAPs	O
30	O
35	O
mmHg	O
.	O
Transesophageal	O
echocardiogram	O
VT	O
compatible	O
with	O
what	O
was	O
seen	O
in	O
TTE	O
thickening	O
of	O
the	O
posterior	O
and	O
lateral	O
region	O
of	O
the	O
annulus	O
as	O
well	O
as	O
the	O
leaflets	O
,	O
without	O
observing	O
abcessed	O
formations	O
.	O
At	O
least	O
two	O
thick	O
,	O
echodense	O
,	O
anarchically	O
moving	O
masses	O
,	O
about	O
16	O
mm	O
long	O
and	O
7	O
mm	O
wide	O
,	O
originating	O
in	O
the	O
atrial	O
slope	O
,	O
at	O
the	O
junction	O
of	O
the	O
posterior	O
and	O
lateral	O
leaflets	O
and	O
annulus	O
,	O
compatible	O
with	O
endocarditic	O
process	O
.	O
Severe	O
tricuspid	O
insufficiency	O
with	O
more	O
echodense	O
formation	O
in	O
distal	O
subvalvular	O
,	O
possibly	O
corresponding	O
to	O
fibrosis	O
,	O
without	O
being	O
able	O
to	O
rule	O
out	O
endocarditic	O
formation	O
at	O
that	O
level	O
.	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
Haematology	O
Department	O
for	O
broad	O
spectrum	O
antibiotic	O
treatment	O
and	O
transfusion	O
of	O
irradiated	O
products	O
2	O
HC	O
and	O
1	O
platelet	O
pool	O
in	O
the	O
Emergency	O
Department	O
.	O
Given	O
the	O
suspicion	O
of	O
reservoir	O
infection	O
and	O
possible	O
endocarditis	O
,	O
a	O
transthoracic	O
echocardiogram	O
was	O
requested	O
,	O
where	O
endocarditis	O
was	O
found	O
at	O
the	O
level	O
of	O
the	O
tricuspid	O
valve	O
,	O
which	O
was	O
confirmed	O
after	O
TEE	O
.	O
Broad	O
spectrum	O
antibiotic	O
treatment	O
was	O
started	O
,	O
awaiting	O
a	O
clinical	O
response	O
and	O
to	O
assess	O
options	O
after	O
6	O
weeks	O
of	O
antibiotic	O
therapy	O
.	O
DIAGNOSIS	O
Severe	O
bone	O
marrow	O
aplasia	O
with	O
no	O
response	O
to	O
immunosuppressive	O
treatment	O
.	O
Endocarditis	O
on	O
tricuspid	O
valve	O
due	O
to	O
Staphylococcus	O
epidermidis	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
The	O
patient	O
is	O
an	O
89	O
year	O
old	O
woman	O
with	O
the	O
following	O
history	O
CVRF	O
HBP	O
.	O
DM	O
2	O
on	O
treatment	O
with	O
ADO	O
.	O
Dyslipidaemia	O
.	O
Severe	O
degenerative	O
aortic	O
stenosis	O
under	O
follow	O
up	O
in	O
outpatient	O
cardiology	O
consultations	O
.	O
Other	O
left	O
ureteral	O
lithiasis	O
.	O
Polyarthrosis	O
.	O
Usual	O
treatment	O
enalapril	B-FARMACO
HCTZ	I-FARMACO
,	O
vildagliptin	B-FARMACO
,	O
ASA	B-FARMACO
,	O
oral	O
iron	B-FARMACO
,	O
pantoprazole	B-FARMACO
,	O
tamsulosin	B-FARMACO
.	O
In	O
June	O
2014	O
,	O
he	O
was	O
admitted	O
to	O
another	O
centre	O
for	O
heart	O
failure	O
.	O
With	O
a	O
history	O
of	O
severe	O
AS	O
,	O
it	O
was	O
decided	O
to	O
replace	O
the	O
aortic	O
valve	O
with	O
a	O
percutaneous	O
transcatheter	O
aortic	O
valve	O
replacement	O
TAVI	O
,	O
via	O
the	O
transfemoral	O
route	O
.	O
The	O
procedure	O
was	O
uneventful	O
,	O
with	O
only	O
one	O
episode	O
of	O
paroxysmal	O
AF	O
with	O
rapid	O
ventricular	O
response	O
before	O
implantation	O
,	O
which	O
resolved	O
spontaneously	O
.	O
Withdrawal	O
of	O
the	O
transient	O
PM	O
24	O
hours	O
after	O
implantation	O
,	O
remaining	O
at	O
all	O
times	O
in	O
sinus	O
rhythm	O
and	O
normal	O
PR	O
,	O
with	O
a	O
previously	O
known	O
LBBB	O
.	O
On	O
06	O
09	O
14	O
she	O
consulted	O
her	O
health	O
centre	O
for	O
a	O
sore	O
throat	O
and	O
fever	O
of	O
up	O
to	O
38	O
.	O
5	O
C	O
.	O
Her	O
GP	O
diagnosed	O
her	O
with	O
pharyngotonsillitis	O
and	O
started	O
treatment	O
with	O
augmentin	B-FARMACO
875	O
125	O
mg	O
vo	O
8h	O
.	O
The	O
following	O
day	O
she	O
consulted	O
the	O
emergency	O
department	O
of	O
our	O
centre	O
because	O
,	O
in	O
addition	O
to	O
the	O
fever	O
,	O
she	O
presented	O
deviation	O
of	O
the	O
corner	O
of	O
her	O
mouth	O
and	O
dysarthria	O
,	O
and	O
a	O
non	O
contrast	O
cranial	O
CT	O
scan	O
was	O
performed	O
,	O
the	O
findings	O
of	O
which	O
are	O
described	O
in	O
the	O
section	O
on	O
complementary	O
tests	O
.	O
She	O
was	O
discharged	O
with	O
a	O
diagnosis	O
of	O
transient	O
ischaemic	O
attack	O
.	O
Three	O
days	O
later	O
,	O
on	O
10	O
09	O
14	O
,	O
she	O
returned	O
to	O
the	O
emergency	O
department	O
because	O
she	O
continued	O
to	O
have	O
fever	O
at	O
home	O
.	O
Although	O
at	O
the	O
time	O
of	O
consultation	O
she	O
did	O
not	O
have	O
a	O
fever	O
36	O
.	O
5	O
C	O
,	O
a	O
blood	O
culture	O
was	O
taken	O
and	O
a	O
chest	O
X	O
ray	O
was	O
performed	O
without	O
conclusive	O
findings	O
.	O
He	O
was	O
discharged	O
with	O
a	O
diagnosis	O
of	O
non	O
condensing	O
respiratory	O
infection	O
and	O
levofloxacin	B-FARMACO
500	O
mg	O
vo	O
12	O
h	O
was	O
added	O
to	O
the	O
treatment	O
he	O
was	O
already	O
receiving	O
with	O
augmentin	B-FARMACO
.	O
Seven	O
days	O
later	O
,	O
on	O
17	O
09	O
14	O
,	O
he	O
consulted	O
the	O
emergency	O
department	O
for	O
the	O
third	O
time	O
because	O
the	O
fever	O
persisted	O
.	O
A	O
new	O
chest	O
X	O
ray	O
was	O
performed	O
,	O
similar	O
to	O
the	O
previous	O
one	O
,	O
and	O
the	O
blood	O
culture	O
from	O
the	O
previous	O
week	O
was	O
reviewed	O
,	O
which	O
was	O
"	O
contaminated	O
"	O
.	O
Finally	O
,	O
it	O
was	O
decided	O
to	O
admit	O
him	O
to	O
Internal	O
Medicine	O
to	O
study	O
the	O
febrile	O
syndrome	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
at	O
discharge	O
after	O
TAVI	O
June	O
2014	O
,	O
another	O
centre	O
sinus	O
rhythm	O
at	O
70	O
bpm	O
.	O
PR	O
130	O
ms	O
.	O
LBBB	O
already	O
known	O
.	O
Cranial	O
CT	O
s	O
c	O
07	O
09	O
14	O
,	O
ER	O
severe	O
ischaemic	O
microangiopathy	O
.	O
Sequela	O
of	O
chronic	O
ischaemic	O
infarction	O
of	O
the	O
left	O
PCA	O
territory	O
.	O
Chronic	O
left	O
lenticular	O
lacunar	O
lacunar	O
infarction	O
.	O
Moderate	O
corticosubcortical	O
atrophy	O
.	O
Portable	O
chest	O
X	O
ray	O
10	O
09	O
14	O
,	O
ED	O
poor	O
quality	O
,	O
rotated	O
.	O
No	O
clear	O
images	O
of	O
pneumonic	O
condensation	O
.	O
Blood	O
culture	O
10	O
09	O
14	O
,	O
ED	O
contaminated	O
sample	O
.	O
EVOLUTION	O
On	O
admission	O
to	O
Internal	O
Medicine	O
auscultation	O
described	O
as	O
"	O
no	O
audible	O
murmurs	O
,	O
valve	O
noise	O
is	O
heard	O
"	O
.	O
ECG	O
sinus	O
rhythm	O
and	O
known	O
LBBB	O
.	O
Augmentin	B-FARMACO
levofloxacin	I-FARMACO
is	O
maintained	O
.	O
We	O
requested	O
culture	O
and	O
Gram	O
of	O
sputum	O
and	O
a	O
TTE	O
ordered	O
due	O
to	O
the	O
history	O
of	O
recent	O
TAVI	O
implantation	O
.	O
Nothing	O
remarkable	O
in	O
the	O
analysis	O
except	O
creatinine	O
1	O
.	O
45	O
,	O
which	O
was	O
attributed	O
to	O
pre	O
renal	O
origin	O
due	O
to	O
lack	O
of	O
water	O
supply	O
.	O
In	O
the	O
TTE	O
,	O
the	O
aortic	O
prosthesis	O
with	O
maximum	O
velocity	O
2	O
.	O
52	O
m	O
s	O
,	O
mean	O
gradient	O
12	O
mmHg	O
and	O
jet	O
of	O
mild	O
insufficiency	O
.	O
Preserved	O
LVEF	O
.	O
Moderate	O
TR	O
.	O
Severe	O
PAH	O
PAPS	O
63	O
mmHg	O
.	O
Twenty	O
four	O
hours	O
after	O
admission	O
to	O
the	O
ward	O
,	O
the	O
patient	O
began	O
to	O
present	O
"	O
shivering	O
"	O
and	O
high	O
fever	O
39	O
C	O
,	O
and	O
the	O
control	O
ECG	O
showed	O
the	O
presence	O
of	O
AF	O
with	O
rapid	O
ventricular	O
response	O
,	O
so	O
she	O
was	O
started	O
on	O
treatment	O
with	O
digoxin	B-FARMACO
.	O
The	O
blood	O
test	O
showed	O
for	O
the	O
first	O
time	O
a	O
leukocytosis	O
of	O
21	O
,	O
270	O
with	O
left	O
deviation	O
90	O
PMN	O
.	O
Serial	O
analyses	O
were	O
requested	O
with	O
CRP	O
which	O
was	O
found	O
to	O
be	O
elevated	O
100	O
and	O
serial	O
blood	O
cultures	O
.	O
.	O
.	O
.	O
The	O
antibiotic	O
treatment	O
prescribed	O
until	O
then	O
was	O
changed	O
to	O
piperacillin	B-FARMACO
tazobactam	I-FARMACO
iv	O
adjusted	O
to	O
renal	O
function	O
.	O
Forty	O
eight	O
hours	O
after	O
admission	O
,	O
he	O
presented	O
with	O
sudden	O
signs	O
of	O
desaturation	O
SatO2	O
80	O
which	O
required	O
oxygen	O
therapy	O
with	O
VMK	O
.	O
Audible	O
wheezing	O
practically	O
on	O
entering	O
the	O
room	O
.	O
An	O
urgent	O
ECG	O
was	O
performed	O
which	O
showed	O
the	O
presence	O
of	O
a	O
complete	O
AVB	O
with	O
an	O
escape	O
HR	O
wide	O
QRS	O
at	O
30	O
bpm	O
,	O
and	O
the	O
Cardiology	O
ward	O
was	O
notified	O
.	O
Although	O
the	O
main	O
suspicion	O
in	O
this	O
patient	O
was	O
already	O
established	O
as	O
complicated	O
infective	O
endocarditis	O
,	O
it	O
was	O
decided	O
to	O
implant	O
an	O
urgent	O
transient	O
pacemaker	O
to	O
stabilise	O
the	O
clinical	O
situation	O
.	O
After	O
implantation	O
via	O
the	O
right	O
subclavian	O
vein	O
,	O
which	O
passed	O
without	O
incident	O
,	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
Cardiology	O
Intermediate	O
Care	O
Unit	O
of	O
our	O
department	O
,	O
and	O
antibiotic	O
treatment	O
was	O
associated	O
with	O
daptomycin	B-FARMACO
600	O
mg	O
iv	O
24	O
h	O
and	O
the	O
digoxin	B-FARMACO
she	O
was	O
taking	O
was	O
withdrawn	O
digoxinaemia	O
was	O
then	O
2	O
ng	O
mL	O
.	O
A	O
new	O
TTE	O
TEE	O
was	O
also	O
requested	O
due	O
to	O
the	O
very	O
high	O
suspicion	O
of	O
infective	O
endocarditis	O
.	O
On	O
23	O
09	O
14	O
,	O
the	O
results	O
of	O
the	O
serial	O
blood	O
cultures	O
from	O
the	O
Internal	O
Medicine	O
ward	O
came	O
back	O
methicillin	O
resistant	O
Staphylococcus	O
epidermidis	O
in	O
3	O
of	O
4	O
samples	O
.	O
TTE	O
TEE	O
was	O
performed	O
with	O
the	O
following	O
findings	O
summary	O
DTDVI	O
32	O
mm	O
.	O
Basal	O
septal	O
hypertrophy	O
of	O
20	O
mm	O
.	O
Normal	O
EF	O
.	O
Rest	O
of	O
cavities	O
normal	O
.	O
Severe	O
extensive	O
calcification	O
of	O
the	O
mitral	O
annulus	O
with	O
normal	O
distal	O
leaflet	O
mobility	O
and	O
no	O
regurgitation	O
.	O
TAVI	O
with	O
periprosthetic	O
eccentric	O
regurgitation	O
with	O
peak	O
gradient	O
of	O
50	O
mmHg	O
and	O
mean	O
of	O
30	O
mmHg	O
.	O
There	O
is	O
mobile	O
vegetation	O
that	O
appears	O
to	O
be	O
inserted	O
below	O
the	O
tricuspid	O
septal	O
leaflet	O
and	O
some	O
aortic	O
periannular	O
thickening	O
adjacent	O
to	O
the	O
tricuspid	O
valve	O
in	O
the	O
right	O
anterior	O
region	O
of	O
the	O
same	O
,	O
compatible	O
with	O
periannular	O
abscess	O
pseudoaneurysm	O
,	O
with	O
microperforation	O
towards	O
the	O
RA	O
.	O
Mild	O
TR	O
with	O
a	O
gradient	O
of	O
46	O
mm	O
and	O
PAPS	O
of	O
50	O
mmHg	O
.	O
In	O
TEE	O
TAVI	O
with	O
thin	O
prosthetic	O
veils	O
and	O
area	O
by	O
planimetry	O
around	O
1	O
cm2	O
.	O
Small	O
prosthetic	O
ring	O
18	O
mm	O
.	O
Filiform	O
vegetation	O
is	O
observed	O
in	O
the	O
right	O
coronary	O
leaflet	O
.	O
Periprosthetic	O
regurgitation	O
in	O
the	O
anterior	O
region	O
of	O
the	O
ring	O
,	O
which	O
appears	O
to	O
be	O
small	O
.	O
In	O
the	O
following	O
days	O
,	O
the	O
BAV	O
resolved	O
completely	O
,	O
becoming	O
first	O
degree	O
BAV	O
PR	O
200	O
ms	O
.	O
Antibiotic	O
treatment	O
with	O
daptomycin	B-FARMACO
was	O
continued	O
.	O
After	O
discussing	O
the	O
patient	O
in	O
a	O
medical	O
surgical	O
session	O
,	O
valve	O
intervention	O
was	O
ruled	O
out	O
due	O
to	O
the	O
patient	O
's	O
age	O
and	O
high	O
morbidity	O
and	O
mortality	O
.	O
After	O
confirming	O
that	O
blood	O
cultures	O
were	O
negative	O
,	O
it	O
was	O
decided	O
to	O
implant	O
a	O
definitive	O
MP	O
,	O
the	O
scheduled	O
date	O
of	O
which	O
had	O
to	O
be	O
postponed	O
several	O
times	O
due	O
to	O
recurrence	O
of	O
fever	O
,	O
development	O
of	O
local	O
infection	O
of	O
the	O
transient	O
MP	O
inflammatory	O
signs	O
in	O
the	O
venipuncture	O
area	O
,	O
nosocomial	O
pneumonia	O
and	O
significant	O
bicytopenia	O
Hb	O
8	O
.	O
5	O
and	O
platelets	O
45	O
,	O
000	O
,	O
the	O
origin	O
of	O
which	O
was	O
not	O
completely	O
clarified	O
and	O
which	O
led	O
to	O
a	O
reduction	O
in	O
the	O
doses	O
of	O
daptomycin	B-FARMACO
.	O
The	O
day	O
before	O
rescheduling	O
for	O
definitive	O
MP	O
implantation	O
,	O
the	O
patient	O
suffered	O
a	O
sudden	O
disconnection	O
from	O
the	O
environment	O
and	O
a	O
deterioration	O
in	O
her	O
level	O
of	O
consciousness	O
.	O
An	O
urgent	O
cranial	O
CT	O
scan	O
was	O
performed	O
,	O
showing	O
ischaemic	O
embolic	O
stroke	O
septic	O
embolism	O
as	O
the	O
first	O
possibility	O
of	O
the	O
left	O
middle	O
cerebral	O
artery	O
.	O
Under	O
these	O
conditions	O
,	O
it	O
was	O
decided	O
to	O
limit	O
therapeutic	O
effort	O
,	O
withdraw	O
the	O
transitional	O
MP	O
and	O
transfer	O
him	O
to	O
the	O
Palliative	O
Care	O
Unit	O
,	O
where	O
he	O
continued	O
with	O
fever	O
and	O
was	O
discharged	O
on	O
10	O
10	O
14	O
.	O
DIAGNOSIS	O
Late	O
2	O
months	O
infective	O
prosthetic	O
endocarditis	O
on	O
percutaneously	O
implanted	O
biological	O
aortic	O
prosthesis	O
TAVI	O
due	O
to	O
S	O
.	O
epidermidis	O
MR	O
,	O
complicated	O
by	O
Periannular	O
abscess	O
pseudoaneurysm	O
with	O
microperforation	O
into	O
the	O
right	O
atrium	O
;	O
development	O
of	O
symptomatic	O
complete	O
atrioventricular	O
block	O
requiring	O
urgent	O
pacing	O
with	O
transient	O
pacemaker	O
,	O
initially	O
resolved	O
;	O
embolic	O
ischaemic	O
stroke	O
septic	O
embolism	O
of	O
the	O
middle	O
cerebral	O
artery	O
;	O
progressive	O
deterioration	O
of	O
the	O
level	O
of	O
consciousness	O
and	O
exitus	O
in	O
the	O
context	O
of	O
the	O
previous	O
point	O
.	O
Possible	O
nosocomial	O
pneumonia	O
of	O
unclear	O
aetiology	O
.	O
Local	O
infection	O
of	O
the	O
transient	O
pacemaker	O
venipuncture	O
area	O
,	O
without	O
having	O
been	O
able	O
to	O
rule	O
out	O
associated	O
endocarditis	O
on	O
the	O
ventricular	O
electrode	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Personal	O
history	O
Well	O
controlled	O
hypertension	O
,	O
well	O
controlled	O
type	O
II	O
DM	O
with	O
diabetic	O
retinopathy	O
,	O
mild	O
CKD	O
and	O
mild	O
vitamin	O
B12	O
deficiency	O
Current	O
illness	O
73	O
year	O
old	O
male	O
patient	O
referred	O
to	O
the	O
Cardiology	O
Department	O
by	O
his	O
primary	O
care	O
physician	O
for	O
the	O
presence	O
of	O
moderate	O
oedema	O
in	O
both	O
legs	O
and	O
exertional	O
dyspnoea	O
of	O
approximately	O
two	O
days	O
'	O
duration	O
.	O
An	O
ambulatory	O
echocardiogram	O
showed	O
circumferential	O
pericardial	O
effusion	O
with	O
no	O
signs	O
of	O
haemodynamic	O
compromise	O
.	O
For	O
the	O
last	O
few	O
months	O
the	O
patient	O
had	O
been	O
losing	O
3	O
4	O
kg	O
in	O
weight	O
,	O
pain	O
in	O
the	O
shoulder	O
girdle	O
,	O
wrists	O
and	O
hips	O
together	O
with	O
difficulty	O
in	O
gripping	O
and	O
paresthesia	O
in	O
the	O
hands	O
and	O
feet	O
.	O
Hospital	O
admission	O
was	O
indicated	O
for	O
investigation	O
.	O
Physical	O
examination	O
Good	O
general	O
condition	O
Conscious	O
and	O
oriented	O
Eupneic	O
at	O
rest	O
and	O
with	O
good	O
tolerance	O
to	O
decubitus	O
Normal	O
jugular	O
venous	O
pressure	O
BP	O
140	O
52	O
mmHg	O
HR	O
87	O
L	O
min	O
No	O
neurological	O
focality	O
No	O
macules	O
or	O
signs	O
of	O
arthritis	O
Normal	O
cardiopulmonary	O
auscultation	O
.	O
No	O
pericardial	O
friction	O
rub	O
Abdomen	O
globular	O
,	O
soft	O
and	O
depressible	O
Extremities	O
with	O
tense	O
oedema	O
and	O
skin	O
induration	O
up	O
to	O
middle	O
1	O
3	O
COMPLEMENTARY	O
TESTS	O
CBC	O
6	O
,	O
800	O
leukocytes	O
with	O
normal	O
formula	O
.	O
Hb	O
10	O
.	O
1	O
;	O
MCV	O
83	O
;	O
platelets	O
310	O
,	O
000	O
;	O
glucose	O
120	O
;	O
creatinine	O
1	O
.	O
48	O
;	O
cholesterol	O
125	O
;	O
triglycerides	O
143	O
;	O
HDL	O
38	O
;	O
LDL	O
58	O
;	O
GOT	O
23	O
;	O
GPT	O
9	O
;	O
LDH	O
391	O
Na	O
142	O
;	O
K	O
5	O
.	O
2	O
.	O
Coagulation	O
Normal	O
.	O
Microbial	O
serology	O
Mycoplasma	O
,	O
Coxiella	O
,	O
Epstein	O
Barr	O
Ig	O
M	O
,	O
Cytomegalovirus	O
,	O
Rose	O
Bengal	O
,	O
Hepatitis	O
B	O
and	O
Hepatitis	O
C	O
negative	O
.	O
Immunology	O
antithyroglobulin	O
antibodies	O
222	O
;	O
antimicrosomal	O
antibodies	O
1300	O
;	O
ANCA	O
negative	O
;	O
anticardiolipin	O
Ig	O
G	O
negative	O
.	O
Anticardiolipin	O
Ig	O
M	O
positive	O
titre	O
25	O
.	O
74	O
.	O
ANA	O
speckled	O
pattern	O
1	O
640	O
.	O
ENAS	O
,	O
Anti	O
DNA	O
;	O
complement	O
C3	O
and	O
C4	O
normal	O
;	O
rheumatoid	O
factor	O
.	O
Peripheral	O
blood	O
smear	O
red	O
series	O
without	O
atypia	O
.	O
Proteinogram	O
and	O
immunoglobulins	O
normal	O
.	O
Mantoux	O
negative	O
Electrocardiogram	O
sinus	O
rhythm	O
at	O
77	O
bpm	O
.	O
QRS	O
axis	O
at	O
0oC	O
.	O
Narrow	O
QRS	O
without	O
repolarisation	O
alterations	O
or	O
signs	O
of	O
pericarditis	O
.	O
Isolated	O
negative	O
T	O
in	O
AVL	O
.	O
Chest	O
X	O
ray	O
no	O
infiltrates	O
or	O
masses	O
.	O
No	O
effusions	O
.	O
Increased	O
CTI	O
.	O
X	O
ray	O
of	O
the	O
pelvis	O
bilateral	O
acetabular	O
subchondral	O
sclerosis	O
.	O
Right	O
pretrochanteric	O
calcification	O
.	O
Spine	O
X	O
ray	O
uncoarthrosis	O
.	O
C3	O
C4	O
dysarthrosis	O
.	O
X	O
ray	O
of	O
the	O
hands	O
pinching	O
of	O
the	O
DFI	O
predominantly	O
of	O
the	O
3rd	O
finger	O
of	O
the	O
right	O
hand	O
,	O
pinching	O
of	O
the	O
PFI	O
of	O
the	O
5th	O
finger	O
of	O
the	O
left	O
hand	O
.	O
No	O
erosions	O
.	O
Echocardiogram	O
mild	O
moderate	O
pericardial	O
effusion	O
without	O
electrocardiographic	O
signs	O
of	O
collapse	O
.	O
V	O
I	O
not	O
dilated	O
with	O
mild	O
concentric	O
hypertrophy	O
and	O
preserved	O
global	O
and	O
segmental	O
systolic	O
function	O
.	O
Normal	O
mitral	O
filling	O
with	O
respiratory	O
variation	O
in	O
E	O
wave	O
,	O
around	O
30	O
.	O
LA	O
slightly	O
dilated	O
24	O
cm2	O
,	O
with	O
constant	O
diastolic	O
collapse	O
.	O
RV	O
not	O
dilated	O
with	O
inconstant	O
protomesodiastolic	O
collapse	O
.	O
TAPSE	O
30	O
mm	O
.	O
Ascending	O
Ao	O
and	O
Ao	O
root	O
not	O
dilated	O
.	O
Mitral	O
V	O
with	O
slight	O
leaflet	O
thickening	O
and	O
mild	O
MR	O
.	O
Aortic	O
V	O
,	O
trivalve	O
with	O
slight	O
fibrosclerosis	O
of	O
leaflets	O
and	O
mild	O
AIo	O
.	O
Very	O
mild	O
TR	O
that	O
does	O
not	O
allow	O
estimation	O
of	O
PSAP	O
.	O
Dilated	O
IVC	O
20	O
mm	O
with	O
abolished	O
respiratory	O
collapse	O
.	O
Control	O
echocardiogram	O
LVEDV	O
63	O
.	O
8	O
ml	O
,	O
LVESV	O
15	O
ml	O
.	O
Left	O
ventricle	O
neither	O
dilated	O
nor	O
hypertrophic	O
,	O
without	O
alterations	O
in	O
segmental	O
contractility	O
,	O
preserved	O
LVEF	O
Simpson	O
72	O
.	O
LA	O
moderately	O
dilated	O
.	O
Area	O
28	O
cm2	O
.	O
Right	O
atrium	O
with	O
partial	O
diastolic	O
collapse	O
.	O
No	O
right	O
ventricular	O
diastolic	O
collapse	O
or	O
signs	O
of	O
ventricular	O
interdependence	O
.	O
Moderate	O
calcification	O
of	O
the	O
mitral	O
valve	O
subvalvular	O
apparatus	O
.	O
Dilated	O
inferior	O
vena	O
cava	O
21mm	O
without	O
inspiratory	O
collapse	O
.	O
Thoracic	O
abdominal	O
CT	O
moderate	O
pericardial	O
effusion	O
with	O
maximum	O
thickness	O
of	O
approximately	O
25	O
mm	O
,	O
in	O
inferior	O
regions	O
.	O
No	O
calcifications	O
were	O
identified	O
in	O
the	O
pleural	O
sheets	O
.	O
Small	O
axillary	O
lymph	O
nodes	O
,	O
smaller	O
than	O
a	O
centimetre	O
in	O
the	O
minor	O
axis	O
,	O
with	O
non	O
specific	O
characteristics	O
.	O
Small	O
paratracheal	O
ganglions	O
,	O
prevascular	O
in	O
aortopulmonary	O
sale	O
,	O
subcarinal	O
,	O
smaller	O
than	O
a	O
centimetre	O
in	O
the	O
minor	O
axis	O
,	O
non	O
specific	O
,	O
some	O
of	O
them	O
partially	O
calcified	O
.	O
In	O
the	O
abdominal	O
region	O
liver	O
,	O
gall	O
bladder	O
,	O
bile	O
duct	O
,	O
spleen	O
,	O
kidneys	O
and	O
adrenal	O
glands	O
without	O
significant	O
alterations	O
.	O
No	O
adenopathies	O
in	O
pathological	O
range	O
were	O
identified	O
.	O
No	O
free	O
fluid	O
is	O
observed	O
.	O
EVOLUTION	O
After	O
finding	O
positive	O
autoantibodies	O
,	O
the	O
patient	O
's	O
clinical	O
manifestations	O
and	O
ruling	O
out	O
other	O
causes	O
of	O
pericardial	O
effusion	O
,	O
connective	O
tissue	O
disease	O
was	O
suspected	O
,	O
and	O
so	O
an	O
assessment	O
was	O
requested	O
by	O
Internal	O
Medicine	O
and	O
Rheumatology	O
,	O
who	O
started	O
corticosteroid	O
treatment	O
and	O
classified	O
it	O
as	O
undifferentiated	O
scleroderma	O
type	O
connective	O
tissue	O
disease	O
.	O
After	O
starting	O
corticosteroid	O
treatment	O
,	O
the	O
patient	O
showed	O
significant	O
clinical	O
improvement	O
.	O
He	O
is	O
currently	O
under	O
follow	O
up	O
in	O
rheumatology	O
consultations	O
with	O
control	O
of	O
the	O
disease	O
.	O
DIAGNOSIS	O
Undifferentiated	O
connective	O
tissue	O
disease	O
of	O
the	O
scleroderma	O
type	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Male	O
,	O
49	O
years	O
old	O
.	O
Secondary	O
school	O
teacher	O
in	O
a	O
public	O
secondary	O
school	O
Stress	O
at	O
work	O
,	O
regular	O
exercise	O
spinning	O
and	O
racket	O
sports	O
Non	O
smoker	O
Dyslipidaemia	O
under	O
dietary	O
treatment	O
No	O
other	O
relevant	O
history	O
He	O
was	O
attended	O
by	O
transport	O
and	O
advanced	O
life	O
support	O
personnel	O
mobile	O
ICU	O
for	O
having	O
presented	O
dizziness	O
followed	O
by	O
chest	O
pain	O
with	O
oppressive	O
characteristics	O
,	O
which	O
started	O
after	O
finishing	O
a	O
moderate	O
exercise	O
session	O
paddle	O
tennis	O
class	O
in	O
a	O
sports	O
centre	O
.	O
Medical	O
staff	O
observed	O
a	O
minimal	O
rise	O
in	O
the	O
ST	O
segment	O
of	O
the	O
non	O
specific	O
electrocardiogram	O
ECG	O
,	O
and	O
he	O
was	O
transferred	O
to	O
his	O
referral	O
centre	O
.	O
Blood	O
pressure	O
120	O
85	O
mmHg	O
.	O
65	O
bpm	O
.	O
Height	O
184	O
cm	O
,	O
weight	O
108	O
kg	O
.	O
BMI	O
31	O
.	O
9	O
kg	O
m2	O
.	O
BP	O
125	O
cm	O
.	O
Pulse	O
oximetry	O
saturation	O
of	O
96	O
with	O
room	O
air	O
.	O
Eupneic	O
,	O
no	O
carotid	O
murmurs	O
,	O
pulmonary	O
ventilation	O
is	O
normal	O
,	O
heart	O
sounds	O
are	O
rhythmic	O
,	O
68	O
bpm	O
,	O
4th	O
apical	O
sound	O
,	O
no	O
murmurs	O
are	O
auscultated	O
.	O
Pulses	O
are	O
permeable	O
and	O
symmetrical	O
in	O
all	O
4	O
extremities	O
.	O
No	O
oedema	O
.	O
COMPLEMENTARY	O
TESTS	O
Initial	O
ECG	O
in	O
the	O
ED	O
precordial	O
pain	O
,	O
no	O
significant	O
alterations	O
.	O
The	O
rhythm	O
is	O
sinus	O
at	O
65	O
bpm	O
and	O
no	O
areas	O
of	O
ischaemia	O
or	O
necrosis	O
are	O
observed	O
.	O
No	O
hypertrophy	O
,	O
ST	O
segment	O
or	O
T	O
wave	O
alterations	O
.	O
Myocardial	O
damage	O
markers	O
were	O
determined	O
,	O
with	O
typical	O
enzyme	O
curve	O
,	O
peak	O
CPK	O
MB	O
of	O
98	O
U	O
L	O
and	O
ultrasensitive	O
troponin	O
T	O
of	O
215	O
ng	O
L	O
.	O
He	O
presented	O
with	O
an	O
episode	O
of	O
paroxysmal	O
atrial	O
fibrillation	O
in	O
the	O
acute	O
phase	O
lasting	O
a	O
few	O
minutes	O
and	O
spontaneous	O
remission	O
.	O
He	O
was	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
.	O
Doppler	O
echocardiogram	O
non	O
dilated	O
left	O
ventricle	O
,	O
with	O
abundant	O
trabeculae	O
and	O
sinusoids	O
in	O
apical	O
and	O
lateral	O
segments	O
and	O
preserved	O
global	O
systolic	O
function	O
.	O
Slight	O
lateroapical	O
hypokinesia	O
.	O
Study	O
suggestive	O
of	O
non	O
compacted	O
left	O
ventricle	O
.	O
LVEF	O
54	O
.	O
More	O
than	O
three	O
trabeculae	O
,	O
protruding	O
from	O
the	O
left	O
ventricular	O
wall	O
,	O
apical	O
to	O
the	O
papillary	O
muscles	O
.	O
Intertrabecular	O
spaces	O
perfused	O
from	O
the	O
ventricular	O
cavity	O
with	O
colour	O
Doppler	O
.	O
Ratio	O
2	O
between	O
uncompacted	O
layer	O
and	O
compacted	O
layer	O
in	O
the	O
segment	O
with	O
greater	O
hypertrabeculation	O
in	O
end	O
systole	O
.	O
Cardioresonance	O
inferolateral	O
and	O
mid	O
and	O
apical	O
lateral	O
akinesia	O
.	O
Increased	O
trabeculation	O
in	O
lateral	O
and	O
medial	O
segments	O
and	O
apical	O
segments	O
,	O
with	O
suspicion	O
of	O
non	O
compacted	O
myocardium	O
.	O
The	O
distance	O
between	O
the	O
epicardial	O
surface	O
to	O
the	O
lowest	O
part	O
of	O
the	O
trabeculae	O
and	O
the	O
distance	O
from	O
the	O
epicardial	O
surface	O
to	O
the	O
peak	O
of	O
the	O
trabeculae	O
is	O
0	O
.	O
5	O
.	O
Diagnostic	O
coronary	O
angiography	O
and	O
coronary	O
intervention	O
1	O
vessel	O
disease	O
circumflex	O
2a	O
obtuse	O
marginal	O
.	O
Balloon	O
PCI	O
and	O
implantation	O
of	O
2	O
drug	O
eluting	O
stents	O
was	O
performed	O
.	O
A	O
neuromuscular	O
examination	O
was	O
performed	O
,	O
which	O
was	O
normal	O
,	O
and	O
the	O
creatine	O
phosphokinase	O
CPK	O
enzyme	O
elevation	O
decreased	O
gradually	O
until	O
it	O
normalised	O
.	O
48	O
hours	O
later	O
,	O
he	O
was	O
admitted	O
to	O
the	O
cardiology	O
ward	O
for	O
treatment	O
with	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
mg	O
24h	O
,	O
clopidrogel	B-FARMACO
75	O
mg	O
24h	O
,	O
rosuvastatin	B-FARMACO
20	O
mg	O
d	O
,	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
d	O
.	O
Once	O
on	O
the	O
ward	O
,	O
new	O
laboratory	O
tests	O
were	O
performed	O
Biochemistry	O
glycaemia	O
297	O
mg	O
dl	O
,	O
total	O
cholesterol	O
208	O
mg	O
dl	O
,	O
HDL	O
36	O
mg	O
dl	O
,	O
LDL	O
129	O
mg	O
dl	O
,	O
triglycerides	O
215	O
mg	O
dl	O
,	O
urea	O
67	O
mg	O
L	O
,	O
creatinine	O
1	O
.	O
2	O
mg	O
dl	O
,	O
creatinine	O
clearance	O
64	O
ml	O
min	O
1	O
.	O
73	O
m2	O
.	O
Basal	O
fasting	O
blood	O
glucose	O
and	O
HbA1C	O
were	O
determined	O
,	O
which	O
showed	O
a	O
value	O
of	O
8	O
.	O
5	O
,	O
and	O
the	O
patient	O
was	O
diagnosed	O
with	O
type	O
II	O
DM	O
.	O
EVOLUTION	O
After	O
an	O
adequate	O
clinical	O
evolution	O
,	O
he	O
was	O
discharged	O
from	O
hospital	O
on	O
the	O
5th	O
day	O
of	O
the	O
acute	O
event	O
,	O
being	O
referred	O
to	O
the	O
cardiac	O
rehabilitation	O
unit	O
within	O
2	O
weeks	O
.	O
A	O
welcome	O
interview	O
is	O
carried	O
out	O
and	O
informed	O
consent	O
is	O
requested	O
,	O
and	O
the	O
patient	O
signs	O
the	O
document	O
.	O
It	O
is	O
necessary	O
to	O
stratify	O
the	O
risk	O
of	O
cardiovascular	O
events	O
in	O
the	O
short	O
and	O
medium	O
term	O
.	O
For	O
this	O
purpose	O
,	O
a	O
functional	O
assessment	O
was	O
carried	O
out	O
by	O
means	O
of	O
ergometry	O
prior	O
to	O
inclusion	O
in	O
the	O
programme	O
,	O
in	O
this	O
case	O
the	O
Bruce	O
protocol	O
,	O
exercise	O
time	O
on	O
a	O
treadmill	O
of	O
6	O
minutes	O
,	O
work	O
of	O
7	O
METs	O
,	O
limited	O
by	O
muscular	O
exhaustion	O
.	O
Maximum	O
HR	O
120	O
l	O
m	O
,	O
reached	O
70	O
of	O
maximum	O
heart	O
rate	O
at	O
age	O
,	O
clinical	O
and	O
electrical	O
negative	O
,	O
basal	O
BP	O
120	O
80	O
mmHg	O
,	O
at	O
maximum	O
effort	O
160	O
70	O
.	O
Normal	O
recovery	O
,	O
no	O
arrhythmias	O
.	O
DIAGNOSIS	O
NSTEACS	O
Small	O
non	O
q	O
AMI	O
.	O
Non	O
compaction	O
cardiomyopathy	O
with	O
left	O
ventricular	O
systolic	O
function	O
LVEF	O
at	O
the	O
lower	O
limit	O
of	O
normal	O
.	O
1	O
vessel	O
coronary	O
artery	O
disease	O
2nd	O
obtuse	O
marginal	O
artery	O
.	O
Percutaneous	O
transluminal	O
coronary	O
angioplasty	O
and	O
implantation	O
of	O
two	O
drug	O
eluting	O
stents	O
.	O
Mixed	O
dyslipidaemia	O
.	O
Diabetes	O
mellitus	O
DM	O
type	O
II	O
.	O
Obesity	O
grade	O
I	O
.	O

Background	O
42	O
year	O
old	O
woman	O
with	O
no	O
known	O
drug	O
allergies	O
.	O
No	O
hypertension	O
,	O
dyslipidaemia	O
or	O
diabetes	O
mellitus	O
.	O
No	O
toxic	O
habits	O
.	O
Inactive	O
ulcerative	O
colitis	O
under	O
treatment	O
.	O
Periodic	O
follow	O
up	O
by	O
digestology	O
.	O
Last	O
colonoscopy	O
in	O
2013	O
.	O
Migraine	O
in	O
treatment	O
with	O
triptans	B-FARMACO
.	O
Current	O
illness	O
Puerpera	O
patient	O
with	O
an	O
uneventful	O
pregnancy	O
who	O
,	O
after	O
the	O
4th	O
day	O
of	O
euthocic	O
delivery	O
,	O
began	O
to	O
feel	O
dyspnoea	O
with	O
slight	O
precordial	O
pressure	O
and	O
headache	O
,	O
not	O
associated	O
with	O
vegetatism	O
.	O
Elevated	O
blood	O
pressure	O
and	O
proteinuria	O
were	O
observed	O
,	O
and	O
a	O
diagnosis	O
of	O
pre	O
eclampsia	O
was	O
made	O
.	O
Creatinine	O
levels	O
were	O
normal	O
.	O
A	O
fundus	O
examination	O
was	O
performed	O
and	O
found	O
to	O
be	O
normal	O
.	O
After	O
starting	O
treatment	O
with	O
labetalol	B-FARMACO
and	O
magnesium	B-FARMACO
sulphate	I-FARMACO
,	O
the	O
patient	O
progressed	O
favourably	O
,	O
with	O
control	O
of	O
blood	O
pressure	O
and	O
improvement	O
in	O
headache	O
and	O
general	O
condition	O
.	O
Laboratory	O
tests	O
showed	O
an	O
initial	O
increase	O
in	O
LDH	O
with	O
a	O
subsequent	O
decrease	O
.	O
Labetalol	B-FARMACO
ev	O
and	O
magnesium	B-FARMACO
sulphate	I-FARMACO
were	O
maintained	O
until	O
48	O
hours	O
had	O
elapsed	O
,	O
and	O
the	O
patient	O
was	O
subsequently	O
switched	O
to	O
oral	O
labetalol	B-FARMACO
300	O
mg	O
6h	O
.	O
Given	O
the	O
clinical	O
and	O
analytical	O
stability	O
,	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
hospital	O
ward	O
.	O
During	O
her	O
stay	O
in	O
the	O
hospital	O
ward	O
,	O
the	O
patient	O
remained	O
hypertensive	O
despite	O
nifedipine	B-FARMACO
10	O
mg	O
6h	O
vo	O
and	O
enalapril	B-FARMACO
5	O
mg	O
12h	O
vo	O
.	O
Recurrence	O
of	O
severe	O
headaches	O
without	O
neurological	O
focality	O
,	O
so	O
a	O
cranial	O
CAT	O
scan	O
was	O
performed	O
,	O
which	O
was	O
normal	O
.	O
Given	O
the	O
persistence	O
of	O
the	O
headache	O
and	O
his	O
history	O
of	O
migraine	O
,	O
sumatriptan	B-FARMACO
was	O
started	O
with	O
clinical	O
improvement	O
.	O
After	O
48	O
hours	O
of	O
her	O
stay	O
on	O
the	O
ward	O
,	O
she	O
presented	O
peak	O
blood	O
pressure	O
of	O
180	O
110	O
mmHg	O
together	O
with	O
chest	O
tightness	O
.	O
An	O
ECG	O
was	O
performed	O
,	O
showing	O
RS	O
at	O
60	O
bpm	O
,	O
with	O
normal	O
PR	O
,	O
HBASHH	O
,	O
ST	O
elevation	O
of	O
0	O
.	O
5	O
mm	O
anterolateral	O
with	O
negative	O
T	O
.	O
Nitroglycerin	B-FARMACO
perfusion	O
was	O
started	O
and	O
the	O
patient	O
was	O
asymptomatic	O
after	O
15	O
minutes	O
.	O
She	O
was	O
transferred	O
to	O
our	O
centre	O
from	O
the	O
maternity	O
hospital	O
.	O
On	O
arrival	O
,	O
no	O
chest	O
pain	O
.	O
BP	O
160	O
90	O
mmHg	O
.	O
HR	O
65	O
bpm	O
.	O
SaO2	O
100	O
ambient	O
air	O
.	O
No	O
semiology	O
of	O
congestion	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
shows	O
normalisation	O
of	O
ST	O
,	O
although	O
HBASHH	O
persists	O
and	O
minimal	O
R	O
in	O
precordial	O
leads	O
.	O
Initial	O
TnI	O
0	O
.	O
7	O
ng	O
ml	O
.	O
Laboratory	O
tests	O
CRP	O
0	O
.	O
95	O
mg	O
dl	O
;	O
creatinine	O
0	O
.	O
44	O
mg	O
dl	O
;	O
Na	O
141	O
mmol	O
L	O
;	O
K	O
3	O
.	O
8	O
mmol	O
l	O
;	O
leukocytes	O
6	O
,	O
800	O
mcl	O
;	O
Hb	O
130	O
g	O
l	O
;	O
Hto	O
40	O
;	O
Plaq	O
298	O
,	O
000	O
mcl	O
;	O
PT	O
86	O
.	O
2	O
;	O
D	O
dimer	O
10	O
,	O
000	O
ng	O
ml	O
.	O
A	O
portable	O
echocardiogram	O
was	O
performed	O
,	O
showing	O
preserved	O
LV	O
systolic	O
function	O
,	O
with	O
hypokinesia	O
of	O
the	O
apical	O
segments	O
and	O
slight	O
pericardial	O
effusion	O
.	O
Chest	O
X	O
ray	O
no	O
cardiomegaly	O
.	O
No	O
signs	O
of	O
parenchymal	O
congestion	O
.	O
Free	O
costophrenic	O
sinuses	O
.	O
EVOLUTION	O
Admitted	O
to	O
the	O
Acute	O
Cardiac	O
Care	O
Unit	O
,	O
presenting	O
haemodynamic	O
stability	O
with	O
a	O
tendency	O
to	O
hypertension	O
.	O
No	O
new	O
episodes	O
of	O
chest	O
pain	O
or	O
signs	O
of	O
congestion	O
.	O
Peak	O
Tn	O
I	O
24	O
ng	O
ml	O
.	O
Normal	O
renal	O
function	O
.	O
Twenty	O
four	O
hours	O
after	O
arrival	O
,	O
coronary	O
angiography	O
showed	O
coronary	O
dissection	O
of	O
the	O
distal	O
LAD	O
with	O
apical	O
recurrence	O
TIMI	O
3	O
flow	O
and	O
conservative	O
management	O
was	O
chosen	O
.	O
The	O
echocardiogram	O
showed	O
non	O
dilated	O
left	O
ventricle	O
with	O
EF	O
50	O
.	O
Septoapical	O
hypokinesia	O
and	O
mild	O
mitral	O
insufficiency	O
.	O
Normal	O
RV	O
function	O
.	O
Anti	O
aggregation	O
treatment	O
was	O
maintained	O
with	O
adiro	B-FARMACO
100	O
mg	O
indefinitely	O
and	O
anticoagulant	O
treatment	O
was	O
discontinued	O
after	O
72	O
hours	O
.	O
Due	O
to	O
a	O
tendency	O
to	O
hypertension	O
,	O
treatment	O
was	O
started	O
with	O
ACE	O
inhibitors	O
,	O
amlodipine	B-FARMACO
and	O
beta	O
blockers	O
.	O
She	O
was	O
discharged	O
home	O
asymptomatic	O
and	O
with	O
controlled	O
blood	O
pressure	O
.	O
DIAGNOSIS	O
Spontaneous	O
coronary	O
artery	O
dissection	O
of	O
the	O
LAD	O
in	O
a	O
postpartum	O
patient	O
.	O

Background	O
Sister	O
with	O
congenital	O
heart	O
disease	O
ventricular	O
septal	O
defect	O
No	O
medical	O
or	O
surgical	O
history	O
of	O
interest	O
No	O
usual	O
treatment	O
No	O
known	O
drug	O
allergies	O
Current	O
illness	O
A	O
21	O
year	O
old	O
male	O
patient	O
came	O
to	O
the	O
emergency	O
department	O
with	O
a	O
sensation	O
of	O
dizziness	O
accompanied	O
by	O
transitory	O
paraesthesia	O
in	O
the	O
left	O
arm	O
,	O
without	O
loss	O
of	O
consciousness	O
or	O
trauma	O
.	O
He	O
reported	O
no	O
chest	O
pain	O
,	O
dyspnoea	O
,	O
palpitations	O
or	O
syncope	O
and	O
was	O
discharged	O
from	O
the	O
emergency	O
department	O
.	O
Previously	O
completely	O
normal	O
life	O
,	O
with	O
intense	O
sport	O
.	O
He	O
is	O
currently	O
a	O
football	O
referee	O
.	O
Two	O
weeks	O
later	O
he	O
presented	O
with	O
dizziness	O
of	O
a	O
few	O
minutes	O
'	O
duration	O
with	O
chest	O
pain	O
while	O
playing	O
sport	O
with	O
subsequent	O
abnormal	O
sensations	O
consisting	O
of	O
general	O
malaise	O
and	O
slight	O
dizziness	O
for	O
at	O
least	O
an	O
hour	O
,	O
relieved	O
by	O
diazepam	B-FARMACO
.	O
Physical	O
examination	O
Normal	O
jugular	O
venous	O
pressure	O
.	O
Carotid	O
pulses	O
full	O
and	O
symmetrical	O
.	O
No	O
frmito	O
or	O
impulsive	O
precordial	O
beats	O
.	O
Cardiorespiratory	O
auscultation	O
preserved	O
vesicular	O
murmur	O
,	O
without	O
added	O
pathological	O
sounds	O
.	O
Rhythmic	O
cardiac	O
tones	O
with	O
holosystolic	O
murmur	O
II	O
VI	O
in	O
the	O
lower	O
left	O
sternal	O
border	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
non	O
painful	O
,	O
without	O
megaliths	O
.	O
Lower	O
limbs	O
no	O
oedema	O
and	O
preserved	O
distal	O
pulses	O
.	O
COMPLEMENTARY	O
TESTS	O
Chest	O
X	O
ray	O
normal	O
cardiothoracic	O
index	O
,	O
normal	O
cardiophrenic	O
and	O
costodiaphragmatic	O
sinuses	O
,	O
no	O
pleural	O
effusion	O
,	O
no	O
infiltrates	O
or	O
condensation	O
.	O
No	O
alterations	O
in	O
bone	O
or	O
soft	O
tissues	O
were	O
observed	O
.	O
Laboratory	O
tests	O
all	O
parameters	O
were	O
normal	O
.	O
Glucemia	O
89	O
mg	O
dL	O
,	O
urea	O
29	O
mg	O
dL	O
,	O
0	O
.	O
89	O
mg	O
dL	O
,	O
sodium	O
144	O
mmol	O
L	O
,	O
potassium	O
4	O
.	O
1	O
mmol	O
L	O
,	O
chlorine	O
108	O
mmol	O
L	O
.	O
Leukocytes	O
10130	O
uL	O
with	O
58	O
.	O
4	O
neutrophils	O
.	O
Haemoglobin	O
17	O
.	O
4	O
g	O
dL	O
with	O
MCV	O
89	O
.	O
4	O
fl	O
,	O
platelets	O
223000Ul	O
.	O
Cardiac	O
markers	O
troponin	O
.	O
0	O
.	O
0	O
in	O
two	O
determinations	O
.	O
ECG	O
sinus	O
rhythm	O
at	O
79lpm	O
with	O
PR	O
180	O
ms	O
.	O
Image	O
of	O
BCRDHH	O
,	O
IAH	O
and	O
biauricular	O
growth	O
.	O
Transthoracic	O
echocardiography	O
situs	O
solitus	O
.	O
Atrioventricular	O
and	O
ventricular	O
arterial	O
concordance	O
.	O
Atrioventricular	O
septal	O
defect	O
AV	O
valves	O
at	O
the	O
same	O
level	O
.	O
Spontaneously	O
closed	O
ventricular	O
septal	O
defect	O
with	O
closing	O
aneurysm	O
.	O
Wide	O
defect	O
of	O
the	O
inflow	O
septum	O
and	O
ostium	O
secundum	O
.	O
Left	O
right	O
shunt	O
.	O
Tabication	O
in	O
the	O
wall	O
of	O
the	O
left	O
atrium	O
cor	O
triatriatum	O
type	O
,	O
delimiting	O
a	O
posterior	O
cavity	O
where	O
the	O
pulmonary	O
veins	O
drain	O
and	O
communicating	O
with	O
a	O
restrictive	O
orifice	O
with	O
the	O
left	O
atrium	O
adjacent	O
to	O
the	O
mitral	O
valve	O
.	O
The	O
four	O
pulmonary	O
veins	O
cannot	O
be	O
precisely	O
located	O
.	O
Moderately	O
dilated	O
right	O
ventricle	O
52	O
mm	O
basal	O
and	O
46	O
mm	O
in	O
the	O
mid	O
region	O
measured	O
in	O
apical	O
4	O
chamber	O
projection	O
.	O
Good	O
longitudinal	O
displacement	O
,	O
TAPSE	O
of	O
22	O
m	O
.	O
Left	O
ventricle	O
of	O
normal	O
diameters	O
,	O
walls	O
and	O
ejection	O
fraction	O
parasternal	O
projection	O
,	O
long	O
axis	O
end	O
diastolic	O
diameter	O
44	O
mm	O
,	O
end	O
systolic	O
diameter	O
23	O
mm	O
,	O
basal	O
septum	O
thickness	O
10	O
mm	O
,	O
posterior	O
wall	O
thickness	O
8	O
mm	O
.	O
Left	O
atrium	O
not	O
dilated	O
.	O
Left	O
atrial	O
valve	O
with	O
elongated	O
leaflets	O
.	O
Good	O
opening	O
.	O
Slight	O
central	O
regurgitation	O
.	O
Right	O
AV	O
valve	O
with	O
leaflet	O
coaptation	O
defect	O
.	O
Moderate	O
central	O
insufficiency	O
.	O
AD	O
VD	O
gradient	O
of	O
32	O
mmHg	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
19mm	O
with	O
preserved	O
inspiratory	O
collapse	O
.	O
No	O
pericardial	O
effusion	O
.	O
Aortic	O
sag	O
without	O
abnormalities	O
.	O
Estimated	O
PSAP	O
between	O
40	O
45	O
mmHg	O
.	O
Transesophageal	O
echocardiography	O
wide	O
interatrial	O
septal	O
defect	O
in	O
the	O
region	O
of	O
ostium	O
primum	O
plus	O
part	O
of	O
ostium	O
secundum	O
.	O
Membrane	O
septum	O
in	O
the	O
upper	O
portion	O
of	O
the	O
left	O
atrium	O
.	O
Appears	O
to	O
have	O
two	O
entry	O
points	O
one	O
posterior	O
approximately	O
17x10	O
mm	O
,	O
with	O
accelerated	O
flow	O
through	O
it	O
and	O
another	O
anterolateral	O
in	O
relation	O
to	O
the	O
entrance	O
of	O
the	O
left	O
atrial	O
appendage	O
and	O
through	O
the	O
entrance	O
region	O
of	O
the	O
left	O
atrial	O
appendage	O
into	O
the	O
inflow	O
tract	O
and	O
mitral	O
valve	O
.	O
Apparent	O
drainage	O
of	O
the	O
four	O
pulmonary	O
veins	O
into	O
this	O
posterior	O
chamber	O
.	O
EVOLUTION	O
Currently	O
asymptomatic	O
,	O
accepted	O
for	O
cardiovascular	O
surgery	O
.	O
DIAGNOSIS	O
Cor	O
triatriatum	O
Partial	O
atrioventricular	O
defect	O
ASD	O
ostium	O
primum	O
type	O

A	O
47	O
year	O
old	O
man	O
was	O
brought	O
to	O
our	O
centre	O
by	O
the	O
emergency	O
services	O
after	O
presenting	O
a	O
recovered	O
cardiorespiratory	O
arrest	O
.	O
History	O
Cardiovascular	O
risk	O
factors	O
type	O
2	O
diabetes	O
mellitus	O
,	O
hypertension	O
,	O
dyslipidaemia	O
,	O
smoker	O
of	O
1	O
pack	O
day	O
.	O
Gout	O
episode	O
in	O
2010	O
treated	O
with	O
colchicine	B-FARMACO
and	O
allopurinol	B-FARMACO
.	O
he	O
underwent	O
bilateral	O
inguinal	O
hernioplasty	O
.	O
	O
No	O
known	O
previous	O
cardiovascular	O
history	O
or	O
family	O
history	O
of	O
early	O
ischaemic	O
heart	O
disease	O
.	O
Usual	O
treatment	O
losartan	B-FARMACO
50	O
mg	O
,	O
metformin	B-FARMACO
850	O
mg	O
half	O
a	O
tablet	O
per	O
day	O
.	O
Present	O
illness	O
he	O
was	O
brought	O
to	O
our	O
centre	O
by	O
the	O
emergency	O
services	O
after	O
presenting	O
with	O
witnessed	O
cardiorespiratory	O
arrest	O
in	O
the	O
street	O
,	O
and	O
basic	O
cardiopulmonary	O
resuscitation	O
CPR	O
manoeuvres	O
were	O
started	O
by	O
a	O
technician	O
for	O
15	O
minutes	O
.	O
After	O
the	O
arrival	O
of	O
the	O
emergency	O
services	O
,	O
advanced	O
CPR	O
and	O
orotracheal	O
intubation	O
OTI	O
were	O
started	O
.	O
A	O
defibrillable	O
rhythm	O
was	O
identified	O
on	O
the	O
monitor	O
and	O
two	O
shocks	O
were	O
applied	O
at	O
maximum	O
energy	O
,	O
after	O
which	O
sinus	O
rhythm	O
was	O
restored	O
and	O
the	O
electrocardiogram	O
ECG	O
showed	O
an	O
ST	O
segment	O
elevation	O
in	O
the	O
lower	O
face	O
.	O
On	O
arrival	O
at	O
our	O
centre	O
,	O
the	O
ECG	O
was	O
repeated	O
,	O
showing	O
normalisation	O
of	O
the	O
ST	O
segment	O
in	O
the	O
inferior	O
face	O
.	O
A	O
portable	O
transthoracic	O
echocardiogram	O
TTE	O
was	O
performed	O
,	O
showing	O
akinesia	O
of	O
the	O
inferior	O
face	O
.	O
The	O
patient	O
was	O
transferred	O
urgently	O
to	O
the	O
haemodynamics	O
room	O
and	O
a	O
therapeutic	O
hypothermia	O
protocol	O
was	O
initiated	O
.	O
Coronary	O
angiography	O
was	O
performed	O
,	O
showing	O
occlusion	O
of	O
the	O
ostial	O
circumflex	O
artery	O
CX	O
,	O
which	O
receives	O
heterocoronary	O
collateral	O
circulation	O
from	O
the	O
anterior	O
descending	O
artery	O
AD	O
,	O
and	O
severe	O
stenosis	O
in	O
the	O
middle	O
segment	O
of	O
the	O
right	O
coronary	O
artery	O
RCA	O
with	O
an	O
image	O
of	O
complex	O
plaque	O
.	O
In	O
view	O
of	O
the	O
electrocardiographic	O
and	O
TTE	O
findings	O
,	O
the	O
CD	O
artery	O
was	O
considered	O
to	O
be	O
responsible	O
for	O
the	O
condition	O
,	O
so	O
angioplasty	O
and	O
implantation	O
of	O
2	O
coated	O
stents	O
was	O
performed	O
with	O
suboptimal	O
results	O
due	O
to	O
poor	O
stent	O
apposition	O
due	O
to	O
the	O
significant	O
calcium	O
load	O
and	O
irregular	O
distribution	O
of	O
calcium	O
.	O
Subsequently	O
,	O
he	O
was	O
transferred	O
to	O
the	O
Acute	O
Cardiac	O
Care	O
Unit	O
intubated	O
,	O
sedoanalgesiated	O
and	O
relaxed	O
,	O
and	O
cooled	O
with	O
physiological	O
saline	O
solution	O
at	O
4oC	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
108	O
60	O
.	O
Heart	O
rate	O
65	O
bpm	O
.	O
oxygen	O
saturation	O
100	O
.	O
Head	O
and	O
neck	O
jugular	O
venous	O
pressure	O
normal	O
.	O
Pulmonary	O
auscultation	O
decreased	O
vesicular	O
murmur	O
in	O
the	O
right	O
hemithorax	O
.	O
Cardiac	O
auscultation	O
no	O
murmurs	O
or	O
extratonos	O
.	O
Abdomen	O
hydro	O
aerial	O
sounds	O
present	O
.	O
Soft	O
,	O
without	O
masses	O
or	O
organomegaly	O
.	O
Extremities	O
pulses	O
of	O
slightly	O
decreased	O
amplitude	O
,	O
symmetrical	O
,	O
no	O
oedema	O
in	O
the	O
lower	O
limbs	O
,	O
slow	O
capillary	O
filling	O
.	O
Neurological	O
reactive	O
symmetrical	O
pupils	O
.	O
Ramsay	O
6	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
after	O
defibrillation	O
sinus	O
rhythm	O
,	O
narrow	O
QRS	O
,	O
ST	O
segment	O
elevation	O
of	O
up	O
to	O
4	O
mm	O
in	O
inferior	O
face	O
,	O
greater	O
in	O
lead	O
III	O
than	O
in	O
II	O
,	O
with	O
specular	O
decrease	O
from	O
V1	O
to	O
V3	O
.	O
ECG	O
on	O
arrival	O
at	O
our	O
centre	O
normalisation	O
of	O
ST	O
segment	O
elevation	O
in	O
the	O
inferior	O
face	O
.	O
Analysis	O
on	O
admission	O
Hb	O
14	O
g	O
dL	O
,	O
leukocytes	O
17300	O
L	O
neutrophils	O
85	O
,	O
platelets	O
270000	O
L	O
,	O
INR	O
1	O
,	O
D	O
dimer	O
15346	O
ng	O
mL	O
,	O
glucose	O
346	O
mg	O
dL	O
,	O
urea	O
27	O
mg	O
dL	O
,	O
creatinine	O
0	O
.	O
83	O
mg	O
dL	O
,	O
Na	O
134	O
mg	O
dL	O
,	O
potassium	O
4	O
.	O
3	O
mg	O
dL	O
,	O
NTproBNP	O
280	O
pg	O
mL	O
,	O
ALT	O
48	O
U	O
L	O
,	O
GGT	O
32U	O
L	O
,	O
alkaline	O
phosphatase	O
76U	O
L	O
,	O
amylase	O
and	O
lipase	O
normal	O
,	O
Mg	O
2	O
.	O
3	O
mg	O
dL	O
,	O
Ca	O
8	O
.	O
1	O
mg	O
dL	O
,	O
P	O
6	O
.	O
4	O
mg	O
dL	O
,	O
total	O
cholesterol	O
138	O
mg	O
dL	O
,	O
LDL	O
84	O
mg	O
dL	O
,	O
HDL	O
35	O
mg	O
dL	O
,	O
triglycerides	O
92	O
mg	O
dL	O
,	O
HbA1c	O
6	O
.	O
2	O
,	O
TSH	O
0	O
.	O
03	O
ulU	O
mL	O
,	O
free	O
T4	O
17	O
.	O
6	O
pg	O
mL	O
,	O
free	O
T3	O
3	O
.	O
9	O
pg	O
mL	O
.	O
Myocardial	O
necrosis	O
markers	O
peak	O
troponin	O
I	O
149	O
ng	O
mL	O
,	O
peak	O
CK	O
2512	O
U	O
L	O
.	O
Neuron	O
specific	O
enolase	O
1st	O
determination	O
29	O
.	O
4	O
ng	O
mL	O
.	O
Second	O
determination	O
43	O
.	O
3	O
ng	O
mL	O
.	O
Blood	O
cultures	O
,	O
urine	O
culture	O
and	O
bronchial	O
aspirate	O
culture	O
negative	O
.	O
Chest	O
X	O
ray	O
on	O
admission	O
atelectasis	O
in	O
the	O
right	O
upper	O
lobe	O
.	O
Chest	O
X	O
ray	O
2	O
days	O
after	O
admission	O
alveolointerstitial	O
infiltrate	O
in	O
right	O
lung	O
and	O
left	O
lung	O
base	O
.	O
Resolution	O
of	O
right	O
upper	O
lobe	O
atelectasis	O
.	O
Portable	O
echocardiogram	O
on	O
admission	O
during	O
induction	O
of	O
hypothermia	O
moderate	O
severe	O
left	O
ventricular	O
dysfunction	O
with	O
estimated	O
LVEF	O
35	O
,	O
with	O
posterior	O
and	O
inferior	O
akinesia	O
and	O
lateral	O
hypokinesia	O
.	O
Right	O
ventricle	O
with	O
slightly	O
reduced	O
systolic	O
function	O
TAPSE	O
15	O
mm	O
,	O
mild	O
mitral	O
insufficiency	O
,	O
no	O
pericardial	O
effusion	O
.	O
Echocardiogram	O
after	O
termination	O
of	O
hypothermia	O
and	O
extubation	O
mildly	O
reduced	O
left	O
ventricular	O
systolic	O
function	O
LVEF	O
by	O
biplane	O
57	O
.	O
Apical	O
akinesia	O
and	O
hypokinesia	O
of	O
the	O
inferior	O
and	O
septal	O
aspect	O
.	O
Mild	O
mitral	O
insufficiency	O
.	O
Urgent	O
coronary	O
angiography	O
left	O
main	O
coronary	O
artery	O
no	O
stenosis	O
.	O
DA	O
artery	O
vessel	O
of	O
adequate	O
calibre	O
and	O
development	O
,	O
without	O
stenosis	O
.	O
Artery	O
CX	O
vessel	O
of	O
adequate	O
size	O
and	O
development	O
,	O
with	O
100	O
ostial	O
occlusion	O
that	O
receives	O
homocoronary	O
Rentrop	O
3	O
collateral	O
circulation	O
from	O
the	O
diagonal	O
branches	O
of	O
the	O
DA	O
artery	O
.	O
CD	O
artery	O
severely	O
calcified	O
dominant	O
vessel	O
,	O
of	O
adequate	O
size	O
and	O
development	O
,	O
with	O
75	O
stenosis	O
in	O
its	O
proximal	O
segment	O
and	O
90	O
ulcerated	O
plaque	O
image	O
in	O
its	O
middle	O
segment	O
.	O
Balloon	O
angioplasty	O
and	O
implantation	O
of	O
2	O
overlapping	O
drug	O
eluting	O
stents	O
in	O
the	O
middle	O
and	O
proximal	O
segments	O
of	O
the	O
CD	O
artery	O
,	O
with	O
TIMI	O
III	O
distal	O
flow	O
.	O
EVOLUTION	O
On	O
arrival	O
at	O
the	O
Acute	O
Cardiac	O
Care	O
Unit	O
,	O
a	O
femoral	O
venous	O
hypothermia	O
catheter	O
Coolgard	O
was	O
inserted	O
and	O
cooling	O
was	O
completed	O
,	O
reaching	O
a	O
target	O
temperature	O
of	O
33	O
C	O
within	O
a	O
few	O
hours	O
.	O
The	O
admission	O
X	O
ray	O
showed	O
an	O
image	O
of	O
atelectasis	O
in	O
the	O
right	O
upper	O
lobe	O
,	O
probably	O
related	O
to	O
secretion	O
impaction	O
,	O
which	O
resolved	O
in	O
the	O
subsequent	O
control	O
X	O
ray	O
after	O
aspiration	O
of	O
the	O
endotracheal	O
tube	O
and	O
mobilisation	O
of	O
the	O
patient	O
.	O
Therapeutic	O
hypothermia	O
was	O
maintained	O
for	O
24	O
hours	O
,	O
and	O
subsequent	O
rewarming	O
was	O
carried	O
out	O
without	O
complications	O
.	O
The	O
patient	O
evolved	O
well	O
,	O
allowing	O
him	O
to	O
be	O
extubated	O
on	O
the	O
third	O
day	O
of	O
admission	O
.	O
After	O
rewarming	O
and	O
extubation	O
,	O
the	O
patient	O
made	O
a	O
good	O
neurological	O
recovery	O
,	O
with	O
adequate	O
mobilisation	O
of	O
all	O
four	O
limbs	O
,	O
and	O
was	O
oriented	O
,	O
able	O
to	O
understand	O
and	O
obey	O
orders	O
,	O
with	O
some	O
frontal	O
deficit	O
,	O
which	O
gradually	O
recovered	O
.	O
On	O
discharge	O
he	O
persisted	O
with	O
mild	O
dysarthria	O
,	O
pending	O
assessment	O
and	O
follow	O
up	O
by	O
rehabilitation	O
and	O
speech	O
therapy	O
.	O
Incidentally	O
,	O
during	O
his	O
admission	O
he	O
presented	O
a	O
bout	O
of	O
atrial	O
fibrillation	O
on	O
telemetry	O
,	O
which	O
cardioverted	O
to	O
sinus	O
rhythm	O
after	O
starting	O
amiodarone	B-FARMACO
,	O
with	O
no	O
new	O
arrhythmic	O
episodes	O
.	O
On	O
arrival	O
at	O
the	O
hospital	O
,	O
the	O
emergency	O
services	O
informed	O
us	O
of	O
the	O
possibility	O
of	O
bronchoaspiration	O
during	O
OTI	O
,	O
so	O
blood	O
,	O
urine	O
and	O
bronchial	O
aspirate	O
cultures	O
were	O
taken	O
on	O
admission	O
,	O
and	O
empirical	O
antibiotic	O
coverage	O
with	O
amoxicillin	B-FARMACO
clavulanic	I-FARMACO
acid	I-FARMACO
was	O
started	O
.	O
The	O
cultures	O
,	O
however	O
,	O
were	O
negative	O
.	O
After	O
completing	O
rewarming	O
,	O
fever	O
was	O
observed	O
for	O
more	O
than	O
24	O
hours	O
,	O
with	O
purulent	O
secretions	O
in	O
the	O
ventilation	O
tube	O
,	O
so	O
antibiotic	O
therapy	O
was	O
modified	O
and	O
meropenem	B-FARMACO
and	O
metronidazole	B-FARMACO
were	O
started	O
,	O
with	O
good	O
evolution	O
,	O
with	O
no	O
new	O
febrile	O
peaks	O
.	O
The	O
patient	O
was	O
discharged	O
with	O
treatment	O
with	O
adiro	B-FARMACO
100	O
mg	O
,	O
prasugrel	B-FARMACO
10	O
mg	O
,	O
pantoprazole	B-FARMACO
20	O
mg	O
,	O
atorvastatin	B-FARMACO
80	O
mg	O
,	O
enalapril	B-FARMACO
10	O
mg	O
and	O
metoprolol	B-FARMACO
50	O
mg	O
at	O
breakfast	O
and	O
25	O
mg	O
at	O
dinner	O
.	O
The	O
patient	O
was	O
referred	O
to	O
the	O
cardiac	O
rehabilitation	O
department	O
of	O
our	O
centre	O
.	O
DIAGNOSIS	O
Cardio	O
respiratory	O
arrest	O
due	O
to	O
recovered	O
ventricular	O
fibrillation	O
.	O
Killip	O
I	O
inferior	O
STEACS	O
.	O
Angioplasty	O
and	O
implantation	O
of	O
drug	O
eluting	O
stents	O
in	O
the	O
proximal	O
and	O
middle	O
right	O
coronary	O
artery	O
.	O
Total	O
occlusion	O
of	O
ostial	O
circumflex	O
artery	O
with	O
collateral	O
circulation	O
.	O
Therapeutic	O
hypothermia	O
.	O
Bronchoaspiration	O
pneumonia	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
53	O
year	O
old	O
male	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
Family	O
history	O
Mother	O
died	O
suddenly	O
at	O
the	O
age	O
of	O
72	O
.	O
Maternal	O
uncle	O
died	O
in	O
the	O
operating	O
theatre	O
during	O
anaesthetic	O
induction	O
.	O
Cardiovascular	O
risk	O
factors	O
Smoker	O
of	O
about	O
30	O
pack	O
years	O
Non	O
drinker	O
No	O
hypertension	O
,	O
DM	O
or	O
LD	O
No	O
known	O
cardiac	O
history	O
Other	O
reactive	O
depression	O
Treatments	O
omeprazole	B-FARMACO
and	O
deprax	B-FARMACO
Current	O
illness	O
53	O
year	O
old	O
patient	O
who	O
consults	O
for	O
syncope	O
.	O
First	O
syncope	O
18	O
months	O
ago	O
,	O
when	O
she	O
consulted	O
this	O
centre	O
,	O
but	O
requested	O
voluntary	O
discharge	O
before	O
the	O
aetiology	O
could	O
be	O
studied	O
.	O
Repeated	O
another	O
6	O
times	O
,	O
with	O
prodromes	O
loss	O
of	O
consciousness	O
rapid	O
recovery	O
.	O
One	O
of	O
them	O
at	O
rest	O
.	O
Physical	O
examination	O
COC	O
.	O
Afebrile	O
.	O
A	O
100	O
60	O
.	O
HR	O
55	O
bpm	O
.	O
BEG	O
.	O
NHNC	O
.	O
Normal	O
PC	O
.	O
Arterial	O
pulse	O
bisferiens	O
.	O
Cardiac	O
auscultation	O
RsCsRs	O
with	O
systolic	O
murmur	O
III	O
VI	O
with	O
preserved	O
s2	O
in	O
aortic	O
focus	O
irradiated	O
to	O
the	O
rest	O
of	O
foci	O
.	O
Decrease	O
in	O
murmur	O
until	O
it	O
disappeared	O
with	O
squatting	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
.	O
Soft	O
,	O
non	O
painful	O
abdomen	O
with	O
no	O
masses	O
or	O
megaliths	O
.	O
Positive	O
radial	O
and	O
pedial	O
arterial	O
pulses	O
,	O
bilateral	O
and	O
symmetrical	O
.	O
COMPLEMENTARY	O
TESTS	O
Blood	O
count	O
,	O
biochemistry	O
and	O
coagulation	O
no	O
alterations	O
.	O
Chest	O
X	O
ray	O
cardiothoracic	O
index	O
normal	O
,	O
without	O
condensation	O
or	O
signs	O
of	O
heart	O
failure	O
.	O
ECG	O
sinus	O
rhythm	O
with	O
LV	O
enlargement	O
and	O
signs	O
of	O
overload	O
.	O
Transthoracic	O
echocardiogram	O
LA	O
moderately	O
dilated	O
33	O
cm2	O
and	O
4	O
.	O
5	O
cm	O
.	O
LV	O
with	O
severe	O
hypertrophy	O
of	O
septal	O
predominance	O
23	O
mm	O
,	O
not	O
dilated	O
,	O
with	O
preserved	O
systolic	O
function	O
.	O
Mitral	O
SAM	O
.	O
LVOT	O
obstruction	O
with	O
maximum	O
gradient	O
111	O
mmHg	O
,	O
baseline	O
.	O
Severe	O
eccentric	O
MI	O
.	O
Telemetry	O
during	O
hospitalisation	O
no	O
rhythm	O
alterations	O
.	O
EVOLUTION	O
Patient	O
admitted	O
to	O
Cardiology	O
for	O
syncope	O
under	O
study	O
.	O
Auscultation	O
revealed	O
a	O
murmur	O
that	O
decreased	O
with	O
manoeuvres	O
that	O
increased	O
ventricular	O
volume	O
increased	O
afterload	O
with	O
squatting	O
and	O
an	O
ECG	O
with	O
criteria	O
of	O
left	O
ventricular	O
hypertrophy	O
and	O
a	O
bisferiens	O
arterial	O
pulse	O
,	O
for	O
which	O
he	O
was	O
admitted	O
with	O
the	O
suspicion	O
of	O
obstructive	O
hypertrophic	O
cardiomyopathy	O
.	O
This	O
suspicion	O
was	O
confirmed	O
by	O
echocardiography	O
,	O
which	O
revealed	O
atrial	O
dilatation	O
and	O
obstruction	O
of	O
the	O
left	O
ventricular	O
outflow	O
tract	O
.	O
The	O
patient	O
was	O
monitored	O
with	O
telemetry	O
from	O
admission	O
,	O
and	O
no	O
arrhythmic	O
events	O
were	O
observed	O
.	O
In	O
accordance	O
with	O
the	O
new	O
guidelines	O
on	O
hypertrophic	O
cardiomyopathy	O
,	O
the	O
risk	O
of	O
sudden	O
death	O
at	O
5	O
years	O
is	O
calculated	O
,	O
with	O
a	O
result	O
of	O
more	O
than	O
6	O
,	O
and	O
therefore	O
the	O
implantation	O
of	O
a	O
defibrillator	O
is	O
recommended	O
.	O
Consent	O
was	O
obtained	O
both	O
for	O
ICD	O
implantation	O
and	O
for	O
blood	O
extraction	O
for	O
genetic	O
study	O
,	O
and	O
the	O
family	O
study	O
of	O
the	O
index	O
case	O
was	O
initiated	O
.	O
DIAGNOSIS	O
Index	O
case	O
obstructive	O
hypertrophic	O
cardiomyopathy	O
.	O
Secondary	O
syncope	O
.	O

HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
Objective	O
the	O
interpretation	O
of	O
the	O
ECG	O
and	O
the	O
clinical	O
context	O
is	O
key	O
to	O
diagnosis	O
and	O
subsequent	O
treatment	O
.	O
A	O
31	O
year	O
old	O
primigravid	O
33	O
week	O
old	O
woman	O
was	O
transferred	O
to	O
the	O
Cardiology	O
Department	O
of	O
the	O
Hospital	O
Central	O
de	O
Asturias	O
due	O
to	O
dizziness	O
,	O
palpitations	O
and	O
electrocardiographic	O
alterations	O
.	O
AP	O
Allergy	O
to	O
diclofenac	B-FARMACO
and	O
naproxen	B-FARMACO
.	O
She	O
works	O
in	O
a	O
supermarket	O
.	O
Cardiovascular	O
risk	O
factors	O
No	O
toxic	O
habits	O
.	O
No	O
hypertension	O
,	O
mixed	O
dyslipidaemia	O
currently	O
discharged	O
by	O
endocrinologist	O
,	O
treated	O
with	O
simvastatin	B-FARMACO
and	O
fenofibrate	B-FARMACO
,	O
no	O
follow	O
up	O
.	O
Gestational	O
diabetes	O
treated	O
with	O
insulin	B-FARMACO
Lispro	I-FARMACO
25	O
75	O
12	O
units	O
in	O
the	O
morning	O
,	O
10	O
units	O
at	O
night	O
.	O
No	O
previous	O
cardiological	O
history	O
.	O
Hepatic	O
steatosis	O
.	O
Herniated	O
disc	O
.	O
Breast	O
reduction	O
surgery	O
.	O
Present	O
illness	O
The	O
patient	O
attended	O
her	O
referral	O
hospital	O
due	O
to	O
dizziness	O
of	O
24	O
hours	O
of	O
evolution	O
in	O
relation	O
to	O
standing	O
upright	O
.	O
The	O
symptoms	O
improve	O
with	O
decubitus	O
.	O
No	O
chest	O
pain	O
or	O
dyspnoea	O
.	O
Occasional	O
episodes	O
of	O
palpitations	O
.	O
The	O
patient	O
reported	O
catarrhal	O
symptoms	O
a	O
few	O
days	O
earlier	O
.	O
ECG	O
was	O
performed	O
and	O
described	O
as	O
wide	O
QRS	O
tachycardia	O
at	O
180	O
bpm	O
.	O
Vagal	O
manoeuvres	O
were	O
performed	O
but	O
were	O
ineffective	O
and	O
6	O
and	O
12	O
mg	O
of	O
adenosine	B-FARMACO
were	O
prescribed	O
with	O
no	O
response	O
,	O
so	O
he	O
was	O
referred	O
to	O
our	O
centre	O
.	O
We	O
do	O
not	O
have	O
the	O
patient	O
's	O
baseline	O
ECG	O
.	O
On	O
arrival	O
at	O
our	O
centre	O
,	O
the	O
patient	O
was	O
asymptomatic	O
and	O
haemodynamically	O
stable	O
.	O
Physical	O
examination	O
BP	O
110	O
75	O
mmHg	O
.	O
HR	O
188	O
bpm	O
.	O
O2	O
Sat	O
98	O
without	O
oxygen	O
therapy	O
.	O
Conscious	O
,	O
oriented	O
,	O
cooperative	O
.	O
Normohydrated	O
and	O
normal	O
colour	O
.	O
AP	O
preserved	O
vesicular	O
murmur	O
with	O
no	O
other	O
superimposed	O
noises	O
.	O
AC	O
rhythmic	O
heart	O
sounds	O
with	O
mitral	O
SS	O
III	O
IV	O
with	O
normal	O
S2	O
.	O
Abdomen	O
33	O
weeks	O
pregnant	O
.	O
Scar	O
on	O
the	O
breasts	O
.	O
MMII	O
no	O
oedema	O
,	O
no	O
signs	O
of	O
DVT	O
.	O
COMPLEMENTARY	O
TESTS	O
Blood	O
count	O
Hb	O
12	O
.	O
5g	O
dl	O
,	O
MCV	O
82	O
.	O
6	O
fL	O
,	O
leukocytes12500	O
uL	O
normal	O
formula	O
,	O
platelets	O
239000	O
uL	O
.	O
Biochemistry	O
glucose	O
125mg	O
dl	O
,	O
urea	O
17	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
61	O
mg	O
dl	O
,	O
sodium	O
135	O
mg	O
dl	O
,	O
CK	O
56	O
U	O
L	O
,	O
troponin	O
T	O
33	O
ng	O
L	O
.	O
Coagulation	O
PT	O
87	O
,	O
INR	O
1	O
.	O
09	O
,	O
fibrinogen	O
686	O
,	O
D	O
dimer	O
1187	O
ng	O
ml	O
.	O
ECG	O
transthoracic	O
echocardiography	O
study	O
performed	O
at	O
160	O
bpm	O
.	O
Non	O
dilated	O
LV	O
,	O
non	O
hypertrophic	O
,	O
hypercontractile	O
,	O
without	O
alterations	O
of	O
regional	O
contractility	O
.	O
Preserved	O
LVEF	O
,	O
no	O
dilatation	O
of	O
the	O
right	O
chambers	O
.	O
Moderate	O
mitral	O
insufficiency	O
.	O
EVOLUTION	O
Admission	O
to	O
the	O
Advanced	O
Cardiac	O
Care	O
Unit	O
for	O
monitoring	O
and	O
treatment	O
.	O
Vagal	O
manoeuvres	O
and	O
adenosine	B-FARMACO
6	O
and	O
12	O
mg	O
were	O
repeated	O
,	O
both	O
without	O
success	O
.	O
IV	O
atenolol	B-FARMACO
4mg	O
was	O
prescribed	O
,	O
with	O
no	O
response	O
,	O
so	O
electrical	O
cardioversion	O
ECV	O
was	O
decided	O
.	O
The	O
case	O
was	O
discussed	O
with	O
the	O
Gynaecology	O
and	O
Anaesthesiology	O
departments	O
and	O
two	O
ECV	O
100	O
and	O
200J	O
were	O
performed	O
under	O
maternal	O
sedation	O
with	O
propofol	B-FARMACO
and	O
foetal	O
monitoring	O
,	O
both	O
of	O
which	O
were	O
unsuccessful	O
.	O
No	O
foetal	O
distress	O
was	O
observed	O
at	O
any	O
time	O
.	O
The	O
patient	O
remained	O
asymptomatic	O
at	O
all	O
times	O
and	O
haemodynamically	O
stable	O
.	O
Monitoring	O
showed	O
persistent	O
wide	O
QRS	O
tachycardia	O
same	O
morphology	O
as	O
on	O
the	O
arrival	O
ECG	O
at	O
similar	O
frequencies	O
170	O
190	O
bpm	O
.	O
Given	O
the	O
persistence	O
of	O
the	O
arrhythmia	O
,	O
it	O
was	O
decided	O
to	O
start	O
treatment	O
with	O
an	O
infusion	O
of	O
beta	O
blockers	O
labetalol	B-FARMACO
at	O
20	O
ml	O
h	O
and	O
an	O
ampoule	O
of	O
0	O
.	O
5	O
mg	O
of	O
intravenous	O
digoxin	B-FARMACO
.	O
The	O
tachycardia	O
rate	O
was	O
initially	O
reduced	O
to	O
around	O
150	O
bpm	O
,	O
with	O
progressively	O
more	O
frequent	O
presence	O
of	O
sinus	O
beats	O
interspersed	O
with	O
the	O
arrhythmia	O
,	O
followed	O
by	O
trigeminy	O
visualisation	O
on	O
telemetry	O
recording	O
.	O
A	O
few	O
hours	O
later	O
,	O
sinus	O
rhythm	O
was	O
observed	O
,	O
with	O
isolated	O
ventricular	O
extrasystoles	O
persisting	O
.	O
At	O
12	O
hours	O
after	O
the	O
start	O
of	O
perfusion	O
,	O
after	O
several	O
hours	O
in	O
stable	O
sinus	O
rhythm	O
,	O
beta	O
blocker	O
perfusion	O
was	O
discontinued	O
and	O
the	O
patient	O
's	O
ECG	O
was	O
as	O
shown	O
in	O
figure	O
2	O
.	O
The	O
patient	O
reported	O
only	O
symptoms	O
of	O
gastro	O
oesophageal	O
reflux	O
,	O
for	O
which	O
oral	O
ranitindin	B-FARMACO
was	O
prescribed	O
if	O
necessary	O
.	O
After	O
a	O
further	O
8	O
hours	O
of	O
monitoring	O
with	O
persistent	O
sinus	O
rhythm	O
,	O
she	O
was	O
transferred	O
to	O
the	O
Cardiology	O
ward	O
and	O
the	O
TTE	O
was	O
repeated	O
.	O
The	O
patient	O
remained	O
hospitalised	O
for	O
a	O
further	O
48	O
hours	O
and	O
after	O
finding	O
that	O
there	O
were	O
no	O
gynaecological	O
complications	O
and	O
that	O
she	O
remained	O
asymptomatic	O
with	O
an	O
ECG	O
recording	O
in	O
sinus	O
rhythm	O
without	O
alterations	O
,	O
discharge	O
was	O
decided	O
with	O
prophylactic	O
treatment	O
with	O
metropolol	B-FARMACO
pending	O
outpatient	O
consultation	O
with	O
the	O
Arrhythmia	O
section	O
of	O
our	O
centre	O
.	O
After	O
assessment	O
by	O
gynaecology	O
,	O
no	O
complications	O
related	O
to	O
pregnancy	O
were	O
detected	O
,	O
so	O
outpatient	O
follow	O
up	O
was	O
decided	O
as	O
planned	O
.	O
DIAGNOSIS	O
This	O
must	O
be	O
resolved	O
by	O
the	O
contestant	O
through	O
the	O
interpretation	O
of	O
the	O
ECG	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Male	O
,	O
36	O
years	O
old	O
.	O
History	O
AHT	O
Stage	O
III	O
chronic	O
renal	O
failure	O
secondary	O
to	O
vesicoureteral	O
reflux	O
Current	O
illness	O
The	O
patient	O
reported	O
fever	O
and	O
vomiting	O
for	O
3	O
days	O
,	O
general	O
malaise	O
,	O
generalised	O
aches	O
and	O
pains	O
,	O
dystrophic	O
sensation	O
,	O
chills	O
,	O
sweating	O
and	O
vomiting	O
.	O
Physical	O
examination	O
BP	O
100	O
40	O
Ta	O
39	O
.	O
5	O
C	O
Normal	O
colour	O
,	O
hydrated	O
and	O
perfused	O
Eupneic	O
at	O
0	O
Cardiac	O
auscultation	O
rhythmic	O
with	O
systolic	O
murmur	O
in	O
EIB	O
Pulmonary	O
auscultation	O
VCM	O
Abdomen	O
no	O
evidence	O
of	O
peritoneal	O
irritation	O
COMPLEMENTARY	O
TESTS	O
ECHOCARDIOGRAPHY	O
RS	O
,	O
BCRIHH	O
.	O
Chest	O
X	O
ray	O
normal	O
.	O
Laboratory	O
tests	O
biochemistry	O
creatinine	O
7	O
.	O
99	O
mg	O
gl	O
;	O
Na	O
131	O
mEq	O
l	O
;	O
K	O
4	O
.	O
59	O
mEq	O
l	O
,	O
CRP	O
23	O
.	O
09	O
mg	O
dl	O
.	O
Gases	O
pH	O
7	O
.	O
23	O
,	O
pCO2	O
36	O
mmHg	O
,	O
pO2	O
14	O
mmHg	O
,	O
HCO3	O
15	O
mmol	O
l	O
,	O
Ebb	O
11	O
.	O
6	O
mmol	O
l	O
.	O
Haemogram	O
Hb	O
11	O
.	O
6	O
g	O
dl	O
,	O
platelets	O
80	O
x1000	O
ul	O
,	O
leucocytes	O
16	O
.	O
30x1000	O
ul	O
,	O
neutrophils	O
94	O
.	O
7	O
.	O
Coagulation	O
prothrombin	O
activity	O
65	O
,	O
INR	O
1	O
.	O
34	O
Abdominal	O
CT	O
scan	O
with	O
chest	O
sections	O
abdomen	O
normal	O
.	O
Chest	O
sections	O
included	O
in	O
the	O
study	O
showed	O
a	O
1	O
cm	O
nodule	O
in	O
LID	O
,	O
two	O
in	O
LII	O
the	O
largest	O
measuring	O
5	O
mm	O
and	O
another	O
in	O
the	O
anterior	O
part	O
of	O
the	O
lingula	O
,	O
all	O
undetermined	O
,	O
with	O
an	O
infectious	O
aetiology	O
to	O
be	O
assessed	O
.	O
Blood	O
cultures	O
methicillin	O
sensitive	O
S	O
.	O
aureus	O
.	O
Transthoracic	O
echocardiogram	O
image	O
compatible	O
with	O
endocardial	O
wart	O
of	O
15x10	O
mm	O
anchored	O
to	O
the	O
IV	O
septum	O
.	O
Restrictive	O
ventricular	O
septal	O
defect	O
.	O
Transesophageal	O
echocardiogram	O
recommended	O
.	O
Transesophageal	O
echocardiogram	O
rules	O
out	O
involvement	O
of	O
other	O
valves	O
.	O
EVOLUTION	O
In	O
view	O
of	O
the	O
febrile	O
syndrome	O
presented	O
by	O
the	O
patient	O
,	O
two	O
sets	O
of	O
blood	O
cultures	O
were	O
requested	O
.	O
A	O
possible	O
abdominal	O
focus	O
was	O
suspected	O
on	O
the	O
basis	O
of	O
the	O
clinical	O
manifestations	O
and	O
an	O
abdominal	O
CT	O
scan	O
was	O
performed	O
,	O
which	O
ruled	O
it	O
out	O
,	O
although	O
possible	O
infectious	O
foci	O
in	O
the	O
lungs	O
were	O
evident	O
.	O
Two	O
sets	O
of	O
blood	O
cultures	O
were	O
taken	O
and	O
were	O
positive	O
for	O
Staphylococcus	O
aureus	O
.	O
After	O
isolation	O
of	O
S	O
.	O
aureus	O
in	O
both	O
sets	O
and	O
the	O
presence	O
of	O
previously	O
unknown	O
left	O
bundle	O
branch	O
block	O
and	O
murmur	O
,	O
a	O
transthoracic	O
echocardiogram	O
was	O
performed	O
showing	O
an	O
endocardial	O
wart	O
dependent	O
on	O
the	O
tricuspid	O
subvalvular	O
apparatus	O
or	O
the	O
interventricular	O
septum	O
;	O
and	O
a	O
restrictive	O
ventricular	O
septal	O
defect	O
GP	O
max	O
140	O
mmHg	O
.	O
Antibiotic	O
therapy	O
with	O
intravenous	O
cloxacillin	B-FARMACO
was	O
started	O
,	O
after	O
which	O
the	O
patient	O
remained	O
afebrile	O
,	O
asymptomatic	O
,	O
with	O
a	O
decrease	O
in	O
acute	O
phase	O
reactants	O
and	O
sterile	O
serial	O
blood	O
cultures	O
.	O
A	O
control	O
transthoracic	O
echocardiogram	O
was	O
performed	O
7	O
days	O
after	O
starting	O
antibiotic	O
therapy	O
and	O
it	O
was	O
found	O
that	O
the	O
wart	O
image	O
had	O
not	O
decreased	O
in	O
size	O
.	O
A	O
wait	O
and	O
see	O
attitude	O
was	O
maintained	O
and	O
14	O
days	O
after	O
starting	O
antibiotic	O
treatment	O
,	O
a	O
new	O
echocardiographic	O
check	O
up	O
was	O
performed	O
,	O
which	O
showed	O
no	O
changes	O
with	O
respect	O
to	O
the	O
diagnostic	O
echocardiogram	O
.	O
Given	O
the	O
persistence	O
of	O
the	O
vegetation	O
,	O
surgical	O
intervention	O
was	O
indicated	O
in	O
conjunction	O
with	O
the	O
Cardiac	O
Surgery	O
Service	O
.	O
The	O
possibilities	O
were	O
explained	O
to	O
the	O
patient	O
and	O
he	O
accepted	O
.	O
The	O
vegetation	O
was	O
resected	O
and	O
the	O
VSD	O
was	O
closed	O
with	O
direct	O
suture	O
.	O
The	O
patient	O
evolved	O
favourably	O
and	O
was	O
included	O
in	O
the	O
haemodialysis	O
programme	O
.	O
DIAGNOSIS	O
Tricuspid	O
endocarditis	O
due	O
to	O
S	O
.	O
aureus	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
56	O
year	O
old	O
male	O
,	O
no	O
known	O
allergies	O
,	O
with	O
a	O
history	O
of	O
arterial	O
hypertension	O
,	O
moderate	O
obesity	O
,	O
paroxysmal	O
paroxysmal	O
atrial	O
fibrillation	O
anticoagulated	O
with	O
sintrom	B-FARMACO
and	O
gout	O
.	O
He	O
was	O
a	O
bus	O
driver	O
by	O
profession	O
.	O
He	O
came	O
to	O
the	O
emergency	O
department	O
with	O
a	O
single	O
episode	O
of	O
oppressive	O
central	O
chest	O
pain	O
that	O
woke	O
him	O
up	O
in	O
the	O
early	O
hours	O
of	O
the	O
morning	O
,	O
of	O
approximately	O
one	O
hour	O
's	O
duration	O
,	O
non	O
radiating	O
and	O
without	O
associated	O
vegetative	O
cortex	O
,	O
with	O
no	O
other	O
concomitant	O
symptoms	O
dyspnoea	O
,	O
palpitations	O
,	O
syncope	O
,	O
etc	O
.	O
.	O
The	O
chest	O
pain	O
subsided	O
during	O
her	O
stay	O
in	O
the	O
emergency	O
department	O
after	O
starting	O
intravenous	O
solinitrin	B-FARMACO
infusion	O
and	O
controlling	O
her	O
blood	O
pressure	O
.	O
On	O
arrival	O
,	O
he	O
was	O
in	O
good	O
general	O
condition	O
.	O
Blood	O
pressure	O
was	O
200	O
121	O
mmHg	O
,	O
heart	O
rate	O
83	O
beats	O
per	O
minute	O
and	O
oxygen	O
saturation	O
96	O
on	O
room	O
air	O
.	O
Cardiopulmonary	O
auscultation	O
and	O
the	O
rest	O
of	O
the	O
physical	O
examination	O
were	O
normal	O
.	O
A	O
patient	O
with	O
an	O
episode	O
of	O
chest	O
pain	O
at	O
rest	O
and	O
troponin	O
elevation	O
in	O
the	O
context	O
of	O
very	O
high	O
blood	O
pressure	O
was	O
admitted	O
to	O
Cardiology	O
with	O
the	O
initial	O
diagnosis	O
of	O
hypertensive	O
emergency	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
on	O
admission	O
sinus	O
rhythm	O
at	O
65	O
bpm	O
.	O
Narrow	O
QRS	O
.	O
Q	O
in	O
III	O
and	O
VF	O
with	O
ST	O
elevation	O
of	O
less	O
than	O
1mm	O
.	O
V3	O
V6	O
and	O
negative	O
T	O
in	O
aVL	O
.	O
Poor	O
progression	O
of	O
R	O
in	O
precordial	O
leads	O
.	O
No	O
changes	O
in	O
serial	O
ECG	O
,	O
all	O
without	O
pain	O
.	O
Laboratory	O
tests	O
in	O
the	O
emergency	O
department	O
haemogram	O
,	O
biochemistry	O
and	O
coagulation	O
normal	O
.	O
Myocardial	O
necrosis	O
markers	O
slightly	O
elevated	O
maximum	O
US	O
TnT	O
16	O
ng	O
ml	O
being	O
the	O
limit	O
14	O
,	O
without	O
typical	O
curve	O
of	O
acute	O
coronary	O
syndrome	O
.	O
Chest	O
X	O
ray	O
cardiomegaly	O
.	O
Aortic	O
elongation	O
.	O
Hilar	O
thickening	O
.	O
Transthoracic	O
echocardiogram	O
non	O
dilated	O
left	O
ventricle	O
with	O
moderate	O
concentric	O
hypertrophy	O
14	O
14	O
mm	O
,	O
without	O
alterations	O
of	O
segmental	O
contractility	O
.	O
Dilatation	O
of	O
the	O
ascending	O
aorta	O
.	O
Stress	O
cardiac	O
MRI	O
with	O
dipyridamole	O
hypertensive	O
heart	O
disease	O
with	O
normal	O
LVEF	O
.	O
Absence	O
of	O
inducible	O
ischaemia	O
or	O
myocardial	O
necrosis	O
.	O
Image	O
of	O
slight	O
thickening	O
of	O
the	O
thoracic	O
aorta	O
at	O
the	O
ascending	O
and	O
descending	O
levels	O
compatible	O
with	O
intramural	O
haematoma	O
.	O
Angio	O
CT	O
scan	O
intramural	O
haematoma	O
affecting	O
the	O
aortic	O
arch	O
and	O
extending	O
to	O
the	O
descending	O
thoracic	O
aorta	O
without	O
reaching	O
the	O
abdominal	O
aorta	O
.	O
No	O
images	O
of	O
penetrating	O
ulcer	O
or	O
signs	O
of	O
dissection	O
were	O
identified	O
.	O
No	O
aneurysmal	O
dilatations	O
were	O
observed	O
.	O
The	O
rest	O
of	O
the	O
aorta	O
had	O
no	O
significant	O
findings	O
.	O
Central	O
laboratory	O
urea	O
38	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
88	O
mg	O
dl	O
,	O
uric	O
acid	O
10	O
.	O
6	O
mg	O
dl	O
.	O
uric	O
acid	O
10	O
.	O
6	O
mg	O
dl	O
,	O
sodium	O
139	O
mmol	O
l	O
,	O
potassium	O
4	O
.	O
4	O
mmol	O
l	O
,	O
chlorine	O
102	O
mmol	O
l	O
,	O
cholesterol	O
273	O
mg	O
dl	O
,	O
triglycerides	O
341	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
44	O
mg	O
dl	O
,	O
direct	O
LDL	O
cholesterol	O
190	O
mg	O
dl	O
,	O
leucocytes	O
9100	O
mm3	O
,	O
haemoglobin	O
13	O
.	O
6	O
g	O
dl	O
,	O
OHT	O
41	O
,	O
platelets	O
250000	O
mm3	O
,	O
INR	O
1	O
.	O
08	O
,	O
HbA1c	O
7	O
,	O
TSH	O
0	O
.	O
7	O
U	O
ml	O
.	O
EVOLUTION	O
During	O
his	O
stay	O
in	O
the	O
cardiology	O
ward	O
,	O
the	O
patient	O
remained	O
clinically	O
stable	O
and	O
asymptomatic	O
,	O
without	O
new	O
episodes	O
of	O
chest	O
pain	O
,	O
with	O
good	O
control	O
of	O
blood	O
pressure	O
under	O
treatment	O
with	O
beta	O
blockers	O
,	O
oral	O
nitrates	O
and	O
ACE	O
inhibitors	O
.	O
After	O
performing	O
a	O
transthoracic	O
echocardiogram	O
on	O
the	O
first	O
day	O
of	O
hospital	O
admission	O
,	O
and	O
finding	O
dilatation	O
of	O
the	O
ascending	O
aorta	O
,	O
a	O
stress	O
MRI	O
with	O
dipyridamole	O
was	O
requested	O
to	O
evaluate	O
the	O
aorta	O
and	O
rule	O
out	O
both	O
acute	O
aortic	O
syndrome	O
and	O
ischaemic	O
heart	O
disease	O
.	O
Following	O
the	O
diagnosis	O
of	O
intramural	O
haematoma	O
with	O
the	O
imaging	O
tests	O
,	O
successive	O
angio	O
CT	O
scans	O
were	O
performed	O
to	O
assess	O
the	O
evolution	O
,	O
given	O
that	O
the	O
patient	O
remained	O
clinically	O
stable	O
.	O
Given	O
the	O
absence	O
of	O
haematoma	O
growth	O
on	O
imaging	O
tests	O
and	O
as	O
the	O
ascending	O
aorta	O
was	O
not	O
compromised	O
,	O
expectant	O
management	O
was	O
decided	O
,	O
with	O
discharge	O
from	O
hospital	O
and	O
preferential	O
follow	O
up	O
in	O
the	O
Cardiovascular	O
Surgery	O
outpatient	O
department	O
.	O
Twenty	O
five	O
days	O
after	O
discharge	O
,	O
the	O
patient	O
returned	O
to	O
the	O
emergency	O
department	O
with	O
a	O
new	O
episode	O
of	O
sudden	O
and	O
intense	O
pain	O
in	O
the	O
lumbar	O
region	O
accompanied	O
by	O
paraesthesia	O
in	O
the	O
right	O
lower	O
limb	O
.	O
Examination	O
revealed	O
an	O
absence	O
of	O
femoral	O
pulses	O
bilaterally	O
.	O
An	O
emergency	O
angio	O
CT	O
scan	O
was	O
performed	O
,	O
revealing	O
a	O
type	O
A	O
dissection	O
with	O
extension	O
from	O
the	O
ascending	O
aorta	O
to	O
both	O
iliac	O
arteries	O
,	O
as	O
well	O
as	O
thrombosis	O
of	O
the	O
false	O
lumen	O
in	O
the	O
ascending	O
aorta	O
,	O
highlighting	O
the	O
significant	O
increase	O
in	O
the	O
diameter	O
of	O
the	O
ascending	O
aorta	O
compared	O
to	O
the	O
previous	O
study	O
.	O
In	O
view	O
of	O
these	O
findings	O
,	O
urgent	O
surgery	O
was	O
decided	O
.	O
During	O
the	O
surgical	O
procedure	O
,	O
it	O
was	O
not	O
possible	O
to	O
detect	O
the	O
entrance	O
door	O
at	O
the	O
level	O
of	O
the	O
ascending	O
aorta	O
or	O
the	O
arch	O
,	O
so	O
a	O
diagnosis	O
of	O
a	O
type	O
B	O
dissection	O
with	O
retrograde	O
progression	O
was	O
finally	O
made	O
,	O
and	O
the	O
ascending	O
aorta	O
was	O
replaced	O
with	O
a	O
32	O
mm	O
Dacron	O
graft	O
.	O
Subsequently	O
,	O
the	O
patient	O
had	O
a	O
torpid	O
evolution	O
during	O
his	O
stay	O
in	O
the	O
ICU	O
,	O
requiring	O
vasoactive	O
drugs	O
and	O
daily	O
haemofiltration	O
in	O
the	O
immediate	O
postoperative	O
period	O
.	O
After	O
clinical	O
stabilisation	O
,	O
the	O
patient	O
was	O
extubated	O
and	O
discharged	O
from	O
the	O
intensive	O
care	O
unit	O
.	O
During	O
his	O
stay	O
in	O
the	O
ward	O
,	O
the	O
patient	O
evolved	O
adequately	O
without	O
new	O
complications	O
and	O
was	O
discharged	O
and	O
referred	O
to	O
outpatients	O
for	O
follow	O
up	O
with	O
an	O
intensive	O
rehabilitation	O
programme	O
.	O
Currently	O
,	O
3	O
months	O
after	O
admission	O
for	O
hypertensive	O
emergency	O
,	O
the	O
patient	O
is	O
clinically	O
stable	O
.	O
DIAGNOSIS	O
The	O
cardiac	O
MRI	O
,	O
which	O
was	O
negative	O
for	O
ischaemia	O
,	O
showed	O
an	O
image	O
compatible	O
with	O
intramural	O
haematoma	O
in	O
the	O
thoracic	O
aorta	O
,	O
without	O
affecting	O
the	O
ascending	O
aorta	O
,	O
so	O
CT	O
angiography	O
was	O
requested	O
and	O
confirmed	O
the	O
findings	O
previously	O
described	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Personal	O
history	O
No	O
known	O
drug	O
allergies	O
.	O
No	O
DM	O
,	O
DLP	O
or	O
AHT	O
.	O
Active	O
smoker	O
.	O
Chronic	O
gastritis	O
.	O
Surgical	O
interventions	O
bilateral	O
breast	O
prosthesis	O
.	O
Family	O
history	O
mother	O
died	O
suddenly	O
at	O
the	O
age	O
of	O
48	O
and	O
sister	O
died	O
at	O
the	O
age	O
of	O
50	O
AMI	O
?	O
.	O
Second	O
degree	O
relatives	O
with	O
Chagas	O
disease	O
.	O
usual	O
treatment	O
pantoprazole	B-FARMACO
.	O
Current	O
disease	O
The	O
patient	O
was	O
a	O
45	O
year	O
old	O
woman	O
from	O
Brazil	O
who	O
presented	O
with	O
two	O
episodes	O
of	O
oppressive	O
central	O
thoracic	O
pain	O
radiating	O
towards	O
the	O
MSI	O
,	O
the	O
first	O
of	O
which	O
was	O
self	O
limiting	O
and	O
lasted	O
5	O
10	O
minutes	O
and	O
the	O
second	O
persistent	O
over	O
time	O
,	O
accompanied	O
by	O
a	O
sensation	O
of	O
dizziness	O
,	O
for	O
which	O
she	O
went	O
to	O
the	O
emergency	O
department	O
of	O
a	O
regional	O
hospital	O
.	O
The	O
patient	O
reported	O
self	O
limited	O
palpitations	O
the	O
previous	O
night	O
,	O
for	O
which	O
reason	O
she	O
did	O
not	O
consult	O
the	O
emergency	O
department	O
.	O
In	O
view	O
of	O
these	O
symptoms	O
,	O
an	O
electrocardiogram	O
was	O
performed	O
showing	O
a	O
regular	O
tachycardia	O
with	O
a	O
wide	O
QRS	O
at	O
230	O
bpm	O
which	O
subsided	O
after	O
administration	O
of	O
flecainide	B-FARMACO
200	O
mg	O
by	O
mouth	O
and	O
went	O
into	O
sinus	O
rhythm	O
20	O
minutes	O
after	O
treatment	O
,	O
with	O
a	O
1st	O
degree	O
BAV	O
and	O
an	O
ST	O
descent	O
of	O
up	O
to	O
2	O
mm	O
with	O
a	O
horizontal	O
slope	O
in	O
V4	O
V6	O
.	O
Examination	O
revealed	O
poor	O
general	O
condition	O
with	O
tachypnoea	O
and	O
tachycardia	O
,	O
with	O
a	O
large	O
component	O
of	O
anxiety	O
.	O
Blood	O
pressure	O
113	O
77	O
mmHg	O
.	O
O2	O
Sat	O
100	O
.	O
Cardiopulmonary	O
auscultation	O
without	O
findings	O
,	O
except	O
tachycardia	O
.	O
No	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
During	O
her	O
stay	O
in	O
the	O
ED	O
,	O
she	O
remained	O
asymptomatic	O
with	O
no	O
new	O
episodes	O
of	O
tachycardia	O
,	O
normalisation	O
of	O
the	O
ST	O
segment	O
and	O
a	O
slight	O
increase	O
in	O
TnI	O
0	O
.	O
019	O
to	O
0	O
.	O
14	O
with	O
normal	O
CPK	O
.	O
He	O
was	O
admitted	O
to	O
the	O
ICU	O
of	O
a	O
regional	O
hospital	O
for	O
monitoring	O
and	O
treatment	O
.	O
During	O
her	O
stay	O
in	O
the	O
ICU	O
,	O
the	O
patient	O
remained	O
asymptomatic	O
and	O
haemodynamically	O
stable	O
,	O
with	O
no	O
new	O
episodes	O
of	O
tachycardia	O
,	O
no	O
changes	O
in	O
the	O
electrocardiogram	O
,	O
no	O
clinical	O
signs	O
of	O
heart	O
failure	O
and	O
normalisation	O
of	O
TnI	O
.	O
An	O
echocardiogram	O
was	O
performed	O
with	O
an	O
LVEF	O
of	O
55	O
with	O
no	O
alterations	O
in	O
contractility	O
and	O
mild	O
mitral	O
insufficiency	O
.	O
From	O
there	O
,	O
the	O
case	O
was	O
discussed	O
with	O
the	O
Arrhythmia	O
Unit	O
and	O
an	O
electrophysiological	O
study	O
was	O
requested	O
in	O
which	O
,	O
after	O
isoproterenol	O
perfusion	O
,	O
regular	O
tachycardia	O
with	O
wide	O
QRS	O
was	O
induced	O
,	O
compatible	O
with	O
ventricular	O
tachycardia	O
of	O
basal	O
and	O
upper	O
left	O
ventricular	O
origin	O
.	O
In	O
view	O
of	O
SMVT	O
in	O
a	O
patient	O
with	O
a	O
family	O
history	O
of	O
sudden	O
death	O
,	O
it	O
was	O
decided	O
to	O
admit	O
him	O
to	O
our	O
hospital	O
ward	O
to	O
complete	O
the	O
study	O
and	O
assess	O
treatment	O
pharmacological	O
vs	O
.	O
ablation	O
.	O
Treatment	O
was	O
started	O
with	O
beta	O
blockers	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
regional	O
hospital	O
emergency	O
department	O
regular	O
tachycardia	O
with	O
wide	O
QRS	O
180	O
ms	O
with	O
morphology	O
of	O
complete	O
right	O
bundle	O
branch	O
block	O
positive	O
V1	O
and	O
lower	O
frontal	O
plane	O
axis	O
,	O
concordant	O
in	O
precodials	O
and	O
atrioventricular	O
dissociation	O
compatible	O
with	O
ventricular	O
tachycardia	O
of	O
basal	O
anterolateral	O
origin	O
of	O
the	O
left	O
ventricle	O
.	O
ECG	O
after	O
TVMS	O
sinus	O
rhythm	O
at	O
65	O
bpm	O
,	O
PR	O
220	O
ms	O
BAV	O
1st	O
degree	O
,	O
normal	O
axis	O
0o	O
,	O
narrow	O
QRS	O
,	O
ST	O
descent	O
2	O
mm	O
maximum	O
in	O
V4	O
V6	O
with	O
negative	O
T	O
in	O
II	O
,	O
III	O
and	O
aVF	O
.	O
CBC	O
ED	O
regional	O
hospital	O
glucose	O
188	O
mg	O
dl	O
,	O
urea	O
26	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
88	O
mg	O
dl	O
,	O
Na	O
140	O
mEq	O
l	O
,	O
K	O
4	O
.	O
2	O
mEq	O
l	O
,	O
Ca	O
8	O
.	O
4	O
mg7dl	O
,	O
CRP	O
0	O
.	O
5	O
mg	O
dl	O
,	O
NT	O
proBNP	O
322	O
ng	O
l	O
,	O
other	O
biochemistry	O
normal	O
.	O
Haemoglobin	O
13	O
.	O
8	O
g	O
dl	O
,	O
haematocrit	O
41	O
.	O
1	O
,	O
leukocytes	O
10400	O
ui	O
neutrophils	O
67	O
,	O
lymphocytes	O
27	O
,	O
platelets	O
385000	O
ui	O
.	O
Coagulation	O
normal	O
.	O
Chest	O
X	O
ray	O
normal	O
CTI	O
with	O
no	O
infiltrates	O
or	O
signs	O
of	O
pleural	O
effusion	O
.	O
Echocardiography	O
non	O
dilated	O
left	O
ventricle	O
with	O
moderate	O
to	O
severe	O
hypertrophy	O
at	O
septal	O
level	O
with	O
preserved	O
global	O
LVEF	O
65	O
with	O
thinning	O
and	O
akinesia	O
at	O
lower	O
basal	O
segments	O
and	O
to	O
a	O
lesser	O
extent	O
inferolateral	O
basal	O
and	O
posterior	O
septal	O
basal	O
segments	O
.	O
Atria	O
not	O
dilated	O
.	O
Non	O
dilated	O
right	O
ventricle	O
with	O
preserved	O
RVEF	O
.	O
Aortic	O
root	O
of	O
normal	O
dimensions	O
.	O
Normal	O
mitral	O
valve	O
with	O
trival	O
mitral	O
regurgitation	O
jet	O
.	O
Trivalve	O
aortic	O
valve	O
of	O
normal	O
morphology	O
and	O
jet	O
of	O
mild	O
aortic	O
insufficiency	O
.	O
Mild	O
tricuspid	O
regurgitation	O
with	O
normal	O
PSAP	O
.	O
No	O
pericardial	O
effusion	O
.	O
Diastolic	O
pattern	O
compatible	O
with	O
type	O
I	O
relaxation	O
disorder	O
.	O
Conclusion	O
aneurysm	O
in	O
the	O
region	O
of	O
the	O
basal	O
inferior	O
septal	O
,	O
basal	O
inferior	O
and	O
basal	O
lateral	O
inferior	O
segments	O
with	O
preserved	O
LVEF	O
.	O
Cardiac	O
MRI	O
mild	O
left	O
ventricular	O
dysfunction	O
LVEF	O
50	O
with	O
akinesia	O
of	O
basal	O
inferior	O
and	O
inferolateral	O
segments	O
and	O
late	O
subendocardial	O
enhancement	O
at	O
this	O
level	O
.	O
Right	O
ventricle	O
of	O
normal	O
morphology	O
and	O
function	O
.	O
Coronary	O
angiography	O
radial	O
approach	O
.	O
Epicardial	O
coronary	O
arteries	O
without	O
lesions	O
.	O
Ventriculography	O
shows	O
a	O
posterobasal	O
aneurysm	O
of	O
the	O
left	O
ventricle	O
and	O
a	O
small	O
apical	O
aneurysm	O
.	O
Preserved	O
LVEF	O
.	O
Electrophysiological	O
study	O
basal	O
conduction	O
intervals	O
are	O
normal	O
.	O
No	O
ventricular	O
pre	O
excitation	O
or	O
double	O
nodal	O
pathway	O
.	O
Pacing	O
manoeuvres	O
from	O
CS	O
and	O
from	O
the	O
basal	O
area	O
of	O
the	O
RV	O
do	O
not	O
induce	O
tachycardia	O
.	O
Under	O
isoproterenol	O
perfusion	O
3	O
mcg	O
min	O
,	O
a	O
tachycardia	O
equal	O
to	O
the	O
clinically	O
documented	O
tachycardia	O
that	O
meets	O
the	O
criteria	O
of	O
ventricular	O
origin	O
is	O
spontaneously	O
induced	O
with	O
ventricular	O
extrasystoles	O
.	O
From	O
the	O
morphology	O
of	O
the	O
complexes	O
,	O
it	O
originates	O
in	O
the	O
basal	O
and	O
superior	O
zone	O
of	O
the	O
LV	O
mitroaortic	O
continuity	O
,	O
aortic	O
semilunar	O
,	O
superior	O
zone	O
of	O
the	O
mitral	O
annulus	O
.	O
Tachycardia	O
is	O
induced	O
on	O
several	O
occasions	O
and	O
is	O
suppressed	O
by	O
ventricular	O
overstimulation	O
.	O
Blood	O
and	O
urine	O
cultures	O
negative	O
.	O
Serology	O
HBV	O
,	O
HCV	O
and	O
HIV	O
negative	O
.	O
Anti	O
Trypanosoma	O
cruzi	O
serology	O
positive	O
.	O
EVOLUTION	O
During	O
her	O
stay	O
on	O
the	O
ward	O
and	O
while	O
the	O
TVMS	O
study	O
was	O
being	O
completed	O
,	O
the	O
patient	O
presented	O
rapid	O
palpitations	O
with	O
general	O
malaise	O
and	O
dizziness	O
,	O
and	O
the	O
monitor	O
showed	O
a	O
wide	O
QRS	O
tachycardia	O
similar	O
to	O
the	O
one	O
described	O
,	O
which	O
spontaneously	O
reverted	O
to	O
sinus	O
rhythm	O
.	O
The	O
patient	O
was	O
transferred	O
to	O
the	O
coronary	O
unit	O
.	O
After	O
performing	O
cardiac	O
MRI	O
and	O
subsequent	O
coronary	O
angiography	O
,	O
which	O
ruled	O
out	O
ischaemic	O
origin	O
in	O
the	O
presence	O
of	O
structural	O
heart	O
disease	O
in	O
the	O
echocardiography	O
posterobasal	O
aneurysm	O
and	O
small	O
apical	O
aneurysm	O
with	O
the	O
patient	O
's	O
personal	O
history	O
,	O
everything	O
led	O
to	O
suspect	O
possible	O
Chagas	O
disease	O
,	O
so	O
serology	O
for	O
Trypanosoma	O
cruzi	O
was	O
requested	O
,	O
with	O
positive	O
results	O
.	O
A	O
referral	O
was	O
made	O
to	O
the	O
Infectious	O
Diseases	O
Unit	O
,	O
which	O
considered	O
the	O
diagnosis	O
of	O
Chagas	O
disease	O
to	O
be	O
highly	O
probable	O
and	O
requested	O
serology	O
and	O
PCR	O
for	O
confirmation	O
.	O
Treatment	O
with	O
benznidazole	B-FARMACO
was	O
started	O
.	O
Due	O
to	O
clinical	O
symptoms	O
of	O
gastro	O
oesophageal	O
reflux	O
and	O
epigastric	O
discomfort	O
,	O
an	O
oesophago	O
gastro	O
duodenal	O
transit	O
was	O
requested	O
,	O
which	O
was	O
negative	O
.	O
On	O
the	O
other	O
hand	O
,	O
a	O
new	O
electrophysiological	O
study	O
was	O
performed	O
in	O
order	O
to	O
try	O
to	O
ablate	O
SMVT	O
.	O
However	O
,	O
no	O
VT	O
was	O
induced	O
during	O
the	O
procedure	O
despite	O
high	O
doses	O
of	O
isoproterenol	O
.	O
Radiofrequency	O
applications	O
were	O
performed	O
in	O
the	O
anterolateral	O
area	O
of	O
the	O
mitral	O
annulus	O
without	O
subsequent	O
complications	O
.	O
After	O
testing	O
positive	O
for	O
Chagas	O
disease	O
,	O
it	O
was	O
decided	O
to	O
implant	O
a	O
self	O
implantable	O
defibrillator	O
ICD	O
.	O
Once	O
the	O
patient	O
's	O
condition	O
had	O
stabilised	O
,	O
it	O
was	O
decided	O
to	O
discharge	O
her	O
home	O
to	O
continue	O
monitoring	O
her	O
at	O
the	O
ECCC	O
.	O
There	O
was	O
no	O
impact	O
on	O
her	O
outpatient	O
evolution	O
.	O
DIAGNOSIS	O
Poorly	O
tolerated	O
sustained	O
monomorphic	O
ventricular	O
tachycardia	O
secondary	O
to	O
probable	O
cardiomyopathy	O
due	O
to	O
Chagas	O
disease	O
.	O
Implantation	O
of	O
a	O
single	O
chamber	O
ICD	O
as	O
secondary	O
prevention	O
.	O

History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
A	O
61	O
year	O
old	O
woman	O
,	O
with	O
no	O
cardiovascular	O
risk	O
factors	O
or	O
relevant	O
medical	O
history	O
,	O
attended	O
her	O
health	O
centre	O
for	O
oppressive	O
chest	O
pain	O
radiating	O
to	O
the	O
back	O
,	O
associated	O
with	O
palpitations	O
and	O
dyspnoea	O
,	O
of	O
one	O
hour	O
's	O
duration	O
.	O
On	O
arrival	O
,	O
he	O
appeared	O
to	O
be	O
in	O
poor	O
general	O
condition	O
with	O
a	O
heart	O
rate	O
of	O
around	O
250	O
bpm	O
and	O
hypotension	O
.	O
An	O
electrocardiogram	O
was	O
performed	O
figure	O
1	O
,	O
after	O
which	O
it	O
was	O
decided	O
to	O
call	O
the	O
emergency	O
services	O
and	O
administer	O
300	O
mg	O
of	O
intravenous	O
amiodarone	B-FARMACO
.	O
On	O
arrival	O
of	O
the	O
mobile	O
ICU	O
,	O
the	O
patient	O
remained	O
symptomatic	O
and	O
cardioversion	O
had	O
not	O
been	O
achieved	O
.	O
Given	O
the	O
presence	O
of	O
a	O
tachyarrhythmia	O
that	O
was	O
interpreted	O
as	O
ventricular	O
tachycardia	O
,	O
poorly	O
tolerated	O
haemodynamically	O
,	O
it	O
was	O
decided	O
to	O
perform	O
electrical	O
cardioversion	O
.	O
After	O
sedation	O
,	O
cardioversion	O
was	O
performed	O
with	O
three	O
shocks	O
200	O
300	O
360	O
joules	O
without	O
success	O
,	O
after	O
which	O
he	O
was	O
transferred	O
urgently	O
to	O
his	O
hospital	O
of	O
reference	O
.	O
Further	O
tests	O
analysis	O
haemogram	O
haemoglobin	O
11	O
.	O
7	O
g	O
dl	O
,	O
haematocrit	O
36	O
,	O
leucocytes	O
9	O
,	O
000	O
uL	O
,	O
platelets	O
183	O
,	O
000	O
uL	O
.	O
Coagulation	O
normal	O
.	O
Blood	O
glucose	O
225	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
2	O
mg	O
dl	O
,	O
sodium	O
138	O
mmol	O
litre	O
,	O
potassium	O
4	O
.	O
1	O
mmol	O
litre	O
,	O
magnesium	O
1	O
.	O
9	O
mg	O
dl	O
,	O
lactate	O
2	O
.	O
4	O
mmol	O
litre	O
,	O
calcium	O
8	O
.	O
3	O
mmol	O
litre	O
and	O
troponin	O
T	O
130	O
pg	O
ml	O
.	O
venous	O
blood	O
gases	O
pH	O
7	O
.	O
16	O
,	O
pCO2	O
54	O
,	O
HCO3	O
19	O
,	O
BE	O
9	O
.	O
7	O
.	O
	O
ECG	O
Clinical	O
evolution	O
Admitted	O
to	O
the	O
intensive	O
care	O
unit	O
where	O
treatment	O
with	O
intravenous	O
lidocaine	B-FARMACO
was	O
started	O
,	O
achieving	O
cardioversion	O
with	O
improvement	O
in	O
blood	O
pressure	O
.	O
Once	O
in	O
sinus	O
rhythm	O
,	O
the	O
electrocardiogram	O
showed	O
a	O
generalised	O
decrease	O
in	O
the	O
ST	O
segment	O
with	O
an	O
increase	O
in	O
aVR	O
,	O
so	O
she	O
contacted	O
the	O
cardiac	O
critical	O
care	O
unit	O
of	O
our	O
centre	O
and	O
was	O
transferred	O
for	O
study	O
.	O
On	O
arrival	O
,	O
the	O
patient	O
was	O
asymptomatic	O
and	O
haemodynamically	O
stable	O
.	O
On	O
questioning	O
,	O
she	O
denied	O
previous	O
episodes	O
of	O
chest	O
pain	O
or	O
palpitations	O
despite	O
walking	O
several	O
kilometres	O
daily	O
.	O
The	O
baseline	O
electrocardiogram	O
showed	O
pre	O
excitation	O
.	O
An	O
echocardiogram	O
was	O
performed	O
showing	O
Ebstein	O
's	O
anomaly	O
with	O
lateral	O
leaflet	O
of	O
the	O
tricuspid	O
valve	O
with	O
low	O
implantation	O
1	O
.	O
4	O
cm	O
from	O
the	O
mitral	O
valve	O
not	O
previously	O
known	O
.	O
The	O
right	O
ventricle	O
was	O
slightly	O
dilated	O
with	O
slightly	O
depressed	O
systolic	O
function	O
and	O
moderate	O
severe	O
tricuspid	O
insufficiency	O
.	O
The	O
tachycardia	O
record	O
was	O
reviewed	O
with	O
the	O
electrophysiology	O
service	O
and	O
,	O
given	O
the	O
suspicion	O
that	O
the	O
patient	O
had	O
supraventricular	O
tachycardia	O
,	O
probably	O
pre	O
excited	O
atrial	O
fibrillation	O
,	O
it	O
was	O
decided	O
to	O
perform	O
an	O
electrophysiological	O
study	O
and	O
ablation	O
.	O
The	O
study	O
detected	O
three	O
accessory	O
pathways	O
right	O
posteroseptal	O
,	O
left	O
posteroseptal	O
and	O
right	O
inferolateral	O
,	O
and	O
these	O
were	O
effectively	O
ablated	O
.	O
As	O
a	O
complication	O
,	O
she	O
presented	O
mild	O
pericardial	O
effusion	O
that	O
remained	O
unchanged	O
during	O
her	O
evolution	O
on	O
the	O
ward	O
,	O
and	O
she	O
was	O
discharged	O
asymptomatic	O
with	O
outpatient	O
monitoring	O
.	O
Diagnosis	O
	O
Wolff	O
Parkinson	O
White	O
Syndrome	O
	O
Ebstein	O
's	O
Anomaly	O
	O
	O
Severe	O
tricuspid	O
insufficiency	O

History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
54	O
year	O
old	O
male	O
patient	O
with	O
a	O
history	O
of	O
arterial	O
hypertension	O
,	O
type	O
2	O
diabetes	O
mellitus	O
,	O
with	O
no	O
known	O
allergies	O
.	O
Home	O
treatment	O
with	O
insulin	O
Lantus	B-FARMACO
24	I-FARMACO
IU	I-FARMACO
24h	I-FARMACO
and	I-FARMACO
rapid	I-FARMACO
insulin	I-FARMACO
4	O
IU	O
8h	O
,	O
losartan	B-FARMACO
100	O
mg	O
24h	O
.	O
She	O
came	O
to	O
the	O
emergency	O
department	O
with	O
a	O
sensation	O
of	O
numbness	O
in	O
the	O
right	O
upper	O
limb	O
MSD	O
the	O
previous	O
night	O
,	O
and	O
when	O
she	O
woke	O
up	O
she	O
was	O
unable	O
to	O
move	O
it	O
.	O
He	O
denied	O
any	O
other	O
symptoms	O
.	O
Conscious	O
,	O
oriented	O
,	O
alert	O
.	O
Normal	O
language	O
.	O
Normal	O
EOM	O
.	O
Normal	O
cranial	O
nerves	O
.	O
Paresis	O
in	O
MSD	O
3	O
5	O
and	O
slight	O
hypoesthesia	O
.	O
Rhythmic	O
heart	O
tones	O
without	O
murmurs	O
.	O
Preserved	O
MV	O
without	O
added	O
noises	O
.	O
No	O
oedema	O
in	O
lower	O
limbs	O
.	O
Rest	O
normal	O
.	O
Complementary	O
tests	O
CBC	O
normal	O
haemogram	O
,	O
normal	O
coagulation	O
.	O
Biochemistry	O
with	O
G	O
123	O
mg	O
dl	O
,	O
Cr	O
1	O
mg	O
dl	O
.	O
Cholesterol	O
192	O
mg	O
dl	O
,	O
LDL	O
133	O
mg	O
dl	O
,	O
TG	O
97	O
mg	O
dl	O
.	O
Rest	O
normal	O
.	O
ECG	O
sinus	O
rhythm	O
at	O
54	O
bpm	O
,	O
normal	O
axis	O
,	O
no	O
repolarisation	O
alterations	O
.	O
Cranial	O
CT	O
scan	O
ischaemic	O
lesion	O
in	O
the	O
most	O
posterior	O
portion	O
of	O
the	O
left	O
parietal	O
lobe	O
.	O
There	O
is	O
another	O
hypodense	O
image	O
of	O
triangular	O
morphology	O
in	O
the	O
left	O
frontal	O
lobe	O
suggesting	O
ischaemic	O
lesion	O
.	O
No	O
other	O
relevant	O
findings	O
.	O
TSA	O
echo	O
Doppler	O
parvus	O
tardus	O
wave	O
at	O
the	O
level	O
of	O
the	O
ICA	O
in	O
discordance	O
with	O
what	O
was	O
seen	O
in	O
B	O
mode	O
and	O
colour	O
,	O
which	O
may	O
be	O
related	O
to	O
stenosis	O
,	O
so	O
angio	O
MRI	O
is	O
recommended	O
.	O
Angio	O
MRI	O
of	O
TSA	O
no	O
significant	O
stenosis	O
data	O
are	O
seen	O
in	O
the	O
carotid	O
bulbs	O
or	O
in	O
the	O
internal	O
or	O
external	O
carotid	O
arteries	O
on	O
both	O
sides	O
.	O
Basilar	O
and	O
vertebral	O
arteries	O
are	O
patent	O
.	O
Cerebral	O
MRI	O
several	O
lesions	O
in	O
the	O
left	O
MCA	O
territory	O
with	O
diffusion	O
restriction	O
,	O
corresponding	O
to	O
acute	O
ischaemic	O
lesions	O
of	O
probable	O
embolic	O
origin	O
.	O
Transthoracic	O
echocardiogram	O
aI	O
35	O
.	O
9	O
mm	O
and	O
Ao	O
32	O
mm	O
.	O
Preserved	O
LV	O
systolic	O
function	O
with	O
LVEF	O
of	O
64	O
.	O
Ventricular	O
filling	O
with	O
altered	O
relaxation	O
pattern	O
.	O
Mild	O
LVH	O
.	O
Peripheral	O
intravenous	O
FSS	O
was	O
injected	O
and	O
no	O
bubbles	O
were	O
observed	O
passing	O
through	O
the	O
interatrial	O
septum	O
suggestive	O
of	O
PFO	O
.	O
Clinical	O
evolution	O
The	O
patient	O
recovered	O
muscle	O
strength	O
,	O
but	O
presented	O
mild	O
hypoaesthesia	O
in	O
the	O
right	O
arm	O
.	O
He	O
was	O
discharged	O
with	O
a	O
diagnosis	O
of	O
left	O
parietal	O
and	O
frontal	O
cerebral	O
infarction	O
of	O
uncertain	O
nature	O
;	O
under	O
treatment	O
with	O
Adiro	B-FARMACO
300	O
mg	O
24h	O
and	O
atorvastatin	B-FARMACO
80	O
mg	O
24h	O
.	O
She	O
was	O
readmitted	O
after	O
8	O
months	O
due	O
to	O
vertiginous	O
symptoms	O
,	O
vomiting	O
,	O
dysarthria	O
and	O
gait	O
instability	O
,	O
as	O
well	O
as	O
horizontal	O
nystagmus	O
to	O
the	O
left	O
which	O
,	O
in	O
addition	O
to	O
the	O
previous	O
infarcts	O
,	O
showed	O
a	O
new	O
lesion	O
in	O
the	O
cranial	O
CAT	O
scan	O
,	O
compatible	O
with	O
acute	O
infarction	O
in	O
the	O
left	O
PICA	O
territory	O
.	O
The	O
cardiological	O
study	O
was	O
normal	O
and	O
transesophageal	O
echocardiography	O
TEE	O
was	O
requested	O
on	O
a	O
scheduled	O
basis	O
.	O
He	O
was	O
discharged	O
with	O
a	O
diagnosis	O
of	O
cryptogenetic	O
left	O
cerebellar	O
ischaemic	O
stroke	O
,	O
and	O
treatment	O
with	O
Sintrom	B-FARMACO
,	O
suspending	O
Adiro	B-FARMACO
.	O
TEE	O
was	O
performed	O
and	O
reported	O
as	O
no	O
dilatation	O
of	O
cavities	O
.	O
Thinning	O
of	O
the	O
interatrial	O
septum	O
at	O
the	O
level	O
of	O
the	O
foramen	O
ovale	O
without	O
macroscopic	O
detachment	O
and	O
without	O
abnormalities	O
in	O
mobility	O
,	O
with	O
no	O
signs	O
of	O
shunt	O
seen	O
with	O
colour	O
Doppler	O
.	O
Echocontrast	O
was	O
performed	O
with	O
agitated	O
colloidal	O
solution	O
both	O
at	O
baseline	O
and	O
after	O
the	O
Valsalva	O
manoeuvre	O
.	O
Early	O
passage	O
of	O
microbubbles	O
to	O
the	O
left	O
cavities	O
was	O
observed	O
after	O
the	O
Valsalva	O
manoeuvre	O
.	O
The	O
patient	O
remained	O
stable	O
during	O
follow	O
up	O
without	O
new	O
cardioembolic	O
episodes	O
.	O
Diagnosis	O
Patent	O
foramen	O
ovale	O
Recurrent	O
cryptogenic	O
ischaemic	O
stroke	O

History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
A	O
64	O
year	O
old	O
man	O
consulted	O
for	O
right	O
sided	O
sudden	O
amaurosis	O
.	O
Personal	O
history	O
allergy	O
to	O
penicillin	B-FARMACO
,	O
hypertension	O
,	O
dyslipidaemia	O
,	O
obesity	O
and	O
smoking	O
.	O
Without	O
providing	O
reports	O
,	O
he	O
refers	O
that	O
he	O
was	O
admitted	O
to	O
another	O
hospital	O
in	O
2007	O
for	O
a	O
left	O
hemispheric	O
stroke	O
from	O
which	O
he	O
recovered	O
without	O
sequelae	O
and	O
was	O
being	O
followed	O
up	O
for	O
valvular	O
heart	O
disease	O
.	O
Regular	O
treatment	O
with	O
enalapril	B-FARMACO
,	O
simvastatin	B-FARMACO
and	O
clopidogrel	B-FARMACO
.	O
Present	O
illness	O
sudden	O
total	O
visual	O
loss	O
of	O
the	O
right	O
eye	O
after	O
24	O
hours	O
of	O
evolution	O
.	O
No	O
dyspnoea	O
,	O
chest	O
pain	O
,	O
fever	O
or	O
any	O
other	O
symptoms	O
.	O
Physical	O
examination	O
BP	O
145	O
88	O
mmHg	O
,	O
88	O
bpm	O
,	O
36	O
.	O
7	O
oC	O
,	O
conscious	O
,	O
oriented	O
,	O
eupneic	O
,	O
hydrated	O
and	O
normal	O
colour	O
.	O
Cardiopulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
without	O
added	O
noise	O
.	O
Cardiac	O
auscultation	O
revealed	O
a	O
grade	O
III	O
VI	O
systolic	O
ejection	O
murmur	O
in	O
the	O
aorta	O
,	O
radiating	O
to	O
the	O
carotids	O
,	O
and	O
a	O
grade	O
III	O
VI	O
systolic	O
murmur	O
in	O
the	O
left	O
sternal	O
border	O
,	O
radiating	O
to	O
the	O
axilla	O
.	O
Abdomen	O
and	O
limbs	O
without	O
notable	O
findings	O
.	O
Complementary	O
tests	O
PA	O
chest	O
X	O
ray	O
absence	O
of	O
cardiomegaly	O
,	O
no	O
pleural	O
effusion	O
,	O
no	O
infiltrates	O
or	O
consolidations	O
.	O
Electrocardiography	O
sinus	O
rhythm	O
at	O
91	O
bpm	O
,	O
left	O
cardiac	O
axis	O
at	O
45o	O
.	O
Left	O
atrial	O
enlargement	O
.	O
Cornell	O
criteria	O
for	O
left	O
ventricular	O
hypertrophy	O
.	O
Left	O
anterior	O
hemiblock	O
.	O
ST	O
descending	O
1	O
mm	O
drop	O
in	O
I	O
and	O
AvL	O
with	O
negative	O
T	O
wave	O
in	O
these	O
leads	O
.	O
No	O
dynamic	O
changes	O
in	O
repolarisation	O
.	O
QTc	O
443	O
msec	O
.	O
CBC	O
12	O
,	O
000	O
leukocytes	O
,	O
Hb	O
11	O
.	O
5	O
g	O
dl	O
,	O
335	O
,	O
000	O
platelets	O
.	O
Coagulation	O
normal	O
.	O
ESR	O
39	O
mm	O
h	O
,	O
CRP	O
4	O
.	O
27	O
mg	O
L	O
.	O
Biochemistry	O
and	O
thyroid	O
function	O
normal	O
.	O
ANA	O
,	O
anti	O
DNA	O
and	O
ANCA	O
negative	O
.	O
Hypercoagulability	O
study	O
without	O
pathological	O
findings	O
.	O
Serology	O
Mycoplasma	O
,	O
Chlamydia	O
,	O
Coxiella	O
,	O
Les	O
,	O
Brucella	O
and	O
HBV	O
negative	O
.	O
Right	O
eye	O
fundus	O
red	O
cherry	O
macula	O
,	O
whitish	O
oedema	O
due	O
to	O
ischaemia	O
,	O
narrowing	O
of	O
retinal	O
arteries	O
and	O
whitish	O
exudates	O
.	O
Transesophageal	O
echocardiogram	O
very	O
unstructured	O
aortic	O
valve	O
with	O
severe	O
thickening	O
and	O
calcification	O
with	O
severe	O
aortic	O
stenosis	O
mean	O
gradient	O
50	O
mmHg	O
,	O
mild	O
aortic	O
insufficiency	O
.	O
Mitral	O
valve	O
with	O
several	O
images	O
suggestive	O
of	O
warts	O
.	O
On	O
the	O
atrial	O
side	O
of	O
the	O
posterior	O
leaflet	O
there	O
are	O
two	O
images	O
of	O
mobile	O
vegetations	O
,	O
the	O
largest	O
of	O
6	O
mm	O
.	O
There	O
is	O
a	O
jet	O
of	O
mild	O
mitral	O
insufficiency	O
suggesting	O
perforation	O
of	O
the	O
posterior	O
leaflet	O
.	O
Severe	O
left	O
ventricular	O
hypertrophy	O
and	O
preserved	O
LVEF	O
.	O
Absence	O
of	O
patent	O
foramen	O
ovale	O
by	O
injection	O
of	O
agitated	O
saline	O
.	O
CT	O
angiography	O
of	O
supra	O
aortic	O
trunks	O
carotid	O
atherosclerosis	O
and	O
in	O
the	O
CT	O
angiography	O
of	O
TSA	O
,	O
60	O
70	O
stenosis	O
of	O
the	O
right	O
internal	O
carotid	O
artery	O
.	O
Independent	O
blood	O
cultures	O
x3	O
positive	O
for	O
Streptococcus	O
viridans	O
.	O
Clinical	O
course	O
After	O
evaluation	O
by	O
ophthalmology	O
at	O
our	O
centre	O
,	O
a	O
diagnosis	O
of	O
right	O
central	O
retinal	O
artery	O
occlusion	O
RTAO	O
was	O
made	O
.	O
The	O
patient	O
was	O
admitted	O
to	O
internal	O
medicine	O
for	O
further	O
investigation	O
.	O
Carotid	O
atherosclerosis	O
was	O
observed	O
in	O
the	O
supra	O
aortic	O
trunk	O
duplex	O
TSA	O
and	O
60	O
70	O
stenosis	O
of	O
the	O
right	O
internal	O
carotid	O
artery	O
in	O
the	O
TSA	O
angio	O
CT	O
scan	O
.	O
Despite	O
the	O
carotid	O
findings	O
that	O
could	O
justify	O
the	O
picture	O
,	O
a	O
transthoracic	O
echocardiogram	O
TTE	O
was	O
performed	O
to	O
search	O
for	O
an	O
embolic	O
source	O
,	O
showing	O
severe	O
aortic	O
stenosis	O
,	O
degenerative	O
signs	O
in	O
the	O
mitral	O
valve	O
MV	O
with	O
mild	O
mitral	O
insufficiency	O
MI	O
and	O
calcium	O
in	O
its	O
annulus	O
.	O
Due	O
to	O
the	O
poor	O
echocardiographic	O
window	O
,	O
a	O
transesophageal	O
echocardiogram	O
TEE	O
was	O
performed	O
,	O
which	O
confirmed	O
the	O
existence	O
of	O
severe	O
aortic	O
stenosis	O
with	O
preserved	O
left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
,	O
visualising	O
vegetations	O
on	O
the	O
MV	O
and	O
perforation	O
of	O
the	O
posterior	O
leaflet	O
.	O
The	O
patient	O
was	O
afebrile	O
and	O
three	O
blood	O
cultures	O
were	O
taken	O
,	O
with	O
Streptococcus	O
viridans	O
growing	O
in	O
all	O
samples	O
.	O
With	O
the	O
diagnosis	O
of	O
subacute	O
mitral	O
infective	O
endocarditis	O
IE	O
on	O
native	O
valve	O
and	O
possibly	O
aortic	O
and	O
the	O
history	O
described	O
,	O
he	O
was	O
treated	O
with	O
vancomycin	B-FARMACO
and	O
gentamicin	B-FARMACO
according	O
to	O
the	O
usual	O
regimen	O
.	O
The	O
patient	O
remained	O
afebrile	O
throughout	O
admission	O
,	O
with	O
negative	O
control	O
blood	O
cultures	O
.	O
Control	O
TTE	O
and	O
TEE	O
were	O
performed	O
,	O
with	O
disappearance	O
of	O
vegetations	O
and	O
mild	O
moderate	O
MI	O
as	O
sequelae	O
.	O
After	O
resolution	O
of	O
the	O
infective	O
endocarditis	O
,	O
he	O
was	O
referred	O
to	O
the	O
outpatient	O
vascular	O
surgery	O
department	O
for	O
evaluation	O
of	O
carotid	O
endarterectomy	O
and	O
to	O
cardiology	O
for	O
follow	O
up	O
of	O
his	O
valvular	O
heart	O
disease	O
.	O
Two	O
months	O
after	O
admission	O
,	O
carotid	O
surgery	O
was	O
performed	O
and	O
subsequently	O
,	O
due	O
to	O
the	O
onset	O
of	O
symptoms	O
,	O
aortic	O
valve	O
replacement	O
with	O
metallic	O
prosthesis	O
was	O
performed	O
without	O
complications	O
and	O
with	O
good	O
cardiovascular	O
evolution	O
.	O
However	O
,	O
the	O
patient	O
has	O
not	O
recovered	O
vision	O
in	O
the	O
right	O
eye	O
.	O
Diagnosis	O
Occlusion	O
of	O
the	O
central	O
artery	O
of	O
the	O
right	O
retina	O
.	O
Subacute	O
endocarditis	O
on	O
native	O
mitral	O
valve	O
due	O
to	O
Streptococcus	O
viridans	O
.	O
Asymptomatic	O
severe	O
aortic	O
stenosis	O
with	O
preserved	O
LVEF	O
.	O
Significant	O
right	O
carotid	O
stenosis	O
.	O

History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
76	O
year	O
old	O
patient	O
with	O
no	O
known	O
drug	O
allergies	O
and	O
a	O
personal	O
medical	O
history	O
of	O
arterial	O
hypertension	O
AHT	O
,	O
dyslipidaemia	O
DLP	O
,	O
sleep	O
apnoea	O
hypopnoea	O
syndrome	O
SAHS	O
under	O
treatment	O
with	O
CPAP	O
and	O
diverticular	O
disease	O
;	O
and	O
surgical	O
history	O
of	O
operation	O
for	O
Morton	O
's	O
neuroma	O
,	O
hallux	O
valgus	O
of	O
both	O
feet	O
and	O
excision	O
of	O
a	O
rectal	O
polyp	O
.	O
Usual	O
treatment	O
enalapril	B-FARMACO
,	O
statin	B-FARMACO
and	O
omeprazole	B-FARMACO
.	O
Current	O
illness	O
she	O
attended	O
the	O
emergency	O
department	O
on	O
10	O
10	O
2013	O
for	O
moderate	O
exertional	O
dyspnoea	O
of	O
15	O
days	O
'	O
evolution	O
,	O
orthopnoea	O
,	O
non	O
radiating	O
pain	O
in	O
the	O
lower	O
sternal	O
region	O
,	O
without	O
vegetative	O
cortex	O
and	O
unrelated	O
to	O
exertion	O
and	O
increasing	O
chronic	O
oedema	O
in	O
the	O
lower	O
extremities	O
.	O
20	O
days	O
earlier	O
she	O
had	O
consulted	O
for	O
the	O
same	O
clinical	O
condition	O
and	O
was	O
admitted	O
with	O
a	O
diagnosis	O
of	O
heart	O
failure	O
,	O
but	O
the	O
patient	O
refused	O
because	O
she	O
had	O
a	O
trip	O
planned	O
,	O
so	O
she	O
was	O
prescribed	O
a	O
diuretic	O
and	O
,	O
in	O
the	O
absence	O
of	O
improvement	O
,	O
consulted	O
again	O
.	O
Physical	O
examination	O
blood	O
pressure	O
BP	O
95	O
65	O
mmHg	O
,	O
heart	O
rate	O
HR	O
79	O
bpm	O
,	O
O2	O
saturation	O
95	O
.	O
Bilateral	O
jugular	O
ingurgitation	O
.	O
Hepatojugular	O
reflux	O
HJR	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
with	O
slightly	O
muffled	O
sounds	O
.	O
Pulmonary	O
auscultation	O
bibasal	O
hypoventilation	O
.	O
Lower	O
extremities	O
bilateral	O
malleolar	O
oedema	O
.	O
Complementary	O
tests	O
ECG	O
sinus	O
rhythm	O
at	O
75	O
bpm	O
with	O
decreased	O
voltages	O
.	O
Blood	O
tests	O
normal	O
cardiac	O
enzymes	O
,	O
normal	O
thyroid	O
function	O
,	O
CRP	O
0	O
.	O
74	O
,	O
urea	O
56	O
,	O
creatinine	O
0	O
.	O
91	O
,	O
normal	O
ions	O
.	O
Haemogram	O
leucocytes	O
8	O
,	O
200	O
68	O
n	O
,	O
red	O
series	O
and	O
platelets	O
normal	O
.	O
Chest	O
X	O
ray	O
cardiomegaly	O
.	O
Echocardiogram	O
pericardial	O
effusion	O
mainly	O
anterolateral	O
to	O
the	O
right	O
cavities	O
,	O
with	O
22	O
mm	O
separation	O
of	O
pericardial	O
sheets	O
.	O
From	O
subxiphoid	O
access	O
,	O
separation	O
of	O
leaves	O
of	O
15	O
20	O
mm	O
.	O
In	O
the	O
posterior	O
area	O
8	O
10	O
mm	O
.	O
In	O
the	O
anterior	O
pericardial	O
sac	O
,	O
a	O
mass	O
of	O
a	O
somewhat	O
heterogeneous	O
appearance	O
cysts	O
?	O
,	O
necrosis	O
areas	O
?	O
approximately	O
5	O
cm	O
thick	O
is	O
observed	O
over	O
the	O
right	O
cavities	O
from	O
just	O
before	O
the	O
AV	O
groove	O
and	O
over	O
the	O
ascending	O
aorta	O
,	O
which	O
does	O
not	O
cause	O
compression	O
of	O
the	O
cavities	O
and	O
does	O
not	O
appear	O
to	O
infiltrate	O
the	O
myocardium	O
.	O
	O
Hemodynamic	O
compromise	O
data	O
AD	O
collapse	O
,	O
respiratory	O
transmitral	O
flow	O
variations	O
25	O
,	O
dilated	O
inferior	O
vena	O
cava	O
22	O
mm	O
without	O
inspiratory	O
collapse	O
.	O
	O
normal	O
LV	O
.	O
Mild	O
moderate	O
aortic	O
insufficiency	O
.	O
Normal	O
RV	O
.	O
Mild	O
TR	O
RV	O
AD	O
gradient	O
20	O
mm	O
Hg	O
.	O
Estimated	O
PAPs	O
40	O
mmHg	O
.	O
Left	O
pleural	O
effusion	O
.	O
Thoracoabdominal	O
CT	O
significant	O
pericardial	O
effusion	O
with	O
separation	O
of	O
sheets	O
up	O
to	O
30	O
mm	O
in	O
the	O
right	O
anterior	O
pericardium	O
.	O
Voluminous	O
mass	O
dependent	O
on	O
pericardial	O
sheets	O
,	O
polylobulated	O
and	O
heterogeneous	O
,	O
which	O
overflows	O
the	O
pericardium	O
and	O
extends	O
to	O
the	O
anterosuperior	O
mediastinum	O
,	O
suggestive	O
of	O
malignant	O
neoplasm	O
,	O
of	O
probable	O
pericardial	O
sarcomatous	O
origin	O
,	O
without	O
being	O
able	O
to	O
exclude	O
other	O
possibilities	O
such	O
as	O
mesothelioma	O
,	O
lymphoma	O
,	O
metastasis	O
,	O
etc	O
.	O
Thyroid	O
enlargement	O
,	O
mainly	O
in	O
the	O
right	O
lobe	O
where	O
small	O
hypodense	O
nodules	O
can	O
be	O
seen	O
.	O
Right	O
tracheobronchial	O
lymph	O
node	O
calcifications	O
and	O
small	O
non	O
specific	O
left	O
prevascular	O
lymphadenopathy	O
,	O
with	O
no	O
evidence	O
of	O
other	O
lymphadenopathy	O
suggesting	O
metastatic	O
origin	O
.	O
Bilateral	O
pleural	O
effusion	O
in	O
greater	O
quantity	O
on	O
the	O
left	O
side	O
,	O
causing	O
passive	O
atelectasis	O
of	O
the	O
left	O
lower	O
lobe	O
,	O
with	O
no	O
evidence	O
of	O
underlying	O
lung	O
mass	O
.	O
Residual	O
fibrous	O
lesions	O
,	O
apical	O
right	O
.	O
Mild	O
hepatomegaly	O
,	O
with	O
no	O
evidence	O
of	O
focal	O
lesions	O
suggestive	O
of	O
metastasis	O
.	O
Normal	O
kidneys	O
and	O
adrenal	O
glands	O
.	O
Spleen	O
,	O
pancreas	O
,	O
gallbladder	O
and	O
biliary	O
tract	O
without	O
notable	O
alterations	O
.	O
Conclusion	O
suspected	O
malignant	O
neoplasm	O
of	O
pericardial	O
origin	O
with	O
significant	O
pericardial	O
effusion	O
.	O
Bilateral	O
pleural	O
effusion	O
,	O
greater	O
on	O
the	O
left	O
side	O
,	O
with	O
passive	O
atelectasis	O
of	O
LII	O
.	O
Pericardial	O
fluid	O
analysis	O
biochemical	O
analysis	O
ADA113	O
.	O
1	O
,	O
glucose	O
0	O
.	O
88	O
,	O
protein	O
37	O
g	O
dl	O
.	O
Cytological	O
analysis	O
oligocellular	O
cytology	O
including	O
mature	O
neutrophils	O
and	O
lymphocytes	O
with	O
some	O
isolated	O
activated	O
mesothelial	O
cells	O
.	O
No	O
atypical	O
cells	O
are	O
seen	O
.	O
Inconclusive	O
.	O
Microbiological	O
analysis	O
negative	O
aerobic	O
and	O
anaerobic	O
culture	O
,	O
direct	O
smear	O
microscopy	O
staining	O
Ziehl	O
Nielsen	O
with	O
no	O
evidence	O
of	O
AARB	O
,	O
smear	O
microscopy	O
after	O
decontamination	O
staining	O
auramine	O
with	O
no	O
evidence	O
of	O
AARB	O
,	O
negative	O
PCR	O
for	O
Mycobacterium	O
tuberculosis	O
complex	O
,	O
negative	O
mycobacterial	O
culture	O
.	O
Biopsy	O
biphasic	O
lesion	O
,	O
epithelial	O
and	O
lymphoid	O
,	O
with	O
pattern	O
suggestive	O
of	O
thymoma	O
.	O
Report	O
notes	O
1st	O
reference	O
of	O
possible	O
mass	O
in	O
anterior	O
mediastinum	O
,	O
not	O
filiated	O
but	O
CT	O
and	O
thoracic	O
surgery	O
impression	O
is	O
of	O
pericardial	O
primary	O
lesion	O
tumour	O
with	O
mediastinal	O
ballooning	O
,	O
2nd	O
the	O
biphasic	O
pattern	O
with	O
epithelial	O
population	O
TTF1	O
and	O
with	O
negative	O
mesothelial	O
markers	O
calretininin	O
and	O
WT1	O
and	O
in	O
symbiosis	O
intimate	O
relationship	O
with	O
small	O
size	O
lymphoid	O
population	O
and	O
"	O
thymic	O
"	O
phenotype	O
CD45	O
CD	O
,	O
Tdt	O
,	O
CD99	O
suggests	O
in	O
the	O
first	O
instance	O
thymoma	O
,	O
but	O
does	O
not	O
refer	O
to	O
a	O
thymic	O
mass	O
although	O
ectopic	O
thymomas	O
have	O
been	O
described	O
,	O
although	O
the	O
unlikely	O
possibility	O
of	O
a	O
T	O
type	O
lymphoblastic	O
lymphoma	O
cannot	O
be	O
ruled	O
out	O
.	O
For	O
all	O
these	O
reasons	O
,	O
a	O
sample	O
was	O
sent	O
to	O
another	O
hospital	O
which	O
confirmed	O
the	O
diagnosis	O
of	O
thymoma	O
.	O
Clinical	O
course	O
Given	O
the	O
presence	O
of	O
pericardial	O
effusion	O
with	O
haemodynamic	O
compromise	O
,	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
ICU	O
and	O
evacuating	O
pericardiocentesis	O
was	O
performed	O
via	O
the	O
subxiphoid	O
route	O
with	O
serohaematic	O
fluid	O
output	O
and	O
samples	O
were	O
sent	O
for	O
biochemistry	O
,	O
microbiology	O
and	O
pathological	O
anatomy	O
.	O
After	O
clinical	O
stabilisation	O
,	O
the	O
patient	O
was	O
sent	O
to	O
the	O
cardiology	O
ward	O
for	O
further	O
study	O
and	O
treatment	O
.	O
A	O
pericardial	O
effusion	O
study	O
was	O
performed	O
,	O
requesting	O
a	O
complete	O
blood	O
analysis	O
,	O
autoimmunity	O
study	O
,	O
Mantoux	O
,	O
smear	O
microscopy	O
,	O
thoracoabdominal	O
CT	O
scan	O
,	O
chest	O
X	O
ray	O
and	O
control	O
echocardiogram	O
.	O
Laboratory	O
tests	O
including	O
thyroid	O
function	O
showed	O
no	O
significant	O
alterations	O
,	O
Mantoux	O
test	O
and	O
smear	O
microscopy	O
were	O
negative	O
and	O
the	O
autoimmunity	O
study	O
was	O
normal	O
.	O
The	O
thoracoabdominal	O
CT	O
scan	O
indicated	O
high	O
suspicion	O
of	O
malignant	O
neoplasm	O
of	O
pericardial	O
origin	O
with	O
significant	O
pericardial	O
effusion	O
and	O
bilateral	O
pleural	O
effusion	O
.	O
In	O
view	O
of	O
the	O
presence	O
of	O
malignant	O
neoplasia	O
in	O
the	O
anterior	O
pericardium	O
extending	O
to	O
the	O
anterior	O
superior	O
mediastinum	O
,	O
the	O
Thoracic	O
Surgery	O
Department	O
was	O
requested	O
to	O
collaborate	O
.	O
On	O
29	O
10	O
13	O
mediastinoscopy	O
was	O
performed	O
with	O
biopsy	O
,	O
and	O
a	O
cardiac	O
mass	O
infiltrating	O
the	O
lung	O
was	O
observed	O
during	O
the	O
procedure	O
.	O
On	O
30	O
October	O
he	O
returned	O
to	O
the	O
ICU	O
for	O
respiratory	O
failure	O
due	O
to	O
increased	O
left	O
pleural	O
effusion	O
that	O
required	O
evacuating	O
thoracentesis	O
with	O
an	O
output	O
of	O
1	O
,	O
000	O
cc	O
.	O
The	O
biopsy	O
reported	O
thymoma	O
,	O
however	O
,	O
a	O
sample	O
was	O
sent	O
to	O
another	O
hospital	O
to	O
corroborate	O
the	O
diagnosis	O
because	O
the	O
impression	O
of	O
the	O
imaging	O
tests	O
CT	O
and	O
thoracic	O
surgery	O
was	O
of	O
a	O
primary	O
pericardial	O
lesion	O
tumour	O
with	O
mediastinal	O
bulging	O
and	O
because	O
the	O
diagnosis	O
of	O
T	O
type	O
lymphoblastic	O
lymphoma	O
could	O
not	O
be	O
definitively	O
ruled	O
out	O
due	O
to	O
the	O
anatomopathological	O
data	O
and	O
the	O
absence	O
of	O
visualisation	O
of	O
thymic	O
masses	O
although	O
ectopic	O
thymomas	O
have	O
been	O
described	O
.	O
The	O
diagnosis	O
of	O
thymoma	O
was	O
confirmed	O
.	O
In	O
view	O
of	O
this	O
finding	O
,	O
a	O
myasthenia	O
gravis	O
study	O
was	O
requested	O
by	O
neurology	O
,	O
which	O
ruled	O
it	O
out	O
.	O
On	O
16	O
December	O
,	O
surgery	O
was	O
performed	O
to	O
try	O
to	O
remove	O
the	O
tumour	O
.	O
This	O
consisted	O
of	O
a	O
median	O
sternotomy	O
and	O
access	O
to	O
the	O
anterior	O
mediastinum	O
,	O
which	O
could	O
only	O
be	O
exploratory	O
as	O
a	O
large	O
tumour	O
mass	O
was	O
observed	O
with	O
infiltration	O
of	O
the	O
right	O
upper	O
lobe	O
,	O
junction	O
to	O
the	O
cava	O
and	O
pericardium	O
,	O
making	O
dissection	O
impossible	O
.	O
She	O
was	O
assessed	O
by	O
the	O
oncology	O
department	O
and	O
no	O
curative	O
treatment	O
could	O
be	O
started	O
.	O
Given	O
the	O
poor	O
clinical	O
situation	O
and	O
the	O
null	O
possibility	O
of	O
curative	O
treatment	O
,	O
analgesia	O
was	O
intensified	O
and	O
the	O
patient	O
died	O
.	O
Diagnosis	O
Invasive	O
thymoma	O
with	O
pericardial	O
involvement	O
as	O
a	O
cause	O
of	O
severe	O
pericardial	O
effusion	O
.	O

History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
A	O
43	O
year	O
old	O
man	O
,	O
with	O
no	O
previous	O
history	O
of	O
interest	O
,	O
who	O
has	O
been	O
doing	O
intense	O
aerobic	O
sports	O
athletics	O
and	O
paddle	O
tennis	O
for	O
about	O
7	O
hours	O
a	O
week	O
since	O
childhood	O
,	O
was	O
referred	O
to	O
the	O
Cardiology	O
department	O
for	O
the	O
finding	O
of	O
isolated	O
monomorphic	O
ventricular	O
extrasystoles	O
VE	O
on	O
ECG	O
performed	O
during	O
an	O
examination	O
at	O
work	O
.	O
Physical	O
examination	O
was	O
normal	O
.	O
Complementary	O
tests	O
Echocardiogram	O
,	O
chest	O
X	O
ray	O
and	O
laboratory	O
tests	O
showed	O
no	O
abnormalities	O
.	O
There	O
were	O
no	O
signs	O
or	O
symptoms	O
of	O
ischaemia	O
in	O
the	O
exercise	O
stress	O
test	O
,	O
but	O
the	O
density	O
of	O
ventricular	O
extrasystoles	O
increased	O
slightly	O
at	O
maximum	O
effort	O
.	O
Clinical	O
course	O
Treatment	O
was	O
started	O
with	O
bisoprolol	B-FARMACO
5	O
mg	O
per	O
day	O
and	O
the	O
Holter	O
monitoring	O
recorded	O
disappearance	O
of	O
VE	O
but	O
nocturnal	O
atrioventricular	O
block	O
AVB	O
with	O
several	O
pauses	O
,	O
the	O
longest	O
of	O
12	O
seconds	O
.	O
The	O
patient	O
remained	O
asymptomatic	O
at	O
all	O
times	O
and	O
denied	O
any	O
family	O
history	O
of	O
conduction	O
disorder	O
,	O
dilated	O
cardiomyopathy	O
or	O
sudden	O
death	O
.	O
The	O
Holter	O
monitoring	O
was	O
interpreted	O
as	O
advanced	O
AVB	O
,	O
bisoprolol	B-FARMACO
was	O
discontinued	O
and	O
the	O
patient	O
was	O
admitted	O
for	O
study	O
and	O
monitoring	O
.	O
Nocturnal	O
pauses	O
were	O
recorded	O
in	O
relation	O
to	O
AVB	O
and	O
or	O
sinus	O
bradycardia	O
of	O
up	O
to	O
7	O
seconds	O
and	O
very	O
occasional	O
VS	O
.	O
Baseline	O
conduction	O
was	O
found	O
to	O
be	O
normal	O
by	O
electrophysiological	O
study	O
and	O
sleep	O
apnoea	O
was	O
ruled	O
out	O
by	O
polysomnography	O
.	O
Given	O
the	O
poor	O
clinical	O
situation	O
and	O
the	O
lack	O
of	O
curative	O
treatment	O
possibilities	O
,	O
analgesia	O
was	O
intensified	O
and	O
the	O
patient	O
died	O
.	O
Diagnosis	O
In	O
view	O
of	O
the	O
absence	O
of	O
structural	O
heart	O
disease	O
and	O
relevant	O
family	O
history	O
,	O
he	O
was	O
diagnosed	O
with	O
VAB	O
mediated	O
by	O
vagal	O
hypertonia	O
and	O
was	O
advised	O
to	O
reduce	O
his	O
sporting	O
activity	O
,	O
but	O
he	O
refused	O
.	O
The	O
risk	O
benefit	O
balance	O
of	O
implanting	O
a	O
single	O
chamber	O
pacemaker	O
was	O
explained	O
to	O
him	O
and	O
he	O
refused	O
.	O
During	O
follow	O
up	O
he	O
remained	O
asymptomatic	O
,	O
although	O
Holter	O
ECG	O
monitoring	O
showed	O
that	O
nocturnal	O
pauses	O
lasting	O
up	O
to	O
9	O
seconds	O
persisted	O
.	O

History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
Personal	O
history	O
54	O
year	O
old	O
male	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
AHT	O
with	O
good	O
control	O
,	O
dyslipidaemic	O
and	O
active	O
smoker	O
1	O
.	O
5	O
packs	O
day	O
.	O
Ex	O
drinker	O
.	O
Hyperuricaemia	O
.	O
Chronic	O
bronchitis	O
type	O
COPD	O
.	O
Under	O
cardiology	O
follow	O
up	O
for	O
moderate	O
double	O
aortic	O
lesion	O
and	O
mild	O
pulmonary	O
hypertension	O
.	O
Occupation	O
waiter	O
.	O
Present	O
illness	O
he	O
came	O
to	O
the	O
emergency	O
department	O
with	O
progressive	O
dyspnoea	O
of	O
one	O
month	O
's	O
duration	O
.	O
Initial	O
evaluation	O
showed	O
narrow	O
QRS	O
tachycardia	O
at	O
144	O
bpm	O
with	O
irregular	O
RR	O
that	O
reverted	O
to	O
sinus	O
rhythm	O
after	O
administration	O
of	O
verapamil	B-FARMACO
and	O
amiodarone	B-FARMACO
.	O
During	O
observation	O
,	O
the	O
patient	O
presented	O
haemodynamic	O
deterioration	O
,	O
with	O
arterial	O
hypotension	O
,	O
poor	O
perfusion	O
,	O
profuse	O
sweating	O
and	O
volumetric	O
resuscitation	O
was	O
started	O
,	O
a	O
femoral	O
line	O
was	O
cannulated	O
and	O
nor	B-FARMACO
adrenaline	I-FARMACO
perfusion	O
was	O
started	O
.	O
A	O
transthoracic	O
echocardiogram	O
was	O
performed	O
,	O
showing	O
biventricular	O
dilatation	O
with	O
severe	O
dysfunction	O
without	O
segmental	O
disorders	O
,	O
moderate	O
mitral	O
insufficiency	O
,	O
moderate	O
double	O
aortic	O
lesion	O
and	O
moderate	O
severe	O
tricuspid	O
insufficiency	O
.	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
ICU	O
and	O
cardiogenic	O
shock	O
persisted	O
.	O
Chest	O
CT	O
was	O
requested	O
and	O
pulmonary	O
thromboembolism	O
was	O
ruled	O
out	O
.	O
The	O
patient	O
was	O
monitored	O
and	O
cardiogenic	O
shock	O
pattern	O
with	O
IC	O
1	O
.	O
5	O
was	O
observed	O
,	O
so	O
dobutamine	B-FARMACO
,	O
noradrenaline	B-FARMACO
and	O
levosimendan	B-FARMACO
were	O
started	O
and	O
the	O
haemodynamic	O
situation	O
recovered	O
and	O
improved	O
progressively	O
,	O
and	O
could	O
be	O
withdrawn	O
in	O
48	O
hours	O
.	O
During	O
his	O
stay	O
in	O
the	O
ICU	O
,	O
a	O
new	O
regulated	O
transthoracic	O
echocardiogram	O
was	O
performed	O
,	O
showing	O
an	O
improvement	O
in	O
LVEF	O
50	O
55	O
subjective	O
,	O
moderate	O
functional	O
mitral	O
regurgitation	O
and	O
double	O
aortic	O
lesion	O
with	O
severe	O
aortic	O
regurgitation	O
.	O
It	O
was	O
decided	O
to	O
perform	O
a	O
TEE	O
and	O
the	O
existence	O
of	O
severe	O
aortic	O
insufficiency	O
was	O
confirmed	O
,	O
with	O
two	O
jets	O
,	O
one	O
due	O
to	O
prolapse	O
of	O
the	O
right	O
coronary	O
leaflet	O
,	O
directed	O
towards	O
the	O
anterior	O
mitral	O
leaflet	O
and	O
the	O
other	O
appears	O
to	O
be	O
caused	O
by	O
a	O
possible	O
perforation	O
of	O
the	O
base	O
of	O
the	O
right	O
coronary	O
leaflet	O
.	O
Physical	O
examination	O
poor	O
general	O
condition	O
.	O
Skin	O
coldness	O
.	O
Profuse	O
sweating	O
.	O
Jugular	O
ingurgitation	O
.	O
ACR	O
arrhythmic	O
tones	O
at	O
130	O
bpm	O
.	O
Systolic	O
diastolic	O
murmur	O
III	O
VI	O
predominantly	O
in	O
aortic	O
focus	O
.	O
MVC	O
with	O
crackles	O
up	O
to	O
midfields	O
in	O
both	O
lung	O
fields	O
.	O
Complementary	O
tests	O
CBC	O
glucose	O
97	O
,	O
creatinine	O
0	O
.	O
65	O
,	O
potassium	O
4	O
.	O
7	O
,	O
GGT	O
44	O
,	O
CT	O
145	O
,	O
LDL	O
88	O
.	O
Hb	O
46	O
.	O
1	O
.	O
Htco	O
47	O
.	O
	O
Blood	O
cultures	O
negative	O
.	O
ECG	O
atrial	O
fibrillation	O
with	O
rapid	O
ventricular	O
response	O
at	O
130	O
bpm	O
.	O
Thoracic	O
CT	O
scan	O
a	O
study	O
was	O
performed	O
with	O
intravenous	O
contrast	O
administration	O
from	O
the	O
bases	O
to	O
the	O
apex	O
of	O
the	O
lungs	O
.	O
Adequate	O
opacification	O
of	O
the	O
pulmonary	O
arterial	O
tree	O
bilaterally	O
,	O
without	O
identifying	O
intravascular	O
repletion	O
defects	O
suggestive	O
of	O
PTE	O
.	O
No	O
evidence	O
of	O
mediastinal	O
or	O
axillary	O
adenopathy	O
of	O
pathological	O
size	O
or	O
other	O
notable	O
abnormalities	O
in	O
the	O
mediastinum	O
.	O
Lung	O
parenchyma	O
was	O
normal	O
bilaterally	O
,	O
without	O
nodular	O
images	O
or	O
alterations	O
of	O
the	O
parenchymal	O
architecture	O
.	O
Contrast	O
reflux	O
to	O
the	O
suprahepatic	O
veins	O
in	O
the	O
context	O
of	O
heart	O
failure	O
.	O
High	O
abdominal	O
sections	O
show	O
perihepatic	O
free	O
fluid	O
lengue	O
and	O
relative	O
hypertrophy	O
of	O
the	O
left	O
hepatic	O
lobe	O
,	O
which	O
may	O
be	O
secondary	O
to	O
chronic	O
liver	O
disease	O
.	O
Conclusion	O
PTE	O
is	O
ruled	O
out	O
.	O
TT	O
echocardiogram	O
moderately	O
severely	O
dilated	O
left	O
ventricle	O
,	O
with	O
mild	O
concentric	O
hypertrophy	O
and	O
global	O
systolic	O
function	O
at	O
low	O
limits	O
of	O
normality	O
monoplane	O
Simpson	O
LVEF	O
49	O
,	O
subjective	O
50	O
55	O
,	O
Teicholz	O
54	O
.	O
LA	O
dilated	O
34	O
cm2	O
.	O
RV	O
neither	O
dilated	O
nor	O
hypertrophic	O
with	O
preserved	O
global	O
systolic	O
function	O
.	O
Dilated	O
RA	O
.	O
Mitral	O
valve	O
with	O
non	O
thickened	O
leaflets	O
,	O
without	O
significant	O
morphological	O
alterations	O
,	O
preserved	O
opening	O
,	O
appreciating	O
MI	O
directed	O
towards	O
the	O
posterolateral	O
wall	O
of	O
LA	O
which	O
appears	O
to	O
be	O
moderately	O
functional	O
.	O
There	O
are	O
no	O
images	O
suggestive	O
of	O
endocarditis	O
at	O
the	O
mitral	O
valve	O
level	O
.	O
Tricuspid	O
aortic	O
valve	O
,	O
fibrosclerosed	O
,	O
with	O
severe	O
thickening	O
of	O
the	O
right	O
coronary	O
leaflet	O
,	O
which	O
presents	O
a	O
hyperechogenic	O
nodular	O
image	O
on	O
which	O
sits	O
a	O
less	O
echodense	O
and	O
flapping	O
image	O
suggestive	O
of	O
endocarditis	O
wart	O
.	O
Prolapse	O
of	O
the	O
right	O
coronary	O
leaflet	O
can	O
be	O
seen	O
,	O
causing	O
a	O
very	O
eccentric	O
AoI	O
,	O
which	O
appears	O
to	O
be	O
severe	O
.	O
The	O
apical	O
projection	O
shows	O
two	O
regurgitation	O
jets	O
,	O
one	O
directed	O
towards	O
the	O
anterior	O
mitral	O
leaflet	O
caused	O
by	O
the	O
prolapse	O
of	O
the	O
right	O
coronary	O
leaflet	O
and	O
the	O
other	O
directed	O
towards	O
the	O
ventricular	O
septum	O
cavity	O
.	O
Slightly	O
restricted	O
opening	O
with	O
mean	O
AoTG	O
of	O
22	O
mmHg	O
,	O
AVAo	O
per	O
EC	O
of	O
1	O
.	O
99	O
cm2	O
.	O
Mild	O
TR	O
allowing	O
estimation	O
of	O
PSAP	O
of	O
29	O
mmHg	O
PAD	O
dilated	O
IVC	O
with	O
inspiratory	O
collapse	O
of	O
approximately	O
50	O
.	O
No	O
pulmonary	O
valvulopathy	O
was	O
observed	O
.	O
Normal	O
ascending	O
aorta	O
.	O
Septum	O
intact	O
.	O
No	O
pericardial	O
effusion	O
.	O
Transesophageal	O
echocardiogram	O
severe	O
AoI	O
was	O
observed	O
,	O
best	O
visualised	O
in	O
the	O
mid	O
oesophageal	O
projection	O
at	O
120o	O
,	O
conditioned	O
by	O
the	O
existence	O
of	O
2	O
regurgitation	O
jets	O
that	O
occupy	O
almost	O
all	O
of	O
the	O
LVOT	O
.	O
One	O
of	O
them	O
originates	O
from	O
prolapse	O
of	O
the	O
right	O
coronary	O
leaflet	O
,	O
directed	O
towards	O
the	O
anterior	O
mitral	O
leaflet	O
.	O
The	O
other	O
appears	O
to	O
be	O
caused	O
by	O
a	O
possible	O
perforation	O
of	O
the	O
base	O
of	O
the	O
right	O
coronary	O
leaflet	O
.	O
Grade	O
III	O
MR	O
is	O
seen	O
,	O
conditioned	O
by	O
a	O
scarce	O
coaptation	O
of	O
mitral	O
leaflets	O
of	O
functional	O
origin	O
,	O
reaching	O
the	O
atrial	O
roof	O
with	O
a	O
6	O
mm	O
vena	O
contracta	O
.	O
There	O
were	O
no	O
images	O
suggestive	O
of	O
endocarditis	O
on	O
the	O
mitral	O
valve	O
.	O
The	O
atrial	O
appendage	O
is	O
free	O
of	O
thrombus	O
.	O
The	O
rest	O
is	O
compatible	O
with	O
the	O
TTE	O
study	O
.	O
Conclusion	O
study	O
suggestive	O
of	O
endocarditis	O
on	O
the	O
aortic	O
valve	O
,	O
severe	O
AoI	O
,	O
mild	O
AoE	O
.	O
Grade	O
III	O
MI	O
.	O
LVEF	O
in	O
low	O
limits	O
of	O
normality	O
.	O
Clinical	O
evolution	O
The	O
patient	O
was	O
referred	O
to	O
the	O
cardiac	O
surgery	O
unit	O
and	O
underwent	O
successful	O
surgery	O
with	O
implantation	O
of	O
mitral	O
and	O
aortic	O
metallic	O
prosthesis	O
.	O
The	O
native	O
mitral	O
and	O
aortic	O
valves	O
were	O
removed	O
and	O
endocardial	O
involvement	O
by	O
Coxiella	O
burnetii	O
was	O
diagnosed	O
.	O
During	O
follow	O
up	O
,	O
the	O
patient	O
presented	O
multiple	O
falls	O
in	O
atrial	O
flutter	O
with	O
2	O
CVE	O
and	O
recurrence	O
,	O
as	O
well	O
as	O
severe	O
ventricular	O
dysfunction	O
and	O
multiple	O
episodes	O
of	O
NSVT	O
on	O
Holter	O
.	O
He	O
was	O
referred	O
to	O
the	O
arrhythmia	O
unit	O
and	O
CTI	O
ablation	O
was	O
performed	O
and	O
a	O
CRT	O
ADI	O
pacemaker	O
was	O
implanted	O
,	O
with	O
improvement	O
in	O
LVEF	O
during	O
follow	O
up	O
,	O
and	O
he	O
is	O
currently	O
in	O
GF	O
I	O
II	O
.	O
Diagnosis	O
Cardiogenic	O
shock	O
in	O
the	O
context	O
of	O
tachycardiomyopathy	O
due	O
to	O
rapid	O
atrial	O
fibrillation	O
of	O
uncertain	O
onset	O
and	O
treatment	O
with	O
verapamil	B-FARMACO
.	O
Mitro	O
aortic	O
endocarditis	O
due	O
to	O
Coxiella	O
burnetii	O
.	O
Implantation	O
of	O
metallic	O
mitral	O
and	O
aortic	O
prostheses	O
.	O
Successful	O
CTI	O
ablation	O
.	O
Implantation	O
of	O
ICD	O
CRT	O
with	O
improvement	O
of	O
LVEF	O
.	O

History	O
,	O
current	O
disease	O
and	O
physical	O
examination	O
A	O
25	O
year	O
old	O
man	O
came	O
to	O
the	O
cardiology	O
department	O
after	O
an	O
episode	O
of	O
atrial	O
fibrillation	O
with	O
rapid	O
ventricular	O
response	O
while	O
exercising	O
on	O
the	O
beach	O
and	O
was	O
treated	O
by	O
pharmacological	O
cardioversion	O
with	O
amiodarone	B-FARMACO
in	O
the	O
emergency	O
department	O
.	O
The	O
patient	O
had	O
been	O
experiencing	O
episodes	O
of	O
palpitations	O
related	O
to	O
intense	O
exertion	O
for	O
a	O
year	O
.	O
He	O
had	O
no	O
functional	O
class	O
deterioration	O
or	O
other	O
cardiovascular	O
symptoms	O
.	O
Personal	O
history	O
In	O
preparation	O
for	O
competitive	O
firefighter	O
training	O
.	O
Labelled	O
episodes	O
of	O
anxiety	O
with	O
chest	O
pain	O
,	O
sensation	O
of	O
dyspnoea	O
and	O
acute	O
elevation	O
of	O
blood	O
pressure	O
.	O
No	O
other	O
cardiovascular	O
risk	O
factors	O
or	O
drug	O
use	O
.	O
Mallory	O
Weiss	O
syndrome	O
.	O
	O
No	O
regular	O
medication	O
.	O
Family	O
history	O
one	O
brother	O
had	O
died	O
of	O
transposition	O
of	O
great	O
vessels	O
and	O
ventricular	O
septal	O
defect	O
,	O
another	O
brother	O
had	O
died	O
in	O
utero	O
due	O
to	O
interruption	O
of	O
the	O
aortic	O
arch	O
and	O
he	O
had	O
a	O
cousin	O
with	O
pre	O
excitation	O
syndrome	O
.	O
Physical	O
examination	O
conscious	O
,	O
oriented	O
,	O
normal	O
colour	O
,	O
eupneic	O
.	O
Normal	O
phenotype	O
.	O
Blood	O
pressure	O
218	O
110	O
mmHg	O
in	O
right	O
upper	O
limb	O
,	O
169	O
86	O
mmHg	O
in	O
left	O
upper	O
limb	O
.	O
Peripheral	O
pulses	O
present	O
.	O
Pulmonary	O
auscultation	O
with	O
preserved	O
vesicular	O
murmur	O
,	O
cardiac	O
auscultation	O
ejective	O
proto	O
mesosystolic	O
murmur	O
in	O
aortic	O
focus	O
and	O
left	O
parasternal	O
border	O
grade	O
II	O
over	O
LV	O
also	O
audible	O
in	O
interscapular	O
focus	O
.	O
Abdomen	O
and	O
lower	O
limbs	O
without	O
findings	O
.	O
Complementary	O
tests	O
Electrocardiogram	O
sinus	O
rhythm	O
with	O
normal	O
cardiac	O
axis	O
.	O
Presence	O
of	O
incomplete	O
right	O
bundle	O
branch	O
block	O
and	O
signs	O
suggestive	O
of	O
left	O
ventricular	O
hypertrophy	O
.	O
Chest	O
X	O
ray	O
no	O
cardiomegaly	O
,	O
absence	O
of	O
pleural	O
effusion	O
or	O
pulmonary	O
infiltrates	O
.	O
Rib	O
indentations	O
are	O
seen	O
.	O
Transthoracic	O
echocardiogram	O
mild	O
septal	O
hypertrophy	O
,	O
mild	O
mitral	O
anterolateral	O
leaflet	O
prolapse	O
with	O
trivial	O
mitral	O
insufficiency	O
.	O
In	O
the	O
suprasternal	O
window	O
,	O
a	O
flow	O
acceleration	O
and	O
gradient	O
of	O
86	O
.	O
6	O
mmHg	O
in	O
the	O
descending	O
thoracic	O
aorta	O
below	O
the	O
left	O
subclavian	O
outflow	O
was	O
noted	O
.	O
The	O
rest	O
of	O
the	O
study	O
including	O
left	O
atrial	O
dimensions	O
and	O
left	O
ventricular	O
diastolic	O
function	O
was	O
normal	O
.	O
Thoracic	O
abdominal	O
CT	O
angiography	O
presence	O
of	O
aortic	O
coarctation	O
distal	O
to	O
the	O
ostium	O
of	O
the	O
left	O
subclavian	O
artery	O
with	O
a	O
reduction	O
of	O
the	O
aortic	O
lumen	O
to	O
0	O
.	O
6	O
cm	O
in	O
diameter	O
,	O
with	O
hypertrophy	O
of	O
the	O
left	O
intercostal	O
arteries	O
distal	O
to	O
the	O
coarctation	O
,	O
the	O
left	O
subclavian	O
artery	O
and	O
the	O
left	O
mammary	O
artery	O
.	O
Nuclear	O
magnetic	O
resonance	O
angiography	O
saccular	O
aneurysm	O
adjacent	O
to	O
the	O
bifurcation	O
of	O
the	O
right	O
middle	O
cerebral	O
artery	O
.	O
Normal	O
karyotype	O
,	O
absence	O
of	O
22q11	O
.	O
2	O
selection	O
.	O
Clinical	O
course	O
Given	O
the	O
findings	O
compatible	O
with	O
coarctation	O
of	O
the	O
descending	O
aorta	O
and	O
the	O
diagnosis	O
of	O
paroxysmal	O
atrial	O
fibrillation	O
,	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
cardiology	O
ward	O
to	O
complete	O
the	O
study	O
and	O
decide	O
on	O
the	O
therapeutic	O
approach	O
.	O
Thoracic	O
abdominal	O
CT	O
angiography	O
was	O
performed	O
,	O
which	O
confirmed	O
coarctation	O
distal	O
to	O
the	O
ostium	O
of	O
the	O
left	O
subclavian	O
artery	O
.	O
Given	O
the	O
association	O
of	O
this	O
aortic	O
pathology	O
with	O
cerebrovascular	O
malformations	O
,	O
it	O
was	O
decided	O
to	O
perform	O
a	O
cerebral	O
magnetic	O
resonance	O
angiography	O
,	O
which	O
revealed	O
an	O
aneurysm	O
in	O
the	O
middle	O
cerebral	O
artery	O
.	O
In	O
addition	O
,	O
given	O
the	O
family	O
history	O
,	O
karyotyping	O
was	O
performed	O
and	O
a	O
FISH	O
hybridisation	O
study	O
of	O
one	O
of	O
the	O
deletions	O
associated	O
with	O
this	O
type	O
of	O
pathology	O
was	O
carried	O
out	O
,	O
both	O
tests	O
being	O
normal	O
.	O
With	O
the	O
diagnoses	O
described	O
,	O
the	O
case	O
was	O
presented	O
at	O
the	O
clinical	O
session	O
,	O
and	O
the	O
decision	O
was	O
made	O
to	O
first	O
operate	O
on	O
the	O
cerebral	O
aneurysm	O
and	O
then	O
to	O
surgically	O
correct	O
the	O
coarctation	O
of	O
the	O
aorta	O
.	O
The	O
patient	O
underwent	O
successful	O
surgery	O
and	O
is	O
currently	O
asymptomatic	O
.	O
Diagnosis	O
Main	O
Coarctation	O
of	O
aorta	O
in	O
descending	O
thoracic	O
AO	O
Intracranial	O
aneurysm	O
in	O
middle	O
cerebral	O
artery	O
Secondary	O
Paroxysmal	O
AF	O
,	O
mild	O
MI	O
with	O
MVP	O
Arterial	O
hypertension	O
in	O
clinical	O
context	O

History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
A	O
48	O
year	O
old	O
male	O
patient	O
with	O
a	O
history	O
of	O
hypertension	O
,	O
dyslipidaemia	O
,	O
obesity	O
and	O
ex	O
smoker	O
.	O
After	O
fumigating	O
for	O
approximately	O
3	O
continuous	O
hours	O
with	O
organophosphates	O
without	O
any	O
protection	O
,	O
he	O
suddenly	O
presented	O
with	O
intense	O
dyspnoea	O
,	O
diaphoresis	O
and	O
intense	O
oppressive	O
central	O
thoracic	O
pain	O
radiating	O
to	O
both	O
upper	O
limbs	O
;	O
his	O
family	O
described	O
that	O
he	O
went	O
home	O
after	O
the	O
onset	O
of	O
the	O
symptoms	O
with	O
twitching	O
in	O
the	O
upper	O
limbs	O
,	O
trembling	O
in	O
both	O
hands	O
and	O
inability	O
to	O
speak	O
due	O
to	O
abundant	O
salivation	O
and	O
bronchorrhoea	O
.	O
His	O
family	O
took	O
him	O
to	O
the	O
local	O
hospital	O
.	O
On	O
arrival	O
he	O
presented	O
cardiorespiratory	O
arrest	O
in	O
VF	O
rhythm	O
,	O
resuscitation	O
manoeuvres	O
were	O
started	O
,	O
and	O
after	O
5	O
shocks	O
the	O
rhythm	O
was	O
reversed	O
,	O
but	O
the	O
patient	O
was	O
still	O
haemodynamically	O
unstable	O
with	O
significant	O
respiratory	O
insufficiency	O
,	O
so	O
vasoactive	O
support	O
and	O
orotracheal	O
intubation	O
were	O
started	O
.	O
After	O
45	O
minutes	O
of	O
resuscitation	O
manoeuvres	O
,	O
ECG	O
showed	O
complete	O
AV	O
block	O
with	O
escape	O
rhythm	O
at	O
45	O
bpm	O
and	O
ST	O
elevation	O
in	O
II	O
III	O
aVF	O
,	O
from	O
V3	O
to	O
V6	O
and	O
V3R	O
V4R	O
,	O
and	O
specular	O
decrease	O
in	O
I	O
aVL	O
V1	O
V2	O
.	O
Fibrinolysis	O
was	O
decided	O
as	O
there	O
was	O
no	O
Haemodynamics	O
Unit	O
at	O
the	O
centre	O
and	O
CORECAM	O
Castilla	O
la	O
Mancha	O
Infarction	O
Code	O
was	O
activated	O
.	O
Despite	O
NKT	B-FARMACO
,	O
the	O
patient	O
persisted	O
with	O
ST	O
elevation	O
and	O
was	O
referred	O
for	O
rescue	O
PTCA	O
.	O
Physical	O
examination	O
relaxed	O
sedentary	O
patient	O
,	O
mechanically	O
ventilated	O
and	O
requiring	O
high	O
doses	O
of	O
vasoactive	O
drugs	O
.	O
BP	O
70	O
40	O
,	O
HR	O
30	O
bpm	O
,	O
RR	O
20	O
,	O
afebrile	O
,	O
SaO2	O
100	O
MV	O
.	O
Head	O
and	O
neck	O
miosis	O
and	O
abundant	O
sialorrhoea	O
.	O
Cardiac	O
auscultation	O
bradycardic	O
,	O
rhythmic	O
and	O
regular	O
.	O
Lung	O
fields	O
with	O
inspiratory	O
and	O
expiratory	O
wheezing	O
,	O
crackling	O
rales	O
in	O
both	O
bases	O
and	O
abundant	O
mobilisation	O
of	O
secretions	O
.	O
Abdomen	O
globular	O
,	O
soft	O
,	O
depressible	O
,	O
not	O
assessable	O
.	O
Extremities	O
with	O
fasciculations	O
and	O
generalised	O
myoclonus	O
.	O
Complementary	O
tests	O
CBC	O
leukocytes	O
22	O
,	O
300	O
with	O
adequate	O
differential	O
count	O
,	O
Hb	O
14	O
.	O
3	O
,	O
haematocrit	O
43	O
,	O
platelets	O
221	O
,	O
000	O
,	O
Act	O
.	O
PT	O
83	O
,	O
fibrinogen	O
258	O
,	O
glucose	O
513	O
mg	O
dl	O
,	O
urea	O
43	O
,	O
creatinine	O
1	O
.	O
6	O
,	O
total	O
protein	O
6	O
.	O
7	O
,	O
GOT	O
832	O
,	O
GPT	O
578	O
,	O
LDH	O
1257	O
,	O
amylase	O
117	O
.	O
	O
Ions	O
Na	O
134	O
,	O
K	O
2	O
.	O
8	O
,	O
Cl	O
101	O
,	O
Ca	O
7	O
.	O
7	O
,	O
P	O
12	O
.	O
8	O
,	O
Mg	O
1	O
.	O
3	O
.	O
	O
Myocardial	O
injury	O
markers	O
at	O
8	O
hours	O
after	O
onset	O
CPK	O
2813	O
,	O
CK	O
MB	O
264	O
and	O
TnI	O
43	O
.	O
4	O
.	O
Peak	O
enzyme	O
at	O
24	O
hours	O
CPK	O
6	O
,	O
586	O
,	O
CK	O
MB	O
304	O
and	O
TnI	O
76	O
.	O
	O
Blood	O
gases	O
PH	O
7	O
.	O
01	O
,	O
PCO2	O
38	O
,	O
PO2	O
261	O
,	O
HCO3	O
12	O
.	O
6	O
,	O
lactic	O
acid	O
92	O
.	O
Electrocardiogram	O
before	O
entering	O
the	O
haemodynamics	O
room	O
unchanged	O
with	O
respect	O
to	O
that	O
described	O
prior	O
to	O
fibrinolysis	O
.	O
Chest	O
X	O
ray	O
cardiothoracic	O
index	O
at	O
the	O
high	O
limit	O
of	O
normality	O
.	O
Interstitial	O
infiltrate	O
in	O
both	O
lower	O
fields	O
.	O
Transthoracic	O
echocardiogram	O
vasoactive	O
support	O
and	O
mechanical	O
ventilation	O
non	O
dilated	O
LV	O
,	O
with	O
inferoposterior	O
akinesia	O
and	O
mid	O
apical	O
septal	O
,	O
without	O
signs	O
of	O
valvular	O
heart	O
disease	O
or	O
mechanical	O
complications	O
,	O
with	O
LVEF	O
of	O
42	O
.	O
Clinical	O
course	O
The	O
patient	O
was	O
admitted	O
directly	O
to	O
the	O
haemodynamics	O
ward	O
.	O
Prior	O
to	O
coronary	O
angiography	O
,	O
a	O
transient	O
intravenous	O
pacemaker	O
was	O
implanted	O
via	O
the	O
right	O
femoral	O
vein	O
and	O
balloon	O
counterpulsation	O
via	O
the	O
left	O
femoral	O
artery	O
.	O
Coronary	O
angiography	O
showed	O
right	O
dominance	O
,	O
LMCA	O
without	O
lesions	O
,	O
LAD	O
with	O
parietal	O
irregularities	O
without	O
significant	O
stenosis	O
,	O
hypodeveloped	O
Cx	O
without	O
stenosis	O
and	O
DC	O
with	O
complicated	O
plaque	O
and	O
associated	O
thrombus	O
in	O
the	O
proximal	O
region	O
,	O
distal	O
vessel	O
permeable	O
with	O
distal	O
flow	O
Timi	O
2	O
3	O
video	O
1	O
.	O
Angioplasty	O
guide	O
wire	O
is	O
passed	O
to	O
distal	O
DC	O
and	O
direct	O
stent	O
implantation	O
in	O
proximal	O
DC	O
up	O
to	O
the	O
ostium	O
;	O
after	O
which	O
she	O
presents	O
no	O
reflow	O
phenomenon	O
that	O
remits	O
after	O
intracoronary	O
vasodilators	O
.	O
In	O
ECG	O
after	O
rescue	O
PTCA	O
,	O
sinus	O
rhythm	O
at	O
105	O
bpm	O
,	O
QS	O
in	O
II	O
III	O
aVF	O
,	O
transition	O
from	O
QRS	O
V1	O
to	O
V2	O
with	O
high	O
R	O
in	O
V2	O
and	O
V3	O
,	O
persistent	O
ST	O
alterations	O
ST	O
elevation	O
in	O
II	O
III	O
aVF	O
and	O
decrease	O
in	O
I	O
aVL	O
V1	O
V2	O
,	O
AV	O
block	O
grade	O
I	O
with	O
PR	O
220	O
msec	O
.	O
In	O
view	O
of	O
the	O
fact	O
that	O
his	O
acute	O
coronary	O
symptoms	O
had	O
resolved	O
and	O
that	O
the	O
patient	O
had	O
symptoms	O
dyspnoea	O
,	O
abundant	O
salivation	O
,	O
bronchorrhoea	O
,	O
fasciculations	O
,	O
hand	O
tremor	O
,	O
signs	O
miosis	O
,	O
sialorrhoea	O
,	O
bronchospasm	O
,	O
bronchorrhoea	O
,	O
bradycardia	O
,	O
AV	O
block	O
,	O
myoclonias	O
and	O
analytical	O
findings	O
leukocytosis	O
,	O
hyperglycaemia	O
,	O
renal	O
failure	O
,	O
hypokalaemia	O
,	O
hyperphosphataemia	O
,	O
hypomagnesaemia	O
,	O
metabolic	O
acidosis	O
suggestive	O
of	O
organophosphate	O
poisoning	O
;	O
given	O
the	O
duration	O
of	O
cardiorespiratory	O
arrest	O
,	O
it	O
was	O
decided	O
to	O
initiate	O
hypothermia	O
,	O
atropinisation	O
,	O
sodium	B-FARMACO
bicarbonate	I-FARMACO
,	O
magnesium	B-FARMACO
sulphate	I-FARMACO
,	O
as	O
well	O
as	O
haemodynamic	O
and	O
ventilatory	O
support	O
.	O
Despite	O
maintaining	O
adequate	O
haemodynamic	O
and	O
ventilatory	O
support	O
,	O
and	O
achieving	O
correction	O
of	O
metabolic	O
acidosis	O
,	O
the	O
patient	O
progressed	O
to	O
progressive	O
deterioration	O
,	O
renal	O
failure	O
requiring	O
continuous	O
haemodiafiltration	O
,	O
signs	O
of	O
hepatotoxicity	O
and	O
systemic	O
inflammatory	O
response	O
syndrome	O
in	O
the	O
first	O
48	O
hours	O
.	O
ECG	O
after	O
48	O
hours	O
of	O
evolution	O
in	O
sinus	O
rhythm	O
at	O
74	O
bpm	O
,	O
QS	O
in	O
II	O
III	O
aVF	O
,	O
high	O
R	O
in	O
V2	O
and	O
V3	O
,	O
slight	O
ST	O
elevation	O
in	O
II	O
III	O
aVF	O
and	O
slight	O
decrease	O
in	O
I	O
aVLV1	O
V2	O
,	O
AV	O
block	O
grade	O
I	O
with	O
PR	O
220	O
msec	O
.	O
Two	O
weeks	O
after	O
being	O
in	O
the	O
ICU	O
,	O
he	O
presented	O
even	O
more	O
neurological	O
deterioration	O
,	O
becoming	O
spastic	O
,	O
with	O
hyper	O
reactivity	O
of	O
tendon	O
reflexes	O
,	O
signs	O
of	O
dysautonomia	O
and	O
coldness	O
of	O
the	O
extremities	O
.	O
After	O
a	O
torpid	O
evolution	O
and	O
presenting	O
,	O
among	O
other	O
complications	O
typical	O
of	O
prolonged	O
admission	O
to	O
the	O
ICU	O
,	O
respiratory	O
distress	O
syndrome	O
and	O
septic	O
shock	O
due	O
to	O
Pseudomona	O
,	O
the	O
patient	O
died	O
after	O
48	O
days	O
in	O
the	O
ICU	O
.	O
Diagnosis	O
Cardiorespiratory	O
arrest	O
witnessed	O
in	O
ventricular	O
fibrillation	O
.	O
Prolonged	O
advanced	O
cardiopulmonary	O
resuscitation	O
.	O
Severe	O
organophosphate	O
poisoning	O
.	O
Acute	O
coronary	O
syndrome	O
with	O
ST	O
elevation	O
of	O
the	O
inferior	O
ST	O
and	O
RV	O
.	O
Fibrinolysis	O
without	O
reperfusion	O
criteria	O
rescue	O
PTCA	O
in	O
proximal	O
DC	O
.	O
Acute	O
renal	O
failure	O
.	O
Continuous	O
veno	O
venous	O
haemodiafiltration	O
.	O
Acute	O
hepatitis	O
of	O
probable	O
mixed	O
toxic	O
ischaemic	O
origin	O
.	O
Adult	O
respiratory	O
distress	O
syndrome	O
.	O
Septic	O
shock	O
due	O
to	O
Pseudomona	O
aeruginosa	O
.	O
Exitus	O
.	O

Male	O
patient	O
,	O
31	O
years	O
old	O
,	O
construction	O
worker	O
.	O
No	O
known	O
drug	O
allergies	O
,	O
ex	O
smoker	O
of	O
half	O
a	O
packet	O
day	O
for	O
5	O
years	O
,	O
not	O
an	O
excessive	O
drinker	O
,	O
not	O
a	O
consumer	O
of	O
other	O
toxic	O
substances	O
.	O
No	O
significant	O
personal	O
or	O
family	O
history	O
.	O
History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
Previously	O
asymptomatic	O
,	O
he	O
presented	O
with	O
intense	O
pain	O
,	O
coldness	O
and	O
generalised	O
pallor	O
in	O
the	O
left	O
hand	O
of	O
sudden	O
onset	O
without	O
previous	O
trauma	O
while	O
carrying	O
out	O
his	O
daily	O
tasks	O
,	O
for	O
which	O
he	O
consulted	O
his	O
health	O
centre	O
.	O
As	O
no	O
radial	O
or	O
ulnar	O
pulse	O
was	O
found	O
,	O
the	O
patient	O
was	O
referred	O
to	O
our	O
hospital	O
where	O
he	O
was	O
assessed	O
in	O
the	O
emergency	O
department	O
by	O
Vascular	O
Surgery	O
,	O
which	O
documented	O
acute	O
occlusion	O
of	O
the	O
humeral	O
artery	O
,	O
which	O
led	O
to	O
an	O
urgent	O
embolectomy	O
without	O
incident	O
,	O
embolic	O
material	O
was	O
sent	O
for	O
pathological	O
anatomy	O
and	O
a	O
cardiological	O
assessment	O
and	O
echocardiography	O
were	O
requested	O
.	O
On	O
physical	O
examination	O
the	O
patient	O
was	O
in	O
good	O
general	O
condition	O
,	O
conscious	O
,	O
oriented	O
and	O
cooperative	O
.	O
Well	O
hydrated	O
and	O
perfused	O
,	O
eupneic	O
at	O
rest	O
and	O
tolerating	O
decubitus	O
.	O
Afebrile	O
,	O
BP	O
110	O
70	O
,	O
HR	O
70xmin	O
,	O
normal	O
cardiopulmonary	O
auscultation	O
,	O
no	O
signs	O
of	O
heart	O
failure	O
.	O
Embolectomy	O
wound	O
in	O
MSI	O
with	O
no	O
data	O
of	O
complication	O
.	O
The	O
rest	O
of	O
the	O
physical	O
examination	O
was	O
completely	O
normal	O
.	O
A	O
transthoracic	O
echocardiography	O
TTE	O
was	O
performed	O
at	O
the	O
bedside	O
,	O
which	O
revealed	O
a	O
mass	O
in	O
the	O
lateral	O
wall	O
of	O
the	O
left	O
atrium	O
and	O
the	O
patient	O
was	O
admitted	O
to	O
Cardiology	O
for	O
further	O
study	O
.	O
Complementary	O
tests	O
Analysis	O
Complete	O
blood	O
count	O
,	O
coagulation	O
and	O
profiles	O
with	O
no	O
noteworthy	O
data	O
.	O
Electrocardiogram	O
Sinus	O
rhythm	O
maintained	O
,	O
no	O
repolarisation	O
alterations	O
,	O
conduction	O
disorders	O
or	O
findings	O
suggestive	O
of	O
cavity	O
growth	O
.	O
Chest	O
X	O
ray	O
Normal	O
cardiac	O
silhouette	O
.	O
Absence	O
of	O
congestive	O
pattern	O
,	O
no	O
pleural	O
effusion	O
.	O
No	O
space	O
occupying	O
images	O
in	O
lung	O
parenchyma	O
.	O
Echocardiography	O
TT	O
TE	O
ECO	O
3D	O
Mass	O
of	O
40x27	O
mm	O
that	O
occupies	O
the	O
entire	O
left	O
atrial	O
appendage	O
,	O
protrudes	O
out	O
of	O
it	O
towards	O
the	O
atrium	O
,	O
has	O
irregular	O
edges	O
with	O
some	O
areas	O
of	O
increased	O
echogenicity	O
suggesting	O
fibrosis	O
and	O
on	O
the	O
atrial	O
surface	O
has	O
filamentous	O
and	O
mobile	O
extension	O
of	O
12	O
mm	O
with	O
characteristics	O
of	O
high	O
embolic	O
risk	O
.	O
The	O
left	O
pulmonary	O
veins	O
are	O
not	O
invaded	O
,	O
with	O
normal	O
flow	O
.	O
The	O
ADA	O
and	O
ACX	O
are	O
seen	O
in	O
the	O
AV	O
groove	O
below	O
the	O
atrial	O
appendage	O
,	O
without	O
being	O
invaded	O
.	O
Normal	O
mitral	O
valve	O
,	O
aortic	O
valve	O
and	O
right	O
valves	O
.	O
Left	O
ventricle	O
of	O
normal	O
dimensions	O
,	O
wall	O
thickness	O
and	O
contractility	O
.	O
Normal	O
right	O
chambers	O
.	O
No	O
pericardial	O
effusion	O
.	O
Cardiac	O
magnetic	O
resonance	O
imaging	O
MRI	O
Tissue	O
formation	O
in	O
the	O
left	O
atrium	O
that	O
completely	O
occupies	O
the	O
atrial	O
appendage	O
and	O
extends	O
into	O
the	O
atrial	O
cavity	O
as	O
a	O
vegetative	O
mass	O
with	O
well	O
defined	O
contours	O
,	O
attached	O
to	O
the	O
upper	O
and	O
lateral	O
wall	O
.	O
It	O
measures	O
approximately	O
4cm	O
in	O
its	O
maximum	O
axis	O
which	O
is	O
craniocaudal	O
.	O
In	O
the	O
four	O
chamber	O
plane	O
it	O
measures	O
approximately	O
34x27mm	O
.	O
Although	O
it	O
is	O
adjacent	O
to	O
the	O
pulmonary	O
ostium	O
,	O
these	O
remain	O
patent	O
.	O
It	O
is	O
not	O
related	O
to	O
the	O
mitral	O
valve	O
or	O
the	O
interatrial	O
septum	O
.	O
It	O
has	O
homogeneous	O
and	O
intermediate	O
signal	O
intensity	O
in	O
all	O
sequences	O
.	O
In	O
the	O
late	O
enhancement	O
sequences	O
,	O
annular	O
peripheral	O
fine	O
enhancement	O
is	O
found	O
,	O
which	O
can	O
be	O
observed	O
in	O
myxomas	O
.	O
No	O
alterations	O
in	O
thickness	O
and	O
segmental	O
and	O
global	O
contractility	O
or	O
alterations	O
in	O
tissue	O
signal	O
or	O
late	O
enhancement	O
in	O
myocardium	O
.	O
No	O
cardiovascular	O
anatomical	O
alterations	O
.	O
Clinical	O
evolution	O
During	O
his	O
stay	O
on	O
the	O
hospital	O
ward	O
,	O
the	O
patient	O
remained	O
asymptomatic	O
and	O
without	O
incident	O
.	O
In	O
the	O
imaging	O
tests	O
mentioned	O
above	O
,	O
a	O
differential	O
diagnosis	O
was	O
made	O
between	O
atrial	O
myxoma	O
of	O
atypical	O
location	O
vs	O
.	O
thrombus	O
.	O
In	O
the	O
pathological	O
anatomy	O
study	O
of	O
embolic	O
material	O
,	O
high	O
grade	O
cellular	O
atypia	O
suggestive	O
of	O
malignant	O
neoplasia	O
was	O
found	O
.	O
Cardiac	O
surgery	O
was	O
consulted	O
and	O
the	O
case	O
was	O
accepted	O
for	O
resection	O
of	O
the	O
mass	O
under	O
extracorporeal	O
circulation	O
and	O
the	O
procedure	O
was	O
carried	O
out	O
without	O
complications	O
.	O
The	O
intraoperative	O
pathological	O
anatomy	O
study	O
confirmed	O
high	O
grade	O
dysplasia	O
,	O
and	O
the	O
left	O
atrial	O
appendage	O
was	O
resected	O
over	O
its	O
entire	O
length	O
,	O
achieving	O
lesion	O
free	O
margins	O
.	O
During	O
his	O
stay	O
in	O
the	O
ICU	O
he	O
evolved	O
favourably	O
without	O
incident	O
and	O
after	O
stabilisation	O
he	O
was	O
transferred	O
to	O
the	O
cardiac	O
surgery	O
ward	O
.	O
The	O
definitive	O
pathological	O
anatomy	O
study	O
of	O
the	O
resected	O
mass	O
was	O
reported	O
as	O
undifferentiated	O
pleomorphic	O
sarcoma	O
,	O
an	O
extension	O
study	O
was	O
performed	O
with	O
thoracoabdominal	O
CT	O
where	O
no	O
metastatic	O
lesions	O
were	O
documented	O
and	O
it	O
was	O
decided	O
to	O
discharge	O
him	O
on	O
anticoagulation	O
and	O
to	O
carry	O
out	O
out	O
outpatient	O
follow	O
up	O
with	O
Oncology	O
.	O
Two	O
weeks	O
after	O
surgery	O
,	O
the	O
patient	O
was	O
readmitted	O
for	O
clinical	O
manifestations	O
compatible	O
with	O
embolic	O
stroke	O
secondary	O
to	O
tandem	O
occlusion	O
of	O
the	O
left	O
internal	O
carotid	O
artery	O
and	O
left	O
middle	O
cerebral	O
artery	O
.	O
He	O
was	O
successfully	O
treated	O
by	O
mechanical	O
thrombectomy	O
and	O
the	O
patient	O
was	O
left	O
without	O
residual	O
neurological	O
deficit	O
;	O
the	O
pathological	O
anatomy	O
study	O
of	O
the	O
embolic	O
material	O
confirmed	O
its	O
tumoural	O
aetiology	O
.	O
He	O
was	O
subsequently	O
admitted	O
to	O
Oncology	O
,	O
and	O
a	O
repeat	O
TTE	O
and	O
extension	O
study	O
cranial	O
MRI	O
,	O
thoracoabdominal	O
CT	O
and	O
bone	O
scintigraphy	O
documented	O
a	O
recurrence	O
of	O
the	O
mass	O
in	O
the	O
left	O
atrium	O
with	O
similar	O
size	O
and	O
characteristics	O
to	O
those	O
described	O
in	O
the	O
pre	O
surgical	O
study	O
and	O
the	O
presence	O
of	O
brain	O
,	O
lung	O
,	O
liver	O
,	O
adrenal	O
and	O
bone	O
metastases	O
.	O
Chemotherapy	O
with	O
adriamycin	B-FARMACO
was	O
started	O
.	O
Despite	O
chemotherapy	O
treatment	O
,	O
the	O
patient	O
had	O
an	O
unfavourable	O
evolution	O
and	O
died	O
three	O
months	O
after	O
the	O
initial	O
diagnosis	O
was	O
made	O
.	O
Diagnosis	O
Undifferentiated	O
pleomorphic	O
cardiac	O
sarcoma	O
with	O
early	O
recurrence	O
after	O
surgical	O
resection	O
.	O
Rapidly	O
progressive	O
multiple	O
metastatic	O
disease	O
.	O

Patient	O
referred	O
to	O
Cardiology	O
from	O
Neurology	O
for	O
assessment	O
.	O
History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
Family	O
history	O
Mother	O
with	O
plicate	O
tongue	O
without	O
facial	O
paralysis	O
.	O
Two	O
brothers	O
and	O
two	O
nephews	O
with	O
Steinert	O
's	O
syndrome	O
.	O
Two	O
healthy	O
children	O
.	O
Current	O
history	O
The	O
patient	O
presented	O
with	O
new	O
electrocardiogram	O
ECG	O
abnormalities	O
consisting	O
of	O
a	O
PR	O
of	O
280	O
milliseconds	O
msg	O
,	O
QRS	O
of	O
150	O
msg	O
,	O
with	O
an	O
image	O
of	O
complete	O
left	O
bundle	O
branch	O
block	O
LBBB	O
.	O
Electrocardiogram	O
two	O
years	O
earlier	O
with	O
no	O
conduction	O
disturbances	O
.	O
He	O
was	O
assessed	O
as	O
an	O
outpatient	O
in	O
the	O
Cardiology	O
Department	O
,	O
and	O
pacemaker	O
implantation	O
was	O
requested	O
.	O
The	O
patient	O
denied	O
syncope	O
,	O
presyncope	O
,	O
palpitations	O
or	O
other	O
symptoms	O
.	O
Complementary	O
tests	O
ECG	O
on	O
admission	O
Sinus	O
rhythm	O
at	O
75	O
bpm	O
.	O
PR	O
240	O
280	O
msg	O
.	O
QRS	O
of	O
150	O
msg	O
.	O
BCRI	O
.	O
ECG	O
in	O
Neurology	O
consultations	O
in	O
2010	O
Sinus	O
rhythm	O
at	O
70	O
bpm	O
.	O
PR	O
180	O
200	O
msg	O
.	O
QRS	O
of	O
80	O
msg	O
.	O
No	O
alterations	O
in	O
intraventricular	O
conduction	O
.	O
Blood	O
tests	O
Glucose	O
,	O
ions	O
and	O
renal	O
function	O
normal	O
.	O
No	O
anaemia	O
or	O
leukopenia	O
.	O
Plateletopenia	O
of	O
84	O
,	O
000	O
platelets	O
mm3	O
.	O
Transthoracic	O
echocardiography	O
Left	O
ventricle	O
not	O
dilated	O
or	O
hypertrophic	O
.	O
Left	O
atrium	O
not	O
dilated	O
.	O
Non	O
thickened	O
thin	O
leaflet	O
mitral	O
valve	O
with	O
jet	O
of	O
mild	O
central	O
insufficiency	O
.	O
Mitral	O
filling	O
pattern	O
with	O
E	O
A	O
wave	O
.	O
Trivalve	O
aortic	O
valve	O
with	O
adequate	O
opening	O
and	O
closing	O
.	O
Aortic	O
root	O
and	O
ascending	O
aorta	O
of	O
normal	O
size	O
.	O
Preserved	O
left	O
ventricular	O
ejection	O
fraction	O
without	O
segmental	O
contractility	O
defects	O
.	O
Right	O
chambers	O
normal	O
in	O
size	O
and	O
function	O
.	O
Mild	O
tricuspid	O
regurgitation	O
directed	O
medially	O
with	O
an	O
atrioventricular	O
gradient	O
of	O
17	O
mmHg	O
,	O
which	O
allows	O
estimating	O
a	O
pulmonary	O
artery	O
pressure	O
of	O
30	O
mmHg	O
.	O
Trivial	O
pulmonary	O
insufficiency	O
.	O
Non	O
collapsed	O
,	O
non	O
dilated	O
vena	O
cava	O
.	O
No	O
pericardial	O
effusion	O
.	O
Chest	O
X	O
ray	O
Cardiac	O
silhouette	O
at	O
the	O
limit	O
of	O
normality	O
without	O
alterations	O
at	O
the	O
pulmonary	O
parenchyma	O
level	O
.	O
No	O
pleural	O
effusion	O
.	O
Clinical	O
evolution	O
The	O
patient	O
was	O
admitted	O
on	O
a	O
scheduled	O
basis	O
for	O
pacemaker	O
implantation	O
due	O
to	O
the	O
appearance	O
in	O
the	O
ECG	O
of	O
conduction	O
disturbances	O
that	O
were	O
not	O
previously	O
present	O
and	O
were	O
not	O
associated	O
with	O
structural	O
heart	O
disease	O
.	O
Diagnosis	O
Steinert	O
's	O
disease	O
with	O
conduction	O
disturbances	O
requiring	O
definitive	O
pacing	O
.	O

A	O
63	O
year	O
old	O
woman	O
presented	O
with	O
a	O
clinical	O
picture	O
of	O
three	O
months	O
'	O
evolution	O
consisting	O
of	O
feverish	O
peaks	O
with	O
shivering	O
,	O
intense	O
asthenia	O
,	O
hyporexia	O
and	O
a	O
weight	O
loss	O
of	O
7	O
kg	O
.	O
She	O
had	O
previously	O
required	O
dental	O
manipulation	O
osseo	O
integrated	O
implants	O
.	O
History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
No	O
medical	O
history	O
of	O
interest	O
,	O
no	O
cardiovascular	O
risk	O
factors	O
,	O
no	O
toxic	O
habits	O
or	O
surgical	O
history	O
,	O
no	O
known	O
drug	O
allergies	O
.	O
Blood	O
tests	O
performed	O
by	O
the	O
primary	O
care	O
physician	O
showed	O
normocytic	O
anaemia	O
and	O
persistent	O
leucocyturia	O
and	O
haematuria	O
in	O
urine	O
,	O
so	O
treatment	O
was	O
started	O
with	O
ferrous	B-FARMACO
salts	I-FARMACO
and	O
two	O
10	O
day	O
cycles	O
of	O
treatment	O
with	O
ciprofloxacin	B-FARMACO
400	O
mg	O
12h	O
,	O
one	O
month	O
apart	O
,	O
achieving	O
improvement	O
in	O
general	O
condition	O
and	O
disappearance	O
of	O
fever	O
,	O
which	O
reappeared	O
7	O
days	O
after	O
the	O
end	O
of	O
the	O
last	O
cycle	O
of	O
treatment	O
.	O
He	O
suddenly	O
presented	O
with	O
motor	O
aphasia	O
,	O
left	O
facial	O
paralysis	O
and	O
loss	O
of	O
strength	O
in	O
the	O
left	O
upper	O
limb	O
;	O
the	O
neurological	O
symptoms	O
were	O
fluctuating	O
and	O
recurrent	O
,	O
with	O
residual	O
weakness	O
persisting	O
in	O
the	O
left	O
upper	O
limb	O
,	O
and	O
after	O
visiting	O
the	O
emergency	O
department	O
he	O
was	O
admitted	O
to	O
the	O
Neurology	O
Department	O
for	O
examination	O
.	O
Physical	O
examination	O
on	O
admission	O
BP	O
110	O
60	O
mmHg	O
,	O
HR	O
90	O
bpm	O
,	O
O2	O
sat	O
98	O
baseline	O
.	O
Conscious	O
,	O
oriented	O
,	O
reactive	O
,	O
perceptive	O
.	O
No	O
palpable	O
lymphadenopathies	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
tones	O
at	O
85	O
bpm	O
,	O
pansystolic	O
murmur	O
of	O
intensity	O
III	O
VI	O
at	O
mitral	O
focus	O
,	O
radiating	O
to	O
the	O
axilla	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
,	O
no	O
masses	O
or	O
megaliths	O
palpable	O
.	O
Lower	O
extremities	O
no	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
Neurological	O
examination	O
in	O
the	O
emergency	O
department	O
revealed	O
very	O
mild	O
motor	O
aphasia	O
,	O
left	O
central	O
facial	O
paralysis	O
and	O
paresis	O
of	O
the	O
left	O
upper	O
limb	O
with	O
strength	O
4	O
5	O
.	O
Complementary	O
tests	O
Blood	O
tests	O
Normal	O
renal	O
function	O
with	O
GRF	O
MDRD	O
4	O
79	O
.	O
27	O
ml	O
min	O
1	O
.	O
73	O
m2	O
,	O
normal	O
ions	O
.	O
ESR	O
up	O
to	O
62	O
mm	O
hour	O
.	O
Maximum	O
CRP	O
of	O
4	O
.	O
65	O
mg	O
dl	O
.	O
Maximum	O
procalcitonin	O
1	O
.	O
08	O
ng	O
ml	O
.	O
Normal	O
liver	O
function	O
FA	O
62U	O
l	O
,	O
GGT	O
41U	O
l	O
,	O
GOT	O
17	O
U	O
l	O
,	O
GPT	O
20U	O
l	O
,	O
LDH	O
222	O
U	O
l	O
.	O
Regarding	O
the	O
haemogram	O
Leukocytes	O
6600	O
l	O
with	O
64	O
neutrophils	O
.	O
Haemoglobin	O
10	O
.	O
1	O
g	O
dl	O
,	O
MCV	O
91	O
.	O
80	O
fL	O
,	O
CHM	O
34	O
pg	O
.	O
Platelets	O
13	O
,	O
600	O
0	O
mcl	O
.	O
ECG	O
Sinus	O
rhythm	O
at	O
90	O
bpm	O
,	O
normal	O
PR	O
,	O
normal	O
QRS	O
,	O
60o	O
axis	O
,	O
without	O
repolarisation	O
alterations	O
.	O
Chest	O
X	O
ray	O
cardiomediastinal	O
silhouette	O
without	O
alterations	O
,	O
without	O
pleuroparenchymal	O
findings	O
of	O
acute	O
evolution	O
.	O
CT	O
scan	O
of	O
the	O
brain	O
No	O
space	O
occupying	O
lesions	O
or	O
midline	O
displacements	O
were	O
observed	O
.	O
No	O
acute	O
ischaemic	O
or	O
haemorrhagic	O
lesions	O
.	O
Cisternal	O
and	O
ventricular	O
system	O
without	O
alterations	O
.	O
No	O
significant	O
radiological	O
findings	O
.	O
Thoracoabdominal	O
CT	O
scan	O
hepatosplenomegaly	O
,	O
uterine	O
myoma	O
.	O
Rest	O
of	O
the	O
examination	O
with	O
no	O
significant	O
findings	O
.	O
Transcranial	O
Doppler	O
and	O
echo	O
Doppler	O
of	O
supra	O
aortic	O
trunks	O
Normal	O
,	O
no	O
findings	O
.	O
Lumbar	O
puncture	O
Cerebrospinal	O
fluid	O
CSF	O
biochemistry	O
No	O
alterations	O
.	O
CSF	O
serology	O
Les	O
,	O
Borrelia	O
and	O
Brucella	O
negative	O
.	O
CSF	O
microbiology	O
CSF	O
Gram	O
no	O
microorganisms	O
were	O
observed	O
.	O
DNA	O
of	O
herpes	O
simplex	O
virus	O
and	O
varicella	O
zoster	O
by	O
PCR	O
negative	O
.	O
Serology	O
of	O
serum	O
plasma	O
No	O
findings	O
for	O
lupus	O
,	O
hepatitis	O
B	O
and	O
C	O
,	O
HIV	O
,	O
cytomegalovirus	O
,	O
varicella	O
zoster	O
,	O
Epstein	O
Barr	O
,	O
Borrelia	O
burgdorferi	O
.	O
Microbiology	O
.	O
Blood	O
cultures	O
Gram	O
positive	O
coccobacilli	O
in	O
chains	O
in	O
2	O
of	O
2	O
samples	O
sent	O
initially	O
with	O
final	O
isolation	O
of	O
Abiotrophia	O
defectiva	O
,	O
of	O
intermediate	O
sensitivity	O
to	O
penicillin	B-FARMACO
MIC	O
0	O
.	O
25	O
,	O
sensitive	O
to	O
the	O
rest	O
of	O
antibiotics	O
tested	O
.	O
Urine	O
culture	O
Negative	O
.	O
Transthoracic	O
and	O
transesophageal	O
echocardiography	O
Left	O
ventricle	O
not	O
dilated	O
,	O
hyperdynamic	O
,	O
LVEF	O
80	O
.	O
Left	O
atrium	O
not	O
dilated	O
.	O
Mitral	O
valve	O
Prolapse	O
of	O
the	O
P1	O
festoon	O
of	O
the	O
posterior	O
leaflet	O
.	O
Image	O
of	O
8x6	O
mm	O
in	O
the	O
cusp	O
of	O
festoon	O
A1	O
of	O
the	O
anterior	O
leaflet	O
,	O
with	O
anarchic	O
movement	O
,	O
echolucent	O
areas	O
inside	O
,	O
suggestive	O
of	O
endocardial	O
vegetation	O
.	O
Severe	O
mitral	O
insufficiency	O
towards	O
the	O
septum	O
and	O
anterior	O
wall	O
that	O
reverses	O
the	O
flow	O
in	O
pulmonary	O
veins	O
.	O
Restrictive	O
filling	O
pattern	O
with	O
elevated	O
end	O
diastolic	O
pressure	O
data	O
.	O
Normal	O
aortic	O
valve	O
and	O
flow	O
.	O
Aortic	O
root	O
of	O
normal	O
size	O
.	O
Normal	O
right	O
chambers	O
,	O
no	O
IT	O
detected	O
that	O
would	O
allow	O
estimation	O
of	O
PAP	O
.	O
No	O
pericardial	O
effusion	O
.	O
Clinical	O
evolution	O
Given	O
the	O
echocardiographic	O
findings	O
of	O
endocarditis	O
on	O
the	O
mitral	O
valve	O
with	O
prolapse	O
of	O
the	O
P1	O
festoon	O
of	O
the	O
posterior	O
leaflet	O
and	O
vegetation	O
on	O
the	O
cusp	O
of	O
the	O
A1	O
festoon	O
of	O
the	O
anterior	O
leaflet	O
with	O
severe	O
mitral	O
insufficiency	O
with	O
haemodynamic	O
repercussions	O
,	O
and	O
data	O
suggestive	O
of	O
acute	O
severe	O
valvular	O
regurgitation	O
absence	O
of	O
dilatation	O
of	O
left	O
chambers	O
with	O
a	O
picture	O
of	O
probable	O
peripheral	O
embolism	O
at	O
cerebral	O
level	O
with	O
normal	O
neurological	O
tests	O
,	O
it	O
was	O
decided	O
to	O
transfer	O
him	O
to	O
the	O
Coronary	O
Unit	O
for	O
initial	O
evolutionary	O
control	O
During	O
five	O
days	O
in	O
the	O
unit	O
,	O
the	O
patient	O
remained	O
haemodynamically	O
stable	O
,	O
without	O
requiring	O
vasoactive	O
drugs	O
,	O
remaining	O
normotensive	O
and	O
in	O
sinus	O
rhythm	O
at	O
90	O
100	O
bpm	O
.	O
Renal	O
function	O
was	O
preserved	O
,	O
with	O
good	O
diuretic	O
response	O
at	O
low	O
doses	O
and	O
no	O
clinical	O
or	O
radiological	O
signs	O
of	O
heart	O
failure	O
.	O
From	O
the	O
neurological	O
point	O
of	O
view	O
Glasgow	O
15	O
,	O
persistence	O
of	O
central	O
left	O
facial	O
paresis	O
and	O
with	O
improvement	O
of	O
strength	O
and	O
sensitivity	O
of	O
the	O
left	O
upper	O
extremity	O
until	O
normalisation	O
.	O
She	O
was	O
subsequently	O
transferred	O
to	O
the	O
cardiology	O
ward	O
for	O
follow	O
up	O
.	O
From	O
the	O
beginning	O
,	O
the	O
patient	O
was	O
followed	O
up	O
by	O
the	O
Infectious	O
Diseases	O
Unit	O
Initially	O
,	O
given	O
the	O
clinical	O
suspicion	O
of	O
endocarditis	O
of	O
three	O
months	O
'	O
evolution	O
and	O
the	O
findings	O
in	O
blood	O
cultures	O
of	O
gram	O
positive	O
coccobacilli	O
in	O
chains	O
suspected	O
streptococcus	O
,	O
empirical	O
antibiotherapy	O
was	O
started	O
with	O
ceftriaxone	B-FARMACO
2	O
g	O
iv	O
24	O
hours	O
associated	O
with	O
gentamicin	B-FARMACO
3	O
mg	O
kg	O
day	O
iv	O
24	O
hours	O
and	O
vancomycin	B-FARMACO
30	O
mg	O
kg	O
day	O
iv	O
in	O
2	O
doses	O
24h	O
,	O
achieving	O
rapid	O
disappearance	O
of	O
fever	O
.	O
Once	O
the	O
germ	O
was	O
identified	O
in	O
blood	O
cultures	O
as	O
abiotrophia	O
defectiva	O
,	O
after	O
10	O
days	O
of	O
empirical	O
treatment	O
,	O
it	O
was	O
decided	O
to	O
modify	O
antiobiotherapy	O
to	O
ampicillin	B-FARMACO
2g	O
4h	O
ceftriaxone	B-FARMACO
2	O
g	O
12h	O
,	O
which	O
had	O
to	O
be	O
suspended	O
after	O
an	O
urticarial	O
reaction	O
secondary	O
to	O
its	O
administration	O
.	O
The	O
new	O
antibiotic	O
regimen	O
consisted	O
of	O
vancomycin	B-FARMACO
gentamicin	I-FARMACO
,	O
with	O
negative	O
fever	O
and	O
blood	O
cultures	O
,	O
and	O
a	O
total	O
of	O
six	O
weeks	O
of	O
antibiotic	O
therapy	O
was	O
recommended	O
.	O
After	O
two	O
weeks	O
of	O
antibiotic	O
treatment	O
,	O
a	O
new	O
transesophageal	O
echocardiogram	O
was	O
performed	O
,	O
with	O
findings	O
similar	O
to	O
the	O
initial	O
one	O
persistence	O
of	O
severe	O
mitral	O
insufficiency	O
,	O
prolapse	O
of	O
the	O
P1	O
festoon	O
and	O
an	O
image	O
suggestive	O
of	O
endocarditis	O
over	O
the	O
A1	O
festoon	O
.	O
Four	O
weeks	O
after	O
the	O
start	O
of	O
antibiotic	O
therapy	O
,	O
scheduled	O
surgery	O
was	O
performed	O
to	O
replace	O
the	O
mitral	O
valve	O
with	O
a	O
St	O
Jude	O
No	O
29	O
mechanical	O
prosthesis	O
,	O
without	O
preservation	O
of	O
the	O
posterior	O
subvalvular	O
apparatus	O
.	O
The	O
entire	O
procedure	O
was	O
uneventful	O
.	O
Good	O
postoperative	O
evolution	O
in	O
the	O
ICU	O
and	O
on	O
the	O
Cardiac	O
Surgery	O
ward	O
without	O
arrhythmias	O
,	O
with	O
early	O
withdrawal	O
of	O
inotropes	O
and	O
mechanical	O
ventilation	O
,	O
normal	O
renal	O
function	O
and	O
absence	O
of	O
fever	O
.	O
In	O
agreement	O
with	O
the	O
Infectious	O
Diseases	O
Unit	O
,	O
it	O
was	O
decided	O
to	O
discontinue	O
antibiotic	O
treatment	O
6	O
weeks	O
after	O
its	O
initiation	O
,	O
after	O
confirming	O
negative	O
microbiology	O
in	O
the	O
heart	O
valve	O
sample	O
,	O
with	O
control	O
blood	O
cultures	O
after	O
48	O
hours	O
which	O
were	O
negative	O
and	O
subsequent	O
follow	O
up	O
in	O
the	O
Outpatient	O
Department	O
.	O
Prior	O
to	O
discharge	O
,	O
a	O
transthoracic	O
echocardiogram	O
was	O
performed	O
,	O
showing	O
normal	O
mitral	O
prosthetic	O
function	O
and	O
no	O
images	O
suggestive	O
of	O
endocarditis	O
.	O
Asymptomatic	O
and	O
stable	O
,	O
she	O
was	O
discharged	O
from	O
hospital	O
.	O
She	O
was	O
followed	O
up	O
in	O
outpatient	O
clinics	O
without	O
incident	O
.	O
Diagnosis	O
Infective	O
endocarditis	O
on	O
native	O
mitral	O
valve	O
with	O
valvular	O
prolapse	O
of	O
the	O
p1	O
leaflet	O
of	O
the	O
posterior	O
leaflet	O
and	O
endocardial	O
vegetation	O
in	O
the	O
a1	O
leaflet	O
of	O
the	O
anterior	O
leaflet	O
with	O
severe	O
mitral	O
insufficiency	O
with	O
haemodynamic	O
repercussions	O
.	O
Cerebrovascular	O
accident	O
of	O
probable	O
embolic	O
origin	O
.	O

A	O
62	O
year	O
old	O
woman	O
was	O
brought	O
in	O
by	O
the	O
UTE	O
for	O
two	O
episodes	O
of	O
epigastralgia	O
,	O
cold	O
sweats	O
and	O
dizziness	O
without	O
loss	O
of	O
consciousness	O
,	O
while	O
sitting	O
down	O
after	O
dinner	O
,	O
while	O
playing	O
Parcheesi	O
.	O
History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
History	O
No	O
CVRF	O
.	O
No	O
cardiological	O
history	O
.	O
Diverticulitis	O
Medical	O
treatment	O
until	O
3	O
days	O
ago	O
.	O
No	O
history	O
of	O
syncope	O
.	O
No	O
other	O
history	O
of	O
interest	O
.	O
No	O
usual	O
treatment	O
.	O
Current	O
illness	O
On	O
arrival	O
at	O
the	O
Emergency	O
Transfer	O
Unit	O
,	O
while	O
a	O
venous	O
line	O
was	O
being	O
cannulated	O
,	O
she	O
had	O
a	O
new	O
episode	O
of	O
dizziness	O
with	O
no	O
ECG	O
recording	O
.	O
During	O
the	O
transfer	O
,	O
while	O
in	O
decubitus	O
position	O
,	O
with	O
no	O
apparent	O
trigger	O
,	O
she	O
had	O
another	O
episode	O
of	O
dizziness	O
with	O
similar	O
characteristics	O
and	O
the	O
monitor	O
showed	O
an	O
asystole	O
of	O
25	O
seconds	O
,	O
without	O
loss	O
of	O
consciousness	O
according	O
to	O
the	O
patient	O
and	O
the	O
ambulance	O
doctor	O
.	O
She	O
arrived	O
at	O
the	O
Emergency	O
Department	O
,	O
the	O
Coronary	O
Unit	O
was	O
notified	O
and	O
it	O
was	O
decided	O
to	O
admit	O
her	O
and	O
implant	O
a	O
temporary	O
pacemaker	O
,	O
which	O
was	O
left	O
deactivated	O
.	O
Physical	O
examination	O
BP	O
120	O
70	O
HR	O
80	O
sat	O
o2	O
96	O
.	O
Conscious	O
,	O
oriented	O
,	O
hydrated	O
,	O
nourished	O
,	O
normal	O
colour	O
,	O
eupneic	O
,	O
afebrile	O
.	O
Head	O
and	O
neck	O
No	O
jugular	O
ingurgitation	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
good	O
general	O
ventilation	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
non	O
painful	O
,	O
Blumberg	O
and	O
Murphy	O
negative	O
.	O
Complementary	O
tests	O
CBC	O
Glucose	O
132	O
mg	O
dl	O
;	O
creatinine	O
0	O
.	O
6	O
mg	O
dl	O
;	O
urea	O
29	O
mg	O
dl	O
;	O
Na	O
141	O
mEq	O
l	O
;	O
K	O
4	O
.	O
4	O
mEq	O
l	O
;	O
Hb	O
13	O
.	O
1	O
g	O
dl	O
;	O
coagulation	O
within	O
normal	O
limits	O
,	O
troponin	O
8	O
.	O
09	O
ngr	O
l	O
;	O
Ck	O
69	O
u	O
l	O
.	O
Chest	O
X	O
ray	O
No	O
increase	O
in	O
cardiac	O
silhouette	O
,	O
normal	O
lung	O
fields	O
.	O
Baseline	O
ECG	O
RS	O
at	O
80	O
bpm	O
,	O
axis	O
at	O
0o	O
,	O
no	O
conduction	O
disturbances	O
or	O
repolarisation	O
.	O
Ambulance	O
ECG	O
Asystole	O
25	O
seconds	O
.	O
Clinical	O
evolution	O
During	O
the	O
night	O
there	O
were	O
no	O
new	O
episodes	O
of	O
asystole	O
,	O
presyncope	O
or	O
syncope	O
.	O
The	O
following	O
morning	O
,	O
while	O
the	O
introducer	O
was	O
being	O
cleaned	O
,	O
the	O
nurse	O
said	O
to	O
the	O
patient	O
,	O
"	O
look	O
,	O
here	O
is	O
the	O
introducer	O
"	O
,	O
at	O
which	O
point	O
the	O
patient	O
said	O
"	O
oh	O
,	O
don	O
'	O
t	O
tell	O
me	O
that	O
"	O
,	O
she	O
lost	O
consciousness	O
and	O
the	O
monitor	O
showed	O
asystole	O
of	O
15	O
seconds	O
,	O
and	O
the	O
pacemaker	O
was	O
manually	O
activated	O
at	O
that	O
moment	O
.	O
After	O
questioning	O
the	O
patient	O
,	O
she	O
reported	O
that	O
she	O
had	O
always	O
felt	O
dizzy	O
when	O
pricked	O
with	O
a	O
needle	O
.	O
It	O
was	O
decided	O
to	O
implant	O
a	O
permanent	O
pacemaker	O
in	O
the	O
patient	O
,	O
she	O
was	O
discharged	O
to	O
the	O
ward	O
,	O
and	O
the	O
following	O
day	O
when	O
she	O
went	O
for	O
a	O
control	O
chest	O
X	O
ray	O
in	O
a	O
wheelchair	O
,	O
the	O
patient	O
presented	O
a	O
new	O
episode	O
of	O
intense	O
dizziness	O
,	O
and	O
it	O
was	O
found	O
that	O
the	O
pacemaker	O
electrode	O
was	O
correctly	O
positioned	O
and	O
no	O
failures	O
were	O
detected	O
in	O
the	O
ECG	O
with	O
magnet	O
.	O
She	O
was	O
discharged	O
.	O

A	O
64	O
year	O
old	O
man	O
consulted	O
the	O
emergency	O
department	O
for	O
three	O
days	O
of	O
clinical	O
symptoms	O
of	O
fever	O
up	O
to	O
40oC	O
associated	O
with	O
polymyalgia	O
,	O
osteoarthralgia	O
,	O
cervical	O
pain	O
and	O
headache	O
.	O
History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
Reason	O
for	O
consultation	O
Fever	O
Personal	O
history	O
Hypertension	O
,	O
nephritic	O
colic	O
,	O
hiatus	O
hernia	O
.	O
On	O
regular	O
treatment	O
with	O
ARA	O
II	O
.	O
Present	O
illness	O
64	O
year	O
old	O
man	O
who	O
consulted	O
the	O
emergency	O
department	O
for	O
three	O
days	O
of	O
clinical	O
symptoms	O
of	O
fever	O
up	O
to	O
40oC	O
associated	O
with	O
polymyalgia	O
,	O
osteoarthralgia	O
,	O
cervical	O
pain	O
and	O
headache	O
.	O
Physical	O
examination	O
Conscious	O
,	O
alert	O
and	O
oriented	O
.	O
BP	O
79	O
54	O
mmHg	O
HR	O
120	O
bpm	O
.	O
Poor	O
distal	O
perfusion	O
with	O
coldness	O
in	O
extremities	O
.	O
AC	O
Tachycardic	O
heart	O
sounds	O
,	O
frequent	O
extrasystoles	O
,	O
no	O
murmurs	O
.	O
AP	O
Pulmonary	O
sounds	O
without	O
aggregates	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
no	O
masses	O
or	O
megaliths	O
.	O
No	O
peritoneal	O
irritation	O
.	O
Osteomuscular	O
Arthralgias	O
in	O
all	O
limb	O
joints	O
with	O
no	O
evidence	O
of	O
inflammation	O
or	O
embolic	O
phenomena	O
.	O
No	O
meningeal	O
signs	O
.	O
The	O
rest	O
of	O
the	O
physical	O
examination	O
was	O
unremarkable	O
.	O
Complementary	O
tests	O
Emergency	O
laboratory	O
tests	O
leucocytes	O
9100	O
,	O
neutrophils	O
88	O
,	O
platelets	O
20	O
,	O
000	O
,	O
creatinine	O
4	O
.	O
8	O
mg	O
dL	O
,	O
urea	O
1	O
.	O
33	O
g	O
L	O
,	O
lactic	O
acidosis	O
.	O
Urinalysis	O
Bacteriuria	O
and	O
leucocytes	O
.	O
Blood	O
cultures	O
.	O
Chest	O
X	O
ray	O
Normal	O
.	O
Abdominal	O
ultrasound	O
Normal	O
.	O
CT	O
scan	O
of	O
the	O
brain	O
Normal	O
.	O
Clinical	O
evolution	O
During	O
his	O
stay	O
in	O
the	O
Emergency	O
Department	O
,	O
he	O
evolved	O
with	O
a	O
tendency	O
to	O
hypotension	O
and	O
oligoanuria	O
which	O
did	O
not	O
recover	O
with	O
vascular	O
filling	O
;	O
with	O
the	O
initial	O
diagnosis	O
of	O
septic	O
shock	O
,	O
treatment	O
was	O
started	O
with	O
ceftriaxone	B-FARMACO
,	O
vancomycin	B-FARMACO
,	O
ampicillin	B-FARMACO
and	O
he	O
was	O
admitted	O
to	O
the	O
Intensive	O
Care	O
Unit	O
where	O
inotropic	O
support	O
was	O
started	O
.	O
A	O
transthoracic	O
echocardiogram	O
was	O
performed	O
which	O
only	O
showed	O
thickening	O
of	O
the	O
posterior	O
leaflet	O
of	O
the	O
mitral	O
valve	O
without	O
clear	O
images	O
of	O
vegetations	O
.	O
The	O
patient	O
evolved	O
in	O
a	O
torpid	O
manner	O
,	O
hypotension	O
,	O
acute	O
pulmonary	O
oedema	O
requiring	O
invasive	O
mechanical	O
ventilation	O
.	O
A	O
few	O
hours	O
after	O
admission	O
,	O
and	O
on	O
suspicion	O
of	O
infective	O
endocarditis	O
,	O
a	O
transesophageal	O
echocardiogram	O
was	O
completed	O
,	O
showing	O
severe	O
mitral	O
insufficiency	O
with	O
a	O
large	O
vegetative	O
image	O
on	O
the	O
posterior	O
leaflet	O
of	O
up	O
to	O
44	O
mm	O
in	O
length	O
and	O
7	O
9	O
mm	O
in	O
base	O
on	O
the	O
atrial	O
side	O
,	O
indicating	O
severe	O
mitral	O
insufficiency	O
suggestive	O
of	O
acute	O
evolution	O
.	O
At	O
this	O
time	O
,	O
blood	O
cultures	O
showed	O
growth	O
of	O
Staphylococcus	O
aureus	O
sensitive	O
to	O
ampicillin	B-FARMACO
and	O
vancomycin	B-FARMACO
.	O
The	O
patient	O
was	O
transferred	O
to	O
the	O
cardiac	O
surgery	O
referral	O
centre	O
.	O
During	O
surgery	O
,	O
a	O
mitral	O
valve	O
with	O
severe	O
endocardial	O
involvement	O
was	O
observed	O
in	O
the	O
mural	O
leaflet	O
that	O
also	O
affected	O
the	O
left	O
ventricular	O
wall	O
,	O
annulus	O
and	O
wall	O
of	O
the	O
right	O
atrium	O
,	O
forming	O
an	O
abscess	O
in	O
the	O
wall	O
and	O
in	O
the	O
atrioventricular	O
groove	O
.	O
The	O
wart	O
and	O
the	O
valve	O
were	O
resected	O
and	O
replaced	O
with	O
a	O
mechanical	O
prosthesis	O
.	O
The	O
patient	O
evolves	O
in	O
a	O
torpid	O
manner	O
requiring	O
inotropic	O
support	O
,	O
IABP	O
or	O
,	O
without	O
achieving	O
haemodynamic	O
stability	O
.	O
Refractory	O
shock	O
and	O
death	O
three	O
days	O
after	O
IQx	O
.	O
Diagnosis	O
Acute	O
mitral	O
endocarditis	O
due	O
to	O
Staphylococcus	O
aureus	O
Mixed	O
shock	O
multi	O
organ	O
dysfunction	O

70	O
year	O
old	O
male	O
,	O
with	O
no	O
cardiovascular	O
risk	O
factors	O
or	O
relevant	O
medical	O
history	O
.	O
He	O
leads	O
an	O
active	O
life	O
.	O
He	O
presented	O
with	O
an	O
episode	O
of	O
dyspnoea	O
on	O
exertion	O
lasting	O
two	O
days	O
,	O
denying	O
chest	O
pain	O
and	O
palpitations	O
.	O
History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
Physical	O
examination	O
revealed	O
low	O
set	O
ears	O
,	O
broad	O
nasal	O
bridge	O
and	O
neck	O
,	O
low	O
hairline	O
,	O
pectus	O
carinatum	O
excavatum	O
and	O
scoliosis	O
.	O
No	O
jugular	O
ingurgitation	O
.	O
Multifocal	O
III	O
VI	O
systolic	O
murmur	O
,	O
of	O
greater	O
intensity	O
in	O
the	O
sternal	O
notch	O
,	O
without	O
irradiation	O
.	O
Pulmonary	O
auscultation	O
was	O
normal	O
.	O
Peripheral	O
pulses	O
were	O
symmetrical	O
.	O
There	O
was	O
no	O
oedema	O
.	O
Complementary	O
tests	O
Electrocardiogram	O
Atrial	O
fibrillation	O
with	O
rapid	O
ventricular	O
response	O
and	O
signs	O
of	O
right	O
ventricular	O
hypertrophy	O
.	O
Echocardiogram	O
Despite	O
a	O
poor	O
window	O
,	O
a	O
very	O
hypertrophic	O
right	O
ventricle	O
was	O
seen	O
,	O
with	O
thickening	O
of	O
the	O
tricuspid	O
valve	O
.	O
Transesophageal	O
echocardiogram	O
This	O
was	O
performed	O
and	O
showed	O
dilatation	O
of	O
the	O
pulmonary	O
artery	O
,	O
with	O
no	O
further	O
data	O
with	O
respect	O
to	O
the	O
transthoracic	O
echocardiogram	O
.	O
CT	O
scan	O
Given	O
the	O
suspicion	O
of	O
pulmonary	O
hypertension	O
,	O
a	O
CT	O
scan	O
was	O
performed	O
to	O
rule	O
out	O
secondary	O
causes	O
,	O
the	O
most	O
relevant	O
finding	O
being	O
an	O
aneurysmal	O
dilatation	O
of	O
the	O
main	O
pulmonary	O
artery	O
4	O
.	O
3	O
cm	O
and	O
left	O
pulmonary	O
artery	O
3	O
.	O
8	O
cm	O
.	O
Cardiac	O
MRI	O
Thickening	O
of	O
the	O
pulmonary	O
valve	O
was	O
observed	O
,	O
with	O
accelerated	O
flow	O
,	O
suggestive	O
of	O
severe	O
pulmonary	O
stenosis	O
.	O
Catheterisation	O
Right	O
catheterisation	O
was	O
performed	O
and	O
ventriculography	O
confirmed	O
pulmonary	O
valve	O
stenosis	O
and	O
another	O
infundibular	O
stenosis	O
,	O
with	O
a	O
gradient	O
between	O
the	O
pulmonary	O
artery	O
and	O
the	O
right	O
ventricle	O
of	O
70	O
mmHg	O
and	O
42	O
with	O
spectral	O
Doppler	O
and	O
DTI	O
in	O
the	O
bordeline	O
range	O
in	O
the	O
1st	O
and	O
normal	O
in	O
the	O
2nd	O
.	O
Minimal	O
IT	O
with	O
gradient	O
of	O
22	O
mmHg	O
and	O
PAPs	O
of	O
30	O
mmHg	O
.	O
LV	O
45	O
mm	O
with	O
very	O
discrete	O
inferobasal	O
hypokinesia	O
and	O
overall	O
preserved	O
EF	O
50	O
55	O
.	O
Clinical	O
evolution	O
Percutaneous	O
dilatation	O
of	O
the	O
pulmonary	O
valve	O
was	O
performed	O
,	O
reducing	O
the	O
transvalvular	O
gradient	O
to	O
30	O
mmHg	O
,	O
leaving	O
moderate	O
pulmonary	O
insufficiency	O
;	O
the	O
subvalvular	O
gradient	O
was	O
60	O
mmHg	O
,	O
so	O
he	O
is	O
receiving	O
high	O
doses	O
of	O
metoprolol	B-FARMACO
250	O
mg	O
c	O
12	O
hours	O
,	O
with	O
good	O
tolerance	O
,	O
maintaining	O
heart	O
rate	O
around	O
65	O
70	O
beats	O
per	O
minute	O
.	O
Diagnosis	O
Noonan	O
syndrome	O
.	O

76	O
year	O
old	O
woman	O
reviewed	O
for	O
bronchial	O
asthma	O
.	O
No	O
drug	O
allergies	O
.	O
Dyslipidaemia	O
.	O
No	O
other	O
known	O
cardiovascular	O
risk	O
factors	O
.	O
Bronchial	O
asthma	O
.	O
Affective	O
disorder	O
.	O
On	O
treatment	O
with	O
lorazepam	B-FARMACO
1	O
mg	O
24h	O
,	O
simvastatin	B-FARMACO
10	O
mg	O
24h	O
,	O
montelukast	B-FARMACO
10	O
mg	O
24h	O
and	O
salmeterol	B-FARMACO
fluticasone	I-FARMACO
25	O
250	O
mcg	O
12h	O
.	O
History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
The	O
patient	O
was	O
referred	O
to	O
the	O
Cardiology	O
Department	O
from	O
the	O
Pneumology	O
Department	O
,	O
where	O
she	O
was	O
being	O
seen	O
for	O
bronchial	O
asthma	O
,	O
when	O
a	O
CT	O
scan	O
of	O
the	O
chest	O
showed	O
a	O
malposition	O
of	O
the	O
great	O
arteries	O
as	O
a	O
chance	O
finding	O
,	O
for	O
diagnosis	O
of	O
possible	O
heart	O
disease	O
.	O
She	O
presented	O
with	O
wheezing	O
and	O
increased	O
secretions	O
related	O
to	O
influenza	O
vaccination	O
.	O
She	O
denied	O
cardiac	O
symptoms	O
such	O
as	O
exertional	O
dyspnoea	O
,	O
angina	O
,	O
palpitations	O
or	O
syncope	O
.	O
Physical	O
examination	O
Conscious	O
,	O
oriented	O
,	O
cooperative	O
.	O
Good	O
general	O
condition	O
.	O
Well	O
hydrated	O
and	O
perfused	O
.	O
Eupneic	O
at	O
rest	O
.	O
No	O
jugular	O
ingurgitation	O
.	O
Rhythmic	O
auscultation	O
without	O
murmurs	O
.	O
Disseminated	O
wheezing	O
.	O
Symmetrical	O
peripheral	O
pulses	O
present	O
.	O
No	O
oedema	O
.	O
Complementary	O
tests	O
ECG	O
Sinus	O
rhythm	O
at	O
63	O
bpm	O
.	O
Normal	O
PR	O
.	O
Left	O
axis	O
.	O
Intraventricular	O
conduction	O
disorder	O
.	O
Anomalous	O
progression	O
of	O
R	O
in	O
right	O
precordial	O
leads	O
.	O
Chest	O
X	O
ray	O
normal	O
cardiothoracic	O
index	O
.	O
Slight	O
aortic	O
elongation	O
.	O
Enlarged	O
pulmonary	O
hilum	O
.	O
CT	O
scan	O
anomalous	O
arrangement	O
of	O
great	O
vessels	O
,	O
with	O
pulmonary	O
artery	O
medial	O
to	O
the	O
aorta	O
aortic	O
overlap	O
or	O
corrected	O
transposition	O
?	O
.	O
Pulmonary	O
cone	O
slightly	O
increased	O
in	O
size	O
radiological	O
pulmonary	O
hypertension	O
.	O
Mosaic	O
pattern	O
of	O
pulmonary	O
parenchyma	O
of	O
vascular	O
cause	O
.	O
Echocardiography	O
Situs	O
solitus	O
.	O
Ventricular	O
inversion	O
.	O
Atrioventricular	O
and	O
ventriculoarterial	O
discordance	O
.	O
Left	O
ventricle	O
of	O
normal	O
size	O
and	O
contractility	O
.	O
Left	O
atrium	O
of	O
normal	O
size	O
.	O
Right	O
chambers	O
of	O
normal	O
size	O
and	O
function	O
.	O
Right	O
AV	O
valve	O
without	O
alterations	O
.	O
Left	O
AV	O
valve	O
with	O
moderate	O
insufficiency	O
.	O
Cardiac	O
MRI	O
Situs	O
solitus	O
.	O
Ventriculoarterial	O
discordance	O
.	O
Aorta	O
seating	O
in	O
the	O
right	O
ventricle	O
and	O
pulmonary	O
in	O
the	O
left	O
ventricle	O
.	O
Atrioventricular	O
discordance	O
.	O
Anterior	O
and	O
left	O
aorta	O
in	O
relation	O
to	O
the	O
pulmonary	O
aorta	O
.	O
Ventricular	O
inversion	O
.	O
Systemic	O
ventricle	O
with	O
increased	O
volumes	O
and	O
function	O
at	O
the	O
limit	O
of	O
normality	O
.	O
Subpulmonary	O
ventricle	O
with	O
reduced	O
volume	O
and	O
normal	O
contractility	O
.	O
Aortic	O
valve	O
with	O
mild	O
regurgitation	O
.	O
Systemic	O
AV	O
valve	O
with	O
dilatation	O
of	O
the	O
annulus	O
,	O
good	O
opening	O
and	O
two	O
jets	O
of	O
moderate	O
central	O
regurgitation	O
.	O
Pulmonary	O
valve	O
without	O
alterations	O
.	O
Severely	O
dilated	O
trunk	O
and	O
main	O
pulmonary	O
branches	O
justified	O
by	O
pulmonary	O
hypertension	O
Clinical	O
evolution	O
The	O
patient	O
was	O
assessed	O
at	O
the	O
Cardiology	O
Department	O
,	O
where	O
an	O
ECG	O
and	O
echocardiography	O
were	O
performed	O
and	O
a	O
cardiac	O
MRI	O
was	O
requested	O
to	O
confirm	O
the	O
diagnosis	O
of	O
congenitally	O
corrected	O
transposition	O
of	O
the	O
great	O
arteries	O
;	O
in	O
addition	O
,	O
moderate	O
systemic	O
AV	O
valve	O
insufficiency	O
with	O
pulmonary	O
hypertension	O
was	O
detected	O
.	O
He	O
started	O
treatment	O
with	O
furosemide	B-FARMACO
40	O
mg	O
24h	O
and	O
remained	O
in	O
good	O
functional	O
grade	O
I	O
IV	O
NYHA	O
at	O
successive	O
check	O
ups	O
.	O
He	O
continues	O
to	O
be	O
reviewed	O
by	O
pulmonology	O
and	O
cardiology	O
without	O
the	O
appearance	O
of	O
rhythm	O
disorders	O
or	O
worsening	O
of	O
the	O
severity	O
of	O
the	O
valvulopathies	O
or	O
the	O
appearance	O
of	O
ventricular	O
dysfunction	O
by	O
echocardiography	O
.	O
No	O
other	O
therapeutic	O
measures	O
are	O
currently	O
being	O
considered	O
.	O
Diagnosis	O
Transposition	O
of	O
the	O
great	O
arteries	O
,	O
congenitally	O
corrected	O
Moderate	O
systemic	O
AV	O
valve	O
insufficiency	O
Pulmonary	O
hypertension	O
Bronchial	O
asthma	O

A	O
20	O
year	O
old	O
man	O
with	O
chest	O
pain	O
presented	O
to	O
the	O
Emergency	O
Department	O
with	O
a	O
clinical	O
picture	O
of	O
epigastric	O
pain	O
of	O
approximately	O
three	O
hours	O
'	O
duration	O
that	O
started	O
after	O
eating	O
,	O
accompanied	O
by	O
vomiting	O
,	O
sweating	O
and	O
palpitations	O
.	O
He	O
reported	O
no	O
other	O
symptoms	O
.	O
History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
The	O
patient	O
denied	O
any	O
previous	O
infectious	O
symptoms	O
or	O
other	O
episodes	O
similar	O
to	O
the	O
present	O
one	O
.	O
At	O
the	O
time	O
of	O
assessment	O
by	O
Cardiology	O
the	O
patient	O
is	O
asymptomatic	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
Smoker	O
of	O
10	O
cigarettes	O
day	O
.	O
No	O
toxic	O
habits	O
or	O
other	O
personal	O
history	O
of	O
interest	O
.	O
Family	O
history	O
not	O
referred	O
during	O
the	O
first	O
assessment	O
Maternal	O
grandfather	O
with	O
a	O
history	O
of	O
pulmonary	O
thromboembolism	O
in	O
relation	O
to	O
orthopaedic	O
surgery	O
and	O
diagnosis	O
of	O
protein	O
C	O
deficiency	O
and	O
antiphospholipid	O
syndrome	O
and	O
mother	O
with	O
a	O
history	O
of	O
deep	O
vein	O
thrombosis	O
with	O
positive	O
thrombophilia	O
study	O
for	O
protein	O
C	O
deficiency	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
150	O
90	O
mmHg	O
.	O
Heart	O
rate	O
93	O
bpm	O
,	O
Ta	O
36	O
oC	O
.	O
Conscious	O
,	O
oriented	O
and	O
cooperative	O
.	O
Normal	O
hydration	O
,	O
normal	O
colour	O
and	O
normal	O
depth	O
.	O
Facial	O
flushing	O
.	O
Head	O
and	O
neck	O
No	O
jugular	O
venous	O
engorgement	O
.	O
Carotids	O
rhythmic	O
and	O
symmetrical	O
with	O
no	O
murmurs	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
tachycardic	O
,	O
no	O
murmurs	O
or	O
superimposed	O
sounds	O
.	O
Pulmonary	O
auscultation	O
Bladder	O
murmur	O
preserved	O
.	O
Lower	O
extremities	O
Pulses	O
present	O
and	O
symmetrical	O
,	O
no	O
oedema	O
.	O
Complementary	O
tests	O
CBC	O
Leukocytes	O
16300	O
mm3	O
87	O
.	O
8	O
neutrophils	O
.	O
Platelets	O
245	O
,	O
000	O
mm3	O
.	O
Haemoglobin	O
16	O
.	O
6	O
g	O
dl	O
.	O
Coagulation	O
normal	O
.	O
Triglycerides	O
113	O
mg	O
dl	O
.	O
Total	O
cholesterol	O
254	O
mg	O
dl	O
LDL	O
195	O
,	O
HDL	O
36	O
.	O
Peak	O
myocardial	O
necrosis	O
markers	O
CPK	O
total	O
1907	O
U	O
L	O
,	O
CPK	O
MB	O
114	O
U	O
L	O
,	O
TnI	O
39	O
.	O
02	O
ng	O
ml	O
.	O
Chest	O
X	O
ray	O
No	O
evidence	O
of	O
acute	O
pleuropulmonary	O
pathology	O
.	O
Electrocardiogram	O
in	O
the	O
emergency	O
department	O
.	O
Electrocardiogram	O
at	O
discharge	O
.	O
Echocardiogram	O
in	O
the	O
emergency	O
department	O
left	O
ventricle	O
of	O
normal	O
dimensions	O
Left	O
ventricular	O
ejection	O
fraction	O
preserved	O
by	O
Simpson	O
biplane	O
technique	O
.	O
However	O
,	O
the	O
visual	O
impression	O
is	O
of	O
generalised	O
hypokinesia	O
,	O
more	O
marked	O
in	O
the	O
apical	O
region	O
,	O
determining	O
a	O
slight	O
depression	O
of	O
the	O
ejection	O
fraction	O
.	O
No	O
significant	O
valvular	O
heart	O
disease	O
.	O
No	O
evidence	O
of	O
pulmonary	O
arterial	O
hypertension	O
.	O
No	O
pericardial	O
effusion	O
.	O
The	O
aortic	O
arch	O
and	O
descending	O
thoracic	O
aorta	O
are	O
not	O
correctly	O
visualised	O
.	O
Coronary	O
angiography	O
.	O
Stenosis	O
of	O
70	O
of	O
AMD	O
at	O
the	O
expense	O
of	O
thrombus	O
at	O
that	O
level	O
.	O
IVUS	O
was	O
performed	O
which	O
confirmed	O
a	O
large	O
amount	O
of	O
thrombus	O
.	O
Thromboaspiration	O
with	O
Hunter	O
device	O
was	O
successful	O
,	O
leaving	O
the	O
artery	O
with	O
TIMI	O
III	O
flow	O
and	O
no	O
residual	O
stenosis	O
.	O
Coagulation	O
study	O
Prothrombin	O
time	O
12	O
.	O
9	O
sec	O
.	O
PT	O
ratio	O
1	O
.	O
14	O
.	O
Activated	O
partial	O
thromboplastin	O
time	O
35	O
.	O
1	O
sec	O
normal	O
up	O
to	O
37	O
sec	O
.	O
Fibrinogen	O
523	O
mg	O
dl	O
.	O
Lupus	O
anticoagulant	O
negative	O
.	O
Antithrombin	O
III	O
89	O
normal	O
80	O
120	O
.	O
Factor	O
VIII	O
111	O
normal	O
80	O
200	O
.	O
Protein	O
C	O
activity	O
55	O
normal	O
80	O
140	O
.	O
Free	O
protein	O
S	O
81	O
normal	O
60	O
140	O
.	O
Prothrombin	O
gene	O
mutation	O
not	O
detected	O
.	O
Homocysteine	O
10	O
.	O
4	O
mcmol	O
L	O
normal	O
up	O
to	O
15	O
mcmol	O
L	O
.	O
IgG	O
anticardiolipin	O
4	O
.	O
2	O
U	O
mL	O
normal	O
0	O
10	O
U	O
mL	O
.	O
IgM	O
anticardiolipin	O
3	O
.	O
1	O
U	O
mL	O
normal	O
0	O
7	O
U	O
mL	O
.	O
Clinical	O
course	O
Asymptomatic	O
for	O
chest	O
pain	O
on	O
arrival	O
at	O
the	O
Emergency	O
Department	O
,	O
given	O
the	O
evolution	O
of	O
the	O
ECG	O
and	O
the	O
alterations	O
in	O
the	O
echocardiogram	O
,	O
coronary	O
angiography	O
was	O
requested	O
,	O
with	O
the	O
aforementioned	O
results	O
in	O
complementary	O
tests	O
.	O
During	O
his	O
hospital	O
stay	O
,	O
the	O
patient	O
remained	O
asymptomatic	O
and	O
stable	O
at	O
all	O
times	O
.	O
A	O
coagulation	O
study	O
was	O
carried	O
out	O
which	O
confirmed	O
the	O
existence	O
of	O
protein	O
C	O
deficiency	O
,	O
so	O
on	O
discharge	O
oral	O
anticoagulation	O
with	O
acenocoumarol	B-FARMACO
was	O
started	O
in	O
addition	O
to	O
the	O
medical	O
treatment	O
indicated	O
as	O
secondary	O
prevention	O
of	O
ischaemic	O
heart	O
disease	O
.	O
Six	O
months	O
after	O
discharge	O
from	O
the	O
outpatient	O
cardiology	O
department	O
,	O
the	O
patient	O
was	O
asymptomatic	O
and	O
adhered	O
well	O
to	O
medical	O
treatment	O
.	O
Given	O
the	O
incidental	O
finding	O
of	O
pre	O
excitation	O
in	O
the	O
baseline	O
electrocardiogram	O
during	O
his	O
hospital	O
stay	O
,	O
conventional	O
ergometry	O
was	O
performed	O
which	O
showed	O
its	O
almost	O
complete	O
disappearance	O
during	O
exercise	O
,	O
which	O
,	O
added	O
to	O
his	O
asymptomatic	O
status	O
in	O
this	O
respect	O
,	O
indicated	O
clinical	O
follow	O
up	O
without	O
the	O
introduction	O
of	O
other	O
measures	O
.	O
Diagnosis	O
Ischaemic	O
heart	O
disease	O
Iamest	O
anterior	O
Killip	O
I	O
.	O
Middle	O
aged	O
mid	O
segment	O
thrombosis	O
in	O
the	O
context	O
of	O
protein	O
C	O
deficiency	O
.	O
Wolff	O
Parkinson	O
White	O
electrocardiographic	O
pattern	O
.	O

Male	O
patient	O
aged	O
16	O
years	O
,	O
youth	O
footballer	O
.	O
He	O
was	O
involved	O
in	O
competitive	O
sports	O
,	O
with	O
a	O
personal	O
history	O
of	O
chickenpox	O
,	O
no	O
known	O
allergies	O
or	O
history	O
of	O
surgery	O
.	O
He	O
was	O
in	O
good	O
health	O
and	O
did	O
not	O
regularly	O
take	O
drugs	O
or	O
have	O
toxic	O
habits	O
.	O
History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
Clinical	O
picture	O
characterised	O
by	O
oppressive	O
central	O
thoracic	O
pain	O
,	O
sometimes	O
referred	O
to	O
as	O
stabbing	O
,	O
non	O
radiating	O
,	O
which	O
appeared	O
at	O
rest	O
and	O
did	O
not	O
change	O
with	O
exertion	O
and	O
lasted	O
one	O
hour	O
.	O
The	O
pain	O
increased	O
with	O
inspiration	O
and	O
when	O
sitting	O
down	O
.	O
He	O
denied	O
vegetative	O
cortex	O
,	O
dyspnoea	O
,	O
palpitations	O
or	O
syncope	O
.	O
He	O
was	O
referred	O
by	O
his	O
primary	O
care	O
physician	O
to	O
the	O
emergency	O
department	O
of	O
our	O
hospital	O
,	O
where	O
he	O
arrived	O
asymptomatic	O
.	O
On	O
taking	O
the	O
medical	O
history	O
,	O
he	O
reported	O
that	O
two	O
days	O
ago	O
he	O
presented	O
with	O
a	O
self	O
limited	O
episode	O
of	O
diffuse	O
abdominal	O
pain	O
and	O
vomiting	O
of	O
food	O
,	O
in	O
the	O
context	O
of	O
nine	O
days	O
of	O
diarrhoeic	O
stools	O
,	O
without	O
pathological	O
products	O
,	O
and	O
afebrile	O
at	O
all	O
times	O
.	O
Physical	O
examination	O
BP	O
120	O
60	O
mmHg	O
HR	O
80x	O
"	O
FR	O
18x	O
"	O
.	O
Alert	O
,	O
conscious	O
,	O
oriented	O
,	O
hydrated	O
and	O
afebrile	O
.	O
Head	O
and	O
neck	O
Oropharyngeal	O
No	O
pathological	O
findings	O
.	O
No	O
jugular	O
ingurgitation	O
at	O
45	O
.	O
AC	O
Rhythmic	O
heart	O
sounds	O
at	O
80x	O
.	O
No	O
pericardial	O
friction	O
rub	O
.	O
AP	O
Normal	O
respiratory	O
sounds	O
.	O
Abdomen	O
Soft	O
,	O
non	O
painful	O
,	O
without	O
masses	O
or	O
visceromegaly	O
and	O
with	O
peristalsis	O
present	O
.	O
LES	O
No	O
oedema	O
and	O
normal	O
pulses	O
.	O
Complementary	O
tests	O
ECG	O
On	O
admission	O
.	O
Sinus	O
rhythm	O
at	O
72	O
x	O
"	O
.	O
QRS	O
axis	O
90	O
with	O
ST	O
supradelevation	O
of	O
2	O
3	O
mm	O
in	O
II	O
,	O
III	O
and	O
aVF	O
and	O
1	O
.	O
5	O
mm	O
in	O
V5	O
,	O
V6	O
concave	O
upwards	O
and	O
PR	O
descent	O
in	O
these	O
leads	O
.	O
Normal	O
QT	O
.	O
Chest	O
X	O
ray	O
Normal	O
cardiac	O
silhouette	O
.	O
No	O
pleuroparenchymal	O
alterations	O
of	O
acute	O
evolution	O
.	O
Emergency	O
laboratory	O
tests	O
Troponin	O
I	O
2	O
.	O
58	O
ng	O
ml	O
.	O
Serum	O
creatinine	O
1	O
mg	O
dL	O
Ions	O
Normal	O
.	O
Haemogram	O
Hb	O
15	O
.	O
8	O
g	O
dL	O
Leucocytes	O
9	O
,	O
500	O
mm3	O
N	O
79	O
.	O
Analysis	O
on	O
the	O
cardiology	O
ward	O
Haemogram	O
Hb	O
16	O
.	O
4	O
g	O
dL	O
;	O
Hct	O
46	O
;	O
leukocytes	O
9	O
.	O
2	O
mil	O
mm3	O
normal	O
formula	O
;	O
platelets	O
217	O
mil	O
mm3	O
.	O
Biochemistry	O
basal	O
glucose	O
84	O
mg	O
dl	O
;	O
HbA1c	O
5	O
.	O
1	O
;	O
urea	O
0	O
.	O
29	O
g	O
L	O
;	O
creatinine	O
1	O
.	O
0	O
mg	O
dl	O
;	O
total	O
cholesterol	O
82	O
mg	O
dl	O
;	O
triglycerides	O
110	O
mg	O
dl	O
;	O
HDL	O
c	O
25	O
mg	O
dL	O
;	O
LDL	O
c	O
35	O
mg	O
dL	O
;	O
AST	O
16	O
U	O
L	O
;	O
ALT	O
14	O
U	O
L	O
;	O
GGT	O
16	O
U	O
L	O
;	O
LDH	O
223	O
U	O
L	O
;	O
sodium	O
143	O
mEq	O
L	O
;	O
potassium	O
4	O
.	O
3	O
mEq	O
L	O
.	O
Myocardial	O
damage	O
markers	O
maximum	O
Troponin	O
I	O
25	O
ng	O
ml	O
.	O
Maximum	O
CK	O
in	O
1st	O
determination	O
in	O
the	O
ER	O
346	O
U	O
L	O
,	O
normal	O
up	O
to	O
270	O
,	O
maximum	O
CK	O
MB	O
36	O
U	O
L	O
.	O
Serology	O
Negative	O
for	O
HBV	O
,	O
HCV	O
,	O
EBV	O
,	O
CMV	O
,	O
HSV	O
,	O
VZV	O
,	O
enterovirus	O
and	O
parvovirus	O
B19	O
.	O
Transthoracic	O
echocardiogram	O
initial	O
Left	O
atrium	O
not	O
dilated	O
.	O
Thin	O
leaflet	O
mitral	O
valve	O
with	O
preserved	O
mobility	O
and	O
opening	O
;	O
normal	O
diastolic	O
flow	O
.	O
Left	O
ventricle	O
neither	O
dilated	O
nor	O
hypertrophied	O
with	O
preserved	O
systolic	O
function	O
and	O
no	O
segmental	O
asymmetries	O
;	O
false	O
tendons	O
and	O
papillary	O
muscles	O
very	O
evident	O
.	O
Fine	O
,	O
trivalve	O
aortic	O
valve	O
with	O
normal	O
opening	O
,	O
mobility	O
and	O
flow	O
.	O
Aortic	O
root	O
not	O
dilated	O
.	O
Right	O
chambers	O
not	O
dilated	O
;	O
right	O
ventricular	O
contractility	O
preserved	O
.	O
Tricuspid	O
valve	O
correctly	O
implanted	O
,	O
fine	O
with	O
good	O
mobility	O
and	O
opening	O
.	O
Fine	O
pulmonary	O
valve	O
with	O
normal	O
opening	O
and	O
flow	O
.	O
No	O
pericardial	O
effusion	O
.	O
LVEF	O
64	O
Conclusions	O
No	O
pathological	O
alterations	O
.	O
ECG	O
at	O
discharge	O
Sinus	O
rhythm	O
at	O
65	O
bpm	O
.	O
Normal	O
PR	O
.	O
No	O
intraventricular	O
conduction	O
block	O
.	O
Slight	O
concave	O
ST	O
supradelevation	O
upwards	O
of	O
1	O
mm	O
in	O
II	O
,	O
III	O
and	O
aVF	O
.	O
Normal	O
QT	O
.	O
Cardiac	O
MRI	O
LV	O
diameter	O
and	O
volumes	O
within	O
normal	O
limits	O
for	O
sex	O
,	O
age	O
and	O
body	O
surface	O
area	O
.	O
Global	O
LV	O
function	O
preserved	O
,	O
without	O
segmental	O
alterations	O
.	O
Normal	O
LV	O
mass	O
.	O
Normal	O
RV	O
volumes	O
and	O
function	O
.	O
No	O
segmental	O
alterations	O
.	O
T2	O
spin	O
echo	O
sequences	O
No	O
significant	O
oedema	O
.	O
Gadolinium	O
with	O
inversion	O
recovery	O
sequences	O
Late	O
subepicardial	O
linear	O
enhancement	O
at	O
basal	O
and	O
inferobasal	O
anterior	O
septum	O
level	O
.	O
Conclusions	O
Subacute	O
myopericarditis	O
Holter	O
ECG	O
study	O
Cardiology	O
consultation	O
Sinus	O
rhythm	O
throughout	O
the	O
recording	O
.	O
No	O
significant	O
rhythm	O
alterations	O
detected	O
.	O
Stress	O
test	O
Cardiology	O
consultation	O
Asymptomatic	O
throughout	O
the	O
test	O
.	O
Exercise	O
time	O
12	O
minutes	O
of	O
Bruce	O
protocol	O
.	O
The	O
test	O
was	O
stopped	O
on	O
completing	O
the	O
4th	O
stage	O
,	O
reaching	O
93	O
of	O
the	O
maximum	O
theoretical	O
heart	O
rate	O
and	O
a	O
double	O
product	O
of	O
2	O
.	O
9	O
.	O
No	O
acute	O
repolarisation	O
disturbances	O
.	O
Basal	O
sinus	O
tachycardia	O
.	O
No	O
ventricular	O
arrhythmias	O
detected	O
.	O
Clinical	O
evolution	O
Admitted	O
to	O
the	O
cardiology	O
ward	O
with	O
a	O
diagnosis	O
of	O
myopericarditis	O
.	O
He	O
was	O
under	O
continuous	O
electrocardiographic	O
monitoring	O
with	O
no	O
conduction	O
disturbances	O
or	O
supra	O
or	O
ventricular	O
arrhythmias	O
.	O
During	O
admission	O
he	O
remained	O
asymptomatic	O
from	O
the	O
cardiovascular	O
point	O
of	O
view	O
,	O
with	O
no	O
signs	O
of	O
heart	O
failure	O
.	O
Serial	O
echocardiograms	O
were	O
performed	O
during	O
admission	O
,	O
with	O
no	O
evidence	O
of	O
deterioration	O
in	O
systolic	O
function	O
.	O
Given	O
the	O
good	O
evolution	O
,	O
the	O
patient	O
was	O
discharged	O
home	O
,	O
indicating	O
limitation	O
of	O
physical	O
activity	O
,	O
and	O
an	O
appointment	O
was	O
made	O
with	O
the	O
outpatient	O
cardiology	O
department	O
.	O
At	O
the	O
first	O
follow	O
up	O
appointment	O
,	O
the	O
patient	O
was	O
asymptomatic	O
and	O
a	O
cardiac	O
magnetic	O
resonance	O
report	O
was	O
received	O
confirming	O
the	O
diagnosis	O
.	O
In	O
addition	O
,	O
after	O
three	O
months	O
,	O
an	O
ECG	O
holter	O
was	O
performed	O
,	O
which	O
was	O
reported	O
with	O
no	O
alterations	O
,	O
as	O
well	O
as	O
conventional	O
ergometry	O
where	O
he	O
completed	O
the	O
4th	O
Bruce	O
stage	O
,	O
with	O
no	O
alterations	O
.	O
Subsequent	O
check	O
ups	O
were	O
uneventful	O
.	O
At	O
present	O
,	O
more	O
than	O
twelve	O
months	O
after	O
diagnosis	O
,	O
the	O
patient	O
is	O
asymptomatic	O
and	O
is	O
involved	O
in	O
competitive	O
physical	O
activity	O
.	O
Diagnosis	O
Acute	O
myopericarditis	O
.	O

We	O
present	O
the	O
case	O
of	O
a	O
41	O
year	O
old	O
patient	O
who	O
was	O
referred	O
to	O
the	O
clinic	O
on	O
the	O
same	O
day	O
for	O
assessment	O
of	O
a	O
pathological	O
ECG	O
,	O
which	O
had	O
been	O
performed	O
as	O
part	O
of	O
the	O
preoperative	O
work	O
up	O
for	O
surgery	O
on	O
his	O
right	O
shoulder	O
,	O
where	O
he	O
was	O
suffering	O
from	O
chronic	O
pain	O
.	O
History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
He	O
did	O
not	O
suffer	O
from	O
any	O
illness	O
,	O
except	O
for	O
pain	O
in	O
his	O
back	O
and	O
right	O
shoulder	O
for	O
which	O
he	O
took	O
painkillers	O
sporadically	O
.	O
He	O
practised	O
sport	O
regularly	O
and	O
was	O
in	O
very	O
good	O
physical	O
condition	O
,	O
although	O
he	O
reported	O
greater	O
fatigue	O
in	O
recent	O
months	O
.	O
The	O
patient	O
showed	O
an	O
obvious	O
absence	O
of	O
several	O
phalanges	O
in	O
his	O
left	O
hand	O
which	O
was	O
attributed	O
,	O
in	O
the	O
country	O
of	O
his	O
birth	O
he	O
was	O
the	O
son	O
of	O
seasonal	O
agricultural	O
workers	O
,	O
to	O
possible	O
maternal	O
exposure	O
to	O
thalidomide	B-FARMACO
.	O
He	O
also	O
had	O
other	O
musculoskeletal	O
anomalies	O
,	O
and	O
claimed	O
to	O
have	O
other	O
relatives	O
with	O
some	O
minor	O
upper	O
limb	O
defects	O
.	O
Physical	O
examination	O
revealed	O
pectus	O
excavatum	O
and	O
other	O
musculoskeletal	O
abnormalities	O
in	O
the	O
upper	O
and	O
lower	O
extremities	O
.	O
On	O
cardiac	O
auscultation	O
,	O
there	O
was	O
a	O
rhythmic	O
heartbeat	O
at	O
35	O
bpm	O
,	O
and	O
a	O
systolic	O
murmur	O
with	O
fixed	O
splitting	O
of	O
the	O
second	O
sound	O
.	O
No	O
signs	O
of	O
heart	O
failure	O
.	O
BP	O
100	O
60	O
.	O
The	O
ECG	O
showed	O
the	O
presence	O
of	O
complete	O
AV	O
block	O
.	O
Transthoracic	O
echocardiography	O
was	O
performed	O
and	O
it	O
was	O
decided	O
to	O
place	O
a	O
definitive	O
bicameral	O
pacemaker	O
and	O
continue	O
the	O
patient	O
's	O
study	O
.	O
Complementary	O
tests	O
Transthoracic	O
echocardiography	O
It	O
had	O
shown	O
dilatation	O
of	O
the	O
right	O
chambers	O
,	O
mild	O
tricuspid	O
insufficiency	O
with	O
a	O
PAP	O
of	O
50	O
mmHg	O
and	O
preserved	O
ventricular	O
function	O
.	O
Due	O
to	O
pectus	O
excavatum	O
,	O
it	O
was	O
not	O
possible	O
to	O
correctly	O
visualise	O
the	O
atrial	O
septum	O
.	O
Chest	O
CT	O
angiography	O
showed	O
dilatation	O
of	O
the	O
right	O
chambers	O
and	O
the	O
pulmonary	O
cone	O
.	O
Transesophageal	O
echocardiography	O
it	O
was	O
possible	O
to	O
verify	O
the	O
existence	O
of	O
a	O
21mm	O
ostium	O
secundum	O
type	O
atrial	O
septal	O
defect	O
,	O
with	O
left	O
right	O
shunt	O
.	O
Traumatologic	O
study	O
It	O
reported	O
the	O
presence	O
of	O
pectus	O
excavatum	O
,	O
glenohumeral	O
subluxation	O
in	O
the	O
right	O
shoulder	O
,	O
patellar	O
subluxation	O
of	O
the	O
right	O
knee	O
,	O
agenesis	O
of	O
several	O
phalanges	O
of	O
the	O
fingers	O
of	O
the	O
left	O
hand	O
,	O
radioulnar	O
synostosis	O
in	O
the	O
left	O
elbow	O
,	O
pes	O
cavus	O
and	O
agenesis	O
of	O
the	O
distal	O
phalanx	O
of	O
the	O
first	O
toe	O
of	O
the	O
right	O
foot	O
.	O
Clinical	O
course	O
Given	O
the	O
combination	O
of	O
musculoskeletal	O
defects	O
,	O
complete	O
AV	O
block	O
and	O
ASD	O
ostium	O
secundum	O
,	O
a	O
genetic	O
study	O
was	O
requested	O
.	O
The	O
family	O
tree	O
showed	O
several	O
cases	O
of	O
musculoskeletal	O
defects	O
and	O
even	O
some	O
cases	O
of	O
sudden	O
death	O
.	O
Genetic	O
testing	O
revealed	O
a	O
mutation	O
c	O
.	O
100	O
101insG	O
in	O
the	O
TBX5	O
gene	O
,	O
and	O
a	O
diagnosis	O
of	O
Holt	O
Oram	O
syndrome	O
was	O
made	O
.	O
Finally	O
,	O
the	O
patient	O
underwent	O
surgery	O
and	O
the	O
interatrial	O
defect	O
was	O
closed	O
using	O
an	O
autologous	O
pericardial	O
patch	O
,	O
without	O
postoperative	O
complications	O
.	O
To	O
date	O
,	O
he	O
remains	O
asymptomatic	O
cardiovascular	O
.	O
Diagnosis	O
Holt	O
Oram	O
syndrome	O
Various	O
musculoskeletal	O
alterations	O
,	O
Ostium	O
Secundum	O
atrial	O
septal	O
defect	O
and	O
complete	O
atrioventricular	O
block	O
.	O

A	O
65	O
year	O
old	O
patient	O
with	O
a	O
history	O
of	O
liver	O
transplantation	O
and	O
cirrhosis	O
due	O
to	O
hepatitis	O
B	O
virus	O
HBV	O
,	O
who	O
came	O
to	O
the	O
emergency	O
department	O
with	O
swelling	O
,	O
oedema	O
and	O
pain	O
in	O
the	O
right	O
lower	O
extremity	O
.	O
Background	O
,	O
current	O
disease	O
and	O
physical	O
examination	O
We	O
present	O
the	O
case	O
of	O
a	O
65	O
year	O
old	O
patient	O
with	O
a	O
history	O
of	O
liver	O
transplantation	O
with	O
cirrhosis	O
due	O
to	O
hepatitis	O
B	O
virus	O
HBV	O
the	O
previous	O
year	O
,	O
smoking	O
and	O
no	O
other	O
cardiovascular	O
risk	O
factors	O
who	O
attended	O
the	O
emergency	O
department	O
for	O
swelling	O
,	O
oedema	O
and	O
pain	O
in	O
the	O
right	O
lower	O
limb	O
twin	O
region	O
.	O
A	O
Doppler	O
ultrasound	O
was	O
performed	O
and	O
a	O
diagnosis	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
was	O
made	O
.	O
The	O
patient	O
was	O
discharged	O
with	O
anticoagulant	O
treatment	O
subcutaneous	O
enoxaparin	B-FARMACO
.	O
The	O
patient	O
returned	O
to	O
the	O
emergency	O
department	O
2	O
hours	O
after	O
discharge	O
with	O
symptoms	O
of	O
motor	O
aphasia	O
and	O
right	O
hemiparesis	O
suggestive	O
of	O
right	O
middle	O
cerebral	O
artery	O
stroke	O
.	O
Complementary	O
tests	O
Cerebral	O
CAT	O
scan	O
Normal	O
.	O
ECG	O
Subepicardial	O
lesion	O
of	O
4	O
5	O
mm	O
in	O
inferior	O
face	O
with	O
specular	O
image	O
in	O
high	O
lateral	O
face	O
and	O
decrease	O
of	O
ST	O
in	O
V1	O
V2	O
of	O
up	O
to	O
4	O
mm	O
compatible	O
with	O
posterior	O
lesion	O
Transthoracic	O
echocardiogram	O
non	O
dilated	O
LV	O
,	O
preserved	O
LVEF	O
,	O
severe	O
infero	O
posterior	O
hypokinesia	O
and	O
we	O
observed	O
a	O
redundant	O
interatrial	O
septum	O
with	O
image	O
in	O
right	O
atrium	O
compatible	O
with	O
persistence	O
of	O
Chiari	O
network	O
.	O
Urgent	O
catheterisation	O
Right	O
coronary	O
occluded	O
medially	O
with	O
an	O
image	O
suggestive	O
of	O
an	O
abundant	O
thrombotic	O
component	O
,	O
mechanical	O
thrombectomy	O
was	O
performed	O
with	O
a	O
catheter	O
,	O
extracting	O
several	O
red	O
thrombi	O
with	O
subsequent	O
normalisation	O
of	O
flow	O
TIMI	O
3	O
without	O
finding	O
a	O
residual	O
lesion	O
,	O
so	O
coronary	O
embolism	O
was	O
suspected	O
as	O
the	O
cause	O
of	O
the	O
occlusion	O
of	O
the	O
right	O
coronary	O
,	O
no	O
stent	O
was	O
placed	O
.	O
The	O
left	O
coronary	O
artery	O
was	O
normal	O
.	O
Clinical	O
Evolution	O
Once	O
the	O
catheterisation	O
was	O
performed	O
,	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
Coronary	O
Unit	O
where	O
he	O
remained	O
for	O
two	O
days	O
with	O
satisfactory	O
evolution	O
from	O
the	O
cardiological	O
and	O
neurological	O
point	O
of	O
view	O
.	O
Subsequently	O
,	O
given	O
the	O
suspicion	O
of	O
paradoxical	O
embolism	O
finding	O
of	O
an	O
infero	O
posterior	O
acute	O
myocardial	O
infarction	O
AMI	O
accompanied	O
by	O
a	O
stroke	O
in	O
a	O
patient	O
with	O
a	O
history	O
of	O
recent	O
DVT	O
,	O
a	O
transthoracic	O
echocardiogram	O
was	O
repeated	O
with	O
injection	O
of	O
agitated	O
saline	O
without	O
observing	O
a	O
clear	O
left	O
right	O
shunt	O
.	O
Given	O
the	O
high	O
level	O
of	O
suspicion	O
,	O
we	O
decided	O
to	O
perform	O
a	O
TEE	O
which	O
confirmed	O
the	O
presence	O
of	O
a	O
patent	O
foramen	O
ovale	O
.	O
A	O
CT	O
body	O
scan	O
was	O
also	O
performed	O
to	O
rule	O
out	O
a	O
neoplastic	O
process	O
as	O
the	O
cause	O
of	O
the	O
prothrombotic	O
state	O
,	O
which	O
showed	O
images	O
compatible	O
with	O
hepatic	O
,	O
splenic	O
and	O
renal	O
embolisms	O
.	O
The	O
hypercoagulability	O
study	O
was	O
normal	O
.	O
The	O
patient	O
was	O
discharged	O
on	O
oral	O
anticoagulant	O
treatment	O
and	O
remained	O
asymptomatic	O
to	O
date	O
.	O
Diagnosis	O
Multiple	O
embolism	O
probably	O
paradoxical	O
in	O
a	O
patient	O
with	O
patent	O
foramen	O
ovale	O
.	O

70	O
year	O
old	O
male	O
.	O
History	O
of	O
pulmonary	O
tuberculosis	O
with	O
residual	O
left	O
fibrothorax	O
,	O
several	O
episodes	O
of	O
severe	O
haemoptysis	O
years	O
earlier	O
.	O
Pulmonary	O
auscultation	O
showed	O
generalised	O
hypophonesis	O
,	O
greater	O
in	O
the	O
left	O
hemithorax	O
and	O
scattered	O
rhonchi	O
.	O
No	O
oedema	O
.	O
History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
70	O
year	O
old	O
male	O
.	O
CVRF	O
Ex	O
smoker	O
of	O
50	O
packs	O
per	O
year	O
,	O
hypercholesterolemia	O
.	O
Mild	O
COPD	O
.	O
Ischaemic	O
stroke	O
in	O
2011	O
.	O
Paroxysmal	O
AF	O
not	O
anticoagulated	O
due	O
to	O
risk	O
of	O
bleeding	O
.	O
History	O
of	O
pulmonary	O
tuberculosis	O
30	O
years	O
ago	O
,	O
with	O
residual	O
left	O
fibrothorax	O
.	O
Several	O
episodes	O
of	O
severe	O
haemoptysis	O
years	O
ago	O
,	O
some	O
with	O
haemodynamic	O
instability	O
that	O
required	O
admission	O
to	O
the	O
ICU	O
.	O
During	O
one	O
of	O
them	O
,	O
during	O
a	O
thoracic	O
CT	O
scan	O
,	O
two	O
heterotopic	O
bronchial	O
arteries	O
were	O
observed	O
,	O
originating	O
in	O
the	O
left	O
subclavian	O
artery	O
and	O
draining	O
into	O
multiple	O
tortuous	O
vessels	O
associated	O
with	O
an	O
area	O
of	O
saccular	O
bronchiectasis	O
located	O
in	O
the	O
left	O
lower	O
pulmonary	O
lobe	O
.	O
Embolisation	O
was	O
then	O
performed	O
using	O
microcoils	O
and	O
embo	O
spheres	O
of	O
these	O
aberrant	O
arteries	O
,	O
despite	O
which	O
episodes	O
of	O
haemoptysis	O
persisted	O
,	O
so	O
pulmonary	O
lobectomy	O
was	O
decided	O
as	O
the	O
best	O
therapeutic	O
option	O
for	O
the	O
patient	O
.	O
Physical	O
examination	O
BP	O
140	O
75	O
,	O
PVY	O
normal	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
without	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
showed	O
generalised	O
hypophonesis	O
,	O
greater	O
in	O
the	O
left	O
hemithorax	O
and	O
scattered	O
rhonchi	O
.	O
No	O
oedema	O
.	O
Complementary	O
tests	O
Prior	O
to	O
surgery	O
,	O
a	O
transthoracic	O
echocardiogram	O
was	O
performed	O
,	O
which	O
showed	O
a	O
left	O
ventricle	O
of	O
normal	O
size	O
and	O
function	O
,	O
a	O
slightly	O
dilated	O
right	O
ventricle	O
with	O
good	O
function	O
,	O
mild	O
biauricular	O
dilatation	O
,	O
mild	O
MR	O
and	O
mild	O
TR	O
with	O
moderate	O
severe	O
pulmonary	O
hypertension	O
.	O
A	O
haemodynamic	O
study	O
and	O
coronary	O
angiography	O
were	O
requested	O
to	O
our	O
hospital	O
for	O
surgical	O
evaluation	O
of	O
the	O
patient	O
.	O
Cardiac	O
catheterisation	O
showed	O
moderate	O
pulmonary	O
hypertension	O
with	O
normal	O
PCP	O
,	O
but	O
coronary	O
angiography	O
revealed	O
a	O
large	O
coronary	O
bronchial	O
fistula	O
originating	O
in	O
the	O
circumflex	O
artery	O
and	O
draining	O
into	O
multiple	O
tortuous	O
vessels	O
located	O
in	O
the	O
left	O
lower	O
pulmonary	O
lobe	O
.	O
Clinical	O
course	O
With	O
the	O
diagnostic	O
suspicion	O
that	O
the	O
coronary	O
bronchial	O
fistula	O
could	O
be	O
the	O
cause	O
of	O
the	O
patient	O
's	O
current	O
episodes	O
of	O
haemoptysis	O
,	O
it	O
was	O
successfully	O
embolised	O
using	O
a	O
6F	O
AL	O
2	O
guide	O
catheter	O
Cordis	O
LBT	O
,	O
NJ	O
,	O
USA	O
and	O
an	O
angioplasty	O
guide	O
Runthrough	O
Hipercoat	O
,	O
Terumo	O
Europe	O
,	O
Netherlands	O
to	O
introduce	O
a	O
microcatheter	O
Progreat	O
,	O
Terumo	O
Europe	O
,	O
Netherlands	O
to	O
the	O
most	O
distal	O
area	O
of	O
the	O
fistula	O
and	O
finally	O
release	O
three	O
microcoils	O
Cook	O
Medical	O
sequentially	O
,	O
until	O
angiographically	O
demonstrating	O
flow	O
abolition	O
.	O
Surgery	O
was	O
postponed	O
until	O
clinical	O
evolution	O
was	O
observed	O
.	O
One	O
year	O
after	O
the	O
procedure	O
the	O
patient	O
remains	O
asymptomatic	O
,	O
with	O
no	O
new	O
episodes	O
of	O
haemoptysis	O
.	O
Diagnosis	O
Recurrent	O
haemoptysis	O
secondary	O
to	O
large	O
coronary	O
bronchial	O
fistula	O
.	O
Successful	O
percutaneous	O
embolisation	O
.	O

The	O
67	O
year	O
old	O
patient	O
,	O
with	O
a	O
history	O
of	O
hypertension	O
and	O
dyslipidaemia	O
,	O
with	O
aortic	O
prosthesis	O
and	O
pacemaker	O
,	O
who	O
attended	O
the	O
Emergency	O
Department	O
for	O
a	O
sudden	O
onset	O
of	O
right	O
hemiparesis	O
,	O
dysphasia	O
,	O
disorientation	O
,	O
headache	O
and	O
vomiting	O
.	O
History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
Personal	O
history	O
67	O
year	O
old	O
male	O
patient	O
with	O
a	O
history	O
of	O
hypertension	O
and	O
dyslipidaemia	O
;	O
aortic	O
prosthesis	O
holder	O
since	O
2004	O
and	O
a	O
normal	O
functioning	O
VDD	O
pacemaker	O
,	O
with	O
replacement	O
3	O
months	O
ago	O
.	O
Present	O
illness	O
The	O
patient	O
consulted	O
the	O
Emergency	O
Department	O
for	O
a	O
sudden	O
onset	O
of	O
right	O
hemiparesis	O
,	O
dysphasia	O
,	O
disorientation	O
,	O
headache	O
and	O
vomiting	O
.	O
He	O
refers	O
to	O
a	O
history	O
of	O
influenza	O
with	O
fever	O
measured	O
by	O
thermometry	O
during	O
the	O
last	O
few	O
days	O
.	O
Physical	O
examination	O
On	O
arrival	O
at	O
the	O
ED	O
,	O
the	O
patient	O
was	O
haemodynamically	O
stable	O
with	O
blood	O
pressure	O
of	O
101	O
63	O
mmHg	O
,	O
heart	O
rate	O
of	O
77	O
bpm	O
and	O
oxygen	O
saturation	O
of	O
94	O
at	O
baseline	O
.	O
On	O
physical	O
examination	O
the	O
patient	O
was	O
vigilant	O
and	O
alert	O
without	O
ophthalmoparesis	O
or	O
campimetric	O
alteration	O
due	O
to	O
threat	O
.	O
He	O
had	O
global	O
dysphasia	O
,	O
slight	O
deviation	O
of	O
the	O
labial	O
commissure	O
to	O
the	O
left	O
and	O
right	O
brachial	O
hemiparesis	O
1	O
5	O
,	O
crural	O
hemiparesis	O
4	O
5	O
with	O
right	O
extensor	O
plantar	O
cutaneous	O
reflex	O
.	O
Cardiopulmonary	O
auscultation	O
revealed	O
periprosthetic	O
aortic	O
sounds	O
with	O
mitral	O
murmur	O
III	O
VI	O
and	O
scattered	O
rhonchi	O
in	O
both	O
lung	O
fields	O
.	O
Given	O
the	O
diagnosis	O
of	O
ischaemic	O
stroke	O
in	O
the	O
left	O
MCA	O
territory	O
of	O
non	O
filial	O
origin	O
,	O
a	O
stroke	O
code	O
was	O
ruled	O
out	O
as	O
it	O
exceeded	O
the	O
window	O
period	O
and	O
admission	O
was	O
decided	O
for	O
aetiological	O
study	O
and	O
treatment	O
.	O
Complementary	O
tests	O
Given	O
the	O
clinical	O
symptoms	O
suggestive	O
of	O
cerebral	O
ischaemia	O
,	O
during	O
his	O
stay	O
in	O
the	O
Emergency	O
Department	O
,	O
a	O
cranial	O
CT	O
scan	O
was	O
requested	O
,	O
showing	O
hypodensity	O
in	O
the	O
left	O
basal	O
ganglia	O
in	O
relation	O
to	O
an	O
acute	O
ischaemic	O
lesion	O
in	O
the	O
middle	O
cerebral	O
artery	O
territory	O
.	O
The	O
study	O
in	O
this	O
department	O
was	O
completed	O
with	O
an	O
ECG	O
,	O
the	O
reading	O
of	O
which	O
revealed	O
a	O
VDD	O
pacemaker	O
rhythm	O
at	O
77	O
bpm	O
;	O
a	O
basic	O
blood	O
test	O
including	O
haemogram	O
and	O
coagulation	O
with	O
Hb	O
11	O
.	O
9	O
g	O
dl	O
,	O
leukocytes	O
18	O
,	O
300	O
N	O
92	O
.	O
2	O
,	O
INR	O
5	O
.	O
7	O
,	O
FD	O
610	O
mg	O
dl	O
,	O
troponin	O
I	O
894	O
pg	O
ml	O
,	O
CRP	O
157	O
mg	O
L	O
;	O
and	O
a	O
chest	O
X	O
ray	O
showing	O
cardiomegaly	O
,	O
with	O
no	O
images	O
of	O
condensation	O
or	O
pleural	O
effusion	O
.	O
Blood	O
cultures	O
were	O
also	O
taken	O
.	O
On	O
admission	O
to	O
the	O
ward	O
,	O
in	O
view	O
of	O
the	O
laboratory	O
findings	O
described	O
and	O
the	O
history	O
of	O
febrile	O
syndrome	O
and	O
recent	O
pacemaker	O
replacement	O
,	O
it	O
was	O
decided	O
to	O
perform	O
urgent	O
transthoracic	O
echocardiography	O
to	O
rule	O
out	O
endocarditis	O
as	O
the	O
aetiological	O
focus	O
of	O
the	O
cerebral	O
infarction	O
.	O
The	O
echocardiogram	O
showed	O
dilatation	O
of	O
the	O
left	O
atrium	O
with	O
preserved	O
FEV1	O
without	O
alterations	O
in	O
contractility	O
and	O
normal	O
mitral	O
valve	O
.	O
There	O
was	O
a	O
dysfunctional	O
aortic	O
prosthesis	O
with	O
high	O
gradients	O
peak	O
gradient	O
60	O
mmHg	O
,	O
mean	O
35	O
mmHg	O
.	O
The	O
peak	O
gradient	O
in	O
the	O
previous	O
control	O
was	O
30	O
mmHg	O
.	O
There	O
is	O
an	O
image	O
compatible	O
with	O
endocardial	O
vegetation	O
in	O
its	O
posterior	O
disc	O
,	O
with	O
thrombus	O
density	O
,	O
pedunculated	O
and	O
sessile	O
.	O
Moderate	O
pulmonary	O
hypertension	O
and	O
mild	O
tricuspid	O
insufficiency	O
,	O
which	O
had	O
already	O
been	O
reported	O
in	O
previous	O
studies	O
,	O
were	O
described	O
.	O
The	O
echocardiographic	O
finding	O
was	O
confirmed	O
within	O
24	O
hours	O
by	O
transesophageal	O
echocardiography	O
,	O
which	O
showed	O
a	O
large	O
vegetation	O
of	O
about	O
20	O
mm	O
in	O
the	O
outflow	O
tract	O
and	O
a	O
large	O
periaortic	O
abscess	O
open	O
to	O
the	O
bloodstream	O
extending	O
to	O
the	O
interatrial	O
septum	O
.	O
The	O
appearance	O
of	O
the	O
mitral	O
valve	O
and	O
left	O
ventricular	O
function	O
are	O
normal	O
.	O
At	O
that	O
time	O
,	O
preliminary	O
blood	O
culture	O
results	O
were	O
received	O
showing	O
growth	O
of	O
Gram	O
positive	O
cocci	O
in	O
clusters	O
.	O
The	O
definitive	O
result	O
was	O
S	O
.	O
epidermidis	O
.	O
Clinical	O
course	O
This	O
is	O
a	O
67	O
year	O
old	O
patient	O
with	O
AHT	O
,	O
DM	O
,	O
aortic	O
prosthesis	O
and	O
VDD	O
pacemaker	O
who	O
was	O
admitted	O
for	O
an	O
abrupt	O
onset	O
of	O
language	O
disorder	O
and	O
right	O
hemiparesis	O
related	O
to	O
ischemic	O
stroke	O
in	O
CMI	O
territory	O
,	O
with	O
an	O
INR	O
on	O
admission	O
of	O
5	O
.	O
7	O
.	O
On	O
admission	O
,	O
given	O
the	O
presence	O
of	O
leukocytosis	O
and	O
elevated	O
CRP	O
supporting	O
the	O
suspicion	O
of	O
endocarditis	O
,	O
an	O
emergency	O
transthoracic	O
echocardiogram	O
was	O
performed	O
which	O
showed	O
endocardial	O
vegetation	O
on	O
the	O
aortic	O
valve	O
,	O
and	O
antibiotic	O
treatment	O
was	O
started	O
with	O
vancomycin	B-FARMACO
,	O
gentamincin	B-FARMACO
and	O
rifampicin	B-FARMACO
after	O
extraction	O
of	O
blood	O
cultures	O
.	O
The	O
patient	O
had	O
undergone	O
a	O
pacemaker	O
replacement	O
three	O
months	O
ago	O
and	O
for	O
the	O
last	O
week	O
had	O
been	O
experiencing	O
general	O
malaise	O
,	O
profuse	O
sweating	O
with	O
fever	O
peaks	O
of	O
up	O
to	O
39oC	O
,	O
which	O
he	O
related	O
to	O
a	O
case	O
of	O
influenza	O
.	O
A	O
transesophageal	O
echocardiogram	O
was	O
completed	O
,	O
confirming	O
vegetation	O
and	O
open	O
periaortic	O
abscess	O
,	O
and	O
the	O
Cardiac	O
Surgery	O
Department	O
of	O
the	O
referral	O
hospital	O
H	O
.	O
Clnico	O
Universitario	O
de	O
Valladolid	O
was	O
contacted	O
for	O
transfer	O
.	O
During	O
his	O
stay	O
in	O
our	O
hospital	O
,	O
the	O
neurological	O
evolution	O
was	O
slightly	O
favourable	O
with	O
improvement	O
of	O
the	O
right	O
brachio	O
crural	O
motor	O
deficit	O
4	O
5	O
,	O
with	O
persistent	O
central	O
facial	O
,	O
hemianopsia	O
due	O
to	O
threat	O
and	O
global	O
dysphasia	O
.	O
There	O
were	O
no	O
signs	O
of	O
heart	O
failure	O
or	O
arrhythmias	O
.	O
Diagnosis	O
Given	O
the	O
findings	O
described	O
above	O
,	O
the	O
final	O
diagnosis	O
was	O
late	O
prosthetic	O
endocarditis	O
due	O
to	O
Staphylococcus	O
epid	O
.	O
complicated	O
with	O
ischaemic	O
stroke	O
and	O
periaortic	O
abscess	O
.	O

26	O
year	O
old	O
male	O
,	O
who	O
attended	O
his	O
point	O
of	O
continuous	O
care	O
in	O
the	O
early	O
hours	O
of	O
the	O
morning	O
due	O
to	O
vomiting	O
and	O
agitation	O
,	O
accompanied	O
by	O
pain	O
in	O
the	O
left	O
rib	O
cage	O
with	O
coughing	O
since	O
the	O
middle	O
of	O
the	O
night	O
.	O
History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
Personal	O
history	O
Male	O
,	O
26	O
years	O
old	O
.	O
Allergy	O
to	O
penicillin	O
.	O
Previous	O
history	O
of	O
drug	O
intoxication	O
.	O
Usual	O
treatment	O
No	O
.	O
Present	O
illness	O
This	O
is	O
a	O
26	O
year	O
old	O
male	O
,	O
who	O
came	O
to	O
his	O
point	O
of	O
continuous	O
care	O
in	O
the	O
early	O
hours	O
of	O
the	O
morning	O
with	O
vomiting	O
and	O
agitation	O
,	O
accompanied	O
by	O
pain	O
in	O
the	O
left	O
rib	O
cage	O
with	O
cough	O
since	O
the	O
middle	O
of	O
the	O
night	O
4	O
5	O
am	O
.	O
Given	O
the	O
patient	O
's	O
condition	O
,	O
it	O
was	O
decided	O
to	O
transfer	O
him	O
to	O
his	O
regional	O
referral	O
hospital	O
.	O
He	O
denied	O
the	O
use	O
of	O
toxic	O
substances	O
and	O
cocaine	O
.	O
Physical	O
examination	O
BP	O
92	O
62	O
mmHg	O
HR	O
71	O
bpm	O
.	O
Conscious	O
,	O
agitated	O
,	O
anxiety	O
,	O
pallor	O
,	O
sweating	O
.	O
Signs	O
of	O
poor	O
peripheral	O
perfusion	O
.	O
Cardiac	O
auscultation	O
showed	O
no	O
murmurs	O
or	O
evidence	O
of	O
heart	O
failure	O
.	O
Complementary	O
tests	O
CBC	O
Haemogram	O
Leukocytes	O
27	O
,	O
900	O
ml	O
N	O
89	O
;	O
L	O
5	O
.	O
6	O
,	O
Hb	O
17	O
.	O
3	O
g	O
dl	O
,	O
Hct	O
48	O
.	O
9	O
,	O
platelets	O
400	O
,	O
000	O
ml	O
.	O
Basic	O
biochemistry	O
Glucose	O
187	O
mg	O
dl	O
;	O
urea	O
30	O
mg	O
dl	O
;	O
creatinine	O
1	O
.	O
2	O
mg	O
dl	O
;	O
Na	O
143	O
meq	O
l	O
,	O
K	O
3	O
.	O
7	O
meq	O
l	O
.	O
Myocardial	O
damage	O
markers	O
TpI	O
0	O
.	O
03	O
.	O
Coagulation	O
PT	O
99	O
;	O
aPTT	O
23	O
.	O
3	O
.	O
Urine	O
toxicity	O
cocaine	O
,	O
benzodiazepines	O
and	O
cannabinoid	O
products	O
.	O
Chest	O
X	O
ray	O
No	O
acute	O
pleuropulmonary	O
pathology	O
.	O
Initial	O
electrocardiogram	O
Sinus	O
rhythm	O
60	O
bpm	O
.	O
ST	O
segment	O
elevation	O
2	O
mm	O
in	O
the	O
anterolateral	O
side	O
.	O
Electrocardiogram	O
2	O
Sinus	O
rhythm	O
80	O
bpm	O
.	O
In	O
view	O
of	O
the	O
clinical	O
findings	O
chest	O
pain	O
,	O
signs	O
of	O
poor	O
peripheral	O
perfusion	O
;	O
preshock	O
K	O
status	O
and	O
electrocardiographic	O
findings	O
AMI	O
with	O
ST	O
segment	O
elevation	O
and	O
given	O
that	O
the	O
patient	O
was	O
in	O
a	O
regional	O
hospital	O
with	O
no	O
possibility	O
of	O
early	O
access	O
to	O
a	O
centre	O
with	O
primary	O
angioplasty	O
,	O
it	O
was	O
decided	O
to	O
perform	O
thrombolysis	O
with	O
8000	O
IU	O
of	O
metalyse	B-FARMACO
.	O
However	O
,	O
after	O
thirty	O
minutes	O
there	O
were	O
no	O
clinical	O
or	O
electrocardiographic	O
criteria	O
for	O
reperfusion	O
,	O
so	O
it	O
was	O
decided	O
to	O
transfer	O
the	O
patient	O
to	O
a	O
reference	O
centre	O
for	O
primary	O
PTCA	O
.	O
At	O
the	O
start	O
of	O
the	O
transfer	O
,	O
the	O
patient	O
presented	O
good	O
saturation	O
and	O
data	O
of	O
capillary	O
hypoperfusion	O
with	O
a	O
capillary	O
refill	O
time	O
2	O
seconds	O
.	O
During	O
the	O
transfer	O
he	O
presented	O
episodes	O
of	O
supraventricular	O
tachycardia	O
and	O
slow	O
ventricular	O
tachycardia	O
.	O
After	O
20	O
minutes	O
he	O
presented	O
with	O
pulseless	O
electrical	O
activity	O
PEA	O
and	O
advanced	O
CPR	O
manoeuvres	O
were	O
initiated	O
.	O
After	O
30	O
minutes	O
,	O
asystole	O
was	O
observed	O
and	O
advanced	O
CPR	O
manoeuvres	O
were	O
continued	O
.	O
He	O
arrived	O
at	O
the	O
haemodynamics	O
room	O
of	O
our	O
centre	O
in	O
asystole	O
,	O
an	O
urgent	O
echocardiogram	O
was	O
performed	O
which	O
showed	O
no	O
evidence	O
of	O
cardiac	O
rupture	O
and	O
after	O
50	O
minutes	O
of	O
unsuccessful	O
advanced	O
CPR	O
,	O
the	O
patient	O
died	O
.	O
Diagnosis	O
Acute	O
myocardial	O
infarction	O
with	O
ST	O
segment	O
elevation	O
due	O
to	O
cocaine	O
use	O
.	O
Exitus	O
.	O

History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
A	O
12	O
year	O
old	O
boy	O
was	O
admitted	O
to	O
the	O
PICU	O
after	O
being	O
transferred	O
by	O
ambulance	O
for	O
cardio	O
respiratory	O
arrest	O
at	O
home	O
.	O
He	O
presented	O
with	O
a	O
12	O
hour	O
history	O
of	O
odynophagia	O
with	O
a	O
fever	O
of	O
38	O
C	O
maximum	O
.	O
After	O
administering	O
antipyretic	O
medication	O
,	O
the	O
mother	O
reported	O
noticing	O
pathological	O
respiratory	O
sounds	O
and	O
loss	O
of	O
consciousness	O
,	O
so	O
she	O
called	O
112	O
.	O
On	O
arrival	O
of	O
the	O
basic	O
support	O
ambulance	O
,	O
an	O
ICD	O
was	O
connected	O
,	O
confirming	O
ventricular	O
fibrillation	O
,	O
and	O
defibrillation	O
and	O
cardiopulmonary	O
resuscitation	O
were	O
performed	O
,	O
achieving	O
an	O
organised	O
rhythm	O
with	O
a	O
pulse	O
after	O
4	O
minutes	O
after	O
two	O
shocks	O
of	O
360	O
J	O
.	O
The	O
medicalised	O
ambulance	O
arrived	O
home	O
,	O
and	O
the	O
patient	O
was	O
intubated	O
,	O
sedated	O
and	O
transferred	O
.	O
Estimated	O
time	O
of	O
cardiac	O
arrest	O
from	O
call	O
to	O
112	O
to	O
rhythm	O
with	O
pulse	O
16	O
minutes	O
.	O
Background	O
history	O
normal	O
pregnancy	O
and	O
delivery	O
.	O
Wheezy	O
bronchitis	O
in	O
infancy	O
.	O
No	O
previous	O
admissions	O
.	O
Vaccination	O
according	O
to	O
schedule	O
.	O
No	O
known	O
allergies	O
.	O
Pending	O
outpatient	O
consultation	O
in	O
paediatric	O
cardiology	O
due	O
to	O
a	O
murmur	O
diagnosed	O
by	O
her	O
paediatrician	O
a	O
month	O
ago	O
.	O
Family	O
history	O
with	O
uncle	O
,	O
grandfather	O
and	O
paternal	O
cousin	O
with	O
acquired	O
cardiac	O
pathology	O
.	O
Physical	O
examination	O
showed	O
an	O
estimated	O
weight	O
of	O
45	O
kg	O
.	O
HR	O
100	O
bpm	O
,	O
RR	O
20	O
rpm	O
,	O
BP	O
.	O
112	O
57	O
,	O
Sat	O
.	O
02	O
100	O
FiO2	O
of	O
0	O
.	O
3	O
.	O
Sedated	O
,	O
connected	O
to	O
mechanical	O
ventilation	O
.	O
Skin	O
pallor	O
.	O
No	O
oedema	O
.	O
No	O
petechiae	O
.	O
ACP	O
Good	O
bilateral	O
air	O
entry	O
.	O
Rhythmic	O
heart	O
tones	O
.	O
Abdomen	O
Soft	O
and	O
depressible	O
,	O
no	O
masses	O
or	O
megaliths	O
.	O
Complementary	O
tests	O
ECG	O
Growth	O
of	O
left	O
cavities	O
and	O
marked	O
decrease	O
of	O
ST	O
especially	O
in	O
I	O
,	O
II	O
,	O
aVR	O
and	O
left	O
precordial	O
.	O
QTC	O
400ms	O
.	O
Enzymatic	O
peak	O
CPK	O
1	O
,	O
722	O
,	O
CKMB	O
42	O
.	O
7	O
.	O
Troponin	O
T	O
360	O
.	O
8	O
,	O
ProBNP	O
3	O
,	O
788	O
.	O
Echocardiography	O
Situs	O
solitus	O
,	O
AV	O
VA	O
concordance	O
.	O
AIS	O
and	O
IVS	O
intact	O
.	O
Slight	O
dilatation	O
of	O
the	O
left	O
ventricle	O
DTD	O
50	O
mm	O
with	O
good	O
systolic	O
function	O
EF	O
55	O
60	O
.	O
Normofunctioning	O
valves	O
.	O
Normal	O
aorta	O
and	O
pulmonary	O
artery	O
.	O
No	O
pericardial	O
effusion	O
.	O
Dilated	O
right	O
coronary	O
artery	O
of	O
6	O
mm	O
.	O
Left	O
coronary	O
artery	O
is	O
not	O
observed	O
in	O
its	O
normal	O
origin	O
.	O
Flow	O
to	O
pulmonary	O
artery	O
mainly	O
systolic	O
although	O
it	O
seems	O
continuous	O
,	O
probably	O
due	O
to	O
anomalous	O
origin	O
of	O
the	O
left	O
coronary	O
artery	O
.	O
Angio	O
CT	O
coronary	O
arteries	O
Anomalous	O
origin	O
of	O
the	O
left	O
coronary	O
artery	O
from	O
the	O
main	O
pulmonary	O
artery	O
with	O
passage	O
of	O
contrast	O
from	O
the	O
left	O
coronary	O
artery	O
to	O
the	O
pulmonary	O
artery	O
.	O
Dilated	O
right	O
coronary	O
artery	O
with	O
origin	O
in	O
right	O
coronary	O
sinus	O
with	O
collateral	O
circulation	O
to	O
the	O
left	O
coronary	O
artery	O
.	O
Clinical	O
evolution	O
On	O
admission	O
,	O
monitoring	O
,	O
connection	O
to	O
mechanical	O
ventilation	O
,	O
hypothermia	O
and	O
serum	O
therapy	O
were	O
started	O
.	O
Respiratory	O
system	O
was	O
connected	O
to	O
conventional	O
mechanical	O
ventilation	O
with	O
adequate	O
oxygenation	O
.	O
Respiratory	O
deterioration	O
from	O
the	O
4th	O
day	O
of	O
admission	O
with	O
worsening	O
oxygenation	O
and	O
pneumonic	O
condensation	O
.	O
Subsequent	O
progressive	O
improvement	O
with	O
slow	O
withdrawal	O
of	O
FiO2	O
and	O
PEEP	O
.	O
Haemodynamically	O
on	O
admission	O
,	O
continuous	O
dopamine	B-FARMACO
perfusion	O
was	O
started	O
up	O
to	O
20	O
mcg	O
kg	O
min	O
for	O
TAM	O
70	O
.	O
Tendency	O
to	O
bradycardia	O
during	O
hypothermia	O
with	O
QTc	O
lengthening	O
to	O
0	O
.	O
55	O
,	O
which	O
normalised	O
after	O
withdrawal	O
.	O
There	O
were	O
no	O
arrhythmias	O
during	O
the	O
entire	O
admission	O
.	O
Neurological	O
On	O
admission	O
,	O
he	O
was	O
connected	O
to	O
continuous	O
perfusion	O
of	O
deep	O
sedoanalgesia	O
with	O
midazolam	B-FARMACO
and	O
fentanyl	B-FARMACO
.	O
Therapeutic	O
hypothermia	O
protocol	O
was	O
applied	O
,	O
maintaining	O
a	O
core	O
temperature	O
of	O
33	O
34	O
C	O
for	O
48	O
hours	O
.	O
Continuous	O
monitoring	O
with	O
amplitude	O
integrated	O
EEG	O
was	O
maintained	O
without	O
the	O
appearance	O
of	O
seizure	O
episodes	O
and	O
with	O
stable	O
and	O
symmetrical	O
cerebral	O
oximetry	O
.	O
Rewarming	O
according	O
to	O
protocol	O
without	O
complications	O
.	O
Progressive	O
withdrawal	O
of	O
sedoanalgesia	O
with	O
the	O
appearance	O
of	O
coordinated	O
spontaneous	O
mobility	O
without	O
focality	O
.	O
Renal	O
Hydrometabolic	O
Maintained	O
throughout	O
admission	O
with	O
adequate	O
diuresis	O
,	O
requiring	O
occasional	O
isolated	O
doses	O
of	O
furosemide	B-FARMACO
for	O
adequate	O
balances	O
.	O
Normal	O
renal	O
function	O
.	O
In	O
view	O
of	O
the	O
echocardiogram	O
findings	O
,	O
a	O
coronary	O
CAT	O
scan	O
was	O
performed	O
which	O
confirmed	O
an	O
anomalous	O
origin	O
of	O
the	O
left	O
coronary	O
artery	O
in	O
the	O
pulmonary	O
artery	O
.	O
With	O
these	O
data	O
,	O
the	O
patient	O
was	O
referred	O
to	O
our	O
paediatric	O
cardiac	O
surgery	O
referral	O
centre	O
where	O
cardiac	O
catheterisation	O
was	O
performed	O
with	O
the	O
same	O
findings	O
as	O
the	O
coronary	O
CT	O
scan	O
.	O
The	O
patient	O
underwent	O
reimplantation	O
of	O
the	O
left	O
coronary	O
artery	O
in	O
the	O
aorta	O
without	O
significant	O
complications	O
.	O
Diagnosis	O
Cardio	O
respiratory	O
arrest	O
due	O
to	O
resuscitated	O
ventricular	O
fibrillation	O
.	O
ALCAPA	O
syndrome	O
anomalous	O
origin	O
of	O
left	O
coronary	O
artery	O
in	O
pulmonary	O
artery	O
.	O
Preserved	O
left	O
ventricular	O
function	O
.	O
Reimplantation	O
of	O
left	O
coronary	O
artery	O
in	O
aorta	O
.	O
Nosocomial	O
pneumonia	O
associated	O
with	O
mechanical	O
ventilation	O
.	O

70	O
year	O
old	O
man	O
with	O
acute	O
myocardial	O
infarction	O
complicated	O
by	O
fever	O
and	O
pericardial	O
effusion	O
.	O
History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
No	O
known	O
drug	O
allergies	O
.	O
Former	O
smoker	O
until	O
20	O
years	O
ago	O
cumulative	O
consumption	O
64	O
packs	O
year	O
.	O
Dyslipidaemia	O
treated	O
with	O
diet	O
.	O
No	O
systemic	O
hypertension	O
,	O
no	O
DM	O
.	O
Primary	O
antiphospholipid	O
syndrome	O
diagnosed	O
in	O
1994	O
after	O
an	O
episode	O
of	O
pulmonary	O
thromboembolism	O
.	O
Chronic	O
venous	O
insufficiency	O
with	O
recurrent	O
vascular	O
venous	O
ulcers	O
in	O
right	O
lower	O
limb	O
.	O
Surgical	O
interventions	O
cholecystectomy	O
and	O
right	O
inguinal	O
hernioplasty	O
.	O
Usual	O
treatment	O
Acenocoumarol	B-FARMACO
,	O
Pentoxifylline	B-FARMACO
and	O
escin	B-FARMACO
.	O
The	O
patient	O
was	O
a	O
70	O
year	O
old	O
male	O
with	O
the	O
aforementioned	O
personal	O
history	O
who	O
,	O
while	O
at	O
rest	O
,	O
presented	O
with	O
severe	O
retrosternal	O
chest	O
pain	O
with	O
oppressive	O
characteristics	O
,	O
radiating	O
to	O
the	O
left	O
upper	O
limb	O
and	O
accompanied	O
by	O
intense	O
vegetative	O
cramping	O
.	O
The	O
emergency	O
department	O
performed	O
an	O
electrocardiogram	O
showing	O
sinus	O
rhythm	O
with	O
ST	O
segment	O
elevation	O
in	O
DI	O
,	O
AVL	O
,	O
V2	O
V3	O
and	O
ST	O
segment	O
depression	O
in	O
DII	O
,	O
DIII	O
and	O
AVF	O
.	O
He	O
was	O
given	O
300	O
mg	O
of	O
ASA	B-FARMACO
and	O
600	O
mg	O
of	O
clopidrogrel	B-FARMACO
plus	O
nitroglycerine	B-FARMACO
and	O
intravenous	O
morphine	B-FARMACO
chloride	I-FARMACO
.	O
He	O
arrived	O
at	O
the	O
Haemodynamics	O
Unit	O
,	O
4	O
,	O
000	O
IU	O
of	O
intravenous	O
sodium	B-FARMACO
heparin	I-FARMACO
was	O
administered	O
and	O
primary	O
PTCA	O
was	O
performed	O
on	O
the	O
culprit	O
lesion	O
of	O
the	O
anterior	O
descending	O
artery	O
at	O
the	O
level	O
of	O
the	O
proximal	O
segment	O
two	O
hours	O
after	O
the	O
onset	O
of	O
symptoms	O
.	O
He	O
was	O
subsequently	O
admitted	O
to	O
the	O
ICU	O
where	O
he	O
remained	O
for	O
48	O
hours	O
,	O
remaining	O
haemodynamically	O
stable	O
with	O
no	O
arrhythmic	O
events	O
or	O
signs	O
of	O
heart	O
failure	O
.	O
Subsequently	O
admitted	O
to	O
the	O
Cardiology	O
ward	O
,	O
the	O
physical	O
examination	O
on	O
admission	O
showed	O
the	O
patient	O
to	O
be	O
asymptomatic	O
with	O
an	O
adequate	O
level	O
of	O
consciousness	O
,	O
oriented	O
and	O
cooperative	O
,	O
BP	O
110	O
70	O
mmhg	O
,	O
HR	O
70	O
bpm	O
.	O
He	O
was	O
afebrile	O
,	O
eupneic	O
,	O
tolerated	O
decubitus	O
,	O
on	O
cardiopulmonary	O
auscultation	O
rhythmic	O
heart	O
sounds	O
without	O
murmurs	O
or	O
pericardial	O
friction	O
,	O
vesicular	O
murmur	O
present	O
bilaterally	O
with	O
minimal	O
crackles	O
in	O
the	O
lung	O
bases	O
,	O
soft	O
abdomen	O
,	O
not	O
distended	O
,	O
hydroaerial	O
sounds	O
present	O
,	O
no	O
peripheral	O
oedema	O
,	O
no	O
neurological	O
deficit	O
.	O
From	O
the	O
seventh	O
day	O
of	O
admission	O
,	O
she	O
presented	O
with	O
chest	O
pain	O
that	O
increased	O
with	O
deep	O
inspiration	O
and	O
changes	O
in	O
posture	O
without	O
new	O
variations	O
in	O
the	O
ECG	O
,	O
accompanied	O
by	O
palpitations	O
,	O
with	O
paroxysms	O
of	O
atrial	O
fibrillation	O
with	O
rapid	O
ventricular	O
response	O
120	O
140	O
bpm	O
associated	O
with	O
daily	O
febrile	O
peaks	O
38	O
40	O
C	O
without	O
infectious	O
symptoms	O
at	O
respiratory	O
,	O
urinary	O
and	O
abdominal	O
levels	O
.	O
Samples	O
were	O
taken	O
for	O
serial	O
blood	O
and	O
urine	O
cultures	O
,	O
which	O
were	O
repeatedly	O
negative	O
.	O
Transthoracic	O
echocardiography	O
showed	O
a	O
non	O
dilated	O
LV	O
with	O
akinesia	O
in	O
anteroseptal	O
and	O
apical	O
segments	O
,	O
LVEF	O
35	O
and	O
circumferential	O
pericardial	O
effusion	O
with	O
moderate	O
fibrin	O
15	O
mm	O
producing	O
partial	O
collapse	O
of	O
the	O
RV	O
in	O
end	O
diastole	O
with	O
respiratory	O
variations	O
in	O
tricuspid	O
and	O
transmitral	O
Doppler	O
velocity	O
.	O
From	O
the	O
analytical	O
point	O
of	O
view	O
,	O
there	O
was	O
discrete	O
leukocytosis	O
,	O
neutrophilia	O
,	O
ESR	O
and	O
elevated	O
CRP	O
.	O
Complementary	O
tests	O
ECG	O
Sinus	O
rhythm	O
at	O
88	O
bpm	O
.	O
IAH	O
.	O
PR	O
200	O
ms	O
.	O
ST	O
elevation	O
of	O
2	O
3	O
mm	O
in	O
DI	O
and	O
AVL	O
,	O
3	O
4	O
mm	O
in	O
V2	O
V3	O
with	O
sharp	O
T	O
wave	O
and	O
specular	O
decrease	O
in	O
the	O
inferior	O
leads	O
CBC	O
haemoglobin	O
15	O
.	O
2	O
g	O
dl	O
,	O
MCV	O
85	O
fl	O
,	O
leukocytes	O
11	O
,	O
400	O
,	O
neutrophils	O
82	O
,	O
lymphocytes	O
12	O
,	O
eosinophils	O
0	O
.	O
5	O
,	O
platelets	O
160	O
,	O
000	O
.	O
Biochemistry	O
Creatinine	O
0	O
.	O
60	O
mg	O
dl	O
,	O
urea	O
34	O
mg	O
dl	O
,	O
sodium	O
140	O
meq	O
l	O
,	O
potassium	O
4	O
.	O
8	O
meq	O
l	O
,	O
glucose	O
114	O
mg	O
dl	O
,	O
CRP	O
89	O
.	O
7	O
mg	O
l	O
.	O
Myocardial	O
damage	O
markers	O
ultrasensitive	O
Troponin	O
T	O
peak	O
10	O
,	O
000	O
ng	O
l	O
,	O
CPK	O
peak	O
5	O
,	O
938	O
mU	O
ml	O
Blood	O
cultures	O
x3	O
No	O
microbiological	O
isolation	O
.	O
Urine	O
culture	O
No	O
microbiological	O
isolation	O
.	O
Portable	O
chest	O
X	O
ray	O
Cardiomegaly	O
,	O
congestive	O
pattern	O
,	O
no	O
pneumonic	O
condensation	O
.	O
Initial	O
transthoracic	O
echocardiography	O
circumferential	O
pericardial	O
effusion	O
,	O
with	O
fibrin	O
,	O
with	O
a	O
width	O
of	O
16	O
mm	O
in	O
the	O
lateral	O
wall	O
of	O
the	O
LV	O
,	O
14	O
mm	O
in	O
the	O
apex	O
,	O
15	O
mm	O
in	O
the	O
RA	O
and	O
15	O
mm	O
in	O
the	O
diaphragmatic	O
face	O
of	O
the	O
RV	O
.	O
There	O
is	O
partial	O
collapse	O
of	O
the	O
RV	O
in	O
end	O
diastole	O
in	O
expiration	O
and	O
25	O
reduction	O
of	O
the	O
mitral	O
E	O
wave	O
in	O
inspiration	O
and	O
50	O
reduction	O
of	O
the	O
tricuspid	O
E	O
wave	O
in	O
expiration	O
.	O
Dilated	O
inferior	O
vena	O
cava	O
29	O
mm	O
,	O
with	O
little	O
inspiratory	O
reduction	O
.	O
LA	O
not	O
dilated	O
.	O
Normal	O
mitral	O
valve	O
.	O
Normal	O
aortic	O
valve	O
.	O
Non	O
dilated	O
LV	O
EDV	O
83	O
ml	O
,	O
without	O
hypertrophy	O
.	O
Inferolateral	O
wall	O
normokinesia	O
,	O
apical	O
and	O
septal	O
akinesia	O
and	O
hypokinesia	O
of	O
the	O
rest	O
.	O
EF	O
35	O
.	O
Normal	O
right	O
ventricle	O
.	O
Tricuspid	O
valve	O
without	O
insufficiency	O
.	O
Cardiac	O
catheterisation	O
TCI	O
without	O
significant	O
angiographic	O
lesions	O
.	O
ADA	O
Atheromatous	O
vessel	O
.	O
Thrombotic	O
obstruction	O
at	O
proximal	O
segment	O
level	O
,	O
with	O
TIMI	O
0	O
initial	O
flow	O
.	O
Non	O
dominant	O
ACx	O
Atheromatous	O
and	O
calcified	O
vessel	O
.	O
Significant	O
disease	O
at	O
the	O
distal	O
segment	O
of	O
the	O
main	O
marginal	O
Bifurcated	O
lesion	O
with	O
distal	O
beds	O
of	O
small	O
calibre	O
,	O
non	O
diseased	O
.	O
Chronic	O
occlusion	O
of	O
the	O
middle	O
segment	O
.	O
Distal	O
beds	O
of	O
good	O
calibre	O
and	O
development	O
,	O
not	O
diseased	O
,	O
visualised	O
through	O
the	O
right	O
coronary	O
artery	O
.	O
Dominant	O
RCA	O
vessel	O
of	O
good	O
calibre	O
and	O
development	O
,	O
with	O
parietal	O
irregularities	O
,	O
without	O
significant	O
angiographic	O
lesions	O
.	O
Primary	O
PTCA	O
on	O
the	O
culprit	O
lesion	O
of	O
the	O
proximal	O
LAD	O
thromboaspiration	O
and	O
direct	O
implantation	O
of	O
conventional	O
stent	O
.	O
Good	O
initial	O
angiographic	O
result	O
,	O
with	O
final	O
TIMI	O
3	O
flow	O
.	O
Good	O
distal	O
vessel	O
,	O
not	O
diseased	O
.	O
Clinical	O
evolution	O
Given	O
these	O
findings	O
,	O
the	O
differential	O
diagnosis	O
of	O
the	O
origin	O
of	O
the	O
fever	O
was	O
considered	O
;	O
firstly	O
in	O
the	O
context	O
of	O
Dressler	O
's	O
syndrome	O
and	O
less	O
likely	O
an	O
infectious	O
aetiology	O
;	O
treatment	O
was	O
started	O
with	O
500	O
mg	O
of	O
ASA	B-FARMACO
every	O
6	O
hours	O
,	O
0	O
.	O
5	O
mg	O
of	O
colchicine	B-FARMACO
every	O
24	O
hours	O
and	O
in	O
conjunction	O
with	O
the	O
Infectious	O
Diseases	O
Unit	O
it	O
was	O
decided	O
to	O
start	O
empirical	O
antibiotic	O
therapy	O
with	O
400	O
mg	O
of	O
teicoplanin	B-FARMACO
every	O
12	O
hours	O
until	O
the	O
results	O
of	O
the	O
blood	O
cultures	O
extracted	O
were	O
obtained	O
.	O
The	O
initial	O
evolution	O
was	O
favourable	O
with	O
disappearance	O
of	O
fever	O
during	O
the	O
next	O
48	O
hours	O
,	O
with	O
evident	O
improvement	O
in	O
the	O
patient	O
's	O
general	O
condition	O
and	O
due	O
to	O
the	O
absence	O
of	O
microbiological	O
isolation	O
in	O
the	O
blood	O
cultures	O
,	O
antibiotic	O
therapy	O
was	O
suspended	O
after	O
72	O
hours	O
.	O
However	O
,	O
in	O
the	O
following	O
days	O
the	O
patient	O
's	O
general	O
condition	O
worsened	O
again	O
with	O
recurrence	O
of	O
fever	O
and	O
the	O
control	O
echocardiography	O
showed	O
an	O
increase	O
in	O
the	O
amount	O
of	O
pericardial	O
effusion	O
36	O
mm	O
at	O
lateral	O
level	O
of	O
the	O
RV	O
,	O
18	O
mm	O
at	O
apical	O
level	O
of	O
the	O
LV	O
and	O
37	O
mm	O
at	O
subcostal	O
level	O
;	O
for	O
this	O
reason	O
it	O
was	O
decided	O
to	O
start	O
oral	O
corticosteroids	O
at	O
a	O
dose	O
of	O
60	O
mg	O
of	O
prednisone	B-FARMACO
every	O
24	O
hours	O
.	O
In	O
the	O
following	O
days	O
the	O
clinical	O
evolution	O
was	O
favourable	O
with	O
disappearance	O
of	O
fever	O
,	O
progressive	O
improvement	O
of	O
general	O
condition	O
and	O
gradual	O
decrease	O
of	O
inflammatory	O
markers	O
,	O
echocardiography	O
at	O
2	O
weeks	O
showed	O
a	O
significant	O
decrease	O
in	O
the	O
amount	O
of	O
pericardial	O
fluid	O
.	O
Finally	O
,	O
the	O
patient	O
was	O
discharged	O
home	O
,	O
asymptomatic	O
and	O
in	O
acceptable	O
functional	O
class	O
with	O
a	O
tapering	O
corticosteroid	O
regimen	O
Diagnosis	O
STEMI	O
anterior	O
Killip	O
I	O
,	O
underwent	O
primary	O
PCI	O
and	O
conventional	O
stent	O
implantation	O
x2	O
in	O
the	O
proximal	O
segment	O
of	O
the	O
LAD	O
.	O
Severely	O
depressed	O
LVEF	O
.	O
Coronary	O
artery	O
disease	O
in	O
mid	O
segment	O
of	O
ACx	O
and	O
distal	O
segment	O
of	O
non	O
revascularised	O
main	O
marginal	O
.	O
Post	O
MI	O
pericarditis	O
and	O
circumferential	O
pericardial	O
effusion	O
in	O
the	O
context	O
of	O
Dressler	O
's	O
syndrome	O
.	O
Paroxysmal	O
atrial	O
fibrillation	O
.	O

40	O
year	O
old	O
patient	O
,	O
referred	O
from	O
Nephrology	O
after	O
an	O
echocardiogram	O
showed	O
severe	O
concentric	O
LVH	O
,	O
suggestive	O
of	O
myocardial	O
infiltration	O
,	O
EF	O
in	O
the	O
lower	O
limits	O
of	O
normality	O
.	O
History	O
,	O
current	O
disease	O
and	O
physical	O
examination	O
History	O
40	O
year	O
old	O
patient	O
,	O
no	O
known	O
drug	O
allergies	O
.	O
Personal	O
history	O
of	O
pulmonary	O
TB	O
in	O
2004	O
,	O
bilateral	O
sensorineural	O
hearing	O
loss	O
,	O
diagnosed	O
at	O
19	O
years	O
of	O
age	O
,	O
uses	O
hearing	O
aid	O
,	O
familial	O
hypomagnesaemia	O
,	O
short	O
stature	O
familial	O
short	O
stature	O
,	O
chronic	O
renal	O
insufficiency	O
of	O
unknown	O
aetiology	O
,	O
being	O
transplanted	O
in	O
2002	O
,	O
evolved	O
with	O
acute	O
tubular	O
necrosis	O
,	O
left	O
eye	O
venous	O
thrombosis	O
,	O
systemic	O
arterial	O
hypertension	O
,	O
post	O
transplant	O
diabetes	O
mellitus	O
,	O
diabetic	O
gastroparesis	O
.	O
Surgical	O
interventions	O
Cholecystectomy	O
.	O
Renal	O
transplant	O
.	O
Current	O
treatment	O
Treatment	O
with	O
prednisone	B-FARMACO
,	O
advagraf	B-FARMACO
,	O
mycophenolate	B-FARMACO
,	O
losartan	B-FARMACO
100	O
mg	O
12	O
hours	O
,	O
insulin	B-FARMACO
,	O
magnesium	B-FARMACO
,	O
acfol	B-FARMACO
,	O
erythromycin	B-FARMACO
and	O
ranitidine	B-FARMACO
.	O
Current	O
illness	O
Referred	O
from	O
Nephrology	O
,	O
after	O
finding	O
severe	O
concentric	O
LVH	O
on	O
echocardiography	O
,	O
suggestive	O
of	O
myocardial	O
infiltration	O
,	O
EF	O
below	O
normal	O
limits	O
.	O
Physical	O
examination	O
Good	O
general	O
condition	O
.	O
Normohydrated	O
and	O
normoperfundio	O
.	O
No	O
signs	O
of	O
heart	O
failure	O
.	O
Venous	O
and	O
central	O
pressures	O
normal	O
.	O
Palpation	O
nondescript	O
.	O
Rhythmic	O
tones	O
,	O
no	O
murmurs	O
.	O
Normal	O
ventilation	O
.	O
No	O
hepatomegaly	O
or	O
oedema	O
.	O
Peripheral	O
pulses	O
preserved	O
.	O
BP	O
115	O
85	O
.	O
Complementary	O
tests	O
MRI	O
without	O
I	O
.	O
V	O
.	O
contrast	O
of	O
the	O
heart	O
11	O
04	O
2012	O
.	O
Regions	O
studied	O
COR	O
Heart	O
.	O
Findings	O
diagnostic	O
indications	O
impression	O
Clinical	O
report	O
Sd	O
Allport	O
.	O
Renal	O
transplanted	O
.	O
DM	O
.	O
De	O
novo	O
HF	O
.	O
Pattern	O
suggestive	O
of	O
restrictive	O
cardiomyopathy	O
by	O
echocardiographic	O
infiltration	O
.	O
Gradient	O
echo	O
sequences	O
were	O
performed	O
in	O
4	O
chamber	O
planes	O
,	O
short	O
axis	O
,	O
T2	O
weighted	O
spin	O
echo	O
sequences	O
and	O
triple	O
IR	O
in	O
short	O
axis	O
,	O
basal	O
perfusion	O
and	O
late	O
enhancement	O
with	O
gadolinium	O
.	O
Informed	O
consent	O
form	O
was	O
given	O
,	O
which	O
the	O
patient	O
read	O
and	O
signed	O
.	O
The	O
study	O
was	O
limited	O
due	O
to	O
the	O
patient	O
's	O
lack	O
of	O
cooperation	O
because	O
of	O
severe	O
hypoacusis	O
.	O
Left	O
ventricle	O
volume	O
within	O
normal	O
limits	O
68	O
.	O
5	O
ml	O
m2	O
,	O
increased	O
myocardial	O
mass	O
114	O
gr	O
m2	O
.	O
Concentric	O
hypertrophy	O
middle	O
septum	O
16	O
mm	O
,	O
inferolateral	O
wall	O
15	O
mm	O
.	O
Ejection	O
fraction	O
at	O
lower	O
limit	O
of	O
normal	O
.	O
Right	O
ventricle	O
of	O
normal	O
volumes	O
,	O
wall	O
hypertrophy	O
.	O
Ejection	O
fraction	O
within	O
normal	O
.	O
Atria	O
volumes	O
within	O
normal	O
.	O
Aortic	O
,	O
mitral	O
and	O
pulmonary	O
valves	O
without	O
significant	O
alterations	O
.	O
Mild	O
tricuspid	O
regurgitation	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
.	O
Normal	O
pericardial	O
thickness	O
.	O
After	O
gadolinium	O
administration	O
,	O
diffuse	O
late	O
enhancement	O
,	O
at	O
basal	O
inferior	O
subepicardial	O
level	O
,	O
subepicardial	O
in	O
lower	O
middle	O
third	O
and	O
inferolateral	O
.	O
Intramyocardial	O
at	O
medial	O
lateral	O
and	O
apicolateral	O
level	O
,	O
pattern	O
suggestive	O
of	O
Fabry	O
disease	O
as	O
first	O
option	O
Severe	O
gastric	O
dilatation	O
with	O
contents	O
inside	O
,	O
in	O
a	O
probable	O
context	O
of	O
gastroparesis	O
in	O
a	O
diabetic	O
patient	O
.	O
In	O
summary	O
Infiltrative	O
cardiomyopathy	O
suggestive	O
of	O
Fabry	O
disease	O
.	O
Gastric	O
gastroparesis	O
.	O
Right	O
ventricle	O
.	O
Sinus	O
end	O
diastolic	O
volume	O
VD	O
47	O
.	O
6	O
ml	O
.	O
Sinus	O
end	O
systolic	O
volume	O
RV	O
17	O
.	O
2	O
ml	O
.	O
Total	O
TVD	O
VD	O
47	O
.	O
6	O
ml	O
.	O
Total	O
RV	O
ESV	O
17	O
.	O
2	O
ml	O
.	O
RV	O
beat	O
volume	O
30	O
.	O
3	O
ml	O
.	O
Sinus	O
EF	O
RV	O
63	O
.	O
8	O
ml	O
.	O
RV	O
ejection	O
fraction	O
63	O
.	O
8	O
.	O
RV	O
end	O
diastolic	O
volume	O
index	O
34	O
.	O
5	O
ml	O
m2	O
.	O
RV	O
tele	O
systolic	O
volume	O
index	O
12	O
.	O
5	O
ml	O
m2	O
.	O
Left	O
ventricle	O
.	O
Anteroseptal	O
Parietal	O
Thickness	O
14	O
.	O
6	O
mm	O
.	O
LV	O
Posterior	O
Parietal	O
Thickness	O
.	O
14	O
.	O
7	O
mm	O
.	O
Tele	O
diastolic	O
diameter	O
43	O
.	O
8	O
mm	O
.	O
LV	O
end	O
systolic	O
diameter	O
31	O
.	O
2	O
mm	O
.	O
LV	O
end	O
diastolic	O
volume	O
82	O
ml	O
.	O
LV	O
end	O
systolic	O
volume	O
42	O
.	O
5	O
ml	O
.	O
Epicardial	O
end	O
diastolic	O
volume	O
227	O
.	O
1	O
ml	O
.	O
LV	O
ejection	O
fraction	O
48	O
.	O
2	O
.	O
LV	O
end	O
diastolic	O
volume	O
index	O
59	O
.	O
5	O
ml	O
m2	O
.	O
LV	O
end	O
systolic	O
volume	O
index	O
30	O
.	O
8	O
ml	O
m2	O
.	O
Fractional	O
shortening	O
28	O
.	O
Beat	O
volume	O
index	O
28	O
.	O
7	O
ml	O
m2	O
.	O
Heart	O
rate	O
52	O
bpm	O
.	O
Cardiac	O
output	O
2	O
.	O
1	O
l	O
min	O
.	O
Cardiac	O
index	O
1	O
.	O
5	O
l	O
min	O
m2	O
.	O
LV	O
TD	O
mass	O
152	O
.	O
3g	O
.	O
Biochemical	O
and	O
genetic	O
analysis	O
Alpha	O
galactosidase	O
A	O
enzyme	O
activity	O
876	O
nmol	O
h	O
per	O
mg	O
protein	O
.	O
Genetic	O
analysis	O
Mutation	O
in	O
the	O
alpha	O
gal	O
A	O
gene	O
,	O
in	O
exon	O
5	O
,	O
c680a	O
t	O
,	O
amino	O
acid	O
change	O
,	O
genotype	O
R227Q	O
.	O
Clinical	O
course	O
The	O
patient	O
is	O
stable	O
from	O
the	O
cardiovascular	O
point	O
of	O
view	O
,	O
with	O
no	O
chest	O
pain	O
,	O
no	O
signs	O
of	O
heart	O
failure	O
,	O
no	O
dyspnoeic	O
or	O
syncopal	O
symptoms	O
.	O
Diagnosis	O
Restrictive	O
infiltrative	O
cardiomyopathy	O
in	O
a	O
patient	O
with	O
symmetric	O
concentric	O
hypertrophy	O
of	O
the	O
left	O
ventricle	O
,	O
mutation	O
of	O
the	O
alpha	O
galacotsidase	O
A	O
gene	O
and	O
enzyme	O
deficiency	O
associated	O
with	O
Fabry	O
Anderson	O
disease	O
.	O

A	O
17	O
year	O
old	O
federated	O
sportsman	O
who	O
consulted	O
the	O
Emergency	O
Department	O
on	O
up	O
to	O
six	O
occasions	O
for	O
episodes	O
of	O
fainting	O
,	O
leading	O
to	O
loss	O
of	O
consciousness	O
in	O
the	O
middle	O
of	O
a	O
sporting	O
competition	O
,	O
over	O
the	O
last	O
two	O
months	O
.	O
History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
Personal	O
history	O
17	O
year	O
old	O
male	O
.	O
Federated	O
sportsman	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
No	O
cardiovascular	O
risk	O
factors	O
.	O
No	O
toxic	O
habits	O
.	O
No	O
personal	O
or	O
family	O
history	O
of	O
heart	O
disease	O
.	O
Present	O
illness	O
A	O
17	O
year	O
old	O
federated	O
sportsman	O
who	O
consulted	O
the	O
Emergency	O
Department	O
on	O
up	O
to	O
6	O
occasions	O
for	O
episodes	O
of	O
fainting	O
,	O
leading	O
to	O
loss	O
of	O
consciousness	O
in	O
the	O
middle	O
of	O
a	O
sporting	O
competition	O
,	O
over	O
the	O
last	O
two	O
months	O
.	O
Given	O
the	O
presence	O
of	O
repeated	O
syncopes	O
related	O
to	O
exercise	O
,	O
the	O
patient	O
was	O
admitted	O
to	O
Cardiology	O
for	O
screening	O
for	O
a	O
cardiac	O
cause	O
.	O
He	O
also	O
reported	O
other	O
episodes	O
of	O
dizziness	O
and	O
syncope	O
with	O
a	O
vaso	O
vagal	O
profile	O
syncope	O
preceded	O
by	O
abdominal	O
discomfort	O
,	O
nausea	O
and	O
dizziness	O
lasting	O
seconds	O
.	O
As	O
additional	O
symptoms	O
,	O
she	O
reported	O
occasional	O
headache	O
that	O
increased	O
with	O
coughing	O
and	O
exertion	O
.	O
She	O
did	O
not	O
report	O
dyspnoea	O
,	O
chest	O
pain	O
or	O
palpitations	O
.	O
Given	O
the	O
normality	O
of	O
the	O
initial	O
complementary	O
tests	O
performed	O
ECG	O
,	O
chest	O
X	O
ray	O
,	O
echocardiogram	O
,	O
ECG	O
monitoring	O
and	O
ergometry	O
,	O
the	O
patient	O
was	O
discharged	O
with	O
the	O
diagnosis	O
of	O
syncope	O
of	O
probable	O
neuromediated	O
origin	O
,	O
and	O
it	O
was	O
recommended	O
that	O
the	O
maximum	O
heart	O
rate	O
should	O
not	O
be	O
exceeded	O
during	O
physical	O
exertion	O
.	O
Two	O
weeks	O
later	O
,	O
he	O
was	O
admitted	O
again	O
after	O
presenting	O
three	O
syncopal	O
episodes	O
,	O
one	O
of	O
them	O
just	O
after	O
performing	O
an	O
exercise	O
stress	O
test	O
,	O
where	O
he	O
reached	O
197	O
bpm	O
.	O
It	O
is	O
reported	O
that	O
at	O
the	O
end	O
of	O
the	O
test	O
,	O
once	O
the	O
recovery	O
period	O
was	O
over	O
and	O
the	O
ECG	O
electrodes	O
had	O
been	O
disconnected	O
,	O
he	O
presented	O
syncope	O
with	O
very	O
severe	O
hypotension	O
and	O
without	O
giving	O
time	O
for	O
electrocardiographic	O
monitoring	O
.	O
The	O
second	O
episode	O
occurred	O
after	O
playing	O
a	O
football	O
match	O
preceded	O
by	O
abdominal	O
discomfort	O
,	O
and	O
finally	O
the	O
third	O
episode	O
occurred	O
after	O
a	O
shower	O
,	O
taking	O
about	O
4	O
minutes	O
to	O
recover	O
,	O
according	O
to	O
the	O
family	O
.	O
To	O
complete	O
the	O
study	O
,	O
a	O
cardiac	O
MRI	O
was	O
performed	O
to	O
rule	O
out	O
arrhythmogenic	O
dysplasia	O
,	O
a	O
flecainide	O
test	O
to	O
simulate	O
a	O
Brugada	O
type	O
II	O
ECG	O
pattern	O
,	O
a	O
tilt	O
table	O
test	O
and	O
a	O
neurological	O
study	O
given	O
the	O
prolonged	O
duration	O
of	O
the	O
last	O
episode	O
.	O
The	O
cardiac	O
MRI	O
was	O
reported	O
as	O
normal	O
,	O
as	O
well	O
as	O
the	O
flecainide	O
test	O
and	O
the	O
electroencephalogram	O
.	O
Neurology	O
was	O
consulted	O
and	O
a	O
cranial	O
MRI	O
was	O
requested	O
,	O
which	O
gave	O
the	O
diagnosis	O
as	O
the	O
cerebellar	O
tonsils	O
were	O
found	O
to	O
be	O
descended	O
with	O
rectification	O
of	O
the	O
floor	O
of	O
the	O
fourth	O
ventricle	O
.	O
The	O
patient	O
was	O
discharged	O
with	O
the	O
diagnosis	O
of	O
Chiari	O
malformation	O
type	O
I	O
.	O
Physical	O
examination	O
BP	O
90	O
50	O
.	O
HR	O
60lpm	O
.	O
Conscious	O
and	O
oriented	O
.	O
Normohydrated	O
and	O
normoperfused	O
.	O
Eupneic	O
at	O
rest	O
.	O
ACR	O
rhythmic	O
tones	O
without	O
audible	O
murmurs	O
.	O
VCM	O
without	O
superimposed	O
noises	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
without	O
masses	O
or	O
megaliths	O
.	O
Not	O
painful	O
on	O
palpation	O
.	O
Lower	O
extremities	O
with	O
preserved	O
and	O
symmetrical	O
pulses	O
.	O
Complementary	O
tests	O
Complementary	O
examination	O
.	O
ECG	O
Sinus	O
rhythm	O
at	O
75	O
bpm	O
and	O
incomplete	O
right	O
bundle	O
branch	O
block	O
with	O
J	O
point	O
elevation	O
in	O
right	O
precordial	O
leads	O
and	O
normal	O
QTc	O
interval	O
.	O
Chest	O
X	O
ray	O
Cardiothoracic	O
index	O
within	O
normal	O
limits	O
.	O
No	O
congestive	O
signs	O
.	O
Echocardiogram	O
Left	O
ventricle	O
not	O
dilated	O
or	O
hypertrophic	O
,	O
with	O
global	O
and	O
segmental	O
systolic	O
function	O
within	O
normal	O
limits	O
.	O
Left	O
atrium	O
not	O
dilated	O
.	O
Normal	O
right	O
chambers	O
.	O
Normal	O
left	O
ventricular	O
filling	O
pattern	O
.	O
No	O
valvular	O
or	O
pericardial	O
abnormalities	O
.	O
Normal	O
aortic	O
root	O
and	O
ascending	O
aorta	O
.	O
Atrial	O
septum	O
and	O
interventricular	O
septum	O
intact	O
.	O
No	O
gradient	O
in	O
descending	O
aorta	O
.	O
Ergometry	O
Stopped	O
due	O
to	O
twin	O
contracture	O
,	O
at	O
78	O
of	O
submaximal	O
heart	O
rate	O
.	O
No	O
clinical	O
or	O
electrical	O
events	O
of	O
interest	O
were	O
observed	O
.	O
Flecainide	O
test	O
Stopped	O
after	O
7	O
minutes	O
of	O
infusion	O
2	O
3	O
dose	O
of	O
the	O
drug	O
as	O
the	O
patient	O
felt	O
dizziness	O
and	O
without	O
any	O
electrocardiographic	O
alteration	O
suspicious	O
of	O
Brugada	O
syndrome	O
.	O
Cardiac	O
MRI	O
non	O
dilated	O
right	O
ventricle	O
,	O
with	O
a	O
free	O
wall	O
of	O
normal	O
thickness	O
,	O
without	O
irregularities	O
or	O
images	O
of	O
pseudoaneurysm	O
.	O
There	O
was	O
no	O
fatty	O
infiltration	O
of	O
the	O
wall	O
.	O
There	O
was	O
no	O
RV	O
dysfunction	O
,	O
with	O
volumes	O
and	O
EF	O
within	O
normal	O
limits	O
.	O
Electroencephalogram	O
baseline	O
cerebral	O
bioelectrical	O
activity	O
was	O
normal	O
.	O
No	O
focal	O
or	O
generalised	O
paroxysmal	O
abnormalities	O
were	O
observed	O
.	O
Cerebral	O
MRI	O
Cerebellar	O
tonsil	O
descent	O
with	O
rectification	O
of	O
the	O
floor	O
of	O
the	O
fourth	O
ventricle	O
.	O
No	O
signs	O
of	O
hydrocephalus	O
or	O
intracerebral	O
lesions	O
were	O
observed	O
.	O
The	O
diagnosis	O
of	O
Arnold	O
Chiari	O
is	O
confirmed	O
.	O
Clinical	O
evolution	O
The	O
patient	O
was	O
referred	O
to	O
neurosurgery	O
and	O
underwent	O
a	O
suboccipital	O
craniectomy	O
and	O
laminectomy	O
of	O
C1	O
.	O
The	O
patient	O
has	O
progressively	O
resumed	O
sporting	O
activity	O
without	O
new	O
syncopal	O
episodes	O
.	O
Diagnosis	O
Recurrent	O
syncope	O
in	O
a	O
patient	O
with	O
Chiari	O
malformation	O
type	O
I	O
.	O

49	O
year	O
old	O
woman	O
,	O
who	O
,	O
while	O
teaching	O
,	O
presented	O
with	O
dizziness	O
and	O
general	O
malaise	O
,	O
followed	O
by	O
loss	O
of	O
consciousness	O
.	O
History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
Personal	O
history	O
No	O
known	O
allergies	O
.	O
Smoker	O
of	O
1	O
pack	O
a	O
day	O
.	O
No	O
alcohol	O
or	O
other	O
drugs	O
.	O
High	O
blood	O
pressure	O
,	O
discontinued	O
pharmacological	O
treatment	O
.	O
Mild	O
dyslipidaemia	O
on	O
dietary	O
treatment	O
.	O
Anxiety	O
depressive	O
syndrome	O
.	O
Episodes	O
of	O
anxiety	O
for	O
8	O
years	O
,	O
consisting	O
of	O
chest	O
pains	O
,	O
palpitations	O
,	O
sweating	O
and	O
paleness	O
.	O
She	O
was	O
assessed	O
by	O
Cardiology	O
for	O
these	O
episodes	O
,	O
with	O
no	O
significant	O
findings	O
.	O
She	O
was	O
subsequently	O
assessed	O
by	O
psychiatry	O
a	O
year	O
ago	O
.	O
Paroxetine	B-FARMACO
was	O
prescribed	O
,	O
and	O
the	O
episodes	O
,	O
which	O
were	O
very	O
frequent	O
almost	O
daily	O
,	O
disappeared	O
.	O
However	O
,	O
in	O
the	O
week	O
prior	O
to	O
the	O
cardiac	O
arrest	O
that	O
led	O
to	O
her	O
admission	O
,	O
she	O
had	O
again	O
presented	O
pictures	O
of	O
central	O
thoracic	O
pain	O
,	O
with	O
significant	O
vegative	O
crusade	O
without	O
syncope	O
or	O
palpitations	O
,	O
lasting	O
a	O
few	O
minutes	O
and	O
spontaneous	O
recovery	O
.	O
No	O
family	O
history	O
of	O
heart	O
disease	O
.	O
Usual	O
treatment	O
paroxetine	B-FARMACO
.	O
Current	O
episode	O
49	O
year	O
old	O
female	O
patient	O
who	O
,	O
while	O
teaching	O
she	O
is	O
a	O
secondary	O
school	O
teacher	O
,	O
presented	O
with	O
dizziness	O
and	O
general	O
malaise	O
,	O
followed	O
by	O
loss	O
of	O
consciousness	O
.	O
According	O
to	O
her	O
co	O
worker	O
,	O
they	O
initially	O
felt	O
for	O
a	O
pulse	O
,	O
noting	O
a	O
very	O
high	O
heart	O
rate	O
,	O
and	O
then	O
stopped	O
feeling	O
a	O
pulse	O
.	O
The	O
school	O
staff	O
started	O
basic	O
cardiopulmonary	O
resuscitation	O
manoeuvres	O
for	O
about	O
20	O
minutes	O
,	O
which	O
was	O
the	O
time	O
it	O
took	O
for	O
the	O
SAMU	O
to	O
arrive	O
.	O
On	O
arrival	O
,	O
the	O
SAMU	O
monitored	O
the	O
patient	O
and	O
found	O
ventricular	O
fibrillation	O
on	O
the	O
monitor	O
and	O
administered	O
a	O
200	O
J	O
shock	O
,	O
leaving	O
the	O
patient	O
in	O
a	O
rhythm	O
that	O
appeared	O
to	O
be	O
atrial	O
fibrillation	O
no	O
clear	O
atrial	O
mechanism	O
,	O
narrow	O
QRS	O
,	O
HR	O
99	O
100	O
bpm	O
.	O
She	O
was	O
intubated	O
after	O
sedation	O
relaxation	O
with	O
30	O
mg	O
midazolam	B-FARMACO
and	O
10	O
mg	O
norcuronium	B-FARMACO
.	O
The	O
patient	O
was	O
transferred	O
to	O
the	O
hospital	O
and	O
admitted	O
to	O
the	O
Intensive	O
Care	O
Unit	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
112	O
62	O
mmHg	O
,	O
HR	O
92	O
beats	O
min	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
no	O
murmurs	O
or	O
friction	O
rubs	O
.	O
Pulmonary	O
auscultation	O
intubated	O
No	O
extra	O
sounds	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
,	O
no	O
masses	O
or	O
megaliths	O
palpable	O
.	O
Lower	O
limbs	O
No	O
oedema	O
.	O
Peripheral	O
pulses	O
preserved	O
and	O
symmetrical	O
.	O
Complementary	O
tests	O
ECG	O
Sinus	O
rhythm	O
at	O
90	O
bpm	O
.	O
Axis	O
at	O
0o	O
.	O
NO	O
alterations	O
in	O
atrioventricular	O
or	O
intraventricular	O
conduction	O
.	O
Adequate	O
progression	O
of	O
R	O
in	O
precordial	O
leads	O
.	O
No	O
repolarisation	O
alterations	O
.	O
Echocardiogram	O
Left	O
ventricle	O
of	O
preserved	O
size	O
and	O
function	O
,	O
without	O
segmental	O
alterations	O
of	O
contractility	O
and	O
with	O
pseudonormal	O
filling	O
pattern	O
E	O
A	O
that	O
reverses	O
with	O
Valsalva	O
.	O
Absence	O
of	O
significant	O
valvulopathies	O
.	O
RV	O
of	O
preserved	O
size	O
and	O
function	O
.	O
Minimal	O
tricuspid	O
insufficiency	O
that	O
allowed	O
estimating	O
a	O
PsAP	O
of	O
35	O
mmHg	O
.	O
NO	O
signs	O
of	O
increased	O
central	O
venous	O
pressure	O
.	O
Chest	O
X	O
ray	O
Bibasal	O
interstitial	O
pattern	O
.	O
Right	O
hilum	O
thickening	O
.	O
Cranial	O
CT	O
No	O
haematic	O
collections	O
or	O
space	O
occupying	O
lesions	O
in	O
cerebellar	O
parenchyma	O
or	O
brainstem	O
.	O
Ventricular	O
system	O
and	O
sulci	O
without	O
alterations	O
.	O
Midline	O
structures	O
centred	O
.	O
Laboratory	O
tests	O
Biochemistry	O
Glucose	O
289	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
69	O
mg	O
dl	O
,	O
CRP	O
3	O
.	O
1	O
mg	O
L	O
,	O
Na	O
140	O
mEq	O
l	O
,	O
K	O
4	O
.	O
9	O
mEq	O
l	O
,	O
CK	O
246	O
to	O
495	O
U	O
l	O
,	O
ultrasensitive	O
troponin	O
T	O
130	O
to	O
1509	O
ng	O
l	O
.	O
Haemogram	O
Hb	O
14	O
.	O
6	O
g	O
dl	O
,	O
haematocrit	O
44	O
.	O
8	O
,	O
leucocytes	O
10	O
,	O
600	O
,	O
neutrophils	O
55	O
.	O
5	O
,	O
platelets	O
307	O
,	O
000	O
.	O
Haemostasis	O
INR	O
1	O
.	O
Urine	O
toxicity	O
Positive	O
for	O
benzodiazepines	O
.	O
Clinical	O
course	O
After	O
a	O
cranial	O
CT	O
scan	O
,	O
the	O
patient	O
was	O
connected	O
to	O
invasive	O
mechanical	O
ventilation	O
and	O
a	O
right	O
subclavian	O
central	O
line	O
was	O
placed	O
.	O
Initially	O
the	O
patient	O
had	O
mydriatic	O
pupils	O
,	O
but	O
reactive	O
to	O
light	O
,	O
under	O
the	O
effects	O
of	O
sedorelaxation	O
administered	O
by	O
the	O
SAMU	O
.	O
Sedoanalgesia	O
was	O
started	O
with	O
propofol	B-FARMACO
and	O
remifentanil	B-FARMACO
,	O
and	O
hypothermia	O
for	O
24	O
hours	O
.	O
Echocardiography	O
ruled	O
out	O
segmental	O
contractility	O
alterations	O
and	O
showed	O
a	O
normal	O
right	O
ventricle	O
.	O
The	O
ECG	O
showed	O
no	O
signs	O
of	O
acute	O
ischaemia	O
,	O
no	O
signs	O
of	O
pre	O
excitation	O
,	O
no	O
QT	O
lengthening	O
,	O
and	O
no	O
changes	O
suggestive	O
of	O
Brugada	O
.	O
Cranial	O
CT	O
ruled	O
out	O
brain	O
lesions	O
justifying	O
the	O
cardiac	O
arrest	O
.	O
Blood	O
tests	O
showed	O
no	O
electrolyte	O
abnormalities	O
.	O
Amiodarone	B-FARMACO
infusion	O
was	O
started	O
,	O
but	O
had	O
to	O
be	O
suspended	O
24	O
hours	O
after	O
the	O
start	O
of	O
administration	O
due	O
to	O
the	O
ECG	O
showing	O
QT	O
prolongation	O
.	O
The	O
day	O
after	O
his	O
admission	O
with	O
normal	O
QT	O
corrected	O
he	O
presented	O
episodes	O
of	O
Torsades	O
de	O
pointes	O
,	O
which	O
led	O
to	O
ventricular	O
fibrillation	O
,	O
for	O
which	O
reason	O
lidocaine	B-FARMACO
perfusion	O
was	O
started	O
for	O
48	O
hours	O
.	O
The	O
ECG	O
prior	O
to	O
the	O
ventricular	O
arrhythmia	O
showed	O
signs	O
suggestive	O
of	O
infero	O
posterior	O
and	O
lateral	O
subepicardial	O
lesions	O
ST	O
segment	O
elevation	O
4mm	O
II	O
,	O
III	O
,	O
aVF	O
,	O
V5	O
and	O
V6	O
with	O
mirror	O
image	O
V1	O
V2	O
.	O
Coronary	O
angiography	O
showed	O
non	O
significant	O
lesions	O
in	O
the	O
anterior	O
descending	O
artery	O
,	O
very	O
spastic	O
,	O
improving	O
with	O
intracoronary	O
nitroglycerine	B-FARMACO
;	O
70	O
stenosis	O
in	O
the	O
middle	O
segment	O
of	O
the	O
right	O
posterolateral	O
branch	O
,	O
with	O
good	O
distal	O
flow	O
.	O
The	O
study	O
was	O
completed	O
with	O
cardiac	O
MRI	O
which	O
ruled	O
out	O
cardiomyopathy	O
.	O
Given	O
the	O
suspicion	O
of	O
sustained	O
vasospasm	O
causing	O
myocardial	O
ischaemia	O
and	O
ventricular	O
arrhythmias	O
,	O
calcium	O
antagonists	O
were	O
prescribed	O
;	O
and	O
due	O
to	O
the	O
coronary	O
lesions	O
,	O
antiplatelet	O
therapy	O
was	O
started	O
initially	O
clopidogrel	B-FARMACO
and	O
adiro	B-FARMACO
,	O
which	O
after	O
an	O
episode	O
of	O
upper	O
gastrointestinal	O
bleeding	O
self	O
limited	O
melena	O
was	O
maintained	O
only	O
with	O
clopidogrel	B-FARMACO
.	O
Since	O
then	O
,	O
no	O
new	O
ventricular	O
arrhythmias	O
were	O
recorded	O
on	O
continuous	O
ECG	O
monitoring	O
.	O
The	O
patient	O
remained	O
haemodynamically	O
stable	O
throughout	O
the	O
admission	O
,	O
being	O
extubated	O
and	O
with	O
progressive	O
improvement	O
of	O
her	O
neurological	O
situation	O
,	O
being	O
completely	O
oriented	O
,	O
without	O
any	O
residual	O
focality	O
and	O
presenting	O
only	O
a	O
certain	O
degree	O
of	O
anterograde	O
amnesia	O
,	O
with	O
difficulty	O
in	O
retaining	O
the	O
events	O
following	O
the	O
cardiac	O
arrest	O
.	O
Despite	O
the	O
absence	O
of	O
new	O
arrhythmic	O
episodes	O
after	O
vasodilator	O
treatment	O
,	O
prior	O
to	O
discharge	O
it	O
was	O
decided	O
to	O
implant	O
a	O
bicameral	O
ICD	O
,	O
which	O
took	O
place	O
without	O
incident	O
.	O
She	O
was	O
reviewed	O
in	O
the	O
outpatient	O
clinic	O
3	O
months	O
after	O
discharge	O
without	O
any	O
new	O
episodes	O
of	O
chest	O
pain	O
or	O
syncope	O
.	O
No	O
sustained	O
ventricular	O
arrhythmias	O
were	O
recorded	O
during	O
device	O
monitoring	O
.	O
Diagnosis	O
Coronary	O
vasospasm	O
Ventricular	O
fibrillation	O
and	O
resuscitated	O
cardiac	O
arrest	O

A	O
46	O
year	O
old	O
woman	O
attended	O
the	O
emergency	O
department	O
for	O
central	O
thoracic	O
pain	O
described	O
as	O
oppressive	O
,	O
sometimes	O
radiating	O
to	O
the	O
throat	O
and	O
on	O
other	O
occasions	O
to	O
the	O
left	O
arm	O
and	O
forearm	O
.	O
History	O
,	O
current	O
illness	O
and	O
physical	O
examination	O
Personal	O
history	O
Female	O
,	O
46	O
years	O
old	O
.	O
No	O
allergies	O
.	O
She	O
denies	O
DM	O
,	O
AHT	O
,	O
dyslipidaemia	O
or	O
hypertriglyceridaemia	O
.	O
Ex	O
smoker	O
for	O
10	O
years	O
,	O
20	O
packs	O
year	O
.	O
Hypothyroidism	O
in	O
substitutive	O
treatment	O
.	O
Depressive	O
syndrome	O
under	O
pharmacological	O
treatment	O
.	O
Surgical	O
interventions	O
Caesarean	O
section	O
.	O
No	O
personal	O
history	O
of	O
heart	O
disease	O
.	O
Family	O
history	O
Three	O
paternal	O
uncles	O
died	O
of	O
ischaemic	O
heart	O
disease	O
at	O
the	O
age	O
of	O
70	O
.	O
Living	O
father	O
does	O
not	O
recognise	O
cardiovascular	O
pathology	O
.	O
Living	O
mother	O
with	O
DM	O
.	O
1	O
apparently	O
healthy	O
brother	O
.	O
No	O
family	O
history	O
of	O
syncope	O
or	O
sudden	O
death	O
.	O
Usual	O
medication	O
Eutirox	B-FARMACO
75	O
mcg	O
day	O
,	O
thymanax	B-FARMACO
agomelatine	I-FARMACO
.	O
Reason	O
for	O
consultation	O
She	O
came	O
to	O
the	O
emergency	O
department	O
for	O
central	O
thoracic	O
pain	O
described	O
as	O
oppressive	O
,	O
sometimes	O
radiating	O
to	O
the	O
throat	O
and	O
on	O
other	O
occasions	O
to	O
the	O
left	O
arm	O
and	O
forearm	O
.	O
There	O
was	O
no	O
vegetative	O
cortex	O
,	O
dyspnoea	O
or	O
palpitations	O
.	O
The	O
pain	O
does	O
not	O
change	O
with	O
changes	O
in	O
posture	O
,	O
inspiration	O
or	O
palpation	O
.	O
First	O
episode	O
of	O
these	O
characteristics	O
3	O
days	O
ago	O
,	O
at	O
rest	O
,	O
unrelated	O
to	O
ingestion	O
.	O
The	O
pain	O
appears	O
and	O
disappears	O
progressively	O
,	O
although	O
its	O
duration	O
is	O
usually	O
short	O
a	O
few	O
minutes	O
and	O
is	O
repeated	O
several	O
times	O
over	O
a	O
couple	O
of	O
hours	O
.	O
They	O
usually	O
occur	O
during	O
the	O
night	O
.	O
Not	O
related	O
to	O
exertion	O
.	O
No	O
sensation	O
of	O
palpitations	O
neither	O
with	O
the	O
pain	O
nor	O
outside	O
these	O
episodes	O
.	O
No	O
clinical	O
signs	O
of	O
heart	O
failure	O
.	O
No	O
febrile	O
or	O
infectious	O
symptoms	O
.	O
She	O
has	O
never	O
presented	O
syncopal	O
episodes	O
.	O
She	O
only	O
refers	O
to	O
a	O
history	O
of	O
short	O
palpitations	O
for	O
which	O
she	O
has	O
never	O
had	O
to	O
consult	O
a	O
doctor	O
and	O
generally	O
in	O
states	O
of	O
increased	O
nervousness	O
she	O
denies	O
having	O
had	O
them	O
these	O
days	O
.	O
She	O
does	O
not	O
take	O
regular	O
physical	O
exercise	O
.	O
Physical	O
examination	O
Vital	O
signs	O
BP	O
163	O
71	O
mmHg	O
;	O
HR	O
60	O
bpm	O
;	O
O2	O
Sat	O
100	O
.	O
Conscious	O
and	O
oriented	O
in	O
time	O
,	O
space	O
and	O
person	O
.	O
Carotid	O
pulses	O
of	O
symmetrical	O
amplitude	O
,	O
non	O
sustained	O
.	O
No	O
murmurs	O
.	O
No	O
jugular	O
ingurgitation	O
.	O
AC	O
rhythmic	O
,	O
first	O
and	O
second	O
sounds	O
preserved	O
.	O
No	O
murmurs	O
or	O
friction	O
rubs	O
.	O
AP	O
preserved	O
vesicular	O
murmur	O
.	O
No	O
pain	O
on	O
palpation	O
of	O
the	O
left	O
costal	O
arches	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
diffusely	O
painful	O
on	O
palpation	O
,	O
with	O
no	O
signs	O
of	O
peritoneal	O
irritation	O
.	O
No	O
masses	O
,	O
hernias	O
or	O
visceromegaly	O
were	O
palpable	O
.	O
Hydro	O
aerial	O
sounds	O
present	O
.	O
No	O
oedema	O
of	O
the	O
lower	O
limbs	O
.	O
Palpable	O
and	O
symmetrical	O
distal	O
pulses	O
.	O
Complementary	O
tests	O
Glucose	O
78	O
mg	O
dL	O
,	O
creatinine	O
0	O
.	O
55	O
mg	O
dL	O
,	O
GOT	O
26	O
U	O
L	O
,	O
GPT	O
36	O
U	O
L	O
,	O
CK	O
42	O
U	O
L	O
,	O
ultrasensitive	O
troponin	O
T	O
7	O
.	O
67	O
ng	O
L	O
,	O
C	O
reactive	O
protein	O
0	O
.	O
8	O
mg	O
L	O
,	O
chlorine	O
105	O
mEq	O
L	O
,	O
sodium	O
140	O
mEq	O
L	O
,	O
potassium	O
3	O
.	O
9	O
mEq	O
L	O
.	O
Haematology	O
Hematies	O
4	O
.	O
3	O
x	O
10	O
6	O
L	O
,	O
haemoglobin	O
13	O
.	O
1	O
g	O
dL	O
,	O
haematocrit	O
37	O
.	O
9	O
,	O
MCV	O
89	O
fL	O
,	O
HBGCM	O
30	O
.	O
8	O
pg	O
,	O
leucocytes	O
8	O
.	O
2x10	O
3	O
L	O
,	O
neutrophil	O
5	O
.	O
0	O
x	O
10	O
3	O
L	O
,	O
lymphocytes	O
2	O
.	O
3x10	O
3	O
L	O
,	O
monocytes	O
0	O
.	O
8x10	O
3	O
L	O
,	O
eosinophils	O
0	O
.	O
1x10	O
3	O
L	O
,	O
basophils	O
0	O
.	O
0	O
x	O
10	O
3	O
L	O
,	O
neutrophils	O
60	O
.	O
9	O
,	O
lymphocytes	O
28	O
.	O
5	O
,	O
monocytes	O
9	O
.	O
3	O
,	O
eosinophils	O
1	O
.	O
1	O
,	O
basophils	O
0	O
.	O
2	O
.	O
Platelets	O
283x10	O
3	O
l	O
.	O
Haemostasis	O
prothrombin	O
T	O
.	O
14	O
.	O
2	O
sec	O
,	O
Quick	O
's	O
index	O
100	O
.	O
0	O
,	O
INR	O
1	O
.	O
00	O
.	O
T	O
.	O
partial	O
thromboplastin	O
activ	O
.	O
26	O
.	O
5	O
sec	O
,	O
derived	O
fibrinogen	O
355	O
mg	O
dL	O
.	O
ECG	O
Sinus	O
bradycardia	O
at	O
55	O
bpm	O
.	O
Axis	O
at	O
0o	O
.	O
Normal	O
atrioventricular	O
and	O
intraventricular	O
conduction	O
.	O
Adequate	O
progression	O
of	O
R	O
in	O
precordial	O
leads	O
.	O
No	O
repolarisation	O
alterations	O
.	O
IQTc	O
normal	O
.	O
Chest	O
X	O
ray	O
No	O
findings	O
of	O
pathological	O
significance	O
.	O
Echocardiogram	O
Dimensions	O
mm	O
.	O
IVT	O
PP	O
11	O
11	O
;	O
VID	O
VIS	O
45	O
24	O
;	O
RAo	O
AI	O
28	O
38	O
;	O
cardiac	O
cavities	O
of	O
normal	O
size	O
,	O
without	O
hypertrophy	O
of	O
the	O
ventricular	O
walls	O
and	O
good	O
biventricular	O
systolic	O
function	O
.	O
Normal	O
flow	O
and	O
valves	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
.	O
Coronary	O
CT	O
Right	O
dominance	O
.	O
Left	O
common	O
trunk	O
Normal	O
.	O
LAD	O
artery	O
Significant	O
stenosis	O
in	O
proximal	O
middle	O
segment	O
,	O
immediately	O
posterior	O
to	O
the	O
exit	O
of	O
the	O
first	O
diagonal	O
,	O
due	O
to	O
soft	O
atheroma	O
plaque	O
.	O
Diagonal	O
arteries	O
No	O
alterations	O
.	O
Circumflex	O
artery	O
No	O
alterations	O
.	O
Obtuse	O
marginal	O
artery	O
Unaltered	O
.	O
CD	O
artery	O
very	O
well	O
developed	O
,	O
without	O
alterations	O
.	O
Acute	O
marginal	O
artery	O
not	O
affected	O
.	O
Posterior	O
interventricular	O
artery	O
not	O
affected	O
.	O
Posterolateral	O
branch	O
Dependent	O
on	O
DC	O
,	O
very	O
developed	O
,	O
without	O
alterations	O
.	O
Coronary	O
angiography	O
Disease	O
of	O
a	O
vessel	O
with	O
short	O
stenosis	O
of	O
75	O
in	O
the	O
middle	O
LAD	O
,	O
which	O
is	O
treated	O
by	O
placing	O
a	O
direct	O
chromocobalt	O
stent	O
,	O
with	O
good	O
angiographic	O
results	O
.	O
Rest	O
of	O
the	O
coronary	O
tree	O
without	O
lesions	O
.	O
Ordinary	O
blood	O
tests	O
total	O
cholesterol	O
249	O
mg	O
dL	O
,	O
HDL	O
cholesterol	O
direct	O
73	O
mg	O
dL	O
,	O
LDL	O
cholesterol	O
calculated	O
161	O
mg	O
DL	O
,	O
VLDL	O
cholesterol	O
calculated	O
15	O
mg	O
dL	O
,	O
triglycerides	O
73	O
mg	O
dL	O
,	O
thyroid	O
hormones	O
TSH	O
3	O
.	O
379	O
mU	O
L	O
,	O
FREE	O
T4	O
1	O
.	O
57	O
ng	O
dL	O
.	O
Glycosylated	O
haemoglobin	O
A1c	O
5	O
.	O
0	O
.	O
Clinical	O
evolution	O
During	O
his	O
stay	O
in	O
the	O
bedridden	O
area	O
,	O
he	O
again	O
presented	O
a	O
new	O
episode	O
of	O
chest	O
pain	O
which	O
coincided	O
with	O
the	O
presence	O
of	O
multiple	O
ventricular	O
extrasystoles	O
on	O
cardiac	O
monitoring	O
.	O
It	O
was	O
decided	O
to	O
discuss	O
this	O
with	O
Cardiology	O
due	O
to	O
the	O
suspicion	O
of	O
haemodynamic	O
angina	O
.	O
The	O
monitor	O
showed	O
episodes	O
of	O
sinus	O
bradycardia	O
around	O
46	O
bpm	O
,	O
ventricular	O
bigeminy	O
and	O
several	O
episodes	O
of	O
non	O
sustained	O
ventricular	O
tachycardia	O
,	O
with	O
a	O
change	O
in	O
the	O
electrical	O
axis	O
with	O
respect	O
to	O
the	O
baseline	O
ECG	O
and	O
with	O
various	O
morphologies	O
.	O
In	O
one	O
of	O
the	O
tracings	O
the	O
tachycardia	O
is	O
monomorphic	O
,	O
although	O
not	O
fully	O
rhythmic	O
.	O
In	O
another	O
tracing	O
it	O
shows	O
two	O
morphologies	O
due	O
to	O
the	O
change	O
of	O
the	O
electrical	O
axis	O
between	O
the	O
complexes	O
,	O
it	O
appears	O
to	O
be	O
a	O
bidirectional	O
tachycardia	O
.	O
The	O
estimated	O
heart	O
rate	O
during	O
the	O
tachycardias	O
we	O
do	O
not	O
have	O
a	O
12	O
lead	O
ECG	O
at	O
any	O
time	O
is	O
around	O
140	O
180	O
bpm	O
.	O
After	O
admission	O
to	O
cardiology	O
,	O
the	O
patient	O
remained	O
asymptomatic	O
,	O
with	O
no	O
new	O
arrhythmic	O
events	O
on	O
monitoring	O
.	O
Given	O
the	O
clinical	O
presentation	O
of	O
chest	O
pain	O
at	O
rest	O
,	O
with	O
ventricular	O
tachycardia	O
on	O
monitoring	O
,	O
in	O
a	O
patient	O
without	O
enzyme	O
elevation	O
and	O
with	O
a	O
normal	O
baseline	O
ECG	O
,	O
it	O
was	O
decided	O
to	O
screen	O
for	O
the	O
different	O
causes	O
that	O
could	O
be	O
related	O
to	O
the	O
appearance	O
of	O
the	O
arrhythmia	O
.	O
Psychiatry	O
was	O
consulted	O
for	O
a	O
joint	O
review	O
of	O
the	O
side	O
effects	O
of	O
agomelatine	B-FARMACO
,	O
a	O
melatoninergic	O
agonist	O
MT1	O
and	O
MT2	O
receptors	O
and	O
a	O
serotonin	O
5	O
HT2C	O
receptor	O
antagonist	O
.	O
There	O
were	O
no	O
data	O
linking	O
this	O
drug	O
to	O
arrhythmic	O
events	O
or	O
prolongation	O
of	O
the	O
QT	O
interval	O
,	O
despite	O
which	O
it	O
was	O
decided	O
to	O
withdraw	O
it	O
.	O
An	O
echocardiogram	O
was	O
performed	O
,	O
which	O
showed	O
no	O
structural	O
heart	O
disease	O
.	O
As	O
a	O
test	O
for	O
anatomical	O
assessment	O
of	O
the	O
coronary	O
arteries	O
,	O
a	O
CT	O
scan	O
of	O
the	O
coronary	O
arteries	O
showed	O
significant	O
stenosis	O
in	O
the	O
middle	O
portion	O
of	O
the	O
anterior	O
descending	O
artery	O
.	O
This	O
finding	O
led	O
to	O
coronary	O
angiography	O
which	O
confirmed	O
the	O
lesion	O
,	O
which	O
was	O
treated	O
by	O
direct	O
conventional	O
stent	O
implantation	O
.	O
Good	O
clinical	O
evolution	O
during	O
admission	O
,	O
with	O
no	O
new	O
episodes	O
of	O
chest	O
pain	O
or	O
ventricular	O
extrasystoles	O
on	O
the	O
monitor	O
.	O
Regular	O
blood	O
tests	O
showed	O
dyslipidaemia	O
.	O
She	O
was	O
discharged	O
with	O
statin	B-FARMACO
,	O
double	O
antiplatelet	O
therapy	O
,	O
ACE	B-FARMACO
inhibitors	I-FARMACO
and	O
hormone	O
replacement	O
therapy	O
for	O
hypothyroidism	O
.	O
The	O
tendency	O
to	O
low	O
heart	O
rate	O
did	O
not	O
allow	O
the	O
introduction	O
of	O
beta	O
blockers	O
.	O
She	O
was	O
assessed	O
in	O
outpatient	O
consultations	O
4	O
months	O
after	O
discharge	O
,	O
with	O
a	O
holter	O
without	O
alterations	O
and	O
asymptomatic	O
.	O
Diagnosis	O
Unstable	O
angina	O
Non	O
sustained	O
ventricular	O
tachycardia	O
Significant	O
lesion	O
in	O
the	O
middle	O
anterior	O
descending	O
artery	O

Clinical	O
history	O
and	O
current	O
disease	O
53	O
year	O
old	O
patient	O
with	O
a	O
history	O
of	O
dyspnoea	O
on	O
exertion	O
of	O
6	O
12	O
months	O
of	O
evolution	O
,	O
poor	O
window	O
in	O
previous	O
echocardiogram	O
.	O
She	O
came	O
for	O
a	O
new	O
echocardiogram	O
after	O
losing	O
weight	O
due	O
to	O
diet	O
.	O
No	O
chest	O
pain	O
or	O
syncope	O
.	O
HIGH	O
BLOOD	O
PRESSURE	O
.	O
Metrorrhagia	O
with	O
uterine	O
curettage	O
in	O
2004	O
.	O
She	O
was	O
assessed	O
in	O
the	O
Internal	O
Medicine	O
outpatient	O
department	O
in	O
2004	O
for	O
severe	O
anaemia	O
secondary	O
to	O
the	O
above	O
,	O
and	O
a	O
colonoscopy	O
was	O
also	O
performed	O
for	O
rectorrhagia	O
with	O
the	O
finding	O
of	O
internal	O
haemorrhoids	O
.	O
Chronic	O
HBsAg	O
carrier	O
followed	O
up	O
in	O
Preventive	O
Medicine	O
.	O
Admitted	O
in	O
2009	O
for	O
pneumonia	O
.	O
Previous	O
medication	O
ibuprofen	B-FARMACO
600	O
mg	O
,	O
spironolactone	B-FARMACO
25	I-FARMACO
hydrochlorothiazide	I-FARMACO
15	O
mg	O
,	O
metoprolol	B-FARMACO
50	O
mg	O
,	O
ramipril	B-FARMACO
5	O
mg	O
.	O
Additional	O
tests	O
CBC	O
white	O
blood	O
cells	O
6	O
,	O
820	O
,	O
red	O
blood	O
cells	O
4	O
.	O
49	O
,	O
haemoglobin	O
13	O
.	O
4	O
,	O
haematocrit	O
38	O
.	O
8	O
,	O
mean	O
corpuscular	O
volume	O
86	O
.	O
4	O
,	O
mean	O
corpuscular	O
haemoglobin	O
29	O
.	O
7	O
,	O
platelets	O
227000	O
,	O
INR	O
1	O
.	O
01	O
,	O
fibrinogen	O
360	O
,	O
glucose	O
94	O
,	O
urea	O
47	O
,	O
creatinine	O
0	O
.	O
92	O
,	O
sodium	O
142	O
,	O
potassium	O
4	O
.	O
8	O
,	O
estimated	O
glomerular	O
filtration	O
rate	O
60	O
,	O
glomerular	O
filtration	O
rate	O
EPI	O
71	O
.	O
Electrocardiogram	O
sinus	O
rhythm	O
at	O
53	O
bpm	O
with	O
no	O
other	O
alterations	O
of	O
interest	O
.	O
No	O
changes	O
suggestive	O
of	O
ischaemia	O
,	O
cavity	O
enlargement	O
perhaps	O
LA	O
enlargement	O
or	O
conduction	O
disturbances	O
.	O
Chest	O
X	O
ray	O
mild	O
cardiomegaly	O
with	O
no	O
radiological	O
signs	O
of	O
heart	O
failure	O
.	O
Echocardiogram	O
LV	O
not	O
dilated	O
or	O
hypertrophic	O
.	O
Preserved	O
systolic	O
function	O
.	O
Mild	O
aortic	O
insufficiency	O
with	O
no	O
gradient	O
across	O
it	O
.	O
Large	O
mass	O
58x42	O
mm	O
in	O
the	O
left	O
atrium	O
with	O
no	O
visible	O
pedicle	O
or	O
Doppler	O
flow	O
inside	O
it	O
,	O
which	O
protrudes	O
minimally	O
into	O
the	O
left	O
ventricle	O
,	O
causing	O
mild	O
mitral	O
insufficiency	O
and	O
moderate	O
mitral	O
obstruction	O
flow	O
.	O
Mild	O
TR	O
with	O
estimated	O
PSP	O
of	O
60	O
65	O
.	O
Clinical	O
evolution	O
In	O
view	O
of	O
the	O
echocardiogram	O
findings	O
,	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
referral	O
hospital	O
where	O
the	O
evaluation	O
was	O
completed	O
with	O
coronary	O
angiography	O
showing	O
coronary	O
arteries	O
with	O
right	O
dominance	O
and	O
no	O
significant	O
angiographic	O
lesions	O
and	O
cardiac	O
magnetic	O
resonance	O
imaging	O
showing	O
a	O
mass	O
in	O
the	O
left	O
atrium	O
62x46x40	O
mm	O
with	O
a	O
pedicle	O
originating	O
in	O
the	O
interatrial	O
septum	O
,	O
the	O
signal	O
was	O
intermediate	O
in	O
T1	O
weighted	O
sequences	O
,	O
hyperintense	O
in	O
T2	O
weighted	O
sequences	O
and	O
with	O
central	O
enhancement	O
in	O
the	O
late	O
phases	O
of	O
the	O
dynamic	O
study	O
with	O
gadolinium	O
compatible	O
with	O
myxoma	O
that	O
prolapses	O
through	O
the	O
mitral	O
annulus	O
during	O
diastole	O
.	O
It	O
was	O
decided	O
to	O
perform	O
elective	O
surgery	O
by	O
transseptal	O
access	O
,	O
myxoma	O
implant	O
was	O
found	O
in	O
the	O
septum	O
ceptum	O
of	O
the	O
left	O
atrium	O
and	O
complete	O
resection	O
of	O
myxoma	O
was	O
performed	O
,	O
closing	O
the	O
septum	O
with	O
an	O
autologous	O
pericardium	O
patch	O
.	O
During	O
the	O
postoperative	O
period	O
,	O
an	O
episode	O
of	O
atrial	O
flutter	O
with	O
variable	O
conduction	O
and	O
good	O
ventricular	O
response	O
that	O
did	O
not	O
reverse	O
despite	O
treatment	O
with	O
amiodarone	B-FARMACO
.	O
At	O
the	O
time	O
of	O
discharge	O
the	O
patient	O
presented	O
atrial	O
flutter	O
at	O
60	O
bpm	O
,	O
continuing	O
treatment	O
with	O
v	O
.	O
o	O
.	O
amiodarone	B-FARMACO
until	O
the	O
review	O
date	O
.	O
Diagnosis	O
Arterial	O
hypertension	O
Obesity	O
Mass	O
in	O
the	O
left	O
atrium	O
,	O
probably	O
myxoma	O

Medical	O
history	O
and	O
current	O
illness	O
49	O
year	O
old	O
woman	O
with	O
a	O
history	O
of	O
chronic	O
Chagas	O
disease	O
,	O
pacemaker	O
wearer	O
for	O
35	O
years	O
,	O
not	O
taking	O
any	O
medication	O
.	O
Diabetes	O
,	O
hypertension	O
.	O
Surgeries	O
3	O
electrode	O
changes	O
the	O
last	O
one	O
9	O
years	O
ago	O
.	O
Physical	O
examination	O
BP	O
110	O
65	O
HR	O
70	O
bpm	O
,	O
weight	O
62	O
kg	O
,	O
height	O
1	O
.	O
65m	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
mild	O
systolic	O
murmur	O
6	O
in	O
mitral	O
focus	O
,	O
peak	O
shock	O
between	O
4th	O
and	O
5th	O
EII	O
.	O
Pulmonary	O
auscultation	O
MV	O
without	O
added	O
noises	O
.	O
Functional	O
Class	O
I	O
according	O
to	O
NYHA	O
.	O
The	O
patient	O
reported	O
frequent	O
dizziness	O
2	O
weeks	O
ago	O
and	O
even	O
presented	O
syncope	O
when	O
she	O
was	O
sitting	O
and	O
talking	O
with	O
her	O
family	O
at	O
home	O
,	O
which	O
is	O
why	O
she	O
decided	O
to	O
consult	O
the	O
doctor	O
.	O
She	O
reports	O
that	O
the	O
pacemaker	O
was	O
implanted	O
when	O
she	O
was	O
14	O
years	O
old	O
and	O
she	O
never	O
changed	O
the	O
generator	O
as	O
it	O
was	O
a	O
pacemaker	O
with	O
a	O
battery	O
based	O
on	O
nuclear	O
energy	O
plutonium	O
that	O
was	O
donated	O
to	O
her	O
in	O
1974	O
.	O
The	O
surgeries	O
he	O
has	O
undergone	O
to	O
date	O
have	O
been	O
electrode	O
replacements	O
,	O
and	O
there	O
is	O
no	O
clinical	O
history	O
to	O
indicate	O
the	O
reason	O
for	O
the	O
change	O
.	O
Complementary	O
tests	O
Blood	O
tests	O
haemoglobin	O
13	O
g	O
dl	O
,	O
leucocytes	O
6	O
,	O
443	O
,	O
platelets	O
254	O
,	O
000	O
,	O
glucose	O
88	O
,	O
creatinine	O
1	O
.	O
1	O
,	O
Na	O
142	O
,	O
K	O
4	O
.	O
0	O
.	O
ECG	O
sinus	O
,	O
with	O
single	O
chamber	O
pacemaker	O
rhythm	O
,	O
unipolar	O
pacing	O
in	O
ventricle	O
FC	O
70	O
bpm	O
,	O
without	O
VA	O
conduction	O
.	O
Chest	O
X	O
ray	O
cardiac	O
area	O
with	O
slight	O
enlargement	O
,	O
2	O
abandoned	O
endocardial	O
electrodes	O
and	O
1	O
epicardial	O
electrode	O
connected	O
to	O
a	O
generator	O
with	O
a	O
plutonium	O
tablet	O
inside	O
.	O
Echocardiogram	O
EF	O
59	O
,	O
LVED	O
57	O
mm	O
,	O
LA	O
45	O
mm	O
,	O
IV	O
septum	O
10	O
mm	O
.	O
Mild	O
hypokinesia	O
inferior	O
wall	O
,	O
no	O
thrombus	O
,	O
no	O
pericardial	O
effusion	O
.	O
Holter	O
24	O
hours	O
.	O
VVI	O
PM	O
rhythm	O
70	O
bpm	O
isolated	O
polymorphic	O
infrequent	O
PVCs	O
,	O
periods	O
of	O
loss	O
of	O
ventricular	O
command	O
generating	O
asystole	O
between	O
5	O
and	O
7	O
seconds	O
in	O
wakefulness	O
and	O
at	O
night	O
the	O
spicule	O
is	O
not	O
recorded	O
during	O
loss	O
of	O
capture	O
.	O
Clinical	O
evolution	O
As	O
no	O
programmer	O
was	O
available	O
for	O
this	O
model	O
of	O
pacemaker	O
,	O
it	O
was	O
decided	O
to	O
perform	O
a	O
surgical	O
procedure	O
to	O
evaluate	O
the	O
integrity	O
of	O
the	O
pacing	O
system	O
the	O
patient	O
requested	O
that	O
if	O
it	O
was	O
a	O
case	O
of	O
electrode	O
failure	O
,	O
the	O
same	O
pacemaker	O
should	O
be	O
kept	O
,	O
as	O
she	O
has	O
had	O
it	O
almost	O
all	O
her	O
life	O
and	O
knows	O
that	O
it	O
has	O
unlimited	O
energy	O
.	O
During	O
the	O
surgical	O
procedure	O
,	O
when	O
the	O
generator	O
was	O
removed	O
from	O
the	O
pocket	O
,	O
the	O
connector	O
was	O
observed	O
to	O
be	O
damaged	O
and	O
making	O
contact	O
with	O
the	O
electrode	O
with	O
silicone	O
material	O
that	O
was	O
placed	O
in	O
the	O
previous	O
surgery	O
,	O
resulting	O
in	O
intermittent	O
contact	O
9	O
years	O
after	O
surgery	O
.	O
The	O
patient	O
received	O
a	O
new	O
St	O
.	O
Jude	O
Zephyr	O
SR	O
pacing	O
system	O
programmed	O
VVIR	O
70	O
bpm	O
,	O
epicardial	O
as	O
she	O
was	O
unable	O
to	O
have	O
access	O
via	O
the	O
venous	O
route	O
.	O
She	O
was	O
discharged	O
within	O
48	O
hours	O
and	O
remained	O
asymptomatic	O
for	O
approximately	O
12	O
months	O
.	O
Diagnosis	O
Capture	O
failure	O
due	O
to	O
intermittent	O
outflow	O
blockage	O
.	O

Clinical	O
history	O
and	O
current	O
illness	O
A	O
73	O
year	O
old	O
man	O
was	O
admitted	O
to	O
the	O
Infectious	O
Diseases	O
Department	O
for	O
a	O
new	O
febrile	O
syndrome	O
of	O
4	O
days	O
'	O
duration	O
,	O
with	O
no	O
clear	O
focal	O
symptoms	O
and	O
a	O
physical	O
examination	O
with	O
no	O
significant	O
findings	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
Ex	O
smoker	O
.	O
High	O
blood	O
pressure	O
under	O
pharmacological	O
treatment	O
.	O
Operated	O
in	O
2008	O
on	O
right	O
femoropopliteal	O
bypass	O
with	O
thrombosis	O
of	O
the	O
bypass	O
one	O
year	O
later	O
and	O
self	O
limited	O
febrile	O
syndrome	O
in	O
relation	O
to	O
the	O
thrombosis	O
.	O
Iron	O
deficiency	O
anaemia	O
and	O
removal	O
of	O
several	O
colonic	O
polyps	O
in	O
2009	O
.	O
Usual	O
treatment	O
amlodipine	B-FARMACO
,	O
lisinopril	B-FARMACO
HCTZ	I-FARMACO
,	O
clopidogrel	B-FARMACO
,	O
ranitidine	B-FARMACO
,	O
haemovas	B-FARMACO
.	O
ECG	O
on	O
admission	O
sinus	O
rhythm	O
at	O
45	O
bpm	O
,	O
PR	O
260	O
msec	O
,	O
HBAI	O
,	O
BCRDHH	O
,	O
negative	O
T	O
waves	O
in	O
III	O
and	O
aVF	O
.	O
Chest	O
X	O
ray	O
on	O
admission	O
no	O
alterations	O
.	O
Blood	O
cultures	O
were	O
taken	O
from	O
the	O
emergency	O
department	O
,	O
treatment	O
with	O
augmentin	B-FARMACO
iv	O
was	O
prescribed	O
and	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
Infectious	O
Diseases	O
Department	O
.	O
During	O
his	O
stay	O
on	O
the	O
ward	O
,	O
after	O
infusion	O
of	O
a	O
dose	O
of	O
augmentin	B-FARMACO
iv	O
,	O
the	O
patient	O
reported	O
intense	O
itching	O
all	O
over	O
the	O
body	O
with	O
the	O
appearance	O
of	O
exanthematous	O
skin	O
lesions	O
,	O
arterial	O
hypotension	O
,	O
precordial	O
pressure	O
and	O
episode	O
of	O
syncope	O
on	O
getting	O
out	O
of	O
bed	O
with	O
spontaneous	O
recovery	O
in	O
a	O
few	O
seconds	O
.	O
A	O
new	O
ECG	O
was	O
performed	O
at	O
that	O
time	O
which	O
showed	O
complete	O
AVB	O
with	O
ST	O
elevation	O
of	O
4mm	O
in	O
the	O
inferior	O
face	O
and	O
specular	O
decrease	O
in	O
I	O
,	O
aVL	O
and	O
V1	O
V4	O
.	O
Treatment	O
was	O
started	O
with	O
iv	O
corticoids	O
iv	O
polaramine	B-FARMACO
serotherapy	O
,	O
which	O
improved	O
the	O
AT	O
and	O
the	O
allergic	O
symptoms	O
.	O
Following	O
this	O
clinical	O
improvement	O
,	O
the	O
ECG	O
was	O
repeated	O
and	O
the	O
aforementioned	O
alterations	O
disappeared	O
,	O
returning	O
to	O
an	O
ECG	O
similar	O
to	O
that	O
on	O
admission	O
.	O
Given	O
the	O
ECG	O
alterations	O
and	O
the	O
presence	O
of	O
chest	O
pain	O
,	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
Cardiology	O
Department	O
.	O
Complementary	O
tests	O
Myocardial	O
damage	O
marker	O
curve	O
negative	O
.	O
Cardiac	O
catheterisation	O
shows	O
coronary	O
arteries	O
without	O
significant	O
lesions	O
and	O
ectasia	O
of	O
CD	O
and	O
middle	O
DA	O
.	O
Holter	O
ECG	O
stable	O
RS	O
with	O
low	O
mean	O
HR	O
.	O
No	O
VE	O
.	O
No	O
significant	O
pauses	O
.	O
TT	O
echocardiography	O
LV	O
slightly	O
dilated	O
with	O
slightly	O
increased	O
wall	O
thickness	O
and	O
preserved	O
global	O
and	O
segmental	O
systolic	O
function	O
.	O
Diastolic	O
pattern	O
of	O
elongated	O
relaxation	O
.	O
Sclerosed	O
MV	O
with	O
mild	O
MR	O
.	O
Aortic	O
valve	O
without	O
alterations	O
.	O
LA	O
slightly	O
dilated	O
.	O
RV	O
not	O
dilated	O
,	O
without	O
dysfunction	O
.	O
Mild	O
TR	O
with	O
RV	O
AD	O
gradient	O
of	O
30	O
mmHg	O
and	O
estimated	O
PSAP	O
of	O
40	O
mmHg	O
.	O
No	O
pericardial	O
effusion	O
.	O
Clinical	O
evolution	O
Once	O
the	O
allergic	O
reaction	O
was	O
overcome	O
,	O
the	O
patient	O
remained	O
asymptomatic	O
and	O
did	O
not	O
present	O
any	O
further	O
episodes	O
of	O
chest	O
pain	O
.	O
Following	O
the	O
results	O
of	O
these	O
complementary	O
tests	O
,	O
the	O
picture	O
was	O
interpreted	O
as	O
right	O
coronary	O
artery	O
vasospasm	O
secondary	O
to	O
anaphylaxis	O
due	O
to	O
the	O
infusion	O
of	O
augmentin	B-FARMACO
iv	O
,	O
causing	O
what	O
is	O
known	O
as	O
allergic	O
angina	O
or	O
Kounis	O
syndrome	O
.	O
The	O
patient	O
was	O
sent	O
to	O
the	O
Allergy	O
Service	O
and	O
was	O
found	O
to	O
be	O
allergic	O
to	O
penicillin	B-FARMACO
G	I-FARMACO
,	O
penicillin	B-FARMACO
V	I-FARMACO
,	O
ampicillin	B-FARMACO
and	O
amoxicillin	B-FARMACO
.	O
The	O
patient	O
evolved	O
favourably	O
and	O
was	O
discharged	O
.	O
Diagnosis	O
Allergic	O
angina	O
Kounis	O
disease	O
Coronary	O
vasospasm	O
secondary	O
to	O
anaphylaxis	O
Anaphylactic	O
reaction	O
secondary	O
to	O
amoxicillin	O
clavulanate	O
infusion	O

Clinical	O
history	O
and	O
current	O
illness	O
A	O
67	O
year	O
old	O
man	O
consulted	O
for	O
a	O
clinical	O
picture	O
of	O
approximately	O
two	O
months	O
of	O
episodes	O
of	O
self	O
limited	O
palpitations	O
lasting	O
seconds	O
,	O
which	O
started	O
and	O
ended	O
spontaneously	O
,	O
in	O
several	O
episodes	O
during	O
the	O
day	O
,	O
with	O
a	O
greater	O
predominance	O
at	O
rest	O
.	O
Reason	O
for	O
consultation	O
tiredness	O
and	O
palpitations	O
.	O
Personal	O
history	O
no	O
relevant	O
medical	O
history	O
.	O
Smoker	O
of	O
one	O
or	O
two	O
cigarettes	O
a	O
week	O
.	O
Family	O
history	O
sudden	O
death	O
of	O
his	O
paternal	O
grandfather	O
at	O
the	O
age	O
of	O
forty	O
,	O
his	O
father	O
died	O
at	O
the	O
age	O
of	O
58	O
during	O
post	O
operative	O
throat	O
surgery	O
for	O
an	O
unclear	O
cause	O
.	O
She	O
does	O
not	O
take	O
any	O
regular	O
pharmacological	O
treatment	O
.	O
Present	O
illness	O
a	O
67	O
year	O
old	O
man	O
consulted	O
for	O
a	O
clinical	O
picture	O
of	O
approximately	O
two	O
months	O
of	O
episodes	O
of	O
self	O
limited	O
palpitations	O
lasting	O
seconds	O
,	O
which	O
begin	O
and	O
end	O
spontaneously	O
,	O
in	O
several	O
episodes	O
during	O
the	O
day	O
,	O
with	O
a	O
greater	O
predominance	O
at	O
rest	O
.	O
At	O
the	O
same	O
time	O
of	O
evolution	O
he	O
presents	O
deterioration	O
of	O
his	O
functional	O
class	O
with	O
dyspnoea	O
on	O
moderate	O
exertion	O
.	O
She	O
denies	O
chest	O
pain	O
or	O
syncopal	O
episodes	O
.	O
Complementary	O
tests	O
Blood	O
tests	O
normal	O
haemogram	O
and	O
biochemistry	O
.	O
ECG	O
sinus	O
,	O
ventricular	O
extrasystoles	O
with	O
LBBB	O
morphology	O
and	O
inferior	O
axis	O
positive	O
QRS	O
DII	O
,	O
III	O
aVF	O
and	O
negative	O
QRS	O
aVL	O
.	O
Late	O
depolarisation	O
wave	O
in	O
V1	O
.	O
Holter	O
ECG	O
24	O
hours	O
sinus	O
rhythm	O
.	O
Isolated	O
supraventricular	O
extrasystoles	O
without	O
significant	O
association	O
.	O
Frequent	O
ventricular	O
extrasystoles	O
with	O
several	O
doublets	O
,	O
phases	O
of	O
bigeminy	O
and	O
episode	O
of	O
NSVT	O
.	O
Tendency	O
to	O
nocturnal	O
sinus	O
bradycardia	O
.	O
No	O
significant	O
pauses	O
.	O
N	O
.	O
Ventricular	O
extrasystoles	O
8572	O
24	O
hours	O
.	O
TT	O
echocardiogram	O
LVEF	O
59	O
,	O
LVEDD	O
54	O
mm	O
,	O
LA	O
54	O
mm	O
,	O
IVS	O
11	O
mm	O
,	O
right	O
ventricle	O
in	O
M	O
mode	O
in	O
long	O
axis	O
36	O
mm	O
.	O
Saccular	O
images	O
on	O
free	O
wall	O
with	O
slightly	O
decreased	O
systolic	O
function	O
.	O
No	O
valvular	O
heart	O
disease	O
.	O
No	O
pericardial	O
effusion	O
.	O
Cardiac	O
MRI	O
functional	O
examination	O
is	O
performed	O
using	O
ECO	O
T2	O
gradient	O
CINE	O
sequences	O
with	O
cardiac	O
synchronisation	O
.	O
Performed	O
after	O
contrast	O
administration	O
.	O
Late	O
enhancement	O
examination	O
left	O
atrial	O
dilatation	O
.	O
Left	O
ventricle	O
neither	O
dilated	O
nor	O
hypertrophied	O
with	O
preserved	O
LVEF	O
66	O
.	O
Dilated	O
right	O
ventricle	O
IVTD	O
121	O
ml	O
m2	O
,	O
IVTS	O
67	O
ml	O
m2	O
with	O
moderate	O
severe	O
depression	O
of	O
RV	O
systolic	O
function	O
EF	O
33	O
.	O
Akinetic	O
aneurysmal	O
sacculations	O
in	O
the	O
right	O
ventricular	O
free	O
wall	O
.	O
Clinical	O
course	O
Treatment	O
with	O
sotalol	B-FARMACO
was	O
started	O
with	O
adequate	O
tolerance	O
and	O
reduction	O
of	O
symptoms	O
.	O
An	O
exercise	O
test	O
was	O
performed	O
under	O
pharmacological	O
treatment	O
in	O
which	O
he	O
remained	O
asymptomatic	O
,	O
doubling	O
the	O
DP	O
.	O
Ventricular	O
extrasystoles	O
were	O
observed	O
at	O
rest	O
,	O
which	O
disappeared	O
on	O
exertion	O
.	O
No	O
other	O
arrhythmias	O
were	O
observed	O
.	O
The	O
patient	O
continued	O
to	O
be	O
monitored	O
in	O
outpatient	O
consultations	O
and	O
was	O
found	O
to	O
be	O
asymptomatic	O
and	O
with	O
improvement	O
in	O
his	O
functional	O
class	O
.	O
Diagnosis	O
Arrhythmogenic	O
cardiomyopathy	O
of	O
the	O
right	O
ventricle	O
.	O

Medical	O
history	O
and	O
current	O
illness	O
Allergic	O
to	O
amoxicillin	B-FARMACO
clavulanic	I-FARMACO
acid	I-FARMACO
and	O
mites	O
.	O
Cholinergic	O
urticaria	O
.	O
No	O
usual	O
treatment	O
.	O
Patient	O
aged	O
25	O
years	O
presenting	O
with	O
general	O
malaise	O
,	O
fever	O
and	O
diarrhoea	O
for	O
the	O
last	O
three	O
days	O
.	O
Tingling	O
in	O
acral	O
areas	O
.	O
Oppressive	O
chest	O
pain	O
yesterday	O
morning	O
and	O
again	O
first	O
thing	O
today	O
,	O
but	O
without	O
vegetative	O
cortex	O
or	O
modification	O
with	O
movement	O
,	O
posture	O
,	O
ventilatory	O
cycle	O
.	O
Physical	O
examination	O
temperature	O
37	O
.	O
5	O
oC	O
,	O
BP	O
129	O
85	O
.	O
Stable	O
,	O
good	O
oxygenation	O
and	O
ventilatory	O
mechanics	O
.	O
Acp	O
rhythmic	O
,	O
no	O
murmurs	O
,	O
no	O
friction	O
rub	O
.	O
CVM	O
.	O
Complementary	O
tests	O
CBC	O
leukocytes	O
4	O
,	O
000	O
S36	O
,	O
C3	O
,	O
haemoglobin	O
14	O
.	O
1	O
,	O
haematocrit	O
40	O
,	O
platelets	O
209	O
,	O
000	O
,	O
coagulation	O
normal	O
,	O
glucose	O
96	O
,	O
urea	O
24	O
,	O
creates	O
0	O
.	O
91	O
,	O
GOT	O
72	O
,	O
GPT	O
36	O
,	O
Na	O
139	O
,	O
K	O
3	O
.	O
8	O
,	O
CPK	O
185	O
,	O
peak	O
TnT	O
0	O
.	O
84	O
.	O
Chest	O
X	O
ray	O
normal	O
.	O
Electrocardiogram	O
sinus	O
rhythm	O
,	O
concave	O
ST	O
elevation	O
in	O
inf	O
and	O
lat	O
leads	O
V4	O
V6	O
,	O
I	O
and	O
aVL	O
.	O
Decrease	O
in	O
successive	O
ECGs	O
of	O
this	O
ST	O
elevation	O
.	O
Echocardiogram	O
on	O
admission	O
normal	O
cardiac	O
cavities	O
.	O
Normal	O
LVEF	O
LVEF	O
60	O
.	O
No	O
alterations	O
in	O
segmental	O
contractility	O
AV	O
and	O
sigmoid	O
valves	O
without	O
alterations	O
.	O
No	O
shunts	O
.	O
Normal	O
aortic	O
root	O
and	O
IVC	O
.	O
No	O
pericardial	O
effusion	O
.	O
Clinical	O
course	O
25	O
year	O
old	O
patient	O
with	O
previous	O
infectious	O
condition	O
of	O
probable	O
viral	O
origin	O
admitted	O
with	O
a	O
diagnosis	O
of	O
myopericarditis	O
.	O
Admitted	O
to	O
ICU	O
for	O
24	O
hours	O
without	O
arrhythmic	O
events	O
.	O
Good	O
evolution	O
.	O
Asymptomatic	O
since	O
admission	O
,	O
stable	O
at	O
all	O
times	O
,	O
improvement	O
with	O
anti	O
inflammatory	O
treatment	O
.	O
Echocardiogram	O
prior	O
to	O
discharge	O
showed	O
no	O
contractility	O
alterations	O
Diagnosis	O
Acute	O
myopericarditis	O
Preserved	O
systolic	O
function	O

Clinical	O
history	O
and	O
current	O
illness	O
A	O
48	O
year	O
old	O
man	O
consulted	O
for	O
recurrent	O
presyncopal	O
symptoms	O
related	O
to	O
exertion	O
and	O
subsequent	O
recovery	O
'	O
ad	O
integrum	O
'	O
within	O
a	O
few	O
seconds	O
.	O
He	O
reported	O
slight	O
dyspnoea	O
without	O
accompanying	O
chest	O
pain	O
or	O
palpitations	O
.	O
In	O
the	O
previous	O
months	O
he	O
had	O
visited	O
the	O
emergency	O
department	O
on	O
several	O
occasions	O
for	O
episodes	O
of	O
fever	O
,	O
dyspnoea	O
and	O
dizziness	O
and	O
was	O
discharged	O
with	O
a	O
diagnosis	O
of	O
respiratory	O
infection	O
.	O
His	O
personal	O
history	O
included	O
chronic	O
alcoholism	O
,	O
smoker	O
with	O
clinical	O
criteria	O
for	O
COPD	O
,	O
hypertension	O
on	O
treatment	O
with	O
candesartan	B-FARMACO
,	O
deep	O
vein	O
thrombosis	O
in	O
the	O
right	O
lower	O
limb	O
in	O
2009	O
on	O
treatment	O
with	O
acenocoumarol	B-FARMACO
since	O
then	O
.	O
Physical	O
examination	O
good	O
general	O
condition	O
,	O
clinical	O
and	O
haemodynamic	O
stability	O
with	O
adequate	O
blood	O
pressure	O
control	O
,	O
maintaining	O
O2	O
saturation	O
of	O
around	O
96	O
with	O
O2	O
supply	O
in	O
nasal	O
goggles	O
at	O
2	O
bpm	O
.	O
Obesity	O
.	O
Eupneic	O
at	O
rest	O
and	O
during	O
conversation	O
,	O
tolerating	O
decubitus	O
adequately	O
.	O
Normal	O
neurological	O
examination	O
.	O
Heart	O
rhythmic	O
,	O
slightly	O
tachycardic	O
,	O
without	O
murmurs	O
or	O
extratonos	O
.	O
Generalised	O
decrease	O
in	O
vesicular	O
murmur	O
with	O
scattered	O
wheezing	O
in	O
both	O
lung	O
fields	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
and	O
without	O
visceromegaly	O
.	O
Slight	O
oedema	O
in	O
both	O
lower	O
limbs	O
,	O
in	O
the	O
absence	O
of	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
Complementary	O
tests	O
Chest	O
X	O
ray	O
cardiomegaly	O
with	O
thickened	O
pulmonary	O
hilarity	O
with	O
a	O
vascular	O
appearance	O
.	O
Electrocardiogram	O
sinus	O
rhythm	O
at	O
95	O
spm	O
.	O
Pulmonary	O
P	O
wave	O
.	O
Asymmetric	O
negative	O
T	O
wave	O
in	O
III	O
,	O
aVF	O
and	O
from	O
V1	O
to	O
V4	O
.	O
Haemogram	O
haemoglobin	O
16	O
.	O
6	O
g	O
dL	O
,	O
haematocrit	O
50	O
.	O
4	O
,	O
MCV	O
99	O
.	O
5	O
fL	O
.	O
Rest	O
of	O
the	O
study	O
normal	O
.	O
Coagulation	O
INR	O
2	O
.	O
85	O
,	O
PT	O
34	O
.	O
66	O
,	O
APTT	O
53	O
.	O
78	O
.	O
Biochemistry	O
creatinine	O
1	O
.	O
4	O
mg	O
dl	O
,	O
urea	O
57	O
mg	O
dl	O
.	O
Minimal	O
mobilisation	O
of	O
ultrasensitive	O
troponin	O
T	O
88	O
.	O
78	O
ng	O
l	O
with	O
normal	O
total	O
CPK	O
.	O
Venous	O
blood	O
gas	O
pH	O
7	O
.	O
356	O
,	O
pCO2	O
45	O
mmHg	O
,	O
pO2	O
50	O
mmHg	O
,	O
EB	O
2	O
mEq	O
l	O
.	O
Rest	O
normal	O
.	O
Urine	O
sediment	O
protein	O
320	O
.	O
8	O
mg	O
dl	O
.	O
Abundant	O
hyaline	O
cylinders	O
.	O
Clinical	O
evolution	O
Given	O
the	O
presence	O
of	O
minimal	O
mobilisation	O
of	O
cardiac	O
ferments	O
in	O
the	O
analytical	O
study	O
and	O
the	O
electrocardiographic	O
findings	O
,	O
the	O
Chest	O
Pain	O
Unit	O
was	O
contacted	O
and	O
it	O
was	O
decided	O
to	O
perform	O
urgent	O
echocardiography	O
,	O
with	O
the	O
following	O
results	O
non	O
dilated	O
left	O
ventricle	O
with	O
moderate	O
concentric	O
hypertrophy	O
and	O
preserved	O
systolic	O
function	O
;	O
dilated	O
right	O
ventricle	O
with	O
marked	O
free	O
wall	O
hypokinesia	O
with	O
flattening	O
of	O
the	O
interventricular	O
septum	O
and	O
moderate	O
systolic	O
dysfunction	O
;	O
slightly	O
dilated	O
inferior	O
vena	O
cava	O
with	O
inspiratory	O
collapse	O
greater	O
than	O
50	O
;	O
absence	O
of	O
pericardial	O
effusion	O
.	O
Chest	O
CT	O
angiography	O
showed	O
a	O
partial	O
repletion	O
defect	O
in	O
the	O
right	O
pulmonary	O
artery	O
that	O
most	O
significantly	O
affected	O
the	O
segmental	O
artery	O
of	O
the	O
right	O
upper	O
lobe	O
,	O
preserving	O
its	O
distal	O
flow	O
;	O
emphysematous	O
pattern	O
of	O
paraseptal	O
location	O
.	O
The	O
patient	O
remains	O
asymptomatic	O
at	O
all	O
times	O
.	O
Anticoagulation	O
was	O
maintained	O
according	O
to	O
the	O
Thrombology	O
Service	O
guidelines	O
and	O
a	O
venous	O
Doppler	O
study	O
was	O
performed	O
,	O
showing	O
deep	O
vein	O
thrombosis	O
DVT	O
of	O
both	O
popliteal	O
and	O
posterior	O
tibial	O
veins	O
,	O
the	O
thrombotic	O
material	O
being	O
partially	O
recanalised	O
.	O
In	O
the	O
control	O
Doppler	O
echocardiography	O
,	O
marked	O
RV	O
dilatation	O
persisted	O
with	O
moderate	O
systolic	O
dysfunction	O
and	O
evidence	O
of	O
pulmonary	O
hypertension	O
.	O
An	O
autoimmunity	O
study	O
ANA	O
,	O
ANCA	O
,	O
AntiDNA	O
,	O
anticardiolipin	O
was	O
performed	O
on	O
the	O
hospital	O
ward	O
and	O
was	O
negative	O
.	O
Studies	O
of	O
iron	O
,	O
thyroid	O
,	O
tumour	O
markers	O
,	O
HIV	O
,	O
HBV	O
,	O
HCV	O
and	O
proteinogram	O
were	O
normal	O
.	O
Nephrotic	O
syndrome	O
was	O
also	O
ruled	O
out	O
as	O
a	O
cause	O
of	O
hypercoagulability	O
by	O
24	O
hour	O
urine	O
study	O
0	O
.	O
5	O
g	O
l	O
protein	O
.	O
Given	O
the	O
persistence	O
of	O
DVT	O
despite	O
anticoagulation	O
with	O
INR	O
at	O
therapeutic	O
target	O
and	O
the	O
diagnosis	O
of	O
pulmonary	O
thromboembolism	O
PTE	O
,	O
an	O
inferior	O
vena	O
cava	O
filter	O
implant	O
was	O
indicated	O
.	O
After	O
discharge	O
,	O
the	O
patient	O
was	O
referred	O
to	O
the	O
Heart	O
Failure	O
and	O
Pulmonary	O
Hypertension	O
department	O
of	O
our	O
centre	O
with	O
suspicion	O
of	O
chronic	O
thromboembolic	O
pulmonary	O
hypertension	O
and	O
to	O
the	O
outpatient	O
haematology	O
department	O
for	O
thrombophilia	O
.	O
Diagnosis	O
Pulmonary	O
thromboembolism	O
of	O
the	O
right	O
main	O
pulmonary	O
artery	O
.	O
Clinical	O
suspicion	O
of	O
recurrent	O
pulmonary	O
thromboembolism	O
.	O
Secondary	O
severe	O
pulmonary	O
hypertension	O
.	O
Suspected	O
chronic	O
thromboembolic	O
pulmonary	O
hypertension	O
.	O
Bilateral	O
deep	O
vein	O
thrombosis	O
.	O

Clinical	O
history	O
and	O
current	O
disease	O
A	O
32	O
year	O
old	O
woman	O
with	O
a	O
personal	O
history	O
of	O
arterial	O
hypertension	O
under	O
treatment	O
with	O
a	O
thiazide	O
diuretic	O
,	O
with	O
good	O
control	O
as	O
usual	O
,	O
and	O
a	O
family	O
history	O
of	O
early	O
ischaemic	O
heart	O
disease	O
without	O
other	O
cardiovascular	O
risk	O
factors	O
.	O
The	O
patient	O
reported	O
episodes	O
in	O
the	O
last	O
five	O
years	O
of	O
oppressive	O
chest	O
pain	O
triggered	O
by	O
exertion	O
mainly	O
related	O
to	O
holding	O
her	O
young	O
child	O
that	O
subsided	O
with	O
rest	O
,	O
sometimes	O
appearing	O
at	O
the	O
same	O
level	O
of	O
exertion	O
and	O
sometimes	O
not	O
,	O
lasting	O
a	O
few	O
minutes	O
and	O
with	O
no	O
accompanying	O
vegetative	O
symptoms	O
for	O
which	O
she	O
had	O
not	O
previously	O
consulted	O
,	O
no	O
dyspnoea	O
,	O
syncope	O
or	O
other	O
associated	O
symptoms	O
.	O
The	O
patient	O
consulted	O
the	O
Emergency	O
Department	O
due	O
to	O
an	O
increase	O
in	O
the	O
frequency	O
and	O
intensity	O
of	O
these	O
episodes	O
in	O
the	O
last	O
month	O
,	O
without	O
ever	O
having	O
presented	O
the	O
symptoms	O
at	O
rest	O
.	O
On	O
arrival	O
at	O
the	O
ED	O
,	O
the	O
patient	O
was	O
asymptomatic	O
.	O
After	O
an	O
initial	O
assessment	O
with	O
physical	O
examination	O
,	O
electrocardiogram	O
,	O
chest	O
X	O
ray	O
and	O
normal	O
laboratory	O
tests	O
in	O
the	O
ED	O
,	O
it	O
was	O
decided	O
to	O
refer	O
her	O
to	O
our	O
Chest	O
Pain	O
Unit	O
for	O
further	O
study	O
.	O
Asymptomatic	O
with	O
good	O
general	O
condition	O
,	O
eupneic	O
with	O
no	O
signs	O
of	O
heart	O
failure	O
,	O
haemodynamically	O
stable	O
and	O
with	O
good	O
peripheral	O
perfusion	O
.	O
On	O
cardiorespiratory	O
auscultation	O
the	O
patient	O
had	O
rhythmic	O
tones	O
without	O
murmurs	O
and	O
a	O
preserved	O
vesicular	O
murmur	O
without	O
pathological	O
sounds	O
.	O
Peripheral	O
pulses	O
were	O
symmetrical	O
and	O
present	O
.	O
The	O
rest	O
of	O
the	O
physical	O
examination	O
was	O
also	O
unremarkable	O
.	O
Complementary	O
tests	O
Electrocardiogram	O
normal	O
sinus	O
rhythm	O
at	O
75	O
bpm	O
without	O
repolarisation	O
alterations	O
Chest	O
X	O
ray	O
normal	O
cardiac	O
silhouette	O
and	O
lung	O
parenchyma	O
CBC	O
including	O
biochemistry	O
with	O
serial	O
markers	O
of	O
myocardial	O
damage	O
,	O
normal	O
red	O
blood	O
count	O
and	O
coagulation	O
Clinical	O
evolution	O
The	O
patient	O
was	O
evaluated	O
in	O
the	O
Chest	O
Pain	O
Unit	O
where	O
transthoracic	O
echocardiography	O
showed	O
a	O
structurally	O
normal	O
heart	O
,	O
with	O
preserved	O
global	O
and	O
segmental	O
systolic	O
function	O
,	O
and	O
an	O
ergometry	O
that	O
was	O
clinically	O
positive	O
at	O
the	O
end	O
of	O
the	O
third	O
stage	O
modified	O
Bruce	O
protocol	O
showing	O
precordial	O
pressure	O
similar	O
to	O
that	O
usually	O
present	O
and	O
electrically	O
positive	O
from	O
the	O
beginning	O
of	O
stage	O
1	O
with	O
a	O
flat	O
ascending	O
ST	O
segment	O
descent	O
that	O
reached	O
a	O
maximum	O
of	O
1	O
.	O
80	O
mm	O
in	O
,	O
with	O
a	O
functional	O
capacity	O
of	O
8	O
.	O
5	O
METS	O
reaching	O
102	O
of	O
the	O
HRQoL	O
.	O
A	O
post	O
exercise	O
echocardiography	O
was	O
performed	O
and	O
showed	O
no	O
alterations	O
in	O
segmental	O
contractility	O
.	O
Echocardiogram	O
aortic	O
root	O
,	O
aortic	O
valve	O
and	O
postvalvular	O
aorta	O
normal	O
.	O
Normal	O
left	O
atrium	O
.	O
Normal	O
mitral	O
valve	O
.	O
Left	O
ventricle	O
of	O
normal	O
size	O
and	O
thickness	O
.	O
Normal	O
global	O
and	O
segmental	O
systolic	O
function	O
.	O
Ventricular	O
filling	O
normal	O
filling	O
pattern	O
.	O
Normal	O
right	O
chambers	O
.	O
Ergometry	O
diagnostic	O
,	O
treadmill	O
,	O
Bruce	O
I	O
protocol	O
,	O
without	O
pharmacological	O
treatment	O
clinically	O
,	O
at	O
the	O
end	O
of	O
the	O
3rd	O
stage	O
at	O
minute	O
6	O
36	O
he	O
begins	O
with	O
precordial	O
pressure	O
of	O
the	O
same	O
characteristics	O
as	O
usual	O
,	O
but	O
of	O
less	O
intensity	O
,	O
which	O
subsides	O
with	O
rest	O
.	O
Electrically	O
,	O
with	O
a	O
decrease	O
in	O
ST	O
from	O
V4	O
V6	O
,	O
with	O
a	O
flat	O
ascending	O
slope	O
,	O
reaching	O
2	O
.	O
40	O
mm	O
,	O
from	O
the	O
beginning	O
of	O
the	O
first	O
stage	O
,	O
and	O
which	O
almost	O
normalises	O
with	O
rest	O
at	O
1	O
35	O
min	O
,	O
and	O
then	O
decreases	O
again	O
to	O
1	O
.	O
85	O
mm	O
with	O
a	O
negative	O
slope	O
.	O
Exercise	O
time	O
6	O
58	O
min	O
,	O
limited	O
by	O
reaching	O
maximal	O
HR	O
and	O
ST	O
decline	O
.	O
Functional	O
capacity	O
8	O
.	O
5	O
METS	O
.	O
Tension	O
response	O
hypertension	O
at	O
rest	O
with	O
exaggerated	O
response	O
.	O
Normal	O
HR	O
response	O
.	O
Normal	O
HR	O
recovery	O
.	O
Reached	O
102	O
of	O
the	O
FCM	O
.	O
No	O
arrhythmias	O
.	O
Based	O
on	O
a	O
low	O
pretest	O
probability	O
for	O
ischaemic	O
heart	O
disease	O
12	O
26	O
and	O
an	O
intermediate	O
post	O
test	O
probability	O
29	O
51	O
,	O
Duke	O
score	O
9	O
,	O
it	O
was	O
decided	O
to	O
continue	O
the	O
outpatient	O
study	O
under	O
anti	O
ischaemic	O
treatment	O
beta	O
blockers	O
and	O
ASA	B-FARMACO
and	O
to	O
request	O
a	O
coronary	O
CT	O
scan	O
.	O
After	O
starting	O
treatment	O
with	O
beta	O
blockers	O
,	O
the	O
patient	O
was	O
asymptomatic	O
.	O
The	O
CT	O
scan	O
showed	O
a	O
calcium	O
score	O
of	O
0	O
,	O
the	O
anterior	O
descending	O
artery	O
ADA	O
without	O
significant	O
lesions	O
with	O
little	O
distal	O
development	O
,	O
the	O
circumflex	O
artery	O
ACx	O
with	O
very	O
little	O
development	O
,	O
practically	O
non	O
existent	O
,	O
and	O
the	O
right	O
coronary	O
artery	O
RCA	O
very	O
developed	O
,	O
without	O
significant	O
lesions	O
,	O
on	O
which	O
two	O
posterolateral	O
branches	O
depended	O
in	O
addition	O
to	O
the	O
posterior	O
descending	O
artery	O
.	O
Given	O
the	O
typicality	O
and	O
intensity	O
of	O
the	O
symptoms	O
in	O
a	O
young	O
patient	O
who	O
responded	O
to	O
treatment	O
with	O
beta	O
blockers	O
and	O
the	O
finding	O
of	O
abnormal	O
coronary	O
anatomy	O
,	O
dobutamine	B-FARMACO
stress	O
echocardiography	O
without	O
beta	O
blocker	O
treatment	O
was	O
performed	O
as	O
a	O
second	O
test	O
to	O
detect	O
ischaemia	O
.	O
In	O
addition	O
to	O
confirming	O
the	O
existence	O
of	O
ischaemia	O
,	O
this	O
allowed	O
localisation	O
of	O
the	O
exposed	O
territory	O
,	O
with	O
hypokinesia	O
of	O
all	O
the	O
apical	O
segments	O
at	O
140	O
bpm	O
and	O
above	O
,	O
accompanied	O
by	O
symptoms	O
typical	O
of	O
ischaemia	O
.	O
In	O
view	O
of	O
these	O
findings	O
,	O
it	O
was	O
decided	O
to	O
admit	O
the	O
patient	O
for	O
coronary	O
angiography	O
,	O
which	O
showed	O
coronary	O
arteries	O
with	O
anatomical	O
findings	O
coinciding	O
with	O
those	O
described	O
in	O
the	O
CT	O
scan	O
.	O
Selective	O
injection	O
of	O
the	O
LAD	O
showed	O
the	O
existence	O
of	O
a	O
unidirectional	O
intercoronary	O
communication	O
from	O
the	O
distal	O
LAD	O
to	O
a	O
well	O
developed	O
posterior	O
interventricular	O
artery	O
PVI	O
,	O
with	O
no	O
evidence	O
of	O
obstructive	O
lesions	O
that	O
could	O
justify	O
the	O
development	O
of	O
collateral	O
circulation	O
.	O
During	O
admission	O
,	O
a	O
hypercoagulability	O
study	O
was	O
performed	O
,	O
which	O
was	O
negative	O
.	O
The	O
patient	O
was	O
discharged	O
with	O
beta	O
blocker	O
treatment	O
with	O
a	O
diagnosis	O
of	O
myocardial	O
ischaemia	O
secondary	O
to	O
unidirectional	O
intercoronary	O
communication	O
between	O
distal	O
LAD	O
and	O
PVI	O
with	O
coronary	O
steal	O
phenomenon	O
.	O
At	O
the	O
one	O
year	O
follow	O
up	O
the	O
patient	O
remained	O
asymptomatic	O
.	O
Diagnosis	O
Myocardial	O
ischaemia	O
secondary	O
to	O
unidirectional	O
intercoronary	O
communication	O
between	O
distal	O
LAD	O
and	O
PVI	O
with	O
coronary	O
steal	O
phenomenon	O
.	O

Clinical	O
history	O
and	O
current	O
illness	O
A	O
68	O
year	O
old	O
man	O
with	O
hypertension	O
,	O
operated	O
in	O
1990	O
for	O
aortic	O
valve	O
disease	O
with	O
mechanical	O
prosthesis	O
.	O
Complete	O
AV	O
block	O
in	O
the	O
immediate	O
postoperative	O
period	O
requiring	O
implantation	O
of	O
a	O
transient	O
ventricular	O
epicardial	O
pacemaker	O
and	O
epicardial	O
lead	O
in	O
AD	O
,	O
subsequently	O
a	O
permanent	O
ventricular	O
endocardial	O
lead	O
was	O
implanted	O
.	O
The	O
generator	O
was	O
replaced	O
in	O
2008	O
and	O
later	O
the	O
ventricular	O
lead	O
was	O
replaced	O
due	O
to	O
malfunction	O
and	O
a	O
new	O
endocardial	O
system	O
was	O
implanted	O
in	O
July	O
2009	O
.	O
Since	O
2009	O
,	O
the	O
patient	O
reported	O
periodic	O
skin	O
erosions	O
in	O
the	O
implantation	O
area	O
,	O
with	O
serofibrinous	O
exudate	O
during	O
the	O
following	O
two	O
years	O
,	O
and	O
during	O
the	O
last	O
six	O
months	O
he	O
had	O
episodes	O
of	O
shivering	O
with	O
a	O
few	O
tenths	O
of	O
fever	O
,	O
especially	O
at	O
night	O
,	O
which	O
led	O
him	O
to	O
consult	O
his	O
doctor	O
on	O
several	O
occasions	O
.	O
He	O
came	O
to	O
our	O
centre	O
feverish	O
,	O
with	O
a	O
marked	O
worsening	O
in	O
the	O
last	O
two	O
weeks	O
39	O
.	O
8oC	O
,	O
affected	O
but	O
haemodynamically	O
stable	O
and	O
with	O
suppuration	O
from	O
the	O
decubitus	O
orifice	O
of	O
the	O
pacemaker	O
,	O
for	O
which	O
he	O
was	O
admitted	O
.	O
Complementary	O
tests	O
Physical	O
examination	O
serofibrinous	O
suppuration	O
through	O
the	O
generator	O
implantation	O
area	O
.	O
Laboratory	O
tests	O
leukocytosis	O
of	O
26	O
,	O
300	O
90	O
PMN	O
,	O
Hb	O
11	O
g	O
dL	O
,	O
CRP	O
63	O
,	O
creatinine	O
0	O
.	O
90	O
mg	O
dL	O
,	O
urea	O
35	O
mg	O
dL	O
.	O
Chest	O
X	O
ray	O
3	O
electrodes	O
are	O
visualised	O
,	O
two	O
of	O
them	O
normoinserted	O
attached	O
to	O
the	O
implanted	O
generator	O
,	O
normoinserted	O
and	O
a	O
dissected	O
epicardial	O
lead	O
lodged	O
in	O
the	O
right	O
atrium	O
.	O
Condensation	O
images	O
are	O
also	O
seen	O
in	O
the	O
right	O
hemithorax	O
.	O
Blood	O
cultures	O
two	O
batches	O
taken	O
30	O
minutes	O
apart	O
from	O
each	O
other	O
from	O
two	O
different	O
sites	O
and	O
on	O
different	O
days	O
with	O
and	O
without	O
fever	O
,	O
with	O
growth	O
of	O
methicillin	O
sensitive	O
Staphylococcus	O
epidermidis	O
.	O
Culture	O
of	O
decubitus	O
exudate	O
methicillin	O
sensitive	O
Staphylococcus	O
epidermidis	O
.	O
Transthoracic	O
echocardiography	O
a	O
vegetation	O
of	O
about	O
20	O
mm	O
is	O
visualised	O
in	O
the	O
right	O
atrial	O
cable	O
.	O
Other	O
echocardiographic	O
parameters	O
were	O
normal	O
.	O
No	O
prosthetic	O
dysfunction	O
.	O
Mild	O
tricuspid	O
regurgitation	O
.	O
Clinical	O
evolution	O
After	O
admission	O
,	O
the	O
infection	O
was	O
treated	O
comprehensively	O
with	O
parenteral	O
bactericidal	O
antibiotherapy	O
directed	O
at	O
the	O
germ	O
isolated	O
in	O
the	O
cultures	O
and	O
the	O
removal	O
of	O
the	O
entire	O
system	O
and	O
a	O
new	O
implant	O
on	O
the	O
right	O
side	O
once	O
the	O
patient	O
remained	O
afebrile	O
and	O
blood	O
cultures	O
were	O
repeatedly	O
negative	O
,	O
after	O
two	O
weeks	O
of	O
antibiotic	O
treatment	O
.	O
Diagnosis	O
Endocarditis	O
due	O
to	O
infection	O
of	O
the	O
pacemaker	O
generator	O
and	O
leads	O
without	O
valvular	O
involvement	O
.	O

Medical	O
history	O
and	O
current	O
illness	O
46	O
year	O
old	O
woman	O
with	O
a	O
history	O
of	O
hypertension	O
and	O
dyslipidaemia	O
.	O
Followed	O
up	O
by	O
cardiology	O
in	O
childhood	O
for	O
a	O
pathology	O
that	O
the	O
patient	O
cannot	O
specify	O
,	O
with	O
no	O
subsequent	O
follow	O
ups	O
.	O
She	O
began	O
with	O
sudden	O
symptoms	O
of	O
speech	O
impairment	O
and	O
lower	O
right	O
facial	O
paralysis	O
.	O
In	O
the	O
absence	O
of	O
contraindications	O
and	O
with	O
a	O
normal	O
brain	O
CT	O
scan	O
,	O
fibrinolytic	O
treatment	O
with	O
alteplase	B-FARMACO
was	O
administered	O
,	O
with	O
a	O
good	O
initial	O
neurological	O
response	O
.	O
After	O
3	O
hours	O
,	O
the	O
patient	O
presented	O
a	O
new	O
clinical	O
deterioration	O
and	O
a	O
new	O
brain	O
CT	O
scan	O
was	O
performed	O
which	O
showed	O
a	O
left	O
frontoparietal	O
haemorrhage	O
with	O
associated	O
small	O
subarachnoid	O
haemorrhage	O
.	O
Physical	O
examination	O
on	O
admission	O
showed	O
baseline	O
O2	O
saturation	O
88	O
,	O
with	O
signs	O
of	O
peripheral	O
hypoperfusion	O
with	O
lip	O
cyanosis	O
.	O
Cardiac	O
auscultation	O
showed	O
rhythmic	O
tones	O
with	O
audible	O
systolic	O
ejection	O
murmur	O
in	O
all	O
foci	O
.	O
Hypoventilation	O
in	O
the	O
lower	O
third	O
of	O
the	O
left	O
hemithorax	O
on	O
pulmonary	O
auscultation	O
.	O
Neurological	O
examination	O
revealed	O
aphasia	O
of	O
expression	O
and	O
right	O
central	O
facial	O
paresis	O
.	O
During	O
admission	O
,	O
lip	O
cyanosis	O
persisted	O
with	O
low	O
oxygen	O
saturation	O
and	O
platypnoea	O
orthodeoxia	O
syndrome	O
.	O
A	O
transthoracic	O
echocardiogram	O
was	O
performed	O
showing	O
tricuspid	O
valve	O
with	O
atrial	O
displacement	O
and	O
severe	O
insufficiency	O
compatible	O
with	O
Ebstein	O
's	O
disease	O
.	O
In	O
addition	O
,	O
an	O
ostium	O
secundum	O
atrial	O
septal	O
defect	O
ASD	O
OS	O
was	O
observed	O
in	O
the	O
posterior	O
septum	O
with	O
bidirectional	O
shunt	O
.	O
Despite	O
the	O
finding	O
of	O
heart	O
disease	O
with	O
a	O
high	O
risk	O
of	O
embolism	O
in	O
the	O
echocardiogram	O
,	O
it	O
was	O
decided	O
to	O
postpone	O
the	O
start	O
of	O
oral	O
anticoagulation	O
due	O
to	O
extensive	O
cerebral	O
bleeding	O
.	O
Complementary	O
tests	O
Laboratory	O
tests	O
normal	O
.	O
Arterial	O
blood	O
gases	O
compensated	O
respiratory	O
acidosis	O
,	O
basal	O
SatO2	O
77	O
.	O
Electrocardiogram	O
sinus	O
rhythm	O
at	O
85	O
bpm	O
,	O
right	O
bundle	O
branch	O
block	O
.	O
Initial	O
brain	O
CT	O
scan	O
normal	O
.	O
Post	O
fibrinolysis	O
brain	O
CT	O
scan	O
left	O
frontoparietal	O
haematoma	O
and	O
associated	O
small	O
subarachnoid	O
haemorrhage	O
.	O
Transesophageal	O
echocardiogram	O
tricuspid	O
with	O
septal	O
leaflet	O
displacement	O
of	O
38	O
mm	O
and	O
severe	O
insufficiency	O
,	O
severe	O
right	O
atrial	O
RA	O
dilatation	O
,	O
normal	O
right	O
ventricular	O
RV	O
contractility	O
,	O
RV	O
RA	O
gradient	O
20	O
mmHg	O
.	O
Celermajer	O
index	O
1	O
.	O
21	O
.	O
Pulmonary	O
flow	O
and	O
other	O
valves	O
normal	O
.	O
Atrial	O
septal	O
defect	O
ASD	O
ostium	O
secundum	O
in	O
posterior	O
septum	O
15	O
mm	O
with	O
bidirectional	O
shunt	O
,	O
absence	O
of	O
superoposterior	O
border	O
.	O
Chest	O
X	O
ray	O
cardiomegaly	O
at	O
the	O
expense	O
of	O
the	O
right	O
cavities	O
.	O
Right	O
pleural	O
effusion	O
.	O
Thoracic	O
CT	O
angiography	O
right	O
PTE	O
with	O
extensive	O
pulmonary	O
infarction	O
in	O
the	O
lower	O
lobe	O
.	O
Echo	O
Doppler	O
of	O
lower	O
limbs	O
normal	O
.	O
Clinical	O
evolution	O
During	O
admission	O
,	O
good	O
neurological	O
evolution	O
with	O
complete	O
recovery	O
at	O
the	O
end	O
of	O
the	O
stay	O
.	O
During	O
her	O
stay	O
on	O
the	O
ward	O
,	O
the	O
patient	O
presented	O
increasingly	O
severe	O
episodes	O
of	O
oxygen	O
desaturation	O
,	O
reaching	O
oxygen	O
saturations	O
of	O
67	O
at	O
baseline	O
,	O
which	O
improved	O
partially	O
with	O
oxygen	O
therapy	O
.	O
The	O
patient	O
reported	O
progressive	O
dyspnoea	O
until	O
minimal	O
exertion	O
,	O
with	O
limited	O
ambulation	O
in	O
the	O
corridor	O
,	O
which	O
improved	O
in	O
the	O
supine	O
position	O
.	O
Given	O
the	O
very	O
low	O
oxygen	O
saturation	O
figures	O
,	O
which	O
the	O
patient	O
had	O
never	O
presented	O
previously	O
,	O
concomitant	O
pulmonary	O
pathology	O
was	O
suspected	O
.	O
Thoracic	O
CT	O
angiography	O
showed	O
right	O
pulmonary	O
thromboembolism	O
PTE	O
with	O
extensive	O
pulmonary	O
infarction	O
in	O
the	O
lower	O
lobe	O
.	O
At	O
the	O
time	O
of	O
diagnosis	O
,	O
10	O
days	O
had	O
passed	O
since	O
the	O
cerebral	O
bleeding	O
.	O
On	O
finding	O
the	O
PTE	O
,	O
treatment	O
with	O
acenocoumarol	B-FARMACO
was	O
started	O
,	O
with	O
clinical	O
improvement	O
and	O
improvement	O
in	O
oxygen	O
saturation	O
figures	O
.	O
Since	O
then	O
,	O
good	O
clinical	O
evolution	O
,	O
with	O
no	O
new	O
brain	O
bleeds	O
or	O
other	O
embolic	O
complications	O
.	O
Given	O
the	O
data	O
of	O
severe	O
TR	O
,	O
the	O
wide	O
OS	O
ASD	O
,	O
the	O
deterioration	O
of	O
functional	O
class	O
and	O
the	O
multiple	O
embolism	O
situation	O
stroke	O
and	O
PTE	O
,	O
tricuspid	O
valve	O
repair	O
surgery	O
and	O
ASD	O
closure	O
were	O
indicated	O
and	O
carried	O
out	O
without	O
complications	O
.	O
The	O
patient	O
is	O
currently	O
in	O
good	O
functional	O
class	O
.	O
Diagnosis	O
Left	O
frontoparietal	O
stroke	O
with	O
haemorrhagic	O
transformation	O
Cardioembolic	O
PTE	O
Ebstein	O
's	O
anomaly	O
and	O
ASD	O
ostium	O
secundum	O
with	O
bidirectional	O
shunt	O

Clinical	O
history	O
and	O
current	O
illness	O
A	O
72	O
year	O
old	O
male	O
smoker	O
with	O
no	O
other	O
history	O
of	O
interest	O
came	O
to	O
the	O
emergency	O
department	O
for	O
abdominal	O
pain	O
,	O
fever	O
and	O
poor	O
general	O
condition	O
.	O
Physical	O
examination	O
revealed	O
calorie	O
and	O
protein	O
malnutrition	O
body	O
mass	O
index	O
of	O
13	O
,	O
fever	O
of	O
38oC	O
and	O
cardiopulmonary	O
auscultation	O
showed	O
a	O
globally	O
decreased	O
vesicular	O
murmur	O
and	O
rhythmic	O
heart	O
sounds	O
with	O
a	O
systolic	O
murmur	O
IV	O
VI	O
in	O
the	O
peak	O
,	O
radiating	O
to	O
the	O
axilla	O
.	O
Complementary	O
tests	O
A	O
transthoracic	O
echocardiogram	O
showed	O
cardiac	O
cavities	O
of	O
normal	O
size	O
and	O
contractility	O
,	O
with	O
a	O
2	O
.	O
5x1	O
cm	O
mobile	O
mass	O
located	O
in	O
the	O
left	O
atrium	O
and	O
implanted	O
in	O
the	O
fossa	O
ovalis	O
suggestive	O
of	O
atrial	O
myxoma	O
and	O
a	O
myxomatous	O
mitral	O
valve	O
with	O
prolapse	O
of	O
the	O
posterior	O
leaflet	O
with	O
significant	O
insufficiency	O
.	O
With	O
the	O
diagnosis	O
of	O
atrial	O
myxoma	O
,	O
he	O
was	O
admitted	O
to	O
the	O
Cardiology	O
Department	O
to	O
complete	O
the	O
study	O
.	O
The	O
blood	O
test	O
showed	O
haemoglobin	O
9	O
.	O
3	O
g	O
dl	O
,	O
15	O
,	O
880	O
leukocytes	O
mm3	O
with	O
86	O
.	O
1	O
neutrophils	O
and	O
ESR	O
92	O
mm	O
.	O
Other	O
parameters	O
and	O
coagulation	O
values	O
were	O
within	O
normal	O
range	O
.	O
Biochemistry	O
showed	O
urea	O
40	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
05	O
mg	O
dl	O
,	O
triglycerides	O
128	O
mg	O
dl	O
,	O
total	O
cholesterol	O
100	O
mg	O
dl	O
,	O
HDL	O
13	O
mg	O
dl	O
,	O
LDL	O
60	O
mg	O
dl	O
,	O
total	O
protein	O
5	O
.	O
4	O
g	O
dl	O
,	O
albumin	O
2	O
g	O
dl	O
.	O
Urine	O
sediment	O
showed	O
microscopic	O
haematuria	O
1	O
5	O
red	O
blood	O
cells	O
field	O
.	O
Blood	O
cultures	O
were	O
taken	O
and	O
were	O
positive	O
for	O
Streptococcus	O
agalactiae	O
.	O
Electrocardiogram	O
showed	O
sinus	O
tachycardia	O
at	O
120	O
beats	O
per	O
minute	O
with	O
normal	O
repolarisation	O
.	O
In	O
view	O
of	O
these	O
findings	O
,	O
transesophageal	O
echocardiography	O
showed	O
a	O
mobile	O
,	O
pedunculated	O
mass	O
located	O
in	O
the	O
left	O
atrium	O
,	O
implanted	O
in	O
the	O
interatrial	O
septum	O
at	O
the	O
level	O
of	O
the	O
fossa	O
ovalis	O
,	O
smooth	O
in	O
outline	O
and	O
with	O
a	O
small	O
cystic	O
area	O
inside	O
,	O
compatible	O
with	O
atrial	O
myxoma	O
.	O
A	O
mitral	O
valve	O
with	O
prolapse	O
of	O
the	O
P3	O
segment	O
and	O
1	O
cm	O
of	O
vegetation	O
on	O
it	O
was	O
also	O
observed	O
;	O
with	O
severe	O
mitral	O
insufficiency	O
and	O
eccentric	O
jet	O
directed	O
towards	O
the	O
interatrial	O
septum	O
and	O
the	O
myxoma	O
area	O
.	O
Twenty	O
four	O
hours	O
after	O
admission	O
,	O
he	O
presented	O
transient	O
paresis	O
of	O
the	O
left	O
upper	O
limb	O
,	O
and	O
an	O
urgent	O
cranial	O
computed	O
tomography	O
CT	O
scan	O
showed	O
a	O
right	O
frontal	O
lacunar	O
stroke	O
semioval	O
centre	O
without	O
being	O
able	O
to	O
determine	O
the	O
time	O
of	O
evolution	O
;	O
therefore	O
,	O
an	O
urgent	O
brain	O
magnetic	O
resonance	O
imaging	O
MRI	O
assessment	O
was	O
requested	O
,	O
which	O
confirmed	O
the	O
acute	O
right	O
frontal	O
lacunar	O
stroke	O
in	O
the	O
semioval	O
centre	O
as	O
well	O
as	O
acute	O
right	O
hemispheric	O
ischaemic	O
cortical	O
lesions	O
.	O
The	O
study	O
of	O
systemic	O
embolisms	O
was	O
completed	O
with	O
thoracoabdominal	O
CT	O
,	O
highlighting	O
the	O
presence	O
of	O
an	O
extensive	O
cortical	O
hypodense	O
area	O
in	O
the	O
upper	O
pole	O
of	O
the	O
right	O
kidney	O
measuring	O
6	O
.	O
5x4	O
.	O
6x3	O
cm	O
and	O
three	O
focal	O
lesions	O
of	O
similar	O
characteristics	O
smaller	O
than	O
1	O
cm	O
in	O
the	O
left	O
kidney	O
,	O
suggestive	O
of	O
bilateral	O
renal	O
infarcts	O
.	O
Catheterisation	O
showed	O
a	O
normal	O
coronary	O
tree	O
.	O
Clinical	O
course	O
Treatment	O
and	O
evolution	O
antibiotic	O
treatment	O
was	O
started	O
with	O
ampicillin	B-FARMACO
and	O
gentamicin	B-FARMACO
,	O
and	O
in	O
view	O
of	O
the	O
patient	O
's	O
calorie	O
and	O
protein	O
malnutrition	O
,	O
the	O
Nutrition	O
and	O
Rehabilitation	O
Service	O
was	O
contacted	O
for	O
support	O
and	O
complementary	O
treatment	O
,	O
with	O
good	O
initial	O
evolution	O
.	O
The	O
transthoracic	O
echocardiogram	O
twelve	O
days	O
after	O
admission	O
showed	O
a	O
mass	O
in	O
the	O
fossa	O
ovalis	O
with	O
multiple	O
hypoechogenic	O
areas	O
in	O
its	O
interior	O
that	O
seemed	O
to	O
have	O
lost	O
the	O
area	O
of	O
greatest	O
motility	O
located	O
at	O
the	O
apical	O
level	O
.	O
Fifteen	O
days	O
after	O
admission	O
,	O
she	O
presented	O
new	O
febrile	O
peaks	O
,	O
abdominal	O
pain	O
and	O
congestive	O
heart	O
failure	O
,	O
requiring	O
depletive	O
treatment	O
and	O
non	O
invasive	O
mechanical	O
ventilation	O
.	O
Once	O
stable	O
,	O
she	O
was	O
transferred	O
to	O
the	O
Cardiac	O
Surgery	O
Department	O
for	O
surgical	O
treatment	O
,	O
and	O
the	O
atrial	O
mass	O
was	O
resected	O
by	O
resection	O
of	O
the	O
fossa	O
ovalis	O
through	O
the	O
right	O
atrium	O
and	O
removal	O
of	O
the	O
tumour	O
and	O
its	O
implantation	O
base	O
through	O
the	O
left	O
atrium	O
.	O
The	O
mitral	O
valve	O
apparatus	O
was	O
completely	O
resected	O
and	O
a	O
St	O
Jude	O
porcine	O
biological	O
prosthesis	O
model	O
Epic	O
E100	O
29M	O
was	O
implanted	O
.	O
The	O
anatomopathological	O
and	O
infectious	O
diagnosis	O
by	O
Polymerase	O
Chain	O
Reaction	O
universal	O
PCR	O
of	O
the	O
16S	O
rRNA	O
gene	O
confirmed	O
atrial	O
myxoma	O
and	O
infectious	O
involvement	O
of	O
the	O
mitral	O
valve	O
by	O
Streptococcus	O
agalactiae	O
and	O
ruled	O
out	O
infection	O
of	O
the	O
mitral	O
valve	O
tumour	O
.	O
Postoperatively	O
,	O
the	O
patient	O
had	O
a	O
torpid	O
evolution	O
with	O
gastrointestinal	O
haemorrhage	O
,	O
and	O
was	O
exsitus	O
.	O
Diagnosis	O
Atrial	O
myxoma	O
and	O
endocarditis	O
on	O
mitral	O
valve	O
with	O
constitutional	O
syndrome	O
and	O
associated	O
systemic	O
embolisms	O
.	O

Clinical	O
history	O
and	O
present	O
illness	O
43	O
year	O
old	O
male	O
admitted	O
for	O
non	O
ST	O
segment	O
elevation	O
acute	O
coronary	O
syndrome	O
NSTEACS	O
.	O
Personal	O
history	O
Allergy	O
to	O
pollen	O
and	O
mites	O
Allergic	O
rhinitis	O
.	O
Strinsic	O
bronchial	O
asthma	O
with	O
frequent	O
flare	O
ups	O
Smoker	O
No	O
known	O
hypertension	O
,	O
dyslipidaemia	O
or	O
DM	O
IQ	O
appendectomy	O
and	O
right	O
ulnar	O
radius	O
fracture	O
Usual	O
treatment	O
seretide	B-FARMACO
50	O
500	O
.	O
Ventolin	B-FARMACO
on	O
demand	O
.	O
Omeprazole	B-FARMACO
and	O
occasional	O
almax	B-FARMACO
.	O
Current	O
illness	O
on	O
15	O
10	O
2011	O
she	O
woke	O
up	O
in	O
the	O
early	O
hours	O
of	O
the	O
morning	O
with	O
oppressive	O
chest	O
pain	O
radiating	O
to	O
the	O
left	O
arm	O
.	O
She	O
went	O
to	O
the	O
hospital	O
emergency	O
department	O
12	O
hours	O
after	O
the	O
onset	O
of	O
the	O
pain	O
,	O
presenting	O
ST	O
segment	O
depression	O
and	O
elevated	O
cardiac	O
enzymes	O
in	O
the	O
ECG	O
.	O
Physical	O
examination	O
good	O
general	O
condition	O
.	O
A	O
.	O
T	O
.	O
100	O
70	O
.	O
Eurnic	O
.	O
No	O
IY	O
.	O
C	O
.	O
C	O
.	O
rhythmic	O
,	O
without	O
murmurs	O
or	O
friction	O
.	O
A	O
.	O
P	O
.	O
normal	O
.	O
Abdomen	O
and	O
EEII	O
no	O
significant	O
findings	O
.	O
Complementary	O
tests	O
ECG	O
sinus	O
rhythm	O
with	O
slight	O
ST	O
segment	O
elevation	O
in	O
II	O
,	O
V3	O
to	O
V5	O
,	O
without	O
Q	O
waves	O
.	O
Laboratory	O
tests	O
creatinine	O
1	O
.	O
14	O
.	O
Glucose	O
78	O
,	O
urate	O
7	O
.	O
6	O
.	O
Cholesterol	O
182	O
.	O
HDL	O
C	O
30	O
.	O
TG	O
136	O
.	O
LDL	O
C	O
125	O
.	O
TnT	O
ultrasensitive	O
on	O
admission	O
306	O
,	O
TnT	O
ultrasensitive	O
peak	O
1	O
,	O
503	O
,	O
ProBNP	O
105	O
,	O
CPK	O
98	O
.	O
GOT	O
47	O
.	O
GPT	O
61	O
.	O
C	O
reactive	O
protein	O
12	O
.	O
2	O
.	O
TSH	O
1	O
.	O
68	O
.	O
Haemogram	O
with	O
12300	O
leucocytes	O
.	O
Coronary	O
angiography	O
angiographically	O
normal	O
coronary	O
arteries	O
.	O
Preserved	O
EF	O
and	O
no	O
regional	O
motility	O
disorders	O
.	O
Echocardiogram	O
left	O
ventricle	O
neither	O
dilated	O
nor	O
hypertrophic	O
,	O
with	O
normal	O
EF	O
60	O
.	O
No	O
alterations	O
in	O
segmental	O
contractility	O
were	O
observed	O
.	O
E	O
52	O
,	O
A	O
57	O
,	O
TDE	O
190	O
.	O
Anatomically	O
and	O
functionally	O
normal	O
valves	O
.	O
Non	O
dilated	O
left	O
atrium	O
.	O
Right	O
chambers	O
not	O
dilated	O
.	O
TAPSE	O
19	O
mm	O
.	O
Aortic	O
root	O
and	O
ascending	O
aorta	O
of	O
normal	O
calibre	O
.	O
No	O
pericardial	O
effusion	O
.	O
Cardiac	O
MRI	O
multiple	O
areas	O
of	O
patchy	O
subepicardial	O
and	O
intramyocardial	O
involvement	O
affecting	O
anterolateral	O
,	O
lateral	O
,	O
apical	O
,	O
inferomedial	O
face	O
in	O
left	O
ventricle	O
.	O
Preserved	O
systolic	O
function	O
.	O
Clinical	O
course	O
On	O
admission	O
the	O
symptoms	O
were	O
interpreted	O
as	O
NSTEACS	O
and	O
treatment	O
was	O
started	O
with	O
double	O
antiplatelet	O
therapy	O
,	O
LMWH	B-FARMACO
,	O
nitrates	O
and	O
ACE	O
inhibitors	O
.	O
Beta	O
blocker	O
treatment	O
was	O
not	O
started	O
due	O
to	O
a	O
history	O
of	O
asthma	O
with	O
frequent	O
flare	O
ups	O
.	O
The	O
clinical	O
evolution	O
was	O
good	O
,	O
with	O
no	O
recurrence	O
of	O
chest	O
pain	O
or	O
signs	O
of	O
heart	O
failure	O
.	O
There	O
was	O
no	O
electrocardiographic	O
evolution	O
and	O
no	O
new	O
Q	O
waves	O
appeared	O
.	O
However	O
,	O
ultrasensitive	O
TnT	O
remained	O
elevated	O
after	O
admission	O
.	O
Cardiac	O
catheterisation	O
was	O
performed	O
the	O
day	O
after	O
admission	O
,	O
showing	O
angiographically	O
normal	O
coronary	O
arteries	O
and	O
preserved	O
global	O
systolic	O
function	O
without	O
segmental	O
alterations	O
of	O
contractility	O
in	O
ventriculography	O
or	O
echocardiography	O
.	O
Cardiac	O
MRI	O
was	O
performed	O
showing	O
late	O
gadolinium	O
enhancement	O
typical	O
of	O
myocarditis	O
.	O
Diagnosis	O
Acute	O
myocarditis	O
Angiographically	O
normal	O
coronary	O
arteries	O
Preserved	O
left	O
ventricular	O
systolic	O
function	O

Clinical	O
history	O
and	O
current	O
illness	O
47	O
year	O
old	O
male	O
admitted	O
to	O
the	O
Infectious	O
Diseases	O
Department	O
for	O
dyspnoea	O
and	O
febrile	O
syndrome	O
.	O
No	O
drug	O
allergies	O
.	O
Ex	O
ADVP	O
.	O
Smoker	O
.	O
HIV	O
C	O
3	O
infection	O
on	O
triple	O
antiretroviral	O
therapy	O
until	O
two	O
months	O
ago	O
with	O
good	O
adherence	O
to	O
ART	O
but	O
not	O
attending	O
check	O
ups	O
.	O
Oesophageal	O
candidiasis	O
.	O
Castlemann	O
's	O
disease	O
diagnosed	O
in	O
2006	O
,	O
completing	O
chemotherapy	O
treatment	O
with	O
good	O
evolution	O
.	O
Kaposi	O
's	O
sarcoma	O
diagnosed	O
in	O
September	O
2007	O
with	O
chemotherapy	O
treatment	O
.	O
Bacteremic	O
pneumonia	O
due	O
to	O
Acinetobacter	O
baumanii	O
in	O
September	O
2007	O
.	O
Chronic	O
hepatopathy	O
due	O
to	O
HCV	O
without	O
previous	O
decompensation	O
.	O
Sporadic	O
use	O
of	O
inhaled	O
cocaine	O
and	O
cannabis	O
,	O
no	O
injecting	O
drug	O
use	O
.	O
A	O
few	O
months	O
ago	O
,	O
he	O
reported	O
a	O
traffic	O
accident	O
with	O
the	O
death	O
of	O
two	O
close	O
relatives	O
,	O
as	O
a	O
result	O
of	O
which	O
he	O
abandoned	O
his	O
usual	O
treatment	O
and	O
started	O
taking	O
drugs	O
intravenous	O
cocaine	O
and	O
smoked	O
heroin	O
.	O
Treatment	O
methadone	B-FARMACO
25	O
0	O
25	O
and	O
atripla	B-FARMACO
.	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
Infectious	O
Diseases	O
Department	O
for	O
symptoms	O
that	O
started	O
approximately	O
30	O
days	O
ago	O
,	O
which	O
debuted	O
as	O
a	O
cough	O
with	O
expectoration	O
that	O
was	O
initially	O
mucopurulent	O
and	O
later	O
rusty	O
.	O
Chest	O
pain	O
that	O
was	O
exacerbated	O
by	O
coughing	O
and	O
inspiration	O
,	O
partially	O
relieved	O
by	O
trunk	O
flexion	O
.	O
Progressive	O
dyspnoea	O
,	O
initially	O
on	O
exertion	O
until	O
becoming	O
resting	O
dyspnoea	O
in	O
the	O
last	O
ten	O
days	O
,	O
with	O
orthopnoea	O
and	O
episodes	O
of	O
paroxysmal	O
nocturnal	O
dyspnoea	O
.	O
Dysthermic	O
sensation	O
with	O
a	O
maximum	O
thermometric	O
fever	O
of	O
39oC	O
.	O
In	O
view	O
of	O
the	O
clinical	O
manifestations	O
,	O
the	O
Cardiology	O
Service	O
was	O
requested	O
to	O
assess	O
the	O
patient	O
.	O
Complementary	O
tests	O
Physical	O
examination	O
BP	O
80	O
45mmHg	O
,	O
HR	O
115	O
bpm	O
,	O
satO2	O
95	O
baseline	O
,	O
afebrile	O
.	O
Conscious	O
and	O
oriented	O
.	O
Cachectic	O
,	O
with	O
good	O
peripheral	O
perfusion	O
.	O
Tachypneic	O
at	O
rest	O
.	O
Multiple	O
venipuncture	O
sites	O
.	O
Jugular	O
ingurgitation	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
and	O
without	O
murmurs	O
.	O
Conservative	O
vesicular	O
murmur	O
.	O
Soft	O
and	O
depressible	O
abdomen	O
,	O
large	O
hepatomegaly	O
,	O
oedema	O
in	O
the	O
lower	O
extremities	O
and	O
trophic	O
skin	O
lesions	O
.	O
ECG	O
sinus	O
tachycardia	O
at	O
120	O
bpm	O
,	O
axis	O
at	O
90o	O
,	O
narrow	O
QRS	O
without	O
repolarisation	O
alterations	O
.	O
CBC	O
urea	O
and	O
Cr	O
normal	O
.	O
Na	O
126	O
,	O
K	O
normal	O
.	O
Hb	O
10	O
.	O
3	O
g	O
dL	O
,	O
leukocytes	O
16	O
,	O
800	O
N	O
70	O
.	O
2	O
,	O
platelets	O
253	O
,	O
000	O
.	O
IP	O
69	O
,	O
INR	O
1	O
.	O
29	O
,	O
APTT	O
34	O
.	O
7	O
.	O
Chest	O
X	O
ray	O
cardiomegaly	O
,	O
condensation	O
in	O
the	O
right	O
pulmonary	O
base	O
.	O
Echocardiogram	O
normal	O
LV	O
with	O
preserved	O
global	O
and	O
segmental	O
systolic	O
function	O
.	O
RV	O
not	O
dilated	O
and	O
with	O
preserved	O
systolic	O
function	O
.	O
No	O
valvulopathies	O
.	O
No	O
stigmata	O
of	O
endocarditis	O
.	O
Severe	O
pericardial	O
effusion	O
,	O
enveloping	O
,	O
about	O
5	O
cm	O
with	O
signs	O
of	O
tamponade	O
.	O
Clinical	O
course	O
The	O
echocardiogram	O
showed	O
severe	O
pericardial	O
effusion	O
with	O
signs	O
of	O
tamponade	O
,	O
so	O
evacuating	O
pericardiocentesis	O
was	O
performed	O
by	O
subxiphoid	O
access	O
draining	O
1000	O
ml	O
of	O
purulent	O
fluid	O
.	O
Gram	O
staining	O
of	O
the	O
fluid	O
showed	O
gram	O
cocci	O
in	O
chains	O
,	O
and	O
the	O
culture	O
was	O
positive	O
for	O
Streptococcus	O
pneumoniae	O
.	O
Blood	O
cultures	O
were	O
negative	O
and	O
pneumococcal	O
antigen	O
positive	O
in	O
urine	O
.	O
Antibiotic	O
treatment	O
was	O
started	O
with	O
ceftriaxone	B-FARMACO
and	O
levofloxacin	B-FARMACO
.	O
A	O
control	O
echocardiogram	O
was	O
performed	O
,	O
showing	O
that	O
the	O
pericardial	O
effusion	O
had	O
practically	O
resolved	O
,	O
with	O
a	O
minimal	O
amount	O
of	O
fluid	O
remaining	O
in	O
the	O
posterior	O
sac	O
.	O
There	O
were	O
no	O
signs	O
of	O
haemodynamic	O
compromise	O
no	O
cavitary	O
collapse	O
or	O
respirophasic	O
variations	O
.	O
In	O
a	O
situation	O
of	O
clinical	O
stability	O
,	O
the	O
patient	O
was	O
discharged	O
to	O
the	O
hospital	O
ward	O
for	O
follow	O
up	O
.	O
Days	O
later	O
,	O
he	O
presented	O
a	O
new	O
clinical	O
and	O
haemodynamic	O
worsening	O
.	O
He	O
was	O
tachycardic	O
and	O
tachypneic	O
,	O
with	O
a	O
tendency	O
to	O
arterial	O
hypotension	O
.	O
The	O
echocardiogram	O
showed	O
severe	O
pericardial	O
effusion	O
and	O
a	O
new	O
evacuating	O
pericardiocentesis	O
was	O
performed	O
,	O
aspirating	O
250	O
ml	O
of	O
purulent	O
liquid	O
and	O
leaving	O
him	O
connected	O
to	O
drainage	O
with	O
aspiration	O
with	O
a	O
total	O
debit	O
of	O
1200	O
ml	O
in	O
48	O
hours	O
.	O
Diagnosis	O
Pneumococcal	O
purulent	O
pericarditis	O
complicated	O
with	O
cardiac	O
tamponade	O
requiring	O
pericardiocentesis	O
.	O

Medical	O
history	O
and	O
current	O
illness	O
51	O
year	O
old	O
male	O
.	O
Cardiovascular	O
risk	O
factors	O
former	O
smoking	O
,	O
hypertension	O
since	O
1998	O
,	O
type	O
2	O
diabetes	O
mellitus	O
treated	O
with	O
oral	O
antidiabetics	O
.	O
Anaplastic	O
T	O
cell	O
lymphoma	O
in	O
2007	O
treated	O
with	O
chemotherapy	O
,	O
radiotherapy	O
and	O
BEAM	O
conditioned	O
autotransplantation	O
,	O
currently	O
in	O
complete	O
remission	O
.	O
Refractory	O
myelodysplastic	O
cytopenia	O
syndrome	O
with	O
multilineage	O
dysplasia	O
and	O
complex	O
karyotype	O
treated	O
with	O
azacitidine	B-FARMACO
as	O
a	O
bridge	O
to	O
bone	O
marrow	O
transplant	O
.	O
Idiopathic	O
thrombopenic	O
purpura	O
.	O
No	O
known	O
allergies	O
.	O
Cardiological	O
check	O
up	O
in	O
2006	O
with	O
normal	O
ECG	O
,	O
echocardiogram	O
and	O
stress	O
test	O
.	O
He	O
usually	O
reports	O
being	O
asymptomatic	O
cardiovascular	O
.	O
Patient	O
presented	O
to	O
the	O
Emergency	O
Department	O
for	O
3	O
days	O
with	O
fever	O
of	O
up	O
to	O
38	O
.	O
3oC	O
,	O
asthenia	O
,	O
general	O
malaise	O
and	O
general	O
aches	O
and	O
pains	O
.	O
Also	O
,	O
on	O
the	O
day	O
of	O
consultation	O
,	O
he	O
had	O
started	O
with	O
oppressive	O
retrosternal	O
pain	O
of	O
increasing	O
intensity	O
,	O
radiating	O
to	O
the	O
back	O
,	O
shoulders	O
and	O
jaw	O
,	O
which	O
increased	O
in	O
intensity	O
with	O
deep	O
inspiration	O
and	O
supine	O
decubitus	O
,	O
with	O
accompanying	O
malaise	O
and	O
dyspnoea	O
and	O
BP	O
levels	O
of	O
70	O
40	O
mmHg	O
.	O
Physical	O
examination	O
was	O
normal	O
,	O
except	O
for	O
hypoventilation	O
in	O
both	O
lung	O
bases	O
.	O
Complementary	O
tests	O
ECG	O
sinus	O
tachycardia	O
with	O
mild	O
diffuse	O
ST	O
segment	O
elevation	O
slightly	O
higher	O
than	O
the	O
previous	O
one	O
and	O
non	O
specific	O
repolarisation	O
alterations	O
.	O
Laboratory	O
tests	O
showed	O
an	O
increase	O
in	O
infectious	O
inflammatory	O
parameters	O
CRP	O
32	O
;	O
procalcitonin	O
10	O
;	O
macrocytic	O
anaemia	O
,	O
plateletopenia	O
and	O
leukopenia	O
.	O
Slight	O
increase	O
in	O
myocardial	O
damage	O
markers	O
CPK	O
210	O
;	O
CPK	O
MB	O
19	O
and	O
troponin	O
T	O
0	O
.	O
62	O
.	O
Acute	O
renal	O
failure	O
Cr	O
2	O
.	O
1	O
with	O
preserved	O
diuresis	O
GFR	O
36	O
mL	O
min	O
.	O
Acid	O
base	O
balance	O
and	O
the	O
rest	O
of	O
the	O
laboratory	O
tests	O
were	O
normal	O
.	O
Urgent	O
Doppler	O
echocardiogram	O
global	O
and	O
segmental	O
contractility	O
alterations	O
,	O
pericardial	O
effusion	O
and	O
acute	O
pathology	O
were	O
ruled	O
out	O
.	O
Chest	O
CT	O
scan	O
ruled	O
out	O
the	O
existence	O
of	O
acute	O
aortic	O
pathology	O
,	O
pulmonary	O
thromboembolism	O
or	O
significant	O
infectious	O
process	O
.	O
Clinical	O
evolution	O
During	O
his	O
admission	O
,	O
broad	O
spectrum	O
antibiotics	O
and	O
antifungals	O
were	O
administered	O
empirically	O
,	O
without	O
microbiological	O
isolation	O
in	O
blood	O
cultures	O
,	O
urine	O
cultures	O
and	O
sputum	O
cultures	O
.	O
Viral	O
serologies	O
were	O
also	O
negative	O
.	O
Monitoring	O
of	O
myocardial	O
damage	O
markers	O
was	O
performed	O
,	O
with	O
maximum	O
troponin	O
T	O
of	O
1	O
.	O
59	O
,	O
CPK	O
of	O
279	O
and	O
CPK	O
of	O
43	O
four	O
days	O
after	O
admission	O
,	O
with	O
progressive	O
decrease	O
and	O
normalisation	O
at	O
discharge	O
.	O
ProBNP	O
was	O
determined	O
and	O
reached	O
a	O
maximum	O
of	O
8319	O
pg	O
mL	O
5	O
days	O
after	O
admission	O
.	O
In	O
the	O
absence	O
of	O
an	O
infectious	O
focus	O
,	O
a	O
transesophageal	O
echocardiogram	O
was	O
performed	O
5	O
days	O
later	O
,	O
showing	O
borderline	O
left	O
ventricular	O
function	O
LVEF	O
0	O
.	O
45	O
0	O
.	O
50	O
,	O
with	O
no	O
images	O
suggestive	O
of	O
endocarditis	O
or	O
other	O
significant	O
findings	O
.	O
Treatment	O
was	O
started	O
with	O
corticoids	O
,	O
beta	O
blockers	O
,	O
ACE	O
inhibitors	O
and	O
diuretics	O
with	O
clinical	O
and	O
analytical	O
improvement	O
,	O
with	O
borderline	O
systolic	O
function	O
persisting	O
in	O
the	O
echocardiogram	O
at	O
discharge	O
.	O
Seen	O
in	O
consultation	O
ten	O
days	O
later	O
,	O
he	O
reported	O
being	O
asymptomatic	O
cardiovascular	O
.	O
He	O
underwent	O
a	O
control	O
electrocardiogram	O
in	O
which	O
the	O
aforementioned	O
alterations	O
persisted	O
,	O
an	O
echocardiogram	O
in	O
which	O
a	O
dilated	O
left	O
ventricle	O
with	O
borderline	O
systolic	O
function	O
was	O
observed	O
,	O
without	O
pericardial	O
effusion	O
or	O
alterations	O
in	O
contractility	O
,	O
and	O
a	O
blood	O
test	O
in	O
which	O
slight	O
thrombopenia	O
and	O
leukopenia	O
persisted	O
,	O
with	O
normal	O
infectious	O
inflammatory	O
parameters	O
.	O
The	O
following	O
day	O
,	O
an	O
MRI	O
of	O
the	O
heart	O
was	O
performed	O
with	O
adenosine	O
stress	O
,	O
showing	O
signs	O
compatible	O
with	O
acute	O
myopericarditis	O
and	O
borderline	O
systolic	O
function	O
,	O
without	O
inducing	O
myocardial	O
ischaemia	O
.	O
The	O
same	O
treatment	O
was	O
maintained	O
and	O
the	O
patient	O
was	O
scheduled	O
for	O
a	O
follow	O
up	O
appointment	O
one	O
month	O
later	O
.	O
Diagnosis	O
Septic	O
shock	O
with	O
an	O
unfiltered	O
focus	O
Acute	O
myopericarditis	O
Myelodysplastic	O
syndrome	O
refractory	O
cytopenia	O
type	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Male	O
,	O
67	O
years	O
old	O
,	O
retired	O
.	O
Active	O
and	O
independent	O
life	O
.	O
PERSONAL	O
HISTORY	O
No	O
known	O
drug	O
allergies	O
.	O
Cardiovascular	O
risk	O
factors	O
ex	O
smoker	O
of	O
30	O
pack	O
years	O
.	O
Arterial	O
hypertension	O
under	O
treatment	O
for	O
years	O
.	O
Dyslipidaemia	O
under	O
dietary	O
treatment	O
.	O
Cardiological	O
history	O
At	O
the	O
age	O
of	O
65	O
he	O
was	O
referred	O
to	O
an	O
outpatient	O
clinic	O
for	O
an	O
asymptomatic	O
systolic	O
murmur	O
in	O
the	O
mitral	O
focus	O
.	O
A	O
transthoracic	O
echocardiogram	O
was	O
performed	O
2016	O
showing	O
preserved	O
left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
and	O
moderate	O
mitral	O
insufficiency	O
,	O
with	O
no	O
other	O
relevant	O
findings	O
.	O
Outpatient	O
follow	O
up	O
is	O
scheduled	O
.	O
Other	O
medical	O
history	O
of	O
interest	O
Severe	O
sleep	O
apnoea	O
syndrome	O
with	O
use	O
of	O
CPAP	O
since	O
2012	O
.	O
Chronic	O
gastritis	O
and	O
hiatal	O
hernia	O
.	O
Depressive	O
syndrome	O
in	O
2016	O
resolved	O
.	O
Associated	O
somatoform	O
disorders	O
.	O
Left	O
vocal	O
cord	O
paralysis	O
after	O
prolonged	O
orotracheal	O
intubation	O
for	O
viral	O
pneumonia	O
in	O
2016	O
.	O
Recent	O
diagnosis	O
of	O
localised	O
prostate	O
neoplasia	O
without	O
distant	O
extension	O
pending	O
prostate	O
resection	O
surgery	O
.	O
Chronic	O
medication	O
Escitalopram	B-FARMACO
10	O
mg	O
1	O
tablet	O
at	O
breakfast	O
;	O
aliskiren	B-FARMACO
HTZ	I-FARMACO
300	O
12	O
.	O
5	O
mg	O
1	O
tablet	O
at	O
breakfast	O
.	O
CURRENT	O
ILLNESS	O
He	O
was	O
transferred	O
to	O
the	O
emergency	O
department	O
of	O
our	O
hospital	O
by	O
the	O
mobile	O
ICU	O
after	O
out	O
of	O
hospital	O
cardiorespiratory	O
arrest	O
,	O
which	O
was	O
recovered	O
in	O
less	O
than	O
ten	O
minutes	O
with	O
basic	O
cardiac	O
resuscitation	O
manoeuvres	O
CPR	O
and	O
a	O
semi	O
automatic	O
external	O
defibrillator	O
AED	O
shock	O
when	O
the	O
rhythm	O
was	O
interpreted	O
as	O
defibrillable	O
.	O
After	O
regaining	O
spontaneous	O
circulation	O
in	O
sinus	O
rhythm	O
,	O
the	O
patient	O
persisted	O
with	O
a	O
low	O
level	O
of	O
consciousness	O
,	O
requiring	O
intubation	O
and	O
connection	O
to	O
mechanical	O
ventilation	O
by	O
the	O
mobile	O
ICU	O
.	O
The	O
event	O
took	O
place	O
in	O
the	O
street	O
,	O
with	O
no	O
close	O
relatives	O
as	O
witnesses	O
.	O
Subsequently	O
,	O
the	O
patient	O
had	O
no	O
memory	O
of	O
what	O
happened	O
at	O
that	O
moment	O
lacunar	O
amnesia	O
and	O
reported	O
having	O
been	O
asymptomatic	O
in	O
the	O
previous	O
days	O
.	O
PHYSICAL	O
EXAMINATION	O
On	O
arrival	O
he	O
was	O
afebrile	O
,	O
with	O
heart	O
rate	O
HR	O
82	O
bpm	O
,	O
blood	O
pressure	O
BP	O
155	O
83	O
mmHg	O
and	O
SatO2	O
100	O
with	O
orotracheal	O
intubation	O
,	O
connected	O
to	O
mechanical	O
ventilation	O
with	O
FiO2	O
50	O
.	O
Carotid	O
auscultation	O
without	O
murmurs	O
.	O
Jugular	O
venous	O
pressure	O
normal	O
.	O
Rhythmic	O
cardiac	O
auscultation	O
with	O
a	O
striking	O
holosystolic	O
murmur	O
in	O
the	O
mitral	O
focus	O
radiating	O
to	O
the	O
axilla	O
similar	O
to	O
that	O
described	O
in	O
previous	O
cardiology	O
examinations	O
.	O
Pulmonary	O
auscultation	O
with	O
preserved	O
vesicular	O
murmur	O
.	O
Abdominal	O
examination	O
with	O
no	O
pathological	O
findings	O
.	O
Good	O
distal	O
perfusion	O
,	O
without	O
oedema	O
.	O
Central	O
and	O
distal	O
pulses	O
present	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
biochemistry	O
glucose	O
260	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
26	O
mg	O
dl	O
,	O
urea	O
36	O
mg	O
dl	O
,	O
normal	O
ions	O
,	O
troponin	O
T	O
US	O
18	O
ng	O
l	O
and	O
at	O
3	O
hours	O
32	O
ng	O
l	O
reference	O
value	O
14	O
ng	O
l	O
and	O
CK	O
107	O
U	O
l	O
.	O
Haemogram	O
Hb	O
15	O
.	O
6	O
g	O
dl	O
,	O
leucocytes	O
and	O
platelets	O
normal	O
.	O
Coagulation	O
PT	O
109	O
,	O
TTPa	O
and	O
D	O
Dimer	O
in	O
normal	O
range	O
.	O
Toxins	O
ethanol	O
not	O
detectable	O
,	O
other	O
toxins	O
in	O
urine	O
negative	O
.	O
Arterial	O
blood	O
gases	O
pH	O
7	O
.	O
2	O
,	O
pCO2	O
65	O
mmHg	O
,	O
pO2	O
163	O
mmHg	O
,	O
bicarbonate	O
21	O
.	O
3	O
mmol	O
l	O
.	O
Portable	O
chest	O
X	O
ray	O
cardiomegaly	O
in	O
anteroposterior	O
projection	O
.	O
Endotracheal	O
tube	O
properly	O
positioned	O
.	O
No	O
evidence	O
of	O
pulmonary	O
congestion	O
.	O
Electrocardiogram	O
ECG	O
sinus	O
rhythm	O
at	O
75	O
bpm	O
.	O
Normal	O
PR	O
.	O
Left	O
axis	O
.	O
Left	O
anterior	O
hemiblock	O
.	O
Narrow	O
QRS	O
.	O
ST	O
segment	O
depression	O
of	O
approximately	O
1	O
mm	O
in	O
V4	O
V6	O
and	O
flattened	O
T	O
wave	O
in	O
aVL	O
.	O
Urgent	O
cranial	O
CT	O
scan	O
no	O
evidence	O
of	O
acute	O
intracranial	O
pathology	O
.	O
Normal	O
perfusion	O
map	O
and	O
normal	O
supra	O
aortic	O
trunks	O
.	O
Emergency	O
echocardioscopy	O
poor	O
echocardiographic	O
window	O
.	O
Left	O
ventricle	O
LV	O
of	O
normal	O
size	O
and	O
slightly	O
hypertrophic	O
.	O
LVEF	O
moderately	O
affected	O
by	O
global	O
hypokinesia	O
with	O
zone	O
of	O
thinning	O
and	O
hypocontractility	O
in	O
the	O
inferoposterior	O
basal	O
segment	O
.	O
Normal	O
right	O
ventricle	O
RV	O
.	O
Mitral	O
regurgitation	O
at	O
least	O
moderate	O
,	O
very	O
eccentric	O
ischaemic	O
versus	O
prolapsed	O
.	O
Normal	O
aortic	O
and	O
tricuspid	O
valves	O
.	O
No	O
pericardial	O
effusion	O
.	O
Coronary	O
angiography	O
epicardial	O
coronary	O
arteries	O
with	O
minimal	O
irregularities	O
,	O
without	O
significant	O
stenosis	O
.	O
Regulated	O
transthoracic	O
echocardiogram	O
preserved	O
LVEF	O
.	O
Posterobasal	O
and	O
inferobasal	O
akinesia	O
.	O
Normal	O
RV	O
.	O
Mitral	O
insufficiency	O
at	O
least	O
moderate	O
probably	O
severe	O
with	O
posterior	O
leaflet	O
prolapse	O
.	O
Rest	O
normal	O
.	O
Transesophageal	O
echocardiogram	O
confirms	O
severe	O
mitral	O
insufficiency	O
due	O
to	O
posterior	O
leaflet	O
prolapse	O
predominantly	O
at	O
P2	O
,	O
with	O
eccentric	O
jet	O
directed	O
anteriorly	O
with	O
Coanda	O
effect	O
.	O
Cardiac	O
magnetic	O
resonance	O
imaging	O
MRI	O
mitral	O
prolapse	O
with	O
associated	O
severe	O
mitral	O
insufficiency	O
.	O
Dilated	O
LV	O
VTD	O
120	O
ml	O
m2	O
.	O
Thinning	O
and	O
hypocontractility	O
of	O
the	O
basal	O
and	O
mid	O
inferolateral	O
segments	O
,	O
with	O
late	O
intramyocardial	O
enhancement	O
in	O
the	O
basal	O
inferolateral	O
segment	O
.	O
RV	O
of	O
normal	O
size	O
and	O
function	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
's	O
evolution	O
was	O
good	O
during	O
his	O
stay	O
in	O
the	O
ICU	O
,	O
and	O
he	O
was	O
extubated	O
after	O
24	O
hours	O
and	O
transferred	O
to	O
the	O
hospital	O
ward	O
stable	O
and	O
asymptomatic	O
.	O
A	O
broad	O
differential	O
diagnosis	O
of	O
cardiorespiratory	O
arrest	O
had	O
already	O
begun	O
in	O
the	O
ED	O
.	O
The	O
complementary	O
tests	O
described	O
above	O
were	O
performed	O
,	O
which	O
led	O
to	O
the	O
diagnosis	O
of	O
malignant	O
mitral	O
prolapse	O
as	O
the	O
cause	O
of	O
the	O
event	O
.	O
During	O
his	O
hospitalisation	O
he	O
presented	O
several	O
bouts	O
of	O
non	O
sustained	O
monomorphic	O
ventricular	O
tachycardia	O
with	O
superior	O
axis	O
and	O
right	O
bundle	O
branch	O
block	O
morphology	O
.	O
In	O
view	O
of	O
the	O
severe	O
mitral	O
insufficiency	O
with	O
LV	O
dilatation	O
confirmed	O
by	O
MRI	O
,	O
it	O
was	O
decided	O
in	O
a	O
medical	O
surgical	O
session	O
to	O
perform	O
mitral	O
valve	O
repair	O
,	O
which	O
took	O
place	O
on	O
admission	O
,	O
with	O
implantation	O
of	O
two	O
4	O
0	O
Goretex	O
neochords	O
at	O
P2	O
and	O
AM	O
Physio	O
30	O
mm	O
plus	O
a	O
30	O
mm	O
mitral	O
ring	O
,	O
without	O
complications	O
.	O
Subsequently	O
,	O
an	O
automatic	O
defibrillator	O
was	O
implanted	O
for	O
secondary	O
prevention	O
.	O
Clinical	O
progress	O
was	O
satisfactory	O
and	O
he	O
was	O
discharged	O
with	O
the	O
following	O
medication	O
torasemide	B-FARMACO
10	O
mg	O
,	O
ramipril	B-FARMACO
2	O
.	O
5	O
mg	O
,	O
bisoprolol	B-FARMACO
5	O
mg	O
,	O
atorvastatin	B-FARMACO
40	O
mg	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
,	O
ferrimanitol	B-FARMACO
ovalbumin	I-FARMACO
40	O
mg	O
,	O
metamizol	B-FARMACO
575	O
mg	O
and	O
tramadol	B-FARMACO
100	O
mg	O
;	O
and	O
follow	O
up	O
in	O
cardiology	O
outpatient	O
clinics	O
.	O
DIAGNOSIS	O
Malignant	O
mitral	O
valve	O
prolapse	O
.	O
Resuscitated	O
cardiorespiratory	O
arrest	O
,	O
in	O
defibrillable	O
rhythm	O
.	O
Severe	O
mitral	O
regurgitation	O
secondary	O
to	O
mitral	O
prolapse	O
.	O
Left	O
ventricular	O
dilatation	O
.	O
Non	O
sustained	O
monoform	O
ventricular	O
tachycardias	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Patient	O
aged	O
53	O
years	O
reporting	O
allergy	O
to	O
penicillin	B-FARMACO
not	O
confirmed	O
by	O
allergy	O
tests	O
.	O
Active	O
smoker	O
15	O
packs	O
year	O
,	O
denies	O
other	O
toxic	O
habits	O
.	O
No	O
pathological	O
history	O
of	O
interest	O
,	O
no	O
surgical	O
interventions	O
.	O
No	O
usual	O
treatment	O
.	O
He	O
came	O
to	O
the	O
emergency	O
department	O
with	O
a	O
high	O
fever	O
of	O
up	O
to	O
39	O
C	O
with	O
drowsiness	O
and	O
"	O
clumsiness	O
"	O
in	O
the	O
right	O
hand	O
for	O
one	O
hour	O
.	O
He	O
reported	O
being	O
a	O
teacher	O
and	O
expressed	O
great	O
concern	O
about	O
being	O
unable	O
to	O
write	O
.	O
In	O
the	O
anamnesis	O
,	O
he	O
reported	O
fever	O
and	O
cough	O
with	O
cervical	O
and	O
axillary	O
lymphadenopathy	O
for	O
the	O
last	O
2	O
months	O
,	O
which	O
his	O
primary	O
care	O
doctor	O
labelled	O
as	O
mononucleosis	O
syndrome	O
,	O
although	O
this	O
was	O
not	O
confirmed	O
and	O
he	O
did	O
not	O
receive	O
any	O
treatment	O
.	O
Subsequently	O
,	O
despite	O
some	O
improvement	O
in	O
her	O
symptoms	O
,	O
she	O
continued	O
with	O
occasional	O
fever	O
,	O
asthenia	O
and	O
unquantified	O
weight	O
loss	O
.	O
She	O
denies	O
recent	O
trips	O
or	O
risky	O
relationships	O
,	O
no	O
contact	O
with	O
animals	O
,	O
has	O
not	O
had	O
any	O
dental	O
procedures	O
,	O
but	O
refers	O
to	O
a	O
tooth	O
that	O
had	O
been	O
affected	O
by	O
caries	O
for	O
months	O
.	O
Examination	O
on	O
admission	O
blood	O
pressure	O
105	O
60	O
mmHg	O
,	O
heart	O
rate	O
81	O
bpm	O
,	O
saturation	O
96	O
basal	O
,	O
39	O
C	O
.	O
Pallor	O
.	O
No	O
jugular	O
ingurgitation	O
.	O
Small	O
cervical	O
and	O
axillary	O
lymph	O
nodes	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
with	O
systolic	O
murmur	O
in	O
mitral	O
focus	O
grade	O
3	O
6	O
radiating	O
to	O
the	O
axilla	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
with	O
no	O
additional	O
sounds	O
.	O
Abdomen	O
soft	O
and	O
non	O
painful	O
,	O
with	O
hepatomegaly	O
of	O
1	O
2	O
fingerbreadths	O
.	O
Upper	O
extremities	O
EESS	O
without	O
skin	O
lesions	O
.	O
Lower	O
extremities	O
LES	O
without	O
oedema	O
with	O
pulses	O
present	O
,	O
but	O
with	O
erythematous	O
macular	O
lesions	O
on	O
both	O
soles	O
compatible	O
with	O
Janeway	O
spots	O
.	O
Basic	O
neurological	O
examination	O
Glasgow	O
14	O
O3	O
V5	O
M6	O
,	O
bradypsychia	O
with	O
tendency	O
to	O
somnolence	O
,	O
cranial	O
nerves	O
without	O
alterations	O
.	O
EESS	O
with	O
dysmetria	O
in	O
the	O
right	O
upper	O
extremity	O
with	O
preserved	O
strength	O
and	O
sensitivity	O
.	O
No	O
other	O
alterations	O
in	O
the	O
lower	O
limbs	O
.	O
COMPLEMENTARY	O
TESTS	O
Blood	O
tests	O
glycaemia	O
105	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
97	O
mg	O
dl	O
,	O
Na	O
132	O
mEq	O
l	O
,	O
Cl	O
98	O
mEq	O
l	O
,	O
K	O
4	O
.	O
1	O
mEq	O
l	O
.	O
Leukocytes	O
15300	O
ml	O
with	O
89	O
neutrophils	O
.	O
Hb	O
12	O
.	O
6	O
g	O
dl	O
,	O
Hto	O
38	O
,	O
platelets	O
136000	O
mcl	O
.	O
INR	O
1	O
.	O
62	O
,	O
PT	O
18	O
.	O
16	O
s	O
,	O
AP	O
58	O
,	O
FD	O
421	O
mg	O
dl	O
.	O
ESR	O
83	O
mm	O
h	O
,	O
CRP	O
21	O
mg	O
l	O
,	O
procalcitonin	O
1	O
.	O
38	O
mg	O
dl	O
.	O
Electrocardiogram	O
ECG	O
on	O
admission	O
sinus	O
rhythm	O
at	O
81	O
bpm	O
,	O
normal	O
axis	O
,	O
normal	O
PR	O
,	O
narrow	O
QRS	O
without	O
repolarisation	O
alterations	O
.	O
Chest	O
X	O
ray	O
on	O
admission	O
normal	O
cardiothoracic	O
index	O
,	O
no	O
signs	O
of	O
consolidating	O
focus	O
or	O
vascular	O
redistribution	O
.	O
Blood	O
cultures	O
positive	O
after	O
72	O
hours	O
of	O
admission	O
Aggregatibacter	O
aphrophilus	O
,	O
no	O
resistance	O
.	O
Serology	O
HIV	O
,	O
HBV	O
,	O
HCV	O
negative	O
.	O
Brucella	O
,	O
Coxiella	O
,	O
Bartonella	O
negative	O
.	O
Transthoracic	O
echocardiography	O
TTE	O
on	O
admission	O
left	O
ventricle	O
LV	O
slightly	O
dilated	O
LVEDD	O
of	O
56	O
mm	O
and	O
LVEDV	O
of	O
165	O
ml	O
with	O
normal	O
wall	O
thickness	O
.	O
Preserved	O
LV	O
systolic	O
function	O
Simpson	O
's	O
estimate	O
s	O
55	O
.	O
No	O
segmental	O
contractility	O
alterations	O
.	O
Pseudonormal	O
diastolic	O
pattern	O
E	O
A	O
1	O
.	O
8	O
.	O
Slightly	O
dilated	O
left	O
atrium	O
area	O
22	O
cm2	O
.	O
Right	O
chambers	O
at	O
the	O
high	O
limit	O
of	O
normality	O
RV	O
baseline	O
diameter	O
on	O
A4C	O
of	O
40	O
mm	O
with	O
preserved	O
right	O
ventricular	O
RV	O
contractility	O
TAPSE	O
of	O
23	O
mm	O
,	O
S	O
in	O
lateral	O
TDI	O
of	O
tricuspid	O
annulus	O
of	O
12	O
cm	O
sg	O
.	O
Mitral	O
valve	O
MV	O
thickened	O
leaflets	O
,	O
not	O
limited	O
in	O
its	O
opening	O
.	O
At	O
the	O
level	O
of	O
the	O
posterior	O
region	O
of	O
the	O
mitral	O
annulus	O
A3	O
P3	O
,	O
hyperdense	O
and	O
heterogeneous	O
image	O
with	O
anarchic	O
movement	O
of	O
18	O
x	O
6	O
7	O
mm	O
,	O
which	O
is	O
difficult	O
to	O
map	O
by	O
transthoracic	O
access	O
,	O
generating	O
mitral	O
valve	O
destructuring	O
causing	O
moderate	O
severe	O
mitral	O
insufficiency	O
MI	O
characterised	O
by	O
a	O
wide	O
eccentric	O
regurgitation	O
jet	O
towards	O
the	O
lateral	O
wall	O
of	O
the	O
left	O
atrium	O
LA	O
,	O
VC	O
of	O
8	O
mm	O
,	O
E	O
wave	O
of	O
1	O
.	O
2	O
m	O
sg	O
,	O
PISA	O
radius	O
of	O
10	O
mm	O
,	O
abolition	O
of	O
flow	O
in	O
the	O
pulmonary	O
valve	O
PV	O
.	O
Regurgitant	O
volume	O
of	O
49	O
ml	O
and	O
ERO	O
of	O
0	O
.	O
35	O
cm2	O
.	O
Aortic	O
valve	O
VAo	O
trivalve	O
,	O
normal	O
sigmoid	O
,	O
not	O
limited	O
in	O
its	O
opening	O
.	O
Competent	O
.	O
No	O
images	O
suggestive	O
of	O
infective	O
endocarditis	O
IE	O
at	O
this	O
level	O
.	O
Mild	O
tricuspid	O
insufficiency	O
TI	O
,	O
estimating	O
pulmonary	O
artery	O
systolic	O
pressure	O
PAAP	O
32	O
mmHg	O
.	O
Inferior	O
vena	O
cava	O
IVC	O
not	O
dilated	O
with	O
normal	O
inspiratory	O
collapse	O
.	O
No	O
pericardial	O
effusion	O
.	O
TTE	O
in	O
the	O
first	O
24	O
hours	O
of	O
admission	O
study	O
similar	O
to	O
previous	O
TTE	O
.	O
With	O
respect	O
to	O
the	O
MV	O
,	O
large	O
mass	O
of	O
approximately	O
27	O
x	O
16	O
mm	O
,	O
with	O
irregular	O
borders	O
and	O
echolucent	O
regions	O
inside	O
,	O
located	O
in	O
the	O
region	O
of	O
the	O
posteromedial	O
commissure	O
encompassing	O
part	O
of	O
the	O
P3	O
A3	O
scallops	O
.	O
It	O
shows	O
increased	O
mobility	O
with	O
protrusion	O
to	O
the	O
LV	O
.	O
Likewise	O
,	O
a	O
solution	O
of	O
continuity	O
can	O
be	O
seen	O
in	O
the	O
commissural	O
region	O
previously	O
described	O
and	O
in	O
P3	O
,	O
allowing	O
a	O
jet	O
that	O
crosses	O
the	O
echolucent	O
tracts	O
and	O
generating	O
a	O
severe	O
MI	O
contained	O
by	O
this	O
mass	O
.	O
In	O
summary	O
,	O
the	O
image	O
is	O
suggestive	O
of	O
a	O
large	O
abscess	O
.	O
Cranial	O
CT	O
scan	O
on	O
admission	O
in	O
the	O
non	O
contrast	O
scan	O
two	O
focal	O
lesions	O
were	O
identified	O
a	O
1	O
cm	O
hyperdense	O
subcortical	O
lesion	O
next	O
to	O
Rolando	O
's	O
fissure	O
surrounded	O
by	O
oedema	O
and	O
another	O
in	O
the	O
right	O
cerebellar	O
hemisphere	O
of	O
heterogeneous	O
density	O
and	O
larger	O
in	O
size	O
3	O
cm	O
with	O
a	O
slight	O
mass	O
effect	O
on	O
the	O
fourth	O
ventricle	O
without	O
producing	O
compressive	O
hydrocephalus	O
.	O
They	O
have	O
a	O
haemorrhagic	O
component	O
.	O
No	O
significant	O
enhancement	O
or	O
annular	O
enhancement	O
after	O
contrast	O
administration	O
.	O
Thoracic	O
abdominal	O
CT	O
scan	O
48	O
hours	O
after	O
admission	O
hypodense	O
mass	O
measuring	O
27	O
x	O
15	O
mm	O
located	O
in	O
the	O
posterior	O
and	O
anterior	O
leaflet	O
of	O
the	O
mitral	O
valve	O
A3	O
and	O
P3	O
with	O
extension	O
towards	O
the	O
left	O
atrial	O
cavity	O
,	O
and	O
continuity	O
of	O
the	O
mass	O
to	O
the	O
mitral	O
periannular	O
region	O
;	O
findings	O
compatible	O
with	O
paravalvular	O
abscess	O
.	O
Hepatomegaly	O
with	O
focal	O
hypodense	O
lesion	O
of	O
4	O
mm	O
in	O
segment	O
VII	O
of	O
cystic	O
nature	O
.	O
Splenomegaly	O
with	O
the	O
presence	O
of	O
three	O
peripherally	O
located	O
focal	O
hypodense	O
lesions	O
in	O
the	O
posteroinferior	O
region	O
of	O
the	O
spleen	O
suggesting	O
infarcts	O
.	O
In	O
the	O
upper	O
cortical	O
pole	O
of	O
the	O
left	O
kidney	O
there	O
is	O
a	O
focal	O
lesion	O
of	O
11	O
mm	O
,	O
with	O
poorly	O
defined	O
contours	O
and	O
small	O
peripheral	O
enhancement	O
suspicious	O
of	O
abscess	O
.	O
Subpleural	O
pulmonary	O
nodules	O
in	O
the	O
posterior	O
segment	O
of	O
the	O
LSD	O
,	O
the	O
largest	O
of	O
5	O
mm	O
with	O
an	O
inflammatory	O
appearance	O
.	O
Cranial	O
magnetic	O
resonance	O
imaging	O
MRI	O
48	O
hours	O
after	O
admission	O
multiple	O
small	O
hyperintense	O
lesions	O
in	O
T2	O
sequences	O
of	O
supratentorial	O
location	O
compatible	O
with	O
microembolism	O
.	O
There	O
is	O
a	O
haemorrhagic	O
lesion	O
already	O
visible	O
on	O
CT	O
imaging	O
in	O
the	O
left	O
parietal	O
convexity	O
with	O
haemorrhagic	O
discharge	O
into	O
the	O
subarachnoid	O
space	O
and	O
another	O
larger	O
lesion	O
located	O
in	O
the	O
right	O
cerebellar	O
hemisphere	O
.	O
Behind	O
it	O
there	O
is	O
another	O
haemorrhagic	O
microfocus	O
.	O
They	O
are	O
hyperintense	O
in	O
T1	O
and	O
show	O
no	O
significant	O
enhancement	O
after	O
gadolinium	O
injection	O
.	O
The	O
cerebellar	O
lesion	O
causes	O
a	O
discrete	O
mass	O
effect	O
on	O
the	O
fourth	O
ventricle	O
without	O
obliterating	O
it	O
,	O
so	O
there	O
is	O
no	O
evidence	O
of	O
hydrocephalus	O
.	O
Non	O
specific	O
diffusion	O
study	O
.	O
Ultrasound	O
scan	O
of	O
the	O
abdomen	O
on	O
day	O
8	O
of	O
admission	O
mild	O
homogeneous	O
global	O
hepatomegaly	O
with	O
homogeneous	O
echostructure	O
.	O
Porta	O
permeable	O
.	O
Suprahepatic	O
veins	O
not	O
dilated	O
.	O
No	O
space	O
occupying	O
lesions	O
LOE	O
were	O
observed	O
.	O
Adequately	O
distended	O
gallbladder	O
with	O
preserved	O
wall	O
and	O
normal	O
content	O
.	O
Bile	O
ducts	O
are	O
not	O
dilated	O
.	O
Pancreas	O
and	O
spleen	O
of	O
preserved	O
size	O
,	O
morphology	O
and	O
echostructure	O
.	O
Kidneys	O
of	O
normal	O
size	O
and	O
morphology	O
.	O
Excretory	O
systems	O
not	O
dilated	O
.	O
No	O
abdominal	O
collections	O
,	O
ascites	O
or	O
ultrasound	O
alterations	O
in	O
the	O
gastrointestinal	O
tract	O
.	O
CLINICAL	O
EVOLUTION	O
Given	O
the	O
clinical	O
manifestations	O
of	O
constitutional	O
syndrome	O
and	O
neurological	O
focality	O
,	O
a	O
cranial	O
CT	O
scan	O
was	O
requested	O
in	O
the	O
emergency	O
department	O
where	O
two	O
lesions	O
with	O
a	O
haemorrhagic	O
component	O
one	O
cerebral	O
and	O
the	O
other	O
cerebellar	O
were	O
observed	O
,	O
which	O
could	O
be	O
related	O
to	O
an	O
embolic	O
or	O
metastatic	O
origin	O
.	O
In	O
order	O
to	O
identify	O
their	O
origin	O
and	O
given	O
the	O
presence	O
of	O
mitral	O
systolic	O
murmur	O
on	O
physical	O
examination	O
,	O
a	O
TTE	O
scan	O
was	O
performed	O
which	O
showed	O
a	O
mass	O
dependent	O
on	O
the	O
posterior	O
mitral	O
leaflet	O
with	O
significant	O
MR	O
and	O
a	O
normal	O
sized	O
left	O
atrium	O
,	O
suggesting	O
acute	O
subacute	O
MR	O
.	O
In	O
addition	O
,	O
blood	O
cultures	O
and	O
serology	O
were	O
taken	O
in	O
the	O
emergency	O
department	O
.	O
The	O
diagnosis	O
of	O
IE	O
was	O
established	O
given	O
the	O
presence	O
of	O
one	O
major	O
criterion	O
mass	O
dependent	O
on	O
the	O
posterior	O
mitral	O
leaflet	O
and	O
two	O
minor	O
criteria	O
fever	O
and	O
embolisms	O
at	O
the	O
level	O
of	O
the	O
brain	O
,	O
cerebellum	O
and	O
IIJS	O
.	O
Despite	O
significant	O
mitral	O
regurgitation	O
,	O
the	O
patient	O
was	O
haemodynamically	O
and	O
neurologically	O
stable	O
,	O
with	O
no	O
signs	O
of	O
heart	O
failure	O
,	O
so	O
it	O
was	O
decided	O
to	O
admit	O
him	O
to	O
the	O
cardiology	O
ward	O
.	O
After	O
discussion	O
with	O
on	O
call	O
internal	O
medicine	O
infectious	O
diseases	O
,	O
given	O
his	O
allergy	O
to	O
beta	B-FARMACO
lactam	I-FARMACO
antibiotics	O
,	O
the	O
aggressiveness	O
of	O
his	O
symptoms	O
and	O
his	O
residence	O
near	O
an	O
area	O
endemic	O
for	O
methicillin	B-FARMACO
and	O
vancomycin	B-FARMACO
resistant	O
Staphylococcus	O
aureus	O
strains	O
,	O
empirical	O
antibiotic	O
treatment	O
was	O
started	O
with	O
daptomycin	B-FARMACO
iv	O
675	O
mg	O
24	O
hours	O
,	O
gentamicin	B-FARMACO
iv	O
200	O
mg	O
24	O
hours	O
and	O
fosfomycin	B-FARMACO
iv	O
4	O
g	O
8	O
hours	O
.	O
Twenty	O
four	O
hours	O
after	O
admission	O
,	O
a	O
thoracoabdominal	O
CT	O
scan	O
was	O
performed	O
,	O
revealing	O
multiple	O
embolisms	O
and	O
abscesses	O
in	O
the	O
left	O
kidney	O
and	O
spleen	O
.	O
Transesophageal	O
echocardiography	O
was	O
also	O
performed	O
,	O
revealing	O
a	O
mitral	O
perivalvular	O
abscess	O
in	O
the	O
region	O
of	O
the	O
posteromedial	O
commissure	O
,	O
encompassing	O
part	O
of	O
the	O
A3	O
P3	O
scallops	O
and	O
causing	O
severe	O
mitral	O
insufficiency	O
due	O
to	O
partial	O
rupture	O
of	O
the	O
posterior	O
mitral	O
leaflet	O
.	O
At	O
48	O
hours	O
later	O
,	O
a	O
cranial	O
MRI	O
was	O
performed	O
,	O
which	O
showed	O
two	O
lesions	O
compatible	O
with	O
infarcts	O
with	O
haemorrhagic	O
transformation	O
and	O
a	O
funduscopic	O
examination	O
to	O
rule	O
out	O
Candida	O
involvement	O
showing	O
emboligenic	O
involvement	O
.	O
Subsequently	O
,	O
intense	O
asthenia	O
persisted	O
,	O
with	O
slight	O
improvement	O
in	O
neurological	O
symptoms	O
and	O
febrile	O
peaks	O
of	O
up	O
to	O
39	O
C	O
.	O
After	O
72	O
hours	O
of	O
admission	O
,	O
Aggregatibacter	O
aphrophilus	O
was	O
isolated	O
in	O
several	O
blood	O
cultures	O
,	O
so	O
with	O
two	O
major	O
and	O
two	O
minor	O
criteria	O
the	O
diagnosis	O
of	O
definite	O
IE	O
was	O
established	O
.	O
Once	O
the	O
antibiogram	O
was	O
obtained	O
fourth	O
day	O
of	O
admission	O
,	O
with	O
no	O
resistance	O
,	O
the	O
infectious	O
diseases	O
department	O
decided	O
to	O
adjust	O
antibiotherapy	O
consisting	O
of	O
ceftriaxone	B-FARMACO
2	O
g	O
24	O
hours	O
and	O
ciprofloxacin	B-FARMACO
500	O
mg	O
24	O
hours	O
controlled	O
administration	O
after	O
verifying	O
an	O
unlikely	O
allergy	O
to	O
penicillins	B-FARMACO
in	O
childhood	O
,	O
and	O
consulting	O
with	O
the	O
HRV	O
allergy	O
department	O
.	O
Clinical	O
improvement	O
in	O
the	O
neurological	O
sphere	O
,	O
with	O
persistence	O
of	O
occasional	O
febrile	O
peaks	O
,	O
so	O
that	O
on	O
the	O
eighth	O
day	O
of	O
admission	O
an	O
ultrasound	O
scan	O
of	O
the	O
abdomen	O
was	O
requested	O
,	O
which	O
was	O
compatible	O
with	O
normality	O
.	O
The	O
case	O
was	O
presented	O
at	O
the	O
medical	O
surgical	O
session	O
on	O
the	O
third	O
day	O
of	O
admission	O
and	O
in	O
constant	O
communication	O
with	O
cardiac	O
surgery	O
,	O
and	O
after	O
consultation	O
with	O
neurology	O
,	O
it	O
was	O
decided	O
to	O
complete	O
a	O
certain	O
period	O
of	O
time	O
with	O
antibiotherapy	O
prior	O
to	O
surgery	O
.	O
Subsequent	O
good	O
clinical	O
evolution	O
,	O
afebrile	O
,	O
with	O
improvement	O
in	O
writing	O
and	O
controls	O
by	O
radiology	O
by	O
means	O
of	O
CT	O
and	O
MRI	O
brain	O
MRI	O
control	O
after	O
10	O
days	O
which	O
showed	O
a	O
reduction	O
in	O
microbleeds	O
,	O
microinfarcts	O
and	O
previous	O
intraparenchymal	O
haemorrhage	O
.	O
Extraction	O
of	O
the	O
affected	O
tooth	O
by	O
maxillofacial	O
surgery	O
.	O
Finally	O
,	O
on	O
the	O
33rd	O
day	O
of	O
admission	O
,	O
mitral	O
valve	O
replacement	O
with	O
Saint	O
Jude	O
mechanical	O
prosthesis	O
no	O
.	O
33	O
was	O
performed	O
,	O
confirming	O
the	O
diagnosis	O
of	O
infective	O
endocarditis	O
perivalvular	O
abscess	O
by	O
pathological	O
anatomy	O
and	O
microbiology	O
.	O
Correct	O
postoperative	O
evolution	O
without	O
incident	O
,	O
being	O
discharged	O
on	O
the	O
16th	O
day	O
after	O
surgery	O
.	O
He	O
has	O
remained	O
clinically	O
stable	O
until	O
the	O
present	O
day	O
,	O
and	O
has	O
resumed	O
his	O
teaching	O
activity	O
.	O
DIAGNOSIS	O
Subacute	O
infective	O
endocarditis	O
on	O
native	O
mitral	O
valve	O
due	O
to	O
Aggregatibacter	O
aphrophilus	O
.	O
Perivalvular	O
mitral	O
abscess	O
in	O
the	O
region	O
of	O
the	O
posteromedial	O
commissure	O
,	O
encompassing	O
part	O
of	O
the	O
A3	O
P3	O
scallops	O
and	O
causing	O
severe	O
mitral	O
insufficiency	O
due	O
to	O
partial	O
rupture	O
of	O
the	O
posterior	O
mitral	O
leaflet	O
.	O
Multiple	O
septic	O
embolisms	O
cerebral	O
,	O
cerebellar	O
,	O
splenic	O
,	O
left	O
renal	O
,	O
retinal	O
,	O
distal	O
extremities	O
.	O
Haemorrhagic	O
transformation	O
of	O
cerebral	O
embolic	O
lesions	O
located	O
in	O
the	O
left	O
parietal	O
convexity	O
and	O
right	O
cerebellar	O
hemisphere	O
.	O
Mitral	O
valve	O
replacement	O
with	O
Saint	O
Jude	O
mechanical	O
prosthesis	O
no	O
.	O
33	O
.	O

PERSONAL	O
HISTORY	O
This	O
is	O
a	O
67	O
year	O
old	O
patient	O
from	O
France	O
,	O
resident	O
in	O
the	O
summer	O
in	O
a	O
town	O
in	O
the	O
Aragonese	O
Pyrenees	O
.	O
He	O
worked	O
in	O
the	O
construction	O
sector	O
,	O
but	O
is	O
currently	O
retired	O
.	O
There	O
is	O
no	O
record	O
of	O
any	O
previous	O
medical	O
history	O
in	O
our	O
health	O
system	O
.	O
In	O
a	O
report	O
provided	O
by	O
his	O
wife	O
,	O
there	O
are	O
no	O
known	O
drug	O
allergies	O
to	O
date	O
,	O
and	O
his	O
medical	O
history	O
only	O
includes	O
active	O
smoking	O
IPA	O
50	O
,	O
type	O
II	O
diabetes	O
mellitus	O
being	O
treated	O
with	O
metformin	B-FARMACO
and	O
hyperuricaemia	O
,	O
for	O
which	O
he	O
takes	O
allopurinol	B-FARMACO
100	O
mg	O
every	O
24	O
hours	O
.	O
CURRENT	O
DISEASE	O
At	O
the	O
end	O
of	O
June	O
2018	O
,	O
after	O
returning	O
home	O
with	O
intense	O
low	O
back	O
pain	O
after	O
doing	O
farm	O
work	O
in	O
an	O
orchard	O
,	O
he	O
takes	O
a	O
diclofenac	B-FARMACO
tablet	O
.	O
Half	O
an	O
hour	O
earlier	O
,	O
he	O
reported	O
having	O
been	O
bitten	O
by	O
an	O
insect	O
that	O
he	O
did	O
not	O
identify	O
.	O
Shortly	O
afterwards	O
,	O
after	O
dinner	O
during	O
which	O
he	O
had	O
not	O
eaten	O
any	O
new	O
food	O
in	O
his	O
diet	O
,	O
he	O
presented	O
with	O
a	O
pruritic	O
rash	O
,	O
initially	O
on	O
his	O
arms	O
,	O
which	O
quickly	O
became	O
generalised	O
,	O
and	O
a	O
feeling	O
of	O
dyspnoea	O
.	O
Subsequently	O
,	O
he	O
began	O
to	O
experience	O
oppressive	O
central	O
thoracic	O
pain	O
and	O
loss	O
of	O
consciousness	O
with	O
rapid	O
spontaneous	O
recovery	O
with	O
blood	O
pressure	O
BP	O
65	O
35	O
and	O
SpO2	O
88	O
recorded	O
by	O
the	O
emergency	O
services	O
mobilised	O
to	O
his	O
home	O
.	O
Systemic	O
treatment	O
with	O
methylprednisolone	B-FARMACO
and	O
dexchlorpheniramine	B-FARMACO
was	O
started	O
,	O
and	O
the	O
anaphylactic	O
symptoms	O
resolved	O
.	O
The	O
electrocardiograms	O
ECG	O
performed	O
showed	O
transient	O
lower	O
posterior	O
and	O
lateral	O
ST	O
segment	O
elevation	O
,	O
so	O
after	O
administering	O
loading	O
doses	O
of	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
and	O
ticagrelor	B-FARMACO
,	O
he	O
was	O
transferred	O
to	O
our	O
centre	O
by	O
helicopter	O
for	O
urgent	O
coronary	O
angiography	O
.	O
Echocardioscopy	O
was	O
performed	O
in	O
the	O
antechamber	O
and	O
showed	O
hypokinesia	O
of	O
anterolateral	O
and	O
inferolateral	O
basal	O
and	O
medial	O
segments	O
.	O
PHYSICAL	O
EXAMINATION	O
On	O
arrival	O
in	O
the	O
haemodynamics	O
room	O
,	O
the	O
physical	O
examination	O
was	O
normal	O
except	O
for	O
the	O
presence	O
of	O
a	O
discrete	O
rash	O
on	O
the	O
trunk	O
which	O
disappeared	O
during	O
the	O
procedure	O
.	O
BP	O
105	O
60	O
mmHg	O
,	O
heart	O
rate	O
HR	O
80	O
bpm	O
.	O
Baseline	O
SpO2	O
97	O
.	O
Afebrile	O
.	O
Oropharynx	O
slightly	O
hyperemic	O
.	O
No	O
jugular	O
venous	O
engorgement	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
sounds	O
without	O
murmurs	O
or	O
extratonos	O
.	O
Pulmonary	O
auscultation	O
minimal	O
scattered	O
wheezing	O
,	O
no	O
hypoventilation	O
.	O
Abdomen	O
nondescript	O
.	O
Lower	O
extremities	O
no	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
COMPLEMENTARY	O
TESTS	O
Initial	O
ECG	O
sinus	O
rhythm	O
at	O
62	O
bpm	O
,	O
normal	O
PR	O
,	O
narrow	O
QRS	O
with	O
axis	O
at	O
80o	O
.	O
Up	O
to	O
4	O
mm	O
ST	O
segment	O
elevation	O
in	O
inferior	O
leads	O
,	O
V4	O
V6	O
,	O
with	O
V1	O
V3	O
descent	O
and	O
in	O
high	O
lateral	O
leads	O
.	O
ECG	O
at	O
60	O
min	O
on	O
arrival	O
in	O
the	O
cath	O
lab	O
sinus	O
rhythm	O
at	O
54	O
bpm	O
,	O
normal	O
PR	O
,	O
narrow	O
QRS	O
,	O
small	O
Q	O
wave	O
in	O
inferior	O
leads	O
with	O
R	O
S	O
in	O
V2	O
.	O
ST	O
isoelectric	O
in	O
all	O
leads	O
,	O
negative	O
T	O
wave	O
in	O
III	O
and	O
aVF	O
.	O
Chest	O
X	O
ray	O
on	O
admission	O
normal	O
cardiomediastinal	O
silhouette	O
.	O
Calcified	O
aortic	O
atheromatosis	O
.	O
No	O
signs	O
of	O
acute	O
haemodynamic	O
decompensation	O
,	O
nor	O
images	O
suggesting	O
pulmonary	O
condensation	O
.	O
Echocardioscopy	O
preserved	O
left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
,	O
hypokinesia	O
of	O
basal	O
and	O
medial	O
anterolateral	O
and	O
lateral	O
segments	O
.	O
No	O
mechanical	O
complications	O
or	O
pericardial	O
effusion	O
.	O
Echocardiogram	O
non	O
dilated	O
left	O
atrium	O
.	O
Fine	O
mitral	O
valve	O
,	O
slight	O
posterior	O
annular	O
calcification	O
that	O
does	O
not	O
restrict	O
valve	O
opening	O
.	O
Minimal	O
central	O
insufficiency	O
.	O
Normal	O
filling	O
pressures	O
.	O
Left	O
ventricle	O
not	O
dilated	O
VTDVI	O
4C	O
114	O
cm3	O
,	O
VTSVI	O
4C	O
44	O
cm3	O
,	O
nor	O
hypertrophied	O
.	O
Biplane	O
LVEF	O
59	O
.	O
7	O
without	O
clear	O
alterations	O
in	O
segmental	O
contractility	O
.	O
Trivalve	O
aortic	O
valve	O
,	O
normal	O
flow	O
.	O
Aortic	O
root	O
not	O
dilated	O
.	O
Non	O
dilated	O
right	O
chambers	O
with	O
normal	O
contractility	O
TAPSE	O
28	O
.	O
Tricuspid	O
valve	O
with	O
normal	O
flow	O
.	O
No	O
indirect	O
evidence	O
of	O
pulmonary	O
hypertension	O
.	O
No	O
pericardial	O
effusion	O
.	O
Urgent	O
coronary	O
angiography	O
29	O
06	O
2018	O
right	O
dominance	O
.	O
Ischaemic	O
heart	O
disease	O
with	O
severe	O
stenosis	O
of	O
obtuse	O
marginal	O
ostioproximal	O
large	O
calibre	O
ostial	O
artery	O
artery	O
responsible	O
for	O
infarction	O
due	O
to	O
severely	O
calcified	O
plaque	O
and	O
severe	O
stenosis	O
of	O
proximal	O
medial	O
anterior	O
descending	O
artery	O
.	O
Percutaneous	O
coronary	O
intervention	O
on	O
severe	O
stenosis	O
of	O
CX	O
MO	O
by	O
means	O
of	O
PTCA	O
with	O
conventional	O
balloons	O
,	O
cutting	O
balloon	O
and	O
rotational	O
atherectomy	O
.	O
Subsequent	O
implantation	O
of	O
a	O
zotarolimus	B-FARMACO
eluting	O
drug	O
eluting	O
stent	O
with	O
good	O
angiographic	O
results	O
.	O
Second	O
time	O
coronary	O
angiography	O
06	O
07	O
2018	O
good	O
result	O
of	O
the	O
drug	O
eluting	O
stent	O
implanted	O
on	O
CX	O
MO	O
.	O
Percutaneous	O
coronary	O
intervention	O
on	O
long	O
calcified	O
plaque	O
in	O
proximal	O
middle	O
anterior	O
descending	O
coronary	O
artery	O
by	O
means	O
of	O
percutaneous	O
transluminal	O
coronary	O
angioplasty	O
PTCA	O
and	O
implantation	O
of	O
zotarolimus	B-FARMACO
eluting	O
drug	O
eluting	O
stent	O
.	O
Blood	O
tests	O
on	O
admission	O
to	O
the	O
ward	O
haemogram	O
Hb	O
13	O
.	O
1	O
g	O
dl	O
;	O
Hct	O
37	O
.	O
5	O
;	O
leukocytes	O
7	O
.	O
3	O
mil	O
mm3	O
;	O
platelets	O
163	O
mil	O
mm3	O
.	O
Biochemistry	O
basal	O
glucose	O
159	O
mg	O
dl	O
;	O
glycated	O
Hb	O
9	O
.	O
6	O
,	O
urea	O
0	O
.	O
33	O
g	O
l	O
,	O
creatinine	O
1	O
mg	O
dl	O
,	O
glomerular	O
filtration	O
rate	O
estimated	O
by	O
CKD	O
EPI	O
76	O
ml	O
min	O
1	O
.	O
73m2	O
,	O
total	O
cholesterol	O
131	O
mg	O
dl	O
,	O
triglycerides	O
200	O
mg	O
dl	O
,	O
HDL	O
c	O
30	O
mg	O
dl	O
,	O
LDL	O
c	O
61	O
mg	O
dl	O
,	O
AST	O
27	O
U	O
l	O
,	O
ALT	O
30	O
U	O
l	O
,	O
GGT	O
28	O
U	O
l	O
,	O
sodium	O
140	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
4	O
mEq	O
l	O
.	O
ESR	O
29	O
mm	O
0	O
20	O
.	O
CRP	O
1	O
.	O
86	O
mg	O
dl	O
.	O
Complement	O
factors	O
C3	O
and	O
C4	O
normal	O
.	O
Normal	O
circulating	O
immunocomplexes	O
.	O
Allergy	O
tests	O
skin	O
tests	O
to	O
common	O
trophoallergens	O
.	O
Negative	O
to	O
profilin	O
and	O
LTP	O
,	O
soya	O
,	O
latex	O
and	O
anisakis	O
.	O
Total	O
IgE	O
value	O
184	O
IU	O
ml	O
0	O
180	O
.	O
Tryptase	O
value	O
29	O
06	O
2018	O
IAM	O
day	O
14	O
mcg	O
ml	O
0	O
10	O
.	O
Tryptase	O
value	O
02	O
07	O
2018	O
6	O
.	O
03	O
mcg	O
ml	O
0	O
10	O
.	O
Specific	O
IgE	O
Pru	O
p	O
3	O
0	O
.	O
1	O
ku	O
l	O
peach	O
protein	O
0	O
0	O
.	O
35	O
,	O
bee	O
venom	O
0	O
.	O
1	O
ku	O
l	O
0	O
0	O
.	O
35	O
;	O
vespula	O
wasp	O
venom	O
0	O
.	O
2	O
ku	O
l	O
0	O
0	O
.	O
35	O
,	O
polistes	O
wasp	O
1	O
.	O
78	O
0	O
0	O
.	O
35	O
,	O
poliste	O
dominulus	O
3	O
.	O
76	O
ku	O
l	O
0	O
0	O
.	O
35	O
.	O
Prick	O
test	O
against	O
diclofenac	B-FARMACO
positive	O
.	O
Maximum	O
myocardial	O
necrosis	O
markers	O
TnTus	O
338	O
ng	O
l	O
0	O
14	O
;	O
CPK	O
97	O
U	O
l	O
39	O
308	O
,	O
CK	O
MB	O
21	O
U	O
l	O
5	O
24	O
.	O
CLINICAL	O
EVOLUTION	O
On	O
arrival	O
at	O
the	O
haemodynamics	O
ward	O
of	O
our	O
centre	O
,	O
the	O
ECG	O
normalised	O
,	O
the	O
chest	O
pain	O
practically	O
disappeared	O
,	O
although	O
some	O
discomfort	O
and	O
regional	O
contractility	O
anomalies	O
persisted	O
as	O
assessed	O
by	O
echocardioscopy	O
,	O
as	O
well	O
as	O
a	O
great	O
improvement	O
in	O
the	O
anaphylactoid	O
reaction	O
.	O
Urgent	O
coronary	O
angiography	O
revealed	O
severe	O
stenosis	O
in	O
an	O
ostioproximal	O
marginal	O
branch	O
with	O
distal	O
TIMI	O
2	O
3	O
flow	O
,	O
in	O
addition	O
to	O
another	O
severe	O
lesion	O
in	O
the	O
LAD	O
.	O
Given	O
the	O
characteristics	O
of	O
the	O
Cx	O
MO	O
lesion	O
,	O
the	O
intervention	O
was	O
complex	O
,	O
requiring	O
PTCA	O
with	O
cutting	O
balloons	O
and	O
even	O
rotational	O
atherectomy	O
.	O
Despite	O
this	O
,	O
a	O
drug	O
eluting	O
stent	O
was	O
implanted	O
with	O
good	O
angiographic	O
results	O
.	O
After	O
the	O
procedure	O
,	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
ICU	O
,	O
where	O
he	O
made	O
a	O
very	O
favourable	O
evolution	O
.	O
Suspicion	O
of	O
possible	O
Kounis	O
syndrome	O
type	O
II	O
led	O
to	O
a	O
request	O
for	O
a	O
tryptase	O
blood	O
test	O
,	O
which	O
was	O
positive	O
.	O
After	O
36	O
hours	O
in	O
the	O
ICU	O
,	O
where	O
he	O
presented	O
no	O
complications	O
,	O
and	O
without	O
significant	O
elevation	O
of	O
myocardial	O
necrosis	O
markers	O
,	O
he	O
was	O
transferred	O
to	O
the	O
cardiology	O
ward	O
.	O
During	O
admission	O
to	O
the	O
ward	O
she	O
did	O
not	O
present	O
any	O
further	O
episodes	O
of	O
chest	O
pain	O
.	O
Second	O
time	O
coronary	O
angiography	O
was	O
performed	O
on	O
a	O
severe	O
lesion	O
of	O
the	O
LAD	O
,	O
and	O
another	O
drug	O
eluting	O
stent	O
was	O
implanted	O
.	O
A	O
regular	O
echocardiogram	O
was	O
performed	O
,	O
showing	O
only	O
slight	O
alterations	O
in	O
LV	O
segmental	O
contractility	O
.	O
The	O
patient	O
was	O
assessed	O
by	O
the	O
allergology	O
department	O
,	O
who	O
performed	O
an	O
analytical	O
study	O
and	O
found	O
normal	O
tryptase	O
,	O
elevated	O
values	O
of	O
specific	O
IgE	O
against	O
wasp	O
venom	O
and	O
a	O
skin	O
test	O
that	O
was	O
positive	O
for	O
diclofenac	B-FARMACO
.	O
Given	O
the	O
good	O
evolution	O
,	O
he	O
was	O
discharged	O
,	O
pending	O
completion	O
of	O
the	O
study	O
and	O
assessment	O
of	O
the	O
need	O
for	O
immunotherapy	O
against	O
wasp	O
venom	O
,	O
which	O
he	O
decided	O
to	O
undergo	O
in	O
his	O
country	O
of	O
origin	O
.	O
DIAGNOSIS	O
Non	O
Q	O
Killip	O
I	O
allergic	O
infarction	O
in	O
the	O
context	O
of	O
anaphylactic	O
shock	O
Kounis	O
syndrome	O
type	O
II	O
.	O
Coronary	O
artery	O
disease	O
of	O
2	O
main	O
vessels	O
anterior	O
descending	O
AD	O
,	O
circumflex	O
Cx	O
with	O
complete	O
revascularisation	O
.	O
Preserved	O
LVEF	O
at	O
discharge	O
.	O
Anaphylactic	O
shock	O
probably	O
secondary	O
to	O
diclofenac	B-FARMACO
.	O
Sensitisation	O
to	O
wasp	O
venom	O
.	O
Type	O
II	O
diabetes	O
mellitus	O
.	O

PERSONAL	O
HISTORY	O
No	O
drug	O
allergies	O
.	O
Family	O
history	O
mother	O
with	O
ischaemic	O
heart	O
disease	O
and	O
stroke	O
at	O
an	O
early	O
age	O
familial	O
hypercholesterolaemia	O
.	O
Cardiovascular	O
risk	O
factors	O
heterozygous	O
familial	O
hypercholesterolemia	O
diagnosed	O
in	O
childhood	O
genetic	O
study	O
with	O
M079	O
c	O
.	O
1342C	O
T	O
mutation	O
.	O
Active	O
smoker	O
.	O
Usual	O
treatment	O
rosuvastatin	B-FARMACO
10	O
mg	O
every	O
24	O
hours	O
CURRENT	O
DISEASE	O
A	O
29	O
year	O
old	O
woman	O
attended	O
the	O
emergency	O
department	O
for	O
intermittent	O
chest	O
pain	O
of	O
3	O
days	O
'	O
duration	O
,	O
which	O
worsened	O
with	O
deep	O
inspiration	O
and	O
improved	O
with	O
sitting	O
,	O
accompanied	O
by	O
fever	O
up	O
to	O
38	O
C	O
and	O
a	O
respiratory	O
infection	O
of	O
the	O
upper	O
respiratory	O
tract	O
.	O
He	O
had	O
been	O
treated	O
with	O
amoxicillin	B-FARMACO
clavulanic	I-FARMACO
acid	I-FARMACO
for	O
a	O
week	O
for	O
an	O
odontogenic	O
infection	O
following	O
the	O
extraction	O
of	O
a	O
molar	O
tooth	O
.	O
No	O
dyspnoea	O
,	O
palpitations	O
or	O
syncope	O
.	O
No	O
previous	O
angina	O
like	O
chest	O
pain	O
either	O
.	O
PHYSICAL	O
EXAMINATION	O
Temperature	O
37	O
.	O
8	O
C	O
.	O
Blood	O
pressure	O
BP	O
123	O
83	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
90	O
bpm	O
.	O
Basal	O
SatO2	O
99	O
.	O
Good	O
general	O
condition	O
,	O
good	O
hydration	O
and	O
colour	O
of	O
extremities	O
.	O
Eupneic	O
at	O
rest	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
no	O
murmurs	O
or	O
pericardial	O
friction	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
with	O
no	O
extra	O
sounds	O
.	O
Abdominal	O
examination	O
showed	O
no	O
alarm	O
signs	O
.	O
No	O
oedema	O
in	O
the	O
lower	O
extremities	O
.	O
Distal	O
pulses	O
present	O
in	O
the	O
extremities	O
and	O
symmetrical	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
tests	O
haemoglobin	O
14	O
.	O
3	O
g	O
dl	O
.	O
Leukocytes	O
19	O
,	O
700	O
u	O
l	O
leukocyte	O
formula	O
with	O
85	O
neutrophils	O
.	O
Platelets	O
256	O
,	O
000	O
u	O
l	O
.	O
Coagulation	O
without	O
alterations	O
.	O
Creatinine	O
0	O
.	O
78	O
mg	O
dl	O
estimated	O
glomerular	O
filtration	O
rate	O
90	O
ml	O
min	O
.	O
Urea	O
36	O
mg	O
dl	O
.	O
Sodium	O
137	O
mEq	O
l	O
.	O
Potassium	O
3	O
.	O
5	O
mEq	O
litre	O
.	O
Glucose	O
78	O
mg	O
dl	O
.	O
HbA1c	O
5	O
.	O
2	O
.	O
Total	O
cholesterol	O
276	O
mg	O
dl	O
.	O
HDL	O
cholesterol	O
44	O
mg	O
dl	O
.	O
LDL	O
cholesterol	O
217	O
mg	O
dl	O
.	O
Triglycerides	O
73	O
mg	O
dl	O
.	O
Liver	O
profile	O
within	O
normal	O
parameters	O
.	O
Serial	O
troponin	O
I	O
3	O
.	O
29	O
ng	O
ml	O
5	O
.	O
70	O
ng	O
ml	O
5	O
.	O
17	O
ng	O
ml	O
normal	O
laboratory	O
values	O
0	O
.	O
04	O
ng	O
ml	O
.	O
ECG	O
sinus	O
rhythm	O
at	O
90	O
beats	O
per	O
minute	O
,	O
PR	O
150	O
ms	O
,	O
narrow	O
QRS	O
with	O
normal	O
axis	O
.	O
QS	O
in	O
V1	O
V3	O
with	O
negative	O
T	O
waves	O
in	O
V1	O
V3	O
.	O
Chest	O
X	O
ray	O
bilateral	O
breast	O
prostheses	O
.	O
Cardiothoracic	O
index	O
within	O
normality	O
.	O
Pulmonary	O
parenchyma	O
without	O
findings	O
.	O
Free	O
costophrenic	O
sinuses	O
.	O
Transthoracic	O
echocardiogram	O
left	O
ventricle	O
neither	O
dilated	O
nor	O
hypertrophic	O
with	O
mild	O
systolic	O
dysfunction	O
LVEF	O
41	O
.	O
Apical	O
akinesia	O
and	O
mid	O
segment	O
akinesia	O
of	O
the	O
anterior	O
face	O
and	O
anterior	O
septum	O
.	O
Non	O
dilated	O
,	O
non	O
hypertrophic	O
right	O
ventricle	O
with	O
preserved	O
longitudinal	O
systolic	O
function	O
.	O
Atria	O
of	O
normal	O
size	O
.	O
No	O
significant	O
valvular	O
heart	O
disease	O
.	O
No	O
pericardial	O
effusion	O
.	O
Cardiac	O
MRI	O
left	O
ventricle	O
with	O
global	O
contractility	O
at	O
the	O
limit	O
of	O
normality	O
LVEF	O
50	O
.	O
Hypokinesia	O
of	O
the	O
apical	O
septum	O
,	O
apical	O
anterior	O
face	O
and	O
apex	O
with	O
subendocardial	O
perfusion	O
defect	O
in	O
the	O
middle	O
and	O
apical	O
septum	O
.	O
Late	O
enhancement	O
with	O
subendocardial	O
gadolinium	O
in	O
mid	O
and	O
apical	O
septum	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
and	O
morphology	O
with	O
preserved	O
function	O
.	O
Angio	O
CT	O
of	O
coronary	O
arteries	O
Coronary	O
arteries	O
with	O
normal	O
anatomical	O
origin	O
.	O
Right	O
dominance	O
.	O
Left	O
coronary	O
artery	O
trunk	O
vessel	O
of	O
good	O
development	O
,	O
without	O
lesions	O
.	O
Anterior	O
descending	O
vessel	O
of	O
good	O
development	O
,	O
which	O
after	O
the	O
exit	O
of	O
the	O
first	O
diagonal	O
,	O
in	O
its	O
middle	O
segment	O
,	O
and	O
up	O
to	O
the	O
exit	O
of	O
the	O
second	O
diagonal	O
,	O
a	O
subocclusive	O
lesion	O
with	O
thrombotic	O
content	O
is	O
observed	O
in	O
its	O
interior	O
which	O
could	O
correspond	O
to	O
thrombotic	O
disease	O
or	O
spiroid	O
dissection	O
with	O
thrombosis	O
of	O
the	O
false	O
lumen	O
;	O
after	O
the	O
exit	O
of	O
the	O
second	O
diagonal	O
,	O
the	O
flow	O
is	O
recovered	O
,	O
the	O
middle	O
distal	O
segment	O
of	O
the	O
anterior	O
descending	O
being	O
of	O
scarce	O
calibre	O
.	O
The	O
ostium	O
of	O
the	O
second	O
diagonal	O
is	O
affected	O
by	O
the	O
lesion	O
previously	O
described	O
in	O
the	O
anterior	O
descending	O
artery	O
.	O
Circumflex	O
artery	O
the	O
proximal	O
and	O
middle	O
segments	O
of	O
the	O
vessel	O
are	O
well	O
developed	O
,	O
the	O
distal	O
segment	O
being	O
of	O
smaller	O
calibre	O
,	O
with	O
no	O
lesions	O
.	O
Marginal	O
obtuse	O
of	O
good	O
calibre	O
,	O
ending	O
in	O
a	O
bifurcation	O
,	O
without	O
lesions	O
.	O
Right	O
coronary	O
dominant	O
vessel	O
of	O
very	O
good	O
development	O
,	O
without	O
lesions	O
.	O
Posterolateral	O
branch	O
of	O
good	O
development	O
,	O
without	O
lesions	O
.	O
Posterior	O
descending	O
branch	O
of	O
good	O
development	O
,	O
without	O
lesions	O
.	O
Conal	O
and	O
acute	O
marginal	O
arteries	O
of	O
moderate	O
development	O
and	O
without	O
lesions	O
.	O
Coronary	O
angiography	O
right	O
radial	O
access	O
.	O
Right	O
coronary	O
tree	O
slight	O
lesion	O
in	O
the	O
proximal	O
third	O
of	O
the	O
right	O
coronary	O
artery	O
CD	O
,	O
the	O
rest	O
without	O
significant	O
lesions	O
.	O
Left	O
coronary	O
tree	O
coronary	O
trunk	O
without	O
lesions	O
.	O
Anterior	O
descending	O
artery	O
AD	O
with	O
acute	O
thrombotic	O
occlusion	O
in	O
the	O
proximal	O
middle	O
third	O
junction	O
with	O
distal	O
TIMI	O
0	O
flow	O
.	O
Circumflex	O
artery	O
of	O
good	O
calibre	O
,	O
without	O
significant	O
lesions	O
.	O
Percutaneous	O
coronary	O
intervention	O
guidewire	O
is	O
advanced	O
to	O
the	O
first	O
diagonal	O
and	O
treated	O
with	O
drug	O
eluting	O
balloon	O
without	O
stenting	O
.	O
A	O
2	O
.	O
5	O
x	O
38	O
mm	O
drug	O
eluting	O
stent	O
was	O
implanted	O
in	O
the	O
middle	O
third	O
of	O
the	O
LAD	O
,	O
leaving	O
TIMI	O
3	O
flow	O
in	O
the	O
LAD	O
and	O
second	O
diagonal	O
.	O
CLINICAL	O
EVOLUTION	O
Pain	O
and	O
fever	O
initially	O
subsided	O
in	O
the	O
emergency	O
department	O
with	O
anti	O
inflammatory	O
drugs	O
.	O
A	O
transthoracic	O
echocardiogram	O
was	O
performed	O
showing	O
mild	O
LV	O
systolic	O
dysfunction	O
with	O
segmental	O
alterations	O
apical	O
akinesia	O
and	O
mid	O
segment	O
akinesia	O
of	O
the	O
anterior	O
face	O
and	O
anterior	O
septum	O
.	O
Due	O
to	O
the	O
pericardial	O
characteristics	O
of	O
the	O
pain	O
and	O
the	O
elevation	O
of	O
myocardial	O
damage	O
enzymes	O
,	O
the	O
first	O
diagnostic	O
suspicion	O
is	O
acute	O
myopericarditis	O
,	O
although	O
the	O
electrocardiogram	O
does	O
not	O
show	O
typical	O
signs	O
.	O
However	O
,	O
taking	O
into	O
account	O
the	O
patient	O
's	O
high	O
cardiovascular	O
risk	O
familial	O
hypercholesterolemia	O
with	O
poor	O
lipid	O
control	O
,	O
active	O
smoking	O
,	O
family	O
history	O
of	O
early	O
ischaemic	O
heart	O
disease	O
,	O
a	O
coronary	O
origin	O
of	O
the	O
condition	O
cannot	O
be	O
ruled	O
out	O
,	O
so	O
the	O
patient	O
is	O
admitted	O
to	O
the	O
coronary	O
unit	O
for	O
monitoring	O
.	O
The	O
patient	O
remained	O
haemodynamically	O
stable	O
,	O
with	O
no	O
arrhythmic	O
events	O
and	O
with	O
disappearance	O
of	O
symptoms	O
with	O
high	O
doses	O
of	O
aspirin	B-FARMACO
and	O
colchicine	B-FARMACO
.	O
In	O
addition	O
,	O
lipid	O
lowering	O
treatment	O
was	O
reinforced	O
with	O
a	O
high	O
intensity	O
statin	O
atorvastatin	B-FARMACO
80	O
mg	O
every	O
24	O
hours	O
and	O
treatment	O
for	O
ventricular	O
dysfunction	O
was	O
started	O
with	O
enalapril	B-FARMACO
2	O
.	O
5	O
mg	O
every	O
12	O
hours	O
she	O
could	O
not	O
tolerate	O
higher	O
doses	O
due	O
to	O
hypotension	O
,	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
every	O
24	O
hours	O
and	O
eplerenone	B-FARMACO
25	O
mg	O
every	O
24	O
hours	O
.	O
With	O
suspicion	O
of	O
myopericarditis	O
,	O
cardiac	O
magnetic	O
resonance	O
imaging	O
MRI	O
was	O
scheduled	O
for	O
the	O
following	O
day	O
,	O
showing	O
a	O
subendocardial	O
perfusion	O
defect	O
at	O
the	O
level	O
of	O
the	O
mid	O
apical	O
septum	O
with	O
late	O
enhancement	O
in	O
this	O
area	O
,	O
suggestive	O
of	O
ischaemic	O
heart	O
disease	O
.	O
On	O
the	O
same	O
day	O
,	O
an	O
angio	O
CT	O
scan	O
of	O
the	O
coronary	O
arteries	O
was	O
also	O
performed	O
,	O
which	O
showed	O
a	O
subocclusive	O
lesion	O
of	O
possible	O
thrombotic	O
origin	O
in	O
the	O
middle	O
LAD	O
,	O
without	O
being	O
able	O
to	O
rule	O
out	O
a	O
coronary	O
dissection	O
.	O
Given	O
that	O
the	O
patient	O
was	O
stable	O
and	O
asymptomatic	O
,	O
it	O
was	O
decided	O
to	O
perform	O
a	O
scheduled	O
coronary	O
angiography	O
two	O
days	O
later	O
,	O
which	O
confirmed	O
the	O
thrombotic	O
occlusion	O
in	O
the	O
proximal	O
medial	O
LAD	O
.	O
Percutaneous	O
coronary	O
intervention	O
was	O
performed	O
on	O
the	O
lesion	O
with	O
implantation	O
of	O
a	O
drug	O
eluting	O
stent	O
.	O
Prasugrel	B-FARMACO
was	O
added	O
as	O
a	O
second	O
antiplatelet	O
agent	O
.	O
Taking	O
into	O
account	O
the	O
clinical	O
presentation	O
,	O
the	O
results	O
and	O
the	O
evolution	O
,	O
the	O
most	O
likely	O
diagnosis	O
is	O
that	O
of	O
acute	O
anterior	O
myocardial	O
infarction	O
with	O
post	O
infarction	O
pericarditis	O
without	O
pericardial	O
effusion	O
.	O
The	O
patient	O
progressed	O
favourably	O
and	O
was	O
discharged	O
7	O
days	O
after	O
admission	O
.	O
She	O
is	O
recommended	O
to	O
attend	O
the	O
cardiac	O
rehabilitation	O
programme	O
,	O
to	O
stop	O
smoking	O
,	O
and	O
to	O
modify	O
her	O
diet	O
and	O
lifestyle	O
towards	O
healthier	O
habits	O
.	O
Taking	O
into	O
account	O
the	O
poor	O
lipid	O
control	O
LDL	O
217	O
mg	O
dl	O
and	O
that	O
she	O
had	O
presented	O
an	O
acute	O
coronary	O
syndrome	O
,	O
it	O
was	O
decided	O
to	O
add	O
ezetimibe	B-FARMACO
10	O
mg	O
every	O
24	O
hours	O
and	O
to	O
evaluate	O
the	O
need	O
for	O
a	O
PCSK9	O
inhibitor	O
in	O
the	O
follow	O
up	O
.	O
The	O
patient	O
subsequently	O
attended	O
cardiac	O
rehabilitation	O
,	O
managed	O
to	O
quit	O
smoking	O
with	O
the	O
help	O
of	O
varenicline	B-FARMACO
and	O
,	O
given	O
that	O
LDL	O
cholesterol	O
remained	O
above	O
target	O
121	O
mg	O
dl	O
6	O
months	O
after	O
the	O
event	O
despite	O
diet	O
and	O
treatment	O
,	O
evolocumab	B-FARMACO
140	O
mg	O
in	O
subcutaneous	O
injections	O
every	O
15	O
days	O
was	O
added	O
with	O
good	O
response	O
a	O
reduction	O
in	O
LDL	O
cholesterol	O
levels	O
to	O
63	O
mg	O
dl	O
was	O
observed	O
at	O
12	O
weeks	O
.	O
DIAGNOSIS	O
Acute	O
anterior	O
myocardial	O
infarction	O
evolved	O
with	O
thrombotic	O
occlusion	O
of	O
the	O
middle	O
anterior	O
descending	O
artery	O
,	O
revascularised	O
with	O
a	O
drug	O
eluting	O
stent	O
.	O
Mild	O
LV	O
systolic	O
dysfunction	O
of	O
ischaemic	O
origin	O
.	O
Acute	O
post	O
infarction	O
pericarditis	O
without	O
associated	O
pericardial	O
effusion	O
.	O
Heterozygous	O
familial	O
hypercholesterolemia	O
with	O
poor	O
lipid	O
control	O
.	O
Active	O
smoking	O
.	O

PERSONAL	O
HISTORY	O
54	O
year	O
old	O
woman	O
,	O
no	O
known	O
drug	O
allergies	O
,	O
active	O
and	O
independent	O
life	O
.	O
Family	O
history	O
of	O
Marfan	O
syndrome	O
in	O
a	O
brother	O
with	O
a	O
positive	O
genetic	O
study	O
mutation	O
in	O
the	O
FBN1	O
gene	O
.	O
Our	O
patient	O
was	O
tested	O
for	O
this	O
mutation	O
,	O
which	O
was	O
negative	O
,	O
and	O
did	O
not	O
have	O
a	O
marfanoid	O
morphotype	O
.	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
smoker	O
of	O
1	O
pack	O
a	O
day	O
IPA	O
30	O
,	O
no	O
hypertension	O
HT	O
,	O
no	O
diabetes	O
mellitus	O
DM	O
,	O
no	O
dyslipidaemia	O
.	O
Cardiological	O
history	O
Admitted	O
to	O
hospital	O
3	O
months	O
ago	O
for	O
chest	O
pain	O
,	O
mainly	O
exertional	O
,	O
of	O
1	O
year	O
's	O
duration	O
,	O
with	O
typical	O
characteristics	O
,	O
but	O
of	O
shortened	O
duration	O
and	O
a	O
syncopal	O
episode	O
with	O
a	O
cardiogenic	O
profile	O
.	O
On	O
admission	O
,	O
no	O
arrhythmic	O
alterations	O
were	O
documented	O
after	O
more	O
than	O
72	O
hours	O
of	O
continuous	O
electrocardiogram	O
ECG	O
monitoring	O
,	O
echocardiography	O
ruled	O
out	O
relevant	O
structural	O
heart	O
disease	O
and	O
an	O
ischaemia	O
detection	O
test	O
was	O
performed	O
using	O
ergometry	O
,	O
which	O
was	O
clinically	O
and	O
electrically	O
negative	O
,	O
so	O
she	O
was	O
discharged	O
with	O
a	O
diagnosis	O
of	O
non	O
coronary	O
chest	O
pain	O
and	O
syncope	O
under	O
study	O
and	O
referred	O
to	O
the	O
syncope	O
clinic	O
.	O
On	O
discharge	O
,	O
hygienic	O
dietary	O
measures	O
were	O
insisted	O
upon	O
,	O
but	O
no	O
pharmacological	O
treatment	O
was	O
started	O
.	O
No	O
other	O
medical	O
or	O
surgical	O
history	O
of	O
interest	O
.	O
No	O
usual	O
medical	O
treatment	O
.	O
CURRENT	O
ILLNESS	O
Three	O
months	O
after	O
discharge	O
from	O
hospital	O
,	O
while	O
accompanying	O
a	O
relative	O
to	O
the	O
hospital	O
,	O
he	O
again	O
lost	O
consciousness	O
and	O
was	O
immediately	O
transferred	O
to	O
the	O
emergency	O
critical	O
care	O
unit	O
.	O
During	O
the	O
transfer	O
,	O
he	O
suffered	O
cardiorespiratory	O
arrest	O
CRA	O
,	O
and	O
cardiopulmonary	O
resuscitation	O
CPR	O
manoeuvres	O
were	O
started	O
,	O
with	O
the	O
first	O
rhythm	O
detected	O
after	O
monitoring	O
in	O
ventricular	O
fibrillation	O
requiring	O
three	O
defibrillations	O
at	O
360J	O
to	O
restore	O
spontaneous	O
circulation	O
and	O
orotracheal	O
intubation	O
OTI	O
and	O
connection	O
to	O
invasive	O
mechanical	O
ventilation	O
IMV	O
,	O
with	O
a	O
total	O
CRA	O
time	O
of	O
9	O
min	O
.	O
According	O
to	O
his	O
relative	O
,	O
moments	O
before	O
the	O
onset	O
of	O
the	O
condition	O
,	O
he	O
reported	O
chest	O
discomfort	O
of	O
rapid	O
onset	O
.	O
The	O
first	O
post	O
arrest	O
ECG	O
,	O
in	O
sinus	O
rhythm	O
,	O
initially	O
showed	O
diffuse	O
ST	O
segment	O
elevation	O
with	O
an	O
increase	O
in	O
aVR	O
and	O
persistent	O
ST	O
segment	O
elevation	O
in	O
lateral	O
leads	O
in	O
serial	O
ECGs	O
.	O
Therefore	O
,	O
emergent	O
coronary	O
angiography	O
was	O
performed	O
,	O
showing	O
coronary	O
arteries	O
without	O
angiographic	O
lesions	O
,	O
aortography	O
and	O
ventriculography	O
without	O
data	O
suggesting	O
acute	O
aortic	O
syndrome	O
or	O
alterations	O
in	O
contractility	O
.	O
Echocardioscopy	O
performed	O
in	O
the	O
acute	O
phase	O
showed	O
no	O
significant	O
alterations	O
,	O
including	O
the	O
absence	O
of	O
dilatation	O
of	O
the	O
right	O
chambers	O
suggestive	O
of	O
pulmonary	O
thromboembolism	O
or	O
aortic	O
flap	O
.	O
Finally	O
,	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
ICU	O
,	O
where	O
she	O
had	O
a	O
good	O
clinical	O
evolution	O
and	O
early	O
weaning	O
was	O
possible	O
.	O
With	O
no	O
recurrence	O
of	O
arrhythmias	O
during	O
her	O
stay	O
in	O
the	O
ICU	O
,	O
she	O
was	O
transferred	O
to	O
the	O
cardiology	O
ward	O
and	O
monitored	O
for	O
further	O
study	O
and	O
treatment	O
.	O
PHYSICAL	O
EXAMINATION	O
Examination	O
on	O
the	O
cardiology	O
ward	O
blood	O
pressure	O
BP	O
122	O
94	O
,	O
heart	O
rate	O
HR	O
62	O
bpm	O
,	O
temperature	O
36	O
.	O
4	O
C	O
,	O
baseline	O
SpO2	O
94	O
.	O
Conscious	O
and	O
oriented	O
.	O
Normal	O
colour	O
,	O
normohydrated	O
.	O
Eupneic	O
at	O
rest	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
tones	O
at	O
78	O
bpm	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
normal	O
ventilation	O
,	O
no	O
added	O
pathological	O
sounds	O
.	O
Abdomen	O
nondescript	O
.	O
Lower	O
extremities	O
symmetrical	O
pulses	O
,	O
no	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
COMPLEMENTARY	O
TESTS	O
Emergency	O
laboratory	O
tests	O
no	O
significant	O
alterations	O
.	O
Glucose	O
195	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
8	O
mg	O
dl	O
,	O
Na	O
141	O
mEq	O
l	O
,	O
K	O
3	O
.	O
9	O
mEq	O
l	O
,	O
Mg2	O
2	O
.	O
2	O
mEq	O
l	O
normal	O
1	O
.	O
5	O
2	O
.	O
5	O
,	O
Ca2	O
9	O
.	O
3	O
mg	O
dl	O
normal	O
8	O
.	O
8	O
10	O
.	O
5	O
mg	O
dl	O
;	O
D	O
dimer	O
452	O
.	O
Myocardial	O
damage	O
markers	O
initial	O
TnTus	O
13	O
ng	O
l	O
,	O
CPK	O
205	O
U	O
l	O
;	O
CK	O
MB	O
23	O
U	O
l	O
normal	O
5	O
24	O
.	O
Maximal	O
TnTus	O
138	O
ng	O
l	O
0	O
14	O
;	O
CPK	O
397	O
U	O
l	O
39	O
308	O
,	O
CK	O
MB	O
51	O
U	O
l	O
5	O
24	O
.	O
General	O
laboratory	O
tests	O
biochemistry	O
glucose	O
81	O
mg	O
dl	O
,	O
urea	O
0	O
.	O
36	O
g	O
l	O
,	O
creatinine	O
0	O
.	O
63	O
mg	O
dl	O
,	O
calculated	O
GFR	O
90	O
ml	O
min	O
1	O
.	O
73	O
m2	O
,	O
albumin	O
3	O
.	O
69	O
g	O
dl	O
,	O
total	O
cholesterol	O
208	O
mg	O
dl	O
,	O
LDL	O
152	O
.	O
8	O
mg	O
dl	O
,	O
liver	O
profile	O
normal	O
,	O
total	O
calcium	O
9	O
.	O
33	O
mg	O
dl	O
,	O
Na	O
139	O
.	O
9	O
mEq	O
l	O
,	O
K	O
4	O
.	O
51	O
meq	O
l	O
,	O
TSH	O
0	O
.	O
79	O
mU	O
l	O
.	O
Haemogram	O
Hb	O
15	O
.	O
2	O
g	O
dl	O
,	O
Ht	O
44	O
.	O
1	O
,	O
leucocytes	O
9	O
,	O
200	O
,	O
N	O
60	O
,	O
platelets	O
267	O
,	O
000	O
.	O
Catecholamines	O
in	O
24	O
hour	O
urine	O
negative	O
.	O
Chest	O
X	O
ray	O
normal	O
CTI	O
,	O
mediastinum	O
and	O
lung	O
fields	O
without	O
significant	O
alterations	O
.	O
Post	O
arrest	O
ECG	O
sinus	O
tachycardia	O
at	O
108	O
bpm	O
,	O
normal	O
PR	O
,	O
no	O
pre	O
excitation	O
,	O
narrow	O
QRS	O
,	O
ST	O
segment	O
elevation	O
of	O
up	O
to	O
3	O
mm	O
in	O
V3	O
V6	O
,	O
and	O
less	O
than	O
1	O
mm	O
in	O
inferior	O
leads	O
,	O
with	O
ST	O
segment	O
elevation	O
of	O
1	O
mm	O
in	O
aVR	O
and	O
V1	O
.	O
At	O
5	O
minutes	O
only	O
the	O
descent	O
from	O
V4	O
V6	O
remains	O
.	O
Normal	O
QTc	O
Normal	O
baseline	O
ECG	O
sinus	O
rhythm	O
at	O
88	O
bpm	O
,	O
normal	O
PR	O
without	O
pre	O
excitation	O
,	O
no	O
conduction	O
or	O
repolarisation	O
disturbances	O
.	O
Slow	O
R	O
wave	O
progression	O
in	O
precordial	O
leads	O
.	O
Normal	O
QTc	O
.	O
Echocardiogram	O
left	O
atrium	O
not	O
dilated	O
.	O
Thin	O
leaflet	O
mitral	O
valve	O
with	O
preserved	O
mobility	O
and	O
opening	O
;	O
no	O
regurgitation	O
.	O
Left	O
ventricle	O
neither	O
dilated	O
LVEDV	O
4C	O
83	O
ml	O
;	O
LVESV	O
25	O
ml	O
nor	O
hypertrophic	O
with	O
preserved	O
ejection	O
fraction	O
and	O
no	O
clear	O
segmental	O
alterations	O
of	O
contractility	O
.	O
Preserved	O
GLS	O
22	O
.	O
3	O
.	O
Trivalve	O
aortic	O
valve	O
,	O
thin	O
with	O
good	O
opening	O
and	O
mobility	O
;	O
normal	O
flow	O
.	O
Valvular	O
annulus	O
and	O
aortic	O
root	O
of	O
normal	O
dimensions	O
;	O
the	O
rest	O
of	O
the	O
thoracic	O
aorta	O
cannot	O
be	O
assessed	O
.	O
Right	O
chambers	O
not	O
dilated	O
;	O
right	O
ventricular	O
contractility	O
preserved	O
.	O
Tricuspid	O
valve	O
with	O
good	O
opening	O
and	O
mobility	O
;	O
minimal	O
regurgitation	O
.	O
Pulmonary	O
valve	O
with	O
good	O
opening	O
;	O
flow	O
curve	O
with	O
normal	O
characteristics	O
.	O
No	O
pulmonary	O
hypertension	O
.	O
No	O
pericardial	O
effusion	O
.	O
Continuous	O
ECG	O
monitoring	O
no	O
arrhythmic	O
or	O
ST	O
alterations	O
for	O
72	O
hours	O
.	O
Emergent	O
catheterisation	O
coronary	O
angiography	O
epicardial	O
coronary	O
arteries	O
without	O
angiographically	O
significant	O
lesions	O
.	O
Ventriculography	O
LV	O
neither	O
dilated	O
nor	O
hypertrophied	O
,	O
with	O
preserved	O
global	O
systolic	O
function	O
,	O
without	O
clear	O
segmental	O
alterations	O
in	O
contractility	O
video	O
6	O
.	O
Aortography	O
aortic	O
root	O
and	O
ascending	O
aorta	O
not	O
dilated	O
without	O
angiographic	O
data	O
suggestive	O
of	O
acute	O
aortic	O
syndrome	O
.	O
Ajmaline	B-FARMACO
test	O
negative	O
.	O
CLINICAL	O
EVOLUTION	O
During	O
admission	O
,	O
he	O
did	O
not	O
present	O
new	O
episodes	O
of	O
chest	O
pain	O
with	O
the	O
treatment	O
given	O
,	O
nor	O
sustained	O
arrhythmias	O
,	O
only	O
a	O
4	O
second	O
NSVT	O
flap	O
.	O
Blood	O
and	O
urine	O
catecholamine	O
tests	O
were	O
requested	O
for	O
24	O
hour	O
urine	O
and	O
blood	O
tests	O
were	O
negative	O
.	O
Therefore	O
,	O
despite	O
the	O
fact	O
that	O
the	O
baseline	O
electrocardiogram	O
showed	O
no	O
data	O
suggestive	O
of	O
channelopathies	O
normal	O
QTc	O
,	O
absence	O
of	O
J	O
wave	O
and	O
spontaneous	O
Brugada	O
pattern	O
,	O
previous	O
ergometry	O
without	O
alterations	O
,	O
ajmaline	B-FARMACO
test	O
was	O
performed	O
to	O
unmask	O
a	O
possible	O
hidden	O
Brugada	O
syndrome	O
pattern	O
,	O
which	O
was	O
negative	O
,	O
and	O
finally	O
,	O
it	O
was	O
decided	O
to	O
implant	O
an	O
implantable	O
cardioverter	O
defibrillator	O
ICD	O
for	O
secondary	O
prevention	O
.	O
After	O
this	O
,	O
the	O
patient	O
was	O
discharged	O
from	O
hospital	O
with	O
a	O
diagnosis	O
of	O
cardiorespiratory	O
arrest	O
due	O
to	O
probable	O
ventricular	O
fibrillation	O
,	O
and	O
treatment	O
was	O
recommended	O
with	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
100	O
mg	O
24h	O
,	O
sotalol	B-FARMACO
80	O
mg	O
8h	O
and	O
a	O
high	O
potency	O
statin	B-FARMACO
given	O
the	O
presence	O
of	O
dyslipidaemia	O
with	O
LDL	O
of	O
152	O
mg	O
dl	O
.	O
One	O
month	O
after	O
implantation	O
,	O
he	O
presented	O
an	O
appropriate	O
ICD	O
discharge	O
due	O
to	O
rapid	O
polymorphic	O
VT	O
and	O
several	O
non	O
sustained	O
episodes	O
of	O
polymorphic	O
VT	O
.	O
For	O
this	O
reason	O
,	O
low	O
dose	O
bisoprolol	B-FARMACO
was	O
added	O
.	O
The	O
patient	O
clinically	O
continued	O
with	O
episodes	O
of	O
short	O
lasting	O
chest	O
discomfort	O
,	O
more	O
frequently	O
since	O
the	O
initiation	O
of	O
beta	O
blockade	O
.	O
In	O
view	O
of	O
the	O
suspicion	O
of	O
vasospasm	O
,	O
ECG	O
recording	O
of	O
the	O
symptoms	O
was	O
insisted	O
on	O
using	O
12	O
lead	O
Holter	O
,	O
which	O
showed	O
,	O
coinciding	O
with	O
two	O
episodes	O
of	O
chest	O
pain	O
,	O
a	O
marked	O
transient	O
ST	O
segment	O
elevation	O
in	O
the	O
inferior	O
and	O
lateral	O
face	O
and	O
ST	O
segment	O
underleveling	O
in	O
V1	O
to	O
V4	O
which	O
appears	O
to	O
be	O
posterior	O
ST	O
segment	O
elevation	O
lasting	O
about	O
3	O
minutes	O
and	O
accompanied	O
by	O
ventricular	O
extrasystoles	O
and	O
a	O
brief	O
NSVT	O
that	O
was	O
interpreted	O
as	O
a	O
transient	O
subepicardial	O
infero	O
posterolateral	O
lesion	O
,	O
supporting	O
the	O
diagnosis	O
of	O
coronary	O
vasospasm	O
.	O
A	O
new	O
hospital	O
admission	O
was	O
decided	O
to	O
adjust	O
his	O
treatment	O
,	O
suspending	O
the	O
beta	O
blocker	O
and	O
starting	O
amlodipine	B-FARMACO
and	O
transdermal	B-FARMACO
nitrites	I-FARMACO
.	O
During	O
the	O
first	O
few	O
days	O
he	O
presented	O
repeated	O
episodes	O
of	O
vasospastic	O
angina	O
,	O
one	O
of	O
them	O
with	O
sustained	O
VT	O
and	O
appropriate	O
ICD	O
discharge	O
.	O
Titration	O
to	O
maximum	O
tolerated	O
doses	O
was	O
achieved	O
and	O
finally	O
after	O
association	O
with	O
a	O
second	O
calcium	O
antagonist	O
verapamil	B-FARMACO
,	O
the	O
clinical	O
symptoms	O
resolved	O
.	O
After	O
more	O
than	O
72	O
hours	O
asymptomatic	O
and	O
without	O
arrhythmias	O
,	O
the	O
patient	O
was	O
discharged	O
from	O
hospital	O
,	O
with	O
the	O
following	O
diagnoses	O
and	O
associated	O
with	O
previous	O
treatment	O
with	O
ASA	B-FARMACO
and	O
statin	B-FARMACO
,	O
verapamil	B-FARMACO
80	O
mg	O
8h	O
,	O
amlodipine	B-FARMACO
5	O
mg	O
day	O
,	O
and	O
nitroglycerin	B-FARMACO
patch	O
5	O
mg	O
24h	O
.	O
The	O
patient	O
has	O
had	O
regular	O
check	O
ups	O
at	O
the	O
cardiology	O
clinic	O
during	O
these	O
3	O
years	O
.	O
Since	O
discharge	O
,	O
she	O
has	O
not	O
presented	O
any	O
further	O
syncopal	O
episodes	O
,	O
episodes	O
of	O
chest	O
pain	O
are	O
practically	O
non	O
existent	O
and	O
ASA	B-FARMACO
has	O
been	O
discontinued	O
after	O
subsequent	O
review	O
that	O
the	O
coronary	O
angiography	O
images	O
showed	O
no	O
significant	O
atherosclerosis	O
,	O
and	O
only	O
in	O
one	O
of	O
the	O
device	O
reviews	O
was	O
there	O
a	O
bout	O
of	O
non	O
sustained	O
ventricular	O
tachycardia	O
NSVT	O
that	O
was	O
successfully	O
treated	O
by	O
means	O
of	O
overstimulation	O
.	O
DIAGNOSIS	O
High	O
risk	O
syncope	O
.	O
Cardiorespiratory	O
arrest	O
probably	O
secondary	O
to	O
ventricular	O
fibrillation	O
.	O
Vasospastic	O
angina	O
.	O
ICD	O
implantation	O
in	O
secondary	O
prevention	O
.	O
Sustained	O
and	O
non	O
sustained	O
ventricular	O
tachycardias	O
in	O
the	O
context	O
of	O
vasospastic	O
angina	O
.	O
Dyslipidaemia	O
with	O
LDL	O
levels	O
outside	O
the	O
target	O
range	O
.	O

PERSONAL	O
HISTORY	O
Intolerance	O
to	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
due	O
to	O
duodenal	O
ulcer	O
.	O
CVRF	O
smoking	O
20	O
pack	O
years	O
.	O
No	O
known	O
cardiological	O
history	O
.	O
Other	O
history	O
duodenal	O
ulcer	O
10	O
years	O
ago	O
.	O
No	O
relevant	O
surgical	O
interventions	O
.	O
Usual	O
treatment	O
not	O
reported	O
.	O
CURRENT	O
ILLNESS	O
A	O
57	O
year	O
old	O
male	O
patient	O
with	O
the	O
aforementioned	O
history	O
attended	O
the	O
emergency	O
department	O
of	O
our	O
centre	O
due	O
to	O
oppressive	O
central	O
thoracic	O
pain	O
,	O
of	O
about	O
30	O
minutes	O
'	O
evolution	O
,	O
radiating	O
to	O
both	O
upper	O
limbs	O
MMSS	O
and	O
neck	O
,	O
which	O
started	O
suddenly	O
while	O
at	O
rest	O
,	O
with	O
associated	O
mild	O
vegetative	O
cramping	O
.	O
On	O
arrival	O
at	O
the	O
emergency	O
department	O
,	O
the	O
clinical	O
manifestations	O
persisted	O
.	O
She	O
denied	O
previous	O
episodes	O
of	O
central	O
thoracic	O
pain	O
.	O
She	O
reported	O
an	O
active	O
daily	O
life	O
.	O
No	O
clinical	O
signs	O
of	O
CHF	O
or	O
infectious	O
disease	O
in	O
previous	O
days	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
BP	O
140	O
60	O
mmHg	O
left	O
arm	O
,	O
90	O
50	O
mmHg	O
right	O
arm	O
,	O
heart	O
rate	O
HR	O
65	O
bpm	O
.	O
SpO2	O
FiO2	O
21	O
99	O
.	O
Regular	O
general	O
condition	O
,	O
affected	O
by	O
severe	O
pain	O
.	O
Eupneic	O
at	O
rest	O
.	O
Normal	O
colour	O
and	O
normohydrated	O
.	O
Sweating	O
.	O
Patient	O
conscious	O
and	O
oriented	O
,	O
cooperative	O
and	O
alert	O
.	O
No	O
neurological	O
focality	O
.	O
Cardiopulmonary	O
auscultation	O
regular	O
sounds	O
,	O
diastolic	O
murmur	O
predominantly	O
in	O
the	O
left	O
sternal	O
border	O
.	O
Conservative	O
vesicular	O
murmur	O
VCM	O
with	O
no	O
added	O
noise	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
,	O
without	O
mass	O
or	O
megaliths	O
,	O
not	O
painful	O
on	O
palpation	O
.	O
MMSS	O
asymmetric	O
radial	O
pulses	O
.	O
Lower	O
limbs	O
weak	O
and	O
symmetrical	O
distal	O
pulses	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
on	O
arrival	O
at	O
the	O
ED	O
sinus	O
rhythm	O
at	O
95	O
bpm	O
,	O
PR	O
170	O
ms	O
,	O
narrow	O
QRS	O
,	O
0o	O
axis	O
,	O
LVH	O
criteria	O
.	O
No	O
changes	O
in	O
serial	O
ECG	O
.	O
Initial	O
laboratory	O
tests	O
CBC	O
red	O
blood	O
cells	O
4	O
.	O
62	O
10	O
12	O
l	O
.	O
Haemoglobin	O
14	O
.	O
3	O
g	O
dl	O
.	O
Haematocrit	O
42	O
.	O
9	O
.	O
MCV	O
92	O
.	O
9	O
fl	O
.	O
MCH	O
30	O
.	O
9	O
pg	O
.	O
MCHC	O
33	O
.	O
3	O
g	O
l	O
.	O
ADE	O
13	O
.	O
1	O
.	O
Leukocytes	O
8	O
.	O
6	O
10	O
9	O
l	O
.	O
Neutrophils	O
54	O
.	O
6	O
.	O
Lymphocytes	O
32	O
,	O
2	O
.	O
Platelets	O
198	O
10	O
9	O
l	O
.	O
Haemostasis	O
prothrombin	O
time	O
PT	O
11	O
sec	O
.	O
Quick	O
's	O
index	O
100	O
,	O
INR	O
0	O
.	O
95	O
.	O
APTT	O
28	O
.	O
7	O
sec	O
.	O
Biochemistry	O
glucose	O
103	O
mg	O
dl	O
.	O
Sodium	O
139	O
mEq	O
l	O
.	O
Potassium	O
4	O
.	O
3	O
mEq	O
l	O
.	O
Chlorine	O
103	O
mEq	O
l	O
.	O
Urea	O
34	O
.	O
2	O
mg	O
dl	O
.	O
Creatinine	O
0	O
.	O
86	O
mg	O
dl	O
.	O
Biomarkers	O
of	O
myocardial	O
damage	O
troponin	O
I	O
hsTnI	O
3	O
,	O
2	O
ng	O
l	O
.	O
Urgent	O
echocardiogram	O
TTE	O
in	O
the	O
critical	O
care	O
unit	O
left	O
ventricle	O
with	O
slight	O
concentric	O
hypertrophy	O
,	O
normal	O
diameters	O
and	O
preserved	O
systolic	O
function	O
,	O
with	O
no	O
alterations	O
in	O
segmental	O
contractility	O
at	O
rest	O
.	O
Significant	O
aortic	O
insufficiency	O
,	O
without	O
other	O
valvulopathies	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
and	O
function	O
.	O
Aortic	O
root	O
with	O
increased	O
diameters	O
45	O
mm	O
,	O
without	O
a	O
clear	O
flap	O
image	O
.	O
Normal	O
inferior	O
vena	O
cava	O
IVC	O
.	O
Mild	O
pericardial	O
effusion	O
.	O
Angio	O
CT	O
of	O
the	O
aorta	O
type	O
A	O
aortic	O
dissection	O
with	O
involvement	O
of	O
the	O
aortic	O
root	O
extending	O
along	O
the	O
anterior	O
aspect	O
of	O
the	O
aortic	O
wall	O
close	O
to	O
the	O
left	O
coronary	O
trunk	O
LMCA	O
from	O
the	O
valvular	O
plane	O
to	O
the	O
origin	O
of	O
the	O
inferior	O
mesenteric	O
artery	O
with	O
involvement	O
of	O
the	O
proximal	O
origin	O
of	O
the	O
ASD	O
.	O
Dilatation	O
of	O
aortic	O
root	O
and	O
tubular	O
portion	O
of	O
ascending	O
aorta	O
47	O
mm	O
.	O
Descending	O
aorta	O
37	O
mm	O
.	O
Descending	O
aorta	O
31	O
mm	O
.	O
At	O
the	O
level	O
of	O
the	O
thoraco	O
abdominal	O
aorta	O
,	O
the	O
true	O
lumen	O
has	O
a	O
reduced	O
calibre	O
.	O
The	O
celiac	O
,	O
superior	O
mesenteric	O
and	O
right	O
renal	O
trunks	O
originate	O
from	O
the	O
true	O
lumen	O
.	O
The	O
left	O
renal	O
arises	O
from	O
a	O
gateway	O
between	O
the	O
true	O
lumen	O
and	O
the	O
false	O
lumen	O
with	O
good	O
renal	O
perfusion	O
.	O
Distal	O
aorta	O
and	O
normal	O
iliofemoral	O
sector	O
.	O
Conclusion	O
type	O
A	O
dissection	O
extending	O
from	O
the	O
aortic	O
root	O
to	O
the	O
aortic	O
segment	O
proximal	O
to	O
the	O
inferior	O
mesenteric	O
origin	O
.	O
CLINICAL	O
EVOLUTION	O
In	O
a	O
patient	O
with	O
intense	O
oppressive	O
chest	O
pain	O
,	O
without	O
significant	O
ECG	O
alterations	O
suggestive	O
of	O
ischaemia	O
,	O
it	O
was	O
decided	O
to	O
perform	O
an	O
urgent	O
TTE	O
,	O
which	O
revealed	O
aortic	O
root	O
dilatation	O
with	O
significant	O
insufficiency	O
.	O
In	O
view	O
of	O
these	O
findings	O
,	O
it	O
was	O
decided	O
to	O
request	O
an	O
angio	O
CT	O
scan	O
,	O
which	O
confirmed	O
the	O
diagnosis	O
of	O
type	O
A	O
aortic	O
dissection	O
.	O
With	O
the	O
results	O
of	O
the	O
complementary	O
examinations	O
and	O
the	O
diagnosis	O
,	O
the	O
cardiac	O
surgery	O
department	O
was	O
contacted	O
and	O
emergency	O
surgery	O
was	O
performed	O
using	O
the	O
mechanical	O
Bono	O
Bentall	O
technique	O
Carboseal	O
29	O
mm	O
consisting	O
of	O
aortic	O
valve	O
replacement	O
,	O
aortic	O
root	O
and	O
ascending	O
aorta	O
replacement	O
,	O
as	O
well	O
as	O
coronary	O
ostium	O
reimplantation	O
in	O
the	O
same	O
surgical	O
procedure	O
,	O
under	O
extracorporeal	O
circulation	O
,	O
electromechanical	O
heart	O
arrest	O
and	O
circulatory	O
arrest	O
with	O
selective	O
bicarotdeal	O
cerebral	O
perfusion	O
.	O
No	O
replacement	O
of	O
the	O
aortic	O
arch	O
or	O
descending	O
aorta	O
was	O
performed	O
,	O
given	O
the	O
critical	O
condition	O
of	O
the	O
patient	O
,	O
the	O
complexity	O
of	O
the	O
intervention	O
and	O
the	O
improvement	O
after	O
elimination	O
of	O
the	O
main	O
tear	O
and	O
reinstatement	O
of	O
true	O
lumen	O
flow	O
.	O
Evolution	O
in	O
ICU	O
prolonged	O
stay	O
to	O
8	O
days	O
after	O
emergent	O
Bentall	O
surgery	O
.	O
Early	O
extubation	O
at	O
12	O
h	O
post	O
IQ	O
without	O
incident	O
.	O
At	O
48	O
hours	O
the	O
patient	O
developed	O
global	O
respiratory	O
failure	O
oriented	O
as	O
postoperative	O
acute	O
respiratory	O
distress	O
syndrome	O
ARDS	O
by	O
congruent	O
radiography	O
with	O
image	O
of	O
scattered	O
infiltrates	O
in	O
both	O
lung	O
fields	O
with	O
heterogeneous	O
distribution	O
.	O
Influenza	O
A	O
negative	O
PCR	O
.	O
He	O
required	O
high	O
flow	O
nasal	O
spectacles	O
,	O
with	O
progressive	O
improvement	O
.	O
On	O
the	O
other	O
hand	O
,	O
acute	O
renal	O
failure	O
resolved	O
.	O
Haemodynamically	O
,	O
the	O
patient	O
remained	O
stable	O
from	O
the	O
immediate	O
postoperative	O
period	O
,	O
with	O
no	O
signs	O
of	O
active	O
bleeding	O
and	O
no	O
transfusion	O
requirements	O
.	O
Good	O
evolution	O
in	O
the	O
cardiac	O
surgery	O
room	O
,	O
with	O
discharge	O
home	O
on	O
7	O
3	O
19	O
.	O
DIAGNOSIS	O
Acute	O
type	O
A	O
aortic	O
dissection	O
.	O
Emergent	O
surgery	O
with	O
metallic	O
Bono	O
Bentall	O
.	O
Smoking	O
.	O
Arterial	O
hypertension	O
.	O
Acute	O
respiratory	O
failure	O
due	O
to	O
ARDS	O
.	O
Resolved	O
prerenal	O
renal	O
failure	O
.	O

PERSONAL	O
HISTORY	O
60	O
year	O
old	O
male	O
patient	O
with	O
the	O
following	O
history	O
Family	O
history	O
of	O
early	O
ischaemic	O
heart	O
disease	O
brother	O
died	O
of	O
acute	O
myocardial	O
infarction	O
at	O
the	O
age	O
of	O
48	O
,	O
sister	O
with	O
chronic	O
ischaemic	O
heart	O
disease	O
since	O
the	O
age	O
of	O
50	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
Arterial	O
hypertension	O
with	O
good	O
control	O
as	O
usual	O
.	O
Diabetes	O
mellitus	O
DM	O
type	O
2	O
in	O
treatment	O
with	O
oral	O
antidiabetics	O
,	O
with	O
last	O
HbA1c	O
7	O
November	O
2017	O
.	O
Probable	O
difficult	O
to	O
control	O
familial	O
hypercholesterolaemia	O
.	O
Chronic	O
ischaemic	O
heart	O
disease	O
with	O
completely	O
revascularised	O
multivessel	O
disease	O
and	O
preserved	O
biventricular	O
systolic	O
function	O
.	O
Debut	O
in	O
January	O
2017	O
with	O
non	O
ST	O
segment	O
elevation	O
acute	O
coronary	O
syndrome	O
NSTEACS	O
of	O
the	O
non	O
Q	O
acute	O
myocardial	O
infarction	O
AMI	O
type	O
,	O
with	O
coronary	O
angiography	O
finding	O
multivessel	O
disease	O
,	O
with	O
severe	O
lesion	O
in	O
the	O
distal	O
trunk	O
affecting	O
the	O
origin	O
of	O
the	O
anterior	O
descending	O
artery	O
LAD	O
and	O
severe	O
lesion	O
in	O
the	O
middle	O
third	O
of	O
the	O
right	O
coronary	O
artery	O
RCA	O
,	O
undergoing	O
triple	O
coronary	O
artery	O
bypass	O
left	O
internal	O
mammary	O
to	O
LAD	O
,	O
saphenous	O
to	O
obtuse	O
marginal	O
and	O
saphenous	O
to	O
RCA	O
.	O
At	O
discharge	O
echocardiography	O
with	O
preserved	O
systolic	O
function	O
LVEF	O
67	O
without	O
segmental	O
alterations	O
of	O
contractility	O
and	O
analysis	O
with	O
hypercholesterolaemia	O
total	O
cholesterol	O
200	O
mg	O
dl	O
,	O
LDL	O
C	O
140	O
mg	O
dl	O
,	O
HDL	O
23	O
mg	O
dl	O
despite	O
treatment	O
with	O
atorvastatin	B-FARMACO
80	O
mg	O
.	O
Admission	O
to	O
cardiology	O
in	O
February	O
2017	O
due	O
to	O
a	O
new	O
episode	O
of	O
chest	O
pain	O
with	O
pleuritic	O
characteristics	O
and	O
no	O
elevation	O
of	O
myocardial	O
damage	O
markers	O
,	O
with	O
a	O
new	O
echocardiogram	O
performed	O
,	O
superimposing	O
the	O
previous	O
one	O
except	O
for	O
the	O
finding	O
of	O
slight	O
pericardial	O
effusion	O
with	O
no	O
data	O
of	O
haemodynamic	O
compromise	O
.	O
Treatment	O
was	O
started	O
with	O
high	O
dose	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
with	O
clinical	O
improvement	O
,	O
and	O
the	O
patient	O
was	O
discharged	O
with	O
a	O
diagnosis	O
of	O
Dressler	O
's	O
syndrome	O
.	O
A	O
new	O
blood	O
test	O
also	O
showed	O
LDL	O
C	O
201	O
mg	O
dl	O
and	O
treatment	O
was	O
started	O
with	O
atorvastatin	B-FARMACO
80	O
mg	O
ezetimibe	B-FARMACO
10	O
mg	O
on	O
discharge	O
.	O
Subsequent	O
follow	O
up	O
in	O
cardiology	O
outpatient	O
clinics	O
,	O
with	O
good	O
functional	O
class	O
and	O
no	O
effort	O
angina	O
,	O
as	O
well	O
as	O
good	O
therapeutic	O
compliance	O
with	O
controlled	O
blood	O
pressure	O
and	O
good	O
glycaemic	O
control	O
.	O
In	O
analytical	O
tests	O
,	O
hypercholesterolemia	O
persisted	O
with	O
marked	O
elevation	O
of	O
LDL	O
C	O
levels	O
.	O
Other	O
surgical	O
interventions	O
meniscopathy	O
.	O
CURRENT	O
DISEASE	O
60	O
year	O
old	O
patient	O
under	O
follow	O
up	O
in	O
cardiology	O
outpatient	O
clinic	O
since	O
previous	O
admission	O
for	O
AMI	O
undergoing	O
surgical	O
revascularisation	O
.	O
The	O
patient	O
reports	O
being	O
in	O
good	O
clinical	O
condition	O
,	O
with	O
no	O
angina	O
or	O
dyspnoea	O
on	O
exertion	O
after	O
discharge	O
.	O
He	O
denies	O
orthopnoea	O
or	O
episodes	O
of	O
paroxysmal	O
nocturnal	O
dyspnoea	O
.	O
He	O
reported	O
having	O
completed	O
the	O
cardiac	O
rehabilitation	O
programme	O
and	O
was	O
living	O
a	O
routine	O
life	O
without	O
limitations	O
.	O
He	O
attended	O
the	O
consultation	O
to	O
collect	O
the	O
results	O
.	O
PHYSICAL	O
EXAMINATION	O
Good	O
general	O
condition	O
.	O
Conscious	O
,	O
oriented	O
.	O
Well	O
hydrated	O
and	O
perfused	O
.	O
Eupneic	O
at	O
rest	O
.	O
SatO2	O
98	O
without	O
oxygen	O
therapy	O
.	O
Blood	O
pressure	O
BP	O
130	O
80	O
,	O
heart	O
rate	O
HR	O
70	O
.	O
No	O
jugular	O
engorgement	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
at	O
a	O
good	O
frequency	O
.	O
No	O
murmurs	O
or	O
audible	O
extratonos	O
.	O
Conserved	O
vesicular	O
murmur	O
,	O
without	O
pathological	O
noises	O
.	O
Lower	O
limbs	O
no	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
Distal	O
pulses	O
preserved	O
and	O
symmetrical	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
April	O
2018	O
sinus	O
rhythm	O
at	O
70	O
bpm	O
,	O
normal	O
axis	O
,	O
normal	O
PR	O
,	O
narrow	O
QRS	O
,	O
Q	O
wave	O
in	O
III	O
and	O
aVF	O
with	O
negative	O
T	O
in	O
I	O
and	O
aVL	O
,	O
no	O
other	O
repolarisation	O
alterations	O
,	O
no	O
signs	O
of	O
acute	O
ischaemia	O
,	O
normal	O
QTc	O
.	O
Echocardiography	O
April	O
2018	O
non	O
dilated	O
left	O
ventricle	O
without	O
hypertrophy	O
of	O
its	O
walls	O
.	O
Left	O
atrium	O
slightly	O
dilated	O
.	O
Thoracic	O
aorta	O
within	O
the	O
normal	O
range	O
.	O
No	O
significant	O
valvular	O
heart	O
disease	O
.	O
Preserved	O
left	O
ventricular	O
systolic	O
function	O
,	O
with	O
LVEF	O
calculated	O
by	O
Simpson	O
BP	O
at	O
67	O
,	O
without	O
segmental	O
contractility	O
disorders	O
.	O
Transmitral	O
filling	O
pattern	O
of	O
impaired	O
relaxation	O
without	O
increased	O
filling	O
pressures	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
with	O
adequate	O
inspiratory	O
collapse	O
.	O
No	O
pericardial	O
effusion	O
.	O
CBC	O
April	O
2018	O
CBC	O
leukocytes	O
8	O
,	O
100	O
units	O
,	O
haemoglobin	O
13	O
.	O
4	O
g	O
dl	O
,	O
platelets	O
339	O
,	O
000	O
units	O
.	O
Biochemistry	O
Cr	O
0	O
.	O
84	O
mg	O
dl	O
,	O
normal	O
ions	O
,	O
normal	O
hepatobiliary	O
profile	O
.	O
HbA1c	O
7	O
.	O
0	O
Lipid	O
profile	O
total	O
cholesterol	O
345	O
mg	O
dl	O
,	O
LDLc	O
278	O
mg	O
dl	O
,	O
HDL	O
52	O
mg	O
dl	O
,	O
triglycerides	O
75	O
mg	O
dl	O
.	O
Blood	O
tests	O
June	O
2018	O
,	O
after	O
starting	O
alirocumab	B-FARMACO
CBC	O
leukocytes	O
9	O
,	O
100	O
units	O
,	O
haemoglobin	O
13	O
.	O
9	O
g	O
dl	O
,	O
platelets	O
280	O
,	O
000	O
units	O
.	O
Biochemistry	O
Cr	O
0	O
.	O
90	O
mg	O
dl	O
,	O
normal	O
ions	O
,	O
normal	O
hepatobiliary	O
profile	O
.	O
HbA1c	O
6	O
.	O
9	O
.	O
Lipid	O
profile	O
total	O
cholesterol	O
147	O
mg	O
dl	O
,	O
LDL	O
C	O
78	O
mg	O
dl	O
,	O
HDL	O
55	O
mg	O
dl	O
,	O
triglycerides	O
72	O
mg	O
dl	O
.	O
CLINICAL	O
COURSE	O
The	O
patient	O
attended	O
the	O
consultation	O
to	O
collect	O
the	O
results	O
,	O
reporting	O
a	O
good	O
clinical	O
condition	O
.	O
He	O
denies	O
myalgia	O
with	O
high	O
dose	O
statin	O
treatment	O
,	O
but	O
reports	O
concern	O
about	O
the	O
difficulty	O
of	O
controlling	O
his	O
cholesterol	O
given	O
his	O
personal	O
and	O
family	O
history	O
.	O
He	O
reported	O
good	O
compliance	O
with	O
treatment	O
,	O
with	O
good	O
control	O
of	O
blood	O
pressure	O
and	O
blood	O
glucose	O
levels	O
at	O
home	O
,	O
as	O
well	O
as	O
the	O
recommended	O
hygienic	O
and	O
dietary	O
measures	O
.	O
The	O
control	O
blood	O
test	O
showed	O
persistent	O
hypercholesterolaemia	O
,	O
with	O
total	O
cholesterol	O
levels	O
of	O
345	O
mg	O
dl	O
and	O
LDL	O
C	O
of	O
278	O
mg	O
dl	O
despite	O
treatment	O
with	O
atorvastatin	B-FARMACO
80	O
mg	O
ezetimibe	B-FARMACO
10	O
mg	O
.	O
Given	O
that	O
the	O
cholesterol	O
levels	O
were	O
far	O
from	O
the	O
optimal	O
range	O
,	O
it	O
was	O
decided	O
to	O
start	O
treatment	O
with	O
alirocumab	B-FARMACO
150	O
mg	O
every	O
two	O
weeks	O
and	O
to	O
review	O
in	O
one	O
month	O
with	O
a	O
new	O
blood	O
test	O
.	O
The	O
patient	O
returned	O
for	O
another	O
check	O
up	O
in	O
June	O
2018	O
,	O
denying	O
having	O
had	O
any	O
adverse	O
reaction	O
after	O
starting	O
treatment	O
.	O
The	O
control	O
analysis	O
showed	O
a	O
total	O
cholesterol	O
level	O
of	O
147	O
mg	O
dl	O
with	O
LDL	O
C	O
levels	O
of	O
78	O
mg	O
dl	O
.	O
DIAGNOSIS	O
Chronic	O
ischaemic	O
heart	O
disease	O
with	O
completely	O
surgically	O
revascularised	O
multivessel	O
disease	O
and	O
preserved	O
left	O
ventricular	O
systolic	O
function	O
.	O
Probable	O
familial	O
hypercholesterolemia	O
of	O
very	O
difficult	O
control	O
.	O
Arterial	O
hypertension	O
and	O
type	O
2	O
diabetes	O
mellitus	O
with	O
good	O
control	O
.	O

PERSONAL	O
HISTORY	O
Female	O
patient	O
aged	O
88	O
years	O
.	O
No	O
known	O
allergic	O
reactions	O
to	O
medication	O
.	O
Cardiovascular	O
risk	O
factors	O
hypertension	O
,	O
dyslipidaemia	O
.	O
No	O
cardiological	O
history	O
of	O
interest	O
.	O
Peripheral	O
arteriopathy	O
with	O
significant	O
atheromatosis	O
of	O
the	O
left	O
superficial	O
femoral	O
artery	O
documented	O
by	O
angiography	O
four	O
years	O
earlier	O
,	O
under	O
medical	O
treatment	O
.	O
Polyarthrosis	O
under	O
follow	O
up	O
by	O
rheumatology	O
.	O
Surgical	O
intervention	O
for	O
appendicitis	O
at	O
the	O
age	O
of	O
25	O
.	O
Usual	O
treatment	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
mg	O
every	O
24	O
hours	O
,	O
clopidogrel	B-FARMACO
75	O
mg	O
every	O
24	O
hours	O
,	O
enalapril	B-FARMACO
20	O
mg	O
every	O
24	O
hours	O
,	O
doxazosin	B-FARMACO
4	O
mg	O
every	O
24	O
hours	O
,	O
simvastatin	B-FARMACO
10	O
mg	O
every	O
24	O
hours	O
,	O
pantoprazole	B-FARMACO
20	O
mg	O
every	O
24	O
hours	O
.	O
CURRENT	O
ILLNESS	O
The	O
patient	O
came	O
to	O
the	O
emergency	O
department	O
with	O
chest	O
pain	O
in	O
the	O
retrosternal	O
region	O
that	O
appeared	O
at	O
rest	O
and	O
was	O
described	O
as	O
severe	O
.	O
This	O
picture	O
lasts	O
approximately	O
20	O
minutes	O
and	O
subsides	O
spontaneously	O
.	O
She	O
describes	O
associated	O
vegetative	O
cramps	O
.	O
In	O
the	O
last	O
two	O
months	O
,	O
the	O
patient	O
reported	O
frequent	O
episodes	O
of	O
epigastric	O
discomfort	O
,	O
with	O
irradiation	O
to	O
the	O
precordium	O
and	O
left	O
upper	O
limb	O
,	O
which	O
occurred	O
with	O
the	O
exertion	O
of	O
her	O
household	O
chores	O
.	O
PHYSICAL	O
EXAMINATION	O
Temperature	O
36	O
.	O
2	O
C	O
,	O
blood	O
pressure	O
150	O
52	O
mmHg	O
,	O
heart	O
rate	O
59	O
beats	O
per	O
minute	O
,	O
oxygen	O
saturation	O
by	O
pulse	O
oximetry	O
93	O
at	O
baseline	O
,	O
no	O
signs	O
of	O
tachypnoea	O
at	O
rest	O
.	O
Neurological	O
examination	O
was	O
unaltered	O
.	O
Cardiac	O
auscultation	O
was	O
rhythmic	O
,	O
without	O
murmurs	O
,	O
pulmonary	O
auscultation	O
with	O
generalised	O
hypophonesis	O
.	O
The	O
abdominal	O
examination	O
showed	O
no	O
palpable	O
organomegaly	O
,	O
negative	O
hepatojugular	O
reflux	O
and	O
no	O
signs	O
of	O
ascites	O
.	O
The	O
lower	O
limbs	O
showed	O
signs	O
of	O
chronic	O
venous	O
insufficiency	O
.	O
COMPLEMENTARY	O
TESTS	O
Analytical	O
parameters	O
during	O
his	O
admission	O
to	O
cardiology	O
leukocytes	O
7	O
.	O
5	O
mil	O
ml	O
,	O
haemoglobin	O
13	O
.	O
3	O
g	O
dl	O
;	O
platelets	O
299	O
mil	O
l	O
;	O
No	O
coagulation	O
alterations	O
;	O
basal	O
glucose	O
81	O
mg	O
dl	O
,	O
glycosylated	O
haemoglobin	O
HbA1c	O
5	O
.	O
6	O
,	O
urea	O
58	O
mg	O
dl	O
;	O
creatinine	O
1	O
.	O
03	O
mg	O
dl	O
;	O
estimated	O
glomerular	O
filtration	O
rate	O
MDRD	O
4	O
56	O
ml	O
min	O
1	O
.	O
73	O
m2	O
,	O
total	O
bilirubin	O
0	O
.	O
4	O
mg	O
dl	O
,	O
GOT	O
19	O
IU	O
l	O
,	O
GPT	O
13	O
IU	O
l	O
,	O
CPK	O
64	O
IU	O
l	O
,	O
Ions	O
in	O
normal	O
range	O
.	O
Seriation	O
of	O
biomarkers	O
troponin	O
I	O
peak	O
0	O
.	O
228	O
ng	O
ml	O
normal	O
range	O
less	O
than	O
0	O
.	O
06	O
ng	O
ml	O
,	O
CKMB	O
3	O
.	O
7	O
ng	O
ml	O
normal	O
range	O
less	O
than	O
6	O
ng	O
ml	O
,	O
CPK	O
111	O
IU	O
l	O
normal	O
range	O
30	O
200	O
IU	O
l	O
.	O
Laboratory	O
parameters	O
during	O
his	O
admission	O
to	O
internal	O
medicine	O
leukocytes	O
12	O
.	O
3	O
mil	O
ml	O
,	O
haemoglobin	O
11	O
.	O
3	O
g	O
dl	O
,	O
platelets	O
336	O
mil	O
l	O
.	O
No	O
coagulation	O
alterations	O
.	O
Basal	O
glucose	O
90	O
mg	O
dl	O
,	O
urea	O
55	O
mg	O
dl	O
.	O
Creatinine	O
1	O
.	O
15	O
mg	O
dl	O
,	O
estimated	O
glomerular	O
filtration	O
rate	O
MDRD	O
4	O
44	O
ml	O
min	O
1	O
.	O
73	O
m2	O
.	O
Total	O
bilirubin	O
2	O
.	O
7	O
mg	O
dl	O
,	O
direct	O
bilirubin	O
1	O
.	O
9	O
mg	O
dl	O
,	O
GOT	O
940	O
IU	O
l	O
,	O
GPT	O
660	O
IU	O
l	O
,	O
GGT	O
2711	O
IU	O
l	O
,	O
CPK	O
5074	O
IU	O
l	O
,	O
Ions	O
in	O
normal	O
range	O
.	O
Immunoglobulins	O
and	O
complement	O
without	O
significant	O
alterations	O
.	O
Proteinogram	O
albumin	O
3	O
.	O
16	O
g	O
dl	O
with	O
no	O
other	O
significant	O
alterations	O
.	O
Negativity	O
in	O
the	O
study	O
for	O
anti	O
nuclear	O
antibodies	O
ANA	O
,	O
anti	O
mitochondrial	O
antibodies	O
AMA	O
,	O
anti	O
smooth	O
muscle	O
antibodies	O
AML	O
and	O
anti	O
LKM	O
1	O
antibodies	O
.	O
Emergency	O
resting	O
electrocardiogram	O
sinus	O
rhythm	O
at	O
77	O
bpm	O
.	O
PR	O
of	O
145	O
ms	O
with	O
atrioventricular	O
conduction	O
1	O
1	O
.	O
Narrow	O
QRS	O
with	O
normal	O
axis	O
.	O
Inframilimetric	O
ST	O
segment	O
depression	O
from	O
V4	O
to	O
V6	O
.	O
QTc	O
interval	O
of	O
444	O
ms	O
.	O
Abdominal	O
ultrasound	O
liver	O
of	O
normal	O
morphology	O
and	O
echogenicity	O
with	O
no	O
evidence	O
of	O
lesions	O
inside	O
.	O
Abdominal	O
pelvic	O
CT	O
scan	O
no	O
space	O
occupying	O
lesions	O
were	O
seen	O
in	O
the	O
blood	O
parenchyma	O
,	O
which	O
had	O
a	O
normal	O
morphology	O
.	O
There	O
is	O
no	O
evidence	O
of	O
retroperitoneal	O
pathology	O
.	O
Kidneys	O
with	O
cortical	O
notches	O
of	O
normal	O
size	O
and	O
morphology	O
.	O
The	O
rest	O
of	O
the	O
examination	O
showed	O
no	O
significant	O
tomographic	O
findings	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
cardiology	O
department	O
with	O
a	O
diagnosis	O
of	O
acute	O
myocardial	O
infarction	O
without	O
ST	O
segment	O
elevation	O
,	O
with	O
an	O
intermediate	O
risk	O
profile	O
.	O
Preferential	O
coronary	O
angiography	O
was	O
performed	O
with	O
implantation	O
of	O
a	O
drug	O
eluting	O
stent	O
in	O
the	O
right	O
ostial	O
coronary	O
artery	O
,	O
which	O
presented	O
a	O
critical	O
ostial	O
lesion	O
,	O
with	O
no	O
other	O
angiographically	O
significant	O
lesions	O
.	O
Transthoracic	O
echocardiography	O
was	O
performed	O
on	O
admission	O
with	O
no	O
notable	O
alterations	O
.	O
The	O
patient	O
,	O
who	O
was	O
already	O
on	O
double	O
antiplatelet	O
therapy	O
,	O
was	O
discharged	O
after	O
an	O
admission	O
without	O
notable	O
complications	O
,	O
adding	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
daily	O
to	O
her	O
usual	O
treatment	O
and	O
replacing	O
the	O
previous	O
lipid	O
lowering	O
treatment	O
with	O
atorvastatin	B-FARMACO
80	O
mg	O
.	O
At	O
this	O
time	O
the	O
patient	O
's	O
LDL	O
cholesterol	O
level	O
was	O
98	O
mg	O
dl	O
.	O
After	O
a	O
period	O
of	O
one	O
month	O
of	O
home	O
treatment	O
,	O
the	O
patient	O
visited	O
her	O
primary	O
care	O
physician	O
for	O
lumbar	O
pain	O
radiating	O
to	O
the	O
right	O
abdomen	O
and	O
the	O
physician	O
performed	O
a	O
blood	O
test	O
showing	O
hypertransaminasemia	O
with	O
GOT	O
levels	O
of	O
677	O
IU	O
l	O
and	O
GPT	O
of	O
701	O
IU	O
l	O
,	O
referring	O
the	O
patient	O
to	O
the	O
emergency	O
department	O
.	O
The	O
patient	O
was	O
readmitted	O
to	O
the	O
emergency	O
department	O
,	O
where	O
she	O
reported	O
asthenia	O
,	O
weakness	O
predominantly	O
in	O
the	O
shoulder	O
girdle	O
,	O
and	O
a	O
repeat	O
laboratory	O
test	O
was	O
performed	O
,	O
expanding	O
the	O
parameters	O
see	O
section	O
on	O
complementary	O
tests	O
.	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
internal	O
medicine	O
department	O
for	O
hypertransaminasemia	O
under	O
study	O
,	O
rhabdomyolysis	O
and	O
acute	O
renal	O
failure	O
with	O
a	O
pre	O
renal	O
profile	O
.	O
During	O
her	O
admission	O
to	O
internal	O
medicine	O
,	O
an	O
ultrasound	O
scan	O
of	O
the	O
abdomen	O
and	O
abdominal	O
CT	O
scan	O
were	O
performed	O
see	O
section	O
on	O
complementary	O
tests	O
to	O
assess	O
retroperitoneal	O
pathology	O
.	O
Finally	O
,	O
she	O
was	O
diagnosed	O
with	O
toxic	O
hepatitis	O
and	O
rhabdomyolysis	O
related	O
to	O
statins	O
.	O
The	O
patient	O
progressed	O
favourably	O
during	O
her	O
admission	O
and	O
was	O
discharged	O
with	O
ezetimibe	B-FARMACO
10	O
mg	O
every	O
24	O
hours	O
.	O
To	O
date	O
,	O
the	O
patient	O
has	O
continued	O
her	O
check	O
ups	O
in	O
cardiology	O
consultations	O
with	O
no	O
new	O
notable	O
events	O
and	O
her	O
LDL	O
cholesterol	O
levels	O
are	O
105	O
mg	O
dl	O
,	O
with	O
transaminase	O
and	O
creatine	O
phosphokinase	O
levels	O
within	O
the	O
normal	O
range	O
.	O
DIAGNOSIS	O
Acute	O
myocardial	O
infarction	O
without	O
ST	O
segment	O
elevation	O
.	O
Toxic	O
hepatitis	O
and	O
rhabdomyolysis	O
related	O
to	O
treatment	O
with	O
statins	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
78	O
year	O
old	O
woman	O
.	O
She	O
is	O
hypertensive	O
,	O
diabetic	O
on	O
oral	O
treatment	O
and	O
hyperuricaemic	O
.	O
In	O
addition	O
,	O
she	O
had	O
an	O
infiltrating	O
breast	O
carcinoma	O
treated	O
8	O
years	O
ago	O
with	O
radical	O
mastectomy	O
,	O
chemotherapy	O
and	O
radiotherapy	O
,	O
and	O
is	O
currently	O
free	O
of	O
disease	O
.	O
Hepatitis	O
B	O
cured	O
.	O
Intrathoracic	O
goitre	O
.	O
As	O
cardiological	O
history	O
,	O
she	O
has	O
permanent	O
atrial	O
fibrillation	O
treated	O
with	O
direct	O
acting	O
anticoagulant	O
and	O
,	O
in	O
the	O
face	O
of	O
severe	O
symptomatic	O
aortic	O
stenosis	O
,	O
due	O
to	O
a	O
history	O
of	O
thoracic	O
radiation	O
,	O
percutaneous	O
replacement	O
with	O
Corevalve	O
Evolut	O
26	O
transfemoral	O
TAVI	O
implant	O
was	O
chosen	O
one	O
year	O
ago	O
,	O
with	O
no	O
incidents	O
.	O
On	O
regular	O
treatment	O
with	O
digoxin	B-FARMACO
0	O
.	O
5	O
mg	O
1	O
0	O
0	O
,	O
dabigatran	B-FARMACO
150	O
mg	O
1	O
0	O
1	O
,	O
valsartan	B-FARMACO
amlodipine	I-FARMACO
160	O
5	O
mg	O
1	O
0	O
0	O
,	O
furosemide	B-FARMACO
40	O
1	O
0	O
0	O
,	O
allopurinol	B-FARMACO
100	O
0	O
1	O
0	O
and	O
metformin	B-FARMACO
850	O
0	O
1	O
0	O
.	O
She	O
reported	O
febrile	O
symptoms	O
of	O
one	O
week	O
's	O
evolution	O
,	O
with	O
fever	O
of	O
more	O
than	O
38	O
C	O
thermometrically	O
measured	O
,	O
treated	O
with	O
fosfomycin	B-FARMACO
by	O
her	O
general	O
practitioner	O
for	O
suspected	O
urinary	O
tract	O
infection	O
,	O
with	O
little	O
improvement	O
.	O
Twenty	O
four	O
hours	O
after	O
starting	O
antibiotic	O
treatment	O
,	O
she	O
began	O
with	O
liquid	O
diarrhoea	O
without	O
pathological	O
products	O
and	O
intense	O
periumbilical	O
pain	O
,	O
also	O
associated	O
with	O
the	O
progressive	O
appearance	O
of	O
oedema	O
in	O
the	O
legs	O
and	O
progressive	O
dyspnoea	O
,	O
for	O
which	O
she	O
went	O
to	O
the	O
emergency	O
department	O
.	O
She	O
denied	O
cough	O
or	O
expectoration	O
,	O
as	O
well	O
as	O
chest	O
pain	O
,	O
dizziness	O
or	O
syncope	O
.	O
She	O
also	O
had	O
no	O
neurological	O
focality	O
.	O
She	O
was	O
admitted	O
to	O
the	O
internal	O
medicine	O
department	O
as	O
a	O
possible	O
complicated	O
urinary	O
tract	O
infection	O
for	O
study	O
and	O
treatment	O
.	O
On	O
examination	O
,	O
she	O
had	O
a	O
blood	O
pressure	O
of	O
95	O
62	O
mmHg	O
,	O
a	O
heart	O
rate	O
of	O
85	O
bpm	O
,	O
fever	O
of	O
37	O
.	O
9	O
C	O
and	O
was	O
eupneic	O
with	O
nasal	O
goggles	O
at	O
2	O
l	O
min	O
O2	O
saturation	O
97	O
.	O
Jugular	O
venous	O
pressure	O
is	O
increased	O
.	O
On	O
auscultation	O
she	O
is	O
arrhythmic	O
at	O
80	O
bpm	O
,	O
with	O
murmur	O
in	O
aortic	O
focus	O
II	O
VI	O
and	O
normal	O
second	O
sound	O
;	O
she	O
also	O
has	O
hypoventilation	O
in	O
the	O
bases	O
and	O
crackles	O
in	O
the	O
midfields	O
.	O
The	O
abdomen	O
was	O
soft	O
,	O
depressible	O
and	O
painful	O
at	O
the	O
epigastric	O
level	O
,	O
with	O
no	O
evidence	O
of	O
peritoneal	O
irritation	O
or	O
visceromegaly	O
.	O
Lower	O
extremities	O
with	O
oedema	O
with	O
pitting	O
up	O
to	O
the	O
knee	O
,	O
with	O
no	O
evidence	O
of	O
venous	O
thrombosis	O
.	O
Peripheral	O
pulses	O
present	O
and	O
symmetrical	O
.	O
No	O
peripheral	O
stigmata	O
of	O
endocarditis	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
atrial	O
fibrillation	O
at	O
80	O
bpm	O
,	O
narrow	O
QRS	O
,	O
normal	O
axis	O
.	O
Repolarisation	O
abnormalities	O
corresponding	O
to	O
a	O
digitalis	O
tray	O
.	O
Chest	O
X	O
ray	O
cardiomegaly	O
.	O
TAVI	O
in	O
aortic	O
position	O
.	O
Vascular	O
redistribution	O
and	O
fluid	O
in	O
cystic	O
cracks	O
compatible	O
with	O
heart	O
failure	O
.	O
Widening	O
of	O
the	O
superior	O
mediastinum	O
compatible	O
with	O
known	O
endothoracic	O
goitre	O
.	O
Analysis	O
Biochemistry	O
glucose	O
98	O
mg	O
dl	O
,	O
Cr	O
1	O
mg	O
dl	O
,	O
GFR	O
54	O
ml	O
min	O
,	O
urea	O
59	O
mg	O
dl	O
,	O
Na	O
125	O
mEq	O
l	O
,	O
K	O
5	O
.	O
8	O
mEq	O
l	O
,	O
digoxinemia	O
2	O
.	O
3	O
ng	O
dl	O
.	O
Thyroid	O
hormones	O
normal	O
.	O
Liver	O
function	O
tests	O
GOT	O
320	O
IU	O
l	O
,	O
GPT	O
270	O
IU	O
l	O
,	O
total	O
bilirubin	O
2	O
.	O
64	O
mg	O
dl	O
direct	O
bilirubin	O
2	O
.	O
22	O
mg	O
dl	O
,	O
albumin	O
2	O
.	O
14	O
g	O
dl	O
,	O
amylase	O
449	O
U	O
l	O
.	O
Iron	O
profile	O
iron	O
156	O
g	O
dl	O
,	O
transferrin	O
120	O
mg	O
dl	O
,	O
IST	O
139	O
,	O
ferritin	O
1	O
,	O
755	O
ng	O
ml	O
.	O
ProBNP	O
3	O
,	O
410	O
pg	O
ml	O
.	O
Infectious	O
markers	O
CRP	O
152	O
mg	O
l	O
,	O
PCT	O
6	O
.	O
9	O
ng	O
ml	O
.	O
Haemogram	O
leucocytes	O
21	O
,	O
000	O
l	O
with	O
12	O
of	O
keys	O
,	O
Hb	O
7	O
.	O
8	O
g	O
dl	O
,	O
platelets	O
91	O
,	O
000	O
l	O
.	O
Coagulation	O
INR	O
1	O
.	O
88	O
,	O
PT	O
42	O
.	O
Blood	O
cultures	O
two	O
positive	O
series	O
for	O
methicillin	O
sensitive	O
Staphylococcus	O
aureus	O
,	O
with	O
positive	O
synergism	O
with	O
aminoglycosides	O
.	O
Urine	O
isolated	O
red	O
blood	O
cells	O
.	O
No	O
leucocyturia	O
or	O
bacteriuria	O
,	O
negative	O
nitrites	O
Faeces	O
usual	O
flora	O
,	O
no	O
parasites	O
and	O
negative	O
Clostridium	O
difficile	O
toxin	O
.	O
Serology	O
HIV	O
and	O
HCV	O
negative	O
.	O
Anti	O
HBs	O
and	O
Anti	O
HBc	O
positive	O
.	O
Autoimmunity	O
study	O
ANA	O
,	O
ANCA	O
,	O
Anti	O
native	O
DNA	O
,	O
ENAS	O
,	O
CH	O
50	O
and	O
C4	O
normal	O
and	O
or	O
negative	O
.	O
Transthoracic	O
echocardiogram	O
left	O
ventricle	O
of	O
normal	O
diameter	O
and	O
thickness	O
with	O
normal	O
global	O
and	O
segmental	O
systolic	O
function	O
.	O
Diastolic	O
dysfunction	O
.	O
Slight	O
dilatation	O
of	O
the	O
left	O
atrium	O
.	O
Normofunctioning	O
aortic	O
biological	O
prosthesis	O
with	O
known	O
trivial	O
insufficiency	O
.	O
Mild	O
mitral	O
insufficiency	O
and	O
tricuspid	O
insufficiency	O
,	O
with	O
mild	O
pulmonary	O
hypertension	O
at	O
rest	O
.	O
No	O
images	O
suggestive	O
of	O
endocarditis	O
are	O
detected	O
.	O
Transesophageal	O
echocardiogram	O
CoreValve	O
TAVI	O
type	O
aortic	O
bioprosthesis	O
with	O
several	O
small	O
mobile	O
images	O
,	O
mainly	O
at	O
the	O
level	O
of	O
the	O
right	O
coronary	O
leaflet	O
equivalent	O
and	O
another	O
small	O
image	O
,	O
with	O
identical	O
characteristics	O
,	O
adhered	O
to	O
the	O
stent	O
at	O
the	O
same	O
level	O
,	O
suggestive	O
of	O
endocarditis	O
.	O
CLINICAL	O
EVOLUTION	O
On	O
admission	O
,	O
antibiotic	O
treatment	O
was	O
started	O
empirically	O
with	O
ceftriaxone	B-FARMACO
with	O
initial	O
suspicion	O
of	O
pyelonephritis	O
,	O
later	O
changing	O
to	O
cloxacillin	B-FARMACO
,	O
rifampicin	B-FARMACO
and	O
gentamicin	B-FARMACO
at	O
a	O
dose	O
of	O
endocarditis	O
due	O
to	O
high	O
clinical	O
suspicion	O
,	O
despite	O
the	O
initial	O
negative	O
transthoracic	O
echocardiogram	O
.	O
The	O
study	O
was	O
later	O
completed	O
with	O
a	O
transesophageal	O
echocardiogram	O
that	O
showed	O
images	O
compatible	O
with	O
endocarditis	O
on	O
TAVI	O
,	O
establishing	O
the	O
diagnosis	O
with	O
positive	O
blood	O
cultures	O
for	O
S	O
.	O
aureus	O
.	O
Treatment	O
with	O
gentamicin	B-FARMACO
was	O
maintained	O
due	O
to	O
microbiological	O
evidence	O
of	O
synergy	O
with	O
cloxacillin	B-FARMACO
,	O
but	O
the	O
patient	O
suffered	O
a	O
rapid	O
deterioration	O
of	O
renal	O
function	O
,	O
with	O
a	O
drop	O
in	O
glomerular	O
filtration	O
rate	O
to	O
6	O
ml	O
min	O
.	O
Rapidly	O
progressive	O
worsening	O
with	O
evidence	O
of	O
septic	O
shock	O
with	O
anuria	O
,	O
decreased	O
level	O
of	O
consciousness	O
and	O
coagulopathy	O
,	O
refractory	O
to	O
initial	O
measures	O
.	O
The	O
case	O
was	O
discussed	O
with	O
cardiology	O
,	O
internal	O
medicine	O
and	O
the	O
infectious	O
diseases	O
department	O
,	O
and	O
in	O
this	O
critical	O
situation	O
,	O
further	O
valve	O
replacement	O
or	O
other	O
aggressive	O
measures	O
were	O
rejected	O
,	O
and	O
the	O
patient	O
died	O
in	O
the	O
context	O
of	O
septic	O
shock	O
secondary	O
to	O
endocarditis	O
on	O
TAVI	O
.	O
DIAGNOSIS	O
Late	O
endocarditis	O
on	O
TAVI	O
aortic	O
bioprosthesis	O
due	O
to	O
Staphylococcus	O
aureus	O
.	O
Acute	O
renal	O
failure	O
in	O
the	O
context	O
of	O
gentamicin	B-FARMACO
.	O
Septic	O
shock	O
with	O
multi	O
organ	O
failure	O
.	O
Death	O
.	O

PERSONAL	O
HISTORY	O
Male	O
,	O
63	O
years	O
of	O
age	O
,	O
his	O
medical	O
history	O
includes	O
No	O
known	O
drug	O
reactions	O
.	O
No	O
previous	O
cardiological	O
history	O
or	O
family	O
history	O
of	O
heart	O
disease	O
known	O
to	O
the	O
patient	O
.	O
Ex	O
smoker	O
of	O
25	O
cigarettes	O
a	O
day	O
for	O
45	O
years	O
.	O
Occasional	O
alcohol	O
consumption	O
.	O
No	O
arterial	O
hypertension	O
AHT	O
,	O
type	O
2	O
diabetes	O
mellitus	O
DM2	O
or	O
dyslipidaemia	O
.	O
Tuberculosis	O
in	O
childhood	O
.	O
Benign	O
prostatic	O
hyperplasia	O
.	O
No	O
previous	O
cardiological	O
history	O
.	O
Usual	O
treatment	O
tamsulosin	B-FARMACO
0	O
.	O
4	O
mg	O
.	O
CURRENT	O
ILLNESS	O
He	O
was	O
referred	O
to	O
the	O
emergency	O
department	O
by	O
his	O
primary	O
care	O
physician	O
for	O
loss	O
of	O
consciousness	O
while	O
seated	O
,	O
lasting	O
1	O
2	O
minutes	O
,	O
with	O
subsequent	O
complete	O
spontaneous	O
recovery	O
.	O
He	O
reported	O
at	O
least	O
two	O
previous	O
episodes	O
of	O
similar	O
characteristics	O
,	O
both	O
at	O
night	O
,	O
in	O
decubitus	O
position	O
,	O
in	O
the	O
last	O
two	O
weeks	O
.	O
PHYSICAL	O
EXAMINATION	O
Temperature	O
36	O
.	O
7	O
C	O
;	O
blood	O
pressure	O
BP	O
123	O
88	O
mmHg	O
;	O
heart	O
rate	O
HR	O
82	O
bpm	O
;	O
SpO2	O
97	O
FiO2	O
0	O
.	O
21	O
.	O
Neurological	O
examination	O
conscious	O
and	O
oriented	O
,	O
language	O
preserved	O
.	O
Isochoric	O
normoreactive	O
pupils	O
.	O
Normal	O
extrinsic	O
ocular	O
motility	O
.	O
Rest	O
of	O
cranial	O
nerves	O
without	O
alterations	O
.	O
Strength	O
and	O
sensitivity	O
preserved	O
.	O
Coordination	O
normal	O
.	O
Romberg	O
negative	O
.	O
No	O
alterations	O
in	O
gait	O
.	O
No	O
jugular	O
ingurgitation	O
.	O
Cardiac	O
auscultation	O
regular	O
heart	O
sounds	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
with	O
some	O
isolated	O
wheezing	O
.	O
Abdomen	O
no	O
masses	O
or	O
megaliths	O
.	O
Peristalsis	O
preserved	O
.	O
No	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
Pulses	O
present	O
and	O
symmetrical	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
tests	O
in	O
the	O
emergency	O
department	O
Glucose	O
117	O
mg	O
dl	O
.	O
Urea	O
48	O
mg	O
dl	O
.	O
Creatinine	O
0	O
.	O
78	O
mg	O
dl	O
.	O
Sodium	O
140	O
mmol	O
l	O
.	O
Potassium	O
4	O
.	O
1	O
mmol	O
l	O
.	O
Calcium	O
9	O
.	O
1	O
mg	O
dl	O
.	O
Total	O
protein	O
6	O
,	O
6	O
g	O
dl	O
.	O
GPT	O
ALT	O
32	O
U	O
l	O
.	O
Creatine	O
phosphokinase	O
CPK	O
397	O
U	O
l	O
.	O
Lactate	O
dehydrogenase	O
LDH	O
356	O
U	O
l	O
.	O
C	O
reactive	O
protein	O
CRP	O
1	O
.	O
5	O
mg	O
l	O
.	O
Leucocytes	O
9	O
.	O
38	O
x10	O
9	O
l	O
.	O
Neutrophils	O
Abs	O
7	O
,	O
30	O
x10	O
9	O
l	O
.	O
Lymphocytes	O
Abs	O
1	O
.	O
16	O
x10	O
9	O
l	O
.	O
Red	O
blood	O
cells	O
5	O
.	O
25	O
x10	O
12	O
l	O
.	O
Haemoglobin	O
16	O
.	O
0	O
g	O
dl	O
.	O
Haematocrit	O
47	O
.	O
Mean	O
corpuscular	O
volume	O
MCV	O
89	O
fl	O
.	O
Platelets	O
208	O
x10	O
9	O
l	O
.	O
Prothrombin	O
time	O
PT	O
13	O
.	O
0	O
seconds	O
,	O
Quick	O
's	O
Index	O
100	O
,	O
INR	O
1	O
.	O
00	O
.	O
Complete	O
blood	O
test	O
during	O
admission	O
glucose	O
103	O
mg	O
dl	O
.	O
Urea	O
43	O
mg	O
dl	O
.	O
Creatinine	O
0	O
.	O
68	O
mg	O
dl	O
.	O
Uric	O
acid	O
5	O
.	O
4	O
mg	O
dl	O
.	O
Sodium	O
140	O
mmol	O
l	O
.	O
Potassium	O
4	O
.	O
1	O
mmol	O
litre	O
.	O
Cholesterol	O
162	O
mg	O
dl	O
.	O
Triglycerides	O
93	O
mg	O
dl	O
.	O
HDL	O
cholesterol	O
45	O
mg	O
dl	O
.	O
Calculated	O
LDL	O
cholesterol	O
108	O
mg	O
dl	O
.	O
Magnesium	O
2	O
,	O
0	O
mg	O
dl	O
.	O
Total	O
Bilirubin	O
0	O
.	O
64	O
mg	O
dl	O
.	O
GPT	O
ALT	O
28	O
U	O
l	O
.	O
GGT	O
22	O
U	O
L	O
Total	O
Alkaline	O
Phosphatase	O
91	O
mU	O
ml	O
.	O
Leucocytes	O
5	O
.	O
05	O
x10	O
9	O
l	O
.	O
Haemoglobin	O
17	O
.	O
4	O
g	O
dL	O
,	O
Haematocrit	O
53	O
,	O
Platelets	O
233	O
x10	O
9	O
l	O
.	O
CA	O
125	O
carbohydrate	O
antigen	O
125	O
7	O
U	O
ml	O
.	O
Glycated	O
haemoglobin	O
HbA1c	O
5	O
.	O
1	O
.	O
NT	O
proBNP	O
natriuretic	O
propeptide	O
B	O
9	O
pg	O
mL	O
.	O
ECG	O
sinus	O
rhythm	O
at	O
80	O
bpm	O
.	O
Normal	O
PR	O
.	O
QRS	O
160	O
ms	O
with	O
morphology	O
similar	O
to	O
complete	O
right	O
bundle	O
branch	O
block	O
of	O
the	O
right	O
bundle	O
branch	O
of	O
the	O
His	O
BCRDHH	O
in	O
V1	O
with	O
end	O
force	O
QRS	O
filling	O
and	O
elevation	O
of	O
the	O
J	O
point	O
in	O
this	O
lead	O
.	O
Chest	O
X	O
ray	O
cardiac	O
silhouette	O
and	O
mediastinum	O
of	O
normal	O
size	O
.	O
No	O
areas	O
of	O
consolidation	O
or	O
pleural	O
effusion	O
.	O
Transthoracic	O
echocardiography	O
left	O
ventricle	O
of	O
normal	O
diameter	O
and	O
thickness	O
with	O
adequate	O
contractility	O
,	O
without	O
segmental	O
alterations	O
.	O
Transmitral	O
flow	O
pattern	O
of	O
prolonged	O
relaxation	O
.	O
Left	O
atrium	O
of	O
normal	O
dimensions	O
.	O
Fine	O
leaflet	O
mitral	O
valve	O
with	O
normal	O
opening	O
,	O
without	O
regurgitation	O
.	O
Tricommissural	O
aortic	O
valve	O
with	O
normal	O
opening	O
,	O
without	O
regurgitation	O
.	O
Right	O
chambers	O
of	O
normal	O
dimensions	O
with	O
no	O
evidence	O
of	O
PHT	O
.	O
Brain	O
CT	O
scan	O
mild	O
corticosubcortical	O
atrophy	O
with	O
ventricular	O
enlargement	O
already	O
described	O
in	O
magnetic	O
resonance	O
imaging	O
MRI	O
in	O
2015	O
.	O
Centred	O
midline	O
.	O
No	O
signs	O
of	O
acute	O
bleeding	O
or	O
oedema	O
.	O
Calota	O
without	O
alterations	O
.	O
Cardiac	O
magnetic	O
resonance	O
CMR	O
video	O
1	O
left	O
ventricle	O
with	O
wall	O
thickness	O
,	O
volumes	O
IVTDVI	O
59	O
ml	O
m2	O
;	O
IVTSVI	O
21	O
ml	O
m2	O
and	O
segmental	O
and	O
global	O
systolic	O
function	O
within	O
normal	O
LVEF	O
65	O
.	O
Right	O
ventricle	O
volume	O
IVTDVD	O
68	O
ml	O
m2	O
;	O
IVTSVD	O
28	O
ml	O
m2	O
and	O
systolic	O
function	O
preserved	O
RVEF	O
58	O
.	O
Free	O
wall	O
morphology	O
and	O
preserved	O
segmental	O
contractility	O
.	O
Atria	O
and	O
great	O
vessels	O
of	O
preserved	O
dimensions	O
.	O
First	O
pass	O
perfusion	O
at	O
rest	O
gadoteric	O
acid	O
iv	O
0	O
.	O
15	O
mmol	O
kg	O
,	O
without	O
complications	O
normal	O
.	O
Absence	O
of	O
myocardial	O
fibrosis	O
or	O
necrosis	O
.	O
Morphological	O
without	O
and	O
with	O
contrast	O
and	O
functional	O
study	O
within	O
normality	O
.	O
Electrophysiological	O
study	O
under	O
local	O
anaesthesia	O
and	O
under	O
fluoroscopic	O
control	O
,	O
three	O
quadripolar	O
electrocatheters	O
are	O
introduced	O
via	O
the	O
right	O
femoral	O
vein	O
and	O
placed	O
alternately	O
in	O
the	O
descending	O
artery	O
DA	O
,	O
AV	O
zone	O
and	O
RV	O
for	O
recording	O
and	O
stimulation	O
.	O
The	O
procedure	O
is	O
performed	O
without	O
complications	O
.	O
Basically	O
the	O
conduction	O
intervals	O
are	O
AV	O
LC	O
704	O
ms	O
,	O
AH	O
95	O
ms	O
,	O
HV	O
44	O
ms	O
.	O
The	O
nodal	O
Wenckebach	O
point	O
was	O
obtained	O
at	O
190	O
bpm	O
.	O
No	O
VA	O
conduction	O
is	O
observed	O
above	O
100	O
bpm	O
.	O
Programmed	O
atrial	O
pacing	O
increasing	O
rates	O
and	O
extrastimulus	O
test	O
with	O
two	O
cycles	O
and	O
up	O
to	O
three	O
ES	O
did	O
not	O
induce	O
significant	O
arrhythmias	O
.	O
Right	O
and	O
left	O
carotid	O
sinus	O
massage	O
CSM	O
did	O
not	O
induce	O
significant	O
block	O
or	O
pauses	O
,	O
nor	O
significant	O
fall	O
in	O
blood	O
pressure	O
BP	O
.	O
Procainamide	B-FARMACO
perfusion	O
10	O
mg	O
kg	O
over	O
10	O
min	O
did	O
not	O
induce	O
significant	O
lengthening	O
of	O
the	O
HV	O
interval	O
.	O
Implantable	O
Holter	O
episode	O
of	O
asystole	O
preceded	O
by	O
polymorphic	O
ventricular	O
tachycardia	O
triggered	O
by	O
ventricular	O
extrasystole	O
with	O
T	O
wave	O
coupling	O
.	O
Coronary	O
angiography	O
no	O
significant	O
angiographic	O
lesions	O
were	O
observed	O
.	O
Flecainide	O
test	O
administration	O
of	O
2	O
mg	O
kg	O
iv	O
flecainide	B-FARMACO
produces	O
an	O
increase	O
in	O
J	O
point	O
elevation	O
of	O
2	O
to	O
4	O
mV	O
without	O
exhibiting	O
typical	O
Brugada	O
type	O
1	O
pattern	O
,	O
so	O
it	O
cannot	O
be	O
considered	O
positive	O
.	O
Genetic	O
testing	O
for	O
sudden	O
death	O
no	O
clinically	O
relevant	O
variants	O
have	O
been	O
identified	O
.	O
CLINICAL	O
EVOLUTION	O
As	O
this	O
was	O
a	O
63	O
year	O
old	O
patient	O
with	O
repeated	O
syncope	O
suggestive	O
of	O
cardiogenic	O
origin	O
,	O
it	O
was	O
decided	O
to	O
admit	O
him	O
to	O
the	O
cardiology	O
department	O
to	O
complete	O
the	O
stiological	O
study	O
.	O
Cardiac	O
imaging	O
studies	O
were	O
performed	O
with	O
transthoracic	O
echocardiography	O
and	O
CMR	O
,	O
which	O
showed	O
no	O
structural	O
alterations	O
.	O
During	O
her	O
hospital	O
stay	O
she	O
did	O
not	O
present	O
arrhythmic	O
events	O
on	O
continuous	O
monitoring	O
.	O
A	O
cranial	O
CT	O
scan	O
was	O
performed	O
,	O
which	O
showed	O
no	O
significant	O
alterations	O
.	O
In	O
addition	O
,	O
as	O
she	O
presented	O
complete	O
right	O
bundle	O
branch	O
block	O
image	O
1	O
,	O
it	O
was	O
decided	O
to	O
complete	O
the	O
aetiological	O
study	O
with	O
an	O
electrophysiological	O
study	O
and	O
carotid	O
sinus	O
massage	O
,	O
which	O
did	O
not	O
prove	O
the	O
cause	O
of	O
the	O
syncope	O
.	O
Finally	O
,	O
given	O
the	O
high	O
suspicion	O
of	O
cardiogenic	O
origin	O
,	O
it	O
was	O
decided	O
to	O
implant	O
a	O
subcutaneous	O
Holter	O
Reveal	O
for	O
continuous	O
ambulatory	O
monitoring	O
.	O
During	O
review	O
of	O
the	O
monitoring	O
alerts	O
,	O
a	O
tracing	O
was	O
detected	O
.	O
The	O
patient	O
was	O
notified	O
to	O
interrogate	O
the	O
subcutaneous	O
Holter	O
Reveal	O
,	O
which	O
revealed	O
an	O
episode	O
of	O
ventricular	O
fibrillation	O
and	O
subsequent	O
asystole	O
triggered	O
by	O
ventricular	O
extrasystole	O
with	O
T	O
wave	O
coupling	O
.	O
The	O
patient	O
reported	O
that	O
he	O
had	O
suffered	O
a	O
syncopal	O
episode	O
of	O
identical	O
characteristics	O
to	O
the	O
previous	O
ones	O
.	O
Given	O
the	O
morphology	O
of	O
the	O
QRS	O
in	O
the	O
baseline	O
ECG	O
,	O
a	O
flecainide	O
test	O
was	O
performed	O
with	O
an	O
increase	O
in	O
the	O
J	O
point	O
in	O
V1	O
and	O
V2	O
without	O
exhibiting	O
a	O
typical	O
Brugada	O
pattern	O
.	O
Following	O
the	O
indications	O
of	O
the	O
clinical	O
practice	O
guidelines	O
on	O
sudden	O
death	O
and	O
ventricular	O
tachycardia	O
,	O
coronary	O
angiography	O
was	O
requested	O
,	O
which	O
showed	O
no	O
significant	O
lesions	O
.	O
Genetic	O
testing	O
was	O
requested	O
for	O
the	O
study	O
of	O
sudden	O
death	O
without	O
structural	O
heart	O
disease	O
,	O
including	O
the	O
genes	O
most	O
frequently	O
associated	O
with	O
Brugada	O
syndrome	O
and	O
catecholaminergic	O
ventricular	O
tachycardia	O
,	O
but	O
no	O
clinically	O
relevant	O
variants	O
were	O
identified	O
.	O
In	O
view	O
of	O
the	O
repeated	O
syncope	O
and	O
the	O
finding	O
of	O
polymorphic	O
ventricular	O
tachycardia	O
and	O
ventricular	O
fibrillation	O
,	O
implantable	O
cardioverter	O
defibrillator	O
ICD	O
implantation	O
was	O
decided	O
for	O
secondary	O
prevention	O
.	O
Subsequently	O
,	O
during	O
follow	O
up	O
in	O
outpatient	O
clinics	O
,	O
on	O
performing	O
a	O
detailed	O
and	O
directed	O
family	O
tree	O
,	O
it	O
was	O
found	O
that	O
the	O
paternal	O
grandfather	O
had	O
sudden	O
death	O
at	O
the	O
age	O
of	O
56	O
and	O
that	O
one	O
of	O
his	O
paternal	O
uncles	O
had	O
been	O
diagnosed	O
with	O
Brugada	O
syndrome	O
after	O
sudden	O
death	O
had	O
been	O
recovered	O
with	O
negative	O
genetics	O
,	O
but	O
with	O
a	O
type	O
1	O
pattern	O
.	O
DIAGNOSIS	O
Repeated	O
cardiogenic	O
syncope	O
in	O
the	O
context	O
of	O
ventricular	O
fibrillation	O
due	O
to	O
probable	O
Brugada	O
syndrome	O
.	O
ICD	O
implantation	O
for	O
secondary	O
prevention	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
26	O
year	O
old	O
male	O
admitted	O
for	O
chest	O
pain	O
and	O
elevated	O
markers	O
of	O
myocardial	O
damage	O
.	O
PERSONAL	O
HISTORY	O
Baseline	O
native	O
of	O
Colombia	O
.	O
Resident	O
in	O
Spain	O
for	O
the	O
last	O
month	O
.	O
Works	O
as	O
a	O
gardener	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
No	O
cardiovascular	O
risk	O
factors	O
.	O
No	O
toxic	O
habits	O
.	O
No	O
personal	O
or	O
family	O
cardiological	O
history	O
.	O
Surgical	O
interventions	O
splenectomy	O
after	O
traffic	O
accident	O
.	O
Previous	O
medication	O
none	O
.	O
CURRENT	O
DISEASE	O
Asymptomatic	O
patient	O
from	O
the	O
cardiovascular	O
point	O
of	O
view	O
,	O
who	O
two	O
weeks	O
before	O
admission	O
started	O
episodes	O
of	O
oppressive	O
central	O
thoracic	O
pain	O
radiating	O
to	O
both	O
jaws	O
,	O
unrelated	O
to	O
exercise	O
or	O
respiratory	O
movements	O
.	O
No	O
vegetative	O
cortex	O
associated	O
.	O
Self	O
limited	O
cessation	O
of	O
these	O
episodes	O
within	O
a	O
few	O
minutes	O
.	O
She	O
also	O
reported	O
non	O
specific	O
dizziness	O
and	O
occasional	O
dystrophic	O
sensation	O
,	O
without	O
thermometric	O
fever	O
.	O
No	O
palpitations	O
,	O
dyspnoea	O
or	O
syncopal	O
symptoms	O
.	O
She	O
denied	O
previous	O
infectious	O
symptoms	O
.	O
PHYSICAL	O
EXAMINATION	O
Afebrile	O
,	O
blood	O
pressure	O
106	O
62	O
mmHg	O
,	O
heart	O
rate	O
60	O
bpm	O
,	O
baseline	O
O2	O
saturation	O
98	O
,	O
referred	O
weight	O
70	O
kg	O
.	O
Conscious	O
,	O
oriented	O
and	O
cooperative	O
.	O
Well	O
hydrated	O
and	O
perfused	O
.	O
Good	O
general	O
condition	O
.	O
Eupneic	O
at	O
rest	O
.	O
Jugular	O
venous	O
pressure	O
normal	O
.	O
No	O
palpable	O
lymph	O
nodes	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
without	O
murmurs	O
or	O
rubbing	O
.	O
Pulmonary	O
auscultation	O
respiratory	O
sounds	O
were	O
preserved	O
with	O
no	O
over	O
additions	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
and	O
non	O
painful	O
.	O
No	O
masses	O
or	O
megaliths	O
palpable	O
.	O
Peristalsis	O
present	O
.	O
Lower	O
extremities	O
no	O
oedema	O
.	O
Distal	O
pulses	O
present	O
and	O
symmetrical	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
sinus	O
bradycardia	O
at	O
50	O
bpm	O
.	O
Normal	O
PR	O
.	O
Narrow	O
QRS	O
.	O
Q	O
wave	O
at	O
the	O
limit	O
of	O
pathological	O
significance	O
and	O
ST	O
elevation	O
0	O
.	O
5	O
mm	O
in	O
the	O
inferior	O
face	O
.	O
Laboratory	O
tests	O
on	O
admission	O
haemoglobin	O
15	O
g	O
dl	O
,	O
platelets	O
350	O
.	O
000	O
u	O
mm3	O
,	O
leukocytes	O
11	O
.	O
3	O
x103	O
mm3	O
neutrophils	O
33	O
.	O
4	O
3790	O
u	O
l	O
,	O
lymphocytes	O
31	O
.	O
4	O
3560	O
u	O
l	O
,	O
eosinophils	O
27	O
.	O
7	O
3150	O
u	O
l	O
,	O
basal	O
glucose	O
81	O
mg	O
dl	O
,	O
urea	O
23	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
79	O
mg	O
dl	O
,	O
sodium	O
131	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
2	O
mEq	O
l	O
,	O
conventional	O
troponin	O
I	O
2	O
.	O
7	O
ng	O
dl	O
normal	O
0	O
.	O
01	O
.	O
Chest	O
X	O
ray	O
normal	O
cardio	O
thoracic	O
index	O
.	O
No	O
acute	O
pleuroparenchymal	O
lesions	O
.	O
Transthoracic	O
echocardiogram	O
non	O
dilated	O
left	O
ventricle	O
,	O
normal	O
thickness	O
,	O
no	O
alterations	O
in	O
segmental	O
contractility	O
.	O
Normal	O
systolic	O
function	O
biplane	O
Simpson	O
LVEF	O
65	O
.	O
Hyperechogenic	O
appearance	O
of	O
the	O
inferolateral	O
wall	O
myocardium	O
respecting	O
the	O
endocardium	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
with	O
preserved	O
systolic	O
function	O
.	O
Mitral	O
valve	O
of	O
normal	O
appearance	O
and	O
function	O
.	O
Trivalve	O
aortic	O
valve	O
,	O
without	O
insufficiency	O
or	O
stenosis	O
.	O
Tricuspid	O
valve	O
of	O
normal	O
appearance	O
,	O
with	O
minimal	O
insufficiency	O
.	O
Normal	O
functioning	O
pulmonary	O
valve	O
.	O
Aortic	O
root	O
of	O
normal	O
size	O
,	O
no	O
coarctation	O
.	O
No	O
pericardial	O
effusion	O
.	O
Cardio	O
MRI	O
ventricles	O
of	O
preserved	O
size	O
and	O
function	O
.	O
Hypokinesia	O
,	O
oedema	O
and	O
late	O
intramyocardial	O
enhancement	O
of	O
subepicardial	O
predominance	O
in	O
the	O
inferolateral	O
face	O
are	O
observed	O
;	O
findings	O
that	O
may	O
be	O
related	O
to	O
myocarditis	O
in	O
the	O
appropriate	O
clinical	O
context	O
.	O
CT	O
of	O
coronary	O
arteries	O
total	O
calcium	O
score	O
according	O
to	O
Agatson	O
index	O
0	O
.	O
Coronary	O
arteries	O
without	O
anatomical	O
variants	O
,	O
with	O
preserved	O
patency	O
,	O
without	O
thrombotic	O
or	O
stenotic	O
images	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
coronary	O
unit	O
for	O
monitoring	O
and	O
further	O
complementary	O
tests	O
.	O
As	O
a	O
specific	O
cardiological	O
test	O
,	O
a	O
transthoracic	O
echocardiogram	O
was	O
performed	O
,	O
which	O
was	O
normal	O
,	O
followed	O
by	O
cardiac	O
magnetic	O
resonance	O
imaging	O
CMR	O
,	O
which	O
was	O
found	O
to	O
be	O
compatible	O
with	O
myocarditis	O
.	O
After	O
48	O
hours	O
without	O
development	O
of	O
arrhythmic	O
complications	O
or	O
heart	O
failure	O
,	O
he	O
was	O
transferred	O
to	O
the	O
hospital	O
ward	O
for	O
further	O
care	O
and	O
to	O
complete	O
studies	O
.	O
The	O
analysis	O
on	O
admission	O
showed	O
leukocytosis	O
due	O
to	O
marked	O
eosinophilia	O
that	O
persisted	O
in	O
subsequent	O
analyses	O
,	O
so	O
an	O
assessment	O
was	O
requested	O
by	O
internal	O
medicine	O
,	O
which	O
expanded	O
the	O
battery	O
of	O
tests	O
with	O
autoimmunity	O
,	O
virus	O
and	O
infectious	O
serology	O
,	O
which	O
was	O
positive	O
for	O
IgM	O
Toxocara	O
spp	O
.	O
Subsequently	O
,	O
a	O
CT	O
scan	O
of	O
the	O
coronary	O
arteries	O
was	O
requested	O
to	O
rule	O
out	O
embolisms	O
,	O
which	O
was	O
also	O
normal	O
.	O
Suspicion	O
of	O
eosinophilic	O
myocarditis	O
secondary	O
to	O
Toxocara	O
parasite	O
infection	O
led	O
to	O
treatment	O
with	O
albendazole	B-FARMACO
.	O
The	O
patient	O
had	O
a	O
good	O
clinical	O
evolution	O
and	O
was	O
discharged	O
from	O
hospital	O
after	O
7	O
days	O
asymptomatic	O
,	O
with	O
normalisation	O
of	O
myocardial	O
damage	O
markers	O
and	O
decreasing	O
eosinophilia	O
.	O
DIAGNOSIS	O
Eosinophilic	O
myocarditis	O
in	O
the	O
context	O
of	O
toxocariasis	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
49	O
year	O
old	O
woman	O
,	O
under	O
cardiology	O
control	O
since	O
admission	O
in	O
2015	O
.	O
BACKGROUND	O
Family	O
history	O
father	O
with	O
infarction	O
at	O
52	O
years	O
of	O
age	O
and	O
mother	O
with	O
ischaemic	O
heart	O
disease	O
from	O
70	O
years	O
of	O
age	O
.	O
No	O
known	O
allergies	O
.	O
No	O
toxic	O
habits	O
,	O
no	O
arterial	O
hypertension	O
AHT	O
or	O
diabetes	O
mellitus	O
DM	O
.	O
Obesity	O
in	O
2015	O
,	O
weight	O
85	O
kg	O
and	O
height	O
165	O
cm	O
,	O
representing	O
a	O
body	O
mass	O
index	O
BMI	O
of	O
31	O
kg	O
m2	O
.	O
Hypercholesterolaemia	O
diagnosed	O
on	O
admission	O
in	O
2015	O
total	O
cholesterol	O
271	O
mg	O
dl	O
,	O
triglycerides	O
184	O
mg	O
dl	O
,	O
high	O
density	O
lipoprotein	O
cholesterol	O
HDL	O
C	O
36	O
mg	O
dl	O
,	O
low	O
density	O
lipoprotein	O
cholesterol	O
LDL	O
C	O
calculated	O
198	O
mg	O
dl	O
.	O
No	O
treatment	O
prior	O
to	O
admission	O
.	O
Cardiological	O
history	O
admission	O
in	O
June	O
2015	O
for	O
acute	O
myocardial	O
infarction	O
with	O
ST	O
elevation	O
STEMI	O
of	O
lateral	O
location	O
.	O
Cardiac	O
catheterisation	O
showed	O
single	O
vessel	O
coronary	O
artery	O
disease	O
,	O
with	O
thrombotic	O
occlusion	O
of	O
the	O
first	O
diagonal	O
,	O
on	O
which	O
percutaneous	O
coronary	O
intervention	O
PCI	O
was	O
performed	O
with	O
drug	O
eluting	O
stent	O
and	O
intermediate	O
stenosis	O
in	O
the	O
middle	O
anterior	O
descending	O
artery	O
LAD	O
FFR	O
0	O
.	O
8	O
videos	O
1	O
3	O
.	O
Echocardiogram	O
showed	O
akinesia	O
in	O
the	O
middle	O
and	O
apical	O
segments	O
of	O
the	O
anterior	O
septum	O
and	O
anterior	O
face	O
,	O
with	O
overall	O
left	O
ventricular	O
LV	O
systolic	O
function	O
of	O
65	O
.	O
He	O
continued	O
the	O
cardiac	O
rehabilitation	O
programme	O
until	O
November	O
2015	O
.	O
CURRENT	O
DISEASE	O
Monitored	O
in	O
cardiology	O
consultation	O
since	O
the	O
end	O
of	O
2016	O
.	O
On	O
treatment	O
with	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
100	O
mg	O
day	O
discontinued	O
ticagrelor	B-FARMACO
one	O
year	O
after	O
acute	O
myocardial	O
infarction	O
AMI	O
,	O
bisoprolol	B-FARMACO
25	O
mg	O
day	O
,	O
losartan	B-FARMACO
50	O
mg	O
day	O
presented	O
cough	O
with	O
ramipril	B-FARMACO
,	O
omeprazole	B-FARMACO
20	O
mg	O
day	O
,	O
atorvastatin	B-FARMACO
80	O
mg	O
day	O
.	O
In	O
the	O
blood	O
test	O
in	O
November	O
2016	O
,	O
LDL	O
C	O
levels	O
of	O
160	O
mg	O
dL	O
persisted	O
,	O
well	O
above	O
the	O
target	O
,	O
so	O
ezetimibe	B-FARMACO
10	O
mg	O
day	O
was	O
associated	O
,	O
with	O
a	O
new	O
control	O
after	O
3	O
months	O
the	O
results	O
and	O
therapeutic	O
strategy	O
will	O
be	O
discussed	O
in	O
the	O
section	O
on	O
clinical	O
course	O
.	O
In	O
August	O
2017	O
,	O
she	O
reported	O
retrosternal	O
discomfort	O
that	O
she	O
described	O
as	O
"	O
burning	O
"	O
unrelated	O
to	O
exertion	O
,	O
although	O
she	O
commented	O
that	O
she	O
had	O
worse	O
tolerance	O
to	O
physical	O
exercise	O
.	O
He	O
acknowledges	O
that	O
he	O
leads	O
a	O
more	O
sedentary	O
life	O
.	O
No	O
significant	O
alterations	O
in	O
the	O
electrocardiogram	O
ECG	O
image	O
1	O
.	O
The	O
echocardiographic	O
window	O
is	O
not	O
adequate	O
for	O
stress	O
echocardiography	O
and	O
stress	O
single	O
photon	O
emission	O
tomography	O
SPECT	O
is	O
requested	O
.	O
At	O
the	O
last	O
review	O
,	O
in	O
December	O
2017	O
,	O
she	O
was	O
cardiologically	O
asymptomatic	O
.	O
The	O
burning	O
discomfort	O
has	O
disappeared	O
after	O
her	O
primary	O
care	O
physician	O
switched	O
her	O
from	O
omeprazole	B-FARMACO
to	O
esomeprazole	B-FARMACO
.	O
She	O
exercises	O
regularly	O
and	O
has	O
lost	O
5	O
kg	O
since	O
August	O
2017	O
.	O
PHYSICAL	O
EXAMINATION	O
Good	O
general	O
condition	O
.	O
Weight	O
75	O
kg	O
,	O
height	O
165	O
cm	O
.	O
Abdominal	O
waist	O
95	O
cm	O
.	O
Blood	O
pressure	O
BP	O
140	O
67	O
mmHg	O
.	O
No	O
corneal	O
arc	O
,	O
no	O
tendon	O
xanthomas	O
on	O
inspection	O
.	O
Cardiopulmonary	O
auscultation	O
ventilation	O
preserved	O
.	O
RsCsRs	O
at	O
70	O
beats	O
min	O
,	O
no	O
murmurs	O
or	O
extratonos	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
without	O
masses	O
or	O
visceromegaly	O
.	O
Peripheral	O
pulses	O
present	O
,	O
no	O
oedema	O
.	O
COMPLEMENTARY	O
TESTS	O
CARDIAC	O
CATHETERISM	O
on	O
admission	O
in	O
2015	O
thrombotic	O
occlusion	O
of	O
the	O
first	O
diagonal	O
of	O
great	O
development	O
.	O
Percutaneous	O
transluminal	O
coronary	O
angioplasty	O
PTCA	O
and	O
drug	O
eluting	O
stent	O
implantation	O
.	O
Intermediate	O
lesion	O
in	O
the	O
middle	O
anterior	O
descending	O
artery	O
AD	O
assessed	O
at	O
a	O
second	O
time	O
FFR	O
0	O
.	O
96	O
and	O
0	O
.	O
89	O
at	O
distal	O
level	O
.	O
Right	O
coronary	O
artery	O
without	O
significant	O
stenosis	O
.	O
ANALYTICS	O
in	O
February	O
2017	O
blood	O
count	O
without	O
alterations	O
.	O
Glycaemia	O
92	O
mg	O
dl	O
.	O
glycohaemoglobin	O
HbA1c	O
5	O
.	O
5	O
.	O
GFR	O
90	O
ml	O
min	O
.	O
Normal	O
liver	O
tests	O
.	O
Total	O
cholesterol	O
226	O
mg	O
dl	O
,	O
HDLc	O
38	O
mg	O
dl	O
,	O
triglycerides	O
170	O
mg	O
dl	O
,	O
LDLc	O
144	O
mg	O
dl	O
.	O
ECG	O
August	O
2017	O
image	O
1	O
sinus	O
rhythm	O
at	O
77	O
bpm	O
,	O
poor	O
R	O
wave	O
progression	O
in	O
right	O
precordial	O
leads	O
with	O
flattened	O
ST	O
unchanged	O
from	O
previous	O
.	O
EFFORT	O
SPECT	O
in	O
August	O
2017	O
image	O
2	O
exercise	O
stress	O
test	O
according	O
to	O
Bruce	O
protocol	O
.	O
Baseline	O
heart	O
rate	O
HR	O
68	O
bpm	O
,	O
BP	O
122	O
85	O
mmHg	O
.	O
Suspended	O
at	O
6	O
30	O
min	O
for	O
reaching	O
targets	O
HR	O
155	O
bpm	O
90	O
FHRT	O
and	O
BP	O
165	O
90	O
mmHg	O
.	O
No	O
angina	O
.	O
Dyspnoea	O
at	O
maximum	O
effort	O
.	O
No	O
ECG	O
changes	O
.	O
Postexercise	O
tomographic	O
images	O
show	O
a	O
severe	O
fixed	O
anteroapical	O
perfusion	O
defect	O
,	O
without	O
reperfusion	O
on	O
rest	O
images	O
.	O
LV	O
systolic	O
function	O
by	O
gated	O
SPECT	O
56	O
,	O
anterior	O
hypokinesia	O
.	O
CLINICAL	O
COURSE	O
Young	O
woman	O
at	O
the	O
onset	O
of	O
her	O
coronary	O
artery	O
disease	O
46	O
years	O
old	O
,	O
premenopausal	O
with	O
unknown	O
history	O
of	O
hypercholesterolemia	O
,	O
probably	O
familial	O
.	O
After	O
admission	O
for	O
AMI	O
,	O
optimal	O
medical	O
treatment	O
was	O
prescribed	O
,	O
including	O
high	O
dose	O
statin	B-FARMACO
and	O
she	O
was	O
referred	O
to	O
a	O
cardiac	O
rehabilitation	O
programme	O
.	O
Subsequent	O
follow	O
up	O
in	O
consultation	O
detected	O
LDL	O
C	O
levels	O
well	O
above	O
target	O
70	O
mg	O
dl	O
,	O
so	O
it	O
was	O
decided	O
to	O
add	O
ezetimibe	B-FARMACO
to	O
the	O
atorvastatin	B-FARMACO
80	O
mg	O
she	O
had	O
been	O
taking	O
since	O
admission	O
,	O
before	O
considering	O
treatment	O
with	O
proprotein	O
convertase	O
subtilisin	O
kexin	O
type	O
9	O
iPCSK9	B-FARMACO
inhibitors	O
which	O
had	O
been	O
available	O
for	O
a	O
very	O
short	O
time	O
.	O
After	O
3	O
months	O
February	O
2017	O
,	O
LDL	O
C	O
was	O
144	O
mg	O
dL	O
,	O
so	O
evolocumab	B-FARMACO
140	O
mg	O
2	O
weeks	O
was	O
added	O
to	O
treatment	O
in	O
March	O
2017	O
.	O
Monthly	O
controls	O
during	O
the	O
following	O
3	O
months	O
were	O
April	O
2017	O
total	O
cholesterol	O
90	O
mg	O
dl	O
,	O
HDLc36	O
mg	O
dl	O
,	O
LDLc	O
37	O
mg	O
dl	O
.	O
May	O
2017	O
total	O
cholesterol	O
73	O
mg	O
dl	O
,	O
HDL	O
C	O
42	O
mg	O
dl	O
,	O
LDL	O
C	O
19	O
mg	O
dl	O
.	O
Ezetimibe	B-FARMACO
is	O
withdrawn	O
.	O
June	O
2017	O
total	O
cholesterol	O
99	O
mg	O
dl	O
,	O
HDL	O
C	O
34	O
mg	O
dl	O
,	O
LDL	O
C	O
47	O
mg	O
dl	O
.	O
And	O
the	O
following	O
LDL	O
C	O
values	O
48	O
mg	O
dl	O
September	O
2017	O
;	O
60	O
mg	O
dl	O
December	O
2017	O
;	O
65	O
mg	O
dl	O
March	O
2018	O
.	O
She	O
has	O
had	O
no	O
adverse	O
effects	O
related	O
to	O
lipid	O
lowering	O
therapy	O
.	O
Blood	O
glucose	O
levels	O
100	O
mg	O
dl	O
;	O
HbA1c	O
5	O
.	O
6	O
,	O
estimated	O
glomerular	O
filtration	O
rate	O
eGFR	O
90	O
ml	O
min	O
and	O
normal	O
liver	O
tests	O
are	O
maintained	O
.	O
The	O
SPECT	O
scan	O
performed	O
to	O
rule	O
out	O
coronary	O
origin	O
of	O
the	O
chest	O
discomfort	O
showed	O
an	O
area	O
of	O
necrosis	O
without	O
inducible	O
ischaemia	O
.	O
Exercise	O
tolerance	O
improved	O
by	O
resuming	O
regular	O
physical	O
activity	O
and	O
it	O
was	O
concluded	O
that	O
the	O
symptoms	O
were	O
of	O
digestive	O
origin	O
.	O
DIAGNOSIS	O
Chronic	O
ischaemic	O
heart	O
disease	O
.	O
AMI	O
in	O
2015	O
,	O
single	O
vessel	O
coronary	O
artery	O
disease	O
first	O
diagonal	O
with	O
complete	O
revascularisation	O
.	O
Moderate	O
stenosis	O
in	O
the	O
middle	O
LAD	O
.	O
Preserved	O
LV	O
ventricular	O
systolic	O
function	O
.	O
Current	O
functional	O
class	O
I	O
.	O
Hypercholesterolemia	O
difficult	O
to	O
control	O
.	O

BACKGROUND	O
Family	O
history	O
father	O
and	O
one	O
brother	O
disease	O
with	O
early	O
coronary	O
heart	O
disease	O
55	O
years	O
and	O
hypercholesterolemia	O
.	O
Non	O
smoker	O
.	O
No	O
arterial	O
hypertension	O
AHT	O
or	O
diabetes	O
mellitus	O
DM	O
.	O
Drinker	O
of	O
two	O
glasses	O
of	O
wine	O
day	O
and	O
a	O
few	O
drinks	O
at	O
weekends	O
.	O
Probable	O
familial	O
hypercholesterolaemia	O
.	O
In	O
2004	O
.	O
Total	O
cholesterol	O
326	O
mg	O
dl	O
,	O
triglycerides	O
102	O
mg	O
dl	O
,	O
high	O
density	O
lipoprotein	O
cholesterol	O
HDL	O
C	O
65	O
mg	O
dl	O
,	O
low	O
density	O
lipoprotein	O
cholesterol	O
LDL	O
C	O
245	O
mg	O
dl	O
.	O
Intolerance	O
to	O
atorvastatin	B-FARMACO
10	O
mg	O
alteration	O
of	O
liver	O
tests	O
in	O
2009	O
GOT	O
366	O
U	O
L	O
;	O
GPT	O
981	O
U	O
L	O
;	O
GGT	O
699	O
U	O
L	O
,	O
normalised	O
after	O
discontinuation	O
of	O
statin	B-FARMACO
.	O
Liver	O
ultrasound	O
with	O
no	O
alterations	O
.	O
Fatty	O
liver	O
slight	O
elevation	O
of	O
GGT	O
and	O
ultrasound	O
in	O
2016	O
.	O
CURRENT	O
ILLNESS	O
February	O
2018	O
consultation	O
for	O
having	O
presented	O
with	O
diffuse	O
chest	O
pain	O
the	O
previous	O
day	O
,	O
oppressive	O
,	O
after	O
climbing	O
a	O
steep	O
slope	O
,	O
lasting	O
approximately	O
5	O
minutes	O
,	O
which	O
subsided	O
after	O
stopping	O
the	O
effort	O
.	O
In	O
the	O
last	O
6	O
months	O
,	O
more	O
sedentary	O
lifestyle	O
;	O
previously	O
well	O
tolerated	O
physical	O
exercise	O
.	O
PHYSICAL	O
EXAMINATION	O
Good	O
general	O
condition	O
,	O
blood	O
pressure	O
BP	O
137	O
80	O
mmHg	O
,	O
height	O
171	O
,	O
weight	O
76	O
,	O
body	O
mass	O
index	O
BMI	O
26	O
,	O
head	O
and	O
neck	O
without	O
alterations	O
.	O
Cardiopulmonary	O
auscultation	O
normal	O
.	O
Abdomen	O
and	O
extremities	O
normal	O
.	O
No	O
corneal	O
arcus	O
,	O
xanthomas	O
or	O
xanthelasmas	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
sinus	O
rhythm	O
80	O
per	O
min	O
,	O
incomplete	O
right	O
bundle	O
branch	O
block	O
,	O
without	O
repolarisation	O
alterations	O
.	O
Laboratory	O
tests	O
ED	O
haemoglobin	O
15	O
.	O
6	O
g	O
dl	O
,	O
leucocytes	O
7410	O
,	O
platelets	O
200	O
,	O
000	O
,	O
glucose	O
108	O
mg	O
dl	O
not	O
basal	O
,	O
creatinine	O
0	O
.	O
91	O
mg	O
d	O
,	O
sodium	O
144	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
5	O
mEq	O
l	O
,	O
transaminases	O
GOT	O
and	O
GPT	O
normal	O
,	O
gamma	O
glutamyltransferase	O
GGT	O
85	O
U	O
L	O
,	O
troponin	O
I	O
negative	O
.	O
ANALYTICS	O
fasting	O
glucose	O
95	O
mg	O
dl	O
,	O
glycohaemoglobin	O
HbA1c	O
5	O
.	O
4	O
,	O
FGE	O
90	O
ml	O
min	O
,	O
total	O
cholesterol	O
267	O
mg	O
dl	O
,	O
high	O
density	O
lipoprotein	O
cholesterol	O
HDL	O
C	O
54	O
mg	O
dl	O
,	O
triglycerides	O
115	O
mg	O
dl	O
,	O
low	O
density	O
lipoprotein	O
cholesterol	O
LDL	O
C	O
190	O
mg	O
dl	O
.	O
ECOCARDIOGRAM	O
cardiac	O
cavities	O
of	O
normal	O
dimensions	O
.	O
Global	O
and	O
segmental	O
systolic	O
function	O
of	O
the	O
left	O
ventricle	O
without	O
alterations	O
.	O
No	O
valvulopathies	O
,	O
short	O
circuits	O
or	O
pericardial	O
effusion	O
.	O
ERGOMETRY	O
Bruce	O
protocol	O
,	O
basal	O
heart	O
rate	O
HR	O
70	O
bpm	O
,	O
BP	O
135	O
70	O
mmHg	O
.	O
Suspended	O
at	O
10	O
.	O
30	O
minutes	O
.	O
HR	O
178	O
bpm	O
and	O
BP	O
175	O
80	O
mmHg	O
.	O
Clinical	O
and	O
ECG	O
negative	O
.	O
12	O
metabolic	O
equivalents	O
METs	O
image	O
2	O
.	O
CORONARY	O
ANGIO	O
CT	O
after	O
administration	O
of	O
atenolol	B-FARMACO
iv	O
,	O
sinus	O
rhythm	O
62	O
per	O
min	O
,	O
acceptable	O
quality	O
of	O
the	O
study	O
,	O
with	O
very	O
slight	O
step	O
artifacts	O
.	O
Origin	O
and	O
course	O
of	O
the	O
coronary	O
arteries	O
normal	O
.	O
Left	O
coronary	O
trunk	O
15	O
mm	O
without	O
stenosis	O
or	O
calcifications	O
,	O
anterior	O
descending	O
artery	O
,	O
after	O
the	O
origin	O
of	O
a	O
large	O
first	O
diagonal	O
presents	O
a	O
moderate	O
stenosis	O
50	O
75	O
concentric	O
,	O
without	O
calcified	O
plaque	O
,	O
in	O
the	O
middle	O
segment	O
of	O
about	O
10	O
mm	O
.	O
Circumflex	O
artery	O
hypoplastic	O
,	O
with	O
a	O
slight	O
non	O
calcified	O
lesion	O
at	O
its	O
origin	O
50	O
.	O
Intermediate	O
branch	O
of	O
small	O
development	O
.	O
Dominant	O
right	O
coronary	O
artery	O
,	O
without	O
significant	O
stenosis	O
or	O
calcifications	O
,	O
originating	O
a	O
large	O
posterolateral	O
branch	O
with	O
a	O
mild	O
,	O
non	O
calcified	O
stenosis	O
50	O
at	O
its	O
origin	O
.	O
CLINICAL	O
EVOLUTION	O
Patient	O
with	O
a	O
family	O
history	O
of	O
early	O
coronary	O
heart	O
disease	O
and	O
suspected	O
familial	O
hypercholesterolemia	O
,	O
asymptomatic	O
from	O
the	O
cardiological	O
point	O
of	O
view	O
until	O
the	O
current	O
episode	O
,	O
highly	O
suggestive	O
of	O
exertional	O
angina	O
.	O
Years	O
earlier	O
he	O
had	O
received	O
treatment	O
with	O
statins	O
,	O
initially	O
simvastatin	B-FARMACO
20	O
,	O
but	O
this	O
was	O
replaced	O
due	O
to	O
ineffectiveness	O
LDL	O
C	O
180	O
mg	O
d	O
by	O
atorvastatin	B-FARMACO
10	O
,	O
which	O
had	O
to	O
be	O
discontinued	O
due	O
to	O
liver	O
damage	O
,	O
reversible	O
when	O
treatment	O
was	O
discontinued	O
.	O
This	O
occurred	O
in	O
2009	O
at	O
that	O
time	O
he	O
had	O
dropped	O
to	O
LDL	O
129	O
mg	O
dl	O
.	O
Since	O
then	O
,	O
without	O
lipid	O
lowering	O
treatment	O
,	O
he	O
has	O
maintained	O
LDL	O
C	O
levels	O
between	O
180	O
and	O
250	O
mg	O
dl	O
.	O
Currently	O
,	O
she	O
consulted	O
for	O
a	O
single	O
chest	O
pain	O
related	O
to	O
greater	O
than	O
usual	O
exertion	O
;	O
an	O
acute	O
event	O
was	O
ruled	O
out	O
and	O
exercise	O
testing	O
was	O
performed	O
,	O
which	O
was	O
negative	O
for	O
12	O
METs	O
,	O
but	O
due	O
to	O
the	O
likelihood	O
of	O
coronary	O
disease	O
typical	O
symptoms	O
,	O
family	O
history	O
and	O
hypercholesterolemia	O
maintained	O
for	O
many	O
years	O
,	O
coronary	O
angio	O
CT	O
was	O
requested	O
,	O
which	O
showed	O
several	O
non	O
significant	O
stenoses	O
in	O
the	O
coronary	O
tree	O
.	O
In	O
view	O
of	O
these	O
results	O
,	O
antiplatelet	O
treatment	O
was	O
started	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
mg	O
,	O
beta	B-FARMACO
blockers	I-FARMACO
bisoprolol	I-FARMACO
2	O
.	O
5	O
mg	O
and	O
ramipril	B-FARMACO
2	O
.	O
5	O
mg	O
,	O
in	O
addition	O
to	O
lipid	O
lowering	O
treatment	O
in	O
this	O
case	O
with	O
a	O
proprotein	O
convertase	O
subtilisin	O
kexin	O
type	O
9	O
iPCSK9	B-FARMACO
inhibitor	O
evolocumab	B-FARMACO
140	O
mg	O
2	O
weeks	O
due	O
to	O
a	O
history	O
of	O
probable	O
familial	O
hypercholesterolaemia	O
,	O
intolerance	O
to	O
the	O
initial	O
dose	O
of	O
atorvastatin	B-FARMACO
and	O
ineffectiveness	O
with	O
another	O
less	O
potent	O
statin	O
and	O
the	O
presence	O
of	O
coronary	O
heart	O
disease	O
.	O
The	O
patient	O
is	O
currently	O
awaiting	O
the	O
results	O
of	O
a	O
genetic	O
study	O
.	O
DIAGNOSIS	O
Probable	O
familial	O
hypercholesterolemia	O
FH	O
.	O
Intolerance	O
to	O
statins	O
.	O
Exertional	O
angina	O
.	O
Coronary	O
artery	O
disease	O
with	O
non	O
significant	O
stenosis	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
56	O
year	O
old	O
male	O
,	O
no	O
allergies	O
,	O
ex	O
smoker	O
and	O
paranoid	O
schizophrenia	O
treated	O
in	O
the	O
past	O
with	O
ECT	O
and	O
multiple	O
antipsychotics	O
.	O
He	O
was	O
found	O
unconscious	O
by	O
his	O
brother	O
;	O
on	O
arrival	O
of	O
the	O
ambulance	O
he	O
presented	O
blood	O
pressure	O
of	O
60	O
40	O
mmHg	O
with	O
O2	O
saturation	O
of	O
65	O
,	O
temperature	O
34	O
.	O
8	O
C	O
.	O
On	O
auscultation	O
he	O
had	O
crackles	O
and	O
rhonchi	O
in	O
both	O
lung	O
fields	O
.	O
Orotracheal	O
intubation	O
was	O
performed	O
and	O
catecholamine	O
perfusion	O
noradrenaline	B-FARMACO
and	O
adrenaline	B-FARMACO
was	O
started	O
.	O
On	O
arrival	O
at	O
the	O
emergency	O
department	O
,	O
a	O
cardiological	O
assessment	O
was	O
requested	O
for	O
an	O
electrocardiogram	O
ECG	O
suggestive	O
of	O
inferolateral	O
infarction	O
.	O
The	O
ECG	O
showed	O
a	O
nodal	O
rhythm	O
with	O
QRS	O
of	O
120	O
ms	O
and	O
rSR	O
morphology	O
of	O
V2	O
V6	O
with	O
the	O
last	O
R	O
tied	O
to	O
the	O
ST	O
.	O
Echocardioscopy	O
with	O
preserved	O
left	O
ventricular	O
LV	O
function	O
and	O
no	O
segmental	O
alterations	O
.	O
Laboratory	O
tests	O
described	O
in	O
evidence	O
.	O
The	O
chest	O
X	O
ray	O
was	O
compatible	O
with	O
multilobar	O
pneumonia	O
.	O
Cardiology	O
maintained	O
a	O
wait	O
and	O
see	O
attitude	O
,	O
and	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
for	O
treatment	O
of	O
the	O
respiratory	O
infectious	O
process	O
.	O
COMPLEMENTARY	O
TESTS	O
Arrival	O
ECG	O
nodal	O
rhythm	O
with	O
QRS	O
of	O
120	O
ms	O
and	O
rSR	O
morphology	O
of	O
V2	O
V6	O
with	O
the	O
last	O
R	O
tied	O
to	O
the	O
ST	O
.	O
ECG	O
after	O
temperature	O
correction	O
virtual	O
disappearance	O
of	O
Osborn	O
waves	O
,	O
returning	O
to	O
normal	O
sinus	O
rhythm	O
.	O
ANALYSIS	O
haemoglobin	O
14	O
.	O
4	O
g	O
dl	O
,	O
haematocrit	O
41	O
.	O
6	O
,	O
leukocytes	O
1700x10	O
3	O
l	O
,	O
neutrophils	O
93	O
.	O
3	O
,	O
platelets	O
133	O
,	O
000x10	O
3	O
l	O
.	O
Coagulation	O
INR	O
1	O
.	O
61	O
,	O
IQ	O
52	O
,	O
PT	O
17	O
.	O
1	O
,	O
APTT	O
42	O
.	O
9	O
,	O
D	O
dimer	O
708	O
ngr	O
ml	O
.	O
BIOCHEMISTRY	O
glucose	O
163	O
mg	O
dl	O
,	O
urea	O
57	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
39	O
mg	O
dl	O
,	O
GFR	O
MDRD4	O
;	O
60	O
ml	O
min	O
1	O
.	O
73m2	O
,	O
sodium	O
127	O
mm	O
l	O
,	O
potassium	O
4	O
.	O
4	O
mm	O
l	O
,	O
magnesium	O
2	O
.	O
2	O
mm	O
l	O
.	O
Creatine	O
kinase	O
672	O
U	O
L	O
.	O
Lactate	O
2	O
.	O
37	O
mm	O
l	O
.	O
Procalcitonin	O
0	O
.	O
96	O
ng	O
ml	O
.	O
Troponin	O
I	O
0	O
.	O
01	O
ng	O
dl	O
.	O
CK	O
MB	O
mass	O
139	O
.	O
93	O
ng	O
ml	O
.	O
Arterial	O
blood	O
gases	O
pH	O
7	O
.	O
29	O
.	O
pCO2	O
67	O
mmHg	O
.	O
pO2	O
42	O
mmHg	O
.	O
HCO3	O
32	O
.	O
2	O
mm	O
l	O
.	O
Base	O
excess	O
3	O
.	O
36	O
mm	O
l	O
.	O
THORAX	O
RADIOGRAPHY	O
compatible	O
with	O
multilobar	O
pneumonia	O
image	O
2	O
.	O
ECOCARDIOSCOPY	O
non	O
dilated	O
left	O
ventricle	O
with	O
preserved	O
function	O
.	O
No	O
segmental	O
alterations	O
of	O
contractility	O
.	O
No	O
aortic	O
valvulopathy	O
.	O
Minimal	O
mitral	O
insufficiency	O
.	O
Right	O
chambers	O
with	O
normal	O
morphology	O
and	O
function	O
.	O
No	O
intracardiac	O
effusion	O
or	O
masses	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
team	O
of	O
intensivists	O
requested	O
a	O
new	O
assessment	O
of	O
the	O
patient	O
due	O
to	O
doubts	O
about	O
the	O
decision	O
taken	O
by	O
cardiology	O
.	O
After	O
re	O
evaluating	O
the	O
electrocardiograms	O
,	O
a	O
new	O
patient	O
temperature	O
was	O
requested	O
,	O
which	O
was	O
undetectable	O
at	O
the	O
time	O
.	O
The	O
patient	O
was	O
gradually	O
warmed	O
with	O
thermal	O
blankets	O
and	O
warm	O
saline	O
.	O
At	O
32	O
C	O
partial	O
correction	O
of	O
the	O
waves	O
is	O
observed	O
,	O
which	O
disappear	O
completely	O
at	O
36	O
C	O
.	O
A	O
diagnosis	O
of	O
Osborn	O
waves	O
due	O
to	O
hypothermia	O
and	O
acidosis	O
was	O
made	O
.	O
The	O
patient	O
finally	O
died	O
of	O
respiratory	O
failure	O
.	O
DIAGNOSIS	O
Community	O
acquired	O
multilobar	O
pneumonia	O
.	O
Acute	O
respiratory	O
failure	O
.	O
Hypothermia	O
and	O
acidosis	O
,	O
with	O
Osborn	O
waves	O
on	O
electrocardiogram	O
.	O
Preserved	O
left	O
ventricular	O
function	O
,	O
no	O
structural	O
heart	O
disease	O
.	O
Death	O
.	O

The	O
patient	O
is	O
a	O
39	O
year	O
old	O
male	O
,	O
170	O
cm	O
tall	O
and	O
weighing	O
65	O
kg	O
.	O
His	O
medical	O
history	O
included	O
Hodgkin	O
's	O
lymphoma	O
at	O
5	O
years	O
of	O
age	O
,	O
which	O
required	O
splenectomy	O
,	O
liver	O
and	O
mesenteric	O
lymph	O
node	O
biopsy	O
for	O
staging	O
and	O
was	O
treated	O
with	O
radiotherapy	O
to	O
the	O
thorax	O
.	O
At	O
the	O
age	O
of	O
34	O
,	O
he	O
underwent	O
haemithroidectomy	O
for	O
follicular	O
adenoma	O
.	O
Previously	O
asymptomatic	O
and	O
leading	O
an	O
active	O
life	O
,	O
he	O
attended	O
the	O
emergency	O
department	O
for	O
2	O
days	O
of	O
general	O
malaise	O
,	O
myalgias	O
,	O
arthralgias	O
,	O
lumbar	O
pain	O
,	O
vomiting	O
,	O
diarrhoea	O
and	O
febrile	O
fever	O
.	O
Laboratory	O
tests	O
showed	O
slight	O
leukocytosis	O
.	O
Abdominal	O
ultrasound	O
and	O
simple	O
thoracic	O
and	O
lumbar	O
radiology	O
revealed	O
no	O
abnormalities	O
.	O
The	O
electrocardiogram	O
showed	O
normal	O
sinus	O
rhythm	O
.	O
The	O
patient	O
was	O
diagnosed	O
with	O
low	O
back	O
pain	O
and	O
discharged	O
.	O
Three	O
days	O
later	O
he	O
was	O
urgently	O
admitted	O
for	O
worsening	O
symptoms	O
with	O
shivering	O
,	O
fever	O
of	O
40	O
C	O
and	O
hypotension	O
.	O
Blood	O
tests	O
showed	O
34	O
.	O
8	O
103	O
leukocytes	O
L	O
92	O
neutrophils	O
and	O
15	O
white	O
blood	O
cells	O
,	O
platelets	O
465	O
103	O
L	O
,	O
ESR	O
of	O
40	O
mm	O
,	O
creatinine	O
1	O
.	O
55	O
mg	O
dL	O
,	O
procalcitonin	O
6	O
.	O
46	O
ng	O
mL	O
,	O
C	O
reactive	O
protein	O
20	O
.	O
18	O
mg	O
dL	O
.	O
Urine	O
sediment	O
showed	O
bacteriuria	O
,	O
5	O
10	O
leucocytes	O
field	O
and	O
oxalate	O
crystals	O
.	O
Blood	O
and	O
urine	O
cultures	O
were	O
taken	O
.	O
With	O
suspicion	O
of	O
severe	O
sepsis	O
,	O
rescue	O
fluid	O
therapy	O
was	O
administered	O
and	O
antibiotic	O
treatment	O
with	O
meropenem	B-FARMACO
and	O
linezolid	B-FARMACO
was	O
started	O
.	O
Two	O
days	O
after	O
admission	O
,	O
the	O
patient	O
presented	O
with	O
dyspnoea	O
at	O
rest	O
and	O
pulmonary	O
oedema	O
,	O
probably	O
related	O
to	O
intravenous	O
fluids	O
,	O
requiring	O
intubation	O
and	O
mechanical	O
ventilation	O
.	O
The	O
electrocardiogram	O
showed	O
2nd	O
degree	O
AV	O
block	O
progressing	O
to	O
complete	O
AV	O
block	O
with	O
output	O
at	O
70	O
bpm	O
.	O
The	O
transesophageal	O
echocardiogram	O
showed	O
moderate	O
tricuspid	O
regurgitation	O
,	O
mild	O
mitral	O
regurgitation	O
and	O
a	O
normofunctioning	O
aortic	O
valve	O
,	O
as	O
well	O
as	O
mobile	O
images	O
suggestive	O
of	O
vegetation	O
on	O
the	O
anterior	O
mitral	O
leaflet	O
.	O
Dopamine	B-FARMACO
perfusion	O
was	O
started	O
to	O
maintain	O
the	O
heart	O
rate	O
,	O
and	O
antibiotic	O
treatment	O
was	O
modified	O
to	O
include	O
cloxacillin	B-FARMACO
,	O
daptomycin	B-FARMACO
and	O
gentamicin	B-FARMACO
on	O
suspicion	O
of	O
infective	O
endocarditis	O
.	O
The	O
patient	O
's	O
evolution	O
was	O
favourable	O
and	O
allowed	O
extubation	O
6	O
days	O
after	O
admission	O
.	O
Ten	O
days	O
after	O
admission	O
,	O
the	O
patient	O
presented	O
retrosternal	O
pain	O
and	O
signs	O
of	O
sudden	O
onset	O
pericarditis	O
.	O
The	O
echocardiogram	O
showed	O
mild	O
pericardial	O
effusion	O
and	O
progression	O
of	O
endocarditis	O
with	O
vegetations	O
on	O
the	O
anterior	O
mitral	O
leaflet	O
,	O
tricuspid	O
septal	O
leaflet	O
and	O
mitro	O
aortic	O
junction	O
without	O
significant	O
valvular	O
insufficiencies	O
.	O
Computed	O
tomography	O
angiography	O
showed	O
an	O
aneurysm	O
of	O
probable	O
mycotic	O
origin	O
on	O
the	O
anterior	O
aspect	O
of	O
the	O
ascending	O
aorta	O
as	O
well	O
as	O
a	O
small	O
thoracic	O
aorta	O
and	O
pulmonary	O
artery	O
.	O
The	O
patient	O
was	O
referred	O
for	O
urgent	O
surgery	O
.	O
After	O
opening	O
the	O
pericardium	O
,	O
the	O
pericardial	O
fluid	O
was	O
bloody	O
in	O
appearance	O
and	O
was	O
sent	O
for	O
culture	O
.	O
Although	O
subjectively	O
appreciated	O
,	O
the	O
aorta	O
,	O
cavae	O
and	O
pulmonary	O
artery	O
appeared	O
to	O
the	O
surgical	O
team	O
to	O
be	O
very	O
small	O
for	O
the	O
size	O
of	O
the	O
patient	O
.	O
A	O
haematoma	O
was	O
noted	O
on	O
the	O
anterior	O
aspect	O
of	O
the	O
aorta	O
and	O
the	O
epicardial	O
fat	O
of	O
the	O
right	O
ventricle	O
.	O
The	O
haematoma	O
was	O
cannulated	O
and	O
then	O
debrided	O
,	O
draining	O
copious	O
pus	O
followed	O
by	O
active	O
arterial	O
bleeding	O
due	O
to	O
possible	O
rupture	O
of	O
the	O
mycotic	O
aneurysm	O
.	O
Once	O
the	O
extracorporeal	O
circulation	O
was	O
connected	O
and	O
the	O
aorta	O
clamped	O
,	O
the	O
ascending	O
aorta	O
was	O
opened	O
,	O
revealing	O
abundant	O
atheroma	O
plaques	O
,	O
a	O
small	O
mycotic	O
aneurysm	O
with	O
signs	O
of	O
inflammation	O
and	O
a	O
small	O
,	O
thin	O
,	O
competent	O
aortic	O
valve	O
with	O
a	O
16	O
mm	O
Hegar	O
ring	O
.	O
Below	O
the	O
aortic	O
valve	O
,	O
vegetation	O
anchored	O
to	O
the	O
membranous	O
septum	O
was	O
observed	O
and	O
resected	O
.	O
After	O
brushing	O
the	O
septum	O
with	O
povidone	O
iodine	O
,	O
a	O
Teflon	O
reinforced	O
stitch	O
was	O
placed	O
because	O
of	O
suspected	O
communication	O
with	O
the	O
right	O
atrium	O
.	O
The	O
portion	O
of	O
the	O
aortic	O
wall	O
including	O
the	O
mycotic	O
aneurysm	O
was	O
resected	O
and	O
direct	O
closure	O
of	O
the	O
aorta	O
was	O
performed	O
respecting	O
the	O
aortic	O
valve	O
.	O
A	O
right	O
atriotomy	O
was	O
performed	O
,	O
revealing	O
a	O
large	O
vegetation	O
in	O
the	O
commissure	O
between	O
the	O
anterior	O
leaflet	O
and	O
the	O
septal	O
leaflet	O
,	O
probably	O
related	O
to	O
the	O
resected	O
vegetation	O
on	O
the	O
left	O
ventricular	O
side	O
.	O
The	O
vegetation	O
was	O
resected	O
,	O
brushed	O
with	O
Betadine	O
and	O
the	O
commissure	O
was	O
reinforced	O
with	O
a	O
stitch	O
.	O
The	O
interatrial	O
septum	O
was	O
then	O
opened	O
and	O
a	O
large	O
vegetation	O
on	O
the	O
anterior	O
mitral	O
leaflet	O
was	O
observed	O
and	O
resected	O
.	O
At	O
the	O
end	O
of	O
the	O
operation	O
,	O
a	O
definitive	O
epicardial	O
pacemaker	O
was	O
implanted	O
over	O
the	O
right	O
ventricle	O
.	O
Blood	O
and	O
urine	O
cultures	O
were	O
negative	O
.	O
Pericardial	O
fluid	O
culture	O
was	O
positive	O
for	O
S	O
.	O
pneumoniae	O
.	O
Although	O
culture	O
of	O
vegetations	O
was	O
negative	O
,	O
DNA	O
polymerase	O
chain	O
reaction	O
PCR	O
was	O
positive	O
for	O
S	O
.	O
pneumoniae	O
in	O
all	O
samples	O
.	O
The	O
patient	O
's	O
postoperative	O
evolution	O
was	O
initially	O
favourable	O
and	O
the	O
echocardiogram	O
showed	O
normally	O
functioning	O
valves	O
with	O
no	O
residual	O
shunts	O
.	O
However	O
,	O
3	O
weeks	O
after	O
surgery	O
the	O
patient	O
suffered	O
progressive	O
deterioration	O
of	O
general	O
condition	O
with	O
fever	O
and	O
hypotension	O
.	O
Several	O
blood	O
cultures	O
were	O
positive	O
for	O
Candida	O
orthopsilosis	O
.	O
Despite	O
antifungal	O
treatment	O
,	O
the	O
patient	O
died	O
of	O
septic	O
shock	O
and	O
multi	O
organ	O
failure	O
2	O
months	O
after	O
surgery	O
.	O
Necropsy	O
showed	O
invasive	O
candidiasis	O
in	O
the	O
liver	O
and	O
lung	O
.	O

This	O
is	O
a	O
63	O
year	O
old	O
male	O
with	O
multiple	O
cardiovascular	O
risk	O
factors	O
hypertension	O
,	O
type	O
2	O
diabetes	O
mellitus	O
on	O
oral	O
antidiabetic	O
treatment	O
,	O
dyslipidaemia	O
and	O
obesity	O
,	O
COPD	O
,	O
chronic	O
kidney	O
disease	O
with	O
baseline	O
creatinine	O
of	O
1	O
.	O
2	O
mg	O
dl	O
and	O
permanent	O
atrial	O
fibrillation	O
,	O
who	O
was	O
admitted	O
to	O
our	O
centre	O
in	O
May	O
2018	O
in	O
cardiogenic	O
shock	O
requiring	O
vasoactive	O
support	O
and	O
non	O
invasive	O
mechanical	O
ventilation	O
.	O
The	O
patient	O
had	O
dilated	O
cardiomyopathy	O
of	O
probable	O
enolic	O
origin	O
,	O
with	O
severe	O
left	O
ventricular	O
systolic	O
dysfunction	O
with	O
an	O
estimated	O
left	O
ventricular	O
ejection	O
fraction	O
of	O
20	O
,	O
with	O
implantation	O
of	O
a	O
single	O
chamber	O
implantable	O
cardioverter	O
defibrillator	O
as	O
primary	O
prevention	O
in	O
2003	O
.	O
The	O
admission	O
echocardiogram	O
showed	O
severe	O
aortic	O
stenosis	O
and	O
double	O
mitral	O
lesion	O
with	O
moderate	O
insufficiency	O
and	O
mild	O
stenosis	O
of	O
probable	O
rheumatic	O
origin	O
with	O
significant	O
calcification	O
of	O
the	O
leaflets	O
.	O
Given	O
the	O
patient	O
's	O
situation	O
and	O
personal	O
history	O
EuroScore	O
II	O
19	O
.	O
35	O
,	O
it	O
was	O
decided	O
to	O
implant	O
a	O
29	O
mm	O
Edwards	O
SapienTM	O
transcatheter	O
aortic	O
prosthesis	O
via	O
the	O
transfemoral	O
route	O
by	O
the	O
interventional	O
cardiology	O
team	O
,	O
and	O
percutaneous	O
treatment	O
of	O
the	O
mitral	O
valve	O
was	O
ruled	O
out	O
at	O
the	O
same	O
surgical	O
time	O
.	O
The	O
post	O
implantation	O
echocardiogram	O
showed	O
a	O
normofunctioning	O
aortic	O
prosthesis	O
with	O
a	O
mean	O
transprosthetic	O
gradient	O
of	O
5	O
mm	O
Hg	O
and	O
mitral	O
regurgitation	O
unchanged	O
from	O
the	O
preoperative	O
echocardiogram	O
.	O
Four	O
months	O
after	O
the	O
procedure	O
the	O
patient	O
was	O
readmitted	O
to	O
our	O
centre	O
for	O
multiple	O
inappropriate	O
shocks	O
of	O
the	O
implantable	O
cardioverter	O
defibrillator	O
,	O
accompanied	O
by	O
fever	O
and	O
chills	O
.	O
We	O
analysed	O
the	O
device	O
data	O
,	O
and	O
observed	O
multiple	O
episodes	O
of	O
polymorphic	O
ventricular	O
tachycardia	O
,	O
most	O
of	O
which	O
ended	O
with	O
a	O
shock	O
,	O
and	O
which	O
were	O
undetected	O
by	O
the	O
patient	O
.	O
All	O
episodes	O
were	O
preceded	O
by	O
marked	O
bradycardia	O
requiring	O
pacemaker	O
pacing	O
.	O
Pacemaker	O
pacing	O
was	O
increased	O
to	O
a	O
minimum	O
heart	O
rate	O
of	O
75	O
bpm	O
and	O
blood	O
cultures	O
were	O
drawn	O
and	O
tested	O
positive	O
for	O
Staphylococcus	O
epidermidis	O
.	O
Given	O
these	O
results	O
,	O
the	O
persistence	O
of	O
fever	O
and	O
elevated	O
acute	O
phase	O
reactants	O
and	O
the	O
history	O
of	O
TAVI	O
implantation	O
,	O
infective	O
endocarditis	O
was	O
suspected	O
and	O
a	O
transesophageal	O
echocardiogram	O
was	O
performed	O
.	O
The	O
echocardiogram	O
showed	O
a	O
large	O
hypoechoic	O
vegetation	O
measuring	O
4	O
.	O
3	O
1	O
.	O
9	O
cm	O
,	O
with	O
a	O
deflected	O
irregular	O
border	O
extending	O
from	O
1	O
cm	O
below	O
the	O
valve	O
plane	O
to	O
3	O
cm	O
above	O
the	O
valve	O
plane	O
,	O
filling	O
most	O
of	O
the	O
TAVI	O
stent	O
and	O
causing	O
the	O
prosthesis	O
to	O
behave	O
as	O
a	O
moderate	O
severe	O
stenosis	O
with	O
a	O
peak	O
gradient	O
of	O
38	O
mm	O
Hg	O
without	O
insufficiency	O
.	O
The	O
mitral	O
valve	O
had	O
extensive	O
degenerative	O
changes	O
,	O
with	O
severe	O
calcification	O
of	O
the	O
leaflets	O
and	O
subvalvular	O
apparatus	O
,	O
and	O
a	O
severe	O
central	O
insufficiency	O
jet	O
.	O
Antibiotic	O
treatment	O
with	O
daptomycin	B-FARMACO
and	O
fosfocimin	B-FARMACO
was	O
started	O
and	O
the	O
case	O
was	O
discussed	O
in	O
a	O
medical	O
surgical	O
session	O
.	O
Given	O
the	O
lack	O
of	O
clinical	O
and	O
echocardiographic	O
improvement	O
,	O
surgery	O
was	O
decided	O
.	O
During	O
surgery	O
,	O
large	O
vegetations	O
were	O
observed	O
on	O
the	O
ventricular	O
and	O
aortic	O
side	O
of	O
the	O
prosthesis	O
.	O
The	O
TAVI	O
was	O
explanted	O
and	O
an	O
aortic	O
valve	O
replacement	O
with	O
a	O
25	O
mm	O
Magna	O
Ease	O
biological	O
aortic	O
prosthesis	O
was	O
performed	O
.	O
In	O
addition	O
,	O
a	O
mitral	O
valve	O
replacement	O
with	O
a	O
25	O
mm	O
Magna	O
Ease	O
biological	O
prosthesis	O
was	O
performed	O
.	O
The	O
explanted	O
prosthesis	O
was	O
analysed	O
microscopically	O
with	O
Gram	O
stain	O
,	O
where	O
gram	O
positive	O
cocci	O
were	O
observed	O
in	O
clusters	O
,	O
and	O
cultures	O
on	O
the	O
prosthesis	O
were	O
positive	O
for	O
Staphylococcus	O
epidermidis	O
.	O
Subsequently	O
,	O
the	O
patient	O
had	O
a	O
good	O
postoperative	O
evolution	O
,	O
with	O
no	O
associated	O
complications	O
,	O
and	O
was	O
discharged	O
from	O
hospital	O
after	O
completing	O
the	O
5	O
week	O
course	O
of	O
antibiotic	O
treatment	O
.	O

A	O
42	O
year	O
old	O
man	O
from	O
China	O
with	O
no	O
past	O
history	O
of	O
interest	O
,	O
who	O
came	O
to	O
the	O
emergency	O
department	O
for	O
an	O
episode	O
of	O
syncope	O
together	O
with	O
general	O
malaise	O
and	O
dysthermia	O
.	O
He	O
was	O
admitted	O
to	O
the	O
ICU	O
with	O
a	O
diagnosis	O
of	O
possible	O
septic	O
shock	O
of	O
respiratory	O
origin	O
with	O
bilateral	O
necrotising	O
pneumonia	O
.	O
Imaging	O
tests	O
showed	O
abscesses	O
in	O
the	O
lung	O
,	O
kidney	O
and	O
liver	O
,	O
as	O
well	O
as	O
a	O
thrombus	O
in	O
the	O
inferior	O
vena	O
cava	O
and	O
in	O
the	O
cavo	O
auricular	O
junction	O
.	O
An	O
echocardiogram	O
was	O
performed	O
,	O
showing	O
a	O
large	O
multilobulated	O
mass	O
with	O
apparent	O
origin	O
in	O
the	O
Eustachian	O
valve	O
.	O
In	O
the	O
first	O
blood	O
cultures	O
and	O
bronchial	O
aspirate	O
Klebsiella	O
pneumoniae	O
was	O
isolated	O
.	O
Subsequent	O
blood	O
cultures	O
isolated	O
oxacycline	O
resistant	O
coagulase	O
negative	O
Staphylococcus	O
epidermidis	O
.	O
Subsequently	O
,	O
no	O
new	O
microorganisms	O
were	O
isolated	O
,	O
and	O
the	O
rest	O
of	O
the	O
cultures	O
were	O
sterile	O
.	O
The	O
main	O
diagnostic	O
possibilities	O
were	O
myxoma	O
,	O
vegetation	O
and	O
thrombus	O
.	O
Despite	O
antibiotic	O
and	O
anticoagulant	O
treatment	O
,	O
new	O
abscesses	O
and	O
pulmonary	O
lesions	O
continued	O
to	O
appear	O
and	O
echocardiography	O
showed	O
no	O
changes	O
in	O
the	O
mass	O
,	O
so	O
that	O
,	O
given	O
the	O
suspicion	O
of	O
vegetation	O
with	O
without	O
associated	O
thrombus	O
,	O
complete	O
surgical	O
resection	O
under	O
extracorporeal	O
circulation	O
was	O
decided	O
upon	O
.	O
In	O
order	O
to	O
carry	O
out	O
the	O
intervention	O
with	O
the	O
greatest	O
possible	O
safety	O
for	O
venous	O
drainage	O
,	O
percutaneous	O
cannulation	O
of	O
the	O
femoral	O
vein	O
progressing	O
the	O
cannula	O
to	O
the	O
inferior	O
vena	O
cava	O
and	O
cannulation	O
of	O
the	O
superior	O
vena	O
cava	O
were	O
chosen	O
.	O
A	O
right	O
longitudinal	O
atriotomy	O
and	O
temporary	O
release	O
of	O
the	O
inferior	O
vena	O
cava	O
tourniquet	O
was	O
performed	O
for	O
resection	O
of	O
the	O
pedicle	O
implantation	O
base	O
.	O
The	O
resected	O
mass	O
had	O
a	O
pedicle	O
insertion	O
into	O
the	O
Eustachian	O
valve	O
and	O
was	O
approximately	O
35	O
10	O
mm	O
in	O
size	O
.	O
As	O
the	O
Eustachian	O
valve	O
was	O
a	O
large	O
and	O
prominent	O
structure	O
,	O
it	O
was	O
resected	O
.	O
No	O
new	O
abscesses	O
or	O
pulmonary	O
lesions	O
appeared	O
after	O
surgery	O
.	O
The	O
microbiological	O
study	O
was	O
sterile	O
,	O
and	O
the	O
histopathological	O
study	O
of	O
the	O
mass	O
was	O
compatible	O
with	O
fibrino	O
thrombotic	O
material	O
,	O
so	O
anticoagulant	O
treatment	O
was	O
maintained	O
.	O
At	O
the	O
end	O
of	O
the	O
course	O
of	O
intravenous	O
antibiotherapy	O
,	O
the	O
patient	O
was	O
discharged	O
without	O
sequelae	O
and	O
underwent	O
rehabilitation	O
.	O
After	O
4	O
months	O
of	O
follow	O
up	O
he	O
was	O
in	O
functional	O
class	O
I	O
,	O
the	O
control	O
echocardiogram	O
showed	O
no	O
new	O
intracardiac	O
masses	O
and	O
the	O
imaging	O
tests	O
showed	O
resolving	O
pulmonary	O
lesions	O
with	O
no	O
new	O
abscesses	O
.	O

A	O
72	O
year	O
old	O
man	O
with	O
an	O
aortic	O
bioprosthesis	O
implanted	O
in	O
2010	O
was	O
diagnosed	O
with	O
prosthetic	O
endocarditis	O
due	O
to	O
Enterococcus	O
faecalis	O
5	O
years	O
after	O
surgery	O
.	O
The	O
transesophageal	O
echocardiogram	O
showed	O
an	O
abscess	O
at	O
the	O
level	O
of	O
the	O
mitroaortic	O
junction	O
,	O
11	O
mm	O
in	O
diameter	O
,	O
with	O
a	O
9	O
mm	O
vegetation	O
attached	O
to	O
the	O
ventricular	O
side	O
of	O
the	O
non	O
coronary	O
leaflet	O
.	O
A	O
computed	O
axial	O
tomography	O
CT	O
scan	O
revealed	O
a	O
large	O
abscess	O
with	O
gas	O
within	O
it	O
,	O
at	O
the	O
level	O
of	O
the	O
aortic	O
root	O
,	O
extending	O
into	O
the	O
right	O
ventricular	O
outflow	O
tract	O
.	O
Gas	O
bubbles	O
were	O
also	O
present	O
within	O
the	O
pulmonary	O
artery	O
trunk	O
.	O
A	O
positron	O
emission	O
tomography	O
PET	O
CT	O
scan	O
with	O
18F	O
fluoro	O
2	O
deoxyglucose	O
18F	O
FDG	O
confirmed	O
the	O
extension	O
of	O
the	O
infection	O
in	O
both	O
locations	O
.	O
At	O
surgery	O
,	O
the	O
infected	O
prosthesis	O
was	O
replaced	O
with	O
a	O
cryopreserved	O
aortic	O
valve	O
homograft	O
,	O
sutured	O
subcoronary	O
.	O
Surgical	O
samples	O
were	O
positive	O
for	O
the	O
same	O
microorganism	O
isolated	O
from	O
the	O
blood	O
.	O
No	O
macroscopic	O
involvement	O
of	O
the	O
main	O
pulmonary	O
artery	O
was	O
found	O
.	O
The	O
free	O
wall	O
of	O
the	O
right	O
ventricular	O
outflow	O
tract	O
was	O
explored	O
,	O
and	O
although	O
it	O
was	O
compacted	O
,	O
its	O
puncture	O
did	O
not	O
yield	O
any	O
pathological	O
product	O
,	O
ruling	O
out	O
frank	O
collections	O
at	O
that	O
level	O
.	O
The	O
postoperative	O
period	O
was	O
uneventful	O
.	O
The	O
control	O
18F	O
FDG	O
PET	O
CT	O
scan	O
showed	O
no	O
evidence	O
of	O
residual	O
gas	O
or	O
significant	O
18F	O
FDG	O
uptake	O
.	O
Control	O
blood	O
cultures	O
were	O
similarly	O
negative	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
62	O
year	O
old	O
male	O
.	O
History	O
No	O
known	O
drug	O
allergies	O
.	O
Baseline	O
functional	O
status	O
independent	O
for	O
daily	O
activities	O
,	O
higher	O
functions	O
preserved	O
.	O
Active	O
life	O
without	O
dyspnoea	O
or	O
angina	O
.	O
No	O
family	O
history	O
of	O
sudden	O
death	O
or	O
early	O
ischaemic	O
heart	O
disease	O
.	O
Non	O
smoker	O
.	O
As	O
the	O
only	O
cardiovascular	O
risk	O
factor	O
arterial	O
hypertension	O
AHT	O
,	O
on	O
pharmacological	O
treatment	O
with	O
telmisartan	B-FARMACO
amlodipine	I-FARMACO
80	O
10	O
mg	O
1	O
0	O
0	O
.	O
No	O
known	O
previous	O
heart	O
disease	O
.	O
Other	O
personal	O
medical	O
history	O
anxiety	O
disorder	O
being	O
monitored	O
by	O
psychiatry	O
and	O
treated	O
with	O
ziprasidone	B-FARMACO
40	O
mg	O
0	O
0	O
1	O
,	O
lorazepam	B-FARMACO
5	O
mg	O
0	O
0	O
0	O
.	O
5	O
,	O
mirtazapine	B-FARMACO
30	O
mg	O
0	O
0	O
1	O
and	O
vortioxetine	B-FARMACO
10	O
mg	O
1	O
0	O
0	O
.	O
Present	O
illness	O
An	O
asymptomatic	O
patient	O
,	O
while	O
in	O
a	O
shoe	O
shop	O
,	O
suddenly	O
lost	O
consciousness	O
witnessed	O
by	O
his	O
wife	O
without	O
subsequent	O
recovery	O
,	O
so	O
she	O
called	O
the	O
emergency	O
services	O
.	O
On	O
arrival	O
of	O
the	O
first	O
resuscitators	O
after	O
5	O
8	O
minutes	O
without	O
basic	O
CPR	O
they	O
observed	O
CPR	O
in	O
a	O
defibrillable	O
rhythm	O
for	O
the	O
AED	O
.	O
S1e	O
administered	O
2	O
adrenaline	B-FARMACO
and	O
4	O
AED	O
shocks	O
.	O
After	O
advanced	O
life	O
support	O
arrived	O
,	O
the	O
patient	O
persisted	O
in	O
CPR	O
with	O
a	O
shockable	O
rhythm	O
,	O
so	O
a	O
new	O
shock	O
was	O
administered	O
and	O
spontaneous	O
circulation	O
was	O
restored	O
.	O
In	O
the	O
output	O
electrocardiogram	O
ECG	O
,	O
atrial	O
fibrillation	O
AF	O
rhythm	O
with	O
ventricular	O
response	O
at	O
160	O
bpm	O
with	O
ST	O
elevation	O
in	O
I	O
,	O
aVL	O
and	O
V3	O
V6	O
.	O
After	O
this	O
,	O
in	O
view	O
of	O
the	O
Glasgow	O
Coma	O
Scale	O
GCS	O
of	O
3	O
points	O
,	O
orotracheal	O
intubation	O
OTI	O
was	O
performed	O
.	O
Contact	O
was	O
made	O
with	O
our	O
cardiology	O
department	O
and	O
,	O
in	O
view	O
of	O
CRA	O
due	O
to	O
shockable	O
rhythm	O
with	O
anterolateral	O
ST	O
elevation	O
,	O
it	O
was	O
decided	O
to	O
transfer	O
the	O
patient	O
directly	O
to	O
the	O
haemodynamics	O
department	O
for	O
emergent	O
coronary	O
angiography	O
,	O
and	O
the	O
hypothermia	O
protocol	O
was	O
initiated	O
.	O
Total	O
time	O
of	O
cardiorespiratory	O
arrest	O
20	O
minutes	O
.	O
Time	O
without	O
assistance	O
5	O
8	O
minutes	O
.	O
Physical	O
examination	O
On	O
arrival	O
at	O
hospital	O
blood	O
pressure	O
BP	O
139	O
87	O
mmHg	O
;	O
heart	O
rate	O
HR	O
94	O
bpm	O
;	O
post	O
OIOT	O
oxygen	O
saturation	O
100	O
;	O
afebrile	O
.	O
GCS	O
4	O
points	O
.	O
On	O
admission	O
he	O
was	O
kept	O
on	O
sedative	O
treatment	O
with	O
continuous	O
perfusion	O
of	O
midazolam	B-FARMACO
.	O
Intubated	O
,	O
well	O
adapted	O
to	O
the	O
ventilator	O
with	O
FiO2	O
35	O
,	O
normal	O
colour	O
and	O
well	O
perfused	O
.	O
On	O
examination	O
no	O
jugular	O
plethora	O
.	O
Rhythmic	O
cardiac	O
auscultation	O
without	O
murmurs	O
.	O
Normal	O
pulmonary	O
auscultation	O
,	O
good	O
bilateral	O
ventilation	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
.	O
No	O
oedema	O
or	O
evidence	O
of	O
venous	O
thrombosis	O
in	O
the	O
lower	O
extremities	O
,	O
with	O
palpable	O
pulses	O
.	O
COMPLEMENTARY	O
TESTS	O
AED	O
recording	O
ventricular	O
fibrillation	O
arrest	O
rhythm	O
.	O
ECG	O
immediately	O
after	O
discharge	O
atrial	O
fibrillation	O
with	O
ventricular	O
response	O
at	O
160	O
bpm	O
and	O
ST	O
elevation	O
of	O
up	O
to	O
3	O
mm	O
anterolateral	O
lateral	O
and	O
precordial	O
.	O
ECG	O
on	O
admission	O
to	O
the	O
coronary	O
unit	O
sinus	O
rhythm	O
at	O
100	O
bpm	O
,	O
axis	O
at	O
60o	O
,	O
normal	O
PR	O
,	O
narrow	O
QRS	O
.	O
Normal	O
QT	O
.	O
Correct	O
progression	O
of	O
R	O
in	O
precordial	O
leads	O
.	O
No	O
acute	O
repolarisation	O
abnormalities	O
.	O
No	O
early	O
repolarisation	O
pattern	O
.	O
Post	O
PCR	O
analysis	O
on	O
admission	O
Biochemical	O
parameters	O
within	O
normal	O
range	O
,	O
including	O
lipid	O
profile	O
,	O
with	O
renal	O
function	O
and	O
ions	O
magnesium	O
,	O
sodium	O
,	O
calcium	O
,	O
potassium	O
in	O
range	O
.	O
Normal	O
haemogram	O
and	O
coagulation	O
.	O
Initial	O
myocardial	O
damage	O
markers	O
CK	O
181	O
U	O
l	O
and	O
ultrasensitive	O
TnT	O
187	O
ng	O
l	O
N	O
0	O
14	O
;	O
with	O
maximum	O
peak	O
CK	O
2	O
,	O
127	O
U	O
l	O
and	O
ultrasensitive	O
TnT	O
951	O
ng	O
l	O
.	O
Urine	O
toxicity	O
test	O
negative	O
.	O
Emergency	O
echocardioscopy	O
LV	O
neither	O
dilated	O
nor	O
hypertrophic	O
with	O
preserved	O
global	O
and	O
segmental	O
systolic	O
function	O
,	O
hyperdynamic	O
.	O
No	O
significant	O
valvulopathies	O
.	O
RV	O
not	O
dilated	O
with	O
good	O
function	O
.	O
No	O
pericardial	O
effusion	O
.	O
Emergency	O
tests	O
performed	O
on	O
arrival	O
Emergent	O
coronary	O
angiography	O
coronary	O
arteries	O
without	O
lesions	O
.	O
Cerebral	O
CT	O
and	O
thoraco	O
abdominal	O
CT	O
angiography	O
no	O
significant	O
findings	O
.	O
Transthoracic	O
echocardiogram	O
in	O
coronary	O
unit	O
left	O
ventricle	O
LV	O
not	O
dilated	O
or	O
hypertrophic	O
with	O
preserved	O
systolic	O
function	O
LVEF	O
65	O
without	O
alterations	O
in	O
segmental	O
contractility	O
.	O
Diastolic	O
pattern	O
of	O
elongated	O
relaxation	O
E	O
E	O
'	O
9	O
.	O
Normal	O
left	O
atrium	O
20	O
cm2	O
.	O
Right	O
ventricle	O
RV	O
not	O
dilated	O
and	O
with	O
good	O
function	O
.	O
Trivalve	O
aortic	O
valve	O
with	O
preserved	O
opening	O
,	O
without	O
functional	O
alterations	O
.	O
Aortic	O
root	O
not	O
dilated	O
30	O
mm	O
.	O
Mitral	O
valve	O
of	O
normal	O
appearance	O
with	O
minimal	O
insufficiency	O
.	O
Tricuspid	O
valve	O
with	O
mild	O
insufficiency	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
with	O
inspiratory	O
collapse	O
50	O
.	O
Estimated	O
pulmonary	O
artery	O
systolic	O
pressure	O
PSAP	O
of	O
25	O
mmHg	O
.	O
No	O
pericardial	O
effusion	O
.	O
Cardiac	O
magnetic	O
resonance	O
imaging	O
MRI	O
on	O
the	O
general	O
cardiology	O
hospital	O
ward	O
non	O
dilated	O
left	O
ventricle	O
LV	O
with	O
preserved	O
global	O
and	O
segmental	O
function	O
LVEF	O
62	O
.	O
Mild	O
moderate	O
concentric	O
LV	O
hypertrophy	O
12	O
13	O
mm	O
.	O
Non	O
dilated	O
right	O
ventricle	O
RV	O
with	O
preserved	O
global	O
and	O
segmental	O
function	O
RVEF	O
63	O
.	O
In	O
the	O
late	O
enhancement	O
sequences	O
no	O
pathological	O
uptakes	O
were	O
seen	O
.	O
Findings	O
compatible	O
with	O
hypertensive	O
heart	O
disease	O
,	O
with	O
good	O
biventricular	O
function	O
,	O
without	O
pathological	O
enhancements	O
.	O
Negative	O
for	O
the	O
phenotype	O
of	O
long	O
QT	O
syndrome	O
standing	O
ECG	O
with	O
normal	O
QTc	O
440	O
ms	O
and	O
stress	O
test	O
with	O
measurement	O
of	O
QTc	O
at	O
the	O
4th	O
minute	O
of	O
recovery	O
also	O
normal	O
445	O
ms	O
.	O
During	O
the	O
stress	O
test	O
,	O
there	O
were	O
no	O
arrhythmic	O
events	O
compatible	O
with	O
catecholaminergic	O
polymorphic	O
ventricular	O
tachycardia	O
.	O
Negative	O
for	O
Brugada	O
syndrome	O
phenotype	O
modified	O
ECG	O
negative	O
for	O
Brugada	O
pattern	O
in	O
right	O
precordial	O
leads	O
,	O
and	O
negative	O
flecainide	O
test	O
normal	O
basal	O
sinus	O
rhythm	O
,	O
normal	O
atrioventricular	O
AV	O
conduction	O
and	O
normal	O
QRS	O
.	O
The	O
test	O
was	O
negative	O
,	O
although	O
during	O
the	O
pharmacological	O
test	O
with	O
flecainide	B-FARMACO
,	O
the	O
frequent	O
appearance	O
of	O
monomorphic	O
ventricular	O
extrasystoles	O
with	O
right	O
bundle	O
branch	O
block	O
morphology	O
RBBB	O
and	O
superior	O
axis	O
,	O
suggestive	O
of	O
origin	O
in	O
the	O
posterior	O
fascicle	O
,	O
drew	O
attention	O
.	O
Finally	O
,	O
with	O
the	O
history	O
of	O
ST	O
elevation	O
in	O
the	O
ECG	O
after	O
the	O
arrest	O
,	O
it	O
was	O
decided	O
to	O
perform	O
an	O
echocardiographic	O
test	O
with	O
ergobasin	O
clinically	O
,	O
electrically	O
and	O
echocardiographically	O
negative	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
coronary	O
unit	O
after	O
coronary	O
angiography	O
,	O
cerebral	O
thoracic	O
abdominal	O
CT	O
and	O
TTE	O
without	O
alterations	O
.	O
After	O
haemodynamic	O
stabilisation	O
with	O
a	O
slow	O
but	O
progressive	O
neurological	O
improvement	O
,	O
and	O
without	O
new	O
arrhythmic	O
events	O
on	O
telemetry	O
,	O
it	O
was	O
decided	O
to	O
transfer	O
him	O
to	O
the	O
general	O
cardiology	O
hospital	O
ward	O
to	O
complete	O
the	O
study	O
with	O
advanced	O
cardiac	O
imaging	O
and	O
provocation	O
tests	O
for	O
channelopathies	O
or	O
coronary	O
vasospasm	O
,	O
the	O
results	O
of	O
which	O
have	O
been	O
detailed	O
previously	O
.	O
The	O
patient	O
remains	O
cardiologically	O
asymptomatic	O
throughout	O
the	O
hospital	O
stay	O
.	O
He	O
was	O
monitored	O
with	O
telemetry	O
,	O
with	O
no	O
recorded	O
arrhythmic	O
events	O
,	O
and	O
daily	O
ECGs	O
were	O
performed	O
,	O
with	O
normal	O
QTc	O
in	O
all	O
of	O
them	O
.	O
The	O
tests	O
performed	O
during	O
admission	O
ruled	O
out	O
the	O
main	O
causes	O
of	O
cardiac	O
arrest	O
1	O
.	O
Ischaemia	O
normal	O
coronary	O
network	O
in	O
urgent	O
coronary	O
angiography	O
.	O
Cardiac	O
magnetic	O
resonance	O
imaging	O
also	O
showed	O
no	O
pathological	O
ischaemic	O
enhancements	O
.	O
2	O
.	O
Structural	O
no	O
evidence	O
of	O
pulmonary	O
thromboembolism	O
PTE	O
or	O
cardiac	O
tamponade	O
in	O
emergency	O
echocardiography	O
or	O
CT	O
;	O
no	O
evidence	O
of	O
underlying	O
cardiomyopathy	O
in	O
regular	O
transthoracic	O
echocardiography	O
or	O
cardiac	O
magnetic	O
resonance	O
imaging	O
.	O
3	O
.	O
Channelopathies	O
negative	O
provocation	O
tests	O
for	O
long	O
QT	O
syndrome	O
,	O
Brugada	O
,	O
and	O
catecholaminergic	O
polymorphic	O
ventricular	O
tachycardia	O
.	O
The	O
baseline	O
ECG	O
also	O
shows	O
no	O
short	O
QTc	O
morphology	O
or	O
early	O
repolarisation	O
pattern	O
.	O
4	O
.	O
Coronary	O
vasospasm	O
negative	O
ergobasin	O
echocardiography	O
test	O
.	O
5	O
.	O
No	O
toxic	O
metabolic	O
alterations	O
to	O
justify	O
the	O
picture	O
.	O
The	O
patient	O
had	O
no	O
family	O
history	O
of	O
sudden	O
death	O
or	O
early	O
ischaemic	O
heart	O
disease	O
.	O
His	O
father	O
has	O
permanent	O
atrial	O
fibrillation	O
and	O
his	O
mother	O
has	O
paroxysmal	O
atrial	O
fibrillation	O
.	O
On	O
discharge	O
,	O
his	O
two	O
children	O
and	O
his	O
sister	O
,	O
all	O
of	O
whom	O
were	O
healthy	O
,	O
were	O
referred	O
to	O
the	O
family	O
heart	O
disease	O
clinic	O
for	O
an	O
ECG	O
and	O
transthoracic	O
echocardiogram	O
.	O
A	O
diagnosis	O
of	O
idiopathic	O
ventricular	O
fibrillation	O
was	O
established	O
.	O
A	O
subcutaneous	O
implantable	O
cardioverter	O
defibrillator	O
ICD	O
was	O
placed	O
for	O
secondary	O
prevention	O
,	O
and	O
the	O
patient	O
underwent	O
outpatient	O
monitoring	O
in	O
the	O
electrophysiology	O
department	O
.	O
DIAGNOSIS	O
Out	O
of	O
hospital	O
CRA	O
resuscitated	O
by	O
shockable	O
rhythm	O
.	O
Idiopathic	O
ventricular	O
fibrillation	O
Angiographically	O
normal	O
coronary	O
network	O
.	O
No	O
structural	O
heart	O
disease	O
.	O
Good	O
biventricular	O
function	O
.	O
Pharmacological	O
tests	O
to	O
unmask	O
channelopathy	O
and	O
vasospasm	O
negative	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Personal	O
history	O
Allergies	O
doubtful	O
intolerance	O
to	O
penicillin	B-FARMACO
syncope	O
in	O
youth	O
after	O
IM	O
penicillin	B-FARMACO
,	O
toxicoderma	O
with	O
ondasetron	B-FARMACO
.	O
Cardiovascular	O
risk	O
factors	O
no	O
hypertension	O
.	O
Dyslipidaemia	O
.	O
No	O
diabetes	O
mellitus	O
.	O
Never	O
smoker	O
.	O
No	O
alcoholism	O
.	O
Overweight	O
.	O
Cardiological	O
history	O
not	O
reported	O
.	O
Other	O
history	O
Nasosinusal	O
polyposis	O
in	O
ASA	O
triad	O
asthma	O
,	O
nasal	O
polyposis	O
and	O
intolerance	O
to	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
.	O
Rhinitis	O
with	O
chronic	O
right	O
ototubaritis	O
with	O
chronic	O
hypereosinophilia	O
.	O
Prostatic	O
adenocarcinoma	O
operated	O
on	O
in	O
2012	O
with	O
subsequent	O
radiotherapy	O
.	O
Underwent	O
check	O
ups	O
and	O
last	O
PET	O
CT	O
scan	O
in	O
May	O
2019	O
with	O
left	O
para	O
aortic	O
adenopathies	O
suggestive	O
of	O
tumour	O
relapse	O
.	O
Usual	O
treatment	O
triptorelin	B-FARMACO
GnRH	O
agonist	O
every	O
six	O
months	O
.	O
Present	O
illness	O
A	O
61	O
year	O
old	O
man	O
came	O
to	O
the	O
emergency	O
department	O
.	O
He	O
reported	O
mild	O
central	O
thoracic	O
pinch	O
like	O
pain	O
,	O
which	O
appeared	O
with	O
deep	O
inspiration	O
a	O
day	O
earlier	O
.	O
For	O
the	O
previous	O
5	O
days	O
he	O
had	O
been	O
experiencing	O
night	O
sweats	O
,	O
arthromyalgia	O
,	O
asthenia	O
and	O
a	O
feeling	O
of	O
dystrophy	O
with	O
a	O
fever	O
of	O
up	O
to	O
37	O
.	O
5oC	O
.	O
She	O
presented	O
with	O
pre	O
syncopal	O
symptoms	O
in	O
relation	O
to	O
these	O
symptoms	O
,	O
which	O
is	O
why	O
she	O
went	O
to	O
the	O
emergency	O
department	O
.	O
No	O
alterations	O
in	O
bowel	O
habits	O
,	O
no	O
pathological	O
products	O
or	O
blood	O
in	O
the	O
stool	O
.	O
She	O
refers	O
to	O
a	O
trip	O
to	O
Japan	O
1	O
month	O
ago	O
,	O
without	O
any	O
notable	O
incident	O
.	O
There	O
was	O
evidence	O
of	O
elevated	O
biomarkers	O
of	O
myocardial	O
damage	O
and	O
the	O
echocardioscopic	O
study	O
showed	O
moderate	O
pericardial	O
effusion	O
,	O
for	O
which	O
reason	O
he	O
was	O
admitted	O
to	O
the	O
coronary	O
unit	O
with	O
suspected	O
myocarditis	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
BP	O
105	O
70	O
mmHg	O
,	O
heart	O
rate	O
HR	O
70	O
bpm	O
,	O
Sat2O98	O
on	O
room	O
air	O
.	O
Jugular	O
venous	O
pressure	O
normal	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
no	O
murmurs	O
or	O
pathological	O
sounds	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
with	O
no	O
extra	O
sounds	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
,	O
no	O
masses	O
or	O
megaliths	O
,	O
Blumberg	O
and	O
Murphy	O
negative	O
.	O
Extremities	O
no	O
oedema	O
in	O
the	O
lower	O
extremities	O
,	O
peripheral	O
pulses	O
preserved	O
and	O
symmetrical	O
,	O
no	O
signs	O
of	O
phlebitis	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
Emergency	O
sinus	O
rhythm	O
at	O
61	O
bpm	O
,	O
PR	O
160	O
ms	O
,	O
QRS	O
100	O
ms	O
with	O
axis	O
at	O
0o	O
,	O
minimal	O
J	O
point	O
descent	O
in	O
V3	O
V6	O
,	O
flat	O
T	O
wave	O
in	O
aVF	O
.	O
At	O
discharge	O
sinus	O
rhythm	O
at	O
70	O
bpm	O
,	O
PR	O
160	O
ms	O
,	O
QRS	O
100	O
ms	O
with	O
axis	O
at	O
0o	O
,	O
without	O
repolarisation	O
alterations	O
.	O
Chest	O
X	O
ray	O
on	O
admission	O
CTI	O
slightly	O
increased	O
,	O
no	O
pulmonary	O
infiltrates	O
or	O
masses	O
,	O
no	O
costophrenic	O
sinus	O
pinching	O
,	O
no	O
signs	O
of	O
venous	O
congestion	O
.	O
Laboratory	O
tests	O
CBC	O
red	O
cells	O
3	O
.	O
8	O
10	O
12	O
l	O
,	O
haemoglobin	O
11	O
.	O
8	O
g	O
dl	O
,	O
haematocrit	O
34	O
.	O
9	O
,	O
MCV	O
91	O
.	O
8	O
fl	O
,	O
MCH	O
31	O
.	O
2	O
pg	O
,	O
MCHC	O
34	O
g	O
dl	O
,	O
ADE	O
14	O
,	O
leukocytes	O
17	O
.	O
9	O
10	O
9	O
l	O
,	O
neutrophils	O
5	O
.	O
8	O
10	O
9	O
l	O
,	O
lymphocytes	O
0	O
.	O
4	O
10	O
9	O
l	O
,	O
monocytes	O
0	O
.	O
8	O
10	O
9	O
l	O
,	O
eosinophils	O
10	O
.	O
9	O
10	O
9	O
l	O
,	O
basophils	O
0	O
10	O
9	O
l	O
,	O
platelets	O
286	O
10	O
9	O
l	O
,	O
reticulocytes	O
1	O
.	O
14	O
,	O
reticulocytes	O
43	O
.	O
3	O
10	O
9	O
l	O
,	O
ESR	O
33	O
mm	O
h	O
.	O
Leukocyte	O
morphology	O
presence	O
of	O
some	O
eosinophils	O
with	O
altered	O
cytoplasmic	O
distribution	O
of	O
granulation	O
.	O
Haemostasis	O
prothrombin	O
time	O
PT	O
13	O
.	O
5	O
sec	O
,	O
Quick	O
's	O
index	O
78	O
,	O
INR	O
1	O
.	O
16	O
,	O
aPTT	O
30	O
sec	O
,	O
ratio	O
aPTT	O
1	O
.	O
01	O
,	O
Clauss	O
fibrinogen	O
498	O
mg	O
dl	O
.	O
Biochemistry	O
glucose	O
97	O
mg	O
dl	O
,	O
sodium	O
140	O
mEq	O
l	O
,	O
potassium	O
3	O
.	O
9	O
mEq	O
l	O
,	O
chlorine	O
105	O
mEq	O
l	O
,	O
magnesium	O
1	O
.	O
9	O
mg	O
dl	O
,	O
total	O
bilirubin	O
0	O
.	O
51	O
mg	O
dl	O
,	O
aspartate	O
aminotransferase	O
GOT	O
37	O
U	O
l	O
,	O
alanine	O
aminotransferase	O
GPT	O
25	O
U	O
l	O
,	O
gamma	O
glutamyl	O
transferase	O
23	O
U	O
l	O
,	O
urea	O
21	O
,	O
1	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
78	O
mg	O
dl	O
,	O
estimated	O
GFR	O
CKD	O
EPI	O
90	O
ml	O
min	O
1	O
.	O
73	O
m	O
,	O
uric	O
acid	O
3	O
.	O
3	O
mg	O
dl	O
,	O
protein	O
5	O
.	O
1	O
g	O
dl	O
,	O
albumin	O
2	O
.	O
9	O
g	O
dl	O
,	O
creatinine	O
phosphokinase	O
274	O
U	O
l	O
,	O
lactate	O
dehydrogenase	O
521	O
U	O
l	O
,	O
C	O
reactive	O
protein	O
3	O
.	O
9	O
mg	O
dl	O
.	O
Iron	O
metabolism	O
ferritin	O
376	O
g	O
l	O
,	O
iron	O
36	O
g	O
dl	O
,	O
total	O
Fe	O
binding	O
capacity	O
184	O
g	O
dl	O
,	O
transferrin	O
saturation	O
index	O
19	O
.	O
5	O
,	O
latent	O
Fe	O
binding	O
capacity	O
148	O
.	O
5	O
ug	O
dl	O
.	O
Lipid	O
profile	O
total	O
cholesterol	O
134	O
mg	O
dl	O
,	O
triglycerides	O
99	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
39	O
mg	O
dl	O
,	O
non	O
HDL	O
cholesterol	O
95	O
mg	O
dl	O
,	O
LDLc	O
cholesterol	O
75	O
mg	O
dl	O
,	O
total	O
cholesterol	O
HDL	O
3	O
.	O
4	O
.	O
Biomarkers	O
of	O
myocardial	O
damage	O
troponin	O
I	O
hsTnI	O
3	O
,	O
109	O
ng	O
l	O
0	O
.	O
0	O
19	O
.	O
8	O
ng	O
l	O
.	O
Immunology	O
immunoglobulin	O
IgG	O
886	O
mg	O
dl	O
,	O
immunoglobulin	O
IgA	O
68	O
mg	O
dl	O
,	O
immunoglobulin	O
IgM	O
38	O
mg	O
dl	O
,	O
total	O
immunoglobulin	O
IgE	O
988	O
KU	O
l	O
,	O
negative	O
anti	O
neutrophil	O
cytoplasm	O
antibodies	O
,	O
negative	O
ANA	O
immunofluorescence	O
,	O
negative	O
IFA	O
pattern	O
,	O
negative	O
rheumatoid	O
factor	O
22	O
U	O
ml	O
,	O
negative	O
direct	O
Coombs	O
test	O
.	O
Complement	O
C3	O
serum	O
108	O
mg	O
dl	O
,	O
complement	O
C4	O
serum	O
24	O
mg	O
dl	O
.	O
Proteinogram	O
serum	O
albumin	O
49	O
.	O
8	O
,	O
alpha	O
1	O
globulin	O
8	O
.	O
3	O
,	O
alpha	O
2	O
globulin	O
14	O
.	O
4	O
,	O
beta	O
globulin	O
12	O
.	O
4	O
,	O
gamma	O
globulin	O
15	O
.	O
1	O
,	O
albumin	O
globulin	O
ratio	O
1	O
,	O
no	O
monoclonal	O
peak	O
observed	O
.	O
Vitamins	O
and	O
hormones	O
vitamin	O
B12	O
308	O
pg	O
ml	O
,	O
folic	O
acid	O
4	O
.	O
1	O
ng	O
ml	O
,	O
basal	O
cortisol	O
15	O
.	O
2	O
g	O
dl	O
,	O
thyrotropin	O
0	O
.	O
57	O
IUU	O
ml	O
.	O
Tumour	O
markers	O
CEA	O
1	O
.	O
7	O
ng	O
ml	O
,	O
PSA	O
0	O
.	O
0	O
ng	O
ml	O
.	O
Microbiology	O
antiStrongyloides	O
stercolaris	O
IgG	O
negative	O
0	O
.	O
80	O
,	O
negative	O
blood	O
cultures	O
,	O
negative	O
stool	O
cultures	O
,	O
negative	O
legionella	O
and	O
pneumococcus	O
antigenuria	O
,	O
negative	O
IGRA	O
.	O
Eosinophil	O
count	O
day	O
by	O
day	O
8	O
.	O
4	O
x109	O
l	O
10	O
.	O
9	O
x10	O
9	O
l	O
0	O
.	O
4	O
x10	O
9	O
l	O
1	O
.	O
2	O
x10	O
9	O
l	O
0	O
.	O
3	O
x10	O
9	O
l	O
0	O
.	O
9	O
x10	O
9	O
l	O
0	O
.	O
4	O
x10	O
9	O
l	O
.	O
Evolution	O
of	O
troponin	O
I	O
levels	O
ng	O
l	O
1	O
,	O
095	O
3	O
,	O
109	O
6	O
,	O
549	O
5	O
,	O
309	O
5	O
,	O
398	O
6	O
,	O
143	O
6	O
,	O
779	O
4	O
,	O
510	O
1	O
,	O
753	O
until	O
negative	O
.	O
Echocardiogram	O
On	O
admission	O
both	O
ventricles	O
of	O
normal	O
diameters	O
and	O
contractility	O
LVEF	O
60	O
,	O
TAPSE	O
24	O
mm	O
.	O
Normal	O
diastolic	O
pattern	O
.	O
Normal	O
filling	O
pressures	O
.	O
Normal	O
LA	O
and	O
aorta	O
.	O
Mild	O
mitral	O
anterior	O
leaflet	O
prolapse	O
,	O
without	O
regurgitation	O
.	O
No	O
data	O
of	O
increased	O
PAPs	O
.	O
Moderate	O
pericardial	O
effusion	O
predominantly	O
lateral	O
and	O
apical	O
maximum	O
17	O
mm	O
posterior	O
and	O
5	O
mm	O
anterior	O
.	O
Normal	O
IVC	O
.	O
No	O
signs	O
of	O
haemodynamic	O
compromise	O
.	O
At	O
discharge	O
left	O
ventricle	O
of	O
normal	O
diameters	O
,	O
volumes	O
and	O
global	O
systolic	O
function	O
.	O
No	O
alterations	O
of	O
segmental	O
contractility	O
at	O
rest	O
.	O
Atria	O
of	O
normal	O
size	O
.	O
Normal	O
diastolic	O
pattern	O
.	O
Absence	O
of	O
significant	O
valvular	O
heart	O
disease	O
.	O
Right	O
ventricle	O
of	O
normal	O
diameters	O
with	O
preserved	O
systolic	O
function	O
.	O
Mild	O
tricuspid	O
regurgitation	O
allowing	O
estimation	O
of	O
a	O
systolic	O
pulmonary	O
artery	O
pressure	O
of	O
25	O
mmHg	O
.	O
Normal	O
inferior	O
vena	O
cava	O
.	O
Mild	O
to	O
moderate	O
pericardial	O
effusion	O
of	O
global	O
distribution	O
,	O
predominantly	O
posterior	O
and	O
lateral	O
posterior	O
12	O
mm	O
especially	O
posteroapical	O
,	O
lateral	O
10	O
mm	O
,	O
anterior	O
5	O
mm	O
,	O
without	O
significant	O
functional	O
repercussions	O
respiratory	O
E	O
wave	O
variation	O
of	O
12	O
.	O
Cardio	O
MRI	O
non	O
dilated	O
left	O
ventricle	O
IVTDVI	O
65	O
ml	O
m2	O
,	O
without	O
hypertrophy	O
or	O
remodelling	O
61	O
g	O
m2	O
,	O
with	O
preserved	O
systolic	O
function	O
and	O
EF	O
calculated	O
by	O
Simpson	O
of	O
56	O
.	O
Non	O
dilated	O
right	O
ventricle	O
IVTDVD	O
92	O
ml	O
m2	O
with	O
good	O
systolic	O
function	O
and	O
an	O
EF	O
calculated	O
by	O
Simpson	O
of	O
65	O
.	O
Normal	O
atria	O
.	O
T2	O
weighted	O
sequences	O
showed	O
oedema	O
in	O
the	O
apex	O
.	O
Perfusion	O
sequences	O
show	O
a	O
slight	O
delay	O
of	O
perfusion	O
in	O
the	O
apex	O
.	O
Mild	O
to	O
moderate	O
pericardial	O
effusion	O
predominantly	O
in	O
the	O
lateral	O
aspect	O
of	O
the	O
left	O
ventricle	O
with	O
a	O
maximum	O
end	O
diastolic	O
thickness	O
of	O
18	O
mm	O
.	O
Late	O
transmural	O
gadolinium	O
enhancement	O
in	O
the	O
apex	O
segment	O
17	O
.	O
Intraventricular	O
thrombus	O
is	O
seen	O
in	O
the	O
area	O
of	O
transmural	O
enhancement	O
.	O
CLINICAL	O
EVOLUTION	O
During	O
his	O
stay	O
in	O
the	O
coronary	O
unit	O
,	O
hypereosinophilia	O
secondary	O
to	O
nasosinusal	O
polyposis	O
ASA	O
triad	O
syndrome	O
was	O
noted	O
,	O
which	O
was	O
present	O
in	O
most	O
of	O
the	O
analytical	O
controls	O
prior	O
to	O
the	O
clinical	O
picture	O
.	O
Haematology	O
was	O
contacted	O
and	O
ruled	O
out	O
monoclonal	O
expansion	O
and	O
alteration	O
of	O
fusion	O
genes	O
tyrosine	O
kinase	O
.	O
Cardio	O
MRI	O
was	O
performed	O
,	O
showing	O
findings	O
compatible	O
with	O
eosinophilic	O
endomyocarditis	O
or	O
Loeffler	O
's	O
with	O
intraventricular	O
thrombus	O
,	O
so	O
treatment	O
was	O
started	O
with	O
methylprenisolone	B-FARMACO
1g	O
IV	O
and	O
later	O
changed	O
to	O
prednisone	B-FARMACO
1	O
mg	O
kg	O
day	O
,	O
with	O
a	O
gradual	O
decrease	O
in	O
eosinophil	O
numbers	O
and	O
pericardial	O
effusion	O
.	O
In	O
addition	O
,	O
enoxaparin	B-FARMACO
was	O
started	O
at	O
an	O
anticoagulant	O
dose	O
.	O
Within	O
hours	O
of	O
enoxaparin	B-FARMACO
administration	O
,	O
the	O
patient	O
presented	O
a	O
reaction	O
consisting	O
of	O
erythematous	O
exanthema	O
with	O
central	O
clearing	O
involving	O
both	O
inguinal	O
flexures	O
,	O
which	O
was	O
categorised	O
by	O
dermatology	O
as	O
SDRIFE	O
symmetric	O
drug	O
related	O
intertriginous	O
and	O
flexural	O
exanthema	O
attenuated	O
by	O
corticosteroids	O
,	O
recommending	O
the	O
replacement	O
of	O
enoxaparin	B-FARMACO
with	O
bemiparin	B-FARMACO
.	O
Subsequent	O
echocardiography	O
showed	O
a	O
reduction	O
in	O
pericardial	O
effusion	O
,	O
located	O
mainly	O
at	O
the	O
posterolateral	O
level	O
,	O
which	O
did	O
not	O
require	O
drainage	O
.	O
Given	O
the	O
favourable	O
response	O
and	O
compatible	O
findings	O
in	O
cardio	O
MRI	O
with	O
idiopathic	O
hypereosinophilic	O
hypereosinophilic	O
syndrome	O
with	O
cardiac	O
involvement	O
eosinophilic	O
endomyocarditis	O
,	O
endomyocardial	O
endomyocarditis	O
was	O
rejected	O
for	O
confirmation	O
given	O
the	O
invasiveness	O
of	O
this	O
test	O
and	O
the	O
limited	O
experience	O
in	O
our	O
centre	O
.	O
Troponin	O
I	O
levels	O
plateaued	O
at	O
6	O
,	O
000	O
ng	O
l	O
for	O
the	O
first	O
6	O
days	O
and	O
subsequently	O
decreased	O
to	O
normal	O
.	O
During	O
his	O
stay	O
in	O
the	O
coronary	O
unit	O
he	O
remained	O
haemodynamically	O
stable	O
,	O
with	O
no	O
arrhythmic	O
events	O
and	O
resolution	O
of	O
flu	O
like	O
symptoms	O
arthromyalgia	O
,	O
fever	O
,	O
etc	O
.	O
.	O
After	O
transfer	O
to	O
the	O
cardiology	O
ward	O
,	O
he	O
presented	O
adequate	O
tolerance	O
to	O
ambulation	O
and	O
remained	O
asymptomatic	O
,	O
so	O
he	O
was	O
discharged	O
home	O
with	O
therapeutic	O
adjustment	O
and	O
follow	O
up	O
in	O
outpatient	O
clinics	O
.	O
Treatment	O
on	O
discharge	O
Bemiparin	B-FARMACO
10	O
,	O
000	O
IU	O
subcutaneous	O
daily	O
as	O
a	O
bridge	O
to	O
acenocoumarol	B-FARMACO
.	O
Acenocoumarol	B-FARMACO
according	O
to	O
guideline	O
.	O
Prednisone	B-FARMACO
110	O
mg	O
orally	O
in	O
the	O
morning	O
and	O
after	O
4	O
weeks	O
reduce	O
the	O
dose	O
by	O
10	O
mg	O
and	O
then	O
reduce	O
by	O
10	O
mg	O
every	O
3	O
weeks	O
to	O
a	O
maintenance	O
dose	O
of	O
5	O
10	O
mg	O
for	O
6	O
months	O
.	O
Omeprazole	B-FARMACO
40	O
mg	O
1	O
tablet	O
per	O
day	O
.	O
Calcium	B-FARMACO
supplement	O
500	O
mg	O
every	O
12	O
hours	O
.	O
DIAGNOSIS	O
Eosinophilic	O
or	O
Loeffler	O
's	O
endocarditis	O
.	O
Intraventricular	O
thrombus	O
.	O
Hypereosinophilic	O
syndrome	O
.	O
ASA	O
triad	O
.	O
Enoxaparin	B-FARMACO
toxicoderma	O
SDRIFE	O
.	O
Prostatic	O
adenocarcinoma	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
Young	O
19	O
year	O
old	O
male	O
Family	O
history	O
paternal	O
grandfather	O
died	O
at	O
an	O
advanced	O
age	O
due	O
to	O
massive	O
pulmonary	O
thromboembolism	O
.	O
Father	O
and	O
mother	O
without	O
thrombosis	O
.	O
Mother	O
without	O
miscarriages	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
Primary	O
antiphospholipid	O
syndrome	O
diagnosed	O
after	O
an	O
episode	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
in	O
2017	O
.	O
High	O
risk	O
serological	O
profile	O
triple	O
antibody	O
positivity	O
AL	O
aCL	O
Anti2	O
GPI	O
positive	O
.	O
Active	O
smoker	O
of	O
3	O
5	O
cigarettes	O
day	O
.	O
No	O
surgical	O
history	O
.	O
Usual	O
treatment	O
acenocoumarol	B-FARMACO
.	O
Present	O
illness	O
A	O
19	O
year	O
old	O
male	O
presented	O
to	O
the	O
emergency	O
department	O
for	O
oppressive	O
central	O
thoracic	O
pain	O
with	O
associated	O
vegetative	O
crusade	O
of	O
3	O
hours	O
'	O
duration	O
that	O
started	O
during	O
exercise	O
and	O
did	O
not	O
subside	O
with	O
rest	O
.	O
It	O
did	O
not	O
radiate	O
,	O
did	O
not	O
change	O
with	O
movement	O
or	O
breathing	O
,	O
no	O
palpitations	O
,	O
dyspnoea	O
or	O
infectious	O
symptoms	O
.	O
He	O
admits	O
not	O
having	O
taken	O
the	O
dose	O
of	O
acenocoumarol	B-FARMACO
for	O
the	O
previous	O
5	O
days	O
for	O
fear	O
of	O
its	O
interaction	O
with	O
alcohol	O
,	O
which	O
he	O
had	O
consumed	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
BP	O
130	O
85	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
65	O
bpm	O
.	O
Basal	O
oxygen	O
saturation	O
99	O
.	O
Respiratory	O
rate	O
16	O
rpm	O
.	O
Good	O
general	O
condition	O
.	O
Conscious	O
and	O
oriented	O
.	O
Afebrile	O
.	O
Sweating	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
without	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
,	O
without	O
added	O
sounds	O
.	O
Lower	O
extremities	O
without	O
oedema	O
or	O
signs	O
of	O
DVT	O
.	O
COMPLEMENTARY	O
TESTS	O
Emergency	O
ECG	O
Sinus	O
bradycardia	O
at	O
55	O
bpm	O
.	O
Normal	O
PR	O
.	O
Narrow	O
QRS	O
with	O
normal	O
axis	O
.	O
ST	O
elevation	O
of	O
3	O
4	O
mm	O
in	O
DII	O
,	O
DIII	O
and	O
aVF	O
and	O
1	O
1	O
.	O
5	O
mm	O
in	O
V5	O
V6	O
,	O
specular	O
ST	O
descent	O
in	O
DI	O
and	O
aVL	O
.	O
Laboratory	O
tests	O
INR	O
on	O
arrival	O
1	O
.	O
1	O
.	O
Haemoglobin	O
15	O
.	O
6	O
g	O
dl	O
,	O
leukocytes	O
11	O
,	O
040	O
l	O
,	O
platelets	O
177	O
,	O
000	O
l	O
.	O
Troponin	O
I	O
hs	O
TnI	O
normal	O
range	O
0	O
53	O
.	O
5	O
initial	O
5	O
,	O
122	O
.	O
3	O
,	O
peak	O
116	O
,	O
052	O
.	O
8	O
ng	O
l	O
,	O
HbA1C	O
5	O
.	O
5	O
,	O
total	O
cholesterol	O
136	O
mg	O
dl	O
,	O
HDL	O
37	O
mg	O
dl	O
,	O
LDL	O
62	O
mg	O
dl	O
,	O
triglycerides	O
188	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
86	O
mg	O
dl	O
,	O
glomerular	O
filtration	O
rate	O
90	O
ml	O
min	O
,	O
sodium	O
136	O
mmol	O
l	O
,	O
potassium	O
3	O
.	O
5	O
mmol	O
l	O
,	O
TSH	O
1	O
IU	O
ml	O
,	O
iron	O
profile	O
normal	O
.	O
Emergent	O
coronary	O
catheterisation	O
right	O
radial	O
access	O
.	O
Truncus	O
no	O
lesions	O
.	O
Anterior	O
descending	O
coronary	O
artery	O
AD	O
normal	O
development	O
,	O
no	O
angiographic	O
lesions	O
.	O
Circumflex	O
coronary	O
artery	O
Cx	O
no	O
angiographic	O
lesions	O
.	O
Right	O
coronary	O
artery	O
RCA	O
dominant	O
,	O
complete	O
thrombotic	O
occlusion	O
in	O
the	O
middle	O
segment	O
.	O
Percutaneous	O
coronary	O
interventionism	O
PCI	O
guidewire	O
is	O
advanced	O
to	O
the	O
distal	O
RCA	O
and	O
several	O
thrombus	O
aspirations	O
are	O
performed	O
,	O
obtaining	O
abundant	O
red	O
thrombus	O
.	O
TIMI	O
3	O
flow	O
was	O
recovered	O
and	O
a	O
long	O
lesion	O
was	O
observed	O
with	O
slight	O
stenosis	O
and	O
remnants	O
of	O
thrombus	O
in	O
the	O
mid	O
distal	O
DC	O
.	O
Distal	O
bed	O
of	O
good	O
development	O
and	O
without	O
lesions	O
.	O
Optical	O
coherence	O
tomography	O
OCT	O
was	O
performed	O
,	O
which	O
showed	O
remains	O
of	O
red	O
thrombus	O
adhered	O
to	O
the	O
wall	O
,	O
without	O
images	O
suggestive	O
of	O
plaque	O
rupture	O
,	O
in	O
a	O
vessel	O
with	O
no	O
signs	O
of	O
atherosclerosis	O
,	O
although	O
at	O
some	O
points	O
the	O
arterial	O
wall	O
was	O
not	O
visible	O
due	O
to	O
the	O
presence	O
of	O
thrombus	O
.	O
In	O
view	O
of	O
these	O
findings	O
,	O
it	O
was	O
decided	O
not	O
to	O
implant	O
a	O
stent	O
.	O
Transthoracic	O
echocardiogram	O
left	O
ventricle	O
not	O
dilated	O
or	O
hypertrophic	O
,	O
with	O
normal	O
overall	O
systolic	O
function	O
LVEF	O
by	O
Simpson	O
biplane	O
of	O
54	O
.	O
Akinesia	O
of	O
medial	O
and	O
basal	O
segments	O
of	O
inferior	O
and	O
inferolateral	O
face	O
.	O
E	O
E	O
'	O
ratio	O
of	O
7	O
.	O
5	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
and	O
function	O
.	O
Atria	O
of	O
normal	O
size	O
.	O
Mild	O
mitral	O
insufficiency	O
.	O
Mild	O
tricuspid	O
insufficiency	O
that	O
allows	O
estimating	O
a	O
PSAP	O
of	O
35	O
mmHg	O
.	O
Normal	O
aortic	O
root	O
and	O
ascending	O
aorta	O
.	O
No	O
pericardial	O
effusion	O
.	O
ECG	O
at	O
discharge	O
sinus	O
rhythm	O
at	O
75	O
bpm	O
.	O
Normal	O
PR	O
.	O
Narrow	O
QRS	O
with	O
Q	O
wave	O
and	O
negative	O
T	O
waves	O
in	O
inferior	O
DII	O
,	O
DIII	O
,	O
aVF	O
and	O
lateral	O
V4	O
V6	O
.	O
CLINICAL	O
EVOLUTION	O
On	O
arrival	O
,	O
an	O
electrocardiogram	O
was	O
performed	O
showing	O
ST	O
elevation	O
and	O
the	O
haemodynamic	O
alert	O
was	O
activated	O
for	O
emergent	O
coronary	O
catheterisation	O
.	O
Thrombotic	O
occlusion	O
was	O
observed	O
in	O
the	O
right	O
coronary	O
artery	O
,	O
and	O
thromboaspiration	O
and	O
balloon	O
angioplasty	O
were	O
performed	O
,	O
recovering	O
TIMI	O
3	O
flow	O
.	O
Intracoronary	O
imaging	O
with	O
OCT	O
was	O
performed	O
with	O
visualisation	O
of	O
residual	O
red	O
thrombus	O
adhered	O
to	O
the	O
wall	O
,	O
with	O
no	O
evidence	O
of	O
plaque	O
rupture	O
or	O
atherosclerosis	O
.	O
In	O
view	O
of	O
these	O
findings	O
,	O
it	O
was	O
decided	O
not	O
to	O
implant	O
a	O
stent	O
.	O
A	O
transthoracic	O
echocardiogram	O
was	O
performed	O
with	O
normal	O
global	O
function	O
and	O
segmental	O
alteration	O
in	O
the	O
DC	O
territory	O
.	O
Double	O
antiplatelet	O
therapy	O
and	O
anticoagulation	O
were	O
started	O
.	O
The	O
patient	O
remained	O
monitored	O
during	O
admission	O
,	O
stable	O
,	O
reintroducing	O
oral	O
anticoagulation	O
,	O
with	O
no	O
complications	O
of	O
renal	O
function	O
or	O
radial	O
puncture	O
.	O
Since	O
this	O
was	O
a	O
thrombotic	O
event	O
,	O
in	O
the	O
context	O
of	O
incorrect	O
anticoagulation	O
and	O
with	O
coronary	O
arteries	O
without	O
lesions	O
,	O
it	O
was	O
decided	O
to	O
maintain	O
anticoagulation	O
and	O
indefinite	O
statins	O
together	O
with	O
antiplatelet	O
therapy	O
with	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
for	O
one	O
month	O
.	O
On	O
discharge	O
,	O
the	O
patient	O
was	O
referred	O
to	O
the	O
cardiac	O
rehabilitation	O
programme	O
.	O
A	O
coronary	O
CT	O
scan	O
at	O
2	O
months	O
showed	O
epicardial	O
coronary	O
arteries	O
without	O
lesions	O
.	O
DIAGNOSIS	O
Acute	O
inferolateral	O
myocardial	O
infarction	O
of	O
thrombotic	O
origin	O
.	O
Urgent	O
right	O
coronary	O
artery	O
revascularisation	O
.	O
Preserved	O
LV	O
systolic	O
function	O
.	O
Primary	O
antiphospholipid	O
syndrome	O
with	O
high	O
risk	O
profile	O
.	O
Abandonment	O
of	O
oral	O
anticoagulant	O
therapy	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
47	O
year	O
old	O
woman	O
referred	O
for	O
syncope	O
with	O
2	O
1	O
atrioventricular	O
block	O
AVB	O
.	O
History	O
Independent	O
for	O
ABVD	O
,	O
but	O
in	O
need	O
of	O
support	O
.	O
Lives	O
with	O
her	O
parents	O
.	O
Separated	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
No	O
family	O
history	O
of	O
heart	O
disease	O
or	O
early	O
sudden	O
cardiac	O
death	O
.	O
No	O
toxic	O
habits	O
.	O
No	O
cardiovascular	O
risk	O
factors	O
.	O
Normal	O
weight	O
weight	O
57	O
.	O
5	O
kg	O
,	O
height	O
1	O
.	O
58	O
m	O
.	O
Mitochondrial	O
cytopathy	O
phenotype	O
MELAS	O
diagnosis	O
at	O
23	O
years	O
of	O
age	O
.	O
Predominance	O
of	O
severe	O
sensorineural	O
deafness	O
and	O
exercise	O
intolerance	O
due	O
to	O
myopathy	O
.	O
On	O
treatment	O
with	O
valproate	B-FARMACO
and	O
phenobarbital	B-FARMACO
,	O
with	O
last	O
complex	O
tonic	O
comical	O
seizure	O
1	O
year	O
ago	O
.	O
CT	O
scan	O
with	O
no	O
new	O
lesions	O
.	O
Frequent	O
hyponatremia	O
.	O
Right	O
bundle	O
branch	O
block	O
and	O
left	O
anterior	O
hemiblock	O
.	O
Surgical	O
interventions	O
cholecystectomy	O
2012	O
and	O
appendectomy	O
in	O
childhood	O
.	O
Usual	O
medication	O
valproate	B-FARMACO
500	O
mg	O
1	O
1	O
1	O
,	O
phenobarbital	B-FARMACO
50	O
mg	O
0	O
0	O
1	O
,	O
ubiquinone	B-FARMACO
100	O
mg	O
0	O
1	O
0	O
,	O
lorazepam	B-FARMACO
1	O
mg	O
0	O
0	O
0	O
1	O
.	O
Present	O
illness	O
Anamnesis	O
through	O
the	O
family	O
for	O
aphasia	O
and	O
severe	O
hypoacusis	O
of	O
the	O
patient	O
.	O
They	O
report	O
that	O
on	O
waking	O
up	O
in	O
the	O
morning	O
she	O
is	O
pale	O
with	O
sweating	O
and	O
nausea	O
.	O
Subsequently	O
,	O
dizziness	O
intensified	O
,	O
falling	O
to	O
the	O
floor	O
with	O
loss	O
of	O
consciousness	O
and	O
rapid	O
recovery	O
.	O
The	O
emergency	O
service	O
was	O
called	O
,	O
but	O
the	O
clinical	O
manifestations	O
persisted	O
on	O
arrival	O
,	O
revealing	O
a	O
2	O
1	O
AVB	O
,	O
conducted	O
heartbeat	O
with	O
morphology	O
of	O
left	O
bundle	O
branch	O
block	O
.	O
She	O
was	O
referred	O
to	O
the	O
regional	O
hospital	O
,	O
being	O
asymptomatic	O
on	O
arrival	O
and	O
with	O
ECG	O
in	O
sinus	O
rhythm	O
with	O
AV	O
conduction	O
1	O
1	O
.	O
No	O
chest	O
pain	O
,	O
palpitations	O
,	O
dyspnoea	O
or	O
other	O
accompanying	O
symptoms	O
.	O
She	O
was	O
referred	O
to	O
our	O
centre	O
for	O
cardiology	O
assessment	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
BP	O
92	O
62	O
mmHg	O
,	O
heart	O
rate	O
HR	O
72	O
bpm	O
,	O
SatO99	O
,	O
temperature	O
35	O
oC	O
.	O
Conscious	O
and	O
oriented	O
.	O
No	O
neurological	O
focality	O
.	O
Rhythmic	O
tones	O
,	O
no	O
murmurs	O
or	O
rubs	O
.	O
Symmetrical	O
pulses	O
.	O
No	O
jugular	O
ingurgitation	O
.	O
No	O
oedema	O
.	O
Good	O
bilateral	O
air	O
entry	O
,	O
no	O
extra	O
sounds	O
.	O
Abdomen	O
soft	O
,	O
slight	O
distension	O
at	O
epigastric	O
level	O
,	O
not	O
painful	O
on	O
palpation	O
.	O
Peristalsis	O
preserved	O
.	O
COMPLEMENTARY	O
TESTS	O
First	O
ECG	O
performed	O
by	O
the	O
emergency	O
service	O
at	O
the	O
first	O
medical	O
contact	O
BAV	O
2	O
1	O
at	O
35	O
bpm	O
,	O
conducted	O
beat	O
with	O
QRS	O
of	O
110	O
msec	O
with	O
short	O
PR	O
of	O
100	O
msec	O
and	O
electrical	O
image	O
compatible	O
with	O
negative	O
delta	O
wave	O
in	O
V1	O
,	O
positive	O
in	O
V3	O
V6	O
,	O
II	O
,	O
III	O
,	O
aVF	O
.	O
ECG	O
on	O
admission	O
to	O
our	O
centre	O
sinus	O
rhythm	O
at	O
80	O
bpm	O
,	O
AV	O
conduction	O
1	O
1	O
PR	O
100	O
ms	O
and	O
QRS	O
of	O
110	O
msec	O
with	O
image	O
compatible	O
with	O
pre	O
excitation	O
,	O
similar	O
to	O
the	O
previous	O
one	O
.	O
Posteroanterior	O
chest	O
X	O
ray	O
performed	O
in	O
the	O
emergency	O
room	O
of	O
our	O
centre	O
normal	O
cardiac	O
silhouette	O
.	O
No	O
condensation	O
in	O
the	O
lung	O
parenchyma	O
.	O
No	O
signs	O
of	O
heart	O
failure	O
or	O
pleural	O
effusion	O
.	O
Initial	O
blood	O
tests	O
glucose	O
305	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
8	O
mg	O
dl	O
GFR	O
90	O
ml	O
min	O
,	O
urea	O
61	O
mmol	O
l	O
,	O
CK	O
328	O
mU	O
ml	O
,	O
TnUs	O
61	O
ng	O
l	O
,	O
Na	O
130	O
mEq	O
l	O
corrected	O
136	O
mEq	O
l	O
,	O
K	O
4	O
.	O
6	O
mEq	O
l	O
.	O
Haemogram	O
leucocytes	O
13	O
.	O
1x109	O
l	O
N	O
53	O
.	O
1	O
,	O
L	O
37	O
.	O
3	O
,	O
haemoglobin	O
12	O
.	O
1	O
g	O
dl	O
,	O
haematocrit	O
36	O
,	O
platelets	O
217	O
x109	O
l	O
,	O
INR	O
0	O
.	O
98	O
.	O
Venous	O
blood	O
gas	O
on	O
admission	O
pH	O
7	O
.	O
231	O
,	O
pCO2	O
40	O
.	O
7	O
mmHg	O
,	O
HCO3	O
15	O
.	O
5	O
mEq	O
L	O
,	O
EB	O
10	O
.	O
5	O
mEq	O
L	O
,	O
lactate	O
8	O
.	O
6	O
mEq	O
l	O
.	O
Control	O
blood	O
test	O
5	O
hours	O
after	O
admission	O
CK	O
292	O
mU	O
ml	O
,	O
troponin	O
I	O
US	O
100	O
ng	O
l	O
,	O
lactate	O
4	O
.	O
4m	O
Eq	O
l	O
.	O
Transthoracic	O
echocardiogram	O
non	O
dilated	O
left	O
ventricle	O
,	O
slightly	O
concentrically	O
hypertrophied	O
,	O
with	O
normal	O
systolic	O
diastolic	O
function	O
.	O
No	O
significant	O
valvulopathies	O
.	O
Mild	O
pulmonary	O
hypertension	O
estimated	O
PAPs	O
36	O
38	O
mmHg	O
.	O
Normal	O
right	O
ventricle	O
.	O
CLINICAL	O
EVOLUTION	O
A	O
47	O
year	O
old	O
woman	O
with	O
MELAS	O
syndrome	O
was	O
admitted	O
for	O
symptomatic	O
syncopal	O
2	O
1	O
AVB	O
and	O
with	O
an	O
image	O
compatible	O
with	O
pre	O
excitation	O
that	O
persisted	O
despite	O
the	O
conduction	O
disorder	O
,	O
leading	O
to	O
the	O
diagnosis	O
of	O
an	O
associated	O
fasciculoventricular	O
accessory	O
pathway	O
origin	O
posterior	O
to	O
the	O
atrioventricular	O
node	O
.	O
The	O
echocardiogram	O
showed	O
mild	O
ventricular	O
hypertrophy	O
with	O
slightly	O
elevated	O
PSAP	O
.	O
Laboratory	O
tests	O
showed	O
initial	O
lactate	O
of	O
8	O
mEq	O
l	O
and	O
later	O
4	O
mEq	O
l	O
,	O
with	O
slight	O
initial	O
acidosis	O
that	O
remained	O
with	O
slightly	O
elevated	O
lactate	O
and	O
was	O
attributed	O
to	O
mitochondrial	O
disease	O
previous	O
lactate	O
always	O
elevated	O
2	O
.	O
5	O
11	O
.	O
Admitted	O
to	O
the	O
coronary	O
unit	O
for	O
close	O
monitoring	O
and	O
implantation	O
of	O
a	O
permanent	O
pacemaker	O
.	O
Favourable	O
evolution	O
since	O
admission	O
,	O
remaining	O
asymptomatic	O
at	O
all	O
times	O
,	O
in	O
sinus	O
rhythm	O
with	O
1	O
1	O
AV	O
conduction	O
,	O
with	O
no	O
recurrence	O
of	O
bradyarrhythmia	O
.	O
Twenty	O
four	O
hours	O
after	O
admission	O
,	O
a	O
bicameral	O
pacemaker	O
was	O
implanted	O
without	O
incident	O
and	O
subsequently	O
,	O
after	O
verifying	O
the	O
normal	O
functioning	O
of	O
the	O
device	O
and	O
the	O
absence	O
of	O
complications	O
,	O
she	O
was	O
discharged	O
home	O
.	O
DIAGNOSIS	O
Symptomatic	O
2	O
1	O
AV	O
block	O
syncopal	O
.	O
Electrocardiographic	O
image	O
compatible	O
with	O
ventricular	O
pre	O
excitation	O
by	O
a	O
fasciculoventricular	O
accessory	O
pathway	O
considering	O
persistence	O
of	O
QRS	O
morphology	O
despite	O
AVB	O
.	O
MELAS	O
syndrome	O
mitochondrial	O
myopathy	O
,	O
encephalopathy	O
,	O
lactic	O
acidosis	O
,	O
and	O
stroke	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Personal	O
history	O
No	O
known	O
drug	O
allergies	O
.	O
Cardiovascular	O
risk	O
factors	O
dyslipidaemia	O
under	O
pharmacological	O
treatment	O
.	O
Active	O
cannabis	O
smoker	O
7	O
cigarettes	O
a	O
day	O
,	O
former	O
tobacco	O
smoker	O
accumulated	O
2	O
packs	O
year	O
.	O
No	O
known	O
arterial	O
hypertension	O
AHT	O
or	O
diabetes	O
mellitus	O
DM	O
.	O
No	O
previous	O
cardiological	O
history	O
.	O
Other	O
Testicular	O
cancer	O
classic	O
clinical	O
stage	O
IIA	O
seminoma	O
after	O
right	O
orchiectomy	O
on	O
active	O
treatment	O
with	O
QT	O
cisplatin	B-FARMACO
etoposide	I-FARMACO
,	O
he	O
has	O
only	O
received	O
one	O
cycle	O
.	O
Ankylopoietic	O
spondylitis	O
diagnosed	O
6	O
years	O
ago	O
.	O
Chronic	O
treatment	O
atorvastatin	B-FARMACO
20	O
mg	O
,	O
1	O
tablet	O
at	O
dinner	O
.	O
Present	O
illness	O
A	O
37	O
year	O
old	O
man	O
came	O
to	O
the	O
emergency	O
department	O
with	O
chest	O
pain	O
of	O
approximately	O
1	O
hour	O
's	O
duration	O
.	O
It	O
subsides	O
after	O
administration	O
of	O
paracetamol	B-FARMACO
.	O
He	O
describes	O
it	O
as	O
oppressive	O
,	O
non	O
radiating	O
,	O
with	O
no	O
accompanying	O
vegetative	O
cortex	O
and	O
onset	O
at	O
rest	O
.	O
It	O
does	O
not	O
increase	O
with	O
inspiration	O
or	O
chest	O
movements	O
.	O
No	O
previous	O
angina	O
.	O
Cough	O
with	O
expectoration	O
for	O
4	O
days	O
.	O
No	O
fever	O
,	O
no	O
dyspnoea	O
,	O
no	O
abdominal	O
pain	O
,	O
no	O
alterations	O
in	O
bowel	O
habits	O
.	O
No	O
other	O
symptoms	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
BP	O
125	O
82	O
mmHg	O
,	O
heart	O
rate	O
HR	O
72	O
bpm	O
,	O
basal	O
O2	O
Sat	O
98	O
.	O
Good	O
general	O
condition	O
.	O
Conscious	O
,	O
oriented	O
and	O
cooperative	O
.	O
Normohydrated	O
and	O
normal	O
colour	O
.	O
Eupneic	O
at	O
rest	O
.	O
No	O
neurological	O
focality	O
.	O
Jugular	O
venous	O
pressure	O
normal	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
vesicular	O
murmur	O
vvm	O
,	O
without	O
added	O
noises	O
.	O
Abdomen	O
normal	O
hydro	O
aerial	O
sounds	O
,	O
soft	O
and	O
depressible	O
,	O
no	O
pain	O
on	O
palpation	O
.	O
No	O
signs	O
of	O
peritoneal	O
irritation	O
.	O
Lower	O
extremities	O
pulses	O
preserved	O
,	O
no	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
tests	O
Serial	O
myocardial	O
damage	O
markers	O
on	O
admission	O
on	O
arrival	O
,	O
at	O
3	O
hours	O
,	O
at	O
24	O
hours	O
,	O
at	O
36	O
hours	O
and	O
at	O
discharge	O
Biochemistry	O
glucose	O
101	O
mg	O
dl	O
,	O
urea	O
52	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
13	O
mg	O
dl	O
,	O
sodium	O
137	O
mmol	O
l	O
,	O
potassium	O
4	O
.	O
5	O
mmol	O
l	O
,	O
magnesium	O
2	O
mg	O
dl	O
.	O
Lipid	O
profile	O
total	O
cholesterol	O
220	O
mg	O
dl	O
,	O
LDL	O
145	O
mg	O
dl	O
,	O
HDL	O
45	O
mg	O
dl	O
,	O
TG	O
147	O
mg	O
dl	O
.	O
HbA1c	O
5	O
.	O
4	O
.	O
TSH	O
1	O
.	O
22	O
UI	O
ml	O
.	O
Haemogram	O
Hb	O
15	O
.	O
6	O
g	O
dl	O
,	O
MCV	O
85	O
.	O
6	O
fl	O
,	O
MCH	O
28	O
.	O
8	O
pg	O
,	O
leukocytes	O
6	O
,	O
900	O
l	O
,	O
platelets	O
222	O
,	O
000	O
l	O
.	O
Creatine	O
kinase	O
33	O
47	O
102	O
47	O
29	O
U	O
l	O
.	O
Troponin	O
t	O
US	O
normal	O
14	O
18	O
102	O
267	O
140	O
99	O
ng	O
l	O
.	O
Coagulation	O
INR	O
1	O
.	O
12	O
,	O
prothrombin	O
time	O
83	O
.	O
0	O
2	O
.	O
Partial	O
thromboplastin	O
time	O
28	O
.	O
6	O
s	O
,	O
partial	O
thromboplastin	O
time	O
ratio	O
0	O
.	O
95	O
.	O
D	O
Dimer	O
411	O
ng	O
mg	O
.	O
Electrocardiogram	O
ECG	O
sinus	O
bradycardia	O
around	O
50	O
bpm	O
.	O
Normal	O
PR	O
.	O
Narrow	O
QRS	O
with	O
normal	O
axis	O
,	O
without	O
acute	O
repolarisation	O
alterations	O
.	O
Chest	O
X	O
ray	O
normal	O
CTI	O
,	O
no	O
masses	O
,	O
no	O
parenchymal	O
condensations	O
,	O
no	O
signs	O
of	O
heart	O
failure	O
.	O
Coronary	O
angiography	O
on	O
admission	O
Left	O
coronary	O
artery	O
no	O
lesions	O
.	O
Anterior	O
descending	O
artery	O
LAD	O
long	O
vessel	O
of	O
good	O
calibre	O
and	O
development	O
.	O
Large	O
intraluminal	O
thrombus	O
organised	O
in	O
the	O
middle	O
segment	O
,	O
causing	O
a	O
stenosis	O
of	O
60	O
and	O
with	O
TIMI	O
3	O
flow	O
.	O
Distal	O
bed	O
good	O
,	O
without	O
lesions	O
or	O
thrombotic	O
material	O
.	O
Circumflex	O
vessel	O
of	O
good	O
calibre	O
and	O
development	O
,	O
without	O
lesions	O
.	O
Right	O
coronary	O
dominant	O
,	O
without	O
lesions	O
.	O
Control	O
coronary	O
angiography	O
after	O
one	O
week	O
of	O
triple	O
antiplatelet	O
and	O
anticoagulant	O
therapy	O
coronary	O
arteries	O
without	O
angiographically	O
significant	O
lesions	O
.	O
Complete	O
resolution	O
of	O
the	O
previous	O
thrombus	O
.	O
Transthoracic	O
echocardiogram	O
on	O
admission	O
,	O
prior	O
to	O
coronary	O
angiography	O
left	O
ventricle	O
LV	O
of	O
normal	O
size	O
and	O
thickness	O
,	O
preserved	O
ejection	O
fraction	O
LVEF	O
,	O
with	O
no	O
alterations	O
in	O
regional	O
contractility	O
.	O
No	O
evidence	O
of	O
ventricular	O
thrombus	O
.	O
No	O
valvular	O
heart	O
disease	O
.	O
No	O
pericardial	O
effusion	O
.	O
Consultation	O
with	O
the	O
medical	O
oncology	O
service	O
chemotherapy	O
was	O
suspended	O
due	O
to	O
its	O
association	O
with	O
arterial	O
thrombotic	O
events	O
.	O
Ipsilateral	O
radiotherapy	O
was	O
proposed	O
as	O
an	O
alternative	O
treatment	O
.	O
ECG	O
at	O
discharge	O
sinus	O
rhythm	O
at	O
60	O
bpm	O
.	O
Normal	O
PR	O
.	O
No	O
pathological	O
Q	O
waves	O
.	O
Narrow	O
QRS	O
with	O
normal	O
axis	O
,	O
without	O
repolarisation	O
alterations	O
.	O
CLINICAL	O
EVOLUTION	O
37	O
year	O
old	O
male	O
smoker	O
and	O
dyslipidaemic	O
,	O
with	O
a	O
history	O
of	O
testicular	O
seminoma	O
and	O
active	O
treatment	O
with	O
chemotherapy	O
cisplatin	B-FARMACO
etoposide	I-FARMACO
with	O
the	O
last	O
dose	O
administered	O
8	O
days	O
before	O
admission	O
.	O
He	O
was	O
admitted	O
for	O
chest	O
pain	O
with	O
mobilisation	O
of	O
markers	O
of	O
myocardial	O
damage	O
without	O
changes	O
in	O
the	O
ECG	O
,	O
and	O
it	O
was	O
decided	O
to	O
admit	O
him	O
as	O
an	O
acute	O
myocardial	O
infarction	O
without	O
ST	O
segment	O
elevation	O
STEMI	O
,	O
postulating	O
a	O
possible	O
relationship	O
with	O
his	O
pathology	O
or	O
oncological	O
treatment	O
.	O
Treatment	O
was	O
started	O
with	O
anticoagulation	O
with	O
low	B-FARMACO
molecular	I-FARMACO
weight	I-FARMACO
heparin	I-FARMACO
and	O
double	O
antiplatelet	O
therapy	O
with	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
and	O
clopidogrel	B-FARMACO
.	O
On	O
admission	O
,	O
coronary	O
angiography	O
showed	O
an	O
organised	O
thrombus	O
in	O
the	O
middle	O
segment	O
of	O
the	O
LAD	O
with	O
a	O
stenosis	O
of	O
60	O
.	O
Given	O
this	O
history	O
,	O
conservative	O
management	O
was	O
decided	O
,	O
initially	O
with	O
tirofiban	B-FARMACO
perfusion	O
for	O
24	O
hours	O
and	O
then	O
a	O
change	O
to	O
ticagrelor	B-FARMACO
together	O
with	O
ASA	B-FARMACO
and	O
anticoagulation	O
with	O
low	B-FARMACO
molecular	I-FARMACO
weight	I-FARMACO
heparin	I-FARMACO
triple	O
antithrombotic	O
therapy	O
,	O
with	O
the	O
idea	O
of	O
repeating	O
the	O
coronary	O
angiography	O
and	O
trying	O
to	O
avoid	O
stent	O
implantation	O
.	O
After	O
a	O
week	O
of	O
treatment	O
,	O
the	O
coronary	O
angiography	O
was	O
repeated	O
and	O
showed	O
disappearance	O
of	O
the	O
previous	O
thrombus	O
,	O
with	O
no	O
significant	O
underlying	O
lesions	O
in	O
the	O
three	O
vessels	O
,	O
and	O
anticoagulant	O
treatment	O
was	O
then	O
suspended	O
.	O
The	O
transthoracic	O
echocardiogram	O
showed	O
preserved	O
LVEF	O
.	O
Good	O
clinical	O
evolution	O
asymptomatic	O
,	O
haemodynamically	O
stable	O
and	O
with	O
troponins	O
in	O
decline	O
.	O
Finally	O
,	O
he	O
was	O
discharged	O
home	O
to	O
continue	O
medical	O
treatment	O
with	O
double	O
platelet	O
antiplatelet	O
therapy	O
with	O
ASA	B-FARMACO
and	O
ticagrelor	B-FARMACO
.	O
From	O
the	O
point	O
of	O
view	O
of	O
his	O
testicular	O
cancer	O
,	O
an	O
assessment	O
was	O
requested	O
from	O
medical	O
oncology	O
,	O
who	O
decided	O
to	O
suspend	O
chemotherapy	O
treatment	O
due	O
to	O
the	O
relationship	O
of	O
cisplatin	B-FARMACO
with	O
acute	O
coronary	O
thrombotic	O
events	O
,	O
proposing	O
a	O
change	O
to	O
radiotherapy	O
outpatient	O
and	O
follow	O
up	O
on	O
his	O
part	O
.	O
DIAGNOSIS	O
STEMI	O
.	O
Acute	O
anterior	O
descending	O
thrombosis	O
secondary	O
to	O
treatment	O
with	O
cisplatin	B-FARMACO
,	O
resolved	O
after	O
one	O
week	O
of	O
triple	O
antiplatelet	O
therapy	O
and	O
anticoagulation	O
.	O
Coronary	O
arteries	O
without	O
underlying	O
atherosclerotic	O
lesions	O
.	O
Preserved	O
LVEF	O
.	O
Classic	O
stage	O
IIA	O
seminoma	O
with	O
active	O
chemotherapy	O
treatment	O
cisplatin	B-FARMACO
etoposide	I-FARMACO
,	O
which	O
was	O
discontinued	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Personal	O
history	O
Male	O
patient	O
aged	O
28	O
years	O
.	O
No	O
known	O
allergic	O
reactions	O
to	O
medication	O
.	O
No	O
cardiovascular	O
risk	O
factors	O
.	O
No	O
known	O
consumption	O
of	O
toxic	O
substances	O
.	O
Cardiological	O
history	O
no	O
known	O
heart	O
disease	O
.	O
No	O
other	O
relevant	O
pathologies	O
.	O
Family	O
history	O
paternal	O
uncle	O
suffered	O
from	O
colorectal	O
cancer	O
at	O
the	O
age	O
of	O
58	O
.	O
No	O
other	O
family	O
history	O
of	O
interest	O
.	O
He	O
does	O
not	O
take	O
treatments	O
on	O
a	O
regular	O
basis	O
.	O
Current	O
illness	O
Patient	O
presented	O
to	O
the	O
emergency	O
department	O
for	O
sudden	O
loss	O
of	O
consciousness	O
while	O
watching	O
a	O
football	O
match	O
.	O
He	O
did	O
not	O
present	O
chest	O
pain	O
before	O
or	O
after	O
the	O
episode	O
,	O
but	O
did	O
report	O
an	O
abrupt	O
onset	O
of	O
palpitations	O
at	O
a	O
high	O
frequency	O
in	O
the	O
moments	O
prior	O
to	O
the	O
event	O
.	O
He	O
reported	O
some	O
previous	O
general	O
malaise	O
,	O
but	O
denied	O
fever	O
or	O
infectious	O
symptoms	O
.	O
He	O
denied	O
the	O
use	O
of	O
drugs	O
or	O
toxic	O
substances	O
.	O
The	O
observers	O
did	O
not	O
describe	O
shaking	O
or	O
signs	O
attributable	O
to	O
neurological	O
focality	O
.	O
The	O
patient	O
's	O
memory	O
of	O
the	O
moments	O
after	O
regaining	O
consciousness	O
was	O
preserved	O
.	O
During	O
his	O
transfer	O
to	O
out	O
of	O
hospital	O
medical	O
services	O
,	O
he	O
presented	O
a	O
new	O
episode	O
of	O
loss	O
of	O
consciousness	O
,	O
at	O
which	O
time	O
the	O
electrocardiographic	O
recording	O
showed	O
a	O
rhythm	O
compatible	O
with	O
ventricular	O
fibrillation	O
,	O
which	O
resolved	O
after	O
2	O
shocks	O
at	O
100	O
J	O
,	O
restoring	O
sinus	O
rhythm	O
.	O
Physical	O
examination	O
Temperature	O
36o	O
C	O
;	O
blood	O
pressure	O
159	O
83	O
mmHg	O
;	O
heart	O
rate	O
86	O
bpm	O
;	O
O2	O
saturation	O
97	O
without	O
contributions	O
.	O
No	O
signs	O
of	O
tachypnoea	O
at	O
rest	O
.	O
Neurological	O
examination	O
without	O
alterations	O
.	O
Cardiac	O
auscultation	O
was	O
rhythmic	O
,	O
without	O
murmurs	O
and	O
pulmonary	O
auscultation	O
without	O
pathological	O
sounds	O
.	O
Abdominal	O
examination	O
showed	O
no	O
palpable	O
organomegaly	O
,	O
hepatojugular	O
reflux	O
was	O
negative	O
.	O
The	O
lower	O
limbs	O
were	O
free	O
of	O
oedema	O
and	O
there	O
were	O
no	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
Pulses	O
were	O
strong	O
and	O
symmetrical	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
tests	O
in	O
the	O
ED	O
leukocytes	O
8300	O
ml	O
,	O
haemoglobin	O
15	O
.	O
3	O
g	O
dl	O
;	O
platelets	O
235000	O
u	O
l	O
.	O
No	O
coagulation	O
alterations	O
;	O
basal	O
glucose	O
108	O
mg	O
dl	O
;	O
urea	O
43	O
mg	O
dl	O
;	O
creatinine	O
0	O
.	O
67	O
mg	O
dl	O
;	O
estimated	O
glomerular	O
filtration	O
rate	O
MDRD	O
4	O
97	O
ml	O
min	O
1	O
.	O
73	O
m2	O
;	O
total	O
bilirubin	O
0	O
.	O
6	O
mg	O
dl	O
;	O
GOT	O
22	O
IU	O
l	O
;	O
CPK	O
107	O
IU	O
l	O
;	O
Na	O
136	O
mmol	O
l	O
;	O
potassium	O
4	O
.	O
4	O
mmol	O
l	O
;	O
corrected	O
calcium	O
9	O
.	O
5	O
mg	O
dl	O
;	O
magnesium	O
2	O
mg	O
dl	O
;	O
urine	O
toxins	O
drugs	O
of	O
abuse	O
negative	O
.	O
Out	O
of	O
hospital	O
electrocardiogram	O
ECG	O
during	O
loss	O
of	O
consciousness	O
ventricular	O
fibrillation	O
rhythm	O
evidenced	O
during	O
out	O
of	O
hospital	O
monitoring	O
.	O
Baseline	O
12	O
lead	O
surface	O
ECG	O
sinus	O
rhythm	O
without	O
pre	O
excitation	O
or	O
atrioventricular	O
AV	O
conduction	O
block	O
.	O
QRS	O
with	O
Ic	O
oved	O
type	O
Brugada	O
pattern	O
morphology	O
.	O
A	O
right	O
bundle	O
branch	O
block	O
morphology	O
with	O
rsR	O
"	O
complex	O
is	O
observed	O
,	O
which	O
continues	O
with	O
a	O
descending	O
ST	O
that	O
crosses	O
the	O
isoelectric	O
line	O
to	O
continue	O
with	O
a	O
negative	O
T	O
.	O
The	O
corrected	O
QT	O
interval	O
is	O
normal	O
.	O
The	O
corrected	O
QT	O
interval	O
is	O
normal	O
.	O
As	O
the	O
electrostatic	O
positioning	O
is	O
moved	O
up	O
one	O
intercostal	O
space	O
the	O
pattern	O
becomes	O
more	O
evident	O
.	O
Urgent	O
transthoracic	O
echocardiogram	O
preserved	O
systolic	O
function	O
,	O
without	O
alterations	O
of	O
segmental	O
contractility	O
.	O
Chambers	O
neither	O
dilated	O
nor	O
hypertrophic	O
.	O
Tricuspid	O
aortic	O
valve	O
with	O
no	O
remarkable	O
valvulopathy	O
.	O
Normally	O
functioning	O
mitral	O
valve	O
.	O
No	O
other	O
significant	O
valvulopathies	O
were	O
observed	O
.	O
No	O
pericardial	O
effusion	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
,	O
with	O
adequate	O
inspiratory	O
collapsibility	O
.	O
Conclusion	O
study	O
within	O
normal	O
parameters	O
Cardiac	O
magnetic	O
resonance	O
imaging	O
MRI	O
MRI	O
study	O
with	O
anatomical	O
sequences	O
in	O
the	O
axial	O
plane	O
enhanced	O
in	O
T1	O
and	O
T2	O
,	O
cine	O
sequences	O
in	O
short	O
axis	O
,	O
four	O
chambers	O
and	O
right	O
ventricular	O
outflow	O
tract	O
RV	O
and	O
,	O
finally	O
,	O
late	O
enhancement	O
in	O
short	O
axis	O
and	O
four	O
chambers	O
.	O
Anatomical	O
assessment	O
cavities	O
neither	O
hypertrophic	O
nor	O
dilated	O
,	O
within	O
normal	O
limits	O
left	O
atrium	O
58	O
x	O
20	O
mm	O
;	O
right	O
atrium	O
52	O
x	O
46	O
mm	O
;	O
left	O
ventricle	O
55	O
x	O
98	O
mm	O
;	O
right	O
ventricle	O
42	O
x	O
88	O
mm	O
.	O
Interventricular	O
septum	O
9	O
mm	O
with	O
free	O
wall	O
7	O
mm	O
.	O
Right	O
ventricle	O
wall	O
3	O
mm	O
.	O
No	O
contractility	O
alterations	O
were	O
observed	O
.	O
No	O
oedema	O
is	O
seen	O
in	O
the	O
T2	O
sequences	O
.	O
No	O
late	O
enhancement	O
after	O
gadolinium	O
administration	O
.	O
There	O
was	O
no	O
pericardial	O
effusion	O
.	O
In	O
the	O
functional	O
study	O
the	O
following	O
parameters	O
were	O
found	O
left	O
ventricular	O
ejection	O
fraction	O
58	O
.	O
8	O
;	O
stroke	O
volume	O
104	O
.	O
3	O
ml	O
;	O
cardiac	O
output	O
5	O
.	O
5	O
l	O
min	O
;	O
end	O
diastolic	O
volume	O
177	O
.	O
5	O
ml	O
;	O
end	O
systolic	O
volume	O
73	O
.	O
2	O
ml	O
.	O
Conclusion	O
no	O
pathological	O
findings	O
.	O
Study	O
not	O
suggestive	O
of	O
structural	O
cardiomyopathy	O
video	O
1	O
.	O
Genetic	O
study	O
channelopathies	O
panel	O
.	O
Missense	O
mutation	O
in	O
geSnCN5	O
.	O
Sequence	O
NM_198056	O
.	O
Nucleotide	O
change	O
G298S	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
cardiology	O
department	O
for	O
study	O
of	O
underlying	O
heart	O
disease	O
and	O
intensive	O
monitoring	O
with	O
the	O
option	O
of	O
defibrillation	O
.	O
A	O
morphological	O
study	O
was	O
performed	O
with	O
transthoracic	O
echocardiography	O
and	O
cardiac	O
magnetic	O
resonance	O
CMR	O
video	O
1	O
.	O
After	O
completing	O
a	O
study	O
that	O
ruled	O
out	O
other	O
heart	O
disease	O
and	O
after	O
the	O
surface	O
ECG	O
of	O
one	O
of	O
the	O
daily	O
controls	O
showed	O
a	O
spontaneous	O
Brugada	O
pattern	O
type	O
1	O
shark	O
fin	O
,	O
the	O
patient	O
was	O
diagnosed	O
with	O
Brugada	O
syndrome	O
and	O
the	O
implantation	O
of	O
an	O
implantable	O
cardioverter	O
defibrillator	O
ICD	O
was	O
indicated	O
for	O
secondary	O
prevention	O
.	O
As	O
this	O
was	O
the	O
first	O
known	O
event	O
,	O
hygienic	O
dietary	O
and	O
lifestyle	O
recommendations	O
were	O
made	O
,	O
but	O
no	O
further	O
treatment	O
was	O
indicated	O
.	O
During	O
follow	O
up	O
,	O
with	O
quarterly	O
reviews	O
of	O
the	O
device	O
,	O
asymptomatic	O
low	O
density	O
ventricular	O
extrasystoles	O
were	O
detected	O
,	O
and	O
beta	O
blocker	O
treatment	O
with	O
carvedilol	B-FARMACO
6	O
.	O
25	O
mg	O
daily	O
was	O
started	O
.	O
A	O
genetic	O
study	O
was	O
performed	O
for	O
family	O
counselling	O
presenting	O
a	O
missense	O
mutation	O
in	O
the	O
SCN5	O
gene	O
and	O
clinical	O
assessment	O
of	O
the	O
family	O
,	O
in	O
which	O
the	O
father	O
was	O
found	O
to	O
be	O
a	O
carrier	O
of	O
the	O
mutation	O
,	O
although	O
with	O
an	O
anodyne	O
surface	O
ECG	O
and	O
negative	O
provocation	O
test	O
.	O
The	O
mother	O
had	O
a	O
type	O
2	O
electrocardiographic	O
pattern	O
,	O
although	O
the	O
provocation	O
test	O
and	O
genetic	O
study	O
were	O
negative	O
.	O
At	O
subsequent	O
follow	O
up	O
,	O
at	O
7	O
months	O
,	O
she	O
presented	O
a	O
new	O
syncopal	O
episode	O
with	O
appropriate	O
discharge	O
of	O
the	O
device	O
due	O
to	O
the	O
presence	O
of	O
ventricular	O
fibrillation	O
VF	O
with	O
a	O
180	O
ms	O
cycle	O
apparently	O
triggered	O
by	O
ventricular	O
extrasystole	O
with	O
right	O
ventricular	O
outflow	O
tract	O
morphology	O
.	O
A	O
new	O
morphological	O
study	O
was	O
performed	O
,	O
which	O
was	O
anodyne	O
,	O
exogenous	O
precipitants	O
were	O
ruled	O
out	O
drugs	O
,	O
toxins	O
,	O
metabolic	O
alterations	O
,	O
etc	O
.	O
and	O
it	O
was	O
proposed	O
to	O
start	O
treatment	O
with	O
quinidine	B-FARMACO
,	O
which	O
the	O
patient	O
refused	O
.	O
The	O
dose	O
of	O
carvedilol	B-FARMACO
was	O
increased	O
to	O
12	O
.	O
5	O
mg	O
daily	O
.	O
Outpatient	O
follow	O
up	O
continued	O
when	O
,	O
after	O
7	O
months	O
,	O
he	O
presented	O
another	O
episode	O
with	O
2	O
shocks	O
due	O
to	O
ventricular	O
fibrillation	O
with	O
similar	O
characteristics	O
to	O
those	O
previously	O
described	O
.	O
Treatment	O
was	O
then	O
started	O
with	O
quinidine	B-FARMACO
at	O
a	O
dose	O
of	O
200	O
mg	O
every	O
6	O
hours	O
.	O
After	O
13	O
months	O
of	O
treatment	O
with	O
quinidine	B-FARMACO
,	O
the	O
patient	O
had	O
no	O
new	O
shocks	O
or	O
events	O
during	O
follow	O
up	O
.	O
There	O
have	O
been	O
no	O
adverse	O
effects	O
related	O
to	O
drug	O
treatment	O
.	O
DIAGNOSIS	O
Brugada	O
syndrome	O
with	O
spontaneous	O
type	O
I	O
pattern	O
and	O
pathological	O
mutation	O
.	O
Recurrent	O
ventricular	O
fibrillation	O
.	O
Carrier	O
of	O
implantable	O
automatic	O
defibrillator	O
in	O
secondary	O
prevention	O
.	O
Absence	O
of	O
structural	O
heart	O
disease	O
in	O
morphological	O
studies	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Personal	O
history	O
Steinert	O
's	O
myotonic	O
dystrophy	O
.	O
Works	O
in	O
a	O
car	O
parts	O
factory	O
.	O
Intervened	O
8	O
years	O
earlier	O
for	O
OS	O
type	O
ASD	O
by	O
minimally	O
invasive	O
surgery	O
modified	O
Heart	O
Port	O
type	O
right	O
mini	O
thoracotomy	O
.	O
Postoperative	O
course	O
without	O
apparent	O
complications	O
.	O
Present	O
illness	O
A	O
45	O
year	O
old	O
woman	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
dyspnoea	O
on	O
exertion	O
of	O
about	O
5	O
years	O
'	O
duration	O
NYHA	O
functional	O
class	O
I	O
II	O
IV	O
,	O
progressing	O
to	O
minimal	O
exertion	O
NYHA	O
III	O
IV	O
with	O
the	O
appearance	O
of	O
cyanosis	O
in	O
recent	O
months	O
.	O
Physical	O
examination	O
Weight	O
50	O
kg	O
,	O
height	O
1	O
.	O
60	O
m	O
.	O
Body	O
mass	O
index	O
BMI	O
19	O
.	O
5	O
kg	O
m	O
.	O
Blood	O
pressure	O
BP	O
104	O
82	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
80	O
bpm	O
.	O
O2	O
saturation	O
SatO2	O
75	O
on	O
room	O
air	O
.	O
Eupneic	O
at	O
rest	O
,	O
without	O
orthopnoea	O
or	O
platypnoea	O
.	O
Generalised	O
cyanosis	O
.	O
Jugular	O
venous	O
pressure	O
normal	O
.	O
Negative	O
hepatojugular	O
reflex	O
.	O
Absence	O
of	O
acropacities	O
.	O
Cardiac	O
auscultation	O
regular	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
.	O
No	O
aggregates	O
.	O
Extremities	O
No	O
oedema	O
.	O
Peripheral	O
pulses	O
preserved	O
and	O
symmetrical	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
sinus	O
rhythm	O
at	O
93	O
bpm	O
.	O
PR	O
120	O
ms	O
.	O
QRS	O
60	O
ms	O
.	O
QTc	O
398ms	O
.	O
No	O
repolarisation	O
alterations	O
.	O
CBC	O
haemoglobin	O
20	O
g	O
dl	O
,	O
haematocrit	O
62	O
,	O
platelets	O
144	O
,	O
000	O
l	O
,	O
leukocytes	O
7400	O
l	O
.	O
Erythropoietin	O
7	O
.	O
71	O
mlU	O
ml	O
2	O
.	O
59	O
18	O
.	O
5	O
.	O
International	O
normalised	O
ratio	O
INR	O
1	O
.	O
05	O
.	O
Basal	O
glycaemia	O
82	O
mg	O
dl	O
.	O
Urea	O
36	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
81	O
mg	O
dl	O
,	O
sodium	O
137	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
1	O
mEq	O
l	O
.	O
Arterial	O
blood	O
gases	O
pH	O
7	O
.	O
42	O
,	O
pCO2	O
35	O
mmHg	O
,	O
pO2	O
41	O
mmHg	O
,	O
HCO3	O
22	O
.	O
7	O
,	O
SpO2	O
70	O
.	O
7	O
,	O
lactate	O
1	O
mmol	O
l	O
.	O
Chest	O
X	O
ray	O
cardiomediastinal	O
silhouette	O
centred	O
.	O
Cardiothoracic	O
index	O
CTI	O
less	O
than	O
0	O
.	O
5	O
.	O
Translucent	O
lung	O
fields	O
without	O
pleural	O
effusion	O
or	O
condensation	O
.	O
Transthoracic	O
and	O
transesophageal	O
echocardiogram	O
transesophageal	O
examination	O
without	O
sedation	O
due	O
to	O
baseline	O
hypoxaemia	O
atrial	O
septal	O
defect	O
without	O
significant	O
residual	O
shunt	O
minimal	O
shunt	O
at	O
the	O
level	O
of	O
the	O
pericardial	O
patch	O
without	O
any	O
functional	O
repercussions	O
.	O
Left	O
ventricle	O
with	O
preserved	O
diameters	O
,	O
volumes	O
and	O
global	O
systolic	O
function	O
.	O
No	O
alterations	O
in	O
segmental	O
contractility	O
were	O
observed	O
.	O
No	O
significant	O
valvulopathies	O
.	O
Left	O
ventricular	O
diastolic	O
pattern	O
within	O
normality	O
.	O
Right	O
ventricle	O
of	O
normal	O
diameters	O
with	O
preserved	O
global	O
systolic	O
function	O
.	O
Mild	O
tricuspid	O
insufficiency	O
allowing	O
PAPs	O
20	O
25	O
mmHg	O
to	O
be	O
quantified	O
.	O
Normal	O
inferior	O
vena	O
cava	O
.	O
Sinus	O
rhythm	O
.	O
Injection	O
of	O
gelafundin	O
shows	O
no	O
bubble	O
passage	O
to	O
left	O
cavities	O
when	O
administered	O
in	O
both	O
upper	O
limbs	O
.	O
Angio	O
CT	O
no	O
evidence	O
of	O
repletion	O
defects	O
in	O
main	O
,	O
lobar	O
,	O
segmental	O
or	O
sub	O
segmental	O
pulmonary	O
arteries	O
suggestive	O
of	O
pulmonary	O
thromboembolism	O
PTE	O
.	O
No	O
signs	O
of	O
pulmonary	O
hypertension	O
or	O
pulmonary	O
infarcts	O
.	O
No	O
pulmonary	O
nodules	O
or	O
pulmonary	O
consolidations	O
are	O
evident	O
.	O
No	O
pleural	O
or	O
pericardial	O
effusion	O
.	O
No	O
bone	O
lesions	O
suggestive	O
of	O
malignancy	O
.	O
No	O
other	O
relevant	O
findings	O
by	O
this	O
technique	O
.	O
Ventilation	O
perfusion	O
scintigraphy	O
scintigraphic	O
study	O
with	O
no	O
perfusion	O
or	O
ventilation	O
defects	O
.	O
Spirometry	O
discrete	O
pulmonary	O
restriction	O
,	O
with	O
normal	O
diffusion	O
.	O
Cardiac	O
magnetic	O
resonance	O
left	O
ventricle	O
LV	O
with	O
small	O
volumes	O
LVOT	O
38	O
ml	O
m	O
,	O
STV	O
13	O
ml	O
m	O
,	O
LVMI	O
35	O
g	O
m	O
without	O
significant	O
hypertrophy	O
of	O
its	O
walls	O
or	O
alterations	O
of	O
segmental	O
contractility	O
at	O
rest	O
and	O
with	O
preserved	O
global	O
systolic	O
function	O
GSF	O
LVEF	O
66	O
.	O
Non	O
dilated	O
right	O
ventricle	O
RV	O
RVOT	O
14	O
ml	O
m	O
,	O
STV	O
5	O
ml	O
m	O
with	O
preserved	O
global	O
systolic	O
function	O
LVEF	O
62	O
.	O
Aorta	O
and	O
great	O
vessels	O
of	O
normal	O
diameter	O
and	O
morphology	O
.	O
Atria	O
of	O
normal	O
dimensions	O
.	O
QP	O
QS	O
1	O
.	O
4	O
4	O
.	O
1	O
0	O
.	O
34	O
,	O
indicative	O
of	O
right	O
left	O
shunt	O
.	O
Gadoteric	O
acid	O
0	O
.	O
15	O
mM	O
kg	O
was	O
administered	O
for	O
3D	O
vascular	O
study	O
aorta	O
and	O
pulmonary	O
trunk	O
with	O
normal	O
diameters	O
and	O
morphology	O
.	O
Abnormal	O
systemic	O
drainage	O
is	O
observed	O
with	O
drainage	O
of	O
the	O
inferior	O
vena	O
cava	O
into	O
the	O
left	O
atrium	O
LA	O
.	O
Normal	O
pulmonary	O
vein	O
drainage	O
.	O
Necrosis	O
and	O
viability	O
study	O
absence	O
of	O
myocardial	O
LGE	O
suggestive	O
of	O
necrosis	O
fibrosis	O
.	O
Conclusion	O
anomalous	O
systemic	O
drainage	O
with	O
inferior	O
vena	O
cava	O
draining	O
into	O
the	O
LA	O
with	O
QP	O
QS	O
of	O
0	O
.	O
34	O
indicative	O
of	O
left	O
right	O
shunt	O
with	O
LV	O
and	O
RV	O
volumes	O
and	O
preserved	O
GSF	O
.	O
CLINICAL	O
EVOLUTION	O
Given	O
the	O
clinical	O
suspicion	O
of	O
a	O
residual	O
right	O
to	O
left	O
shunt	O
,	O
transthoracic	O
echocardiography	O
TTE	O
and	O
transesophageal	O
echocardiography	O
TEE	O
were	O
initially	O
requested	O
to	O
try	O
to	O
confirm	O
the	O
diagnosis	O
.	O
Both	O
studies	O
demonstrated	O
normal	O
biventricular	O
function	O
without	O
associated	O
pulmonary	O
hypertension	O
.	O
Contrast	O
was	O
administered	O
through	O
both	O
upper	O
limbs	O
with	O
no	O
evidence	O
of	O
bubble	O
passage	O
to	O
the	O
left	O
cavities	O
.	O
Continuing	O
with	O
the	O
diagnostic	O
process	O
,	O
a	O
pulmonary	O
CT	O
scan	O
and	O
a	O
ventilation	O
perfusion	O
scan	O
were	O
performed	O
,	O
both	O
with	O
normal	O
results	O
.	O
However	O
,	O
given	O
the	O
high	O
clinical	O
suspicion	O
,	O
it	O
was	O
decided	O
to	O
conclude	O
the	O
study	O
with	O
a	O
cardiac	O
magnetic	O
resonance	O
CMR	O
in	O
which	O
an	O
anomalous	O
drainage	O
of	O
the	O
inferior	O
vena	O
cava	O
IVC	O
to	O
the	O
left	O
atrium	O
was	O
observed	O
.	O
In	O
view	O
of	O
these	O
findings	O
,	O
an	O
anatomical	O
correction	O
of	O
the	O
anomalous	O
IVC	O
drainage	O
was	O
performed	O
.	O
During	O
the	O
operation	O
,	O
a	O
repaired	O
atrial	O
septal	O
defect	O
ASD	O
located	O
in	O
the	O
lower	O
portion	O
of	O
the	O
atrial	O
septum	O
was	O
observed	O
,	O
with	O
a	O
prominent	O
Eustachian	O
valve	O
and	O
an	O
erroneous	O
suture	O
causing	O
drainage	O
of	O
the	O
IVC	O
into	O
the	O
left	O
atrium	O
LA	O
.	O
In	O
the	O
absence	O
of	O
postoperative	O
complications	O
,	O
the	O
patient	O
was	O
discharged	O
and	O
remained	O
asymptomatic	O
with	O
normal	O
arterial	O
blood	O
gases	O
and	O
echocardiography	O
.	O
DIAGNOSIS	O
Anomalous	O
drainage	O
of	O
the	O
inferior	O
vena	O
cava	O
in	O
the	O
left	O
atrium	O
after	O
surgical	O
repair	O
of	O
atrial	O
septal	O
defect	O
.	O

HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
This	O
is	O
a	O
37	O
year	O
old	O
female	O
patient	O
,	O
with	O
no	O
family	O
or	O
personal	O
history	O
of	O
interest	O
,	O
except	O
for	O
smoking	O
pack	O
year	O
index	O
15	O
,	O
which	O
was	O
her	O
only	O
known	O
cardiovascular	O
risk	O
factor	O
.	O
He	O
had	O
been	O
under	O
cardiology	O
consultation	O
for	O
20	O
years	O
due	O
to	O
palpitations	O
.	O
These	O
symptoms	O
corresponded	O
to	O
frequent	O
monomorphic	O
ventricular	O
extrasystoles	O
with	O
an	O
extrasystolic	O
load	O
of	O
up	O
to	O
20	O
and	O
non	O
sustained	O
ventricular	O
tachycardias	O
of	O
up	O
to	O
8	O
10	O
complexes	O
,	O
without	O
echocardiographic	O
or	O
cardiac	O
MRI	O
evidence	O
of	O
structural	O
heart	O
disease	O
,	O
gadolinium	O
enhancement	O
or	O
deterioration	O
of	O
left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
.	O
He	O
had	O
recently	O
undergone	O
a	O
coronary	O
CT	O
scan	O
with	O
a	O
calcium	O
score	O
of	O
0	O
points	O
and	O
coronary	O
artery	O
disease	O
was	O
ruled	O
out	O
by	O
non	O
invasive	O
coronary	O
angiography	O
.	O
During	O
this	O
period	O
,	O
several	O
attempts	O
were	O
made	O
to	O
initiate	O
antiarrhythmic	O
treatment	O
beta	O
blockers	O
,	O
calcium	O
antagonists	O
,	O
amiodarone	B-FARMACO
and	O
flecainide	B-FARMACO
,	O
which	O
he	O
was	O
unable	O
to	O
tolerate	O
due	O
to	O
marked	O
asthenia	O
,	O
dizziness	O
and	O
hypotension	O
.	O
Since	O
the	O
summer	O
of	O
2019	O
,	O
she	O
has	O
presented	O
clinical	O
deterioration	O
that	O
she	O
refers	O
to	O
as	O
increased	O
palpitations	O
,	O
mainly	O
on	O
exertion	O
and	O
limitation	O
of	O
physical	O
activity	O
,	O
without	O
associated	O
chest	O
pain	O
and	O
without	O
a	O
clear	O
increase	O
in	O
functional	O
class	O
,	O
orthopnoea	O
or	O
oedematisation	O
of	O
the	O
lower	O
limbs	O
.	O
He	O
has	O
never	O
presented	O
with	O
syncopal	O
or	O
presyncopal	O
symptoms	O
.	O
At	O
the	O
first	O
consultation	O
September	O
2019	O
,	O
a	O
new	O
attempt	O
was	O
made	O
to	O
start	O
beta	B-FARMACO
blockers	I-FARMACO
at	O
low	O
doses	O
nebivolol	B-FARMACO
1	O
.	O
25	O
mg	O
24	O
h	O
and	O
she	O
was	O
assessed	O
again	O
in	O
consultation	O
3	O
weeks	O
after	O
starting	O
treatment	O
with	O
transthoracic	O
echocardiography	O
,	O
ergometry	O
and	O
Holter	O
ECG	O
.	O
Physical	O
examination	O
in	O
consultation	O
good	O
general	O
condition	O
,	O
blood	O
pressure	O
95	O
60	O
mmHg	O
,	O
heart	O
rate	O
HR	O
80	O
bpm	O
.	O
Baseline	O
SpO2	O
99	O
.	O
Afebrile	O
.	O
Head	O
and	O
neck	O
no	O
jugular	O
venous	O
engorgement	O
.	O
Cardiac	O
auscultation	O
arrhythmic	O
sounds	O
at	O
75	O
bpm	O
without	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
normoventilation	O
in	O
all	O
fields	O
Abdomen	O
nondescript	O
.	O
Lower	O
extremities	O
no	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
COMPLEMENTARY	O
TESTS	O
Initial	O
electrocardiogram	O
ECG	O
sinus	O
rhythm	O
at	O
90	O
bpm	O
,	O
normal	O
PR	O
,	O
narrow	O
QRS	O
,	O
isolated	O
supraventricular	O
extrasystoles	O
.	O
Ventricular	O
extrasystoles	O
with	O
right	O
bundle	O
branch	O
block	O
RBBB	O
morphology	O
,	O
inferior	O
axis	O
and	O
V1	O
V2	O
transition	O
.	O
Holter	O
ECG	O
under	O
treatment	O
with	O
nebivolol	B-FARMACO
1	O
.	O
25	O
mg	O
24	O
h	O
sinus	O
rhythm	O
throughout	O
the	O
tracing	O
with	O
adequate	O
heart	O
rates	O
mean	O
65	O
,	O
maximum	O
130	O
and	O
min	O
45	O
bpm	O
.	O
Frequent	O
monomorphic	O
ventricular	O
extrasystoles	O
extrasystolic	O
load	O
17	O
.	O
2	O
previous	O
load	O
12	O
,	O
sometimes	O
grouped	O
in	O
the	O
form	O
of	O
ventricular	O
bigeminy	O
and	O
2	O
short	O
bursts	O
of	O
up	O
to	O
9	O
complexes	O
coinciding	O
with	O
the	O
time	O
of	O
physical	O
activity	O
reported	O
by	O
the	O
patient	O
between	O
13	O
and	O
14	O
h	O
.	O
Very	O
isolated	O
supraventricular	O
extrasystoles	O
.	O
No	O
significant	O
bradycardias	O
or	O
pauses	O
.	O
Conventional	O
ergometry	O
Bruce	O
protocol	O
on	O
treadmill	O
stopped	O
at	O
the	O
beginning	O
of	O
stage	O
4	O
,	O
at	O
9	O
min	O
34	O
of	O
exercise	O
due	O
to	O
physical	O
fatigue	O
,	O
reaching	O
165	O
bpm	O
90	O
of	O
maximum	O
theoretical	O
HR	O
.	O
No	O
clinical	O
signs	O
suggestive	O
of	O
angina	O
.	O
12	O
.	O
3	O
METS	O
,	O
good	O
functional	O
capacity	O
for	O
age	O
and	O
sex	O
.	O
No	O
alterations	O
in	O
the	O
ST	O
.	O
Adequate	O
blood	O
pressure	O
behaviour	O
.	O
Monomorphic	O
ventricular	O
extrasystoles	O
throughout	O
the	O
recording	O
,	O
which	O
became	O
more	O
frequent	O
during	O
maximum	O
effort	O
and	O
early	O
recovery	O
by	O
means	O
of	O
ventricular	O
trigeminy	O
.	O
Isolated	O
ventricular	O
doublet	O
without	O
VT	O
.	O
Conclusion	O
ventricular	O
extrasystoles	O
more	O
frequent	O
during	O
maximal	O
exercise	O
without	O
complex	O
forms	O
.	O
Clinically	O
and	O
electrically	O
negative	O
for	O
ischaemia	O
.	O
Transthoracic	O
echocardiogram	O
left	O
atrium	O
not	O
dilated	O
.	O
Normal	O
mitral	O
valve	O
.	O
Minimal	O
central	O
insufficiency	O
.	O
Normal	O
filling	O
pressures	O
.	O
Left	O
ventricle	O
not	O
dilated	O
VTDVI	O
4C	O
114	O
cm	O
,	O
VTSVI	O
4C	O
44	O
cm	O
,	O
nor	O
hypertrophied	O
.	O
Biplane	O
LVEF	O
59	O
.	O
7	O
without	O
segmental	O
alterations	O
.	O
Trivalve	O
aortic	O
valve	O
,	O
normal	O
flow	O
.	O
Aortic	O
root	O
not	O
dilated	O
.	O
Non	O
dilated	O
right	O
chambers	O
with	O
normal	O
contractility	O
TAPSE	O
28	O
.	O
Tricuspid	O
valve	O
with	O
normal	O
flow	O
.	O
No	O
indirect	O
evidence	O
of	O
pulmonary	O
hypertension	O
.	O
No	O
pericardial	O
effusion	O
.	O
Blood	O
analysis	O
no	O
alterations	O
,	O
including	O
normal	O
TSH	O
.	O
Electrophysiological	O
study	O
images	O
3	O
6	O
and	O
video	O
2	O
double	O
right	O
femoral	O
venous	O
puncture	O
.	O
Introduction	O
of	O
a	O
decapolar	O
diagnostic	O
catheter	O
in	O
the	O
coronary	O
sinus	O
and	O
tetrapolar	O
to	O
His	O
VD	O
.	O
Pacing	O
protocol	O
was	O
performed	O
from	O
the	O
base	O
of	O
the	O
RV	O
at	O
two	O
frequencies	O
and	O
two	O
extras	O
,	O
basal	O
and	O
under	O
isoproterol	O
perfusion	O
without	O
inducing	O
tachycardia	O
,	O
although	O
extras	O
appeared	O
spontaneously	O
.	O
Right	O
femoral	O
arterial	O
puncture	O
and	O
introduction	O
of	O
Orion	O
catheter	O
.	O
The	O
Rhythmia	O
system	O
was	O
used	O
to	O
map	O
LVOT	O
and	O
aortic	O
sinuses	O
first	O
surface	O
ECG	O
with	O
ventricular	O
extrasystoles	O
at	O
the	O
BRD	O
and	O
inferior	O
axis	O
,	O
r	O
wave	O
in	O
V1	O
V2	O
and	O
V2	O
transition	O
.	O
Subsequent	O
RVOT	O
mapping	O
.	O
The	O
best	O
precocities	O
24	O
ms	O
are	O
found	O
with	O
respect	O
to	O
QRS	O
onset	O
between	O
the	O
left	O
and	O
right	O
aortic	O
sinus	O
,	O
with	O
fragmented	O
bipolar	O
electrogram	O
and	O
unipolar	O
qs	O
.	O
Pacemapping	O
was	O
performed	O
from	O
the	O
theoretical	O
ablation	O
point	O
,	O
obtaining	O
ventricular	O
complexes	O
that	O
were	O
98	O
concordant	O
with	O
the	O
mapped	O
extrasystole	O
.	O
After	O
verifying	O
by	O
electroanatomical	O
integration	O
with	O
previous	O
coronary	O
CT	O
a	O
distance	O
6	O
mm	O
14	O
mm	O
with	O
respect	O
to	O
the	O
LMCA	O
ostium	O
,	O
and	O
absence	O
of	O
proximity	O
to	O
His	O
,	O
radiofrequency	O
ablation	O
was	O
performed	O
40	O
W	O
,	O
48o	O
C	O
with	O
a	O
gold	O
tipped	O
irrigated	O
catheter	O
at	O
that	O
point	O
,	O
and	O
the	O
extrasystoles	O
disappeared	O
after	O
the	O
third	O
second	O
of	O
the	O
single	O
application	O
.	O
After	O
10	O
min	O
after	O
ablation	O
,	O
the	O
pacing	O
protocol	O
was	O
repeated	O
without	O
the	O
appearance	O
of	O
extrasystoles	O
.	O
CLINICAL	O
EVOLUTION	O
At	O
the	O
next	O
consultation	O
October	O
2019	O
,	O
the	O
patient	O
reported	O
withdrawal	O
of	O
medication	O
due	O
to	O
orthostatism	O
and	O
marked	O
asthenia	O
.	O
The	O
results	O
of	O
the	O
tests	O
requested	O
in	O
the	O
previous	O
consultation	O
highlighted	O
an	O
increase	O
in	O
extrasystolic	O
load	O
in	O
Holter	O
ECG	O
17	O
.	O
2	O
,	O
which	O
was	O
5	O
more	O
than	O
in	O
the	O
previous	O
one	O
with	O
very	O
brief	O
and	O
isolated	O
bouts	O
of	O
ventricular	O
tachycardia	O
VT	O
,	O
without	O
deterioration	O
of	O
systolic	O
function	O
in	O
echocardiography	O
.	O
Given	O
the	O
evolution	O
of	O
our	O
patient	O
,	O
and	O
in	O
accordance	O
with	O
her	O
preferences	O
,	O
an	O
electrophysiological	O
study	O
was	O
proposed	O
.	O
We	O
explained	O
in	O
detail	O
the	O
suspected	O
left	O
origin	O
of	O
the	O
extrasystoles	O
,	O
probably	O
in	O
the	O
region	O
of	O
the	O
LV	O
outflow	O
tract	O
or	O
aortic	O
cusps	O
,	O
and	O
the	O
risks	O
derived	O
both	O
from	O
the	O
approach	O
and	O
from	O
a	O
possible	O
ablation	O
in	O
this	O
region	O
,	O
which	O
she	O
accepted	O
.	O
An	O
electrophysiological	O
study	O
November	O
2019	O
revealed	O
the	O
left	O
origin	O
of	O
the	O
extrasystoles	O
,	O
specifically	O
between	O
the	O
left	O
and	O
right	O
aortic	O
cusps	O
.	O
After	O
checking	O
the	O
safety	O
distance	O
with	O
respect	O
to	O
His	O
and	O
aostium	O
of	O
the	O
coronary	O
arteries	O
,	O
radiofrequency	O
was	O
applied	O
in	O
this	O
region	O
,	O
which	O
was	O
successful	O
,	O
achieving	O
the	O
disappearance	O
of	O
the	O
arrhythmia	O
.	O
After	O
verifying	O
the	O
absence	O
of	O
post	O
procedural	O
complications	O
,	O
the	O
patient	O
was	O
discharged	O
after	O
24	O
hours	O
.	O
Since	O
then	O
,	O
she	O
has	O
visited	O
us	O
twice	O
,	O
reporting	O
a	O
very	O
significant	O
clinical	O
improvement	O
.	O
In	O
the	O
control	O
Holter	O
ECG	O
only	O
very	O
isolated	O
ventricular	O
extrasystoles	O
were	O
recorded	O
150	O
VE	O
in	O
24	O
h	O
,	O
so	O
she	O
is	O
not	O
currently	O
receiving	O
any	O
antiarrhythmic	O
treatment	O
.	O
DIAGNOSIS	O
Frequent	O
ventricular	O
extrasystoles	O
originating	O
in	O
the	O
left	O
ventricular	O
outflow	O
tract	O
.	O
Electrophysiological	O
study	O
successful	O
ablation	O
of	O
the	O
extrasystolic	O
focus	O
.	O
Absence	O
of	O
structural	O
heart	O
disease	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Background	O
27	O
year	O
old	O
male	O
,	O
student	O
and	O
candidate	O
for	O
the	O
state	O
security	O
forces	O
.	O
Athletic	O
build	O
,	O
with	O
no	O
known	O
toxic	O
habits	O
or	O
metabolic	O
disorders	O
.	O
Cardiological	O
history	O
No	O
cardiological	O
history	O
of	O
interest	O
,	O
no	O
family	O
history	O
of	O
heart	O
disease	O
or	O
sudden	O
death	O
.	O
Other	O
history	O
Infiltrating	O
adenocarcinoma	O
of	O
the	O
rectosigmoid	O
junction	O
T2N2	O
,	O
diagnosed	O
after	O
anaemia	O
study	O
five	O
months	O
before	O
the	O
episode	O
.	O
Treated	O
by	O
laparoscopic	O
rectosigmoidectomy	O
one	O
month	O
after	O
diagnosis	O
.	O
Currently	O
on	O
chemotherapy	O
treatment	O
with	O
oxaliplatin	B-FARMACO
and	O
capecitabine	B-FARMACO
,	O
having	O
received	O
a	O
first	O
cycle	O
15	O
days	O
before	O
the	O
cardiorespiratory	O
arrest	O
.	O
Stage	O
II	O
pulmonary	O
sarcoidosis	O
,	O
diagnosed	O
four	O
months	O
before	O
the	O
episode	O
,	O
following	O
extension	O
studies	O
of	O
the	O
rectal	O
neoplasia	O
.	O
Diagnosis	O
confirmed	O
by	O
biopsy	O
of	O
paratracheal	O
adenopathy	O
and	O
untreated	O
at	O
the	O
time	O
of	O
cardiorespiratory	O
arrest	O
.	O
No	O
other	O
medical	O
treatment	O
apart	O
from	O
chemotherapy	O
oxaliplatin	B-FARMACO
and	O
capecitabine	B-FARMACO
,	O
having	O
received	O
a	O
first	O
cycle	O
15	O
days	O
ago	O
.	O
Current	O
illness	O
The	O
patient	O
suffered	O
a	O
cardiorespiratory	O
arrest	O
during	O
a	O
football	O
match	O
.	O
On	O
arrival	O
of	O
the	O
emergency	O
services	O
,	O
advanced	O
cardiopulmonary	O
resuscitation	O
CPR	O
was	O
started	O
and	O
the	O
patient	O
presented	O
with	O
a	O
shockable	O
rhythm	O
of	O
ventricular	O
fibrillation	O
.	O
After	O
two	O
shocks	O
and	O
a	O
single	O
dose	O
of	O
adrenaline	B-FARMACO
,	O
the	O
patient	O
regained	O
rhythm	O
and	O
was	O
transferred	O
to	O
our	O
hospital	O
under	O
orotracheal	O
intubation	O
OTI	O
and	O
mechanical	O
ventilation	O
.	O
When	O
the	O
patient	O
was	O
questioned	O
during	O
his	O
stay	O
on	O
the	O
ward	O
,	O
he	O
reported	O
having	O
no	O
memory	O
of	O
the	O
episode	O
.	O
He	O
denied	O
any	O
clinical	O
manifestations	O
prior	O
to	O
the	O
cardiorespiratory	O
arrest	O
.	O
He	O
also	O
reported	O
no	O
previous	O
symptoms	O
of	O
angina	O
,	O
dyspnoea	O
or	O
syncope	O
and	O
maintained	O
his	O
usual	O
NYHA	O
I	O
IV	O
functional	O
class	O
without	O
any	O
symptoms	O
of	O
heart	O
failure	O
.	O
Physical	O
examination	O
The	O
first	O
examination	O
was	O
performed	O
on	O
arrival	O
at	O
the	O
emergency	O
critical	O
care	O
ward	O
of	O
our	O
hospital	O
,	O
with	O
the	O
patient	O
sedated	O
,	O
relaxed	O
and	O
on	O
invasive	O
ventilation	O
and	O
OTI	O
.	O
The	O
temperature	O
was	O
36	O
.	O
8oC	O
;	O
heart	O
rate	O
100	O
bpm	O
;	O
blood	O
pressure	O
105	O
67	O
mmHg	O
;	O
saturation	O
100	O
OTI	O
.	O
He	O
is	O
well	O
hydrated	O
,	O
skin	O
warm	O
and	O
well	O
perfused	O
.	O
Rhythmic	O
heart	O
sounds	O
without	O
over	O
additions	O
.	O
Bladder	O
murmur	O
preserved	O
with	O
symmetrical	O
ventilation	O
in	O
both	O
hemithoraxes	O
and	O
no	O
over	O
added	O
sounds	O
.	O
Abdomen	O
with	O
a	O
recent	O
laparoscopic	O
scar	O
of	O
good	O
appearance	O
.	O
Soft	O
,	O
with	O
no	O
palpable	O
masses	O
or	O
megaliths	O
.	O
No	O
defence	O
on	O
palpation	O
.	O
Extremities	O
well	O
perfused	O
,	O
pulses	O
present	O
and	O
symmetrical	O
.	O
No	O
signs	O
of	O
oedema	O
or	O
venous	O
thrombosis	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
tests	O
Biochemistry	O
glucose	O
83	O
mg	O
dl	O
,	O
urea	O
30	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
94	O
mg	O
dl	O
,	O
glomerular	O
filtration	O
rate	O
90	O
ml	O
min	O
1	O
.	O
78	O
m	O
,	O
sodium	O
ion	O
142	O
mmol	O
l	O
,	O
potassium	O
ion	O
4	O
.	O
3	O
mmol	O
l	O
,	O
ultrasensitive	O
troponin	O
T	O
110	O
ng	O
l	O
VN	O
14	O
ng	O
l	O
,	O
creatine	O
kinase	O
537	O
U	O
l	O
VN	O
200	O
U	O
l	O
,	O
alkaline	O
phosphatase	O
49	O
U	O
l	O
,	O
AST	O
64	O
U	O
l	O
,	O
ALT	O
78	O
U	O
l	O
,	O
GGT	O
22	O
U	O
l	O
,	O
total	O
bilirubin	O
1	O
.	O
0	O
mg	O
dl	O
,	O
total	O
cholesterol	O
142	O
mg	O
dl	O
,	O
HDL	O
35	O
mg	O
dl	O
,	O
triglycerides	O
134	O
mg	O
dl	O
,	O
calculated	O
LDL	O
cholesterol	O
80	O
mg	O
dl	O
,	O
HbA1C	O
4	O
.	O
9	O
,	O
TSH	O
0	O
.	O
92	O
mU	O
l	O
.	O
CBC	O
haemoglobin	O
16	O
.	O
3	O
g	O
dl	O
,	O
haematocrit	O
45	O
.	O
8	O
,	O
red	O
blood	O
cells	O
5	O
.	O
67x106	O
l	O
,	O
leukocytes	O
8	O
,	O
360	O
l	O
,	O
neutrophils	O
7	O
,	O
110	O
l	O
,	O
lymphocytes	O
680	O
l	O
,	O
monocytes	O
540	O
l	O
,	O
eosinophils	O
8	O
l	O
,	O
basophils	O
16	O
l	O
,	O
platelets	O
105	O
,	O
000	O
l	O
.	O
Coagulation	O
prothrombin	O
time	O
PT	O
11	O
.	O
8	O
sec	O
;	O
partial	O
thromboplastin	O
time	O
PTT	O
24	O
sec	O
;	O
INR	O
1	O
.	O
04	O
;	O
derived	O
fibrinogen	O
37	O
mg	O
l	O
Urine	O
toxicity	O
negative	O
for	O
benzodiazepine	O
,	O
cocaine	O
,	O
methadone	O
,	O
opiates	O
,	O
methamphetamines	O
,	O
amphetamines	O
,	O
cannabis	O
,	O
ecstasy	O
,	O
barbiturates	O
,	O
tricyclic	O
antidepressants	O
.	O
Urine	O
system	O
and	O
urine	O
sediment	O
normal	O
.	O
3	O
lead	O
electrocardiogram	O
ECG	O
cardiorespiratory	O
arrest	O
rhythm	O
ventricular	O
fibrillation	O
.	O
12	O
lead	O
ECG	O
arrival	O
at	O
the	O
hospital	O
emergency	O
room	O
sinus	O
tachycardia	O
at	O
120	O
bpm	O
.	O
P	O
wave	O
of	O
normal	O
size	O
and	O
duration	O
.	O
Normal	O
PR	O
segment	O
.	O
Narrow	O
QRS	O
complex	O
,	O
axis	O
at	O
60o	O
and	O
transition	O
in	O
V3	O
in	O
precordial	O
leads	O
.	O
ST	O
segment	O
without	O
suprathreshold	O
.	O
Negative	O
T	O
wave	O
in	O
lateral	O
leads	O
V6	O
,	O
I	O
and	O
aVL	O
and	O
in	O
inferior	O
face	O
II	O
and	O
aVF	O
.	O
Chest	O
X	O
ray	O
cardiac	O
silhouette	O
of	O
normal	O
size	O
.	O
Mediastinal	O
enlargement	O
with	O
bilateral	O
hilar	O
adenopathies	O
without	O
tracheal	O
deviation	O
or	O
compression	O
.	O
Endotracheal	O
tube	O
2	O
cm	O
above	O
the	O
tracheal	O
carina	O
.	O
No	O
vascular	O
redistribution	O
,	O
pleural	O
effusion	O
or	O
pneumothorax	O
.	O
Distended	O
gastric	O
chamber	O
.	O
Transthoracic	O
echocardiogram	O
normal	O
sized	O
atria	O
.	O
Left	O
ventricle	O
LV	O
slightly	O
dilated	O
with	O
normal	O
thickness	O
,	O
normal	O
global	O
and	O
segmental	O
systolic	O
function	O
LVEF	O
60	O
,	O
normal	O
left	O
ventricular	O
filling	O
pressures	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
,	O
preserved	O
systolic	O
function	O
TAPSE	O
31	O
mm	O
.	O
Normally	O
functioning	O
atrioventricular	O
valves	O
with	O
no	O
evidence	O
of	O
stenosis	O
or	O
insufficiency	O
.	O
Thin	O
trivalve	O
aortic	O
valve	O
,	O
normal	O
function	O
.	O
Pulmonary	O
valve	O
without	O
stenosis	O
,	O
with	O
mild	O
pulmonary	O
insufficiency	O
.	O
No	O
pericardial	O
effusion	O
.	O
Normal	O
flow	O
in	O
descending	O
aorta	O
and	O
abdominal	O
aorta	O
.	O
Computed	O
tomography	O
CT	O
coronary	O
arteries	O
epicardial	O
arteries	O
without	O
lesions	O
or	O
congenital	O
anatomical	O
alterations	O
.	O
Cardiac	O
magnetic	O
resonance	O
CMR	O
left	O
ventricle	O
slightly	O
dilated	O
TVD	O
118	O
ml	O
m2	O
and	O
STV	O
49	O
ml	O
m2	O
,	O
normal	O
myocardial	O
mass	O
104	O
g	O
m2	O
without	O
contractility	O
alterations	O
and	O
with	O
normal	O
systolic	O
function	O
EF	O
58	O
.	O
No	O
areas	O
of	O
hypertrophy	O
or	O
non	O
compaction	O
are	O
seen	O
.	O
No	O
hyperintense	O
areas	O
suggestive	O
of	O
intramyocardial	O
oedema	O
are	O
seen	O
in	O
the	O
STIR	O
sequence	O
.	O
Several	O
areas	O
of	O
intramural	O
late	O
gadolinium	O
enhancement	O
LGE	O
are	O
seen	O
in	O
the	O
basal	O
anteroseptal	O
segment	O
and	O
in	O
the	O
inferior	O
junction	O
of	O
both	O
ventricles	O
compatible	O
with	O
areas	O
of	O
intramyocardial	O
scarring	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
,	O
with	O
preserved	O
systolic	O
function	O
.	O
Left	O
atrium	O
slightly	O
dilated	O
22	O
cm2	O
and	O
right	O
atrium	O
of	O
normal	O
size	O
.	O
Aorta	O
,	O
pulmonary	O
artery	O
and	O
pericardium	O
without	O
alterations	O
.	O
Positron	O
emission	O
tomography	O
with	O
18F	O
deoxyglucose	O
PET	O
multiple	O
hypermetabolic	O
adenopathies	O
located	O
in	O
supraclavicular	O
,	O
mediastinal	O
and	O
hilar	O
compartments	O
compatible	O
with	O
confirmed	O
stage	O
II	O
pulmonary	O
sarcoidosis	O
.	O
No	O
hypermetabolic	O
pathological	O
foci	O
in	O
the	O
myocardium	O
suspicious	O
of	O
acute	O
sarcoidotic	O
or	O
other	O
inflammatory	O
involvement	O
.	O
The	O
rest	O
of	O
the	O
study	O
showed	O
no	O
findings	O
of	O
interest	O
.	O
CLINICAL	O
COURSE	O
A	O
27	O
year	O
old	O
man	O
who	O
presented	O
with	O
out	O
of	O
hospital	O
cardiorespiratory	O
arrest	O
due	O
to	O
recovered	O
ventricular	O
fibrillation	O
.	O
The	O
patient	O
was	O
admitted	O
intubated	O
to	O
the	O
cardiac	O
intensive	O
care	O
unit	O
where	O
he	O
remained	O
for	O
4	O
days	O
and	O
was	O
extubated	O
in	O
the	O
first	O
24	O
hours	O
.	O
He	O
was	O
subsequently	O
transferred	O
to	O
the	O
cardiology	O
ward	O
to	O
complete	O
the	O
studies	O
.	O
Throughout	O
his	O
stay	O
,	O
he	O
remained	O
asymptomatic	O
from	O
the	O
cardiovascular	O
point	O
of	O
view	O
,	O
with	O
no	O
rhythm	O
alterations	O
detected	O
on	O
telemetry	O
.	O
The	O
aforementioned	O
studies	O
were	O
performed	O
in	O
order	O
to	O
reach	O
a	O
diagnosis	O
and	O
guide	O
treatment	O
.	O
Initially	O
,	O
many	O
diagnostic	O
options	O
were	O
considered	O
as	O
possible	O
aetiologies	O
for	O
ventricular	O
fibrillation	O
ischaemic	O
heart	O
disease	O
,	O
ventricular	O
arrhythmias	O
in	O
a	O
structurally	O
healthy	O
heart	O
or	O
even	O
the	O
possibility	O
of	O
cardiac	O
toxicity	O
due	O
to	O
chemotherapy	O
treatment	O
.	O
After	O
the	O
initial	O
echocardiographic	O
study	O
,	O
CT	O
of	O
the	O
coronary	O
arteries	O
and	O
the	O
subsequent	O
CMR	O
study	O
,	O
the	O
presence	O
of	O
intramyocardial	O
fibrosis	O
was	O
confirmed	O
.	O
This	O
finding	O
,	O
together	O
with	O
the	O
episode	O
of	O
ventricular	O
fibrillation	O
and	O
the	O
previous	O
diagnosis	O
of	O
systemic	O
sarcoidosis	O
by	O
biopsy	O
confirmed	O
the	O
diagnosis	O
of	O
cardiac	O
sarcoidosis	O
and	O
thus	O
the	O
cause	O
of	O
cardiorespiratory	O
arrest	O
.	O
In	O
the	O
absence	O
of	O
data	O
of	O
acute	O
inflammatory	O
activity	O
in	O
the	O
CMR	O
,	O
and	O
with	O
a	O
view	O
to	O
assessing	O
possible	O
anti	O
inflammatory	O
treatment	O
,	O
it	O
was	O
decided	O
to	O
complete	O
studies	O
with	O
PET	O
CT	O
,	O
which	O
again	O
ruled	O
out	O
the	O
presence	O
of	O
intramyocardial	O
inflammatory	O
activity	O
.	O
For	O
this	O
reason	O
,	O
in	O
agreement	O
with	O
the	O
autoimmune	O
unit	O
of	O
the	O
internal	O
medicine	O
department	O
,	O
anti	O
inflammatory	O
treatment	O
was	O
finally	O
rejected	O
and	O
a	O
subcutaneous	O
implantable	O
cardioverter	O
defibrillator	O
ICD	O
was	O
implanted	O
for	O
secondary	O
prevention	O
of	O
sudden	O
death	O
.	O
To	O
date	O
,	O
the	O
patient	O
remains	O
stable	O
and	O
without	O
new	O
arrhythmic	O
events	O
.	O
DIAGNOSIS	O
Out	O
of	O
hospital	O
cardiorespiratory	O
arrest	O
due	O
to	O
ventricular	O
fibrillation	O
.	O
Cardiac	O
sarcoidosis	O
with	O
intramyocardial	O
scarring	O
but	O
no	O
evidence	O
of	O
active	O
intramyocardial	O
inflammation	O
.	O
Left	O
ventricular	O
systolic	O
function	O
preserved	O
.	O
Coronary	O
arteries	O
without	O
lesions	O
or	O
coronary	O
anomalies	O
.	O
Subcutaneous	O
ICD	O
implantation	O
for	O
secondary	O
prevention	O
.	O

A	O
58	O
year	O
old	O
male	O
patient	O
,	O
a	O
high	O
intensity	O
sportsman	O
,	O
with	O
an	O
electrocardiogram	O
ECG	O
compatible	O
with	O
left	O
ventricular	O
hypertrophy	O
and	O
cardiac	O
magnetic	O
resonance	O
imaging	O
MRI	O
suggestive	O
of	O
athlete	O
's	O
heart	O
.	O
Subsequent	O
follow	O
up	O
in	O
the	O
arrhythmia	O
unit	O
following	O
an	O
episode	O
of	O
flutter	O
,	O
with	O
persistence	O
of	O
the	O
electrocardiographic	O
alterations	O
described	O
.	O
HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
No	O
family	O
history	O
of	O
heart	O
disease	O
or	O
early	O
sudden	O
death	O
.	O
Active	O
high	O
intensity	O
sportsman	O
cyclist	O
,	O
cycling	O
about	O
100	O
km	O
per	O
day	O
.	O
Allergy	O
to	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
.	O
Ex	O
smoker	O
of	O
half	O
a	O
pack	O
day	O
until	O
4	O
years	O
ago	O
.	O
Non	O
drinker	O
.	O
High	O
blood	O
pressure	O
HBP	O
under	O
treatment	O
with	O
good	O
control	O
as	O
usual	O
.	O
No	O
known	O
diabetes	O
mellitus	O
DM	O
or	O
dyslipidaemia	O
DLP	O
.	O
Admission	O
to	O
cardiology	O
in	O
February	O
2016	O
due	O
to	O
chest	O
pain	O
with	O
atypical	O
characteristics	O
for	O
ischaemic	O
heart	O
disease	O
associated	O
with	O
hypertensive	O
crisis	O
,	O
ECG	O
with	O
negative	O
inferolateral	O
T	O
findings	O
and	O
echocardiogram	O
with	O
preserved	O
LVEF	O
,	O
without	O
segmental	O
alterations	O
of	O
contractility	O
and	O
concentric	O
ventricular	O
hypertrophy	O
IVS	O
15	O
mm	O
,	O
PIL	O
15	O
mm	O
,	O
without	O
intraventricular	O
dynamic	O
gradient	O
.	O
Ergometry	O
was	O
performed	O
with	O
negative	O
results	O
for	O
myocardial	O
ischaemia	O
and	O
ventricular	O
arrhythmias	O
.	O
Cardiac	O
MRI	O
was	O
requested	O
on	O
discharge	O
to	O
complete	O
the	O
study	O
,	O
which	O
was	O
performed	O
at	O
another	O
centre	O
due	O
to	O
lack	O
of	O
availability	O
at	O
our	O
centre	O
,	O
with	O
the	O
finding	O
of	O
maximum	O
thickness	O
at	O
the	O
level	O
of	O
the	O
basal	O
septum	O
of	O
12	O
mm	O
upper	O
limit	O
of	O
normality	O
,	O
with	O
the	O
rest	O
of	O
the	O
segments	O
with	O
preserved	O
thicknesses	O
and	O
without	O
late	O
enhancement	O
,	O
classifying	O
it	O
as	O
an	O
athlete	O
's	O
heart	O
.	O
Episode	O
of	O
palpitations	O
in	O
May	O
2018	O
,	O
ECG	O
in	O
the	O
emergency	O
department	O
compatible	O
with	O
paroxysmal	O
counterclockwise	O
atrial	O
flutter	O
.	O
Programmed	O
electrical	O
cardioversion	O
was	O
performed	O
after	O
anticoagulation	O
for	O
3	O
weeks	O
,	O
and	O
the	O
patient	O
went	O
into	O
sinus	O
rhythm	O
.	O
In	O
September	O
2018	O
,	O
cavotricuspid	O
isthmus	O
ablation	O
CTI	O
was	O
performed	O
with	O
the	O
CARTO	O
system	O
without	O
the	O
use	O
of	O
scopy	O
.	O
Subsequent	O
follow	O
up	O
in	O
the	O
arrhythmia	O
unit	O
showed	O
that	O
the	O
patient	O
remained	O
asymptomatic	O
and	O
in	O
sinus	O
rhythm	O
,	O
with	O
persistent	O
negative	O
inferolateral	O
T	O
segments	O
and	O
concentric	O
hypertrophy	O
on	O
serial	O
echocardiograms	O
.	O
The	O
patient	O
was	O
instructed	O
to	O
cease	O
high	O
intensity	O
exercise	O
for	O
further	O
re	O
evaluation	O
.	O
No	O
surgical	O
interventions	O
of	O
interest	O
.	O
Usual	O
treatment	O
Ramipril	B-FARMACO
2	O
.	O
5	O
mg	O
one	O
tablet	O
at	O
breakfast	O
.	O
Current	O
illness	O
The	O
patient	O
was	O
reviewed	O
at	O
the	O
arrhythmia	O
clinic	O
after	O
having	O
stopped	O
all	O
physical	O
exercise	O
for	O
the	O
last	O
8	O
months	O
.	O
The	O
patient	O
remains	O
asymptomatic	O
,	O
with	O
no	O
new	O
episodes	O
of	O
palpitations	O
.	O
He	O
denied	O
exertional	O
dyspnoea	O
,	O
syncope	O
or	O
other	O
symptoms	O
.	O
An	O
ECG	O
was	O
performed	O
in	O
consultation	O
,	O
with	O
persistence	O
of	O
left	O
ventricular	O
hypertrophy	O
criteria	O
together	O
with	O
deep	O
and	O
asymmetrical	O
negative	O
T	O
in	O
precordial	O
leads	O
and	O
inferior	O
face	O
.	O
An	O
echocardiogram	O
was	O
performed	O
,	O
with	O
the	O
finding	O
of	O
mild	O
moderate	O
concentric	O
hypertrophy	O
of	O
its	O
walls	O
IVS	O
13	O
mm	O
,	O
LIP	O
11	O
mm	O
but	O
with	O
the	O
presence	O
at	O
the	O
apical	O
level	O
of	O
a	O
greater	O
myocardial	O
thickness	O
of	O
about	O
15	O
16	O
mm	O
,	O
with	O
systolic	O
closure	O
in	O
"	O
ace	O
of	O
spades	O
"	O
morphology	O
with	O
slight	O
hypokinesia	O
of	O
the	O
most	O
apical	O
segments	O
.	O
No	O
SAM	O
or	O
intraventricular	O
gradient	O
was	O
observed	O
.	O
Given	O
the	O
electrocardiographic	O
and	O
echocardiographic	O
findings	O
after	O
stopping	O
exercise	O
,	O
despite	O
the	O
patient	O
having	O
a	O
cardiac	O
MRI	O
3	O
years	O
earlier	O
compatible	O
with	O
athlete	O
's	O
heart	O
and	O
without	O
findings	O
compatible	O
with	O
hypertrophic	O
cardiomyopathy	O
,	O
it	O
was	O
decided	O
to	O
request	O
a	O
new	O
cardiac	O
MRI	O
to	O
complete	O
the	O
study	O
.	O
Physical	O
examination	O
Acceptable	O
general	O
condition	O
.	O
Eupneic	O
at	O
rest	O
.	O
O2	O
saturation	O
98	O
without	O
oxygen	O
therapy	O
.	O
Blood	O
pressure	O
142	O
83	O
.	O
Heart	O
rate	O
55	O
bpm	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
at	O
a	O
good	O
frequency	O
.	O
No	O
audible	O
murmurs	O
at	O
baseline	O
or	O
after	O
Valsalva	O
manoeuvre	O
.	O
Bladder	O
murmur	O
preserved	O
,	O
without	O
pathological	O
noises	O
added	O
.	O
Lower	O
limbs	O
no	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
Distal	O
pulses	O
preserved	O
and	O
symmetrical	O
.	O
COMPLEMENTARY	O
TESTS	O
Cardiac	O
MRI	O
February	O
2016	O
left	O
ventricle	O
LV	O
not	O
dilated	O
,	O
with	O
preserved	O
global	O
and	O
segmental	O
mobility	O
.	O
EF	O
measured	O
with	O
the	O
Simpson	O
method	O
of	O
72	O
.	O
Maximum	O
basal	O
septal	O
thickness	O
of	O
12	O
mm	O
,	O
with	O
the	O
rest	O
of	O
the	O
segments	O
with	O
preserved	O
thicknesses	O
.	O
The	O
myocardial	O
mass	O
is	O
107	O
g	O
,	O
indexed	O
at	O
61	O
.	O
43	O
g	O
m	O
.	O
The	O
right	O
ventricle	O
is	O
normal	O
.	O
No	O
abnormalities	O
were	O
observed	O
in	O
the	O
late	O
enhancement	O
sequence	O
.	O
Electrocardiogram	O
June	O
2019	O
sinus	O
bradycardia	O
at	O
50	O
bpm	O
,	O
30o	O
axis	O
,	O
PR	O
224	O
ms	O
,	O
Narrow	O
QRS	O
with	O
criteria	O
of	O
left	O
ventricular	O
hypertrophy	O
by	O
Sokolow	O
criteria	O
,	O
biphasic	O
T	O
in	O
V1	O
V2	O
,	O
negative	O
in	O
I	O
,	O
II	O
,	O
III	O
,	O
aVF	O
and	O
deep	O
and	O
asymmetric	O
negative	O
in	O
V3	O
V6	O
,	O
with	O
ST	O
rectification	O
in	O
these	O
leads	O
,	O
QTc	O
428	O
ms	O
.	O
Echocardiogram	O
June	O
2019	O
non	O
dilated	O
left	O
ventricle	O
with	O
mild	O
concentric	O
hypertrophy	O
of	O
its	O
walls	O
IVS	O
13	O
.	O
5	O
mm	O
,	O
LIP	O
11	O
.	O
5	O
mm	O
,	O
a	O
greater	O
myocardial	O
thickness	O
is	O
seen	O
at	O
the	O
apical	O
level	O
,	O
about	O
15	O
16	O
mm	O
,	O
with	O
systolic	O
closure	O
in	O
"	O
ace	O
of	O
spades	O
"	O
morphology	O
with	O
slight	O
hypokinesia	O
of	O
the	O
most	O
apical	O
segments	O
,	O
so	O
it	O
could	O
not	O
be	O
ruled	O
out	O
that	O
it	O
is	O
an	O
apical	O
hypertrophic	O
cardiomyopathy	O
with	O
little	O
myocardial	O
involvement	O
.	O
Biauricular	O
dilatation	O
.	O
Mitral	O
with	O
mild	O
insufficiency	O
,	O
without	O
SAM	O
.	O
Mild	O
aortic	O
insufficiency	O
due	O
to	O
slight	O
dilatation	O
of	O
the	O
aortic	O
root	O
.	O
Rest	O
of	O
valves	O
without	O
alterations	O
.	O
Preserved	O
LV	O
systolic	O
function	O
with	O
LVEF	O
65	O
70	O
.	O
LV	O
diastolic	O
and	O
RV	O
systolic	O
function	O
unaltered	O
.	O
Cardiac	O
MRI	O
June	O
2019	O
non	O
dilated	O
left	O
ventricle	O
with	O
hypertrophy	O
only	O
at	O
the	O
apical	O
level	O
,	O
mainly	O
of	O
the	O
lower	O
apical	O
segments	O
and	O
the	O
true	O
apex	O
with	O
thicknesses	O
between	O
12	O
13	O
mm	O
and	O
maximum	O
thickness	O
in	O
the	O
lower	O
apical	O
segment	O
reaching	O
15	O
mm	O
.	O
In	O
cine	O
sequences	O
in	O
the	O
vertical	O
long	O
axis	O
plane	O
,	O
the	O
left	O
ventricle	O
shows	O
the	O
typical	O
"	O
ace	O
of	O
spades	O
"	O
morphology	O
.	O
The	O
EF	O
measured	O
with	O
the	O
Simpson	O
method	O
is	O
60	O
.	O
Myocardial	O
mass	O
93	O
g	O
,	O
indexed	O
by	O
body	O
surface	O
area	O
of	O
54	O
g	O
m	O
.	O
Right	O
ventricle	O
without	O
alterations	O
.	O
In	O
the	O
first	O
pass	O
perfusion	O
sequence	O
,	O
no	O
basal	O
perfusion	O
defects	O
.	O
Late	O
enhancement	O
viability	O
sequence	O
shows	O
no	O
fibrosis	O
or	O
necrosis	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
underwent	O
a	O
new	O
outpatient	O
cardiac	O
MRI	O
at	O
our	O
centre	O
,	O
with	O
the	O
finding	O
of	O
a	O
non	O
dilated	O
left	O
ventricle	O
with	O
hypertrophy	O
only	O
at	O
the	O
apical	O
level	O
,	O
mainly	O
of	O
the	O
lower	O
apical	O
segments	O
and	O
the	O
true	O
apex	O
with	O
thicknesses	O
of	O
between	O
12	O
13	O
mm	O
,	O
with	O
the	O
lower	O
apical	O
segment	O
reaching	O
15	O
mm	O
and	O
the	O
left	O
ventricle	O
presenting	O
the	O
typical	O
"	O
ace	O
of	O
spades	O
"	O
morphology	O
in	O
cine	O
2C	O
.	O
The	O
EF	O
measured	O
with	O
the	O
Simpson	O
method	O
is	O
60	O
.	O
The	O
late	O
enhancement	O
viability	O
sequence	O
showed	O
no	O
fibrosis	O
or	O
necrosis	O
.	O
The	O
patient	O
subsequently	O
visited	O
the	O
clinic	O
to	O
collect	O
the	O
results	O
and	O
reported	O
to	O
be	O
completely	O
asymptomatic	O
.	O
The	O
nature	O
of	O
the	O
disease	O
and	O
its	O
hereditary	O
nature	O
were	O
explained	O
to	O
the	O
patient	O
,	O
and	O
it	O
was	O
decided	O
,	O
given	O
the	O
low	O
diagnostic	O
yield	O
of	O
the	O
genetic	O
study	O
in	O
the	O
apical	O
variant	O
of	O
hypertrophic	O
cardiomyopathy	O
HCM	O
and	O
that	O
the	O
patient	O
had	O
no	O
children	O
and	O
only	O
one	O
sibling	O
,	O
to	O
continue	O
the	O
family	O
study	O
by	O
echocardiography	O
and	O
or	O
cardiac	O
MRI	O
if	O
this	O
was	O
inconclusive	O
.	O
Subsequent	O
follow	O
up	O
in	O
the	O
arrhythmia	O
unit	O
with	O
24	O
hour	O
Holter	O
monitoring	O
is	O
indicated	O
.	O
DIAGNOSIS	O
Non	O
obstructive	O
apical	O
hypertrophic	O
cardiomyopathy	O
.	O
No	O
fibrosis	O
by	O
cardiac	O
MRI	O
.	O
HCM	O
SCD	O
Score	O
0	O
.	O
99	O
.	O
Paroxysmal	O
counterclockwise	O
atrial	O
flutter	O
.	O
Effective	O
CTI	O
ablation	O
without	O
the	O
use	O
of	O
scopy	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
A	O
60	O
year	O
old	O
man	O
attended	O
the	O
emergency	O
department	O
of	O
our	O
centre	O
due	O
to	O
chest	O
pain	O
.	O
History	O
The	O
patient	O
had	O
the	O
following	O
medical	O
history	O
Cardiovascular	O
risk	O
factors	O
type	O
2	O
diabetes	O
mellitus	O
,	O
non	O
insulin	O
dependent	O
,	O
on	O
treatment	O
with	O
two	O
drugs	O
,	O
with	O
good	O
metabolic	O
control	O
HbA1c	O
6	O
.	O
8	O
;	O
well	O
controlled	O
arterial	O
hypertension	O
home	O
blood	O
pressure	O
BP	O
140	O
80	O
mmHg	O
with	O
two	O
drugs	O
.	O
No	O
previous	O
cardiological	O
history	O
.	O
Other	O
relevant	O
medical	O
history	O
peripheral	O
vascular	O
disease	O
,	O
with	O
stenosis	O
in	O
the	O
right	O
superficial	O
femoral	O
artery	O
and	O
absence	O
of	O
right	O
pedal	O
pulse	O
,	O
treated	O
with	O
drug	O
eluting	O
balloon	O
angioplasty	O
with	O
good	O
results	O
.	O
Usual	O
treatment	O
Sitagliptin	B-FARMACO
metformin	I-FARMACO
50	O
1000	O
mg	O
,	O
1	O
tablet	O
every	O
12	O
hours	O
.	O
Valsartan	B-FARMACO
amlodipine	I-FARMACO
40	O
10	O
mg	O
,	O
1	O
tablet	O
per	O
day	O
.	O
Omeprazole	B-FARMACO
20	O
mg	O
,	O
1	O
capsule	O
per	O
day	O
.	O
Acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
100	O
mg	O
,	O
1	O
tablet	O
per	O
day	O
.	O
Present	O
illness	O
On	O
arrival	O
at	O
the	O
emergency	O
department	O
,	O
the	O
patient	O
presented	O
with	O
oppressive	O
central	O
thoracic	O
pain	O
radiating	O
to	O
the	O
neck	O
and	O
both	O
arms	O
,	O
lasting	O
2	O
hours	O
from	O
onset	O
at	O
rest	O
,	O
associated	O
with	O
cold	O
sweating	O
.	O
No	O
previous	O
similar	O
episodes	O
.	O
No	O
symptoms	O
suggestive	O
of	O
exertional	O
angina	O
with	O
usual	O
physical	O
activity	O
.	O
Physical	O
examination	O
BP	O
105	O
70	O
mmHg	O
,	O
heart	O
rate	O
HR	O
100	O
bpm	O
,	O
oxygen	O
saturation	O
95	O
on	O
room	O
air	O
.	O
Jugular	O
venous	O
pressure	O
normal	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
no	O
murmurs	O
or	O
pathological	O
sounds	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
with	O
no	O
extra	O
sounds	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
,	O
no	O
masses	O
or	O
megaliths	O
,	O
Blumberg	O
and	O
Murphy	O
negative	O
.	O
Extremities	O
no	O
oedema	O
in	O
the	O
lower	O
extremities	O
,	O
peripheral	O
pulses	O
preserved	O
and	O
symmetrical	O
,	O
no	O
signs	O
of	O
phlebitis	O
An	O
electrocardiogram	O
ECG	O
was	O
performed	O
in	O
less	O
than	O
10	O
minutes	O
,	O
which	O
showed	O
the	O
presence	O
of	O
subepicardial	O
lesion	O
current	O
in	O
the	O
inferior	O
face	O
,	O
so	O
a	O
haemodynamic	O
alert	O
was	O
activated	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
on	O
arrival	O
at	O
the	O
emergency	O
department	O
sinus	O
rhythm	O
at	O
100	O
bpm	O
.	O
Normal	O
PR	O
.	O
QRS	O
90	O
ms	O
.	O
qS	O
in	O
V1	O
.	O
ST	O
segment	O
elevation	O
up	O
to	O
3	O
mm	O
in	O
DII	O
,	O
DIII	O
and	O
aVF	O
with	O
specular	O
decrease	O
in	O
DI	O
and	O
aVL	O
.	O
Portable	O
chest	O
X	O
ray	O
slightly	O
increased	O
cardiothoracic	O
index	O
in	O
this	O
anteroposterior	O
projection	O
.	O
No	O
pleural	O
effusion	O
,	O
no	O
signs	O
of	O
vascular	O
redistribution	O
.	O
No	O
condensation	O
.	O
Emergent	O
coronary	O
angiography	O
right	O
dominance	O
.	O
Left	O
main	O
coronary	O
artery	O
LMCA	O
without	O
lesions	O
.	O
Anterior	O
descending	O
artery	O
AD	O
with	O
severe	O
lesion	O
of	O
90	O
in	O
the	O
middle	O
segment	O
.	O
Circumflex	O
with	O
40	O
lesion	O
in	O
distal	O
segment	O
.	O
Right	O
coronary	O
artery	O
RCA	O
with	O
90	O
long	O
lesion	O
that	O
starts	O
in	O
the	O
proximal	O
segment	O
and	O
extends	O
to	O
the	O
middle	O
segment	O
.	O
Good	O
distal	O
bed	O
.	O
It	O
was	O
decided	O
to	O
perform	O
percutaneous	O
coronary	O
intervention	O
PCI	O
on	O
the	O
DC	O
lesion	O
.	O
After	O
predilating	O
with	O
a	O
2	O
.	O
5	O
x	O
20	O
mm	O
semi	O
compliant	O
balloon	O
,	O
a	O
2	O
.	O
75	O
x	O
30	O
mm	O
sirolimus	B-FARMACO
eluting	O
drug	O
eluting	O
stent	O
was	O
implanted	O
with	O
a	O
good	O
final	O
angiographic	O
result	O
.	O
Echocardiogram	O
in	O
the	O
coronary	O
unit	O
mild	O
left	O
ventricular	O
LV	O
hypertrophy	O
,	O
with	O
preserved	O
diameters	O
and	O
slightly	O
depressed	O
LVEF	O
Simpson	O
BP	O
50	O
secondary	O
to	O
inferolateral	O
and	O
inferior	O
mediobasal	O
hypokinesia	O
.	O
Absence	O
of	O
significant	O
valvular	O
heart	O
disease	O
.	O
Normal	O
transmitral	O
filling	O
,	O
estimated	O
normal	O
LV	O
end	O
diastolic	O
pressure	O
E	O
E	O
'	O
7	O
.	O
RV	O
with	O
normal	O
diameters	O
and	O
preserved	O
function	O
.	O
Absence	O
of	O
tricuspid	O
insufficiency	O
TI	O
allowing	O
estimation	O
of	O
pulmonary	O
artery	O
systolic	O
pressure	O
PSAP	O
.	O
Normal	O
inferior	O
vena	O
cava	O
IVC	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
.	O
Ordinary	O
laboratory	O
tests	O
Blood	O
count	O
haemoglobin	O
13	O
.	O
9	O
g	O
dl	O
,	O
without	O
leukocytosis	O
or	O
left	O
shift	O
.	O
Platelets	O
241	O
x	O
10	O
9	O
l	O
.	O
Haemostasis	O
INR	O
0	O
.	O
99	O
,	O
TTPa	O
29	O
.	O
3	O
sec	O
.	O
Biochemistry	O
fasting	O
glucose	O
118	O
mg	O
dl	O
,	O
sodium	O
139	O
mEq	O
l	O
,	O
potassium	O
4	O
mEq	O
l	O
,	O
creatinine	O
0	O
.	O
49	O
mg	O
dl	O
GFR	O
90	O
ml	O
min	O
1	O
.	O
72	O
m2	O
,	O
NT	O
proBNP	O
266	O
pg	O
ml	O
,	O
C	O
reactive	O
protein	O
0	O
.	O
7	O
mg	O
dl	O
,	O
HbA1c	O
6	O
.	O
8	O
,	O
total	O
cholesterol	O
176	O
mg	O
dl	O
,	O
triglycerides	O
102	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
37	O
mg	O
dl	O
,	O
LDL	O
cholesterol	O
119	O
mg	O
dl	O
.	O
Myocardial	O
damage	O
biomarker	O
curve	O
hsTnI	O
,	O
normal	O
19	O
.	O
8	O
ng	O
l	O
53	O
24	O
,	O
900	O
above	O
detection	O
limit	O
15	O
,	O
000	O
4	O
,	O
408	O
2	O
,	O
977	O
ng	O
l	O
.	O
ECG	O
at	O
discharge	O
image	O
3	O
sinus	O
rhythm	O
at	O
65	O
bpm	O
.	O
Normal	O
PR	O
.	O
QRS	O
90	O
ms	O
with	O
axis	O
at	O
60o	O
.	O
Negative	O
T	O
wave	O
in	O
DII	O
,	O
DIII	O
and	O
aVF	O
.	O
Elective	O
coronary	O
angiography	O
video	O
4	O
good	O
result	O
of	O
stent	O
implanted	O
in	O
CD	O
.	O
PCI	O
on	O
LAD	O
lesion	O
is	O
predilated	O
with	O
SC	O
balloon	O
2	O
.	O
5	O
x	O
20	O
mm	O
and	O
NC	O
3	O
x	O
20	O
mm	O
,	O
implanting	O
a	O
3	O
x	O
26	O
mm	O
zotarolimus	B-FARMACO
eluting	O
drug	O
eluting	O
stent	O
,	O
with	O
a	O
good	O
final	O
angiographic	O
result	O
.	O
CLINICAL	O
EVOLUTION	O
After	O
finding	O
ST	O
segment	O
elevation	O
in	O
the	O
inferior	O
face	O
in	O
a	O
patient	O
with	O
anginal	O
chest	O
pain	O
,	O
a	O
loading	O
dose	O
of	O
prasugrel	B-FARMACO
was	O
administered	O
the	O
patient	O
was	O
already	O
receiving	O
chronic	O
treatment	O
with	O
ASA	B-FARMACO
100	O
mg	O
and	O
the	O
infarction	O
code	O
was	O
activated	O
.	O
Emergent	O
coronary	O
angiography	O
showed	O
three	O
vessel	O
disease	O
,	O
with	O
two	O
severe	O
lesions	O
in	O
the	O
MD	O
and	O
DCM	O
and	O
a	O
moderate	O
lesion	O
in	O
the	O
distal	O
circumflex	O
DC	O
.	O
A	O
decision	O
was	O
made	O
to	O
perform	O
constant	O
pharmacoactive	O
PCI	O
on	O
the	O
middle	O
DC	O
,	O
the	O
artery	O
responsible	O
for	O
the	O
infarction	O
ARI	O
,	O
which	O
was	O
performed	O
without	O
incident	O
.	O
After	O
angioplasty	O
,	O
he	O
was	O
admitted	O
to	O
the	O
coronary	O
unit	O
,	O
where	O
beta	O
blocker	O
and	O
lipid	O
lowering	O
treatment	O
was	O
started	O
,	O
and	O
he	O
remained	O
asymptomatic	O
and	O
haemodynamically	O
stable	O
.	O
After	O
48	O
hours	O
without	O
arrhythmic	O
events	O
,	O
it	O
was	O
decided	O
to	O
discharge	O
him	O
to	O
the	O
cardiology	O
ward	O
and	O
,	O
after	O
mobilisation	O
without	O
incident	O
,	O
to	O
his	O
home	O
.	O
Medical	O
treatment	O
at	O
discharge	O
was	O
Acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
mg	O
,	O
1	O
tablet	O
per	O
day	O
.	O
Prasugrel	B-FARMACO
10	O
mg	O
,	O
1	O
tablet	O
per	O
day	O
.	O
Rosuvastatin	B-FARMACO
20	O
mg	O
,	O
1	O
tablet	O
at	O
night	O
.	O
Dapagliflozin	B-FARMACO
metformin	I-FARMACO
5	O
1000	O
mg	O
,	O
1	O
tablet	O
every	O
12	O
hours	O
.	O
Nebivolol	B-FARMACO
2	O
.	O
5	O
mg	O
,	O
1	O
tablet	O
per	O
day	O
.	O
Omeprazole	B-FARMACO
20	O
mg	O
,	O
1	O
capsule	O
per	O
day	O
.	O
Valsartan	B-FARMACO
amlodipine	I-FARMACO
40	O
10	O
mg	O
,	O
1	O
tablet	O
per	O
day	O
.	O
After	O
discharge	O
,	O
the	O
patient	O
was	O
scheduled	O
3	O
weeks	O
later	O
for	O
elective	O
outpatient	O
angioplasty	O
on	O
the	O
severe	O
lesion	O
of	O
the	O
middle	O
anterior	O
descending	O
artery	O
,	O
which	O
was	O
performed	O
without	O
complications	O
.	O
After	O
this	O
second	O
procedure	O
,	O
the	O
patient	O
was	O
included	O
in	O
the	O
cardiovascular	O
rehabilitation	O
programme	O
of	O
our	O
centre	O
.	O
DIAGNOSIS	O
Acute	O
myocardial	O
infarction	O
with	O
ST	O
segment	O
elevation	O
of	O
inferior	O
location	O
.	O
Killip	O
I	O
.	O
Three	O
vessel	O
coronary	O
artery	O
disease	O
Mid	O
CD	O
ARI	O
90	O
,	O
mid	O
DA	O
90	O
,	O
distal	O
Cx	O
40	O
.	O
Primary	O
PCI	O
with	O
drug	O
eluting	O
stentliberator	O
over	O
mid	O
CD	O
.	O
Second	O
outpatient	O
elective	O
PCI	O
on	O
severe	O
mid	O
LAD	O
lesion	O
.	O
Mild	O
left	O
ventricular	O
dysfunction	O
LVEF	O
50	O
.	O
Peripheral	O
arterial	O
disease	O
.	O
Type	O
2	O
diabetes	O
mellitus	O
with	O
good	O
metabolic	O
control	O
.	O
LDL	O
cholesterol	O
above	O
target	O
50	O
mg	O
dl	O
.	O
Arterial	O
hypertension	O
.	O

HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
57	O
year	O
old	O
male	O
with	O
a	O
personal	O
history	O
of	O
arterial	O
hypertension	O
AHT	O
,	O
no	O
other	O
known	O
cardiovascular	O
risk	O
factors	O
and	O
Wolff	O
Parkinson	O
White	O
syndrome	O
WPW	O
with	O
no	O
invasive	O
treatment	O
to	O
date	O
.	O
On	O
treatment	O
only	O
with	O
atenolol	B-FARMACO
100	O
mg	O
per	O
day	O
.	O
On	O
waking	O
up	O
on	O
the	O
morning	O
of	O
admission	O
at	O
8	O
00	O
a	O
.	O
m	O
.	O
,	O
he	O
felt	O
dizzy	O
and	O
unstable	O
and	O
fell	O
to	O
the	O
floor	O
.	O
He	O
was	O
rushed	O
to	O
the	O
emergency	O
department	O
for	O
assessment	O
.	O
Haemodynamic	O
stability	O
was	O
observed	O
,	O
with	O
elevated	O
blood	O
pressure	O
190	O
117	O
mmHg	O
,	O
heart	O
rate	O
59	O
bpm	O
,	O
afebrile	O
state	O
and	O
baseline	O
oxygen	O
saturation	O
of	O
92	O
.	O
The	O
neurological	O
examination	O
showed	O
a	O
NIHSS	O
7	O
dysarthric	O
speech	O
,	O
left	O
central	O
facial	O
paresis	O
,	O
striking	O
horizontal	O
rotatory	O
nystagmus	O
with	O
rapid	O
leftward	O
movement	O
,	O
claudication	O
of	O
the	O
lower	O
limbs	O
and	O
mild	O
hypoaesthesia	O
of	O
algesic	O
predominance	O
in	O
the	O
right	O
hemibody	O
including	O
the	O
face	O
.	O
The	O
rest	O
of	O
the	O
physical	O
examination	O
showed	O
cardiac	O
auscultation	O
without	O
murmurs	O
or	O
extratonos	O
and	O
respiratory	O
auscultation	O
with	O
preserved	O
vesicular	O
murmur	O
without	O
added	O
noises	O
.	O
An	O
electrocardiogram	O
in	O
sinus	O
rhythm	O
was	O
requested	O
,	O
and	O
blood	O
tests	O
showed	O
platelets	O
and	O
normal	O
coagulation	O
,	O
with	O
only	O
an	O
elevated	O
D	O
dimer	O
.	O
An	O
emergency	O
multimodal	O
computed	O
tomography	O
CT	O
scan	O
without	O
perfusion	O
was	O
performed	O
,	O
showing	O
occlusion	O
of	O
the	O
left	O
vertebral	O
artery	O
along	O
segment	O
V3	O
4	O
,	O
compatible	O
with	O
acute	O
thrombus	O
,	O
as	O
well	O
as	O
chronic	O
ischaemic	O
lesions	O
in	O
the	O
basal	O
ganglia	O
,	O
left	O
thalamus	O
and	O
cerebellar	O
hemispheres	O
.	O
Given	O
the	O
acute	O
nature	O
of	O
the	O
picture	O
,	O
the	O
clear	O
neurological	O
deficit	O
,	O
the	O
evidence	O
of	O
thrombus	O
,	O
a	O
good	O
baseline	O
situation	O
assessed	O
on	O
the	O
Ratkin	O
Scale	O
and	O
the	O
absence	O
of	O
contraindications	O
for	O
the	O
same	O
,	O
a	O
pharmacoinvasive	O
strategy	O
was	O
decided	O
,	O
so	O
r	B-FARMACO
TPA	B-FARMACO
was	O
administered	O
and	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
referral	O
hospital	O
for	O
clinical	O
monitoring	O
in	O
the	O
Stroke	O
Unit	O
due	O
to	O
the	O
possibility	O
of	O
progression	O
to	O
the	O
basilar	O
artery	O
and	O
the	O
need	O
for	O
surgical	O
treatment	O
.	O
COMPLEMENTARY	O
TESTS	O
Baseline	O
electrocardiogram	O
ECG	O
sinus	O
rhythm	O
at	O
78	O
bpm	O
,	O
short	O
PR	O
with	O
initial	O
QRS	O
flattening	O
compatible	O
with	O
a	O
delta	O
wave	O
,	O
repolarisation	O
disturbance	O
consisting	O
of	O
non	O
significant	O
ST	O
segment	O
underleveling	O
in	O
left	O
precordial	O
leads	O
and	O
lateral	O
face	O
with	O
negative	O
T	O
wave	O
,	O
probably	O
secondary	O
to	O
WPW	O
.	O
ED	O
CBC	O
leukocytes	O
8	O
,	O
500	O
l	O
,	O
segmented	O
45	O
.	O
4	O
3	O
,	O
800	O
	O
l	O
,	O
lymphocytes	O
40	O
.	O
3	O
3	O
,	O
400	O
l	O
,	O
red	O
blood	O
cells	O
5	O
.	O
790	O
million	O
l	O
,	O
haemoglobin	O
15	O
.	O
1	O
g	O
dl	O
,	O
haematocrit	O
47	O
.	O
5	O
,	O
MCV	O
82	O
fl	O
,	O
platelets	O
163	O
thousands	O
l	O
,	O
prothrombin	O
time	O
11	O
.	O
4	O
seconds	O
,	O
prothrombin	O
activity	O
94	O
,	O
aTTP	O
28	O
.	O
2	O
seconds	O
,	O
fibrinogen	O
484	O
mg	O
dl	O
,	O
urgent	O
D	O
dimer	O
2	O
,	O
099	O
ng	O
ml	O
,	O
INR	O
1	O
.	O
04	O
,	O
serum	O
glucose	O
109	O
mg	O
dl	O
,	O
urea	O
26	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
88	O
mg	O
dl	O
.	O
Urgent	O
cranial	O
CT	O
and	O
perfusion	O
CT	O
subcortical	O
hypodensity	O
of	O
about	O
5	O
mm	O
in	O
the	O
right	O
cerebellar	O
hemisphere	O
suggestive	O
of	O
chronic	O
ischaemic	O
lesion	O
.	O
Hypodensities	O
in	O
the	O
anterior	O
arm	O
of	O
the	O
internal	O
capsule	O
,	O
in	O
the	O
lenticular	O
nucleus	O
and	O
in	O
the	O
thalamic	O
region	O
of	O
the	O
left	O
hemisphere	O
,	O
with	O
attenuation	O
similar	O
to	O
CSF	O
,	O
suggestive	O
of	O
chronic	O
lacunar	O
infarcts	O
.	O
Fourth	O
ventricle	O
of	O
normal	O
size	O
and	O
morphology	O
,	O
centred	O
in	O
the	O
midline	O
.	O
Basal	O
cisterns	O
free	O
and	O
symmetrical	O
.	O
No	O
densitometric	O
alterations	O
were	O
observed	O
in	O
the	O
brainstem	O
.	O
No	O
intra	O
or	O
extra	O
axial	O
bleeding	O
or	O
midline	O
deviation	O
.	O
Hyperdensity	O
of	O
the	O
V4	O
segment	O
of	O
the	O
left	O
vertebral	O
artery	O
in	O
probable	O
relation	O
to	O
acute	O
thrombus	O
.	O
The	O
perfusion	O
study	O
is	O
not	O
valid	O
in	O
the	O
study	O
performed	O
to	O
assess	O
the	O
vertebrobasilar	O
axis	O
.	O
Retention	O
cysts	O
in	O
maxillary	O
and	O
left	O
sphenoidal	O
sinuses	O
.	O
Angio	O
CT	O
of	O
TSA	O
and	O
urgent	O
cerebral	O
arteries	O
carotid	O
axes	O
of	O
normal	O
morphology	O
and	O
paths	O
up	O
to	O
the	O
bifurcation	O
,	O
with	O
non	O
obstructive	O
flat	O
calcified	O
atheroma	O
plaque	O
at	O
the	O
origin	O
of	O
the	O
left	O
internal	O
carotid	O
artery	O
.	O
Both	O
internal	O
carotid	O
arteries	O
are	O
patent	O
and	O
of	O
normal	O
calibre	O
.	O
Right	O
vertebral	O
artery	O
patent	O
up	O
to	O
the	O
basilar	O
trunk	O
.	O
Repletion	O
defect	O
along	O
V3	O
and	O
V4	O
of	O
the	O
left	O
vertebral	O
artery	O
,	O
compatible	O
with	O
acute	O
thrombus	O
.	O
No	O
associated	O
collaterals	O
were	O
seen	O
in	O
this	O
segment	O
.	O
Intracranially	O
,	O
the	O
vascular	O
structures	O
of	O
the	O
polygon	O
of	O
Willis	O
are	O
permeable	O
and	O
of	O
normal	O
calibre	O
with	O
no	O
repletion	O
defects	O
or	O
aneurysms	O
.	O
Conclusion	O
findings	O
compatible	O
with	O
acute	O
thrombus	O
in	O
V3	O
and	O
V4	O
of	O
the	O
left	O
vertebral	O
artery	O
.	O
Chronic	O
ischaemic	O
lesions	O
in	O
the	O
left	O
basal	O
ganglia	O
and	O
thalamus	O
and	O
in	O
the	O
right	O
cerebellar	O
hemisphere	O
.	O
Routine	O
laboratory	O
tests	O
on	O
the	O
neurology	O
ward	O
glucose	O
111	O
mg	O
dl	O
.	O
Urea	O
20	O
mg	O
dl	O
.	O
Creatinine	O
0	O
.	O
69	O
mg	O
dl	O
.	O
Estimated	O
glomerular	O
filtration	O
rate	O
CKD	O
EPI	O
90	O
ml	O
min	O
1	O
.	O
73	O
m	O
.	O
Uric	O
acid	O
3	O
.	O
2	O
mg	O
dl	O
.	O
Sodium	O
140	O
.	O
4	O
mEq	O
l	O
.	O
Potassium	O
3	O
,	O
71	O
mEq	O
l	O
.	O
Chlorine	O
104	O
,	O
4	O
mEq	O
l	O
.	O
Calcium	O
9	O
mg	O
dl	O
.	O
Phosphorus	O
2	O
,	O
6	O
mg	O
dl	O
.	O
Total	O
proteins	O
6	O
,	O
85	O
g	O
dl	O
.	O
Albumin	O
4	O
.	O
1	O
g	O
dl	O
.	O
Cholesterol	O
205	O
mg	O
dl	O
.	O
HDL	O
cholesterol	O
55	O
mg	O
dl	O
.	O
Calculated	O
LDL	O
cholesterol	O
117	O
mg	O
dl	O
.	O
Triglycerides	O
166	O
mg	O
dl	O
.	O
GOT	O
AST	O
17	O
U	O
l	O
.	O
GPT	O
ALT	O
16	O
U	O
l	O
.	O
GGT	O
21	O
U	O
l	O
.	O
Total	O
bilirubin	O
0	O
.	O
5	O
mg	O
dl	O
.	O
Alkaline	O
phosphatase	O
38	O
U	O
l	O
.	O
Glycosylated	O
haemoglobin	O
5	O
.	O
7	O
.	O
Thrombophilia	O
study	O
normal	O
results	O
.	O
Antithrombin	O
III	O
84	O
,	O
protein	O
C	O
145	O
,	O
resistance	O
to	O
activated	O
protein	O
C	O
3	O
.	O
1	O
,	O
antigenic	O
free	O
protein	O
S	O
108	O
,	O
prothrombin	O
factor	O
20210	O
A	O
gene	O
negative	O
,	O
momocysteine	O
8	O
MicroMol	O
l	O
.	O
Chest	O
CT	O
with	O
VSD	O
PET	O
protocol	O
multiple	O
entral	O
repletion	O
defects	O
are	O
observed	O
at	O
the	O
level	O
of	O
lobar	O
artery	O
for	O
LID	O
with	O
extension	O
to	O
segmental	O
and	O
subsegmental	O
branches	O
,	O
segmental	O
arteries	O
for	O
LM	O
,	O
LSD	O
and	O
LII	O
,	O
some	O
with	O
extension	O
to	O
subsegmental	O
branches	O
.	O
Findings	O
in	O
relation	O
to	O
bilateral	O
acute	O
pulmonary	O
thromboembolism	O
PTE	O
.	O
Increased	O
calibre	O
of	O
the	O
pulmonary	O
artery	O
trunk	O
35	O
mm	O
and	O
its	O
main	O
branches	O
APD	O
of	O
25	O
mm	O
,	O
API	O
of	O
25	O
mm	O
,	O
in	O
relation	O
to	O
PTE	O
.	O
No	O
signs	O
suggestive	O
of	O
right	O
heart	O
cavity	O
overload	O
.	O
No	O
pericardial	O
effusion	O
is	O
observed	O
.	O
No	O
significant	O
supraclavicular	O
,	O
axillary	O
,	O
mediastinal	O
or	O
hilar	O
lymphadenopathy	O
.	O
Accessory	O
fissure	O
of	O
the	O
azygos	O
as	O
an	O
anatomical	O
variant	O
of	O
normality	O
.	O
Laminar	O
bibasal	O
atelectasis	O
.	O
Small	O
calcified	O
granuloma	O
in	O
LSD	O
.	O
Rest	O
of	O
the	O
lung	O
parenchyma	O
without	O
pathological	O
findings	O
.	O
No	O
pleural	O
effusion	O
.	O
Mild	O
dorsal	O
spondyloarthrosis	O
.	O
Hiatal	O
hernia	O
.	O
Diagnostic	O
impression	O
findings	O
compatible	O
with	O
bilateral	O
acute	O
PTE	O
and	O
PHT	O
.	O
Post	O
fibrinolysis	O
control	O
CT	O
scan	O
evolving	O
ischaemic	O
lesion	O
in	O
the	O
left	O
cerebellar	O
hemisphere	O
in	O
the	O
territory	O
of	O
the	O
PICA	O
.	O
No	O
signs	O
suggesting	O
haemorrhagic	O
transformation	O
.	O
Echo	O
Doppler	O
of	O
the	O
lower	O
extremities	O
no	O
evidence	O
of	O
DVT	O
.	O
Transthoracic	O
echocardiogram	O
performed	O
in	O
the	O
stroke	O
unit	O
non	O
dilated	O
left	O
ventricle	O
,	O
mild	O
septal	O
hypertrophy	O
with	O
preserved	O
systolic	O
function	O
LVEF	O
60	O
without	O
alterations	O
in	O
segmental	O
contractility	O
.	O
Right	O
ventricle	O
not	O
dilated	O
,	O
normofunctioning	O
TAPSE	O
24	O
mm	O
,	O
S	O
wave	O
0	O
.	O
21m	O
s	O
.	O
Diastolic	O
flattening	O
of	O
the	O
IVS	O
suggestive	O
of	O
volume	O
overload	O
in	O
the	O
right	O
chambers	O
;	O
no	O
other	O
signs	O
suggestive	O
of	O
right	O
chamber	O
involvement	O
.	O
Degenerative	O
aortic	O
valve	O
disease	O
resulting	O
in	O
mild	O
aortic	O
insufficiency	O
VC	O
3	O
mm	O
.	O
Mitral	O
filling	O
pattern	O
not	O
assessable	O
by	O
wave	O
fusion	O
.	O
Mild	O
tricuspid	O
insufficiency	O
allowing	O
estimation	O
of	O
PSAP	O
33	O
mmHg	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
.	O
IVC	O
at	O
the	O
upper	O
limit	O
of	O
normality	O
with	O
respirophasic	O
variations	O
in	O
its	O
calibre	O
.	O
Aneurysm	O
of	O
the	O
interatrial	O
septum	O
with	O
redundant	O
movement	O
,	O
without	O
intracavitary	O
claroshunt	O
.	O
It	O
is	O
recommended	O
to	O
complete	O
the	O
study	O
with	O
bubble	O
echocardiogram	O
to	O
rule	O
out	O
shunt	O
from	O
right	O
to	O
left	O
cavities	O
.	O
Transthoracic	O
echocardiogram	O
with	O
bubbles	O
very	O
positive	O
bubble	O
test	O
,	O
with	O
passage	O
of	O
abundant	O
bubbles	O
30	O
in	O
first	O
beats	O
without	O
Valsalva	O
.	O
Transesophageal	O
echocardiogram	O
a	O
study	O
was	O
performed	O
to	O
assess	O
the	O
interatrial	O
septum	O
due	O
to	O
stroke	O
,	O
PTE	O
and	O
positive	O
bubble	O
test	O
.	O
The	O
presence	O
of	O
PFO	O
of	O
the	O
tunneled	O
type	O
with	O
significant	O
passage	O
of	O
bubbles	O
to	O
the	O
left	O
cavities	O
at	O
baseline	O
was	O
confirmed	O
.	O
The	O
edges	O
of	O
the	O
septum	O
secundum	O
are	O
thick	O
,	O
18	O
mm	O
long	O
inferiorly	O
and	O
26	O
mm	O
posteriorly	O
,	O
the	O
distance	O
between	O
the	O
two	O
edges	O
being	O
about	O
25	O
mm	O
.	O
Left	O
atrial	O
appendage	O
without	O
thrombus	O
and	O
with	O
normal	O
flow	O
.	O
Conclusions	O
patent	O
foramen	O
ovale	O
tunnel	O
type	O
.	O
Electrophysiological	O
study	O
baseline	O
findings	O
HV	O
0	O
ms	O
.	O
Concentric	O
and	O
decremental	O
retrograde	O
conduction	O
therefore	O
absence	O
of	O
retrograde	O
conduction	O
through	O
the	O
pathway	O
1	O
1	O
up	O
to	O
400	O
ms	O
.	O
Preexcitation	O
with	O
1	O
1	O
accessory	O
pathway	O
conduction	O
only	O
up	O
to	O
560	O
ms	O
.	O
Anterograde	O
PW	O
450	O
ms	O
,	O
PRENAV	O
600	O
350	O
ms	O
.	O
An	O
area	O
with	O
AV	O
continuity	O
and	O
ventriculogram	O
with	O
precocity	O
with	O
respect	O
to	O
the	O
onset	O
of	O
delta	O
is	O
identified	O
.	O
Anterograde	O
conduction	O
via	O
the	O
accessory	O
pathway	O
is	O
transiently	O
interrupted	O
very	O
easily	O
in	O
relation	O
to	O
the	O
manipulation	O
of	O
the	O
catheter	O
in	O
the	O
area	O
.	O
A	O
35	O
W	O
RF	O
application	O
is	O
performed	O
,	O
with	O
interruption	O
of	O
the	O
pre	O
excitation	O
at	O
the	O
start	O
of	O
the	O
application	O
.	O
A	O
total	O
of	O
7	O
applications	O
are	O
performed	O
,	O
with	O
a	O
total	O
RF	O
time	O
of	O
154	O
ms	O
.	O
After	O
the	O
waiting	O
period	O
,	O
the	O
absence	O
of	O
bidirectional	O
conduction	O
in	O
the	O
pathway	O
was	O
verified	O
.	O
Complete	O
atrial	O
and	O
ventricular	O
pacing	O
protocols	O
were	O
repeated	O
after	O
the	O
ablation	O
,	O
confirming	O
1	O
1	O
concentric	O
and	O
decremental	O
VA	O
conduction	O
up	O
to	O
380	O
ms	O
,	O
a	O
PW	O
of	O
133	O
bpm	O
,	O
with	O
an	O
anterograde	O
nodal	O
curve	O
without	O
AH	O
jump	O
and	O
without	O
inducing	O
echoes	O
or	O
tachycardia	O
.	O
After	O
the	O
wait	O
,	O
two	O
additional	O
safety	O
applications	O
were	O
performed	O
with	O
the	O
same	O
parameters	O
duration	O
58	O
s	O
.	O
A	O
subcutaneous	O
Holter	O
was	O
implanted	O
in	O
the	O
left	O
parasternal	O
position	O
.	O
Post	O
ablation	O
ECG	O
sinus	O
rhythm	O
at	O
68	O
bpm	O
.	O
No	O
signs	O
of	O
pre	O
excitation	O
.	O
No	O
alteration	O
in	O
repolarisation	O
or	O
intraventricular	O
conduction	O
.	O
Percutaneous	O
closure	O
of	O
PFO	O
a	O
30	O
mm	O
cribriform	O
closure	O
device	O
was	O
implanted	O
.	O
By	O
means	O
of	O
the	O
depush	O
and	O
pull	O
manoeuvre	O
and	O
angiography	O
,	O
its	O
correct	O
position	O
is	O
verified	O
.	O
CLINICAL	O
EVOLUTION	O
During	O
his	O
stay	O
in	O
the	O
stroke	O
unit	O
,	O
haemodynamic	O
support	O
,	O
cardiorespiratory	O
monitoring	O
and	O
strict	O
control	O
of	O
cardiovascular	O
risk	O
factors	O
were	O
carried	O
out	O
.	O
On	O
arrival	O
on	O
the	O
ward	O
,	O
a	O
blood	O
test	O
was	O
drawn	O
with	O
a	O
coagulation	O
study	O
that	O
included	O
a	O
D	O
dimer	O
determination	O
,	O
as	O
the	O
first	O
determination	O
carried	O
out	O
in	O
the	O
emergency	O
department	O
was	O
elevated	O
,	O
the	O
new	O
result	O
being	O
even	O
higher	O
.	O
For	O
this	O
reason	O
,	O
together	O
with	O
the	O
presence	O
of	O
slight	O
dyspnoea	O
,	O
it	O
was	O
decided	O
to	O
rule	O
out	O
pulmonary	O
thromboembolism	O
PTE	O
.	O
After	O
an	O
angio	O
CT	O
scan	O
of	O
the	O
pulmonary	O
arteries	O
revealed	O
the	O
existence	O
of	O
acute	O
bilateral	O
PTE	O
,	O
a	O
control	O
cranial	O
CT	O
scan	O
was	O
performed	O
to	O
rule	O
out	O
haemorrhagic	O
transformation	O
after	O
fibrinolysis	O
.	O
Therefore	O
,	O
after	O
a	O
risk	O
benefit	O
assessment	O
,	O
it	O
was	O
decided	O
to	O
start	O
anticoagulation	O
with	O
IV	O
sodium	B-FARMACO
heparin	I-FARMACO
,	O
with	O
subsequent	O
transition	O
to	O
LMWH	B-FARMACO
.	O
A	O
Doppler	O
ultrasound	O
of	O
the	O
lower	O
limbs	O
was	O
performed	O
,	O
which	O
ruled	O
out	O
the	O
existence	O
of	O
deep	O
vein	O
thrombosis	O
,	O
and	O
a	O
transthoracic	O
echocardiogram	O
ruled	O
out	O
right	O
ventricular	O
dysfunction	O
but	O
revealed	O
the	O
existence	O
of	O
an	O
aneurysm	O
of	O
the	O
interatrial	O
septum	O
,	O
which	O
was	O
studied	O
by	O
means	O
of	O
a	O
bubble	O
echocardiogram	O
and	O
a	O
transesophageal	O
echocardiogram	O
,	O
revealing	O
the	O
existence	O
of	O
a	O
PFO	O
,	O
unknown	O
until	O
then	O
.	O
The	O
most	O
likely	O
cause	O
of	O
the	O
stroke	O
PTE	O
was	O
considered	O
to	O
be	O
paradoxical	O
embolism	O
due	O
to	O
PFO	O
in	O
a	O
patient	O
with	O
WPW	O
and	O
possible	O
associated	O
arrhythmia	O
the	O
most	O
plausible	O
being	O
atrial	O
fibrillation	O
associated	O
with	O
WPW	O
.	O
It	O
was	O
then	O
decided	O
to	O
study	O
and	O
ablate	O
the	O
accessory	O
pathway	O
,	O
implanting	O
a	O
subcutaneous	O
Holter	O
at	O
the	O
same	O
time	O
to	O
study	O
subsequent	O
arrhythmias	O
,	O
whether	O
unrelated	O
to	O
WPW	O
syndrome	O
or	O
due	O
to	O
recurrence	O
.	O
The	O
evolution	O
from	O
the	O
neurological	O
point	O
of	O
view	O
was	O
very	O
favourable	O
,	O
with	O
practically	O
complete	O
resolution	O
of	O
the	O
clinical	O
manifestations	O
,	O
although	O
instability	O
persisted	O
,	O
so	O
it	O
was	O
decided	O
to	O
discharge	O
the	O
patient	O
.	O
In	O
a	O
second	O
stage	O
,	O
after	O
one	O
month	O
,	O
percutaneous	O
closure	O
of	O
the	O
tunneled	O
PFO	O
is	O
performed	O
,	O
given	O
that	O
it	O
has	O
anatomical	O
risk	O
criteria	O
.	O
After	O
this	O
last	O
intervention	O
,	O
the	O
patient	O
is	O
recommended	O
hygienic	O
dietary	O
measures	O
,	O
gradually	O
introducing	O
light	O
physical	O
activity	O
,	O
as	O
well	O
as	O
a	O
varied	O
diet	O
,	O
without	O
excess	O
salt	O
,	O
and	O
with	O
sugar	O
control	O
given	O
his	O
pre	O
diabetes	O
stage	O
.	O
Endocarditis	O
prophylaxis	O
for	O
the	O
next	O
6	O
months	O
,	O
if	O
invasive	O
dental	O
procedures	O
are	O
performed	O
.	O
Regarding	O
medication	O
rivaroxaban	B-FARMACO
20	O
mg	O
24	O
hours	O
,	O
clopidogrel	B-FARMACO
75	O
mg	O
24	O
hours	O
for	O
6	O
months	O
,	O
candersartan	B-FARMACO
hydrochlorothiazide	I-FARMACO
16	O
12	O
.	O
5	O
mg	O
24	O
hours	O
,	O
atorvastatin	B-FARMACO
80	O
mg	O
24	O
hours	O
.	O
Regarding	O
the	O
maintenance	O
of	O
anticoagulation	O
,	O
a	O
new	O
control	O
angio	O
CT	O
scan	O
could	O
be	O
considered	O
to	O
rule	O
out	O
thrombotic	O
remnants	O
of	O
the	O
PTE	O
and	O
in	O
that	O
case	O
its	O
withdrawal	O
could	O
be	O
considered	O
,	O
also	O
subject	O
to	O
the	O
possible	O
detection	O
of	O
atrial	O
fibrillation	O
with	O
the	O
subcutaneous	O
Holter	O
.	O
DIAGNOSIS	O
Acute	O
ischaemic	O
stroke	O
in	O
vertebrobasilar	O
territory	O
,	O
acute	O
occlusion	O
segment	O
V3	O
4	O
of	O
the	O
left	O
vertebral	O
artery	O
with	O
involvement	O
of	O
the	O
ipsilateral	O
posterior	O
inferior	O
cerebellar	O
artery	O
PICA	O
and	O
bilateral	O
acute	O
pulmonary	O
thromboembolism	O
on	O
admission	O
with	O
fibrinolysis	O
.	O
Permeable	O
tunnelled	O
foramen	O
ovale	O
closed	O
percutaneously	O
.	O
WPW	O
accessory	O
pathway	O
ablation	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
80	O
year	O
old	O
male	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
Ex	O
smoker	O
for	O
20	O
years	O
AE	O
15	O
packs	O
year	O
.	O
Cardiovascular	O
risk	O
factors	O
include	O
arterial	O
hypertension	O
AHT	O
on	O
treatment	O
with	O
candesartan	B-FARMACO
32	O
mg	O
per	O
day	O
and	O
type	O
2	O
diabetes	O
mellitus	O
on	O
treatment	O
with	O
empagliflozin	B-FARMACO
metformin	I-FARMACO
5	O
1	O
,	O
000	O
mg	O
per	O
day	O
.	O
No	O
known	O
cardiological	O
history	O
.	O
History	O
only	O
includes	O
benign	O
prostatic	O
hyperplasia	O
and	O
cataract	O
surgery	O
in	O
both	O
eyes	O
.	O
Independent	O
for	O
all	O
basic	O
activities	O
of	O
daily	O
living	O
,	O
including	O
advanced	O
activities	O
Rankin	O
0	O
.	O
Present	O
illness	O
The	O
patient	O
was	O
brought	O
to	O
the	O
emergency	O
department	O
of	O
our	O
centre	O
by	O
basic	O
life	O
support	O
after	O
being	O
found	O
by	O
his	O
sister	O
on	O
the	O
floor	O
of	O
her	O
home	O
at	O
15	O
00	O
hours	O
with	O
clinical	O
symptoms	O
consisting	O
of	O
deviation	O
of	O
the	O
right	O
corner	O
of	O
the	O
mouth	O
,	O
ocular	O
deviation	O
to	O
the	O
left	O
and	O
speech	O
impairment	O
.	O
He	O
had	O
a	O
scalp	O
injury	O
suggestive	O
of	O
cranioencephalic	O
trauma	O
.	O
The	O
last	O
time	O
he	O
was	O
seen	O
asymptomatic	O
was	O
the	O
previous	O
day	O
at	O
around	O
11	O
00	O
am	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
BP	O
187	O
98	O
mmHg	O
,	O
heart	O
rate	O
HR	O
98	O
bpm	O
,	O
basal	O
oxygen	O
saturation	O
94	O
.	O
Mixed	O
aphasia	O
language	O
not	O
very	O
fluent	O
,	O
although	O
communication	O
is	O
possible	O
.	O
Understands	O
some	O
simple	O
commands	O
.	O
Altered	O
naming	O
.	O
Left	O
visual	O
preference	O
.	O
Right	O
homonymous	O
hemianopsia	O
on	O
confrontational	O
campimetry	O
.	O
Left	O
supranuclear	O
facial	O
paresis	O
.	O
Rest	O
of	O
cranial	O
nerves	O
preserved	O
.	O
Claudication	O
of	O
the	O
right	O
lower	O
limb	O
NIHSS	O
of	O
8	O
points	O
.	O
Cardiac	O
auscultation	O
regular	O
sounds	O
without	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
,	O
without	O
pathological	O
sounds	O
.	O
Abdomen	O
was	O
normal	O
.	O
Normal	O
and	O
symmetrical	O
pulses	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
sinus	O
rhythm	O
at	O
95	O
bpm	O
.	O
PR	O
140	O
ms	O
.	O
Narrow	O
QRS	O
with	O
normal	O
axis	O
.	O
Embryonic	O
R	O
in	O
precordials	O
up	O
to	O
V4	O
with	O
negative	O
T	O
in	O
I	O
,	O
aVL	O
,	O
V5	O
V6	O
.	O
CBC	O
glucose	O
138	O
mg	O
dl	O
.	O
Urea	O
39	O
mg	O
dl	O
.	O
Creatinine	O
0	O
.	O
91	O
mg	O
dl	O
.	O
Sodium	O
141	O
mmol	O
l	O
.	O
Potassium	O
4	O
.	O
4	O
mmol	O
l	O
.	O
CPK	O
98	O
U	O
l	O
.	O
CRP	O
7	O
.	O
0	O
mg	O
l	O
.	O
Hb	O
15	O
.	O
7	O
g	O
dl	O
.	O
MCV	O
92	O
fl	O
.	O
Leukocytes	O
4	O
,	O
6x10	O
9	O
l	O
.	O
Platelets	O
165	O
x10	O
9	O
l	O
.	O
INR	O
1	O
.	O
07	O
.	O
Troponin	O
T	O
ultrasensitive	O
76	O
pg	O
ml	O
68	O
.	O
3	O
at	O
6	O
hours	O
normal	O
14	O
.	O
Chest	O
X	O
ray	O
no	O
consolidation	O
or	O
pleural	O
effusion	O
.	O
Vacuum	O
cranial	O
computed	O
tomography	O
CT	O
discrete	O
cerebral	O
corticosubcortical	O
atrophy	O
.	O
Left	O
occipital	O
and	O
left	O
thalamus	O
hypodensities	O
of	O
acute	O
ischaemic	O
origin	O
of	O
new	O
onset	O
,	O
not	O
present	O
in	O
previous	O
CT	O
2015	O
.	O
Hypodensity	O
in	O
left	O
insula	O
of	O
probable	O
chronic	O
ischaemic	O
origin	O
already	O
present	O
in	O
previous	O
CT	O
scan	O
.	O
Angio	O
CT	O
of	O
supra	O
aortic	O
trunks	O
and	O
Willis	O
polygon	O
after	O
administration	O
of	O
intravenous	O
contrast	O
image	O
2	O
repletion	O
defect	O
in	O
P2A	O
segment	O
of	O
left	O
posterior	O
cerebral	O
artery	O
.	O
The	O
rest	O
of	O
the	O
arteries	O
of	O
the	O
polygon	O
of	O
Willis	O
are	O
patent	O
,	O
with	O
no	O
aneurysmal	O
dilatations	O
or	O
significant	O
stenosis	O
or	O
images	O
suggestive	O
of	O
thrombosis	O
occlusion	O
.	O
Perfusion	O
CT	O
scan	O
after	O
administration	O
of	O
IVC	O
penumbra	O
area	O
in	O
the	O
left	O
posterior	O
cerebral	O
artery	O
territory	O
,	O
with	O
mismatch	O
greater	O
than	O
20	O
.	O
Magnetic	O
resonance	O
imaging	O
MRI	O
with	O
angio	O
MRI	O
extensive	O
acute	O
ischaemic	O
infarction	O
in	O
the	O
left	O
temporo	O
occipital	O
and	O
left	O
thalamic	O
territory	O
the	O
latter	O
with	O
haemorrhagic	O
transformation	O
.	O
Angiographic	O
sequences	O
identify	O
supra	O
aortic	O
trunks	O
with	O
no	O
evidence	O
of	O
significant	O
stenosis	O
.	O
The	O
arterial	O
structures	O
of	O
the	O
polygon	O
of	O
Willis	O
show	O
a	O
normal	O
carotid	O
system	O
and	O
basilar	O
system	O
with	O
no	O
evidence	O
of	O
vascular	O
malformations	O
or	O
significant	O
stenosis	O
.	O
Transthoracic	O
echocardiography	O
cardiac	O
cavities	O
of	O
normal	O
size	O
,	O
with	O
moderate	O
hypertrophy	O
,	O
predominantly	O
septal	O
.	O
Slightly	O
depressed	O
LVEF	O
48	O
by	O
Simpson	O
at	O
the	O
expense	O
of	O
akinesia	O
of	O
the	O
septum	O
and	O
anterior	O
wall	O
in	O
its	O
apical	O
segments	O
and	O
strict	O
apex	O
akinesia	O
.	O
Normal	O
TAPSE	O
.	O
No	O
significant	O
valvulopathy	O
.	O
There	O
was	O
a	O
mass	O
attached	O
to	O
the	O
septoapical	O
wall	O
,	O
protruding	O
and	O
mobile	O
,	O
measuring	O
20x17	O
mm	O
,	O
compatible	O
with	O
left	O
intraventricular	O
thrombus	O
.	O
Cardiac	O
magnetic	O
resonance	O
CMR	O
.	O
Late	O
enhancement	O
sequence	O
rounded	O
thrombus	O
of	O
11x16x15	O
mm	O
adhered	O
to	O
septoapical	O
wall	O
.	O
Lateral	O
hypokinesia	O
,	O
apical	O
segments	O
and	O
strict	O
apex	O
.	O
Absence	O
of	O
myocardial	O
oedema	O
.	O
Non	O
transmural	O
subendocardial	O
necrosis	O
on	O
the	O
lateral	O
aspect	O
.	O
Absence	O
of	O
necrosis	O
in	O
the	O
apical	O
segments	O
.	O
Transthoracic	O
echocardiography	O
two	O
months	O
after	O
discharge	O
resolution	O
of	O
the	O
thrombus	O
observed	O
in	O
the	O
previous	O
echography	O
with	O
persistence	O
of	O
the	O
contractility	O
alterations	O
described	O
in	O
previous	O
echocardiographies	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
80	O
years	O
of	O
age	O
,	O
with	O
a	O
good	O
functional	O
level	O
,	O
who	O
presented	O
with	O
clinical	O
symptoms	O
compatible	O
with	O
ischaemic	O
stroke	O
in	O
the	O
left	O
posterior	O
cerebral	O
artery	O
territory	O
with	O
NISS	O
6	O
.	O
The	O
emergency	O
department	O
activated	O
the	O
stroke	O
code	O
,	O
observing	O
P2	O
segment	O
occlusion	O
in	O
the	O
CT	O
angiography	O
.	O
Fibrinolytic	O
treatment	O
was	O
ruled	O
out	O
due	O
to	O
the	O
uncertain	O
evolution	O
time	O
and	O
interventional	O
radiology	O
was	O
contacted	O
for	O
evaluation	O
of	O
endovascular	O
treatment	O
,	O
which	O
was	O
also	O
ruled	O
out	O
due	O
to	O
hypodensity	O
established	O
in	O
the	O
vacuum	O
CT	O
scan	O
and	O
occlusion	O
distal	O
to	O
P1	O
.	O
Subsequently	O
,	O
ischaemia	O
was	O
observed	O
in	O
different	O
arterial	O
territories	O
in	O
cerebral	O
MRI	O
.	O
Angiography	O
showed	O
a	O
normal	O
carotid	O
and	O
basilar	O
system	O
with	O
no	O
evidence	O
of	O
vascular	O
malformations	O
or	O
significant	O
stenosis	O
.	O
As	O
part	O
of	O
the	O
aetiological	O
study	O
of	O
the	O
stroke	O
,	O
a	O
regular	O
transthoracic	O
echocardiography	O
was	O
requested	O
,	O
showing	O
intraventricular	O
thrombus	O
adhered	O
to	O
the	O
septoapical	O
wall	O
.	O
The	O
cardiology	O
department	O
was	O
consulted	O
and	O
the	O
study	O
was	O
completed	O
with	O
cardiac	O
magnetic	O
resonance	O
imaging	O
,	O
which	O
also	O
showed	O
lateral	O
hypokinesia	O
of	O
the	O
apical	O
segments	O
and	O
strict	O
apex	O
and	O
non	O
transmural	O
subendocardial	O
necrosis	O
on	O
the	O
lateral	O
aspect	O
compatible	O
with	O
old	O
infarction	O
.	O
In	O
the	O
directed	O
anamnesis	O
,	O
the	O
patient	O
had	O
no	O
previous	O
symptoms	O
of	O
chest	O
pain	O
,	O
dyspnoea	O
or	O
other	O
cardiological	O
symptoms	O
.	O
Given	O
the	O
characteristics	O
of	O
the	O
patient	O
;	O
elderly	O
and	O
with	O
a	O
recent	O
stroke	O
with	O
haemorrhagic	O
transformation	O
in	O
some	O
of	O
the	O
affected	O
brain	O
territories	O
,	O
anticoagulation	O
with	O
rivaroxaban	B-FARMACO
20	O
mg	O
per	O
day	O
was	O
agreed	O
with	O
the	O
neurology	O
department	O
.	O
Given	O
that	O
the	O
patient	O
had	O
not	O
previously	O
experienced	O
chest	O
pain	O
,	O
LVEF	O
was	O
not	O
severely	O
compromised	O
and	O
given	O
the	O
acute	O
situation	O
of	O
stroke	O
with	O
haemorrhagic	O
transformation	O
,	O
it	O
was	O
decided	O
not	O
to	O
perform	O
coronary	O
catheterisation	O
for	O
the	O
time	O
being	O
and	O
to	O
assess	O
after	O
resolution	O
of	O
the	O
apical	O
thrombus	O
.	O
On	O
discharge	O
,	O
the	O
patient	O
's	O
language	O
was	O
not	O
very	O
fluent	O
,	O
but	O
he	O
understood	O
orders	O
,	O
named	O
correctly	O
and	O
repeated	O
.	O
Persistence	O
of	O
campimetric	O
deficit	O
consisting	O
of	O
right	O
homonymous	O
hemianopsia	O
.	O
No	O
motor	O
deficit	O
NIHSS	O
of	O
3	O
points	O
.	O
The	O
control	O
echocardiography	O
at	O
one	O
month	O
on	O
an	O
outpatient	O
basis	O
showed	O
a	O
decrease	O
in	O
the	O
size	O
of	O
the	O
thrombus	O
and	O
in	O
the	O
control	O
echocardiography	O
at	O
two	O
months	O
,	O
resolution	O
of	O
the	O
thrombus	O
with	O
persistence	O
of	O
the	O
contractility	O
alterations	O
described	O
in	O
previous	O
echocardiographies	O
.	O
DIAGNOSIS	O
Ischaemic	O
stroke	O
in	O
the	O
left	O
posterior	O
cerebral	O
artery	O
territory	O
of	O
embolic	O
aetiology	O
.	O
Intraventricular	O
thrombus	O
.	O
Old	O
myocardial	O
infarction	O
in	O
lateral	O
face	O
and	O
apical	O
segments	O
.	O
Type	O
2	O
diabetes	O
mellitus	O
.	O
Arterial	O
hypertension	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
No	O
known	O
allergic	O
drug	O
reactions	O
.	O
Active	O
smoking	O
.	O
Morbid	O
obesity	O
with	O
a	O
body	O
mass	O
index	O
BMI	O
of	O
41	O
.	O
Diabetes	O
mellitus	O
treated	O
with	O
oral	O
antidiabetics	O
.	O
Dyslipidaemia	O
.	O
Stage	O
3A	O
chronic	O
kidney	O
disease	O
.	O
Chronic	O
ischaemic	O
heart	O
disease	O
three	O
vessel	O
lesion	O
surgically	O
revascularised	O
in	O
1981	O
,	O
by	O
endarterectomy	O
and	O
resection	O
of	O
endothelial	O
membrane	O
of	O
left	O
coronary	O
ostium	O
and	O
saphenous	O
bypass	O
to	O
anterior	O
descending	O
artery	O
LAD	O
,	O
with	O
posterior	O
occlusion	O
of	O
the	O
bypass	O
.	O
Chronic	O
total	O
occlusion	O
of	O
the	O
LAD	O
since	O
2012	O
.	O
Several	O
admissions	O
for	O
non	O
ST	O
segment	O
elevation	O
acute	O
coronary	O
syndrome	O
NSTEACS	O
since	O
2012	O
,	O
with	O
multiple	O
percutaneous	O
revascularisations	O
left	O
main	O
coronary	O
artery	O
LMCA	O
,	O
first	O
marginal	O
branch	O
MB	O
,	O
circumflex	O
bifurcation	O
Cx	O
first	O
MB	O
,	O
right	O
coronary	O
artery	O
RCA	O
.	O
Usual	O
treatment	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
100	O
mg	O
daily	O
,	O
clopidogrel	B-FARMACO
75	O
mg	O
daily	O
,	O
enalapril	B-FARMACO
5	O
mg	O
every	O
12	O
hours	O
,	O
metoprolol	B-FARMACO
100	O
mg	O
every	O
12	O
hours	O
,	O
amlodipine	B-FARMACO
5	O
mg	O
every	O
12	O
hours	O
,	O
isosorbide	B-FARMACO
mononitrate	I-FARMACO
40	O
mg	O
daily	O
,	O
ranolazine	B-FARMACO
500	O
mg	O
every	O
12	O
hours	O
,	O
furosemide	B-FARMACO
40	O
mg	O
daily	O
,	O
atorvastatin	B-FARMACO
80	O
mg	O
daily	O
,	O
empagliflozin	B-FARMACO
metformin	I-FARMACO
5	O
1000	O
mg	O
every	O
12	O
hours	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
daily	O
.	O
Present	O
illness	O
A	O
72	O
year	O
old	O
man	O
with	O
complex	O
chronic	O
ischaemic	O
heart	O
disease	O
,	O
with	O
multiple	O
revascularisations	O
,	O
came	O
to	O
the	O
emergency	O
department	O
for	O
an	O
episode	O
of	O
oppressive	O
central	O
thoracic	O
pain	O
at	O
rest	O
lasting	O
about	O
15	O
minutes	O
,	O
with	O
partial	O
relief	O
after	O
taking	O
sublingual	O
nitroglycerin	B-FARMACO
,	O
with	O
residual	O
discomfort	O
remaining	O
afterwards	O
.	O
During	O
the	O
previous	O
two	O
months	O
she	O
had	O
presented	O
episodes	O
of	O
chest	O
pain	O
with	O
moderate	O
exertion	O
climbing	O
stairs	O
,	O
which	O
resolved	O
with	O
rest	O
or	O
taking	O
nitroglycerine	B-FARMACO
,	O
which	O
is	O
why	O
ranolazine	B-FARMACO
had	O
been	O
associated	O
with	O
her	O
last	O
visit	O
.	O
She	O
denied	O
other	O
symptoms	O
,	O
such	O
as	O
dyspnoea	O
,	O
oedema	O
of	O
the	O
lower	O
limbs	O
,	O
palpitations	O
or	O
infectious	O
symptoms	O
.	O
Physical	O
examination	O
Vital	O
signs	O
blood	O
pressure	O
182	O
132	O
mmHg	O
.	O
Heart	O
rate	O
69	O
bpm	O
.	O
Oxygen	O
saturation	O
98	O
basal	O
.	O
Good	O
general	O
condition	O
.	O
Conscious	O
and	O
oriented	O
,	O
cooperative	O
,	O
normohydrated	O
and	O
normoperfused	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
,	O
no	O
extra	O
sounds	O
.	O
Abdomen	O
hydro	O
aerial	O
sounds	O
preserved	O
,	O
soft	O
and	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
.	O
Lower	O
limbs	O
no	O
oedema	O
,	O
distal	O
pulses	O
preserved	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
tests	O
on	O
admission	O
glucose	O
83	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
46	O
mg	O
dl	O
,	O
glomerular	O
filtration	O
rate	O
47	O
.	O
30	O
ml	O
min	O
,	O
sodium	O
139	O
mmol	O
l	O
,	O
potassium	O
3	O
.	O
9	O
mmol	O
l	O
,	O
chlorine	O
106	O
mmol	O
l	O
,	O
C	O
reactive	O
protein	O
2	O
.	O
6	O
mg	O
l	O
0	O
5	O
,	O
two	O
troponin	O
I	O
determinations	O
0	O
.	O
0	O
ng	O
ml	O
,	O
natriuretic	O
peptide	O
BNP	O
83	O
.	O
8	O
pg	O
ml	O
.	O
Analysis	O
of	O
cardiovascular	O
risk	O
factors	O
HbA1c	O
7	O
.	O
6	O
,	O
LDL	O
73	O
mg	O
dl	O
,	O
triglycerides	O
110	O
mg	O
dl	O
.	O
Electrocardiogram	O
ECG	O
with	O
chest	O
pain	O
sinus	O
rhythm	O
at	O
78	O
bpm	O
.	O
ST	O
segment	O
elevation	O
downward	O
sloping	O
by	O
1	O
mm	O
,	O
especially	O
in	O
precordial	O
leads	O
,	O
I	O
and	O
aVL	O
.	O
Pain	O
free	O
ECG	O
image	O
2	O
sinus	O
rhythm	O
at	O
72	O
bpm	O
.	O
Correction	O
of	O
dynamic	O
repolarisation	O
changes	O
.	O
Coronary	O
angiography	O
LMCA	O
with	O
a	O
mild	O
calcified	O
plaque	O
in	O
the	O
distal	O
segment	O
of	O
30	O
.	O
Calcified	O
LAD	O
with	O
total	O
occlusion	O
in	O
the	O
middle	O
segment	O
,	O
with	O
retrograde	O
distal	O
collateral	O
filling	O
.	O
Cx	O
of	O
good	O
calibre	O
and	O
development	O
with	O
a	O
stent	O
in	O
the	O
middle	O
segment	O
permeable	O
and	O
without	O
restenosis	O
,	O
and	O
another	O
stent	O
in	O
the	O
first	O
marginal	O
branch	O
permeable	O
and	O
without	O
restenosis	O
.	O
Distally	O
in	O
the	O
obtuse	O
marginal	O
branch	O
he	O
has	O
a	O
significant	O
lesion	O
of	O
70	O
,	O
evaluated	O
with	O
pressure	O
guide	O
and	O
intracoronary	O
adenosine	O
with	O
a	O
result	O
of	O
0	O
.	O
77	O
significant	O
.	O
Dominant	O
DC	O
of	O
good	O
calibre	O
and	O
development	O
with	O
a	O
moderate	O
plaque	O
in	O
the	O
proximal	O
segment	O
of	O
60	O
evaluated	O
with	O
pressure	O
guide	O
and	O
intracoronary	O
adenosine	O
with	O
FFR	O
0	O
.	O
87	O
not	O
significant	O
,	O
distally	O
with	O
diffuse	O
irregularities	O
and	O
an	O
under	O
occlusion	O
of	O
the	O
PL	O
branch	O
of	O
chronic	O
aspect	O
.	O
Echocardiogram	O
non	O
dilated	O
left	O
ventricle	O
with	O
preserved	O
ejection	O
fraction	O
,	O
without	O
gross	O
alterations	O
of	O
segmental	O
contractility	O
.	O
Mild	O
left	O
ventricular	O
hypertrophy	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
and	O
function	O
.	O
No	O
significant	O
valvulopathies	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
to	O
cardiology	O
and	O
,	O
given	O
the	O
progression	O
of	O
his	O
symptoms	O
over	O
the	O
last	O
few	O
months	O
despite	O
the	O
adjustment	O
of	O
anti	O
anginal	O
medication	O
,	O
it	O
was	O
decided	O
to	O
perform	O
coronary	O
angiography	O
,	O
where	O
a	O
significant	O
lesion	O
was	O
found	O
in	O
the	O
first	O
MVO	O
assessed	O
by	O
pressure	O
guidewire	O
,	O
which	O
was	O
revascularised	O
with	O
a	O
drug	O
eluting	O
stent	O
.	O
During	O
hospitalisation	O
,	O
the	O
patient	O
had	O
no	O
new	O
episodes	O
of	O
chest	O
pain	O
and	O
was	O
discharged	O
early	O
.	O
Despite	O
being	O
a	O
patient	O
widely	O
known	O
to	O
cardiology	O
,	O
cardiovascular	O
risk	O
factors	O
are	O
not	O
controlled	O
,	O
so	O
special	O
emphasis	O
is	O
placed	O
on	O
this	O
aspect	O
.	O
It	O
seems	O
particularly	O
important	O
to	O
optimise	O
glycaemic	O
control	O
and	O
,	O
given	O
that	O
the	O
patient	O
is	O
obese	O
,	O
it	O
is	O
decided	O
to	O
associate	O
a	O
GLP1	O
agonist	O
semaglutide	B-FARMACO
0	O
.	O
25	O
mg	O
once	O
a	O
week	O
,	O
with	O
a	O
target	O
HbA1c	O
of	O
less	O
than	O
7	O
.	O
In	O
addition	O
,	O
ezetimibe	B-FARMACO
was	O
added	O
to	O
his	O
treatment	O
,	O
with	O
a	O
target	O
LDL	O
of	O
less	O
than	O
55	O
mg	O
dl	O
.	O
At	O
the	O
follow	O
up	O
consultation	O
after	O
completion	O
of	O
the	O
cardiac	O
rehabilitation	O
programme	O
,	O
the	O
patient	O
had	O
achieved	O
weight	O
loss	O
of	O
8	O
kg	O
,	O
smoking	O
cessation	O
and	O
better	O
laboratory	O
control	O
HbA1c	O
6	O
.	O
8	O
,	O
LDL	O
54	O
mg	O
dl	O
.	O
DIAGNOSIS	O
NSTEACS	O
type	O
unstable	O
angina	O
.	O
Significant	O
lesion	O
of	O
70	O
in	O
the	O
first	O
OM	O
assessed	O
by	O
pressure	O
guidewire	O
FFR	O
0	O
.	O
77	O
revascularised	O
percutaneously	O
by	O
means	O
of	O
a	O
pharmacoactive	O
destenting	O
implant	O
.	O
Chronic	O
total	O
occlusion	O
of	O
the	O
middle	O
anterior	O
descending	O
artery	O
.	O
Complex	O
chronic	O
ischaemic	O
heart	O
disease	O
,	O
revascularised	O
in	O
a	O
mixed	O
form	O
on	O
multiple	O
occasions	O
.	O
Type	O
2	O
diabetes	O
mellitus	O
with	O
poor	O
glycaemic	O
control	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
The	O
patient	O
is	O
an	O
18	O
year	O
old	O
male	O
,	O
with	O
no	O
known	O
drug	O
allergies	O
or	O
toxic	O
habits	O
.	O
He	O
had	O
presented	O
in	O
childhood	O
with	O
some	O
episodes	O
of	O
bronchospasm	O
related	O
to	O
mite	O
and	O
pollen	O
allergy	O
that	O
improved	O
with	O
beta	O
2	O
mimetic	O
inhalers	O
,	O
but	O
he	O
had	O
been	O
crisis	O
free	O
since	O
the	O
age	O
of	O
14	O
years	O
,	O
and	O
he	O
regularly	O
played	O
sports	O
with	O
good	O
tolerance	O
.	O
He	O
first	O
consulted	O
the	O
emergency	O
department	O
of	O
our	O
hospital	O
in	O
2004	O
for	O
self	O
limited	O
abdominal	O
pain	O
,	O
and	O
the	O
following	O
findings	O
were	O
noted	O
in	O
the	O
complementary	O
tests	O
performed	O
The	O
electrocardiogram	O
ECG	O
showed	O
sinus	O
rhythm	O
at	O
55	O
bpm	O
,	O
with	O
a	O
right	O
QRS	O
axis	O
and	O
morphology	O
of	O
complete	O
right	O
bundle	O
branch	O
block	O
RBBB	O
,	O
criteria	O
for	O
right	O
ventricular	O
hypertrophy	O
RVH	O
,	O
and	O
repolarisation	O
abnormalities	O
in	O
V1	O
V4	O
.	O
Laboratory	O
tests	O
showed	O
discrete	O
polyglobulia	O
17	O
.	O
3	O
gn	O
dl	O
.	O
The	O
chest	O
X	O
ray	O
showed	O
prominence	O
of	O
the	O
pulmonary	O
arteries	O
and	O
the	O
arch	O
of	O
the	O
azygos	O
.	O
In	O
view	O
of	O
these	O
findings	O
,	O
a	O
transthoracic	O
echocardiogram	O
TTE	O
was	O
performed	O
,	O
which	O
revealed	O
indirect	O
evidence	O
of	O
severe	O
pulmonary	O
hypertension	O
,	O
with	O
moderate	O
hypertrophy	O
and	O
mild	O
dilatation	O
of	O
the	O
right	O
ventricle	O
RV	O
,	O
as	O
well	O
as	O
a	O
hitherto	O
unknown	O
patent	O
ductus	O
arteriosus	O
PDA	O
.	O
Subsequently	O
,	O
a	O
right	O
heart	O
catheterisation	O
confirmed	O
the	O
presence	O
of	O
severe	O
pulmonary	O
hypertension	O
PHT	O
high	O
mean	O
pulmonary	O
artery	O
pressure	O
mPAP	O
and	O
normal	O
pulmonary	O
capillary	O
pressure	O
PCP	O
.	O
In	O
May	O
2004	O
,	O
the	O
patient	O
underwent	O
surgery	O
at	O
a	O
private	O
centre	O
,	O
with	O
section	O
and	O
closure	O
of	O
both	O
ductal	O
stumps	O
by	O
left	O
thoracotomy	O
.	O
He	O
had	O
the	O
following	O
complications	O
from	O
the	O
procedure	O
a	O
resolved	O
left	O
recurrent	O
nerve	O
palsy	O
and	O
a	O
left	O
pneumothorax	O
.	O
In	O
the	O
following	O
years	O
,	O
fibrosing	O
mediastinitis	O
was	O
also	O
discovered	O
,	O
requiring	O
treatment	O
with	O
systemic	O
corticosteroids	O
.	O
In	O
September	O
2005	O
,	O
a	O
post	O
surgery	O
right	O
heart	O
catheterisation	O
was	O
performed	O
,	O
which	O
revealed	O
persistent	O
severe	O
pulmonary	O
arterial	O
hypertension	O
PAH	O
PAPm	O
73	O
mmHg	O
,	O
PCP	O
7	O
mmHg	O
,	O
pulmonary	O
vascular	O
resistance	O
PVR	O
13	O
.	O
75	O
UW	O
,	O
cardiac	O
output	O
CO	O
4	O
.	O
8	O
l	O
min	O
.	O
In	O
addition	O
,	O
there	O
was	O
evidence	O
of	O
reopening	O
of	O
the	O
PDA	O
with	O
residual	O
flow	O
.	O
In	O
view	O
of	O
these	O
findings	O
,	O
the	O
patient	O
began	O
follow	O
up	O
in	O
the	O
monographic	O
pulmonary	O
hypertension	O
clinic	O
at	O
our	O
hospital	O
.	O
He	O
had	O
normal	O
respiratory	O
function	O
tests	O
,	O
NT	O
proBNP	O
22	O
ng	O
ml	O
and	O
persistent	O
polyglobulia	O
20	O
g	O
dl	O
,	O
no	O
nocturnal	O
desaturation	O
in	O
pulse	O
oximetry	O
and	O
in	O
the	O
6	O
minute	O
walk	O
test	O
he	O
covered	O
705	O
m	O
with	O
maintained	O
constants	O
.	O
In	O
2008	O
he	O
was	O
referred	O
to	O
a	O
pulmonary	O
hypertension	O
unit	O
of	O
a	O
reference	O
hospital	O
for	O
pulmonary	O
hypertension	O
.	O
At	O
that	O
time	O
the	O
patient	O
was	O
in	O
functional	O
class	O
I	O
,	O
without	O
cyanosis	O
or	O
signs	O
of	O
right	O
heart	O
failure	O
HF	O
.	O
Discrete	O
polyglobulia	O
persists	O
,	O
and	O
on	O
TTE	O
the	O
PAWD	O
is	O
seen	O
with	O
a	O
right	O
to	O
left	O
flow	O
and	O
a	O
hypertrophic	O
RV	O
with	O
moderate	O
dysfunction	O
.	O
Ergospirometry	O
shows	O
functional	O
class	O
I	O
with	O
moderately	O
reduced	O
functional	O
capacity	O
and	O
normal	O
blood	O
pressure	O
BP	O
.	O
Given	O
the	O
patient	O
's	O
good	O
functional	O
class	O
,	O
re	O
evaluation	O
in	O
9	O
months	O
is	O
recommended	O
before	O
starting	O
specific	O
treatment	O
for	O
PAH	O
.	O
Finally	O
,	O
given	O
the	O
persistence	O
of	O
severe	O
PAH	O
in	O
a	O
new	O
catheterisation	O
PAPm	O
90	O
mmHg	O
,	O
PCP	O
10	O
mmHg	O
,	O
PVR	O
14	O
UW	O
,	O
GC	O
5	O
.	O
6	O
l	O
min	O
,	O
it	O
was	O
decided	O
to	O
start	O
specific	O
treatment	O
for	O
PAH	O
,	O
initially	O
with	O
sitaxentan	B-FARMACO
,	O
which	O
was	O
suspended	O
due	O
to	O
its	O
withdrawal	O
from	O
the	O
market	O
and	O
replaced	O
by	O
ambrisentan	B-FARMACO
5	O
mg	O
24	O
hours	O
,	O
later	O
adding	O
tadalafil	B-FARMACO
40	O
mg	O
24	O
hours	O
.	O
In	O
November	O
2018	O
,	O
he	O
was	O
referred	O
for	O
the	O
first	O
time	O
to	O
the	O
adult	O
congenital	O
heart	O
disease	O
clinic	O
at	O
our	O
hospital	O
.	O
At	O
that	O
time	O
he	O
was	O
clinically	O
stable	O
with	O
NYHA	O
I	O
II	O
IV	O
dyspnoea	O
.	O
NT	O
proBNP	O
279	O
pg	O
ml	O
.	O
TTE	O
unchanged	O
with	O
respect	O
to	O
previous	O
ones	O
.	O
On	O
treatment	O
with	O
ambrisentan	B-FARMACO
10	O
mg	O
24	O
hours	O
tadalafil	B-FARMACO
40	O
mg	O
24	O
hours	O
symbicort	B-FARMACO
160	O
4	O
.	O
5	O
mcg	O
1	O
inhalations	O
12	O
hours	O
.	O
Subsequent	O
check	O
ups	O
did	O
not	O
show	O
much	O
functional	O
change	O
,	O
changes	O
in	O
TTE	O
or	O
treatment	O
.	O
In	O
April	O
2019	O
,	O
a	O
cardiac	O
MRI	O
was	O
performed	O
,	O
showing	O
progression	O
of	O
RV	O
dysfunction	O
with	O
RV	O
ejection	O
fraction	O
RVEF	O
of	O
37	O
RVEF	O
in	O
May	O
2018	O
was	O
57	O
.	O
However	O
,	O
it	O
seems	O
that	O
the	O
patient	O
is	O
reluctant	O
to	O
have	O
a	O
follow	O
up	O
right	O
heart	O
catheterisation	O
,	O
even	O
though	O
it	O
is	O
suggested	O
to	O
him	O
to	O
consider	O
adding	O
a	O
third	O
drug	O
to	O
the	O
treatment	O
of	O
his	O
PAH	O
.	O
Current	O
disease	O
In	O
June	O
2019	O
,	O
the	O
patient	O
was	O
admitted	O
for	O
an	O
episode	O
of	O
frank	O
haemoptysis	O
50	O
cc	O
and	O
a	O
gurgling	O
sensation	O
in	O
the	O
left	O
hemithorax	O
that	O
required	O
admission	O
to	O
the	O
coronary	O
unit	O
of	O
our	O
hospital	O
for	O
close	O
monitoring	O
.	O
He	O
had	O
previously	O
presented	O
another	O
episode	O
of	O
haemoptysis	O
in	O
April	O
of	O
the	O
same	O
year	O
,	O
which	O
required	O
admission	O
to	O
the	O
respiratory	O
department	O
and	O
had	O
been	O
managed	O
conservatively	O
.	O
Physical	O
examination	O
On	O
admission	O
to	O
the	O
coronary	O
unit	O
,	O
the	O
patient	O
was	O
haemodynamically	O
stable	O
blood	O
pressure	O
BP	O
110	O
58	O
mmHg	O
,	O
heart	O
rate	O
HR	O
98	O
bpm	O
,	O
oxygen	O
saturation	O
O2	O
96	O
with	O
inspired	O
O2	O
fraction	O
FiO2	O
21	O
and	O
no	O
signs	O
of	O
right	O
HF	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
sinus	O
rhythm	O
at	O
50	O
bpm	O
,	O
normal	O
PR	O
,	O
right	O
axis	O
,	O
QRS	O
with	O
BCRDHH	O
morphology	O
with	O
criteria	O
of	O
HVD	O
and	O
secondary	O
repolarisation	O
alterations	O
in	O
precordial	O
leads	O
.	O
CBC	O
glucose	O
93	O
mg	O
dl	O
,	O
urea	O
32	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
09	O
mg	O
dl	O
,	O
GPT	O
14	O
U	O
L	O
,	O
bilirubin	O
0	O
.	O
9	O
mg	O
dl	O
,	O
calcium	O
9	O
.	O
6	O
mg	O
dl	O
,	O
sodium	O
140	O
mEq	O
l	O
,	O
potassium	O
null	O
,	O
chlorine	O
105	O
mEq	O
l	O
,	O
albumin	O
4	O
.	O
4	O
g	O
dl	O
,	O
C	O
reactive	O
protein	O
CRP	O
1	O
.	O
60	O
mg	O
l	O
,	O
creatine	O
kinase	O
CK	O
104	O
U	O
l	O
,	O
lactate	O
dehydrogenase	O
LDH	O
null	O
.	O
Haemoglobin	O
20	O
.	O
9	O
g	O
dl	O
,	O
haematocrit	O
59	O
.	O
5	O
,	O
mean	O
corpuscular	O
volume	O
MCV	O
85	O
.	O
5	O
fL	O
,	O
mean	O
corpuscular	O
haemoglobin	O
MCH	O
30	O
pg	O
,	O
erythrocyte	O
distribution	O
amplitude	O
EDA	O
14	O
.	O
8	O
,	O
platelets	O
172000	O
,	O
5170	O
leukocytes	O
35	O
.	O
40	O
lymphocytes	O
,	O
52	O
.	O
60	O
neutrophils	O
,	O
7	O
.	O
70	O
monocytes	O
.	O
Prothrombin	O
time	O
66	O
,	O
international	O
normalised	O
ratio	O
INR	O
1	O
.	O
3	O
,	O
activated	O
partial	O
thromboplastin	O
time	O
APTT	O
42s	O
,	O
fibrinogen	O
313	O
mg	O
dl	O
.	O
Chest	O
X	O
ray	O
cardiothoracic	O
index	O
0	O
.	O
5	O
,	O
with	O
prominence	O
of	O
the	O
pulmonary	O
arteries	O
.	O
TTE	O
left	O
ventricle	O
LV	O
neither	O
dilated	O
nor	O
hypertrophic	O
with	O
preserved	O
global	O
function	O
,	O
very	O
marked	O
septal	O
flattening	O
due	O
to	O
overload	O
of	O
right	O
pressures	O
,	O
with	O
a	O
diastolic	O
eccentricity	O
index	O
of	O
1	O
.	O
5	O
.	O
The	O
mitral	O
valve	O
is	O
normofunctioning	O
and	O
the	O
aortic	O
valve	O
is	O
bicuspid	O
due	O
to	O
complete	O
fusion	O
of	O
the	O
right	O
and	O
left	O
coronary	O
sinuses	O
,	O
with	O
minimal	O
aortic	O
insufficiency	O
.	O
The	O
RV	O
is	O
moderately	O
dilated	O
and	O
severely	O
hypertrophic	O
,	O
with	O
moderately	O
depressed	O
function	O
.	O
The	O
tricuspid	O
valve	O
is	O
thickened	O
with	O
poorly	O
visualised	O
right	O
ventricle	O
right	O
atrium	O
RV	O
RA	O
gradient	O
,	O
but	O
at	O
least	O
100	O
mmHg	O
.	O
The	O
inferior	O
vena	O
cava	O
is	O
not	O
dilated	O
,	O
with	O
inspiratory	O
collapse	O
greater	O
than	O
50	O
.	O
Mild	O
flow	O
acceleration	O
of	O
up	O
to	O
26	O
mmHg	O
without	O
diastolic	O
tail	O
is	O
seen	O
in	O
the	O
arch	O
.	O
Dilated	O
pulmonary	O
artery	O
trunk	O
40	O
mm	O
.	O
The	O
ductus	O
is	O
wide	O
,	O
with	O
right	O
to	O
left	O
systolic	O
flow	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
remained	O
monitored	O
and	O
under	O
conservative	O
treatment	O
with	O
oral	O
codeine	B-FARMACO
and	O
morphine	B-FARMACO
chloride	I-FARMACO
for	O
24	O
hours	O
in	O
the	O
coronary	O
unit	O
,	O
haemodynamically	O
stable	O
at	O
all	O
times	O
and	O
with	O
no	O
new	O
episodes	O
of	O
haemoptysis	O
.	O
The	O
patient	O
was	O
transferred	O
to	O
the	O
reference	O
hospital	O
for	O
pulmonary	O
hypertension	O
to	O
assess	O
the	O
possibility	O
of	O
starting	O
a	O
third	O
line	O
of	O
treatment	O
for	O
PAH	O
.	O
At	O
this	O
hospital	O
,	O
a	O
new	O
right	O
catheterisation	O
was	O
performed	O
prior	O
to	O
starting	O
intravenous	O
prostacyclin	O
PAPm	O
87	O
mmHg	O
,	O
PCP	O
6	O
mmHg	O
,	O
PVR	O
17	O
.	O
34	O
UW	O
,	O
GC	O
by	O
thermodilution	O
4	O
.	O
67	O
l	O
min	O
.	O
Initially	O
,	O
epoprostenol	B-FARMACO
was	O
prescribed	O
,	O
but	O
it	O
required	O
several	O
changes	O
of	O
venous	O
line	O
due	O
to	O
phlebitis	O
,	O
so	O
finally	O
,	O
titration	O
with	O
subcutaneous	O
treprostinil	B-FARMACO
was	O
started	O
with	O
good	O
tolerance	O
,	O
reaching	O
a	O
dose	O
of	O
24	O
ng	O
kg	O
min	O
at	O
discharge	O
.	O
After	O
implantation	O
of	O
the	O
subcutaneous	O
pump	O
,	O
treprostinil	B-FARMACO
can	O
be	O
progressively	O
increased	O
.	O
Since	O
the	O
start	O
of	O
the	O
drug	O
,	O
the	O
patient	O
reports	O
clinical	O
improvement	O
,	O
no	O
alarm	O
symptoms	O
and	O
no	O
new	O
episodes	O
of	O
haemoptysis	O
.	O
In	O
addition	O
,	O
the	O
control	O
echocardiogram	O
performed	O
showed	O
an	O
improvement	O
in	O
RV	O
function	O
,	O
which	O
was	O
currently	O
at	O
the	O
lower	O
limit	O
of	O
normality	O
.	O
DIAGNOSIS	O
Severe	O
residual	O
pulmonary	O
arterial	O
hypertension	O
after	O
surgery	O
.	O
Intervened	O
patent	O
ductus	O
arteriosus	O
.	O
Right	O
ventricular	O
function	O
at	O
the	O
lower	O
limit	O
of	O
normal	O
.	O
Fibrosing	O
mediastinitis	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
32	O
year	O
old	O
male	O
with	O
no	O
known	O
drug	O
allergies	O
,	O
moderate	O
drinker	O
with	O
no	O
other	O
cardiovascular	O
risk	O
factors	O
CVRF	O
,	O
no	O
personal	O
medical	O
or	O
surgical	O
history	O
of	O
interest	O
and	O
not	O
under	O
chronic	O
medical	O
treatment	O
.	O
His	O
family	O
history	O
includes	O
three	O
maternal	O
uncles	O
who	O
died	O
of	O
sudden	O
death	O
at	O
a	O
young	O
age	O
specify	O
the	O
years	O
,	O
if	O
you	O
have	O
them	O
,	O
the	O
aetiology	O
of	O
which	O
is	O
unknown	O
.	O
Father	O
and	O
mother	O
without	O
heart	O
disease	O
or	O
sudden	O
death	O
events	O
.	O
They	O
lead	O
an	O
active	O
life	O
appropriate	O
to	O
their	O
age	O
.	O
Current	O
illness	O
The	O
patient	O
reports	O
recurrent	O
and	O
intermittent	O
symptoms	O
characterised	O
by	O
palpitations	O
,	O
since	O
adolescence	O
.	O
The	O
symptoms	O
have	O
worsened	O
in	O
recent	O
months	O
with	O
syncopal	O
episodes	O
with	O
loss	O
of	O
postural	O
position	O
and	O
level	O
of	O
consciousness	O
,	O
for	O
which	O
he	O
consulted	O
as	O
an	O
outpatient	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
BP	O
120	O
80	O
mmHG	O
,	O
heart	O
rate	O
HR	O
70	O
bpm	O
,	O
respiratory	O
rate	O
RR	O
20	O
rpm	O
,	O
oxygen	O
saturation	O
O2	O
Sat	O
95	O
.	O
Normal	O
colour	O
and	O
normohydrated	O
.	O
No	O
jugular	O
ingurgitation	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
without	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
.	O
Abdomen	O
soft	O
,	O
non	O
painful	O
,	O
no	O
masses	O
or	O
megaliths	O
.	O
Lower	O
extremities	O
no	O
oedema	O
,	O
no	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
haemogram	O
leucocytes	O
7x10	O
9	O
l	O
,	O
Hb	O
13	O
g	O
dl	O
,	O
platelets	O
310x10	O
9	O
l	O
.	O
Biochemistry	O
glucose	O
181	O
mg	O
dl	O
70	O
110	O
,	O
urea	O
59	O
mg	O
dl	O
10	O
50	O
,	O
creatinine	O
1	O
.	O
53	O
mg	O
dl	O
.	O
40	O
1	O
.	O
20	O
total	O
bilirubin	O
1	O
.	O
47	O
mg	O
dl	O
0	O
1	O
.	O
2	O
,	O
GPT	O
154	O
U	O
L	O
5	O
41	O
.	O
Electrocardiogram	O
ECG	O
regular	O
sinus	O
rhythm	O
with	O
a	O
frequency	O
of	O
70	O
bpm	O
,	O
rSr	O
in	O
V1	O
and	O
V2	O
,	O
with	O
ST	O
segment	O
elevation	O
of	O
5	O
mm	O
and	O
inverted	O
T	O
in	O
these	O
leads	O
,	O
Brugada	O
type	O
I	O
pattern	O
.	O
Colour	O
Doppler	O
echocardiogram	O
DDVI	O
DSVI	O
50	O
30	O
,	O
SIVD	O
PPD	O
11	O
11	O
,	O
EF	O
68	O
,	O
RV	O
20	O
,	O
free	O
wall	O
thickness	O
10	O
mm	O
.	O
Left	O
atrium	O
area	O
23	O
cm2	O
without	O
ventricular	O
motility	O
disorders	O
,	O
no	O
alterations	O
in	O
transvalvular	O
flow	O
,	O
PSAP	O
20	O
.	O
24	O
hour	O
Holter	O
ECG	O
detection	O
of	O
monomorphic	O
non	O
sustained	O
ventricular	O
tachycardia	O
NSVT	O
tracing	O
of	O
short	O
duration	O
up	O
to	O
200	O
bpm	O
that	O
correlates	O
with	O
the	O
patient	O
's	O
symptoms	O
.	O
Chest	O
X	O
ray	O
after	O
ICD	O
implantation	O
cardiothoracic	O
index	O
less	O
than	O
0	O
.	O
5	O
with	O
presence	O
of	O
generator	O
in	O
left	O
hemithorax	O
and	O
lead	O
to	O
RV	O
.	O
ICD	O
telemetry	O
at	O
follow	O
up	O
1	O
or	O
6	O
months	O
evidence	O
in	O
evolutionary	O
controls	O
of	O
appropriate	O
ICD	O
discharges	O
in	O
the	O
event	O
of	O
arrhythmic	O
events	O
in	O
the	O
form	O
of	O
rapid	O
ventricular	O
fibrillation	O
VF	O
and	O
ventricular	O
tachycardia	O
VT	O
.	O
CLINICAL	O
EVOLUTION	O
Patient	O
with	O
clinical	O
syncopal	O
episodes	O
and	O
cardiovascular	O
history	O
of	O
sudden	O
death	O
in	O
relatives	O
without	O
genetic	O
study	O
,	O
with	O
morphological	O
studies	O
with	O
echocardiogram	O
without	O
pathological	O
findings	O
.	O
Taking	O
into	O
account	O
her	O
baseline	O
ECG	O
with	O
Brugada	O
type	O
I	O
pattern	O
,	O
her	O
family	O
history	O
,	O
repeated	O
syncopal	O
clinical	O
events	O
and	O
evidence	O
of	O
symptomatic	O
arrhythmic	O
events	O
NSVT	O
on	O
24	O
hour	O
Holter	O
,	O
the	O
diagnosis	O
of	O
Brugada	O
syndrome	O
was	O
established	O
and	O
implantation	O
of	O
an	O
implantable	O
cardioverter	O
defibrillator	O
ICD	O
was	O
decided	O
as	O
primary	O
prevention	O
in	O
a	O
patient	O
with	O
Brugada	O
syndrome	O
at	O
very	O
high	O
risk	O
of	O
sudden	O
death	O
.	O
The	O
implantation	O
was	O
uneventful	O
and	O
the	O
patient	O
reported	O
being	O
in	O
GF	O
I	O
in	O
subsequent	O
check	O
ups	O
6	O
months	O
post	O
implantation	O
,	O
and	O
had	O
had	O
a	O
few	O
very	O
isolated	O
syncopal	O
episodes	O
.	O
On	O
review	O
of	O
the	O
device	O
ICD	O
,	O
VT	O
episodes	O
were	O
observed	O
in	O
VT2	O
180	O
bpm	O
and	O
VF	O
200	O
bpm	O
with	O
antitachycardia	O
ventricular	O
pacing	O
therapy	O
ATP	O
and	O
appropriate	O
ICD	O
shocks	O
.	O
DIAGNOSIS	O
Brugada	O
syndrome	O
.	O
Implantation	O
of	O
an	O
implantable	O
cardioverter	O
defibrillator	O
ICD	O
.	O
No	O
structural	O
heart	O
disease	O
normal	O
LVEF	O
.	O
GF	O
I	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
53	O
year	O
old	O
woman	O
with	O
no	O
known	O
allergic	O
reactions	O
to	O
medications	O
.	O
History	O
Family	O
history	O
sudden	O
death	O
during	O
sleep	O
of	O
maternal	O
grandfather	O
at	O
70	O
years	O
of	O
age	O
and	O
of	O
a	O
maternal	O
uncle	O
at	O
50	O
years	O
of	O
age	O
,	O
also	O
during	O
sleep	O
.	O
Daughter	O
with	O
long	O
QT	O
on	O
baseline	O
ECG	O
and	O
son	O
with	O
incipient	O
hypertrophic	O
cardiomyopathy	O
phenotype	O
.	O
Personal	O
history	O
No	O
toxic	O
habits	O
,	O
no	O
arterial	O
hypertension	O
AHT	O
,	O
no	O
diabetes	O
,	O
no	O
dyslipidaemia	O
.	O
Non	O
obstructive	O
hypertrophic	O
cardiomyopathy	O
accidental	O
diagnosis	O
in	O
another	O
centre	O
after	O
starting	O
a	O
study	O
due	O
to	O
palpitations	O
.	O
Phenotype	O
with	O
asymmetric	O
septal	O
hypertrophy	O
,	O
with	O
a	O
maximum	O
thickness	O
of	O
18	O
mm	O
in	O
the	O
basal	O
anterior	O
septum	O
,	O
maximum	O
gradient	O
of	O
15	O
mmHg	O
,	O
LVEF	O
65	O
and	O
faint	O
mesocardial	O
fibrosis	O
in	O
areas	O
of	O
hypertrophy	O
and	O
at	O
the	O
lower	O
insertion	O
point	O
of	O
the	O
RV	O
in	O
cardiac	O
MRI	O
.	O
Holter	O
sinus	O
rhythm	O
with	O
an	O
average	O
heart	O
rate	O
of	O
60	O
bpm	O
,	O
anecdotal	O
supraventricular	O
extrasystoles	O
with	O
a	O
SVT	O
salvo	O
of	O
4	O
beats	O
,	O
anecdotal	O
ventricular	O
extrasystoles	O
with	O
a	O
nocturnal	O
triplet	O
at	O
90	O
bpm	O
,	O
with	O
no	O
other	O
events	O
.	O
Ergometry	O
with	O
8	O
.	O
8	O
METS	O
,	O
clinically	O
negative	O
,	O
electrocardiographically	O
positive	O
from	O
minute	O
5	O
upward	O
sloping	O
ST	O
segment	O
depression	O
in	O
II	O
,	O
III	O
,	O
aVF	O
,	O
V5	O
and	O
V6	O
of	O
up	O
to	O
1	O
.	O
5	O
mm	O
,	O
which	O
persists	O
at	O
minute	O
2	O
of	O
recovery	O
,	O
subsiding	O
spontaneously	O
,	O
with	O
a	O
drop	O
in	O
blood	O
pressure	O
at	O
maximum	O
effort	O
,	O
although	O
asymptomatic	O
.	O
Overlap	O
with	O
long	O
QT	O
syndrome	O
LQTS	O
.	O
Genetic	O
study	O
no	O
pathogenic	O
probably	O
pathogenic	O
variant	O
related	O
to	O
hypertrophic	O
cardiomyopathy	O
is	O
identified	O
.	O
A	O
probably	O
pathogenic	O
variant	O
in	O
KCNQ1	O
compatible	O
with	O
LQTS	O
type	O
1	O
is	O
identified	O
,	O
also	O
confirmed	O
in	O
his	O
daughter	O
.	O
Other	O
fibromyalgia	O
,	O
chronic	O
low	O
back	O
pain	O
.	O
Surgical	O
interventions	O
hysterectomy	O
and	O
double	O
adnexectomy	O
due	O
to	O
metrorrhagia	O
.	O
Usual	O
treatment	O
propanolol	B-FARMACO
10	O
mg	O
every	O
8	O
hours	O
,	O
duloxetine	B-FARMACO
60	O
mg	O
every	O
24	O
hours	O
.	O
Present	O
illness	O
The	O
patient	O
was	O
referred	O
from	O
another	O
centre	O
for	O
an	O
episode	O
of	O
loss	O
of	O
consciousness	O
the	O
previous	O
night	O
in	O
bed	O
,	O
witnessed	O
by	O
her	O
husband	O
,	O
who	O
reported	O
snoring	O
,	O
ocular	O
eversion	O
and	O
tonic	O
spasm	O
lasting	O
a	O
few	O
seconds	O
,	O
for	O
which	O
she	O
did	O
not	O
consult	O
.	O
The	O
following	O
morning	O
she	O
presented	O
with	O
precordial	O
pressure	O
and	O
went	O
to	O
the	O
emergency	O
department	O
,	O
where	O
atrial	O
fibrillation	O
with	O
controlled	O
response	O
was	O
observed	O
,	O
which	O
spontaneously	O
reverted	O
to	O
sinus	O
bradycardia	O
with	O
complete	O
cessation	O
of	O
the	O
precordial	O
pressure	O
.	O
He	O
reported	O
almost	O
daily	O
palpitations	O
lasting	O
a	O
few	O
minutes	O
,	O
unrelated	O
to	O
exertion	O
,	O
for	O
the	O
last	O
2	O
years	O
,	O
as	O
well	O
as	O
dyspnoea	O
on	O
moderate	O
exertion	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
BP	O
120	O
80	O
mmHg	O
;	O
heart	O
rate	O
HR	O
55	O
bpm	O
.	O
Good	O
general	O
condition	O
.	O
Conscious	O
and	O
oriented	O
,	O
eupneic	O
,	O
well	O
perfused	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
no	O
murmurs	O
at	O
rest	O
or	O
with	O
Valsalva	O
manoeuvres	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
with	O
no	O
added	O
sounds	O
.	O
Lower	O
limbs	O
no	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
,	O
pulses	O
present	O
and	O
symmetrical	O
.	O
COMPLEMENTARY	O
TESTS	O
Baseline	O
ECG	O
sinus	O
bradycardia	O
at	O
50	O
bpm	O
,	O
normal	O
PR	O
,	O
narrow	O
QRS	O
with	O
normal	O
axis	O
,	O
biphasic	O
T	O
wave	O
with	O
predominance	O
of	O
the	O
negative	O
component	O
in	O
III	O
,	O
aVF	O
,	O
V4	O
and	O
V5	O
,	O
notched	O
in	O
V2	O
and	O
V3	O
.	O
QTc	O
511	O
ms	O
.	O
Laboratory	O
tests	O
haemoglobin	O
12	O
.	O
9	O
g	O
dl	O
,	O
leukocytes	O
6	O
,	O
370	O
l	O
,	O
platelets	O
191	O
.	O
000	O
l	O
,	O
HbA1C	O
5	O
.	O
5	O
,	O
total	O
cholesterol	O
190	O
mg	O
dl	O
,	O
HDL	O
40	O
mg	O
dl	O
,	O
LDL	O
110	O
mg	O
dl	O
,	O
triglycerides	O
130	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
63	O
mg	O
dl	O
,	O
glomerular	O
filtration	O
rate	O
90	O
ml	O
min	O
,	O
sodium	O
142	O
mmol	O
l	O
,	O
potassium	O
4	O
.	O
8	O
mmol	O
l	O
,	O
CRP	O
1	O
.	O
1	O
mg	O
l	O
,	O
TSH	O
2	O
.	O
13	O
IU	O
ml	O
,	O
troponin	O
I	O
hs	O
TnI	O
10	O
,	O
CK	O
50	O
U	O
l	O
.	O
Transthoracic	O
echocardiogram	O
left	O
ventricle	O
of	O
normal	O
size	O
with	O
severe	O
asymmetric	O
septal	O
hypertrophy	O
IVSd	O
18	O
mm	O
;	O
PPd	O
13	O
mm	O
generating	O
acceleration	O
in	O
the	O
LV	O
outflow	O
tract	O
without	O
significant	O
obstruction	O
either	O
at	O
baseline	O
or	O
with	O
Valsalva	O
maximum	O
gradient	O
15	O
mmHg	O
.	O
Preserved	O
global	O
systolic	O
function	O
without	O
segmental	O
alterations	O
of	O
contractility	O
LVEF	O
65	O
.	O
Diastolic	O
pattern	O
compatible	O
with	O
impaired	O
relaxation	O
.	O
Moderately	O
dilated	O
left	O
atrium	O
area	O
30	O
cm2	O
.	O
Preserved	O
RVEF	O
.	O
Mitral	O
valve	O
with	O
good	O
opening	O
and	O
mild	O
mitral	O
insufficiency	O
MI	O
.	O
No	O
SAM	O
is	O
seen	O
.	O
Poorly	O
visualised	O
aortic	O
valve	O
with	O
trivalve	O
impression	O
and	O
no	O
pathological	O
flow	O
.	O
Poorly	O
visualised	O
tricuspid	O
valve	O
that	O
appears	O
normal	O
without	O
tricuspid	O
insufficiency	O
TI	O
that	O
would	O
allow	O
estimation	O
of	O
pulmonary	O
artery	O
systolic	O
pressure	O
PSAP	O
.	O
No	O
indirect	O
evidence	O
of	O
pulmonary	O
hypertension	O
PHT	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
with	O
adequate	O
inspiratory	O
collapse	O
.	O
Aortic	O
root	O
of	O
normal	O
size	O
with	O
slight	O
dilatation	O
of	O
tubular	O
ascending	O
aorta	O
40	O
mm	O
,	O
with	O
non	O
dilated	O
aortic	O
arch	O
.	O
No	O
pericardial	O
effusion	O
.	O
Post	O
implantation	O
chest	O
X	O
ray	O
bicameral	O
implantable	O
cardioverter	O
defibrillator	O
ICD	O
normo	O
inserted	O
AD	O
and	O
RV	O
electrodes	O
,	O
surgical	O
clamps	O
,	O
cardiothoracic	O
index	O
within	O
normal	O
,	O
lung	O
parenchyma	O
without	O
alterations	O
,	O
no	O
signs	O
of	O
pneumothorax	O
.	O
Electrocardiogram	O
ECG	O
at	O
discharge	O
atrial	O
activity	O
stimulated	O
by	O
pacemaker	O
at	O
60	O
bpm	O
,	O
narrow	O
QRS	O
with	O
normal	O
axis	O
,	O
biphasic	O
T	O
wave	O
in	O
III	O
,	O
aVF	O
,	O
V4	O
and	O
V5	O
,	O
notched	O
in	O
V2	O
.	O
QTc	O
480	O
ms	O
.	O
CLINICAL	O
EVOLUTION	O
This	O
is	O
a	O
patient	O
with	O
a	O
previous	O
diagnosis	O
of	O
non	O
obstructive	O
hypertrophic	O
cardiomyopathy	O
with	O
overlapping	O
long	O
QT	O
syndrome	O
type	O
1	O
who	O
presented	O
with	O
syncope	O
of	O
cardiogenic	O
profile	O
under	O
beta	O
blocker	O
treatment	O
.	O
Given	O
the	O
patient	O
's	O
HCM	O
Risk	O
SCD	O
of	O
3	O
.	O
52	O
low	O
5	O
year	O
risk	O
,	O
the	O
nocturnal	O
profile	O
of	O
syncope	O
and	O
family	O
history	O
of	O
nocturnal	O
sudden	O
death	O
SD	O
,	O
it	O
seems	O
likely	O
that	O
the	O
syncopal	O
event	O
is	O
related	O
to	O
long	O
QT	O
syndrome	O
type	O
1	O
rather	O
than	O
to	O
her	O
hypertrophic	O
cardiomyopathy	O
.	O
In	O
the	O
presence	O
of	O
cardiogenic	O
syncope	O
under	O
beta	O
blocker	O
treatment	O
,	O
ICD	O
implantation	O
was	O
decided	O
.	O
Given	O
the	O
diagnosis	O
of	O
hypertrophic	O
cardiomyopathy	O
and	O
the	O
finding	O
of	O
paroxysmal	O
atrial	O
fibrillation	O
not	O
previously	O
documented	O
,	O
anticoagulant	O
treatment	O
was	O
started	O
.	O
Bicameral	O
ICD	O
implantation	O
was	O
performed	O
without	O
incident	O
,	O
being	O
programmed	O
in	O
DDDR	O
ICD	O
mode	O
,	O
at	O
a	O
pacing	O
rate	O
of	O
60	O
bpm	O
.	O
DIAGNOSIS	O
Syncope	O
with	O
cardiogenic	O
profile	O
.	O
Non	O
obstructive	O
hypertrophic	O
cardiomyopathy	O
with	O
overlapping	O
long	O
QT	O
syndrome	O
type	O
1	O
probably	O
pathogenic	O
variant	O
in	O
KCNQ1	O
.	O
Symptomatic	O
paroxysmal	O
atrial	O
fibrillation	O
haemodynamic	O
angina	O
in	O
relation	O
to	O
rapid	O
ventricular	O
response	O
.	O
Implantation	O
of	O
bicameral	O
ICD	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
Male	O
,	O
73	O
years	O
old	O
.	O
No	O
general	O
or	O
cardiovascular	O
family	O
history	O
of	O
interest	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
No	O
toxic	O
habits	O
.	O
No	O
known	O
cardiovascular	O
risk	O
factors	O
.	O
Chronic	O
hypokalaemia	O
previous	O
analyses	O
recorded	O
in	O
the	O
computer	O
system	O
show	O
previous	O
values	O
of	O
around	O
3	O
mEq	O
l	O
,	O
possible	O
renal	O
tubulopathy	O
.	O
No	O
history	O
of	O
renal	O
colic	O
,	O
diarrhoea	O
,	O
liquorice	O
intake	O
or	O
low	O
potassium	O
diet	O
.	O
Previous	O
episodes	O
of	O
benign	O
paroxysmal	O
positional	O
vertigo	O
.	O
Under	O
dermatological	O
control	O
for	O
lichen	O
planus	O
and	O
psoriasis	O
.	O
Lumboarthrosis	O
with	O
L5	O
S1	O
disc	O
disease	O
.	O
Usual	O
treatment	O
omeprazole	B-FARMACO
20	O
mg	O
1	O
tablet	O
at	O
breakfast	O
.	O
Present	O
illness	O
A	O
78	O
year	O
old	O
man	O
was	O
admitted	O
from	O
the	O
emergency	O
department	O
to	O
the	O
internal	O
medicine	O
department	O
for	O
painless	O
swelling	O
of	O
the	O
right	O
knee	O
for	O
the	O
last	O
1	O
month	O
with	O
no	O
history	O
of	O
trauma	O
and	O
no	O
additional	O
inflammatory	O
semiology	O
.	O
An	O
anamnesis	O
was	O
carried	O
out	O
by	O
apparatus	O
and	O
was	O
anodyne	O
,	O
with	O
no	O
clinical	O
manifestations	O
of	O
the	O
cardiovascular	O
system	O
either	O
at	O
the	O
present	O
time	O
or	O
previously	O
no	O
dyspnoea	O
,	O
angina	O
,	O
syncope	O
,	O
palpitations	O
or	O
congestive	O
symptoms	O
.	O
Physical	O
examination	O
Patient	O
conscious	O
and	O
oriented	O
.	O
Well	O
perfused	O
,	O
hydrated	O
and	O
nourished	O
.	O
Eupneic	O
at	O
rest	O
.	O
Head	O
and	O
neck	O
no	O
jugular	O
engorgement	O
.	O
No	O
palpable	O
adenopathies	O
.	O
Oropharynx	O
without	O
alterations	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
no	O
murmurs	O
or	O
extratonos	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
.	O
No	O
masses	O
or	O
megaliths	O
were	O
palpable	O
.	O
No	O
signs	O
of	O
peritoneal	O
irritation	O
.	O
Preserved	O
hydro	O
aerial	O
sounds	O
.	O
No	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
Peripheral	O
venous	O
insufficiency	O
.	O
Swelling	O
of	O
both	O
knees	O
,	O
without	O
skin	O
erythema	O
or	O
local	O
temperature	O
increase	O
.	O
Mild	O
pain	O
on	O
movement	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
performed	O
in	O
the	O
emergency	O
department	O
with	O
magnesium	O
1	O
.	O
15	O
mg	O
dl	O
and	O
potassium	O
2	O
.	O
5	O
mg	O
dl	O
sinus	O
rhythm	O
at	O
80	O
beats	O
per	O
minute	O
.	O
Normal	O
PR	O
.	O
Narrow	O
QRS	O
.	O
ST	O
segment	O
elevation	O
of	O
2	O
mm	O
in	O
V1	O
V2	O
with	O
rectilinear	O
morphology	O
and	O
crossing	O
the	O
baseline	O
,	O
continuing	O
with	O
a	O
negative	O
and	O
symmetrical	O
T	O
wave	O
.	O
Normal	O
QTc	O
.	O
Laboratory	O
tests	O
performed	O
in	O
the	O
emergency	O
department	O
Biochemistry	O
glucose	O
121	O
mg	O
dl	O
,	O
urea	O
46	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
85	O
mg	O
dl	O
,	O
GPT	O
63	O
U	O
l	O
,	O
bilirubin	O
0	O
.	O
5	O
mg	O
dl	O
,	O
calcium	O
9	O
.	O
2	O
mg	O
dl	O
,	O
magnesium	O
1	O
.	O
15	O
mg	O
dl	O
,	O
albumin	O
4	O
g	O
dl	O
,	O
sodium	O
138	O
mEq	O
l	O
,	O
potassium	O
2	O
.	O
5	O
mEq	O
l	O
,	O
CRP	O
131	O
mg	O
l	O
,	O
CK	O
70	O
U	O
l	O
,	O
LDH	O
317	O
U	O
l	O
.	O
Venous	O
blood	O
gases	O
Fi02	O
21	O
pH	O
7	O
.	O
48	O
,	O
pCO2	O
40	O
mmHg	O
,	O
pO2	O
48	O
mmHg	O
,	O
bicarbonate	O
30	O
mmol	O
l	O
,	O
base	O
excess	O
5	O
.	O
8	O
,	O
lactate	O
1	O
.	O
7	O
mmol	O
l	O
.	O
Haemogram	O
haemoglobin	O
13	O
.	O
5	O
g	O
dl	O
,	O
platelets	O
252	O
,	O
000	O
per	O
microlitre	O
,	O
7	O
,	O
790	O
leukocytes	O
per	O
microlitre	O
with	O
91	O
neutrophils	O
and	O
5	O
.	O
4	O
lymphocytes	O
.	O
Haemostasis	O
aPTT	O
33	O
sec	O
,	O
prothrombin	O
time	O
92	O
,	O
INR	O
1	O
.	O
1	O
,	O
fibrinogen	O
652	O
mg	O
dl	O
.	O
Knee	O
X	O
ray	O
bilateral	O
condocalcinosis	O
,	O
more	O
striking	O
in	O
the	O
right	O
knee	O
.	O
ECG	O
performed	O
with	O
magnesium	O
correction	O
and	O
potassium	O
3	O
.	O
1	O
mEq	O
l	O
sinus	O
rhythm	O
at	O
75	O
beats	O
per	O
minute	O
.	O
Normal	O
PR	O
.	O
Narrow	O
QRS	O
.	O
Negative	O
T	O
waves	O
in	O
V1	O
V2	O
with	O
Rsr	O
'	O
morphology	O
in	O
V2	O
.	O
Normal	O
QTc	O
.	O
ECG	O
performed	O
with	O
magnesium	O
and	O
potassium	O
correction	O
sinus	O
rhythm	O
at	O
80	O
beats	O
per	O
minute	O
.	O
Normal	O
PR	O
.	O
Narrow	O
QRS	O
.	O
No	O
acute	O
repolarisation	O
alterations	O
.	O
Normal	O
QTc	O
.	O
Transthoracic	O
echocardiography	O
mild	O
ventricular	O
hypertrophy	O
.	O
Preserved	O
LVEF	O
.	O
Flecainide	O
test	O
after	O
infusion	O
of	O
flecainide	O
at	O
a	O
dose	O
of	O
2	O
mg	O
kg	O
,	O
the	O
patient	O
develops	O
a	O
Brugada	O
type	O
1	O
pattern	O
.	O
Genetic	O
test	O
for	O
Brugada	O
syndrome	O
negative	O
.	O
CLINICAL	O
COURSE	O
The	O
gonalgia	O
was	O
treated	O
with	O
non	O
steroidal	O
anti	O
inflammatory	O
drugs	O
NSAIDs	O
with	O
suspicion	O
of	O
a	O
pseudogout	O
crisis	O
due	O
to	O
probable	O
chondrocalcinosis	O
,	O
with	O
complete	O
resolution	O
of	O
the	O
symptoms	O
within	O
several	O
days	O
.	O
In	O
view	O
of	O
the	O
ECG	O
findings	O
described	O
above	O
,	O
the	O
ionic	O
alterations	O
were	O
corrected	O
and	O
the	O
ECG	O
pattern	O
evolved	O
as	O
shown	O
in	O
the	O
images	O
.	O
The	O
patient	O
remained	O
completely	O
asymptomatic	O
from	O
the	O
cardiovascular	O
point	O
of	O
view	O
,	O
and	O
was	O
discharged	O
with	O
subsequent	O
controls	O
in	O
outpatient	O
electrophysiology	O
consultations	O
,	O
with	O
suspicion	O
of	O
Brugada	O
pattern	O
phenocopy	O
in	O
the	O
context	O
of	O
ionic	O
alterations	O
.	O
A	O
flecainide	O
test	O
was	O
performed	O
on	O
an	O
outpatient	O
basis	O
with	O
intravenous	O
administration	O
of	O
this	O
drug	O
at	O
a	O
dose	O
of	O
2	O
mg	O
kg	O
in	O
10	O
minutes	O
,	O
obtaining	O
a	O
Brugada	O
type	O
1	O
pattern	O
.	O
He	O
remained	O
in	O
the	O
hospital	O
for	O
several	O
hours	O
with	O
telemetry	O
without	O
observing	O
arrhythmic	O
events	O
.	O
Subsequently	O
,	O
echocardiography	O
was	O
performed	O
without	O
showing	O
notable	O
alterations	O
preserved	O
LVEF	O
,	O
without	O
significant	O
valvular	O
heart	O
disease	O
.	O
A	O
genetic	O
study	O
of	O
p	O
channelopathies	O
myocardiopathy	O
was	O
performed	O
,	O
which	O
was	O
negative	O
.	O
The	O
patient	O
has	O
remained	O
asymptomatic	O
in	O
his	O
73	O
years	O
of	O
life	O
from	O
the	O
cardiovascular	O
point	O
of	O
view	O
,	O
with	O
no	O
notable	O
family	O
history	O
or	O
sudden	O
deaths	O
.	O
An	O
echocardiogram	O
was	O
also	O
performed	O
without	O
showing	O
any	O
notable	O
alterations	O
preserved	O
LVEF	O
,	O
no	O
significant	O
valvular	O
heart	O
disease	O
.	O
Therefore	O
,	O
what	O
initially	O
appeared	O
to	O
be	O
only	O
a	O
Brugada	O
pattern	O
phenocopy	O
turned	O
out	O
to	O
be	O
true	O
Brugada	O
syndrome	O
.	O
He	O
was	O
informed	O
of	O
the	O
current	O
process	O
and	O
of	O
the	O
prohibited	O
drugs	O
,	O
prohibition	O
of	O
alcohol	O
and	O
the	O
rapid	O
treatment	O
of	O
fever	O
with	O
antipyretics	O
,	O
which	O
is	O
also	O
reflected	O
in	O
his	O
history	O
.	O
At	O
present	O
,	O
she	O
has	O
also	O
started	O
the	O
family	O
study	O
for	O
the	O
control	O
of	O
her	O
relatives	O
.	O
DIAGNOSIS	O
Brugada	O
syndrome	O
.	O
No	O
structural	O
heart	O
disease	O
preserved	O
LVEF	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
No	O
known	O
allergic	O
drug	O
reactions	O
.	O
Active	O
smoking	O
30	O
cigarettes	O
a	O
day	O
.	O
Morbid	O
obesity	O
.	O
Arterial	O
hypertension	O
.	O
Insulin	B-FARMACO
dependent	O
diabetes	O
mellitus	O
.	O
Dyslipidaemia	O
.	O
Hyperuricaemia	O
.	O
Hypothyroidism	O
.	O
Stage	O
3B	O
chronic	O
kidney	O
disease	O
basal	O
glomerular	O
filtration	O
rate	O
30	O
35	O
ml	O
min	O
.	O
Peripheral	O
arterial	O
disease	O
intermittent	O
claudication	O
Fontaine	O
grade	O
IIa	O
.	O
Ischaemic	O
heart	O
disease	O
admitted	O
for	O
unstable	O
angina	O
in	O
2008	O
.	O
Catheterisation	O
revealed	O
severe	O
damage	O
to	O
three	O
vessels	O
anterior	O
descending	O
DA	O
,	O
right	O
coronary	O
CD	O
,	O
first	O
obtuse	O
marginal	O
OM	O
.	O
Only	O
the	O
LAD	O
was	O
surgically	O
revascularised	O
with	O
a	O
left	O
internal	O
mammary	O
artery	O
graft	O
.	O
Usual	O
treatment	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
100	O
mg	O
per	O
day	O
,	O
enalapril	B-FARMACO
20	O
mg	O
per	O
day	O
,	O
atenolol	B-FARMACO
12	O
.	O
5	O
mg	O
per	O
day	O
,	O
furosemide	B-FARMACO
40	O
mg	O
at	O
breakfast	O
and	O
lunch	O
,	O
metformin	B-FARMACO
850	O
mg	O
every	O
12	O
hours	O
,	O
mixed	O
insulin	B-FARMACO
regular	O
30	O
,	O
isophane	O
70	O
30	O
units	O
in	O
the	O
morning	O
and	O
20	O
units	O
in	O
the	O
evening	O
,	O
simvastatin	B-FARMACO
40	O
mg	O
per	O
day	O
,	O
allopurinol	B-FARMACO
100	O
mg	O
per	O
day	O
,	O
eutirox	B-FARMACO
50	O
mcg	O
per	O
day	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
per	O
day	O
.	O
Present	O
illness	O
An	O
84	O
year	O
old	O
woman	O
came	O
to	O
the	O
emergency	O
department	O
for	O
an	O
episode	O
of	O
non	O
radiating	O
central	O
thoracic	O
pain	O
that	O
appeared	O
with	O
minimal	O
effort	O
,	O
lasting	O
minutes	O
and	O
ceased	O
spontaneously	O
,	O
with	O
similar	O
characteristics	O
to	O
her	O
previous	O
angina	O
,	O
although	O
of	O
lesser	O
intensity	O
.	O
While	O
in	O
the	O
emergency	O
department	O
,	O
she	O
presented	O
another	O
episode	O
,	O
during	O
which	O
dynamic	O
electrocardiographic	O
changes	O
were	O
observed	O
,	O
which	O
subsided	O
with	O
the	O
administration	O
of	O
sublingual	O
nitroglycerine	B-FARMACO
.	O
The	O
patient	O
had	O
been	O
asymptomatic	O
from	O
the	O
cardiovascular	O
point	O
of	O
view	O
since	O
her	O
previous	O
admission	O
in	O
2008	O
.	O
Physical	O
examination	O
Vital	O
signs	O
blood	O
pressure	O
in	O
left	O
arm	O
125	O
63	O
mmHg	O
,	O
in	O
right	O
arm	O
143	O
75	O
mmHg	O
.	O
Heart	O
rate	O
63	O
bpm	O
.	O
Oxygen	O
saturation	O
97	O
basal	O
.	O
Good	O
general	O
condition	O
.	O
Conscious	O
and	O
oriented	O
,	O
cooperative	O
,	O
normohydrated	O
and	O
normoperfused	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
systolic	O
murmur	O
II	O
VI	O
predominantly	O
in	O
aortic	O
focus	O
,	O
with	O
second	O
noise	O
present	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
,	O
with	O
no	O
added	O
sounds	O
.	O
Abdomen	O
hydro	O
aerial	O
sounds	O
preserved	O
,	O
soft	O
and	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
.	O
Lower	O
limbs	O
no	O
oedema	O
,	O
weak	O
distal	O
pulses	O
.	O
COMPLEMENTARY	O
TESTS	O
CBC	O
on	O
admission	O
haemoglobin	O
16	O
.	O
6	O
g	O
dL	O
without	O
alterations	O
,	O
no	O
leukocytosis	O
.	O
Normal	O
haemostasis	O
.	O
Glucose	O
152	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
44	O
mg	O
dl	O
,	O
glomerular	O
filtration	O
35	O
.	O
20	O
ml	O
min	O
,	O
sodium	O
143	O
mmol	O
l	O
,	O
potassium	O
4	O
.	O
1	O
mmol	O
l	O
,	O
chlorine	O
106	O
mmol	O
l	O
,	O
C	O
reactive	O
protein	O
3	O
.	O
8	O
mg	O
l	O
,	O
two	O
determinations	O
of	O
troponin	O
I	O
0	O
.	O
0	O
ng	O
ml	O
.	O
LDL	O
119	O
mg	O
dl	O
.	O
HbA1c	O
8	O
.	O
6	O
.	O
Electrocardiogram	O
ECG	O
with	O
chest	O
pain	O
atrial	O
fibrillation	O
at	O
95	O
bpm	O
.	O
Narrow	O
QRS	O
.	O
Low	O
voltages	O
.	O
Infradevelation	O
of	O
1	O
mm	O
and	O
ST	O
rectification	O
from	O
V2	O
to	O
V6	O
,	O
DI	O
and	O
aVL	O
.	O
Painless	O
ECG	O
sinus	O
rhythm	O
at	O
65	O
bpm	O
.	O
Correction	O
of	O
repolarisation	O
alterations	O
.	O
Coronary	O
angiography	O
90	O
lesion	O
in	O
the	O
mid	O
segment	O
of	O
the	O
LAD	O
.	O
Mammary	O
bridge	O
to	O
mid	O
distal	O
LAD	O
is	O
observed	O
,	O
which	O
fills	O
retrograde	O
from	O
the	O
LAD	O
.	O
Dominant	O
circumflex	O
Cx	O
chronically	O
occluded	O
from	O
the	O
proximal	O
segment	O
,	O
with	O
poor	O
filling	O
by	O
homocoronary	O
collaterals	O
distally	O
.	O
Poorly	O
developed	O
DC	O
with	O
chronic	O
occlusion	O
in	O
the	O
middle	O
segment	O
,	O
distally	O
filled	O
by	O
homocoronary	O
collateral	O
circulation	O
.	O
The	O
bridge	O
from	O
the	O
mammary	O
to	O
the	O
LAD	O
is	O
patent	O
and	O
without	O
lesions	O
.	O
Significant	O
stenosis	O
is	O
observed	O
at	O
the	O
origin	O
of	O
the	O
left	O
subclavian	O
artery	O
with	O
a	O
pressure	O
gradient	O
across	O
it	O
of	O
60	O
mmHg	O
.	O
Angio	O
CT	O
scan	O
chronic	O
stenosis	O
of	O
the	O
proximal	O
left	O
subclavian	O
artery	O
about	O
32	O
mm	O
from	O
its	O
origin	O
,	O
conditioned	O
by	O
a	O
mixed	O
plaque	O
.	O
The	O
origin	O
of	O
the	O
left	O
internal	O
mammary	O
artery	O
is	O
11	O
mm	O
from	O
the	O
plaque	O
.	O
Echocardiogram	O
non	O
dilated	O
left	O
ventricle	O
with	O
preserved	O
ejection	O
fraction	O
.	O
Alterations	O
of	O
segmental	O
contractility	O
in	O
inferior	O
and	O
inferolateral	O
segments	O
.	O
Mild	O
left	O
ventricular	O
hypertrophy	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
and	O
function	O
.	O
Biauricular	O
dilatation	O
.	O
No	O
significant	O
valvulopathies	O
.	O
CLINICAL	O
EVOLUTION	O
After	O
finding	O
significant	O
stenosis	O
of	O
the	O
left	O
subclavian	O
artery	O
with	O
compromised	O
flow	O
towards	O
the	O
mammary	O
bypass	O
to	O
the	O
anterior	O
descending	O
artery	O
,	O
CT	O
angiography	O
was	O
performed	O
to	O
evaluate	O
the	O
three	O
dimensional	O
anatomy	O
of	O
the	O
stenosis	O
.	O
Given	O
the	O
patient	O
's	O
profile	O
and	O
her	O
high	O
surgical	O
risk	O
,	O
percutaneous	O
revascularisation	O
was	O
chosen	O
,	O
with	O
angioplasty	O
and	O
destent	O
implantation	O
in	O
the	O
left	O
subclavian	O
artery	O
,	O
which	O
proceeded	O
without	O
complications	O
.	O
During	O
admission	O
,	O
deterioration	O
of	O
renal	O
function	O
was	O
observed	O
in	O
relation	O
to	O
contrast	O
administration	O
and	O
insufficient	O
fluid	O
intake	O
,	O
which	O
improved	O
with	O
serum	O
therapy	O
,	O
returning	O
to	O
baseline	O
creatinine	O
and	O
glomerular	O
filtration	O
rates	O
.	O
The	O
patient	O
was	O
discharged	O
with	O
special	O
emphasis	O
on	O
the	O
control	O
of	O
cardiovascular	O
risk	O
factors	O
smoking	O
cessation	O
,	O
heart	O
healthy	O
diet	O
,	O
weight	O
loss	O
,	O
physical	O
exercise	O
.	O
.	O
.	O
As	O
for	O
pharmacological	O
treatment	O
of	O
risk	O
factors	O
,	O
liraglutide	B-FARMACO
was	O
added	O
to	O
improve	O
glycaemic	O
control	O
and	O
promote	O
weight	O
loss	O
,	O
and	O
simvastatin	B-FARMACO
40	O
mg	O
was	O
replaced	O
by	O
atorvastatin	B-FARMACO
80	O
mg	O
to	O
achieve	O
LDL	O
target	O
of	O
less	O
than	O
55	O
mg	O
dl	O
.	O
Regarding	O
the	O
antithrombotic	O
regimen	O
,	O
at	O
discharge	O
,	O
double	O
therapy	O
was	O
prescribed	O
with	O
rivaroxaban	B-FARMACO
10	O
mg	O
per	O
day	O
and	O
clopidogrel	B-FARMACO
75	O
mg	O
per	O
day	O
,	O
suspending	O
the	O
ASA	B-FARMACO
previously	O
taken	O
by	O
the	O
patient	O
.	O
After	O
the	O
intervention	O
,	O
the	O
patient	O
remained	O
asymptomatic	O
,	O
with	O
no	O
new	O
episodes	O
of	O
chest	O
pain	O
during	O
admission	O
and	O
subsequent	O
follow	O
up	O
in	O
outpatient	O
clinics	O
.	O
DIAGNOSIS	O
Unstable	O
angina	O
due	O
to	O
subclavian	O
coronary	O
steal	O
syndrome	O
.	O
In	O
a	O
patient	O
with	O
severe	O
three	O
vessel	O
coronary	O
artery	O
disease	O
and	O
partial	O
surgical	O
revascularisation	O
with	O
left	O
internal	O
mammary	O
bypass	O
to	O
anterior	O
descending	O
artery	O
in	O
2008	O
.	O
Preserved	O
LV	O
systolic	O
function	O
.	O
Paroxysmal	O
atrial	O
fibrillation	O
in	O
this	O
context	O
.	O
Acute	O
renal	O
failure	O
AKIN	O
III	O
on	O
chronic	O
kidney	O
disease	O
,	O
prerenal	O
origin	O
and	O
iodinated	O
contrast	O
nephrotoxicity	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
No	O
known	O
drug	O
allergies	O
.	O
Cardiovascular	O
risk	O
factors	O
smoking	O
and	O
occasional	O
alcohol	O
consumption	O
very	O
low	O
burden	O
.	O
No	O
other	O
drug	O
use	O
.	O
No	O
arterial	O
hypertension	O
AHT	O
,	O
no	O
dyslipidaemia	O
,	O
no	O
diabetes	O
mellitus	O
.	O
Cardiological	O
history	O
no	O
known	O
cardiological	O
history	O
,	O
no	O
family	O
history	O
of	O
heart	O
disease	O
or	O
sudden	O
death	O
in	O
the	O
family	O
.	O
Surgical	O
interventions	O
tonsillectomy	O
.	O
No	O
usual	O
treatment	O
.	O
Present	O
illness	O
A	O
36	O
year	O
old	O
male	O
patient	O
came	O
to	O
the	O
emergency	O
department	O
referred	O
from	O
his	O
health	O
centre	O
for	O
palpitations	O
and	O
syncope	O
,	O
with	O
an	O
electrocardiogram	O
ECG	O
showing	O
irregular	O
tachycardia	O
with	O
wide	O
QRS	O
.	O
After	O
getting	O
up	O
quickly	O
from	O
the	O
sofa	O
,	O
the	O
patient	O
reported	O
sudden	O
onset	O
of	O
palpitations	O
,	O
without	O
initial	O
dizziness	O
.	O
Subsequently	O
,	O
after	O
approximately	O
one	O
minute	O
,	O
he	O
went	O
to	O
the	O
bathroom	O
to	O
urinate	O
and	O
after	O
urinating	O
,	O
he	O
reported	O
a	O
rapid	O
sensation	O
of	O
dizziness	O
and	O
fell	O
to	O
the	O
floor	O
,	O
with	O
spontaneous	O
recovery	O
of	O
consciousness	O
he	O
reported	O
approximately	O
10	O
minutes	O
of	O
loss	O
of	O
consciousness	O
,	O
he	O
was	O
alone	O
at	O
home	O
,	O
with	O
no	O
witnesses	O
.	O
After	O
the	O
episode	O
,	O
he	O
reported	O
only	O
palpitations	O
,	O
denying	O
chest	O
pain	O
,	O
dyspnoea	O
or	O
other	O
symptoms	O
.	O
Given	O
the	O
persistence	O
of	O
the	O
palpitations	O
and	O
after	O
recovering	O
from	O
the	O
syncope	O
,	O
he	O
decided	O
to	O
consult	O
his	O
health	O
centre	O
and	O
was	O
referred	O
to	O
our	O
centre	O
.	O
The	O
patient	O
denies	O
the	O
use	O
of	O
toxic	O
substances	O
.	O
He	O
reported	O
4	O
similar	O
episodes	O
of	O
palpitations	O
related	O
to	O
physical	O
effort	O
for	O
which	O
he	O
had	O
never	O
consulted	O
before	O
,	O
self	O
limited	O
,	O
without	O
syncope	O
.	O
Physical	O
examination	O
On	O
arrival	O
at	O
the	O
emergency	O
department	O
,	O
good	O
general	O
condition	O
,	O
normal	O
colour	O
,	O
normohydrated	O
,	O
eupneic	O
at	O
rest	O
.	O
Blood	O
pressure	O
BP	O
147	O
68	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
180	O
210	O
bpm	O
.	O
SpO2	O
FiO2	O
21	O
99	O
.	O
Neurological	O
examination	O
conscious	O
and	O
oriented	O
,	O
alert	O
,	O
cooperative	O
.	O
No	O
neurological	O
focality	O
.	O
Cardiac	O
and	O
pulmonary	O
auscultation	O
irregular	O
tachycardic	O
sounds	O
,	O
no	O
murmurs	O
.	O
Preserved	O
vesicular	O
murmur	O
VCM	O
,	O
without	O
added	O
noises	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
without	O
masses	O
or	O
megaliths	O
.	O
No	O
pain	O
on	O
palpation	O
.	O
No	O
signs	O
of	O
peritoneal	O
irritation	O
.	O
Lower	O
limbs	O
no	O
oedema	O
,	O
no	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
Initial	O
ECG	O
on	O
arrival	O
at	O
the	O
ED	O
wide	O
QRS	O
irregular	O
tachycardia	O
with	O
approximate	O
ventricular	O
response	O
between	O
180	O
210	O
bpm	O
.	O
Occasionally	O
there	O
are	O
narrow	O
QRS	O
beats	O
.	O
ECG	O
after	O
CVE	O
sinus	O
rhythm	O
at	O
95	O
bpm	O
,	O
PR	O
100	O
ms	O
,	O
60o	O
axis	O
,	O
QRS	O
120	O
ms	O
with	O
positive	O
delta	O
wave	O
in	O
inferior	O
aspect	O
and	O
from	O
V3	O
to	O
V5	O
.	O
No	O
repolarisation	O
abnormalities	O
.	O
ECG	O
at	O
discharge	O
sinus	O
rhythm	O
80	O
bpm	O
.	O
PR	O
150	O
msg	O
.	O
Narrow	O
QRS	O
without	O
repolarisation	O
alterations	O
.	O
Chest	O
X	O
ray	O
cardiothoracic	O
index	O
CTI	O
within	O
normal	O
,	O
no	O
condensation	O
or	O
pleural	O
effusion	O
,	O
no	O
signs	O
of	O
pneumothorax	O
.	O
Laboratory	O
tests	O
CBC	O
red	O
blood	O
cells	O
5	O
.	O
08	O
10	O
12	O
l	O
,	O
haemoglobin	O
15	O
.	O
6	O
g	O
dl	O
,	O
haematocrit	O
47	O
,	O
leukocytes	O
11	O
.	O
6	O
10	O
9	O
l	O
,	O
neutrophils	O
50	O
.	O
5	O
,	O
lymphocytes	O
38	O
.	O
3	O
,	O
platelets	O
295	O
10	O
9	O
l	O
.	O
Biochemistry	O
glucose	O
111	O
mg	O
dl	O
,	O
sodium	O
139	O
mEq	O
l	O
,	O
potassium	O
3	O
.	O
6	O
mEq	O
l	O
,	O
chlorine	O
102	O
mEq	O
l	O
,	O
GPT	O
39	O
U	O
l	O
,	O
urea	O
23	O
.	O
1	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
87	O
mg	O
dl	O
,	O
C	O
reactive	O
protein	O
0	O
.	O
06	O
mg	O
dl	O
.	O
Baseline	O
haemostasis	O
prothrombin	O
time	O
10	O
.	O
3	O
sec	O
;	O
I	O
.	O
Quick	O
99	O
;	O
INR	O
1	O
.	O
02	O
;	O
aPTT	O
25	O
.	O
9	O
sec	O
.	O
Echocardiogram	O
left	O
ventricle	O
with	O
preserved	O
diameters	O
and	O
global	O
systolic	O
function	O
.	O
Absence	O
of	O
alterations	O
in	O
segmental	O
contractility	O
at	O
rest	O
.	O
Trivial	O
mitral	O
insufficiency	O
.	O
Aortic	O
root	O
36	O
mm	O
,	O
without	O
valvulopathies	O
.	O
Right	O
ventricle	O
of	O
preserved	O
size	O
and	O
function	O
.	O
Minimal	O
tricuspid	O
insufficiency	O
that	O
allows	O
estimating	O
PAPs	O
of	O
approximately	O
30	O
mmHg	O
.	O
Normal	O
inferior	O
vena	O
cava	O
.	O
Electrophysiological	O
study	O
EEF	O
on	O
ECG	O
suspicion	O
of	O
a	O
possible	O
left	O
lateral	O
accessory	O
pathway	O
,	O
access	O
was	O
gained	O
via	O
the	O
retrograde	O
aortic	O
route	O
and	O
an	O
ablation	O
catheter	O
was	O
located	O
in	O
the	O
lateral	O
mitral	O
annulus	O
,	O
obtaining	O
precocities	O
of	O
up	O
to	O
10	O
ms	O
with	O
respect	O
to	O
delta	O
wave	O
and	O
QS	O
in	O
unipolar	O
,	O
performing	O
3	O
applications	O
of	O
RF	O
reaching	O
up	O
to	O
56	O
oC	O
temperature	O
with	O
cessation	O
of	O
anterograde	O
and	O
retrograde	O
conduction	O
of	O
the	O
pathway	O
.	O
With	O
programmed	O
st	O
.	O
A	O
programmed	O
600	O
260	O
,	O
orthodromic	O
tachycardia	O
is	O
induced	O
by	O
another	O
left	O
posterior	O
accessory	O
pathway	O
and	O
ablation	O
is	O
performed	O
during	O
tachycardia	O
,	O
observing	O
cessation	O
of	O
tachycardia	O
with	O
a	O
V	O
without	O
rising	O
to	O
A	O
.	O
After	O
this	O
,	O
no	O
eccentric	O
retrograde	O
conduction	O
is	O
observed	O
and	O
tachycardia	O
is	O
not	O
induced	O
.	O
The	O
result	O
was	O
maintained	O
after	O
20	O
min	O
of	O
waiting	O
and	O
the	O
procedure	O
was	O
terminated	O
.	O
CLINICAL	O
EVOLUTION	O
On	O
arrival	O
at	O
the	O
emergency	O
department	O
of	O
our	O
centre	O
,	O
given	O
the	O
clinical	O
and	O
ECG	O
findings	O
at	O
the	O
health	O
centre	O
,	O
the	O
patient	O
was	O
transferred	O
directly	O
to	O
the	O
critical	O
care	O
unit	O
.	O
An	O
ECG	O
was	O
performed	O
with	O
persistent	O
wide	O
QRS	O
irregular	O
tachycardia	O
and	O
,	O
given	O
haemodynamic	O
stability	O
and	O
good	O
clinical	O
tolerance	O
to	O
the	O
tachycardia	O
,	O
pharmacological	O
cardioversion	O
was	O
decided	O
with	O
procainamide	B-FARMACO
200	O
mg	O
i	O
.	O
v	O
.	O
without	O
cessation	O
of	O
tachycardia	O
.	O
Subsequently	O
,	O
the	O
patient	O
was	O
sedated	O
with	O
2	O
mg	O
of	O
midazolam	B-FARMACO
and	O
6	O
mg	O
of	O
etomidate	B-FARMACO
,	O
and	O
electrical	O
cardioversion	O
ECV	O
was	O
performed	O
with	O
a	O
200	O
J	O
shock	O
,	O
and	O
the	O
patient	O
went	O
into	O
sinus	O
rhythm	O
at	O
75	O
bpm	O
.	O
The	O
post	O
CVE	O
ECG	O
showed	O
sinus	O
rhythm	O
with	O
short	O
PR	O
with	O
delta	O
wave	O
in	O
inferior	O
and	O
lateral	O
leads	O
.	O
In	O
light	O
of	O
the	O
ECGs	O
,	O
the	O
patient	O
was	O
labelled	O
as	O
having	O
syncopal	O
pre	O
excited	O
atrial	O
fibrillation	O
and	O
was	O
admitted	O
to	O
cardiology	O
with	O
continuous	O
monitoring	O
to	O
complete	O
the	O
study	O
and	O
treatment	O
.	O
During	O
his	O
stay	O
in	O
cardiology	O
the	O
patient	O
remained	O
asymptomatic	O
and	O
without	O
arrhythmic	O
events	O
on	O
monitoring	O
.	O
Morphological	O
studies	O
were	O
completed	O
with	O
transthoracic	O
echocardiography	O
TTE	O
,	O
which	O
showed	O
no	O
significant	O
alterations	O
.	O
The	O
convenience	O
of	O
performing	O
accessory	O
pathway	O
ablation	O
was	O
explained	O
to	O
the	O
patient	O
,	O
as	O
well	O
as	O
the	O
risks	O
of	O
not	O
doing	O
so	O
,	O
and	O
the	O
patient	O
accepted	O
the	O
procedure	O
.	O
In	O
the	O
EPS	O
,	O
2	O
accessory	O
pathways	O
were	O
located	O
left	O
lateral	O
and	O
left	O
posterior	O
and	O
both	O
were	O
effectively	O
ablated	O
.	O
In	O
the	O
absence	O
of	O
complications	O
24	O
hours	O
after	O
the	O
procedure	O
,	O
the	O
patient	O
was	O
discharged	O
home	O
with	O
ECG	O
with	O
no	O
signs	O
of	O
pre	O
excitation	O
.	O
In	O
subsequent	O
ambulatory	O
controls	O
,	O
the	O
patient	O
remained	O
asymptomatic	O
and	O
no	O
pre	O
excitation	O
was	O
observed	O
in	O
the	O
control	O
ECGs	O
.	O
DIAGNOSIS	O
Syncopal	O
pre	O
excited	O
atrial	O
fibrillation	O
AF	O
.	O
Left	O
lateral	O
and	O
left	O
posterior	O
accessory	O
pathway	O
ablation	O
.	O
Normal	O
left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
with	O
trivial	O
mitral	O
regurgitation	O
MR	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Male	O
,	O
41	O
years	O
old	O
,	O
from	O
Romania	O
.	O
Hypertensive	O
and	O
smoker	O
.	O
History	O
of	O
syncope	O
1999	O
in	O
Romania	O
attributed	O
according	O
to	O
the	O
patient	O
to	O
a	O
first	O
CHF	O
episode	O
no	O
reports	O
available	O
.	O
2012	O
non	O
specific	O
symptoms	O
with	O
suspected	O
vasovagal	O
aetiology	O
.	O
2015	O
new	O
episode	O
with	O
prodromes	O
and	O
post	O
critical	O
period	O
,	O
leading	O
to	O
a	O
neurological	O
study	O
with	O
cranial	O
computed	O
tomography	O
CT	O
,	O
which	O
was	O
found	O
to	O
be	O
normal	O
.	O
2016	O
two	O
episodes	O
,	O
with	O
a	O
cardiogenic	O
profile	O
.	O
Admission	O
to	O
the	O
cardiology	O
ward	O
.	O
She	O
came	O
to	O
the	O
emergency	O
department	O
for	O
two	O
consecutive	O
syncopal	O
episodes	O
,	O
the	O
first	O
of	O
which	O
was	O
not	O
witnessed	O
,	O
while	O
walking	O
,	O
without	O
prodromes	O
,	O
with	O
a	O
fall	O
to	O
the	O
ground	O
and	O
trauma	O
to	O
the	O
jaw	O
and	O
mouth	O
.	O
While	O
recovering	O
from	O
this	O
he	O
got	O
up	O
and	O
went	O
to	O
drink	O
water	O
,	O
he	O
had	O
another	O
episode	O
,	O
this	O
time	O
preceded	O
by	O
intense	O
heat	O
and	O
dizziness	O
,	O
with	O
loss	O
of	O
consciousness	O
lasting	O
seconds	O
.	O
Subsequent	O
full	O
recovery	O
.	O
No	O
tonic	O
clonic	O
movements	O
or	O
sphincter	O
relaxation	O
.	O
Subsequently	O
asymptomatic	O
.	O
No	O
clinical	O
chest	O
pain	O
or	O
palpitations	O
.	O
No	O
dyspnoea	O
or	O
signs	O
of	O
heart	O
failure	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
BP	O
144	O
91	O
mmHg	O
,	O
Spo2	O
99	O
,	O
heart	O
rate	O
HR	O
72	O
bpm	O
.	O
Conscious	O
and	O
oriented	O
.	O
Eupneic	O
.	O
Cardiopulmonary	O
auscultation	O
normal	O
.	O
Lower	O
limbs	O
no	O
oedema	O
.	O
Palpable	O
and	O
symmetrical	O
pulses	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
sinus	O
rhythm	O
at	O
52	O
bpm	O
,	O
90o	O
axis	O
,	O
narrow	O
QRS	O
,	O
asymmetric	O
negative	O
T	O
in	O
III	O
and	O
up	O
to	O
V2	O
,	O
biphasic	O
in	O
V3	O
.	O
Notched	O
QRS	O
in	O
V3	O
.	O
Early	O
repolarisation	O
in	O
V6	O
.	O
Chest	O
X	O
ray	O
cardiac	O
shift	O
to	O
the	O
left	O
.	O
Erasure	O
of	O
the	O
right	O
cardiac	O
border	O
overlapping	O
of	O
the	O
spinal	O
column	O
.	O
Pectus	O
excavatum	O
.	O
CBC	O
ultrasensitive	O
troponin	O
T	O
4	O
pg	O
ml	O
.	O
Glucose	O
85	O
mg	O
dl	O
,	O
urea	O
35	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
95	O
mg	O
dl	O
.	O
Sodium	O
137	O
mmol	O
l	O
.	O
Potassium	O
4	O
.	O
2	O
mmol	O
l	O
.	O
CK	O
279	O
U	O
l	O
.	O
Haemoglobin	O
14	O
.	O
5	O
x10	O
3	O
mcl	O
,	O
platelets	O
304x10	O
3	O
mcl	O
,	O
leucocytes	O
13	O
.	O
29x10	O
3	O
mcl	O
N	O
86	O
.	O
D	O
dimer	O
198	O
g	O
ml	O
.	O
PET	O
scan	O
protocol	O
no	O
repletion	O
defects	O
in	O
main	O
,	O
lobar	O
or	O
segmental	O
pulmonary	O
arteries	O
.	O
No	O
mediastinal	O
or	O
hilar	O
adenopathies	O
of	O
significant	O
size	O
.	O
No	O
images	O
compatible	O
with	O
infiltrates	O
,	O
nodules	O
or	O
pleural	O
effusion	O
.	O
Echocardiogram	O
left	O
ventricle	O
LV	O
not	O
dilated	O
or	O
hypertrophic	O
with	O
preserved	O
LVEF	O
and	O
no	O
alterations	O
in	O
segmental	O
contractility	O
except	O
septal	O
flattening	O
and	O
anomalous	O
movement	O
in	O
relation	O
to	O
right	O
ventricular	O
dilatation	O
.	O
Non	O
dilated	O
left	O
atrium	O
LA	O
with	O
an	O
AP	O
diameter	O
of	O
26	O
mm	O
and	O
area	O
of	O
14	O
cm	O
.	O
Dilated	O
right	O
ventricle	O
RV	O
with	O
diameters	O
of	O
45	O
mm	O
basally	O
,	O
40	O
mm	O
medially	O
and	O
59	O
mm	O
longitudinally	O
with	O
borderline	O
RVEF	O
TAPSE	O
16	O
,	O
S	O
DTI	O
14	O
with	O
free	O
wall	O
hypokinesia	O
and	O
akinesia	O
dyskinesia	O
at	O
the	O
apex	O
.	O
Aortic	O
root	O
and	O
ascending	O
aorta	O
not	O
dilated	O
.	O
Tricommissural	O
aortic	O
valve	O
with	O
preserved	O
opening	O
.	O
Mitral	O
and	O
tricuspid	O
of	O
normal	O
morphology	O
.	O
Inferior	O
vena	O
cava	O
IVC	O
not	O
dilated	O
.	O
Aneurysm	O
of	O
the	O
interatrial	O
septum	O
AIS	O
that	O
appears	O
to	O
be	O
intact	O
.	O
No	O
pericardial	O
effusion	O
is	O
visualised	O
.	O
Normal	O
diastolic	O
function	O
.	O
Trivial	O
mitral	O
regurgitation	O
MR	O
.	O
Mild	O
tricuspid	O
regurgitation	O
TR	O
.	O
Signal	O
averaged	O
ECG	O
filtered	O
QRS	O
duration	O
108	O
ms	O
,	O
RMS40	O
37	O
mcV	O
,	O
SAB	O
23	O
ms	O
.	O
No	O
positive	O
criteria	O
.	O
Negative	O
signal	O
averaging	O
study	O
.	O
Cardiac	O
magnetic	O
resonance	O
imaging	O
MRI	O
morphological	O
and	O
functional	O
sequences	O
show	O
non	O
dilated	O
LV	O
with	O
normal	O
wall	O
thickness	O
and	O
normal	O
global	O
and	O
regional	O
EF	O
.	O
Normal	O
LA	O
.	O
RA	O
not	O
dilated	O
.	O
RV	O
not	O
dilated	O
,	O
with	O
estimated	O
RVEF	O
47	O
.	O
At	O
the	O
level	O
of	O
the	O
RV	O
outflow	O
tract	O
,	O
a	O
very	O
localised	O
hypokinetic	O
area	O
,	O
with	O
no	O
other	O
significant	O
alterations	O
in	O
segmental	O
contractility	O
or	O
aneurysmal	O
areas	O
.	O
Cardiac	O
displacement	O
towards	O
the	O
left	O
hemithorax	O
,	O
with	O
significant	O
horizontalisation	O
of	O
the	O
cardiac	O
axis	O
.	O
No	O
oedema	O
is	O
seen	O
in	O
T2	O
sequences	O
.	O
Perfusion	O
sequences	O
do	O
not	O
show	O
any	O
first	O
pass	O
defects	O
.	O
No	O
enhancement	O
indicating	O
pathological	O
substrate	O
was	O
observed	O
in	O
the	O
viability	O
sequences	O
.	O
Extracardiac	O
findings	O
lungs	O
with	O
normal	O
vascularisation	O
,	O
although	O
there	O
is	O
volume	O
loss	O
in	O
lingular	O
segments	O
associated	O
with	O
cardiac	O
displacement	O
.	O
Conclusion	O
Normal	O
LV	O
.	O
RV	O
not	O
dilated	O
,	O
with	O
borderline	O
EF	O
47	O
,	O
without	O
conclusive	O
data	O
for	O
diagnosis	O
of	O
dysplasia	O
.	O
Electrophysiological	O
study	O
negative	O
study	O
,	O
no	O
data	O
of	O
channelopathy	O
.	O
At	O
the	O
end	O
of	O
the	O
study	O
and	O
to	O
complete	O
the	O
study	O
,	O
a	O
SJM	O
model	O
Confirm	O
DM2100	O
subcutaneous	O
Holter	O
was	O
implanted	O
.	O
Coronary	O
CAT	O
scan	O
image	O
4	O
normal	O
cardiac	O
cavities	O
.	O
Atria	O
not	O
dilated	O
.	O
Aortic	O
valve	O
tricuspid	O
,	O
morphologically	O
normal	O
.	O
Mitral	O
valve	O
morphologically	O
normal	O
.	O
Coronary	O
tree	O
Agatston	O
0	O
.	O
Dominance	O
right	O
.	O
Normal	O
coronary	O
anatomy	O
.	O
No	O
abnormalities	O
or	O
stenosis	O
.	O
Rotation	O
of	O
the	O
cardiac	O
silhouette	O
to	O
the	O
left	O
and	O
posterior	O
and	O
virtual	O
absence	O
of	O
the	O
pericardium	O
,	O
with	O
some	O
residual	O
tracts	O
in	O
the	O
anterior	O
margin	O
of	O
the	O
right	O
ventricle	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
cardiology	O
ward	O
for	O
further	O
investigation	O
.	O
In	O
the	O
emergency	O
department	O
,	O
angio	O
CT	O
ruled	O
out	O
PTE	O
.	O
Initially	O
,	O
right	O
ventricular	O
dysplasia	O
was	O
suspected	O
ECG	O
with	O
negative	O
T1	O
V2	O
,	O
echocardiogram	O
with	O
a	O
doubtful	O
aneurysmal	O
image	O
in	O
the	O
right	O
ventricle	O
,	O
so	O
the	O
study	O
was	O
completed	O
with	O
MRI	O
and	O
a	O
new	O
echocardiogram	O
was	O
repeated	O
the	O
right	O
ventricle	O
was	O
of	O
normal	O
size	O
,	O
without	O
dilatation	O
or	O
clear	O
criteria	O
of	O
dysplasia	O
.	O
During	O
admission	O
,	O
he	O
remained	O
asymptomatic	O
and	O
stable	O
,	O
without	O
dizziness	O
or	O
syncope	O
and	O
with	O
telemetry	O
that	O
did	O
not	O
record	O
any	O
event	O
no	O
ventricular	O
or	O
supraventricular	O
extrasystoles	O
or	O
arrhythmias	O
of	O
any	O
kind	O
.	O
The	O
syncope	O
study	O
was	O
completed	O
with	O
signal	O
averaged	O
ECG	O
,	O
flecainide	O
test	O
and	O
electrophysiological	O
study	O
with	O
no	O
inducibility	O
of	O
ventricular	O
tachycardia	O
or	O
findings	O
justifying	O
an	O
arrhythmic	O
mechanism	O
.	O
A	O
subcutaneous	O
Holter	O
was	O
implanted	O
.	O
A	O
coronary	O
CAT	O
scan	O
was	O
also	O
performed	O
which	O
ruled	O
out	O
coronary	O
anomalies	O
,	O
with	O
probable	O
almost	O
total	O
agenesis	O
of	O
the	O
left	O
pericardium	O
chest	O
X	O
ray	O
also	O
compatible	O
with	O
this	O
diagnosis	O
,	O
which	O
does	O
not	O
justify	O
the	O
current	O
clinical	O
picture	O
.	O
DIAGNOSIS	O
Repeated	O
syncope	O
of	O
non	O
filarial	O
origin	O
probably	O
neuromediated	O
.	O
Negative	O
electrophysiological	O
study	O
.	O
Implantable	O
Holter	O
.	O
Coronary	O
CAT	O
scan	O
with	O
no	O
coronary	O
lesions	O
or	O
anomalies	O
.	O
Almost	O
total	O
pericardial	O
agenesis	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
70	O
year	O
old	O
woman	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
No	O
toxic	O
habits	O
.	O
Cardiovascular	O
risk	O
factors	O
hypertension	O
and	O
dyslipidaemia	O
.	O
Permanent	O
atrial	O
fibrillation	O
AF	O
anticoagulated	O
with	O
acenucoumarol	B-FARMACO
since	O
2014	O
.	O
Surgical	O
interventions	O
right	O
knee	O
.	O
Autonomous	O
for	O
basic	O
activities	O
of	O
daily	O
living	O
.	O
Active	O
life	O
,	O
no	O
previous	O
angina	O
or	O
dyspnoea	O
.	O
Usual	O
treatment	O
digoxin	B-FARMACO
0	O
.	O
25	O
mg	O
daily	O
,	O
lorazepam	B-FARMACO
1	O
mg	O
at	O
bedtime	O
,	O
acenocoumarol	B-FARMACO
4	O
mg	O
as	O
prescribed	O
,	O
amlodipine	B-FARMACO
telmisartan	I-FARMACO
80	O
5	O
mg	O
at	O
dinner	O
,	O
verapamil	B-FARMACO
240	O
mg	O
at	O
breakfast	O
,	O
atorvastatin	B-FARMACO
40	O
mg	O
at	O
dinner	O
,	O
tramadol	B-FARMACO
100	O
mg	O
if	O
required	O
,	O
paracetamol	B-FARMACO
1	O
g	O
if	O
required	O
,	O
topical	O
calcipotriol	B-FARMACO
0	O
.	O
005	O
.	O
Present	O
illness	O
70	O
year	O
old	O
woman	O
who	O
started	O
the	O
morning	O
of	O
admission	O
,	O
while	O
doing	O
housework	O
,	O
with	O
oppressive	O
chest	O
pain	O
,	O
radiating	O
to	O
the	O
left	O
upper	O
limb	O
,	O
without	O
accompanying	O
vegetative	O
cortex	O
,	O
which	O
forced	O
her	O
to	O
stop	O
and	O
persisted	O
at	O
rest	O
for	O
about	O
30	O
minutes	O
.	O
Slight	O
discomfort	O
persisted	O
in	O
the	O
left	O
hemithorax	O
at	O
the	O
time	O
of	O
assessment	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
BP	O
147	O
80	O
mmHg	O
;	O
heart	O
rate	O
HR	O
80	O
bpm	O
;	O
SatO2	O
97	O
on	O
room	O
air	O
;	O
afebrile	O
.	O
Conscious	O
,	O
oriented	O
,	O
normal	O
colour	O
and	O
well	O
perfused	O
.	O
Head	O
and	O
neck	O
no	O
jugular	O
plethora	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
.	O
Abdomen	O
nondescript	O
.	O
Lower	O
limbs	O
trophic	O
disorders	O
due	O
to	O
chronic	O
venous	O
insufficiency	O
.	O
Right	O
paedial	O
pulse	O
present	O
,	O
left	O
absent	O
.	O
No	O
oedema	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
on	O
arrival	O
at	O
the	O
emergency	O
department	O
AF	O
with	O
ventricular	O
response	O
at	O
75	O
bpm	O
.	O
Narrow	O
QRS	O
,	O
axis	O
at	O
30o	O
.	O
No	O
repolarisation	O
alterations	O
.	O
Normal	O
QTc	O
.	O
Laboratory	O
tests	O
on	O
admission	O
urea	O
24	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
58	O
mg	O
dl	O
,	O
albumin	O
3	O
.	O
5	O
g	O
dl	O
,	O
total	O
bilirubin	O
0	O
.	O
9	O
mg	O
dl	O
,	O
GPT	O
13	O
U	O
L	O
,	O
CK	O
134	O
U	O
l	O
,	O
troponin	O
T	O
US	O
482	O
ng	O
l	O
normal	O
14	O
ng	O
l	O
,	O
LDH	O
233	O
U	O
l	O
,	O
sodium	O
140	O
mEq	O
l	O
,	O
potassium	O
3	O
.	O
6	O
mEq	O
l	O
,	O
CRP	O
11	O
mg	O
l	O
,	O
haemoglobin	O
14	O
.	O
5	O
g	O
dl	O
,	O
platelets	O
232	O
.	O
000	O
l	O
,	O
leukocytes	O
8	O
,	O
300	O
l	O
lymphocytes	O
25	O
,	O
neutrophils	O
64	O
.	O
Protombin	O
index	O
66	O
,	O
INR	O
1	O
.	O
3	O
,	O
aPTT	O
38	O
sec	O
.	O
Total	O
cholesterol	O
181	O
mg	O
dl	O
,	O
triglycerides	O
116	O
mg	O
dl	O
,	O
LDL	O
109	O
mg	O
dl	O
,	O
HDL	O
49	O
mg	O
dl	O
,	O
non	O
HDL	O
cholesterol	O
132	O
mg	O
dl	O
.	O
Serum	O
chylomicrons	O
negative	O
.	O
Chest	O
X	O
ray	O
on	O
admission	O
normal	O
cardiothoracic	O
index	O
.	O
No	O
congestive	O
signs	O
,	O
no	O
condensation	O
in	O
the	O
lung	O
parenchyma	O
.	O
Free	O
costophrenic	O
sinuses	O
.	O
Echocardiogram	O
on	O
admission	O
to	O
the	O
coronary	O
unit	O
left	O
ventricle	O
LV	O
not	O
dilated	O
,	O
with	O
hypertrophy	O
at	O
the	O
level	O
of	O
the	O
interventricular	O
septum	O
.	O
Moderately	O
depressed	O
global	O
systolic	O
function	O
LVEF	O
35	O
due	O
to	O
akinesia	O
of	O
the	O
mid	O
apical	O
segments	O
of	O
the	O
septum	O
,	O
anterior	O
and	O
lateral	O
face	O
and	O
apical	O
of	O
the	O
inferolateral	O
and	O
inferior	O
face	O
.	O
Aortic	O
root	O
not	O
dilated	O
.	O
Trivalve	O
aortic	O
valve	O
,	O
sclerocalcified	O
,	O
with	O
preserved	O
opening	O
and	O
mild	O
insufficiency	O
.	O
Sclerocalcified	O
mitral	O
valve	O
with	O
restriction	O
of	O
the	O
posterior	O
leaflet	O
and	O
moderate	O
insufficiency	O
.	O
Moderately	O
dilated	O
left	O
atrium	O
.	O
Right	O
ventricle	O
RV	O
not	O
dilated	O
,	O
normocontractile	O
.	O
Mild	O
tricuspid	O
insufficiency	O
that	O
does	O
not	O
allow	O
estimation	O
of	O
RV	O
AD	O
gradient	O
.	O
Acceleration	O
time	O
in	O
pulmonary	O
artery	O
not	O
suggestive	O
of	O
pulmonary	O
hypertension	O
.	O
No	O
pericardial	O
effusion	O
.	O
ECG	O
on	O
readmission	O
to	O
the	O
coronary	O
unit	O
after	O
an	O
episode	O
of	O
pain	O
on	O
the	O
ward	O
AF	O
with	O
ventricular	O
response	O
at	O
75	O
bpm	O
.	O
Q	O
wave	O
in	O
V3	O
V4	O
with	O
ST	O
elevation	O
in	O
V3	O
V5	O
,	O
maximum	O
of	O
2	O
mm	O
in	O
V4	O
,	O
negative	O
T	O
wave	O
in	O
V2	O
V6	O
,	O
not	O
present	O
in	O
previous	O
ECGs	O
.	O
Urgent	O
cardiac	O
catheterisation	O
right	O
radial	O
access	O
.	O
Normal	O
left	O
main	O
coronary	O
artery	O
.	O
Dissection	O
of	O
the	O
distal	O
anterior	O
descending	O
artery	O
DA	O
up	O
to	O
the	O
tip	O
,	O
with	O
occlusion	O
of	O
the	O
vessel	O
at	O
a	O
very	O
distal	O
level	O
.	O
Right	O
circumflex	O
and	O
coronary	O
artery	O
without	O
lesions	O
.	O
The	O
patient	O
was	O
not	O
considered	O
suitable	O
for	O
percutaneous	O
coronary	O
intervention	O
PCI	O
.	O
Balloon	O
counterpulsation	O
is	O
implanted	O
via	O
the	O
right	O
femoral	O
artery	O
.	O
Echocardiogram	O
at	O
discharge	O
from	O
the	O
coronary	O
unit	O
left	O
ventricle	O
of	O
normal	O
size	O
.	O
Basal	O
anterior	O
septum	O
with	O
severe	O
hypertrophy	O
with	O
remaining	O
wall	O
thickness	O
slightly	O
increased	O
.	O
Ejection	O
fraction	O
by	O
Simpson	O
biplane	O
of	O
48	O
.	O
Akinesia	O
of	O
the	O
apical	O
segments	O
,	O
with	O
an	O
area	O
near	O
the	O
RV	O
tip	O
suggestive	O
of	O
pseudoaneurysm	O
1	O
cm	O
with	O
a	O
narrow	O
and	O
anfractuous	O
neck	O
filled	O
with	O
Sonovue	O
contrast	O
.	O
Mild	O
moderate	O
mitral	O
insufficiency	O
.	O
Mild	O
moderate	O
tricuspid	O
insufficiency	O
.	O
RV	O
AD	O
gradient	O
of	O
35	O
mmHg	O
,	O
undilated	O
inferior	O
vena	O
cava	O
with	O
inspiratory	O
collapse	O
greater	O
than	O
50	O
.	O
Estimated	O
PSAP	O
of	O
40	O
mmHg	O
.	O
Minimal	O
aortic	O
insufficiency	O
.	O
Aortic	O
root	O
of	O
normal	O
size	O
.	O
No	O
pericardial	O
effusion	O
.	O
Angio	O
CT	O
of	O
coronary	O
arteries	O
synchronised	O
helical	O
study	O
without	O
and	O
with	O
intravenous	O
contrast	O
.	O
Median	O
sternotomy	O
.	O
Post	O
surgical	O
patch	O
at	O
apex	O
level	O
.	O
Aneurysm	O
and	O
apical	O
pseudoaneurysm	O
up	O
to	O
6	O
x	O
3	O
cm	O
with	O
several	O
lobulations	O
towards	O
inferior	O
aspect	O
.	O
No	O
pericardial	O
effusion	O
.	O
Small	O
left	O
pleural	O
effusion	O
and	O
subsegmental	O
atelectasis	O
in	O
the	O
left	O
lower	O
lobe	O
.	O
ECG	O
at	O
discharge	O
AF	O
with	O
ventricular	O
response	O
at	O
88	O
bpm	O
.	O
Deep	O
negative	O
T	O
waves	O
from	O
V2	O
to	O
V6	O
,	O
less	O
pronounced	O
negative	O
T	O
waves	O
in	O
DI	O
,	O
aVL	O
and	O
DII	O
.	O
CLINICAL	O
EVOLUTION	O
Woman	O
with	O
angina	O
at	O
rest	O
,	O
ECG	O
without	O
repolarisation	O
alterations	O
,	O
ultrasensitive	O
troponin	O
T	O
elevation	O
and	O
apical	O
akinesia	O
.	O
Given	O
the	O
suspicion	O
of	O
tako	O
tsubo	O
syndrome	O
versus	O
previous	O
high	O
risk	O
NSTEACS	O
,	O
it	O
was	O
decided	O
to	O
admit	O
her	O
to	O
the	O
coronary	O
unit	O
for	O
monitoring	O
and	O
clinical	O
surveillance	O
.	O
Pending	O
invasive	O
coronary	O
angiography	O
,	O
treatment	O
was	O
started	O
with	O
double	O
antiplatelet	O
therapy	O
and	O
anticoagulation	O
with	O
enoxaparin	B-FARMACO
INR	O
below	O
2	O
.	O
During	O
the	O
first	O
24	O
hours	O
the	O
patient	O
remained	O
asymptomatic	O
,	O
without	O
new	O
episodes	O
of	O
pain	O
,	O
haemodynamically	O
and	O
respiratory	O
stable	O
,	O
with	O
no	O
arrhythmic	O
events	O
on	O
telemetry	O
.	O
Given	O
her	O
clinical	O
stability	O
,	O
it	O
was	O
decided	O
to	O
transfer	O
her	O
to	O
the	O
hospital	O
ward	O
with	O
telemetry	O
the	O
day	O
after	O
her	O
admission	O
,	O
pending	O
catheterisation	O
.	O
However	O
,	O
a	O
few	O
hours	O
after	O
his	O
admission	O
to	O
the	O
ward	O
,	O
he	O
started	O
again	O
with	O
chest	O
pain	O
of	O
similar	O
characteristics	O
to	O
the	O
previous	O
one	O
,	O
this	O
time	O
presenting	O
ST	O
segment	O
elevation	O
from	O
V3	O
to	O
V5	O
,	O
so	O
emergent	O
catheterisation	O
was	O
performed	O
.	O
The	O
catheterisation	O
showed	O
spontaneous	O
dissection	O
at	O
the	O
level	O
of	O
the	O
distal	O
LAD	O
,	O
with	O
very	O
distal	O
occlusion	O
that	O
was	O
not	O
considered	O
susceptible	O
to	O
percutaneous	O
treatment	O
,	O
and	O
it	O
was	O
decided	O
to	O
implant	O
an	O
intra	O
aortic	O
balloon	O
counterpulsation	O
device	O
to	O
improve	O
coronary	O
perfusion	O
.	O
The	O
patient	O
was	O
readmitted	O
to	O
the	O
coronary	O
unit	O
,	O
maintaining	O
the	O
previously	O
established	O
treatment	O
with	O
double	O
antiplatelet	O
therapy	O
clopidogrel	B-FARMACO
ASA	I-FARMACO
and	O
anticoagulation	O
with	O
enoxaparin	B-FARMACO
.	O
While	O
stable	O
,	O
12	O
hours	O
after	O
the	O
catheterisation	O
,	O
she	O
suddenly	O
began	O
to	O
feel	O
unwell	O
,	O
with	O
sinus	O
tachycardia	O
and	O
hypotension	O
up	O
to	O
50	O
30	O
mmHg	O
,	O
with	O
rapid	O
worsening	O
and	O
deterioration	O
of	O
the	O
level	O
of	O
consciousness	O
.	O
Echocardioscopy	O
showed	O
severe	O
hyperechogenic	O
pericardial	O
effusion	O
not	O
previously	O
present	O
,	O
with	O
involvement	O
of	O
the	O
right	O
chambers	O
.	O
Suspicion	O
of	O
cardiac	O
tamponade	O
secondary	O
to	O
cardiac	O
rupture	O
led	O
to	O
orotracheal	O
intubation	O
,	O
emergency	O
pericardiocentesis	O
with	O
scant	O
haemorrhagic	O
fluid	O
output	O
,	O
and	O
the	O
cardiac	O
surgery	O
team	O
was	O
notified	O
for	O
emergency	O
surgery	O
.	O
Noradrenaline	B-FARMACO
perfusion	O
is	O
started	O
at	O
increasing	O
doses	O
,	O
intensive	O
serum	O
therapy	O
and	O
several	O
red	O
blood	O
cell	O
concentrates	O
are	O
transfused	O
.	O
On	O
arrival	O
of	O
the	O
cardiac	O
surgeons	O
,	O
an	O
urgent	O
sternotomy	O
was	O
performed	O
in	O
the	O
coronary	O
unit	O
box	O
with	O
extraction	O
of	O
abundant	O
clots	O
and	O
visualisation	O
of	O
active	O
bleeding	O
in	O
the	O
apical	O
infarcted	O
region	O
,	O
making	O
it	O
difficult	O
to	O
contain	O
the	O
bleeding	O
.	O
He	O
presented	O
with	O
brief	O
CRA	O
due	O
to	O
AESP	O
which	O
returned	O
after	O
direct	O
cardiac	O
massage	O
and	O
digital	O
tamponade	O
of	O
the	O
bleeding	O
point	O
.	O
After	O
obtaining	O
systolic	O
blood	O
pressure	O
SBP	O
figures	O
of	O
around	O
70	O
100	O
mmHg	O
,	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
cardiac	O
surgery	O
operating	O
theatre	O
and	O
the	O
apical	O
defect	O
was	O
repaired	O
with	O
direct	O
suture	O
and	O
BioGlue	O
,	O
which	O
proved	O
difficult	O
due	O
to	O
the	O
extensive	O
friable	O
area	O
,	O
with	O
the	O
need	O
for	O
resternotomy	O
after	O
further	O
bleeding	O
on	O
the	O
first	O
attempt	O
to	O
transfer	O
him	O
to	O
the	O
coronary	O
unit	O
.	O
After	O
surgery	O
,	O
she	O
was	O
admitted	O
to	O
the	O
coronary	O
unit	O
sedated	O
,	O
well	O
adapted	O
to	O
the	O
ventilator	O
in	O
"	O
Pressure	O
Controlled	O
Volume	O
"	O
mode	O
with	O
standard	O
parameters	O
,	O
with	O
continuous	O
perfusion	O
of	O
dobutamine	B-FARMACO
,	O
noradrenaline	B-FARMACO
and	O
adrenaline	B-FARMACO
for	O
mean	O
arterial	O
pressure	O
MAP	O
of	O
100	O
mmHg	O
,	O
with	O
1	O
1	O
balloon	O
counterpulsation	O
.	O
In	O
the	O
days	O
following	O
this	O
event	O
,	O
she	O
remained	O
sedated	O
and	O
intubated	O
,	O
requiring	O
inotropic	O
and	O
vasoactive	O
drugs	O
,	O
although	O
progressively	O
at	O
lower	O
doses	O
.	O
Persistent	O
anuria	O
,	O
so	O
on	O
the	O
third	O
day	O
of	O
admission	O
she	O
consulted	O
the	O
nephrology	O
department	O
,	O
which	O
started	O
haemofiltration	O
.	O
On	O
the	O
fourth	O
day	O
and	O
again	O
suddenly	O
,	O
he	O
presented	O
a	O
new	O
episode	O
of	O
severe	O
hypotension	O
up	O
to	O
40	O
50	O
mmHg	O
with	O
500	O
ml	O
of	O
rapid	O
haematic	O
output	O
in	O
the	O
thoracic	O
drainage	O
tubes	O
.	O
Echocardioscopy	O
was	O
performed	O
and	O
showed	O
cardiac	O
tamponade	O
secondary	O
to	O
effusion	O
and	O
the	O
presence	O
of	O
clots	O
in	O
the	O
right	O
chambers	O
.	O
In	O
view	O
of	O
the	O
findings	O
,	O
cardiac	O
surgery	O
was	O
immediately	O
notified	O
and	O
the	O
sternotomy	O
was	O
opened	O
in	O
the	O
same	O
room	O
,	O
extracting	O
abundant	O
clots	O
from	O
the	O
pericardial	O
sac	O
,	O
again	O
visualising	O
apical	O
tearing	O
with	O
abundant	O
active	O
bleeding	O
.	O
They	O
proceeded	O
to	O
perform	O
multiple	O
stitches	O
with	O
Teflon	O
support	O
.	O
During	O
the	O
procedure	O
,	O
he	O
presented	O
severe	O
arterial	O
hypotension	O
requiring	O
high	O
doses	O
of	O
catecholamines	O
noradrenaline	B-FARMACO
and	O
adrenaline	B-FARMACO
,	O
as	O
well	O
as	O
repeated	O
boluses	O
of	O
phenylephrine	B-FARMACO
.	O
Sternotomy	O
was	O
left	O
open	O
with	O
a	O
Bogot	O
bag	O
until	O
48	O
hours	O
later	O
,	O
when	O
sternal	O
closure	O
was	O
performed	O
as	O
scheduled	O
,	O
which	O
passed	O
without	O
incident	O
.	O
The	O
patient	O
was	O
subsequently	O
admitted	O
to	O
the	O
coronary	O
unit	O
for	O
a	O
further	O
21	O
days	O
,	O
with	O
a	O
slow	O
but	O
favourable	O
clinical	O
evolution	O
.	O
In	O
the	O
control	O
echocardiogram	O
prior	O
to	O
discharge	O
to	O
the	O
ward	O
,	O
a	O
progressive	O
improvement	O
in	O
biventricular	O
function	O
was	O
observed	O
,	O
with	O
LVEF	O
of	O
48	O
,	O
due	O
to	O
the	O
presence	O
of	O
a	O
patch	O
in	O
the	O
apex	O
,	O
drawing	O
attention	O
to	O
the	O
existence	O
of	O
a	O
1	O
cm	O
pseudoaneurysm	O
in	O
the	O
junctions	O
of	O
the	O
middle	O
segment	O
with	O
the	O
apical	O
segment	O
of	O
the	O
inferior	O
face	O
.	O
After	O
improvement	O
in	O
renal	O
function	O
,	O
a	O
CT	O
angiography	O
of	O
the	O
coronary	O
arteries	O
was	O
requested	O
on	O
the	O
ward	O
,	O
showing	O
an	O
aneurysm	O
and	O
apical	O
and	O
lower	O
apical	O
polylobulated	O
pseudoaneurysm	O
.	O
After	O
discussing	O
the	O
case	O
with	O
cardiac	O
surgery	O
,	O
given	O
the	O
high	O
risk	O
of	O
reoperation	O
,	O
conservative	O
medical	O
treatment	O
was	O
decided	O
.	O
After	O
a	O
total	O
of	O
74	O
days	O
in	O
hospital	O
,	O
the	O
patient	O
was	O
discharged	O
home	O
with	O
haemodialysis	O
sessions	O
scheduled	O
every	O
other	O
day	O
,	O
and	O
is	O
currently	O
progressively	O
recovering	O
renal	O
function	O
,	O
asymptomatic	O
from	O
the	O
cardiological	O
point	O
of	O
view	O
,	O
pending	O
an	O
outpatient	O
echocardiogram	O
.	O
Medication	O
at	O
discharge	O
omeprazole	B-FARMACO
20	O
mg	O
at	O
breakfast	O
,	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
100	O
mg	O
at	O
lunch	O
,	O
enoxaparin	B-FARMACO
40	O
mg	O
intra	O
dialysis	O
circuit	O
on	O
Tuesdays	O
,	O
Thursdays	O
and	O
Sundays	O
and	O
subcutaneous	O
the	O
rest	O
of	O
the	O
days	O
,	O
carvedilol	B-FARMACO
6	O
.	O
25	O
mg	O
1	O
every	O
12	O
hours	O
,	O
atorvastatin	B-FARMACO
20	O
mg	O
at	O
dinner	O
.	O
DIAGNOSIS	O
Main	O
diagnosis	O
Killip	O
I	O
anterior	O
STEMI	O
.	O
Spontaneous	O
distal	O
LAD	O
dissection	O
with	O
distal	O
vessel	O
occlusion	O
,	O
not	O
amenable	O
to	O
coronary	O
intervention	O
.	O
CRA	O
by	O
pulseless	O
electrical	O
activity	O
PEA	O
in	O
the	O
context	O
of	O
cardiac	O
tamponade	O
due	O
to	O
rupture	O
of	O
the	O
free	O
wall	O
of	O
the	O
left	O
ventricle	O
,	O
on	O
two	O
occasions	O
.	O
Secondary	O
diagnoses	O
Pseudonaneurysm	O
and	O
apical	O
and	O
lower	O
apical	O
polylobulated	O
aneurysm	O
.	O
Slightly	O
depressed	O
LVEF	O
.	O
Severe	O
acute	O
renal	O
failure	O
on	O
haemodialysis	O
.	O
Polytransfusion	O
.	O
Permanent	O
anticoagulated	O
atrial	O
fibrillation	O
.	O
Arterial	O
hypertension	O
.	O
Dyslipidaemia	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
50	O
year	O
old	O
male	O
,	O
no	O
known	O
drug	O
allergies	O
.	O
No	O
toxic	O
habits	O
.	O
No	O
cardiovascular	O
risk	O
factors	O
.	O
No	O
relevant	O
family	O
history	O
.	O
No	O
medical	O
or	O
surgical	O
history	O
.	O
No	O
chronic	O
treatments	O
.	O
First	O
consultation	O
Referred	O
to	O
cardiology	O
consultation	O
from	O
the	O
emergency	O
department	O
.	O
He	O
had	O
consulted	O
for	O
an	O
episode	O
of	O
palpitations	O
and	O
supraventricular	O
tachycardia	O
SVT	O
was	O
identified	O
,	O
which	O
slowed	O
with	O
vagal	O
manoeuvres	O
but	O
was	O
reversed	O
with	O
IV	O
atenolol	B-FARMACO
.	O
Physical	O
examination	O
was	O
unaltered	O
.	O
At	O
the	O
consultation	O
,	O
the	O
diagnosis	O
of	O
paroxysmal	O
supraventricular	O
tachycardia	O
was	O
established	O
and	O
it	O
was	O
decided	O
to	O
start	O
treatment	O
with	O
beta	O
blockers	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
at	O
breakfast	O
,	O
request	O
24	O
hour	O
Holter	O
and	O
transthoracic	O
echocardiography	O
TTE	O
.	O
Second	O
consultation	O
at	O
5	O
months	O
In	O
the	O
time	O
between	O
consultations	O
,	O
he	O
attended	O
the	O
emergency	O
department	O
three	O
times	O
for	O
palpitations	O
related	O
to	O
SVT	O
episodes	O
that	O
sometimes	O
reverted	O
with	O
vagal	O
manoeuvres	O
.	O
Several	O
medication	O
changes	O
due	O
to	O
intolerance	O
or	O
ineffectiveness	O
.	O
At	O
the	O
time	O
of	O
the	O
second	O
assessment	O
she	O
was	O
on	O
atenolol	B-FARMACO
50	O
mg	O
c	O
24	O
hours	O
.	O
Prior	O
to	O
the	O
consultation	O
,	O
a	O
TTE	O
was	O
performed	O
which	O
showed	O
dilatation	O
of	O
the	O
right	O
chambers	O
with	O
normal	O
RV	O
systolic	O
function	O
and	O
PSAP	O
26	O
PVC	O
.	O
An	O
agitated	O
saline	O
test	O
was	O
performed	O
with	O
no	O
evidence	O
of	O
bubble	O
passage	O
between	O
cavities	O
,	O
which	O
was	O
interpreted	O
as	O
an	O
improbable	O
sign	O
of	O
shunt	O
.	O
24	O
hour	O
Holter	O
in	O
sinus	O
rhythm	O
with	O
adequate	O
heart	O
rate	O
HR	O
and	O
one	O
episode	O
of	O
non	O
sustained	O
SVT	O
30	O
seconds	O
.	O
Given	O
the	O
frequency	O
of	O
tachyarrhythmic	O
episodes	O
,	O
the	O
patient	O
was	O
referred	O
to	O
the	O
electrophysiology	O
department	O
for	O
evaluation	O
of	O
ablation	O
.	O
In	O
view	O
of	O
the	O
echocardiographic	O
findings	O
,	O
cardiac	O
magnetic	O
resonance	O
imaging	O
MRI	O
was	O
requested	O
in	O
order	O
to	O
try	O
to	O
identify	O
the	O
aetiology	O
of	O
the	O
dilatation	O
of	O
the	O
right	O
chambers	O
.	O
Electrophysiology	O
consultation	O
It	O
was	O
decided	O
to	O
request	O
an	O
electrophysiological	O
study	O
and	O
ablation	O
in	O
the	O
face	O
of	O
symptomatic	O
and	O
recurrent	O
TPSV	O
of	O
one	O
year	O
's	O
evolution	O
,	O
despite	O
beta	B-FARMACO
blockers	I-FARMACO
and	O
which	O
were	O
suppressed	O
by	O
vagal	O
manoeuvres	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
in	O
the	O
emergency	O
department	O
supraventricular	O
rhythm	O
at	O
120	O
bpm	O
,	O
one	O
sinus	O
beat	O
and	O
in	O
the	O
rest	O
with	O
variable	O
RP	O
PR	O
intervals	O
and	O
RP	O
70ms	O
.	O
Narrow	O
QRS	O
with	O
60o	O
axis	O
.	O
ST	O
segment	O
depression	O
of	O
1mm	O
from	O
V3	O
V5	O
.	O
Baseline	O
ECG	O
sinus	O
rhythm	O
.	O
No	O
data	O
of	O
pre	O
excitation	O
.	O
No	O
other	O
specific	O
alterations	O
.	O
CBC	O
glucose	O
108	O
mg	O
dl	O
,	O
urea	O
48	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
86	O
mg	O
dl	O
,	O
sodium	O
137	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
2	O
mEq	O
l	O
,	O
TSH	O
1	O
.	O
83	O
mU	O
l	O
,	O
haemoglobin	O
16	O
.	O
6	O
g	O
dl	O
,	O
leucocytes	O
9250	O
microL	O
,	O
platelets	O
331000	O
microL	O
.	O
24	O
hour	O
Holter	O
24	O
hour	O
electrocardiographic	O
recording	O
.	O
Sinus	O
rhythm	O
throughout	O
the	O
tracing	O
,	O
mean	O
HR	O
85	O
bpm	O
.	O
No	O
significant	O
block	O
or	O
pauses	O
.	O
Streak	O
of	O
non	O
sustained	O
supraventricular	O
tachycardia	O
.	O
TTE	O
right	O
ventricular	O
dilatation	O
RV	O
LV	O
ratio	O
1	O
.	O
1	O
,	O
baseline	O
DTD	O
55	O
mm	O
and	O
RV	O
outflow	O
tract	O
43	O
mm	O
,	O
with	O
preserved	O
systolic	O
function	O
.	O
Mild	O
functional	O
tricuspid	O
regurgitation	O
.	O
Estimated	O
PSAP	O
of	O
26	O
mmHg	O
PVC	O
.	O
Non	O
dilated	O
left	O
ventricle	O
with	O
normal	O
wall	O
thickness	O
.	O
Preserved	O
systolic	O
function	O
.	O
Prolonged	O
relaxation	O
.	O
No	O
significant	O
valvulopathies	O
.	O
TTE	O
with	O
agitated	O
saline	O
injection	O
of	O
agitated	O
saline	O
without	O
bubbles	O
passing	O
into	O
the	O
left	O
cavities	O
either	O
at	O
baseline	O
or	O
after	O
the	O
Valsalva	O
manoeuvre	O
.	O
The	O
existence	O
of	O
intra	O
or	O
extracardiac	O
shunt	O
is	O
unlikely	O
.	O
MRI	O
of	O
the	O
heart	O
Conclusion	O
LV	O
of	O
normal	O
size	O
and	O
systolic	O
function	O
.	O
No	O
areas	O
of	O
hypertrophy	O
,	O
no	O
compaction	O
or	O
late	O
enhancement	O
.	O
Dilated	O
RV	O
with	O
normal	O
systolic	O
function	O
.	O
Extracardiac	O
left	O
right	O
shunt	O
due	O
to	O
anomalous	O
venous	O
drainage	O
from	O
the	O
right	O
superior	O
pulmonary	O
vein	O
to	O
the	O
superior	O
vena	O
cava	O
with	O
Qp	O
Qs	O
of	O
1	O
.	O
7	O
.	O
Most	O
relevant	O
data	O
RV	O
dilated	O
,	O
without	O
morphological	O
alterations	O
,	O
with	O
VTD	O
of	O
125	O
ml	O
m2	O
range	O
55	O
105	O
ml	O
m2	O
and	O
STV	O
of	O
51	O
ml	O
m2	O
range	O
15	O
43	O
ml	O
m2	O
.	O
EF	O
59	O
,	O
cardiac	O
output	O
7	O
.	O
9	O
l	O
min	O
and	O
stroke	O
volume	O
beat	O
149	O
ml	O
.	O
Normal	O
contractility	O
.	O
Anomalous	O
venous	O
drainage	O
from	O
the	O
right	O
superior	O
pulmonary	O
vein	O
to	O
the	O
superior	O
vena	O
cava	O
.	O
LA	O
area	O
21	O
cm2	O
,	O
slightly	O
dilated	O
.	O
RA	O
area	O
of	O
29	O
cm2	O
,	O
slightly	O
dilated	O
.	O
Flow	O
quantification	O
in	O
aortic	O
root	O
phase	O
contrast	O
velocity	O
coding	O
.	O
Anterograde	O
volume	O
80	O
ml	O
and	O
retrograde	O
volume	O
4	O
.	O
7	O
ml	O
.	O
Regurgitation	O
fraction	O
5	O
.	O
9	O
.	O
Quantification	O
of	O
flow	O
in	O
main	O
pulmonary	O
artery	O
phase	O
contrast	O
velocity	O
coding	O
.	O
Anterograde	O
volume	O
139	O
ml	O
and	O
retrograde	O
volume	O
4	O
ml	O
.	O
Regurgitation	O
fraction	O
3	O
.	O
Qp	O
Qs	O
1	O
.	O
7	O
.	O
CLINICAL	O
EVOLUTION	O
In	O
the	O
time	O
until	O
the	O
next	O
consultation	O
,	O
an	O
electrophysiological	O
study	O
was	O
carried	O
out	O
with	O
the	O
finding	O
of	O
focal	O
atrial	O
tachycardia	O
,	O
with	O
greater	O
precocities	O
at	O
the	O
level	O
of	O
the	O
superior	O
vena	O
cava	O
to	O
the	O
RA	O
.	O
Radiofrequency	O
ablation	O
of	O
the	O
focus	O
was	O
performed	O
and	O
proved	O
effective	O
.	O
As	O
can	O
be	O
seen	O
in	O
the	O
results	O
of	O
the	O
cardiac	O
MRI	O
,	O
an	O
anomalous	O
pulmonary	O
venous	O
connection	O
APVC	O
was	O
found	O
due	O
to	O
drainage	O
of	O
the	O
right	O
superior	O
pulmonary	O
vein	O
to	O
the	O
superior	O
vena	O
cava	O
,	O
which	O
caused	O
a	O
volume	O
overload	O
of	O
the	O
right	O
cavities	O
that	O
explained	O
the	O
dilatation	O
,	O
with	O
a	O
significant	O
left	O
right	O
conshunt	O
Qp	O
Qs	O
1	O
.	O
7	O
.	O
No	O
evidence	O
of	O
other	O
associated	O
defects	O
.	O
After	O
ablation	O
,	O
the	O
episodes	O
of	O
supraventricular	O
tachycardia	O
ceased	O
and	O
the	O
patient	O
was	O
in	O
very	O
good	O
functional	O
class	O
.	O
At	O
this	O
time	O
,	O
according	O
to	O
the	O
adult	O
congenital	O
heart	O
disease	O
guidelines	O
AHA	O
ACC	O
2018	O
,	O
we	O
find	O
that	O
surgical	O
repair	O
in	O
our	O
patient	O
has	O
a	O
grade	O
IIA	O
recommendation	O
"	O
surgery	O
may	O
be	O
useful	O
for	O
partial	O
anomalous	O
connections	O
of	O
both	O
left	O
and	O
right	O
pulmonary	O
veins	O
,	O
in	O
asymptomatic	O
adults	O
with	O
RV	O
volume	O
overload	O
,	O
left	O
right	O
shunt	O
large	O
enough	O
to	O
cause	O
physiological	O
sequelae	O
e	O
.	O
g	O
.	O
,	O
QP	O
QS	O
or	O
1	O
.	O
7	O
,	O
and	O
in	O
those	O
with	O
a	O
left	O
right	O
shunt	O
large	O
enough	O
to	O
cause	O
physiological	O
sequelae	O
e	O
.	O
g	O
.	O
,	O
QP	O
QS	O
or	O
1	O
.	O
7	O
,	O
and	O
in	O
those	O
with	O
a	O
left	O
right	O
shunt	O
large	O
enough	O
to	O
cause	O
physiological	O
sequelae	O
e	O
.	O
g	O
.	O
,	O
QP	O
QS	O
or	O
1	O
.	O
7	O
"	O
.	O
QP	O
QS	O
or	O
1	O
.	O
5	O
,	O
in	O
the	O
presence	O
of	O
pulmonary	O
pressures	O
that	O
are	O
50	O
lower	O
than	O
systemic	O
pressures	O
and	O
pulmonary	O
resistances	O
less	O
than	O
one	O
third	O
of	O
systemic	O
pressures	O
"	O
.	O
It	O
was	O
decided	O
to	O
refer	O
the	O
patient	O
to	O
the	O
adult	O
congenital	O
heart	O
disease	O
clinic	O
where	O
the	O
need	O
to	O
request	O
a	O
right	O
heart	O
catheterisation	O
to	O
complete	O
the	O
haemodynamic	O
study	O
will	O
be	O
assessed	O
before	O
referring	O
to	O
cardiac	O
surgery	O
for	O
repair	O
.	O
DIAGNOSIS	O
Anomalous	O
pulmonary	O
venous	O
connection	O
drainage	O
from	O
right	O
superior	O
pulmonary	O
vein	O
to	O
superior	O
vena	O
cava	O
.	O
Significant	O
left	O
right	O
shunt	O
with	O
right	O
ventricular	O
volume	O
overload	O
.	O
Normal	O
RV	O
systolic	O
function	O
.	O
Focal	O
atrial	O
tachycardia	O
.	O
Radiofrequency	O
ablation	O
effective	O
.	O

HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
A	O
59	O
year	O
old	O
man	O
,	O
hypertensive	O
and	O
hypercholesterolemic	O
,	O
with	O
a	O
history	O
of	O
Bentall	O
surgery	O
with	O
implantation	O
of	O
a	O
mechanical	O
aortic	O
prosthesis	O
and	O
a	O
valved	O
tube	O
,	O
as	O
well	O
as	O
coronary	O
revascularisation	O
in	O
the	O
same	O
procedure	O
by	O
means	O
of	O
a	O
bypass	O
of	O
the	O
left	O
internal	O
mammary	O
artery	O
to	O
the	O
anterior	O
descending	O
artery	O
,	O
in	O
its	O
middle	O
segment	O
.	O
This	O
intervention	O
took	O
place	O
4	O
years	O
ago	O
.	O
She	O
has	O
no	O
other	O
personal	O
history	O
of	O
interest	O
.	O
On	O
treatment	O
with	O
acenocoumarol	B-FARMACO
,	O
atorvastatin	B-FARMACO
40	O
mg	O
day	O
,	O
enalapril	B-FARMACO
10	O
mg	O
day	O
and	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
day	O
.	O
At	O
the	O
present	O
time	O
,	O
she	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
fever	O
,	O
shivering	O
and	O
marked	O
asthenia	O
of	O
24	O
hours	O
'	O
evolution	O
,	O
with	O
no	O
other	O
associated	O
clinical	O
manifestations	O
or	O
epidemiological	O
history	O
of	O
interest	O
.	O
On	O
arrival	O
,	O
he	O
presented	O
with	O
fever	O
temperature	O
39	O
C	O
and	O
hypotension	O
BP	O
85	O
45	O
mmHg	O
,	O
as	O
well	O
as	O
sinus	O
tachycardia	O
110	O
bpm	O
.	O
SatO2	O
90	O
on	O
room	O
air	O
.	O
Poor	O
peripheral	O
perfusion	O
with	O
coldness	O
of	O
acral	O
parts	O
.	O
High	O
jugular	O
venous	O
pressure	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
prosthetic	O
sounds	O
.	O
Pulmonary	O
auscultation	O
crackles	O
in	O
both	O
bases	O
.	O
Lower	O
extremities	O
without	O
oedema	O
.	O
The	O
initial	O
examinations	O
and	O
complementary	O
tests	O
revealed	O
a	O
situation	O
of	O
hyperlactacidemic	O
metabolic	O
acidosis	O
,	O
which	O
appeared	O
serious	O
,	O
with	O
haemoglobin	O
levels	O
of	O
12	O
.	O
7	O
g	O
dl	O
and	O
leukocytes	O
of	O
11	O
,	O
500	O
with	O
neutrophilia	O
80	O
,	O
and	O
blood	O
cultures	O
were	O
taken	O
a	O
few	O
minutes	O
after	O
arrival	O
.	O
In	O
this	O
context	O
,	O
volume	O
expansion	O
,	O
empirical	O
antibiotic	O
therapy	O
with	O
cloxacillin	B-FARMACO
,	O
ampicillin	B-FARMACO
and	O
gentamicin	B-FARMACO
was	O
started	O
,	O
as	O
well	O
as	O
administration	O
of	O
vasoactive	O
drugs	O
,	O
and	O
he	O
was	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
.	O
Initially	O
,	O
a	O
transesophageal	O
echocardiogram	O
was	O
performed	O
,	O
with	O
no	O
data	O
suggestive	O
of	O
infective	O
endocarditis	O
IE	O
.	O
COMPLEMENTARY	O
TESTS	O
Two	O
days	O
after	O
admission	O
,	O
the	O
patient	O
developed	O
marked	O
right	O
hemiparesis	O
,	O
and	O
an	O
emergency	O
CT	O
scan	O
and	O
cranial	O
MRI	O
scan	O
were	O
performed	O
,	O
showing	O
the	O
presence	O
of	O
a	O
2	O
x	O
2	O
cm	O
intraparenchymal	O
cerebral	O
haemorrhage	O
at	O
the	O
level	O
of	O
the	O
left	O
prerirolandic	O
cortex	O
,	O
interrupting	O
his	O
anticoagulant	O
treatment	O
prescribed	O
by	O
his	O
mechanical	O
prosthesis	O
.	O
At	O
this	O
point	O
in	O
his	O
evolution	O
,	O
the	O
results	O
of	O
the	O
blood	O
cultures	O
taken	O
were	O
positive	O
for	O
Staphylococcus	O
aureus	O
,	O
and	O
given	O
the	O
high	O
suspicion	O
of	O
infective	O
endocarditis	O
,	O
a	O
cerebral	O
angiography	O
was	O
performed	O
which	O
ruled	O
out	O
the	O
presence	O
of	O
mycotic	O
aneurysms	O
.	O
Given	O
the	O
existence	O
of	O
a	O
transesophageal	O
echocardiogram	O
3	O
days	O
earlier	O
with	O
no	O
signs	O
of	O
endocarditis	O
,	O
a	O
positron	O
emission	O
tomography	O
computed	O
tomography	O
PET	O
CT	O
with	O
18F	O
Fluorodeoxyglucose	O
18F	O
FDG	O
was	O
performed	O
,	O
which	O
revealed	O
abnormal	O
uptake	O
in	O
the	O
aortic	O
valve	O
prosthesis	O
and	O
in	O
the	O
aortic	O
peritubular	O
area	O
.	O
CT	O
reconstruction	O
showed	O
periaortic	O
thickening	O
,	O
with	O
irregular	O
contour	O
and	O
peripheral	O
late	O
enhancement	O
,	O
compatible	O
with	O
the	O
existence	O
of	O
a	O
periaortic	O
abscess	O
.	O
No	O
abnormal	O
uptake	O
of	O
18F	O
FDG	O
was	O
observed	O
in	O
extracardiac	O
locations	O
.	O
At	O
this	O
point	O
,	O
the	O
patient	O
already	O
met	O
the	O
criteria	O
for	O
infective	O
endocarditis	O
1	O
major	O
and	O
3	O
minor	O
criteria	O
due	O
to	O
S	O
.	O
aureus	O
on	O
the	O
prosthetic	O
aortic	O
valve	O
and	O
valved	O
tube	O
.	O
Three	O
days	O
later	O
,	O
a	O
new	O
transesophageal	O
echocardiogram	O
was	O
performed	O
,	O
which	O
documented	O
the	O
presence	O
of	O
a	O
large	O
aortic	O
vegetation	O
of	O
11	O
mm	O
in	O
greatest	O
diameter	O
.	O
At	O
this	O
point	O
,	O
one	O
of	O
the	O
first	O
debates	O
in	O
the	O
patient	O
's	O
evolution	O
arose	O
,	O
with	O
the	O
complex	O
decision	O
to	O
choose	O
the	O
optimal	O
time	O
for	O
surgery	O
,	O
which	O
was	O
postponed	O
due	O
to	O
intracranial	O
bleeding	O
.	O
As	O
for	O
the	O
clinical	O
situation	O
at	O
this	O
time	O
,	O
the	O
patient	O
remained	O
afebrile	O
and	O
progressively	O
experienced	O
an	O
ad	O
integrum	O
recovery	O
of	O
his	O
neurological	O
deficits	O
.	O
18	O
days	O
after	O
his	O
admission	O
,	O
after	O
an	O
apparent	O
good	O
evolution	O
,	O
6	O
days	O
before	O
his	O
scheduled	O
surgery	O
,	O
he	O
presented	O
with	O
sudden	O
abdominal	O
pain	O
,	O
arterial	O
hypotension	O
and	O
a	O
syncopal	O
episode	O
,	O
and	O
an	O
urgent	O
venous	O
blood	O
gas	O
analysis	O
showed	O
acute	O
anaemisation	O
with	O
Hb	O
of	O
6	O
g	O
dl	O
.	O
Intravenous	O
crystalloids	O
and	O
red	O
cell	O
concentrates	O
were	O
administered	O
.	O
An	O
emergency	O
abdominal	O
ultrasound	O
showed	O
the	O
presence	O
of	O
free	O
intra	O
abdominal	O
fluid	O
compatible	O
with	O
haemoperitoneum	O
,	O
and	O
a	O
large	O
splenic	O
haematoma	O
,	O
and	O
he	O
was	O
readmitted	O
to	O
the	O
intensive	O
care	O
unit	O
.	O
Thus	O
,	O
with	O
the	O
diagnosis	O
of	O
acute	O
abdomen	O
,	O
urgent	O
abdominal	O
surgery	O
was	O
performed	O
,	O
which	O
confirmed	O
the	O
diagnosis	O
of	O
haemoperitoneum	O
and	O
acute	O
splenic	O
rupture	O
,	O
making	O
it	O
necessary	O
to	O
proceed	O
with	O
a	O
splenectomy	O
to	O
contain	O
the	O
bleeding	O
,	O
with	O
subsequent	O
anatomopathological	O
analysis	O
confirming	O
the	O
aetiology	O
of	O
the	O
aforementioned	O
splenic	O
rupture	O
as	O
secondary	O
to	O
septic	O
embolism	O
.	O
Five	O
days	O
later	O
,	O
when	O
the	O
patient	O
was	O
once	O
again	O
on	O
the	O
hospital	O
ward	O
,	O
he	O
presented	O
with	O
severe	O
rectorrhagia	O
with	O
anaemia	O
and	O
haemodynamic	O
instability	O
,	O
requiring	O
transfusion	O
of	O
haemoconcentrates	O
.	O
Initially	O
,	O
endoscopic	O
management	O
was	O
performed	O
and	O
a	O
diagnosis	O
was	O
made	O
of	O
stress	O
gastropathy	O
with	O
multiple	O
duodenal	O
ulcers	O
,	O
treated	O
by	O
implantation	O
of	O
haemoclips	O
.	O
Despite	O
all	O
this	O
,	O
the	O
bleeding	O
recurred	O
on	O
two	O
occasions	O
,	O
so	O
that	O
emergency	O
surgery	O
was	O
finally	O
necessary	O
,	O
and	O
a	O
partial	O
duodenectomy	O
was	O
performed	O
,	O
removing	O
the	O
affected	O
segment	O
.	O
CLINICAL	O
EVOLUTION	O
Finally	O
,	O
one	O
month	O
after	O
the	O
initial	O
admission	O
,	O
his	O
cardiac	O
surgery	O
for	O
infective	O
endocarditis	O
was	O
performed	O
and	O
the	O
infected	O
material	O
was	O
replaced	O
by	O
a	O
new	O
mechanical	O
aortic	O
prosthesis	O
and	O
a	O
valved	O
tube	O
.	O
S	O
.	O
aureus	O
growth	O
was	O
confirmed	O
in	O
the	O
removed	O
prosthetic	O
material	O
.	O
On	O
the	O
fifth	O
day	O
post	O
surgery	O
,	O
the	O
patient	O
presented	O
with	O
dizziness	O
and	O
severe	O
arterial	O
hypotension	O
and	O
tachycardia	O
,	O
and	O
a	O
transthoracic	O
echocardiogram	O
confirmed	O
the	O
diagnosis	O
of	O
cardiac	O
tamponade	O
,	O
and	O
he	O
underwent	O
urgent	O
pericardiectomy	O
,	O
with	O
an	O
apparent	O
good	O
result	O
.	O
After	O
his	O
return	O
to	O
the	O
hospital	O
ward	O
,	O
a	O
control	O
echocardiogram	O
was	O
performed	O
to	O
rule	O
out	O
further	O
complications	O
,	O
which	O
revealed	O
the	O
presence	O
of	O
a	O
pericardial	O
haematoma	O
measuring	O
6	O
x	O
7	O
x	O
9	O
cm	O
,	O
involving	O
the	O
right	O
atrium	O
,	O
which	O
had	O
to	O
be	O
evacuated	O
again	O
in	O
the	O
operating	O
theatre	O
.	O
Finally	O
,	O
the	O
patient	O
managed	O
to	O
complete	O
the	O
6	O
weeks	O
of	O
antibiotic	O
therapy	O
,	O
without	O
presenting	O
new	O
complications	O
,	O
and	O
was	O
discharged	O
after	O
7	O
weeks	O
of	O
hospitalisation	O
.	O
Currently	O
,	O
2	O
years	O
after	O
his	O
infective	O
endocarditis	O
due	O
to	O
S	O
.	O
aureus	O
,	O
he	O
is	O
asymptomatic	O
from	O
the	O
cardiovascular	O
point	O
of	O
view	O
.	O
DIAGNOSIS	O
Late	O
prosthetic	O
infective	O
endocarditis	O
due	O
to	O
S	O
.	O
aureus	O
.	O
Aortic	O
valve	O
and	O
tube	O
replacement	O
in	O
ascending	O
aorta	O
.	O
Complicated	O
with	O
Intraparenchymal	O
cerebral	O
haemorrhage	O
secondary	O
to	O
septic	O
embolism	O
.	O
Acute	O
abdomen	O
due	O
to	O
splenic	O
rupture	O
due	O
to	O
septic	O
embolism	O
.	O
Upper	O
gastrointestinal	O
bleeding	O
secondary	O
to	O
duodenal	O
stress	O
ulcers	O
.	O
Partial	O
duodenectomy	O
.	O
Post	O
surgical	O
cardiac	O
tamponade	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
51	O
year	O
old	O
male	O
,	O
no	O
known	O
drug	O
allergies	O
to	O
date	O
.	O
Cardiovascular	O
risk	O
factors	O
ex	O
smoker	O
for	O
3	O
years	O
and	O
dyslipidaemia	O
on	O
treatment	O
with	O
atorvastatin	B-FARMACO
40	O
mg	O
24	O
hours	O
.	O
No	O
family	O
history	O
of	O
heart	O
disease	O
or	O
sudden	O
death	O
.	O
No	O
other	O
pathological	O
history	O
of	O
interest	O
.	O
She	O
came	O
to	O
the	O
emergency	O
department	O
the	O
previous	O
night	O
while	O
walking	O
to	O
the	O
toilet	O
,	O
presenting	O
with	O
oppressive	O
central	O
thoracic	O
pain	O
radiating	O
to	O
the	O
left	O
upper	O
limb	O
with	O
accompanying	O
vegetative	O
symptoms	O
that	O
subsided	O
self	O
limited	O
in	O
approximately	O
20	O
minutes	O
.	O
No	O
previous	O
history	O
of	O
syncope	O
,	O
exertional	O
angina	O
or	O
palpitations	O
.	O
Usual	O
NYHA	O
functional	O
class	O
I	O
.	O
Physical	O
examination	O
blood	O
pressure	O
BP	O
120	O
80	O
.	O
Baseline	O
SatO2	O
99	O
.	O
Heart	O
rate	O
HR	O
90	O
bpm	O
.	O
Jugular	O
venous	O
pressure	O
normal	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
,	O
without	O
murmurs	O
or	O
extratonos	O
.	O
Pulmonary	O
auscultation	O
normal	O
ventilation	O
.	O
Lower	O
limbs	O
no	O
oedema	O
,	O
no	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
Palpable	O
and	O
symmetrical	O
distal	O
pulses	O
.	O
COMPLEMENTARY	O
TESTS	O
Blood	O
tests	O
creatinine	O
0	O
.	O
74	O
mg	O
dl	O
,	O
urea	O
43	O
mg	O
dl	O
,	O
total	O
cholesterol	O
207	O
mg	O
dl	O
,	O
LDL	O
128	O
mg	O
dl	O
,	O
triglycerides	O
182	O
mg	O
dl	O
,	O
Na	O
138	O
mEq	O
l	O
,	O
potassium	O
5	O
mEq	O
l	O
,	O
troponin	O
I	O
US	O
15	O
40	O
ng	O
l	O
normal	O
0	O
19	O
.	O
8	O
,	O
Hb1AC	O
5	O
.	O
5	O
,	O
haemoglobin	O
16	O
.	O
4	O
g	O
dl	O
,	O
leukocytes	O
7	O
,	O
500	O
mm3	O
,	O
platelets	O
201	O
,	O
000	O
mm3	O
.	O
Basic	O
coagulation	O
without	O
alterations	O
.	O
Chest	O
X	O
ray	O
normal	O
cardiothoracic	O
index	O
.	O
No	O
pleuroparenchymal	O
alterations	O
.	O
Electrocardiogram	O
ECG	O
sinus	O
rhythm	O
with	O
rectified	O
ST	O
segment	O
in	O
lateral	O
leads	O
.	O
No	O
dynamic	O
changes	O
in	O
successive	O
ECGs	O
.	O
Transthoracic	O
echocardiogram	O
left	O
ventricle	O
of	O
normal	O
size	O
and	O
systolic	O
function	O
EF	O
estimated	O
by	O
Simpson	O
biplane	O
65	O
,	O
without	O
segmental	O
alterations	O
of	O
contractility	O
.	O
Normal	O
wall	O
thickness	O
.	O
Altered	O
relaxation	O
pattern	O
.	O
Trivalve	O
aortic	O
valve	O
with	O
thin	O
leaflets	O
,	O
competent	O
.	O
Mitral	O
valve	O
with	O
thin	O
leaflets	O
,	O
without	O
restriction	O
to	O
its	O
opening	O
,	O
with	O
central	O
trivial	O
reflux	O
.	O
Right	O
ventricle	O
not	O
dilated	O
,	O
with	O
normal	O
systolic	O
function	O
TAPSE	O
20	O
mm	O
.	O
Tricuspid	O
valve	O
with	O
thin	O
leaflets	O
,	O
minimal	O
insufficiency	O
that	O
prevents	O
estimation	O
of	O
PAPs	O
.	O
Inferior	O
vena	O
cava	O
IVC	O
not	O
dilated	O
with	O
preserved	O
inspiratory	O
collapse	O
.	O
Aortic	O
root	O
and	O
ascending	O
thoracic	O
aorta	O
visualised	O
as	O
normal	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
or	O
intracavitary	O
masses	O
by	O
this	O
technique	O
.	O
Cardiac	O
catheterisation	O
left	O
coronary	O
artery	O
LMCA	O
no	O
lesions	O
.	O
Anterior	O
descending	O
LAD	O
no	O
angiographically	O
significant	O
lesions	O
.	O
Sign	O
of	O
non	O
perfused	O
myocardium	O
,	O
with	O
avascular	O
area	O
in	O
the	O
posterolateral	O
area	O
of	O
the	O
left	O
ventricle	O
.	O
Circumflex	O
Cx	O
anomalous	O
origin	O
of	O
its	O
origin	O
from	O
the	O
right	O
coronary	O
sinus	O
adjacent	O
to	O
the	O
DC	O
ostium	O
,	O
with	O
retroaortic	O
trajectory	O
.	O
Subocclusive	O
artery	O
from	O
its	O
origin	O
that	O
receives	O
collateral	O
circulation	O
to	O
the	O
marginal	O
branch	O
from	O
the	O
CD	O
artery	O
.	O
Right	O
coronary	O
RCA	O
dominant	O
.	O
Diffuse	O
atheromatosis	O
with	O
two	O
moderate	O
tandem	O
lesions	O
in	O
distal	O
RCA	O
.	O
The	O
posterior	O
descending	O
PD	O
artery	O
presents	O
angiographically	O
moderate	O
lesion	O
at	O
the	O
ostium	O
level	O
and	O
significant	O
at	O
the	O
medial	O
level	O
.	O
Percutaneous	O
coronary	O
interventionism	O
PCI	O
was	O
performed	O
on	O
Cx	O
multipurpose	O
catheter	O
and	O
hydrophilic	O
guide	O
.	O
Predilatation	O
with	O
conventional	O
2	O
x	O
20	O
mm	O
balloon	O
.	O
Implantation	O
of	O
two	O
overlapping	O
drug	O
eluting	O
stents	O
,	O
everolimus	B-FARMACO
eluting	O
,	O
2	O
.	O
25	O
x	O
28	O
and	O
2	O
.	O
25	O
x	O
32	O
mm	O
.	O
Good	O
angiographic	O
result	O
.	O
PD	O
AR2	O
catheter	O
and	O
hydrophilic	O
guidewire	O
.	O
Implantation	O
of	O
a	O
2	O
.	O
75	O
x	O
26	O
mm	O
everolimus	O
eluting	O
drug	O
eluting	O
stent	O
.	O
Good	O
angiographic	O
result	O
.	O
CLINICAL	O
EVOLUTION	O
With	O
the	O
diagnosis	O
of	O
NSTEACS	O
,	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
coronary	O
unit	O
.	O
Anti	O
aggregation	O
treatment	O
was	O
started	O
with	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
and	O
ticagrelor	B-FARMACO
and	O
anticoagulation	O
with	O
fondaparinux	B-FARMACO
.	O
In	O
the	O
first	O
24	O
hours	O
,	O
cardiac	O
catheterisation	O
showed	O
a	O
suboccluded	O
circumflex	O
artery	O
with	O
anomalous	O
origin	O
from	O
the	O
right	O
coronary	O
sinus	O
adjacent	O
to	O
the	O
ostium	O
of	O
the	O
right	O
coronary	O
artery	O
,	O
with	O
a	O
retroaortic	O
trajectory	O
,	O
which	O
received	O
collateral	O
circulation	O
from	O
the	O
right	O
coronary	O
artery	O
.	O
Given	O
the	O
favourable	O
coronary	O
anatomy	O
,	O
two	O
overlapping	O
drug	O
eluting	O
stents	O
were	O
implanted	O
over	O
the	O
circumflex	O
artery	O
and	O
one	O
drug	O
eluting	O
stent	O
over	O
the	O
significant	O
lesion	O
in	O
the	O
posterior	O
descending	O
artery	O
.	O
The	O
patient	O
had	O
a	O
good	O
clinical	O
evolution	O
during	O
his	O
admission	O
,	O
with	O
no	O
heart	O
failure	O
or	O
arrhythmic	O
events	O
.	O
No	O
clinical	O
events	O
occurred	O
after	O
three	O
months	O
of	O
outpatient	O
follow	O
up	O
.	O
DIAGNOSIS	O
Acute	O
coronary	O
syndrome	O
without	O
ST	O
elevation	O
of	O
lateral	O
location	O
.	O
Evolution	O
to	O
non	O
Q	O
AMI	O
.	O
Killip	O
I	O
.	O
Anomalous	O
origin	O
of	O
circumflex	O
coronary	O
artery	O
from	O
right	O
coronary	O
sinus	O
with	O
retroaortic	O
course	O
.	O
Two	O
vessel	O
coronary	O
artery	O
disease	O
circumflex	O
artery	O
suboccluded	O
at	O
the	O
origin	O
,	O
significant	O
stenosis	O
in	O
the	O
posterior	O
descending	O
branch	O
of	O
the	O
right	O
coronary	O
artery	O
.	O
Complete	O
percutaneous	O
revascularisation	O
with	O
drug	O
eluting	O
stents	O
.	O
Preserved	O
left	O
ventricular	O
systolic	O
function	O
.	O

This	O
is	O
a	O
50	O
year	O
old	O
woman	O
with	O
a	O
finding	O
of	O
complete	O
left	O
bundle	O
branch	O
block	O
LBBB	O
and	O
long	O
QT	O
QTc	O
on	O
a	O
routine	O
electrocardiogram	O
ECG	O
.	O
The	O
main	O
diagnostic	O
tests	O
for	O
the	O
complete	O
study	O
of	O
long	O
QT	O
syndrome	O
LQTS	O
were	O
performed	O
and	O
she	O
was	O
diagnosed	O
with	O
LQTS	O
but	O
no	O
underlying	O
genetic	O
mutation	O
was	O
found	O
.	O
HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
Family	O
history	O
No	O
history	O
of	O
heart	O
disease	O
or	O
sudden	O
death	O
.	O
Maternal	O
cousin	O
studied	O
for	O
recurrent	O
syncope	O
.	O
Personal	O
history	O
No	O
known	O
drug	O
allergies	O
Smoker	O
of	O
5	O
cigarettes	O
day	O
8	O
packs	O
year	O
.	O
Non	O
drinker	O
.	O
Arterial	O
hypertension	O
under	O
pharmacological	O
treatment	O
,	O
with	O
good	O
control	O
as	O
usual	O
.	O
No	O
known	O
diabetes	O
mellitus	O
or	O
dyslipidaemia	O
.	O
Admitted	O
for	O
acute	O
bacterial	O
meningitis	O
at	O
the	O
age	O
of	O
20	O
,	O
with	O
no	O
sequelae	O
.	O
Surgical	O
interventions	O
appendectomy	O
.	O
Left	O
inguinal	O
herniaplasty	O
Usual	O
treatment	O
Ramipril	B-FARMACO
5	O
mg	O
per	O
day	O
.	O
Present	O
illness	O
A	O
50	O
year	O
old	O
woman	O
was	O
referred	O
to	O
the	O
cardiology	O
department	O
for	O
routine	O
ECG	O
findings	O
of	O
LBBB	O
.	O
The	O
patient	O
reported	O
being	O
completely	O
asymptomatic	O
,	O
without	O
dyspnoea	O
on	O
exertion	O
,	O
without	O
episodes	O
of	O
chest	O
pain	O
,	O
palpitations	O
or	O
syncope	O
.	O
Physical	O
examination	O
Good	O
general	O
condition	O
.	O
Well	O
hydrated	O
and	O
perfused	O
.	O
Eupneic	O
at	O
rest	O
.	O
SatO2	O
99	O
with	O
FiO2	O
0	O
.	O
21	O
.	O
Blood	O
pressure	O
BP	O
128	O
64	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
63	O
bpm	O
.	O
Neck	O
absence	O
of	O
IY	O
.	O
No	O
palpable	O
lymph	O
nodes	O
.	O
Carotid	O
arteries	O
without	O
murmurs	O
.	O
Cardiac	O
and	O
pulmonary	O
auscultation	O
rhythmic	O
,	O
at	O
a	O
good	O
frequency	O
.	O
No	O
murmurs	O
or	O
audible	O
extratonos	O
.	O
Vesicular	O
murmur	O
preserved	O
,	O
no	O
pathological	O
sounds	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
.	O
Not	O
painful	O
on	O
palpation	O
,	O
no	O
signs	O
of	O
peritonism	O
.	O
No	O
masses	O
or	O
megaliths	O
.	O
Lower	O
limbs	O
no	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
Distal	O
pulses	O
present	O
and	O
symmetrical	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
in	O
consultation	O
sinus	O
bradycardia	O
at	O
57	O
bpm	O
,	O
normal	O
axis	O
,	O
PR	O
120	O
ms	O
,	O
wide	O
QRS	O
130	O
ms	O
with	O
LBBB	O
morphology	O
with	O
secondary	O
repolarisation	O
alterations	O
,	O
QT	O
480ms	O
,	O
QTc	O
470	O
ms	O
.	O
Echocardiogram	O
Cavities	O
and	O
great	O
vessels	O
left	O
ventricle	O
not	O
dilated	O
DTDVI	O
42mm	O
,	O
with	O
slight	O
concentric	O
hypertrophy	O
of	O
its	O
walls	O
SIV	O
12mm	O
,	O
PIL	O
11mm	O
.	O
Non	O
dilated	O
left	O
atrium	O
.	O
Right	O
ventricle	O
of	O
normal	O
dimensions	O
.	O
Normal	O
right	O
atrium	O
.	O
Normal	O
visualisation	O
of	O
the	O
aorta	O
.	O
Valves	O
Trivalve	O
aortic	O
valve	O
with	O
mild	O
degenerative	O
signs	O
and	O
jet	O
of	O
mild	O
insufficiency	O
,	O
with	O
normal	O
anterograde	O
gradients	O
.	O
Mitral	O
valve	O
with	O
normal	O
appearance	O
and	O
function	O
.	O
No	O
tricuspid	O
insufficiency	O
detected	O
.	O
Ventricular	O
function	O
Preserved	O
LV	O
systolic	O
function	O
,	O
estimated	O
at	O
55	O
by	O
Simpson	O
BP	O
.	O
No	O
segmental	O
alterations	O
in	O
contractility	O
were	O
observed	O
,	O
although	O
there	O
was	O
a	O
marked	O
asynchrony	O
of	O
the	O
interventricular	O
septum	O
by	O
LBBB	O
.	O
Diastolic	O
function	O
compatible	O
with	O
impaired	O
relaxation	O
,	O
with	O
no	O
increase	O
in	O
filling	O
pressures	O
.	O
Preserved	O
RV	O
systolic	O
function	O
.	O
Other	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
and	O
with	O
adequate	O
inspiratory	O
collapse	O
.	O
No	O
pericardial	O
effusion	O
.	O
Cardiac	O
single	O
photon	O
emission	O
tomography	O
SPECT	O
negative	O
for	O
myocardial	O
ischaemia	O
.	O
24	O
hour	O
Holter	O
tracing	O
in	O
sinus	O
rhythm	O
with	O
LBBB	O
,	O
with	O
minimum	O
HR	O
49	O
bpm	O
,	O
mean	O
68	O
bpm	O
and	O
maximum	O
115	O
bpm	O
,	O
without	O
significant	O
pauses	O
.	O
QTc	O
minimum	O
391	O
ms	O
,	O
mean	O
461	O
ms	O
and	O
maximum	O
562ms	O
.	O
No	O
T	O
wave	O
alternans	O
or	O
ventricular	O
arrhythmias	O
were	O
observed	O
.	O
Ergometry	O
images	O
2	O
,	O
3	O
and	O
4	O
Baseline	O
HR	O
63	O
bpm	O
.	O
Basal	O
QT	O
480	O
ms	O
.	O
Basal	O
QTc	O
511	O
ms	O
.	O
Maximum	O
HR	O
of	O
138	O
bpm	O
81	O
of	O
maximum	O
HR	O
reached	O
at	O
5	O
20	O
minutes	O
of	O
exercise	O
.	O
Peak	O
exercise	O
QT	O
320	O
ms	O
.	O
Maximal	O
exercise	O
QTc	O
482	O
ms	O
.	O
Presence	O
of	O
isolated	O
ventricular	O
extrasystoles	O
during	O
exercise	O
.	O
In	O
recovery	O
phase	O
5	O
minutes	O
HR	O
74	O
bpm	O
,	O
QT	O
460	O
ms	O
and	O
QTc	O
490	O
ms	O
.	O
No	O
evidence	O
of	O
ischaemic	O
signs	O
throughout	O
the	O
test	O
.	O
Viskin	O
bideptation	O
test	O
.	O
At	O
rest	O
HR	O
60	O
bpm	O
,	O
QT	O
480	O
ms	O
and	O
QTc	O
480	O
ms	O
.	O
After	O
standing	O
HR	O
70	O
bpm	O
,	O
QT	O
500	O
ms	O
,	O
QTc	O
559	O
ms	O
.	O
Genetic	O
test	O
channelopathy	O
panel	O
negative	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
referred	O
by	O
her	O
primary	O
care	O
physician	O
due	O
to	O
a	O
routine	O
ECG	O
finding	O
of	O
LBBB	O
.	O
The	O
ECG	O
at	O
the	O
consultation	O
confirmed	O
this	O
finding	O
together	O
with	O
the	O
presence	O
of	O
secondary	O
repolarisation	O
alterations	O
,	O
a	O
QT	O
of	O
480	O
ms	O
and	O
a	O
QTc	O
of	O
470	O
ms	O
.	O
The	O
patient	O
denied	O
at	O
all	O
times	O
having	O
presented	O
any	O
symptoms	O
,	O
denying	O
syncopal	O
episodes	O
,	O
palpitations	O
or	O
chest	O
pain	O
on	O
exertion	O
.	O
Given	O
the	O
electrical	O
alterations	O
,	O
it	O
was	O
decided	O
to	O
complete	O
the	O
study	O
with	O
an	O
echocardiogram	O
,	O
which	O
showed	O
a	O
left	O
ventricle	O
with	O
mild	O
concentric	O
hypertrophy	O
of	O
its	O
walls	O
with	O
normal	O
function	O
and	O
mild	O
degenerative	O
aortic	O
insufficiency	O
,	O
with	O
the	O
rest	O
of	O
the	O
study	O
compatible	O
with	O
normality	O
.	O
Myocardial	O
SPECT	O
was	O
also	O
requested	O
,	O
which	O
ruled	O
out	O
the	O
presence	O
of	O
ischaemia	O
.	O
To	O
complete	O
the	O
study	O
of	O
the	O
suspected	O
long	O
QT	O
syndrome	O
,	O
the	O
Viskin	O
standing	O
test	O
was	O
performed	O
,	O
which	O
showed	O
a	O
lengthening	O
of	O
the	O
QTc	O
interval	O
,	O
from	O
480	O
ms	O
in	O
the	O
supine	O
position	O
after	O
10	O
minutes	O
of	O
rest	O
to	O
559	O
ms	O
after	O
standing	O
.	O
An	O
ergometry	O
test	O
was	O
also	O
performed	O
with	O
baseline	O
QTc	O
and	O
at	O
maximum	O
exercise	O
,	O
presence	O
of	O
isolated	O
ventricular	O
extrasystoles	O
and	O
QTc	O
in	O
recovery	O
of	O
490	O
ms	O
.	O
Finally	O
,	O
a	O
24	O
hour	O
Holter	O
is	O
requested	O
without	O
observing	O
arrhythmic	O
events	O
or	O
T	O
wave	O
alternation	O
.	O
Based	O
on	O
these	O
tests	O
,	O
the	O
patient	O
was	O
diagnosed	O
with	O
asymptomatic	O
long	O
QT	O
syndrome	O
LQTS	O
and	O
treatment	O
was	O
started	O
with	O
beta	O
blockers	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
per	O
day	O
.	O
In	O
addition	O
,	O
a	O
genetic	O
study	O
was	O
requested	O
,	O
but	O
it	O
was	O
negative	O
.	O
Subsequently	O
,	O
the	O
patient	O
explained	O
to	O
us	O
that	O
her	O
two	O
maternal	O
cousins	O
had	O
been	O
diagnosed	O
with	O
LQTS	O
but	O
both	O
had	O
a	O
negative	O
genetic	O
study	O
.	O
Currently	O
the	O
patient	O
remains	O
asymptomatic	O
,	O
with	O
no	O
cardiac	O
events	O
during	O
follow	O
up	O
.	O
DIAGNOSIS	O
Long	O
QT	O
syndrome	O
negative	O
genetics	O
.	O
Mild	O
aortic	O
insufficiency	O
.	O
Normal	O
systolic	O
function	O
.	O
Complete	O
left	O
bundle	O
branch	O
block	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
65	O
year	O
old	O
male	O
referred	O
preferentially	O
from	O
primary	O
care	O
to	O
cardiology	O
outpatient	O
clinics	O
due	O
to	O
chest	O
pain	O
.	O
History	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
ex	O
smoker	O
for	O
10	O
years	O
35	O
pack	O
years	O
.	O
No	O
arterial	O
hypertension	O
AHT	O
,	O
diabetes	O
mellitus	O
DM	O
or	O
dyslipidaemia	O
.	O
No	O
previous	O
cardiological	O
history	O
.	O
No	O
family	O
history	O
of	O
heart	O
disease	O
.	O
Other	O
history	O
glaucoma	O
,	O
peptic	O
ulcus	O
.	O
Treatment	O
omeprazole	B-FARMACO
20	O
mg	O
1	O
tablet	O
per	O
day	O
.	O
Latanoprost	B-FARMACO
,	O
dorzolamide	B-FARMACO
and	O
timolol	B-FARMACO
eye	O
drops	O
.	O
Present	O
illness	O
He	O
reported	O
chest	O
pain	O
in	O
the	O
left	O
hemithorax	O
with	O
oppressive	O
characteristics	O
,	O
without	O
irradiation	O
,	O
sometimes	O
accompanied	O
by	O
cold	O
sweating	O
,	O
generally	O
triggered	O
by	O
exertion	O
,	O
although	O
there	O
were	O
also	O
some	O
episodes	O
at	O
rest	O
,	O
and	O
progressive	O
improvement	O
of	O
the	O
pain	O
in	O
about	O
30	O
minutes	O
after	O
cessation	O
of	O
exertion	O
.	O
The	O
patient	O
denied	O
changes	O
in	O
the	O
threshold	O
of	O
exertion	O
or	O
progression	O
of	O
the	O
symptoms	O
in	O
recent	O
weeks	O
.	O
He	O
reported	O
no	O
symptoms	O
suggestive	O
of	O
heart	O
failure	O
,	O
palpitations	O
or	O
episodes	O
of	O
loss	O
of	O
consciousness	O
.	O
Physical	O
examination	O
Good	O
general	O
condition	O
,	O
normal	O
colour	O
and	O
normohydrated	O
,	O
eupneic	O
at	O
rest	O
and	O
conscious	O
,	O
oriented	O
and	O
cooperative	O
.	O
Blood	O
pressure	O
BP	O
124	O
73	O
mmHg	O
,	O
heart	O
rate	O
HR	O
55	O
bpm	O
,	O
SatO2	O
98	O
on	O
room	O
air	O
.	O
No	O
murmurs	O
were	O
detected	O
on	O
cardiac	O
auscultation	O
and	O
pulmonary	O
auscultation	O
showed	O
a	O
preserved	O
vesicular	O
murmur	O
with	O
no	O
added	O
noises	O
except	O
for	O
some	O
isolated	O
tele	O
expiratory	O
wheezing	O
.	O
Radial	O
and	O
pedial	O
pulses	O
were	O
palpable	O
,	O
rhythmic	O
and	O
symmetrical	O
.	O
COMPLEMENTARY	O
TESTS	O
Basal	O
electrocardiogram	O
ECG	O
sinus	O
rhythm	O
at	O
55	O
beats	O
per	O
minute	O
.	O
Axis	O
60o	O
.	O
PR	O
0	O
.	O
16s	O
.	O
Narrow	O
QRS	O
.	O
No	O
repolarisation	O
alterations	O
.	O
Laboratory	O
tests	O
glucose	O
91	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
78	O
mg	O
dl	O
,	O
estimated	O
glomerular	O
filtration	O
rate	O
CKD	O
EPI	O
over	O
90	O
ml	O
min	O
1	O
.	O
73	O
m2	O
,	O
total	O
cholesterol	O
172	O
mg	O
dl	O
,	O
triglycerides	O
71	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
54	O
mg	O
dl	O
,	O
calculated	O
LDL	O
cholesterol	O
113	O
mg	O
dl	O
.	O
Transthoracic	O
echocardiography	O
left	O
ventricle	O
of	O
normal	O
diameter	O
and	O
wall	O
thickness	O
with	O
preserved	O
LVEF	O
67	O
.	O
No	O
segmental	O
alterations	O
in	O
contractility	O
were	O
observed	O
.	O
Normal	O
transmitral	O
filling	O
pattern	O
.	O
Mean	O
E	O
e	O
"	O
of	O
9	O
.	O
5	O
LVEDP	O
globally	O
estimated	O
as	O
normal	O
.	O
Non	O
dilated	O
right	O
ventricle	O
with	O
good	O
contractility	O
TAPSE	O
21	O
mm	O
,	O
s	O
"	O
tricuspid	O
annulus	O
13	O
.	O
2	O
cm	O
s	O
.	O
Atria	O
of	O
normal	O
size	O
.	O
No	O
relevant	O
valvulopathies	O
.	O
Inferior	O
vena	O
cava	O
IVC	O
not	O
dilated	O
with	O
adequate	O
inspiratory	O
collapse	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
.	O
Ergometry	O
on	O
treadmill	O
maximum	O
ergometry	O
with	O
Bruce	O
protocol	O
on	O
a	O
moving	O
treadmill	O
,	O
the	O
test	O
was	O
stopped	O
due	O
to	O
oppressive	O
,	O
non	O
limiting	O
precordial	O
pain	O
,	O
similar	O
to	O
that	O
which	O
motivated	O
the	O
request	O
,	O
and	O
maximum	O
horizontal	O
ST	O
depression	O
of	O
2	O
mm	O
in	O
5	O
leads	O
II	O
,	O
III	O
,	O
aVF	O
,	O
V4	O
and	O
V5	O
;	O
both	O
the	O
clinical	O
and	O
ECG	O
changes	O
persisted	O
for	O
about	O
5	O
minutes	O
after	O
the	O
end	O
of	O
the	O
effort	O
.	O
Correct	O
adaptation	O
of	O
HR	O
and	O
BP	O
.	O
Normal	O
functional	O
capacity	O
reaches	O
12	O
.	O
6	O
METS	O
.	O
No	O
significant	O
arrhythmias	O
detected	O
.	O
Coronary	O
angiography	O
video	O
2	O
left	O
dominance	O
.	O
Left	O
coronary	O
trunk	O
,	O
anterior	O
descending	O
artery	O
and	O
circumflex	O
artery	O
without	O
significant	O
angiographic	O
lesions	O
.	O
Right	O
coronary	O
artery	O
with	O
anomalous	O
origin	O
from	O
left	O
coronary	O
sinus	O
and	O
probable	O
interarterial	O
trajectory	O
,	O
of	O
scarce	O
development	O
and	O
without	O
significant	O
angiographic	O
lesions	O
.	O
CT	O
of	O
the	O
coronary	O
arteries	O
with	O
cardiac	O
synchronisation	O
and	O
prospective	O
acquisition	O
coronary	O
anatomy	O
left	O
dominance	O
.	O
Intermediate	O
branch	O
as	O
an	O
anatomical	O
variant	O
of	O
normality	O
.	O
Anomalous	O
right	O
coronary	O
outflow	O
from	O
left	O
coronary	O
sinus	O
with	O
high	O
interarterial	O
course	O
.	O
Left	O
main	O
coronary	O
artery	O
long	O
,	O
without	O
lesions	O
.	O
Anterior	O
descending	O
no	O
lesions	O
.	O
Circumflex	O
no	O
lesions	O
.	O
Right	O
coronary	O
artery	O
outflow	O
from	O
contralateral	O
coronary	O
sinus	O
with	O
high	O
interarterial	O
course	O
,	O
without	O
lesions	O
.	O
Other	O
cardiac	O
findings	O
small	O
diverticulum	O
in	O
the	O
left	O
inferoposterior	O
wall	O
of	O
the	O
left	O
atrium	O
.	O
No	O
intra	O
atrial	O
thrombus	O
.	O
Extracardiac	O
findings	O
hiatal	O
hernia	O
.	O
Stress	O
cardiac	O
MRI	O
with	O
dipyridamole	O
left	O
ventricle	O
with	O
wall	O
thickness	O
,	O
volumes	O
and	O
segmental	O
and	O
global	O
systolic	O
function	O
within	O
normal	O
LVEF	O
70	O
.	O
Right	O
ventricle	O
volume	O
and	O
systolic	O
function	O
within	O
normal	O
LVEF	O
64	O
.	O
Atria	O
and	O
great	O
vessels	O
of	O
normal	O
size	O
.	O
Provocation	O
of	O
ischaemia	O
with	O
i	O
.	O
v	O
.	O
dipyridamole	O
0	O
.	O
84	O
mg	O
kg	O
,	O
well	O
tolerated	O
NEGATIVE	O
.	O
Basal	O
57	O
bpm	O
and	O
137	O
76	O
mmHg	O
.	O
Stress	O
84	O
bpm	O
and	O
127	O
70	O
mmHg	O
.	O
Absence	O
of	O
myocardial	O
fibrosis	O
or	O
necrosis	O
.	O
In	O
short	O
,	O
absence	O
of	O
inducible	O
ischaemia	O
.	O
CLINICAL	O
EVOLUTION	O
Following	O
the	O
echocardiographic	O
assessment	O
,	O
which	O
showed	O
no	O
structural	O
heart	O
disease	O
,	O
the	O
available	O
data	O
,	O
the	O
clinical	O
management	O
recommendations	O
at	O
that	O
time	O
,	O
the	O
local	O
availability	O
of	O
complementary	O
tests	O
and	O
estimating	O
an	O
intermediate	O
pretest	O
probability	O
,	O
treadmill	O
exercise	O
testing	O
was	O
requested	O
to	O
assess	O
the	O
presence	O
of	O
ischaemia	O
and	O
confirm	O
the	O
diagnosis	O
of	O
suspected	O
stable	O
exertional	O
angina	O
.	O
This	O
was	O
clinically	O
and	O
electrically	O
compatible	O
with	O
high	O
load	O
ischaemia	O
.	O
With	O
this	O
result	O
and	O
the	O
patient	O
's	O
clinical	O
presentation	O
,	O
treatment	O
was	O
started	O
with	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
mg	O
1	O
tablet	O
per	O
day	O
and	O
atorvastatin	B-FARMACO
20	O
mg	O
1	O
tablet	O
per	O
day	O
,	O
and	O
coronary	O
angiography	O
was	O
requested	O
.	O
During	O
the	O
technique	O
,	O
cannulation	O
of	O
the	O
left	O
main	O
coronary	O
artery	O
showed	O
left	O
dominant	O
anterior	O
descending	O
and	O
circumflex	O
arteries	O
without	O
significant	O
lesions	O
.	O
The	O
right	O
coronary	O
artery	O
could	O
not	O
be	O
cannulated	O
from	O
the	O
right	O
coronary	O
sinus	O
,	O
so	O
the	O
origin	O
of	O
the	O
right	O
coronary	O
artery	O
was	O
sought	O
in	O
the	O
left	O
coronary	O
sinus	O
.	O
After	O
several	O
attempts	O
and	O
sub	O
selective	O
injections	O
,	O
the	O
right	O
coronary	O
artery	O
was	O
found	O
to	O
have	O
an	O
anomalous	O
origin	O
in	O
the	O
left	O
coronary	O
sinus	O
,	O
with	O
a	O
probable	O
interarterial	O
course	O
.	O
The	O
artery	O
itself	O
was	O
poorly	O
developed	O
and	O
practically	O
rudimentary	O
.	O
To	O
confirm	O
the	O
origin	O
and	O
especially	O
the	O
course	O
of	O
the	O
right	O
coronary	O
artery	O
,	O
a	O
coronary	O
CT	O
scan	O
was	O
requested	O
,	O
which	O
showed	O
,	O
in	O
agreement	O
with	O
the	O
coronary	O
angiography	O
,	O
an	O
origin	O
from	O
the	O
left	O
sinus	O
,	O
as	O
well	O
as	O
a	O
high	O
interarterial	O
course	O
.	O
The	O
patient	O
was	O
presented	O
at	O
a	O
medical	O
surgical	O
session	O
to	O
consider	O
reimplantation	O
of	O
the	O
right	O
coronary	O
artery	O
,	O
parietal	O
resection	O
or	O
unroofing	O
or	O
bypass	O
with	O
proximal	O
ligation	O
.	O
It	O
was	O
decided	O
to	O
request	O
an	O
imaging	O
test	O
to	O
assess	O
and	O
locate	O
the	O
presence	O
of	O
ischaemia	O
as	O
additional	O
data	O
to	O
indicate	O
possible	O
surgery	O
.	O
Antianginal	O
treatment	O
was	O
added	O
sequentially	O
with	O
nitrate	B-FARMACO
patch	O
5	O
mg	O
per	O
day	O
,	O
lercanidipine	B-FARMACO
10	O
mg	O
1	O
tablet	O
per	O
day	O
and	O
ranolazine	B-FARMACO
500	O
mg	O
1	O
tablet	O
every	O
12	O
hours	O
.	O
Beta	O
blockers	O
were	O
not	O
tolerated	O
due	O
to	O
a	O
tendency	O
to	O
sinus	O
bradycardia	O
.	O
A	O
stress	O
CMR	O
with	O
vasodilator	O
dipyridamole	O
was	O
performed	O
,	O
which	O
ruled	O
out	O
the	O
presence	O
of	O
myocardial	O
necrosis	O
and	O
also	O
showed	O
no	O
evidence	O
of	O
ischaemia	O
.	O
It	O
should	O
be	O
noted	O
that	O
the	O
mechanism	O
of	O
stress	O
induction	O
by	O
this	O
technique	O
vasodilatation	O
did	O
not	O
produce	O
an	O
increase	O
in	O
BP	O
,	O
so	O
there	O
would	O
have	O
been	O
no	O
evidence	O
of	O
ischaemia	O
if	O
the	O
mechanism	O
had	O
been	O
compression	O
of	O
the	O
coronary	O
artery	O
with	O
interarterial	O
trajectory	O
by	O
expansion	O
of	O
the	O
aorta	O
and	O
pulmonary	O
trunk	O
,	O
a	O
mechanism	O
that	O
would	O
have	O
occurred	O
if	O
the	O
stress	O
induction	O
had	O
been	O
due	O
to	O
exertion	O
.	O
Finally	O
,	O
surgery	O
by	O
cardiac	O
surgery	O
was	O
ruled	O
out	O
due	O
to	O
the	O
small	O
calibre	O
and	O
development	O
of	O
the	O
affected	O
artery	O
,	O
the	O
technical	O
difficulties	O
of	O
the	O
intervention	O
and	O
the	O
good	O
response	O
to	O
medical	O
treatment	O
.	O
To	O
date	O
,	O
the	O
patient	O
remains	O
stable	O
with	O
a	O
CCS	O
Canadian	O
Cardiovascular	O
Society	O
functional	O
class	O
for	O
angina	O
II	O
IV	O
,	O
pending	O
full	O
optimisation	O
of	O
anti	O
anginal	O
treatment	O
.	O
He	O
has	O
had	O
no	O
cardiovascular	O
events	O
during	O
follow	O
up	O
.	O
DIAGNOSIS	O
Coronary	O
anomaly	O
right	O
coronary	O
artery	O
with	O
origin	O
in	O
left	O
coronary	O
sinus	O
and	O
high	O
interarterial	O
path	O
.	O
Stable	O
angina	O
.	O
Normal	O
LVEF	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
This	O
is	O
a	O
73	O
year	O
old	O
woman	O
with	O
arterial	O
hypertension	O
as	O
a	O
cardiovascular	O
risk	O
factor	O
.	O
She	O
was	O
assessed	O
by	O
cardiology	O
in	O
a	O
private	O
centre	O
for	O
mitral	O
prolapse	O
,	O
with	O
normal	O
ventricular	O
function	O
and	O
asymptomatic	O
during	O
follow	O
up	O
.	O
Her	O
main	O
comorbidity	O
is	O
oncological	O
,	O
with	O
a	O
history	O
of	O
moderately	O
differentiated	O
adenocarcinoma	O
of	O
the	O
descending	O
colon	O
stage	O
II	O
pT3	O
pN0	O
cM0	O
,	O
which	O
debuted	O
with	O
intestinal	O
obstruction	O
in	O
2014	O
,	O
initially	O
treated	O
with	O
total	O
colectomy	O
in	O
August	O
2014	O
,	O
followed	O
by	O
adjuvant	O
chemotherapy	O
with	O
Gramont	O
scheme	O
with	O
5	B-FARMACO
fluorouracil	B-FARMACO
5	B-FARMACO
FU	B-FARMACO
x	O
12	O
cycles	O
last	O
cycle	O
date	O
February	O
2015	O
.	O
A	O
CT	O
scan	O
in	O
December	O
2015	O
revealed	O
millimetric	O
lung	O
lesions	O
,	O
which	O
were	O
observed	O
until	O
their	O
growth	O
was	O
confirmed	O
by	O
PET	O
scan	O
in	O
June	O
2016	O
,	O
so	O
first	O
line	O
chemotherapy	O
with	O
FOLFOX	O
oxaliplatin	B-FARMACO
,	O
5	B-FARMACO
fluorouracil	B-FARMACO
and	O
folinic	B-FARMACO
acid	I-FARMACO
was	O
started	O
,	O
with	O
oxaliplatin	B-FARMACO
being	O
discontinued	O
after	O
7	O
cycles	O
due	O
to	O
neurotoxicity	O
.	O
She	O
was	O
maintained	O
on	O
5	B-FARMACO
fluorouracil	B-FARMACO
until	O
the	O
present	O
day	O
,	O
achieving	O
stabilisation	O
of	O
the	O
disease	O
Current	O
disease	O
While	O
the	O
patient	O
was	O
in	O
the	O
supermarket	O
,	O
she	O
had	O
an	O
apparently	O
sudden	O
loss	O
of	O
consciousness	O
and	O
cardiorespiratory	O
arrest	O
was	O
observed	O
,	O
and	O
basic	O
cardiopulmonary	O
resuscitation	O
CPR	O
manoeuvres	O
were	O
started	O
immediately	O
by	O
the	O
health	O
personnel	O
present	O
.	O
The	O
semi	O
automatic	O
external	O
defibrillator	O
AED	O
detected	O
a	O
shockable	O
rhythm	O
and	O
2	O
shocks	O
were	O
administered	O
,	O
with	O
recovery	O
of	O
pulse	O
and	O
consciousness	O
,	O
and	O
orotracheal	O
intubation	O
was	O
not	O
required	O
.	O
The	O
output	O
electrocardiogram	O
ECG	O
showed	O
complete	O
right	O
bundle	O
branch	O
block	O
,	O
with	O
no	O
evidence	O
of	O
acute	O
ischaemia	O
.	O
She	O
was	O
transferred	O
by	O
the	O
out	O
of	O
hospital	O
emergency	O
services	O
to	O
our	O
centre	O
,	O
where	O
she	O
arrived	O
haemodynamically	O
stable	O
,	O
conscious	O
and	O
oriented	O
.	O
On	O
initial	O
anamnesis	O
,	O
the	O
patient	O
reported	O
short	O
episodes	O
2	O
minutes	O
of	O
chest	O
pain	O
in	O
the	O
previous	O
days	O
,	O
at	O
rest	O
,	O
with	O
no	O
other	O
associated	O
symptoms	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
BP	O
115	O
70	O
mmHg	O
,	O
heart	O
rate	O
HR	O
74	O
bpm	O
.	O
Good	O
general	O
condition	O
,	O
conscious	O
and	O
oriented	O
,	O
eupneic	O
at	O
rest	O
.	O
Normoperfused	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
no	O
murmurs	O
or	O
extratonos	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
with	O
no	O
extra	O
sounds	O
.	O
Lower	O
limbs	O
no	O
oedema	O
.	O
COMPLEMENTARY	O
TESTS	O
EGC	O
sinus	O
rhythm	O
at	O
80lpm	O
.	O
Normal	O
PR	O
.	O
QRS	O
120	O
msec	O
with	O
BCRDHH	O
morphology	O
.	O
No	O
significant	O
repolarisation	O
alterations	O
.	O
Blood	O
tests	O
on	O
admission	O
normal	O
haemogram	O
.	O
Normal	O
coagulation	O
except	O
D	O
dimer	O
4477	O
ng	O
ml	O
.	O
Arterial	O
blood	O
gases	O
pH	O
7	O
.	O
38	O
,	O
pCO2	O
35	O
mmHg	O
,	O
bicarbonate	O
21	O
mEq	O
l	O
,	O
lactate	O
4	O
.	O
2	O
mmol	O
l	O
.	O
In	O
the	O
biochemistry	O
normal	O
renal	O
function	O
,	O
without	O
ionic	O
alterations	O
and	O
with	O
negative	O
acute	O
phase	O
reactants	O
.	O
Cardiac	O
markers	O
evolution	O
of	O
ultrasensitive	O
troponin	O
I	O
7	O
.	O
7	O
174	O
40	O
ng	O
ml	O
,	O
with	O
normal	O
CK	O
.	O
Nt	O
proBNP	O
457	O
pg	O
ml	O
.	O
Chest	O
X	O
ray	O
on	O
admission	O
normal	O
cardiothoracic	O
index	O
,	O
no	O
evidence	O
of	O
heart	O
failure	O
.	O
Control	O
chest	O
X	O
ray	O
after	O
ICD	O
implantation	O
subcutaneous	O
defibrillator	O
with	O
pre	O
sternal	O
electrode	O
.	O
Minimal	O
subcutaneous	O
emphysema	O
.	O
Subcutaneous	O
reservoir	O
with	O
terminal	O
at	O
the	O
confluence	O
of	O
the	O
brachiocephalic	O
venous	O
trunks	O
.	O
Urgent	O
coronary	O
angiography	O
access	O
via	O
right	O
radial	O
artery	O
.	O
177	O
cc	O
of	O
contrast	O
.	O
Left	O
coronary	O
trunk	O
without	O
lesions	O
.	O
Anterior	O
descending	O
artery	O
of	O
small	O
calibre	O
and	O
development	O
with	O
a	O
non	O
significant	O
lesion	O
in	O
the	O
distal	O
portion	O
corresponding	O
to	O
the	O
middle	O
third	O
of	O
the	O
theoretical	O
trajectory	O
with	O
a	O
blurred	O
image	O
and	O
with	O
a	O
distal	O
vessel	O
of	O
small	O
development	O
and	O
calibre	O
.	O
Coronary	O
anomaly	O
with	O
middle	O
and	O
distal	O
portion	O
of	O
the	O
anterior	O
descending	O
artery	O
with	O
exit	O
from	O
the	O
right	O
coronary	O
sinus	O
,	O
close	O
to	O
the	O
exit	O
of	O
the	O
right	O
coronary	O
artery	O
.	O
Circumflex	O
and	O
right	O
coronary	O
without	O
lesions	O
.	O
Echocardiogram	O
left	O
ventricle	O
not	O
dilated	O
,	O
with	O
normal	O
wall	O
thickness	O
.	O
Normal	O
global	O
systolic	O
function	O
LVEF	O
60	O
65	O
,	O
hypokinesia	O
of	O
inferior	O
septum	O
and	O
inferior	O
face	O
.	O
Transmitral	O
filling	O
pattern	O
of	O
impaired	O
relaxation	O
.	O
E	O
e	O
'	O
ratio	O
6	O
.	O
Left	O
atrium	O
not	O
dilated	O
.	O
Non	O
dilated	O
right	O
atrium	O
.	O
Non	O
dilated	O
right	O
ventricle	O
,	O
with	O
normal	O
global	O
systolic	O
function	O
.	O
Mitral	O
valve	O
with	O
calcium	O
in	O
the	O
annulus	O
and	O
leaflets	O
.	O
No	O
stenosis	O
.	O
Slight	O
insufficiency	O
.	O
Aortic	O
valve	O
morphologically	O
and	O
functionally	O
normal	O
.	O
Tricuspid	O
valve	O
morphologically	O
normal	O
.	O
Slight	O
insufficiency	O
.	O
Pulmonary	O
artery	O
systolic	O
pressure	O
not	O
estimable	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
with	O
physiological	O
inspiratory	O
collapse	O
.	O
No	O
pericardial	O
effusion	O
.	O
Epicardial	O
fat	O
.	O
Non	O
dilated	O
aortic	O
root	O
.	O
Cardiac	O
magnetic	O
resonance	O
study	O
within	O
normal	O
limits	O
.	O
No	O
areas	O
of	O
myocardial	O
inflammation	O
or	O
ischaemic	O
scarring	O
.	O
Biventricular	O
size	O
and	O
systolic	O
function	O
within	O
normal	O
limits	O
.	O
CT	O
coronary	O
arteries	O
calcium	O
quantification	O
Agatston	O
410	O
80th	O
percentile	O
for	O
age	O
,	O
sex	O
and	O
race	O
.	O
CT	O
angiography	O
extensive	O
coronary	O
atheromatosis	O
.	O
Anterior	O
descending	O
artery	O
that	O
exhausts	O
at	O
the	O
proximal	O
middle	O
level	O
of	O
the	O
IV	O
anterior	O
sulcus	O
.	O
Ectopic	O
vessel	O
originating	O
in	O
the	O
right	O
sinus	O
running	O
anterior	O
to	O
the	O
TAP	O
that	O
reaches	O
the	O
IV	O
groove	O
at	O
mid	O
level	O
.	O
It	O
has	O
a	O
concentric	O
stenosis	O
at	O
its	O
origin	O
of	O
30	O
.	O
Assessment	O
by	O
medical	O
oncology	O
in	O
the	O
absence	O
of	O
further	O
information	O
,	O
it	O
appears	O
that	O
pulmonary	O
metastases	O
have	O
an	O
indolent	O
behaviour	O
,	O
with	O
long	O
lasting	O
stabilisation	O
,	O
so	O
that	O
in	O
the	O
face	O
of	O
this	O
complication	O
and	O
the	O
current	O
suspicion	O
,	O
therapeutic	O
rest	O
could	O
even	O
be	O
considered	O
.	O
If	O
this	O
is	O
not	O
the	O
case	O
or	O
if	O
progression	O
occurs	O
,	O
there	O
are	O
non	O
cardiotoxic	O
alternatives	O
to	O
5	B-FARMACO
fluorouracil	B-FARMACO
raltitrexed	I-FARMACO
,	O
irinotecan	B-FARMACO
.	O
It	O
will	O
be	O
up	O
to	O
the	O
discretion	O
of	O
your	O
regular	O
oncologist	O
to	O
choose	O
the	O
most	O
suitable	O
treatment	O
depending	O
on	O
the	O
clinical	O
situation	O
at	O
discharge	O
.	O
Electrophysiology	O
a	O
6	O
cm	O
incision	O
is	O
made	O
in	O
the	O
left	O
mid	O
axillary	O
region	O
and	O
dissection	O
is	O
carried	O
out	O
up	O
to	O
the	O
muscular	O
plane	O
,	O
the	O
serratus	O
anterior	O
muscle	O
is	O
divided	O
to	O
form	O
the	O
pocket	O
for	O
the	O
generator	O
;	O
tunneling	O
is	O
carried	O
out	O
from	O
the	O
left	O
mid	O
axillary	O
line	O
to	O
the	O
left	O
parasternal	O
region	O
where	O
a	O
3	O
cm	O
incision	O
is	O
made	O
at	O
the	O
level	O
of	O
the	O
sixth	O
intercostal	O
space	O
EIC	O
and	O
from	O
the	O
latter	O
it	O
is	O
tunneled	O
to	O
the	O
second	O
EIC	O
left	O
parasternal	O
.	O
An	O
electrode	O
is	O
fixed	O
at	O
the	O
level	O
of	O
the	O
sixth	O
parasternal	O
left	O
EIC	O
and	O
connected	O
to	O
the	O
generator	O
,	O
which	O
is	O
fixed	O
to	O
the	O
muscular	O
plane	O
;	O
it	O
is	O
closed	O
in	O
planes	O
.	O
The	O
procedure	O
was	O
concluded	O
without	O
complications	O
.	O
Induction	O
of	O
ventricular	O
fibrillation	O
VF	O
was	O
performed	O
on	O
three	O
occasions	O
,	O
which	O
cardioverted	O
to	O
sinus	O
rhythm	O
spontaneously	O
,	O
for	O
which	O
a	O
10	O
J	O
shock	O
was	O
performed	O
to	O
measure	O
the	O
impedance	O
of	O
the	O
circuit	O
,	O
which	O
was	O
normal	O
75	O
Ohm	O
;	O
at	O
the	O
end	O
of	O
the	O
procedure	O
the	O
radiological	O
position	O
was	O
assessed	O
as	O
adequate	O
and	O
a	O
low	O
probability	O
of	O
defibrillation	O
failure	O
was	O
estimated	O
PRAETORIAN	O
SCORE	O
.	O
Conditional	O
zone	O
is	O
programmed	O
at	O
220	O
bpm	O
and	O
VF	O
zone	O
at	O
250	O
bpm	O
5	O
therapies	O
of	O
80	O
J	O
.	O
Post	O
discharge	O
pacing	O
on	O
.	O
Shock	O
impedance	O
in	O
normal	O
range	O
.	O
Smart	O
Pass	O
filter	O
on	O
.	O
Vector	O
chosen	O
primary	O
x	O
1	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
arrived	O
at	O
our	O
centre	O
haemodynamically	O
stable	O
,	O
without	O
chest	O
pain	O
or	O
signs	O
of	O
heart	O
failure	O
,	O
without	O
ionic	O
or	O
other	O
alterations	O
.	O
In	O
the	O
transthoracic	O
echocardiogram	O
,	O
biventricular	O
size	O
and	O
function	O
were	O
normal	O
,	O
with	O
no	O
significant	O
alterations	O
.	O
It	O
was	O
decided	O
to	O
perform	O
emergent	O
coronary	O
angiography	O
,	O
which	O
showed	O
the	O
anomaly	O
in	O
the	O
anterior	O
descending	O
artery	O
LAD	O
described	O
,	O
with	O
no	O
images	O
suggestive	O
of	O
significant	O
disease	O
.	O
Analytically	O
,	O
there	O
was	O
minimal	O
elevation	O
of	O
myocardial	O
damage	O
markers	O
in	O
the	O
serialisation	O
,	O
with	O
a	O
peak	O
of	O
140	O
of	O
ultra	O
sensitive	O
troponin	O
I	O
.	O
Once	O
the	O
initial	O
study	O
had	O
been	O
performed	O
,	O
three	O
aetiologies	O
of	O
the	O
arrest	O
were	O
considered	O
Coronary	O
anomaly	O
,	O
although	O
coronary	O
angiography	O
did	O
not	O
show	O
an	O
inter	O
or	O
intra	O
arterial	O
trajectory	O
of	O
the	O
LAD	O
.	O
Acute	O
coronary	O
syndrome	O
due	O
to	O
plaque	O
rupture	O
in	O
the	O
distal	O
LAD	O
,	O
this	O
entity	O
being	O
unlikely	O
.	O
Vasospasm	O
secondary	O
to	O
treatment	O
with	O
5	B-FARMACO
fluorouracil	B-FARMACO
on	O
previous	O
plaque	O
.	O
With	O
these	O
options	O
,	O
it	O
was	O
decided	O
to	O
first	O
perform	O
a	O
coronary	O
CT	O
scan	O
,	O
which	O
ruled	O
out	O
an	O
intra	O
arterial	O
trajectory	O
of	O
the	O
anterior	O
descending	O
artery	O
.	O
The	O
study	O
continued	O
with	O
cardiac	O
MRI	O
as	O
a	O
myocardial	O
study	O
,	O
with	O
no	O
evidence	O
of	O
structural	O
heart	O
disease	O
or	O
ischaemic	O
lesions	O
.	O
During	O
admission	O
,	O
the	O
patient	O
remained	O
on	O
cardiac	O
monitoring	O
,	O
with	O
no	O
arrhythmic	O
events	O
.	O
At	O
this	O
point	O
,	O
having	O
ruled	O
out	O
all	O
other	O
aetiologies	O
,	O
the	O
first	O
diagnostic	O
possibility	O
was	O
vasospasm	O
due	O
to	O
5	B-FARMACO
fluorouracil	B-FARMACO
;	O
however	O
,	O
as	O
this	O
could	O
not	O
be	O
confirmed	O
reliably	O
,	O
she	O
was	O
presented	O
at	O
an	O
interdisciplinary	O
medical	O
surgical	O
session	O
clinical	O
and	O
interventional	O
cardiology	O
,	O
cardiac	O
surgery	O
and	O
medical	O
oncology	O
,	O
where	O
it	O
was	O
considered	O
that	O
the	O
implantation	O
of	O
an	O
ICD	O
device	O
was	O
indicated	O
for	O
secondary	O
prevention	O
,	O
with	O
a	O
subcutaneous	O
ICD	O
being	O
the	O
ICD	O
of	O
choice	O
,	O
as	O
she	O
was	O
a	O
carrier	O
of	O
a	O
central	O
venous	O
reservoir	O
for	O
active	O
use	O
.	O
The	O
procedure	O
was	O
performed	O
without	O
periprocedural	O
complications	O
.	O
However	O
,	O
in	O
the	O
following	O
12	O
hours	O
on	O
the	O
ward	O
,	O
she	O
presented	O
two	O
inappropriate	O
shocks	O
,	O
assessed	O
by	O
electrophysiology	O
and	O
the	O
company	O
's	O
technicians	O
,	O
and	O
showed	O
evidence	O
of	O
retrosternal	O
air	O
interference	O
visualised	O
in	O
the	O
first	O
control	O
X	O
ray	O
after	O
the	O
procedure	O
.	O
After	O
two	O
days	O
of	O
monitoring	O
,	O
a	O
new	O
X	O
ray	O
was	O
taken	O
which	O
showed	O
reabsorption	O
of	O
the	O
subcutaneous	O
emphysema	O
,	O
with	O
no	O
further	O
discharges	O
after	O
48	O
hours	O
of	O
observation	O
.	O
In	O
view	O
of	O
the	O
good	O
evolution	O
,	O
the	O
patient	O
was	O
discharged	O
from	O
hospital	O
with	O
follow	O
up	O
in	O
monographic	O
cardio	O
oncology	O
consultations	O
.	O
During	O
the	O
follow	O
up	O
,	O
new	O
administrations	O
of	O
5	B-FARMACO
fluouracil	B-FARMACO
were	O
prohibited	O
and	O
replaced	O
by	O
a	O
new	O
chemotherapy	O
agent	O
,	O
and	O
the	O
patient	O
progressed	O
favourably	O
from	O
both	O
the	O
cardiological	O
and	O
oncological	O
points	O
of	O
view	O
.	O
She	O
has	O
not	O
presented	O
any	O
new	O
discharges	O
since	O
discharge	O
.	O
DIAGNOSIS	O
Out	O
of	O
hospital	O
cardiorespiratory	O
arrest	O
with	O
immediate	O
cardiopulmonary	O
resuscitation	O
CPR	O
recovered	O
in	O
second	O
shock	O
.	O
Possible	O
vasospasm	O
due	O
to	O
fluoropyrimidines	O
.	O
Subcutaneous	O
ICD	O
implantation	O
in	O
secondary	O
prevention	O
.	O
Inappropriate	O
discharge	O
due	O
to	O
air	O
interference	O
.	O
Anterior	O
descending	O
with	O
middle	O
and	O
distal	O
portion	O
with	O
exit	O
from	O
right	O
coronary	O
sinus	O
.	O
Normal	O
biventricular	O
function	O
.	O
Adenocarcinoma	O
of	O
the	O
colon	O
intervened	O
in	O
control	O
with	O
5	B-FARMACO
FU	B-FARMACO
chemotherapy	O
.	O
Arterial	O
hypertension	O
.	O

We	O
present	O
the	O
case	O
of	O
a	O
70	O
year	O
old	O
man	O
with	O
ischaemic	O
heart	O
disease	O
and	O
atrial	O
fibrillation	O
with	O
indication	O
for	O
anticoagulation	O
.	O
HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
No	O
known	O
drug	O
allergies	O
.	O
Cardiovascular	O
risk	O
factors	O
hypertension	O
,	O
dyslipidaemia	O
,	O
ex	O
smoker	O
for	O
12	O
years	O
smoking	O
history	O
20	O
packs	O
year	O
.	O
Drinker	O
of	O
two	O
beers	O
per	O
day	O
and	O
one	O
glass	O
of	O
wine	O
per	O
day	O
.	O
Previous	O
cardiological	O
history	O
Chronic	O
ischaemic	O
heart	O
disease	O
;	O
debut	O
as	O
acute	O
myocardial	O
infarction	O
in	O
1998	O
.	O
Diffuse	O
multivessel	O
coronary	O
artery	O
disease	O
.	O
Catheterisation	O
4	O
11	O
2008	O
atheromatous	O
and	O
calcified	O
anterior	O
descending	O
artery	O
in	O
proximal	O
and	O
middle	O
segments	O
,	O
diseased	O
vessel	O
not	O
approachable	O
.	O
Circumflex	O
artery	O
with	O
diffuse	O
disease	O
of	O
the	O
whole	O
vessel	O
with	O
poor	O
distal	O
beds	O
.	O
Atheromatous	O
right	O
coronary	O
artery	O
with	O
irregularities	O
.	O
Preserved	O
left	O
ventricular	O
ejection	O
fraction	O
.	O
Other	O
medical	O
history	O
Mild	O
chronic	O
obstructive	O
pulmonary	O
disease	O
.	O
No	O
surgical	O
interventions	O
.	O
Current	O
treatment	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
mg	O
24	O
hours	O
,	O
nitroglycerin	B-FARMACO
patch	O
15	O
mg	O
24	O
hours	O
,	O
carvedilol	B-FARMACO
25	O
mg	O
12	O
hours	O
,	O
ivabradine	B-FARMACO
5	O
mg	O
12	O
hours	O
,	O
candesartan	B-FARMACO
4	O
mg	O
24	O
hours	O
,	O
rosuvastatin	B-FARMACO
20	O
mg	O
24	O
hours	O
,	O
ezetimibe	B-FARMACO
10	O
mg	O
24	O
hours	O
,	O
inhaled	O
tiotropium	B-FARMACO
and	O
budesonide	B-FARMACO
.	O
Present	O
illness	O
70	O
year	O
old	O
man	O
with	O
episodes	O
of	O
exertional	O
angina	O
for	O
the	O
past	O
year	O
.	O
When	O
climbing	O
hills	O
or	O
accelerating	O
his	O
pace	O
,	O
he	O
experienced	O
oppressive	O
discomfort	O
in	O
the	O
left	O
hemithorax	O
that	O
sometimes	O
radiated	O
to	O
the	O
inner	O
arm	O
,	O
which	O
self	O
limited	O
within	O
5	O
10	O
minutes	O
after	O
stopping	O
the	O
activity	O
.	O
It	O
is	O
also	O
associated	O
with	O
chest	O
pain	O
during	O
sexual	O
intercourse	O
.	O
No	O
episodes	O
at	O
rest	O
.	O
Physical	O
examination	O
Good	O
general	O
condition	O
.	O
Conscious	O
,	O
oriented	O
and	O
cooperative	O
.	O
Normal	O
colour	O
.	O
Blood	O
pressure	O
BP	O
130	O
71	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
75	O
bpm	O
.	O
No	O
semiology	O
of	O
heart	O
failure	O
.	O
Cardiopulmonary	O
auscultation	O
arrhythmic	O
heart	O
,	O
no	O
murmurs	O
.	O
Bladder	O
murmur	O
preserved	O
with	O
no	O
added	O
pathological	O
noises	O
.	O
Lower	O
limbs	O
no	O
oedema	O
or	O
fovea	O
.	O
No	O
evidence	O
of	O
deep	O
vein	O
thrombosis	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
atrial	O
fibrillation	O
at	O
90	O
bpm	O
.	O
Narrow	O
QRS	O
,	O
normal	O
axis	O
.	O
No	O
repolarisation	O
alterations	O
.	O
Chest	O
X	O
ray	O
normal	O
cardiothoracic	O
index	O
.	O
Free	O
costophrenic	O
sinuses	O
.	O
No	O
images	O
of	O
pulmonary	O
condensation	O
.	O
Laboratory	O
tests	O
creatinine	O
0	O
.	O
8	O
mg	O
dl	O
.	O
Haemoglobin	O
15	O
.	O
4	O
g	O
dl	O
.	O
Ultrasensitive	O
troponin	O
T	O
17	O
ng	O
l	O
normal	O
14	O
ng	O
l	O
.	O
Echocardiogram	O
normal	O
aortic	O
root	O
,	O
trivalve	O
aortic	O
valve	O
with	O
preserved	O
opening	O
and	O
closing	O
.	O
Left	O
atrium	O
not	O
dilated	O
.	O
Normal	O
mitral	O
valve	O
.	O
Left	O
ventricle	O
of	O
normal	O
size	O
,	O
with	O
normal	O
myocardial	O
thickness	O
.	O
Normal	O
global	O
and	O
segmental	O
systolic	O
function	O
.	O
Ventricular	O
filling	O
with	O
monophasic	O
pattern	O
.	O
Normal	O
right	O
chambers	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
.	O
Prognostic	O
ergometry	O
,	O
treadmill	O
,	O
Bruce	O
protocol	O
,	O
under	O
beta	O
blocker	O
treatment	O
clinically	O
negative	O
.	O
Electrically	O
positive	O
with	O
ST	O
segment	O
elevation	O
at	O
the	O
end	O
of	O
stage	O
2	O
,	O
due	O
to	O
ST	O
segment	O
elevation	O
in	O
V3	O
V6	O
of	O
1	O
mm	O
,	O
with	O
an	O
accentuated	O
decrease	O
in	O
recovery	O
up	O
to	O
3	O
mm	O
.	O
Slow	O
recovery	O
,	O
persisting	O
after	O
6	O
minutes	O
with	O
a	O
2	O
mm	O
decline	O
in	O
V3	O
V2	O
V6	O
decline	O
.	O
Exercise	O
time	O
6	O
06	O
minutes	O
,	O
limited	O
by	O
leg	O
fatigue	O
.	O
Functional	O
capacity	O
7	O
.	O
2	O
METS	O
.	O
Normal	O
blood	O
pressure	O
response	O
.	O
HR	O
response	O
attenuated	O
by	O
beta	O
blockers	O
.	O
Normal	O
HR	O
recovery	O
.	O
Reached	O
86	O
of	O
maximum	O
heart	O
rate	O
.	O
All	O
tracing	O
in	O
atrial	O
fibrillation	O
.	O
Immediate	O
post	O
stress	O
echocardiogram	O
physiological	O
hypercontractility	O
with	O
apical	O
akinesia	O
.	O
Diagnostic	O
and	O
therapeutic	O
coronary	O
angiography	O
right	O
radial	O
access	O
.	O
Left	O
dominance	O
.	O
Left	O
common	O
trunk	O
practically	O
non	O
existent	O
giving	O
rise	O
to	O
2	O
independent	O
ostia	O
of	O
the	O
anterior	O
descending	O
artery	O
ADA	O
and	O
circumflex	O
artery	O
ACx	O
.	O
ADA	O
very	O
calcified	O
,	O
of	O
small	O
calibre	O
with	O
diffuse	O
atheromatosis	O
along	O
its	O
entire	O
length	O
,	O
causing	O
areas	O
of	O
significant	O
stenosis	O
at	O
mid	O
distal	O
level	O
over	O
a	O
small	O
calibre	O
,	O
thin	O
and	O
diseased	O
vessel	O
.	O
Dominant	O
circumflex	O
artery	O
,	O
of	O
large	O
calibre	O
and	O
course	O
.	O
It	O
presents	O
significant	O
eccentric	O
stenosis	O
proximally	O
and	O
medially	O
.	O
It	O
emits	O
a	O
first	O
marginal	O
branch	O
of	O
little	O
entity	O
and	O
a	O
second	O
branch	O
of	O
large	O
calibre	O
and	O
route	O
where	O
there	O
is	O
a	O
short	O
and	O
significant	O
stenosis	O
in	O
its	O
proximal	O
segment	O
.	O
Hypodeveloped	O
right	O
coronary	O
artery	O
with	O
diffuse	O
atheromatosis	O
.	O
Percutaneous	O
coronary	O
intervention	O
on	O
marginal	O
branch	O
of	O
the	O
LMCA	O
by	O
means	O
of	O
simple	O
angioplasty	O
with	O
conventional	O
balloon	O
2	O
mm	O
.	O
On	O
CAx	O
by	O
implanting	O
two	O
drug	O
eluting	O
stents	O
after	O
dilatation	O
with	O
conventional	O
balloon	O
at	O
mid	O
distal	O
Resolute	O
Onyx	O
3	O
x	O
30	O
mm	O
,	O
post	O
dilated	O
at	O
high	O
pressure	O
with	O
a	O
3	O
.	O
5	O
mm	O
non	O
compliant	O
balloon	O
and	O
proximal	O
Resolute	O
Onyx	O
3	O
.	O
5	O
x	O
22	O
mm	O
at	O
16	O
atmospheres	O
levels	O
.	O
Good	O
final	O
angiographic	O
result	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
evaluated	O
in	O
the	O
chest	O
pain	O
unit	O
where	O
an	O
ergometry	O
was	O
performed	O
with	O
electrical	O
positivity	O
with	O
segmental	O
alterations	O
in	O
immediate	O
post	O
strengthening	O
echocardiography	O
,	O
so	O
it	O
was	O
decided	O
to	O
admit	O
the	O
patient	O
to	O
hospital	O
for	O
coronary	O
angiography	O
.	O
In	O
addition	O
,	O
an	O
electrocardiogram	O
showed	O
atrial	O
fibrillation	O
of	O
uncertain	O
chronology	O
with	O
controlled	O
ventricular	O
response	O
.	O
After	O
coronary	O
angiography	O
revealed	O
approachable	O
coronary	O
lesions	O
,	O
given	O
that	O
the	O
patient	O
had	O
angina	O
despite	O
optimal	O
antianginal	O
treatment	O
and	O
inducible	O
ischaemia	O
in	O
the	O
non	O
invasive	O
ischaemia	O
detection	O
test	O
,	O
percutaneous	O
intervention	O
was	O
performed	O
on	O
the	O
marginal	O
branch	O
and	O
on	O
the	O
proximal	O
and	O
middle	O
circumflex	O
artery	O
in	O
order	O
to	O
improve	O
the	O
patient	O
's	O
symptoms	O
.	O
On	O
discharge	O
,	O
the	O
patient	O
required	O
anticoagulation	O
atrial	O
fibrillation	O
with	O
CHA2DS2	O
VASc	O
3	O
points	O
and	O
antiplatelet	O
therapy	O
coronary	O
revascularisation	O
,	O
so	O
taking	O
into	O
account	O
that	O
the	O
bleeding	O
risk	O
is	O
high	O
HAS	O
BLED	O
4	O
points	O
and	O
exceeds	O
the	O
ischaemic	O
risk	O
,	O
a	O
PIONEER	O
strategy	O
was	O
decided	O
and	O
the	O
patient	O
was	O
discharged	O
with	O
clopidogrel	B-FARMACO
75	O
mg	O
24	O
hours	O
and	O
rivaroxaban	B-FARMACO
15	O
mg	O
24	O
hours	O
including	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
mg	O
24	O
hours	O
for	O
the	O
first	O
week	O
.	O
Clopidogrel	B-FARMACO
,	O
if	O
there	O
are	O
no	O
incidents	O
,	O
will	O
be	O
withdrawn	O
after	O
6	O
months	O
,	O
to	O
continue	O
with	O
rivaroxaban	B-FARMACO
at	O
a	O
dose	O
of	O
20	O
mg	O
per	O
day	O
if	O
the	O
renal	O
glomerular	O
filtration	O
rate	O
remains	O
above	O
50	O
ml	O
min	O
.	O
DIAGNOSIS	O
Chronic	O
ischaemic	O
heart	O
disease	O
with	O
multivessel	O
coronary	O
artery	O
disease	O
and	O
exertional	O
angina	O
despite	O
medical	O
treatment	O
.	O
Preserved	O
LV	O
systolic	O
function	O
.	O
Percutaneous	O
revascularisation	O
of	O
circumflex	O
artery	O
and	O
marginal	O
branch	O
.	O
Atrial	O
fibrillation	O
of	O
uncertain	O
chronology	O
CHA2DS2	O
VASc	O
3	O
points	O
;	O
HAS	O
BLED	O
4	O
points	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
51	O
year	O
old	O
male	O
admitted	O
for	O
out	O
of	O
hospital	O
cardiorespiratory	O
arrest	O
.	O
History	O
Allergic	O
to	O
rifampicin	B-FARMACO
.	O
Hypertension	O
of	O
short	O
evolution	O
.	O
No	O
toxic	O
habits	O
.	O
No	O
previous	O
cardiological	O
history	O
,	O
no	O
family	O
history	O
of	O
heart	O
disease	O
or	O
sudden	O
death	O
.	O
No	O
other	O
history	O
of	O
interest	O
.	O
Usual	O
treatment	O
losartan	B-FARMACO
hydrochlorothiazide	I-FARMACO
50	O
12	O
.	O
5	O
mg	O
1	O
tablet	O
per	O
day	O
.	O
Present	O
illness	O
Previously	O
asymptomatic	O
,	O
on	O
the	O
day	O
of	O
admission	O
he	O
presented	O
,	O
while	O
at	O
work	O
,	O
a	O
syncopal	O
episode	O
without	O
previous	O
symptoms	O
,	O
witnessed	O
by	O
a	O
relative	O
.	O
No	O
pulse	O
was	O
noted	O
and	O
basic	O
cardiopulmonary	O
resuscitation	O
manoeuvres	O
were	O
started	O
for	O
15	O
minutes	O
.	O
On	O
arrival	O
of	O
the	O
emergency	O
services	O
,	O
orotracheal	O
intubation	O
was	O
performed	O
and	O
advanced	O
cardiopulmonary	O
resuscitation	O
manoeuvres	O
continued	O
for	O
20	O
minutes	O
.	O
AED	O
recording	O
showed	O
ventricular	O
fibrillation	O
and	O
after	O
5	O
defibrillation	O
attempts	O
and	O
administration	O
of	O
5	O
mg	O
of	O
adrenaline	B-FARMACO
,	O
3	O
mg	O
of	O
atropine	B-FARMACO
and	O
300	O
mg	O
of	O
amiodarone	B-FARMACO
intravenously	O
,	O
the	O
patient	O
recovered	O
a	O
pulse	O
,	O
recording	O
sinus	O
rhythm	O
with	O
ST	O
segment	O
elevation	O
in	O
leads	O
V1	O
V5	O
,	O
DI	O
and	O
aVL	O
.	O
During	O
transfer	O
to	O
the	O
hospital	O
,	O
he	O
suffered	O
a	O
new	O
episode	O
of	O
cardiorespiratory	O
arrest	O
with	O
pulseless	O
ventricular	O
tachycardia	O
,	O
this	O
time	O
recovering	O
a	O
pulse	O
after	O
a	O
single	O
electrical	O
cardioversion	O
.	O
On	O
arrival	O
at	O
the	O
hospital	O
,	O
an	O
urgent	O
haemodynamic	O
study	O
was	O
performed	O
,	O
which	O
revealed	O
epicardial	O
coronary	O
arteries	O
without	O
angiographically	O
significant	O
stenosis	O
.	O
In	O
view	O
of	O
the	O
results	O
of	O
the	O
catheterisation	O
,	O
it	O
was	O
decided	O
to	O
perform	O
a	O
cranial	O
CT	O
scan	O
without	O
contrast	O
and	O
a	O
chest	O
CT	O
scan	O
with	O
contrast	O
to	O
assess	O
the	O
pulmonary	O
arteries	O
and	O
rule	O
out	O
other	O
causes	O
of	O
cardiorespiratory	O
arrest	O
,	O
ruling	O
out	O
intracranial	O
haemorrhage	O
,	O
pulmonary	O
thromboembolism	O
and	O
acute	O
aortic	O
syndrome	O
.	O
Physical	O
examination	O
Systolic	O
blood	O
pressure	O
SBP	O
134	O
mmHg	O
,	O
diastolic	O
blood	O
pressure	O
DBP	O
98	O
mmHg	O
,	O
heart	O
rate	O
HR	O
81	O
bpm	O
.	O
Afebrile	O
.	O
Intubated	O
and	O
connected	O
to	O
mechanical	O
ventilation	O
,	O
SatO2	O
100	O
with	O
FiO2	O
80	O
.	O
No	O
jugular	O
ingurgitation	O
.	O
Negative	O
hepatojugular	O
reflux	O
.	O
Glasgow	O
8	O
,	O
under	O
the	O
effect	O
of	O
midazolam	B-FARMACO
and	O
cisatracurium	B-FARMACO
used	O
in	O
the	O
induction	O
prior	O
to	O
orotracheal	O
intubation	O
.	O
Rhythmic	O
heart	O
sounds	O
without	O
murmurs	O
.	O
Scattered	O
rhonchi	O
in	O
both	O
lung	O
fields	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
,	O
not	O
distended	O
.	O
Lower	O
extremities	O
without	O
oedema	O
,	O
with	O
femoral	O
,	O
popliteal	O
,	O
tibial	O
and	O
pedial	O
pulses	O
bilaterally	O
present	O
and	O
symmetrical	O
.	O
Radial	O
pulses	O
preserved	O
.	O
COMPLEMENTARY	O
TESTS	O
Semiautomatic	O
defibrillator	O
AED	O
recording	O
ventricular	O
fibrillation	O
.	O
After	O
electrical	O
cardioversion	O
,	O
sinus	O
rhythm	O
at	O
75	O
bpm	O
,	O
QRS	O
of	O
120	O
ms	O
with	O
intraventricular	O
conduction	O
disturbance	O
,	O
ST	O
segment	O
elevation	O
from	O
V1	O
to	O
V5	O
,	O
DI	O
and	O
aVL	O
,	O
with	O
specular	O
decrease	O
in	O
inferior	O
face	O
.	O
Electrocardiogram	O
ECG	O
on	O
admission	O
to	O
the	O
coronary	O
unit	O
sinus	O
rhythm	O
at	O
80	O
bpm	O
,	O
narrow	O
QRS	O
with	O
normal	O
axis	O
,	O
no	O
ST	O
alterations	O
,	O
flattened	O
T	O
wave	O
in	O
limb	O
leads	O
.	O
Venous	O
blood	O
gases	O
on	O
arrival	O
at	O
our	O
centre	O
pH	O
7	O
.	O
11	O
,	O
pCO2	O
67	O
.	O
9	O
mmHg	O
,	O
pO2	O
56	O
.	O
9	O
mmHg	O
,	O
HCO3	O
16	O
.	O
7	O
mmol	O
l	O
,	O
Sat	O
O2	O
78	O
,	O
lactic	O
acid	O
5	O
.	O
4	O
mmol	O
l	O
,	O
pO2	O
a	O
,	O
T	O
FIO2	O
56	O
.	O
9	O
mmHg	O
.	O
Biochemistry	O
admission	O
glucose	O
223	O
mg	O
dl	O
,	O
urea	O
49	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
04	O
mg	O
dl	O
,	O
CKDEPI	O
estimate	O
83	O
ml	O
min	O
1	O
.	O
73	O
m2	O
,	O
sodium	O
138	O
mmol	O
l	O
,	O
potassium	O
4	O
.	O
4	O
mEq	O
l	O
,	O
chlorine	O
106	O
mEq	O
l	O
,	O
calcium	O
8	O
,	O
2	O
mg	O
dl	O
,	O
magnesium	O
1	O
.	O
8	O
mg	O
dl	O
,	O
CK	O
359	O
IU	O
l	O
,	O
CKMB	O
50	O
U	O
l	O
,	O
ultrasensitive	O
troponin	O
996	O
.	O
1	O
ng	O
l	O
normal	O
15	O
ng	O
l	O
,	O
procalcitonin	O
6	O
.	O
45	O
ng	O
ml	O
,	O
C	O
reactive	O
protein	O
8	O
.	O
3	O
mg	O
l	O
.	O
Haemogram	O
admission	O
leucocytes	O
23	O
,	O
300	O
l	O
,	O
84	O
neutrophils	O
,	O
haemoglobin	O
17	O
g	O
dl	O
,	O
haematocrit	O
50	O
,	O
platelets	O
302	O
,	O
000	O
l	O
.	O
Coagulation	O
admission	O
prothrombin	O
rate	O
100	O
,	O
INR	O
1	O
,	O
derived	O
fibrinogen	O
361	O
mg	O
dl	O
.	O
Haemodynamic	O
study	O
admission	O
coronary	O
arteries	O
without	O
angiographically	O
significant	O
stenosis	O
.	O
Ventriculography	O
left	O
ventricle	O
with	O
normal	O
function	O
,	O
with	O
LVEF	O
53	O
TVD	O
144	O
ml	O
and	O
STV	O
67ml	O
.	O
Aortography	O
trivalve	O
aorta	O
without	O
insufficiency	O
or	O
significant	O
transvalvular	O
gradient	O
.	O
Ascending	O
aorta	O
not	O
dilated	O
.	O
No	O
images	O
suggestive	O
of	O
aortic	O
dissection	O
.	O
Chest	O
CT	O
with	O
contrast	O
admission	O
no	O
signs	O
of	O
pulmonary	O
thromboembolism	O
.	O
Pulmonary	O
artery	O
trunk	O
and	O
thoracic	O
aorta	O
of	O
normal	O
size	O
.	O
No	O
pericardial	O
or	O
pleural	O
effusion	O
.	O
Right	O
hilar	O
adenopathy	O
of	O
1	O
.	O
5	O
cm	O
,	O
non	O
specific	O
.	O
Small	O
ipsilateral	O
ipsilateral	O
lateroaortic	O
and	O
interlobar	O
prevascular	O
calcified	O
adenopathies	O
,	O
probably	O
residual	O
.	O
Lung	O
apexes	O
artefacted	O
by	O
respiratory	O
movements	O
.	O
Endotracheal	O
tube	O
about	O
3	O
cm	O
from	O
the	O
carina	O
.	O
The	O
posterior	O
segment	O
of	O
the	O
LSD	O
,	O
part	O
of	O
the	O
apical	O
segment	O
and	O
posterobasal	O
segments	O
of	O
the	O
LID	O
,	O
as	O
well	O
as	O
the	O
apical	O
and	O
posterobasal	O
segments	O
of	O
the	O
LII	O
are	O
consolidated	O
with	O
air	O
bronchogram	O
suggesting	O
atelectasis	O
,	O
probably	O
secondary	O
to	O
accumulation	O
of	O
secretions	O
,	O
decubitus	O
or	O
bronchoaspiration	O
.	O
Linear	O
subpleural	O
calcification	O
in	O
the	O
posterior	O
subsegment	O
of	O
the	O
LSI	O
of	O
cicatricial	O
or	O
residual	O
appearance	O
.	O
Secretions	O
in	O
proximal	O
trachea	O
.	O
Marked	O
dilatation	O
of	O
gastric	O
chamber	O
with	O
hydro	O
aerial	O
level	O
in	O
relation	O
to	O
previous	O
CPR	O
manoeuvres	O
.	O
CT	O
scan	O
of	O
the	O
brain	O
without	O
contrast	O
admission	O
no	O
significant	O
alterations	O
.	O
Echocardiogram	O
left	O
ventricle	O
of	O
normal	O
dimensions	O
and	O
geometry	O
,	O
with	O
preserved	O
ejection	O
fraction	O
LVEF	O
60	O
.	O
Right	O
ventricle	O
of	O
normal	O
dimensions	O
,	O
with	O
normal	O
systolic	O
function	O
.	O
Morphologically	O
normal	O
valves	O
,	O
with	O
trivial	O
mitral	O
insufficiency	O
.	O
No	O
alterations	O
of	O
note	O
.	O
Chest	O
X	O
ray	O
admission	O
normal	O
cardiothoracic	O
index	O
,	O
lung	O
parenchyma	O
and	O
bronchovascular	O
tract	O
without	O
alterations	O
.	O
Continuous	O
electrocardiographic	O
monitoring	O
second	O
day	O
of	O
admission	O
sinus	O
rhythm	O
without	O
repolarisation	O
alterations	O
.	O
Progressive	O
ST	O
segment	O
elevation	O
was	O
observed	O
in	O
the	O
only	O
lead	O
recorded	O
,	O
subsequently	O
presenting	O
sustained	O
monomorphic	O
ventricular	O
tachycardia	O
that	O
degenerated	O
into	O
ventricular	O
fibrillation	O
with	O
normalisation	O
of	O
repolarisation	O
alterations	O
after	O
administration	O
of	O
intravenous	O
nitroglycerine	B-FARMACO
.	O
MRI	O
12th	O
day	O
of	O
admission	O
no	O
global	O
or	O
segmental	O
alterations	O
in	O
myocardial	O
contractility	O
.	O
Late	O
enhancement	O
sequences	O
without	O
alterations	O
.	O
Normal	O
first	O
pass	O
myocardial	O
perfusion	O
study	O
.	O
Cardiac	O
cavity	O
diameters	O
VITD	O
50	O
mm	O
,	O
VITS	O
34	O
mm	O
,	O
LA	O
23	O
cm2	O
,	O
VDTD	O
40	O
mm	O
,	O
VDTS	O
31	O
mm	O
,	O
AD	O
22	O
cm2	O
.	O
Left	O
ventricular	O
function	O
preserved	O
,	O
with	O
LVEF	O
62	O
,	O
with	O
values	O
indexed	O
by	O
body	O
surface	O
area	O
m2	O
VTD	O
125	O
ml	O
,	O
VTS	O
47	O
ml	O
,	O
stroke	O
volume	O
78	O
ml	O
.	O
Flow	O
artefacts	O
compatible	O
with	O
mitral	O
insufficiency	O
MI	O
and	O
tricuspid	O
insufficiency	O
TI	O
,	O
not	O
significant	O
.	O
Conclusion	O
study	O
within	O
normal	O
limits	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
transferred	O
to	O
the	O
emergency	O
department	O
of	O
our	O
centre	O
due	O
to	O
out	O
of	O
hospital	O
cardiorespiratory	O
arrest	O
.	O
Given	O
that	O
he	O
presented	O
electrocardiographic	O
alterations	O
suggestive	O
of	O
acute	O
coronary	O
syndrome	O
,	O
urgent	O
coronary	O
angiography	O
was	O
performed	O
showing	O
coronary	O
arteries	O
without	O
lesions	O
,	O
cranial	O
CT	O
and	O
thoracic	O
CT	O
angiography	O
,	O
which	O
ruled	O
out	O
acute	O
pathology	O
justifying	O
the	O
arrest	O
.	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
cardiac	O
critical	O
care	O
unit	O
and	O
therapeutic	O
hypothermia	O
was	O
started	O
.	O
Echocardioscopy	O
was	O
performed	O
,	O
showing	O
a	O
left	O
ventricle	O
with	O
preserved	O
ventricular	O
function	O
and	O
no	O
abnormalities	O
of	O
contractility	O
,	O
with	O
no	O
significant	O
alterations	O
.	O
On	O
the	O
second	O
day	O
of	O
admission	O
he	O
presented	O
a	O
sudden	O
rise	O
in	O
the	O
ST	O
segment	O
recorded	O
in	O
the	O
single	O
lead	O
of	O
the	O
continuous	O
electrocardiographic	O
monitoring	O
,	O
with	O
a	O
subsequent	O
bout	O
of	O
sustained	O
ventricular	O
tachycardia	O
that	O
degenerated	O
into	O
ventricular	O
fibrillation	O
without	O
haemodynamic	O
compromise	O
,	O
which	O
resolved	O
after	O
treatment	O
with	O
intravenous	O
nitroglycerine	B-FARMACO
.	O
Given	O
clinical	O
suspicion	O
of	O
vasospasm	O
,	O
an	O
urgent	O
blood	O
test	O
and	O
arterial	O
blood	O
gas	O
analysis	O
were	O
performed	O
,	O
ruling	O
out	O
hydroelectrolyte	O
alterations	O
;	O
even	O
so	O
,	O
hypothermia	O
therapy	O
was	O
withdrawn	O
.	O
During	O
his	O
stay	O
in	O
the	O
cardiovascular	O
critical	O
care	O
unit	O
,	O
the	O
patient	O
presented	O
a	O
febrile	O
peak	O
and	O
parameters	O
of	O
infection	O
of	O
probable	O
respiratory	O
origin	O
,	O
which	O
was	O
resolved	O
with	O
antibiotic	O
therapy	O
with	O
imipenem	B-FARMACO
1	O
g	O
i	O
.	O
v	O
.	O
every	O
8	O
hours	O
and	O
linezolid	B-FARMACO
600	O
mg	O
i	O
.	O
v	O
.	O
every	O
12	O
hours	O
for	O
10	O
days	O
.	O
Given	O
the	O
good	O
haemodynamic	O
,	O
neurological	O
and	O
respiratory	O
evolution	O
,	O
the	O
patient	O
was	O
extubated	O
without	O
incident	O
on	O
the	O
eighth	O
day	O
of	O
admission	O
.	O
After	O
being	O
discharged	O
to	O
the	O
hospital	O
ward	O
,	O
he	O
made	O
good	O
progress	O
.	O
Cardiac	O
magnetic	O
resonance	O
was	O
performed	O
,	O
which	O
was	O
normal	O
,	O
ruling	O
out	O
structural	O
heart	O
disease	O
.	O
Prior	O
to	O
discharge	O
,	O
it	O
was	O
decided	O
to	O
implant	O
a	O
single	O
chamber	O
automatic	O
implantable	O
cardioverter	O
defibrillator	O
ICD	O
as	O
secondary	O
prevention	O
,	O
and	O
he	O
was	O
discharged	O
stable	O
and	O
asymptomatic	O
.	O
DIAGNOSIS	O
Out	O
of	O
hospital	O
cardiorespiratory	O
arrest	O
recovered	O
due	O
to	O
ventricular	O
fibrillation	O
.	O
Structurally	O
normal	O
heart	O
.	O
Acute	O
coronary	O
syndrome	O
with	O
non	O
persistent	O
ST	O
segment	O
elevation	O
due	O
to	O
coronary	O
vasospasm	O
.	O
Single	O
chamber	O
ICD	O
implantation	O
for	O
secondary	O
prevention	O
.	O
Respiratory	O
infection	O
secondary	O
to	O
bronchoaspiration	O
,	O
resolved	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
A	O
66	O
year	O
old	O
male	O
,	O
hypertensive	O
,	O
type	O
2	O
diabetic	O
,	O
dyslipidaemic	O
and	O
ex	O
smoker	O
,	O
with	O
no	O
other	O
history	O
of	O
interest	O
,	O
attended	O
the	O
emergency	O
department	O
in	O
April	O
2020	O
for	O
progressive	O
dyspnoea	O
of	O
several	O
days	O
'	O
evolution	O
and	O
fever	O
,	O
with	O
no	O
other	O
associated	O
cardiovascular	O
symptoms	O
.	O
Home	O
treatment	O
with	O
enalapril	B-FARMACO
5	O
mg	O
24	O
hours	O
,	O
atorvastatin	B-FARMACO
40	O
mg	O
24	O
hours	O
and	O
metformin	B-FARMACO
850	O
mg	O
24	O
hours	O
.	O
On	O
first	O
examination	O
,	O
the	O
patient	O
was	O
haemodynamically	O
stable	O
,	O
although	O
his	O
general	O
condition	O
was	O
poor	O
.	O
Blood	O
pressure	O
BP	O
130	O
75	O
mmHg	O
,	O
heart	O
rate	O
HR	O
75	O
bpm	O
,	O
RR	O
30	O
rpm	O
,	O
basal	O
saturation	O
85	O
,	O
temperature	O
38	O
.	O
3	O
oC	O
.	O
Pulmonary	O
auscultation	O
showed	O
bilateral	O
crackles	O
in	O
both	O
fields	O
,	O
with	O
normal	O
cardiac	O
auscultation	O
and	O
no	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
COMPLEMENTARY	O
TESTS	O
Arterial	O
blood	O
gases	O
Hypoxaemic	O
respiratory	O
failure	O
.	O
pH	O
7	O
.	O
35	O
,	O
pCO2	O
30	O
mmHg	O
,	O
pO2	O
62	O
mmHg	O
,	O
HCO3	O
25	O
mmol	O
l	O
,	O
lactic	O
2	O
.	O
3	O
.	O
Electrocardiogram	O
ECG	O
sinus	O
rhythm	O
at	O
75	O
bpm	O
,	O
normal	O
PR	O
,	O
narrow	O
QRS	O
,	O
normal	O
axis	O
,	O
diffuse	O
repolarisation	O
alterations	O
flattened	O
T	O
in	O
inferior	O
and	O
lateral	O
face	O
not	O
suggestive	O
of	O
acute	O
ischaemia	O
.	O
Chest	O
X	O
ray	O
peripheral	O
infiltrate	O
in	O
the	O
left	O
mid	O
inferior	O
field	O
and	O
of	O
lesser	O
density	O
in	O
the	O
peripheral	O
region	O
of	O
the	O
midfield	O
and	O
right	O
paracardiac	O
region	O
,	O
compatible	O
with	O
SARS	O
CoV2	O
infection	O
of	O
moderate	O
degree	O
from	O
the	O
radiological	O
point	O
of	O
view	O
.	O
CBC	O
creatinine	O
0	O
.	O
96	O
mg	O
dl	O
,	O
no	O
ionic	O
alterations	O
,	O
liver	O
profile	O
with	O
mild	O
elevation	O
of	O
transaminases	O
,	O
first	O
troponin	O
T	O
150	O
ng	O
dl	O
,	O
second	O
troponin	O
T	O
200	O
ng	O
dl	O
,	O
CK	O
100U	O
l	O
,	O
LDH	O
450U	O
l	O
,	O
Hb	O
11mg	O
dl	O
,	O
platelets	O
160	O
,	O
000	O
ul	O
,	O
leukocytes	O
9000	O
ul	O
,	O
neutrophils	O
80	O
,	O
lymphocytes	O
1000	O
ul	O
,	O
D	O
dimers	O
900	O
ng	O
ml	O
.	O
Nasopharyngeal	O
PCR	O
for	O
SARS	O
CoV2	O
positive	O
.	O
CLINICAL	O
COURSE	O
In	O
view	O
of	O
these	O
findings	O
,	O
the	O
patient	O
was	O
diagnosed	O
with	O
bilateral	O
SARS	O
CoV2	O
pneumonia	O
with	O
associated	O
acute	O
hypoxaemic	O
respiratory	O
failure	O
,	O
so	O
he	O
was	O
admitted	O
and	O
treatment	O
was	O
started	O
with	O
oxygen	O
therapy	O
for	O
SatO2	O
90	O
,	O
reducing	O
the	O
patient	O
's	O
respiratory	O
rate	O
,	O
hydroxychloroquine	B-FARMACO
400	O
mg	O
12	O
hours	O
for	O
the	O
first	O
24	O
hours	O
and	O
then	O
200	O
mg	O
12	O
hours	O
v	O
.	O
o	O
.	O
,	O
liponavir	O
and	O
liponavir	O
400	O
mg	O
12	O
hours	O
for	O
the	O
first	O
24	O
hours	O
and	O
then	O
200	O
mg	O
12	O
hours	O
v	O
.	O
o	O
.	O
.	O
o	O
.	O
,	O
liponavir	B-FARMACO
ritonavir	I-FARMACO
200	O
50	O
mg	O
12	O
hours	O
o	O
.	O
v	O
.	O
,	O
azithromycin	B-FARMACO
500	O
mg	O
24	O
hours	O
o	O
.	O
v	O
.	O
and	O
ceftriaxone	B-FARMACO
2	O
g	O
24	O
hours	O
i	O
.	O
v	O
.	O
When	O
markers	O
of	O
myocardial	O
damage	O
were	O
elevated	O
due	O
to	O
suspicion	O
of	O
associated	O
myocarditis	O
,	O
the	O
cardiology	O
department	O
was	O
consulted	O
.	O
In	O
the	O
transthoracic	O
echocardiogram	O
,	O
the	O
patient	O
showed	O
a	O
non	O
dilated	O
,	O
slightly	O
hypertrophic	O
left	O
ventricle	O
,	O
with	O
hypokinesia	O
of	O
the	O
distal	O
middle	O
segments	O
of	O
the	O
inferior	O
septum	O
,	O
and	O
normal	O
LVEF	O
;	O
a	O
non	O
dilated	O
,	O
normofunctioning	O
right	O
ventricle	O
,	O
and	O
absence	O
of	O
significant	O
valvular	O
heart	O
disease	O
or	O
pericardial	O
effusion	O
video	O
1	O
.	O
We	O
interpreted	O
the	O
elevated	O
markers	O
of	O
myocardial	O
damage	O
as	O
justifiable	O
by	O
the	O
clinical	O
context	O
of	O
the	O
patient	O
hypoxaemia	O
,	O
acute	O
infection	O
,	O
possible	O
underlying	O
heart	O
disease	O
and	O
did	O
not	O
perform	O
further	O
tests	O
.	O
The	O
patient	O
evolved	O
favourably	O
and	O
was	O
discharged	O
10	O
days	O
after	O
admission	O
.	O
DIAGNOSIS	O
Bilateral	O
SARS	O
CoV2	O
pneumonia	O
with	O
elevated	O
markers	O
of	O
myocardial	O
damage	O
in	O
this	O
context	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
No	O
drug	O
allergies	O
.	O
No	O
toxic	O
habits	O
.	O
Cardiovascular	O
risk	O
factors	O
Arterial	O
hypertension	O
.	O
Dyslipidaemia	O
.	O
Cardiological	O
history	O
PAF	O
subjected	O
to	O
ablation	O
in	O
2015	O
.	O
Chronic	O
ischaemic	O
heart	O
disease	O
,	O
debut	O
in	O
2010	O
as	O
exertional	O
angina	O
,	O
and	O
underwent	O
percutaneous	O
revascularisation	O
by	O
implanting	O
a	O
conventional	O
stent	O
in	O
the	O
circumflex	O
artery	O
.	O
In	O
2013	O
,	O
readmission	O
for	O
unstable	O
angina	O
with	O
percutaneous	O
revascularisation	O
and	O
implantation	O
of	O
a	O
stent	O
eluting	O
stent	O
in	O
the	O
proximal	O
segment	O
of	O
the	O
anterior	O
descending	O
artery	O
.	O
Ejection	O
fraction	O
preserved	O
.	O
Other	O
antecedents	O
Spondyloarthrosis	O
.	O
Prostatic	O
syndrome	O
.	O
Bilateral	O
hearing	O
loss	O
.	O
Surgical	O
interventions	O
Pertrochanteric	O
fracture	O
of	O
the	O
left	O
hip	O
in	O
2018	O
.	O
Baseline	O
situation	O
independent	O
for	O
basic	O
activities	O
of	O
daily	O
living	O
.	O
Preserved	O
higher	O
functions	O
.	O
Home	O
treatment	O
carvedilol	B-FARMACO
25	O
mg	O
,	O
half	O
a	O
tablet	O
every	O
12	O
hours	O
.	O
Omeprazole	B-FARMACO
20	O
mg	O
,	O
1	O
tablet	O
every	O
24	O
hours	O
.	O
Ramipril	B-FARMACO
5	O
mg	O
,	O
1	O
tablet	O
every	O
24	O
hours	O
.	O
Ezetimibe	B-FARMACO
10	O
mg	O
atorvastatin	B-FARMACO
80	O
mg	O
,	O
1	O
tablet	O
every	O
24	O
hours	O
.	O
Edoxaban	B-FARMACO
60	O
mg	O
,	O
1	O
tablet	O
every	O
24	O
hours	O
.	O
Alendronic	B-FARMACO
acid	O
every	O
28	O
days	O
.	O
Present	O
illness	O
A	O
76	O
year	O
old	O
man	O
came	O
to	O
the	O
emergency	O
department	O
with	O
fluctuating	O
weakness	O
of	O
the	O
left	O
limbs	O
after	O
a	O
fierce	O
argument	O
with	O
his	O
son	O
and	O
associated	O
nervousness	O
.	O
He	O
was	O
assessed	O
by	O
neurology	O
with	O
no	O
other	O
neurological	O
deficit	O
and	O
a	O
simple	O
CT	O
scan	O
of	O
the	O
skull	O
was	O
performed	O
with	O
no	O
early	O
signs	O
or	O
acute	O
ischaemic	O
lesions	O
,	O
and	O
angio	O
CT	O
without	O
occlusion	O
of	O
a	O
large	O
vessel	O
.	O
As	O
a	O
result	O
,	O
and	O
in	O
view	O
of	O
the	O
improvement	O
in	O
symptoms	O
,	O
the	O
patient	O
was	O
discharged	O
with	O
recommendations	O
on	O
alarm	O
data	O
.	O
Four	O
days	O
later	O
,	O
he	O
returned	O
to	O
the	O
emergency	O
department	O
due	O
to	O
a	O
progressive	O
worsening	O
of	O
his	O
symptoms	O
,	O
and	O
a	O
new	O
cranial	O
CT	O
scan	O
was	O
performed	O
which	O
confirmed	O
the	O
existence	O
of	O
an	O
established	O
infarct	O
with	O
a	O
new	O
appearance	O
of	O
a	O
hypodense	O
focal	O
area	O
in	O
the	O
right	O
lenticular	O
and	O
radial	O
crown	O
.	O
The	O
patient	O
was	O
treated	O
with	O
edoxaban	B-FARMACO
as	O
anticoagulation	O
for	O
PAF	O
,	O
ensuring	O
good	O
compliance	O
with	O
treatment	O
.	O
Physical	O
examination	O
Good	O
general	O
condition	O
.	O
Haemodynamically	O
stable	O
,	O
blood	O
pressure	O
128	O
68	O
mmHg	O
and	O
heart	O
rate	O
53	O
bpm	O
.	O
Afebrile	O
.	O
Eupneic	O
at	O
rest	O
and	O
when	O
speaking	O
,	O
with	O
total	O
tolerance	O
of	O
decubitus	O
.	O
Normal	O
colour	O
and	O
no	O
skin	O
lesions	O
.	O
Neurological	O
examination	O
good	O
level	O
of	O
consciousness	O
,	O
he	O
was	O
able	O
to	O
name	O
,	O
understand	O
and	O
repeat	O
without	O
language	O
alterations	O
.	O
No	O
oculocephalic	O
deviation	O
or	O
campimetric	O
deficit	O
.	O
Pupils	O
isochoric	O
and	O
normoreactive	O
to	O
light	O
and	O
accommodation	O
.	O
Preserved	O
external	O
ocular	O
motors	O
.	O
Left	O
gestural	O
asymmetry	O
.	O
Claudica	O
without	O
contact	O
with	O
bed	O
with	O
left	O
limbs	O
requires	O
insistence	O
to	O
perform	O
antigravity	O
manoeuvres	O
.	O
Hypoalgesia	O
in	O
left	O
hemibody	O
.	O
No	O
dysmetria	O
,	O
no	O
dysarthria	O
,	O
no	O
parietal	O
cortical	O
data	O
.	O
Walking	O
with	O
the	O
help	O
of	O
two	O
people	O
.	O
Cardiopulmonary	O
auscultation	O
rhythmic	O
,	O
without	O
murmurs	O
and	O
with	O
preserved	O
vesicular	O
murmur	O
without	O
added	O
pathological	O
noises	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
no	O
masses	O
or	O
megaliths	O
palpable	O
and	O
painless	O
on	O
palpation	O
.	O
Lower	O
limbs	O
no	O
oedema	O
,	O
no	O
fovea	O
and	O
no	O
evidence	O
of	O
deep	O
vein	O
thrombosis	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
sinus	O
bradycardia	O
at	O
53	O
beats	O
per	O
minute	O
.	O
Normal	O
axis	O
.	O
PR	O
240	O
ms	O
.	O
QRS	O
80	O
ms	O
.	O
R	O
amputated	O
in	O
aVL	O
.	O
Elevation	O
of	O
the	O
J	O
point	O
in	O
the	O
inferolateral	O
face	O
.	O
CBC	O
glucose	O
105	O
mg	O
dl	O
.	O
Creatinine	O
0	O
.	O
84	O
mg	O
dl	O
.	O
Sodium	O
140	O
mEq	O
l	O
.	O
Potassium	O
4	O
mEq	O
l	O
.	O
Leukocytes	O
7900	O
68	O
polymorphonuclear	O
.	O
Haemoglobin	O
12	O
g	O
dl	O
.	O
Platelets	O
183	O
,	O
000	O
.	O
INR	O
1	O
.	O
21	O
.	O
Troponin	O
T	O
ultrasensitive	O
15	O
ng	O
l	O
.	O
Creatine	O
kinase	O
59	O
U	O
l	O
.	O
Chest	O
X	O
ray	O
normal	O
cardiothoracic	O
index	O
.	O
Prominent	O
aortic	O
button	O
.	O
Thickened	O
hilae	O
,	O
with	O
increased	O
bronchovascular	O
raster	O
and	O
redistribution	O
to	O
the	O
vertex	O
.	O
Cranial	O
CT	O
scan	O
hypodense	O
focal	O
area	O
in	O
the	O
right	O
lenticular	O
and	O
radial	O
crown	O
,	O
compatible	O
with	O
established	O
focal	O
infarction	O
.	O
No	O
other	O
relevant	O
findings	O
.	O
Transthoracic	O
and	O
transesophageal	O
echocardiography	O
the	O
left	O
atrium	O
LA	O
is	O
not	O
dilated	O
36	O
mm	O
.	O
The	O
mitral	O
valve	O
has	O
normal	O
leaflets	O
,	O
without	O
insufficiency	O
.	O
The	O
left	O
ventricle	O
LV	O
is	O
of	O
normal	O
dimensions	O
end	O
diastolic	O
diameter	O
44	O
mm	O
.	O
Ejection	O
fraction	O
by	O
Simpson	O
biplane	O
60	O
without	O
regional	O
contractility	O
alterations	O
.	O
Septum	O
10	O
mm	O
.	O
Posterior	O
wall	O
8	O
mm	O
.	O
Mitral	O
E	O
79	O
cm	O
s	O
,	O
A	O
64	O
cm	O
s	O
.	O
Trivalve	O
aortic	O
valve	O
with	O
good	O
opening	O
and	O
closing	O
.	O
Sinuses	O
of	O
Valsalva	O
37	O
mm	O
,	O
ascending	O
tubular	O
aorta	O
32	O
mm	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
and	O
contractility	O
.	O
Normal	O
tricuspid	O
valve	O
without	O
insufficiency	O
.	O
Mild	O
pulmonary	O
insufficiency	O
with	O
mean	O
pulmonary	O
artery	O
pressure	O
14	O
mmHg	O
.	O
Normal	O
inferior	O
vena	O
cava	O
.	O
No	O
pericardial	O
effusion	O
.	O
Large	O
mobile	O
mass	O
in	O
LA	O
with	O
wide	O
insertion	O
pedicle	O
of	O
21	O
mm	O
,	O
in	O
the	O
posterior	O
wall	O
of	O
the	O
atrial	O
roof	O
.	O
In	O
this	O
area	O
of	O
the	O
atrial	O
wall	O
there	O
is	O
a	O
minimal	O
pericardial	O
fluid	O
sheet	O
of	O
1	O
.	O
5	O
mm	O
.	O
The	O
mass	O
is	O
6	O
.	O
1	O
cm	O
long	O
maximum	O
width	O
2	O
cm	O
,	O
highly	O
mobile	O
,	O
polylobulated	O
branched	O
,	O
with	O
an	O
irregular	O
surface	O
and	O
several	O
long	O
,	O
mobile	O
outgrowths	O
.	O
The	O
length	O
of	O
the	O
mass	O
causes	O
it	O
to	O
prolapse	O
in	O
diastole	O
through	O
the	O
mitral	O
orifice	O
into	O
the	O
base	O
of	O
the	O
LV	O
without	O
causing	O
mitral	O
obstruction	O
.	O
The	O
echogenicity	O
of	O
the	O
mass	O
is	O
hypoechoic	O
in	O
the	O
area	O
of	O
implantation	O
,	O
with	O
the	O
rest	O
being	O
of	O
higher	O
echogenicity	O
,	O
with	O
some	O
rounded	O
hypoechoic	O
area	O
in	O
the	O
body	O
.	O
Mitral	O
valve	O
with	O
normal	O
leaflets	O
,	O
without	O
insufficiency	O
.	O
Left	O
atrial	O
appendage	O
without	O
thrombus	O
.	O
Normal	O
aortic	O
valve	O
and	O
proximal	O
aorta	O
.	O
Descending	O
thoracic	O
aorta	O
with	O
some	O
uncomplicated	O
atheroma	O
plaque	O
.	O
Conclusions	O
large	O
mass	O
6	O
.	O
1	O
x	O
2	O
cm	O
mobile	O
in	O
left	O
atrium	O
,	O
inserted	O
with	O
wide	O
pedicle	O
2	O
.	O
1	O
cm	O
in	O
atrial	O
roof	O
posterior	O
wall	O
.	O
Thoracoabdominal	O
CT	O
scan	O
LA	O
of	O
normal	O
dimensions	O
.	O
Hypodense	O
mass	O
of	O
irregular	O
contours	O
and	O
with	O
excrescences	O
that	O
seems	O
to	O
be	O
fixed	O
in	O
the	O
angle	O
formed	O
by	O
the	O
posterior	O
wall	O
of	O
the	O
LA	O
with	O
the	O
inferoposterior	O
slope	O
of	O
the	O
interatrial	O
septum	O
below	O
the	O
mouth	O
of	O
the	O
right	O
inferior	O
pulmonary	O
vein	O
without	O
affecting	O
its	O
drainage	O
.	O
Its	O
approximate	O
dimensions	O
are	O
47	O
x	O
21	O
mm	O
in	O
the	O
apical	O
4C	O
Ap	O
x	O
T	O
plane	O
and	O
a	O
CC	O
axis	O
of	O
29	O
mm	O
in	O
the	O
EL	O
plane	O
.	O
Apart	O
from	O
the	O
described	O
anchorage	O
,	O
its	O
growth	O
is	O
fundamentally	O
intracavitary	O
,	O
with	O
no	O
invasiveness	O
of	O
adjacent	O
cardiovascular	O
structures	O
.	O
Slight	O
overlapping	O
of	O
the	O
mitral	O
valve	O
plane	O
towards	O
the	O
LV	O
.	O
LV	O
and	O
right	O
chambers	O
of	O
normal	O
dimensions	O
.	O
High	O
coronary	O
calcium	O
load	O
in	O
the	O
proximal	O
course	O
of	O
the	O
coronary	O
arteries	O
.	O
Thoracic	O
aorta	O
of	O
normal	O
calibre	O
,	O
slightly	O
elongated	O
and	O
with	O
calcium	O
predominant	O
atheromatosis	O
in	O
the	O
arch	O
and	O
origin	O
of	O
supra	O
aortic	O
trunks	O
.	O
Pulmonary	O
trunk	O
of	O
normal	O
dimensions	O
,	O
as	O
well	O
as	O
the	O
branches	O
,	O
without	O
repletion	O
defects	O
.	O
No	O
adenomegaly	O
or	O
suspicious	O
lymph	O
nodes	O
.	O
Signs	O
of	O
smoking	O
can	O
be	O
seen	O
in	O
the	O
lung	O
parenchyma	O
.	O
Biapical	O
fibrocystic	O
tracts	O
.	O
No	O
pulmonary	O
consolidations	O
or	O
nodules	O
are	O
identified	O
.	O
Liver	O
of	O
adequate	O
size	O
and	O
attenuation	O
,	O
without	O
identifying	O
LOEs	O
.	O
No	O
significant	O
findings	O
in	O
the	O
gallbladder	O
,	O
bile	O
duct	O
,	O
splenoportal	O
axis	O
,	O
spleen	O
,	O
adrenal	O
or	O
pancreas	O
.	O
Kidneys	O
of	O
normal	O
size	O
and	O
differentiation	O
with	O
several	O
post	O
pelonephritic	O
cortical	O
scars	O
and	O
parapelvic	O
and	O
cortical	O
cysts	O
.	O
No	O
dilatation	O
of	O
their	O
excretory	O
systems	O
.	O
Moderately	O
replete	O
urinary	O
bladder	O
with	O
no	O
areas	O
of	O
mural	O
thickening	O
.	O
Moderate	O
prostatic	O
hypertrophy	O
.	O
Stomach	O
almost	O
empty	O
,	O
not	O
very	O
appreciable	O
.	O
Small	O
bowel	O
loops	O
and	O
right	O
colon	O
with	O
mural	O
thickness	O
caliber	O
disruption	O
.	O
Moderate	O
aortoiliac	O
atheromatosis	O
.	O
No	O
inguinal	O
adenomegaly	O
of	O
suspicious	O
appearance	O
.	O
Osteoporosis	O
.	O
Central	O
wedging	O
of	O
L2	O
in	O
this	O
context	O
AND	O
more	O
mildly	O
in	O
some	O
dorsal	O
bodies	O
.	O
Fracture	O
of	O
the	O
left	O
femur	O
treated	O
with	O
nail	O
and	O
screw	O
consolidated	O
.	O
Conclusion	O
irregular	O
hypodense	O
mass	O
anchored	O
in	O
the	O
angle	O
between	O
the	O
lower	O
wall	O
of	O
the	O
LA	O
and	O
the	O
posteroinferior	O
aspect	O
of	O
the	O
interatrial	O
septum	O
.	O
No	O
signs	O
of	O
current	O
metastatic	O
spread	O
.	O
Coronary	O
angiography	O
right	O
radial	O
access	O
.	O
Coronary	O
arteries	O
with	O
previously	O
implanted	O
stents	O
in	O
anterior	O
descending	O
artery	O
and	O
circumflex	O
artery	O
without	O
restenosis	O
and	O
without	O
other	O
significant	O
lesions	O
.	O
Right	O
dominance	O
.	O
Pathological	O
anatomy	O
multiple	O
tissue	O
fragments	O
of	O
gelatinous	O
consistency	O
,	O
the	O
largest	O
of	O
which	O
was	O
2x1	O
cm	O
,	O
one	O
of	O
which	O
was	O
found	O
adhered	O
to	O
the	O
muscle	O
wall	O
.	O
Conclusion	O
myxoma	O
with	O
respect	O
of	O
the	O
implantation	O
base	O
.	O
CLINICAL	O
EVOLUTION	O
On	O
admission	O
to	O
the	O
neurology	O
ward	O
,	O
and	O
in	O
view	O
of	O
the	O
suspected	O
embolic	O
origin	O
of	O
the	O
stroke	O
,	O
a	O
regular	O
echocardiography	O
was	O
requested	O
,	O
where	O
the	O
culprit	O
of	O
the	O
event	O
was	O
discovered	O
.	O
Initially	O
,	O
a	O
transthoracic	O
study	O
was	O
performed	O
,	O
where	O
a	O
normal	O
heart	O
was	O
visualised	O
,	O
finding	O
a	O
large	O
mobile	O
mass	O
6	O
.	O
1	O
x	O
2	O
cm	O
attached	O
to	O
the	O
posterior	O
wall	O
of	O
the	O
left	O
atrium	O
,	O
so	O
for	O
a	O
better	O
characterisation	O
the	O
study	O
was	O
completed	O
with	O
transesophageal	O
echocardiography	O
.	O
Despite	O
the	O
high	O
suspicion	O
of	O
myxoma	O
,	O
the	O
characteristics	O
of	O
the	O
mass	O
wide	O
insertion	O
not	O
in	O
the	O
interatrial	O
septum	O
,	O
polylobulated	O
branched	O
and	O
with	O
hypoechoic	O
areas	O
inside	O
do	O
not	O
clearly	O
indicate	O
this	O
aetiology	O
,	O
but	O
rather	O
extend	O
the	O
differential	O
diagnosis	O
to	O
other	O
entities	O
with	O
a	O
worse	O
prognosis	O
.	O
.	O
.	O
such	O
as	O
sarcoma	O
.	O
A	O
CT	O
scan	O
of	O
the	O
thorax	O
and	O
abdomen	O
was	O
performed	O
,	O
which	O
provided	O
some	O
reassurance	O
as	O
no	O
signs	O
of	O
metastatic	O
dissemination	O
were	O
observed	O
.	O
After	O
diagnosis	O
,	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
cardiology	O
ward	O
,	O
where	O
the	O
pre	O
surgical	O
study	O
was	O
completed	O
coronary	O
angiography	O
with	O
stability	O
of	O
coronary	O
disease	O
.	O
After	O
a	O
week	O
of	O
hospitalisation	O
,	O
without	O
complications	O
and	O
with	O
greater	O
safety	O
from	O
the	O
point	O
of	O
view	O
of	O
intracranial	O
haemorrhagic	O
risk	O
,	O
surgery	O
was	O
performed	O
,	O
in	O
which	O
wedge	O
resection	O
of	O
the	O
floor	O
of	O
the	O
left	O
atrium	O
was	O
performed	O
with	O
the	O
implantation	O
base	O
of	O
the	O
tumour	O
,	O
which	O
the	O
surgeons	O
described	O
as	O
a	O
brownish	O
,	O
gelatinous	O
and	O
very	O
friable	O
tumour	O
.	O
Subsequent	O
evolution	O
in	O
the	O
intensive	O
care	O
unit	O
and	O
on	O
the	O
cardiology	O
ward	O
was	O
very	O
favourable	O
and	O
without	O
complications	O
.	O
The	O
patient	O
was	O
discharged	O
7	O
days	O
after	O
the	O
operation	O
,	O
and	O
in	O
agreement	O
with	O
neurology	O
,	O
anticoagulation	O
was	O
restarted	O
with	O
edoxaban	B-FARMACO
60	O
mg	O
every	O
24	O
hours	O
.	O
After	O
the	O
anatomopathological	O
study	O
of	O
the	O
surgical	O
specimen	O
,	O
it	O
was	O
possible	O
to	O
name	O
the	O
tumour	O
,	O
confirming	O
the	O
initial	O
suspicion	O
of	O
myxoma	O
that	O
the	O
echocardiography	O
had	O
provided	O
.	O
The	O
patient	O
is	O
currently	O
undergoing	O
motor	O
rehabilitation	O
due	O
to	O
the	O
sequelae	O
of	O
left	O
lower	O
limb	O
hemiparesis	O
,	O
and	O
from	O
the	O
cardiological	O
point	O
of	O
view	O
he	O
is	O
asymptomatic	O
and	O
without	O
any	O
complications	O
.	O
DIAGNOSIS	O
Ischaemic	O
stroke	O
in	O
the	O
right	O
choroidal	O
artery	O
of	O
embolic	O
origin	O
.	O
Pedunculated	O
atrial	O
myxoma	O
implanted	O
in	O
the	O
roof	O
of	O
the	O
left	O
atrium	O
.	O
Surgical	O
excision	O
of	O
left	O
atrial	O
myxoma	O
without	O
complications	O
.	O
Normal	O
left	O
ventricular	O
function	O
.	O
Stable	O
chronic	O
coronary	O
syndrome	O
with	O
two	O
vessel	O
disease	O
Cx	O
and	O
LAD	O
with	O
complete	O
percutaneous	O
revascularisation	O
.	O
Residual	O
left	O
lower	O
limb	O
hemiparesis	O
as	O
a	O
sequel	O
to	O
the	O
ischemic	O
stroke	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
A	O
52	O
year	O
old	O
man	O
consulted	O
for	O
chest	O
pain	O
.	O
History	O
No	O
known	O
drug	O
allergies	O
.	O
Toxic	O
habits	O
ex	O
smoker	O
,	O
30	O
packs	O
year	O
,	O
quit	O
in	O
2013	O
.	O
Drinker	O
of	O
100	O
g	O
day	O
of	O
alcohol	O
until	O
2012	O
.	O
Former	O
injecting	O
drug	O
user	O
between	O
1987	O
and	O
1990	O
.	O
Currently	O
abstinent	O
.	O
No	O
known	O
cardiovascular	O
risk	O
factors	O
.	O
Hepatitis	O
C	O
virus	O
genotype	O
1a	O
infection	O
,	O
cured	O
with	O
triple	O
therapy	O
with	O
boceprevir	B-FARMACO
in	O
2012	O
.	O
HIV	O
serology	O
negative	O
.	O
Secondary	O
liver	O
cirrhosis	O
,	O
CHILD	O
PUGH	O
A	O
.	O
Admitted	O
in	O
2016	O
for	O
community	O
acquired	O
pneumonia	O
,	O
CURB65	O
1	O
,	O
FINE	O
IV	O
and	O
secondary	O
partial	O
respiratory	O
failure	O
.	O
Usual	O
home	O
treatment	O
not	O
performed	O
.	O
Baseline	O
functional	O
status	O
active	O
life	O
,	O
New	O
York	O
Heart	O
Association	O
NYHA	O
functional	O
class	O
I	O
NYHA	O
FUNCTIONAL	O
CLASS	O
I	O
.	O
Current	O
illness	O
Consultation	O
for	O
episodes	O
of	O
oppressive	O
non	O
radiating	O
central	O
thoracic	O
pain	O
,	O
of	O
one	O
month	O
's	O
duration	O
,	O
unrelated	O
to	O
exertion	O
,	O
which	O
subside	O
spontaneously	O
in	O
approximately	O
5	O
minutes	O
.	O
They	O
are	O
associated	O
with	O
dyspnoea	O
and	O
occasional	O
diaphoresis	O
.	O
She	O
also	O
reported	O
syncope	O
with	O
a	O
neuromediated	O
clinical	O
profile	O
that	O
had	O
been	O
evolving	O
for	O
years	O
.	O
In	O
the	O
last	O
episode	O
,	O
unlike	O
the	O
previous	O
ones	O
,	O
she	O
presented	O
chest	O
pain	O
on	O
recovery	O
.	O
In	O
the	O
hospital	O
emergency	O
department	O
,	O
an	O
initial	O
assessment	O
was	O
performed	O
,	O
with	O
an	O
electrocardiogram	O
ECG	O
and	O
serum	O
markers	O
of	O
myocardial	O
damage	O
,	O
which	O
were	O
normal	O
.	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
cardiology	O
department	O
to	O
complete	O
the	O
study	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
BP	O
80	O
40	O
mmHg	O
,	O
oxygen	O
saturation	O
97	O
without	O
oxygen	O
therapy	O
.	O
Conscious	O
and	O
oriented	O
.	O
Acceptable	O
general	O
condition	O
,	O
cachectic	O
45	O
kg	O
on	O
admission	O
,	O
normal	O
colour	O
.	O
Eupneic	O
at	O
rest	O
,	O
without	O
congestive	O
symptoms	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
about	O
65	O
bpm	O
,	O
no	O
murmurs	O
or	O
extratonos	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
without	O
added	O
pathological	O
noises	O
.	O
Abdominal	O
examination	O
was	O
unremarkable	O
.	O
Lower	O
extremities	O
without	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
COMPLEMENTARY	O
TESTS	O
Emergency	O
ECG	O
sinus	O
rhythm	O
at	O
60	O
beats	O
per	O
minute	O
.	O
Narrow	O
QRS	O
,	O
morphology	O
of	O
incomplete	O
right	O
bundle	O
branch	O
block	O
.	O
No	O
conduction	O
or	O
repolarisation	O
disturbances	O
.	O
Normal	O
QTc	O
.	O
A	O
few	O
hours	O
after	O
admission	O
sinus	O
bradycardia	O
at	O
50	O
bpm	O
.	O
PR	O
220	O
ms	O
.	O
QRS	O
120	O
ms	O
.	O
ST	O
segment	O
elevation	O
of	O
2	O
mm	O
in	O
inferior	O
face	O
.	O
ST	O
segment	O
depression	O
in	O
V1	O
V4	O
,	O
aVR	O
and	O
aVL	O
,	O
maximum	O
in	O
V3	O
5	O
mm	O
with	O
deep	O
negative	O
T	O
waves	O
in	O
V1	O
V3	O
.	O
Laboratory	O
tests	O
normal	O
haemogram	O
and	O
coagulation	O
study	O
.	O
Biochemistry	O
renal	O
function	O
and	O
ions	O
normal	O
.	O
Hepatobiliary	O
profile	O
without	O
pathological	O
findings	O
.	O
Autoimmunity	O
negative	O
.	O
Toxicity	O
test	O
positive	O
for	O
benzodiazepines	O
,	O
negative	O
for	O
other	O
toxins	O
.	O
Proteinogram	O
with	O
monoclonal	O
IgM	O
Kappa	O
band	O
M	O
component	O
0	O
.	O
24	O
g	O
dl	O
.	O
Basal	O
cortisol	O
0	O
.	O
7	O
g	O
dl	O
.	O
Synacthen	O
Synacthen	O
test	O
cortisol	O
13	O
g	O
dl	O
intermediate	O
response	O
.	O
Chest	O
X	O
ray	O
normal	O
cardiothoracic	O
index	O
.	O
Free	O
costophrenic	O
sinuses	O
.	O
No	O
consolidation	O
or	O
parenchymal	O
infiltrates	O
.	O
Emergent	O
cardiac	O
catheterisation	O
severe	O
spasm	O
of	O
the	O
left	O
main	O
coronary	O
artery	O
LMCA	O
,	O
right	O
coronary	O
artery	O
RCA	O
and	O
circumflex	O
artery	O
CxA	O
,	O
with	O
fine	O
calibre	O
of	O
the	O
entire	O
coronary	O
tree	O
,	O
which	O
resolved	O
with	O
intracoronary	O
nitroglycerine	B-FARMACO
.	O
Transthoracic	O
echocardiogram	O
cardiac	O
cavities	O
of	O
normal	O
size	O
and	O
morphology	O
.	O
Mitral	O
valve	O
with	O
a	O
very	O
redundant	O
anterior	O
leaflet	O
,	O
without	O
associated	O
prolapse	O
.	O
Moderate	O
degree	O
of	O
insufficiency	O
regurgitant	O
volume	O
23	O
ml	O
and	O
ORE	O
by	O
PISA	O
0	O
.	O
12	O
cm2	O
.	O
Normal	O
left	O
ventricular	O
segmental	O
contractility	O
with	O
LVEF	O
60	O
by	O
Simpson	O
biplane	O
.	O
Mild	O
diastolic	O
dysfunction	O
with	O
no	O
evidence	O
of	O
increased	O
filling	O
pressures	O
.	O
Normal	O
right	O
ventricular	O
function	O
.	O
Normal	O
pericardium	O
,	O
no	O
pericardial	O
effusion	O
.	O
12	O
lead	O
ECG	O
performed	O
on	O
the	O
cardiology	O
ward	O
after	O
cardiorespiratory	O
arrest	O
sinus	O
rhythm	O
at	O
65	O
bpm	O
.	O
Narrow	O
QRS	O
.	O
Deep	O
negative	O
T	O
waves	O
V2	O
V6	O
.	O
Negative	O
T	O
waves	O
of	O
lesser	O
magnitude	O
in	O
inferior	O
face	O
,	O
I	O
and	O
aVL	O
.	O
Brain	O
magnetic	O
resonance	O
imaging	O
MRI	O
no	O
evidence	O
of	O
space	O
occupying	O
lesion	O
,	O
haemorrhage	O
or	O
recent	O
acute	O
or	O
subacute	O
infarction	O
.	O
CT	O
scan	O
of	O
the	O
chest	O
and	O
abdomen	O
with	O
contrast	O
thickening	O
of	O
the	O
duodenal	O
papilla	O
.	O
Adenopathies	O
of	O
non	O
specific	O
appearance	O
in	O
the	O
lesser	O
sac	O
,	O
mesentery	O
and	O
retroperitoneum	O
.	O
Bilateral	O
pleural	O
effusion	O
with	O
passive	O
collapse	O
of	O
posterior	O
basal	O
subsegments	O
.	O
Nonspecific	O
micro	O
nodule	O
in	O
the	O
right	O
lower	O
lobe	O
.	O
CLINICAL	O
EVOLUTION	O
After	O
being	O
assessed	O
in	O
the	O
emergency	O
department	O
with	O
normal	O
complementary	O
tests	O
,	O
he	O
was	O
admitted	O
to	O
the	O
cardiology	O
ward	O
to	O
complete	O
the	O
study	O
.	O
A	O
few	O
hours	O
after	O
admission	O
,	O
he	O
began	O
to	O
experience	O
chest	O
pain	O
and	O
the	O
ECG	O
showed	O
ST	O
elevation	O
in	O
the	O
lower	O
lobe	O
.	O
Urgent	O
coronary	O
angiography	O
showed	O
severe	O
spasm	O
of	O
the	O
left	O
main	O
coronary	O
artery	O
,	O
right	O
coronary	O
artery	O
and	O
circumflex	O
artery	O
,	O
with	O
fine	O
calibre	O
of	O
the	O
entire	O
coronary	O
tree	O
,	O
which	O
resolved	O
with	O
intracoronary	O
nitroglycerine	B-FARMACO
.	O
After	O
administration	O
of	O
intravenous	O
nitroglycerine	B-FARMACO
,	O
no	O
angiographically	O
significant	O
lesions	O
were	O
detected	O
.	O
Subsequently	O
,	O
he	O
was	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
ICU	O
where	O
myocardial	O
damage	O
markers	O
were	O
normal	O
and	O
,	O
after	O
remaining	O
stable	O
for	O
48	O
hours	O
,	O
he	O
was	O
returned	O
to	O
the	O
cardiology	O
ward	O
.	O
Once	O
on	O
the	O
ward	O
,	O
treatment	O
was	O
started	O
with	O
calcium	O
antagonists	O
ACA	O
and	O
nitrates	O
,	O
which	O
were	O
titrated	O
to	O
the	O
maximum	O
tolerated	O
doses	O
.	O
Despite	O
this	O
,	O
he	O
presented	O
with	O
a	O
new	O
episode	O
of	O
precordial	O
pain	O
followed	O
by	O
cardiorespiratory	O
arrest	O
CRA	O
in	O
electromechanical	O
dissociation	O
.	O
After	O
advanced	O
cardiopulmonary	O
resuscitation	O
manoeuvres	O
for	O
10	O
minutes	O
with	O
the	O
need	O
for	O
orotracheal	O
intubation	O
,	O
he	O
recovered	O
a	O
pulse	O
in	O
sinus	O
tachycardia	O
for	O
1	O
minute	O
and	O
subsequently	O
presented	O
with	O
polymorphic	O
ventricular	O
tachycardia	O
requiring	O
urgent	O
electrical	O
cardioversion	O
.	O
He	O
was	O
transferred	O
to	O
the	O
ICU	O
where	O
he	O
again	O
registered	O
polymorphic	O
ventricular	O
tachycardia	O
,	O
requiring	O
a	O
new	O
electrical	O
cardioversion	O
,	O
with	O
exit	O
in	O
sinus	O
rhythm	O
.	O
After	O
CRP	O
,	O
myocardial	O
damage	O
markers	O
were	O
serum	O
tested	O
and	O
an	O
enzyme	O
curve	O
was	O
found	O
compatible	O
with	O
acute	O
myocardial	O
infarction	O
and	O
electrocardiographic	O
changes	O
compatible	O
with	O
subendocardial	O
ischaemia	O
.	O
A	O
new	O
urgent	O
echocardiogram	O
was	O
performed	O
with	O
no	O
changes	O
with	O
respect	O
to	O
the	O
previous	O
one	O
.	O
In	O
the	O
control	O
analysis	O
that	O
had	O
been	O
drawn	O
just	O
before	O
the	O
CRA	O
,	O
renal	O
function	O
and	O
ions	O
,	O
including	O
potassium	O
and	O
magnesium	O
,	O
were	O
normal	O
.	O
Subsequently	O
,	O
he	O
required	O
prolonged	O
admission	O
to	O
the	O
ICU	O
due	O
to	O
haemodynamic	O
instability	O
requiring	O
treatment	O
with	O
vasoactive	O
amines	O
.	O
After	O
achieving	O
haemodynamic	O
stability	O
,	O
he	O
returned	O
to	O
the	O
cardiology	O
ward	O
,	O
where	O
treatment	O
was	O
optimised	O
with	O
the	O
addition	O
of	O
fluvastatin	B-FARMACO
and	O
high	O
doses	O
of	O
calcium	O
antagonists	O
and	O
nitrates	O
,	O
which	O
were	O
poorly	O
tolerated	O
due	O
to	O
hypotension	O
.	O
Despite	O
this	O
,	O
the	O
patient	O
presented	O
recurrent	O
vasospasm	O
crises	O
with	O
electrocardiographic	O
confirmation	O
.	O
In	O
view	O
of	O
the	O
severe	O
vasospasm	O
refractory	O
to	O
treatment	O
,	O
an	O
extensive	O
study	O
was	O
carried	O
out	O
to	O
detect	O
underlying	O
pathologies	O
that	O
could	O
be	O
associated	O
with	O
or	O
justify	O
the	O
recurrent	O
vasospasm	O
metabolic	O
,	O
tumour	O
,	O
autoimmune	O
,	O
etc	O
.	O
.	O
As	O
the	O
only	O
findings	O
during	O
admission	O
,	O
the	O
endocrinology	O
department	O
diagnosed	O
partial	O
adrenal	O
insufficiency	O
of	O
pituitary	O
origin	O
due	O
to	O
moderate	O
hypoosmolar	O
hyponatraemia	O
with	O
clinical	O
repercussions	O
drowsiness	O
,	O
which	O
was	O
corrected	O
with	O
hydrocortisone	B-FARMACO
.	O
In	O
addition	O
,	O
a	O
monoclonal	O
IgM	O
Kappa	O
band	O
was	O
detected	O
in	O
the	O
proteinogram	O
.	O
Finally	O
,	O
after	O
ruling	O
out	O
a	O
correctable	O
cause	O
associated	O
with	O
the	O
recurrent	O
vasospasm	O
crises	O
and	O
given	O
the	O
lack	O
of	O
response	O
and	O
poor	O
tolerance	O
of	O
nitrates	O
,	O
it	O
was	O
decided	O
to	O
withdraw	O
the	O
latter	O
and	O
empirically	O
add	O
cilostazol	B-FARMACO
phosphodiesterase	O
3	O
inhibitor	O
to	O
the	O
ACAs	O
.	O
After	O
starting	O
this	O
treatment	O
,	O
the	O
patient	O
remained	O
asymptomatic	O
,	O
with	O
no	O
new	O
episodes	O
of	O
chest	O
pain	O
or	O
vasospasm	O
.	O
After	O
ruling	O
out	O
other	O
possible	O
causes	O
of	O
CRA	O
,	O
it	O
was	O
determined	O
that	O
there	O
was	O
a	O
high	O
possibility	O
that	O
CRA	O
occurred	O
in	O
the	O
context	O
of	O
prolonged	O
vasospasm	O
.	O
Therefore	O
,	O
it	O
was	O
decided	O
to	O
implant	O
an	O
implantable	O
cardioverter	O
defibrillator	O
ICD	O
for	O
secondary	O
prevention	O
.	O
Once	O
the	O
ICD	O
was	O
implanted	O
and	O
the	O
vasospasm	O
crises	O
were	O
controlled	O
,	O
we	O
progressively	O
reduced	O
cilostazol	B-FARMACO
until	O
complete	O
withdrawal	O
of	O
the	O
drug	O
,	O
after	O
which	O
the	O
patient	O
was	O
asymptomatic	O
and	O
haemodynamically	O
stable	O
.	O
At	O
discharge	O
,	O
treatment	O
with	O
ACA	O
and	O
fluvastatin	B-FARMACO
was	O
maintained	O
with	O
excellent	O
response	O
,	O
with	O
no	O
new	O
events	O
occurring	O
in	O
the	O
first	O
year	O
of	O
follow	O
up	O
.	O
DIAGNOSIS	O
Recurrent	O
vasospastic	O
angina	O
refractory	O
to	O
treatment	O
.	O
In	O
hospital	O
cardiorespiratory	O
arrest	O
related	O
to	O
acute	O
myocardial	O
infarction	O
secondary	O
to	O
vasospastic	O
angina	O
.	O
Implantation	O
of	O
an	O
implantable	O
cardioverter	O
defibrillator	O
ICD	O
VR	O
in	O
secondary	O
prevention	O
.	O
Partial	O
adrenal	O
insufficiency	O
of	O
pituitary	O
origin	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
85	O
year	O
old	O
male	O
.	O
No	O
drug	O
allergies	O
.	O
Independent	O
for	O
basic	O
activities	O
of	O
daily	O
living	O
.	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
hypertension	O
.	O
Cardiological	O
history	O
chest	O
pain	O
with	O
coronary	O
angiography	O
in	O
2017	O
with	O
moderate	O
lesions	O
in	O
the	O
middle	O
segment	O
of	O
the	O
anterior	O
descending	O
artery	O
and	O
in	O
the	O
middle	O
segment	O
of	O
the	O
right	O
coronary	O
artery	O
labelled	O
with	O
stable	O
angina	O
chronic	O
coronary	O
syndrome	O
,	O
with	O
echocardiogram	O
with	O
normal	O
left	O
ventricular	O
ejection	O
fraction	O
.	O
Other	O
history	O
chronic	O
kidney	O
disease	O
not	O
studied	O
with	O
baseline	O
creatinine	O
around	O
1	O
.	O
3	O
mg	O
dl	O
,	O
gastritis	O
,	O
Helicobacter	O
pylori	O
infection	O
not	O
eradicated	O
,	O
hiatal	O
hernia	O
,	O
Schatzki	O
's	O
ring	O
and	O
diverticulosis	O
.	O
Previous	O
treatments	O
chlorthalidone	B-FARMACO
50	O
mg	O
1	O
0	O
0	O
0	O
;	O
losartan	B-FARMACO
100	O
mg	O
1	O
0	O
0	O
0	O
0	O
,	O
pitavastatin	B-FARMACO
1	O
mg	O
0	O
0	O
1	O
0	O
ranitidine	B-FARMACO
150	O
mg	O
0	O
0	O
1	O
0	O
;	O
clopidogrel	B-FARMACO
75	O
mg	O
1	O
0	O
0	O
0	O
0	O
;	O
isosorbide	B-FARMACO
mononitrate	I-FARMACO
50	O
mg	O
1	O
0	O
0	O
0	O
0	O
.	O
Present	O
illness	O
He	O
was	O
brought	O
in	O
by	O
ambulance	O
due	O
to	O
a	O
condition	O
that	O
started	O
at	O
5	O
a	O
.	O
m	O
.	O
and	O
woke	O
him	O
up	O
,	O
consisting	O
of	O
central	O
thoracic	O
pain	O
of	O
intensity	O
10	O
10	O
,	O
oppressive	O
,	O
radiating	O
to	O
the	O
jaw	O
and	O
back	O
,	O
accompanied	O
by	O
nausea	O
without	O
vomiting	O
.	O
At	O
home	O
he	O
took	O
paracetamol	B-FARMACO
with	O
partial	O
relief	O
of	O
the	O
pain	O
,	O
which	O
subsided	O
after	O
3	O
hours	O
.	O
He	O
reports	O
that	O
the	O
previous	O
day	O
he	O
had	O
been	O
doing	O
strenuous	O
physical	O
exertion	O
at	O
home	O
sanding	O
parquet	O
.	O
He	O
denied	O
fever	O
or	O
other	O
clinical	O
symptoms	O
in	O
the	O
previous	O
days	O
.	O
The	O
emergency	O
team	O
SUMMA	O
initially	O
administered	O
275	O
mg	O
of	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
,	O
performed	O
an	O
electrocardiogram	O
with	O
no	O
notable	O
alterations	O
and	O
transferred	O
him	O
to	O
the	O
hospital	O
emergency	O
department	O
.	O
Physical	O
examination	O
On	O
arrival	O
at	O
the	O
hospital	O
,	O
blood	O
pressure	O
of	O
156	O
68	O
mmHg	O
,	O
heart	O
rate	O
of	O
55	O
bpm	O
,	O
ambient	O
air	O
saturation	O
of	O
98	O
and	O
temperature	O
of	O
35	O
.	O
3oC	O
were	O
observed	O
.	O
He	O
was	O
also	O
found	O
to	O
be	O
in	O
good	O
general	O
condition	O
,	O
conscious	O
and	O
oriented	O
,	O
eupneic	O
at	O
rest	O
and	O
well	O
perfused	O
.	O
No	O
IY	O
.	O
Cardiopulmonary	O
auscultation	O
without	O
alterations	O
.	O
Abdomen	O
soft	O
and	O
not	O
painful	O
.	O
Lower	O
limbs	O
without	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
COMPLEMENTARY	O
TESTS	O
Blood	O
tests	O
Biochemistry	O
glucose	O
133	O
.	O
6	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
69	O
previous	O
1	O
.	O
3	O
mg	O
dl	O
,	O
sodium	O
136	O
.	O
6	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
53	O
mEq	O
l	O
,	O
chlorine	O
94	O
.	O
5	O
mEq	O
l	O
,	O
total	O
protein	O
7	O
.	O
31	O
g	O
dl	O
,	O
albumin	O
4	O
.	O
2	O
g	O
dl	O
,	O
ALT	O
GPT	O
18	O
.	O
1	O
U	O
l	O
,	O
AST	O
GOT	O
haemolysis	O
,	O
gamma	O
GT	O
11	O
U	O
l	O
alkaline	O
phosphatase	O
56	O
U	O
l	O
,	O
LDH	O
haemolysis	O
,	O
bilirubin	O
.	O
6	O
mg	O
dl	O
,	O
C	O
reactive	O
protein	O
.	O
79	O
mg	O
dl	O
,	O
CK	O
188	O
U	O
l	O
second	O
determination	O
309	O
,	O
troponin	O
T	O
hs	O
44	O
.	O
75	O
ng	O
l	O
second	O
profile	O
599	O
.	O
2	O
.	O
Haematology	O
leukocytes	O
8	O
.	O
3	O
x1000	O
l	O
,	O
red	O
cells	O
4	O
.	O
59	O
xmill	O
l	O
,	O
haemoglobin	O
14	O
.	O
6	O
g	O
dl	O
,	O
haematocrit	O
43	O
,	O
MCV	O
93	O
.	O
5	O
fl	O
,	O
MCH	O
31	O
.	O
9	O
pg	O
,	O
MCHC	O
34	O
.	O
1	O
g	O
dl	O
,	O
RDW	O
13	O
.	O
3	O
,	O
platelets	O
80	O
x1000	O
l	O
,	O
MPV	O
10	O
.	O
1	O
fl	O
,	O
neutrophils	O
7	O
x1000	O
l	O
,	O
neutrophils	O
84	O
.	O
6	O
,	O
lymphocytes	O
.	O
8	O
x1000	O
l	O
,	O
lymphocytes	O
9	O
.	O
2	O
,	O
monocytes	O
.	O
4	O
x1000	O
l	O
,	O
monocytes	O
5	O
.	O
3	O
,	O
eosinophils	O
0	O
x1000	O
l	O
,	O
eosinophils	O
.	O
6	O
,	O
basophils	O
0	O
x1000	O
l	O
,	O
basophils	O
.	O
3	O
.	O
Haemostasis	O
prothrombin	O
activity	O
92	O
,	O
prothrombin	O
time	O
12	O
.	O
2	O
sec	O
,	O
INR	O
lab	O
1	O
.	O
06	O
,	O
TTPa	O
34	O
sec	O
,	O
fibrinogen	O
derivative	O
594	O
mg	O
dl	O
,	O
D	O
dimer	O
257	O
ng	O
ml	O
.	O
Electrocardiogram	O
ECG	O
sinus	O
rhythm	O
at	O
75	O
bpm	O
,	O
PR	O
in	O
range	O
,	O
normal	O
axis	O
,	O
narrow	O
QRS	O
,	O
QTc	O
not	O
prolonged	O
,	O
without	O
acute	O
repolarisation	O
alterations	O
,	O
with	O
flattened	O
T	O
wave	O
in	O
high	O
lateral	O
face	O
and	O
left	O
precordial	O
.	O
Similar	O
to	O
previous	O
ones	O
.	O
Chest	O
X	O
ray	O
normal	O
cardiothoracic	O
index	O
CTI	O
with	O
no	O
signs	O
of	O
pulmonary	O
congestion	O
or	O
other	O
alterations	O
.	O
Echocardioscopy	O
left	O
ventricle	O
neither	O
dilated	O
nor	O
hypertrophic	O
.	O
Subjective	O
systolic	O
function	O
preserved	O
,	O
dyskinesia	O
of	O
the	O
middle	O
segment	O
of	O
the	O
anteroseptal	O
face	O
,	O
without	O
other	O
alterations	O
of	O
segmental	O
contractility	O
.	O
Mitral	O
insufficiency	O
,	O
which	O
appears	O
mild	O
moderate	O
by	O
colour	O
Doppler	O
.	O
Transthoracic	O
echocardiogram	O
video	O
1	O
non	O
dilated	O
left	O
ventricle	O
,	O
with	O
a	O
slight	O
increase	O
in	O
wall	O
thickness	O
.	O
Localised	O
akinesia	O
at	O
the	O
level	O
of	O
the	O
middle	O
interventricular	O
septum	O
,	O
both	O
anterior	O
and	O
inferior	O
,	O
with	O
the	O
rest	O
of	O
the	O
segments	O
normocontractile	O
.	O
Preserved	O
systolic	O
function	O
LVEF	O
70	O
by	O
Simpson	O
biplane	O
.	O
Normal	O
diastolic	O
function	O
.	O
Non	O
dilated	O
right	O
ventricle	O
with	O
normal	O
systolic	O
function	O
.	O
No	O
other	O
findings	O
.	O
Cardiac	O
catheterisation	O
common	O
trunk	O
without	O
lesions	O
.	O
Dominant	O
circumflex	O
,	O
of	O
good	O
calibre	O
and	O
great	O
development	O
,	O
without	O
significant	O
lesions	O
.	O
Anterior	O
descending	O
artery	O
with	O
moderate	O
plaque	O
of	O
stable	O
appearance	O
in	O
the	O
middle	O
segment	O
,	O
with	O
good	O
distal	O
vessel	O
,	O
without	O
other	O
significant	O
lesions	O
.	O
Non	O
dominant	O
right	O
coronary	O
artery	O
,	O
with	O
a	O
slight	O
plaque	O
in	O
the	O
proximal	O
segment	O
,	O
with	O
no	O
other	O
lesions	O
,	O
being	O
a	O
poorly	O
developed	O
vessel	O
.	O
Cardiac	O
MRI	O
ventricles	O
neither	O
dilated	O
nor	O
hypertrophic	O
.	O
In	O
the	O
sequences	O
for	O
assessment	O
of	O
myocardial	O
oedema	O
T2	O
STIR	O
,	O
a	O
pathological	O
increase	O
in	O
signal	O
intensity	O
was	O
observed	O
in	O
the	O
middle	O
segment	O
of	O
the	O
anterior	O
septum	O
,	O
suggestive	O
of	O
oedema	O
.	O
In	O
the	O
late	O
enhancement	O
sequences	O
there	O
are	O
patchy	O
areas	O
of	O
intramyocardial	O
enhancement	O
in	O
the	O
middle	O
segment	O
of	O
the	O
anterior	O
and	O
posterior	O
septum	O
,	O
basal	O
segment	O
of	O
the	O
anterior	O
septum	O
,	O
insertion	O
of	O
the	O
RV	O
free	O
wall	O
,	O
and	O
small	O
foci	O
of	O
intramyocardial	O
enhancement	O
in	O
the	O
basal	O
and	O
middle	O
segment	O
of	O
the	O
lateral	O
face	O
and	O
basal	O
segment	O
of	O
the	O
posterior	O
face	O
.	O
Nasopharyngeal	O
swab	O
for	O
SARS	O
CoV	O
2	O
negative	O
.	O
CLINICAL	O
EVOLUTION	O
Given	O
the	O
clinical	O
picture	O
in	O
the	O
ED	O
of	O
chest	O
pain	O
with	O
initial	O
tests	O
with	O
no	O
particularly	O
noteworthy	O
findings	O
except	O
for	O
a	O
slightly	O
increased	O
first	O
troponin	O
in	O
a	O
patient	O
with	O
acute	O
chronic	O
kidney	O
disease	O
,	O
it	O
was	O
decided	O
to	O
perform	O
enzyme	O
serology	O
,	O
with	O
a	O
second	O
determination	O
substantially	O
higher	O
than	O
the	O
previous	O
one	O
,	O
so	O
that	O
the	O
ED	O
notified	O
cardiology	O
.	O
Urgent	O
echocardioscopy	O
revealed	O
a	O
dyskinetic	O
segment	O
at	O
septal	O
level	O
,	O
which	O
together	O
with	O
the	O
elevation	O
of	O
markers	O
of	O
myocardial	O
damage	O
led	O
to	O
the	O
initial	O
diagnosis	O
of	O
acute	O
myocardial	O
infarction	O
without	O
ST	O
elevation	O
,	O
so	O
previous	O
treatment	O
with	O
clopidogrel	B-FARMACO
was	O
maintained	O
and	O
fondaparinux	B-FARMACO
,	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
and	O
atorvastatin	B-FARMACO
were	O
added	O
.	O
Urgent	O
coronary	O
angiography	O
was	O
performed	O
in	O
the	O
first	O
24	O
hours	O
,	O
which	O
revealed	O
no	O
significant	O
coronary	O
lesions	O
,	O
so	O
the	O
patient	O
was	O
classified	O
as	O
a	O
myocardial	O
infarction	O
without	O
obstructive	O
coronary	O
lesions	O
MINOCA	O
and	O
was	O
transferred	O
to	O
the	O
cardiology	O
hospital	O
ward	O
,	O
monitored	O
for	O
further	O
study	O
.	O
Once	O
there	O
,	O
a	O
regulated	O
transthoracic	O
echocardiogram	O
was	O
performed	O
,	O
confirming	O
the	O
previous	O
findings	O
,	O
and	O
a	O
cardiac	O
magnetic	O
resonance	O
was	O
performed	O
,	O
showing	O
findings	O
compatible	O
with	O
acute	O
myocarditis	O
,	O
with	O
peak	O
troponin	O
of	O
678	O
.	O
9	O
ng	O
l	O
.	O
Paracetamol	B-FARMACO
was	O
prescribed	O
as	O
symptomatic	O
treatment	O
and	O
the	O
patient	O
was	O
discharged	O
home	O
after	O
several	O
days	O
of	O
stability	O
,	O
with	O
no	O
recurrence	O
of	O
the	O
symptoms	O
or	O
appearance	O
of	O
significant	O
events	O
on	O
telemetry	O
.	O
In	O
addition	O
,	O
due	O
to	O
the	O
presence	O
of	O
coronary	O
artery	O
disease	O
and	O
LDL	O
of	O
171	O
mg	O
dl	O
,	O
it	O
was	O
decided	O
to	O
change	O
from	O
pitavastatin	B-FARMACO
to	O
rosuvastatin	B-FARMACO
ezetimibe	I-FARMACO
the	O
patient	O
reported	O
previous	O
intolerance	O
to	O
atorvastatin	B-FARMACO
with	O
a	O
target	O
LDL	O
cholesterol	O
55	O
mg	O
dl	O
,	O
and	O
an	O
appointment	O
for	O
a	O
review	O
at	O
the	O
next	O
consultation	O
.	O
DIAGNOSIS	O
Acute	O
non	O
COVID	O
myocarditis	O
.	O
Normal	O
left	O
ventricular	O
function	O
.	O
Acute	O
chronic	O
kidney	O
disease	O
on	O
admission	O
of	O
probable	O
pre	O
renal	O
origin	O
.	O
Chronic	O
coronary	O
syndrome	O
with	O
non	O
significant	O
two	O
vessel	O
coronary	O
artery	O
disease	O
.	O
Hypercholesterolemia	O
with	O
LDL	O
out	O
of	O
target	O
very	O
high	O
cardiovascular	O
risk	O
patient	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
81	O
year	O
old	O
male	O
.	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
dyslipidaemia	O
,	O
arterial	O
hypertension	O
,	O
overweight	O
grade	O
2	O
,	O
type	O
2	O
diabetes	O
mellitus	O
.	O
Cardiological	O
history	O
permanent	O
atrial	O
fibrillation	O
anticoagulated	O
with	O
dabigatran	B-FARMACO
150	O
mg	O
12	O
hours	O
.	O
Other	O
history	O
complete	O
constitutional	O
syndrome	O
weight	O
loss	O
of	O
10	O
kg	O
in	O
the	O
last	O
4	O
months	O
,	O
night	O
sweats	O
of	O
2	O
years	O
of	O
evolution	O
suspected	O
histiocytosis	O
.	O
Gastro	O
colonoscopy	O
negative	O
.	O
PET	O
scan	O
perirenal	O
fat	O
deposits	O
with	O
involvement	O
of	O
hip	O
and	O
spine	O
bones	O
.	O
Perirenal	O
fat	O
biopsy	O
fibroadipose	O
tissue	O
with	O
mild	O
lymphoplasmacytic	O
inflammatory	O
infiltrate	O
with	O
isolated	O
eosinophils	O
,	O
perivascular	O
and	O
diffuse	O
.	O
Mixed	O
phenotype	O
COPD	O
.	O
Intermittent	O
claudication	O
MMII	O
.	O
Usual	O
treatment	O
empagliflozin	B-FARMACO
10	O
mg	O
1	O
tablet	O
daily	O
metformin	B-FARMACO
850	O
mg	O
1	O
tablet	O
every	O
12	O
hours	O
;	O
dabigatran	B-FARMACO
150	O
mg	O
1	O
tablet	O
every	O
12	O
hours	O
;	O
inhaler	O
salmeterol	B-FARMACO
fluticasone	I-FARMACO
;	O
atorvastatin	B-FARMACO
40	O
mg	O
1	O
tablet	O
per	O
day	O
;	O
diltiazem	B-FARMACO
120	O
mg	O
per	O
day	O
;	O
dutasteride	B-FARMACO
tamsulosin	I-FARMACO
0	O
.	O
5	O
0	O
.	O
4	O
mg	O
1	O
tablet	O
per	O
day	O
;	O
oral	O
iron	B-FARMACO
;	O
lorazepam	B-FARMACO
1	O
mg	O
1	O
tablet	O
per	O
day	O
;	O
omeprazole	B-FARMACO
20	O
mg	O
1	O
tablet	O
per	O
day	O
,	O
valsartan	B-FARMACO
80	O
mg	O
1	O
tablet	O
per	O
day	O
.	O
Current	O
illness	O
Patient	O
admitted	O
to	O
the	O
internal	O
medicine	O
department	O
MIN	O
for	O
progressive	O
worsening	O
of	O
functional	O
class	O
to	O
the	O
point	O
of	O
presenting	O
minimal	O
effort	O
dyspnoea	O
NYHA	O
III	O
,	O
associated	O
with	O
orthopnoea	O
,	O
paroxysmal	O
dyspnoea	O
and	O
intense	O
asthenia	O
.	O
No	O
chest	O
pain	O
or	O
palpitations	O
.	O
Under	O
study	O
for	O
known	O
serositis	O
pleural	O
and	O
asthenia	O
in	O
constitutional	O
syndrome	O
followed	O
in	O
MIN	O
outpatient	O
clinic	O
CCEE	O
.	O
Once	O
admitted	O
to	O
the	O
MIN	O
ward	O
,	O
he	O
showed	O
little	O
improvement	O
with	O
the	O
prescribed	O
intravenous	O
treatment	O
.	O
Forty	O
eight	O
hours	O
after	O
admission	O
,	O
there	O
was	O
a	O
significant	O
clinical	O
deterioration	O
and	O
an	O
assessment	O
by	O
the	O
on	O
call	O
cardiology	O
department	O
was	O
requested	O
.	O
Physical	O
examination	O
Tachypnoea	O
with	O
poor	O
tolerance	O
to	O
decubitus	O
,	O
mucocutaneous	O
pallor	O
,	O
MEG	O
.	O
Blood	O
pressure	O
BP	O
80	O
50	O
mmHg	O
,	O
O2	O
saturation	O
90	O
with	O
GN	O
at	O
3L	O
min	O
,	O
respiratory	O
rate	O
RR	O
28	O
rpm	O
,	O
heart	O
rate	O
HR	O
118	O
bpm	O
.	O
Jugular	O
ingurgitation	O
.	O
Positive	O
hepatojugular	O
reflex	O
.	O
Cardiopulmonary	O
irregular	O
and	O
hypophonetic	O
heart	O
sounds	O
without	O
murmurs	O
.	O
Respiratory	O
sounds	O
present	O
with	O
generalised	O
hypoventilation	O
.	O
Abdomen	O
globular	O
,	O
soft	O
and	O
depressible	O
,	O
diffusely	O
painful	O
on	O
palpation	O
,	O
no	O
Bloomberg	O
,	O
no	O
Murphy	O
.	O
Extremities	O
no	O
oedema	O
in	O
declining	O
parts	O
,	O
no	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
Signs	O
of	O
distal	O
hypoperfusion	O
.	O
COMPLEMENTARY	O
TESTS	O
AP	O
chest	O
X	O
ray	O
from	O
2019	O
prior	O
to	O
current	O
admission	O
centred	O
cardiomediastinal	O
silhouette	O
with	O
no	O
widening	O
or	O
retractions	O
.	O
Cardiothoracic	O
index	O
CTI	O
less	O
than	O
0	O
.	O
5	O
.	O
Translucent	O
lung	O
fields	O
with	O
no	O
evidence	O
of	O
pleural	O
effusion	O
or	O
pneumonic	O
condensation	O
.	O
Current	O
AP	O
chest	O
X	O
ray	O
enlarged	O
cardiomediastinal	O
silhouette	O
with	O
CTI	O
greater	O
than	O
0	O
.	O
5	O
.	O
Bilateral	O
interstitial	O
infiltrate	O
with	O
apical	O
vascular	O
flow	O
redistribution	O
.	O
Right	O
cysuritis	O
.	O
No	O
evidence	O
of	O
pleural	O
effusion	O
or	O
pneumonic	O
condensation	O
.	O
Electrocardiogram	O
ECG	O
atrial	O
fibrillation	O
at	O
145	O
bpm	O
.	O
QRS	O
60	O
ms	O
.	O
AXIS	O
60o	O
.	O
Left	O
anterior	O
hemiblock	O
of	O
the	O
His	O
bundle	O
.	O
Negative	O
T	O
waves	O
in	O
DI	O
and	O
aVL	O
.	O
Isolated	O
ventricular	O
extrasystoles	O
.	O
Low	O
voltages	O
.	O
Blood	O
tests	O
CBC	O
red	O
blood	O
cells	O
3	O
.	O
11	O
10	O
12	O
l	O
.	O
Haemoglobin	O
8	O
.	O
8	O
g	O
dl	O
.	O
Haematocrit	O
27	O
.	O
1	O
.	O
MCV	O
87	O
.	O
2	O
fl	O
.	O
MCH	O
28	O
.	O
2	O
pg	O
.	O
MCHC	O
32	O
.	O
3	O
g	O
dl	O
.	O
ADE	O
15	O
.	O
3	O
.	O
Leukocytes	O
8	O
.	O
9	O
10	O
9	O
l	O
.	O
Neutrophils	O
7	O
.	O
9	O
10	O
9	O
l	O
.	O
Lymphocytes	O
0	O
.	O
5	O
10	O
9	O
l	O
.	O
Monocytes	O
0	O
,	O
4	O
10	O
9	O
l	O
.	O
Eosinophils	O
0	O
,	O
1	O
10	O
9	O
l	O
.	O
Basophils	O
0	O
,	O
1	O
10	O
9	O
l	O
.	O
Platelets	O
539	O
10	O
9	O
l	O
.	O
Haemostasis	O
initial	O
prothrombin	O
time	O
PT	O
22	O
.	O
8	O
sec	O
.	O
Quick	O
index	O
31	O
.	O
INR	O
1	O
.	O
97	O
.	O
APTT	O
55	O
.	O
5	O
sec	O
.	O
Ratio	O
aPTT	O
1	O
.	O
86	O
.	O
Derived	O
fibrinogen	O
890	O
mg	O
dl	O
.	O
Haemostasis	O
after	O
idarucizumab	B-FARMACO
administration	O
prothrombin	O
time	O
PT	O
15	O
.	O
8	O
sec	O
.	O
Quick	O
ratio	O
62	O
.	O
INR	O
1	O
.	O
26	O
APTT	O
23	O
.	O
4	O
sec	O
.	O
Ratio	O
aPTT	O
0	O
.	O
79	O
Derived	O
fibrinogen	O
700	O
mg	O
dl	O
.	O
Biochemistry	O
Glucose	O
125	O
mg	O
dl	O
.	O
Sodium	O
133	O
mEq	O
l	O
.	O
Potassium	O
3	O
.	O
8	O
mEq	O
l	O
.	O
Chlorine	O
103	O
mEq	O
l	O
.	O
Total	O
bilirubin	O
1	O
.	O
54	O
mg	O
dl	O
.	O
Aspartate	O
aminotransferase	O
GOT	O
69	O
U	O
l	O
.	O
Alanine	O
aminotransferase	O
GPT	O
59	O
U	O
l	O
.	O
Alkaline	O
phosphatase	O
110	O
U	O
l	O
.	O
Gamma	O
glutamyl	O
transferase	O
80	O
U	O
l	O
.	O
Creatinine	O
2	O
.	O
20	O
mg	O
dl	O
.	O
Uric	O
acid	O
4	O
.	O
8	O
mg	O
dl	O
.	O
Protein	O
7	O
.	O
2	O
g	O
dl	O
.	O
Creatin	O
phosphokinase	O
119	O
U	O
l	O
.	O
CRP	O
15	O
.	O
1	O
mg	O
dl	O
.	O
Iron	B-FARMACO
profile	O
ferritin	O
54	O
g	O
l	O
.	O
Iron	B-FARMACO
94	O
g	O
dl	O
.	O
Total	O
Fe	O
fixation	O
capacity	O
371	O
ug	O
dl	O
.	O
Transferrin	O
saturation	O
index	O
12	O
.	O
3	O
.	O
Latent	O
Fe	O
binding	O
capacity	O
277	O
ug	O
dl	O
.	O
Congestion	O
markers	O
NT	O
proBNP	O
5700	O
pg	O
ml	O
,	O
Ag	O
.	O
carbohydrate	O
125	O
CA125	O
225	O
IU	O
ml	O
.	O
Lipid	O
profile	O
total	O
cholesterol	O
319	O
mg	O
d	O
.	O
Triglycerides	O
90	O
mg	O
dl	O
.	O
HDL	O
cholesterol	O
72	O
mg	O
dl	O
.	O
LDL	O
cholesterol	O
229	O
mg	O
dl	O
.	O
Total	O
cholesterol	O
HDL	O
4	O
.	O
4	O
.	O
Hormones	O
thyrotropin	O
TSH	O
1	O
.	O
77	O
uIU	O
ml	O
.	O
Transthoracic	O
echocardiography	O
TTE	O
video	O
1	O
left	O
ventricle	O
with	O
preserved	O
diameters	O
,	O
preserved	O
global	O
systolic	O
function	O
LVEF	O
64	O
.	O
Atria	O
of	O
normal	O
size	O
.	O
Absence	O
of	O
alterations	O
in	O
segmental	O
contractility	O
at	O
rest	O
.	O
Absence	O
of	O
significant	O
valvulopathies	O
.	O
Right	O
ventricle	O
with	O
preserved	O
contractility	O
.	O
Trivial	O
tricuspid	O
insufficiency	O
TI	O
with	O
PAPs	O
45	O
mmHg	O
.	O
Dilated	O
inferior	O
vena	O
cava	O
24	O
mm	O
without	O
inspiratory	O
collapse	O
.	O
Severe	O
pericardial	O
effusion	O
of	O
global	O
distribution	O
with	O
significant	O
haemodynamic	O
compromise	O
of	O
the	O
right	O
cavities	O
.	O
CLINICAL	O
EVOLUTION	O
On	O
evaluation	O
by	O
the	O
cardiologist	O
on	O
duty	O
,	O
the	O
patient	O
was	O
in	O
obstructive	O
shock	O
secondary	O
to	O
cardiac	O
tamponade	O
as	O
seen	O
by	O
transthoracic	O
echocardiography	O
.	O
It	O
was	O
decided	O
to	O
cautiously	O
administer	O
intravascular	O
volume	O
,	O
to	O
associate	O
treatment	O
with	O
norepinephrine	B-FARMACO
and	O
to	O
immediately	O
transfer	O
him	O
to	O
the	O
coronary	O
care	O
unit	O
.	O
Once	O
in	O
the	O
coronary	O
care	O
unit	O
,	O
it	O
was	O
decided	O
to	O
check	O
the	O
patient	O
's	O
haemogram	O
and	O
haemostasis	O
in	O
order	O
to	O
perform	O
diagnostic	O
therapeutic	O
pericardiocentesis	O
,	O
with	O
unacceptable	O
figures	O
for	O
this	O
procedure	O
without	O
haemorrhagic	O
risk	O
.	O
Given	O
the	O
persistence	O
of	O
obstructive	O
shock	O
in	O
the	O
context	O
of	O
cardiac	O
tamponade	O
despite	O
the	O
prescribed	O
intravenous	O
treatment	O
,	O
it	O
was	O
decided	O
to	O
request	O
and	O
administer	O
2	O
ampoules	O
of	O
idarucizumab	B-FARMACO
as	O
an	O
antidote	O
for	O
the	O
patient	O
's	O
anticoagulation	O
.	O
The	O
improvement	O
of	O
haemostatic	O
parameters	O
was	O
verified	O
in	O
control	O
analyses	O
,	O
which	O
allowed	O
the	O
procedure	O
to	O
be	O
carried	O
out	O
one	O
hour	O
after	O
administration	O
.	O
Diagnostic	O
therapeutic	O
pericardiocentesis	O
guided	O
by	O
echocardiography	O
was	O
performed	O
and	O
650	O
cc	O
of	O
serohematic	O
fluid	O
was	O
extracted	O
with	O
evident	O
haemodynamic	O
improvement	O
.	O
Samples	O
of	O
pericardial	O
fluid	O
were	O
sent	O
for	O
study	O
.	O
In	O
the	O
following	O
days	O
the	O
patient	O
showed	O
a	O
favourable	O
evolution	O
with	O
haemodynamic	O
stability	O
without	O
vasoactive	O
inothropic	O
support	O
and	O
negative	O
balances	O
and	O
progressive	O
improvement	O
of	O
clinical	O
and	O
radiological	O
signs	O
of	O
congestion	O
.	O
A	O
control	O
echocardiogram	O
was	O
performed	O
showing	O
minimal	O
residual	O
pericardial	O
effusion	O
with	O
no	O
evidence	O
of	O
haemodynamic	O
compromise	O
,	O
so	O
the	O
drain	O
was	O
removed	O
without	O
complications	O
after	O
24	O
hours	O
,	O
dabigatran	B-FARMACO
was	O
reintroduced	O
and	O
medical	O
discharge	O
was	O
decided	O
.	O
DIAGNOSIS	O
Obstructive	O
shock	O
in	O
the	O
context	O
of	O
cardiac	O
tamponade	O
.	O
Severe	O
pericardial	O
effusion	O
complicated	O
by	O
cardiac	O
tamponade	O
.	O
Reversal	O
of	O
dabigatran	B-FARMACO
anticoagulation	O
with	O
idarucizumab	B-FARMACO
for	O
emergent	O
pericardiocentesis	O
.	O
Pericardiocentesis	O
with	O
drainage	O
of	O
560	O
cc	O
serohematic	O
cc	O
.	O
Permanent	O
atrial	O
fibrillation	O
anticoagulated	O
with	O
dabigatran	B-FARMACO
.	O
Polyserositis	O
under	O
study	O
.	O
Constitutional	O
syndrome	O
under	O
study	O
,	O
probably	O
Erdheim	O
Chester	O
syndrome	O
polyostotic	O
sclerosing	O
histiocytosis	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
A	O
68	O
year	O
old	O
woman	O
was	O
referred	O
to	O
the	O
outpatient	O
cardiology	O
department	O
for	O
a	O
cardiac	O
mass	O
found	O
on	O
computed	O
axial	O
tomography	O
CT	O
.	O
History	O
No	O
known	O
cardiovascular	O
risk	O
factors	O
.	O
Independent	O
for	O
basic	O
activities	O
of	O
daily	O
living	O
.	O
Left	O
renal	O
neoplasm	O
clear	O
cell	O
carcinoma	O
with	O
sarcomatoid	O
differentiation	O
80	O
,	O
PT3A	O
with	O
left	O
nephrectomy	O
in	O
2013	O
and	O
reoperation	O
for	O
secondary	O
eventration	O
in	O
2017	O
.	O
Normofunctioning	O
multinodular	O
goitre	O
,	O
in	O
evolutionary	O
follow	O
up	O
.	O
No	O
other	O
history	O
of	O
interest	O
and	O
without	O
usual	O
pharmacological	O
treatment	O
.	O
Current	O
disease	O
Previously	O
asymptomatic	O
cardiovascular	O
patient	O
,	O
she	O
presented	O
with	O
pain	O
in	O
the	O
left	O
hemithorax	O
VAS	O
4	O
,	O
with	O
pleuritic	O
characteristics	O
,	O
not	O
triggered	O
by	O
exertion	O
,	O
of	O
prolonged	O
duration	O
and	O
appearing	O
sporadically	O
at	O
rest	O
.	O
In	O
the	O
CT	O
scan	O
of	O
renal	O
neoplasia	O
,	O
a	O
left	O
ventricle	O
dependent	O
mass	O
was	O
detected	O
,	O
with	O
progressive	O
growth	O
,	O
and	O
the	O
patient	O
was	O
referred	O
to	O
cardiology	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
120	O
80	O
mmHg	O
.	O
Heart	O
rate	O
70	O
bpm	O
.	O
Eupneic	O
at	O
rest	O
.	O
Jugular	O
venous	O
pressure	O
normal	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
with	O
protomesosystolic	O
murmur	O
II	O
VI	O
in	O
aortic	O
focus	O
with	O
preserved	O
second	O
sound	O
,	O
pulmonary	O
auscultation	O
with	O
preserved	O
vesicular	O
murmur	O
,	O
without	O
added	O
pathological	O
noises	O
.	O
Abdominal	O
examination	O
with	O
no	O
significant	O
findings	O
.	O
No	O
oedema	O
in	O
the	O
lower	O
extremities	O
,	O
with	O
preserved	O
and	O
symmetrical	O
peripheral	O
pulses	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
sinus	O
rhythm	O
at	O
85	O
bpm	O
,	O
PR	O
160ms	O
,	O
QRS	O
100ms	O
,	O
cardiac	O
axis	O
15o	O
with	O
HBAI	O
,	O
non	O
pathological	O
septal	O
Q	O
wave	O
,	O
isolated	O
negative	O
T	O
in	O
V1	O
without	O
other	O
alterations	O
.	O
Analysis	O
leukocytes	O
6	O
,	O
600	O
l	O
,	O
haemoglobin	O
14	O
.	O
2	O
g	O
dl	O
,	O
platelets	O
190	O
,	O
000	O
l	O
,	O
glucose	O
93	O
mg	O
dl	O
,	O
urea	O
53	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
91	O
mg	O
dl	O
,	O
MDRD	O
IDMS	O
60	O
ml	O
min	O
,	O
AST	O
16	O
IU	O
l	O
,	O
ALT	O
14IU	O
l	O
,	O
GGT	O
16IU	O
l	O
,	O
Na	O
141	O
mmol	O
l	O
,	O
K	O
4	O
.	O
4	O
mmol	O
l	O
.	O
Chest	O
X	O
ray	O
normal	O
cardiothoracic	O
index	O
.	O
No	O
mediastinal	O
widening	O
.	O
No	O
evidence	O
of	O
heart	O
failure	O
.	O
Echocardiogram	O
left	O
ventricle	O
of	O
normal	O
size	O
with	O
preserved	O
ejection	O
fraction	O
,	O
without	O
segmental	O
contractility	O
abnormalities	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
and	O
function	O
.	O
Grade	O
I	O
diastolic	O
dysfunction	O
.	O
Mild	O
mitral	O
regurgitation	O
.	O
Large	O
mass	O
of	O
irregular	O
echogenicity	O
,	O
paracardiac	O
,	O
in	O
the	O
posterior	O
and	O
lateral	O
area	O
of	O
the	O
left	O
ventricle	O
,	O
which	O
does	O
not	O
compromise	O
ventricular	O
function	O
.	O
Thoracic	O
abdominal	O
CT	O
with	O
contrast	O
solid	O
mass	O
with	O
heterogeneous	O
attenuation	O
and	O
estimated	O
maximum	O
diameters	O
of	O
6	O
.	O
3	O
x	O
5	O
.	O
5	O
x	O
3	O
.	O
8	O
cm	O
craniocaudal	O
,	O
AP	O
and	O
transverse	O
axes	O
respectively	O
,	O
dependent	O
on	O
the	O
lateral	O
and	O
basal	O
wall	O
of	O
the	O
left	O
ventricle	O
,	O
which	O
imprints	O
and	O
slightly	O
deforms	O
the	O
lateral	O
wall	O
of	O
the	O
left	O
atrium	O
.	O
An	O
asymmetric	O
thickening	O
of	O
the	O
left	O
ventricular	O
wall	O
is	O
observed	O
coinciding	O
with	O
the	O
location	O
of	O
the	O
current	O
lesion	O
.	O
Cardiac	O
MRI	O
large	O
mass	O
in	O
the	O
lateral	O
area	O
of	O
the	O
left	O
ventricle	O
and	O
atrioventricular	O
groove	O
6	O
.	O
4	O
x	O
5	O
.	O
2	O
cm	O
maximum	O
diameter	O
,	O
affecting	O
the	O
full	O
thickness	O
of	O
the	O
wall	O
and	O
with	O
a	O
mass	O
effect	O
on	O
the	O
lateral	O
aspect	O
of	O
the	O
left	O
atrium	O
.	O
Well	O
defined	O
outline	O
,	O
with	O
myocardial	O
and	O
pericardial	O
infiltration	O
.	O
The	O
signal	O
is	O
isointense	O
on	O
T1	O
enhancement	O
,	O
faintly	O
hyperintense	O
on	O
T2	O
and	O
markedly	O
hyperintense	O
on	O
STIR	O
,	O
with	O
evidence	O
of	O
intense	O
vascularisation	O
on	O
first	O
pass	O
images	O
after	O
intravenous	O
gadolinium	O
administration	O
.	O
Heterogeneous	O
late	O
enhancement	O
,	O
predominantly	O
central	O
,	O
in	O
the	O
form	O
of	O
a	O
ring	O
surrounding	O
the	O
necrotic	O
area	O
.	O
Pathology	O
the	O
endomyocardial	O
fragments	O
show	O
areas	O
of	O
infiltration	O
by	O
a	O
tumour	O
with	O
a	O
growth	O
pattern	O
in	O
solid	O
nests	O
or	O
irregular	O
cords	O
,	O
with	O
dense	O
inflammatory	O
response	O
,	O
and	O
consisting	O
of	O
cells	O
with	O
rounded	O
or	O
lobulated	O
nuclei	O
with	O
moderate	O
anisokaryosis	O
,	O
and	O
clato	O
or	O
acidophilic	O
cytoplasm	O
.	O
Focally	O
the	O
tumour	O
adopts	O
a	O
rhabdoid	O
pattern	O
and	O
morphology	O
.	O
Immunohistochemistry	O
shows	O
expression	O
of	O
CK	O
AE1	O
AE3	O
,	O
vimentin	O
and	O
CD10	O
in	O
neoplastic	O
cells	O
.	O
Diagnosis	O
endomyocardial	O
fragments	O
with	O
metastasis	O
of	O
renal	O
cell	O
carcinoma	O
sarcomatoid	O
histopathological	O
pattern	O
,	O
similar	O
to	O
that	O
described	O
in	O
the	O
patient	O
's	O
previous	O
biopsy	O
.	O
CLINICAL	O
EVOLUTION	O
It	O
was	O
decided	O
to	O
extend	O
the	O
study	O
with	O
magnetic	O
resonance	O
imaging	O
MRI	O
to	O
better	O
identify	O
the	O
cardiac	O
mass	O
,	O
with	O
the	O
results	O
described	O
above	O
.	O
Given	O
the	O
findings	O
of	O
the	O
MRI	O
and	O
the	O
patient	O
's	O
clinical	O
history	O
,	O
metastatic	O
implantation	O
was	O
suspected	O
as	O
the	O
first	O
option	O
,	O
and	O
an	O
endomyocardial	O
biopsy	O
was	O
performed	O
,	O
which	O
was	O
found	O
to	O
be	O
compatible	O
with	O
metastasis	O
of	O
renal	O
cell	O
carcinoma	O
.	O
Subsequently	O
,	O
the	O
patient	O
was	O
referred	O
to	O
the	O
oncology	O
outpatient	O
department	O
,	O
which	O
started	O
treatment	O
with	O
sunitinib	B-FARMACO
50	O
mg	O
every	O
24	O
hours	O
,	O
2	O
1	O
schedule	O
,	O
presenting	O
growth	O
of	O
the	O
cardiac	O
mass	O
and	O
increased	O
pericardial	O
effusion	O
after	O
5	O
months	O
of	O
treatment	O
,	O
so	O
it	O
was	O
decided	O
to	O
start	O
immunotherapy	O
with	O
nivolumab	B-FARMACO
,	O
achieving	O
a	O
complete	O
tumour	O
response	O
,	O
with	O
regression	O
of	O
the	O
cardiac	O
tumour	O
mass	O
,	O
with	O
no	O
evidence	O
of	O
progression	O
at	O
present	O
.	O
DIAGNOSIS	O
Paracardiac	O
mass	O
with	O
pericardial	O
and	O
intramural	O
infiltration	O
,	O
compatible	O
with	O
metastasis	O
of	O
renal	O
carcinoma	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
Brother	O
with	O
previous	O
recurrent	O
myocarditis	O
in	O
2000	O
,	O
with	O
clinical	O
diagnosis	O
and	O
no	O
subsequent	O
follow	O
up	O
.	O
No	O
history	O
of	O
sudden	O
death	O
or	O
other	O
heart	O
disease	O
in	O
first	O
degree	O
relatives	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
No	O
toxic	O
habits	O
.	O
She	O
had	O
no	O
cardiovascular	O
risk	O
factors	O
or	O
medical	O
or	O
surgical	O
history	O
of	O
interest	O
.	O
Present	O
illness	O
A	O
36	O
year	O
old	O
man	O
consulted	O
for	O
non	O
radiating	O
,	O
oppressive	O
,	O
central	O
thoracic	O
pain	O
that	O
started	O
at	O
rest	O
and	O
woke	O
him	O
from	O
sleep	O
.	O
The	O
pain	O
was	O
accompanied	O
by	O
nausea	O
,	O
sweating	O
and	O
a	O
sensation	O
of	O
dyspnoea	O
and	O
improved	O
slightly	O
when	O
he	O
got	O
into	O
bed	O
.	O
The	O
patient	O
mentioned	O
the	O
presence	O
of	O
fever	O
and	O
pharyngeal	O
pain	O
2	O
days	O
before	O
the	O
onset	O
of	O
the	O
symptoms	O
.	O
On	O
arrival	O
at	O
the	O
hospital	O
,	O
electrocardiographic	O
alterations	O
and	O
elevated	O
markers	O
of	O
myocardial	O
damage	O
in	O
the	O
infarct	O
range	O
were	O
observed	O
,	O
so	O
an	O
urgent	O
coronary	O
angiography	O
was	O
performed	O
in	O
which	O
no	O
coronary	O
lesions	O
were	O
found	O
.	O
Physical	O
examination	O
Good	O
general	O
condition	O
,	O
conscious	O
and	O
oriented	O
in	O
all	O
3	O
spheres	O
.	O
Haemodynamically	O
stable	O
.	O
Eupneic	O
at	O
rest	O
.	O
Normal	O
colour	O
,	O
well	O
hydrated	O
and	O
perfused	O
.	O
Afebrile	O
.	O
Blood	O
pressure	O
BP	O
151	O
84	O
mmHg	O
,	O
heart	O
rate	O
HR	O
72	O
bpm	O
,	O
SatO2	O
99	O
without	O
contributions	O
.	O
No	O
signs	O
of	O
heart	O
failure	O
.	O
Cardiorespiratory	O
auscultation	O
rhythmic	O
at	O
a	O
good	O
frequency	O
,	O
no	O
murmurs	O
or	O
extratonos	O
.	O
Vesicular	O
murmur	O
preserved	O
,	O
no	O
pathological	O
noises	O
added	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
.	O
No	O
signs	O
of	O
defence	O
or	O
peritoneal	O
irritation	O
.	O
Lower	O
limbs	O
without	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
on	O
admission	O
to	O
the	O
ward	O
sinus	O
rhythm	O
at	O
64	O
bpm	O
.	O
Normal	O
PR	O
.	O
QTc	O
441	O
msec	O
.	O
J	O
point	O
elevation	O
of	O
1	O
mm	O
from	O
V4	O
to	O
V6	O
.	O
Negative	O
T	O
wave	O
from	O
V4	O
to	O
V6	O
.	O
Emergency	O
laboratory	O
tests	O
CBC	O
leukocytes	O
10420	O
1360	O
lymphocytes	O
,	O
Hb	O
15	O
.	O
7	O
g	O
dl	O
,	O
platelets	O
182000	O
.	O
Biochemistry	O
glucose	O
142	O
mg	O
dl	O
,	O
AST	O
42	O
U	O
l	O
,	O
renal	O
function	O
and	O
ions	O
normal	O
,	O
CRP	O
195	O
.	O
4	O
mg	O
l	O
.	O
Enzyme	O
serum	O
creatine	O
kinase	O
270	O
641	O
723	O
U	O
l	O
,	O
ultrasensitive	O
troponin	O
T	O
500	O
1061	O
1744	O
1184	O
1225	O
ng	O
dl	O
.	O
Chest	O
X	O
ray	O
normal	O
.	O
Cardiothoracic	O
index	O
normal	O
.	O
No	O
signs	O
of	O
pulmonary	O
congestion	O
,	O
condensation	O
or	O
effusion	O
.	O
Coronary	O
angiography	O
angiographically	O
normal	O
coronary	O
arteries	O
.	O
Anomalous	O
outflow	O
of	O
the	O
right	O
coronary	O
artery	O
from	O
the	O
left	O
sinus	O
,	O
without	O
angiographically	O
significant	O
lesions	O
.	O
Serology	O
negative	O
for	O
HIV	O
,	O
syphilis	O
and	O
Mycoplasma	O
pneumoniae	O
.	O
Positive	O
for	O
past	O
infection	O
by	O
adenovirus	O
,	O
CMV	O
,	O
Echovirus	O
,	O
EBV	O
,	O
parvovirus	O
B19	O
and	O
Coxsackie	O
.	O
Laboratory	O
tests	O
Biochemistry	O
glucose	O
87	O
mg	O
dl	O
,	O
renal	O
function	O
and	O
ions	O
normal	O
,	O
LDH	O
388	O
.	O
00	O
U	O
l	O
,	O
hepatobiliary	O
profile	O
without	O
alterations	O
.	O
Total	O
protein	O
7	O
.	O
7	O
g	O
dl	O
.	O
NT	O
proBNP	O
379	O
pg	O
ml	O
.	O
C	O
reactive	O
protein	O
65	O
.	O
0	O
mg	O
l	O
.	O
Lipid	O
profile	O
cholesterol	O
210	O
mg	O
dl	O
,	O
LDL	O
153	O
mg	O
dl	O
,	O
HDL	O
26	O
mg	O
dl	O
,	O
triglycerides	O
156	O
.	O
00	O
mg	O
dl	O
.	O
Thyroid	O
hormones	O
and	O
HbA1c	O
normal	O
.	O
CBC	O
three	O
normal	O
series	O
.	O
Cardiac	O
magnetic	O
resonance	O
imaging	O
MRI	O
left	O
ventricle	O
neither	O
dilated	O
nor	O
hypertrophic	O
,	O
with	O
preserved	O
global	O
and	O
segmental	O
mobility	O
.	O
Ejection	O
fraction	O
EF	O
measured	O
with	O
the	O
Simpson	O
method	O
68	O
.	O
8	O
.	O
LVEDV	O
of	O
140	O
ml	O
,	O
indexed	O
by	O
body	O
surface	O
area	O
of	O
67	O
ml	O
m2	O
,	O
LVESV	O
of	O
44	O
ml	O
,	O
indexed	O
by	O
body	O
surface	O
area	O
of	O
21	O
ml	O
m2	O
.	O
Myocardial	O
mass	O
119	O
g	O
,	O
indexed	O
by	O
body	O
surface	O
area	O
of	O
57	O
g	O
m	O
.	O
Right	O
ventricle	O
not	O
dilated	O
or	O
hypertrophic	O
,	O
with	O
preserved	O
global	O
and	O
segmental	O
mobility	O
;	O
EF	O
measured	O
by	O
Simpson	O
's	O
method	O
of	O
81	O
VTDVD	O
of	O
110	O
ml	O
,	O
indexed	O
by	O
body	O
surface	O
area	O
of	O
53	O
ml	O
m	O
.	O
VTSVD	O
of	O
21	O
ml	O
,	O
indexed	O
by	O
body	O
surface	O
area	O
22	O
of	O
10	O
ml	O
m	O
.	O
Both	O
atria	O
of	O
normal	O
size	O
left	O
atrium	O
with	O
an	O
area	O
of	O
22	O
cm	O
,	O
indexed	O
to	O
11	O
cm	O
m	O
and	O
right	O
atrium	O
of	O
19	O
cm	O
,	O
indexed	O
to	O
9	O
cm	O
m	O
.	O
In	O
the	O
sequence	O
STIR	O
shows	O
hyperintense	O
signal	O
compatible	O
with	O
oedema	O
in	O
the	O
inferior	O
and	O
anterior	O
basal	O
and	O
medial	O
segments	O
,	O
medial	O
lateral	O
and	O
in	O
all	O
apical	O
segments	O
.	O
The	O
first	O
pass	O
perfusion	O
sequence	O
shows	O
no	O
basal	O
perfusion	O
defects	O
.	O
In	O
the	O
late	O
enhancement	O
viability	O
sequence	O
,	O
there	O
was	O
extensive	O
subepicardial	O
and	O
intramyocardial	O
fibrosis	O
in	O
the	O
basal	O
and	O
middle	O
inferior	O
and	O
middle	O
anterior	O
and	O
inferolateral	O
segments	O
and	O
in	O
all	O
apical	O
segments	O
.	O
Conclusion	O
acute	O
myocarditis	O
with	O
extensive	O
fibrosis	O
and	O
preserved	O
biventricular	O
function	O
.	O
CLINICAL	O
EVOLUTION	O
After	O
a	O
favourable	O
evolution	O
during	O
admission	O
,	O
our	O
patient	O
was	O
discharged	O
,	O
with	O
initiation	O
of	O
5	O
mg	O
of	O
enalapril	B-FARMACO
per	O
day	O
.	O
After	O
4	O
months	O
during	O
which	O
he	O
was	O
asymptomatic	O
,	O
he	O
was	O
admitted	O
again	O
for	O
symptoms	O
compatible	O
with	O
acute	O
myopericarditis	O
ultrasensitive	O
troponin	O
T	O
peak	O
of	O
2174	O
ng	O
dl	O
,	O
with	O
gastroenteritis	O
of	O
probable	O
viral	O
origin	O
as	O
a	O
possible	O
trigger	O
.	O
A	O
new	O
transthoracic	O
echocardiogram	O
was	O
performed	O
,	O
showing	O
slight	O
global	O
hypokinesia	O
with	O
an	O
EF	O
of	O
50	O
.	O
After	O
a	O
satisfactory	O
evolution	O
,	O
the	O
patient	O
was	O
discharged	O
,	O
and	O
colchicine	B-FARMACO
was	O
prescribed	O
as	O
a	O
preventive	O
treatment	O
for	O
new	O
recurrences	O
.	O
A	O
new	O
cardiac	O
MRI	O
was	O
performed	O
on	O
an	O
outpatient	O
basis	O
,	O
in	O
the	O
first	O
2	O
weeks	O
after	O
discharge	O
,	O
which	O
showed	O
the	O
persistence	O
of	O
extensive	O
fibrosis	O
of	O
similar	O
distribution	O
to	O
the	O
previous	O
study	O
,	O
as	O
well	O
as	O
denovo	O
fibrosis	O
at	O
the	O
level	O
of	O
the	O
basal	O
and	O
medial	O
septum	O
images	O
5	O
and	O
6	O
.	O
Both	O
ventricles	O
had	O
normal	O
morphology	O
and	O
volumes	O
,	O
with	O
no	O
detectable	O
segmental	O
contractility	O
disturbances	O
,	O
and	O
biventricular	O
systolic	O
function	O
was	O
preserved	O
.	O
In	O
the	O
STIR	O
and	O
black	O
blood	O
sequences	O
,	O
there	O
were	O
no	O
intramyocardial	O
fatty	O
deposits	O
and	O
there	O
was	O
significant	O
oedema	O
at	O
the	O
level	O
of	O
the	O
septum	O
.	O
In	O
view	O
of	O
the	O
results	O
of	O
the	O
MRI	O
,	O
a	O
24	O
hour	O
Holter	O
monitor	O
was	O
requested	O
,	O
which	O
showed	O
isolated	O
monotopic	O
ventricular	O
extrasystoles	O
with	O
morphology	O
of	O
right	O
bundle	O
branch	O
block	O
with	O
transition	O
in	O
V3	O
and	O
superior	O
axis	O
,	O
and	O
it	O
was	O
decided	O
to	O
increase	O
the	O
doses	O
of	O
ACE	B-FARMACO
inhibitors	I-FARMACO
enalapril	I-FARMACO
5	O
mg	O
12	O
hours	O
and	O
to	O
start	O
beta	O
blocker	O
treatment	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
24	O
hours	O
.	O
His	O
brother	O
was	O
seen	O
at	O
our	O
clinic	O
due	O
to	O
a	O
history	O
of	O
recurrent	O
myocarditis	O
,	O
and	O
a	O
cardiac	O
MRI	O
was	O
performed	O
,	O
confirming	O
the	O
presence	O
of	O
subepicardial	O
fibrosis	O
in	O
the	O
free	O
wall	O
of	O
the	O
left	O
ventricle	O
,	O
compatible	O
with	O
past	O
myocarditis	O
.	O
Finally	O
,	O
given	O
the	O
pattern	O
of	O
fibrosis	O
in	O
the	O
MRI	O
together	O
with	O
the	O
history	O
of	O
a	O
first	O
degree	O
relative	O
with	O
recurrent	O
myocarditis	O
,	O
the	O
differential	O
diagnosis	O
of	O
acute	O
recurrent	O
myocarditis	O
with	O
extensive	O
fibrosis	O
versus	O
arrhythmogenic	O
cardiomyopathy	O
of	O
the	O
left	O
ventricle	O
was	O
considered	O
and	O
it	O
was	O
decided	O
to	O
request	O
a	O
genetic	O
study	O
with	O
a	O
cardiomyopathy	O
panel	O
,	O
the	O
results	O
of	O
which	O
are	O
still	O
pending	O
.	O
DIAGNOSIS	O
Acute	O
myocarditis	O
with	O
extensive	O
fibrosis	O
and	O
preserved	O
biventricular	O
function	O
versus	O
arrhythmogenic	O
left	O
ventricular	O
dysplasia	O
with	O
myocarditis	O
e	O
flares	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
58	O
year	O
old	O
woman	O
,	O
no	O
known	O
drug	O
allergies	O
.	O
History	O
Cardiovascular	O
risk	O
factors	O
active	O
smoker	O
8	O
10	O
cigarettes	O
a	O
day	O
.	O
Depressive	O
syndrome	O
.	O
Menopause	O
at	O
50	O
51	O
years	O
of	O
age	O
.	O
No	O
known	O
cardiological	O
history	O
,	O
neither	O
in	O
relatives	O
.	O
Usual	O
treatment	O
citalopram	B-FARMACO
10	O
mg	O
.	O
Current	O
illness	O
Consultation	O
in	O
the	O
emergency	O
department	O
for	O
chest	O
discomfort	O
onset	O
at	O
rest	O
,	O
with	O
associated	O
presyncopal	O
symptoms	O
lasting	O
approximately	O
50	O
minutes	O
.	O
On	O
assessment	O
,	O
she	O
was	O
asymptomatic	O
,	O
with	O
an	O
initial	O
electrocardiogram	O
ECG	O
with	O
no	O
abnormalities	O
and	O
positive	O
troponin	O
determination	O
,	O
so	O
the	O
patient	O
was	O
diagnosed	O
as	O
non	O
ST	O
segment	O
elevation	O
acute	O
coronary	O
syndrome	O
NSTEACS	O
Killip	O
I	O
and	O
admission	O
to	O
the	O
intermediate	O
care	O
unit	O
was	O
decided	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
BP	O
110	O
60	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
60	O
bpm	O
.	O
Oxygen	O
saturation	O
basal	O
96	O
.	O
Afebrile	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
without	O
audible	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
normal	O
.	O
Abdomen	O
nondescript	O
.	O
Lower	O
limbs	O
no	O
oedema	O
,	O
no	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
sinus	O
rhythm	O
at	O
72	O
bpm	O
,	O
normal	O
PR	O
,	O
narrow	O
QRS	O
,	O
without	O
acute	O
repolarisation	O
alterations	O
.	O
Laboratory	O
tests	O
NT	O
proBNP	O
22	O
pg	O
ml	O
,	O
troponin	O
I	O
US	O
1	O
,	O
871	O
peak	O
5	O
,	O
212	O
pg	O
ml	O
normal	O
value	O
14	O
pg	O
ml	O
.	O
Renal	O
function	O
and	O
ions	O
normal	O
.	O
Haemoglobin	O
14	O
.	O
4	O
g	O
dl	O
,	O
platelets	O
201	O
,	O
000	O
l	O
,	O
leucocytes	O
5	O
,	O
600	O
l	O
.	O
Glucose	O
87	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
74	O
mg	O
dl	O
,	O
Na	O
139	O
mEq	O
l	O
,	O
K	O
4	O
.	O
9	O
mEq	O
l	O
,	O
TSH	O
normal	O
,	O
total	O
cholesterol	O
259	O
mg	O
dl	O
,	O
HDL	O
58	O
mg	O
dl	O
,	O
LDL	O
183	O
mg	O
dl	O
.	O
Chest	O
X	O
ray	O
cardiac	O
silhouette	O
,	O
parenchyma	O
and	O
pulmonary	O
vascularisation	O
without	O
pathological	O
findings	O
.	O
Cardiac	O
catheterisation	O
epicardial	O
coronary	O
arteries	O
without	O
angiographic	O
lesions	O
in	O
main	O
vessels	O
.	O
Only	O
a	O
third	O
obtuse	O
marginal	O
branch	O
showed	O
a	O
sudden	O
change	O
in	O
calibre	O
from	O
1	O
.	O
5	O
mm	O
to	O
less	O
than	O
1	O
mm	O
,	O
which	O
subsequently	O
recovered	O
the	O
size	O
of	O
the	O
vessel	O
,	O
which	O
could	O
correspond	O
to	O
an	O
area	O
of	O
haematoma	O
spontaneous	O
dissection	O
.	O
Ventriculography	O
left	O
ventricle	O
LV	O
with	O
preserved	O
systolic	O
function	O
,	O
very	O
localised	O
akinesia	O
of	O
the	O
mid	O
basal	O
inferolateral	O
area	O
.	O
Echocardiogram	O
non	O
dilated	O
LV	O
,	O
normal	O
wall	O
thickness	O
,	O
preserved	O
systolic	O
function	O
LVEF	O
59	O
,	O
no	O
segmental	O
alterations	O
.	O
Atria	O
not	O
dilated	O
.	O
Right	O
ventricle	O
RV	O
not	O
dilated	O
with	O
normal	O
contractility	O
TAPSE	O
20	O
mm	O
,	O
S	O
wave	O
11	O
.	O
5	O
cm	O
s	O
.	O
Slight	O
mitral	O
sclerosis	O
,	O
correct	O
and	O
competent	O
opening	O
.	O
Trivalve	O
aortic	O
valve	O
with	O
calcium	O
spot	O
in	O
non	O
coronary	O
leaflet	O
and	O
mild	O
sclerosis	O
,	O
not	O
restricted	O
in	O
opening	O
and	O
with	O
mild	O
central	O
insufficiency	O
.	O
Mild	O
tricuspid	O
insufficiency	O
,	O
RV	O
AD	O
gradient	O
15	O
mmHg	O
.	O
Mild	O
pulmonary	O
insufficiency	O
,	O
protodiastolic	O
gradient	O
6	O
mmHg	O
.	O
Pulmonary	O
acceleration	O
time	O
130	O
ms	O
.	O
Inferior	O
vena	O
cava	O
IVC	O
not	O
dilated	O
13	O
mm	O
with	O
normal	O
collapse	O
.	O
Normal	O
PAPs	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
.	O
Computed	O
tomography	O
CT	O
body	O
origin	O
of	O
the	O
supra	O
aortic	O
trunks	O
of	O
normal	O
morphology	O
.	O
Axillary	O
subclavian	O
arterial	O
axes	O
and	O
carotid	O
axes	O
permeable	O
and	O
of	O
normal	O
calibre	O
.	O
Cervical	O
segment	O
of	O
internal	O
carotid	O
artery	O
with	O
slight	O
irregularity	O
,	O
not	O
conclusive	O
of	O
dysplasia	O
.	O
Left	O
vertebral	O
dominance	O
.	O
Left	O
coronary	O
trunk	O
and	O
circumflex	O
artery	O
of	O
normal	O
calibre	O
.	O
Patent	O
aorta	O
with	O
preserved	O
calibre	O
.	O
Bilateral	O
accessory	O
renal	O
artery	O
with	O
origin	O
cranial	O
to	O
the	O
ipsilateral	O
main	O
renal	O
artery	O
.	O
Main	O
renal	O
arteries	O
of	O
arrosariado	O
displastic	O
appearance	O
.	O
Patent	O
and	O
ectatic	O
iliac	O
arterial	O
shafts	O
.	O
External	O
iliac	O
arteries	O
with	O
arrosative	O
dysplastic	O
appearance	O
.	O
None	O
of	O
the	O
focal	O
stenoses	O
that	O
condition	O
the	O
dysplastic	O
appearance	O
of	O
the	O
main	O
renal	O
arteries	O
and	O
the	O
external	O
iliac	O
arteries	O
is	O
significant	O
.	O
Extravascular	O
findings	O
left	O
adrenal	O
with	O
nodular	O
thickening	O
of	O
adenomatous	O
appearance	O
.	O
Right	O
kidney	O
with	O
small	O
fatty	O
nodule	O
in	O
its	O
lower	O
third	O
compatible	O
with	O
small	O
angiomyolipoma	O
and	O
left	O
kidney	O
with	O
small	O
cortical	O
cyst	O
in	O
its	O
upper	O
third	O
.	O
Calcified	O
uterine	O
myoma	O
.	O
Sigmoid	O
diverticulosis	O
.	O
Conclusion	O
main	O
renal	O
arteries	O
and	O
external	O
iliac	O
arteries	O
of	O
arrosariado	O
aspect	O
,	O
a	O
finding	O
that	O
suggests	O
fibromuscular	O
dysplasia	O
.	O
CLINICAL	O
EVOLUTION	O
Coronary	O
angiography	O
was	O
performed	O
in	O
the	O
first	O
24	O
hours	O
with	O
the	O
finding	O
of	O
epicardial	O
coronary	O
arteries	O
without	O
angiographic	O
lesions	O
in	O
the	O
main	O
vessels	O
,	O
but	O
a	O
sudden	O
decrease	O
in	O
calibre	O
was	O
observed	O
in	O
the	O
third	O
obtuse	O
marginal	O
branch	O
,	O
compatible	O
with	O
spontaneous	O
coronary	O
dissection	O
at	O
that	O
level	O
.	O
Subsequent	O
evolution	O
was	O
favourable	O
,	O
with	O
no	O
complications	O
in	O
the	O
vascular	O
access	O
area	O
or	O
clinical	O
recurrence	O
.	O
A	O
transthoracic	O
echocardiogram	O
was	O
requested	O
with	O
overall	O
systolic	O
function	O
preserved	O
,	O
with	O
no	O
segmental	O
asymmetries	O
at	O
discharge	O
,	O
and	O
no	O
notable	O
valvulopathies	O
.	O
Given	O
the	O
diagnosis	O
of	O
spontaneous	O
coronary	O
artery	O
dissection	O
,	O
the	O
study	O
was	O
completed	O
with	O
a	O
body	O
CT	O
scan	O
to	O
detect	O
fibromuscular	O
dysplasia	O
,	O
which	O
was	O
finally	O
confirmed	O
,	O
with	O
involvement	O
of	O
the	O
main	O
renal	O
and	O
external	O
iliac	O
arteries	O
.	O
In	O
a	O
situation	O
of	O
clinical	O
stability	O
,	O
the	O
patient	O
was	O
discharged	O
,	O
indicating	O
cessation	O
of	O
smoking	O
and	O
indefinite	O
taking	O
of	O
simple	O
antiplatelet	O
therapy	O
and	O
high	O
potency	O
statins	O
.	O
DIAGNOSIS	O
Acute	O
myocardial	O
infarction	O
without	O
Q	O
wave	O
due	O
to	O
spontaneous	O
coronary	O
dissection	O
of	O
the	O
third	O
obtuse	O
marginal	O
branch	O
.	O
Normal	O
LV	O
systolic	O
function	O
.	O
Fibromuscular	O
dysplasia	O
with	O
involvement	O
of	O
renal	O
and	O
iliac	O
arteries	O
.	O
Smoking	O
.	O
Dyslipidaemia	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
The	O
patient	O
is	O
an	O
80	O
year	O
old	O
woman	O
,	O
with	O
a	O
history	O
of	O
Risk	O
factors	O
hypertension	O
,	O
dyslipidaemia	O
,	O
smoker	O
of	O
2	O
3	O
cigarettes	O
day	O
.	O
She	O
has	O
had	O
a	O
dual	O
chamber	O
pacemaker	O
since	O
July	O
2015	O
due	O
to	O
sinus	O
dysfunction	O
and	O
paroxysmal	O
atrioventricular	O
block	O
AVB	O
reprogrammed	O
in	O
VVI	O
due	O
to	O
atrial	O
lead	O
failure	O
.	O
In	O
2014	O
she	O
was	O
referred	O
to	O
cardiology	O
for	O
gait	O
instability	O
and	O
palpitations	O
.	O
A	O
regular	O
echocardiogram	O
was	O
performed	O
,	O
which	O
revealed	O
a	O
tumour	O
mass	O
in	O
the	O
left	O
atrium	O
,	O
starting	O
from	O
the	O
foramen	O
ovale	O
,	O
probably	O
an	O
atrial	O
myxoma	O
,	O
which	O
slightly	O
interfered	O
with	O
mitral	O
valve	O
kinetics	O
,	O
causing	O
mild	O
dynamic	O
stenosis	O
.	O
One	O
year	O
later	O
,	O
she	O
had	O
an	O
ischaemic	O
stroke	O
of	O
probable	O
cardioembolic	O
origin	O
,	O
and	O
once	O
she	O
had	O
recovered	O
,	O
it	O
was	O
decided	O
to	O
perform	O
surgery	O
on	O
the	O
myxoma	O
,	O
and	O
a	O
complete	O
resection	O
of	O
the	O
myxoma	O
was	O
performed	O
with	O
good	O
results	O
.	O
In	O
2016	O
and	O
2018	O
,	O
she	O
had	O
two	O
episodes	O
of	O
posterior	O
circulation	O
stroke	O
POCI	O
of	O
undetermined	O
origin	O
,	O
with	O
diplopia	O
and	O
instability	O
.	O
During	O
these	O
admissions	O
,	O
an	O
echocardiogram	O
was	O
performed	O
,	O
which	O
was	O
normal	O
,	O
and	O
Doppler	O
of	O
the	O
supra	O
aortic	O
trunk	O
showed	O
moderate	O
stenosis	O
of	O
both	O
carotid	O
arteries	O
,	O
so	O
it	O
was	O
decided	O
to	O
start	O
antiplatelet	O
therapy	O
with	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
.	O
Current	O
disease	O
Admitted	O
in	O
October	O
2019	O
for	O
intermittent	O
episodes	O
of	O
gait	O
instability	O
,	O
assessed	O
by	O
neurology	O
,	O
a	O
diagnosis	O
of	O
repeated	O
vertebrobasilar	O
transient	O
ischaemic	O
attack	O
TIA	O
was	O
made	O
and	O
she	O
was	O
admitted	O
to	O
complete	O
the	O
study	O
.	O
During	O
admission	O
,	O
an	O
echocardiogram	O
was	O
performed	O
which	O
revealed	O
a	O
mass	O
in	O
the	O
left	O
atrium	O
,	O
suggesting	O
recurrence	O
of	O
myxoma	O
.	O
Physical	O
examination	O
The	O
patient	O
was	O
conscious	O
and	O
oriented	O
in	O
space	O
and	O
time	O
.	O
No	O
language	O
alterations	O
,	O
preserved	O
nomation	O
.	O
Pupils	O
isochoric	O
and	O
normoreactive	O
.	O
No	O
nystagmus	O
.	O
EOM	O
external	O
ocular	O
motor	O
preserved	O
.	O
Examination	O
of	O
cranial	O
nerves	O
normal	O
.	O
Upper	O
and	O
lower	O
limb	O
strength	O
preserved	O
.	O
Examination	O
of	O
superficial	O
and	O
deep	O
sensitivity	O
preserved	O
.	O
Bicipital	O
and	O
patellar	O
osteotendinous	O
reflexes	O
preserved	O
.	O
Finger	O
nose	O
and	O
finger	O
finger	O
test	O
with	O
some	O
slowness	O
,	O
possible	O
dysmetria	O
.	O
Romberg	O
's	O
sign	O
doubtful	O
.	O
Stability	O
with	O
increased	O
base	O
of	O
support	O
,	O
unstable	O
gait	O
with	O
lateropulsion	O
to	O
the	O
left	O
.	O
Tandem	O
gait	O
impossible	O
for	O
her	O
.	O
No	O
signs	O
of	O
meningeal	O
irritation	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
tones	O
without	O
audible	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
,	O
no	O
extra	O
sounds	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
,	O
no	O
palpable	O
masses	O
or	O
megaliths	O
,	O
no	O
signs	O
of	O
peritoneal	O
irritation	O
,	O
preserved	O
peristalsis	O
.	O
Lower	O
limbs	O
no	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
Pedial	O
pulses	O
were	O
preserved	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
sinus	O
rhythm	O
at	O
74	O
bpm	O
,	O
normal	O
PR	O
,	O
narrow	O
QRS	O
,	O
no	O
repolarisation	O
alterations	O
.	O
Blood	O
tests	O
biochemistry	O
glucose	O
105	O
mg	O
dl	O
,	O
urea	O
22	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
66	O
mg	O
dl	O
,	O
Na	O
136	O
mmol	O
l	O
,	O
K	O
4	O
.	O
0	O
mmol	O
l	O
.	O
Haemogram	O
leucocytes	O
8400	O
mcl	O
,	O
Hb	O
13	O
.	O
3	O
mg	O
dl	O
,	O
Hto	O
39	O
.	O
8	O
,	O
platelets	O
356000	O
.	O
Coagulation	O
INR	O
1	O
.	O
04	O
,	O
AP	O
99	O
,	O
fibrinogen	O
5	O
.	O
9	O
g	O
l	O
.	O
Chest	O
X	O
ray	O
cardiomediastinal	O
silhouette	O
and	O
pulmonary	O
vascularisation	O
within	O
normality	O
.	O
Signs	O
of	O
chronic	O
bronchopneumopathy	O
.	O
No	O
other	O
significant	O
pleuroparenchymal	O
alterations	O
were	O
observed	O
.	O
MCP	O
with	O
electrodes	O
in	O
the	O
right	O
cavities	O
.	O
Mid	O
sternotomy	O
sutures	O
.	O
Dorsal	O
spondylosis	O
Brain	O
computed	O
tomography	O
CT	O
signs	O
of	O
chronic	O
ischaemia	O
.	O
Infarcts	O
in	O
the	O
right	O
parietal	O
lobe	O
and	O
at	O
the	O
left	O
parasagittal	O
level	O
next	O
to	O
the	O
convexity	O
,	O
both	O
with	O
an	O
old	O
appearance	O
.	O
Transesophageal	O
echocardiogram	O
left	O
atrium	O
LA	O
of	O
normal	O
dimensions	O
.	O
Inside	O
the	O
left	O
atrium	O
there	O
is	O
an	O
image	O
of	O
a	O
heterogeneous	O
,	O
rounded	O
,	O
echodense	O
mass	O
,	O
21	O
x	O
23	O
mm	O
in	O
size	O
,	O
with	O
a	O
wide	O
implantation	O
base	O
15	O
mm	O
on	O
the	O
interatrial	O
septum	O
,	O
which	O
does	O
not	O
interfere	O
with	O
the	O
correct	O
kinetics	O
of	O
the	O
mitral	O
valve	O
.	O
Compatible	O
with	O
recurrence	O
of	O
atrial	O
myxoma	O
.	O
Left	O
ventricle	O
not	O
dilated	O
,	O
not	O
hypertrophic	O
.	O
Preserved	O
systolic	O
function	O
,	O
without	O
asymmetry	O
of	O
segmental	O
contractility	O
.	O
Altered	O
diastolic	O
relaxation	O
pattern	O
.	O
Right	O
chambers	O
of	O
normal	O
dimensions	O
,	O
normocontractile	O
right	O
ventricle	O
.	O
Aortic	O
valve	O
trivalve	O
,	O
not	O
limited	O
in	O
its	O
opening	O
and	O
competent	O
.	O
Mitral	O
valve	O
not	O
limited	O
in	O
its	O
opening	O
,	O
with	O
mild	O
mitral	O
insufficiency	O
.	O
Mild	O
tricuspid	O
insufficiency	O
TI	O
,	O
with	O
RV	O
AD	O
gradient	O
25	O
mmHg	O
.	O
Inferior	O
vena	O
cana	O
IVC	O
not	O
dilated	O
,	O
with	O
preserved	O
inspiratory	O
collapse	O
.	O
Estimated	O
normal	O
PSAP	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
or	O
intracardiac	O
masses	O
.	O
CLINICAL	O
EVOLUTION	O
During	O
admission	O
to	O
neurology	O
,	O
anticoagulation	O
with	O
synthroid	B-FARMACO
was	O
started	O
and	O
the	O
patient	O
was	O
considered	O
for	O
surgical	O
reintervention	O
.	O
A	O
diagnostic	O
cardiac	O
catheterisation	O
was	O
performed	O
,	O
which	O
revealed	O
coronary	O
arteries	O
without	O
significant	O
lesions	O
,	O
and	O
an	O
evaluation	O
by	O
the	O
geriatrics	O
department	O
estimated	O
a	O
short	O
term	O
mortality	O
risk	O
of	O
21	O
,	O
recommending	O
that	O
surgery	O
should	O
be	O
performed	O
within	O
a	O
period	O
of	O
less	O
than	O
6	O
months	O
.	O
Finally	O
,	O
she	O
was	O
re	O
evaluated	O
in	O
a	O
medical	O
surgical	O
session	O
,	O
and	O
given	O
the	O
high	O
surgical	O
risk	O
of	O
the	O
patient	O
and	O
her	O
baseline	O
clinical	O
situation	O
,	O
conservative	O
management	O
was	O
decided	O
.	O
During	O
follow	O
up	O
,	O
she	O
has	O
not	O
presented	O
any	O
further	O
neurological	O
symptoms	O
.	O
DIAGNOSIS	O
Recurrence	O
of	O
atrial	O
myxoma	O
.	O
Repeated	O
TIA	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
Male	O
,	O
35	O
years	O
old	O
.	O
Native	O
of	O
Morocco	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
Smoker	O
of	O
1	O
pack	O
a	O
day	O
AI	O
20	O
pack	O
years	O
.	O
Non	O
drinker	O
.	O
No	O
cardiovascular	O
risk	O
factors	O
.	O
No	O
history	O
of	O
known	O
heart	O
disease	O
.	O
Single	O
admission	O
in	O
Spain	O
for	O
middle	O
lobe	O
pneumonia	O
in	O
2015	O
.	O
He	O
reported	O
few	O
medical	O
check	O
ups	O
in	O
his	O
country	O
previously	O
.	O
History	O
of	O
rheumatic	O
fever	O
at	O
10	O
years	O
of	O
age	O
.	O
No	O
surgical	O
interventions	O
.	O
No	O
usual	O
treatment	O
.	O
Present	O
illness	O
She	O
came	O
to	O
the	O
emergency	O
department	O
with	O
a	O
cough	O
with	O
yellowish	O
expectoration	O
and	O
a	O
feeling	O
of	O
dystrophy	O
,	O
of	O
2	O
days	O
'	O
evolution	O
.	O
She	O
also	O
reported	O
medium	O
effort	O
dyspnoea	O
of	O
progressive	O
onset	O
during	O
the	O
last	O
6	O
12	O
months	O
,	O
for	O
which	O
she	O
had	O
not	O
consulted	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
BP	O
108	O
72	O
mmHg	O
,	O
heart	O
rate	O
HR	O
96	O
bpm	O
,	O
temperature	O
36	O
.	O
3	O
oC	O
,	O
oxygen	O
saturation	O
96	O
at	O
baseline	O
.	O
Conscious	O
and	O
oriented	O
in	O
all	O
3	O
spheres	O
.	O
Good	O
general	O
condition	O
.	O
Good	O
hydration	O
and	O
perfusion	O
status	O
.	O
Eupneic	O
at	O
rest	O
.	O
Head	O
and	O
neck	O
no	O
IY	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
at	O
110	O
bpm	O
,	O
in	O
mitral	O
focus	O
opening	O
snap	O
and	O
diastolic	O
rumble	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
.	O
No	O
masses	O
or	O
megaliths	O
.	O
No	O
signs	O
of	O
peritoneal	O
irritation	O
.	O
Lower	O
extremities	O
No	O
oedema	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
sinus	O
rhythm	O
at	O
70	O
bpm	O
.	O
P	O
wave	O
of	O
0	O
.	O
12	O
msec	O
,	O
bimodal	O
,	O
predominantly	O
negative	O
in	O
V1	O
,	O
compatible	O
with	O
LA	O
growth	O
.	O
Normal	O
PR	O
.	O
Narrow	O
QRS	O
with	O
axis	O
at	O
90o	O
.	O
No	O
acute	O
repolarisation	O
alterations	O
.	O
Chest	O
X	O
ray	O
PA	O
LAT	O
projections	O
normal	O
cardiomediastinal	O
silhouette	O
.	O
Pattern	O
of	O
vascular	O
redistribution	O
.	O
Fluid	O
in	O
cystole	O
.	O
No	O
pulmonary	O
condensation	O
or	O
pleural	O
effusion	O
.	O
Blood	O
tests	O
glucose	O
85	O
mg	O
dl	O
,	O
urea	O
44	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
99	O
mg	O
dl	O
,	O
sodium	O
137	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
4	O
mEq	O
l	O
,	O
albumin	O
4	O
.	O
5	O
g	O
dl	O
,	O
C	O
reactive	O
protein	O
CRP	O
1	O
.	O
75	O
mg	O
l	O
,	O
haemoglobin	O
13	O
.	O
7	O
g	O
dl	O
,	O
platelets	O
157	O
10	O
3	O
L	O
,	O
leukocytes	O
17	O
.	O
2	O
10	O
3	O
L	O
,	O
neutrophils	O
87	O
.	O
1	O
43	O
.	O
Echocardiogram	O
left	O
ventricle	O
LV	O
not	O
dilated	O
or	O
hypertrophic	O
with	O
preserved	O
function	O
.	O
Diastolic	O
pattern	O
of	O
elongated	O
relaxation	O
.	O
Mild	O
right	O
ventricular	O
RV	O
dysfunction	O
.	O
Moderately	O
to	O
severely	O
dilated	O
LA	O
.	O
Severely	O
calcified	O
and	O
thickened	O
mitral	O
valve	O
and	O
subvalvular	O
apparatus	O
,	O
predominantly	O
at	O
free	O
edges	O
,	O
with	O
bicommissural	O
fusion	O
,	O
resulting	O
in	O
severe	O
stenosis	O
area	O
calculated	O
by	O
hemi	O
pressure	O
time	O
0	O
.	O
94	O
cm2	O
and	O
by	O
planimetry	O
0	O
.	O
76	O
cm	O
,	O
with	O
maximum	O
gradient	O
17	O
mmHg	O
and	O
mean	O
gradient	O
13	O
mmHg	O
.	O
Wilkins	O
scale	O
13	O
14	O
points	O
mobility	O
3	O
points	O
valve	O
continues	O
to	O
move	O
forward	O
in	O
diastole	O
;	O
subvalvular	O
thickening	O
3	O
4	O
points	O
extensive	O
thickening	O
extending	O
to	O
distal	O
third	O
of	O
chordae	O
up	O
to	O
papillary	O
muscles	O
;	O
valvular	O
thickening	O
4	O
points	O
extending	O
over	O
the	O
entire	O
leaflet	O
8	O
10	O
mm	O
;	O
calcification	O
3	O
points	O
sheen	O
reaching	O
the	O
medial	O
areas	O
of	O
the	O
leaflets	O
.	O
No	O
mitral	O
insufficiency	O
.	O
Calcified	O
aortic	O
valve	O
with	O
mild	O
regurgitation	O
.	O
Mild	O
tricuspid	O
insufficiency	O
.	O
Normal	O
pulmonary	O
pressure	O
.	O
No	O
pericardial	O
effusion	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
,	O
who	O
initially	O
attended	O
the	O
emergency	O
department	O
with	O
symptoms	O
compatible	O
with	O
a	O
respiratory	O
infection	O
,	O
was	O
finally	O
diagnosed	O
with	O
severe	O
mitral	O
stenosis	O
on	O
the	O
basis	O
of	O
exploratory	O
and	O
echocardiographic	O
findings	O
.	O
Given	O
the	O
clinical	O
manifestations	O
and	O
severity	O
of	O
the	O
valve	O
disease	O
,	O
it	O
was	O
decided	O
to	O
schedule	O
surgery	O
.	O
Beforehand	O
,	O
the	O
patient	O
underwent	O
an	O
angio	O
CT	O
scan	O
that	O
ruled	O
out	O
coronary	O
lesions	O
.	O
Given	O
the	O
score	O
of	O
13	O
14	O
on	O
the	O
Wilkins	O
scale	O
,	O
it	O
was	O
decided	O
to	O
replace	O
the	O
valve	O
with	O
a	O
mechanical	O
prosthesis	O
,	O
which	O
was	O
carried	O
out	O
without	O
incident	O
.	O
The	O
patient	O
was	O
discharged	O
home	O
.	O
DIAGNOSIS	O
Severe	O
mitral	O
stenosis	O
of	O
rheumatic	O
origin	O
.	O
History	O
of	O
rheumatic	O
fever	O
in	O
childhood	O
.	O
Respiratory	O
tract	O
infection	O
.	O

Young	O
woman	O
who	O
,	O
after	O
excessive	O
cocaine	O
consumption	O
,	O
presented	O
with	O
peripheral	O
embolism	O
and	O
was	O
admitted	O
to	O
our	O
hospital	O
.	O
During	O
hospitalisation	O
,	O
she	O
presented	O
electrocardiographic	O
alterations	O
,	O
elevated	O
markers	O
of	O
myocardial	O
damage	O
and	O
pathological	O
findings	O
on	O
imaging	O
tests	O
that	O
led	O
to	O
the	O
final	O
diagnosis	O
.	O
HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
FAMILY	O
HISTORY	O
Absence	O
of	O
family	O
history	O
of	O
heart	O
disease	O
.	O
PERSONAL	O
HISTORY	O
No	O
known	O
allergic	O
drug	O
reactions	O
.	O
No	O
classic	O
cardiovascular	O
risk	O
factors	O
.	O
Toxic	O
habits	O
sporadic	O
consumption	O
of	O
alcohol	O
and	O
other	O
toxic	O
substances	O
.	O
Non	O
smoker	O
.	O
Coeliac	O
disease	O
.	O
Previous	O
medication	O
The	O
patient	O
denies	O
taking	O
chronic	O
home	O
medication	O
.	O
CURRENT	O
ILLNESS	O
This	O
is	O
a	O
35	O
year	O
old	O
woman	O
with	O
coeliac	O
disease	O
,	O
with	O
no	O
other	O
family	O
or	O
personal	O
medical	O
history	O
of	O
interest	O
,	O
who	O
attended	O
the	O
emergency	O
department	O
of	O
the	O
Hospital	O
del	O
Tajo	O
with	O
symptoms	O
compatible	O
with	O
acute	O
arterial	O
ischaemia	O
of	O
the	O
right	O
upper	O
limb	O
,	O
and	O
was	O
transferred	O
to	O
our	O
centre	O
for	O
assessment	O
by	O
vascular	O
surgery	O
.	O
An	O
urgent	O
angio	O
CT	O
scan	O
was	O
performed	O
which	O
revealed	O
proximal	O
occlusion	O
of	O
the	O
right	O
humeral	O
artery	O
with	O
distal	O
repermeabilisation	O
,	O
probably	O
embolic	O
in	O
nature	O
,	O
and	O
incidentally	O
a	O
filling	O
defect	O
in	O
the	O
left	O
ventricle	O
suggestive	O
of	O
intracavitary	O
thrombus	O
.	O
On	O
questioning	O
the	O
patient	O
,	O
she	O
reported	O
consumption	O
of	O
high	O
doses	O
of	O
toxic	O
alpha	O
agonists	O
cocaine	O
in	O
the	O
previous	O
days	O
,	O
although	O
she	O
denied	O
episodes	O
of	O
chest	O
pain	O
or	O
any	O
other	O
cardiovascular	O
symptoms	O
.	O
An	O
urgent	O
echocardiogram	O
was	O
performed	O
,	O
showing	O
severe	O
apical	O
hypokinesia	O
and	O
severe	O
hypokinesia	O
of	O
distal	O
segments	O
of	O
the	O
lateral	O
face	O
and	O
distal	O
septum	O
,	O
with	O
a	O
visual	O
left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
of	O
45	O
and	O
images	O
compatible	O
with	O
two	O
mobile	O
apical	O
thrombi	O
.	O
Urgent	O
revascularisation	O
surgery	O
with	O
Fogarty	O
probe	O
was	O
successfully	O
performed	O
.	O
Given	O
the	O
electro	O
and	O
echocardiographic	O
findings	O
,	O
as	O
well	O
as	O
the	O
elevation	O
of	O
myocardial	O
damage	O
markers	O
,	O
once	O
the	O
humeral	O
artery	O
had	O
been	O
repermeabilised	O
,	O
it	O
was	O
decided	O
to	O
perform	O
urgent	O
coronary	O
angiography	O
,	O
which	O
ruled	O
out	O
the	O
presence	O
of	O
coronary	O
lesions	O
.	O
After	O
this	O
,	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
coronary	O
unit	O
under	O
conditions	O
of	O
respiratory	O
and	O
haemodynamic	O
stability	O
and	O
anticoagulation	O
with	O
sodium	B-FARMACO
heparin	I-FARMACO
was	O
started	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
BP	O
90	O
60	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
85	O
bpm	O
.	O
Respiratory	O
frequency	O
RF	O
18	O
rpm	O
.	O
Temperature	O
37	O
C	O
.	O
SpO2	O
98	O
basal	O
.	O
Conscious	O
,	O
oriented	O
in	O
all	O
three	O
spheres	O
and	O
cooperative	O
.	O
Normal	O
colour	O
,	O
normohydrated	O
and	O
normoperfused	O
.	O
Eupneic	O
at	O
rest	O
,	O
with	O
good	O
respiratory	O
dynamics	O
,	O
tolerating	O
decubitus	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
of	O
good	O
intensity	O
.	O
No	O
murmurs	O
or	O
extratonos	O
were	O
heard	O
.	O
Pulmonary	O
auscultation	O
vesicular	O
murmur	O
preserved	O
and	O
symmetrical	O
in	O
both	O
hemithoraxes	O
,	O
with	O
no	O
extra	O
sounds	O
.	O
Abdomen	O
hydro	O
aerial	O
sounds	O
present	O
and	O
of	O
normal	O
characteristics	O
.	O
Soft	O
,	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
,	O
without	O
masses	O
or	O
organomegaly	O
.	O
Lower	O
limbs	O
pedial	O
pulses	O
present	O
and	O
symmetrical	O
.	O
Absence	O
of	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
Upper	O
limbs	O
absence	O
of	O
distal	O
pulse	O
in	O
the	O
right	O
upper	O
limb	O
.	O
COMPLEMENTARY	O
TESTS	O
Admission	O
ECG	O
sinus	O
rhythm	O
at	O
80	O
bpm	O
.	O
Normal	O
PR	O
.	O
Narrow	O
QRS	O
.	O
Generalised	O
negative	O
T	O
waves	O
.	O
Prolongation	O
of	O
the	O
QTc	O
interval	O
590	O
ms	O
.	O
Angio	O
CT	O
of	O
the	O
chest	O
and	O
upper	O
limbs	O
proximal	O
occlusion	O
of	O
the	O
right	O
humeral	O
artery	O
with	O
distal	O
repermeabilisation	O
,	O
of	O
probable	O
embolic	O
origin	O
.	O
Repletion	O
defect	O
in	O
the	O
LV	O
,	O
making	O
it	O
necessary	O
to	O
rule	O
out	O
thrombus	O
.	O
Right	O
pulmonary	O
involvement	O
which	O
,	O
in	O
the	O
clinical	O
context	O
,	O
could	O
also	O
indicate	O
the	O
presence	O
of	O
emboli	O
.	O
Urgent	O
transthoracic	O
echocardiogram	O
left	O
ventricle	O
LV	O
not	O
dilated	O
or	O
hypertrophic	O
,	O
severe	O
apical	O
hypokinesia	O
and	O
distal	O
segments	O
of	O
the	O
lateral	O
face	O
and	O
distal	O
septum	O
,	O
LVEF	O
45	O
,	O
image	O
compatible	O
with	O
two	O
mobile	O
apical	O
thrombi	O
;	O
the	O
largest	O
measuring	O
at	O
least	O
25	O
mm	O
.	O
Non	O
dilated	O
right	O
ventricle	O
RV	O
normocontractile	O
.	O
Morphologically	O
and	O
functionally	O
normal	O
valves	O
.	O
Admission	O
blood	O
tests	O
Haemogram	O
red	O
blood	O
cells	O
4	O
.	O
20	O
x	O
1000	O
l	O
.	O
Haemoglobin	O
12	O
.	O
3	O
g	O
dl	O
.	O
Haematocrit	O
37	O
.	O
5	O
.	O
MCV	O
89	O
.	O
2	O
fl	O
.	O
MCH	O
29	O
.	O
2	O
pg	O
.	O
MCHC	O
32	O
.	O
7	O
g	O
dl	O
.	O
RDW	O
14	O
.	O
6	O
.	O
Platelets	O
153	O
x	O
1000	O
l	O
.	O
VPM	O
9	O
.	O
2	O
fl	O
.	O
Leukocytes	O
10	O
.	O
70	O
x	O
1000	O
l	O
.	O
Neutrophils	O
5	O
.	O
50	O
x	O
1000	O
l	O
.	O
Neutrophils	O
51	O
.	O
9	O
.	O
Lymphocytes	O
3	O
.	O
90	O
x	O
1000	O
l	O
.	O
Lymphocytes	O
36	O
.	O
6	O
.	O
Monocytes	O
0	O
.	O
80	O
x	O
1000	O
l	O
,	O
Monocytes	O
7	O
.	O
9	O
.	O
Eosinophils	O
0	O
.	O
30	O
x	O
1000	O
l	O
.	O
Eosinophils	O
3	O
.	O
0	O
.	O
Basophils	O
0	O
.	O
10	O
x	O
1000	O
l	O
.	O
Basophils	O
0	O
.	O
6	O
.	O
Biochemistry	O
glucose	O
95	O
mg	O
dl	O
.	O
Creatinine	O
0	O
.	O
67	O
mg	O
dl	O
.	O
Sodium	O
139	O
mEq	O
l	O
.	O
Potassium	O
3	O
.	O
44	O
mEq	O
l	O
.	O
Chlorine	O
106	O
mEq	O
l	O
.	O
Total	O
protein	O
6	O
,	O
0	O
g	O
dl	O
.	O
Albumin	O
3	O
,	O
3	O
g	O
dl	O
.	O
Calcium	O
8	O
.	O
2	O
mg	O
dl	O
.	O
ALT	O
GPT	O
24	O
U	O
l	O
.	O
AST	O
GOT	O
32	O
U	O
l	O
.	O
Gamma	O
GT	O
8	O
U	O
l	O
.	O
Alkaline	O
phosphatase	O
64	O
U	O
l	O
.	O
Bilirubin	O
0	O
.	O
4	O
mg	O
dl	O
.	O
Coagulation	O
prothrombin	O
activity	O
91	O
.	O
Prothrombin	O
time	O
12	O
,	O
1	O
sec	O
.	O
INR	O
laboratory	O
1	O
.	O
05	O
.	O
TTPa	O
26	O
sec	O
.	O
Fibrinogen	O
derivative	O
375	O
mg	O
dl	O
.	O
Serialisation	O
of	O
markers	O
of	O
myocardial	O
damage	O
1st	O
profile	O
CK	O
456	O
U	O
l	O
,	O
troponin	O
T	O
hs	O
217	O
.	O
8	O
ng	O
l	O
.	O
2nd	O
profile	O
CK	O
340	O
U	O
l	O
,	O
troponin	O
T	O
hs	O
206	O
.	O
9	O
ng	O
l	O
.	O
3rd	O
profile	O
CK	O
353	O
U	O
l	O
,	O
troponin	O
T	O
hs	O
224	O
.	O
3	O
ng	O
l	O
Urgent	O
coronary	O
angiography	O
right	O
dominance	O
.	O
Coronary	O
arteries	O
without	O
angiographic	O
lesions	O
short	O
intramyocardial	O
stretch	O
in	O
mid	O
AD	O
.	O
Regulated	O
transthoracic	O
echocardiogram	O
study	O
performed	O
in	O
sinus	O
rhythm	O
at	O
66	O
bpm	O
.	O
Left	O
ventricle	O
not	O
dilated	O
,	O
with	O
normal	O
wall	O
thickness	O
.	O
Segmental	O
contractility	O
with	O
hypokinesia	O
of	O
the	O
apex	O
and	O
lateral	O
apical	O
segment	O
.	O
Preserved	O
systolic	O
function	O
LVEF	O
57	O
by	O
Simpson	O
biplane	O
.	O
Normal	O
diastolic	O
function	O
.	O
Non	O
dilated	O
right	O
ventricle	O
with	O
normal	O
systolic	O
function	O
.	O
Normal	O
sized	O
left	O
atrium	O
.	O
Right	O
atrium	O
of	O
normal	O
size	O
.	O
Aortic	O
valve	O
morphologically	O
and	O
functionally	O
normal	O
.	O
Mitral	O
valve	O
morphologically	O
and	O
functionally	O
normal	O
.	O
Tricuspid	O
valve	O
morphologically	O
normal	O
,	O
with	O
trivial	O
insufficiency	O
that	O
allows	O
estimating	O
PSP	O
of	O
24	O
mmHg	O
.	O
No	O
indirect	O
signs	O
of	O
pulmonary	O
hypertension	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
with	O
collapse	O
50	O
with	O
inspiration	O
.	O
Aortic	O
root	O
and	O
aortic	O
arch	O
of	O
normal	O
size	O
.	O
No	O
coarctation	O
.	O
Atrial	O
septum	O
intact	O
,	O
without	O
suspicion	O
of	O
intracardiac	O
shunt	O
by	O
colour	O
Doppler	O
.	O
Pericardium	O
of	O
normal	O
thickness	O
and	O
refractoriness	O
,	O
without	O
effusion	O
.	O
Presence	O
of	O
two	O
apical	O
masses	O
of	O
at	O
least	O
23	O
x	O
11	O
mm	O
and	O
16	O
x	O
11	O
mm	O
assessed	O
in	O
short	O
axis	O
with	O
medium	O
echogenicity	O
,	O
both	O
with	O
pedicle	O
and	O
slightly	O
mobile	O
in	O
the	O
left	O
ventricle	O
.	O
With	O
respect	O
to	O
the	O
study	O
of	O
48	O
hours	O
ago	O
,	O
very	O
discreet	O
reduction	O
in	O
size	O
,	O
with	O
the	O
two	O
masses	O
persisting	O
with	O
the	O
appearance	O
of	O
a	O
thrombus	O
in	O
the	O
LV	O
apex	O
.	O
Urgent	O
CT	O
angiography	O
of	O
the	O
abdomen	O
and	O
lower	O
limbs	O
findings	O
compatible	O
with	O
arterial	O
occlusions	O
in	O
the	O
common	O
iliac	O
and	O
left	O
popliteal	O
arteries	O
.	O
Renal	O
infarction	O
in	O
the	O
right	O
lower	O
pole	O
of	O
new	O
appearance	O
with	O
respect	O
to	O
the	O
previous	O
one	O
.	O
Adrenal	O
glands	O
with	O
no	O
notable	O
findings	O
.	O
Cardiac	O
magnetic	O
radiography	O
CMR	O
left	O
ventricle	O
not	O
dilated	O
or	O
hypertrophic	O
.	O
Normal	O
systolic	O
function	O
.	O
Right	O
ventricle	O
not	O
dilated	O
with	O
normal	O
systolic	O
function	O
.	O
No	O
alterations	O
in	O
segmental	O
contractility	O
.	O
Atria	O
not	O
dilated	O
.	O
Morphologically	O
and	O
functionally	O
normal	O
valves	O
.	O
No	O
pericardial	O
abnormalities	O
.	O
T2	O
STIR	O
sequences	O
do	O
not	O
show	O
areas	O
suggestive	O
of	O
oedema	O
.	O
In	O
the	O
first	O
pass	O
myocardial	O
perfusion	O
sequence	O
there	O
are	O
no	O
perfusion	O
defects	O
.	O
In	O
the	O
early	O
enhancement	O
sequence	O
,	O
no	O
intracavitary	O
thrombus	O
images	O
are	O
identified	O
.	O
In	O
the	O
late	O
enhancement	O
sequences	O
no	O
areas	O
of	O
pathological	O
uptake	O
in	O
the	O
myocardium	O
of	O
both	O
ventricles	O
suggesting	O
the	O
presence	O
of	O
fibrosis	O
are	O
seen	O
.	O
CONCLUSION	O
Absence	O
of	O
images	O
compatible	O
with	O
ventricular	O
thrombus	O
.	O
Absence	O
of	O
myocardial	O
oedema	O
and	O
late	O
enhancement	O
suggestive	O
of	O
ischaemic	O
heart	O
disease	O
.	O
Qp	O
Qs	O
1	O
.	O
33	O
with	O
presence	O
of	O
partial	O
anomalous	O
pulmonary	O
venous	O
drainage	O
with	O
left	O
superior	O
pulmonary	O
vein	O
draining	O
into	O
left	O
brachiocephalic	O
trunk	O
.	O
CLINICAL	O
COURSE	O
This	O
is	O
a	O
35	O
year	O
old	O
woman	O
with	O
no	O
medical	O
history	O
of	O
interest	O
who	O
was	O
admitted	O
from	O
the	O
Tajo	O
Hospital	O
for	O
peripheral	O
arterial	O
embolism	O
in	O
the	O
right	O
upper	O
limb	O
.	O
The	O
angio	O
CT	O
scan	O
showed	O
proximal	O
occlusion	O
of	O
the	O
right	O
humeral	O
artery	O
,	O
so	O
a	O
Fogarty	O
catheter	O
embolectomy	O
was	O
performed	O
,	O
as	O
well	O
as	O
,	O
incidentally	O
,	O
an	O
image	O
compatible	O
with	O
intraventricular	O
thrombus	O
.	O
A	O
review	O
of	O
the	O
study	O
revealed	O
an	O
area	O
of	O
subendocardial	O
hypoperfusion	O
with	O
almost	O
transmural	O
extension	O
in	O
apical	O
segments	O
of	O
the	O
anterior	O
septum	O
and	O
a	O
large	O
apical	O
thrombus	O
.	O
An	O
urgent	O
echocardiogram	O
was	O
performed	O
which	O
showed	O
an	O
LVEF	O
of	O
45	O
with	O
alterations	O
in	O
apical	O
contractility	O
,	O
confirming	O
the	O
presence	O
of	O
two	O
apical	O
thrombi	O
,	O
so	O
,	O
given	O
the	O
suspicion	O
of	O
complicated	O
acute	O
myocardial	O
infarction	O
of	O
undetermined	O
time	O
of	O
evolution	O
,	O
an	O
urgent	O
coronary	O
angiography	O
was	O
performed	O
which	O
showed	O
normal	O
coronary	O
arteries	O
.	O
He	O
was	O
transferred	O
to	O
the	O
coronary	O
unit	O
,	O
where	O
sodium	B-FARMACO
heparin	I-FARMACO
perfusion	O
was	O
started	O
and	O
,	O
in	O
stable	O
condition	O
,	O
he	O
was	O
transferred	O
to	O
the	O
conventional	O
hospital	O
ward	O
.	O
During	O
his	O
stay	O
there	O
,	O
he	O
presented	O
a	O
new	O
embolic	O
event	O
in	O
the	O
right	O
lower	O
limb	O
despite	O
correct	O
anticoagulation	O
evidenced	O
by	O
serial	O
controls	O
by	O
aPTT	O
,	O
with	O
frequent	O
adjustments	O
of	O
the	O
sodium	B-FARMACO
heparin	I-FARMACO
infusion	O
rate	O
which	O
required	O
urgent	O
thrombectomy	O
,	O
with	O
good	O
subsequent	O
evolution	O
.	O
A	O
regular	O
CMR	O
was	O
performed	O
,	O
which	O
showed	O
LVEF	O
recovery	O
,	O
without	O
late	O
enhancement	O
and	O
with	O
resolution	O
of	O
the	O
thrombus	O
.	O
Given	O
the	O
clinical	O
stability	O
and	O
the	O
resolution	O
of	O
the	O
medical	O
surgical	O
processes	O
that	O
led	O
to	O
his	O
admission	O
,	O
after	O
10	O
days	O
of	O
hospitalisation	O
he	O
was	O
discharged	O
from	O
hospital	O
with	O
outpatient	O
monitoring	O
.	O
Anticoagulation	O
with	O
acenocoumarol	B-FARMACO
was	O
decided	O
for	O
3	O
6	O
months	O
with	O
subsequent	O
review	O
in	O
vascular	O
surgery	O
and	O
cardiology	O
consultations	O
.	O
DIAGNOSIS	O
Cocaine	O
induced	O
stress	O
cardiomyopathy	O
tako	O
tsubo	O
syndrome	O
.	O
Intraventricular	O
thrombus	O
in	O
the	O
context	O
of	O
the	O
above	O
,	O
resolved	O
on	O
discharge	O
.	O
Proximal	O
occlusion	O
of	O
right	O
humeral	O
artery	O
of	O
embolic	O
nature	O
,	O
treated	O
by	O
embolectomy	O
.	O
Embolism	O
in	O
the	O
left	O
common	O
and	O
external	O
iliac	O
arteries	O
and	O
in	O
the	O
third	O
portion	O
of	O
the	O
left	O
popliteal	O
artery	O
,	O
treated	O
by	O
transfemoral	O
thromboembolectomy	O
.	O
Asymptomatic	O
right	O
lower	O
pole	O
renal	O
infarction	O
.	O
Partial	O
anomalous	O
pulmonary	O
venous	O
drainage	O
with	O
left	O
superior	O
pulmonary	O
vein	O
draining	O
into	O
left	O
brachiocephalic	O
trunk	O
.	O
QP	O
QS	O
1	O
.	O
33	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
PERSONAL	O
HISTORY	O
No	O
adverse	O
drug	O
reaction	O
.	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
smoking	O
10	O
cig	O
day	O
,	O
dyslipidaemia	O
.	O
Suprarenal	O
incidentaloma	O
in	O
follow	O
up	O
by	O
endocrinologist	O
negative	O
catecholamines	O
and	O
metanephrines	O
in	O
urine	O
and	O
normal	O
cortisol	O
.	O
Cardiological	O
history	O
Admission	O
for	O
tako	O
tsubo	O
syndrome	O
in	O
2017	O
.	O
The	O
electrocardiogram	O
ECG	O
on	O
admission	O
showed	O
ST	O
elevation	O
in	O
the	O
inferior	O
face	O
,	O
so	O
the	O
infarction	O
code	O
was	O
initially	O
activated	O
,	O
showing	O
normal	O
coronary	O
arteries	O
.	O
Ventriculography	O
and	O
echocardiography	O
showed	O
akinesia	O
of	O
all	O
apical	O
segments	O
with	O
preserved	O
contractility	O
at	O
baseline	O
left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
by	O
Simpson	O
42	O
,	O
with	O
an	O
image	O
of	O
apical	O
ballooning	O
compatible	O
with	O
tako	O
tsubo	O
syndrome	O
.	O
Peak	O
ultrasensitive	O
troponin	O
T	O
568	O
.	O
4	O
pg	O
ml	O
.	O
She	O
was	O
discharged	O
with	O
beta	O
blockers	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
and	O
angiotensin	O
converting	O
enzyme	O
inhibitor	O
ACE	O
inhibitor	O
enalapril	B-FARMACO
2	O
.	O
5	O
mg	O
.	O
Four	O
months	O
after	O
discharge	O
,	O
a	O
control	O
echocardiogram	O
was	O
performed	O
,	O
showing	O
complete	O
normalisation	O
of	O
contractility	O
alterations	O
and	O
LVEF	O
of	O
67	O
.	O
New	O
admission	O
in	O
2018	O
for	O
non	O
ST	O
segment	O
elevation	O
myocardial	O
infarction	O
NSTEMI	O
.	O
The	O
ECG	O
in	O
the	O
emergency	O
department	O
showed	O
prominent	O
T	O
waves	O
on	O
the	O
inferolateral	O
side	O
.	O
Elevation	O
of	O
troponin	O
T	O
Us	O
up	O
to	O
487	O
pg	O
ml	O
.	O
Catheterisation	O
with	O
normal	O
coronary	O
arteries	O
,	O
with	O
multiple	O
fistulas	O
from	O
the	O
left	O
coronary	O
tree	O
to	O
the	O
left	O
ventricle	O
.	O
Cardiac	O
magnetic	O
resonance	O
CMR	O
was	O
also	O
requested	O
,	O
with	O
no	O
signs	O
of	O
acute	O
ischaemia	O
,	O
myocarditis	O
or	O
transmural	O
necrosis	O
.	O
It	O
was	O
decided	O
to	O
increase	O
the	O
dose	O
of	O
beta	O
blocker	O
bisoprolol	B-FARMACO
to	O
5	O
mg	O
day	O
,	O
aspirin	B-FARMACO
100	O
mg	O
day	O
and	O
atorvastatin	B-FARMACO
40	O
mg	O
day	O
were	O
added	O
.	O
CURRENT	O
DISEASE	O
A	O
60	O
year	O
old	O
woman	O
came	O
to	O
the	O
emergency	O
department	O
one	O
month	O
after	O
her	O
last	O
admission	O
for	O
an	O
episode	O
of	O
central	O
thoracic	O
oppression	O
lasting	O
one	O
hour	O
,	O
which	O
started	O
at	O
rest	O
and	O
was	O
accompanied	O
by	O
a	O
significant	O
vegetative	O
cortex	O
in	O
the	O
form	O
of	O
profuse	O
sweating	O
and	O
nausea	O
.	O
On	O
arrival	O
at	O
the	O
ED	O
,	O
still	O
symptomatic	O
with	O
slight	O
discomfort	O
in	O
the	O
left	O
hemithorax	O
.	O
Treatment	O
on	O
current	O
admission	O
bisoprolol	B-FARMACO
5	O
mg	O
,	O
atorvastatin	B-FARMACO
40	O
mg	O
day	O
,	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
100	O
mg	O
day	O
,	O
hydroferol	B-FARMACO
0	O
.	O
266	O
1	O
capsule	O
per	O
month	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
BP	O
135	O
65	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
75	O
bpm	O
.	O
SatO2	O
98	O
FIO2	O
21	O
.	O
Regular	O
general	O
condition	O
,	O
conscious	O
and	O
oriented	O
,	O
cooperative	O
,	O
without	O
focality	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
VCM	O
without	O
over	O
aggregation	O
.	O
Lower	O
limbs	O
symmetrical	O
without	O
oedema	O
,	O
palpable	O
peripheral	O
pulses	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
on	O
arrival	O
,	O
with	O
pain	O
nodal	O
rhythm	O
at	O
80	O
bpm	O
that	O
precedes	O
the	O
sinus	O
P	O
wave	O
with	O
a	O
frequency	O
of	O
about	O
70	O
bpm	O
.	O
Narrow	O
QRS	O
,	O
ST	O
segment	O
depression	O
less	O
than	O
0	O
.	O
5	O
mm	O
in	O
II	O
and	O
avF	O
,	O
and	O
up	O
to	O
1	O
.	O
5	O
mm	O
in	O
V4	O
V6	O
,	O
which	O
normalises	O
completely	O
after	O
sublingual	O
caffeine	B-FARMACO
.	O
Laboratory	O
tests	O
Biochemistry	O
glucose	O
162	O
mg	O
dl	O
.	O
Urea	O
42	O
mg	O
d	O
.	O
Creatinine	O
1	O
.	O
03	O
mg	O
dl	O
.	O
Sodium	O
139	O
mmol	O
l	O
.	O
Potassium	O
3	O
.	O
4	O
mmol	O
l	O
.	O
C	O
reactive	O
protein	O
CRP	O
3	O
.	O
0	O
mg	O
dl	O
.	O
Total	O
cholesterol	O
121	O
mg	O
dl	O
.	O
Triglycerides	O
57	O
mg	O
dl	O
.	O
HDL	O
cholesterol	O
43	O
mg	O
dl	O
.	O
Calculated	O
LDL	O
cholesterol	O
78	O
mg	O
dl	O
.	O
Haemogram	O
white	O
blood	O
cells	O
15	O
.	O
88	O
x10	O
9	O
l	O
.	O
Red	O
blood	O
cells	O
4	O
.	O
45	O
x10	O
12	O
l	O
.	O
Haemoglobin	O
14	O
.	O
4	O
g	O
dl	O
.	O
Platelets	O
249	O
x10	O
9	O
l	O
.	O
Haemostasis	O
PT	O
14s	O
,	O
aPTT	O
35s	O
.	O
Quick	O
85	O
.	O
INR	O
1	O
.	O
0	O
.	O
Myocardial	O
damage	O
markers	O
ultrasensitive	O
troponin	O
T	O
10	O
.	O
5	O
pg	O
ml	O
280	O
pg	O
ml	O
17	O
pg	O
ml	O
.	O
Echocardiography	O
left	O
ventricle	O
LV	O
with	O
normal	O
diameters	O
LVEDD	O
46	O
mm	O
,	O
without	O
hypertrophy	O
of	O
its	O
walls	O
and	O
with	O
preserved	O
systolic	O
function	O
EF	O
65	O
.	O
No	O
alterations	O
in	O
segmental	O
contractility	O
were	O
observed	O
at	O
rest	O
.	O
Non	O
dilated	O
right	O
ventricle	O
with	O
preserved	O
systolic	O
function	O
.	O
Normal	O
LV	O
diastolic	O
pattern	O
.	O
Atria	O
of	O
normal	O
size	O
.	O
Aortic	O
root	O
of	O
normal	O
diameter	O
with	O
sigmoid	O
leaflets	O
of	O
normal	O
thickness	O
and	O
opening	O
.	O
No	O
valvular	O
dysfunction	O
.	O
Mitral	O
valve	O
with	O
leaflets	O
of	O
normal	O
thickness	O
and	O
mobility	O
.	O
Trivial	O
central	O
regurgitant	O
jet	O
.	O
Minimal	O
tricuspid	O
insufficiency	O
TI	O
,	O
in	O
the	O
absence	O
of	O
pulmonary	O
hypertension	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
.	O
Ergometry	O
with	O
hyperventilation	O
test	O
hyperventilation	O
test	O
is	O
performed	O
for	O
2	O
minutes	O
without	O
appreciating	O
significant	O
changes	O
in	O
ventricular	O
repolarisation	O
.	O
Subsequently	O
,	O
he	O
exercised	O
according	O
to	O
the	O
Bruce	O
protocol	O
,	O
stopping	O
the	O
test	O
at	O
the	O
beginning	O
of	O
the	O
4th	O
stage	O
of	O
the	O
Bruce	O
protocol	O
11	O
METS	O
due	O
to	O
maladaptation	O
to	O
the	O
treadmill	O
,	O
not	O
reaching	O
submaximal	O
FC	O
81	O
of	O
FCMT	O
under	O
the	O
effect	O
of	O
beta	O
blockers	O
.	O
No	O
angina	O
or	O
ST	O
segment	O
elevation	O
.	O
Correct	O
chronotropic	O
adaptation	O
.	O
Absence	O
of	O
arrhythmia	O
induction	O
.	O
Good	O
functional	O
capacity	O
120	O
for	O
active	O
women	O
.	O
Coronary	O
catheterisation	O
left	O
main	O
coronary	O
artery	O
LMCA	O
no	O
lesions	O
.	O
Anterior	O
descending	O
artery	O
ADA	O
good	O
calibre	O
and	O
development	O
,	O
without	O
lesions	O
.	O
Coronary	O
fistulas	O
to	O
LV	O
.	O
Circumflex	O
artery	O
ACX	O
non	O
dominant	O
without	O
lesions	O
.	O
Right	O
coronary	O
artery	O
RCA	O
dominant	O
,	O
without	O
lesions	O
.	O
Vasospasm	O
test	O
with	O
acetylcholine	O
acetylcholine	O
test	O
was	O
performed	O
with	O
increasing	O
doses	O
in	O
the	O
left	O
coronary	O
artery	O
,	O
with	O
no	O
clinical	O
changes	O
observed	O
in	O
ECG	O
or	O
vasospasm	O
.	O
In	O
ACD	O
,	O
significant	O
spasm	O
was	O
observed	O
75	O
associated	O
with	O
nodal	O
rhythm	O
,	O
followed	O
by	O
transient	O
complete	O
atrioventricular	O
block	O
AVB	O
,	O
reproducing	O
the	O
electrocardiographic	O
alterations	O
in	O
the	O
inferolateral	O
face	O
,	O
present	O
in	O
the	O
admission	O
ECG	O
.	O
Intracoronary	O
nitroglycerin	B-FARMACO
NTG	I-FARMACO
was	O
administered	O
,	O
and	O
the	O
procedure	O
was	O
completed	O
without	O
further	O
complications	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
has	O
remained	O
stable	O
since	O
admission	O
to	O
the	O
cardiology	O
ward	O
with	O
no	O
recurrence	O
of	O
the	O
symptoms	O
that	O
led	O
to	O
her	O
admission	O
.	O
Given	O
the	O
presence	O
of	O
ischaemic	O
changes	O
in	O
the	O
admission	O
ECG	O
and	O
relatively	O
recent	O
coronary	O
angiograms	O
without	O
lesions	O
,	O
a	O
hyperventilation	O
test	O
was	O
requested	O
with	O
suspicion	O
of	O
coronary	O
vasospasm	O
,	O
which	O
was	O
normal	O
,	O
so	O
a	O
coronary	O
vasospasm	O
test	O
with	O
acetylcholine	O
was	O
requested	O
.	O
Four	O
injections	O
were	O
performed	O
with	O
increasing	O
doses	O
in	O
the	O
left	O
tree	O
without	O
producing	O
any	O
angiographic	O
or	O
electrocardiographic	O
changes	O
and	O
one	O
injection	O
in	O
the	O
right	O
coronary	O
artery	O
which	O
triggered	O
spasm	O
greater	O
than	O
75	O
of	O
the	O
initial	O
vessel	O
calibre	O
with	O
ischaemic	O
changes	O
in	O
the	O
electrocardiogram	O
.	O
Given	O
that	O
the	O
patient	O
under	O
treatment	O
with	O
beta	O
blockers	O
and	O
ASA	B-FARMACO
has	O
presented	O
recurrences	O
of	O
the	O
current	O
clinical	O
picture	O
,	O
it	O
was	O
decided	O
to	O
discontinue	O
them	O
and	O
start	O
NTG	B-FARMACO
patches	O
,	O
which	O
the	O
patient	O
did	O
not	O
tolerate	O
due	O
to	O
headache	O
and	O
weakness	O
,	O
diltiazem	B-FARMACO
was	O
prescribed	O
in	O
low	O
doses	O
,	O
with	O
good	O
tolerance	O
,	O
so	O
that	O
this	O
drug	O
was	O
maintained	O
at	O
discharge	O
.	O
The	O
importance	O
of	O
smoking	O
cessation	O
was	O
stressed	O
.	O
Several	O
months	O
after	O
admission	O
,	O
the	O
patient	O
remained	O
asymptomatic	O
,	O
with	O
good	O
tolerance	O
to	O
the	O
medication	O
,	O
no	O
changes	O
in	O
her	O
functional	O
class	O
,	O
and	O
no	O
recurrence	O
of	O
episodes	O
of	O
chest	O
pain	O
.	O
DIAGNOSIS	O
Recurrent	O
acute	O
coronary	O
syndrome	O
ACS	O
,	O
with	O
normal	O
coronary	O
arteries	O
.	O
Vasospastic	O
angina	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
A	O
37	O
year	O
old	O
woman	O
reported	O
an	O
episode	O
of	O
transfixing	O
interscapular	O
pain	O
radiating	O
to	O
the	O
cervical	O
region	O
and	O
to	O
both	O
upper	O
limbs	O
MMSS	O
,	O
which	O
had	O
been	O
going	O
on	O
for	O
hours	O
.	O
She	O
reported	O
episodes	O
of	O
chest	O
pain	O
of	O
identical	O
characteristics	O
related	O
to	O
exertion	O
,	O
which	O
subsided	O
with	O
rest	O
,	O
of	O
several	O
months	O
'	O
evolution	O
,	O
without	O
having	O
presented	O
episodes	O
of	O
prolonged	O
chest	O
pain	O
up	O
to	O
the	O
present	O
time	O
,	O
for	O
which	O
she	O
had	O
not	O
consulted	O
.	O
As	O
personal	O
history	O
,	O
he	O
had	O
no	O
known	O
cardiovascular	O
risk	O
factors	O
CVRF	O
and	O
was	O
being	O
followed	O
up	O
by	O
cardiology	O
at	O
a	O
private	O
centre	O
for	O
moderate	O
aortic	O
insufficiency	O
of	O
unknown	O
aetiology	O
,	O
without	O
access	O
to	O
previous	O
echocardiogram	O
images	O
.	O
Vital	O
signs	O
at	O
triage	O
.	O
Blood	O
pressure	O
BP	O
140	O
80	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
110	O
bpm	O
.	O
SatO2	O
FiO2	O
21	O
93	O
.	O
Temperature	O
37	O
.	O
2	O
C	O
.	O
PHYSICAL	O
EXAMINATION	O
Good	O
general	O
condition	O
,	O
normal	O
colour	O
and	O
normal	O
hydration	O
.	O
Eupneic	O
at	O
rest	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
with	O
systolic	O
murmur	O
III	O
VI	O
already	O
known	O
previously	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
without	O
added	O
noise	O
.	O
No	O
lower	O
limb	O
oedema	O
.	O
Radial	O
,	O
femoral	O
and	O
pedial	O
pulses	O
present	O
,	O
bilateral	O
and	O
symmetrical	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
on	O
arrival	O
at	O
the	O
MEDU	O
with	O
pain	O
sinus	O
rhythm	O
at	O
85	O
bpm	O
.	O
PR	O
150ms	O
.	O
Narrow	O
QRS	O
with	O
axis	O
in	O
the	O
lower	O
left	O
quadrant	O
.	O
ST	O
elevation	O
of	O
up	O
to	O
3	O
mm	O
in	O
avR	O
with	O
generalised	O
ST	O
descent	O
of	O
up	O
to	O
5	O
mm	O
.	O
Chest	O
X	O
ray	O
normal	O
cardiomediastinal	O
silhouette	O
,	O
without	O
images	O
of	O
consolidation	O
or	O
pleural	O
effusion	O
.	O
Urgent	O
transthoracic	O
echocardiogram	O
left	O
ventricle	O
LV	O
neither	O
dilated	O
nor	O
hypertrophied	O
,	O
with	O
moderately	O
depressed	O
systolic	O
function	O
Simpson	O
40	O
45	O
with	O
study	O
performed	O
with	O
HR	O
120	O
130	O
bpm	O
,	O
with	O
inferior	O
and	O
lateral	O
hypokinesia	O
at	O
mid	O
and	O
apical	O
levels	O
.	O
Non	O
dilated	O
right	O
ventricle	O
RV	O
with	O
normal	O
TDI	O
.	O
Aortic	O
valve	O
VAo	O
apparently	O
tricuspid	O
with	O
hypoplastic	O
non	O
coronary	O
leaflet	O
and	O
moderate	O
severe	O
aortic	O
insufficiency	O
with	O
diastolic	O
reverse	O
flow	O
in	O
descending	O
aorta	O
.	O
Mild	O
eccentric	O
mitral	O
insufficiency	O
.	O
No	O
biauricular	O
dilatation	O
.	O
Aortic	O
root	O
,	O
ascending	O
aorta	O
,	O
aortic	O
arch	O
and	O
descending	O
aorta	O
of	O
normal	O
size	O
.	O
Doubtful	O
image	O
in	O
the	O
arch	O
.	O
No	O
IT	O
signal	O
detected	O
to	O
estimate	O
pulmonary	O
artery	O
pressure	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
.	O
CT	O
of	O
the	O
aorta	O
no	O
signs	O
of	O
aortic	O
dissection	O
,	O
penetrating	O
ulcer	O
or	O
intramural	O
haematoma	O
.	O
No	O
pericardial	O
or	O
pleural	O
effusion	O
.	O
Cardiomegaly	O
.	O
No	O
signs	O
suggestive	O
of	O
pulmonary	O
thromboembolism	O
in	O
pulmonary	O
,	O
lobar	O
or	O
segmental	O
arteries	O
.	O
Bilateral	O
diffuse	O
septal	O
thickening	O
suggestive	O
of	O
interstitial	O
oedema	O
.	O
No	O
pulmonary	O
nodules	O
or	O
masses	O
.	O
Air	O
trapping	O
in	O
the	O
apical	O
segment	O
of	O
the	O
left	O
lower	O
lobe	O
LII	O
.	O
Small	O
area	O
of	O
subpleural	O
ground	O
glass	O
in	O
LII	O
.	O
No	O
mediastinal	O
,	O
hilar	O
or	O
axillary	O
adenopathy	O
.	O
Laboratory	O
tests	O
Myocardial	O
damage	O
marker	O
curve	O
ultrasensitive	O
troponin	O
T	O
TnT	O
us	O
480	O
4	O
h	O
499	O
.	O
Normal	O
values	O
14	O
pg	O
ml	O
.	O
N	O
terminal	O
pro	O
brain	O
natriuretic	O
peptide	O
NT	O
proBNP	O
2050	O
pg	O
ml	O
.	O
Rest	O
of	O
biochemistry	O
,	O
haemogram	O
and	O
coagulation	O
anodine	O
.	O
CLINICAL	O
EVOLUTION	O
After	O
the	O
introduction	O
of	O
perfused	O
nitrates	O
,	O
symptomatology	O
was	O
controlled	O
,	O
the	O
patient	O
remained	O
asymptomatic	O
and	O
the	O
generalised	O
decrease	O
in	O
the	O
ST	O
segment	O
normalised	O
.	O
Given	O
the	O
electrical	O
changes	O
,	O
signs	O
of	O
systolic	O
dysfunction	O
in	O
the	O
urgent	O
echocardiogram	O
and	O
elevated	O
markers	O
of	O
myocardial	O
damage	O
,	O
admission	O
to	O
the	O
coronary	O
unit	O
was	O
decided	O
with	O
a	O
diagnosis	O
of	O
non	O
ST	O
segment	O
elevation	O
myocardial	O
infarction	O
NSTEMI	O
,	O
and	O
double	O
antiplatelet	O
therapy	O
DAPT	O
was	O
initiated	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
clopidogrel	I-FARMACO
and	O
antiplatelet	O
treatment	O
with	O
subcutaneous	O
fondaparinux	B-FARMACO
2	O
.	O
5	O
mg	O
.	O
14	O
hours	O
after	O
admission	O
,	O
early	O
coronary	O
angiography	O
was	O
performed	O
,	O
showing	O
a	O
conical	O
aortic	O
root	O
morphology	O
that	O
made	O
catheterisation	O
of	O
the	O
left	O
coronary	O
trunk	O
LMCA	O
impossible	O
due	O
to	O
the	O
recurrent	O
drop	O
in	O
pressure	O
,	O
which	O
was	O
visualised	O
indirectly	O
,	O
with	O
an	O
image	O
of	O
impingement	O
at	O
its	O
origin	O
.	O
The	O
ostium	O
of	O
the	O
right	O
coronary	O
artery	O
RCA	O
also	O
appears	O
to	O
be	O
compromised	O
.	O
After	O
performing	O
the	O
diagnostic	O
coronary	O
angiography	O
,	O
the	O
case	O
was	O
discussed	O
again	O
with	O
radiology	O
who	O
,	O
after	O
re	O
evaluating	O
the	O
images	O
,	O
commented	O
that	O
there	O
was	O
a	O
striking	O
deformity	O
of	O
the	O
circumference	O
of	O
the	O
aortic	O
root	O
,	O
with	O
areas	O
of	O
flattening	O
in	O
the	O
medial	O
wall	O
forming	O
a	O
conical	O
morphology	O
and	O
thickening	O
of	O
the	O
lateral	O
wall	O
.	O
Both	O
findings	O
may	O
correspond	O
to	O
an	O
intramural	O
haematoma	O
in	O
the	O
aortic	O
root	O
.	O
Absence	O
of	O
visualisation	O
of	O
the	O
outflow	O
ostium	O
of	O
both	O
coronary	O
arteries	O
.	O
The	O
diagnostic	O
study	O
was	O
completed	O
by	O
transesophageal	O
echocardiography	O
,	O
which	O
showed	O
a	O
retraction	O
of	O
the	O
non	O
coronary	O
leaflet	O
with	O
a	O
regurgitation	O
jet	O
originating	O
at	O
its	O
junction	O
with	O
the	O
right	O
coronary	O
artery	O
,	O
leading	O
to	O
valvular	O
insufficiency	O
that	O
was	O
classified	O
as	O
severe	O
.	O
With	O
this	O
information	O
,	O
the	O
case	O
was	O
discussed	O
with	O
the	O
cardiac	O
surgery	O
department	O
,	O
and	O
the	O
patient	O
was	O
left	O
pending	O
surgical	O
revascularisation	O
.	O
In	O
the	O
following	O
12	O
hours	O
,	O
the	O
patient	O
continued	O
to	O
present	O
episodes	O
of	O
precordial	O
pain	O
with	O
dynamic	O
electrical	O
changes	O
,	O
similar	O
to	O
those	O
described	O
previously	O
,	O
which	O
were	O
controlled	O
with	O
antianginal	O
drugs	O
,	O
with	O
markers	O
of	O
myocardial	O
damage	O
on	O
the	O
rise	O
maximum	O
TnT	O
us	O
of	O
6000	O
,	O
and	O
she	O
was	O
scheduled	O
for	O
coronary	O
revascularisation	O
surgery	O
24	O
hours	O
after	O
her	O
consultation	O
in	O
the	O
emergency	O
department	O
.	O
The	O
surgical	O
report	O
highlights	O
"	O
a	O
severely	O
thickened	O
aortic	O
root	O
wall	O
,	O
which	O
appears	O
to	O
be	O
aortitis	O
.	O
A	O
small	O
ulcer	O
in	O
the	O
wall	O
of	O
the	O
aorta	O
Ao	O
is	O
also	O
identified	O
.	O
Trivalve	O
AoA	O
,	O
with	O
thickened	O
leaflets	O
and	O
non	O
coronary	O
leaflet	O
collapse	O
,	O
which	O
would	O
justify	O
the	O
picture	O
of	O
severe	O
aortic	O
insufficiency	O
AIo	O
.	O
Coronary	O
ostia	O
with	O
complete	O
occlusion	O
of	O
ACDp	O
and	O
subtotal	O
occlusion	O
of	O
the	O
LMCA	O
.	O
Healthy	O
coronary	O
arteries	O
"	O
.	O
With	O
all	O
this	O
,	O
aortic	O
valve	O
replacement	O
AVR	O
with	O
a	O
23	O
mm	O
mechanical	O
valve	O
double	O
coronary	O
artery	O
bypass	O
saphenous	O
to	O
ADAp	O
and	O
saphenous	O
to	O
ACDp	O
was	O
performed	O
,	O
and	O
samples	O
of	O
the	O
aortic	O
root	O
were	O
sent	O
to	O
pathological	O
anatomy	O
.	O
The	O
patient	O
had	O
a	O
favourable	O
postoperative	O
evaluation	O
,	O
with	O
no	O
complications	O
and	O
a	O
control	O
transthoracic	O
echocardiogram	O
with	O
a	O
normofunctioning	O
aortic	O
valve	O
and	O
left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
of	O
50	O
,	O
with	O
no	O
new	O
episodes	O
of	O
precordial	O
pain	O
and	O
was	O
discharged	O
home	O
7	O
days	O
after	O
surgery	O
,	O
with	O
early	O
clinical	O
control	O
in	O
cardiology	O
outpatient	O
clinics	O
.	O
A	O
few	O
weeks	O
later	O
,	O
the	O
results	O
of	O
the	O
pathological	O
anatomy	O
showed	O
a	O
chronic	O
inflammatory	O
infiltrate	O
with	O
congestive	O
blood	O
vessels	O
accompanied	O
by	O
haemorrhagic	O
areas	O
suggestive	O
of	O
active	O
aortitis	O
.	O
The	O
excisional	O
biopsy	O
of	O
the	O
valve	O
showed	O
extensive	O
sclerosis	O
and	O
abundant	O
areas	O
of	O
myxoid	O
degeneration	O
,	O
corresponding	O
to	O
scar	O
tissue	O
.	O
DIAGNOSIS	O
Acute	O
non	O
infectious	O
aortitis	O
with	O
NSTEMI	O
secondary	O
to	O
involvement	O
of	O
the	O
coronary	O
ostia	O
.	O
Severe	O
aortic	O
insufficiency	O
.	O
Aortic	O
valve	O
replacement	O
and	O
double	O
coronary	O
artery	O
bypass	O
grafting	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
PERSONAL	O
HISTORY	O
No	O
known	O
drug	O
allergies	O
.	O
No	O
toxic	O
habits	O
.	O
Essential	O
arterial	O
hypertension	O
in	O
treatment	O
with	O
two	O
drugs	O
.	O
Dyslipidaemia	O
.	O
Usual	O
treatment	O
amlodipine	B-FARMACO
5	O
mg	O
1	O
tablet	O
per	O
day	O
,	O
ramipril	B-FARMACO
5	O
mg	O
1	O
tablet	O
per	O
day	O
,	O
atorvastatin	B-FARMACO
40	O
mg	O
1	O
tablet	O
per	O
day	O
.	O
CURRENT	O
ILLNESS	O
The	O
patient	O
is	O
admitted	O
to	O
the	O
stroke	O
unit	O
for	O
40	O
minutes	O
of	O
headache	O
and	O
transient	O
loss	O
of	O
vision	O
in	O
the	O
left	O
half	O
of	O
the	O
visual	O
field	O
.	O
He	O
denies	O
infectious	O
symptoms	O
.	O
PHYSICAL	O
EXAMINATION	O
Vital	O
signs	O
blood	O
pressure	O
130	O
72	O
mmHg	O
.	O
Basal	O
oxygen	O
saturation	O
98	O
,	O
temperature	O
36	O
.	O
8	O
C	O
.	O
Patient	O
conscious	O
,	O
oriented	O
,	O
alert	O
.	O
Normoperfused	O
,	O
normohydrated	O
.	O
Head	O
and	O
neck	O
no	O
jugular	O
engorgement	O
,	O
no	O
nuchal	O
rigidity	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
,	O
no	O
extra	O
sounds	O
.	O
Lower	O
extremities	O
pulses	O
present	O
,	O
symmetrical	O
.	O
No	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
Neurological	O
examination	O
preserved	O
nomation	O
and	O
repetition	O
.	O
No	O
alterations	O
in	O
cranial	O
nerves	O
.	O
Strength	O
and	O
sensitivity	O
preserved	O
.	O
No	O
dysmetria	O
or	O
dysdiadochokinesias	O
.	O
No	O
presence	O
of	O
meningeal	O
signs	O
.	O
COMPLEMENTARY	O
TESTS	O
Blood	O
tests	O
glucose	O
84	O
mg	O
dl	O
.	O
Creatinine	O
1	O
.	O
17	O
mg	O
dl	O
.	O
Glomerular	O
filtration	O
rate	O
66	O
.	O
82	O
ml	O
min	O
.	O
Sodium	O
145	O
mm	O
l	O
.	O
Potassium	O
4	O
.	O
0	O
mm	O
l	O
.	O
AST	O
23	O
U	O
l	O
.	O
ALT	O
38	O
U	O
l	O
.	O
LDH	O
214	O
U	O
l	O
.	O
Alkaline	O
phosphatase	O
43	O
U	O
l	O
.	O
Haemoglobin	O
15	O
.	O
8	O
g	O
dl	O
.	O
Platelets	O
245	O
,	O
000	O
l	O
.	O
Leukocytes	O
7	O
,	O
800	O
l	O
.	O
INR	O
0	O
.	O
99	O
.	O
HbA1c	O
5	O
.	O
5	O
.	O
Antinuclear	O
antibodies	O
ANA	O
,	O
Beta	O
2	O
glycoprotein	O
IgM	O
,	O
IgG	O
cardiolipin	O
IgM	O
,	O
IgG	O
negative	O
.	O
HIV	O
Elisa	O
negative	O
.	O
Syphilis	O
IgG	O
,	O
IgM	O
negative	O
.	O
Electrocardiogram	O
RS	O
,	O
70	O
bpm	O
,	O
PR	O
180	O
msec	O
,	O
narrow	O
QRS	O
,	O
lateral	O
ST	O
rectification	O
.	O
Chest	O
X	O
ray	O
cardiothoracic	O
index	O
within	O
normal	O
.	O
No	O
infiltrate	O
or	O
condensation	O
.	O
No	O
pleural	O
effusion	O
.	O
Multimodal	O
computed	O
tomography	O
CT	O
Cranial	O
CT	O
without	O
VSD	O
No	O
early	O
signs	O
of	O
acute	O
ischaemia	O
.	O
No	O
foci	O
of	O
intra	O
extra	O
axial	O
haemorrhage	O
are	O
identified	O
.	O
ASPECTS	O
10	O
10	O
.	O
CT	O
perfusion	O
image	O
4	O
increased	O
times	O
in	O
the	O
right	O
occipital	O
region	O
.	O
Angio	O
CT	O
extracranial	O
supra	O
aortic	O
trunks	O
permeable	O
,	O
with	O
no	O
evidence	O
of	O
significant	O
stenosis	O
.	O
Intracranial	O
anterior	O
and	O
posterior	O
circulation	O
permeable	O
.	O
Degree	O
of	O
leptomeningeal	O
collaterality	O
good	O
3	O
3	O
CS	O
Collateral	O
Score	O
.	O
Brain	O
MRI	O
small	O
right	O
temporoccipital	O
corticosubcortical	O
ischaemic	O
lesions	O
in	O
subacute	O
phase	O
in	O
the	O
territory	O
of	O
the	O
right	O
posterior	O
cerebral	O
artery	O
,	O
hyperintense	O
in	O
Flair	O
T2	O
,	O
hypointense	O
in	O
T1	O
and	O
restricting	O
in	O
diffusion	O
characteristic	O
of	O
subacute	O
lesions	O
5	O
days	O
.	O
Transthoracic	O
echocardiogram	O
non	O
dilated	O
left	O
ventricle	O
with	O
preserved	O
systolic	O
function	O
.	O
Normal	O
right	O
chambers	O
.	O
Atria	O
of	O
normal	O
size	O
.	O
No	O
significant	O
valvulopathy	O
or	O
pericardial	O
effusion	O
.	O
Hypermobile	O
atrial	O
septum	O
.	O
Agitated	O
saline	B-FARMACO
was	O
administered	O
and	O
bubble	O
passage	O
was	O
observed	O
from	O
the	O
first	O
beat	O
,	O
compatible	O
with	O
patent	O
foramen	O
ovale	O
PFO	O
.	O
Transesophageal	O
echocardiogram	O
aneurysmal	O
atrial	O
septum	O
.	O
PFO	O
both	O
anatomically	O
and	O
by	O
passage	O
of	O
abundant	O
bubbles	O
from	O
the	O
first	O
heartbeat	O
.	O
Non	O
dilated	O
left	O
ventricle	O
with	O
preserved	O
function	O
.	O
Normal	O
right	O
chambers	O
.	O
Normal	O
sized	O
atria	O
.	O
No	O
significant	O
valvulopathy	O
or	O
pericardial	O
effusion	O
.	O
Atrial	O
appendage	O
free	O
of	O
thrombus	O
.	O
No	O
significant	O
aortic	O
atheromatosis	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
had	O
a	O
good	O
neurological	O
evolution	O
,	O
with	O
recovery	O
ad	O
integrum	O
of	O
the	O
visual	O
defect	O
.	O
He	O
was	O
discharged	O
and	O
referred	O
to	O
the	O
outpatient	O
cardiology	O
department	O
to	O
assess	O
percutaneous	O
closure	O
of	O
the	O
PFO	O
.	O
After	O
joint	O
assessment	O
by	O
neurology	O
and	O
cardiology	O
,	O
he	O
was	O
scheduled	O
for	O
percutaneous	O
closure	O
of	O
the	O
defect	O
.	O
Under	O
general	O
anaesthesia	O
and	O
under	O
echocardiographic	O
control	O
,	O
the	O
foramen	O
was	O
closed	O
.	O
Access	O
was	O
gained	O
through	O
the	O
right	O
femoral	O
vein	O
.	O
The	O
left	O
atrium	O
is	O
passed	O
through	O
the	O
PFO	O
with	O
an	O
MP	O
catheter	O
and	O
a	O
support	O
guidewire	O
is	O
passed	O
into	O
the	O
left	O
superior	O
pulmonary	O
vein	O
.	O
Occlutech	O
9	O
F	O
releasing	O
sheath	O
is	O
advanced	O
and	O
the	O
Occlutech	O
Figulla	O
Flex	O
II	O
30	O
27	O
mm	O
closure	O
device	O
is	O
advanced	O
through	O
the	O
sheath	O
and	O
positioned	O
at	O
the	O
level	O
of	O
the	O
atrial	O
septum	O
.	O
After	O
verification	O
of	O
adequate	O
anchorage	O
on	O
transesophageal	O
echocardiography	O
imaging	O
,	O
the	O
device	O
is	O
successfully	O
released	O
.	O
DIAGNOSIS	O
Cryptogenic	O
right	O
temporo	O
occipital	O
ischaemic	O
stroke	O
.	O
PFO	O
.	O
PFO	O
closure	O
with	O
Figulla	O
Flex	O
30	O
27	O
mm	O
device	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
PERSONAL	O
HISTORY	O
76	O
year	O
old	O
male	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
Lives	O
alone	O
,	O
independent	O
for	O
basic	O
activities	O
of	O
daily	O
living	O
,	O
no	O
cognitive	O
impairment	O
.	O
Ex	O
smoker	O
80	O
pack	O
years	O
and	O
former	O
heavy	O
drinker	O
for	O
7	O
years	O
.	O
No	O
known	O
metabolic	O
diseases	O
of	O
interest	O
.	O
Cardiological	O
history	O
self	O
limited	O
episode	O
of	O
atrial	O
fibrillation	O
AF	O
,	O
diagnosed	O
2	O
months	O
ago	O
in	O
the	O
emergency	O
department	O
,	O
for	O
which	O
oral	O
anticoagulation	O
with	O
acenocoumarol	B-FARMACO
was	O
started	O
.	O
Surgical	O
interventions	O
cataracts	O
both	O
eyes	O
.	O
Chronic	O
medication	O
omeprazole	B-FARMACO
20	O
mg	O
24h	O
,	O
acenocoumarol	B-FARMACO
according	O
to	O
haematology	O
guidelines	O
and	O
clomethiazole	B-FARMACO
192	O
mg	O
24h	O
.	O
CURRENT	O
ILLNESS	O
Referred	O
for	O
cardiology	O
consultation	O
following	O
diagnosis	O
of	O
AF	O
on	O
presentation	O
to	O
the	O
emergency	O
department	O
2	O
months	O
ago	O
due	O
to	O
dizziness	O
and	O
loss	O
of	O
consciousness	O
lasting	O
a	O
few	O
seconds	O
,	O
with	O
subsequent	O
recovery	O
ad	O
integrum	O
.	O
AF	O
was	O
recorded	O
in	O
the	O
ED	O
and	O
spontaneously	O
reverted	O
to	O
sinus	O
rhythm	O
and	O
treatment	O
was	O
started	O
with	O
acenocoumarol	B-FARMACO
and	O
amiodarone	B-FARMACO
.	O
After	O
3	O
weeks	O
of	O
treatment	O
,	O
the	O
patient	O
discontinued	O
amiodarone	B-FARMACO
due	O
to	O
an	O
error	O
in	O
dosage	O
.	O
Currently	O
,	O
he	O
denies	O
dyspnoea	O
,	O
chest	O
pain	O
or	O
palpitations	O
and	O
has	O
not	O
experienced	O
dizziness	O
or	O
syncope	O
.	O
He	O
also	O
reports	O
no	O
constitutional	O
syndrome	O
or	O
other	O
accompanying	O
symptoms	O
and	O
reports	O
leading	O
an	O
active	O
life	O
without	O
limitations	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
156	O
89	O
mmHg	O
.	O
Heart	O
rate	O
68	O
bpm	O
.	O
Good	O
general	O
condition	O
.	O
Conscious	O
,	O
oriented	O
and	O
cooperative	O
.	O
Eupneic	O
.	O
Thinness	O
and	O
skin	O
pallor	O
.	O
Well	O
perfused	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
,	O
no	O
masses	O
or	O
megaliths	O
.	O
Lower	O
extremities	O
no	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
tests	O
biochemistry	O
glucose	O
108	O
mg	O
dl	O
.	O
Urea	O
32	O
mg	O
dl	O
.	O
Creatinine	O
1	O
.	O
11mg	O
dl	O
.	O
Sodium	O
142	O
mmol	O
l	O
.	O
Potassium	O
4	O
mmol	O
l	O
.	O
Troponin	O
I	O
ultrasensitive	O
17ng	O
l	O
.	O
Haemogram	O
13	O
,	O
550	O
leucocytes	O
10	O
,	O
080	O
neutrophils	O
.	O
Haemoglobin	O
16	O
.	O
5	O
g	O
dl	O
.	O
182	O
.	O
000	O
platelets	O
.	O
Coagulation	O
PT	O
92	O
,	O
fibrinogen	O
509	O
mg	O
dl	O
,	O
D	O
dimer	O
380	O
ng	O
ml	O
.	O
Electrocardiogram	O
ECG	O
in	O
the	O
emergency	O
department	O
AF	O
with	O
ventricular	O
response	O
at	O
120	O
bpm	O
,	O
incomplete	O
right	O
bundle	O
branch	O
block	O
RBBB	O
,	O
without	O
repolarisation	O
alterations	O
.	O
ECG	O
in	O
cardiology	O
consultation	O
sinus	O
rhythm	O
SR	O
at	O
68	O
bpm	O
,	O
normal	O
PR	O
,	O
RBBB	O
,	O
no	O
repolarisation	O
abnormalities	O
.	O
Chest	O
X	O
ray	O
normal	O
cardiothoracic	O
index	O
,	O
no	O
condensation	O
or	O
vascular	O
redistribution	O
.	O
Transthoracic	O
echocardiogram	O
TTE	O
non	O
dilated	O
left	O
ventricle	O
DTD	O
47	O
,	O
non	O
hypertrophic	O
,	O
with	O
normal	O
global	O
systolic	O
function	O
LVEF	O
65	O
,	O
without	O
alterations	O
of	O
segmental	O
contractility	O
.	O
Non	O
dilated	O
right	O
ventricle	O
,	O
with	O
normal	O
morphology	O
and	O
systolic	O
function	O
TAPSE	O
20	O
.	O
Normal	O
mitral	O
filling	O
pattern	O
of	O
impaired	O
relaxation	O
without	O
elevation	O
of	O
filling	O
pressures	O
E	O
E	O
11	O
.	O
Normal	O
mitral	O
valve	O
.	O
Aortic	O
valve	O
sclerotic	O
,	O
appears	O
trivalve	O
,	O
normal	O
function	O
.	O
Atria	O
of	O
normal	O
size	O
.	O
Atrial	O
septum	O
AIS	O
apparently	O
intact	O
.	O
Implanted	O
mass	O
on	O
the	O
atrial	O
side	O
of	O
the	O
tricuspid	O
valve	O
,	O
at	O
lateral	O
level	O
,	O
2	O
x	O
1	O
.	O
8	O
cm	O
,	O
mottled	O
echocardiographic	O
pattern	O
.	O
Absence	O
of	O
stenosis	O
and	O
minimal	O
tricuspid	O
insufficiency	O
that	O
does	O
not	O
allow	O
estimation	O
of	O
pulmonary	O
arterial	O
systolic	O
pressure	O
PSAP	O
.	O
No	O
indirect	O
evidence	O
of	O
pulmonary	O
hypertension	O
.	O
Visible	O
segments	O
of	O
aortic	O
root	O
and	O
arch	O
and	O
pulmonary	O
artery	O
without	O
alterations	O
.	O
Normal	O
inferior	O
vena	O
cava	O
.	O
No	O
pericardial	O
effusion	O
.	O
CLINICAL	O
EVOLUTION	O
In	O
view	O
of	O
the	O
echocardiographic	O
findings	O
,	O
the	O
mass	O
implanted	O
on	O
the	O
atrial	O
side	O
of	O
the	O
tricuspid	O
valve	O
was	O
interpreted	O
as	O
a	O
myxoma	O
of	O
atypical	O
location	O
as	O
a	O
first	O
possibility	O
.	O
The	O
diagnostic	O
suspicion	O
and	O
the	O
need	O
for	O
surgical	O
intervention	O
to	O
remove	O
the	O
mass	O
for	O
diagnostic	O
and	O
therapeutic	O
purposes	O
is	O
explained	O
to	O
the	O
patient	O
.	O
The	O
patient	O
understands	O
the	O
situation	O
and	O
accepts	O
the	O
procedure	O
;	O
therefore	O
,	O
pre	O
surgical	O
studies	O
are	O
completed	O
with	O
coronary	O
angiography	O
which	O
shows	O
no	O
coronary	O
lesions	O
.	O
The	O
patient	O
underwent	O
surgery	O
,	O
without	O
incident	O
,	O
and	O
the	O
diagnosis	O
of	O
myxoma	O
was	O
confirmed	O
in	O
the	O
histological	O
study	O
of	O
the	O
excised	O
specimen	O
.	O
DIAGNOSIS	O
Myxoma	O
located	O
on	O
the	O
atrial	O
side	O
of	O
the	O
tricuspid	O
valve	O
.	O
Paroxysmal	O
AF	O
,	O
first	O
recorded	O
episode	O
,	O
CHA2DVASc	O
2	O
,	O
HASBLED	O
1	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
PERSONAL	O
HISTORY	O
Previous	O
illnesses	O
Cardiovascular	O
risk	O
factors	O
arterial	O
hypertension	O
.	O
No	O
previous	O
cardiological	O
history	O
.	O
Primary	O
biliary	O
cirrhosis	O
AMA	O
M2	O
Child	O
Pugh	O
A6	O
with	O
portal	O
hypertension	O
Haemorrhage	O
from	O
oesophageal	O
varices	O
10	O
years	O
ago	O
.	O
Secondary	O
prophylaxis	O
with	O
endoscopic	O
ligation	O
last	O
ligation	O
in	O
2014	O
,	O
last	O
gastroscopy	O
in	O
October	O
2018	O
no	O
varices	O
and	O
low	O
dose	O
beta	O
blocker	O
propranolol	B-FARMACO
10	O
mg	O
every	O
24h	O
.	O
Chronic	O
portal	O
thrombosis	O
,	O
suspended	O
anticoagulation	O
.	O
Single	O
episode	O
of	O
grade	O
II	O
hepatic	O
encephalopathy	O
in	O
March	O
2018	O
in	O
the	O
context	O
of	O
constipation	O
.	O
Osteoporosis	O
.	O
No	O
surgical	O
history	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
Previous	O
medication	O
metamizole	B-FARMACO
575	O
mg	O
8h	O
,	O
alendronic	B-FARMACO
acid	I-FARMACO
70	O
mg	O
weekly	O
,	O
resincholestyramine	B-FARMACO
4	O
g	O
8h	O
,	O
hydroxyzine	B-FARMACO
25	O
mg	O
day	O
,	O
propranolol	B-FARMACO
10	O
mg	O
day	O
,	O
hydroferol	B-FARMACO
266	O
mcg	O
in	O
1	O
ampoule	O
weekly	O
,	O
lactulose	B-FARMACO
10	O
g	O
8h	O
,	O
rifaximin	B-FARMACO
.	O
CURRENT	O
ILLNESS	O
Referred	O
to	O
the	O
emergency	O
department	O
by	O
her	O
primary	O
care	O
physician	O
for	O
progressive	O
dyspnoea	O
to	O
minimal	O
effort	O
.	O
The	O
patient	O
reported	O
progressive	O
deterioration	O
of	O
exertional	O
capacity	O
over	O
the	O
past	O
year	O
to	O
current	O
New	O
York	O
Heart	O
Association	O
NYHA	O
functional	O
class	O
III	O
IV	O
.	O
She	O
denies	O
orthopnoea	O
or	O
episodes	O
of	O
paroxysmal	O
nocturnal	O
dyspnoea	O
.	O
No	O
haemoptysis	O
,	O
chest	O
tightness	O
or	O
syncope	O
on	O
exertion	O
or	O
at	O
rest	O
.	O
No	O
wheezing	O
,	O
no	O
infectious	O
symptoms	O
,	O
no	O
new	O
externalisation	O
of	O
bleeding	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
110	O
74	O
mmHg	O
.	O
Heart	O
rate	O
70	O
bpm	O
.	O
Haemodynamically	O
stable	O
and	O
eupneic	O
at	O
rest	O
,	O
tolerating	O
decubitus	O
.	O
Jugular	O
ingurgitation	O
up	O
to	O
the	O
upper	O
third	O
,	O
positive	O
hepatojugular	O
reflux	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
rough	O
holosystolic	O
murmur	O
III	O
VI	O
in	O
left	O
sternal	O
border	O
,	O
reinforcement	O
of	O
S2	O
and	O
third	O
audible	O
noise	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
,	O
no	O
additional	O
sounds	O
.	O
Abdomen	O
hepatomegaly	O
of	O
two	O
tracts	O
,	O
non	O
pulsatile	O
and	O
without	O
semiology	O
of	O
ascites	O
.	O
Lower	O
limbs	O
no	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
sinus	O
bradycardia	O
at	O
56	O
bpm	O
,	O
normal	O
PR	O
,	O
wide	O
QRS	O
of	O
150	O
ms	O
,	O
with	O
morphology	O
of	O
right	O
bundle	O
branch	O
block	O
RBBB	O
,	O
right	O
ventricular	O
RV	O
overload	O
pattern	O
,	O
negative	O
T	O
wave	O
in	O
V1	O
V3	O
in	O
relation	O
to	O
previous	O
alterations	O
.	O
Blood	O
tests	O
on	O
admission	O
Hb	O
13	O
.	O
2	O
g	O
dl	O
,	O
platelets	O
75	O
,	O
000	O
l	O
,	O
leukocytes	O
3	O
,	O
600	O
l	O
.	O
Spontaneous	O
INR	O
of	O
1	O
.	O
45	O
.	O
Glucose	O
134	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
68	O
mg	O
dl	O
,	O
estimated	O
glomerular	O
filtration	O
rate	O
MDRD	O
4	O
IDMS	O
60	O
ml	O
min	O
1	O
.	O
73	O
m2	O
,	O
protein	O
6	O
.	O
7	O
g	O
dl	O
,	O
albumin	O
3	O
.	O
2	O
g	O
dl	O
,	O
sodium	O
141	O
mmol	O
l	O
,	O
potassium	O
4	O
.	O
2	O
mmol	O
l	O
,	O
NT	O
proBNP	O
1	O
,	O
132	O
ng	O
l	O
.	O
Autoimmunity	O
ANCA	O
negative	O
.	O
Native	O
anti	O
DNA	O
2	O
.	O
30	O
IU	O
mL	O
negative	O
.	O
Antibodies	O
associated	O
with	O
connective	O
tissue	O
diseases	O
negative	O
.	O
HIV	O
,	O
HCV	O
and	O
HBV	O
serologies	O
negative	O
.	O
CMV	O
IgG	O
positive	O
,	O
IgM	O
negative	O
.	O
Ferritin	O
12	O
g	O
l	O
,	O
iron	O
79	O
g	O
dl	O
,	O
IST	O
31	O
,	O
transferrin	O
200	O
mg	O
dl	O
.	O
TSH	O
1	O
.	O
86	O
mIU	O
l	O
.	O
Proteinogram	O
albumin	O
47	O
.	O
7	O
,	O
alpha	O
1	O
3	O
.	O
7	O
,	O
alpha	O
2	O
7	O
.	O
6	O
,	O
beta	O
1	O
5	O
.	O
5	O
,	O
beta	O
2	O
6	O
.	O
8	O
,	O
gamma	O
28	O
.	O
7	O
,	O
albumin	O
globulin	O
index	O
0	O
.	O
9	O
.	O
Glycosylated	O
haemoglobin	O
4	O
.	O
6	O
.	O
HDL	O
cholesterol	O
54	O
mg	O
dl	O
,	O
LDL	O
cholesterol	O
48	O
mg	O
dl	O
,	O
total	O
cholesterol	O
115	O
mg	O
dl	O
,	O
atherogenicity	O
index	O
2	O
.	O
1	O
,	O
triglycerides	O
63	O
mg	O
dl	O
.	O
At	O
discharge	O
NT	O
proBNP	O
704	O
ng	O
l	O
.	O
Chest	O
X	O
ray	O
on	O
admission	O
slight	O
cardiomegaly	O
,	O
prominent	O
pulmonary	O
hilarity	O
,	O
absence	O
of	O
pleural	O
effusion	O
and	O
infiltrates	O
.	O
Transthoracic	O
echocardiogram	O
non	O
dilated	O
left	O
ventricle	O
,	O
with	O
normal	O
wall	O
thickness	O
.	O
Marked	O
flattening	O
of	O
the	O
septum	O
.	O
Normal	O
global	O
systolic	O
function	O
estimated	O
left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
61	O
,	O
without	O
alterations	O
in	O
segmental	O
contraction	O
.	O
Transmitral	O
filling	O
pattern	O
of	O
impaired	O
relaxation	O
.	O
Non	O
dilated	O
left	O
atrium	O
.	O
Right	O
atrium	O
slightly	O
dilated	O
area	O
24	O
cm2	O
.	O
Severely	O
dilated	O
,	O
hypertrophic	O
and	O
trabeculated	O
right	O
ventricle	O
with	O
severely	O
depressed	O
global	O
systolic	O
function	O
.	O
Mitral	O
valve	O
with	O
calcium	O
in	O
the	O
annulus	O
and	O
functionally	O
normal	O
.	O
Sclerosed	O
aortic	O
valve	O
without	O
signs	O
of	O
stenosis	O
,	O
with	O
mild	O
insufficiency	O
.	O
Aortic	O
root	O
not	O
dilated	O
.	O
Proximal	O
ascending	O
aorta	O
not	O
dilated	O
.	O
Tricuspid	O
valve	O
morphologically	O
normal	O
,	O
with	O
moderate	O
severe	O
III	O
IV	O
IV	O
functional	O
insufficiency	O
.	O
Pulmonary	O
artery	O
systolic	O
pressure	O
estimated	O
at	O
75	O
mmHg	O
.	O
RV	O
gradient	O
70	O
mmHg	O
.	O
Pulmonary	O
flow	O
systolic	O
notch	O
suggestive	O
of	O
significant	O
pulmonary	O
hypertension	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
with	O
physiological	O
inspiratory	O
collapse	O
.	O
No	O
pericardial	O
effusion	O
.	O
V	O
Q	O
scan	O
acceptably	O
homogeneous	O
distribution	O
of	O
the	O
macroaggregates	O
injected	O
in	O
the	O
perfusion	O
study	O
,	O
without	O
subsegmental	O
and	O
or	O
wedge	O
shaped	O
defects	O
that	O
are	O
discordant	O
in	O
the	O
ventilation	O
study	O
and	O
that	O
could	O
be	O
gammagraphically	O
suggestive	O
of	O
pulmonary	O
thromboembolism	O
.	O
Conclusion	O
low	O
probability	O
of	O
pulmonary	O
thromboembolism	O
.	O
Respiratory	O
function	O
tests	O
FEV1	O
1	O
.	O
47	O
L	O
92	O
.	O
7	O
.	O
FVC	O
1	O
.	O
85	O
L	O
94	O
.	O
FEV1	O
FVC	O
0	O
.	O
79	O
.	O
MMEF	O
75	O
25	O
0	O
.	O
42	O
18	O
.	O
6	O
.	O
DLCOc	O
VA	O
0	O
.	O
85	O
60	O
.	O
6	O
.	O
CT	O
of	O
pulmonary	O
arteries	O
and	O
lung	O
parenchyma	O
small	O
amount	O
of	O
fluid	O
in	O
upper	O
pericardial	O
recesses	O
.	O
Calcifications	O
of	O
the	O
coronary	O
tree	O
.	O
Millimetric	O
prevascular	O
lymph	O
nodes	O
,	O
low	O
right	O
paratracheal	O
,	O
right	O
hilar	O
and	O
subcarinal	O
adenopathy	O
of	O
10	O
mm	O
.	O
Increased	O
calibre	O
of	O
central	O
pulmonary	O
arteries	O
,	O
as	O
a	O
sign	O
of	O
precapillary	O
pulmonary	O
hypertension	O
.	O
No	O
repletion	O
defects	O
were	O
observed	O
in	O
the	O
main	O
,	O
lobar	O
or	O
segmental	O
pulmonary	O
arteries	O
,	O
suggesting	O
pulmonary	O
thromboembolism	O
.	O
Although	O
there	O
is	O
a	O
slight	O
asymmetry	O
in	O
the	O
vascularisation	O
of	O
both	O
upper	O
lobes	O
,	O
there	O
are	O
no	O
alterations	O
suggestive	O
of	O
chronic	O
thromboembolic	O
disease	O
.	O
Liver	O
with	O
polylobulated	O
contours	O
,	O
with	O
enlargement	O
of	O
the	O
left	O
lobe	O
,	O
as	O
evidence	O
of	O
chronic	O
liver	O
disease	O
.	O
Adenomatous	O
hyperplasia	O
of	O
both	O
adrenal	O
glands	O
.	O
Accessory	O
spleen	O
of	O
11	O
mm	O
,	O
adjacent	O
to	O
the	O
anterior	O
splenic	O
margin	O
.	O
Right	O
catheterisation	O
pressures	O
Ao	O
128	O
60	O
87	O
mmHg	O
;	O
AD	O
10	O
mmHg	O
;	O
VD	O
83	O
14	O
mmHg	O
;	O
AP	O
83	O
30	O
48	O
mmHg	O
;	O
PCP	O
14	O
mmHg	O
.	O
O2	O
saturations	O
Ao	O
94	O
;	O
AP	O
68	O
.	O
Calculations	O
GC	O
thermodilution	O
5	O
.	O
47	O
l	O
min	O
;	O
IC	O
thermodilution	O
3	O
.	O
2	O
l	O
min	O
m2	O
.	O
GC	O
Fick	O
5	O
.	O
9	O
l	O
min	O
;	O
IC	O
Fick	O
3	O
.	O
45	O
l	O
min	O
m2	O
.	O
SVR	O
1	O
,	O
126	O
.	O
14	O
dynes	O
.	O
PVR	O
6	O
.	O
03	O
UW	O
.	O
Baseline	O
arterial	O
blood	O
gases	O
pH	O
7	O
.	O
46	O
,	O
pCO2	O
30	O
mmHg	O
,	O
pO2	O
59	O
mmHg	O
,	O
lactate	O
1	O
.	O
8	O
.	O
CLINICAL	O
EVOLUTION	O
Admitted	O
for	O
study	O
of	O
possible	O
pulmonary	O
hypertension	O
based	O
on	O
the	O
results	O
of	O
transthoracic	O
echocardiography	O
,	O
with	O
indirect	O
data	O
of	O
pulmonary	O
hypertension	O
,	O
severe	O
dilatation	O
and	O
dysfunction	O
of	O
the	O
right	O
ventricle	O
.	O
A	O
complete	O
aetiological	O
study	O
of	O
pulmonary	O
hypertension	O
was	O
performed	O
,	O
with	O
full	O
laboratory	O
tests	O
,	O
respiratory	O
function	O
tests	O
and	O
ventilation	O
perfusion	O
scintigraphy	O
,	O
with	O
no	O
relevant	O
findings	O
.	O
After	O
ruling	O
out	O
Dana	O
Point	O
groups	O
2	O
,	O
3	O
and	O
4	O
,	O
a	O
right	O
heart	O
catheterisation	O
was	O
performed	O
,	O
which	O
confirmed	O
precapillary	O
pulmonary	O
hypertension	O
,	O
with	O
a	O
mean	O
pulmonary	O
artery	O
pressure	O
mPAP	O
of	O
48	O
mmHg	O
,	O
probably	O
related	O
to	O
portopulmonary	O
syndrome	O
given	O
the	O
patient	O
's	O
clinical	O
context	O
.	O
Pulmonary	O
hypertension	O
was	O
classified	O
as	O
intermediate	O
risk	O
,	O
and	O
bosentan	B-FARMACO
and	O
oral	O
tadalafil	B-FARMACO
were	O
started	O
during	O
admission	O
at	O
low	O
doses	O
,	O
with	O
good	O
tolerance	O
,	O
for	O
subsequent	O
titration	O
on	O
an	O
outpatient	O
basis	O
.	O
On	O
the	O
other	O
hand	O
,	O
propranolol	B-FARMACO
was	O
discontinued	O
in	O
agreement	O
with	O
the	O
digestive	O
system	O
specialists	O
due	O
to	O
severe	O
RV	O
dysfunction	O
.	O
On	O
discharge	O
,	O
haemodynamically	O
stable	O
,	O
with	O
minimal	O
right	O
congestion	O
data	O
controlled	O
with	O
low	O
doses	O
of	O
oral	O
furosemide	B-FARMACO
,	O
with	O
no	O
alarm	O
data	O
of	O
pulmonary	O
hypertension	O
.	O
Appointment	O
for	O
follow	O
up	O
in	O
pulmonary	O
hypertension	O
consultations	O
,	O
pending	O
ergospirometry	O
and	O
6	O
ambulatory	O
MWT	O
to	O
complete	O
risk	O
stratification	O
.	O
DIAGNOSIS	O
Portopulmonary	O
hypertension	O
.	O
WHO	O
functional	O
class	O
III	O
.	O
Intermediate	O
risk	O
.	O
Primary	O
biliary	O
cirrhosis	O
.	O
Chronic	O
portal	O
thrombosis	O
with	O
portal	O
hypertension	O
.	O
Previous	O
episode	O
of	O
upper	O
gastrointestinal	O
bleeding	O
.	O
No	O
oesophageal	O
varices	O
at	O
last	O
examination	O
.	O
Previous	O
episode	O
of	O
hepatic	O
encephalopathy	O
.	O
Arterial	O
hypertension	O
.	O
Osteoporosis	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
PERSONAL	O
HISTORY	O
50	O
year	O
old	O
male	O
.	O
Allergy	O
to	O
streptomycin	B-FARMACO
.	O
No	O
family	O
history	O
of	O
ischaemic	O
heart	O
disease	O
.	O
Toxic	O
habits	O
smoker	O
1	O
.	O
5	O
2	O
packs	O
a	O
day	O
for	O
30	O
years	O
until	O
1	O
week	O
before	O
the	O
event	O
.	O
Alcohol	O
consumption	O
not	O
until	O
the	O
event	O
.	O
Other	O
intoxicants	O
cannabis	O
use	O
in	O
youth	O
,	O
not	O
for	O
years	O
.	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
hypertension	O
HT	O
under	O
treatment	O
.	O
Mixed	O
dyslipidaemia	O
.	O
Cardiological	O
history	O
admission	O
to	O
cardiology	O
from	O
8	O
7	O
to	O
19	O
7	O
for	O
acute	O
myocardial	O
infarction	O
without	O
ST	O
segment	O
elevation	O
STEMI	O
.	O
A	O
first	O
catheterisation	O
was	O
performed	O
8	O
7	O
2017	O
which	O
revealed	O
severe	O
three	O
vessel	O
coronary	O
artery	O
disease	O
CAD	O
with	O
acute	O
obstruction	O
of	O
the	O
cuneiform	O
artery	O
Cx	O
.	O
Percutaneous	O
coronary	O
intervention	O
PCI	O
was	O
performed	O
with	O
two	O
stents	O
coated	O
in	O
CX	O
with	O
good	O
results	O
.	O
The	O
right	O
coronary	O
artery	O
RCA	O
and	O
anterior	O
descending	O
AD	O
had	O
significant	O
lesions	O
amenable	O
to	O
percutaneous	O
transluminal	O
coronary	O
angioplasty	O
PTCA	O
in	O
the	O
second	O
stage	O
.	O
Another	O
catheterisation	O
was	O
performed	O
at	O
a	O
second	O
time	O
18	O
7	O
2017	O
with	O
scheduled	O
PCI	O
with	O
implantation	O
of	O
two	O
coated	O
stents	O
in	O
the	O
DA	O
,	O
DX	O
and	O
another	O
two	O
in	O
the	O
CD	O
with	O
a	O
good	O
final	O
angiographic	O
result	O
.	O
The	O
echocardiogram	O
performed	O
during	O
admission	O
8	O
7	O
17	O
reports	O
non	O
dilated	O
left	O
ventricle	O
LV	O
with	O
LVEF	O
45	O
50	O
.	O
Inferolateral	O
hypokinesia	O
.	O
Normal	O
right	O
ventricle	O
RV	O
.	O
No	O
valvulopathies	O
.	O
Rest	O
normal	O
.	O
From	O
the	O
clinical	O
point	O
of	O
view	O
,	O
no	O
complications	O
during	O
admission	O
.	O
Double	O
antiplatelet	O
therapy	O
was	O
started	O
with	O
ticagrelor	B-FARMACO
,	O
which	O
was	O
later	O
changed	O
to	O
prasugrel	B-FARMACO
due	O
to	O
possible	O
interaction	O
with	O
antiretrovirals	O
.	O
Good	O
tolerance	O
to	O
angiotensin	B-FARMACO
converting	I-FARMACO
enzyme	I-FARMACO
inhibitor	I-FARMACO
ACE	I-FARMACO
inhibitor	I-FARMACO
and	O
beta	O
blocker	O
at	O
medium	O
doses	O
.	O
Other	O
personal	O
history	O
HIV	O
infection	O
,	O
currently	O
on	O
treatment	O
with	O
undetectable	O
viral	O
load	O
.	O
With	O
proteinuria	O
,	O
hepatic	O
haemangiomas	O
and	O
hypovitaminosis	O
D	O
.	O
No	O
other	O
relevant	O
medical	O
surgical	O
history	O
.	O
Baseline	O
functional	O
status	O
Diet	O
average	O
adherence	O
to	O
Mediterranean	O
diet	O
.	O
Physical	O
activity	O
before	O
the	O
event	O
,	O
moderate	O
activity	O
during	O
working	O
hours	O
,	O
not	O
in	O
leisure	O
time	O
.	O
Psychosocial	O
profile	O
he	O
was	O
a	O
baker	O
and	O
deliveryman	O
,	O
he	O
closed	O
his	O
company	O
2	O
years	O
ago	O
.	O
He	O
now	O
takes	O
care	O
of	O
his	O
mother	O
.	O
He	O
has	O
two	O
children	O
aged	O
13	O
and	O
15	O
.	O
Previous	O
treatment	O
adiro	B-FARMACO
100	O
mg	O
every	O
24	O
hours	O
,	O
prasugrel	B-FARMACO
10	O
mg	O
every	O
24	O
hours	O
,	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
every	O
12	O
hours	O
,	O
enalapril	B-FARMACO
5	O
mg	O
every	O
12	O
hours	O
,	O
atorvastatin	B-FARMACO
ezetimibe	I-FARMACO
80	O
10	O
mg	O
every	O
24	O
hours	O
,	O
fortnightly	O
calcifediol	B-FARMACO
.	O
Antiretroviral	O
treatment	O
abacavir	B-FARMACO
lamivudine	I-FARMACO
nevirapine	I-FARMACO
.	O
Pre	O
programme	O
status	O
referred	O
from	O
cardiology	O
outpatient	O
clinic	O
for	O
cardiac	O
rehabilitation	O
programme	O
.	O
Cardiovascular	O
asymptomatic	O
after	O
discharge	O
.	O
PHYSICAL	O
EXAMINATION	O
Cooximetry	O
3	O
bpm	O
.	O
Blood	O
pressure	O
BP	O
156	O
96	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
62	O
bpm	O
.	O
Weight	O
80	O
.	O
4	O
kg	O
,	O
height	O
1	O
.	O
76	O
m	O
.	O
BMI	O
25	O
.	O
9	O
kg	O
m2	O
.	O
Abdominal	O
circumference	O
98	O
cm	O
.	O
ABI	O
0	O
.	O
97	O
right	O
and	O
0	O
.	O
96	O
left	O
.	O
Rest	O
without	O
findings	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
sinus	O
rhythm	O
at	O
62	O
bpm	O
.	O
Normal	O
PR	O
.	O
Narrow	O
QRS	O
with	O
0o	O
axis	O
and	O
prominent	O
R	O
from	O
V2	O
.	O
Small	O
negative	O
T	O
in	O
V6	O
.	O
Ergospirometry	O
preprogramme	O
January	O
18	O
submaximal	O
stress	O
test	O
limited	O
by	O
hypertensive	O
reaction	O
to	O
peak	O
stress	O
.	O
Completed	O
11	O
minutes	O
and	O
7	O
seconds	O
of	O
the	O
modified	O
Bruce	O
protocol	O
in	O
ramp	O
reaching	O
a	O
HR	O
of	O
106	O
bpm	O
62	O
of	O
the	O
MHRF	O
and	O
a	O
peak	O
VO2	O
of	O
16	O
.	O
5	O
ml	O
min	O
kg	O
52	O
of	O
the	O
predicted	O
for	O
a	O
person	O
of	O
his	O
characteristics	O
.	O
No	O
clinical	O
or	O
electrical	O
data	O
of	O
ischaemia	O
.	O
Good	O
initial	O
BP	O
progression	O
with	O
excessive	O
elevation	O
at	O
peak	O
effort	O
.	O
Normal	O
submaximal	O
cardiovascular	O
parameters	O
.	O
Limited	O
aerobic	O
capacity	O
due	O
to	O
peripheral	O
cause	O
and	O
hypertensive	O
reaction	O
.	O
Anaerobic	O
threshold	O
at	O
83	O
bpm	O
.	O
Respiratory	O
compensation	O
point	O
at	O
102	O
bpm	O
.	O
Pre	O
programme	O
blood	O
tests	O
16	O
10	O
17	O
glucose	O
101	O
mg	O
dl	O
,	O
haemoglobin	O
A1c	O
5	O
.	O
5	O
,	O
cholesterol	O
193	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
50	O
mg	O
dl	O
,	O
triglycerides	O
351	O
mg	O
dl	O
,	O
non	O
HDL	O
cholesterol	O
143	O
mg	O
dl	O
.	O
Glomerular	O
filtration	O
rate	O
90	O
ml	O
min	O
.	O
Other	O
biochemistry	O
and	O
haemogram	O
normal	O
.	O
Undetectable	O
viral	O
load	O
.	O
Control	O
laboratory	O
tests	O
15	O
02	O
18	O
glucose	O
89	O
mg	O
dl	O
,	O
HBA1c	O
5	O
.	O
5	O
,	O
glomerular	O
filtration	O
rate	O
64	O
ml	O
min	O
.	O
Total	O
cholesterol	O
288	O
mg	O
dl	O
,	O
triglycerides	O
1670	O
mg	O
dl	O
,	O
non	O
HDL	O
cholesterol	O
253	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
35	O
mg	O
dl	O
,	O
QM	O
negative	O
.	O
TSH	O
normal	O
.	O
Normal	O
iron	O
profile	O
and	O
haemogram	O
.	O
Control	O
blood	O
test	O
20	O
03	O
18	O
non	O
HDL	O
cholesterol	O
174	O
mg	O
dl	O
,	O
triglycerides	O
230	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
60	O
mg	O
dl	O
.	O
Hb	O
13	O
.	O
4	O
g	O
dl	O
.	O
Renal	O
function	O
stable	O
with	O
a	O
glomerular	O
filtration	O
rate	O
of	O
64	O
ml	O
min	O
.	O
Control	O
echocardiogram	O
07	O
02	O
18	O
left	O
ventricle	O
slightly	O
dilated	O
with	O
basal	O
and	O
mid	O
inferoposterior	O
and	O
lateral	O
hypokinesia	O
akinesia	O
.	O
Slightly	O
depressed	O
systolic	O
function	O
with	O
biplane	O
LVEF	O
of	O
49	O
.	O
Normal	O
mitral	O
valve	O
with	O
mildly	O
moderate	O
mitral	O
regurgitation	O
.	O
Rest	O
without	O
findings	O
.	O
Post	O
programme	O
ergospirometry	O
March	O
18	O
normal	O
baseline	O
spirometry	O
.	O
Maximal	O
exercise	O
test	O
limited	O
by	O
hip	O
pain	O
as	O
a	O
limiting	O
symptom	O
.	O
Completed	O
12	O
minutes	O
and	O
23	O
seconds	O
of	O
the	O
modified	O
Bruce	O
ramped	O
protocol	O
reaching	O
a	O
HR	O
of	O
109	O
bpm	O
65	O
of	O
the	O
MHRF	O
and	O
a	O
peak	O
VO2	O
of	O
18	O
.	O
4	O
ml	O
kg	O
min	O
60	O
of	O
predicted	O
for	O
a	O
person	O
of	O
his	O
characteristics	O
.	O
Despite	O
a	O
low	O
VO2	O
for	O
his	O
reference	O
population	O
the	O
intermediate	O
cardiovascular	O
parameters	O
are	O
acceptable	O
.	O
Anaerobic	O
threshold	O
at	O
86	O
bpm	O
.	O
Respiratory	O
compensation	O
point	O
at	O
102	O
bpm	O
.	O
Normal	O
pulmonary	O
V	O
Q	O
ratio	O
parameters	O
.	O
Control	O
blood	O
test	O
17	O
7	O
2018	O
with	O
ultracentrifugation	O
cholesterol	O
229	O
mg	O
dl	O
,	O
triglycerides	O
273	O
,	O
HDL	O
cholesterol	O
61	O
mg	O
dl	O
,	O
non	O
HDL	O
cholesterol	O
168	O
mg	O
dl	O
.	O
Chylomicrons	O
negative	O
.	O
Apolipoprotein	O
A	O
I	O
199	O
mg	O
dl	O
,	O
apolipoprotein	O
B100	O
129	O
mg	O
dl	O
.	O
Lipoprotein	O
a	O
134	O
mg	O
dl	O
,	O
VLDL	O
cholesterol	O
32	O
mg	O
dl	O
,	O
VLDL	O
triglyceride	O
145	O
mg	O
dl	O
,	O
LDL	O
cholesterol	O
142	O
mg	O
dl	O
,	O
LDL	O
triglyceride	O
125	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
63	O
mg	O
dl	O
,	O
HDL	O
triglyceride	O
11	O
mg	O
dl	O
,	O
VLDL	O
cholesterol	O
triglyceride	O
0	O
.	O
12	O
.	O
CLINICAL	O
COURSE	O
EVOLUTION	O
IN	O
THE	O
CARDIAC	O
REHABILITATION	O
UNIT	O
The	O
patient	O
is	O
included	O
as	O
moderate	O
risk	O
in	O
the	O
programme	O
,	O
attending	O
training	O
sessions	O
3	O
days	O
a	O
week	O
for	O
2	O
months	O
.	O
He	O
underwent	O
aerobic	O
and	O
strength	O
training	O
,	O
monitored	O
with	O
telemetry	O
for	O
6	O
weeks	O
and	O
then	O
with	O
a	O
heart	O
rate	O
monitor	O
for	O
the	O
last	O
2	O
weeks	O
,	O
tolerating	O
exercise	O
well	O
.	O
Coronary	O
asymptomatic	O
at	O
all	O
times	O
,	O
no	O
arrhythmias	O
,	O
no	O
episodes	O
of	O
pain	O
.	O
Brg	O
14	O
16	O
.	O
In	O
February	O
2018	O
he	O
starts	O
with	O
self	O
limited	O
but	O
recurrent	O
episodes	O
of	O
rectorrhagia	O
with	O
slight	O
anaemisation	O
.	O
After	O
7	O
months	O
of	O
the	O
event	O
,	O
it	O
is	O
decided	O
to	O
change	O
prasugrel	B-FARMACO
for	O
clopidogrel	B-FARMACO
,	O
in	O
order	O
to	O
reduce	O
the	O
risk	O
of	O
bleeding	O
.	O
On	O
the	O
other	O
hand	O
,	O
she	O
continued	O
with	O
mixed	O
dyslipidaemia	O
with	O
elevated	O
non	O
HDL	O
and	O
moderate	O
hypertriglyceridaemia	O
despite	O
treatment	O
with	O
atorvastatin	B-FARMACO
and	O
ezetimibe	B-FARMACO
80	O
10	O
mg	O
.	O
Treatment	O
with	O
fenofibrate	B-FARMACO
145	O
mg	O
every	O
24	O
hours	O
was	O
started	O
.	O
In	O
the	O
control	O
echocardiogram	O
,	O
left	O
ventricular	O
systolic	O
function	O
remained	O
slightly	O
depressed	O
.	O
SITUATION	O
AT	O
DISCHARGE	O
In	O
March	O
2018	O
,	O
the	O
cardiac	O
rehabilitation	O
programme	O
was	O
completed	O
and	O
new	O
ergospirometry	O
was	O
performed	O
,	O
in	O
which	O
a	O
low	O
peak	O
VO2	O
persisted	O
for	O
his	O
reference	O
population	O
in	O
the	O
context	O
of	O
peripheral	O
exercise	O
limitation	O
;	O
however	O
,	O
the	O
intermediate	O
cardiovascular	O
parameters	O
were	O
acceptable	O
.	O
With	O
regard	O
to	O
the	O
control	O
of	O
cardiovascular	O
risk	O
factors	O
,	O
adherence	O
to	O
the	O
Mediterranean	O
diet	O
improved	O
and	O
the	O
abdominal	O
circumference	O
decreased	O
by	O
5	O
cm	O
.	O
In	O
the	O
control	O
analysis	O
,	O
there	O
was	O
a	O
clear	O
improvement	O
in	O
the	O
lipid	O
profile	O
but	O
it	O
was	O
still	O
outside	O
the	O
target	O
ranges	O
in	O
two	O
determinations	O
performed	O
by	O
ultracentrifugation	O
of	O
the	O
sample	O
.	O
She	O
therefore	O
met	O
the	O
criteria	O
for	O
initiation	O
and	O
funding	O
of	O
treatment	O
with	O
proprotein	O
convertase	O
subtilisin	O
kexin	O
type	O
9	O
iPCSK9	O
inhibitors	O
,	O
and	O
the	O
case	O
was	O
presented	O
to	O
our	O
centre	O
's	O
committee	O
and	O
accepted	O
.	O
In	O
September	O
2018	O
,	O
he	O
attended	O
the	O
cardiac	O
rehabilitation	O
unit	O
for	O
the	O
administration	O
of	O
the	O
first	O
dose	O
of	O
evolocumab	B-FARMACO
and	O
education	O
.	O
In	O
October	O
2018	O
,	O
he	O
underwent	O
his	O
first	O
check	O
up	O
after	O
starting	O
treatment	O
with	O
iPCSK9	O
,	O
with	O
a	O
lipid	O
profile	O
in	O
range	O
.	O
Last	O
control	O
analysis	O
10	O
10	O
18	O
with	O
ultracentrifugation	O
triglyceride	O
98	O
mg	O
dl	O
,	O
cholesterol	O
96	O
mg	O
dl	O
,	O
apolipoprotein	O
A1	O
181	O
mg	O
dl	O
,	O
apolipoprotein	O
B	O
31	O
mg	O
dl	O
,	O
lipoprotein	O
a	O
58	O
mg	O
dl	O
,	O
lipid	O
ultracentrifugation	O
VLDL	O
cholesterol	O
12	O
mg	O
dl	O
,	O
VLDL	O
triglyceride	O
83	O
mg	O
dl	O
,	O
LDLcholesterol	O
31	O
mg	O
dl	O
,	O
LDL	O
triglyceride	O
91	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
65	O
mg	O
dl	O
,	O
HDL	O
triglyceride	O
7	O
mg	O
dl	O
,	O
VLDL	O
cholesterol	O
triglyceride	O
0	O
.	O
07	O
,	O
chylomicrons	O
negative	O
.	O
Next	O
check	O
up	O
in	O
6	O
months	O
.	O
DIAGNOSIS	O
Inferolateral	O
non	O
ST	O
segment	O
elevation	O
myocardial	O
infarction	O
NSTEMI	O
in	O
July	O
2017	O
.	O
Three	O
vessel	O
CAD	O
.	O
Revascularisation	O
with	O
coated	O
stents	O
in	O
CX	O
1st	O
time	O
,	O
DA	O
,	O
DX	O
and	O
CD	O
in	O
2nd	O
time	O
.	O
Slightly	O
decreased	O
left	O
ventricular	O
systolic	O
function	O
LVEF	O
49	O
.	O
HIV	O
infection	O
on	O
antiretroviral	O
treatment	O
with	O
undetectable	O
viral	O
load	O
.	O
Complete	O
phase	O
II	O
cardiac	O
rehabilitation	O
programme	O
.	O
Mild	O
moderately	O
reduced	O
aerobic	O
capacity	O
.	O
Severe	O
mixed	O
dyslipidaemia	O
,	O
currently	O
under	O
optimal	O
control	O
on	O
treatment	O
with	O
evolocumab	B-FARMACO
.	O
Hypertension	O
with	O
good	O
control	O
.	O
Smoker	O
in	O
abstinence	O
for	O
14	O
months	O
.	O
Overweight	O
.	O
Mild	O
renal	O
insufficiency	O
glomerular	O
filtration	O
rate	O
of	O
64	O
ml	O
min	O
.	O
Self	O
limited	O
rheumatoid	O
arthritis	O
in	O
the	O
context	O
of	O
double	O
antiplatelet	O
therapy	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
A	O
69	O
year	O
old	O
man	O
was	O
referred	O
to	O
the	O
outpatient	O
cardiology	O
department	O
for	O
presenting	O
coronary	O
calcifications	O
evidenced	O
in	O
a	O
thoracic	O
CT	O
scan	O
for	O
lung	O
cancer	O
screening	O
.	O
The	O
patient	O
has	O
a	O
history	O
of	O
arterial	O
hypertension	O
AHT	O
with	O
good	O
home	O
control	O
,	O
impaired	O
fasting	O
blood	O
glucose	O
pre	O
diabetes	O
,	O
obesity	O
body	O
mass	O
index	O
BMI	O
33	O
.	O
2	O
kg	O
m2	O
,	O
past	O
smoking	O
with	O
cumulative	O
exposure	O
of	O
50	O
pack	O
years	O
,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
COPD	O
of	O
the	O
chronic	O
bronchitis	O
type	O
and	O
benign	O
prostatic	O
hypertrophy	O
BPH	O
.	O
His	O
usual	O
treatment	O
consists	O
of	O
simvastatin	B-FARMACO
10	O
mg	O
day	O
,	O
terazosin	B-FARMACO
2	O
mg	O
day	O
,	O
valsartan	B-FARMACO
hydrochlorothiazide	I-FARMACO
320	O
25	O
mg	O
day	O
and	O
omeprazole	B-FARMACO
20	O
mg	O
day	O
.	O
He	O
has	O
no	O
chest	O
pain	O
at	O
rest	O
or	O
on	O
exertion	O
or	O
symptoms	O
suggestive	O
of	O
heart	O
failure	O
.	O
He	O
is	O
completely	O
asymptomatic	O
.	O
During	O
the	O
consultation	O
,	O
he	O
was	O
in	O
good	O
general	O
condition	O
,	O
normal	O
colour	O
and	O
normohydrated	O
.	O
Eupneic	O
at	O
rest	O
.	O
Blood	O
pressure	O
BP	O
125	O
70	O
mmHg	O
,	O
heart	O
rate	O
HR	O
65	O
bpm	O
,	O
SatO2	O
98	O
with	O
room	O
air	O
.	O
Jugular	O
venous	O
pressure	O
normal	O
.	O
Cardiac	O
auscultation	O
is	O
rhythmic	O
with	O
no	O
audible	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
shows	O
preserved	O
vesicular	O
murmur	O
without	O
added	O
sounds	O
.	O
Radial	O
and	O
pedial	O
pulses	O
are	O
palpable	O
,	O
rhythmic	O
and	O
symmetrical	O
.	O
There	O
was	O
no	O
oedema	O
.	O
With	O
the	O
available	O
data	O
,	O
treadmill	O
exercise	O
testing	O
was	O
requested	O
in	O
order	O
to	O
rule	O
out	O
silent	O
myocardial	O
ischaemia	O
.	O
COMPLEMENTARY	O
TESTS	O
Chest	O
CT	O
scan	O
without	O
contrast	O
signs	O
of	O
pulmonary	O
emphysema	O
predominantly	O
in	O
the	O
upper	O
lobes	O
.	O
No	O
visible	O
pulmonary	O
masses	O
or	O
nodules	O
.	O
No	O
adenopathy	O
in	O
the	O
mediastinal	O
region	O
.	O
Severe	O
calcification	O
of	O
coronary	O
arteries	O
visual	O
CAC	O
DRS	O
3	O
.	O
Slight	O
aortic	O
calcification	O
.	O
Chest	O
X	O
ray	O
PA	O
and	O
lateral	O
no	O
alterations	O
in	O
the	O
cardiomediastinal	O
silhouette	O
.	O
No	O
signs	O
of	O
consolidation	O
,	O
masses	O
or	O
pleural	O
effusion	O
.	O
Apparent	O
calcifications	O
in	O
coronary	O
arteries	O
and	O
aorta	O
.	O
Blood	O
tests	O
glucose	O
110	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
89	O
mg	O
dl	O
,	O
estimated	O
GFR	O
by	O
CKD	O
EPI	O
87	O
.	O
51	O
mg	O
dl	O
,	O
total	O
cholesterol	O
215	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
58	O
mg	O
dl	O
,	O
LDL	O
cholesterol	O
149	O
mg	O
dl	O
,	O
HbA1c	O
5	O
.	O
6	O
,	O
haemogram	O
and	O
coagulation	O
without	O
alterations	O
.	O
Baseline	O
ECG	O
sinus	O
rhythm	O
at	O
85	O
bpm	O
.	O
Normal	O
PR	O
160	O
ms	O
.	O
Left	O
axis	O
HSAI	O
.	O
Narrow	O
QRS	O
,	O
q	O
wave	O
in	O
I	O
and	O
aVL	O
.	O
T	O
wave	O
inversion	O
in	O
aVL	O
.	O
Occasional	O
supraventricular	O
extrasystoles	O
.	O
Ergometry	O
on	O
treadmill	O
performed	O
according	O
to	O
Bruce	O
protocol	O
and	O
stopped	O
due	O
to	O
physical	O
exhaustion	O
.	O
Maximum	O
effort	O
test	O
maximum	O
HR	O
157	O
bpm	O
,	O
103	O
theoretical	O
maximum	O
HR	O
normal	O
.	O
Well	O
tolerated	O
.	O
Adequate	O
adaptation	O
of	O
heart	O
rate	O
and	O
blood	O
pressure	O
maximum	O
BP	O
200	O
100	O
mmHg	O
.	O
Normal	O
aerobic	O
functional	O
capacity	O
exercised	O
for	O
8	O
minutes	O
and	O
reached	O
a	O
work	O
level	O
of	O
10	O
.	O
2	O
METS	O
,	O
adequate	O
double	O
product	O
reserve	O
19	O
,	O
385	O
.	O
No	O
significant	O
arrhythmias	O
have	O
occurred	O
.	O
No	O
electrocardiographic	O
or	O
clinical	O
signs	O
of	O
inducible	O
ischaemia	O
during	O
the	O
test	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
has	O
remained	O
cardiologically	O
asymptomatic	O
.	O
Given	O
the	O
finding	O
of	O
severe	O
calcification	O
of	O
the	O
coronary	O
arteries	O
by	O
visual	O
score	O
,	O
without	O
clinical	O
angina	O
or	O
evidence	O
of	O
ischaemia	O
in	O
the	O
ergometry	O
,	O
conservative	O
treatment	O
with	O
optimisation	O
of	O
pharmacological	O
treatment	O
was	O
decided	O
upon	O
.	O
The	O
patient	O
was	O
considered	O
at	O
very	O
high	O
risk	O
,	O
so	O
simvastatin	B-FARMACO
10	O
mg	O
day	O
was	O
replaced	O
by	O
rosuvastatin	B-FARMACO
20	O
mg	O
day	O
with	O
a	O
target	O
LDL	O
70	O
mg	O
dl	O
and	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
100	O
mg	O
day	O
was	O
added	O
to	O
the	O
usual	O
treatment	O
.	O
We	O
insisted	O
on	O
hygienic	O
dietary	O
measures	O
,	O
BP	O
measurements	O
at	O
home	O
and	O
the	O
need	O
for	O
weight	O
loss	O
,	O
as	O
well	O
as	O
the	O
symptoms	O
for	O
which	O
she	O
should	O
consult	O
.	O
Follow	O
up	O
with	O
blood	O
tests	O
were	O
scheduled	O
to	O
assess	O
LDL	O
cholesterol	O
and	O
impaired	O
fasting	O
blood	O
glucose	O
levels	O
.	O
DIAGNOSIS	O
Subclinical	O
coronary	O
atherosclerosis	O
.	O
Severe	O
coronary	O
calcification	O
,	O
asymptomatic	O
.	O
Very	O
high	O
cardiovascular	O
risk	O
exobtachism	O
.	O
Dyslipidaemia	O
with	O
suboptimal	O
control	O
.	O
Hypertension	O
with	O
good	O
control	O
.	O
Impaired	O
fasting	O
blood	O
glucose	O
.	O
Obesity	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
PERSONAL	O
HISTORY	O
No	O
known	O
drug	O
allergies	O
.	O
No	O
known	O
cardiovascular	O
risk	O
factors	O
.	O
No	O
toxic	O
habits	O
.	O
Depressive	O
syndrome	O
.	O
Admitted	O
in	O
2016	O
to	O
another	O
hospital	O
for	O
situational	O
syncope	O
and	O
chest	O
pain	O
.	O
Discharged	O
with	O
a	O
diagnosis	O
of	O
acute	O
myocarditis	O
.	O
Usual	O
treatment	O
fluoxetine	B-FARMACO
20	O
mg	O
every	O
12	O
hours	O
.	O
PRESENT	O
ILLNESS	O
A	O
32	O
year	O
old	O
male	O
with	O
the	O
previously	O
described	O
personal	O
history	O
was	O
brought	O
to	O
the	O
emergency	O
department	O
of	O
our	O
hospital	O
for	O
fainting	O
with	O
loss	O
of	O
consciousness	O
not	O
witnessed	O
,	O
coinciding	O
with	O
defecation	O
,	O
and	O
preceded	O
by	O
dizziness	O
and	O
chest	O
pain	O
that	O
continued	O
after	O
regaining	O
consciousness	O
.	O
The	O
patient	O
defines	O
the	O
chest	O
pain	O
as	O
oppressive	O
,	O
radiating	O
to	O
the	O
throat	O
and	O
without	O
associated	O
vegetative	O
cortex	O
,	O
which	O
has	O
subsided	O
spontaneously	O
.	O
He	O
denies	O
palpitations	O
,	O
no	O
dyspnoea	O
or	O
other	O
associated	O
symptoms	O
.	O
The	O
patient	O
reports	O
that	O
the	O
episode	O
is	O
similar	O
to	O
the	O
one	O
he	O
presented	O
in	O
2016	O
and	O
that	O
he	O
had	O
not	O
presented	O
any	O
similar	O
symptoms	O
since	O
then	O
.	O
He	O
denies	O
worsening	O
of	O
functional	O
class	O
and	O
no	O
other	O
symptoms	O
from	O
a	O
cardiological	O
point	O
of	O
view	O
.	O
He	O
regularly	O
practises	O
sport	O
and	O
has	O
not	O
presented	O
any	O
infectious	O
symptoms	O
in	O
previous	O
days	O
.	O
PHYSICAL	O
EXAMINATION	O
Stable	O
patient	O
in	O
good	O
general	O
condition	O
.	O
Eupneic	O
at	O
rest	O
,	O
tolerating	O
decubitus	O
.	O
Afebrile	O
and	O
haemodynamically	O
stable	O
.	O
Blood	O
pressure	O
BP	O
115	O
70	O
mmHg	O
,	O
heart	O
rate	O
HR	O
58	O
bpm	O
.	O
No	O
congestive	O
semiology	O
.	O
Cardiorespiratory	O
auscultation	O
with	O
rhythmic	O
tones	O
,	O
no	O
murmurs	O
.	O
Conservative	O
vesicular	O
murmur	O
with	O
no	O
other	O
superimposed	O
noises	O
.	O
Lower	O
limbs	O
without	O
oedema	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
on	O
admission	O
sinus	O
bradycardia	O
at	O
49	O
bpm	O
,	O
normal	O
axis	O
,	O
normal	O
PR	O
,	O
narrow	O
QRS	O
with	O
tendency	O
to	O
ST	O
elevation	O
1	O
mm	O
in	O
inferior	O
aspect	O
,	O
V5	O
V6	O
.	O
Chest	O
X	O
ray	O
CTI	O
in	O
the	O
upper	O
limit	O
of	O
normality	O
.	O
Free	O
costophrenic	O
sinuses	O
.	O
No	O
evidence	O
of	O
pulmonary	O
congestion	O
.	O
No	O
image	O
of	O
pneumothorax	O
,	O
no	O
consolidation	O
.	O
CBC	O
glucose	O
77	O
mg	O
dl	O
,	O
peak	O
creatinine	O
1	O
.	O
34	O
mg	O
dl	O
previous	O
normal	O
,	O
at	O
discharge	O
normal	O
,	O
glucose	O
and	O
ions	O
in	O
normal	O
range	O
.	O
Relative	O
neutrophilia	O
without	O
leukocytosis	O
.	O
Haemoglobin	O
16	O
.	O
2	O
g	O
dl	O
.	O
Platelets	O
218	O
,	O
000	O
.	O
Coagulation	O
without	O
alterations	O
.	O
TnTus	O
55	O
234	O
72	O
.	O
7	O
5	O
.	O
5	O
ng	O
l	O
.	O
CPK	O
127	O
136	O
121	O
mU	O
ml	O
.	O
Lipid	O
profile	O
total	O
cholesterol	O
169	O
mg	O
dl	O
,	O
HDL	O
47	O
mg	O
dl	O
,	O
LDL	O
105	O
mg	O
dl	O
,	O
triglycerides	O
84	O
mg	O
dl	O
.	O
LDL	O
HDL	O
2	O
.	O
2	O
.	O
Autoimmunity	O
test	O
negative	O
.	O
Iron	O
metabolism	O
sideremia	O
106	O
.	O
4	O
micrograms	O
dl	O
,	O
transferrin	O
253	O
mg	O
dl	O
,	O
transferrin	O
saturation	O
index	O
30	O
,	O
ferritin	O
85	O
micrograms	O
litre	O
.	O
Transthoracic	O
echocardiography	O
left	O
atrium	O
of	O
normal	O
dimensions	O
AP	O
37	O
mm	O
,	O
volume	O
19	O
ml	O
m2	O
.	O
Normal	O
mitral	O
valve	O
,	O
with	O
leaflets	O
without	O
organic	O
involvement	O
,	O
no	O
insufficiency	O
.	O
Left	O
ventricle	O
with	O
slightly	O
increased	O
volumes	O
DTD	O
56	O
mm	O
,	O
DTDi	O
26	O
mm	O
m2	O
,	O
VTD	O
160	O
ml	O
,	O
VTDi	O
80	O
ml	O
m2	O
,	O
VTS	O
66	O
ml	O
.	O
EF	O
59	O
without	O
segmental	O
alterations	O
of	O
contractility	O
.	O
Normal	O
myocardial	O
thickness	O
,	O
with	O
8	O
mm	O
septum	O
and	O
8	O
mm	O
posterior	O
wall	O
.	O
Normal	O
mitral	O
filling	O
pattern	O
with	O
E	O
wave	O
69	O
cm	O
s	O
and	O
A	O
wave	O
38	O
cm	O
s	O
.	O
Septal	O
E	O
"	O
7	O
cm	O
s	O
and	O
lateral	O
E	O
"	O
15	O
.	O
3	O
cm	O
s	O
.	O
Trivalve	O
aortic	O
valve	O
,	O
with	O
anatomically	O
normal	O
leaflets	O
,	O
without	O
insufficiency	O
.	O
Sinuses	O
of	O
Valsalva	O
36	O
mm	O
.	O
Right	O
ventricle	O
of	O
normal	O
dimensions	O
and	O
contractility	O
.	O
TAPSE	O
22	O
mm	O
,	O
tricuspid	O
S	O
"	O
12	O
.	O
7	O
cm	O
s	O
.	O
Trivial	O
tricuspid	O
insufficiency	O
with	O
Vmax	O
2m	O
s	O
.	O
Mild	O
pulmonary	O
insufficiency	O
.	O
Normal	O
inferior	O
vena	O
cava	O
with	O
adequate	O
inspiratory	O
collapse	O
.	O
Systolic	O
pulmonary	O
artery	O
pressure	O
19	O
mmHg	O
.	O
No	O
pericardial	O
effusion	O
.	O
Coronary	O
angio	O
CT	O
Agastson	O
calcium	O
score	O
of	O
1	O
no	O
identifiable	O
plaques	O
.	O
Coronary	O
angiography	O
from	O
axial	O
slices	O
,	O
multiplanar	O
,	O
curved	O
and	O
3D	O
reconstructions	O
left	O
common	O
trunk	O
arising	O
from	O
the	O
left	O
coronary	O
sinus	O
,	O
long	O
,	O
21	O
mm	O
long	O
and	O
without	O
significant	O
alterations	O
.	O
It	O
bifurcates	O
into	O
the	O
anterior	O
descending	O
artery	O
ADA	O
and	O
circumflex	O
artery	O
ACx	O
.	O
ADA	O
without	O
angiographically	O
significant	O
lesions	O
,	O
of	O
good	O
development	O
and	O
calibre	O
,	O
giving	O
multiple	O
diagonal	O
branches	O
of	O
small	O
calibre	O
up	O
to	O
3	O
diagonal	O
branches	O
,	O
all	O
of	O
them	O
without	O
lesions	O
.	O
ACx	O
without	O
angiographically	O
significant	O
alterations	O
,	O
which	O
is	O
of	O
small	O
calibre	O
,	O
but	O
almost	O
at	O
its	O
origin	O
gives	O
an	O
Om1	O
branch	O
of	O
very	O
good	O
development	O
and	O
calibre	O
,	O
which	O
has	O
a	O
normal	O
proximal	O
trajectory	O
,	O
but	O
its	O
entire	O
middle	O
and	O
distal	O
course	O
follows	O
an	O
intramyocardial	O
route	O
presenting	O
an	O
"	O
intramyocardial	O
bridge	O
of	O
significant	O
length	O
"	O
and	O
which	O
in	O
systolic	O
sections	O
shows	O
a	O
decrease	O
in	O
its	O
calibre	O
and	O
systolic	O
compression	O
phenomenon	O
coincides	O
with	O
the	O
inferolateral	O
side	O
as	O
it	O
depends	O
on	O
the	O
circumflex	O
artery	O
and	O
the	O
course	O
of	O
an	O
OM	O
artery	O
.	O
Right	O
coronary	O
artery	O
RCA	O
arising	O
from	O
the	O
right	O
coronary	O
sinus	O
without	O
angiographically	O
significant	O
alterations	O
.	O
It	O
gives	O
two	O
posterolateral	O
branches	O
,	O
but	O
does	O
not	O
clearly	O
give	O
the	O
posterior	O
descending	O
branch	O
or	O
this	O
is	O
a	O
very	O
small	O
branch	O
.	O
Right	O
dominant	O
pattern	O
.	O
Conclusion	O
OM1	O
of	O
very	O
good	O
development	O
and	O
calibre	O
,	O
which	O
has	O
a	O
normal	O
proximal	O
trajectory	O
,	O
but	O
its	O
entire	O
middle	O
and	O
distal	O
trajectory	O
follows	O
an	O
intramyocardial	O
course	O
presenting	O
an	O
"	O
intramyocardial	O
bridge	O
of	O
significant	O
length	O
"	O
and	O
which	O
in	O
systolic	O
sections	O
presents	O
a	O
decrease	O
in	O
its	O
calibre	O
and	O
a	O
phenomenon	O
of	O
systolic	O
compression	O
.	O
The	O
trajectory	O
has	O
been	O
estimated	O
at	O
7	O
.	O
5	O
8	O
cm	O
.	O
The	O
rest	O
of	O
the	O
coronary	O
arteries	O
had	O
no	O
angiographically	O
significant	O
lesions	O
,	O
no	O
anomalies	O
in	O
their	O
trajectory	O
or	O
disposition	O
.	O
CLINICAL	O
EVOLUTION	O
After	O
documenting	O
in	O
enzyme	O
serology	O
in	O
the	O
emergency	O
department	O
,	O
discrete	O
enzyme	O
mobilisation	O
with	O
ischaemia	O
curve	O
peak	O
TNT	O
Us	O
234	O
ng	O
l	O
,	O
it	O
was	O
decided	O
to	O
admit	O
the	O
patient	O
to	O
cardiology	O
on	O
suspicion	O
of	O
a	O
new	O
episode	O
of	O
myopericarditis	O
given	O
his	O
history	O
.	O
During	O
his	O
admission	O
,	O
the	O
patient	O
evolved	O
favourably	O
,	O
with	O
no	O
further	O
chest	O
pain	O
and	O
no	O
other	O
symptoms	O
.	O
Given	O
that	O
the	O
clinical	O
picture	O
was	O
not	O
characteristic	O
of	O
myopericarditis	O
,	O
due	O
to	O
its	O
characteristics	O
and	O
duration	O
,	O
nor	O
did	O
he	O
present	O
compatible	O
electrical	O
alterations	O
,	O
with	O
alterations	O
on	O
the	O
underside	O
more	O
suggestive	O
of	O
ischaemic	O
aetiology	O
,	O
as	O
well	O
as	O
the	O
behaviour	O
of	O
the	O
cardiac	O
ferment	O
serum	O
,	O
with	O
a	O
very	O
rapid	O
rise	O
and	O
fall	O
,	O
again	O
more	O
characteristic	O
of	O
an	O
ischaemic	O
profile	O
,	O
it	O
was	O
decided	O
to	O
request	O
an	O
intermediate	O
test	O
to	O
detect	O
ischaemia	O
during	O
admission	O
as	O
a	O
screening	O
test	O
for	O
coronary	O
artery	O
disease	O
.	O
A	O
coronary	O
angio	O
CT	O
scan	O
was	O
performed	O
which	O
revealed	O
the	O
existence	O
of	O
an	O
intramyocardial	O
tract	O
of	O
significant	O
length	O
in	O
the	O
OM1	O
branch	O
and	O
which	O
in	O
the	O
systolic	O
sections	O
showed	O
a	O
decrease	O
in	O
its	O
calibre	O
and	O
systolic	O
compression	O
phenomenon	O
,	O
with	O
the	O
rest	O
of	O
the	O
coronary	O
arteries	O
being	O
normal	O
.	O
Given	O
the	O
findings	O
,	O
it	O
is	O
considered	O
that	O
the	O
picture	O
of	O
situational	O
vagal	O
syncope	O
with	O
associated	O
hypotension	O
and	O
the	O
presence	O
of	O
the	O
long	O
intramyocardial	O
tract	O
would	O
explain	O
the	O
picture	O
of	O
transient	O
ischaemia	O
that	O
led	O
to	O
admission	O
.	O
The	O
patient	O
also	O
provided	O
the	O
report	O
of	O
the	O
cardiac	O
magnetic	O
resonance	O
CMR	O
performed	O
in	O
the	O
previous	O
admission	O
in	O
2016	O
,	O
which	O
described	O
the	O
presence	O
of	O
mild	O
enhancement	O
of	O
predominantly	O
subendocardial	O
enhancement	O
in	O
the	O
inferolateral	O
wall	O
,	O
coinciding	O
with	O
the	O
trajectory	O
and	O
could	O
be	O
explained	O
by	O
this	O
same	O
reason	O
.	O
Given	O
the	O
good	O
evolution	O
,	O
the	O
patient	O
was	O
discharged	O
with	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
100	O
mg	O
every	O
24	O
hours	O
and	O
amlodipine	B-FARMACO
5	O
mg	O
every	O
12	O
hours	O
.	O
It	O
is	O
recommended	O
to	O
avoid	O
high	O
intensity	O
exercise	O
,	O
especially	O
isometric	O
exercise	O
weight	O
lifting	O
.	O
The	O
patient	O
is	O
seen	O
in	O
an	O
outpatient	O
clinic	O
2	O
months	O
later	O
and	O
remains	O
asymptomatic	O
.	O
DIAGNOSIS	O
Myocardial	O
infarction	O
with	O
coronary	O
arteries	O
without	O
obstructive	O
lesions	O
MINOCA	O
secondary	O
to	O
significant	O
intramyocardial	O
trajectory	O
of	O
the	O
obtuse	O
marginal	O
artery	O
with	O
systolic	O
compression	O
phenomenon	O
.	O

HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
We	O
present	O
the	O
case	O
of	O
a	O
45	O
year	O
old	O
man	O
with	O
an	O
active	O
life	O
,	O
currently	O
asymptomatic	O
,	O
who	O
came	O
to	O
the	O
echocardiography	O
department	O
of	O
our	O
hospital	O
for	O
transesophageal	O
monitoring	O
after	O
percutaneous	O
closure	O
of	O
the	O
left	O
atrial	O
appendage	O
with	O
an	O
Amulet	O
device	O
St	O
Jude	O
Medical	O
due	O
to	O
repeated	O
strokes	O
despite	O
having	O
been	O
under	O
anticoagulant	O
treatment	O
.	O
PERSONAL	O
HISTORY	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
hypertension	O
.	O
Dyslipidaemia	O
.	O
Smoker	O
of	O
7	O
8	O
cigarettes	O
a	O
day	O
10	O
.	O
5	O
packs	O
a	O
year	O
Cardiological	O
history	O
Permanent	O
atrial	O
fibrillation	O
diagnosed	O
in	O
December	O
2001	O
2	O
unsuccessful	O
attempts	O
at	O
CVE	O
in	O
2002	O
after	O
which	O
frequency	O
control	O
strategy	O
was	O
chosen	O
.	O
Transthoracic	O
echocardiography	O
left	O
ventricle	O
of	O
normal	O
diameters	O
and	O
volumes	O
,	O
with	O
preserved	O
global	O
systolic	O
function	O
LVEF	O
58	O
.	O
Very	O
dilated	O
left	O
atrium	O
volume	O
4c	O
154	O
ml	O
.	O
Transmitral	O
filling	O
with	O
single	O
E	O
wave	O
.	O
Absence	O
of	O
significant	O
valvular	O
heart	O
disease	O
.	O
Right	O
ventricle	O
with	O
preserved	O
diameters	O
and	O
global	O
systolic	O
function	O
.	O
Absence	O
of	O
tricuspid	O
insufficiency	O
TI	O
allowing	O
estimation	O
of	O
pulmonary	O
arterial	O
systolic	O
pressure	O
PsAP	O
.	O
Percutaneous	O
closure	O
of	O
the	O
left	O
atrial	O
appendage	O
with	O
Amulet	O
device	O
St	O
.	O
Jude	O
Medical	O
in	O
2018	O
In	O
2016	O
,	O
the	O
patient	O
presented	O
with	O
a	O
stroke	O
with	O
a	O
cardioembolic	O
profile	O
under	O
treatment	O
with	O
acenocoumarol	B-FARMACO
anticoagulation	O
with	O
poor	O
INR	O
control	O
,	O
so	O
acenocoumarol	B-FARMACO
was	O
discontinued	O
and	O
rivaroxaban	B-FARMACO
was	O
started	O
.	O
Under	O
treatment	O
with	O
rivaroxaban	B-FARMACO
20	O
mg	O
24	O
hours	O
correctly	O
adjusted	O
to	O
his	O
renal	O
function	O
,	O
he	O
suffered	O
a	O
new	O
cardioembolic	O
stroke	O
in	O
2017	O
,	O
so	O
it	O
was	O
decided	O
to	O
close	O
his	O
left	O
atrial	O
appendage	O
.	O
In	O
2018	O
,	O
percutaneous	O
closure	O
of	O
the	O
left	O
atrial	O
appendage	O
was	O
performed	O
with	O
an	O
Amulet	O
device	O
St	O
.	O
Jude	O
Medical	O
without	O
complications	O
.	O
On	O
discharge	O
,	O
following	O
the	O
recommendations	O
of	O
the	O
commercial	O
company	O
,	O
double	O
antiplatelet	O
therapy	O
was	O
started	O
with	O
aspirin	B-FARMACO
100	O
mg	O
and	O
clopidogrel	B-FARMACO
75	O
mg	O
.	O
Although	O
,	O
according	O
to	O
the	O
guidelines	O
,	O
the	O
patient	O
had	O
an	O
indication	O
for	O
anticoagulant	O
treatment	O
due	O
to	O
the	O
risk	O
of	O
stroke	O
,	O
this	O
was	O
rejected	O
because	O
he	O
had	O
experienced	O
minor	O
bleeding	O
episodes	O
during	O
treatment	O
with	O
rivaroxaban	B-FARMACO
.	O
Other	O
medical	O
history	O
Repeated	O
cardioembolic	O
stroke	O
2016	O
and	O
2017	O
expressed	O
as	O
TIA	O
,	O
despite	O
anticoagulation	O
.	O
The	O
first	O
of	O
these	O
was	O
located	O
in	O
the	O
left	O
occipital	O
lobe	O
,	O
confirmed	O
by	O
imaging	O
techniques	O
.	O
The	O
second	O
was	O
in	O
the	O
left	O
carotid	O
profile	O
and	O
was	O
not	O
confirmed	O
by	O
imaging	O
techniques	O
.	O
Clinical	O
criteria	O
of	O
chronic	O
bronchitis	O
without	O
respiratory	O
functional	O
tests	O
Surgical	O
interventions	O
gastric	O
bypass	O
.	O
Supraumbilical	O
hernia	O
.	O
Current	O
treatment	O
Foli	B-FARMACO
Doce	I-FARMACO
1	O
tablet	O
per	O
day	O
,	O
olmesartan	B-FARMACO
HCT	I-FARMACO
40	O
25	O
mg	O
,	O
atenolol	B-FARMACO
50	O
mg	O
1	O
tablet	O
per	O
day	O
,	O
atorvastatin	B-FARMACO
20	O
mg	O
1	O
tablet	O
per	O
day	O
,	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
mg	O
1	O
tablet	O
per	O
day	O
.	O
PHYSICAL	O
EXAMINATION	O
Good	O
general	O
condition	O
,	O
conscious	O
,	O
oriented	O
,	O
normohydrated	O
and	O
normal	O
colour	O
.	O
Blood	O
pressure	O
BP	O
132	O
76	O
mmHg	O
,	O
heart	O
rate	O
HR	O
67	O
bpm	O
,	O
SatO2	O
94	O
FiO2	O
21	O
.	O
Cardiac	O
auscultation	O
irregular	O
sounds	O
without	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
slight	O
global	O
hypophonesis	O
,	O
with	O
scattered	O
rhonchi	O
.	O
Soft	O
abdomen	O
with	O
no	O
masses	O
or	O
megaliths	O
,	O
not	O
painful	O
on	O
palpation	O
.	O
Lower	O
extremities	O
without	O
oedema	O
.	O
Peripheral	O
pulses	O
present	O
and	O
symmetrical	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
tests	O
Blood	O
count	O
haemoglobin	O
15	O
.	O
1	O
g	O
dL	O
.	O
MCV	O
84	O
fl	O
.	O
MCH	O
30	O
.	O
7	O
pg	O
.	O
Leukocytes	O
5	O
.	O
8x10	O
9	O
l	O
.	O
Platelets	O
316x10	O
9	O
l	O
.	O
Biochemistry	O
glucose	O
83	O
mg	O
dl	O
.	O
HbA1c	O
5	O
.	O
8	O
.	O
Sodium	O
138	O
mEq	O
l	O
.	O
Potassium	O
4	O
.	O
3	O
mEq	O
l	O
.	O
Chlorine	O
104	O
mEq	O
l	O
.	O
Bilirubin	O
0	O
.	O
46	O
mg	O
dl	O
.	O
GOT	O
16	O
U	O
l	O
.	O
GPT	O
14	O
U	O
l	O
.	O
Alkaline	O
phosphatase	O
77	O
U	O
l	O
.	O
Gamma	O
glutamyl	O
transferase	O
13	O
U	O
l	O
.	O
Creatinine	O
0	O
.	O
96	O
mg	O
dl	O
GFR	O
CKD	O
EPI	O
90	O
ml	O
min	O
1	O
.	O
73	O
m2	O
.	O
Iron	O
metabolism	O
transferrin	O
249	O
mg	O
dl	O
.	O
Ferritin	O
26	O
ug	O
l	O
.	O
Iron	O
60	O
ug	O
l	O
,	O
IST	O
17	O
.	O
8	O
.	O
Lipid	O
metabolism	O
total	O
cholesterol	O
150	O
mg	O
dl	O
.	O
Triglycerides	O
64	O
mg	O
dl	O
.	O
HDLc	O
34	O
mg	O
dl	O
.	O
LDLc	O
126	O
mg	O
dl	O
.	O
Haemostasis	O
prothrombin	O
time	O
12	O
s	O
,	O
IQ	O
84	O
.	O
INR	O
1	O
.	O
03	O
.	O
APTT	O
27	O
.	O
3	O
s	O
.	O
Electrocardiogram	O
ECG	O
atrial	O
fibrillation	O
with	O
MVR	O
at	O
67	O
bpm	O
.	O
Axis	O
15o	O
.	O
QRS	O
90	O
ms	O
.	O
non	O
significant	O
Q	O
wave	O
and	O
negative	O
T	O
in	O
dIII	O
.	O
Flattened	O
T	O
in	O
avF	O
.	O
No	O
other	O
repolarisation	O
alterations	O
.	O
Transesophageal	O
echocardiography	O
TEE	O
2D	O
and	O
3D	O
5	O
months	O
after	O
implantation	O
of	O
atrial	O
appendage	O
closure	O
device	O
marked	O
left	O
atrial	O
dilatation	O
volume	O
4c	O
175	O
ml	O
with	O
presence	O
of	O
spontaneous	O
echocontrast	O
.	O
An	O
image	O
suggestive	O
of	O
a	O
small	O
protruding	O
thrombus	O
is	O
seen	O
on	O
the	O
disc	O
of	O
the	O
normally	O
positioned	O
atrial	O
appendage	O
closure	O
device	O
.	O
Left	O
ventricle	O
with	O
increased	O
diameters	O
and	O
normal	O
global	O
systolic	O
function	O
LVEF	O
60	O
.	O
Absence	O
of	O
significant	O
valvular	O
heart	O
disease	O
.	O
Right	O
ventricle	O
with	O
normal	O
diameters	O
and	O
preserved	O
function	O
.	O
Absence	O
of	O
IT	O
allowing	O
estimation	O
of	O
PsAP	O
.	O
Exploration	O
in	O
atrial	O
fibrillation	O
.	O
CLINICAL	O
EVOLUTION	O
Taking	O
into	O
account	O
that	O
the	O
patient	O
was	O
an	O
asymptomatic	O
45	O
year	O
old	O
man	O
who	O
,	O
although	O
he	O
had	O
correctly	O
completed	O
the	O
double	O
antiplatelet	O
therapy	O
prescribed	O
according	O
to	O
the	O
recommendations	O
of	O
the	O
device	O
manufacturer	O
,	O
without	O
anticoagulant	O
treatment	O
by	O
the	O
patient	O
's	O
own	O
decision	O
,	O
a	O
thrombosis	O
of	O
the	O
Amulet	O
device	O
St	O
Jude	O
Medical	O
for	O
closure	O
of	O
the	O
left	O
atrial	O
appendage	O
was	O
detected	O
in	O
the	O
control	O
TEE	O
.	O
It	O
was	O
decided	O
to	O
restart	O
anticoagulant	O
treatment	O
with	O
acenocoumarol	B-FARMACO
with	O
INR	O
targets	O
2	O
3	O
.	O
Three	O
months	O
later	O
a	O
new	O
follow	O
up	O
TEE	O
was	O
performed	O
and	O
the	O
thrombus	O
had	O
resolved	O
.	O
However	O
,	O
despite	O
the	O
resolution	O
of	O
the	O
condition	O
,	O
it	O
was	O
decided	O
to	O
maintain	O
oral	O
anticoagulation	O
with	O
acenocoumarol	B-FARMACO
INR	O
2	O
3	O
and	O
to	O
perform	O
a	O
new	O
echocardiographic	O
control	O
in	O
12	O
months	O
,	O
in	O
order	O
to	O
assess	O
the	O
definitive	O
withdrawal	O
of	O
anticoagulant	O
treatment	O
.	O
At	O
present	O
,	O
8	O
months	O
have	O
passed	O
and	O
the	O
patient	O
remains	O
asymptomatic	O
,	O
without	O
haemorrhagic	O
or	O
thrombotic	O
complications	O
,	O
under	O
treatment	O
with	O
acenocoumarol	B-FARMACO
and	O
awaiting	O
a	O
repeat	O
transesophageal	O
echocardiography	O
control	O
.	O
DIAGNOSIS	O
Permanent	O
atrial	O
fibrillation	O
with	O
controlled	O
ventricular	O
response	O
.	O
CHA2DS2VAS	O
c	O
3	O
,	O
HASBLED	O
2	O
.	O
Two	O
strokes	O
with	O
cardioembolic	O
profile	O
despite	O
anticoagulation	O
with	O
acenocoumarol	B-FARMACO
or	O
rivaroxaban	B-FARMACO
left	O
atrial	O
appendage	O
preclosure	O
.	O
Left	O
atrial	O
appendage	O
closure	O
with	O
Amulet	O
device	O
St	O
Jude	O
Medical	O
.	O
Thrombosis	O
on	O
left	O
atrial	O
appendage	O
closure	O
device	O
,	O
resolved	O
with	O
oral	O
anticoagulation	O
with	O
acenocoumarol	B-FARMACO
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
PERSONAL	O
HISTORY	O
Intolerance	O
to	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
due	O
to	O
duodenal	O
ulcer	O
.	O
CVRF	O
smoking	O
20	O
pack	O
years	O
.	O
No	O
known	O
cardiological	O
history	O
.	O
Other	O
history	O
duodenal	O
ulcer	O
10	O
years	O
ago	O
.	O
No	O
relevant	O
surgical	O
interventions	O
.	O
Usual	O
treatment	O
not	O
reported	O
.	O
CURRENT	O
ILLNESS	O
A	O
57	O
year	O
old	O
male	O
patient	O
with	O
the	O
aforementioned	O
history	O
attended	O
the	O
emergency	O
department	O
of	O
our	O
centre	O
due	O
to	O
oppressive	O
central	O
thoracic	O
pain	O
,	O
of	O
about	O
30	O
minutes	O
'	O
evolution	O
,	O
radiating	O
to	O
both	O
upper	O
limbs	O
MMSS	O
and	O
neck	O
,	O
which	O
started	O
suddenly	O
while	O
at	O
rest	O
,	O
with	O
associated	O
mild	O
vegetative	O
cramping	O
.	O
On	O
arrival	O
at	O
the	O
emergency	O
department	O
,	O
the	O
clinical	O
manifestations	O
persisted	O
.	O
She	O
denied	O
previous	O
episodes	O
of	O
central	O
thoracic	O
pain	O
.	O
She	O
reported	O
an	O
active	O
daily	O
life	O
.	O
No	O
clinical	O
signs	O
of	O
CHF	O
or	O
infectious	O
disease	O
in	O
previous	O
days	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
BP	O
140	O
60	O
mmHg	O
left	O
arm	O
,	O
90	O
50	O
mmHg	O
right	O
arm	O
,	O
heart	O
rate	O
HR	O
65	O
bpm	O
.	O
SpO2	O
FiO2	O
21	O
99	O
.	O
Regular	O
general	O
condition	O
,	O
affected	O
by	O
severe	O
pain	O
.	O
Eupneic	O
at	O
rest	O
.	O
Normal	O
colour	O
and	O
normohydrated	O
.	O
Sweating	O
.	O
Patient	O
conscious	O
and	O
oriented	O
,	O
cooperative	O
and	O
alert	O
.	O
No	O
neurological	O
focality	O
.	O
Cardiopulmonary	O
auscultation	O
regular	O
sounds	O
,	O
diastolic	O
murmur	O
predominantly	O
in	O
the	O
left	O
sternal	O
border	O
.	O
Conservative	O
vesicular	O
murmur	O
VCM	O
with	O
no	O
added	O
noise	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
,	O
without	O
mass	O
or	O
megaliths	O
,	O
not	O
painful	O
on	O
palpation	O
.	O
MMSS	O
asymmetric	O
radial	O
pulses	O
.	O
Lower	O
limbs	O
weak	O
and	O
symmetrical	O
distal	O
pulses	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
on	O
arrival	O
at	O
the	O
ED	O
sinus	O
rhythm	O
at	O
95	O
bpm	O
,	O
PR	O
170	O
ms	O
,	O
narrow	O
QRS	O
,	O
0o	O
axis	O
,	O
LVH	O
criteria	O
.	O
No	O
changes	O
in	O
serial	O
ECG	O
.	O
Initial	O
laboratory	O
tests	O
CBC	O
red	O
blood	O
cells	O
4	O
,	O
62	O
10	O
12	O
l	O
.	O
Haemoglobin	O
14	O
.	O
3	O
g	O
dl	O
.	O
Haematocrit	O
42	O
.	O
9	O
.	O
VCM	O
92	O
.	O
9	O
fl	O
.	O
HCM	O
30	O
.	O
9	O
pg	O
.	O
CHCM	O
33	O
.	O
3	O
g	O
l	O
.	O
ADE	O
13	O
.	O
1	O
.	O
Leukocytes	O
8	O
.	O
6	O
10	O
9	O
l	O
.	O
Neutrophils	O
54	O
.	O
6	O
.	O
Lymphocytes	O
32	O
,	O
2	O
.	O
Platelets	O
198	O
10	O
9	O
l	O
.	O
Haemostasis	O
prothrombin	O
time	O
PT	O
11	O
sec	O
.	O
Quick	O
's	O
index	O
100	O
,	O
INR	O
0	O
.	O
95	O
.	O
APTT	O
28	O
.	O
7	O
sec	O
.	O
Biochemistry	O
glucose	O
103	O
mg	O
dl	O
.	O
Sodium	O
139	O
mEq	O
l	O
.	O
Potassium	O
4	O
.	O
3	O
mEq	O
l	O
.	O
Chlorine	O
103	O
mEq	O
l	O
.	O
Urea	O
34	O
.	O
2	O
mg	O
dl	O
.	O
Creatinine	O
0	O
.	O
86	O
mg	O
dl	O
.	O
Biomarkers	O
of	O
myocardial	O
damage	O
troponin	O
I	O
hsTnI	O
3	O
,	O
2	O
ng	O
l	O
.	O
Urgent	O
echocardiogram	O
TTE	O
in	O
critical	O
care	O
unit	O
no	O
images	O
available	O
left	O
ventricle	O
with	O
slight	O
concentric	O
hypertrophy	O
,	O
normal	O
diameters	O
and	O
preserved	O
systolic	O
function	O
,	O
with	O
no	O
alterations	O
in	O
segmental	O
contractility	O
at	O
rest	O
.	O
Significant	O
aortic	O
insufficiency	O
,	O
without	O
other	O
valvulopathies	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
and	O
function	O
.	O
Aortic	O
root	O
with	O
increased	O
diameters	O
45	O
mm	O
,	O
without	O
a	O
clear	O
flap	O
image	O
.	O
Normal	O
inferior	O
vena	O
cava	O
IVC	O
.	O
Mild	O
pericardial	O
effusion	O
.	O
Angio	O
CT	O
of	O
the	O
aorta	O
type	O
A	O
aortic	O
dissection	O
with	O
involvement	O
of	O
the	O
aortic	O
root	O
extending	O
along	O
the	O
anterior	O
aspect	O
of	O
the	O
aortic	O
wall	O
close	O
to	O
the	O
left	O
coronary	O
trunk	O
LMCA	O
from	O
the	O
valvular	O
plane	O
to	O
the	O
origin	O
of	O
the	O
inferior	O
mesenteric	O
artery	O
with	O
involvement	O
of	O
the	O
proximal	O
origin	O
of	O
the	O
ASD	O
.	O
Dilatation	O
of	O
aortic	O
root	O
and	O
tubular	O
portion	O
of	O
ascending	O
aorta	O
47	O
mm	O
.	O
Descending	O
aorta	O
37	O
mm	O
.	O
Descending	O
aorta	O
31	O
mm	O
.	O
At	O
the	O
level	O
of	O
the	O
thoraco	O
abdominal	O
aorta	O
,	O
the	O
true	O
lumen	O
has	O
a	O
reduced	O
calibre	O
.	O
The	O
celiac	O
,	O
superior	O
mesenteric	O
and	O
right	O
renal	O
trunks	O
originate	O
from	O
the	O
true	O
lumen	O
.	O
The	O
left	O
renal	O
arises	O
from	O
a	O
gateway	O
between	O
the	O
true	O
lumen	O
and	O
the	O
false	O
lumen	O
with	O
good	O
renal	O
perfusion	O
.	O
Distal	O
aorta	O
and	O
normal	O
iliofemoral	O
sector	O
.	O
Conclusion	O
type	O
A	O
dissection	O
extending	O
from	O
the	O
aortic	O
root	O
to	O
the	O
aortic	O
segment	O
proximal	O
to	O
the	O
inferior	O
mesenteric	O
origin	O
.	O
CLINICAL	O
EVOLUTION	O
In	O
a	O
patient	O
with	O
intense	O
oppressive	O
chest	O
pain	O
,	O
without	O
significant	O
ECG	O
alterations	O
suggestive	O
of	O
ischaemia	O
,	O
it	O
was	O
decided	O
to	O
perform	O
an	O
urgent	O
TTE	O
,	O
which	O
revealed	O
aortic	O
root	O
dilatation	O
with	O
significant	O
insufficiency	O
.	O
In	O
view	O
of	O
these	O
findings	O
,	O
it	O
was	O
decided	O
to	O
request	O
an	O
angio	O
CT	O
scan	O
,	O
which	O
confirmed	O
the	O
diagnosis	O
of	O
type	O
A	O
aortic	O
dissection	O
.	O
With	O
the	O
results	O
of	O
the	O
complementary	O
examinations	O
and	O
the	O
diagnosis	O
,	O
the	O
cardiac	O
surgery	O
department	O
was	O
contacted	O
and	O
emergency	O
surgery	O
was	O
performed	O
using	O
the	O
mechanical	O
Bono	O
Bentall	O
technique	O
Carboseal	O
29	O
mm	O
consisting	O
of	O
aortic	O
valve	O
replacement	O
,	O
aortic	O
root	O
and	O
ascending	O
aorta	O
replacement	O
,	O
as	O
well	O
as	O
coronary	O
ostium	O
reimplantation	O
in	O
the	O
same	O
surgical	O
procedure	O
,	O
under	O
extracorporeal	O
circulation	O
,	O
electromechanical	O
heart	O
arrest	O
and	O
circulatory	O
arrest	O
with	O
selective	O
bicarotdeal	O
cerebral	O
perfusion	O
.	O
No	O
replacement	O
of	O
the	O
aortic	O
arch	O
or	O
descending	O
aorta	O
was	O
performed	O
,	O
given	O
the	O
critical	O
condition	O
of	O
the	O
patient	O
,	O
the	O
complexity	O
of	O
the	O
intervention	O
and	O
the	O
improvement	O
after	O
elimination	O
of	O
the	O
main	O
tear	O
and	O
reinstatement	O
of	O
true	O
lumen	O
flow	O
.	O
Evolution	O
in	O
ICU	O
prolonged	O
stay	O
to	O
8	O
days	O
after	O
emergent	O
Bentall	O
surgery	O
.	O
Early	O
extubation	O
at	O
12	O
h	O
post	O
IQ	O
without	O
incident	O
.	O
At	O
48	O
hours	O
the	O
patient	O
developed	O
global	O
respiratory	O
failure	O
oriented	O
as	O
postoperative	O
acute	O
respiratory	O
distress	O
syndrome	O
ARDS	O
by	O
congruent	O
radiography	O
with	O
image	O
of	O
scattered	O
infiltrates	O
in	O
both	O
lung	O
fields	O
with	O
heterogeneous	O
distribution	O
.	O
Influenza	O
A	O
negative	O
PCR	O
.	O
He	O
required	O
high	O
flow	O
nasal	O
spectacles	O
,	O
with	O
progressive	O
improvement	O
.	O
On	O
the	O
other	O
hand	O
,	O
acute	O
renal	O
failure	O
resolved	O
.	O
Haemodynamically	O
,	O
the	O
patient	O
remained	O
stable	O
from	O
the	O
immediate	O
postoperative	O
period	O
,	O
with	O
no	O
signs	O
of	O
active	O
bleeding	O
and	O
no	O
transfusion	O
requirements	O
.	O
Good	O
evolution	O
in	O
the	O
cardiac	O
surgery	O
room	O
,	O
with	O
discharge	O
home	O
on	O
7	O
3	O
19	O
.	O
DIAGNOSIS	O
Type	O
A	O
acute	O
aortic	O
dissection	O
.	O
Emergent	O
surgery	O
with	O
metallic	O
Bono	O
Bentall	O
.	O
Smoking	O
.	O
Arterial	O
hypertension	O
.	O
Acute	O
respiratory	O
failure	O
due	O
to	O
ARDS	O
.	O
Resolved	O
prerenal	O
renal	O
failure	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
PERSONAL	O
HISTORY	O
Male	O
,	O
43	O
years	O
old	O
,	O
regular	O
moderate	O
high	O
intensity	O
sportsman	O
.	O
No	O
drug	O
allergies	O
.	O
No	O
toxic	O
habits	O
or	O
cardiovascular	O
risk	O
factors	O
.	O
No	O
previous	O
cardiological	O
history	O
.	O
Migraine	O
with	O
aura	O
studied	O
in	O
2015	O
with	O
brain	O
MRI	O
without	O
pathological	O
findings	O
and	O
asymptomatic	O
since	O
then	O
.	O
No	O
surgical	O
interventions	O
or	O
chronic	O
treatments	O
.	O
CURRENT	O
ILLNESS	O
A	O
43	O
year	O
old	O
male	O
presented	O
with	O
sudden	O
loss	O
of	O
consciousness	O
while	O
performing	O
moderate	O
intensity	O
physical	O
exercise	O
running	O
,	O
with	O
no	O
previous	O
clinical	O
manifestations	O
.	O
The	O
witnesses	O
who	O
accompanied	O
him	O
reported	O
having	O
observed	O
him	O
fall	O
to	O
the	O
ground	O
with	O
no	O
response	O
to	O
stimuli	O
and	O
with	O
no	O
spontaneous	O
breathing	O
and	O
no	O
palpable	O
pulse	O
,	O
so	O
they	O
started	O
basic	O
cardiopulmonary	O
resuscitation	O
CPR	O
manoeuvres	O
and	O
called	O
the	O
emergency	O
services	O
.	O
On	O
arrival	O
of	O
the	O
medical	O
team	O
,	O
ventricular	O
fibrillation	O
was	O
detected	O
.	O
A	O
single	O
effective	O
shock	O
was	O
administered	O
,	O
achieving	O
sinus	O
rhythm	O
with	O
a	O
pulse	O
.	O
He	O
was	O
immediately	O
transferred	O
to	O
the	O
reference	O
centre	O
sedated	O
and	O
anaesthetised	O
,	O
with	O
orotracheal	O
intubation	O
on	O
mechanical	O
ventilation	O
and	O
haemodynamically	O
stable	O
without	O
amines	O
.	O
PHYSICAL	O
EXAMINATION	O
Anthropometric	O
data	O
weight	O
74	O
kg	O
,	O
height	O
1	O
.	O
82m	O
.	O
Body	O
mass	O
index	O
BMI	O
22	O
.	O
3	O
kg	O
m2	O
.	O
Vital	O
signs	O
blood	O
pressure	O
BP	O
104	O
82	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
62	O
bpm	O
.	O
O2	O
saturation	O
SatO2	O
98	O
with	O
FiO2	O
at	O
21	O
.	O
Cardiovascular	O
jugular	O
venous	O
pressure	O
normal	O
.	O
Hepatojugular	O
reflex	O
negative	O
.	O
Cardiac	O
auscultation	O
regular	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
.	O
No	O
aggregates	O
.	O
Abdomen	O
flat	O
.	O
Hydro	O
aerial	O
sounds	O
present	O
.	O
Soft	O
,	O
depressible	O
.	O
No	O
visceromegaly	O
.	O
Neurological	O
isochoric	O
pupils	O
.	O
Pupillary	O
reflexes	O
preserved	O
.	O
Motor	O
reflexes	O
in	O
extremities	O
without	O
alterations	O
II	O
IV	O
.	O
Extremities	O
no	O
oedema	O
.	O
Peripheral	O
pulses	O
preserved	O
and	O
symmetrical	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
sinus	O
rhythm	O
at	O
93	O
bpm	O
.	O
PR	O
120	O
ms	O
.	O
QRS	O
60	O
ms	O
.	O
QTc	O
398ms	O
.	O
No	O
repolarisation	O
alterations	O
.	O
Admission	O
blood	O
tests	O
haemoglobin	O
16	O
g	O
dl	O
,	O
haematocrit	O
47	O
.	O
5	O
,	O
platelets	O
223	O
,	O
000	O
l	O
,	O
leukocytes	O
7	O
,	O
400	O
l	O
.	O
International	O
normalised	O
ratio	O
INR	O
1	O
.	O
05	O
.	O
Basal	O
glycaemia	O
82	O
mg	O
dl	O
.	O
Urea	O
36	O
mg	O
dl	O
.	O
Creatinine	O
0	O
.	O
81	O
mg	O
dl	O
.	O
Sodium	O
137	O
mEq	O
l	O
.	O
Potassium	O
4	O
.	O
1	O
mEq	O
l	O
.	O
Myocardial	O
damage	O
markers	O
troponin	O
I	O
US	O
0	O
.	O
0	O
ng	O
ml	O
.	O
Chest	O
X	O
ray	O
centred	O
cardiomediastinal	O
silhouette	O
.	O
CTI	O
less	O
than	O
0	O
.	O
5	O
.	O
Lung	O
fields	O
without	O
condensation	O
or	O
pleural	O
effusion	O
.	O
Transthoracic	O
echocardiogram	O
left	O
ventricle	O
with	O
preserved	O
diameters	O
,	O
volumes	O
and	O
global	O
systolic	O
function	O
LVEF	O
65	O
.	O
Absence	O
of	O
alterations	O
in	O
segmental	O
contractility	O
at	O
rest	O
.	O
Normal	O
transmitral	O
filling	O
pattern	O
.	O
Absence	O
of	O
significant	O
valvulopathies	O
.	O
Normal	O
left	O
atrium	O
.	O
Normal	O
right	O
ventricle	O
.	O
Absence	O
of	O
tricuspid	O
insufficiency	O
TI	O
allowing	O
estimation	O
of	O
pulmonary	O
artery	O
systolic	O
pressure	O
PAPs	O
without	O
data	O
suggestive	O
of	O
pulmonary	O
hypertension	O
PHT	O
.	O
Normal	O
inferior	O
vena	O
cava	O
IVC	O
.	O
Exploration	O
in	O
sinus	O
rhythm	O
.	O
Coronary	O
angiography	O
epicardial	O
coronary	O
arteries	O
without	O
atheromatosis	O
.	O
Anomalous	O
origin	O
of	O
the	O
left	O
coronary	O
throne	O
LCT	O
in	O
the	O
right	O
sinus	O
of	O
Valsalva	O
,	O
high	O
and	O
anterior	O
,	O
opposite	O
to	O
the	O
origin	O
of	O
the	O
right	O
coronary	O
artery	O
RCA	O
which	O
is	O
filled	O
during	O
the	O
administration	O
of	O
contrast	O
in	O
the	O
cannulation	O
of	O
the	O
LCT	O
.	O
Possible	O
interarterial	O
tract	O
of	O
the	O
LMCA	O
.	O
Coronary	O
CT	O
angiography	O
trivalve	O
aortic	O
valve	O
with	O
preserved	O
diameters	O
.	O
The	O
presence	O
of	O
an	O
LMCA	O
with	O
origin	O
in	O
the	O
right	O
sinus	O
of	O
Valsalva	O
and	O
interarterial	O
trajectory	O
between	O
the	O
pulmonary	O
trunk	O
and	O
the	O
aorta	O
is	O
confirmed	O
.	O
Descending	O
artery	O
with	O
evidence	O
of	O
large	O
diagonal	O
without	O
significant	O
lesions	O
.	O
Circumflex	O
artery	O
without	O
lesions	O
.	O
Origin	O
of	O
the	O
right	O
coronary	O
artery	O
in	O
the	O
right	O
sinus	O
of	O
Valsalva	O
without	O
lesions	O
.	O
Conclusion	O
origin	O
of	O
the	O
left	O
coronary	O
artery	O
in	O
the	O
right	O
sinus	O
of	O
Valsalva	O
with	O
interarterial	O
trajectory	O
.	O
Post	O
surgical	O
ergometry	O
maximal	O
test	O
stopped	O
at	O
13	O
33	O
minutes	O
of	O
the	O
Bruce	O
protocol	O
14	O
.	O
5	O
METS	O
due	O
to	O
physical	O
exhaustion	O
.	O
No	O
angina	O
or	O
ST	O
segment	O
alterations	O
that	O
meet	O
the	O
criteria	O
for	O
positivity	O
in	O
relation	O
to	O
the	O
baseline	O
electrocardiogram	O
.	O
No	O
arrhythmias	O
.	O
Adequate	O
blood	O
pressure	O
and	O
chronotropic	O
response	O
.	O
Good	O
functional	O
capacity	O
.	O
Post	O
surgical	O
stress	O
echocardiogram	O
cycloergometer	O
stress	O
test	O
.	O
Maximum	O
test	O
reaching	O
103	O
of	O
the	O
maximum	O
theoretical	O
heart	O
rate	O
.	O
Performs	O
a	O
total	O
of	O
15	O
minutes	O
26	O
seconds	O
of	O
exercise	O
,	O
corresponding	O
to	O
1	O
minute	O
27	O
seconds	O
of	O
stage	O
8	O
of	O
the	O
WHO	O
protocol	O
200	O
watts	O
.	O
No	O
alterations	O
in	O
segmental	O
contractility	O
were	O
observed	O
at	O
rest	O
or	O
on	O
exertion	O
,	O
with	O
no	O
electrical	O
changes	O
or	O
chest	O
pain	O
.	O
CLINICAL	O
EVOLUTION	O
Young	O
man	O
with	O
cardiorespiratory	O
arrest	O
recovered	O
in	O
ventricular	O
fibrillation	O
during	O
moderate	O
exertion	O
,	O
presenting	O
post	O
CRP	O
electrocardiogram	O
in	O
sinus	O
rhythm	O
,	O
without	O
repolarisation	O
alterations	O
and	O
with	O
normal	O
QTc	O
interval	O
.	O
An	O
emergent	O
echocardiogram	O
showed	O
no	O
abnormalities	O
with	O
normal	O
LVEF	O
,	O
no	O
indirect	O
signs	O
of	O
massive	O
pulmonary	O
thromboembolism	O
PTE	O
,	O
no	O
aortic	O
flap	O
and	O
no	O
pericardial	O
effusion	O
.	O
The	O
emergency	O
chest	O
X	O
ray	O
ruled	O
out	O
pneumothorax	O
.	O
Arterial	O
blood	O
gas	O
analysis	O
showed	O
hyperlactacidemia	O
with	O
other	O
parameters	O
and	O
normal	O
haemoglobin	O
levels	O
.	O
Emergent	O
brain	O
computed	O
tomography	O
CT	O
without	O
haemorrhagic	O
or	O
acute	O
ischaemic	O
event	O
.	O
Given	O
the	O
normality	O
of	O
the	O
initial	O
aetiological	O
studies	O
,	O
it	O
was	O
decided	O
to	O
perform	O
an	O
emergent	O
coronary	O
angiography	O
where	O
epicardial	O
arteries	O
were	O
found	O
without	O
angiographic	O
lesions	O
with	O
anomalous	O
origin	O
of	O
the	O
left	O
main	O
coronary	O
artery	O
LMCA	O
in	O
the	O
right	O
sinus	O
of	O
Valsalva	O
with	O
a	O
possible	O
interarterial	O
trajectory	O
.	O
Admitted	O
to	O
the	O
coronary	O
unit	O
,	O
haemodynamically	O
stable	O
without	O
the	O
need	O
for	O
amines	O
,	O
in	O
sinus	O
rhythm	O
without	O
arrhythmic	O
events	O
and	O
allowing	O
progress	O
in	O
weaning	O
with	O
early	O
extubation	O
in	O
the	O
first	O
48	O
hours	O
with	O
no	O
neurological	O
deficit	O
.	O
Studies	O
were	O
completed	O
with	O
CT	O
of	O
the	O
coronary	O
arteries	O
which	O
confirmed	O
the	O
anomalous	O
origin	O
of	O
the	O
LMCA	O
in	O
the	O
right	O
sinus	O
of	O
Valsalva	O
with	O
interarterial	O
trajectory	O
.	O
During	O
his	O
admission	O
to	O
the	O
coronary	O
unit	O
he	O
remained	O
asymptomatic	O
and	O
haemodynamically	O
stable	O
.	O
The	O
case	O
was	O
discussed	O
in	O
a	O
medical	O
surgical	O
session	O
and	O
it	O
was	O
decided	O
to	O
perform	O
surgery	O
with	O
double	O
bypass	O
implantation	O
right	O
mammary	O
artery	O
to	O
obtuse	O
marginal	O
artery	O
and	O
left	O
mammary	O
artery	O
to	O
anterior	O
descending	O
artery	O
with	O
a	O
favourable	O
postoperative	O
period	O
with	O
no	O
incidents	O
.	O
The	O
patient	O
remained	O
asymptomatic	O
in	O
subsequent	O
outpatient	O
check	O
ups	O
.	O
Ergometry	O
and	O
stress	O
echocardiography	O
were	O
performed	O
,	O
both	O
tests	O
being	O
maximal	O
and	O
negative	O
for	O
ischaemia	O
.	O
DIAGNOSIS	O
Cardiorespiratory	O
arrest	O
during	O
physical	O
exercise	O
in	O
ventricular	O
fibrillation	O
.	O
Anomalous	O
origin	O
of	O
the	O
left	O
coronary	O
trunk	O
from	O
the	O
right	O
sinus	O
of	O
Valsalva	O
with	O
interarterial	O
trajectory	O
.	O
Surgical	O
revascularisation	O
with	O
double	O
bypass	O
.	O

HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
A	O
71	O
year	O
old	O
woman	O
,	O
with	O
no	O
toxic	O
habits	O
or	O
cardiovascular	O
risk	O
factors	O
and	O
with	O
a	O
personal	O
history	O
of	O
aortic	O
sclerosis	O
,	O
hypertensive	O
heart	O
disease	O
,	O
recurrent	O
paroxysmal	O
supraventricular	O
tachycardia	O
and	O
renal	O
lithiasis	O
,	O
attended	O
the	O
emergency	O
department	O
for	O
oppressive	O
central	O
thoracic	O
pain	O
,	O
not	O
radiating	O
or	O
associated	O
with	O
vegetative	O
cortex	O
,	O
which	O
did	O
not	O
change	O
with	O
palpation	O
,	O
deep	O
inspiration	O
or	O
movement	O
,	O
lasting	O
about	O
3	O
hours	O
.	O
He	O
denied	O
orthopnoea	O
,	O
paroxysmal	O
nocturnal	O
dyspnoea	O
,	O
palpitations	O
,	O
dyspnoea	O
at	O
rest	O
exertion	O
,	O
malleolar	O
oedema	O
or	O
reduced	O
diuresis	O
.	O
He	O
had	O
not	O
made	O
any	O
dietary	O
transgressions	O
or	O
modified	O
his	O
usual	O
medication	O
.	O
As	O
a	O
point	O
of	O
interest	O
,	O
she	O
commented	O
that	O
she	O
had	O
gone	O
to	O
the	O
dentist	O
hours	O
earlier	O
having	O
undergone	O
a	O
root	O
canal	O
.	O
On	O
arrival	O
at	O
the	O
emergency	O
department	O
the	O
patient	O
was	O
stable	O
,	O
normotensive	O
124	O
74	O
mmHg	O
,	O
with	O
heart	O
rate	O
78	O
bpm	O
and	O
oxygen	O
saturation	O
98	O
baseline	O
normal	O
.	O
Afebrile	O
.	O
Conscious	O
and	O
oriented	O
,	O
good	O
general	O
condition	O
,	O
eupneic	O
at	O
rest	O
,	O
normohydrated	O
,	O
normo	O
coloured	O
and	O
normoperfused	O
.	O
Carotid	O
pulses	O
were	O
rhythmic	O
and	O
symmetrical	O
and	O
we	O
did	O
not	O
detect	O
jugular	O
ingurgitation	O
.	O
Cardiopulmonary	O
auscultation	O
was	O
rhythmic	O
and	O
without	O
murmurs	O
,	O
with	O
subcrepitant	O
rales	O
from	O
middle	O
and	O
lower	O
lung	O
fields	O
.	O
Abdominal	O
examination	O
revealed	O
a	O
soft	O
and	O
depressible	O
abdomen	O
,	O
no	O
pain	O
on	O
superficial	O
or	O
deep	O
palpation	O
,	O
no	O
masses	O
or	O
megaliths	O
,	O
generalised	O
tympanism	O
,	O
no	O
peritonism	O
and	O
positive	O
hydro	O
aerial	O
sounds	O
.	O
The	O
lower	O
extremities	O
showed	O
no	O
malleolar	O
oedema	O
;	O
pedial	O
and	O
posterior	O
tibial	O
pulses	O
were	O
present	O
and	O
symmetrical	O
,	O
with	O
no	O
stigmata	O
of	O
venous	O
insufficiency	O
or	O
deep	O
vein	O
thrombosis	O
.	O
No	O
skin	O
rash	O
was	O
observed	O
.	O
COMPLEMENTARY	O
TESTS	O
Blood	O
analysis	O
haemoglobin	O
12	O
.	O
9	O
g	O
dl	O
,	O
hcto	O
38	O
.	O
7	O
,	O
MCH	O
26	O
pg	O
,	O
MCV	O
78	O
.	O
2	O
fl	O
,	O
leukocytes	O
13300	O
microlitre	O
,	O
platelets	O
200000	O
microlitre	O
,	O
normal	O
biochemistry	O
,	O
CPK	O
1127	O
IU	O
l	O
peak	O
30	O
200	O
IU	O
l	O
,	O
CK	O
MB	O
119	O
.	O
11	O
ng	O
ml	O
peak	O
6	O
ng	O
ml	O
and	O
troponin	O
I	O
29	O
.	O
130	O
ng	O
ml	O
peak	O
0	O
.	O
06	O
,	O
normal	O
renal	O
function	O
,	O
normal	O
ions	O
and	O
normal	O
coagulation	O
.	O
Anteroposterior	O
chest	O
X	O
ray	O
portable	O
preserved	O
cardiothoracic	O
index	O
,	O
vascular	O
redistribution	O
with	O
bilateral	O
bronchovascular	O
enhancement	O
and	O
bilateral	O
and	O
diffuse	O
interstitial	O
infiltrates	O
Electrocardiogram	O
sinus	O
rhythm	O
at	O
60	O
bpm	O
,	O
PR	O
180	O
msec	O
,	O
narrow	O
QRS	O
,	O
QRS	O
axis	O
at	O
30o	O
,	O
ST	O
segment	O
elevation	O
in	O
II	O
,	O
III	O
,	O
AVF	O
,	O
V3	O
V6	O
.	O
QTc	O
394	O
msec	O
.	O
Catheterisation	O
right	O
dominance	O
.	O
Right	O
coronary	O
artery	O
of	O
good	O
calibre	O
and	O
development	O
,	O
without	O
lesions	O
.	O
Anterior	O
descending	O
artery	O
of	O
good	O
calibre	O
,	O
with	O
very	O
distal	O
thrombotic	O
occlusion	O
,	O
this	O
being	O
a	O
very	O
long	O
vessel	O
,	O
which	O
appears	O
to	O
go	O
around	O
the	O
apex	O
.	O
Circumflex	O
artery	O
of	O
intermediate	O
calibre	O
and	O
good	O
development	O
,	O
without	O
lesions	O
.	O
Transthoracic	O
echocardiogram	O
left	O
ventricle	O
neither	O
dilated	O
nor	O
hypertrophied	O
,	O
with	O
apical	O
akinesia	O
,	O
diastolic	O
pattern	O
of	O
impaired	O
relaxation	O
and	O
preserved	O
systolic	O
function	O
LVEF	O
55	O
by	O
Simpson	O
biplane	O
.	O
Right	O
and	O
left	O
atrium	O
of	O
normal	O
size	O
.	O
Right	O
ventricle	O
neither	O
dilated	O
nor	O
hypertrophied	O
,	O
with	O
normal	O
systolic	O
function	O
TAPSE	O
18	O
mm	O
.	O
Mitral	O
valve	O
of	O
normal	O
morphology	O
,	O
with	O
good	O
opening	O
and	O
no	O
regurgitant	O
jets	O
.	O
Aortic	O
valve	O
of	O
trivalve	O
morphology	O
,	O
with	O
restriction	O
of	O
its	O
opening	O
in	O
the	O
range	O
of	O
moderate	O
stenosis	O
GP	O
53	O
mmHg	O
and	O
regurgitant	O
jet	O
that	O
conditioned	O
mild	O
aortic	O
insufficiency	O
AIo	O
,	O
without	O
apparent	O
dilatation	O
of	O
the	O
aortic	O
root	O
.	O
Morphologically	O
normal	O
tricuspid	O
valve	O
,	O
with	O
good	O
opening	O
and	O
mild	O
insufficiency	O
,	O
did	O
not	O
allow	O
adequate	O
estimation	O
of	O
pulmonary	O
artery	O
systolic	O
pressure	O
PSAP	O
although	O
there	O
were	O
no	O
indirect	O
signs	O
of	O
pulmonary	O
hypertension	O
PHT	O
.	O
Pericardium	O
of	O
normal	O
thickness	O
and	O
refractoriness	O
,	O
without	O
effusion	O
,	O
and	O
non	O
dilated	O
inferior	O
vena	O
cava	O
,	O
with	O
collapse	O
50	O
with	O
inspiration	O
Cardio	O
MRI	O
with	O
gadolinium	O
apical	O
anteroseptal	O
akinesia	O
with	O
subendocardial	O
uptake	O
greater	O
than	O
50	O
at	O
the	O
apical	O
and	O
strict	O
apical	O
anteroseptal	O
level	O
,	O
and	O
less	O
than	O
50	O
in	O
the	O
basal	O
anterolateral	O
region	O
.	O
Rest	O
of	O
the	O
study	O
without	O
alterations	O
.	O
CLINICAL	O
EVOLUTION	O
A	O
loading	O
dose	O
of	O
double	O
antiplatelet	O
therapy	O
was	O
administered	O
and	O
antianginal	O
medical	O
treatment	O
was	O
started	O
.	O
Given	O
the	O
persistence	O
of	O
the	O
clinical	O
and	O
electrocardiographic	O
findings	O
,	O
an	O
urgent	O
catheterisation	O
was	O
performed	O
,	O
which	O
showed	O
thrombotic	O
occlusion	O
of	O
the	O
anterior	O
descending	O
artery	O
at	O
a	O
very	O
distal	O
level	O
,	O
this	O
being	O
a	O
very	O
long	O
vessel	O
,	O
which	O
probably	O
went	O
around	O
the	O
apex	O
.	O
Ventriculography	O
showed	O
anterior	O
apical	O
and	O
inferior	O
apical	O
hypokinesia	O
.	O
Neither	O
thromboaspiration	O
nor	O
coronary	O
angioplasty	O
was	O
performed	O
due	O
to	O
the	O
distal	O
location	O
of	O
the	O
thrombus	O
and	O
he	O
was	O
treated	O
with	O
double	O
antiplatelet	O
therapy	O
and	O
anticoagulation	O
.	O
He	O
was	O
then	O
transferred	O
to	O
the	O
coronary	O
unit	O
,	O
where	O
enzymatic	O
and	O
electrocardiographic	O
serialisation	O
was	O
completed	O
.	O
A	O
transthoracic	O
echocardiogram	O
showed	O
a	O
non	O
dilated	O
and	O
non	O
hypertrophied	O
left	O
ventricle	O
with	O
septoapical	O
akinesia	O
,	O
diastolic	O
pattern	O
of	O
impaired	O
relaxation	O
and	O
preserved	O
systolic	O
function	O
LVEF	O
55	O
by	O
Simpson	O
biplane	O
.	O
Right	O
and	O
left	O
atrium	O
of	O
normal	O
size	O
.	O
Right	O
ventricle	O
neither	O
dilated	O
nor	O
hypertrophied	O
,	O
with	O
normal	O
systolic	O
function	O
TAPSE	O
18	O
mm	O
.	O
Mitral	O
valve	O
of	O
normal	O
morphology	O
,	O
with	O
good	O
opening	O
and	O
no	O
regurgitant	O
jets	O
.	O
Aortic	O
valve	O
of	O
trivalve	O
morphology	O
,	O
with	O
restriction	O
of	O
its	O
opening	O
in	O
the	O
range	O
of	O
moderate	O
stenosis	O
GP	O
53	O
mmHg	O
and	O
regurgitant	O
jet	O
that	O
conditioned	O
mild	O
AoI	O
,	O
without	O
apparent	O
dilatation	O
of	O
the	O
aortic	O
root	O
.	O
Morphologically	O
normal	O
tricuspid	O
valve	O
,	O
with	O
good	O
opening	O
and	O
mild	O
insufficiency	O
,	O
did	O
not	O
allow	O
adequate	O
estimation	O
of	O
PSAP	O
although	O
there	O
were	O
no	O
indirect	O
signs	O
of	O
PHT	O
.	O
Pericardium	O
of	O
normal	O
thickness	O
and	O
refractoriness	O
,	O
without	O
effusion	O
,	O
and	O
non	O
dilated	O
inferior	O
vena	O
cava	O
,	O
with	O
collapse	O
50	O
with	O
inspiration	O
.	O
During	O
his	O
stay	O
in	O
the	O
unit	O
he	O
remained	O
cardiologically	O
stable	O
,	O
with	O
blood	O
pressure	O
figures	O
with	O
a	O
tendency	O
to	O
hypotension	O
and	O
afebrile	O
.	O
She	O
did	O
not	O
present	O
new	O
episodes	O
of	O
angina	O
at	O
rest	O
light	O
exertion	O
,	O
palpitations	O
or	O
dyspnoea	O
.	O
Given	O
the	O
clinical	O
and	O
haemodynamic	O
stability	O
,	O
the	O
patient	O
was	O
discharged	O
to	O
the	O
cardiology	O
ward	O
.	O
Prior	O
to	O
discharge	O
,	O
the	O
patient	O
provided	O
the	O
report	O
of	O
the	O
dental	O
extraction	O
performed	O
a	O
few	O
hours	O
before	O
the	O
onset	O
of	O
the	O
symptoms	O
,	O
in	O
a	O
private	O
centre	O
,	O
which	O
included	O
the	O
use	O
of	O
a	O
local	O
anaesthetic	O
consisting	O
of	O
lidocaine	B-FARMACO
2	O
36	O
mg	O
epinephrine	B-FARMACO
0	O
.	O
0225	O
mg	O
.	O
Subsequently	O
,	O
cardiac	O
magnetic	O
resonance	O
imaging	O
with	O
gadolinium	O
was	O
performed	O
,	O
which	O
revealed	O
apical	O
anteroseptal	O
akinesia	O
with	O
subendocardial	O
uptake	O
greater	O
than	O
50	O
at	O
the	O
apical	O
and	O
strict	O
apical	O
anteroseptal	O
level	O
,	O
and	O
less	O
than	O
50	O
in	O
the	O
basal	O
anterolateral	O
region	O
,	O
all	O
compatible	O
with	O
acute	O
myocardial	O
infarction	O
AMI	O
as	O
a	O
first	O
possibility	O
.	O
Thus	O
,	O
the	O
patient	O
was	O
discharged	O
with	O
hygienic	O
dietary	O
recommendations	O
,	O
double	O
antiplatelet	O
therapy	O
,	O
beta	O
blockers	O
,	O
angiotensin	B-FARMACO
converting	I-FARMACO
enzyme	I-FARMACO
inhibitors	I-FARMACO
ACE	I-FARMACO
inhibitors	I-FARMACO
and	O
statins	O
.	O
One	O
year	O
later	O
,	O
the	O
patient	O
remains	O
clinically	O
asymptomatic	O
,	O
with	O
no	O
alterations	O
in	O
segmental	O
contractility	O
by	O
echocardiography	O
.	O
DIAGNOSIS	O
Acute	O
ST	O
segment	O
elevation	O
myocardial	O
infarction	O
STEMI	O
apical	O
Killip	O
I	O
.	O
Thrombotic	O
occlusion	O
of	O
the	O
very	O
distal	O
anterior	O
descending	O
artery	O
AD	O
.	O
Rest	O
of	O
the	O
coronary	O
tree	O
without	O
lesions	O
.	O
Apical	O
akinesia	O
.	O
Preserved	O
LVEF	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
PERSONAL	O
HISTORY	O
The	O
patient	O
is	O
a	O
52	O
year	O
old	O
female	O
active	O
smoker	O
with	O
chronic	O
non	O
revascularised	O
ischaemic	O
heart	O
disease	O
and	O
preserved	O
ventricular	O
function	O
.	O
She	O
made	O
her	O
debut	O
in	O
October	O
2018	O
as	O
a	O
non	O
ST	O
elevation	O
Killip	O
I	O
acute	O
myocardial	O
infarction	O
,	O
diagnosed	O
by	O
coronary	O
angiography	O
as	O
spontaneous	O
coronary	O
artery	O
dissection	O
with	O
haematoma	O
image	O
in	O
the	O
posterior	O
interventricular	O
branch	O
.	O
She	O
progressed	O
favourably	O
with	O
medical	O
treatment	O
and	O
was	O
discharged	O
without	O
complications	O
after	O
72	O
hours	O
of	O
hospitalisation	O
.	O
She	O
had	O
no	O
family	O
history	O
of	O
early	O
sudden	O
death	O
or	O
cardiovascular	O
disease	O
.	O
She	O
is	O
being	O
treated	O
with	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
mg	O
at	O
lunch	O
,	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
at	O
breakfast	O
,	O
atorvastatin	B-FARMACO
40	O
mg	O
at	O
dinner	O
and	O
omeprazole	B-FARMACO
20	O
mg	O
at	O
breakfast	O
.	O
CURRENT	O
ILLNESS	O
Consultation	O
in	O
November	O
2018	O
for	O
sudden	O
syncope	O
while	O
standing	O
upright	O
,	O
with	O
spontaneous	O
recovery	O
and	O
no	O
periepisodic	O
symptoms	O
palpitations	O
,	O
dizziness	O
,	O
sweating	O
,	O
nausea	O
,	O
etc	O
.	O
.	O
She	O
denied	O
recurrent	O
angina	O
in	O
the	O
previous	O
days	O
,	O
changes	O
in	O
medication	O
or	O
other	O
intercurrent	O
events	O
infections	O
,	O
etc	O
.	O
that	O
could	O
have	O
acted	O
as	O
triggers	O
.	O
On	O
arrival	O
at	O
the	O
emergency	O
department	O
,	O
telemetry	O
monitoring	O
was	O
started	O
pending	O
the	O
results	O
of	O
the	O
complementary	O
tests	O
and	O
assessment	O
by	O
the	O
on	O
call	O
cardiologist	O
.	O
In	O
the	O
meantime	O
,	O
he	O
presented	O
with	O
polymorphic	O
ventricular	O
tachycardia	O
that	O
rapidly	O
degenerated	O
into	O
ventricular	O
fibrillation	O
.	O
ROSC	O
return	O
of	O
spontaneous	O
circulation	O
after	O
single	O
electrical	O
cardioversion	O
ECV	O
and	O
iv	O
amiodarone	B-FARMACO
embolisation	O
.	O
Subsequently	O
,	O
she	O
presented	O
with	O
a	O
new	O
rhythm	O
of	O
ventricular	O
fibrillation	O
VF	O
with	O
ROSC	O
after	O
two	O
ECV	O
.	O
She	O
remained	O
asymptomatic	O
and	O
was	O
admitted	O
to	O
the	O
acute	O
cardiac	O
care	O
unit	O
ACCU	O
for	O
monitoring	O
.	O
With	O
no	O
new	O
arrhythmic	O
events	O
or	O
heart	O
failure	O
since	O
admission	O
,	O
she	O
was	O
transferred	O
to	O
the	O
hospital	O
ward	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
BP	O
165	O
80	O
mmHg	O
,	O
heart	O
rate	O
HR	O
85	O
bpm	O
.	O
Good	O
general	O
appearance	O
.	O
Capillary	O
refill	O
2	O
seconds	O
,	O
no	O
sweating	O
.	O
Eupneic	O
in	O
decubitus	O
.	O
No	O
jugular	O
ingurgitation	O
.	O
Rhythmic	O
cardiac	O
auscultation	O
without	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
with	O
preserved	O
vesicular	O
murmur	O
,	O
without	O
added	O
sounds	O
.	O
No	O
oedema	O
in	O
the	O
lower	O
limbs	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
on	O
admission	O
sinus	O
rhythm	O
at	O
80	O
bpm	O
with	O
normopositioned	O
narrow	O
QRS	O
and	O
adequate	O
progression	O
in	O
precordial	O
leads	O
.	O
Small	O
non	O
significant	O
q	O
wave	O
in	O
III	O
and	O
aVF	O
.	O
No	O
repolarisation	O
alterations	O
.	O
ECG	O
on	O
discharge	O
no	O
relevant	O
changes	O
.	O
Urgent	O
blood	O
tests	O
on	O
arrival	O
haemoglobin	O
14	O
g	O
dl	O
volumes	O
and	O
indices	O
within	O
normal	O
ranges	O
,	O
platelets	O
275000	O
ul	O
,	O
leukocytes	O
9520	O
ul	O
with	O
normal	O
formula	O
.	O
INR	O
1	O
.	O
02	O
,	O
APTT	O
27	O
.	O
2	O
sec	O
.	O
Glucose	O
99	O
mg	O
dl	O
.	O
Uric	O
acid	O
4	O
.	O
8	O
mg	O
dl	O
.	O
ALT	O
28	O
U	O
l	O
.	O
GGT	O
34	O
U	O
l	O
.	O
Alkaline	O
phosphatase	O
110	O
U	O
l	O
.	O
Creatinine	O
0	O
.	O
57	O
mg	O
dl	O
estimated	O
glomerular	O
filtration	O
rate	O
60	O
ml	O
min	O
1	O
.	O
73	O
m2	O
,	O
sodium	O
144	O
mmol	O
l	O
,	O
potassium	O
4	O
.	O
1	O
mmol	O
l	O
,	O
C	O
reactive	O
protein	O
1	O
.	O
7	O
mg	O
dl	O
.	O
Peak	O
myocardial	O
damage	O
markers	O
on	O
serialisation	O
ultrasensitive	O
troponin	O
I	O
392	O
ng	O
l	O
normal	O
15	O
.	O
6	O
,	O
CK	O
186	O
U	O
l	O
normal	O
192	O
.	O
Blood	O
tests	O
with	O
profiles	O
glycosylated	O
haemoglobin	O
6	O
.	O
3	O
,	O
TSH	O
1	O
.	O
55	O
mIU	O
l	O
,	O
total	O
cholesterol	O
125	O
mg	O
dl	O
,	O
LDL	O
cholesterol	O
51	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
47	O
mg	O
dl	O
,	O
triglycerides	O
134	O
mg	O
dl	O
.	O
Transthoracic	O
echocardiogram	O
biventricular	O
function	O
preserved	O
without	O
valvulopathy	O
or	O
cavity	O
dilatation	O
.	O
Akinesia	O
of	O
the	O
middle	O
and	O
distal	O
segments	O
of	O
the	O
inferior	O
face	O
and	O
hypokinesia	O
of	O
the	O
middle	O
and	O
distal	O
segments	O
of	O
the	O
inferolateral	O
face	O
.	O
Cardiac	O
MRI	O
with	O
contrast	O
non	O
dilated	O
left	O
ventricle	O
,	O
with	O
normal	O
thickness	O
.	O
Focal	O
dyskinesia	O
of	O
the	O
mediodistal	O
segment	O
of	O
the	O
inferior	O
face	O
.	O
Akinesia	O
of	O
the	O
inferior	O
distal	O
segment	O
and	O
inferolateral	O
segment	O
respecting	O
the	O
strictly	O
apical	O
segment	O
.	O
Rest	O
of	O
segmental	O
contraction	O
without	O
alterations	O
.	O
Normal	O
global	O
systolic	O
function	O
LVEF	O
55	O
.	O
T2	O
STIR	O
sequences	O
show	O
a	O
very	O
localised	O
hyperintense	O
transmural	O
area	O
in	O
the	O
distal	O
segment	O
of	O
the	O
inferior	O
face	O
with	O
subendocardial	O
extension	O
towards	O
the	O
apex	O
.	O
Perfusion	O
in	O
first	O
subendocardial	O
perfusion	O
defect	O
affecting	O
the	O
distal	O
thirds	O
of	O
the	O
inferior	O
septum	O
,	O
inferior	O
and	O
inferolateral	O
aspect	O
.	O
T2	O
MAPs	O
at	O
septal	O
level	O
49	O
ms	O
within	O
normal	O
limits	O
,	O
at	O
distal	O
lateral	O
level	O
72	O
ms	O
value	O
above	O
normal	O
,	O
suggestive	O
of	O
acute	O
inflammation	O
T1	O
MAPs	O
native	O
septal	O
value	O
1013	O
30	O
ms	O
within	O
normal	O
limits	O
.	O
Late	O
enhancement	O
an	O
area	O
of	O
enhancement	O
compatible	O
with	O
an	O
ischaemic	O
eschar	O
occupying	O
approximately	O
70	O
of	O
the	O
myocardial	O
thickness	O
is	O
observed	O
in	O
the	O
distal	O
segment	O
of	O
the	O
inferior	O
and	O
inferolateral	O
face	O
respecting	O
the	O
apex	O
.	O
Minimal	O
subendocardial	O
focus	O
in	O
the	O
distal	O
lateral	O
aspect	O
.	O
Right	O
ventricle	O
neither	O
dilated	O
nor	O
hypertrophic	O
.	O
No	O
alterations	O
of	O
segmental	O
contraction	O
.	O
Normal	O
systolic	O
function	O
.	O
No	O
late	O
enhancement	O
foci	O
.	O
Left	O
and	O
right	O
atrium	O
of	O
normal	O
size	O
.	O
Mitral	O
valve	O
with	O
thin	O
leaflets	O
,	O
normal	O
opening	O
.	O
Trivalve	O
aortic	O
valve	O
,	O
functionally	O
normal	O
.	O
Sinus	O
aorta	O
not	O
dilated	O
.	O
Coronary	O
angiography	O
short	O
left	O
main	O
coronary	O
artery	O
,	O
without	O
lesions	O
.	O
Anterior	O
descending	O
artery	O
of	O
good	O
development	O
and	O
calibre	O
,	O
without	O
lesions	O
.	O
Circumflex	O
artery	O
of	O
good	O
development	O
and	O
calibre	O
,	O
without	O
lesions	O
.	O
Right	O
coronary	O
artery	O
vessel	O
of	O
good	O
development	O
and	O
calibre	O
,	O
with	O
an	O
image	O
suggestive	O
of	O
haematoma	O
in	O
the	O
posterior	O
interventricular	O
branch	O
,	O
with	O
a	O
vessel	O
distal	O
to	O
the	O
lesion	O
of	O
small	O
calibre	O
and	O
short	O
course	O
.	O
Study	O
superimposed	O
on	O
the	O
one	O
performed	O
10	O
days	O
earlier	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
evolved	O
favourably	O
,	O
with	O
no	O
new	O
arrhythmic	O
events	O
after	O
transfer	O
to	O
the	O
hospital	O
ward	O
.	O
Beta	O
blockers	O
were	O
prescribed	O
up	O
to	O
the	O
maximum	O
tolerated	O
dose	O
,	O
as	O
well	O
as	O
other	O
antihypertensive	O
drugs	O
.	O
Coronary	O
angiography	O
showed	O
persistence	O
of	O
haematoma	O
in	O
PVI	O
and	O
only	O
discrete	O
acute	O
myocardial	O
damage	O
in	O
the	O
context	O
of	O
ventricular	O
arrhythmias	O
and	O
resuscitation	O
.	O
Therefore	O
,	O
ruling	O
out	O
the	O
existence	O
of	O
new	O
dissections	O
,	O
progression	O
of	O
the	O
previous	O
one	O
or	O
other	O
potential	O
triggers	O
of	O
ventricular	O
fibrillation	O
,	O
it	O
was	O
decided	O
to	O
implant	O
a	O
subcutaneous	O
ICD	O
for	O
secondary	O
prevention	O
in	O
a	O
patient	O
with	O
ischaemic	O
heart	O
disease	O
with	O
preserved	O
ventricular	O
function	O
and	O
recovered	O
sudden	O
death	O
.	O
After	O
this	O
,	O
the	O
patient	O
was	O
discharged	O
DIAGNOSIS	O
In	O
hospital	O
cardiac	O
arrest	O
recovered	O
in	O
ventricular	O
fibrillation	O
.	O
Chronic	O
ischaemic	O
heart	O
disease	O
inferior	O
infarction	O
.	O
Spontaneous	O
PVI	O
coronary	O
artery	O
dissection	O
.	O
Preserved	O
systolic	O
ventricular	O
function	O
.	O
Subcutaneous	O
ICD	O
implantation	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Patient	O
aged	O
15	O
years	O
.	O
Correct	O
vaccination	O
schedule	O
,	O
with	O
no	O
relevant	O
history	O
at	O
birth	O
,	O
during	O
the	O
neonatal	O
period	O
or	O
in	O
childhood	O
.	O
His	O
father	O
reported	O
that	O
he	O
had	O
a	O
"	O
benign	O
murmur	O
"	O
at	O
cardiac	O
level	O
,	O
discharged	O
without	O
further	O
check	O
ups	O
.	O
Personal	O
history	O
of	O
streptococcal	O
pharyngitis	O
and	O
attention	O
deficit	O
hyperactivity	O
disorder	O
.	O
Absence	O
of	O
usual	O
treatment	O
.	O
He	O
came	O
to	O
the	O
emergency	O
department	O
after	O
finding	O
elevated	O
blood	O
pressure	O
210	O
90	O
mmHg	O
,	O
asymptomatic	O
,	O
taken	O
at	O
home	O
with	O
a	O
blood	O
pressure	O
monitor	O
.	O
Given	O
the	O
patient	O
's	O
age	O
and	O
the	O
suspicion	O
of	O
secondary	O
hypertension	O
,	O
nephrological	O
assessment	O
was	O
requested	O
.	O
Following	O
blood	O
and	O
urine	O
tests	O
with	O
no	O
findings	O
and	O
a	O
normal	O
abdominal	O
ultrasound	O
scan	O
,	O
we	O
requested	O
an	O
assessment	O
by	O
us	O
.	O
His	O
grandfather	O
,	O
who	O
was	O
undergoing	O
treatment	O
for	O
hypertension	O
,	O
measured	O
his	O
blood	O
pressure	O
BP	O
daily	O
.	O
As	O
an	O
entertainment	O
,	O
imitating	O
his	O
grandfather	O
,	O
he	O
started	O
to	O
use	O
his	O
blood	O
pressure	O
monitor	O
,	O
with	O
a	O
very	O
different	O
result	O
to	O
the	O
expected	O
.	O
.	O
.	O
He	O
tells	O
us	O
that	O
in	O
the	O
last	O
two	O
weeks	O
he	O
has	O
been	O
taking	O
daily	O
BP	O
readings	O
,	O
with	O
average	O
BPs	O
of	O
160	O
170	O
mmHg	O
.	O
Today	O
,	O
on	O
finding	O
a	O
higher	O
figure	O
than	O
usual	O
,	O
he	O
decided	O
to	O
go	O
to	O
the	O
emergency	O
room	O
.	O
Asymptomatic	O
,	O
no	O
neurological	O
or	O
cardiovascular	O
symptoms	O
.	O
Physical	O
examination	O
showed	O
good	O
general	O
condition	O
,	O
correct	O
growth	O
and	O
development	O
.	O
Normal	O
features	O
.	O
BP	O
after	O
initiation	O
of	O
short	O
half	O
life	O
antihypertensive	O
drugs	O
159	O
92	O
mmHg	O
.	O
Heart	O
rate	O
80	O
bpm	O
,	O
no	O
audible	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
normal	O
ventilation	O
,	O
interscapular	O
systolic	O
murmur	O
.	O
Radial	O
pulses	O
present	O
and	O
symmetrical	O
.	O
Femoral	O
and	O
pedial	O
pulses	O
decreased	O
.	O
BP	O
measurement	O
in	O
both	O
arms	O
and	O
legs	O
with	O
the	O
following	O
result	O
ESD	O
155	O
85	O
mmHg	O
,	O
ESI	O
142	O
81	O
mmHg	O
,	O
EID	O
105	O
65	O
mmHg	O
,	O
EII	O
105	O
70	O
mmHg	O
.	O
S	O
ECG	O
sinus	O
rhythm	O
at	O
65	O
bpm	O
.	O
Revisema	O
a	O
Narrow	O
QRS	O
,	O
normal	O
axis	O
around	O
70o	O
.	O
LV	O
hypertrophy	O
criteria	O
Sokolow	O
Lyon	O
39	O
mm	O
.	O
No	O
relevant	O
repolarisation	O
alterations	O
.	O
Chest	O
X	O
ray	O
Roesler	O
's	O
notches	O
and	O
3	O
's	O
sign	O
with	O
absence	O
of	O
aortic	O
button	O
.	O
Echocardiogram	O
non	O
dilated	O
left	O
ventricle	O
LV	O
,	O
moderate	O
concentric	O
LV	O
hypertrophy	O
12	O
mm	O
.	O
Preserved	O
systolic	O
function	O
EF	O
68	O
,	O
without	O
alterations	O
of	O
segmental	O
wall	O
contractility	O
.	O
Normal	O
diastolic	O
pattern	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
,	O
preserved	O
function	O
TAPSE	O
22	O
mm	O
.	O
Atria	O
of	O
normal	O
size	O
.	O
Mitral	O
valve	O
thin	O
leaflets	O
,	O
preserved	O
opening	O
kinetics	O
.	O
No	O
reflux	O
.	O
Mild	O
TR	O
.	O
PAPS	O
33	O
mmHg	O
.	O
Bicuspid	O
type	O
I	O
aortic	O
valve	O
VAo	O
with	O
fusion	O
of	O
right	O
coronary	O
leaflet	O
and	O
left	O
coronary	O
leaflet	O
.	O
Preserved	O
opening	O
kinetics	O
,	O
mild	O
central	O
regurgitation	O
jet	O
.	O
Aortic	O
root	O
,	O
visualised	O
ascending	O
aorta	O
and	O
aortic	O
arch	O
of	O
normal	O
size	O
29	O
mm	O
.	O
Coarctation	O
of	O
the	O
aorta	O
after	O
left	O
subclavian	O
outflow	O
with	O
a	O
diameter	O
of	O
4	O
mm	O
,	O
peak	O
systolic	O
gradient	O
of	O
63	O
mmHg	O
and	O
significant	O
diastolic	O
prolongation	O
.	O
Distal	O
aortic	O
arch	O
13	O
mm	O
.	O
Continuous	O
abdominal	O
aortic	O
Doppler	O
with	O
peak	O
systolic	O
at	O
0	O
.	O
86	O
m	O
s	O
.	O
Decreased	O
protomesosystolic	O
flow	O
in	O
left	O
femoral	O
artery	O
without	O
protodiastolic	O
inversion	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
,	O
with	O
preserved	O
inspiratory	O
collapse	O
.	O
No	O
pericardial	O
effusion	O
.	O
Chest	O
CT	O
angiography	O
aortic	O
coarctation	O
with	O
severe	O
compromise	O
of	O
the	O
aortic	O
lumen	O
minimum	O
diameter	O
in	O
the	O
coarctation	O
5	O
mm	O
.	O
Presence	O
of	O
abundant	O
collateral	O
circulation	O
through	O
internal	O
mammary	O
,	O
intercostal	O
and	O
posterior	O
scapular	O
arteries	O
.	O
Bicuspid	O
aortic	O
valve	O
.	O
MIX	O
DUB	O
After	O
initial	O
suspicion	O
based	O
on	O
anamnesis	O
and	O
physical	O
examination	O
findings	O
,	O
an	O
echocardiogram	O
was	O
performed	O
,	O
confirming	O
the	O
presumptive	O
diagnosis	O
coarctation	O
of	O
the	O
aorta	O
and	O
secondary	O
hypertension	O
.	O
He	O
was	O
admitted	O
to	O
the	O
cardiology	O
ward	O
for	O
blood	O
pressure	O
control	O
and	O
to	O
complete	O
the	O
study	O
.	O
Thoracic	O
CT	O
angiography	O
was	O
performed	O
to	O
assess	O
management	O
.	O
He	O
was	O
assessed	O
by	O
the	O
congenital	O
heart	O
unit	O
of	O
our	O
hospital	O
,	O
with	O
controlled	O
BP	O
,	O
and	O
was	O
discharged	O
from	O
hospital	O
pending	O
percutaneous	O
intervention	O
.	O
Treatment	O
on	O
discharge	O
olmesartan	B-FARMACO
amlodipine	I-FARMACO
40	O
5	O
mg	O
,	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
,	O
eplerenone	B-FARMACO
25	O
mg	O
.	O
DIAGNOSIS	O
Coarctation	O
of	O
the	O
aorta	O
.	O
Secondary	O
arterial	O
hypertension	O
.	O
Bicuspid	O
aortic	O
valve	O
without	O
dysfunction	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
PERSONAL	O
HISTORY	O
Patient	O
aged	O
49	O
years	O
,	O
no	O
known	O
drug	O
allergies	O
,	O
Romanian	O
nationality	O
.	O
No	O
known	O
family	O
history	O
.	O
Personal	O
history	O
of	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
ex	O
smoker	O
since	O
2014	O
,	O
dyslipidaemic	O
with	O
poor	O
control	O
with	O
statins	O
and	O
overweight	O
.	O
Chronic	O
ischaemic	O
heart	O
disease	O
acute	O
myocardial	O
infarction	O
AMI	O
q	O
inferior	O
in	O
March	O
2014	O
,	O
fibrinolised	O
with	O
reperfusion	O
criteria	O
.	O
Epistenocardial	O
pericarditis	O
during	O
admission	O
.	O
Coronary	O
angiography	O
2014	O
2	O
vessel	O
coronary	O
artery	O
disease	O
.	O
Severe	O
right	O
coronary	O
artery	O
RCA	O
artery	O
responsible	O
for	O
AMI	O
implantation	O
of	O
two	O
drug	O
eluting	O
stents	O
proximally	O
and	O
distally	O
.	O
Descending	O
anterior	O
descending	O
DA	O
with	O
moderate	O
stenosis	O
,	O
no	O
action	O
taken	O
.	O
Echocardiogram	O
at	O
discharge	O
preserved	O
LVEF	O
,	O
with	O
basal	O
inferior	O
and	O
inferior	O
septal	O
hypokinesia	O
.	O
Isotope	O
stress	O
test	O
at	O
one	O
month	O
after	O
discharge	O
with	O
inferior	O
necrosis	O
.	O
LVEF	O
47	O
and	O
the	O
rest	O
of	O
the	O
segments	O
without	O
evidence	O
of	O
ischaemia	O
or	O
contractility	O
alterations	O
.	O
At	O
discharge	O
on	O
treatment	O
with	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
mg	O
24	O
hours	O
,	O
clopidogrel	B-FARMACO
75	O
mg	O
24	O
hours	O
,	O
bisoprolol	B-FARMACO
5	O
mg	O
24	O
hours	O
and	O
atorvastatin	B-FARMACO
80	O
mg	O
24	O
hours	O
.	O
CURRENT	O
ILLNESS	O
Since	O
discharge	O
he	O
has	O
been	O
monitored	O
in	O
cardiology	O
consultations	O
.	O
He	O
was	O
asymptomatic	O
,	O
in	O
class	O
I	O
,	O
with	O
no	O
recurrence	O
of	O
chest	O
pain	O
or	O
evidence	O
of	O
inducible	O
ischaemia	O
in	O
an	O
isotope	O
stress	O
test	O
performed	O
one	O
month	O
later	O
.	O
He	O
was	O
started	O
on	O
a	O
low	O
dose	O
angiotensin	B-FARMACO
converting	I-FARMACO
enzyme	I-FARMACO
inhibitor	I-FARMACO
ACE	I-FARMACO
inhibitor	I-FARMACO
,	O
which	O
he	O
had	O
not	O
tolerated	O
during	O
admission	O
due	O
to	O
hypotension	O
,	O
and	O
clopidogrel	B-FARMACO
was	O
withdrawn	O
after	O
one	O
year	O
without	O
incident	O
.	O
However	O
,	O
from	O
the	O
time	O
of	O
admission	O
,	O
LDL	O
cholesterol	O
levels	O
180	O
mg	O
dL	O
despite	O
switching	O
to	O
a	O
high	O
dose	O
high	O
potency	O
statin	O
atorvastatin	B-FARMACO
and	O
elevated	O
levels	O
of	O
lipoprotein	O
A	O
,	O
apoB	O
and	O
homocystinuria	O
were	O
striking	O
.	O
In	O
2016	O
,	O
he	O
reported	O
myalgias	O
and	O
laboratory	O
tests	O
showed	O
elevated	O
CPK	O
and	O
mild	O
AST	O
and	O
insufficient	O
LDL	O
control	O
,	O
so	O
atorvastatin	B-FARMACO
was	O
replaced	O
by	O
rosuvastatin	B-FARMACO
20	O
mg	O
day	O
and	O
ezetimibe	B-FARMACO
was	O
added	O
.	O
The	O
patient	O
stopped	O
coming	O
for	O
check	O
ups	O
,	O
until	O
2018	O
,	O
when	O
he	O
was	O
again	O
referred	O
to	O
our	O
clinic	O
for	O
analytical	O
abnormalities	O
in	O
lipid	O
metabolism	O
.	O
According	O
to	O
the	O
patient	O
,	O
he	O
continues	O
to	O
be	O
asymptomatic	O
from	O
a	O
cardiovascular	O
point	O
of	O
view	O
,	O
reporting	O
only	O
mild	O
myalgias	O
.	O
He	O
is	O
taking	O
medication	O
correctly	O
,	O
including	O
the	O
two	O
lipid	O
lowering	O
drugs	O
.	O
At	O
this	O
consultation	O
it	O
was	O
decided	O
to	O
study	O
the	O
patient	O
further	O
.	O
PHYSICAL	O
EXAMINATION	O
At	O
consultation	O
in	O
2018	O
Blood	O
pressure	O
BP	O
115	O
60	O
mmHg	O
,	O
heart	O
rate	O
HR	O
60	O
bpm	O
.	O
Baseline	O
SpO2	O
97	O
.	O
No	O
jugular	O
venous	O
engorgement	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
sounds	O
without	O
murmurs	O
or	O
extratonos	O
.	O
Pulmonary	O
auscultation	O
normal	O
.	O
Abdomen	O
nondescript	O
.	O
Lower	O
extremities	O
no	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
AMI	O
2014	O
sinus	O
rhythm	O
at	O
66	O
bpm	O
,	O
normal	O
PR	O
,	O
narrow	O
QRS	O
,	O
normal	O
axis	O
,	O
up	O
to	O
1	O
.	O
5	O
mm	O
ST	O
supradelevation	O
in	O
inferior	O
face	O
,	O
V5	O
V6	O
with	O
specular	O
image	O
in	O
I	O
,	O
and	O
AVL	O
.	O
ECG	O
in	O
consultation	O
2018	O
sinus	O
rhythm	O
at	O
56	O
bpm	O
,	O
normal	O
PR	O
,	O
narrow	O
QRS	O
,	O
lower	O
qR	O
with	O
negative	O
asymmetric	O
T	O
wave	O
in	O
II	O
,	O
III	O
,	O
AVF	O
,	O
and	O
flattened	O
in	O
I	O
,	O
AVL	O
,	O
V5	O
V6	O
,	O
unchanged	O
from	O
ECG	O
of	O
previous	O
consultation	O
in	O
2015	O
.	O
Normal	O
QTc	O
.	O
Coronary	O
angiography	O
2014	O
2	O
vessel	O
coronary	O
artery	O
disease	O
CD	O
severe	O
stenosis	O
due	O
to	O
complicated	O
plaque	O
extending	O
from	O
the	O
end	O
of	O
the	O
proximal	O
segment	O
responsible	O
for	O
AMI	O
.	O
Significant	O
stenosis	O
in	O
the	O
mid	O
distal	O
segment	O
percutaneous	O
transluminal	O
coronary	O
angioplasty	O
PTCA	O
implantation	O
of	O
two	O
non	O
overlapping	O
drug	O
eluting	O
stents	O
proximally	O
and	O
distally	O
.	O
AD	O
moderate	O
stenosis	O
in	O
medial	O
proximal	O
segment	O
,	O
uncomplicated	O
,	O
assessed	O
by	O
intravascular	O
echocardiography	O
IVUS	O
.	O
Echocardiogram	O
at	O
discharge	O
2014	O
left	O
ventricle	O
neither	O
dilated	O
nor	O
hypertrophied	O
LVEDDVI	O
56	O
mm	O
,	O
IVUS	O
10	O
mm	O
,	O
PP	O
10	O
mm	O
with	O
preserved	O
systolic	O
function	O
LVEF	O
54	O
and	O
inferior	O
septal	O
and	O
basal	O
inferior	O
segment	O
hypokinesia	O
.	O
Mild	O
mitral	O
and	O
aortic	O
regurgitation	O
.	O
Minimal	O
pericardial	O
effusion	O
of	O
3	O
mm	O
in	O
posterior	O
sac	O
.	O
Blood	O
tests	O
in	O
AMI	O
2014	O
haemogram	O
Hb	O
14	O
.	O
2	O
g	O
dl	O
;	O
Hct	O
43	O
.	O
1	O
;	O
leukocytes	O
10	O
.	O
9	O
mil	O
mm3	O
;	O
platelets	O
241	O
mil	O
mm3	O
.	O
Biochemistry	O
basal	O
glucose	O
96	O
mg	O
dl	O
;	O
creatinine	O
0	O
.	O
91	O
mg	O
dl	O
;	O
total	O
cholesterol	O
234	O
mg	O
dl	O
;	O
triglycerides	O
102	O
mg	O
dl	O
;	O
HDL	O
C	O
30	O
mg	O
dl	O
;	O
LDL	O
C	O
183	O
.	O
6	O
mg	O
dl	O
;	O
APO	O
B	O
148	O
mg	O
dl	O
.	O
Lipoprotein	O
A	O
49	O
.	O
4mg	O
dl	O
,	O
basal	O
homocysteine	O
16	O
.	O
34	O
micromol	O
l	O
,	O
16	O
.	O
34U	O
l	O
,	O
AST	O
24	O
U	O
l	O
;	O
ALT	O
31	O
U	O
l	O
;	O
GGT	O
54	O
U	O
l	O
.	O
Maximal	O
myocardial	O
necrosis	O
markers	O
TnI	O
97	O
ng	O
ml	O
0	O
0	O
.	O
04	O
;	O
CPK	O
4443	O
U	O
l	O
39	O
308	O
,	O
CK	O
MB	O
510	O
U	O
l	O
5	O
24	O
.	O
Isotope	O
stress	O
test	O
one	O
month	O
after	O
discharge	O
inferior	O
necrosis	O
.	O
LVEF	O
47	O
.	O
Rest	O
of	O
segments	O
without	O
evidence	O
of	O
ischaemia	O
or	O
contractility	O
alterations	O
.	O
Blood	O
tests	O
at	O
consultation	O
in	O
January	O
2016	O
haemogram	O
normal	O
.	O
Biochemistry	O
basal	O
glucose	O
117	O
mg	O
dl	O
;	O
creatinine	O
1	O
.	O
05	O
mg	O
dl	O
;	O
total	O
cholesterol	O
261	O
mg	O
dl	O
;	O
triglycerides	O
117	O
mg	O
dl	O
;	O
HDL	O
C	O
47	O
mg	O
dl	O
;	O
LDL	O
C	O
190	O
.	O
6	O
mg	O
dl	O
,	O
AST	O
63	O
U	O
l	O
0	O
37	O
;	O
ALT	O
70	O
U	O
l	O
0	O
41	O
;	O
GGT	O
64	O
U	O
l	O
0	O
60	O
,	O
CPK	O
507	O
U	O
l	O
39	O
308	O
.	O
Blood	O
tests	O
in	O
consultation	O
,	O
September	O
2018	O
total	O
cholesterol	O
196	O
mg	O
dl	O
;	O
triglycerides	O
67	O
mg	O
dl	O
;	O
HDL	O
C	O
42	O
mg	O
dl	O
;	O
LDL	O
C	O
145	O
mg	O
dl	O
,	O
AST	O
28	O
U	O
l	O
0	O
37	O
;	O
CPK	O
305	O
U	O
l	O
39	O
308	O
.	O
Genetic	O
study	O
of	O
familial	O
hypercholesterolemia	O
positive	O
.	O
Heterozygosis	O
of	O
the	O
variant	O
c	O
.	O
2478del	O
,	O
p	O
.	O
Val827Serfs	O
102	O
,	O
of	O
the	O
LDLR	O
gene	O
,	O
classified	O
as	O
pathogenic	O
with	O
respect	O
to	O
familial	O
hypercholesterolemia	O
.	O
Heterozygosis	O
rs4149056	O
polymorphism	O
in	O
the	O
SLCO1B1	O
gene	O
and	O
rs17244841	O
of	O
the	O
HMGCR	O
gene	O
.	O
Homozygosis	O
rs2032582	O
polymorphism	O
of	O
the	O
ABCB1	O
gene	O
.	O
Blood	O
tests	O
at	O
consultation	O
after	O
starting	O
iPCSK9	B-FARMACO
in	O
April	O
2019	O
total	O
cholesterol	O
120	O
mg	O
dl	O
;	O
triglycerides	O
99	O
mg	O
dl	O
;	O
HDL	O
C	O
49	O
mg	O
dl	O
;	O
LDL	O
C	O
58	O
mg	O
dl	O
.	O
CLINICAL	O
EVOLUTION	O
This	O
is	O
a	O
smoker	O
,	O
sedentary	O
,	O
obese	O
and	O
dyslipidaemic	O
patient	O
on	O
treatment	O
with	O
simvastatin	B-FARMACO
with	O
LDL	O
who	O
debuted	O
in	O
2014	O
with	O
a	O
lower	O
AMI	O
.	O
On	O
admission	O
,	O
LDL	O
levels	O
180	O
mg	O
dl	O
were	O
found	O
despite	O
a	O
change	O
to	O
a	O
high	O
dose	O
high	O
potency	O
statin	B-FARMACO
since	O
the	O
event	O
.	O
In	O
the	O
first	O
consultations	O
after	O
the	O
coronary	O
event	O
,	O
the	O
patient	O
had	O
not	O
presented	O
chest	O
pain	O
again	O
,	O
and	O
isotope	O
exercise	O
stress	O
test	O
showed	O
no	O
inducible	O
ischaemia	O
in	O
the	O
anterior	O
descending	O
artery	O
territory	O
,	O
so	O
percutaneous	O
coronary	O
intervention	O
PCI	O
was	O
not	O
performed	O
on	O
this	O
lesion	O
.	O
On	O
anamnesis	O
,	O
he	O
reported	O
weakness	O
and	O
myalgia	O
in	O
the	O
extremities	O
,	O
in	O
addition	O
to	O
a	O
discrete	O
elevation	O
of	O
AST	O
and	O
CPK	O
,	O
for	O
which	O
reason	O
intolerance	O
to	O
atorvastatin	B-FARMACO
was	O
assumed	O
,	O
so	O
it	O
was	O
replaced	O
by	O
rosuvastatin	B-FARMACO
20	O
mg	O
day	O
and	O
ezetimibe	B-FARMACO
was	O
added	O
to	O
optimise	O
LDL	O
control	O
.	O
In	O
2016	O
,	O
he	O
stopped	O
coming	O
for	O
check	O
ups	O
,	O
until	O
2018	O
,	O
when	O
he	O
was	O
again	O
referred	O
to	O
our	O
offices	O
for	O
analytical	O
alterations	O
in	O
lipid	O
metabolism	O
.	O
According	O
to	O
him	O
,	O
he	O
remains	O
asymptomatic	O
from	O
a	O
cardiovascular	O
point	O
of	O
view	O
.	O
He	O
was	O
taking	O
medication	O
correctly	O
,	O
including	O
the	O
two	O
lipid	O
lowering	O
drugs	O
,	O
but	O
his	O
LDL	O
levels	O
were	O
still	O
around	O
150	O
mg	O
dl	O
.	O
At	O
this	O
consultation	O
,	O
it	O
was	O
decided	O
to	O
further	O
study	O
the	O
patient	O
and	O
request	O
genetic	O
testing	O
for	O
familial	O
hypercholesterolaemia	O
,	O
which	O
was	O
positive	O
.	O
For	O
this	O
reason	O
,	O
treatment	O
was	O
finally	O
started	O
with	O
a	O
PCSK9	B-FARMACO
inhibitor	I-FARMACO
,	O
evolocumab	B-FARMACO
at	O
a	O
dose	O
of	O
140	O
mg	O
every	O
2	O
weeks	O
,	O
achieving	O
a	O
greater	O
than	O
50	O
decrease	O
with	O
respect	O
to	O
the	O
previous	O
LDL	O
figures	O
with	O
combined	O
treatment	O
.	O
DIAGNOSIS	O
Chronic	O
ischaemic	O
heart	O
disease	O
AMI	O
Q	O
lower	O
Killip	O
I	O
in	O
2014	O
2	O
vessel	O
coronary	O
artery	O
disease	O
DC	O
responsible	O
and	O
LAD	O
effective	O
fibrinolysis	O
and	O
subsequent	O
PCI	O
with	O
implantation	O
of	O
two	O
drug	O
eluting	O
stents	O
in	O
DC	O
.	O
Absence	O
of	O
inducible	O
ischaemia	O
in	O
the	O
LAD	O
territory	O
.	O
Preserved	O
LVEF	O
.	O
Familial	O
hypercholesterolemia	O
in	O
heterozygosis	O
.	O
Intolerance	O
to	O
atorvastatin	B-FARMACO
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
PERSONAL	O
HISTORY	O
Aj	O
deny	O
'	O
Problemas	O
1x	O
traba	O
Nuestras	O
a	O
No	O
toxic	O
habits	O
.	O
Mo	O
nariz	O
fcilmentearhythm	O
Catalog	O
Jado	O
Rosmier	O
De	O
a	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
hypertension	O
HT	O
with	O
good	O
home	O
control	O
,	O
dyslipidaemia	O
LDL	O
with	O
good	O
control	O
April	O
2018	O
LDL	O
107	O
mg	O
dl	O
,	O
no	O
diabetes	O
mellitus	O
DM	O
.	O
Prostate	O
adenocarcinoma	O
stage	O
T1CN0MX	O
intermediate	O
risk	O
pending	O
surgery	O
radical	O
prostatectomy	O
.	O
Ask	O
inclase	O
hac	O
ofg	O
IND	O
a	O
Prostate	O
biopsy	O
Gleason	O
score	O
7	O
.	O
Four	O
foci	O
of	O
infiltrating	O
acinar	O
adenocarcinoma	O
,	O
Gleason	O
score	O
6	O
3	O
3	O
and	O
7	O
3	O
4	O
are	O
observed	O
.	O
Chronic	O
gastritis	O
.	O
Anxious	O
depressive	O
syndrome	O
.	O
Wooden	O
inalamberspanet	O
Asith	O
acusado	O
thick	O
in	O
all	O
instve	O
businessem	O
a	O
Usual	O
treatment	O
olmesartan	B-FARMACO
10	O
mg	O
day	O
,	O
clorazepate	B-FARMACO
25	O
mg	O
day	O
,	O
diazepam	B-FARMACO
10	O
mg	O
8	O
hours	O
,	O
escitalopram	B-FARMACO
20	O
mg	O
day	O
,	O
pregabalin	B-FARMACO
75	O
mg	O
12	O
hours	O
,	O
dexchlorpheniramine	B-FARMACO
2	O
mg	O
8	O
hours	O
,	O
loratadine	B-FARMACO
10	O
mg	O
day	O
,	O
hydroxyzine	B-FARMACO
25	O
mg	O
8	O
hours	O
.	O
CURRENT	O
ILLNESS	O
We	O
present	O
the	O
case	O
of	O
a	O
60	O
year	O
old	O
male	O
patient	O
with	O
the	O
previously	O
described	O
history	O
who	O
was	O
referred	O
to	O
the	O
outpatient	O
cardiology	O
department	O
for	O
a	O
casual	O
finding	O
of	O
calcification	O
in	O
the	O
three	O
coronary	O
arteries	O
in	O
the	O
thoraco	O
abdomino	O
pelvic	O
CT	O
scan	O
performed	O
for	O
staging	O
of	O
prostate	O
adenocarcinoma	O
.	O
The	O
patient	O
denies	O
clinical	O
chest	O
pain	O
on	O
exertion	O
,	O
although	O
he	O
occasionally	O
presents	O
chest	O
discomfort	O
related	O
to	O
anxiety	O
.	O
Melaj	O
heavyestion	O
procur	O
S	O
an	O
merc	O
Consus	O
Escar	O
Toristi	O
fuck	O
a	O
PHYSICAL	O
EXAMINATION	O
The	O
patient	O
was	O
found	O
to	O
be	O
in	O
good	O
general	O
condition	O
,	O
normal	O
colour	O
,	O
normohydrated	O
,	O
eupneic	O
at	O
rest	O
,	O
conscious	O
,	O
oriented	O
and	O
cooperative	O
,	O
with	O
no	O
signs	O
of	O
neurological	O
focality	O
.	O
The	O
constants	O
recorded	O
in	O
the	O
consultation	O
room	O
were	O
normal	O
blood	O
pressure	O
BP	O
124	O
82	O
mmHg	O
,	O
heart	O
rate	O
HR	O
75	O
bpm	O
,	O
SaO2	O
98	O
ambient	O
air	O
,	O
afebrile	O
.	O
Cardiac	O
auscultation	O
was	O
rhythmic	O
with	O
no	O
murmurs	O
and	O
pulmonary	O
auscultation	O
showed	O
preserved	O
vesicular	O
murmur	O
with	O
no	O
added	O
sounds	O
.	O
There	O
are	O
no	O
congestive	O
signs	O
on	O
examination	O
and	O
the	O
radial	O
pulses	O
are	O
palpable	O
,	O
rhythmic	O
and	O
symmetrical	O
.	O
COMPLEMENTARY	O
TESTS	O
CBC	O
April	O
2018	O
Glucose	O
97	O
mg	O
dl	O
.	O
Glycated	O
haemoglobin	O
HbA1c	O
5	O
.	O
1	O
.	O
Renal	O
function	O
preserved	O
creatinine	O
0	O
.	O
74	O
mg	O
dl	O
with	O
electrolytes	O
in	O
range	O
.	O
Oliveariento	O
haun	O
sostenysety	O
P	O
haiento	O
their	O
emphascre	O
a	O
Lipid	O
profile	O
triglycerides	O
81	O
mg	O
dl	O
,	O
cholesterol	O
177	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
54	O
mg	O
dl	O
,	O
LDL	O
cholesterol	O
107	O
mg	O
dl	O
.	O
Prostate	O
markers	O
PSA	O
7	O
.	O
57	O
ng	O
ml	O
,	O
free	O
PSA	O
FPSA	O
1	O
.	O
51	O
ng	O
ml	O
,	O
free	O
PSA	O
total	O
PSA	O
ratio	O
0	O
.	O
20	O
.	O
Dutch	O
distintaathunice	O
paratividad	O
their	O
emphascre	O
a	O
No	O
'	O
etbiernos	O
their	O
Six	O
t	O
specific	O
londo	O
a	O
Normal	O
PR	O
.	O
M	O
Christive	O
porocusoem	O
a	O
Narrow	O
QRS	O
with	O
left	O
superoanterior	O
hemiblock	O
morphology	O
HSAI	O
.	O
Emphasajcre	O
P	O
laaldzanture	O
a	O
Chest	O
X	O
ray	O
PA	O
lateral	O
cardiomediastinal	O
silhouette	O
without	O
alterations	O
.	O
Hilar	O
thickening	O
of	O
vascular	O
origin	O
.	O
No	O
signs	O
of	O
consolidation	O
or	O
pleural	O
effusion	O
.	O
Thoracic	O
abdominal	O
pelvic	O
CT	O
with	O
IV	O
contrast	O
no	O
evidence	O
of	O
distant	O
disease	O
,	O
but	O
calcified	O
coronary	O
atheromatosis	O
of	O
the	O
three	O
vessels	O
and	O
mild	O
aortic	O
valve	O
calcification	O
.	O
Transthoracic	O
echocardiography	O
left	O
ventricle	O
of	O
normal	O
diameters	O
,	O
with	O
slight	O
concentric	O
hypertrophy	O
IVT	O
11	O
mm	O
,	O
PP	O
11	O
mm	O
and	O
with	O
good	O
systolic	O
function	O
LVEF	O
60	O
,	O
without	O
alterations	O
in	O
segmental	O
contractility	O
.	O
Non	O
dilated	O
right	O
ventricle	O
with	O
good	O
systolic	O
function	O
TAPSE	O
20	O
mm	O
.	O
Type	O
I	O
diastolic	O
dysfunction	O
impaired	O
relaxation	O
.	O
E	O
e	O
'	O
4	O
.	O
Left	O
atrium	O
slightly	O
dilated	O
41	O
mm	O
.	O
Aortic	O
root	O
not	O
dilated	O
.	O
Trivalve	O
aortic	O
valve	O
with	O
normal	O
gradient	O
and	O
no	O
insufficiency	O
.	O
Normal	O
appearing	O
mitral	O
valve	O
with	O
minimal	O
insufficiency	O
.	O
Absence	O
of	O
tricuspid	O
insufficiency	O
that	O
would	O
allow	O
estimation	O
of	O
PAPS	O
.	O
Conclusion	O
mild	O
hypertensive	O
heart	O
disease	O
with	O
good	O
biventricular	O
systolic	O
function	O
.	O
Electrocardiographic	O
stress	O
test	O
maximal	O
stress	O
test	O
104	O
of	O
predicted	O
FCM	O
performed	O
with	O
Bruce	O
protocol	O
on	O
treadmill	O
,	O
stopped	O
due	O
to	O
physical	O
exhaustion	O
.	O
Abnormal	O
for	O
maximum	O
ST	O
segment	O
depression	O
of	O
1	O
.	O
5	O
mm	O
horizontal	O
in	O
5	O
leads	O
II	O
,	O
III	O
,	O
aVF	O
and	O
V5	O
V6	O
in	O
the	O
recovery	O
phase	O
that	O
normalises	O
after	O
5	O
minutes	O
,	O
without	O
clinical	O
chest	O
pain	O
.	O
Adequate	O
chronotropic	O
response	O
and	O
adaptation	O
of	O
BP	O
to	O
effort	O
.	O
Good	O
functional	O
capacity	O
reaches	O
11	O
.	O
2	O
METS	O
,	O
exercise	O
time	O
of	O
9	O
min	O
35	O
sec	O
.	O
No	O
arrhythmias	O
detected	O
during	O
the	O
test	O
.	O
Duke	O
Treadmill	O
score	O
1	O
.	O
5	O
intermediate	O
risk	O
.	O
Coronary	O
angiography	O
left	O
main	O
coronary	O
artery	O
LMCA	O
no	O
significant	O
irregularities	O
.	O
Anterior	O
descending	O
artery	O
ADA	O
severe	O
stenosis	O
in	O
proximal	O
and	O
middle	O
segment	O
,	O
and	O
significant	O
stenosis	O
in	O
distal	O
middle	O
segment	O
.	O
First	O
diagonal	O
of	O
good	O
calibre	O
with	O
early	O
bifurcation	O
and	O
severe	O
stenosis	O
in	O
proximal	O
segment	O
with	O
distal	O
vessel	O
of	O
intermediate	O
calibre	O
.	O
Circumflex	O
artery	O
ACx	O
Non	O
dominant	O
,	O
without	O
significant	O
lesions	O
.	O
Right	O
coronary	O
artery	O
RCA	O
dominant	O
,	O
highly	O
developed	O
,	O
without	O
lesions	O
.	O
Percutaneous	O
coronary	O
intervention	O
with	O
drug	O
eluting	O
balloon	O
angioplasty	O
on	O
the	O
first	O
diagonal	O
and	O
implantation	O
of	O
two	O
overlapping	O
stents	O
BioFreedom	O
in	O
the	O
proximal	O
and	O
middle	O
RCA	O
,	O
recommending	O
6	O
months	O
of	O
dual	O
antiplatelet	O
therapy	O
,	O
although	O
with	O
the	O
possibility	O
of	O
suspending	O
it	O
one	O
month	O
after	O
the	O
procedure	O
.	O
Blood	O
tests	O
May	O
2019	O
Glucose	O
99	O
mg	O
dl	O
.	O
Renal	O
function	O
preserved	O
creatinine	O
0	O
.	O
87	O
mg	O
dl	O
with	O
electrolytes	O
in	O
range	O
.	O
Urine	O
sediment	O
and	O
urine	O
electrolytes	O
without	O
alterations	O
.	O
Lipid	O
profile	O
triglycerides	O
55	O
mg	O
dl	O
,	O
cholesterol	O
93	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
48	O
mg	O
dl	O
,	O
LDL	O
cholesterol	O
34	O
mg	O
dl	O
.	O
Transaminases	O
and	O
cholestasis	O
enzymes	O
in	O
range	O
.	O
CPK	O
not	O
elevated	O
139	O
U	O
l	O
.	O
Haemogram	O
and	O
coagulation	O
without	O
alterations	O
.	O
CLINICAL	O
EVOLUTION	O
After	O
discussing	O
the	O
different	O
diagnostic	O
and	O
therapeutic	O
options	O
with	O
the	O
patient	O
,	O
it	O
was	O
decided	O
on	O
the	O
first	O
visit	O
to	O
request	O
an	O
echocardiography	O
,	O
paying	O
special	O
attention	O
to	O
ventricular	O
function	O
,	O
and	O
an	O
electrocardiographic	O
stress	O
test	O
for	O
diagnostic	O
to	O
assess	O
the	O
presence	O
of	O
silent	O
ischaemia	O
and	O
prognostic	O
purposes	O
.	O
It	O
was	O
also	O
decided	O
at	O
that	O
time	O
to	O
add	O
to	O
the	O
treatment	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
100	O
mg	O
day	O
,	O
atorvastatin	B-FARMACO
40	O
mg	O
day	O
the	O
patient	O
is	O
considered	O
to	O
have	O
established	O
cardiovascular	O
disease	O
due	O
to	O
the	O
presence	O
of	O
coronary	O
calcification	O
and	O
therefore	O
his	O
LDL	O
target	O
is	O
less	O
than	O
70	O
mg	O
dl	O
,	O
bisoprolol	B-FARMACO
5	O
mg	O
day	O
initially	O
at	O
half	O
dose	O
,	O
instructing	O
to	O
start	O
depending	O
on	O
the	O
heart	O
rate	O
at	O
home	O
and	O
omeprazole	B-FARMACO
20	O
mg	O
day	O
.	O
Echocardiography	O
showed	O
preserved	O
left	O
ventricular	O
function	O
LVEF	O
60	O
with	O
no	O
alterations	O
in	O
segmental	O
contractility	O
.	O
On	O
the	O
other	O
hand	O
,	O
in	O
the	O
stress	O
test	O
the	O
patient	O
presented	O
electrocardiogram	O
ECG	O
changes	O
suggestive	O
of	O
myocardial	O
ischaemia	O
,	O
although	O
at	O
high	O
load	O
,	O
without	O
clinical	O
chest	O
pain	O
and	O
reaching	O
11	O
.	O
2	O
METS	O
,	O
so	O
it	O
is	O
considered	O
a	O
low	O
risk	O
exercise	O
test	O
with	O
a	O
good	O
prognosis	O
.	O
After	O
reviewing	O
the	O
information	O
provided	O
by	O
the	O
complementary	O
tests	O
and	O
again	O
discussing	O
the	O
management	O
options	O
with	O
the	O
patient	O
,	O
it	O
was	O
decided	O
,	O
due	O
to	O
the	O
presence	O
of	O
coronary	O
calcification	O
and	O
the	O
ischaemia	O
data	O
in	O
the	O
treadmill	O
test	O
,	O
to	O
request	O
a	O
coronary	O
angiography	O
,	O
with	O
special	O
emphasis	O
on	O
the	O
need	O
for	O
surgery	O
in	O
the	O
short	O
medium	O
term	O
due	O
to	O
prostate	O
adenocarcinoma	O
,	O
with	O
respect	O
to	O
the	O
need	O
for	O
percutaneous	O
revascularisation	O
and	O
subsequent	O
double	O
antiplatelet	O
therapy	O
.	O
Coronary	O
angiography	O
showed	O
severe	O
stenosis	O
in	O
the	O
proximal	O
and	O
middle	O
LAD	O
and	O
in	O
the	O
first	O
diagonal	O
branch	O
,	O
treated	O
with	O
implantation	O
of	O
two	O
overlapping	O
drug	O
eluting	O
stents	O
in	O
the	O
proximal	O
and	O
middle	O
LAD	O
and	O
drug	O
eluting	O
balloon	O
angioplasty	O
in	O
the	O
diagonal	O
branch	O
.	O
Biofreedom	O
stents	O
were	O
selected	O
,	O
allowing	O
,	O
if	O
deemed	O
necessary	O
,	O
interruption	O
of	O
the	O
double	O
antiplatelet	O
therapy	O
one	O
month	O
after	O
implantation	O
,	O
to	O
allow	O
,	O
in	O
this	O
case	O
,	O
to	O
perform	O
the	O
surgery	O
required	O
by	O
the	O
prostatic	O
pathology	O
without	O
increasing	O
either	O
the	O
risk	O
of	O
stent	O
thrombosis	O
or	O
bleeding	O
in	O
the	O
perioperative	O
period	O
.	O
Treatment	O
was	O
therefore	O
started	O
with	O
clopidogrel	B-FARMACO
75	O
mg	O
day	O
.	O
The	O
patient	O
's	O
subsequent	O
evolution	O
has	O
been	O
good	O
.	O
There	O
were	O
no	O
complications	O
arising	O
from	O
the	O
procedure	O
and	O
he	O
has	O
remained	O
asymptomatic	O
from	O
the	O
cardiological	O
point	O
of	O
view	O
.	O
He	O
has	O
an	O
excellent	O
control	O
of	O
cardiovascular	O
risk	O
factors	O
after	O
treatment	O
adjustment	O
,	O
being	O
within	O
the	O
LDL	O
targets	O
which	O
went	O
from	O
107	O
to	O
34	O
mg	O
dl	O
.	O
He	O
is	O
currently	O
awaiting	O
the	O
end	O
of	O
a	O
month	O
of	O
double	O
antiplatelet	O
therapy	O
with	O
ASA	B-FARMACO
clopidogrel	I-FARMACO
,	O
and	O
then	O
only	O
simple	O
antiplatelet	O
therapy	O
with	O
ASA	O
and	O
radical	O
prostatectomy	O
.	O
DIAGNOSIS	O
Asymptomatic	O
coronary	O
artery	O
disease	O
with	O
evidence	O
of	O
silent	O
ischaemia	O
.	O
Single	O
vessel	O
disease	O
severe	O
stenosis	O
in	O
proximal	O
and	O
middle	O
LAD	O
and	O
first	O
diagonal	O
branch	O
.	O
Percutaneous	O
revascularisation	O
drug	O
eluting	O
balloon	O
angioplasty	O
in	O
diagonal	O
branch	O
and	O
implantation	O
of	O
two	O
drug	O
eluting	O
stents	O
.	O
BioFreedom	O
in	O
proximal	O
and	O
mid	O
LAD	O
.	O
Dyslipidaemia	O
.	O
Arterial	O
hypertension	O
.	O
Prostate	O
adenocarcinoma	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
PERSONAL	O
HISTORY	O
No	O
known	O
drug	O
allergies	O
.	O
Active	O
smoker	O
of	O
20	O
cigarettes	O
day	O
cumulative	O
consumption	O
of	O
20	O
packs	O
year	O
.	O
Cardiovascular	O
risk	O
factors	O
hypertension	O
HT	O
and	O
dyslipidaemia	O
.	O
No	O
type	O
2	O
diabetes	O
mellitus	O
DM2	O
.	O
Anxiety	O
depressive	O
syndrome	O
.	O
Surgical	O
intervention	O
left	O
inguinal	O
hernia	O
and	O
appendicitis	O
.	O
Family	O
history	O
of	O
ischaemic	O
heart	O
disease	O
in	O
his	O
father	O
at	O
78	O
years	O
of	O
age	O
.	O
Usual	O
treatment	O
losartan	B-FARMACO
50	O
mg	O
1	O
tablet	O
every	O
24	O
hours	O
,	O
simvastatin	B-FARMACO
40	O
mg	O
1	O
tablet	O
every	O
24	O
hours	O
.	O
CURRENT	O
DISEASE	O
The	O
patient	O
is	O
a	O
47	O
year	O
old	O
man	O
,	O
with	O
the	O
previously	O
described	O
personal	O
history	O
,	O
who	O
one	O
summer	O
morning	O
,	O
while	O
working	O
in	O
his	O
field	O
,	O
presented	O
with	O
an	O
episode	O
of	O
central	O
thoracic	O
pain	O
,	O
with	O
oppressive	O
characteristics	O
,	O
radiating	O
to	O
the	O
throat	O
,	O
accompanied	O
by	O
cold	O
sweating	O
and	O
nausea	O
without	O
vomiting	O
.	O
There	O
were	O
no	O
symptoms	O
of	O
dyspnoea	O
or	O
palpitations	O
.	O
The	O
patient	O
leads	O
an	O
active	O
life	O
.	O
He	O
had	O
never	O
before	O
presented	O
episodes	O
similar	O
to	O
the	O
one	O
that	O
prompted	O
the	O
consultation	O
.	O
No	O
intercurrent	O
infectious	O
conditions	O
or	O
fever	O
.	O
No	O
clinical	O
signs	O
of	O
heart	O
failure	O
.	O
He	O
was	O
attended	O
by	O
the	O
emergency	O
services	O
who	O
found	O
the	O
patient	O
haemodynamically	O
stable	O
with	O
blood	O
pressure	O
BP	O
135	O
85	O
mmHG	O
,	O
heart	O
rate	O
HR	O
84	O
bpm	O
,	O
conscious	O
,	O
oriented	O
and	O
cooperative	O
.	O
An	O
ECG	O
was	O
performed	O
on	O
arrival	O
documenting	O
ST	O
segment	O
elevation	O
of	O
2	O
mm	O
in	O
the	O
inferior	O
aspect	O
and	O
V6	O
,	O
and	O
the	O
patient	O
was	O
transferred	O
urgently	O
to	O
our	O
hospital	O
.	O
The	O
pain	O
subsided	O
during	O
the	O
transfer	O
with	O
sublingual	O
nitroglycerine	B-FARMACO
.	O
On	O
arrival	O
at	O
the	O
emergency	O
department	O
of	O
our	O
hospital	O
,	O
the	O
patient	O
was	O
asymptomatic	O
from	O
the	O
cardiovascular	O
point	O
of	O
view	O
.	O
A	O
new	O
ECG	O
was	O
performed	O
showing	O
normalisation	O
of	O
the	O
electrical	O
changes	O
no	O
ST	O
segment	O
elevation	O
.	O
The	O
patient	O
was	O
monitored	O
and	O
on	O
call	O
cardiology	O
was	O
contacted	O
for	O
urgent	O
assessment	O
.	O
Given	O
that	O
the	O
patient	O
remained	O
clinically	O
and	O
haemodynamically	O
stable	O
,	O
with	O
no	O
changes	O
suggestive	O
of	O
ischaemia	O
on	O
the	O
electrocardiogram	O
and	O
with	O
normal	O
bedside	O
echocardioscopy	O
Vscan	O
,	O
it	O
was	O
decided	O
not	O
to	O
activate	O
the	O
infarction	O
code	O
,	O
and	O
the	O
patient	O
was	O
classified	O
as	O
non	O
ST	O
segment	O
elevation	O
acute	O
coronary	O
syndrome	O
NSTEACS	O
due	O
to	O
transient	O
ST	O
segment	O
elevation	O
.	O
PHYSICAL	O
EXAMINATION	O
When	O
assessed	O
by	O
cardiology	O
,	O
the	O
patient	O
was	O
asymptomatic	O
from	O
the	O
cardiovascular	O
point	O
of	O
view	O
,	O
with	O
no	O
new	O
episodes	O
of	O
chest	O
pain	O
or	O
any	O
other	O
anginal	O
symptoms	O
.	O
Haemodynamically	O
stable	O
with	O
BP	O
125	O
76	O
mmHg	O
,	O
HR	O
79	O
bpm	O
.	O
Eupneic	O
at	O
rest	O
and	O
speech	O
,	O
without	O
supplementary	O
oxygen	O
therapy	O
.	O
Tolerating	O
decubitus	O
at	O
0	O
.	O
Afebrile	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
tones	O
,	O
no	O
audible	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
,	O
without	O
added	O
pathological	O
sounds	O
.	O
Lower	O
limbs	O
no	O
oedema	O
,	O
no	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
with	O
pain	O
sinus	O
rhythm	O
at	O
80	O
bpm	O
,	O
normal	O
axis	O
,	O
PR	O
120	O
ms	O
,	O
narrow	O
QRS	O
with	O
ST	O
segment	O
elevation	O
of	O
maximum	O
2	O
mm	O
in	O
inferior	O
face	O
and	O
V6	O
;	O
1	O
mm	O
ST	O
decrease	O
in	O
V1	O
and	O
aVR	O
with	O
negative	O
T	O
waves	O
in	O
these	O
leads	O
.	O
Chest	O
X	O
ray	O
normal	O
cardiothoracic	O
index	O
.	O
Free	O
costophrenic	O
sinuses	O
.	O
No	O
evidence	O
of	O
pulmonary	O
congestion	O
.	O
No	O
evidence	O
of	O
pneumothorax	O
or	O
consolidation	O
.	O
CBC	O
glucose	O
125	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
05	O
mg	O
dl	O
,	O
ions	O
in	O
normal	O
range	O
.	O
No	O
leukocytosis	O
.	O
Haemoglobin	O
14	O
.	O
2	O
g	O
dl	O
.	O
Platelets	O
235	O
,	O
000	O
.	O
Coagulation	O
without	O
alterations	O
INR	O
1	O
.	O
02	O
.	O
Myocardial	O
damage	O
markers	O
TnTus	O
135	O
580	O
420	O
289	O
ng	O
l	O
.	O
CPK	O
320	O
450	O
177	O
102	O
mU	O
ml	O
.	O
Lipid	O
profile	O
total	O
cholesterol	O
233	O
mg	O
dl	O
,	O
HDL	O
35	O
mg	O
dl	O
,	O
LDL	O
166	O
mg	O
dl	O
,	O
triglycerides	O
156	O
mg	O
dl	O
.	O
Glycated	O
haemoglobin	O
5	O
.	O
1	O
Bedside	O
echocardioscopy	O
left	O
ventricle	O
not	O
appearing	O
dilated	O
,	O
with	O
normal	O
qualitative	O
systolic	O
function	O
55	O
60	O
,	O
without	O
segmental	O
alterations	O
of	O
contractility	O
.	O
Right	O
ventricle	O
with	O
normal	O
qualitative	O
systolic	O
function	O
.	O
Aortic	O
root	O
not	O
dilated	O
sinuses	O
of	O
Valsalva	O
36	O
mm	O
,	O
no	O
flap	O
image	O
visualised	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
,	O
respiratory	O
variations	O
.	O
No	O
pericardial	O
effusion	O
.	O
No	O
valvulopathies	O
of	O
entity	O
are	O
visualized	O
.	O
Echocardiography	O
left	O
atrium	O
of	O
normal	O
dimensions	O
AP	O
37	O
mm	O
,	O
volume	O
19	O
ml	O
m2	O
.	O
Normal	O
mitral	O
valve	O
,	O
with	O
leaflets	O
without	O
organic	O
involvement	O
or	O
insufficiency	O
.	O
Left	O
ventricle	O
with	O
normal	O
volumes	O
DTD	O
49	O
mm	O
,	O
VTD	O
125	O
ml	O
,	O
VTDi	O
70	O
ml	O
m2	O
,	O
VTS	O
55	O
ml	O
.	O
EF	O
59	O
without	O
segmental	O
alterations	O
of	O
contractility	O
.	O
Normal	O
myocardial	O
thickness	O
,	O
with	O
8	O
mm	O
septum	O
and	O
8	O
mm	O
posterior	O
wall	O
.	O
Normal	O
mitral	O
filling	O
pattern	O
with	O
E	O
wave	O
78	O
cm	O
s	O
and	O
A	O
wave	O
45	O
cm	O
s	O
.	O
Trivalve	O
aortic	O
valve	O
,	O
with	O
anatomically	O
normal	O
leaflets	O
,	O
without	O
insufficiency	O
.	O
Sine	O
of	O
Valsalva	O
36	O
mm	O
.	O
Right	O
ventricle	O
of	O
normal	O
dimensions	O
and	O
contractility	O
.	O
TAPSE	O
22	O
mm	O
,	O
tricuspid	O
S	O
"	O
12	O
.	O
7	O
cm	O
s	O
.	O
Tricuspid	O
valve	O
without	O
insufficiency	O
.	O
Pulmonary	O
valve	O
with	O
slight	O
central	O
jet	O
.	O
Normal	O
inferior	O
vena	O
cava	O
with	O
adequate	O
inspiratory	O
collapse	O
.	O
No	O
pericardial	O
effusion	O
.	O
No	O
indirect	O
evidence	O
of	O
pulmonary	O
hypertension	O
PH	O
.	O
Coronary	O
angiography	O
right	O
radial	O
artery	O
.	O
Ectatic	O
right	O
coronary	O
artery	O
RCA	O
with	O
severe	O
stenosis	O
90	O
in	O
its	O
middle	O
segment	O
treated	O
by	O
implantation	O
of	O
a	O
direct	O
drug	O
eluting	O
stent	O
Synergy	O
4	O
x	O
38	O
mm	O
and	O
post	O
dilatation	O
with	O
non	O
compliant	O
balloon	O
4	O
.	O
5	O
x	O
20	O
mm	O
.	O
Mild	O
atheromatosis	O
of	O
the	O
anterior	O
descending	O
artery	O
ADA	O
and	O
circumflex	O
artery	O
ACx	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
cardiology	O
intermediate	O
care	O
unit	O
.	O
During	O
his	O
stay	O
in	O
the	O
unit	O
,	O
his	O
evolution	O
was	O
favourable	O
;	O
he	O
remained	O
haemodynamically	O
stable	O
at	O
all	O
times	O
,	O
with	O
no	O
new	O
episodes	O
of	O
chest	O
pain	O
or	O
electrical	O
changes	O
.	O
Continuous	O
monitoring	O
did	O
not	O
detect	O
any	O
arrhythmic	O
events	O
.	O
Coronary	O
angiography	O
was	O
performed	O
36	O
hours	O
after	O
admission	O
to	O
the	O
unit	O
,	O
revealing	O
a	O
significant	O
lesion	O
in	O
the	O
middle	O
segment	O
of	O
the	O
RCA	O
,	O
which	O
was	O
revascularised	O
by	O
implanting	O
a	O
drug	O
eluting	O
stent	O
and	O
post	O
dilatation	O
with	O
a	O
balloon	O
.	O
The	O
procedure	O
passed	O
without	O
complications	O
.	O
Medical	O
treatment	O
was	O
adjusted	O
during	O
admission	O
,	O
insisting	O
on	O
secondary	O
prevention	O
measures	O
for	O
ischaemic	O
heart	O
disease	O
and	O
,	O
above	O
all	O
,	O
smoking	O
cessation	O
.	O
On	O
discharge	O
he	O
was	O
referred	O
to	O
the	O
cardiac	O
rehabilitation	O
unit	O
,	O
with	O
the	O
following	O
treatment	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
100	O
mg	O
1	O
tablet	O
every	O
24	O
hours	O
,	O
ticagrelor	B-FARMACO
90	O
mg	O
1	O
tablet	O
every	O
12	O
hours	O
,	O
atorvastatin	B-FARMACO
80	O
mg	O
1	O
tablet	O
every	O
24	O
hours	O
,	O
losartan	B-FARMACO
50	O
mg	O
1	O
tablet	O
every	O
24	O
hours	O
,	O
bisoprolol	B-FARMACO
5	O
mg	O
1	O
tablet	O
every	O
24	O
hours	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
1	O
tablet	O
every	O
24	O
hours	O
,	O
sublingual	O
nitroglycerin	B-FARMACO
if	O
chest	O
pain	O
.	O
DIAGNOSIS	O
NSTEACS	O
type	O
transient	O
ST	O
elevation	O
secondary	O
to	O
severe	O
mid	O
RCA	O
lesion	O
revascularised	O
by	O
1	O
drug	O
eluting	O
stent	O
.	O
Preserved	O
ventricular	O
function	O
.	O
Hypertension	O
and	O
dyslipidaemia	O
.	O
Smoker	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
PERSONAL	O
HISTORY	O
Independent	O
in	O
basic	O
and	O
instrumental	O
activities	O
of	O
daily	O
living	O
.	O
Active	O
life	O
.	O
Works	O
in	O
the	O
countryside	O
.	O
Toxic	O
habits	O
active	O
smoker	O
of	O
1	O
pack	O
a	O
day	O
20	O
cigarettes	O
day	O
since	O
the	O
age	O
of	O
17	O
.	O
No	O
history	O
of	O
hypertension	O
,	O
diabetes	O
or	O
dyslipidaemia	O
.	O
No	O
history	O
of	O
cardiovascular	O
disease	O
.	O
Other	O
medical	O
history	O
chronic	O
pharyngitis	O
,	O
herniated	O
disc	O
at	O
C5	O
C6	O
and	O
C7	O
D1	O
.	O
No	O
previous	O
surgical	O
interventions	O
.	O
No	O
medical	O
treatment	O
at	O
present	O
.	O
CURRENT	O
ILLNESS	O
She	O
initially	O
consulted	O
the	O
emergency	O
department	O
of	O
our	O
hospital	O
for	O
symptoms	O
consisting	O
of	O
diffuse	O
abdominal	O
pain	O
,	O
persistent	O
nausea	O
and	O
vomiting	O
despite	O
home	O
treatment	O
.	O
As	O
associated	O
symptomatology	O
,	O
she	O
reported	O
a	O
non	O
thermometric	O
dysthermic	O
sensation	O
of	O
months	O
of	O
evolution	O
together	O
with	O
associated	O
diaphoresis	O
,	O
predominantly	O
at	O
night	O
.	O
The	O
complementary	O
tests	O
performed	O
were	O
suggestive	O
of	O
acute	O
pancreatitis	O
increased	O
amylase	O
in	O
blood	O
and	O
urine	O
,	O
so	O
a	O
CT	O
scan	O
of	O
the	O
abdomen	O
with	O
contrast	O
showed	O
findings	O
compatible	O
with	O
mild	O
pancreatitis	O
.	O
At	O
the	O
same	O
time	O
,	O
the	O
images	O
obtained	O
at	O
the	O
lower	O
thoracic	O
level	O
showed	O
a	O
hypodense	O
image	O
with	O
well	O
defined	O
borders	O
located	O
in	O
the	O
left	O
atrium	O
dependent	O
on	O
the	O
interatrial	O
septum	O
compatible	O
with	O
an	O
intracardiac	O
mass	O
,	O
and	O
atrial	O
myxoma	O
was	O
considered	O
the	O
first	O
possibility	O
.	O
Based	O
on	O
these	O
findings	O
,	O
the	O
patient	O
was	O
assessed	O
by	O
cardiology	O
,	O
who	O
decided	O
to	O
admit	O
the	O
patient	O
to	O
our	O
care	O
to	O
continue	O
the	O
study	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
BP	O
163	O
95	O
.	O
Heart	O
rate	O
HR	O
60	O
beats	O
per	O
minute	O
.	O
Baseline	O
O2	O
saturation	O
98	O
by	O
pulse	O
oximetry	O
.	O
Acceptable	O
general	O
condition	O
.	O
Conscious	O
,	O
oriented	O
and	O
cooperative	O
.	O
Haemodynamically	O
stable	O
.	O
Eupneic	O
at	O
rest	O
.	O
Normal	O
skin	O
colour	O
and	O
no	O
lesions	O
,	O
with	O
increased	O
body	O
temperature	O
temperature	O
38	O
C	O
.	O
No	O
palpable	O
lymph	O
nodes	O
in	O
the	O
cervical	O
,	O
axillary	O
,	O
inguinal	O
or	O
other	O
areas	O
.	O
No	O
jugular	O
venous	O
engorgement	O
.	O
Cardiac	O
auscultation	O
with	O
rhythmic	O
tones	O
at	O
a	O
good	O
frequency	O
with	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
with	O
preserved	O
vesicular	O
murmur	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
,	O
with	O
pain	O
on	O
palpation	O
in	O
the	O
epigastrium	O
and	O
both	O
hypochondrium	O
.	O
Purphy	O
negative	O
.	O
Hydro	O
aerial	O
sounds	O
were	O
preserved	O
on	O
abdominal	O
auscultation	O
.	O
No	O
masses	O
or	O
visceromegaly	O
palpable	O
.	O
Lower	O
limbs	O
without	O
malleolar	O
oedema	O
.	O
Pulses	O
preserved	O
and	O
symmetrical	O
.	O
COMPLEMENTARY	O
TESTS	O
Precios	O
bill	O
'	O
Pun	O
a	O
Haemogram	O
red	O
blood	O
cells	O
4	O
,	O
350	O
,	O
000	O
ul	O
.	O
Dutch	O
anall	O
interpreyesase	O
reiter	O
a	O
MCV	O
97	O
.	O
2	O
fl	O
.	O
MCH	O
33	O
.	O
6	O
pg	O
Leukocytes	O
10090	O
ul	O
.	O
Neutrophils	O
9070	O
ul	O
89	O
.	O
9	O
of	O
the	O
total	O
.	O
Lymphocytes	O
390	O
ul	O
6	O
of	O
the	O
total	O
.	O
Rest	O
of	O
the	O
differential	O
count	O
without	O
alterations	O
.	O
Atacados	O
WAME	O
WAME	O
prin	O
F	O
a	O
Coagulation	O
INR	O
0	O
.	O
97	O
.	O
En	O
Independa	O
graasete	O
25	O
a	O
Blood	O
biochemistry	O
not	O
carried	O
out	O
on	O
an	O
empty	O
stomach	O
glycaemia	O
168	O
mg	O
dl	O
.	O
Ex	O
serviciosology	O
discustendol	O
a	O
Creatinine	O
0	O
.	O
62	O
mg	O
dl	O
.	O
Dices	O
invitacinti0P	O
dual	O
a	O
Potassium	O
4	O
.	O
2	O
mEq	O
l	O
.	O
Calcium	O
9	O
.	O
6	O
mg	O
dl	O
.	O
Boparas	O
ex	O
dual	O
a	O
Fridqournal	O
dual	O
a	O
Synopsisque	O
revil	O
exzuki	O
dual	O
a	O
Total	O
bilirubin	O
0	O
.	O
3	O
mg	O
dl	O
.	O
Asi	O
as8	O
ex	O
dual	O
a	O
CPK	O
182	O
U	O
l	O
.	O
TnThs	O
171	O
ng	O
l	O
2nd	O
a	O
posteriori	O
determination	O
250	O
ng	O
l	O
.	O
CRP	O
54	O
.	O
Urinalysis	O
density	O
1041	O
.	O
pH	O
6	O
.	O
Proteins	O
20	O
mg	O
dl	O
.	O
Glucose	O
0	O
.	O
Ketone	O
bodies	O
.	O
Bilirubin	O
.	O
Nitrites	O
.	O
Red	O
blood	O
cells	O
.	O
Leucocytes	O
.	O
Alpha	O
amylase	O
1109	O
.	O
Chest	O
X	O
ray	O
poorly	O
inspired	O
.	O
Enlargement	O
of	O
the	O
bronchovascular	O
tract	O
.	O
No	O
increase	O
in	O
cardiac	O
silhouette	O
,	O
with	O
normal	O
cardiothoracic	O
index	O
.	O
Electrocardiogram	O
ECG	O
on	O
admission	O
sinus	O
rhythm	O
at	O
68	O
beats	O
per	O
minute	O
.	O
No	O
pathological	O
increase	O
in	O
voltage	O
or	O
P	O
wave	O
duration	O
.	O
160	O
msec	O
PR	O
interval	O
.	O
Narrow	O
QRS	O
of	O
80	O
msec	O
duration	O
,	O
with	O
axis	O
at	O
30o	O
,	O
with	O
morphology	O
of	O
incomplete	O
right	O
bundle	O
branch	O
block	O
.	O
No	O
pathological	O
alterations	O
of	O
repolarisation	O
were	O
observed	O
.	O
QTc	O
of	O
404	O
msec	O
.	O
Contrast	O
enhanced	O
CT	O
scan	O
of	O
the	O
abdomen	O
and	O
pelvis	O
slight	O
enlargement	O
of	O
the	O
pancreatic	O
head	O
and	O
uncinate	O
process	O
with	O
infiltration	O
of	O
the	O
adjacent	O
fat	O
,	O
without	O
evidence	O
of	O
collections	O
,	O
suggestive	O
of	O
mild	O
acute	O
pancreatitis	O
.	O
Hepatic	O
steatosis	O
,	O
with	O
several	O
simple	O
cysts	O
.	O
Aliased	O
gallbladder	O
,	O
without	O
intrahepatic	O
or	O
extrahepatic	O
bile	O
duct	O
dilatation	O
.	O
Spleen	O
without	O
pathological	O
alterations	O
.	O
No	O
intra	O
abdominal	O
free	O
fluid	O
is	O
seen	O
.	O
Hypodense	O
mass	O
inside	O
the	O
left	O
atrium	O
of	O
about	O
4	O
cm	O
.	O
This	O
lesion	O
has	O
well	O
defined	O
borders	O
,	O
spherical	O
morphology	O
,	O
with	O
a	O
calcific	O
point	O
inside	O
and	O
a	O
pedicle	O
that	O
depends	O
on	O
the	O
interatrial	O
septum	O
.	O
The	O
mass	O
prolapses	O
towards	O
the	O
left	O
ventricle	O
,	O
as	O
can	O
be	O
seen	O
in	O
successive	O
slices	O
.	O
Transthoracic	O
echocardiography	O
left	O
ventricle	O
neither	O
dilated	O
nor	O
hypertrophic	O
LVED	O
50	O
mm	O
;	O
IVS	O
10	O
mm	O
;	O
PP	O
10	O
mm	O
with	O
preserved	O
global	O
systolic	O
function	O
LVEF	O
59	O
by	O
Simpson	O
.	O
No	O
segmental	O
alterations	O
of	O
contractility	O
were	O
observed	O
.	O
Aortic	O
root	O
not	O
dilated	O
.	O
Trivalve	O
aortic	O
valve	O
with	O
mild	O
degenerative	O
involvement	O
.	O
Dilated	O
left	O
atrium	O
volume	O
81	O
cm3	O
,	O
showing	O
a	O
pedunculated	O
mass	O
with	O
well	O
defined	O
borders	O
anchored	O
at	O
the	O
level	O
of	O
the	O
fossa	O
ovalis	O
,	O
measuring	O
50	O
x	O
26	O
mm	O
,	O
which	O
prolapses	O
towards	O
the	O
ventricle	O
in	O
diastole	O
,	O
dragging	O
the	O
anterior	O
mitral	O
leaflet	O
.	O
These	O
findings	O
suggest	O
left	O
atrial	O
myxoma	O
as	O
the	O
first	O
diagnostic	O
option	O
.	O
Non	O
dilated	O
right	O
chambers	O
,	O
with	O
a	O
normofunctioning	O
right	O
ventricle	O
TAPSE	O
25	O
mm	O
.	O
Doppler	O
study	O
with	O
normal	O
transmitral	O
flows	O
Vel	O
.	O
E	O
1	O
.	O
09	O
m	O
s	O
;	O
Vel	O
A	O
0	O
.	O
9	O
m	O
s	O
,	O
without	O
pathological	O
increase	O
in	O
pressure	O
gradients	O
mean	O
gradient	O
3	O
mmHg	O
.	O
Mitral	O
insufficiency	O
grade	O
II	O
with	O
jet	O
projected	O
towards	O
the	O
lateral	O
wall	O
of	O
the	O
left	O
atrium	O
.	O
Aortic	O
valve	O
with	O
normal	O
antegrade	O
flows	O
max	O
.	O
velocity	O
1	O
.	O
15	O
m	O
s	O
,	O
with	O
no	O
evidence	O
of	O
valvular	O
insufficiency	O
.	O
Coronary	O
angiography	O
left	O
dominance	O
,	O
without	O
lesions	O
in	O
coronary	O
arteries	O
.	O
Pathological	O
anatomy	O
of	O
the	O
resected	O
mass	O
nodular	O
formation	O
of	O
26	O
g	O
and	O
4	O
.	O
5	O
x	O
4	O
x	O
3	O
cm	O
in	O
size	O
.	O
Smooth	O
,	O
shiny	O
and	O
brownish	O
surface	O
.	O
Serial	O
sections	O
show	O
a	O
heterogeneous	O
surface	O
with	O
blackish	O
and	O
other	O
irregular	O
whitish	O
areas	O
,	O
including	O
some	O
cystic	O
areas	O
histologically	O
compatible	O
with	O
atrial	O
myxoma	O
with	O
large	O
areas	O
of	O
haemorrhage	O
and	O
thrombosis	O
.	O
CLINICAL	O
EVOLUTION	O
When	O
atrial	O
myxoma	O
was	O
suspected	O
in	O
the	O
CT	O
scan	O
,	O
studies	O
were	O
completed	O
with	O
transthoracic	O
echocardiography	O
and	O
coronary	O
angiography	O
.	O
With	O
the	O
presumptive	O
diagnosis	O
of	O
left	O
atrial	O
myxoma	O
,	O
the	O
case	O
was	O
discussed	O
with	O
cardiovascular	O
surgery	O
,	O
who	O
advised	O
deferring	O
surgery	O
until	O
the	O
pancreatic	O
symptoms	O
were	O
controlled	O
.	O
During	O
the	O
first	O
few	O
days	O
of	O
admission	O
,	O
the	O
patient	O
remained	O
stable	O
from	O
a	O
clinical	O
and	O
haemodynamic	O
point	O
of	O
view	O
.	O
There	O
was	O
a	O
progressive	O
improvement	O
in	O
the	O
abdominal	O
symptoms	O
,	O
which	O
allowed	O
for	O
the	O
reintroduction	O
of	O
an	O
oral	O
diet	O
,	O
without	O
incident	O
.	O
A	O
new	O
abdominal	O
CT	O
scan	O
was	O
performed	O
,	O
which	O
ruled	O
out	O
late	O
complications	O
derived	O
from	O
the	O
pancreatic	O
symptoms	O
.	O
In	O
view	O
of	O
the	O
evolutionary	O
course	O
,	O
surgery	O
was	O
performed	O
on	O
the	O
14th	O
day	O
of	O
admission	O
.	O
Opening	O
was	O
performed	O
by	O
conventional	O
median	O
sternotomy	O
and	O
,	O
accessing	O
through	O
the	O
right	O
atriotomy	O
,	O
the	O
left	O
atrial	O
mass	O
was	O
resected	O
along	O
with	O
its	O
pedicle	O
,	O
closing	O
the	O
residual	O
septal	O
defect	O
by	O
direct	O
suture	O
.	O
Pathological	O
anatomy	O
confirms	O
the	O
diagnosis	O
of	O
atrial	O
myxoma	O
,	O
with	O
extensive	O
areas	O
of	O
haemorrhage	O
and	O
thrombosis	O
.	O
The	O
evolution	O
after	O
surgery	O
was	O
long	O
and	O
torpid	O
.	O
His	O
stay	O
in	O
the	O
post	O
surgical	O
unit	O
was	O
marked	O
by	O
the	O
appearance	O
of	O
supraventricular	O
tachycardia	O
at	O
130	O
bpm	O
compatible	O
with	O
atrial	O
flutter	O
,	O
with	O
recurrent	O
behaviour	O
despite	O
several	O
attempts	O
at	O
electrical	O
cardioversion	O
,	O
some	O
of	O
which	O
caused	O
the	O
tachyarrhythmia	O
to	O
temporarily	O
degenerate	O
into	O
atrial	O
fibrillation	O
.	O
Rhythm	O
control	O
was	O
attempted	O
with	O
antiarrhythmic	O
treatment	O
amiodarone	B-FARMACO
,	O
but	O
had	O
to	O
be	O
discontinued	O
due	O
to	O
the	O
appearance	O
of	O
complete	O
atrioventricular	O
block	O
.	O
Optimal	O
ventricular	O
rate	O
control	O
is	O
also	O
not	O
achieved	O
by	O
adding	O
beta	O
blockers	O
to	O
the	O
treatment	O
.	O
Given	O
that	O
the	O
ventricular	O
response	O
to	O
the	O
arrhythmia	O
was	O
well	O
tolerated	O
by	O
the	O
patient	O
,	O
it	O
was	O
decided	O
to	O
discharge	O
the	O
patient	O
to	O
the	O
cardiology	O
ward	O
to	O
optimise	O
treatment	O
.	O
The	O
situation	O
was	O
discussed	O
with	O
the	O
arrhythmology	O
department	O
and	O
an	O
electrophysiological	O
study	O
was	O
scheduled	O
,	O
which	O
revealed	O
counterclockwise	O
atrial	O
flutter	O
,	O
and	O
successful	O
ablation	O
of	O
the	O
cavotricuspid	O
isthmus	O
was	O
performed	O
.	O
After	O
completing	O
the	O
procedure	O
,	O
together	O
with	O
the	O
cessation	O
of	O
the	O
arrhythmia	O
,	O
loss	O
of	O
sinus	O
leakage	O
above	O
40	O
bpm	O
was	O
observed	O
.	O
This	O
situation	O
required	O
the	O
placement	O
of	O
a	O
transient	O
pacing	O
device	O
and	O
the	O
implantation	O
of	O
a	O
permanent	O
pacemaker	O
DDDR	O
was	O
programmed	O
.	O
After	O
implantation	O
,	O
the	O
patient	O
evolved	O
satisfactorily	O
and	O
was	O
discharged	O
a	O
few	O
days	O
after	O
implantation	O
.	O
DIAGNOSIS	O
Left	O
atrial	O
myxoma	O
.	O
Mild	O
acute	O
pancreatitis	O
RANSON	O
0	O
.	O
Counterclockwise	O
isthmic	O
atrial	O
flutter	O
with	O
successful	O
ablation	O
.	O
Transient	O
atrial	O
fibrillation	O
in	O
immediate	O
postoperative	O
period	O
CHA2DS2	O
VASc	O
1	O
;	O
HAS	O
BLED	O
1	O
.	O
Sinus	O
dysfunction	O
with	O
need	O
for	O
DDDR	O
permanent	O
pacemaker	O
implantation	O
,	O
in	O
sinus	O
rhythm	O
at	O
discharge	O
.	O

HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
We	O
present	O
the	O
case	O
of	O
a	O
4	O
year	O
old	O
female	O
patient	O
,	O
under	O
follow	O
up	O
by	O
her	O
paediatrician	O
,	O
who	O
was	O
found	O
to	O
have	O
a	O
systolic	O
murmur	O
at	O
the	O
last	O
check	O
up	O
.	O
She	O
had	O
no	O
relevant	O
history	O
normal	O
vaginal	O
delivery	O
and	O
no	O
incidents	O
in	O
previous	O
examinations	O
.	O
The	O
parents	O
were	O
asked	O
about	O
unusual	O
signs	O
symptoms	O
in	O
recent	O
months	O
.	O
Although	O
there	O
was	O
no	O
limitation	O
in	O
terms	O
of	O
exercise	O
"	O
she	O
plays	O
in	O
the	O
park	O
with	O
the	O
other	O
children	O
"	O
,	O
in	O
the	O
last	O
few	O
months	O
they	O
noticed	O
that	O
she	O
was	O
more	O
tired	O
.	O
They	O
also	O
report	O
that	O
"	O
when	O
she	O
runs	O
she	O
sometimes	O
stops	O
because	O
of	O
coughing	O
fits	O
"	O
.	O
No	O
sweating	O
and	O
or	O
noticeable	O
tachypnoea	O
in	O
the	O
context	O
of	O
meals	O
.	O
Adequate	O
nutrition	O
,	O
with	O
a	O
good	O
natural	O
weight	O
curve	O
.	O
Good	O
night	O
's	O
rest	O
.	O
No	O
dizziness	O
or	O
loss	O
of	O
consciousness	O
.	O
No	O
complaints	O
of	O
chest	O
pain	O
.	O
Inquiries	O
were	O
made	O
about	O
a	O
history	O
of	O
heart	O
disease	O
in	O
the	O
family	O
,	O
which	O
the	O
parents	O
denied	O
.	O
At	O
the	O
consultation	O
,	O
the	O
child	O
was	O
in	O
an	O
acceptable	O
general	O
state	O
.	O
Skin	O
and	O
mucous	O
membranes	O
were	O
well	O
coloured	O
,	O
weight	O
and	O
height	O
P75	O
.	O
Weight	O
and	O
height	O
in	O
P75	O
.	O
Blood	O
pressure	O
90	O
60	O
mmHg	O
,	O
with	O
no	O
differences	O
between	O
members	O
of	O
the	O
family	O
.	O
Saturation	O
of	O
100	O
without	O
oxygen	O
therapy	O
.	O
On	O
auscultation	O
,	O
systolic	O
murmur	O
III	O
VI	O
predominantly	O
in	O
mitral	O
focus	O
with	O
irradiation	O
to	O
the	O
axilla	O
.	O
No	O
crackles	O
or	O
other	O
noises	O
added	O
to	O
the	O
pulmonary	O
auscultation	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
,	O
without	O
hepatomegaly	O
or	O
hepatalgia	O
.	O
Lower	O
limbs	O
with	O
good	O
distal	O
perfusion	O
and	O
preserved	O
and	O
symmetrical	O
pulses	O
.	O
The	O
patient	O
was	O
referred	O
to	O
the	O
local	O
cardiology	O
department	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
tests	O
renal	O
function	O
preserved	O
creatinine	O
0	O
.	O
6	O
mg	O
dl	O
with	O
ions	O
in	O
range	O
.	O
Liver	O
profile	O
without	O
alterations	O
.	O
NT	O
proBNP	O
600	O
pg	O
l	O
.	O
CBC	O
98	O
.	O
Haemogram	O
anodyne	O
,	O
with	O
white	O
and	O
red	O
series	O
and	O
platelets	O
in	O
range	O
.	O
Coagulation	O
without	O
findings	O
.	O
Chest	O
X	O
ray	O
increased	O
cardiothoracic	O
index	O
.	O
SCF	O
free	O
.	O
No	O
condensation	O
or	O
any	O
other	O
noticeable	O
congestion	O
.	O
Electrocardiogram	O
ECG	O
sinus	O
rhythm	O
at	O
100	O
bpm	O
.	O
Normal	O
axis	O
.	O
Normal	O
PR	O
.	O
Narrow	O
QRS	O
with	O
anterolateral	O
Q	O
wave	O
.	O
ST	O
elevation	O
in	O
precordial	O
leads	O
.	O
Transthoracic	O
echocardiography	O
TTE	O
situs	O
solitus	O
.	O
Atrioventricular	O
AV	O
concordance	O
.	O
Normal	O
venous	O
drainage	O
.	O
Inferior	O
vena	O
cava	O
IVC	O
not	O
dilated	O
with	O
adequate	O
respiratory	O
variations	O
.	O
No	O
effusion	O
.	O
Dilated	O
left	O
atrium	O
LA	O
.	O
Dilated	O
left	O
ventricle	O
LV	O
with	O
systolic	O
function	O
at	O
lower	O
limits	O
LVEF	O
by	O
Simpson	O
and	O
Teich	O
of	O
50	O
.	O
Moderate	O
severe	O
mitral	O
insufficiency	O
MI	O
with	O
anterior	O
leaflet	O
prolapse	O
.	O
Hyperechogenic	O
anterior	O
subvalvular	O
apparatus	O
,	O
suggestive	O
of	O
fibrosis	O
.	O
Trivalve	O
aortic	O
valve	O
with	O
good	O
opening	O
and	O
no	O
aortic	O
insufficiency	O
AIo	O
.	O
The	O
large	O
vessel	O
view	O
shows	O
dilatation	O
of	O
the	O
ostium	O
of	O
the	O
right	O
coronary	O
artery	O
RCA	O
,	O
with	O
a	O
proximal	O
course	O
of	O
the	O
artery	O
of	O
good	O
calibre	O
.	O
The	O
LMCA	O
ostium	O
is	O
absent	O
,	O
with	O
proximal	O
fine	O
calibre	O
hypoplastic	O
anterior	O
descending	O
artery	O
ADA	O
and	O
circumflex	O
artery	O
ACx	O
.	O
Retrograde	O
flow	O
in	O
left	O
branches	O
by	O
colour	O
Doppler	O
.	O
No	O
communication	O
with	O
the	O
pulmonary	O
artery	O
is	O
visualised	O
.	O
Right	O
ventricle	O
RV	O
not	O
dilated	O
with	O
preserved	O
systolic	O
function	O
.	O
Trivial	O
tricuspid	O
insufficiency	O
TI	O
jet	O
with	O
no	O
entity	O
gradient	O
to	O
estimate	O
pulmonary	O
pressures	O
.	O
Angiographic	O
study	O
procedure	O
performed	O
under	O
general	O
anaesthesia	O
.	O
Right	O
femoral	O
access	O
.	O
Contrast	O
injection	O
is	O
performed	O
and	O
anterograde	O
filling	O
of	O
the	O
RCA	O
is	O
observed	O
,	O
which	O
is	O
dominant	O
.	O
The	O
left	O
coronary	O
tree	O
is	O
not	O
filled	O
at	O
first	O
.	O
Late	O
and	O
retrograde	O
filling	O
of	O
the	O
left	O
tree	O
,	O
from	O
collateral	O
branches	O
provided	O
by	O
the	O
right	O
tree	O
.	O
ACx	O
and	O
ADA	O
converge	O
proximally	O
in	O
a	O
blind	O
cul	O
de	O
sac	O
,	O
with	O
no	O
connection	O
to	O
the	O
IVC	O
,	O
which	O
is	O
absent	O
.	O
Conclusion	O
diagnosis	O
of	O
congenital	O
atresia	O
of	O
the	O
LMCA	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
assessed	O
in	O
cardiology	O
,	O
where	O
the	O
anamnesis	O
was	O
similar	O
to	O
that	O
carried	O
out	O
in	O
her	O
health	O
centre	O
.	O
An	O
ECG	O
was	O
initially	O
performed	O
which	O
was	O
clearly	O
pathological	O
see	O
complementary	O
tests	O
.	O
Transthoracic	O
echocardiography	O
showed	O
,	O
as	O
the	O
most	O
significant	O
finding	O
,	O
mitral	O
regurgitation	O
of	O
entity	O
by	O
colour	O
Doppler	O
.	O
The	O
fibrosis	O
of	O
the	O
subvalvular	O
apparatus	O
is	O
striking	O
.	O
The	O
left	O
ventricle	O
is	O
dilated	O
but	O
systolic	O
function	O
is	O
preserved	O
.	O
A	O
search	O
for	O
the	O
origin	O
of	O
the	O
coronary	O
arteries	O
was	O
performed	O
in	O
the	O
ECP	O
large	O
vessel	O
plane	O
,	O
and	O
the	O
origin	O
of	O
the	O
dilated	O
RCA	O
was	O
found	O
,	O
without	O
visualising	O
the	O
origin	O
of	O
the	O
LMCA	O
.	O
Given	O
these	O
findings	O
,	O
the	O
patient	O
was	O
referred	O
to	O
a	O
tertiary	O
referral	O
hospital	O
.	O
Aortography	O
was	O
scheduled	O
by	O
the	O
haemodynamics	O
team	O
and	O
the	O
procedure	O
was	O
performed	O
under	O
general	O
anaesthesia	O
.	O
On	O
injecting	O
the	O
contrast	O
agent	O
,	O
the	O
ACD	O
was	O
found	O
to	O
be	O
filled	O
in	O
an	O
anterograde	O
manner	O
,	O
with	O
an	O
initial	O
absence	O
of	O
filling	O
of	O
the	O
left	O
aortic	O
tree	O
.	O
Late	O
retrograde	O
filling	O
of	O
left	O
branches	O
from	O
the	O
RCA	O
,	O
which	O
provides	O
collateral	O
circulation	O
.	O
Poor	O
tolerance	O
to	O
the	O
procedure	O
,	O
with	O
arterial	O
hypotension	O
and	O
bradycardia	O
requiring	O
vasoactive	O
inothropic	O
support	O
.	O
Urgent	O
echocardiography	O
showed	O
acute	O
left	O
ventricular	O
dysfunction	O
,	O
requiring	O
mechanical	O
circulatory	O
support	O
.	O
Haemodynamic	O
and	O
echocardiographic	O
improvement	O
in	O
the	O
first	O
30	O
minutes	O
,	O
with	O
subsequent	O
transfer	O
to	O
the	O
intensive	O
care	O
unit	O
ICU	O
for	O
close	O
monitoring	O
and	O
stabilisation	O
.	O
The	O
patient	O
remained	O
in	O
the	O
ICU	O
for	O
15	O
days	O
with	O
progressive	O
clinical	O
improvement	O
.	O
After	O
stabilisation	O
,	O
the	O
patient	O
was	O
proposed	O
and	O
accepted	O
for	O
revascularisation	O
surgery	O
.	O
A	O
coronary	O
CT	O
scan	O
was	O
requested	O
beforehand	O
for	O
better	O
pre	O
surgical	O
characterisation	O
of	O
the	O
anatomy	O
.	O
DIAGNOSIS	O
Congenital	O
atresia	O
of	O
the	O
left	O
main	O
coronary	O
artery	O
.	O
Severe	O
ischaemic	O
mitral	O
regurgitation	O
in	O
this	O
context	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
PERSONAL	O
HISTORY	O
No	O
known	O
drug	O
allergies	O
.	O
No	O
toxic	O
habits	O
.	O
Cardiovascular	O
risk	O
factors	O
regularly	O
controlled	O
hypertension	O
.	O
No	O
known	O
dyslipidaemia	O
or	O
diabetes	O
.	O
Overweight	O
.	O
No	O
medical	O
or	O
surgical	O
history	O
of	O
interest	O
.	O
Usual	O
treatment	O
losartan	B-FARMACO
50	O
mg	O
hydrochlorothiazide	B-FARMACO
12	O
.	O
5	O
mg	O
1	O
tablet	O
every	O
24	O
hours	O
.	O
CURRENT	O
ILLNESS	O
A	O
53	O
year	O
old	O
man	O
with	O
hypertension	O
of	O
approximately	O
two	O
years	O
of	O
evolution	O
with	O
poor	O
control	O
at	O
home	O
,	O
who	O
consulted	O
the	O
emergency	O
department	O
for	O
clinical	O
pain	O
described	O
as	O
shooting	O
oppressive	O
in	O
the	O
interscapular	O
region	O
radiating	O
towards	O
the	O
anterior	O
region	O
of	O
the	O
thorax	O
and	O
internal	O
face	O
of	O
the	O
left	O
upper	O
limb	O
on	O
moderate	O
high	O
intensity	O
exertion	O
,	O
gradually	O
subsiding	O
with	O
rest	O
,	O
for	O
the	O
last	O
2	O
weeks	O
.	O
He	O
also	O
reported	O
a	O
slight	O
sensation	O
of	O
dyspnoea	O
,	O
without	O
palpitations	O
or	O
vegetative	O
cortex	O
,	O
and	O
denied	O
previous	O
similar	O
episodes	O
.	O
After	O
performing	O
complementary	O
tests	O
in	O
the	O
emergency	O
department	O
detailed	O
below	O
,	O
it	O
was	O
decided	O
to	O
monitor	O
her	O
for	O
the	O
first	O
24	O
hours	O
in	O
the	O
observation	O
area	O
,	O
with	O
no	O
new	O
events	O
.	O
PHYSICAL	O
EXAMINATION	O
Good	O
general	O
condition	O
.	O
Conscious	O
and	O
oriented	O
.	O
Collaborative	O
.	O
Well	O
hydrated	O
and	O
perfused	O
.	O
Afebrile	O
.	O
Haemodynamically	O
stable	O
with	O
blood	O
pressure	O
132	O
87	O
mmHg	O
on	O
arrival	O
at	O
the	O
ED	O
200	O
112	O
mmHg	O
and	O
heart	O
rate	O
70	O
bpm	O
.	O
Eupneic	O
at	O
rest	O
and	O
when	O
speaking	O
,	O
tolerating	O
full	O
decubitus	O
and	O
with	O
no	O
need	O
for	O
supplementary	O
oxygen	O
therapy	O
.	O
On	O
auscultation	O
,	O
rhythmic	O
heart	O
tones	O
without	O
audible	O
murmurs	O
.	O
Bladder	O
murmur	O
was	O
preserved	O
without	O
crackles	O
or	O
other	O
pathological	O
noises	O
.	O
Abdominal	O
examination	O
was	O
unremarkable	O
.	O
Lower	O
limbs	O
without	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
No	O
other	O
noteworthy	O
findings	O
on	O
examination	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
on	O
admission	O
sinus	O
rhythm	O
at	O
65	O
bpm	O
.	O
Normal	O
axis	O
.	O
PR	O
160	O
msec	O
.	O
Narrow	O
QRS	O
with	O
little	O
R	O
wave	O
progression	O
in	O
right	O
precordial	O
leads	O
.	O
Symmetrical	O
and	O
deep	O
negative	O
T	O
waves	O
from	O
V1	O
to	O
V4	O
and	O
isodiphasic	O
in	O
V5	O
Wellens	O
pattern	O
.	O
ECG	O
after	O
percutaneous	O
coronary	O
intervention	O
sinus	O
rhythm	O
at	O
70	O
bpm	O
.	O
Normal	O
axis	O
.	O
Normal	O
PR	O
.	O
Narrow	O
QRS	O
with	O
little	O
progression	O
of	O
R	O
in	O
right	O
precordials	O
and	O
normalisation	O
of	O
T	O
waves	O
in	O
precordial	O
series	O
.	O
Blood	O
tests	O
glycaemia	O
102	O
mg	O
dl	O
.	O
Creatinine	O
1	O
.	O
24	O
mg	O
dl	O
.	O
Urea	O
36	O
mg	O
dl	O
.	O
Sodium	O
143	O
mEq	O
l	O
.	O
Potassium	O
4	O
.	O
3	O
mEq	O
l	O
.	O
Lipid	O
profile	O
total	O
cholesterol	O
206	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
43	O
mg	O
dl	O
,	O
LDL	O
cholesterol	O
133	O
mg	O
dl	O
,	O
triglycerides	O
148	O
mg	O
dl	O
.	O
Normal	O
liver	O
and	O
thyroid	O
profiles	O
.	O
Glycated	O
haemoglobin	O
5	O
.	O
9	O
.	O
Myocardial	O
damage	O
markers	O
with	O
ultrasensitive	O
cTnT	O
peak	O
of	O
121	O
.	O
8	O
ng	O
l	O
.	O
Haemogram	O
without	O
leukocytosis	O
with	O
normal	O
formula	O
.	O
Hb	O
150	O
g	O
l	O
.	O
Platelets	O
229	O
,	O
000	O
.	O
Normal	O
coagulation	O
study	O
.	O
Chest	O
X	O
ray	O
normal	O
cardiothoracic	O
index	O
.	O
Well	O
defined	O
hilarity	O
,	O
no	O
evidence	O
of	O
pulmonary	O
congestion	O
or	O
parenchymal	O
condensation	O
.	O
Free	O
costophrenic	O
sinuses	O
.	O
Transthoracic	O
echocardiography	O
non	O
dilated	O
left	O
ventricle	O
LVEDD	O
45	O
mm	O
,	O
LVOT	O
148	O
ml	O
,	O
STV	O
54	O
ml	O
with	O
12	O
.	O
5	O
mm	O
mid	O
basal	O
septum	O
,	O
with	O
largely	O
preserved	O
systolic	O
function	O
LVEF	O
63	O
by	O
Simpson	O
biplane	O
.	O
No	O
segmental	O
contractility	O
defects	O
are	O
seen	O
.	O
Left	O
atrium	O
at	O
the	O
high	O
limit	O
of	O
normality	O
AP	O
diameter	O
36	O
mm	O
,	O
indexed	O
volume	O
30	O
ml	O
m2	O
.	O
Normal	O
mitral	O
valve	O
.	O
Mitral	O
E	O
wave	O
velocity	O
5	O
cm	O
sec	O
,	O
A	O
wave	O
61	O
cm	O
sec	O
.	O
Septal	O
E	O
"	O
7	O
.	O
7	O
,	O
lateral	O
E	O
"	O
8	O
.	O
8	O
,	O
E	O
E	O
"	O
7	O
.	O
6	O
.	O
Trivalve	O
aortic	O
valve	O
with	O
normal	O
flows	O
.	O
Aortic	O
root	O
not	O
dilated	O
sinuses	O
of	O
Valsalva	O
38	O
mm	O
.	O
Right	O
chambers	O
not	O
dilated	O
,	O
without	O
tricuspid	O
insufficiency	O
that	O
would	O
allow	O
estimation	O
of	O
systolic	O
pulmonary	O
artery	O
pressure	O
PAPs	O
no	O
indirect	O
data	O
of	O
PHT	O
.	O
Inferior	O
vena	O
cava	O
IVC	O
not	O
dilated	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
.	O
Coronary	O
angiography	O
right	O
radial	O
access	O
.	O
Left	O
main	O
coronary	O
artery	O
without	O
lesions	O
.	O
Anterior	O
descending	O
artery	O
with	O
proximal	O
subtotal	O
lesion	O
with	O
good	O
distal	O
vessel	O
.	O
Dominant	O
circumflex	O
artery	O
without	O
lesions	O
.	O
Hypodense	O
right	O
coronary	O
artery	O
without	O
lesions	O
.	O
Direct	O
implantation	O
of	O
a	O
zotarolimus	B-FARMACO
eluting	O
stent	O
Resolute	O
Onyx	O
3	O
.	O
5	O
x	O
18	O
mm	O
was	O
performed	O
on	O
the	O
proximal	O
anterior	O
descending	O
artery	O
ADA	O
,	O
without	O
immediate	O
complications	O
and	O
with	O
good	O
final	O
angiographic	O
results	O
.	O
CLINICAL	O
EVOLUTION	O
During	O
his	O
hospital	O
stay	O
,	O
the	O
patient	O
presented	O
an	O
episode	O
of	O
chest	O
pain	O
with	O
a	O
typical	O
profile	O
for	O
ischaemia	O
without	O
associated	O
vegetative	O
cortex	O
,	O
during	O
which	O
minimal	O
ST	O
segment	O
elevation	O
was	O
observed	O
in	O
the	O
anterior	O
face	O
,	O
which	O
subsided	O
after	O
the	O
administration	O
of	O
nitrates	B-FARMACO
,	O
while	O
the	O
T	O
wave	O
inversion	O
described	O
prior	O
to	O
admission	O
persisted	O
.	O
Serial	O
analytical	O
controls	O
showed	O
discrete	O
mobilisation	O
of	O
biomarkers	O
of	O
myocardial	O
damage	O
peak	O
TnTus	O
121	O
.	O
8	O
ng	O
l	O
.	O
Based	O
on	O
clinical	O
symptoms	O
compatible	O
with	O
recent	O
onset	O
angina	O
and	O
the	O
findings	O
described	O
,	O
preferential	O
coronary	O
angiography	O
was	O
requested	O
,	O
which	O
revealed	O
a	O
subtotal	O
lesion	O
at	O
the	O
proximal	O
level	O
of	O
the	O
anterior	O
descending	O
artery	O
,	O
with	O
no	O
other	O
associated	O
coronary	O
lesions	O
.	O
This	O
lesion	O
was	O
percutaneously	O
revascularised	O
and	O
a	O
drug	O
eluting	O
stent	O
was	O
implanted	O
without	O
incident	O
and	O
with	O
good	O
angiographic	O
results	O
.	O
At	O
the	O
end	O
of	O
the	O
procedure	O
,	O
a	O
new	O
electrocardiogram	O
was	O
performed	O
which	O
showed	O
normalisation	O
of	O
the	O
repolarisation	O
disorders	O
described	O
on	O
admission	O
.	O
With	O
regard	O
to	O
the	O
imaging	O
tests	O
,	O
the	O
echocardiography	O
showed	O
a	O
ventricle	O
of	O
normal	O
size	O
and	O
morphology	O
with	O
preserved	O
ejection	O
fraction	O
LVEF	O
63	O
,	O
without	O
identifying	O
segmental	O
alterations	O
in	O
contractility	O
.	O
After	O
the	O
coronary	O
intervention	O
,	O
the	O
patient	O
remained	O
completely	O
asymptomatic	O
and	O
without	O
complications	O
derived	O
from	O
the	O
procedure	O
and	O
was	O
discharged	O
.	O
He	O
is	O
currently	O
undergoing	O
a	O
cardiac	O
rehabilitation	O
programme	O
at	O
our	O
centre	O
,	O
with	O
good	O
tolerance	O
to	O
the	O
exercises	O
performed	O
at	O
the	O
gym	O
,	O
remaining	O
asymptomatic	O
and	O
with	O
no	O
notable	O
clinical	O
incidents	O
.	O
DIAGNOSIS	O
Acute	O
non	O
ST	O
segment	O
elevation	O
myocardial	O
infarction	O
NSTEMI	O
with	O
single	O
vessel	O
coronary	O
artery	O
disease	O
subtotal	O
lesion	O
of	O
the	O
proximal	O
LAD	O
.	O
Percutaneous	O
coronary	O
intervention	O
PCI	O
with	O
direct	O
drug	O
eluting	O
stent	O
DES	O
without	O
incident	O
.	O
Initial	O
electrical	O
manifestation	O
with	O
Wellens	O
pattern	O
.	O
Poorly	O
controlled	O
hypertension	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
85	O
year	O
old	O
woman	O
referred	O
for	O
chest	O
pain	O
.	O
BACKGROUND	O
Intolerance	O
to	O
non	O
steroidal	O
anti	O
inflammatory	O
drugs	O
NSAIDs	O
.	O
No	O
toxic	O
habits	O
.	O
Hypertension	O
.	O
No	O
diabetes	O
mellitus	O
or	O
dyslipidaemia	O
.	O
Cardiology	O
evaluation	O
in	O
2013	O
for	O
palpitations	O
with	O
normal	O
Holter	O
and	O
mild	O
concentric	O
hypertrophy	O
in	O
the	O
echocardiogram	O
.	O
Other	O
history	O
polymyalgia	O
rheumatica	O
,	O
lumbar	O
spondylosis	O
,	O
macular	O
degeneration	O
,	O
anxious	O
depressive	O
syndrome	O
,	O
chronic	O
venous	O
insufficiency	O
.	O
Surgical	O
interventions	O
total	O
right	O
hip	O
replacement	O
2011	O
after	O
fracture	O
and	O
uterine	O
myomectomy	O
.	O
Current	O
treatment	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
every	O
24	O
hours	O
,	O
valsartan	B-FARMACO
hydrochlorothiazide	I-FARMACO
80	O
12	O
.	O
5	O
mg	O
every	O
24	O
hours	O
,	O
esomeprazole	B-FARMACO
20	O
mg	O
every	O
24	O
hours	O
and	O
venlafaxine	B-FARMACO
150	O
mg	O
every	O
24	O
hours	O
.	O
Baseline	O
situation	O
lives	O
alone	O
.	O
Independent	O
for	O
basic	O
activities	O
of	O
daily	O
living	O
.	O
CURRENT	O
ILLNESS	O
85	O
year	O
old	O
woman	O
who	O
came	O
to	O
our	O
centre	O
brought	O
by	O
the	O
emergency	O
services	O
for	O
an	O
episode	O
of	O
oppressive	O
central	O
thoracic	O
pain	O
radiating	O
to	O
the	O
jaw	O
and	O
shoulders	O
,	O
with	O
onset	O
at	O
rest	O
and	O
accompanied	O
by	O
vegetative	O
cortex	O
.	O
During	O
transfer	O
to	O
the	O
emergency	O
department	O
,	O
sublingual	O
nitroglycerin	B-FARMACO
was	O
administered	O
with	O
improvement	O
,	O
and	O
the	O
patient	O
was	O
subsequently	O
asymptomatic	O
.	O
The	O
clinic	O
was	O
present	O
for	O
approximately	O
45	O
minutes	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
BP	O
131	O
72	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
74	O
bpm	O
.	O
Baseline	O
O2	O
saturation	O
SatO2	O
100	O
.	O
Afebrile	O
.	O
Conscious	O
,	O
oriented	O
and	O
cooperative	O
.	O
Eupneic	O
at	O
rest	O
.	O
Good	O
general	O
condition	O
,	O
normohydrated	O
and	O
normal	O
colour	O
.	O
Rhythmic	O
carotids	O
without	O
murmurs	O
,	O
no	O
jugular	O
ingurgitation	O
.	O
Cardiac	O
auscultation	O
CA	O
rhythmic	O
without	O
audible	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
PA	O
with	O
preserved	O
vesicular	O
murmur	O
without	O
over	O
additions	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
,	O
without	O
masses	O
or	O
megaliths	O
.	O
Lower	O
limbs	O
without	O
oedema	O
or	O
signs	O
of	O
phlebitis	O
.	O
Radial	O
,	O
femoral	O
and	O
anterior	O
tibial	O
pulses	O
preserved	O
and	O
symmetrical	O
.	O
COMPLEMENTARY	O
TESTS	O
ANALYSIS	O
haemoglobin	O
11	O
.	O
9	O
g	O
dl	O
,	O
platelets	O
268	O
,	O
000	O
mm3	O
,	O
leukocytes	O
6	O
,	O
790	O
mm3	O
with	O
normal	O
formula	O
.	O
Coagulation	O
normal	O
.	O
Glucose	O
91	O
mg	O
dl	O
,	O
urea	O
56	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
09	O
mg	O
dl	O
,	O
CKDEPI	O
46	O
ml	O
min	O
,	O
sodium	O
140	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
9	O
mEq	O
l	O
,	O
triglycerides	O
121	O
mg	O
dl	O
,	O
total	O
cholesterol	O
184	O
mg	O
dl	O
HDL	O
42	O
mg	O
dl	O
,	O
LDL	O
118	O
mg	O
dl	O
,	O
uric	O
acid	O
7	O
,	O
0	O
mg	O
dl	O
,	O
ALT	O
42	O
IU	O
l	O
,	O
AST	O
262	O
IU	O
l	O
,	O
GGT	O
22	O
IU	O
l	O
,	O
alkaline	O
phosphatase	O
98	O
IU	O
l	O
,	O
total	O
bilirubin	O
0	O
.	O
3	O
mg	O
dl	O
,	O
iron	O
42	O
ug	O
dl	O
,	O
transferrin	O
2	O
.	O
12	O
mg	O
dl	O
,	O
IST	O
15	O
.	O
6	O
,	O
ferritin	O
52	O
.	O
3	O
ng	O
ml	O
,	O
TSH	O
1	O
.	O
33	O
ng	O
dl	O
,	O
HbA1c	O
5	O
.	O
8	O
.	O
Troponin	O
I	O
0	O
.	O
87	O
ng	O
ml	O
on	O
admission	O
,	O
peak	O
126	O
ng	O
ml	O
high	O
limit	O
of	O
normal	O
0	O
.	O
08	O
ng	O
ml	O
.	O
AP	O
THORAX	O
RADIOGRAPHY	O
slight	O
elongation	O
of	O
the	O
aorta	O
,	O
right	O
costophrenic	O
sinus	O
impingement	O
,	O
fluid	O
in	O
the	O
right	O
major	O
fissure	O
.	O
Cardiovascular	O
silhouette	O
poorly	O
assessable	O
by	O
technique	O
.	O
ECG	O
admission	O
sinus	O
rhythm	O
at	O
70	O
bpm	O
with	O
normal	O
PR	O
and	O
narrow	O
QRS	O
,	O
ST	O
segment	O
rectification	O
on	O
the	O
lateral	O
side	O
.	O
ECG	O
coronary	O
unit	O
sinus	O
rhythm	O
at	O
75	O
bpm	O
,	O
normal	O
PR	O
,	O
subepicardial	O
lesion	O
wave	O
with	O
lateral	O
negative	O
T	O
.	O
ECOCARDIOGRAM	O
regular	O
echocardiographic	O
window	O
.	O
LV	O
of	O
normal	O
size	O
and	O
global	O
systolic	O
function	O
,	O
with	O
hypokinesia	O
of	O
the	O
posterior	O
face	O
.	O
Dilated	O
left	O
atrium	O
with	O
area	O
28	O
.	O
3	O
cm2	O
.	O
Right	O
chambers	O
of	O
normal	O
size	O
.	O
Calcification	O
of	O
the	O
mitral	O
annulus	O
.	O
No	O
significant	O
insufficiency	O
detected	O
.	O
Normal	O
tricuspid	O
with	O
moderate	O
insufficiency	O
.	O
RV	O
AD	O
systolic	O
gradient	O
34	O
mmHg	O
.	O
Normal	O
inferior	O
vena	O
cava	O
.	O
Normal	O
aortic	O
with	O
mild	O
trivial	O
insufficiency	O
,	O
without	O
pathological	O
gradient	O
.	O
CARDIAC	O
CATHETERISM	O
coronary	O
arteries	O
without	O
lesions	O
except	O
for	O
a	O
filling	O
defect	O
in	O
the	O
first	O
obtuse	O
marginal	O
.	O
Aspiration	O
of	O
whitish	O
material	O
was	O
performed	O
with	O
two	O
fragments	O
of	O
1	O
cm	O
each	O
,	O
which	O
were	O
sent	O
to	O
pathological	O
anatomy	O
for	O
study	O
.	O
After	O
extraction	O
,	O
the	O
artery	O
was	O
left	O
with	O
TIMI	O
3	O
flow	O
.	O
PATHOLOGICAL	O
ANATOMY	O
calcified	O
,	O
acellular	O
material	O
with	O
atheroembolic	O
morphology	O
.	O
CLINICAL	O
EVOLUTION	O
With	O
the	O
diagnosis	O
of	O
NSTEACS	O
,	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
coronary	O
unit	O
and	O
remained	O
asymptomatic	O
from	O
the	O
cardiovascular	O
point	O
of	O
view	O
throughout	O
her	O
admission	O
.	O
Early	O
catheterisation	O
showed	O
coronary	O
occlusion	O
of	O
embolic	O
aetiology	O
,	O
without	O
being	O
able	O
to	O
establish	O
the	O
source	O
of	O
atheroembolism	O
,	O
so	O
given	O
that	O
she	O
did	O
not	O
present	O
a	O
high	O
risk	O
of	O
haemorrhage	O
,	O
anticoagulation	O
was	O
started	O
empirically	O
.	O
Blood	O
pressure	O
and	O
heart	O
rate	O
were	O
controlled	O
during	O
admission	O
,	O
with	O
no	O
arrhythmias	O
observed	O
.	O
The	O
patient	O
was	O
discharged	O
three	O
days	O
after	O
admission	O
.	O
DIAGNOSIS	O
Ischaemic	O
heart	O
disease	O
.	O
Acute	O
myocardial	O
infarction	O
AMI	O
non	O
Q	O
,	O
Killip	O
I	O
.	O
Repletion	O
defect	O
in	O
obtuse	O
marginal	O
artery	O
of	O
embolic	O
aetiology	O
.	O
Coronary	O
arteries	O
without	O
lesions	O
.	O
Preserved	O
left	O
ventricular	O
ejection	O
fraction	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
67	O
year	O
old	O
male	O
under	O
follow	O
up	O
with	O
cardiology	O
consultation	O
.	O
BACKGROUND	O
Allergy	O
to	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
.	O
Coronary	O
ischaemic	O
heart	O
disease	O
with	O
single	O
vessel	O
disease	O
percutaneous	O
transluminal	O
coronary	O
angioplasty	O
PTCA	O
and	O
drug	O
eluting	O
stent	O
implantation	O
in	O
the	O
middle	O
anterior	O
descending	O
artery	O
AD	O
.	O
Normal	O
LV	O
function	O
.	O
Arterial	O
hypertension	O
AHT	O
.	O
Stage	O
III	O
chronic	O
renal	O
failure	O
.	O
Deep	O
vein	O
thrombosis	O
with	O
factor	O
V	O
Leiden	O
mutation	O
Arg506Gln	O
.	O
Bicameral	O
pacing	O
due	O
to	O
complete	O
atrioventricular	O
block	O
AVB	O
2015	O
.	O
Paroxysmal	O
atrial	O
fibrillation	O
.	O
Home	O
treatment	O
clopidogrel	B-FARMACO
75	O
,	O
esomeprazole	B-FARMACO
20	O
mg	O
,	O
bisoprolol	B-FARMACO
5	O
mg	O
1	O
0	O
0	O
,	O
losartan	B-FARMACO
50	O
mg	O
1	O
0	O
0	O
,	O
acenocoumarol	B-FARMACO
,	O
simvastatin	B-FARMACO
40	O
mg	O
0	O
0	O
1	O
,	O
tamsulosin	B-FARMACO
.	O
CURRENT	O
ILLNESS	O
Patient	O
under	O
outpatient	O
follow	O
up	O
for	O
single	O
vessel	O
coronary	O
artery	O
disease	O
and	O
paroxysmal	O
atrial	O
fibrillation	O
,	O
who	O
came	O
for	O
cardiology	O
consultation	O
one	O
year	O
after	O
the	O
event	O
.	O
He	O
reported	O
not	O
having	O
angina	O
,	O
but	O
with	O
asthenia	O
and	O
dyspnoea	O
on	O
moderate	O
exertion	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
BP	O
130	O
70	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
54	O
bpm	O
.	O
Weight	O
66	O
bpm	O
.	O
Height	O
175	O
cm	O
.	O
Abdominal	O
circumference	O
85	O
cm	O
.	O
Rhythmic	O
heart	O
sounds	O
without	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
with	O
preserved	O
vesicular	O
murmur	O
.	O
Abdomen	O
without	O
palpable	O
masses	O
.	O
No	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
Pedial	O
pulses	O
present	O
and	O
symmetrical	O
.	O
COMPLEMENTARY	O
TESTS	O
ANALYTICS	O
haemoglobin	O
13	O
.	O
8	O
g	O
dl	O
,	O
platelets	O
200	O
,	O
000	O
,	O
creatinine	O
3	O
.	O
2	O
mg	O
dl	O
,	O
MDRD	O
4	O
20	O
ml	O
min	O
sup	O
,	O
sodium	O
140	O
meq	O
l	O
,	O
potassium	O
5	O
.	O
1	O
mel	O
l	O
,	O
GOT	O
9	O
U	O
L	O
,	O
GPT	O
15	O
U	O
l	O
.	O
Lipid	O
profile	O
total	O
cholesterol	O
244	O
mg	O
dl	O
,	O
251	O
mg	O
dl	O
,	O
HDL	O
31	O
mg	O
dl	O
,	O
LDL	O
162	O
mg	O
dl	O
.	O
ELECTROCARDIOGRAM	O
ECG	O
sinus	O
rhythm	O
with	O
ventricular	O
stimulation	O
.	O
ECOCARDIOGRAPHY	O
non	O
dilated	O
left	O
ventricle	O
with	O
preserved	O
global	O
systolic	O
function	O
,	O
without	O
segmental	O
contractility	O
disorders	O
.	O
ANALYSIS	O
after	O
starting	O
proprotein	B-FARMACO
convertase	I-FARMACO
subtilisin	I-FARMACO
kexin	I-FARMACO
type	I-FARMACO
9	I-FARMACO
PCSK9	I-FARMACO
inhibitors	O
total	O
cholesterol	O
108	O
mg	O
dl	O
,	O
HDL	O
46	O
mg	O
dl	O
,	O
LDL	O
45	O
mg	O
dl	O
.	O
CLINICAL	O
COURSE	O
In	O
the	O
annual	O
follow	O
up	O
assessment	O
,	O
a	O
stress	O
echocardiogram	O
was	O
requested	O
due	O
to	O
the	O
patient	O
's	O
dyspnoea	O
on	O
exertion	O
.	O
In	O
the	O
lipid	O
profile	O
,	O
high	O
levels	O
of	O
low	O
density	O
lipoprotein	O
cholesterol	O
LDL	O
C	O
were	O
detected	O
,	O
so	O
lipid	O
lowering	O
treatment	O
was	O
intensified	O
,	O
replacing	O
simvastatin	B-FARMACO
40	O
with	O
rosuvastatin	B-FARMACO
10	O
mg	O
.	O
The	O
patient	O
returned	O
to	O
the	O
clinic	O
with	O
the	O
results	O
of	O
the	O
stress	O
echocardiogram	O
,	O
which	O
was	O
negative	O
for	O
ischaemia	O
85	O
of	O
BMF	O
;	O
7	O
metabolic	O
equivalents	O
MET	O
;	O
no	O
data	O
of	O
ischaemia	O
in	O
echocardiography	O
.	O
The	O
patient	O
also	O
reported	O
muscle	O
discomfort	O
since	O
the	O
last	O
visit	O
and	O
decided	O
to	O
discontinue	O
treatment	O
with	O
rosuvastatin	B-FARMACO
.	O
For	O
this	O
reason	O
,	O
a	O
new	O
lipid	O
profile	O
was	O
requested	O
and	O
pitavastatin	B-FARMACO
2	O
mg	O
and	O
ezetimibe	B-FARMACO
10	O
mg	O
were	O
prescribed	O
.	O
At	O
the	O
same	O
time	O
,	O
the	O
patient	O
's	O
beta	O
blocker	O
dose	O
was	O
reduced	O
,	O
in	O
case	O
the	O
feeling	O
of	O
asthenia	O
could	O
be	O
related	O
to	O
this	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
24	O
hours	O
.	O
The	O
patient	O
returned	O
for	O
consultation	O
3	O
months	O
later	O
,	O
reporting	O
the	O
same	O
symptoms	O
and	O
that	O
he	O
could	O
not	O
tolerate	O
the	O
new	O
statin	B-FARMACO
.	O
The	O
blood	O
test	O
did	O
not	O
detect	O
any	O
liver	O
alteration	O
or	O
muscle	O
damage	O
GOT	O
GPT	O
19	O
18	O
U	O
L	O
,	O
but	O
due	O
to	O
the	O
patient	O
's	O
poor	O
tolerance	O
with	O
up	O
to	O
three	O
different	O
statins	B-FARMACO
,	O
it	O
was	O
proposed	O
to	O
start	O
treatment	O
with	O
evolocumab	B-FARMACO
.	O
Evolocumab	B-FARMACO
140	O
mg	O
2	O
weeks	O
was	O
started	O
,	O
with	O
good	O
tolerance	O
.	O
In	O
the	O
analytical	O
control	O
2	O
months	O
after	O
starting	O
treatment	O
,	O
a	O
lipid	O
control	O
was	O
requested	O
with	O
LDL	O
45	O
mg	O
dl	O
.	O
After	O
one	O
year	O
of	O
follow	O
up	O
,	O
and	O
due	O
to	O
the	O
need	O
for	O
oral	O
anticoagulation	O
,	O
it	O
was	O
decided	O
to	O
discontinue	O
clopidogrel	B-FARMACO
and	O
maintain	O
acenocoumarol	B-FARMACO
,	O
in	O
order	O
to	O
reduce	O
the	O
risk	O
of	O
haemorrhage	O
.	O
DIAGNOSIS	O
Single	O
vessel	O
coronary	O
artery	O
disease	O
.	O
Paroxysmal	O
atrial	O
fibrillation	O
.	O
Intolerance	O
to	O
statins	B-FARMACO
,	O
with	O
very	O
high	O
cardiovascular	O
risk	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
A	O
72	O
year	O
old	O
man	O
attended	O
the	O
emergency	O
department	O
for	O
an	O
episode	O
of	O
sudden	O
dyspnoea	O
.	O
Personal	O
history	O
of	O
interest	O
ischaemic	O
cerebrovascular	O
accident	O
in	O
2009	O
with	O
an	O
unidentified	O
aetiology	O
echo	O
Doppler	O
of	O
supra	O
aortic	O
trunks	O
with	O
no	O
pathological	O
findings	O
,	O
infrarenal	O
abdominal	O
aortic	O
aneurysm	O
and	O
squamous	O
cell	O
carcinoma	O
of	O
the	O
lung	O
operated	O
on	O
with	O
right	O
upper	O
lobectomy	O
5	O
months	O
ago	O
.	O
He	O
was	O
under	O
chronic	O
treatment	O
with	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
300	O
mg	O
24	O
hours	O
and	O
inhaled	O
salmeterol	B-FARMACO
fluticasone	I-FARMACO
propionate	I-FARMACO
50	O
500	O
mcg	O
12	O
hours	O
.	O
He	O
reported	O
several	O
episodes	O
of	O
dyspnoea	O
over	O
the	O
last	O
month	O
,	O
always	O
standing	O
upright	O
,	O
unrelated	O
to	O
exertion	O
.	O
No	O
orthopnoea	O
or	O
paroxysmal	O
nocturnal	O
dyspnoea	O
.	O
No	O
cough	O
,	O
expectoration	O
or	O
chest	O
pain	O
.	O
Physical	O
examination	O
revealed	O
oxygen	O
desaturation	O
up	O
to	O
80	O
,	O
which	O
improved	O
with	O
decubitus	O
.	O
Jugular	O
venous	O
pressure	O
was	O
normal	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
without	O
murmurs	O
or	O
extratonos	O
.	O
Pulmonary	O
auscultation	O
with	O
hypophonesis	O
in	O
the	O
right	O
lung	O
base	O
,	O
absence	O
of	O
crackles	O
or	O
rhonchi	O
.	O
Absence	O
of	O
oedema	O
in	O
the	O
extremities	O
.	O
COMPLEMENTARY	O
TESTS	O
ANALYSIS	O
glucose	O
80	O
mg	O
dl	O
,	O
urea	O
50	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
85	O
mg	O
dl	O
,	O
sodium	O
136	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
1	O
mEq	O
l	O
,	O
troponin	O
I	O
0	O
.	O
01	O
ng	O
ml	O
,	O
BNP	O
102	O
.	O
6	O
pg	O
ml	O
,	O
haemoglobin	O
16	O
.	O
1	O
g	O
dl	O
,	O
haematocrit	O
50	O
.	O
8	O
,	O
MCV	O
96	O
.	O
8	O
fl	O
,	O
leukocytes	O
9	O
,	O
100	O
,	O
platelets	O
111	O
,	O
000	O
,	O
D	O
dimer	O
2	O
,	O
005	O
ng	O
l	O
.	O
Coagulation	O
normal	O
.	O
ARTERIAL	O
GASOMETRY	O
pH	O
7	O
,	O
43	O
,	O
pCO2	O
26	O
,	O
5	O
mmHg	O
,	O
p02	O
100	O
,	O
3	O
mmHg	O
,	O
oxygen	O
saturation	O
SatO2	O
98	O
,	O
7	O
,	O
bicarbonate	O
17	O
,	O
5	O
mEq	O
l	O
.	O
ELECTROCARDIOGRAM	O
ECG	O
sinus	O
rhythm	O
at	O
95	O
bpm	O
.	O
PR	O
200	O
ms	O
,	O
QRS	O
of	O
100	O
ms	O
,	O
with	O
morphology	O
of	O
left	O
anterosuperior	O
hemiblock	O
.	O
No	O
repolarisation	O
alterations	O
.	O
THORAX	O
RADIOGRAPHY	O
elevation	O
of	O
the	O
right	O
hemidiaphragm	O
.	O
Normal	O
cardiac	O
silhouette	O
.	O
THORACIC	O
CT	O
scan	O
loss	O
of	O
volume	O
in	O
the	O
right	O
upper	O
lobe	O
in	O
relation	O
to	O
lobectomy	O
.	O
Residual	O
middle	O
lobe	O
atelectasis	O
and	O
elevated	O
right	O
hemidiaphragm	O
.	O
No	O
repletion	O
defects	O
in	O
pulmonary	O
arteries	O
suggestive	O
of	O
pulmonary	O
thromboembolism	O
.	O
Transthoracic	O
echocardiogram	O
left	O
ventricle	O
of	O
normal	O
dimensions	O
and	O
systolic	O
function	O
,	O
without	O
segmental	O
alterations	O
of	O
contractility	O
.	O
Normal	O
right	O
chambers	O
with	O
preserved	O
ventricular	O
function	O
.	O
Mitral	O
and	O
aortic	O
valves	O
without	O
abnormalities	O
.	O
Hypermobile	O
interatrial	O
septum	O
.	O
Normal	O
pulmonary	O
pressure	O
.	O
Bubble	O
test	O
was	O
performed	O
with	O
agitated	O
saline	B-FARMACO
with	O
massive	O
passage	O
of	O
bubbles	O
from	O
right	O
to	O
left	O
cavities	O
in	O
the	O
first	O
and	O
second	O
beats	O
suggesting	O
right	O
left	O
shunt	O
.	O
Transesophageal	O
echocardiogram	O
aneurysmal	O
interatrial	O
septum	O
with	O
extensive	O
detachment	O
of	O
the	O
membrane	O
of	O
the	O
fossa	O
ovalis	O
and	O
massive	O
passage	O
of	O
bubbles	O
with	O
agitated	O
physiological	B-FARMACO
saline	I-FARMACO
from	O
the	O
right	O
to	O
the	O
left	O
atrium	O
.	O
CLINICAL	O
COURSE	O
Initially	O
the	O
patient	O
responded	O
to	O
oxygen	O
therapy	O
with	O
nasal	O
goggles	O
and	O
was	O
admitted	O
to	O
the	O
ward	O
for	O
investigation	O
.	O
A	O
thoracic	O
CT	O
scan	O
was	O
first	O
performed	O
to	O
rule	O
out	O
pulmonary	O
thromboembolism	O
PTE	O
or	O
a	O
complication	O
of	O
the	O
recent	O
lobectomy	O
.	O
In	O
the	O
absence	O
of	O
pulmonary	O
pathology	O
to	O
justify	O
the	O
symptoms	O
,	O
an	O
echocardiogram	O
was	O
requested	O
to	O
rule	O
out	O
intracardiac	O
shunt	O
.	O
The	O
baseline	O
study	O
showed	O
a	O
hypermobile	O
interatrial	O
septum	O
with	O
possible	O
shunt	O
,	O
which	O
was	O
evident	O
in	O
the	O
bubble	O
test	O
with	O
agitated	O
saline	B-FARMACO
.	O
The	O
study	O
was	O
completed	O
with	O
a	O
transesophageal	O
echocardiogram	O
that	O
confirmed	O
the	O
presence	O
of	O
an	O
atrial	O
septal	O
aneurysm	O
with	O
patent	O
foramen	O
ovale	O
PFO	O
and	O
left	O
right	O
shunt	O
.	O
The	O
patient	O
presented	O
rapidly	O
progressive	O
worsening	O
,	O
with	O
severe	O
sustained	O
hypoxaemia	O
SatO2	O
65	O
that	O
was	O
not	O
corrected	O
with	O
position	O
or	O
oxygen	O
therapy	O
.	O
In	O
view	O
of	O
this	O
situation	O
,	O
urgent	O
percutaneous	O
closure	O
of	O
the	O
PFO	O
was	O
decided	O
under	O
intracardiac	O
echo	O
monitoring	O
.	O
After	O
PFO	O
closure	O
,	O
oxygen	O
saturation	O
normalised	O
and	O
dyspnoea	O
disappeared	O
.	O
DIAGNOSIS	O
Platypnoea	O
orthodeoxia	O
syndrome	O
due	O
to	O
patent	O
foramen	O
ovale	O
after	O
right	O
lobectomy	O
.	O
Urgent	O
percutaneous	O
closure	O
of	O
patent	O
foramen	O
ovale	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
BACKGROUND	O
72	O
year	O
old	O
male	O
.	O
No	O
known	O
allergies	O
.	O
Retired	O
administrative	O
worker	O
.	O
Cardiovascular	O
risk	O
factors	O
CVR	O
arterial	O
hypertension	O
AHT	O
of	O
10	O
years	O
of	O
evolution	O
with	O
good	O
control	O
with	O
two	O
drugs	O
.	O
Diabetes	O
mellitus	O
DM	O
type	O
2	O
of	O
3	O
years	O
of	O
evolution	O
under	O
treatment	O
with	O
an	O
oral	O
antidiabetic	O
ADO	O
,	O
with	O
good	O
control	O
.	O
Dyslipidaemia	O
treated	O
with	O
statins	O
since	O
2002	O
.	O
Ex	O
smoker	O
since	O
2002	O
20	O
packs	O
year	O
.	O
Previous	O
cardiological	O
history	O
Ischaemic	O
heart	O
disease	O
.	O
Debuted	O
in	O
2002	O
with	O
acute	O
coronary	O
syndrome	O
ACS	O
of	O
the	O
unstable	O
angina	O
type	O
with	O
disease	O
of	O
a	O
vessel	O
proximal	O
anterior	O
descending	O
LAD	O
with	O
80	O
stenosis	O
,	O
revascularised	O
with	O
conventional	O
stent	O
.	O
Normal	O
left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
.	O
Subsequently	O
stable	O
,	O
without	O
angina	O
.	O
Mild	O
aortic	O
stenosis	O
with	O
last	O
echocardiographic	O
study	O
in	O
October	O
2016	O
normal	O
ascending	O
aorta	O
.	O
Left	O
atrium	O
LA	O
slightly	O
dilated	O
area	O
of	O
28	O
cm2	O
.	O
Left	O
ventricle	O
LV	O
slightly	O
hypertrophic	O
,	O
not	O
dilated	O
,	O
without	O
alterations	O
in	O
segmental	O
contractility	O
and	O
preserved	O
LVEF	O
.	O
Diastolic	O
pattern	O
of	O
poor	O
relaxation	O
.	O
Degenerative	O
aortic	O
valve	O
disease	O
with	O
mild	O
stenosis	O
maximum	O
gradient	O
of	O
31	O
mmHg	O
,	O
without	O
insufficiency	O
.	O
Mitral	O
valve	O
with	O
good	O
opening	O
and	O
no	O
insufficiency	O
.	O
Normal	O
right	O
chambers	O
.	O
Trivial	O
tricuspid	O
insufficiency	O
.	O
Pulmonary	O
arterial	O
systolic	O
pressure	O
PSAP	O
32	O
mmHg	O
central	O
venous	O
pressure	O
CVP	O
estimated	O
at	O
3	O
5	O
mmHg	O
.	O
Normal	O
inferior	O
vena	O
cava	O
and	O
pericardium	O
.	O
Paroxysmal	O
atrial	O
fibrillation	O
.	O
CHA2DS2	O
VASc	O
4	O
,	O
on	O
treatment	O
with	O
rivaroxaban	B-FARMACO
since	O
2016	O
without	O
haemorrhagic	O
events	O
.	O
No	O
other	O
history	O
of	O
interest	O
,	O
nor	O
surgical	O
interventions	O
.	O
Home	O
medication	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
100	O
mg	O
0	O
1	O
0	O
,	O
diltiazem	B-FARMACO
60	O
mg	O
1	O
0	O
0	O
,	O
simvastatin	B-FARMACO
20	O
mg	O
0	O
0	O
1	O
,	O
enalapril	B-FARMACO
10	O
mg	O
1	O
0	O
0	O
,	O
metformin	B-FARMACO
850	O
mg	O
1	O
0	O
1	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
1	O
0	O
0	O
,	O
rivaroxaban	B-FARMACO
20	O
mg	O
1	O
0	O
0	O
.	O
CURRENT	O
ILLNESS	O
She	O
came	O
to	O
the	O
emergency	O
department	O
of	O
our	O
centre	O
for	O
episodes	O
of	O
oppressive	O
central	O
thoracic	O
pain	O
,	O
accompanied	O
by	O
dyspnoea	O
and	O
vegetative	O
cortex	O
,	O
which	O
had	O
started	O
3	O
weeks	O
previously	O
.	O
Initially	O
they	O
appeared	O
with	O
intense	O
exertion	O
,	O
but	O
over	O
the	O
days	O
they	O
became	O
more	O
frequent	O
and	O
were	O
triggered	O
by	O
progressively	O
less	O
exertion	O
.	O
On	O
the	O
day	O
of	O
admission	O
,	O
she	O
had	O
a	O
15	O
minute	O
episode	O
at	O
rest	O
that	O
subsided	O
spontaneously	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
BP	O
136	O
82	O
mmHg	O
,	O
heart	O
rate	O
HR	O
66	O
bpm	O
,	O
baseline	O
oxygen	O
saturation	O
SatO2	O
96	O
.	O
Afebrile	O
.	O
COC	O
.	O
BEG	O
.	O
NH	O
.	O
NC	O
.	O
Body	O
mass	O
index	O
BMI	O
28	O
kg	O
m2	O
.	O
Jugular	O
venous	O
pressure	O
normal	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
aortic	O
systolic	O
murmur	O
II	O
VI	O
with	O
second	O
sound	O
respected	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
non	O
painful	O
,	O
without	O
masses	O
or	O
megaliths	O
.	O
Lower	O
extremities	O
without	O
oedema	O
,	O
with	O
evidence	O
of	O
diabetic	O
dermopathy	O
and	O
weak	O
but	O
present	O
paedial	O
pulses	O
.	O
COMPLEMENTARY	O
TESTS	O
ANALYSIS	O
coagulation	O
prothrombin	O
time	O
12	O
.	O
9	O
sec	O
,	O
prothrombin	O
time	O
ratio	O
1	O
.	O
15	O
.	O
Partial	O
thromboplastin	O
time	O
26	O
.	O
6	O
sec	O
,	O
partial	O
thromboplastin	O
time	O
ratio	O
0	O
.	O
89	O
,	O
INR	O
1	O
.	O
15	O
.	O
Haemogram	O
haematitis	O
4	O
.	O
14	O
x106	O
l	O
,	O
haemoglobin	O
11	O
.	O
7	O
g	O
dl	O
,	O
haematocrit	O
34	O
.	O
6	O
,	O
mean	O
corpuscular	O
volume	O
83	O
.	O
6	O
fl	O
,	O
MCH	O
28	O
.	O
3	O
pg	O
,	O
MCHC	O
33	O
.	O
8	O
g	O
dl	O
.	O
Leukocytes	O
4	O
.	O
82	O
x103	O
l	O
with	O
normal	O
formula	O
.	O
Platelets	O
158	O
x103	O
l	O
.	O
Complete	O
biochemistry	O
glucose	O
89	O
mg	O
dl	O
,	O
urea	O
32	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
73	O
mg	O
dl	O
,	O
glomerular	O
filtration	O
rate	O
GRF	O
90	O
ml	O
min	O
,	O
sodium	O
142	O
mmol	O
l	O
,	O
potassium	O
4	O
.	O
7	O
mmol	O
l	O
.	O
Amylase	O
67	O
U	O
l	O
,	O
lipase	O
30	O
U	O
l	O
.	O
Alkaline	O
phosphatase	O
44	O
U	O
l	O
,	O
aspartate	O
aminotransferase	O
16	O
U	O
l	O
,	O
alanine	O
aminotransferase	O
19	O
U	O
l	O
,	O
gamma	O
glutamyl	O
transferase	O
41	O
U	O
l	O
,	O
total	O
bilirubin	O
1	O
mg	O
dl	O
,	O
total	O
cholesterol	O
163	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
53	O
mg	O
dl	O
,	O
triglycerides	O
82	O
mg	O
dl	O
,	O
calculated	O
LDL	O
cholesterol	O
94	O
mg	O
dl	O
.	O
HbA1c	O
6	O
,	O
5	O
,	O
TSH	O
2	O
,	O
4	O
mU	O
l	O
.	O
Cardiac	O
enzymes	O
creatine	O
kinase	O
48	O
U	O
l	O
with	O
increase	O
to	O
50	O
U	O
l	O
at	O
3	O
hours	O
,	O
ultrasensitive	O
troponin	O
T	O
TnT	O
us	O
22	O
ng	O
l	O
with	O
increase	O
to	O
70	O
ng	O
l	O
at	O
3	O
hours	O
normal	O
up	O
to	O
14	O
ng	O
l	O
.	O
ELECTROCARDIOGRAM	O
ECG	O
sinus	O
rhythm	O
at	O
62	O
bpm	O
,	O
complete	O
left	O
bundle	O
branch	O
block	O
without	O
Sgarbossa	O
criteria	O
LBBB	O
already	O
present	O
in	O
previous	O
ECGs	O
.	O
Serial	O
ECG	O
without	O
changes	O
.	O
THORAX	O
RADIOGRAPHY	O
portable	O
,	O
AP	O
projection	O
.	O
Normal	O
cardiothoracic	O
index	O
,	O
without	O
costophrenic	O
sinus	O
pinching	O
or	O
vascular	O
redistribution	O
data	O
.	O
No	O
pneumonic	O
condensation	O
.	O
TELEMETRY	O
during	O
admission	O
sinus	O
rhythm	O
without	O
arrhythmic	O
events	O
.	O
Transthoracic	O
echocardiography	O
TTE	O
left	O
atrium	O
LA	O
moderately	O
dilated	O
.	O
Left	O
ventricle	O
LV	O
not	O
dilated	O
,	O
with	O
moderate	O
hypertrophy	O
and	O
preserved	O
LVEF	O
.	O
No	O
segmental	O
alterations	O
.	O
Prolonged	O
LV	O
relaxation	O
.	O
Right	O
ventricle	O
RV	O
of	O
normal	O
size	O
and	O
function	O
.	O
Fibrosed	O
mitral	O
valve	O
,	O
not	O
stenotic	O
.	O
Mild	O
mitral	O
insufficiency	O
.	O
Calcified	O
aortic	O
valve	O
,	O
mobile	O
,	O
with	O
mild	O
aortic	O
stenosis	O
by	O
gradient	O
,	O
moderate	O
by	O
estimated	O
area	O
.	O
Mild	O
tricuspid	O
insufficiency	O
.	O
PSAP	O
32	O
mmHg	O
PVC	O
.	O
CORONARYGRAPHY	O
left	O
coronary	O
trunk	O
no	O
stenosis	O
.	O
Proximal	O
LAD	O
with	O
80	O
stenosis	O
in	O
the	O
context	O
of	O
in	O
stent	O
restenosis	O
,	O
TIMI	O
grade	O
3	O
flow	O
with	O
good	O
distal	O
bed	O
.	O
Mid	O
LAD	O
with	O
70	O
stenosis	O
,	O
TIMI	O
grade	O
3	O
flow	O
with	O
good	O
distal	O
bed	O
.	O
Distal	O
DA	O
with	O
70	O
stenosis	O
and	O
TIMI	O
grade	O
3	O
flow	O
.	O
Distal	O
circumflex	O
artery	O
Cx	O
has	O
60	O
stenosis	O
,	O
TIMI	O
grade	O
3	O
flow	O
and	O
good	O
distal	O
bed	O
.	O
Right	O
coronary	O
artery	O
no	O
stenosis	O
.	O
PERCUTANEOUS	O
CORONARY	O
INTERVENTION	O
PCI	O
on	O
the	O
LAD	O
Percutaneous	O
transluminal	O
coronary	O
angioplasty	O
PTCA	O
is	O
performed	O
on	O
in	O
stent	O
restenosis	O
in	O
the	O
proximal	O
LAD	O
,	O
with	O
predilatation	O
and	O
subsequent	O
implantation	O
of	O
a	O
3	O
x	O
20	O
mm	O
everolimus	B-FARMACO
eluting	O
stent	O
.	O
Another	O
3	O
x	O
12	O
mm	O
everolimus	B-FARMACO
eluting	O
stent	O
is	O
overlapped	O
distally	O
in	O
the	O
middle	O
third	O
stenosis	O
.	O
We	O
finished	O
by	O
implanting	O
another	O
2	O
.	O
5	O
x	O
12	O
mm	O
everolimus	B-FARMACO
eluting	O
stent	O
over	O
the	O
distal	O
LAD	O
stenosis	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
hospital	O
ward	O
as	O
non	O
ST	O
segment	O
elevation	O
acute	O
coronary	O
syndrome	O
NSTEACS	O
of	O
the	O
non	O
Q	O
acute	O
myocardial	O
infarction	O
AMI	O
type	O
in	O
a	O
stable	O
haemodynamic	O
situation	O
Killip	O
Kimball	O
KK	O
I	O
.	O
Given	O
the	O
aortic	O
murmur	O
and	O
the	O
history	O
of	O
mild	O
aortic	O
valve	O
disease	O
,	O
echocardiography	O
was	O
performed	O
to	O
confirm	O
that	O
there	O
was	O
no	O
severe	O
stenosis	O
and	O
to	O
assess	O
LV	O
systolic	O
function	O
.	O
TTE	O
reveals	O
mildly	O
moderate	O
aortic	O
stenosis	O
with	O
preserved	O
LVEF	O
.	O
Given	O
a	O
high	O
risk	O
ACS	O
,	O
coronary	O
angiography	O
was	O
performed	O
in	O
the	O
first	O
24	O
hours	O
,	O
revealing	O
severe	O
in	O
stent	O
restenosis	O
in	O
the	O
proximal	O
LAD	O
and	O
severe	O
lesions	O
in	O
the	O
mid	O
and	O
distal	O
LAD	O
with	O
moderate	O
lesions	O
in	O
the	O
distal	O
Cx	O
.	O
In	O
the	O
same	O
procedure	O
,	O
PCI	O
was	O
performed	O
on	O
the	O
LAD	O
with	O
implantation	O
of	O
three	O
overlapping	O
drug	O
eluting	O
stents	O
from	O
proximal	O
to	O
distal	O
.	O
The	O
patient	O
evolved	O
favourably	O
without	O
complications	O
.	O
As	O
for	O
his	O
CVRF	O
,	O
it	O
seems	O
clear	O
that	O
LDL	O
cholesterol	O
is	O
off	O
target	O
and	O
we	O
will	O
increase	O
his	O
statin	B-FARMACO
;	O
but	O
will	O
this	O
be	O
enough	O
?	O
And	O
regarding	O
his	O
type	O
2	O
DM	O
,	O
he	O
is	O
well	O
controlled	O
with	O
metformin	B-FARMACO
HbA1c	O
6	O
.	O
5	O
.	O
So	O
,	O
do	O
I	O
maintain	O
his	O
treatment	O
or	O
should	O
I	O
take	O
advantage	O
of	O
this	O
moment	O
to	O
do	O
something	O
else	O
?	O
DIAGNOSIS	O
Ischaemic	O
heart	O
disease	O
.	O
NSTEACS	O
non	O
Q	O
AMI	O
.	O
KKI	O
.	O
2	O
vessel	O
coronary	O
artery	O
disease	O
Severe	O
proximal	O
LAD	O
with	O
in	O
stent	O
restenosis	O
and	O
severe	O
mid	O
and	O
distal	O
LAD	O
;	O
moderate	O
distal	O
Cx	O
.	O
PCI	O
over	O
LAD	O
with	O
three	O
overlapping	O
drug	O
eluting	O
stents	O
.	O
Preserved	O
LVEF	O
without	O
asynergies	O
.	O
Degenerative	O
aortic	O
valve	O
disease	O
,	O
mild	O
moderate	O
aortic	O
stenosis	O
.	O
Paroxysmal	O
atrial	O
fibrillation	O
,	O
CHA2DS2	O
VASc	O
4	O
,	O
HAS	O
BLED	O
2	O
.	O
Type	O
2	O
DM	O
with	O
good	O
control	O
HbA1c	O
6	O
.	O
5	O
.	O
LDL	O
cholesterol	O
out	O
of	O
target	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Male	O
,	O
41	O
years	O
old	O
,	O
no	O
drug	O
allergies	O
.	O
BACKGROUND	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
dyslipidaemia	O
.	O
Ex	O
smoker	O
of	O
20	O
cigarettes	O
day	O
.	O
Sporadic	O
cocaine	O
and	O
alcohol	O
user	O
.	O
Left	O
frontoparietal	O
ischaemic	O
stroke	O
in	O
the	O
context	O
of	O
cocaine	O
use	O
2009	O
.	O
Complementary	O
studies	O
performed	O
electrocardiogram	O
ECG	O
monitoring	O
,	O
Doppler	O
of	O
supra	O
aortic	O
trunks	O
,	O
transthoracic	O
echocardiography	O
TTE	O
with	O
bubble	O
test	O
,	O
study	O
of	O
coagulopathy	O
compatible	O
with	O
normality	O
.	O
No	O
sequelae	O
at	O
present	O
.	O
No	O
personal	O
or	O
family	O
cardiological	O
history	O
.	O
Usual	O
treatment	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
300	O
mg	O
day	O
,	O
simvastatin	B-FARMACO
20	O
mg	O
day	O
.	O
CURRENT	O
ILLNESS	O
She	O
attended	O
the	O
emergency	O
department	O
for	O
neurological	O
focality	O
consisting	O
of	O
motor	O
aphasia	O
and	O
dysarthria	O
of	O
onset	O
30	O
minutes	O
ago	O
.	O
A	O
cranial	O
computed	O
tomography	O
CT	O
scan	O
was	O
performed	O
showing	O
a	O
known	O
left	O
frontoparietal	O
lesion	O
,	O
with	O
no	O
acute	O
ischaemic	O
or	O
haemorrhagic	O
findings	O
.	O
The	O
on	O
call	O
neurology	O
department	O
was	O
contacted	O
and	O
,	O
given	O
a	O
National	O
Institute	O
of	O
Health	O
Stroke	O
Scale	O
NIHSS	O
score	O
of	O
less	O
than	O
4	O
not	O
very	O
disabling	O
symptoms	O
,	O
he	O
was	O
not	O
considered	O
a	O
candidate	O
for	O
reperfusion	O
treatment	O
.	O
He	O
was	O
admitted	O
to	O
the	O
stroke	O
unit	O
for	O
haemodynamic	O
control	O
,	O
evolution	O
and	O
study	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
BP	O
130	O
70	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
65	O
bpm	O
.	O
Oxygen	O
saturation	O
SatO2	O
96	O
with	O
room	O
air	O
.	O
Afebrile	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
without	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
normoventilation	O
.	O
Abdomen	O
nondescript	O
.	O
Lower	O
extremities	O
without	O
oedema	O
or	O
indirect	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
Pedial	O
pulses	O
present	O
and	O
symmetrical	O
.	O
Neurological	O
examination	O
normoreactive	O
isochoric	O
pupils	O
.	O
Normal	O
cranial	O
nerves	O
.	O
Motor	O
aphasia	O
with	O
mild	O
dysarthria	O
.	O
Strength	O
and	O
sensitivity	O
preserved	O
and	O
symmetrical	O
.	O
No	O
campimetric	O
alterations	O
,	O
dysmetria	O
or	O
gait	O
disturbances	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
sinus	O
rhythm	O
at	O
65	O
bpm	O
,	O
without	O
conduction	O
disorders	O
,	O
without	O
repolarisation	O
alterations	O
.	O
CHEST	O
X	O
RAY	O
cardiothoracic	O
index	O
within	O
the	O
normal	O
range	O
,	O
lung	O
fields	O
without	O
condensation	O
.	O
ANALYSIS	O
Biochemistry	O
glucose	O
90	O
mg	O
dl	O
,	O
urea	O
24	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
9	O
mg	O
dl	O
,	O
chlorine	O
99	O
mEq	O
l	O
,	O
sodium	O
141	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
5	O
mEq	O
l	O
.	O
Thyroid	O
function	O
,	O
vitamin	O
B12	O
and	O
folic	O
acid	O
normal	O
.	O
Haemogram	O
leucocytes	O
10	O
,	O
100	O
,	O
Hb	O
16	O
.	O
4	O
g	O
dl	O
,	O
Ht	O
47	O
.	O
8	O
,	O
platelets	O
260	O
,	O
000	O
.	O
Serology	O
negative	O
.	O
Urine	O
toxins	O
negative	O
.	O
TROMBOPHILY	O
STUDY	O
heterozygous	O
for	O
C677T	O
polymorphism	O
,	O
normal	O
for	O
factor	O
V	O
Leyden	O
and	O
prothrombin	O
G20210A	O
mutations	O
.	O
TTE	O
left	O
ventricle	O
LV	O
not	O
dilated	O
or	O
hypertrophic	O
,	O
normal	O
global	O
and	O
segmental	O
systolic	O
function	O
.	O
Left	O
atrium	O
slightly	O
dilated	O
.	O
Right	O
chambers	O
normal	O
,	O
right	O
ventricular	O
RV	O
contractility	O
normal	O
.	O
Mitral	O
valve	O
on	O
the	O
free	O
edge	O
of	O
the	O
anterior	O
mitral	O
leaflet	O
there	O
is	O
a	O
nodular	O
,	O
homogeneous	O
image	O
,	O
which	O
does	O
not	O
interfere	O
with	O
valve	O
kinetics	O
.	O
Aortic	O
valve	O
trivalve	O
,	O
thin	O
leaflets	O
,	O
competent	O
.	O
Mild	O
tricuspid	O
insufficiency	O
TI	O
.	O
Inferior	O
vena	O
cava	O
IVC	O
not	O
dilated	O
with	O
preserved	O
inspiratory	O
collapse	O
.	O
Normal	O
systolic	O
pulmonary	O
artery	O
pressure	O
PAPS	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
.	O
CARDIAC	O
NUCLEAR	O
MAGNETIC	O
RESONANCE	O
MRI	O
nodular	O
image	O
of	O
about	O
7	O
mm	O
attached	O
to	O
the	O
septal	O
leaflet	O
of	O
the	O
mitral	O
valve	O
,	O
poorly	O
defined	O
,	O
which	O
could	O
correspond	O
to	O
fibroelastoma	O
.	O
Late	O
enhancement	O
sequences	O
show	O
no	O
foci	O
of	O
uptake	O
indicating	O
areas	O
of	O
myocardial	O
necrosis	O
or	O
fibrosis	O
.	O
Given	O
the	O
suspicion	O
,	O
transesophageal	O
echocardiography	O
is	O
recommended	O
.	O
Transesophageal	O
echocardiogram	O
Atrial	O
septum	O
intact	O
.	O
Left	O
atrial	O
septum	O
free	O
of	O
thrombus	O
.	O
Mitral	O
valve	O
thin	O
leaflets	O
,	O
mobility	O
and	O
opening	O
preserved	O
.	O
On	O
the	O
atrial	O
side	O
of	O
the	O
anterior	O
mitral	O
leaflet	O
festoon	O
A1	O
A2	O
there	O
is	O
an	O
oval	O
mass	O
,	O
heterogeneous	O
in	O
appearance	O
,	O
sessile	O
,	O
without	O
interfering	O
with	O
valve	O
function	O
,	O
suggesting	O
papillary	O
fibroelastoma	O
as	O
a	O
first	O
diagnostic	O
possibility	O
.	O
The	O
rest	O
of	O
the	O
study	O
is	O
superimposable	O
on	O
the	O
transthoracic	O
study	O
.	O
CARDIAC	O
CATHETERISM	O
coronary	O
angiography	O
right	O
dominance	O
.	O
Left	O
coronary	O
artery	O
LMCA	O
good	O
calibre	O
,	O
without	O
lesions	O
.	O
Descending	O
anterior	O
descending	O
artery	O
DA	O
no	O
stenosis	O
,	O
intramyocardial	O
middle	O
segment	O
with	O
slight	O
associated	O
milking	O
.	O
Circumflex	O
Cx	O
moderate	O
development	O
,	O
no	O
lesions	O
.	O
Bisector	O
long	O
and	O
of	O
good	O
calibre	O
,	O
without	O
stenosis	O
.	O
CD	O
no	O
stenosis	O
.	O
Aortography	O
ascending	O
aorta	O
of	O
normal	O
size	O
,	O
trivalve	O
aortic	O
valve	O
,	O
normofunctioning	O
.	O
CLINICAL	O
EVOLUTION	O
During	O
his	O
stay	O
on	O
the	O
ward	O
,	O
progressive	O
improvement	O
with	O
complete	O
resolution	O
of	O
the	O
neurological	O
symptoms	O
within	O
24	O
hours	O
.	O
No	O
arrhythmic	O
events	O
were	O
observed	O
on	O
ECG	O
monitoring	O
.	O
The	O
echocardiographic	O
study	O
showed	O
a	O
mass	O
in	O
the	O
anterior	O
mitral	O
leaflet	O
suggesting	O
papillary	O
fibroelastoma	O
as	O
the	O
underlying	O
aetiological	O
process	O
of	O
the	O
vascular	O
event	O
presented	O
by	O
the	O
patient	O
.	O
Given	O
the	O
risk	O
of	O
potential	O
embolic	O
complications	O
,	O
it	O
was	O
decided	O
to	O
complete	O
the	O
study	O
on	O
an	O
outpatient	O
basis	O
and	O
to	O
consider	O
tumour	O
excision	O
,	O
and	O
the	O
patient	O
was	O
referred	O
to	O
the	O
cardiac	O
surgery	O
department	O
,	O
which	O
accepted	O
the	O
case	O
.	O
Valve	O
repair	O
surgery	O
and	O
tumour	O
excision	O
was	O
performed	O
CPB	O
time	O
100	O
minutes	O
triangular	O
resection	O
of	O
the	O
anterior	O
leaflet	O
A1	O
festoon	O
where	O
the	O
tumour	O
was	O
located	O
and	O
annuloplasty	O
with	O
Physio	O
ring	O
no	O
.	O
34	O
.	O
Postoperative	O
period	O
in	O
the	O
intensive	O
care	O
unit	O
ICU	O
without	O
incident	O
,	O
starting	O
rehabilitation	O
and	O
early	O
discharge	O
from	O
the	O
ward	O
.	O
The	O
biopsy	O
was	O
sent	O
to	O
the	O
pathological	O
anatomy	O
service	O
,	O
confirming	O
the	O
definitive	O
diagnosis	O
of	O
papillary	O
fibroelastoma	O
.	O
DIAGNOSIS	O
Cardioembolic	O
transient	O
ischaemic	O
attack	O
.	O
Mitral	O
papillary	O
fibroelastoma	O
.	O
Tumour	O
resection	O
surgery	O
and	O
mitral	O
annuloplasty	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
BACKGROUND	O
No	O
known	O
drug	O
allergies	O
.	O
CVRF	O
ex	O
smoker	O
of	O
one	O
pack	O
day	O
for	O
2	O
years	O
after	O
an	O
acute	O
myocardial	O
infarction	O
AMI	O
.	O
Dyslipidaemia	O
under	O
pharmacological	O
treatment	O
.	O
Cardiological	O
history	O
under	O
outpatient	O
control	O
for	O
chronic	O
ischaemic	O
heart	O
disease	O
and	O
dyslipidaemia	O
.	O
In	O
2016	O
,	O
inferoposterolateral	O
ST	O
segment	O
elevation	O
acute	O
coronary	O
syndrome	O
STEMI	O
catheterisation	O
revealed	O
severe	O
coronary	O
artery	O
disease	O
in	O
two	O
vessels	O
circumflex	O
acute	O
lesion	O
and	O
right	O
coronary	O
artery	O
,	O
with	O
implantation	O
of	O
a	O
drug	O
eluting	O
stent	O
in	O
each	O
of	O
the	O
vessels	O
.	O
Last	O
echocardiogram	O
July	O
2017	O
non	O
dilated	O
,	O
mildly	O
hypertrophic	O
left	O
ventricle	O
LV	O
with	O
preserved	O
global	O
systolic	O
function	O
and	O
inferoposterior	O
hypokinesia	O
.	O
Trivalve	O
aortic	O
valve	O
without	O
functional	O
alterations	O
.	O
Mitral	O
valve	O
without	O
detectable	O
functional	O
alterations	O
.	O
Non	O
dilated	O
right	O
ventricle	O
RV	O
with	O
good	O
function	O
.	O
No	O
tricuspid	O
insufficiency	O
TI	O
detected	O
.	O
Pulmonary	O
acceleration	O
curve	O
not	O
suggestive	O
of	O
pulmonary	O
hypertension	O
.	O
No	O
pericardial	O
effusion	O
.	O
No	O
known	O
bronchopathy	O
.	O
No	O
history	O
of	O
surgery	O
.	O
Usual	O
treatment	O
omeprazole	B-FARMACO
20	O
mg	O
1	O
0	O
0	O
,	O
aceltisalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
100	O
mg	O
0	O
1	O
0	O
,	O
ramipril	B-FARMACO
2	O
.	O
5	O
mg	O
0	O
1	O
0	O
,	O
rosuvastatin	B-FARMACO
20	O
mg	O
0	O
0	O
1	O
,	O
ezetimibe	B-FARMACO
10	O
mg	O
0	O
0	O
1	O
.	O
CURRENT	O
DISEASE	O
The	O
patient	O
attends	O
his	O
cardiology	O
outpatient	O
appointment	O
,	O
one	O
year	O
after	O
the	O
infarction	O
.	O
Subjectively	O
he	O
is	O
well	O
,	O
without	O
dyspnoea	O
or	O
new	O
episodes	O
of	O
chest	O
pain	O
on	O
exertion	O
.	O
Since	O
the	O
last	O
change	O
in	O
his	O
statin	O
treatment	O
,	O
he	O
has	O
had	O
no	O
more	O
muscle	O
pain	O
.	O
He	O
goes	O
outside	O
daily	O
and	O
walks	O
for	O
more	O
than	O
1	O
hour	O
.	O
He	O
climbs	O
up	O
to	O
his	O
usual	O
home	O
3rd	O
floor	O
using	O
the	O
stairs	O
without	O
dyspnoea	O
which	O
forces	O
him	O
to	O
stop	O
to	O
rest	O
.	O
He	O
denies	O
orthopnoea	O
and	O
paroxysmal	O
nocturnal	O
dyspnoea	O
.	O
Impatient	O
for	O
the	O
results	O
of	O
the	O
blood	O
test	O
.	O
Since	O
admission	O
for	O
the	O
AMI	O
,	O
he	O
was	O
diagnosed	O
with	O
dyslipidaemia	O
,	O
starting	O
treatment	O
with	O
atorvastatin	B-FARMACO
80	O
mg	O
,	O
which	O
had	O
to	O
be	O
suspended	O
4	O
months	O
after	O
starting	O
it	O
due	O
to	O
disabling	O
muscle	O
pain	O
.	O
He	O
is	O
currently	O
being	O
treated	O
with	O
rosuvastatin	B-FARMACO
20	O
mg	O
and	O
ezetimibe	B-FARMACO
10	O
mg	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
BP	O
135	O
70	O
mmHg	O
,	O
heart	O
rate	O
HR	O
85	O
bpm	O
,	O
arterial	O
oxygen	O
saturation	O
measured	O
by	O
pulsimetry	O
SpO2	O
98	O
room	O
air	O
.	O
Eupneic	O
at	O
rest	O
.	O
C	O
C	O
No	O
jugular	O
plethora	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
without	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
.	O
Extremities	O
no	O
oedema	O
or	O
evidence	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
COMPLEMENTARY	O
TESTS	O
ELECTROCARDIOGRAM	O
ECG	O
sinus	O
rhythm	O
at	O
80	O
bpm	O
.	O
Normal	O
axis	O
.	O
Normal	O
PR	O
.	O
Narrow	O
QRS	O
.	O
Q	O
wave	O
in	O
DIII	O
and	O
avF	O
,	O
without	O
acute	O
repolarisation	O
alterations	O
.	O
ANALYSIS	O
glucose	O
83	O
mg	O
dl	O
,	O
urea	O
53	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
93mg	O
dl	O
,	O
total	O
cholesterol	O
160	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
47mg	O
dl	O
,	O
LDL	O
cholesterol	O
70	O
mg	O
dl	O
,	O
triglycerides	O
130	O
mg	O
dl	O
,	O
CK	O
112	O
U	O
l	O
,	O
GOT	O
17	O
U	O
l	O
,	O
GPT	O
30	O
U	O
l	O
,	O
GGT	O
45	O
U	O
l	O
,	O
sodium	O
141	O
mmol	O
l	O
,	O
potassium	O
4	O
.	O
6	O
mmol	O
l	O
,	O
haemoglobin	O
14	O
.	O
6	O
g	O
dl	O
,	O
leucocytes	O
8	O
.	O
40010	O
3	O
l	O
N	O
45	O
,	O
platelets	O
267	O
.	O
000	O
10	O
3	O
l	O
.	O
Transthoracic	O
echocardiogram	O
non	O
dilated	O
,	O
mildly	O
hypertrophic	O
LV	O
with	O
preserved	O
global	O
systolic	O
function	O
and	O
inferoposterior	O
basal	O
hypokinesia	O
.	O
Pseudonormalised	O
diastolic	O
pattern	O
.	O
Normal	O
aortic	O
root	O
35	O
mm	O
.	O
Trivalve	O
aortic	O
valve	O
without	O
functional	O
alterations	O
.	O
Normal	O
mitral	O
valve	O
in	O
structure	O
and	O
function	O
.	O
Non	O
dilated	O
RV	O
with	O
good	O
function	O
.	O
No	O
TR	O
detected	O
.	O
Pulmonary	O
acceleration	O
curve	O
not	O
suggestive	O
of	O
pulmonary	O
hypertension	O
.	O
No	O
pericardial	O
effusion	O
.	O
CLINICAL	O
EVOLUTION	O
After	O
the	O
AMI	O
,	O
the	O
patient	O
was	O
diagnosed	O
with	O
dyslipidaemia	O
.	O
He	O
initially	O
started	O
treatment	O
with	O
atorvastatin	B-FARMACO
80	O
mg	O
,	O
which	O
had	O
to	O
be	O
discontinued	O
after	O
3	O
months	O
due	O
to	O
incapacitating	O
myalgias	O
,	O
with	O
no	O
evidence	O
of	O
myositis	O
or	O
rhabdomyolysis	O
.	O
Subsequently	O
,	O
rosuvastatin	B-FARMACO
40	O
mg	O
was	O
prescribed	O
,	O
achieving	O
improvement	O
in	O
muscle	O
pain	O
,	O
but	O
without	O
complete	O
cessation	O
,	O
requiring	O
a	O
decrease	O
in	O
the	O
dose	O
to	O
rosuvastatin	B-FARMACO
20	O
mg	O
in	O
the	O
fourth	O
month	O
of	O
the	O
event	O
.	O
This	O
brought	O
about	O
a	O
great	O
symptomatic	O
improvement	O
with	O
disappearance	O
of	O
the	O
myalgias	O
,	O
and	O
she	O
was	O
able	O
to	O
maintain	O
a	O
normal	O
active	O
life	O
.	O
However	O
,	O
at	O
the	O
next	O
outpatient	O
check	O
up	O
6	O
months	O
after	O
the	O
cardiovascular	O
event	O
,	O
the	O
low	O
density	O
lipoprotein	O
cholesterol	O
LDL	O
C	O
levels	O
recommended	O
for	O
secondary	O
prevention	O
were	O
not	O
achieved	O
,	O
so	O
ezetimibe	B-FARMACO
was	O
added	O
to	O
the	O
treatment	O
,	O
and	O
special	O
emphasis	O
was	O
placed	O
on	O
the	O
importance	O
of	O
compliance	O
with	O
hygiene	O
and	O
dietary	O
measures	O
.	O
He	O
was	O
seen	O
again	O
one	O
year	O
after	O
the	O
AMI	O
.	O
At	O
the	O
present	O
time	O
,	O
the	O
patient	O
reports	O
being	O
completely	O
asymptomatic	O
from	O
the	O
cardiological	O
point	O
of	O
view	O
,	O
although	O
somewhat	O
nervous	O
and	O
desperate	O
due	O
to	O
the	O
impossibility	O
of	O
achieving	O
adequate	O
control	O
of	O
LDL	O
C	O
levels	O
.	O
He	O
follows	O
a	O
Mediterranean	O
diet	O
with	O
low	O
fat	O
intake	O
,	O
walks	O
daily	O
at	O
a	O
brisk	O
pace	O
for	O
2	O
hours	O
and	O
takes	O
all	O
his	O
medication	O
exhaustively	O
.	O
With	O
all	O
this	O
,	O
finally	O
,	O
optimal	O
target	O
LDL	O
C	O
levels	O
have	O
been	O
achieved	O
,	O
knowing	O
that	O
our	O
patient	O
has	O
a	O
very	O
high	O
established	O
cardiovascular	O
risk	O
.	O
DIAGNOSIS	O
Chronic	O
ischaemic	O
heart	O
disease	O
.	O
Dyslipidaemia	O
that	O
is	O
difficult	O
to	O
control	O
.	O
Intolerance	O
to	O
statins	O
myalgias	O
.	O
Preserved	O
LV	O
systolic	O
function	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
BACKGROUND	O
Family	O
history	O
several	O
affected	O
relatives	O
in	O
the	O
previous	O
two	O
generations	O
of	O
early	O
ischaemic	O
heart	O
disease	O
.	O
Personal	O
history	O
No	O
known	O
drug	O
allergies	O
.	O
Cardiovascular	O
risk	O
factors	O
ex	O
smoker	O
for	O
20	O
years	O
5	O
packs	O
year	O
.	O
Dyslipidaemia	O
type	O
heterozygous	O
monogenic	O
familial	O
hypercholesterolaemia	O
and	O
hypertriglyceridaemia	O
.	O
Hyperuricemia	O
.	O
No	O
arterial	O
hypertension	O
or	O
diabetes	O
mellitus	O
.	O
Other	O
history	O
stable	O
meningioma	O
in	O
the	O
pontocerebellar	O
angle	O
followed	O
periodically	O
with	O
magnetic	O
resonance	O
imaging	O
.	O
Cardiological	O
history	O
Ischaemic	O
heart	O
disease	O
debuting	O
in	O
2000	O
with	O
exertional	O
angina	O
.	O
An	O
ischaemia	O
test	O
was	O
performed	O
,	O
which	O
was	O
positive	O
with	O
high	O
risk	O
criteria	O
,	O
so	O
the	O
patient	O
was	O
offered	O
a	O
cardiac	O
catheterisation	O
,	O
which	O
he	O
accepted	O
.	O
Two	O
vessel	O
coronary	O
artery	O
disease	O
was	O
detected	O
99	O
stenosis	O
in	O
the	O
proximal	O
and	O
middle	O
anterior	O
descending	O
AD	O
and	O
under	O
occlusion	O
of	O
the	O
right	O
coronary	O
artery	O
RCA	O
at	O
a	O
very	O
distal	O
level	O
.	O
Percutaneous	O
revascularisation	O
was	O
performed	O
with	O
two	O
drug	O
eluting	O
stents	O
in	O
the	O
proximal	O
and	O
middle	O
LAD	O
.	O
Normal	O
left	O
ventricular	O
ejection	O
fraction	O
.	O
Valvular	O
heart	O
disease	O
of	O
the	O
severe	O
aortic	O
stenosis	O
type	O
,	O
symptomatic	O
due	O
to	O
exertional	O
dyspnoea	O
since	O
March	O
2015	O
.	O
He	O
had	O
been	O
asymptomatic	O
from	O
the	O
point	O
of	O
view	O
of	O
angina	O
.	O
Pre	O
surgery	O
cardiac	O
catheterisation	O
severely	O
calcified	O
coronary	O
arteries	O
,	O
with	O
moderate	O
and	O
short	O
stenosis	O
of	O
the	O
ostium	O
of	O
the	O
left	O
coronary	O
trunk	O
LMCA	O
not	O
significant	O
by	O
intravascular	O
ultrasound	O
IVUS	O
,	O
the	O
stents	O
of	O
the	O
middle	O
LAD	O
are	O
patent	O
and	O
without	O
restenosis	O
.	O
Stenosis	O
of	O
90	O
in	O
the	O
middle	O
LAD	O
,	O
distal	O
to	O
the	O
stents	O
.	O
Chronic	O
occlusion	O
of	O
proximal	O
DC	O
,	O
the	O
middle	O
DC	O
is	O
filled	O
by	O
homocoronary	O
collaterals	O
,	O
the	O
posterior	O
descending	O
and	O
posterolateral	O
collaterals	O
are	O
dependent	O
on	O
the	O
left	O
coronary	O
artery	O
.	O
Cardiac	O
surgery	O
in	O
August	O
2015	O
,	O
aortic	O
valve	O
replacement	O
with	O
St	O
.	O
Jude	O
mechanical	O
prosthesis	O
no	O
.	O
19	O
and	O
bypass	O
of	O
the	O
left	O
mammary	O
artery	O
to	O
the	O
LAD	O
,	O
with	O
good	O
postoperative	O
evolution	O
.	O
Chronic	O
treatment	O
warfarin	B-FARMACO
,	O
omeprazole	B-FARMACO
20	O
mg	O
24	O
hours	O
,	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
24	O
hours	O
,	O
allopurinol	B-FARMACO
100	O
mg	O
24	O
hours	O
,	O
rosuvastatin	B-FARMACO
40	O
mg	O
24	O
hours	O
,	O
ezetimibe	B-FARMACO
10	O
mg	O
24	O
hours	O
.	O
Current	O
status	O
asymptomatic	O
from	O
the	O
cardiovascular	O
point	O
of	O
view	O
.	O
Walks	O
1	O
1	O
.	O
5	O
hours	O
a	O
day	O
,	O
reports	O
a	O
low	O
salt	O
diet	O
and	O
no	O
saturated	O
fats	O
,	O
never	O
smoked	O
again	O
.	O
Good	O
adherence	O
to	O
treatment	O
assured	O
by	O
the	O
patient	O
and	O
his	O
close	O
family	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
BP	O
127	O
78	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
68	O
bpm	O
.	O
Body	O
mass	O
index	O
BMI	O
26	O
.	O
5	O
kg	O
m2	O
.	O
Corneal	O
arcus	O
already	O
described	O
since	O
2000	O
,	O
when	O
ischaemic	O
heart	O
disease	O
debuted	O
at	O
the	O
age	O
of	O
39	O
.	O
Jugular	O
venous	O
pressure	O
normal	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
normal	O
prosthetic	O
sounds	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
non	O
painful	O
,	O
no	O
palpable	O
masses	O
or	O
megaliths	O
.	O
Lower	O
extremities	O
without	O
oedema	O
,	O
with	O
peripheral	O
pulses	O
present	O
and	O
symmetrical	O
.	O
No	O
tendon	O
xanthomas	O
were	O
observed	O
on	O
inspection	O
.	O
COMPLEMENTARY	O
TESTS	O
ELECTROCARDIOGRAM	O
ECG	O
sinus	O
rhythm	O
at	O
68	O
bpm	O
.	O
Normal	O
axis	O
.	O
Normal	O
PR	O
.	O
Narrow	O
QRS	O
.	O
No	O
repolarisation	O
alterations	O
.	O
Current	O
ANALYTICS	O
2018	O
glucose	O
95	O
mg	O
dl	O
,	O
normal	O
renal	O
function	O
FGR	O
80	O
ml	O
min	O
.	O
Total	O
cholesterol	O
145	O
mg	O
dl	O
,	O
LDL	O
cholesterol	O
67	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
48	O
mg	O
dl	O
.	O
Triglycerides	O
149	O
mg	O
dl	O
.	O
Transaminases	O
normal	O
.	O
CK	O
normal	O
.	O
TSH	O
normal	O
.	O
HbA1c	O
5	O
.	O
5	O
.	O
Previous	O
LDL	O
cholesterol	O
figures	O
and	O
lipid	O
lowering	O
treatments	O
prescribed	O
April	O
2000	O
,	O
no	O
treatment	O
LDL	O
210	O
mg	O
dl	O
.	O
June	O
2000	O
,	O
simvastatin	B-FARMACO
40	O
mg	O
LDL	O
135	O
mg	O
dl	O
.	O
April	O
2015	O
,	O
atorvastatin	B-FARMACO
40	O
mg	O
ezetimibe	B-FARMACO
10	O
mg	O
LDL	O
85	O
mg	O
dl	O
.	O
October	O
2015	O
,	O
rosuvastatin	B-FARMACO
20	O
mg	O
ezetimibe	B-FARMACO
10	O
mg	O
LDL	O
73	O
mg	O
dl	O
.	O
June	O
2016	O
,	O
rosuvastatin	B-FARMACO
40	O
mg	O
ezetimibe	B-FARMACO
10	O
mg	O
LDL	O
65	O
mg	O
dl	O
.	O
CLINICAL	O
EVOLUTION	O
Patient	O
at	O
very	O
high	O
cardiovascular	O
risk	O
with	O
early	O
ischaemic	O
heart	O
disease	O
and	O
clinical	O
diagnosis	O
of	O
familial	O
hypercholesterolaemia	O
FH	O
.	O
Throughout	O
the	O
follow	O
up	O
,	O
she	O
complies	O
well	O
with	O
the	O
lifestyle	O
recommendations	O
and	O
adheres	O
well	O
to	O
treatment	O
.	O
Increasing	O
lipid	O
lowering	O
treatment	O
with	O
good	O
tolerance	O
is	O
required	O
until	O
LDL	O
cholesterol	O
LDL	O
C	O
levels	O
70	O
mg	O
dl	O
are	O
achieved	O
with	O
rosuvastatin	B-FARMACO
40	O
mg	O
and	O
ezetimibe	B-FARMACO
10	O
mg	O
.	O
DIAGNOSIS	O
Chronic	O
stable	O
ischaemic	O
heart	O
disease	O
two	O
vessel	O
coronary	O
artery	O
disease	O
partially	O
revascularised	O
percutaneously	O
and	O
surgically	O
.	O
Valvular	O
heart	O
disease	O
severe	O
symptomatic	O
aortic	O
stenosis	O
on	O
trivalve	O
valve	O
,	O
corrected	O
by	O
aortic	O
valve	O
replacement	O
with	O
a	O
mechanical	O
prosthesis	O
.	O
Normal	O
left	O
ventricular	O
systolic	O
function	O
.	O
Heterozygous	O
monogenic	O
FH	O
.	O
LDL	O
C	O
in	O
range	O
with	O
combined	O
treatment	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
A	O
31	O
year	O
old	O
woman	O
with	O
no	O
past	O
history	O
of	O
interest	O
consulted	O
for	O
occasional	O
palpitations	O
and	O
syncope	O
related	O
to	O
physical	O
and	O
emotional	O
stress	O
that	O
had	O
started	O
5	O
months	O
earlier	O
.	O
She	O
had	O
a	O
family	O
history	O
of	O
infarction	O
in	O
a	O
paternal	O
grandfather	O
88	O
years	O
old	O
and	O
vasovagal	O
syncope	O
in	O
a	O
brother	O
25	O
years	O
old	O
.	O
On	O
first	O
examination	O
,	O
the	O
patient	O
was	O
normotensive	O
and	O
afebrile	O
,	O
well	O
perfused	O
,	O
eupneic	O
at	O
rest	O
and	O
with	O
good	O
skin	O
and	O
mucous	O
membrane	O
colouring	O
.	O
Carotid	O
pulses	O
were	O
rhythmic	O
and	O
symmetrical	O
and	O
there	O
was	O
no	O
jugular	O
engorgement	O
.	O
Cardiopulmonary	O
auscultation	O
showed	O
rhythmic	O
tones	O
and	O
no	O
murmurs	O
with	O
preserved	O
vesicular	O
murmur	O
.	O
There	O
was	O
no	O
pain	O
on	O
superficial	O
or	O
deep	O
abdominal	O
palpation	O
,	O
no	O
masses	O
or	O
megaliths	O
and	O
hydroaerial	O
sounds	O
were	O
present	O
.	O
Pedial	O
and	O
posterior	O
tibial	O
pulses	O
were	O
present	O
and	O
symmetrical	O
and	O
there	O
was	O
no	O
malleolar	O
oedema	O
or	O
stigmata	O
of	O
venous	O
insufficiency	O
or	O
deep	O
vein	O
thrombosis	O
.	O
COMPLEMENTARY	O
TESTS	O
Blood	O
tests	O
were	O
unremarkable	O
and	O
the	O
chest	O
X	O
ray	O
showed	O
a	O
normal	O
cardiac	O
silhouette	O
,	O
with	O
no	O
alterations	O
in	O
the	O
bronchovascular	O
pattern	O
or	O
alveolar	O
or	O
interstitial	O
infiltrates	O
and	O
free	O
costodiaphragmatic	O
angles	O
.	O
The	O
electrocardiogram	O
showed	O
sinus	O
rhythm	O
at	O
54	O
bpm	O
,	O
axis	O
at	O
60o	O
,	O
PR	O
124	O
msec	O
,	O
narrow	O
QRS	O
,	O
without	O
ST	O
segment	O
or	O
T	O
wave	O
abnormalities	O
.	O
An	O
urgent	O
transthoracic	O
echocardiogram	O
showed	O
a	O
non	O
dilated	O
and	O
non	O
hypertrophied	O
left	O
ventricle	O
,	O
no	O
gross	O
alterations	O
of	O
segmental	O
contractility	O
,	O
preserved	O
ejection	O
fraction	O
62	O
and	O
no	O
pericardial	O
effusion	O
.	O
A	O
24	O
hour	O
Holter	O
electrocardiogram	O
showed	O
frequent	O
bouts	O
of	O
non	O
sustained	O
polymorphic	O
ventricular	O
tachycardia	O
of	O
helical	O
morphology	O
and	O
high	O
density	O
ventricular	O
extrasystoles	O
of	O
various	O
morphologies	O
,	O
the	O
most	O
frequent	O
being	O
complete	O
left	O
bundle	O
branch	O
block	O
with	O
inferior	O
axis	O
,	O
with	O
frequent	O
R	O
over	O
T	O
phenomena	O
.	O
EVOLUTION	O
In	O
view	O
of	O
these	O
findings	O
,	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
Cardiology	O
Department	O
.	O
The	O
determination	O
of	O
metanephrines	O
and	O
vanillylmandelic	O
acid	O
in	O
24	O
hour	O
urine	O
was	O
normal	O
.	O
During	O
her	O
stay	O
she	O
remained	O
with	O
telemetry	O
,	O
presenting	O
occasional	O
ventricular	O
extrasystoles	O
,	O
some	O
couple	O
and	O
very	O
occasional	O
triplets	O
,	O
without	O
more	O
complex	O
forms	O
.	O
A	O
transthoracic	O
echocardiogram	O
with	O
contrast	O
showed	O
areas	O
of	O
non	O
compaction	O
in	O
the	O
postero	O
lateral	O
mid	O
apical	O
region	O
ratio	O
compacted	O
non	O
compacted	O
myocardium	O
1	O
.	O
5	O
in	O
end	O
systole	O
and	O
2	O
.	O
2	O
in	O
end	O
diastole	O
,	O
with	O
Doppler	O
flow	O
between	O
the	O
intertrabecular	O
recesses	O
.	O
On	O
the	O
other	O
hand	O
,	O
simple	O
ergometry	O
was	O
performed	O
without	O
beta	O
blockers	O
,	O
which	O
was	O
conclusive	O
,	O
clinically	O
and	O
electrically	O
negative	O
for	O
ischaemia	O
,	O
although	O
showing	O
frequent	O
ventricular	O
extrasystoles	O
of	O
different	O
morphology	O
from	O
the	O
second	O
Bruce	O
stage	O
onwards	O
,	O
which	O
joined	O
in	O
pairs	O
from	O
the	O
third	O
stage	O
onwards	O
,	O
and	O
bouts	O
of	O
polymorphic	O
ventricular	O
tachycardia	O
from	O
the	O
fourth	O
stage	O
onwards	O
.	O
Beta	O
blocker	O
therapy	O
was	O
started	O
,	O
with	O
good	O
tolerance	O
,	O
and	O
a	O
second	O
ergometry	O
performed	O
48	O
hours	O
later	O
showed	O
a	O
marked	O
improvement	O
of	O
arrhythmias	O
with	O
extrasystoles	O
and	O
isolated	O
triplets	O
at	O
high	O
load	O
.	O
Cardiac	O
magnetic	O
resonance	O
imaging	O
was	O
also	O
performed	O
,	O
which	O
confirmed	O
areas	O
of	O
non	O
compaction	O
in	O
anterior	O
and	O
lateral	O
mid	O
apical	O
regions	O
,	O
with	O
a	O
ratio	O
between	O
non	O
compacted	O
compacted	O
myocardium	O
of	O
3	O
.	O
75	O
and	O
4	O
.	O
5	O
respectively	O
,	O
with	O
no	O
enhancement	O
in	O
the	O
late	O
uptake	O
sequence	O
or	O
hyperintensity	O
in	O
the	O
pT2	O
sequences	O
with	O
fat	O
suppression	O
and	O
preserved	O
LVEF	O
68	O
.	O
The	O
genetic	O
study	O
revealed	O
that	O
the	O
patient	O
carried	O
the	O
variant	O
1	O
237947553	O
G	O
A	O
in	O
heterozygosis	O
of	O
the	O
RyR2	O
gene	O
,	O
a	O
missense	O
mutation	O
that	O
causes	O
an	O
amino	O
acid	O
substitution	O
of	O
glycine	O
for	O
arginine	O
Gly4181Arg	O
,	O
not	O
previously	O
described	O
as	O
pathogenic	O
for	O
catecholaminergic	O
polymorphic	O
ventricular	O
tachycardia	O
non	O
conclusive	O
result	O
or	O
non	O
compaction	O
cardiomyopathy	O
.	O
The	O
patient	O
evolved	O
well	O
and	O
three	O
months	O
later	O
is	O
asymptomatic	O
with	O
no	O
evidence	O
of	O
recurrence	O
.	O
DIAGNOSIS	O
Polymorphic	O
non	O
sustained	O
catecholaminergic	O
ventricular	O
tachycardia	O
with	O
inconclusive	O
genetic	O
study	O
.	O
Non	O
compacted	O
left	O
ventricle	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
BACKGROUND	O
69	O
year	O
old	O
male	O
,	O
worked	O
in	O
indoor	O
mining	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
ex	O
smoker	O
for	O
40	O
years	O
,	O
accumulated	O
25	O
paq	O
year	O
.	O
Ex	O
drinker	O
.	O
No	O
known	O
metabolic	O
disorders	O
.	O
Meets	O
criteria	O
for	O
antiphospholipid	O
syndrome	O
APS	O
and	O
partially	O
for	O
systemic	O
lupus	O
erythematosus	O
SLE	O
.	O
Segmental	O
pulmonary	O
thromboembolism	O
PTE	O
in	O
2015	O
for	O
which	O
she	O
received	O
anticoagulation	O
with	O
acenocoumarol	B-FARMACO
.	O
Cardiological	O
history	O
in	O
December	O
2017	O
,	O
acute	O
non	O
ST	O
segment	O
elevation	O
myocardial	O
infarction	O
NSTEMI	O
with	O
2	O
vessel	O
coronary	O
artery	O
disease	O
AMD	O
and	O
PD	O
with	O
partial	O
revascularisation	O
.	O
On	O
admission	O
,	O
transthoracic	O
echocardiography	O
TTE	O
was	O
performed	O
and	O
detected	O
mild	O
left	O
ventricular	O
hypertrophy	O
LVH	O
without	O
valvular	O
heart	O
disease	O
.	O
Left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
preserved	O
with	O
normofunctioning	O
right	O
ventricle	O
RV	O
.	O
No	O
family	O
history	O
of	O
early	O
sudden	O
death	O
.	O
Treatment	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
100	O
mg	O
,	O
clopidogrel	B-FARMACO
75	O
mg	O
,	O
acenocoumarol	B-FARMACO
,	O
atorvastatin	B-FARMACO
80	O
mg	O
,	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
,	O
hydroxychloroquine	B-FARMACO
,	O
hydroxyzine	B-FARMACO
and	O
ranitidine	B-FARMACO
.	O
CURRENT	O
ILLNESS	O
The	O
patient	O
attends	O
the	O
emergency	O
department	O
for	O
chest	O
pain	O
.	O
He	O
reports	O
that	O
2	O
hours	O
before	O
consulting	O
and	O
while	O
sitting	O
down	O
after	O
eating	O
,	O
he	O
began	O
to	O
experience	O
central	O
thoracic	O
oppression	O
with	O
irradiation	O
to	O
the	O
left	O
upper	O
limb	O
that	O
reminded	O
him	O
of	O
the	O
previous	O
STEMI	O
,	O
although	O
of	O
lesser	O
intensity	O
.	O
He	O
denied	O
having	O
had	O
anginal	O
episodes	O
since	O
revascularisation	O
.	O
Good	O
adherence	O
to	O
the	O
prescribed	O
treatment	O
.	O
On	O
arrival	O
,	O
an	O
electrocardiogram	O
ECG	O
was	O
performed	O
which	O
showed	O
sustained	O
monosystolic	O
ventricular	O
tachycardia	O
SMVT	O
that	O
was	O
well	O
tolerated	O
haemodynamically	O
,	O
so	O
it	O
was	O
decided	O
to	O
perform	O
pharmacological	O
cardioversion	O
with	O
procainamide	B-FARMACO
.	O
After	O
700	O
mg	O
in	O
100	O
mg	O
boluses	O
,	O
the	O
patient	O
reverted	O
to	O
sinus	O
rhythm	O
.	O
The	O
patient	O
was	O
admitted	O
to	O
complete	O
studies	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
BP	O
140	O
80	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
160	O
bpm	O
.	O
SatO2	O
without	O
oxygen	O
therapy	O
98	O
.	O
Afebrile	O
.	O
Conscious	O
,	O
oriented	O
and	O
cooperative	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
,	O
tachycardic	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
,	O
no	O
added	O
sounds	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
.	O
Lower	O
limbs	O
well	O
perfused	O
,	O
positive	O
and	O
symmetrical	O
pulses	O
.	O
No	O
neurological	O
focality	O
on	O
examination	O
.	O
COMPLEMENTARY	O
TESTS	O
BIOCHEMISTRY	O
renal	O
function	O
and	O
ions	O
normal	O
.	O
Ultrasensitive	O
troponin	O
T	O
17	O
ng	O
l	O
,	O
without	O
significant	O
elevation	O
limit	O
35	O
ng	O
l	O
.	O
Haemogram	O
haemoglobin	O
14	O
.	O
9	O
g	O
dl	O
,	O
leucocytes	O
8170	O
with	O
normal	O
formula	O
,	O
platelets	O
278000	O
.	O
CHEST	O
X	O
RAY	O
normal	O
cardiothoracic	O
index	O
with	O
no	O
evidence	O
of	O
acute	O
pathology	O
.	O
ECG	O
on	O
arrival	O
VT	O
with	O
morphology	O
of	O
left	O
bundle	O
branch	O
block	O
LBBB	O
,	O
inferior	O
axis	O
and	O
V3	O
V4	O
transition	O
.	O
Postcardioversion	O
ECG	O
sinus	O
rhythm	O
at	O
60	O
bpm	O
,	O
negative	O
T	O
in	O
I	O
and	O
aVL	O
and	O
from	O
V4	O
to	O
V6	O
.	O
Baseline	O
ECG	O
2015	O
SR	O
at	O
65	O
bpm	O
,	O
negative	O
T	O
in	O
I	O
and	O
aVL	O
and	O
from	O
V4	O
to	O
V6	O
.	O
Cardiac	O
magnetic	O
resonance	O
CMR	O
RV	O
of	O
normal	O
size	O
with	O
dyskinesia	O
in	O
the	O
anterior	O
wall	O
at	O
mid	O
ventricular	O
level	O
and	O
small	O
sacculations	O
of	O
the	O
free	O
wall	O
at	O
subtricuspid	O
level	O
,	O
right	O
ventricular	O
ejection	O
fraction	O
RVEF	O
44	O
.	O
Normal	O
sized	O
LV	O
with	O
basal	O
septal	O
hypertrophy	O
14	O
mm	O
and	O
mildly	O
depressed	O
LVEF	O
.	O
Small	O
area	O
of	O
intramyocardial	O
late	O
enhancement	O
at	O
the	O
inferior	O
junction	O
of	O
both	O
ventricles	O
at	O
mid	O
level	O
.	O
TTE	O
mild	O
LVH	O
with	O
preserved	O
LVEF	O
.	O
CLINICAL	O
EVOLUTION	O
Given	O
the	O
morphology	O
of	O
the	O
VT	O
,	O
suggestive	O
of	O
right	O
ventricular	O
outflow	O
tract	O
RVOT	O
,	O
a	O
CMR	O
was	O
performed	O
to	O
rule	O
out	O
myocardial	O
eschar	O
as	O
the	O
origin	O
of	O
the	O
same	O
and	O
a	O
slightly	O
affected	O
LVEF	O
was	O
observed	O
,	O
but	O
an	O
LVEF	O
of	O
44	O
with	O
small	O
subtricuspid	O
sacculations	O
and	O
an	O
area	O
of	O
dyskinesia	O
.	O
An	O
electrophysiological	O
study	O
EPS	O
was	O
performed	O
,	O
showing	O
VT	O
with	O
LBBB	O
morphology	O
,	O
inferior	O
axis	O
and	O
transition	O
in	O
V3	O
and	O
V4	O
.	O
In	O
addition	O
,	O
a	O
zone	O
of	O
maximum	O
precocity	O
is	O
determined	O
at	O
this	O
subtricuspid	O
level	O
where	O
the	O
tachycardia	O
is	O
terminated	O
by	O
performing	O
an	O
effective	O
ablation	O
.	O
The	O
patient	O
remained	O
asymptomatic	O
and	O
without	O
new	O
arrhythmic	O
events	O
at	O
post	O
discharge	O
follow	O
up	O
.	O
However	O
,	O
given	O
the	O
VT	O
morphology	O
,	O
CMR	O
alterations	O
and	O
baseline	O
ECG	O
characteristics	O
,	O
all	O
minor	O
criteria	O
for	O
RV	O
arrhythmogenic	O
dysplasia	O
,	O
the	O
borderline	O
diagnosis	O
of	O
arrhythmogenic	O
right	O
ventricular	O
dysplasia	O
ARVD	O
is	O
established	O
.	O
DIAGNOSIS	O
TVMS	O
of	O
the	O
anterolateral	O
aspect	O
of	O
the	O
RV	O
cardioverted	O
pharmacologically	O
with	O
procainamide	B-FARMACO
and	O
successfully	O
ablated	O
.	O
2	O
vessel	O
coronary	O
artery	O
disease	O
with	O
partial	O
revascularisation	O
.	O
Slightly	O
impaired	O
LVEF	O
.	O
Possible	O
arrhythmogenic	O
RV	O
dysplasia	O
3	O
minor	O
criteria	O
borderline	O
diagnosis	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
BACKGROUND	O
64	O
year	O
old	O
male	O
diagnosed	O
with	O
dextrocardia	O
at	O
54	O
years	O
of	O
age	O
,	O
following	O
family	O
screening	O
.	O
Toxic	O
habits	O
non	O
smoker	O
,	O
moderate	O
drinker	O
.	O
He	O
leads	O
an	O
active	O
life	O
.	O
CURRENT	O
DISEASE	O
At	O
the	O
time	O
of	O
diagnosis	O
in	O
New	O
York	O
Heart	O
Association	O
NYHA	O
functional	O
class	O
I	O
with	O
recurrent	O
symptoms	O
of	O
palpitations	O
,	O
dizziness	O
and	O
syncope	O
,	O
limiting	O
his	O
quality	O
of	O
life	O
.	O
The	O
night	O
before	O
admission	O
she	O
presented	O
with	O
precordial	O
pain	O
and	O
palpitations	O
together	O
with	O
loss	O
of	O
postural	O
tone	O
and	O
level	O
of	O
consciousness	O
,	O
for	O
which	O
she	O
consulted	O
her	O
doctor	O
,	O
who	O
arranged	O
hospital	O
admission	O
for	O
medical	O
care	O
and	O
examination	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
120	O
80	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
100	O
bpm	O
.	O
Oxygen	O
saturation	O
97	O
.	O
No	O
jugular	O
ingurgitation	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
without	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
normoventilation	O
,	O
no	O
crackles	O
.	O
Abdomen	O
nondescript	O
.	O
Lower	O
limbs	O
without	O
oedema	O
.	O
Neurological	O
examination	O
normoreactive	O
isochoric	O
pupils	O
.	O
Normal	O
cranial	O
nerves	O
.	O
Normal	O
language	O
.	O
Strength	O
and	O
sensitivity	O
preserved	O
.	O
Normal	O
gait	O
.	O
COMPLEMENTARY	O
TESTS	O
THORAX	O
RADIOGRAPHY	O
dextrocardia	O
.	O
Cardiothoracic	O
index	O
greater	O
than	O
0	O
.	O
5	O
with	O
slight	O
vascular	O
redistribution	O
to	O
upper	O
fields	O
.	O
ELECTROCARDIOGRAM	O
ECG	O
sinus	O
rhythm	O
.	O
Atrioventricular	O
conduction	O
preserved	O
,	O
QRS	O
120	O
ms	O
with	O
axis	O
30o	O
.	O
Initial	O
Q	O
wave	O
in	O
aVL	O
.	O
Negative	O
T	O
wave	O
in	O
DIII	O
aVF	O
,	O
DI	O
aVL	O
and	O
V5	O
V6	O
.	O
ANALYTICS	O
Hb	O
14	O
g	O
dl	O
,	O
Ht	O
42	O
,	O
Cr	O
0	O
.	O
9	O
mg	O
dl	O
,	O
NT	O
proBNP	O
1	O
,	O
000	O
pg	O
ml	O
.	O
HOLTER	O
ECG	O
sinus	O
rhythm	O
with	O
a	O
maximum	O
HR	O
of	O
93	O
bpm	O
,	O
minimum	O
of	O
50	O
bpm	O
,	O
average	O
of	O
61	O
bpm	O
.	O
Ventricular	O
extrasystoles	O
in	O
repetitive	O
forms	O
,	O
three	O
bouts	O
of	O
non	O
sustained	O
ventricular	O
tachycardia	O
,	O
lasting	O
seconds	O
,	O
with	O
a	O
maximum	O
HR	O
of	O
166	O
bpm	O
.	O
ECOCARDIOGRAM	O
left	O
atrium	O
LA	O
slightly	O
dilated	O
.	O
Left	O
ventricle	O
LV	O
of	O
normal	O
diameter	O
with	O
moderate	O
asymmetric	O
septal	O
hypertrophy	O
15	O
mm	O
with	O
no	O
obstruction	O
across	O
the	O
LV	O
outflow	O
tract	O
and	O
no	O
systolic	O
anterior	O
motion	O
of	O
the	O
mitral	O
valve	O
.	O
Mild	O
LV	O
systolic	O
dysfunction	O
EF	O
55	O
and	O
grade	O
1	O
diastolic	O
dysfunction	O
.	O
CARDIAC	O
NUCLEAR	O
MAGNETIC	O
RESONANCE	O
CMRI	O
late	O
gadolinium	O
enhancement	O
irregularly	O
distributed	O
in	O
the	O
medial	O
wall	O
of	O
the	O
entire	O
septum	O
,	O
anterior	O
wall	O
and	O
free	O
wall	O
of	O
the	O
right	O
ventricle	O
.	O
Interventricular	O
septum	O
15	O
mm	O
thick	O
.	O
CARDIODESFIBRILLATOR	O
CONTROL	O
programmer	O
shows	O
appropriate	O
shocks	O
.	O
CLINICAL	O
EVOLUTION	O
During	O
his	O
admission	O
,	O
the	O
patient	O
was	O
asked	O
about	O
his	O
family	O
history	O
his	O
paternal	O
grandfather	O
and	O
two	O
of	O
his	O
uncles	O
died	O
of	O
MS	O
.	O
We	O
found	O
a	O
patient	O
with	O
clinical	O
symptoms	O
that	O
limited	O
his	O
quality	O
of	O
life	O
and	O
,	O
after	O
the	O
studies	O
performed	O
,	O
the	O
diagnosis	O
of	O
hypertrophic	O
cardiomyopathy	O
was	O
confirmed	O
.	O
An	O
intermediate	O
risk	O
of	O
SD	O
was	O
estimated	O
HCM	O
Risk	O
SCD	O
Calculator	O
5	O
year	O
risk	O
of	O
4	O
.	O
68	O
,	O
and	O
a	O
decision	O
was	O
made	O
to	O
implant	O
an	O
implantable	O
cardioverter	O
defibrillator	O
ICD	O
for	O
primary	O
prevention	O
of	O
SD	O
.	O
After	O
a	O
stable	O
period	O
of	O
11	O
months	O
,	O
he	O
presented	O
appropriate	O
ICD	O
shocks	O
at	O
80	O
J	O
,	O
demonstrating	O
the	O
effectiveness	O
of	O
the	O
therapy	O
in	O
the	O
prevention	O
of	O
SD	O
in	O
a	O
patient	O
with	O
hypertrophic	O
cardiomyopathy	O
.	O
The	O
evolution	O
at	O
the	O
following	O
year	O
is	O
favourable	O
.	O
Medical	O
treatment	O
was	O
optimised	O
,	O
and	O
the	O
absence	O
of	O
ICD	O
discharges	O
was	O
found	O
in	O
the	O
controls	O
,	O
and	O
the	O
control	O
electrocardiogram	O
was	O
in	O
sinus	O
rhythm	O
.	O
A	O
control	O
echocardiogram	O
was	O
performed	O
,	O
showing	O
LV	O
with	O
moderate	O
asymmetric	O
septal	O
hypertrophy	O
,	O
which	O
has	O
not	O
progressed	O
,	O
and	O
maintaining	O
LV	O
systolic	O
function	O
EF	O
57	O
.	O
No	O
dynamic	O
gradient	O
was	O
observed	O
in	O
the	O
LV	O
outflow	O
tract	O
.	O
DIAGNOSIS	O
Non	O
obstructive	O
asymmetric	O
septal	O
hypertrophic	O
cardiomyopathy	O
HCM	O
.	O
Family	O
history	O
of	O
MS	O
2nd	O
degree	O
.	O
Repeated	O
syncope	O
.	O
Record	O
of	O
non	O
sustained	O
ventricular	O
tachycardia	O
NSVT	O
.	O
Late	O
intramyocardial	O
enhancement	O
on	O
cardiac	O
MRI	O
.	O
ICD	O
carrier	O
with	O
appropriate	O
shocks	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Male	O
,	O
65	O
years	O
old	O
.	O
BACKGROUND	O
No	O
known	O
allergies	O
.	O
Toxic	O
habits	O
ex	O
smoker	O
IPA	O
20	O
packs	O
year	O
.	O
Occasional	O
alcohol	O
consumption	O
1	O
beer	O
at	O
weekends	O
.	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
hypertension	O
HT	O
,	O
mixed	O
dyslipidaemia	O
,	O
no	O
diabetes	O
mellitus	O
DM	O
.	O
Cardiovascular	O
history	O
chronic	O
ischaemic	O
heart	O
disease	O
admission	O
for	O
non	O
Q	O
AMI	O
in	O
2010	O
with	O
complete	O
percutaneous	O
revascularisation	O
of	O
severe	O
lesion	O
in	O
middle	O
anterior	O
descending	O
and	O
distal	O
right	O
coronary	O
artery	O
.	O
Asymptomatic	O
for	O
angina	O
.	O
No	O
new	O
events	O
.	O
Echocardiogram	O
left	O
ventricle	O
of	O
normal	O
size	O
and	O
wall	O
thickness	O
.	O
Left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
preserved	O
with	O
akinesia	O
of	O
the	O
basal	O
segment	O
of	O
the	O
inferior	O
face	O
,	O
the	O
rest	O
preserved	O
.	O
Left	O
atrium	O
of	O
normal	O
size	O
.	O
Right	O
chambers	O
of	O
normal	O
size	O
.	O
Normal	O
right	O
ventricular	O
ejection	O
fraction	O
RVEF	O
.	O
Tricuspid	O
aortic	O
valve	O
anatomically	O
and	O
functionally	O
normal	O
.	O
Mitral	O
valve	O
with	O
focal	O
annular	O
calcification	O
and	O
trivial	O
mitral	O
regurgitation	O
.	O
Mild	O
tricuspid	O
insufficiency	O
allowing	O
estimation	O
of	O
normal	O
pulmonary	O
systolic	O
pressure	O
.	O
Inferior	O
vena	O
cava	O
of	O
normal	O
size	O
and	O
inspiratory	O
collapse	O
50	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
.	O
ECG	O
sinus	O
rhythm	O
at	O
65	O
bpm	O
.	O
Normal	O
PR	O
.	O
Narrow	O
QRS	O
.	O
Normal	O
axis	O
.	O
Q	O
wave	O
in	O
lead	O
III	O
.	O
Negative	O
T	O
waves	O
in	O
V4	O
6	O
.	O
Poor	O
tolerance	O
to	O
atorvastatin	B-FARMACO
80	O
mg	O
,	O
atorvastatin	B-FARMACO
40	O
mg	O
and	O
pitavastatin	B-FARMACO
2	O
mg	O
due	O
to	O
myalgias	O
and	O
asthenia	O
,	O
without	O
CPK	O
elevation	O
.	O
Other	O
antecedents	O
hypothyroidism	O
in	O
substitutive	O
treatment	O
.	O
Altered	O
fasting	O
blood	O
glucose	O
in	O
dietary	O
treatment	O
.	O
Fracture	O
of	O
the	O
right	O
radius	O
after	O
a	O
traffic	O
accident	O
in	O
1995	O
.	O
Usual	O
treatment	O
aspirin	B-FARMACO
100	O
mg	O
,	O
lisinopril	B-FARMACO
10	O
mg	O
,	O
levothyroxine	B-FARMACO
50	O
mcg	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
,	O
rosuvastatin	B-FARMACO
40	O
mg	O
.	O
CURRENT	O
DISEASE	O
Annual	O
follow	O
up	O
in	O
cardiology	O
consultation	O
.	O
She	O
went	O
for	O
consultation	O
in	O
April	O
2017	O
stable	O
from	O
a	O
cardiovascular	O
point	O
of	O
view	O
.	O
She	O
reports	O
that	O
after	O
the	O
last	O
check	O
up	O
where	O
the	O
lipid	O
lowering	O
treatment	O
was	O
changed	O
due	O
to	O
intolerance	O
,	O
she	O
has	O
had	O
slightly	O
elevated	O
blood	O
glucose	O
levels	O
,	O
for	O
which	O
her	O
primary	O
care	O
doctor	O
is	O
closely	O
monitoring	O
her	O
.	O
However	O
,	O
he	O
reports	O
good	O
tolerance	O
to	O
the	O
new	O
drug	O
in	O
terms	O
of	O
asthenia	O
and	O
myalgia	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
BP	O
130	O
65	O
mmhg	O
.	O
Heart	O
rate	O
HR	O
70	O
bpm	O
.	O
Body	O
mass	O
index	O
BMI	O
24	O
.	O
5	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
PA	O
normal	O
,	O
no	O
extra	O
sounds	O
.	O
No	O
peripheral	O
oedema	O
.	O
Signs	O
of	O
chronic	O
venous	O
insufficiency	O
.	O
COMPLEMENTARY	O
TESTS	O
ANALYTICS	O
March	O
2017	O
total	O
cholesterol	O
235	O
mg	O
dl	O
;	O
LDL	O
cholesterol	O
110	O
mg	O
dl	O
baseline	O
levels	O
around	O
160	O
mg	O
dl	O
,	O
fasting	O
blood	O
glucose	O
110	O
mg	O
dl	O
.	O
HbA1c	O
5	O
.	O
9	O
.	O
Rest	O
without	O
relevant	O
alterations	O
.	O
ECG	O
sinus	O
rhythm	O
at	O
70	O
bpm	O
.	O
PR	O
200	O
msg	O
.	O
Narrow	O
QRS	O
.	O
Q	O
wave	O
in	O
III	O
.	O
Negative	O
T	O
waves	O
in	O
V4	O
6	O
.	O
Similar	O
to	O
previous	O
.	O
THORAX	O
RADIOGRAPHY	O
normal	O
cardiothoracic	O
index	O
.	O
Free	O
costophrenic	O
sinuses	O
.	O
No	O
images	O
of	O
infiltrates	O
or	O
signs	O
of	O
consolidation	O
.	O
CLINICAL	O
EVOLUTION	O
It	O
was	O
decided	O
to	O
change	O
treatment	O
with	O
rosuvastatin	B-FARMACO
to	O
start	O
evolocumab	B-FARMACO
140	O
mg	O
1	O
injection	O
every	O
15	O
days	O
at	O
home	O
.	O
DIAGNOSIS	O
Chronic	O
ischaemic	O
heart	O
disease	O
.	O
Poor	O
control	O
of	O
target	O
lipid	O
levels	O
LDL	O
110	O
mg	O
dl	O
.	O
HYPERTENSION	O
.	O
Impaired	O
fasting	O
blood	O
glucose	O
Borderline	O
BMI	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
BACKGROUND	O
This	O
is	O
a	O
17	O
year	O
old	O
male	O
patient	O
,	O
the	O
younger	O
of	O
two	O
siblings	O
.	O
His	O
older	O
sister	O
index	O
case	O
has	O
clinical	O
suspicion	O
of	O
MFS	O
,	O
presenting	O
with	O
marfanoid	O
habitus	O
and	O
ectopia	O
lentis	O
but	O
no	O
aortic	O
dilatation	O
she	O
is	O
the	O
index	O
case	O
but	O
does	O
not	O
meet	O
diagnostic	O
criteria	O
for	O
MFS	O
.	O
The	O
patient	O
's	O
mother	O
has	O
marfanoid	O
habitus	O
,	O
but	O
has	O
not	O
developed	O
ectopia	O
lentis	O
or	O
aortic	O
dilatation	O
.	O
After	O
family	O
screening	O
,	O
our	O
patient	O
,	O
a	O
competitive	O
sportsman	O
basketball	O
,	O
was	O
studied	O
.	O
PHYSICAL	O
EXAMINATION	O
The	O
patient	O
was	O
normotensive	O
and	O
afebrile	O
,	O
well	O
perfused	O
,	O
eupneic	O
at	O
rest	O
and	O
with	O
good	O
skin	O
and	O
mucous	O
membrane	O
colouring	O
.	O
Carotid	O
pulses	O
rhythmic	O
and	O
symmetrical	O
.	O
No	O
jugular	O
ingurgitation	O
.	O
Thoracic	O
deformity	O
due	O
to	O
pectus	O
carinatum	O
.	O
Cardiopulmonary	O
auscultation	O
with	O
rhythmic	O
tones	O
and	O
no	O
murmurs	O
,	O
with	O
preserved	O
vesicular	O
murmur	O
.	O
Pedial	O
and	O
posterior	O
tibial	O
pulses	O
present	O
and	O
symmetrical	O
without	O
malleolar	O
oedema	O
or	O
stigmata	O
of	O
venous	O
insufficiency	O
or	O
deep	O
vein	O
thrombosis	O
.	O
Positive	O
wrist	O
and	O
thumb	O
sign	O
.	O
Increased	O
arm	O
stature	O
ratio	O
.	O
Scoliosis	O
.	O
Subluxation	O
of	O
the	O
crystalline	O
lens	O
.	O
COMPLEMENTARY	O
TESTS	O
ELECTROCARDIOGRAM	O
ECG	O
RS	O
at	O
47	O
bpm	O
.	O
Narrow	O
QRS	O
.	O
Normal	O
axis	O
.	O
No	O
repolarisation	O
alterations	O
.	O
ECOCARDIOGRAM	O
left	O
ventricle	O
not	O
dilated	O
,	O
with	O
normal	O
thickness	O
and	O
preserved	O
function	O
EF	O
60	O
,	O
highlights	O
inferolateral	O
and	O
apical	O
hypertrabeculation	O
.	O
Normal	O
right	O
cavities	O
.	O
Absence	O
of	O
valvular	O
heart	O
disease	O
.	O
Aorta	O
not	O
dilated	O
with	O
maximum	O
diameter	O
at	O
sinus	O
level	O
31	O
mm	O
.	O
CARDIAC	O
NUCLEAR	O
MAGNETIC	O
RESONANCE	O
MRI	O
no	O
alterations	O
of	O
interest	O
,	O
except	O
for	O
increased	O
trabeculation	O
in	O
the	O
areas	O
referred	O
to	O
in	O
the	O
echocardiogram	O
,	O
without	O
fulfilling	O
the	O
criteria	O
for	O
non	O
compacted	O
myocardium	O
.	O
Aorta	O
within	O
the	O
normal	O
range	O
.	O
EXERCISE	O
TEST	O
stopped	O
at	O
minute	O
14	O
.	O
30	O
of	O
the	O
Bruce	O
protocol	O
after	O
reaching	O
the	O
maximum	O
theoretical	O
heart	O
rate	O
HR	O
.	O
Normal	O
tension	O
and	O
chronotropic	O
response	O
.	O
Isolated	O
supraventricular	O
extrasystoles	O
.	O
Conclusion	O
clinically	O
and	O
electrically	O
negative	O
for	O
ischaemia	O
.	O
Good	O
functional	O
capacity	O
.	O
No	O
significant	O
arrhythmias	O
.	O
HOLTER	O
ECG	O
no	O
significant	O
arrhythmias	O
.	O
GENETIC	O
STUDY	O
studied	O
by	O
massively	O
parallel	O
sequencing	O
method	O
using	O
a	O
library	O
that	O
includes	O
35	O
genes	O
related	O
to	O
aortic	O
vascular	O
syndromes	O
.	O
A	O
heterozygous	O
mutation	O
in	O
the	O
FBN1	O
gene	O
p	O
.	O
Glu	O
1811Lys	O
previously	O
described	O
and	O
considered	O
pathogenic	O
or	O
associated	O
with	O
the	O
disease	O
and	O
another	O
heterozygous	O
mutation	O
in	O
the	O
FBN1	O
gene	O
p	O
.	O
Arg2Cys	O
previously	O
undescribed	O
and	O
with	O
uncertain	O
pathogenicity	O
are	O
identified	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
presents	O
with	O
marfanoid	O
habitus	O
more	O
than	O
7	O
points	O
between	O
characteristic	O
systemic	O
findings	O
,	O
including	O
pectus	O
carinatum	O
and	O
scoliosis	O
and	O
lens	O
subluxation	O
.	O
However	O
,	O
there	O
was	O
no	O
aortic	O
dilatation	O
.	O
In	O
the	O
absence	O
of	O
a	O
family	O
history	O
of	O
MFS	O
,	O
the	O
diagnosis	O
is	O
not	O
confirmed	O
and	O
genetic	O
testing	O
is	O
necessary	O
.	O
After	O
confirming	O
the	O
pathogenic	O
mutation	O
in	O
the	O
FBN1	O
gene	O
,	O
the	O
diagnosis	O
of	O
MFS	O
was	O
confirmed	O
,	O
and	O
the	O
patient	O
was	O
advised	O
against	O
intense	O
physical	O
exercise	O
and	O
competition	O
.	O
DIAGNOSIS	O
MFS	O
systemic	O
scores	O
7	O
points	O
and	O
lens	O
subluxation	O
without	O
involvement	O
of	O
the	O
cardiovascular	O
system	O
,	O
with	O
heterozygous	O
mutation	O
of	O
the	O
FBN1	O
gene	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
BACKGROUND	O
Patient	O
aged	O
47	O
years	O
,	O
with	O
no	O
known	O
allergies	O
.	O
No	O
personal	O
history	O
of	O
interest	O
.	O
Family	O
history	O
of	O
father	O
with	O
acute	O
myocardial	O
infarction	O
AMI	O
70	O
years	O
.	O
CURRENT	O
ILLNESS	O
Previously	O
asymptomatic	O
,	O
suffers	O
episode	O
of	O
palpitations	O
,	O
with	O
sensation	O
of	O
dizziness	O
,	O
sphincter	O
relaxation	O
,	O
without	O
tonic	O
clonic	O
crisis	O
,	O
tongue	O
biting	O
and	O
loss	O
of	O
consciousness	O
.	O
On	O
arrival	O
of	O
061	O
,	O
the	O
electrocardiogram	O
ECG	O
showed	O
ventricular	O
fibrillation	O
VF	O
,	O
requiring	O
three	O
defibrillations	O
to	O
restore	O
cardiac	O
rhythm	O
and	O
level	O
of	O
consciousness	O
.	O
The	O
subsequent	O
ECG	O
showed	O
rhythmic	O
tachycardia	O
with	O
narrow	O
QRS	O
at	O
150	O
bpm	O
with	O
ST	O
elevation	O
from	O
V1	O
to	O
V4	O
on	O
the	O
lateral	O
side	O
and	O
a	O
decrease	O
on	O
the	O
inferior	O
side	O
.	O
The	O
infarction	O
code	O
was	O
activated	O
and	O
cardiac	O
catheterisation	O
was	O
performed	O
with	O
LAD	O
showing	O
mild	O
proximal	O
stenosis	O
and	O
40	O
stenosis	O
at	O
the	O
mid	O
segment	O
level	O
.	O
In	O
conclusion	O
,	O
there	O
were	O
no	O
significant	O
coronary	O
lesions	O
.	O
Admission	O
to	O
the	O
intensive	O
care	O
unit	O
ICU	O
was	O
decided	O
.	O
PHYSICAL	O
EXAMINATION	O
On	O
arrival	O
at	O
the	O
ICU	O
,	O
the	O
patient	O
was	O
conscious	O
and	O
oriented	O
.	O
Eupneic	O
at	O
rest	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
normoventila	O
.	O
No	O
congestive	O
signs	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
sinus	O
rhythm	O
,	O
BRD	O
and	O
elevation	O
of	O
J	O
point	O
and	O
anteroseptal	O
ST	O
that	O
normalizes	O
in	O
evolution	O
.	O
ANALYTICS	O
biochemistry	O
glucose	O
94	O
mg	O
dl	O
,	O
glycated	O
haemoglobin	O
5	O
.	O
8	O
,	O
urea	O
40	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
94	O
mg	O
dl	O
,	O
uric	O
acid	O
5	O
.	O
2	O
mg	O
dl	O
,	O
triglycerides	O
138	O
mg	O
dl	O
,	O
total	O
cholesterol	O
157	O
mg	O
dl	O
,	O
HDL	O
37	O
mg	O
dl	O
,	O
LDL	O
92	O
mg	O
dl	O
,	O
Apo	O
A1	O
121	O
mg	O
dl	O
,	O
Apo	O
B	O
82	O
.	O
6	O
mg	O
dl	O
,	O
sodium	O
138	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
3	O
mEq	O
l	O
,	O
AST	O
19	O
U	O
l	O
,	O
ALT	O
29	O
U	O
l	O
,	O
GGT	O
127	O
U	O
l	O
,	O
FA	O
102	O
U	O
l	O
,	O
proteinogram	O
normal	O
.	O
Cardiac	O
markers	O
troponin	O
I	O
0	O
.	O
03	O
ng	O
ml	O
,	O
myoglobin	O
20	O
.	O
9	O
ng	O
ml	O
,	O
pro	O
BNP	O
430	O
.	O
9	O
pg	O
ml	O
.	O
Thyroid	O
function	O
TSH	O
3	O
.	O
37	O
mIU	O
l	O
,	O
T4	O
0	O
.	O
83	O
ng	O
dl	O
.	O
CBC	O
red	O
blood	O
cells	O
4	O
.	O
55	O
mill	O
mm3	O
,	O
haemoglobin	O
13	O
.	O
8	O
g	O
dl	O
,	O
haematocrit	O
39	O
.	O
8	O
,	O
MCV	O
87	O
.	O
50	O
fl	O
,	O
leukocytes	O
9200	O
mm3	O
N	O
66	O
.	O
2	O
,	O
L	O
18	O
.	O
2	O
,	O
platelets	O
242	O
,	O
000	O
mm3	O
.	O
Coagulation	O
INR	O
1	O
.	O
07	O
,	O
prothrombin	O
activity	O
90	O
.	O
CORONARYGRAPHY	O
23	O
04	O
18	O
right	O
radial	O
access	O
6F	O
right	O
dominance	O
.	O
Coronary	O
arteries	O
without	O
significant	O
stenosis	O
.	O
Coronary	O
flow	O
normal	O
.	O
Common	O
trunk	O
No	O
lesions	O
.	O
Anterior	O
descending	O
slight	O
proximal	O
stenosis	O
.	O
Stenosis	O
40	O
in	O
the	O
middle	O
segment	O
.	O
Circumflex	O
no	O
stenosis	O
.	O
Right	O
no	O
stenosis	O
.	O
Ventriculography	O
correct	O
global	O
systolic	O
function	O
.	O
No	O
segmental	O
alterations	O
.	O
Mitral	O
insufficiency	O
MI	O
is	O
observed	O
which	O
is	O
not	O
quantifiable	O
by	O
EV	O
during	O
contrast	O
injection	O
,	O
it	O
could	O
be	O
significant	O
.	O
Evaluation	O
by	O
echocardiography	O
.	O
ECOCARDIOGRAM	O
24	O
04	O
18	O
left	O
ventricle	O
LV	O
neither	O
dilated	O
nor	O
hypertrophic	O
.	O
Global	O
systolic	O
function	O
preserved	O
or	O
correct	O
,	O
without	O
segmental	O
defects	O
.	O
Left	O
atrium	O
of	O
size	O
at	O
the	O
upper	O
limit	O
of	O
normality	O
,	O
as	O
well	O
as	O
the	O
aortic	O
root	O
.	O
RV	O
dilatation	O
.	O
Impression	O
of	O
pailary	O
muscle	O
hyperplasia	O
and	O
wall	O
thickness	O
up	O
to	O
8	O
mm	O
.	O
No	O
tricuspid	O
insufficiency	O
TI	O
.	O
May	O
be	O
abnormal	O
musculature	O
.	O
Inferior	O
cava	O
not	O
dilated	O
and	O
with	O
inspiratory	O
collapse	O
greater	O
than	O
normal	O
aortic	O
.	O
Normal	O
mitral	O
without	O
regurgitation	O
.	O
Normal	O
diastolic	O
pattern	O
.	O
Pulmonary	O
artery	O
with	O
very	O
slight	O
increase	O
in	O
diameter	O
.	O
Pulmonary	O
flow	O
type	O
I	O
up	O
to	O
valvular	O
plane	O
,	O
where	O
it	O
appears	O
as	O
type	O
2	O
,	O
with	O
shortened	O
acceleration	O
time	O
.	O
Mild	O
pulmonary	O
arterial	O
hypertension	O
PAH	O
.	O
MRI	O
LV	O
normal	O
size	O
,	O
with	O
normal	O
systolic	O
function	O
.	O
Mild	O
dilatation	O
of	O
the	O
right	O
ventricle	O
RV	O
,	O
with	O
preserved	O
function	O
.	O
Papillary	O
accessory	O
muscle	O
in	O
the	O
ventricular	O
sinus	O
.	O
No	O
focal	O
areas	O
of	O
late	O
myocardial	O
enhancement	O
.	O
Atria	O
are	O
not	O
dilated	O
.	O
THORAX	O
RADIOGRAPHY	O
post	O
implantation	O
of	O
a	O
subcutaneous	O
implantable	O
cardioverter	O
defibrillator	O
ICD	O
no	O
notable	O
alterations	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
evolved	O
favourably	O
in	O
the	O
ICU	O
,	O
remaining	O
asymptomatic	O
and	O
tolerating	O
low	O
doses	O
of	O
beta	O
blockers	O
.	O
An	O
echocardiogram	O
was	O
performed	O
,	O
showing	O
normal	O
LV	O
function	O
.	O
RV	O
dilatation	O
with	O
impression	O
of	O
hyperplasia	O
of	O
papillary	O
muscles	O
and	O
anterior	O
wall	O
up	O
to	O
8	O
mm	O
thick	O
,	O
slight	O
increase	O
in	O
pulmonary	O
artery	O
diameter	O
mild	O
PAH	O
.	O
It	O
was	O
decided	O
to	O
implant	O
a	O
subcutaneous	O
ICD	O
,	O
following	O
prior	O
screening	O
and	O
after	O
performing	O
a	O
flecainide	O
test	O
due	O
to	O
suspicion	O
of	O
underlying	O
Brugada	O
syndrome	O
,	O
which	O
was	O
confirmed	O
.	O
She	O
was	O
discharged	O
with	O
a	O
diagnosis	O
of	O
cardiorespiratory	O
arrest	O
CRP	O
due	O
to	O
VF	O
recovered	O
by	O
Brugada	O
syndrome	O
,	O
pending	O
the	O
results	O
of	O
the	O
genetic	O
test	O
.	O
DIAGNOSIS	O
CRA	O
due	O
to	O
VF	O
.	O
Coronary	O
arteries	O
free	O
of	O
significant	O
lesions	O
.	O
Brugada	O
syndrome	O
pending	O
genetic	O
study	O
.	O
Subcutaneous	O
ICD	O
implantation	O
.	O

HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
An	O
81	O
year	O
old	O
hypertensive	O
woman	O
,	O
type	O
2	O
diabetic	O
,	O
dyslipidaemic	O
,	O
ex	O
smoker	O
and	O
hypothyroid	O
,	O
with	O
a	O
history	O
of	O
rectorrhagia	O
and	O
a	O
transient	O
cerebrovascular	O
accident	O
in	O
the	O
middle	O
cerebral	O
artery	O
territory	O
10	O
years	O
ago	O
,	O
who	O
came	O
to	O
the	O
emergency	O
department	O
for	O
chest	O
pain	O
and	O
dyspnoea	O
.	O
For	O
the	O
last	O
5	O
hours	O
,	O
she	O
reported	O
intermittent	O
episodes	O
of	O
about	O
10	O
minutes	O
duration	O
,	O
oppressive	O
central	O
chest	O
pain	O
,	O
non	O
radiating	O
,	O
not	O
clearly	O
related	O
to	O
exertion	O
,	O
with	O
associated	O
dyspnoea	O
and	O
no	O
vegetative	O
cortex	O
.	O
On	O
first	O
assessment	O
,	O
the	O
patient	O
was	O
haemodynamically	O
stable	O
blood	O
pressure	O
BP	O
105	O
65	O
mmHg	O
,	O
heart	O
rate	O
HR	O
75	O
bpm	O
,	O
well	O
perfused	O
,	O
basal	O
saturation	O
94	O
,	O
eupneic	O
,	O
in	O
good	O
general	O
condition	O
,	O
conscious	O
and	O
oriented	O
.	O
Carotid	O
pulses	O
were	O
rhythmic	O
and	O
symmetrical	O
,	O
with	O
no	O
jugular	O
engorgement	O
.	O
Cardiopulmonary	O
auscultation	O
revealed	O
an	O
aortic	O
systolic	O
murmur	O
that	O
respected	O
the	O
second	O
tone	O
,	O
with	O
normal	O
pulmonary	O
auscultation	O
.	O
There	O
was	O
no	O
oedema	O
in	O
the	O
lower	O
limbs	O
and	O
pulses	O
were	O
preserved	O
.	O
COMPLEMENTARY	O
TESTS	O
ELECTROCARDIOGRAM	O
ECG	O
AF	O
at	O
120	O
bpm	O
,	O
narrow	O
QRS	O
,	O
left	O
axis	O
,	O
left	O
anterior	O
hemiblock	O
,	O
right	O
bundle	O
branch	O
conduction	O
disorder	O
,	O
with	O
no	O
evidence	O
of	O
acute	O
ischaemia	O
.	O
ANALYSIS	O
creatinine	O
0	O
.	O
86	O
mg	O
dl	O
,	O
no	O
ionic	O
alterations	O
,	O
liver	O
profile	O
within	O
normality	O
,	O
first	O
troponin	O
T	O
100	O
ng	O
dl	O
,	O
second	O
troponin	O
T	O
60	O
ng	O
dl	O
,	O
Hb	O
10	O
mg	O
dl	O
,	O
platelets	O
140	O
,	O
000	O
,	O
no	O
leukocytosis	O
or	O
neutrophilia	O
,	O
no	O
coagulopathy	O
.	O
Transthoracic	O
echocardiogram	O
TTE	O
non	O
dilated	O
left	O
ventricle	O
LV	O
with	O
severe	O
hypertrophy	O
of	O
the	O
basal	O
septum	O
17	O
mm	O
.	O
Left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
preserved	O
65	O
with	O
normal	O
segmental	O
contractility	O
and	O
impaired	O
relaxation	O
.	O
Normal	O
right	O
ventricle	O
RV	O
.	O
Mild	O
aortic	O
stenosis	O
without	O
other	O
valvulopathies	O
.	O
No	O
pericardial	O
effusion	O
.	O
CORONARYGRAPHY	O
severe	O
lesion	O
in	O
the	O
ostium	O
of	O
the	O
right	O
coronary	O
artery	O
RCA	O
which	O
is	O
revascularised	O
with	O
a	O
drug	O
eluting	O
stent	O
DES	O
of	O
biolimus	O
without	O
polymer	O
.	O
Moderate	O
lesion	O
in	O
the	O
first	O
diagonal	O
,	O
with	O
no	O
lesions	O
in	O
the	O
rest	O
of	O
the	O
coronary	O
arteries	O
.	O
CLINICAL	O
EVOLUTION	O
In	O
view	O
of	O
these	O
findings	O
,	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
coronary	O
unit	O
and	O
,	O
after	O
a	O
loading	O
dose	O
,	O
was	O
started	O
on	O
double	O
antiplatelet	O
therapy	O
with	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
100	O
mg	O
24	O
hours	O
by	O
mouth	O
and	O
ticagrelor	B-FARMACO
90	O
mg	O
24	O
hours	O
by	O
mouth	O
.	O
On	O
the	O
fourth	O
day	O
of	O
admission	O
,	O
she	O
presented	O
an	O
episode	O
of	O
AF	O
with	O
rapid	O
ventricular	O
response	O
that	O
was	O
cardioverted	O
pharmacologically	O
with	O
amiodarone	B-FARMACO
.	O
As	O
this	O
was	O
a	O
patient	O
with	O
a	O
high	O
embolic	O
risk	O
CHA2DS2	O
VASc	O
7	O
and	O
a	O
history	O
of	O
previous	O
haemorrhage	O
HASBLED	O
of	O
5	O
,	O
the	O
problem	O
of	O
triple	O
therapy	O
was	O
raised	O
and	O
it	O
was	O
decided	O
to	O
opt	O
for	O
the	O
Redual	O
PCI	O
strategy	O
,	O
continuing	O
treatment	O
with	O
ticagrelor	B-FARMACO
90	O
mg	O
12	O
hours	O
by	O
mouth	O
for	O
one	O
year	O
,	O
and	O
dabigatran	B-FARMACO
110	O
mg	O
12	O
hours	O
by	O
mouth	O
indefinitely	O
.	O
To	O
date	O
,	O
no	O
thrombotic	O
or	O
haemorrhagic	O
events	O
have	O
been	O
documented	O
in	O
the	O
patient	O
.	O
DIAGNOSIS	O
Acute	O
non	O
ST	O
segment	O
elevation	O
myocardial	O
infarction	O
NSTEMI	O
.	O
Critical	O
lesion	O
in	O
ostial	O
DC	O
revascularised	O
with	O
DES	O
.	O
Newly	O
diagnosed	O
AF	O
CHA2DS2	O
VASc	O
7	O
HASBLED	O
5	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Male	O
,	O
70	O
years	O
old	O
.	O
BACKGROUND	O
No	O
known	O
allergic	O
drug	O
reactions	O
.	O
Toxic	O
habits	O
ex	O
smoker	O
.	O
Hypertension	O
.	O
No	O
known	O
diabetes	O
mellitus	O
or	O
dyslipidaemia	O
.	O
Aortic	O
valve	O
replacement	O
due	O
to	O
double	O
lesion	O
Carbomedics	O
mechanical	O
prosthesis	O
no21	O
on	O
24	O
September	O
1993	O
.	O
Multiple	O
subsequent	O
complications	O
9	O
November	O
1993	O
aortic	O
pseudoaneurysm	O
with	O
compression	O
of	O
the	O
right	O
ventricle	O
RV	O
and	O
aorto	O
cutaneous	O
fistula	O
with	O
sternal	O
osteolysis	O
.	O
The	O
fistula	O
was	O
closed	O
at	O
the	O
aortic	O
level	O
and	O
a	O
sternal	O
exeresis	O
and	O
plasty	O
of	O
both	O
pectoral	O
muscles	O
with	O
disinsertion	O
of	O
the	O
humerus	O
muscles	O
pectoralis	O
major	O
myoplasty	O
was	O
performed	O
.	O
During	O
this	O
admission	O
he	O
required	O
several	O
re	O
interventions	O
for	O
bleeding	O
in	O
the	O
context	O
of	O
coagulopathy	O
,	O
both	O
cardiac	O
surgery	O
and	O
plastic	O
surgery	O
.	O
During	O
his	O
two	O
months	O
in	O
intensive	O
care	O
ICU	O
he	O
developed	O
multi	O
organ	O
failure	O
.	O
23	O
February	O
1995	O
reoperation	O
for	O
dehiscence	O
of	O
the	O
prosthesis	O
periprosthetic	O
leak	O
and	O
implantation	O
of	O
a	O
St	O
.	O
Jude	O
prosthesis	O
no	O
.	O
21	O
.	O
Femoral	O
pseudoaneurysm	O
after	O
preoperative	O
coronary	O
angiography	O
.	O
Duodenal	O
ulcer	O
with	O
gastrointestinal	O
bleeding	O
in	O
1999	O
.	O
Spontaneous	O
retroperitoneal	O
haematoma	O
in	O
the	O
context	O
of	O
anticoagulation	O
.	O
Admission	O
to	O
cardiology	O
in	O
September	O
2017	O
for	O
syncope	O
with	O
cardiogenic	O
profile	O
and	O
no	O
clear	O
cause	O
.	O
Electrocardiogram	O
ECG	O
in	O
sinus	O
rhythm	O
with	O
left	O
anterior	O
hemiblock	O
of	O
the	O
His	O
bundle	O
HARIHH	O
,	O
absence	O
of	O
findings	O
in	O
telemetry	O
monitoring	O
and	O
echocardiogram	O
without	O
relevant	O
findings	O
with	O
mild	O
moderate	O
left	O
ventricular	O
hypertrophy	O
,	O
normal	O
biventricular	O
function	O
and	O
normofunctioning	O
aortic	O
prosthesis	O
.	O
For	O
all	O
these	O
reasons	O
,	O
it	O
was	O
decided	O
to	O
implant	O
a	O
subcutaneous	O
Holter	O
.	O
Other	O
Repeated	O
acute	O
otitis	O
media	O
in	O
both	O
ears	O
,	O
predominantly	O
in	O
the	O
left	O
ear	O
.	O
Benign	O
prostatic	O
hyperplasia	O
.	O
Usual	O
treatment	O
acenocoumarol	B-FARMACO
,	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
24	O
hours	O
,	O
simvastatin	B-FARMACO
40	O
mg	O
24	O
hours	O
,	O
valsartan	B-FARMACO
160	O
mg	O
24	O
hours	O
,	O
dutasteride	B-FARMACO
tamsulosin	I-FARMACO
0	O
.	O
5	O
0	O
.	O
4	O
mg	O
24	O
hours	O
.	O
CURRENT	O
ILLNESS	O
Admitted	O
on	O
7	O
12	O
2017	O
to	O
the	O
multipurpose	O
ICU	O
after	O
presenting	O
with	O
traumatic	O
brain	O
injury	O
TBI	O
in	O
the	O
context	O
of	O
a	O
new	O
syncopal	O
episode	O
with	O
amnesia	O
of	O
the	O
episode	O
,	O
with	O
witnesses	O
referring	O
trauma	O
to	O
the	O
frontal	O
region	O
and	O
objectifying	O
hypotension	O
and	O
bradycardia	O
.	O
On	O
arrival	O
at	O
the	O
ED	O
,	O
the	O
patient	O
was	O
haemodynamically	O
and	O
respiratory	O
stable	O
with	O
blood	O
pressure	O
BP	O
120	O
70	O
mmHg	O
,	O
INR	O
4	O
.	O
65	O
and	O
sinus	O
rhythm	O
at	O
60	O
bpm	O
.	O
A	O
cranial	O
CT	O
scan	O
was	O
performed	O
showing	O
subdural	O
haematoma	O
in	O
the	O
cerebral	O
sickle	O
without	O
midline	O
displacement	O
.	O
The	O
subcutaneous	O
Holter	O
During	O
the	O
episode	O
,	O
the	O
subcutaneous	O
Holter	O
monitor	O
showed	O
sinus	O
bradycardia	O
at	O
50	O
bpm	O
without	O
pauses	O
,	O
and	O
pacemaker	O
implantation	O
was	O
not	O
recommended	O
.	O
During	O
his	O
stay	O
in	O
the	O
ED	O
,	O
the	O
patient	O
began	O
to	O
have	O
paresis	O
of	O
the	O
right	O
lower	O
limb	O
,	O
so	O
a	O
repeat	O
CT	O
scan	O
was	O
performed	O
,	O
which	O
showed	O
an	O
increase	O
in	O
subdural	O
haematoma	O
and	O
foci	O
of	O
subarachnoid	O
haemorrhage	O
,	O
and	O
it	O
was	O
decided	O
to	O
admit	O
him	O
to	O
the	O
ICU	O
.	O
Initially	O
,	O
the	O
patient	O
presented	O
with	O
right	O
hemiparesis	O
and	O
comical	O
crises	O
that	O
required	O
orotracheal	O
intubation	O
and	O
surgical	O
tracheostomy	O
.	O
Conservative	O
management	O
was	O
decided	O
with	O
good	O
subsequent	O
evolution	O
,	O
and	O
the	O
patient	O
was	O
transferred	O
to	O
neurosurgery	O
,	O
who	O
requested	O
a	O
cardiology	O
consultation	O
due	O
to	O
syncope	O
and	O
a	O
tendency	O
to	O
bradycardia	O
without	O
beta	O
blocker	O
treatment	O
,	O
and	O
on	O
review	O
of	O
the	O
subcutaneous	O
Holter	O
,	O
multiple	O
episodes	O
of	O
bradycardia	O
and	O
spells	O
of	O
complete	O
atrioventricular	O
block	O
AVB	O
were	O
observed	O
.	O
Given	O
the	O
presence	O
of	O
these	O
episodes	O
,	O
the	O
patient	O
was	O
transferred	O
to	O
cardiology	O
for	O
monitoring	O
and	O
to	O
evaluate	O
the	O
implantation	O
of	O
a	O
permanent	O
pacemaker	O
.	O
PHYSICAL	O
EXPLORATION	O
on	O
admission	O
to	O
the	O
ICU	O
Head	O
and	O
face	O
soft	O
tissue	O
wound	O
in	O
the	O
right	O
frontal	O
region	O
,	O
without	O
active	O
bleeding	O
.	O
No	O
other	O
injuries	O
.	O
Neck	O
no	O
wounds	O
,	O
haematomas	O
or	O
deformities	O
were	O
identified	O
.	O
Chest	O
Inspection	O
no	O
bruises	O
,	O
good	O
respiratory	O
mechanics	O
.	O
No	O
crepitus	O
on	O
palpation	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
,	O
no	O
pathological	O
sounds	O
.	O
Cardiac	O
auscultation	O
muffled	O
,	O
rhythmic	O
tones	O
,	O
prosthetic	O
opening	O
click	O
,	O
no	O
murmurs	O
or	O
extratones	O
.	O
Abdomen	O
inspection	O
abdomen	O
not	O
distended	O
,	O
not	O
painful	O
.	O
Perineum	O
no	O
signs	O
of	O
haematoma	O
,	O
no	O
rectorrhagia	O
.	O
Back	O
no	O
painful	O
stitches	O
or	O
deformities	O
.	O
Extremities	O
no	O
excoriations	O
.	O
No	O
deformities	O
.	O
No	O
joint	O
instability	O
.	O
Neurological	O
examination	O
GSC	O
15	O
M6	O
,	O
O4	O
,	O
V5	O
.	O
Pupils	O
isochoric	O
,	O
normoreactive	O
.	O
Motor	O
right	O
lower	O
limb	O
paralysis	O
.	O
Muscle	O
strength	O
right	O
upper	O
limb	O
5	O
5	O
,	O
right	O
upper	O
limb	O
5	O
5	O
,	O
left	O
lower	O
limb	O
5	O
5	O
,	O
right	O
lower	O
limb	O
0	O
5	O
.	O
COMPLEMENTARY	O
TESTS	O
MICROBIOLOGY	O
blood	O
cultures	O
08	O
01	O
18	O
in	O
two	O
sets	O
Enterococcus	O
faecalis	O
with	O
antibiogram	O
ampicillin	O
amoxicillin	O
S	O
1	O
,	O
gentamicin	O
500	O
S	O
500	O
,	O
strepto	O
1000	O
S	O
1	O
.	O
000	O
,	O
vancomycin	O
S	O
1	O
,	O
teicoplanin	O
S	O
1	O
.	O
Subsequent	O
blood	O
cultures	O
negative	O
.	O
ANALYSIS	O
On	O
admission	O
normocytic	O
normochromic	O
anaemia	O
with	O
Hb	O
9	O
.	O
7g	O
dl	O
,	O
normal	O
platelets	O
,	O
normal	O
leukocytes	O
,	O
with	O
elevated	O
C	O
reactive	O
protein	O
CRP	O
10	O
.	O
39	O
mg	O
dl	O
,	O
INR	O
5	O
.	O
22	O
.	O
Biochemistry	O
with	O
renal	O
profile	O
without	O
alterations	O
,	O
including	O
creatinine	O
0	O
.	O
45	O
mg	O
dl	O
which	O
means	O
a	O
glomerular	O
filtration	O
rate	O
CKD	O
EPI	O
90	O
ml	O
min	O
,	O
normal	O
liver	O
profile	O
and	O
thyroid	O
profile	O
.	O
On	O
discharge	O
06	O
03	O
CRP	O
0	O
.	O
73	O
mg	O
dl	O
,	O
without	O
leukocytosis	O
or	O
neutrophilia	O
,	O
with	O
Hb	O
10	O
.	O
2g	O
dl	O
.	O
Emergency	O
ECG	O
sinus	O
rhythm	O
at	O
60	O
bpm	O
.	O
Left	O
axis	O
,	O
narrow	O
QRS	O
,	O
HARIHH	O
similar	O
to	O
previous	O
ones	O
,	O
without	O
repolarisation	O
alterations	O
.	O
CRANIAL	O
CT	O
07	O
12	O
18	O
subdural	O
haematoma	O
in	O
cerebral	O
sickle	O
with	O
haematocrit	O
levels	O
.	O
There	O
is	O
no	O
midline	O
displacement	O
.	O
Inflammatory	O
changes	O
in	O
the	O
left	O
middle	O
ear	O
and	O
maxillary	O
sinuses	O
.	O
ECHOCARDIOGRAPHIC	O
STUDY	O
11	O
1	O
18	O
TRANSTORACIC	O
TTE	O
left	O
ventricle	O
not	O
dilated	O
,	O
with	O
preserved	O
systolic	O
function	O
.	O
Normal	O
right	O
ventricle	O
.	O
Bidisc	O
mechanical	O
prosthesis	O
in	O
aortic	O
position	O
movement	O
of	O
both	O
occluders	O
with	O
increased	O
transvalvular	O
gradients	O
maximum	O
average	O
40	O
19	O
mmHg	O
without	O
suspicion	O
of	O
obstruction	O
triangular	O
jet	O
morphology	O
,	O
acceleration	O
time	O
of	O
70	O
ms	O
,	O
AT	O
ET	O
0	O
.	O
3	O
,	O
DVI	O
0	O
.	O
57	O
.	O
Mitral	O
valve	O
thickened	O
leaflets	O
,	O
mild	O
insufficiency	O
.	O
Tricuspid	O
valve	O
poor	O
visualisation	O
,	O
no	O
significant	O
insufficiency	O
by	O
colour	O
Doppler	O
.	O
No	O
indirect	O
signs	O
of	O
pulmonary	O
hypertension	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
with	O
physiological	O
inspiratory	O
collapse	O
estimated	O
DBP	O
5	O
mmHg	O
.	O
Aortic	O
root	O
,	O
ascending	O
aorta	O
and	O
aortic	O
arch	O
not	O
visualised	O
.	O
Atrial	O
septum	O
intact	O
,	O
without	O
suspicion	O
of	O
intracardiac	O
shunt	O
by	O
colour	O
Doppler	O
.	O
Pericardium	O
of	O
normal	O
thickness	O
and	O
refractoriness	O
,	O
without	O
effusion	O
.	O
Conclusions	O
increased	O
aortic	O
transprosthetic	O
gradients	O
without	O
suspicion	O
of	O
obstruction	O
.	O
Transesophageal	O
echocardiography	O
TEE	O
bidisc	O
mechanical	O
prosthesis	O
in	O
aortic	O
position	O
with	O
movement	O
of	O
both	O
occluders	O
.	O
Intraprosthetic	O
lavage	O
insufficiency	O
is	O
visualised	O
with	O
three	O
trivial	O
regurgitation	O
jets	O
.	O
Rounded	O
image	O
of	O
4	O
mm	O
x	O
3	O
mm	O
visualised	O
on	O
the	O
aortic	O
side	O
of	O
the	O
prosthesis	O
suggestive	O
of	O
a	O
wart	O
.	O
Thickening	O
of	O
the	O
posterior	O
area	O
of	O
the	O
prosthetic	O
ring	O
,	O
with	O
extension	O
towards	O
mitroaortic	O
fibrosis	O
,	O
thickened	O
anterior	O
mitral	O
leaflet	O
at	O
the	O
level	O
of	O
A1	O
A2	O
and	O
towards	O
the	O
interatrial	O
septum	O
,	O
no	O
fistulous	O
tracts	O
are	O
visualised	O
.	O
Mitral	O
valve	O
with	O
thickening	O
of	O
the	O
anterior	O
leaflet	O
,	O
no	O
images	O
compatible	O
with	O
vegetation	O
.	O
No	O
mitral	O
insufficiency	O
.	O
Rest	O
of	O
valves	O
with	O
no	O
images	O
compatible	O
with	O
vegetation	O
.	O
Conclusions	O
signs	O
of	O
IE	O
thickening	O
at	O
the	O
posterior	O
level	O
of	O
the	O
aortic	O
annulus	O
,	O
mitroaortic	O
fibrosis	O
and	O
at	O
the	O
base	O
of	O
the	O
anterior	O
mitral	O
leaflet	O
suggestive	O
of	O
phlegmon	O
.	O
Small	O
endocardial	O
wart	O
,	O
visualised	O
on	O
the	O
aortic	O
side	O
of	O
the	O
aortic	O
prosthesis	O
.	O
Normal	O
functioning	O
aortic	O
prosthesis	O
.	O
Control	O
TEE	O
23	O
1	O
18	O
signs	O
suggestive	O
of	O
IE	O
with	O
slight	O
progression	O
with	O
respect	O
to	O
the	O
previous	O
study	O
at	O
the	O
level	O
of	O
the	O
aortic	O
annulus	O
,	O
but	O
above	O
all	O
progression	O
at	O
the	O
level	O
of	O
the	O
anterior	O
mitral	O
leaflet	O
with	O
an	O
image	O
of	O
an	O
endocardial	O
wart	O
.	O
Normally	O
functioning	O
aortic	O
prosthesis	O
.	O
Mild	O
mitral	O
insufficiency	O
.	O
CRANIAL	O
MRI	O
15	O
01	O
18	O
multiple	O
acute	O
cortical	O
microinfarcts	O
of	O
supra	O
and	O
infratentorial	O
location	O
.	O
Given	O
the	O
multi	O
territorial	O
involvement	O
,	O
they	O
suggest	O
embolic	O
origin	O
.	O
Decreased	O
size	O
of	O
the	O
left	O
frontal	O
parenchymal	O
parenchymal	O
contusions	O
and	O
subdural	O
haematoma	O
.	O
Abdominal	O
CT	O
scan	O
with	O
intravenous	O
contrast	O
07	O
02	O
2018	O
appearance	O
of	O
focal	O
infarcts	O
in	O
the	O
left	O
kidney	O
,	O
of	O
probable	O
embolic	O
aetiology	O
.	O
TEE	O
16	O
02	O
2018	O
signs	O
suggestive	O
of	O
IE	O
with	O
abscessation	O
at	O
the	O
level	O
of	O
the	O
aortic	O
ring	O
fibrous	O
mitroaortic	O
ring	O
,	O
aortic	O
prosthesis	O
with	O
normal	O
gradients	O
,	O
posterior	O
periprosthetic	O
leak	O
related	O
to	O
the	O
abscessed	O
area	O
of	O
moderate	O
degree	O
.	O
CLINICAL	O
EVOLUTION	O
On	O
arrival	O
at	O
the	O
cardiology	O
department	O
,	O
fever	O
peaks	O
were	O
observed	O
,	O
with	O
Enterococcus	O
faecalis	O
growing	O
in	O
blood	O
cultures	O
.	O
He	O
also	O
had	O
a	O
positive	O
urine	O
culture	O
for	O
Citrobacter	O
freundii	O
sensitive	O
to	O
fosfomycin	B-FARMACO
and	O
was	O
treated	O
.	O
In	O
view	O
of	O
the	O
blood	O
culture	O
findings	O
,	O
treatment	O
was	O
started	O
with	O
ampicillin	B-FARMACO
and	O
ceftriaxone	B-FARMACO
and	O
an	O
echocardiogram	O
was	O
requested	O
to	O
screen	O
for	O
endocarditis	O
,	O
which	O
showed	O
thickening	O
at	O
the	O
posterior	O
level	O
of	O
the	O
aortic	O
ring	O
,	O
mitroaortic	O
fibrosis	O
and	O
the	O
base	O
of	O
the	O
anterior	O
mitral	O
leaflet	O
suggestive	O
of	O
abscess	O
,	O
while	O
at	O
the	O
same	O
time	O
a	O
small	O
wart	O
was	O
seen	O
on	O
the	O
aortic	O
prosthesis	O
,	O
all	O
of	O
which	O
was	O
compatible	O
with	O
endocarditis	O
.	O
As	O
part	O
of	O
the	O
protocol	O
to	O
search	O
for	O
septic	O
embolisms	O
,	O
a	O
cerebral	O
MRI	O
angiography	O
showed	O
multiple	O
acute	O
cortical	O
micro	O
infarctions	O
of	O
supra	O
and	O
infratentorial	O
location	O
suggesting	O
embolic	O
origin	O
and	O
a	O
CT	O
scan	O
with	O
no	O
evidence	O
of	O
other	O
peripheral	O
embolisms	O
.	O
Given	O
the	O
presence	O
of	O
advanced	O
local	O
involvement	O
,	O
the	O
case	O
was	O
presented	O
at	O
a	O
medical	O
surgical	O
session	O
and	O
surgery	O
was	O
ruled	O
out	O
,	O
given	O
the	O
previous	O
surgical	O
history	O
and	O
the	O
high	O
technical	O
complexity	O
.	O
A	O
control	O
echocardiogram	O
was	O
performed	O
after	O
2	O
weeks	O
of	O
antibiotic	O
therapy	O
which	O
showed	O
progression	O
with	O
respect	O
to	O
the	O
previous	O
study	O
with	O
the	O
appearance	O
of	O
an	O
aortic	O
perivalvular	O
leak	O
leading	O
to	O
mild	O
aortic	O
insufficiency	O
,	O
disappearance	O
of	O
the	O
aortic	O
wart	O
and	O
the	O
appearance	O
of	O
a	O
wart	O
at	O
mitral	O
level	O
.	O
In	O
this	O
context	O
,	O
it	O
was	O
decided	O
to	O
add	O
tigecycline	B-FARMACO
to	O
the	O
antibiotic	O
treatment	O
due	O
to	O
its	O
better	O
penetration	O
into	O
soft	O
tissues	O
.	O
Subsequently	O
,	O
in	O
the	O
fourth	O
week	O
of	O
antibiotic	O
therapy	O
,	O
he	O
developed	O
sudden	O
pain	O
in	O
the	O
left	O
flank	O
with	O
elevated	O
LDH	O
and	O
CRP	O
,	O
so	O
a	O
new	O
abdominal	O
CT	O
scan	O
was	O
performed	O
which	O
showed	O
the	O
appearance	O
of	O
left	O
renal	O
infarcts	O
.	O
During	O
the	O
sixth	O
week	O
of	O
antibiotic	O
therapy	O
,	O
a	O
new	O
transesophageal	O
echocardiogram	O
was	O
performed	O
showing	O
progression	O
of	O
the	O
valvular	O
lesions	O
with	O
abscessation	O
at	O
the	O
level	O
of	O
the	O
aortic	O
annulus	O
mitroaortic	O
fibrosis	O
,	O
which	O
had	O
previously	O
been	O
phlegmonous	O
,	O
with	O
disappearance	O
of	O
the	O
mitral	O
wart	O
and	O
progression	O
of	O
the	O
amount	O
of	O
leak	O
,	O
which	O
was	O
moderate	O
.	O
However	O
,	O
the	O
patient	O
was	O
stable	O
,	O
with	O
no	O
evidence	O
of	O
heart	O
failure	O
,	O
syncope	O
or	O
new	O
relevant	O
alterations	O
in	O
the	O
electrocardiogram	O
or	O
telemetry	O
,	O
remaining	O
afebrile	O
with	O
three	O
rounds	O
of	O
sterile	O
control	O
blood	O
cultures	O
after	O
1	O
,	O
2	O
and	O
6	O
weeks	O
of	O
antibiotic	O
treatment	O
,	O
completing	O
a	O
6	O
week	O
intravenous	O
antibiotic	O
cycle	O
of	O
ampicillin	B-FARMACO
and	O
ceftriaxone	B-FARMACO
and	O
4	O
weeks	O
of	O
tigecycline	B-FARMACO
with	O
good	O
tolerance	O
.	O
From	O
the	O
neurological	O
point	O
of	O
view	O
,	O
she	O
showed	O
clear	O
improvement	O
with	O
rehabilitation	O
,	O
being	O
able	O
to	O
perform	O
gross	O
and	O
fine	O
motor	O
exercises	O
with	O
the	O
affected	O
upper	O
limb	O
and	O
to	O
ambulate	O
with	O
the	O
help	O
of	O
a	O
support	O
.	O
Given	O
the	O
good	O
clinical	O
evolution	O
and	O
the	O
echocardiographic	O
worsening	O
,	O
outpatient	O
antibiotherapy	O
with	O
dalbavancin	B-FARMACO
1	O
,	O
500	O
mg	O
intravenous	O
every	O
15	O
days	O
was	O
decided	O
,	O
once	O
adequate	O
tolerance	O
had	O
been	O
verified	O
,	O
after	O
administering	O
the	O
first	O
two	O
doses	O
in	O
hospital	O
without	O
complications	O
,	O
fever	O
or	O
positive	O
control	O
blood	O
cultures	O
.	O
With	O
respect	O
to	O
paroxysmal	O
complete	O
AVB	O
,	O
beta	O
blocker	O
treatment	O
was	O
withdrawn	O
.	O
Given	O
the	O
presence	O
of	O
endocarditis	O
,	O
it	O
was	O
decided	O
not	O
to	O
implant	O
a	O
pacemaker	O
for	O
the	O
time	O
being	O
,	O
maintaining	O
subcutaneous	O
Holter	O
monitoring	O
and	O
outpatient	O
follow	O
up	O
by	O
both	O
cardiology	O
and	O
the	O
infectious	O
diseases	O
unit	O
,	O
with	O
the	O
patient	O
remaining	O
clinically	O
stable	O
until	O
the	O
present	O
day	O
.	O
DIAGNOSIS	O
Main	O
diagnosis	O
IE	O
due	O
to	O
Enterococcus	O
faecalis	O
on	O
mechanical	O
aortic	O
prosthesis	O
with	O
undetermined	O
door	O
of	O
entry	O
bacteraemia	O
,	O
dismissed	O
for	O
surgical	O
treatment	O
.	O
Other	O
diagnoses	O
Mitroaortic	O
abscess	O
with	O
secondary	O
mild	O
moderate	O
aortic	O
insufficiency	O
.	O
Multiple	O
cortical	O
cerebral	O
microinfarcts	O
and	O
left	O
renal	O
infarction	O
secondary	O
to	O
IE	O
.	O
Anaemia	O
in	O
the	O
context	O
of	O
IE	O
.	O
Traumatic	O
subdural	O
haematoma	O
and	O
left	O
frontal	O
parenchymal	O
parenchymal	O
contusions	O
in	O
the	O
context	O
of	O
traumatic	O
brain	O
injury	O
after	O
syncopal	O
episode	O
,	O
with	O
hemiparesis	O
and	O
comical	O
crises	O
in	O
the	O
acute	O
phase	O
.	O
Paroxysmal	O
AVB	O
.	O
Urinary	O
tract	O
infection	O
by	O
Citrobacter	O
freundii	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
BACKGROUND	O
Essential	O
arterial	O
hypertension	O
.	O
Grade	O
II	O
obesity	O
of	O
central	O
predominance	O
.	O
Non	O
ST	O
elevation	O
acute	O
coronary	O
syndrome	O
NSTEACS	O
in	O
87	O
and	O
98	O
,	O
being	O
treated	O
with	O
conventional	O
stent	O
in	O
the	O
second	O
episode	O
in	O
the	O
right	O
coronary	O
artery	O
.	O
Heterozygous	O
familial	O
hypercholesterolemia	O
with	O
pathogenic	O
LDL	O
receptor	O
mutation	O
.	O
Two	O
sons	O
with	O
the	O
same	O
mutation	O
.	O
Atheromatosis	O
of	O
large	O
vessels	O
,	O
with	O
carotid	O
involvement	O
detected	O
by	O
echo	O
Doppler	O
.	O
Restrictive	O
pulmonary	O
disorder	O
in	O
relation	O
to	O
obesity	O
hypoventilation	O
syndrome	O
.	O
Pending	O
polysomnographic	O
study	O
.	O
No	O
known	O
allergies	O
.	O
Intolerance	O
to	O
statins	B-FARMACO
,	O
with	O
clinical	O
manifestations	O
of	O
myalgias	O
and	O
elevated	O
muscle	O
damage	O
enzymes	O
CK	O
.	O
Previous	O
treatment	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
100	O
mg	O
,	O
atenolol	B-FARMACO
50	O
mg	O
,	O
atorvastatin	B-FARMACO
40	O
mg	O
,	O
ezetimibe	B-FARMACO
10	O
mg	O
.	O
CURRENT	O
DISEASE	O
A	O
79	O
year	O
old	O
man	O
with	O
the	O
history	O
described	O
above	O
came	O
to	O
the	O
endocrinology	O
department	O
for	O
review	O
of	O
lipid	O
lowering	O
treatment	O
for	O
secondary	O
prevention	O
after	O
NSTEACS	O
.	O
The	O
patient	O
presented	O
poor	O
tolerance	O
to	O
statins	B-FARMACO
,	O
with	O
muscle	O
pain	O
and	O
elevated	O
CK	O
levels	O
after	O
attempting	O
to	O
increase	O
the	O
dose	O
of	O
40	O
mg	O
of	O
atorvastatin	B-FARMACO
.	O
Despite	O
the	O
combination	O
of	O
40	O
mg	O
atorvastatin	B-FARMACO
with	O
10	O
mg	O
ezetimibe	B-FARMACO
,	O
the	O
patient	O
has	O
LDL	O
cholesterol	O
levels	O
of	O
145	O
mg	O
dl	O
well	O
above	O
the	O
recommended	O
limit	O
of	O
70	O
mg	O
dl	O
for	O
this	O
patient	O
group	O
.	O
Therefore	O
,	O
treatment	O
with	O
PCSK9	O
protein	O
inhibitors	O
,	O
specifically	O
evolocumab	B-FARMACO
,	O
is	O
proposed	O
and	O
accepted	O
,	O
starting	O
at	O
a	O
dose	O
of	O
140	O
mg	O
subcutaneous	O
every	O
two	O
weeks	O
.	O
PHYSICAL	O
EXAMINATION	O
Congestive	O
appearance	O
.	O
Weight	O
93	O
.	O
5	O
kg	O
.	O
Height	O
166	O
cm	O
.	O
Muscle	O
mass	O
index	O
BMI	O
34	O
kg	O
m2	O
.	O
Blood	O
pressure	O
BP	O
140	O
80	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
without	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
hypoventilation	O
in	O
the	O
bases	O
.	O
Peripheral	O
pulses	O
present	O
.	O
Discrete	O
oedema	O
with	O
fovea	O
in	O
the	O
lower	O
limbs	O
.	O
COMPLEMENTARY	O
TESTS	O
Last	O
blood	O
test	O
22	O
02	O
2018	O
glucose	O
101	O
mg	O
dl	O
.	O
Creatinine	O
0	O
.	O
79	O
mg	O
dl	O
.	O
GFR	O
MDRD	O
6	O
97	O
.	O
50	O
ml	O
min	O
.	O
Urea	O
37	O
mg	O
dl	O
.	O
Uric	O
acid	O
7	O
.	O
8	O
mg	O
dl	O
.	O
Sodium	O
141	O
mm	O
l	O
.	O
Potassium	O
4	O
.	O
9	O
mm	O
l	O
.	O
Chlorine	O
106	O
mm	O
l	O
.	O
Calcium	O
9	O
.	O
1	O
mg	O
dl	O
.	O
Phosphorus	O
3	O
.	O
1	O
mg	O
dl	O
.	O
Magnesium	O
1	O
.	O
80	O
mg	O
dl	O
.	O
Albumin	O
4	O
,	O
0	O
g	O
dl	O
.	O
Total	O
bilirubin	O
0	O
.	O
78	O
mg	O
dl	O
.	O
AST	O
GOT	O
33	O
U	O
l	O
.	O
ALT	O
GPT	O
44	O
U	O
l	O
.	O
GGT	O
24	O
U	O
l	O
.	O
Alkaline	O
phosphatase	O
54	O
U	O
l	O
.	O
Creatine	O
kinase	O
CK	O
170	O
U	O
l	O
.	O
Total	O
cholesterol	O
102	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
30	O
mg	O
dl	O
,	O
LDL	O
cholesterol	O
calc	O
.	O
37	O
mg	O
dl	O
,	O
triglycerides	O
174	O
mg	O
dl	O
.	O
C	O
reactive	O
protein	O
ultra	O
2	O
.	O
38	O
mg	O
l	O
.	O
Glycated	O
haemoglobin	O
DCCT	O
5	O
.	O
9	O
.	O
ECG	O
sinus	O
rhythm	O
at	O
66	O
bpm	O
,	O
PR	O
of	O
180	O
ms	O
,	O
narrow	O
QRS	O
at	O
60	O
degrees	O
without	O
acute	O
repolarisation	O
alterations	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
started	O
treatment	O
with	O
evolocumab	B-FARMACO
with	O
LDL	O
cholesterol	O
levels	O
of	O
145	O
mg	O
dl	O
.	O
After	O
one	O
month	O
of	O
treatment	O
the	O
LDL	O
cholesterol	O
level	O
dropped	O
to	O
26	O
mg	O
dl	O
.	O
Because	O
of	O
this	O
sharp	O
drop	O
,	O
both	O
the	O
patient	O
and	O
his	O
general	O
practitioner	O
decide	O
to	O
discontinue	O
evolocumab	B-FARMACO
without	O
consulting	O
his	O
cardiologist	O
or	O
endocrinologist	O
,	O
for	O
fear	O
of	O
adverse	O
effects	O
related	O
to	O
such	O
low	O
cholesterol	O
levels	O
.	O
Despite	O
the	O
endocrinologist	O
explaining	O
the	O
absence	O
of	O
complications	O
due	O
to	O
such	O
low	O
cholesterol	O
levels	O
,	O
the	O
patient	O
has	O
poor	O
adherence	O
to	O
treatment	O
with	O
a	O
rise	O
in	O
LDL	O
cholesterol	O
levels	O
for	O
one	O
year	O
,	O
after	O
which	O
the	O
patient	O
agrees	O
to	O
resume	O
treatment	O
correctly	O
.	O
A	O
further	O
decrease	O
in	O
LDL	O
cholesterol	O
levels	O
to	O
19	O
is	O
obtained	O
,	O
so	O
the	O
patient	O
is	O
de	O
escalated	O
by	O
withdrawing	O
ezetimibe	B-FARMACO
,	O
and	O
the	O
control	O
observed	O
in	O
the	O
last	O
analysis	O
is	O
obtained	O
.	O
Image	O
2	O
shows	O
the	O
cholesterol	O
evolution	O
profile	O
during	O
this	O
time	O
.	O
DIAGNOSIS	O
Heterozygous	O
familial	O
hypercholesterolemia	O
with	O
established	O
vascular	O
damage	O
and	O
good	O
control	O
of	O
cholesterol	O
levels	O
after	O
starting	O
treatment	O
with	O
PCSK9	O
protein	O
inhibitors	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
50	O
year	O
old	O
male	O
,	O
ex	O
smoker	O
with	O
no	O
other	O
history	O
of	O
interest	O
,	O
suffered	O
out	O
of	O
hospital	O
CPR	O
.	O
On	O
arrival	O
of	O
the	O
emergency	O
services	O
,	O
advanced	O
cardiopulmonary	O
resuscitation	O
CPR	O
manoeuvres	O
were	O
started	O
and	O
VF	O
was	O
observed	O
,	O
requiring	O
five	O
shocks	O
to	O
restore	O
sinus	O
rhythm	O
.	O
Total	O
CPR	O
time	O
was	O
40	O
minutes	O
.	O
She	O
was	O
transferred	O
to	O
the	O
intensive	O
care	O
unit	O
for	O
support	O
and	O
treatment	O
.	O
Physical	O
examination	O
revealed	O
no	O
significant	O
findings	O
,	O
and	O
the	O
patient	O
remained	O
haemodynamically	O
stable	O
with	O
no	O
signs	O
of	O
heart	O
failure	O
HF	O
or	O
audible	O
murmurs	O
.	O
COMPLEMENTARY	O
TESTS	O
TROPONIN	O
I	O
0	O
.	O
33	O
5	O
.	O
39	O
mcg	O
l	O
.	O
ELECTROCARDIOGRAM	O
ECG	O
sinus	O
rhythm	O
with	O
evolution	O
towards	O
inferior	O
necrosis	O
Q	O
wave	O
in	O
II	O
,	O
III	O
and	O
aVf	O
with	O
accompanying	O
R	O
and	O
flattened	O
repolarisation	O
.	O
THORAX	O
RADIOGRAPHY	O
no	O
alterations	O
.	O
CRANIAL	O
CT	O
no	O
significant	O
alterations	O
.	O
CORONARY	O
CHORONARYGRAPHY	O
coronary	O
arteries	O
without	O
significant	O
stenosis	O
.	O
Transthoracic	O
echocardiogram	O
left	O
ventricle	O
LV	O
neither	O
dilated	O
nor	O
hypertrophic	O
,	O
borderline	O
LVEF	O
50	O
52	O
,	O
akinesia	O
of	O
inferior	O
face	O
and	O
basal	O
inferior	O
septum	O
.	O
Normal	O
diastolic	O
pattern	O
for	O
age	O
.	O
Right	O
ventricle	O
RV	O
neither	O
dilated	O
nor	O
hypertrophic	O
,	O
preserved	O
systolic	O
function	O
TAPSE	O
20	O
mm	O
,	O
S	O
wave	O
12	O
cm	O
sec	O
.	O
Atria	O
of	O
normal	O
size	O
.	O
Aortic	O
valve	O
trivalve	O
,	O
thin	O
leaflets	O
normofunctioning	O
.	O
Thin	O
leaflet	O
mitral	O
valve	O
with	O
mild	O
central	O
insufficiency	O
.	O
Structurally	O
normal	O
tricuspid	O
valve	O
without	O
insufficiency	O
allowing	O
estimation	O
of	O
pulmonary	O
arterial	O
systolic	O
pressure	O
PSAP	O
.	O
No	O
indirect	O
evidence	O
of	O
pulmonary	O
hypertension	O
.	O
Inferior	O
vena	O
cava	O
IVC	O
slightly	O
dilated	O
23	O
mm	O
with	O
inspiratory	O
collapse	O
50	O
.	O
Aortic	O
root	O
not	O
dilated	O
34	O
mm	O
sinuses	O
of	O
Valsalva	O
.	O
No	O
pericardial	O
effusion	O
.	O
CARDIAC	O
MRI9	O
MAGNETIC	O
RESONANCE	O
showing	O
LV	O
slightly	O
dilated	O
with	O
preserved	O
systolic	O
function	O
.	O
Thinning	O
and	O
hypocontractility	O
in	O
inferoseptal	O
,	O
inferior	O
and	O
inferolateral	O
segments	O
at	O
basal	O
and	O
medial	O
level	O
with	O
oedema	O
,	O
hypoperfusion	O
and	O
subendocardial	O
late	O
enhancement	O
greater	O
than	O
50	O
in	O
these	O
segments	O
.	O
RV	O
of	O
normal	O
size	O
and	O
function	O
.	O
These	O
findings	O
are	O
compatible	O
with	O
acute	O
phase	O
infarction	O
.	O
CLINICAL	O
EVOLUTION	O
Given	O
the	O
high	O
suspicion	O
of	O
acute	O
myocardial	O
infarction	O
AMI	O
as	O
the	O
cause	O
of	O
the	O
CRA	O
,	O
and	O
that	O
it	O
was	O
a	O
primary	O
VF	O
,	O
cardiac	O
MRI	O
was	O
requested	O
in	O
which	O
signs	O
compatible	O
with	O
acute	O
phase	O
infarction	O
were	O
observed	O
.	O
The	O
patient	O
evolved	O
favourably	O
,	O
with	O
early	O
extubation	O
,	O
without	O
neurological	O
sequelae	O
and	O
maintaining	O
haemodynamic	O
stability	O
.	O
Days	O
later	O
he	O
was	O
discharged	O
under	O
double	O
antiplatelet	O
therapy	O
,	O
beta	O
blocker	O
,	O
high	O
potency	O
statin	O
and	O
proton	O
pump	O
inhibitors	O
PPI	O
.	O
Up	O
to	O
the	O
present	O
time	O
,	O
he	O
continues	O
to	O
progress	O
well	O
.	O
DIAGNOSIS	O
CRP	O
in	O
VF	O
in	O
the	O
context	O
of	O
inferior	O
AMI	O
.	O
Coronary	O
arteries	O
without	O
significant	O
lesions	O
.	O
Preserved	O
LV	O
systolic	O
function	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
BACKGROUND	O
47	O
year	O
old	O
female	O
,	O
ex	O
smoker	O
as	O
the	O
only	O
cardiovascular	O
risk	O
factor	O
and	O
no	O
previous	O
cardiological	O
history	O
.	O
In	O
2004	O
she	O
underwent	O
a	O
right	O
hemithyroidectomy	O
for	O
a	O
thyroid	O
nodule	O
.	O
Anatomopathological	O
diagnosis	O
of	O
follicular	O
adenoma	O
.	O
In	O
2013	O
,	O
he	O
was	O
diagnosed	O
with	O
diffuse	O
fibrocystic	O
mastopathy	O
.	O
In	O
2016	O
,	O
following	O
abdominal	O
distension	O
,	O
a	O
large	O
left	O
retroperitoneal	O
mass	O
suggestive	O
of	O
primary	O
adrenal	O
neoplasia	O
was	O
found	O
on	O
CT	O
scan	O
.	O
Functionality	O
was	O
ruled	O
out	O
and	O
a	O
unilateral	O
adrenal	O
adrenalectomy	O
,	O
left	O
nephrectomy	O
,	O
splenectomy	O
and	O
para	O
aortic	O
lymphadenectomy	O
were	O
performed	O
.	O
The	O
anatomopathological	O
study	O
confirmed	O
the	O
diagnosis	O
of	O
stage	O
II	O
adrenal	O
carcinoma	O
.	O
In	O
2017	O
diagnosis	O
of	O
uterine	O
myoma	O
.	O
Family	O
history	O
maternal	O
grandmother	O
breast	O
neoplasia	O
.	O
Maternal	O
grandfather	O
lung	O
neoplasia	O
.	O
Paternal	O
grandmother	O
leukaemia	O
.	O
Usual	O
treatment	O
oral	O
contraceptives	O
,	O
levothyroxine	B-FARMACO
,	O
hydrocortisone	B-FARMACO
.	O
CURRENT	O
ILLNESS	O
Regular	O
follow	O
up	O
in	O
endocrinology	O
and	O
gynaecology	O
.	O
In	O
the	O
last	O
control	O
CT	O
scan	O
in	O
endocrinology	O
,	O
no	O
signs	O
of	O
recurrence	O
of	O
adrenal	O
carcinoma	O
were	O
found	O
.	O
However	O
,	O
a	O
mass	O
was	O
found	O
in	O
the	O
left	O
atrium	O
,	O
for	O
which	O
a	O
study	O
was	O
requested	O
in	O
our	O
consultations	O
.	O
She	O
is	O
asymptomatic	O
from	O
the	O
cardiovascular	O
point	O
of	O
view	O
.	O
She	O
reported	O
mild	O
asthenia	O
and	O
weight	O
gain	O
in	O
the	O
last	O
year	O
,	O
which	O
she	O
related	O
to	O
changes	O
in	O
pharmacological	O
treatment	O
.	O
PHYSICAL	O
EXAMINATION	O
The	O
presence	O
of	O
cutaneous	O
lentigines	O
at	O
multiple	O
levels	O
is	O
noteworthy	O
.	O
Cardiopulmonary	O
auscultation	O
was	O
normal	O
.	O
No	O
other	O
striking	O
findings	O
.	O
COMPLEMENTARY	O
TESTS	O
Thoracic	O
abdomino	O
pelvic	O
CT	O
scan	O
for	O
endocrinology	O
control	O
no	O
signs	O
of	O
recurrence	O
of	O
adrenal	O
carcinoma	O
.	O
Cystic	O
lesion	O
of	O
35	O
mm	O
in	O
the	O
right	O
adnexal	O
region	O
.	O
Focal	O
nodular	O
hyperplasia	O
of	O
the	O
liver	O
.	O
Juxtacisural	O
pseudonodular	O
lesion	O
in	O
LSI	O
.	O
Mass	O
in	O
left	O
atrium	O
,	O
requesting	O
study	O
in	O
our	O
offices	O
.	O
ELECTROCARDIOGRAM	O
ECG	O
sinus	O
rhythm	O
at	O
80	O
bpm	O
.	O
No	O
repolarisation	O
alterations	O
.	O
Transthoracic	O
echocardiogram	O
there	O
was	O
evidence	O
of	O
a	O
mass	O
in	O
the	O
left	O
atrium	O
LA	O
,	O
of	O
heterogeneous	O
texture	O
,	O
adhered	O
to	O
the	O
interatrial	O
septum	O
at	O
the	O
level	O
of	O
the	O
fossa	O
ovalis	O
myxoma	O
as	O
a	O
first	O
possibility	O
;	O
possible	O
lipoma	O
.	O
Left	O
ventricle	O
LV	O
of	O
normal	O
size	O
,	O
non	O
hypertrophic	O
with	O
preserved	O
systolic	O
function	O
,	O
without	O
significant	O
valvulopathy	O
.	O
Right	O
ventricle	O
RV	O
not	O
dilated	O
with	O
preserved	O
systolic	O
function	O
.	O
CARDIAC	O
MRI	O
oval	O
,	O
well	O
defined	O
mass	O
depending	O
on	O
the	O
interatrial	O
septum	O
2	O
x	O
1	O
.	O
5	O
cm	O
;	O
craniocaudal	O
axis	O
2	O
.	O
2	O
cm	O
,	O
implanted	O
in	O
the	O
area	O
of	O
the	O
foramen	O
ovale	O
,	O
little	O
pedunculated	O
and	O
does	O
not	O
alter	O
the	O
functionality	O
of	O
the	O
mitral	O
valve	O
.	O
Low	O
signal	O
intensity	O
in	O
cine	O
sequences	O
with	O
central	O
predominant	O
contrast	O
uptake	O
,	O
compatible	O
with	O
myxoma	O
.	O
Normal	O
sized	O
cavities	O
and	O
preserved	O
biventricular	O
function	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
mass	O
and	O
its	O
implantation	O
base	O
were	O
resected	O
and	O
the	O
defect	O
was	O
closed	O
with	O
a	O
pericardial	O
patch	O
.	O
The	O
patient	O
's	O
evolution	O
was	O
favourable	O
after	O
surgery	O
and	O
the	O
control	O
transthoracic	O
echocardiogram	O
showed	O
preserved	O
biventricular	O
function	O
and	O
interatrial	O
septum	O
with	O
no	O
flow	O
through	O
it	O
and	O
no	O
evidence	O
of	O
myxoma	O
.	O
The	O
anatomopathological	O
study	O
confirms	O
the	O
diagnosis	O
of	O
myxoma	O
.	O
DIAGNOSIS	O
Cardiac	O
myxoma	O
.	O
Multiple	O
neoplasia	O
syndrome	O
Carney	O
syndrome	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
BACKGROUND	O
29	O
year	O
old	O
male	O
ex	O
smoker	O
for	O
the	O
last	O
year	O
of	O
a	O
pack	O
a	O
day	O
for	O
15	O
years	O
,	O
with	O
no	O
other	O
personal	O
history	O
of	O
interest	O
.	O
He	O
does	O
not	O
take	O
any	O
treatment	O
on	O
a	O
regular	O
basis	O
.	O
As	O
family	O
history	O
,	O
his	O
paternal	O
uncle	O
and	O
grandfather	O
died	O
of	O
acute	O
myocardial	O
infarction	O
AMI	O
at	O
an	O
age	O
over	O
65	O
years	O
.	O
Previous	O
baseline	O
ECG	O
is	O
in	O
sinus	O
rhythm	O
with	O
normal	O
axis	O
,	O
narrow	O
QRS	O
with	O
no	O
repolarisation	O
abnormalities	O
.	O
CURRENT	O
ILLNESS	O
The	O
patient	O
comes	O
to	O
the	O
emergency	O
department	O
of	O
our	O
centre	O
in	O
July	O
2017	O
for	O
a	O
48	O
hour	O
course	O
of	O
intense	O
odynophagia	O
,	O
making	O
swallowing	O
difficult	O
and	O
thermometric	O
fever	O
at	O
home	O
of	O
up	O
to	O
39	O
oC	O
.	O
She	O
denies	O
dyspnoea	O
,	O
cough	O
or	O
purulent	O
expectoration	O
.	O
He	O
has	O
also	O
been	O
complaining	O
for	O
months	O
of	O
mechanical	O
central	O
thoracic	O
discomfort	O
that	O
does	O
not	O
limit	O
his	O
usual	O
activity	O
.	O
PHYSICAL	O
EXAMINATION	O
On	O
arrival	O
at	O
the	O
ED	O
,	O
fever	O
of	O
38	O
C	O
and	O
sinus	O
tachycardia	O
at	O
110	O
bpm	O
were	O
observed	O
.	O
He	O
was	O
haemodynamically	O
stable	O
with	O
adequate	O
blood	O
pressure	O
and	O
good	O
baseline	O
oxygen	O
saturation	O
.	O
Physical	O
examination	O
revealed	O
an	O
erythematous	O
oropharynx	O
with	O
bilateral	O
tonsillar	O
pustular	O
plaques	O
and	O
traces	O
of	O
secretions	O
in	O
the	O
posterior	O
pharyngeal	O
wall	O
,	O
with	O
no	O
palpable	O
lymphadenopathies	O
.	O
Cardiopulmonary	O
auscultation	O
was	O
normal	O
.	O
COMPLEMENTARY	O
TESTS	O
ANALYSIS	O
leukocytosis	O
with	O
neutrophilia	O
,	O
normal	O
ions	O
.	O
VENOUS	O
GASOMETRY	O
respiratory	O
alkalosis	O
.	O
ECG	O
on	O
arrival	O
at	O
the	O
ED	O
with	O
fever	O
of	O
38oC	O
sinus	O
tachycardia	O
at	O
110	O
bpm	O
,	O
normal	O
PR	O
,	O
QRS	O
120	O
milliseconds	O
.	O
In	O
V1	O
V2	O
there	O
was	O
an	O
image	O
of	O
RsR	O
'	O
with	O
descending	O
ST	O
segment	O
elevation	O
and	O
negative	O
T	O
wave	O
.	O
Compatible	O
with	O
Brugada	O
type	O
I	O
pattern	O
.	O
ESG	O
after	O
an	O
iv	O
dose	O
of	O
paracetamol	B-FARMACO
,	O
37	O
oC	O
sinus	O
rhythm	O
at	O
95	O
bpm	O
,	O
normal	O
PR	O
,	O
QRS	O
113	O
milliseconds	O
.	O
In	O
V1	O
V2	O
there	O
is	O
an	O
image	O
of	O
RsR	O
'	O
with	O
descending	O
ST	O
segment	O
elevation	O
but	O
less	O
pronounced	O
than	O
in	O
previous	O
ECG	O
and	O
negative	O
T	O
wave	O
.	O
THORAX	O
RADIOGRAPHY	O
normal	O
.	O
Transthoracic	O
echocardiogram	O
no	O
data	O
of	O
structural	O
heart	O
disease	O
.	O
Non	O
dilated	O
left	O
ventricle	O
with	O
normal	O
wall	O
thickness	O
and	O
normal	O
systolic	O
function	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
with	O
normal	O
systolic	O
function	O
.	O
Normal	O
sized	O
atria	O
.	O
No	O
valvular	O
heart	O
disease	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
.	O
CLINICAL	O
EVOLUTION	O
Following	O
these	O
findings	O
,	O
the	O
patient	O
was	O
re	O
interviewed	O
and	O
reported	O
syncopal	O
episodes	O
of	O
vasovagal	O
profile	O
one	O
episode	O
in	O
the	O
last	O
two	O
years	O
related	O
to	O
heat	O
or	O
blood	O
draws	O
,	O
with	O
no	O
other	O
cardiovascular	O
symptoms	O
.	O
He	O
also	O
denies	O
a	O
history	O
of	O
sudden	O
death	O
in	O
his	O
family	O
.	O
The	O
patient	O
was	O
discharged	O
with	O
antibiotic	O
treatment	O
with	O
amoxicillin	B-FARMACO
for	O
acute	O
pharyngotonsillitis	O
and	O
was	O
referred	O
to	O
the	O
arrhythmia	O
unit	O
to	O
complete	O
the	O
study	O
,	O
where	O
a	O
provocation	O
test	O
with	O
flecainide	O
was	O
performed	O
,	O
which	O
was	O
positive	O
.	O
An	O
electrophysiological	O
study	O
was	O
performed	O
,	O
during	O
which	O
no	O
inducible	O
ventricular	O
arrhythmias	O
or	O
prolongation	O
of	O
the	O
HV	O
interval	O
were	O
found	O
.	O
As	O
the	O
patient	O
had	O
no	O
history	O
of	O
sudden	O
death	O
in	O
the	O
family	O
,	O
no	O
spontaneous	O
Brugada	O
type	O
1	O
pattern	O
,	O
very	O
low	O
recurrence	O
of	O
syncope	O
and	O
a	O
clear	O
vasovagal	O
profile	O
,	O
it	O
was	O
decided	O
not	O
to	O
implant	O
an	O
implantable	O
cardioverter	O
defibrillator	O
ICD	O
and	O
to	O
perform	O
clinical	O
follow	O
up	O
.	O
DIAGNOSIS	O
Electrocardiographic	O
pattern	O
of	O
Brugada	O
type	O
I	O
unmasked	O
by	O
fever	O
.	O
Syncope	O
with	O
a	O
probable	O
vasovagal	O
profile	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
BACKGROUND	O
60	O
year	O
old	O
patient	O
,	O
with	O
a	O
history	O
of	O
active	O
smoking	O
of	O
1	O
pack	O
day	O
,	O
dyslipidaemia	O
,	O
eosinophilic	O
oesophagitis	O
under	O
treatment	O
with	O
inhaled	O
corticosteroids	O
and	O
Tarlov	O
's	O
cyst	O
with	O
compression	O
of	O
left	O
sacral	O
roots	O
.	O
Family	O
history	O
of	O
ischaemic	O
heart	O
disease	O
.	O
Cardiological	O
history	O
recurrent	O
episodes	O
of	O
chest	O
pain	O
.	O
In	O
2015	O
an	O
ischaemia	O
test	O
was	O
performed	O
,	O
which	O
was	O
negative	O
,	O
and	O
subsequently	O
a	O
coronary	O
CT	O
scan	O
showed	O
significant	O
coronary	O
artery	O
disease	O
.	O
Coronary	O
angiography	O
showed	O
severe	O
right	O
circumflex	O
and	O
coronary	O
artery	O
disease	O
,	O
and	O
percutaneous	O
coronary	O
intervention	O
PCI	O
with	O
drug	O
eluting	O
stents	O
was	O
performed	O
.	O
CURRENT	O
ILLNESS	O
After	O
taking	O
moxifloxacin	B-FARMACO
for	O
bronchitis	O
,	O
she	O
presented	O
with	O
an	O
episode	O
of	O
sudden	O
dyspnoea	O
with	O
generalised	O
pruritus	O
and	O
chest	O
tightness	O
radiating	O
to	O
both	O
extremities	O
.	O
She	O
then	O
suffered	O
a	O
syncopal	O
episode	O
.	O
She	O
was	O
attended	O
by	O
061	O
who	O
observed	O
poor	O
general	O
condition	O
,	O
blood	O
pressure	O
BP	O
69	O
20	O
,	O
oxygen	O
saturation	O
SatO2	O
82	O
and	O
on	O
the	O
electrocardiogram	O
ECG	O
sharp	O
T	O
waves	O
with	O
J	O
point	O
elevation	O
of	O
2	O
mm	O
in	O
V3	O
V6	O
.	O
O2	B-FARMACO
,	O
fluid	O
therapy	O
and	O
treatment	O
as	O
ST	O
segment	O
elevation	O
acute	O
coronary	O
syndrome	O
STEMI	O
were	O
started	O
and	O
the	O
patient	O
was	O
transferred	O
to	O
hospital	O
for	O
primary	O
PCI	O
.	O
The	O
patient	O
arrived	O
at	O
the	O
haemodynamics	O
ward	O
with	O
systolic	O
blood	O
pressure	O
SBP	O
60	O
mmHg	O
and	O
drowsy	O
,	O
and	O
treatment	O
was	O
started	O
with	O
plasma	O
expanders	O
and	O
inotropes	O
.	O
Coronary	O
angiography	O
coronary	O
arteries	O
without	O
lesions	O
and	O
excellent	O
results	O
of	O
previously	O
implanted	O
stents	O
.	O
Absence	O
of	O
aortic	O
dissection	O
.	O
Ventriculography	O
without	O
segmental	O
alterations	O
and	O
with	O
competent	O
mitral	O
.	O
On	O
arrival	O
in	O
the	O
ward	O
,	O
skin	O
erythema	O
.	O
Subsequent	O
control	O
ECG	O
in	O
the	O
observation	O
room	O
normalisation	O
of	O
repolarisation	O
with	O
flattening	O
of	O
the	O
T	O
waves	O
on	O
the	O
anterolateral	O
side	O
.	O
Favourable	O
clinical	O
evolution	O
with	O
progressive	O
disappearance	O
of	O
the	O
skin	O
rash	O
and	O
normalisation	O
of	O
blood	O
pressure	O
,	O
and	O
inotropic	O
support	O
could	O
be	O
withdrawn	O
.	O
Slight	O
elevation	O
of	O
troponin	O
I	O
peak	O
TnI	O
0	O
.	O
46	O
in	O
the	O
biomarker	O
serum	O
.	O
Admitted	O
to	O
cardiology	O
with	O
a	O
diagnosis	O
of	O
anaphylactic	O
shock	O
after	O
taking	O
moxifloxacin	B-FARMACO
probable	O
Kounis	O
syndrome	O
KS	O
coronary	O
spasm	O
in	O
the	O
context	O
of	O
allergic	O
reaction	O
.	O
PHYSICAL	O
EXAMINATION	O
BP	O
122	O
71	O
,	O
heart	O
rate	O
HR	O
82	O
bpm	O
,	O
SatO2	O
95	O
.	O
Conscious	O
and	O
oriented	O
,	O
skin	O
congestion	O
,	O
normohydrated	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
,	O
no	O
murmurs	O
.	O
No	O
jugular	O
ingurgitation	O
.	O
Pulmonary	O
auscultation	O
normal	O
ventilation	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
.	O
No	O
masses	O
or	O
megaliths	O
.	O
No	O
signs	O
of	O
peritoneal	O
irritation	O
.	O
Peristalsis	O
preserved	O
.	O
Lower	O
extremities	O
no	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
COMPLEMENTARY	O
TESTS	O
ANALYTICS	O
glucose	O
96	O
mg	O
dl	O
.	O
Creatinine	O
0	O
.	O
54	O
mg	O
dl	O
,	O
Na	O
130	O
mEq	O
l	O
,	O
TSH	O
normal	O
.	O
Cholesterol	O
116	O
mg	O
dl	O
,	O
HDL	O
46	O
mg	O
dl	O
,	O
LDL	O
54	O
mg	O
dl	O
.	O
Haemoglobin	O
11	O
.	O
1	O
g	O
dl	O
,	O
platelets	O
236	O
x	O
10	O
3	O
microl	O
.	O
Chest	O
X	O
ray	O
no	O
relevant	O
findings	O
.	O
ECG	O
061	O
sinus	O
rhythm	O
at	O
97	O
bpm	O
,	O
hyperacute	O
T	O
waves	O
with	O
J	O
point	O
elevation	O
of	O
about	O
2	O
mm	O
in	O
V3	O
V6	O
.	O
ECG	O
at	O
discharge	O
sinus	O
rhythm	O
at	O
63	O
bpm	O
.	O
rs	O
in	O
III	O
,	O
aVF	O
.	O
T	O
negative	O
in	O
III	O
.	O
ST	O
rectilinear	O
in	O
V5	O
V6	O
.	O
ECOCARDIOGRAM	O
left	O
ventricle	O
LV	O
of	O
normal	O
dimensions	O
and	O
wall	O
thickness	O
.	O
Normal	O
global	O
systolic	O
function	O
,	O
without	O
segmental	O
asymmetries	O
of	O
contractility	O
.	O
Normal	O
diastolic	O
pattern	O
.	O
Left	O
atrium	O
of	O
normal	O
dimensions	O
.	O
Normal	O
right	O
chambers	O
,	O
normocontractile	O
right	O
ventricle	O
RV	O
.	O
Mitral	O
valve	O
MV	O
thin	O
leaflets	O
,	O
not	O
limited	O
in	O
its	O
opening	O
,	O
competent	O
.	O
Aortic	O
valve	O
VAo	O
trivalve	O
,	O
normal	O
sigmoid	O
leaflets	O
,	O
not	O
limited	O
in	O
opening	O
,	O
competent	O
.	O
Aortic	O
root	O
and	O
visualised	O
portion	O
of	O
proximal	O
ascending	O
aorta	O
normal	O
.	O
Tricuspid	O
insufficiency	O
TI	O
minimal	O
.	O
Inferior	O
vena	O
cava	O
IVC	O
not	O
dilated	O
with	O
normal	O
inspiratory	O
collapse	O
.	O
Normal	O
estimated	O
systolic	O
pulmonary	O
artery	O
pressure	O
PAPs	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
and	O
intracavitary	O
masses	O
through	O
this	O
access	O
route	O
.	O
CORONARYGRAPHY	O
coronary	O
tree	O
without	O
lesions	O
of	O
interest	O
,	O
with	O
TIMI	O
3	O
flow	O
and	O
excellent	O
results	O
of	O
previously	O
implanted	O
stents	O
.	O
Absence	O
of	O
aortic	O
dissection	O
.	O
Good	O
left	O
ventricular	O
function	O
,	O
without	O
segmental	O
alterations	O
and	O
with	O
competent	O
mitral	O
valve	O
.	O
CLINICAL	O
EVOLUTION	O
On	O
the	O
ward	O
the	O
patient	O
remained	O
stable	O
,	O
asymptomatic	O
at	O
all	O
times	O
.	O
A	O
control	O
echocardiogram	O
was	O
performed	O
showing	O
normal	O
systolic	O
function	O
,	O
with	O
no	O
other	O
alterations	O
of	O
interest	O
.	O
Due	O
to	O
a	O
history	O
of	O
hyperreactivity	O
in	O
a	O
patient	O
with	O
normal	O
systolic	O
function	O
,	O
without	O
previous	O
acute	O
myocardial	O
infarction	O
AMI	O
,	O
beta	O
blockers	O
were	O
discontinued	O
.	O
The	O
patient	O
was	O
preferentially	O
referred	O
to	O
the	O
allergology	O
department	O
for	O
monitoring	O
.	O
Asymptomatic	O
and	O
stable	O
,	O
the	O
patient	O
was	O
discharged	O
from	O
hospital	O
.	O
DIAGNOSIS	O
Anaphylactic	O
shock	O
after	O
taking	O
moxifloxacin	B-FARMACO
.	O
Kounis	O
syndrome	O
.	O
Chronic	O
ischaemic	O
heart	O
disease	O
coronary	O
arteries	O
without	O
significant	O
angiographic	O
lesions	O
.	O
Good	O
results	O
of	O
previous	O
stents	O
.	O

We	O
present	O
the	O
case	O
of	O
an	O
83	O
year	O
old	O
man	O
who	O
came	O
to	O
our	O
hospital	O
with	O
syncope	O
of	O
unclear	O
aetiology	O
.	O
HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
BACKGROUND	O
No	O
AMC	O
.	O
Hypertensive	O
,	O
type	O
2	O
diabetic	O
,	O
dyslipidaemic	O
,	O
ex	O
smoker	O
.	O
Chronic	O
obstructive	O
pulmonary	O
disease	O
COPD	O
moderate	O
grade	O
,	O
chronic	O
kidney	O
disease	O
stage	O
IIIB	O
,	O
and	O
peripheral	O
vascular	O
vascular	O
disease	O
in	O
follow	O
up	O
by	O
vascular	O
surgery	O
.	O
Surgical	O
interventions	O
ascending	O
aorta	O
endoprosthesis	O
in	O
2000	O
in	O
another	O
centre	O
outside	O
our	O
community	O
with	O
left	O
carotid	O
subclavian	O
bypass	O
and	O
occlusion	O
of	O
left	O
subclavian	O
artery	O
.	O
He	O
underwent	O
an	O
infrarenal	O
aorto	O
bi	O
iliac	O
abdominal	O
endoprosthesis	O
.	O
Usual	O
treatment	O
metformin	B-FARMACO
850	O
12	O
hours	O
,	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
100	O
mg	O
24	O
hours	O
,	O
nevibololol	B-FARMACO
hydrochlorothiazide	I-FARMACO
5	O
25	O
mg	O
24	O
hours	O
,	O
atorvastatin	B-FARMACO
40	O
mg	O
24	O
hours	O
.	O
CURRENT	O
ILLNESS	O
83	O
year	O
old	O
male	O
who	O
comes	O
to	O
the	O
emergency	O
department	O
of	O
our	O
centre	O
brought	O
by	O
a	O
neighbour	O
for	O
finding	O
him	O
fallen	O
at	O
home	O
.	O
He	O
lives	O
alone	O
,	O
with	O
no	O
direct	O
family	O
.	O
Anamnesis	O
was	O
difficult	O
due	O
to	O
the	O
patient	O
being	O
disorientated	O
in	O
time	O
and	O
space	O
.	O
On	O
rehistorising	O
the	O
patient	O
during	O
his	O
hospital	O
stay	O
,	O
the	O
day	O
before	O
admission	O
he	O
began	O
with	O
central	O
thoracic	O
pain	O
and	O
paraparesis	O
of	O
the	O
lower	O
limbs	O
,	O
which	O
prevented	O
him	O
from	O
standing	O
upright	O
,	O
as	O
well	O
as	O
diffuse	O
abdominal	O
discomfort	O
,	O
with	O
no	O
other	O
apparent	O
associated	O
symptoms	O
.	O
On	O
asking	O
his	O
neighbour	O
,	O
he	O
reported	O
finding	O
him	O
at	O
home	O
with	O
a	O
wound	O
in	O
the	O
occipital	O
region	O
,	O
without	O
loss	O
of	O
sphincter	O
control	O
;	O
apparently	O
the	O
patient	O
had	O
been	O
asymptomatic	O
from	O
a	O
cardiovascular	O
point	O
of	O
view	O
for	O
the	O
previous	O
few	O
days	O
.	O
PHYSICAL	O
EXAMINATION	O
Disoriented	O
in	O
time	O
and	O
space	O
.	O
Verbose	O
.	O
Blood	O
pressure	O
BP	O
160	O
85	O
mmHg	O
.	O
Heart	O
rate	O
90	O
bpm	O
.	O
Afebrile	O
.	O
No	O
IY	O
.	O
Occipital	O
trauma	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
without	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
generalised	O
hypoventilation	O
with	O
some	O
scattered	O
rhonchi	O
.	O
Lower	O
limbs	O
no	O
oedema	O
,	O
femoral	O
and	O
popliteal	O
pulses	O
present	O
with	O
abolished	O
distal	O
pulses	O
.	O
Abdomen	O
no	O
pain	O
on	O
palpation	O
,	O
hydroaerial	O
sounds	O
present	O
,	O
no	O
signs	O
of	O
peritoneal	O
irritation	O
.	O
NRL	O
Bilateral	O
PPCC	O
preserved	O
.	O
Strength	O
and	O
sensibility	O
preserved	O
in	O
all	O
four	O
limbs	O
.	O
COMPLEMENTARY	O
TESTS	O
ANALYTICS	O
ED	O
biochemistry	O
glucose	O
250	O
mg	O
dl	O
.	O
Creatinine	O
3	O
.	O
19	O
mg	O
dl	O
,	O
GFR	O
MDRD	O
19	O
ml	O
min	O
m2	O
.	O
nA	O
140	O
mEq	O
l	O
.	O
K	O
4	O
.	O
9	O
mEq	O
l	O
.	O
Urea	O
89	O
mg	O
dl	O
.	O
GOT	O
25IU	O
l	O
.	O
GPT	O
16IU	O
l	O
.	O
Bilirubin	O
05	O
mg	O
dl	O
.	O
Haemogram	O
21100	O
leukocytes	O
84	O
PMN	O
,	O
4	O
keys	O
,	O
Hb	O
7	O
.	O
8	O
g	O
dl	O
,	O
haematocrit	O
23	O
,	O
192000	O
platelets	O
mm3	O
.	O
Coagulation	O
INR	O
1	O
.	O
0	O
,	O
PT	O
100	O
ELECTROCARDIOGRAM	O
ECG	O
sinus	O
rhythm	O
at	O
85	O
bpm	O
,	O
PR	O
180	O
ms	O
,	O
wide	O
QRS	O
with	O
right	O
bundle	O
branch	O
block	O
.	O
Chest	O
X	O
ray	O
P	O
A	O
cardiomegaly	O
.	O
Significant	O
mediastinal	O
enlargement	O
displacing	O
the	O
left	O
lung	O
.	O
Left	O
pleural	O
effusion	O
.	O
Cranial	O
CT	O
scan	O
emergency	O
bilateral	O
frontoparietal	O
extra	O
axial	O
collection	O
,	O
suggestive	O
of	O
subdural	O
haematoma	O
with	O
little	O
compressive	O
effect	O
on	O
the	O
cerebral	O
parenchyma	O
.	O
Small	O
vessel	O
ischaemic	O
lesions	O
.	O
ECHOcardiogram	O
urgent	O
left	O
ventricle	O
of	O
normal	O
size	O
,	O
with	O
preserved	O
global	O
and	O
segmental	O
systolic	O
function	O
calculated	O
at	O
65	O
.	O
No	O
contractility	O
alterations	O
are	O
evident	O
.	O
Right	O
chambers	O
of	O
preserved	O
size	O
and	O
function	O
.	O
No	O
significant	O
valvulopathies	O
.	O
No	O
evidence	O
of	O
pericardial	O
effusion	O
Thoracic	O
ANGIO	O
CT	O
emergency	O
performed	O
without	O
contrast	O
due	O
to	O
creatinine	O
levels	O
.	O
Increase	O
in	O
the	O
aneurysmal	O
sac	O
with	O
respect	O
to	O
the	O
previous	O
study	O
in	O
December	O
2011	O
.	O
The	O
current	O
measurements	O
are	O
11	O
x	O
11	O
x	O
14	O
cm	O
in	O
the	O
transverse	O
,	O
anteroposterior	O
and	O
cranio	O
caudal	O
axes	O
respectively	O
the	O
measurements	O
of	O
the	O
previous	O
study	O
were	O
6	O
x	O
6	O
x	O
7	O
x	O
7	O
cm	O
.	O
There	O
is	O
a	O
significant	O
loculated	O
left	O
pleural	O
effusion	O
.	O
Both	O
in	O
the	O
aneurysmal	O
sac	O
and	O
in	O
the	O
effusion	O
,	O
areas	O
of	O
increased	O
attenuation	O
are	O
identified	O
suggesting	O
extravasation	O
of	O
blood	O
.	O
In	O
the	O
prosthesis	O
located	O
in	O
the	O
aortic	O
arch	O
,	O
at	O
the	O
junction	O
of	O
the	O
distal	O
portion	O
of	O
the	O
arch	O
with	O
the	O
descending	O
aorta	O
,	O
there	O
is	O
an	O
area	O
of	O
irregularity	O
and	O
apparent	O
interruption	O
of	O
the	O
continuity	O
of	O
the	O
prosthesis	O
walls	O
.	O
ANGIO	O
CT	O
scan	O
of	O
the	O
aorta	O
day	O
1	O
of	O
admission	O
endoprosthesis	O
in	O
the	O
aortic	O
arch	O
,	O
with	O
slight	O
bending	O
in	O
the	O
proximal	O
and	O
distal	O
areas	O
.	O
Large	O
aortic	O
aneurysm	O
11	O
.	O
5	O
cm	O
thrombosed	O
,	O
although	O
with	O
dense	O
areas	O
suggesting	O
haemorrhage	O
and	O
therefore	O
instability	O
,	O
especially	O
in	O
the	O
anterior	O
area	O
.	O
No	O
direct	O
or	O
indirect	O
leakage	O
is	O
demonstrated	O
by	O
this	O
study	O
.	O
Above	O
all	O
,	O
in	O
the	O
superior	O
zone	O
,	O
calcifications	O
are	O
evident	O
in	O
the	O
mural	O
thrombus	O
,	O
indicating	O
dissection	O
,	O
but	O
no	O
false	O
lumen	O
filling	O
is	O
seen	O
.	O
Pre	O
stent	O
aorta	O
of	O
36	O
mm	O
and	O
distal	O
aorta	O
of	O
31	O
mm	O
.	O
Patent	O
left	O
carotid	O
subclavian	O
anastomosis	O
.	O
Significant	O
left	O
pleural	O
effusion	O
with	O
haemorrhagic	O
component	O
with	O
no	O
visible	O
leaks	O
;	O
it	O
is	O
loculated	O
and	O
lobulated	O
,	O
with	O
collapse	O
of	O
LII	O
and	O
atelectasis	O
of	O
the	O
lingula	O
.	O
Discrete	O
mediastinal	O
shift	O
to	O
the	O
right	O
side	O
.	O
The	O
aneurysm	O
compresses	O
the	O
pulmonary	O
artery	O
and	O
the	O
left	O
pulmonary	O
artery	O
branch	O
.	O
Coronary	O
calcifications	O
.	O
Aorto	O
bi	O
iliac	O
endoprosthesis	O
without	O
complications	O
.	O
Thoracic	O
ARTERIOGRAPHY	O
day	O
2	O
of	O
admission	O
performed	O
via	O
the	O
right	O
humeral	O
route	O
.	O
No	O
contrast	O
leakage	O
or	O
branches	O
contributing	O
to	O
the	O
aneurysmal	O
sac	O
were	O
identified	O
.	O
CLINICAL	O
EVOLUTION	O
An	O
83	O
year	O
old	O
man	O
with	O
the	O
aforementioned	O
history	O
was	O
admitted	O
to	O
the	O
hospital	O
emergency	O
department	O
for	O
syncope	O
;	O
after	O
performing	O
the	O
appropriate	O
complementary	O
tests	O
,	O
acute	O
aortic	O
syndrome	O
was	O
detected	O
and	O
he	O
was	O
admitted	O
to	O
the	O
coronary	O
unit	O
of	O
our	O
hospital	O
.	O
In	O
view	O
of	O
the	O
clinical	O
stability	O
of	O
the	O
patient	O
,	O
his	O
comorbidity	O
and	O
in	O
agreement	O
with	O
the	O
cardiac	O
surgery	O
department	O
of	O
our	O
hospital	O
,	O
intensive	O
surveillance	O
and	O
conservative	O
management	O
were	O
decided	O
,	O
starting	O
first	O
with	O
antihypertensive	O
treatment	O
,	O
transfusion	O
of	O
two	O
red	O
blood	O
cell	O
concentrates	O
and	O
serum	O
therapy	O
with	O
a	O
view	O
to	O
improving	O
renal	O
function	O
in	O
order	O
to	O
complete	O
the	O
study	O
.	O
On	O
the	O
first	O
day	O
of	O
admission	O
,	O
a	O
new	O
control	O
CT	O
angiography	O
was	O
performed	O
,	O
this	O
time	O
with	O
contrast	O
,	O
with	O
no	O
evident	O
leakage	O
and	O
showing	O
thrombosis	O
of	O
the	O
aneurysm	O
,	O
and	O
on	O
the	O
second	O
day	O
of	O
hospitalisation	O
,	O
after	O
stabilising	O
the	O
patient	O
's	O
renal	O
function	O
and	O
in	O
a	O
situation	O
of	O
haemodynamic	O
stability	O
,	O
a	O
thoracic	O
arteriography	O
was	O
performed	O
with	O
no	O
evidence	O
of	O
contrast	O
leakage	O
.	O
During	O
his	O
admission	O
,	O
the	O
patient	O
showed	O
good	O
clinical	O
evolution	O
,	O
with	O
haemodynamic	O
stability	O
,	O
no	O
neurological	O
deterioration	O
and	O
progressive	O
improvement	O
in	O
renal	O
function	O
.	O
Finally	O
,	O
given	O
the	O
favourable	O
evolution	O
of	O
the	O
patient	O
's	O
condition	O
,	O
conservative	O
management	O
of	O
his	O
acute	O
aortic	O
syndrome	O
was	O
decided	O
.	O
On	O
discharge	O
,	O
he	O
was	O
haemodynamically	O
stable	O
and	O
asymptomatic	O
from	O
the	O
cardiovascular	O
point	O
of	O
view	O
,	O
and	O
treatment	O
was	O
prescribed	O
with	O
beta	O
blockers	O
and	O
vasodilators	O
at	O
low	O
doses	O
.	O
Likewise	O
,	O
he	O
was	O
assessed	O
by	O
the	O
neurosurgery	O
service	O
without	O
requiring	O
treatment	O
and	O
,	O
due	O
to	O
the	O
lack	O
of	O
family	O
support	O
,	O
he	O
was	O
assessed	O
by	O
the	O
social	O
worker	O
and	O
institutionalised	O
.	O
DIAGNOSIS	O
Acute	O
aortic	O
syndrome	O
.	O
Intramural	O
haematoma	O
secondary	O
to	O
leakage	O
of	O
ascending	O
aortic	O
stent	O
.	O
Rupture	O
of	O
aneurysmal	O
sac	O
with	O
haemothorax	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
BACKGROUND	O
60	O
year	O
old	O
male	O
,	O
no	O
known	O
drug	O
allergies	O
,	O
as	O
cardiovascular	O
risk	O
factors	O
he	O
is	O
a	O
smoker	O
of	O
15	O
cigarettes	O
day	O
,	O
hypertensive	O
and	O
dyslipidaemic	O
.	O
Other	O
antecedents	O
include	O
an	O
anxious	O
depressive	O
syndrome	O
,	O
chronic	O
bronchitis	O
with	O
bronchodilator	O
treatment	O
and	O
he	O
is	O
an	O
ex	O
miner	O
.	O
He	O
underwent	O
surgery	O
for	O
a	O
right	O
hip	O
fracture	O
5	O
years	O
ago	O
and	O
a	O
right	O
ankle	O
fracture	O
more	O
than	O
20	O
years	O
ago	O
.	O
No	O
personal	O
or	O
family	O
history	O
of	O
heart	O
disease	O
or	O
sudden	O
death	O
.	O
He	O
follows	O
regular	O
treatment	O
with	O
fluoxetine	B-FARMACO
40	O
mg	O
24	O
hours	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
24	O
hours	O
,	O
bromazepam	B-FARMACO
1	O
.	O
5	O
mg	O
24	O
hours	O
,	O
valsartan	B-FARMACO
160	O
mg	O
24	O
hours	O
,	O
pravastatin	B-FARMACO
20	O
mg	O
24	O
hours	O
,	O
formoterol	B-FARMACO
100	O
beclomethasone	B-FARMACO
6	O
mcg	O
1	O
inhalation	O
24	O
hours	O
,	O
and	O
salbutamol	B-FARMACO
on	O
demand	O
.	O
CURRENT	O
ILLNESS	O
On	O
the	O
day	O
prior	O
to	O
admission	O
,	O
the	O
patient	O
reported	O
starting	O
with	O
a	O
catarrhal	O
condition	O
,	O
with	O
general	O
malaise	O
and	O
no	O
fever	O
,	O
for	O
which	O
reason	O
he	O
went	O
to	O
his	O
primary	O
care	O
physician	O
on	O
the	O
day	O
of	O
admission	O
,	O
who	O
prescribed	O
antibiotic	O
treatment	O
with	O
moxifloxacin	B-FARMACO
400	O
mg	O
.	O
After	O
taking	O
the	O
first	O
dose	O
,	O
he	O
began	O
with	O
intense	O
itching	O
of	O
the	O
scalp	O
,	O
followed	O
by	O
sweating	O
,	O
skin	O
rash	O
,	O
oppressive	O
non	O
radiating	O
central	O
thoracic	O
pain	O
and	O
intense	O
dyspnoea	O
.	O
They	O
called	O
emergency	O
services	O
and	O
on	O
arrival	O
of	O
112	O
they	O
found	O
the	O
patient	O
dyspnoeic	O
,	O
with	O
significant	O
respiratory	O
distress	O
,	O
hypotensive	O
blood	O
pressure	O
BP	O
80	O
60	O
and	O
with	O
an	O
oxygen	O
saturation	O
of	O
78	O
,	O
which	O
improved	O
after	O
administration	O
of	O
serum	O
therapy	O
and	O
bronchodilators	O
,	O
so	O
he	O
was	O
transferred	O
to	O
our	O
centre	O
.	O
On	O
arrival	O
at	O
our	O
centre	O
,	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
emergency	O
department	O
and	O
found	O
to	O
be	O
haemodynamically	O
stable	O
and	O
not	O
in	O
respiratory	O
distress	O
,	O
with	O
improvement	O
in	O
oxygenation	O
parameters	O
,	O
and	O
cardiology	O
was	O
contacted	O
and	O
he	O
was	O
admitted	O
to	O
the	O
coronary	O
unit	O
of	O
our	O
centre	O
.	O
PHYSICAL	O
EXAMINATION	O
Blood	O
pressure	O
130	O
70	O
.	O
Heart	O
rate	O
85	O
bpm	O
.	O
Temperature	O
36	O
C	O
.	O
Conscious	O
,	O
oriented	O
,	O
good	O
distal	O
perfusion	O
.	O
Eupneic	O
on	O
room	O
air	O
without	O
supplementary	O
oxygen	B-FARMACO
.	O
Chest	O
emphysematous	O
.	O
Head	O
and	O
neck	O
no	O
IVY	O
,	O
no	O
hepatojugular	O
reflux	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
no	O
audible	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
Global	O
hypoventilation	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
.	O
Extremities	O
no	O
oedema	O
,	O
no	O
evidence	O
of	O
deep	O
vein	O
thrombosis	O
.	O
COMPLEMENTARY	O
TESTS	O
ELECTROCARDIOGRAM	O
ECG	O
112	O
sinus	O
rhythm	O
at	O
95	O
bpm	O
,	O
PR	O
160	O
MS	O
,	O
narrow	O
QRS	O
.	O
Axis	O
60o	O
.	O
Inferior	O
ST	O
supra	O
segment	O
elevation	O
.	O
ECG	O
coronary	O
unit	O
SR	O
at	O
100	O
bpm	O
,	O
PR	O
160ms	O
,	O
narrow	O
QRS	O
.	O
q	O
III	O
.	O
ST	O
segment	O
normalisation	O
.	O
THORAX	O
RADIOGRAPHY	O
normal	O
cardiothoracic	O
index	O
with	O
no	O
evidence	O
of	O
vascular	O
redistribution	O
.	O
ANALYSIS	O
in	O
the	O
coronary	O
unit	O
CBC	O
leukocytes	O
18	O
.	O
8	O
10e3	O
ul	O
80	O
.	O
2	O
neutrophils	O
,	O
16	O
.	O
7	O
lymphocytes	O
;	O
haemoglobin	O
17	O
.	O
5	O
g	O
dl	O
;	O
platelets	O
331	O
10e3	O
u	O
.	O
Biochemistry	O
creatinine	O
1	O
.	O
02	O
mg	O
dl	O
GFR	O
72ml	O
min	O
m2	O
;	O
urea	O
42	O
mg	O
dl	O
,	O
sodium	O
140	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
1	O
mEq	O
l	O
,	O
blood	O
glucose	O
119	O
mg	O
dl	O
.	O
Peak	O
CK	O
232	O
U	O
l	O
normal	O
range	O
10	O
192	O
;	O
peak	O
CKMB	O
35	O
U	O
l	O
;	O
peak	O
ultrasensitive	O
troponin	O
195	O
ng	O
l	O
normal	O
range	O
0	O
13	O
.	O
Total	O
cholesterol	O
187	O
;	O
LDL	O
106	O
;	O
HDL	O
38	O
;	O
triglycerides	O
212	O
.	O
AST	O
23	O
U	O
l	O
normal	O
range	O
15	O
41	O
;	O
ALT	O
15	O
U	O
l	O
normal	O
range	O
0	O
13	O
.	O
Thyroid	O
hormones	O
within	O
normal	O
range	O
.	O
Coagulation	O
INR	O
1	O
.	O
02	O
;	O
prothrombin	O
rate	O
89	O
.	O
Arterial	O
blood	O
gas	O
FiO2	O
21	O
pH	O
7	O
.	O
30	O
,	O
PCO2	O
37	O
,	O
PO2	O
76	O
,	O
bicarbonate	O
18	O
,	O
saturation	O
90	O
.	O
CARDIAC	O
CATHETERISM	O
coronary	O
arteries	O
without	O
angiographically	O
significant	O
lesions	O
.	O
ECOCARDIOGRAM	O
left	O
ventricle	O
not	O
dilated	O
,	O
with	O
slight	O
hypertrophy	O
,	O
with	O
preserved	O
global	O
function	O
without	O
segmental	O
abnormalities	O
of	O
contractility	O
LVEF	O
calculated	O
at	O
60	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
and	O
function	O
.	O
Left	O
atrium	O
slightly	O
dilated	O
.	O
No	O
valvular	O
heart	O
disease	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
with	O
adequate	O
inspiratory	O
collapse	O
.	O
No	O
pericardial	O
effusion	O
.	O
Normal	O
aortic	O
arch	O
.	O
CLINICAL	O
EVOLUTION	O
On	O
arrival	O
at	O
the	O
coronary	O
unit	O
,	O
the	O
patient	O
was	O
asymptomatic	O
,	O
with	O
no	O
new	O
episodes	O
of	O
angina	O
,	O
and	O
haemodynamically	O
stable	O
,	O
with	O
normalisation	O
of	O
the	O
repolarisation	O
alterations	O
that	O
he	O
presented	O
at	O
the	O
beginning	O
of	O
the	O
picture	O
.	O
A	O
haemodynamic	O
study	O
was	O
performed	O
,	O
showing	O
coronary	O
arteries	O
without	O
lesions	O
and	O
an	O
echocardiogram	O
showing	O
a	O
ventricle	O
of	O
preserved	O
size	O
and	O
function	O
with	O
no	O
contractility	O
abnormalities	O
.	O
During	O
admission	O
,	O
he	O
presented	O
acute	O
renal	O
failure	O
,	O
with	O
metabolic	O
acidosis	O
that	O
resolved	O
with	O
treatment	O
,	O
and	O
a	O
referral	O
was	O
made	O
to	O
the	O
allergology	O
department	O
.	O
After	O
performing	O
skin	O
tests	O
,	O
the	O
symptoms	O
were	O
interpreted	O
as	O
allergic	O
vasospastic	O
angina	O
or	O
KS	O
secondary	O
to	O
moxifloxacin	B-FARMACO
.	O
Subsequently	O
,	O
during	O
his	O
stay	O
in	O
the	O
cardiology	O
ward	O
,	O
he	O
remained	O
asymptomatic	O
from	O
the	O
cardiovascular	O
point	O
of	O
view	O
and	O
it	O
was	O
decided	O
to	O
discharge	O
him	O
on	O
the	O
fifth	O
day	O
and	O
continue	O
outpatient	O
controls	O
.	O
DIAGNOSIS	O
Allergic	O
vasospastic	O
angina	O
SK	O
.	O
Allergy	O
to	O
quinolones	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
BACKGROUND	O
Family	O
history	O
Mother	O
with	O
early	O
ischaemic	O
heart	O
disease	O
46	O
years	O
old	O
.	O
Died	O
at	O
the	O
age	O
of	O
50	O
due	O
to	O
acute	O
myocardial	O
infarction	O
AMI	O
.	O
Uncles	O
on	O
maternal	O
side	O
with	O
early	O
ischaemic	O
heart	O
disease	O
.	O
Brother	O
died	O
at	O
the	O
age	O
of	O
28	O
due	O
to	O
AMI	O
.	O
Brother	O
with	O
ischaemic	O
heart	O
disease	O
at	O
the	O
age	O
of	O
39	O
.	O
Personal	O
history	O
No	O
known	O
drug	O
allergies	O
No	O
known	O
toxic	O
habits	O
.	O
Cardiovascular	O
risk	O
factors	O
CVRF	O
no	O
hypertension	O
HT	O
,	O
no	O
known	O
diabetes	O
mellitus	O
DM	O
.	O
Heterozygous	O
familial	O
hypercholesterolemia	O
with	O
positive	O
genetic	O
study	O
M334	O
mutation	O
under	O
follow	O
up	O
in	O
the	O
lipid	O
and	O
cardiovascular	O
CV	O
risk	O
unit	O
.	O
Cardiological	O
history	O
chronic	O
multivessel	O
ischaemic	O
cardiopathy	O
debut	O
in	O
December	O
2006	O
with	O
inferoposterior	O
AMI	O
with	O
partially	O
revascularised	O
multivessel	O
disease	O
ADA	O
and	O
marginal	O
with	O
implantation	O
of	O
4	O
drug	O
eluting	O
stents	O
,	O
chronically	O
occluded	O
right	O
coronary	O
artery	O
RCA	O
with	O
very	O
diseased	O
vessel	O
.	O
Left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
preserved	O
.	O
New	O
admission	O
in	O
2008	O
for	O
unstable	O
angina	O
with	O
new	O
coronary	O
angiography	O
with	O
slight	O
luminal	O
loss	O
of	O
previously	O
implanted	O
stents	O
.	O
Chronic	O
occlusion	O
of	O
the	O
RCA	O
and	O
no	O
progression	O
of	O
the	O
disease	O
to	O
other	O
levels	O
.	O
In	O
2011	O
,	O
stress	O
echocardiography	O
was	O
performed	O
and	O
was	O
positive	O
with	O
ischaemia	O
in	O
the	O
RCA	O
territory	O
,	O
new	O
catheterisation	O
without	O
restenosis	O
of	O
the	O
stents	O
implanted	O
in	O
the	O
anterior	O
descending	O
artery	O
AD	O
and	O
circumflex	O
artery	O
CX	O
.	O
100	O
occlusion	O
of	O
the	O
middle	O
RCA	O
treated	O
by	O
percutaneous	O
transluminal	O
coronary	O
angioplasty	O
PTCA	O
and	O
two	O
drug	O
eluting	O
stents	O
in	O
the	O
proximal	O
and	O
middle	O
segments	O
.	O
Left	O
hemispheric	O
stroke	O
in	O
November	O
2010	O
.	O
Fibromyalgia	O
.	O
Operated	O
on	O
lumbar	O
hernia	O
.	O
Usual	O
treatment	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
100	O
mg	O
c	O
24	O
hours	O
;	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
c	O
24	O
hours	O
;	O
telmisartan	B-FARMACO
40	O
mg	O
c	O
24	O
hours	O
;	O
pantoprazole	B-FARMACO
20	O
mg	O
c	O
24	O
hours	O
;	O
NTG	B-FARMACO
transdermal	O
patch	O
10	O
mg	O
;	O
ezetimibe	B-FARMACO
10	O
mg	O
c	O
24	O
hours	O
;	O
rosuvastatin	B-FARMACO
20	O
mg	O
c	O
24	O
hours	O
,	O
duloxetine	B-FARMACO
60	O
mg	O
c	O
24	O
hours	O
;	O
sublingual	O
NFC	B-FARMACO
if	O
chest	O
pain	O
.	O
CURRENT	O
ILLNESS	O
Patient	O
with	O
personal	O
history	O
of	O
heterozygous	O
familial	O
hypercholesterolaemia	O
with	O
positive	O
genetic	O
diagnosis	O
and	O
a	O
history	O
of	O
revascularised	O
early	O
multivessel	O
chronic	O
ischaemic	O
heart	O
disease	O
under	O
follow	O
up	O
in	O
the	O
lipid	O
and	O
CV	O
risk	O
unit	O
of	O
our	O
hospital	O
without	O
reaching	O
target	O
therapeutic	O
levels	O
of	O
LDL	O
cholesterol	O
according	O
to	O
current	O
indications	O
in	O
secondary	O
prevention	O
,	O
despite	O
treatment	O
with	O
combined	O
lipid	O
lowering	O
agents	O
at	O
maximum	O
tolerated	O
doses	O
in	O
addition	O
to	O
multiple	O
readmissions	O
to	O
cardiology	O
for	O
unstable	O
angina	O
with	O
progression	O
of	O
coronary	O
heart	O
disease	O
.	O
In	O
October	O
2014	O
,	O
given	O
the	O
persistent	O
poor	O
control	O
of	O
LDL	O
cholesterol	O
levels	O
and	O
his	O
high	O
cardiovascular	O
risk	O
,	O
it	O
was	O
decided	O
to	O
include	O
the	O
patient	O
in	O
the	O
LDL	O
apheresis	O
programme	O
,	O
which	O
was	O
started	O
after	O
performing	O
an	O
A	O
V	O
fistula	O
in	O
MSI	O
with	O
good	O
initial	O
tolerance	O
.	O
PHYSICAL	O
EXAMINATION	O
Good	O
general	O
condition	O
,	O
well	O
hydrated	O
and	O
perfused	O
.	O
Eupneic	O
at	O
rest	O
,	O
tolerates	O
decubitus	O
.	O
Afebrile	O
and	O
haemodynamically	O
stable	O
.	O
Blood	O
pressure	O
BP	O
129	O
60	O
mmHg	O
,	O
heart	O
rate	O
HR	O
65	O
bpm	O
.	O
Positive	O
corneal	O
arc	O
.	O
Cardiorespiratory	O
auscultation	O
with	O
rhythmic	O
tones	O
,	O
no	O
murmurs	O
.	O
Conservative	O
vesicular	O
murmur	O
with	O
no	O
superimposed	O
noises	O
.	O
Absence	O
of	O
oedema	O
in	O
the	O
lower	O
limbs	O
with	O
pulses	O
present	O
.	O
Bilateral	O
femoral	O
murmurs	O
.	O
COMPLEMENTARY	O
TESTS	O
ELECTROCARDIOGRAM	O
ECG	O
sinus	O
rhythm	O
at	O
78	O
bpm	O
,	O
normal	O
axis	O
.	O
PR	O
128	O
msec	O
,	O
narrow	O
QRS	O
with	O
low	O
voltages	O
in	O
DIII	O
.	O
LIPID	O
PROFILE	O
2014	O
total	O
cholesterol	O
210	O
mg	O
Dl	O
.	O
Triglycerides	O
139	O
mg	O
dl	O
.	O
Apo	O
A	O
Apolipoprotein	O
151	O
mg	O
dl	O
.	O
HDL	O
cholesterol	O
52	O
mg	O
dl	O
.	O
LDL	O
cholesterol	O
130	O
mg	O
dl	O
.	O
Apo	O
B	O
Apolipoprotein	O
134	O
mg	O
dl	O
.	O
LDL	O
HDL	O
2	O
.	O
5	O
.	O
Lipoprotein	O
a	O
59	O
mg	O
dl	O
.	O
ECOCARDIOGRAPHY	O
left	O
atrium	O
not	O
dilated	O
.	O
Left	O
ventricle	O
LV	O
of	O
size	O
LVEDD	O
45	O
mm	O
and	O
without	O
wall	O
thickening	O
septum	O
10	O
mm	O
,	O
slight	O
apical	O
hypokinesia	O
with	O
preserved	O
global	O
EF	O
.	O
Mitral	O
valve	O
with	O
thin	O
leaflets	O
and	O
preserved	O
opening	O
.	O
Normal	O
aortic	O
root	O
and	O
valve	O
.	O
Normal	O
right	O
chambers	O
.	O
RV	O
with	O
preserved	O
LVEF	O
.	O
No	O
tricuspid	O
insufficiency	O
TI	O
.	O
Carotid	O
Doppler	O
ultrasound	O
right	O
internal	O
carotid	O
artery	O
with	O
concentric	O
iosechoic	O
plaque	O
at	O
its	O
origin	O
causing	O
a	O
stenosis	O
of	O
around	O
30	O
.	O
Left	O
internal	O
carotid	O
artery	O
with	O
hyperechoic	O
plaque	O
in	O
the	O
far	O
wall	O
of	O
the	O
bifurcation	O
causing	O
a	O
stenosis	O
of	O
around	O
35	O
.	O
A	O
.	O
dominant	O
left	O
and	O
hypoplastic	O
right	O
vertebra	O
.	O
ILEO	O
FEMORAL	O
DOPPLER	O
ECOGRAPHY	O
using	O
colour	O
Doppler	O
the	O
iliac	O
,	O
common	O
superficial	O
femoral	O
and	O
popliteal	O
arterial	O
systems	O
of	O
both	O
lower	O
limbs	O
,	O
obtaining	O
flow	O
curves	O
with	O
practically	O
normal	O
morphology	O
and	O
velocities	O
in	O
all	O
the	O
paths	O
examined	O
,	O
with	O
only	O
minimal	O
alterations	O
being	O
observed	O
,	O
although	O
in	O
no	O
case	O
compatible	O
with	O
significant	O
stenosis	O
.	O
Conclusions	O
minimal	O
atheromatous	O
irregularities	O
that	O
in	O
no	O
case	O
produce	O
significant	O
stenosis	O
.	O
Lipid	O
profile	O
pre	O
apheresis	O
cholesterol	O
190	O
mg	O
dl	O
.	O
HDL	O
cholesterol	O
51	O
mg	O
dl	O
.	O
LDL	O
cholesterol	O
117	O
mg	O
dl	O
.	O
Triglycerides	O
110	O
mg	O
dl	O
.	O
Apo	O
A	O
lipoprotein	O
145	O
mg	O
dl	O
.	O
Apo	O
B	O
Apolipoprotein	O
128	O
mg	O
dl	O
.	O
LDL	O
HDL	O
2	O
.	O
3	O
.	O
Lipoprotein	O
65	O
mg	O
dl	O
.	O
Lipid	O
profile	O
post	O
apheresis	O
cholesterol	O
76	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
41	O
mg	O
dl	O
,	O
LDL	O
cholesterol	O
28	O
mg	O
dl	O
.	O
Triglycerides	O
35	O
mg	O
dl	O
.	O
Apo	O
A	O
Apolipoprotein	O
119	O
mg	O
dl	O
.	O
Apo	O
B	O
Apolipoprotein	O
33	O
mg	O
dl	O
.	O
Last	O
lipid	O
profile	O
cholesterol	O
118	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
43	O
mg	O
dl	O
,	O
LDL	O
cholesterol	O
52	O
mg	O
dl	O
,	O
triglycerides	O
115	O
mg	O
dl	O
.	O
CLINICAL	O
COURSE	O
The	O
patient	O
started	O
the	O
LDL	O
apheresis	O
programme	O
in	O
October	O
2014	O
with	O
good	O
tolerance	O
,	O
although	O
he	O
reported	O
intense	O
asthenia	O
in	O
the	O
days	O
following	O
the	O
sessions	O
,	O
which	O
gradually	O
improved	O
.	O
In	O
the	O
months	O
following	O
the	O
start	O
of	O
the	O
apheresis	O
programme	O
,	O
the	O
various	O
follow	O
up	O
visits	O
showed	O
that	O
target	O
LDL	O
cholesterol	O
levels	O
were	O
reached	O
after	O
the	O
apheresis	O
sessions	O
,	O
which	O
remained	O
above	O
target	O
levels	O
during	O
the	O
interapheresis	O
periods	O
,	O
but	O
the	O
patient	O
began	O
to	O
show	O
weight	O
gain	O
and	O
progressive	O
oedematisation	O
from	O
the	O
start	O
of	O
the	O
sessions	O
,	O
with	O
significant	O
fatigue	O
after	O
the	O
sessions	O
,	O
which	O
limited	O
his	O
life	O
.	O
A	O
regular	O
echocardiography	O
was	O
requested	O
with	O
preserved	O
systolic	O
function	O
,	O
known	O
segmental	O
contractility	O
alterations	O
and	O
no	O
significant	O
valvulopathies	O
.	O
Given	O
the	O
regular	O
tolerance	O
to	O
the	O
last	O
sessions	O
,	O
it	O
was	O
decided	O
,	O
together	O
with	O
the	O
patient	O
,	O
to	O
start	O
treatment	O
with	O
a	O
recently	O
marketed	O
anti	B-FARMACO
PCKS9	I-FARMACO
drug	O
and	O
to	O
consider	O
ending	O
the	O
LDL	O
apheresis	O
programme	O
if	O
good	O
progress	O
was	O
made	O
.	O
In	O
the	O
following	O
months	O
,	O
after	O
starting	O
treatment	O
with	O
an	O
anti	B-FARMACO
PCSK9	I-FARMACO
drug	O
combined	O
with	O
rosuvastatin	B-FARMACO
and	O
ezetimibe	B-FARMACO
,	O
LDL	O
levels	O
of	O
70	O
mg	O
dl	O
were	O
maintained	O
in	O
the	O
inter	O
apheresis	O
lipid	O
profiles	O
,	O
and	O
so	O
in	O
August	O
2016	O
the	O
patient	O
was	O
finally	O
withdrawn	O
from	O
apheresis	O
sessions	O
.	O
Subsequently	O
,	O
he	O
has	O
continued	O
to	O
undergo	O
check	O
ups	O
in	O
the	O
lipid	O
unit	O
until	O
today	O
,	O
maintaining	O
LDL	O
cholesterol	O
levels	O
below	O
the	O
target	O
levels	O
in	O
secondary	O
prevention	O
without	O
complications	O
or	O
adverse	O
effects	O
related	O
to	O
the	O
drug	O
and	O
allowing	O
the	O
titration	O
of	O
statin	O
doses	O
,	O
as	O
well	O
as	O
without	O
new	O
admissions	O
or	O
consultations	O
for	O
angina	O
.	O
DIAGNOSIS	O
Heterozygous	O
familial	O
hypercholesterolemia	O
with	O
positive	O
genetic	O
study	O
M334	O
mutation	O
controlled	O
under	O
treatment	O
with	O
an	O
anti	B-FARMACO
PCSK9	I-FARMACO
drug	O
.	O
Early	O
revascularised	O
chronic	O
multivessel	O
ischaemic	O
heart	O
disease	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
BACKGROUND	O
47	O
year	O
old	O
female	O
patient	O
with	O
the	O
only	O
history	O
of	O
being	O
an	O
active	O
smoker	O
of	O
10	O
cigarettes	O
day	O
IPA	O
9	O
and	O
family	O
history	O
of	O
myotonic	O
dystrophy	O
MD	O
type	O
I	O
Steinert	O
's	O
disease	O
in	O
her	O
brother	O
and	O
death	O
of	O
her	O
father	O
with	O
no	O
clear	O
etiology	O
.	O
Younger	O
brother	O
aged	O
37	O
years	O
with	O
a	O
diagnosis	O
of	O
type	O
I	O
DM	O
;	O
an	O
older	O
son	O
who	O
died	O
at	O
the	O
age	O
of	O
17	O
,	O
with	O
the	O
same	O
diagnosis	O
and	O
autism	O
spectrum	O
disorder	O
;	O
and	O
a	O
25	O
year	O
old	O
daughter	O
diagnosed	O
with	O
type	O
1	O
DM	O
who	O
presented	O
cerebral	O
haemorrhage	O
at	O
birth	O
and	O
is	O
under	O
investigation	O
for	O
long	O
QT	O
.	O
CURRENT	O
ILLNESS	O
Referred	O
from	O
neurology	O
with	O
a	O
diagnosis	O
of	O
type	O
I	O
DM	O
to	O
the	O
family	O
heart	O
disease	O
consultation	O
for	O
assessment	O
.	O
She	O
reported	O
asthenia	O
and	O
muscle	O
fatigue	O
with	O
slightly	O
less	O
exertion	O
than	O
usual	O
for	O
the	O
last	O
2	O
months	O
.	O
The	O
patient	O
is	O
in	O
New	O
York	O
Heart	O
Association	O
NYHA	O
functional	O
class	O
I	O
and	O
otherwise	O
asymptomatic	O
from	O
a	O
cardiovascular	O
point	O
of	O
view	O
.	O
PHYSICAL	O
EXAMINATION	O
Normal	O
vital	O
signs	O
.	O
Cardiopulmonary	O
auscultation	O
was	O
normal	O
.	O
Neurological	O
examination	O
showed	O
mild	O
bilateral	O
ptosis	O
,	O
mild	O
facial	O
weakness	O
despite	O
complete	O
ocular	O
closure	O
,	O
generalised	O
hyporeflexia	O
,	O
paresis	O
4	O
5	O
and	O
myotonic	O
buckle	O
.	O
The	O
rest	O
of	O
the	O
examination	O
was	O
unremarkable	O
.	O
COMPLEMENTARY	O
TESTS	O
Echocardiogram	O
TT	O
non	O
dilated	O
left	O
ventricle	O
LV	O
with	O
normal	O
wall	O
thickness	O
,	O
left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
60	O
65	O
,	O
no	O
alterations	O
of	O
segmental	O
contractility	O
,	O
anomalous	O
movement	O
of	O
the	O
septum	O
in	O
relation	O
to	O
conduction	O
disorder	O
,	O
normal	O
transmitral	O
filling	O
pattern	O
,	O
non	O
dilated	O
right	O
ventricle	O
normocrontractile	O
,	O
non	O
dilated	O
atria	O
.	O
Aortic	O
,	O
mitral	O
,	O
tricuspid	O
and	O
pulmonary	O
valves	O
morphologically	O
and	O
functionally	O
normal	O
.	O
No	O
signs	O
of	O
pulmonary	O
hypertension	O
.	O
No	O
pericardial	O
effusion	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
and	O
with	O
collapse	O
greater	O
than	O
50	O
.	O
Aorta	O
not	O
dilated	O
and	O
no	O
flow	O
acceleration	O
.	O
ECG	O
sinus	O
rhythm	O
at	O
50	O
beats	O
per	O
minute	O
,	O
PR	O
220	O
milliseconds	O
,	O
axis	O
at	O
30	O
o	O
,	O
QRS	O
130	O
milliseconds	O
with	O
image	O
of	O
left	O
bundle	O
branch	O
conduction	O
disorder	O
,	O
inverted	O
T	O
from	O
V1	O
to	O
V3	O
,	O
QTc	O
445	O
milliseconds	O
.	O
HOLTER	O
sinus	O
rhythm	O
throughout	O
the	O
recording	O
.	O
Average	O
heart	O
rate	O
61	O
bpm	O
.	O
No	O
ventricular	O
or	O
supraventricular	O
arrhythmias	O
.	O
QTc	O
31	O
470	O
490	O
msec	O
,	O
5	O
490	O
510	O
msec	O
.	O
ANALYSIS	O
biochemistry	O
,	O
haemogram	O
and	O
coagulation	O
without	O
findings	O
.	O
GENETIC	O
STUDY	O
negative	O
for	O
long	O
QT	O
.	O
MYBPC3	O
p	O
.	O
Arg726Cys	O
,	O
rare	O
variant	O
possibly	O
associated	O
with	O
hypertrophic	O
cardiomyopathy	O
although	O
with	O
reports	O
of	O
families	O
with	O
second	O
mutations	O
and	O
found	O
in	O
the	O
general	O
population	O
low	O
frequency	O
.	O
CLINICAL	O
EVOLUTION	O
In	O
summary	O
,	O
we	O
are	O
dealing	O
with	O
a	O
47	O
year	O
old	O
patient	O
diagnosed	O
with	O
type	O
I	O
DM	O
with	O
a	O
family	O
history	O
of	O
sudden	O
death	O
.	O
In	O
addition	O
,	O
she	O
had	O
a	O
conduction	O
disorder	O
with	O
wide	O
QRS	O
,	O
first	O
degree	O
atrioventricular	O
block	O
AVB	O
and	O
a	O
borderline	O
QT	O
on	O
the	O
Holter	O
monitor	O
.	O
Although	O
the	O
conduction	O
disturbance	O
may	O
influence	O
the	O
duration	O
of	O
the	O
QT	O
interval	O
,	O
there	O
is	O
a	O
small	O
percentage	O
above	O
490	O
milliseconds	O
.	O
Conduction	O
study	O
and	O
epinephrine	O
test	O
were	O
requested	O
.	O
Positive	O
epinephrine	O
test	O
Shimizu	O
protocol	O
after	O
the	O
bolus	O
there	O
is	O
pathological	O
QTc	O
prolongation	O
up	O
to	O
566	O
milliseconds	O
.	O
Throughout	O
the	O
infusion	O
the	O
absolute	O
QT	O
slowly	O
decreases	O
to	O
baseline	O
values	O
.	O
Electrophysiological	O
study	O
diagnostic	O
quadripolar	O
catheters	O
are	O
placed	O
in	O
the	O
right	O
atrium	O
,	O
His	O
and	O
right	O
ventricular	O
apex	O
.	O
Abnormal	O
basal	O
intervals	O
HV	O
78	O
milliseconds	O
.	O
Basally	O
poor	O
AV	O
conduction	O
with	O
Wenckebach	O
point	O
at	O
78	O
bpm	O
,	O
concentric	O
and	O
decremental	O
.	O
Absence	O
of	O
V	O
A	O
conduction	O
.	O
Due	O
to	O
the	O
results	O
of	O
the	O
previous	O
tests	O
,	O
it	O
was	O
decided	O
to	O
implant	O
a	O
bicameral	O
implantable	O
cardioverter	O
defibrillator	O
ICD	O
after	O
cardiac	O
magnetic	O
resonance	O
imaging	O
MRI	O
to	O
complete	O
the	O
study	O
.	O
After	O
ICD	O
implantation	O
,	O
treatment	O
was	O
started	O
with	O
1	O
.	O
25	O
mg	O
of	O
bisoprolol	B-FARMACO
every	O
24	O
hours	O
.	O
Cardiac	O
MRI	O
showed	O
a	O
slightly	O
dilated	O
but	O
not	O
hypertrophic	O
LV	O
,	O
with	O
preserved	O
systolic	O
function	O
LVEF	O
55	O
and	O
no	O
intramyocardial	O
late	O
enhancement	O
or	O
other	O
alterations	O
of	O
interest	O
.	O
From	O
the	O
point	O
of	O
view	O
of	O
relatives	O
,	O
a	O
long	O
QT	O
panel	O
was	O
performed	O
,	O
which	O
was	O
negative	O
.	O
DIAGNOSIS	O
Myotonic	O
dystrophy	O
type	O
1	O
Steinert	O
's	O
disease	O
.	O
Absence	O
of	O
significant	O
structural	O
heart	O
disease	O
on	O
TT	O
echocardiogram	O
and	O
cardiac	O
MRI	O
.	O
Long	O
QT	O
syndrome	O
probably	O
associated	O
with	O
DM	O
.	O
First	O
degree	O
history	O
of	O
sudden	O
death	O
,	O
probably	O
arrhythmic	O
.	O
Significant	O
nodal	O
conduction	O
disorder	O
and	O
His	O
Purkinje	O
system	O
with	O
implantation	O
of	O
bicameral	O
ICD	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
51	O
year	O
old	O
woman	O
with	O
no	O
known	O
drug	O
allergies	O
,	O
no	O
cardiovascular	O
risk	O
factors	O
.	O
Cardiological	O
history	O
Ebstein	O
's	O
anomaly	O
type	O
congenital	O
heart	O
disease	O
.	O
Wolff	O
Parkinson	O
White	O
syndrome	O
WPW	O
diagnosed	O
at	O
18	O
years	O
of	O
age	O
.	O
Followed	O
in	O
cardiology	O
outpatient	O
clinic	O
,	O
in	O
usual	O
New	O
York	O
Heart	O
Association	O
NYHA	O
functional	O
class	O
II	O
III	O
IV	O
.	O
Episodes	O
of	O
orthodromic	O
paroxysmal	O
supraventricular	O
tachycardia	O
PSVT	O
.	O
Holter	O
study	O
October	O
2016	O
sinus	O
rhythm	O
without	O
arrhythmic	O
events	O
.	O
She	O
does	O
not	O
take	O
any	O
treatment	O
on	O
a	O
regular	O
basis	O
.	O
Admitted	O
to	O
a	O
regional	O
hospital	O
due	O
to	O
progressive	O
worsening	O
of	O
his	O
functional	O
class	O
in	O
the	O
last	O
3	O
months	O
with	O
progressive	O
dyspnoea	O
until	O
becoming	O
minimal	O
effort	O
.	O
She	O
reported	O
a	O
case	O
of	O
upper	O
respiratory	O
tract	O
infection	O
one	O
month	O
prior	O
to	O
admission	O
,	O
coinciding	O
with	O
worsening	O
dyspnoea	O
until	O
she	O
was	O
at	O
rest	O
and	O
orthopnoea	O
.	O
No	O
other	O
symptoms	O
.	O
During	O
his	O
admission	O
to	O
El	O
Bierzo	O
Hospital	O
,	O
depletive	O
treatment	O
was	O
started	O
for	O
congestive	O
heart	O
failure	O
with	O
a	O
tendency	O
to	O
hypotension	O
.	O
Transfer	O
to	O
our	O
centre	O
was	O
requested	O
to	O
complete	O
studies	O
and	O
assess	O
treatment	O
options	O
.	O
When	O
assessed	O
in	O
our	O
department	O
,	O
she	O
reported	O
intense	O
asthenia	O
with	O
improvement	O
in	O
dyspnoea	O
.	O
Blood	O
pressure	O
124	O
88	O
mmHg	O
,	O
heart	O
rate	O
80	O
bpm	O
.	O
Cyanosis	O
.	O
Acropaquias	O
.	O
Basal	O
oxygen	O
saturation	O
in	O
the	O
supine	O
position	O
80	O
,	O
in	O
the	O
sitting	O
position	O
65	O
.	O
Jugular	O
venous	O
pressure	O
normal	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
systolic	O
murmur	O
in	O
tricuspid	O
focus	O
III	O
VI	O
,	O
holosystolic	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
without	O
added	O
noise	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
.	O
No	O
palpation	O
of	O
hepatomegaly	O
or	O
other	O
masses	O
.	O
Lower	O
extremities	O
without	O
oedema	O
,	O
no	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
and	O
symmetrical	O
peripheral	O
pulses	O
.	O
COMPLEMENTARY	O
TESTS	O
ELECTROCARDIOGRAM	O
ECG	O
sinus	O
rhythm	O
at	O
75	O
bpm	O
.	O
PR	O
200ms	O
.	O
Qtc	O
480ms	O
.	O
Right	O
bundle	O
branch	O
block	O
RBBB	O
.	O
Predominance	O
of	O
positive	O
P	O
wave	O
component	O
in	O
V1	O
.	O
THORAX	O
RADIOGRAPHY	O
cardiomegaly	O
,	O
without	O
signs	O
of	O
vascular	O
redistribution	O
.	O
Free	O
costophrenic	O
sinuses	O
.	O
No	O
condensation	O
.	O
ANALYSIS	O
haemogram	O
leucocytes	O
9000	O
mil	O
mm3	O
N	O
78	O
,	O
L	O
11	O
,	O
Hb	O
13	O
.	O
9	O
g	O
dl	O
,	O
haematocrit	O
41	O
.	O
7	O
.	O
MCV	O
92	O
.	O
4	O
fl	O
,	O
platelets	O
114000	O
mm3	O
,	O
haptoglobin	O
100	O
mg	O
.	O
Coagulation	O
INR	O
1	O
.	O
2	O
,	O
PT	O
72	O
,	O
TTPa	O
32	O
seconds	O
.	O
Biochemistry	O
glucose	O
87	O
mg	O
dl	O
,	O
urea	O
30	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
98	O
mg	O
dl	O
FG	O
60	O
,	O
total	O
cholesterol	O
108	O
mg	O
dl	O
,	O
HDL	O
31	O
mg	O
dl	O
,	O
LDL	O
64	O
mg	O
dl	O
,	O
triglycerides	O
64	O
mg	O
dl	O
,	O
GOT	O
24	O
U	O
l	O
,	O
GPT	O
2624U	O
l	O
,	O
total	O
bilirubin	O
0	O
.	O
72	O
mg	O
dl	O
,	O
NT	O
proBNP	O
207	O
pg	O
ml	O
.	O
Arterial	O
blood	O
gases	O
pH	O
7	O
.	O
53	O
,	O
PCO2	O
30	O
.	O
4	O
,	O
PO2	O
51	O
,	O
bicarbonate	O
25	O
.	O
2	O
.	O
Echocardiogram	O
severely	O
dilated	O
right	O
ventricle	O
with	O
depressed	O
contractility	O
.	O
Normal	O
sized	O
left	O
ventricle	O
with	O
preserved	O
function	O
.	O
Severely	O
dilated	O
right	O
atrium	O
RA	O
with	O
interventricular	O
septum	O
bulging	O
to	O
the	O
left	O
.	O
Thin	O
leaflet	O
pulmonary	O
valve	O
with	O
normal	O
opening	O
.	O
Post	O
valvular	O
flow	O
of	O
1	O
m	O
s	O
with	O
symmetrical	O
branch	O
Doppler	O
flow	O
.	O
Tricuspid	O
valve	O
with	O
Ebstein	O
's	O
morphology	O
,	O
more	O
apical	O
implantation	O
of	O
the	O
septal	O
leaflet	O
,	O
48	O
mm	O
from	O
the	O
mitral	O
annulus	O
,	O
with	O
IV	O
IV	O
regurgitation	O
.	O
Triangular	O
morphology	O
in	O
spectral	O
Doppler	O
,	O
with	O
maximum	O
velocity	O
of	O
2	O
.	O
4	O
m	O
sg	O
.	O
Normal	O
mitral	O
and	O
aortic	O
valves	O
.	O
After	O
the	O
injection	O
of	O
agitated	O
saline	O
,	O
there	O
was	O
abundant	O
spontaneous	O
passage	O
of	O
bubbles	O
to	O
the	O
left	O
cavities	O
,	O
presenting	O
syncope	O
during	O
the	O
procedure	O
,	O
with	O
subsequent	O
progressive	O
recovery	O
and	O
headache	O
.	O
No	O
obvious	O
atrial	O
septal	O
defect	O
ASD	O
was	O
observed	O
,	O
so	O
it	O
was	O
attributed	O
to	O
PFO	O
.	O
Conclusion	O
Ebstein	O
's	O
disease	O
,	O
IV	O
IV	O
tricuspid	O
regurgitation	O
with	O
ventricular	O
dysfunction	O
,	O
right	O
to	O
left	O
shunt	O
due	O
to	O
probable	O
PFO	O
.	O
HEMODYNAMIC	O
STUDY	O
right	O
femoral	O
artery	O
ventriculography	O
shows	O
right	O
left	O
shunt	O
.	O
After	O
temporary	O
occlusion	O
of	O
the	O
defect	O
with	O
a	O
balloon	O
,	O
it	O
was	O
found	O
that	O
the	O
pressures	O
in	O
the	O
right	O
atrium	O
did	O
not	O
increase	O
and	O
the	O
arterial	O
pressures	O
did	O
not	O
fall	O
.	O
With	O
the	O
use	O
of	O
a	O
35	O
mm	O
Amplatzer	O
FOP	O
Tribiform	O
MF	O
35	O
mm	O
device	O
,	O
the	O
defect	O
is	O
almost	O
completely	O
occluded	O
,	O
with	O
minimal	O
residual	O
shunt	O
,	O
with	O
arterial	O
saturation	O
from	O
81	O
to	O
99	O
video	O
4	O
.	O
No	O
complications	O
.	O
Under	O
control	O
with	O
intracardiac	O
echocardiography	O
and	O
transesophageal	O
echocardiography	O
TEE	O
,	O
an	O
18	O
mm	O
balloon	O
test	O
was	O
performed	O
,	O
showing	O
no	O
significant	O
haemodynamic	O
changes	O
blood	O
pressure	O
and	O
right	O
atrial	O
pressure	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
to	O
complete	O
the	O
study	O
due	O
to	O
progressive	O
worsening	O
of	O
functional	O
class	O
.	O
An	O
echocardiographic	O
study	O
showed	O
significant	O
right	O
to	O
left	O
interatrial	O
shunt	O
suggestive	O
of	O
PFO	O
with	O
platypnoea	O
ortodesoxia	O
behaviour	O
.	O
With	O
these	O
results	O
,	O
it	O
was	O
decided	O
to	O
perform	O
a	O
percutaneous	O
technique	O
on	O
PFO	O
.	O
Prior	O
to	O
definitive	O
closure	O
,	O
haemodynamic	O
response	O
was	O
assessed	O
with	O
transient	O
balloon	O
closure	O
,	O
which	O
was	O
favourable	O
,	O
so	O
a	O
35	O
mm	O
Amplatzer	O
cribriform	O
closure	O
device	O
was	O
implanted	O
,	O
with	O
good	O
final	O
results	O
and	O
arterial	O
saturation	O
increased	O
from	O
81	O
baseline	O
to	O
99	O
.	O
Post	O
procedure	O
,	O
the	O
patient	O
was	O
stable	O
and	O
asymptomatic	O
,	O
with	O
improvement	O
in	O
functional	O
class	O
and	O
baseline	O
saturation	O
,	O
and	O
it	O
was	O
decided	O
to	O
transfer	O
her	O
to	O
her	O
hospital	O
of	O
reference	O
.	O
DIAGNOSIS	O
Platypnoea	O
ortodesoxia	O
syndrome	O
.	O
PFO	O
with	O
significant	O
spontaneous	O
right	O
left	O
shunt	O
.	O
Congenital	O
heart	O
disease	O
of	O
the	O
Ebstein	O
's	O
anomaly	O
type	O
.	O
Global	O
respiratory	O
failure	O
secondary	O
to	O
intracardiac	O
shunt	O
,	O
resolved	O
.	O
Implantation	O
of	O
a	O
percutaneous	O
Amplatzer	O
cribriform	O
35	O
mm	O
PFO	O
closure	O
device	O
.	O
Massive	O
tricuspid	O
regurgitation	O
with	O
no	O
signs	O
of	O
pulmonary	O
hypertension	O
.	O
Preserved	O
LVEF	O
.	O
Intermittent	O
WPW	O
syndrome	O
.	O
Episodes	O
of	O
orthodromic	O
TPSV	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Personal	O
history	O
53	O
year	O
old	O
male	O
,	O
active	O
,	O
civil	O
servant	O
.	O
He	O
had	O
no	O
drug	O
allergies	O
,	O
had	O
smoked	O
sporadically	O
1	O
2	O
packs	O
year	O
accumulated	O
and	O
was	O
diagnosed	O
with	O
mild	O
arterial	O
hypertension	O
,	O
with	O
no	O
other	O
associated	O
cardiovascular	O
risk	O
factors	O
.	O
He	O
took	O
omeprazole	B-FARMACO
on	O
demand	O
for	O
occasional	O
dyspepsia	O
,	O
but	O
did	O
not	O
take	O
any	O
treatment	O
on	O
a	O
regular	O
basis	O
.	O
Current	O
history	O
She	O
consulted	O
her	O
primary	O
care	O
physician	O
for	O
several	O
episodes	O
of	O
oppressive	O
central	O
thoracic	O
pain	O
,	O
of	O
sudden	O
onset	O
,	O
at	O
rest	O
,	O
lasting	O
a	O
few	O
minutes	O
.	O
The	O
pain	O
is	O
not	O
related	O
to	O
meals	O
,	O
does	O
not	O
change	O
with	O
respiratory	O
movements	O
or	O
postural	O
changes	O
and	O
is	O
accompanied	O
only	O
by	O
mild	O
sweating	O
.	O
He	O
was	O
prescribed	O
treatment	O
with	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
mg	O
1	O
0	O
0	O
,	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
1	O
0	O
1	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
1	O
0	O
0	O
and	O
sublingual	O
nitroglycerin	B-FARMACO
on	O
demand	O
and	O
was	O
referred	O
to	O
the	O
Cardiology	O
Department	O
.	O
He	O
went	O
to	O
the	O
emergency	O
department	O
a	O
few	O
days	O
later	O
because	O
the	O
symptoms	O
persisted	O
despite	O
treatment	O
.	O
With	O
the	O
use	O
of	O
nitroglycerine	B-FARMACO
,	O
the	O
duration	O
was	O
shorter	O
,	O
but	O
not	O
the	O
frequency	O
;	O
he	O
reported	O
up	O
to	O
7	O
episodes	O
in	O
the	O
last	O
3	O
weeks	O
,	O
with	O
a	O
clear	O
predominance	O
at	O
night	O
.	O
Physical	O
examination	O
in	O
the	O
emergency	O
department	O
Blood	O
pressure	O
145	O
89	O
mmHg	O
.	O
Heart	O
rate	O
60	O
beats	O
per	O
minute	O
,	O
basal	O
oxygen	O
saturation	O
100	O
.	O
Temperature	O
36	O
.	O
5	O
C	O
.	O
Good	O
general	O
condition	O
.	O
Conscious	O
,	O
oriented	O
,	O
cooperative	O
.	O
Eupneic	O
at	O
rest	O
.	O
Not	O
hydrated	O
.	O
Normal	O
colour	O
.	O
Jugular	O
venous	O
pressure	O
normal	O
.	O
Carotid	O
rhythmic	O
,	O
no	O
murmurs	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
without	O
murmurs	O
,	O
friction	O
rubs	O
or	O
extratonos	O
.	O
Pulmonary	O
auscultation	O
with	O
preserved	O
vesicular	O
murmur	O
,	O
without	O
extra	O
sounds	O
.	O
Abdomen	O
with	O
no	O
notable	O
alterations	O
.	O
Lower	O
extremities	O
normal	O
.	O
Peripheral	O
pulses	O
present	O
and	O
symmetrical	O
.	O
COMPLEMENTARY	O
TESTS	O
Emergency	O
ECG	O
sinus	O
rhythm	O
at	O
55	O
bpm	O
,	O
normal	O
PR	O
,	O
narrow	O
QRS	O
,	O
without	O
repolarisation	O
alterations	O
.	O
Emergency	O
laboratory	O
tests	O
haemoglobin	O
15	O
.	O
8	O
g	O
dl	O
,	O
leukocytes	O
8	O
,	O
650	O
mm3	O
normal	O
formula	O
,	O
platelets	O
212	O
,	O
000	O
mm3	O
.	O
Coagulation	O
prothrombin	O
rate	O
91	O
,	O
activated	O
partial	O
thromboplastin	O
time	O
26	O
.	O
6	O
s	O
,	O
fibrinogen	O
309	O
mg	O
dl	O
.	O
Biochemistry	O
glucose	O
113	O
mg	O
dl	O
,	O
urea	O
40	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
13	O
mg	O
dl	O
,	O
sodium	O
140	O
mEq	O
l	O
,	O
potassium	O
3	O
.	O
4	O
mEq	O
l	O
,	O
serial	O
troponin	O
I	O
0	O
.	O
00	O
ng	O
ml	O
.	O
Chest	O
X	O
ray	O
in	O
the	O
emergency	O
department	O
normal	O
.	O
Echocardioscopy	O
in	O
the	O
ED	O
left	O
ventricle	O
of	O
normal	O
size	O
and	O
overall	O
systolic	O
function	O
,	O
without	O
alterations	O
in	O
segmental	O
contractility	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
and	O
systolic	O
function	O
Normal	O
atria	O
.	O
Absence	O
of	O
significant	O
valvular	O
heart	O
disease	O
.	O
Visible	O
segments	O
of	O
the	O
great	O
vessels	O
normal	O
.	O
Normal	O
pericardium	O
.	O
Stress	O
test	O
discontinued	O
at	O
minute	O
10	O
.	O
50	O
of	O
the	O
Bruce	O
protocol	O
11	O
.	O
80	O
METS	O
for	O
reaching	O
the	O
maximum	O
theoretical	O
heart	O
rate	O
.	O
Normal	O
blood	O
pressure	O
and	O
chronotropic	O
response	O
.	O
No	O
arrhythmias	O
were	O
recorded	O
.	O
Conclusion	O
clinically	O
and	O
electrically	O
negative	O
for	O
ischaemia	O
.	O
Holter	O
ECG	O
of	O
events	O
of	O
10	O
days	O
duration	O
coinciding	O
with	O
an	O
episode	O
of	O
chest	O
pain	O
identical	O
to	O
the	O
previous	O
ones	O
,	O
ST	O
segment	O
elevation	O
of	O
a	O
few	O
minutes	O
duration	O
is	O
recorded	O
,	O
as	O
well	O
as	O
frequent	O
supraventricular	O
and	O
ventricular	O
extrasystoles	O
.	O
CT	O
scan	O
of	O
the	O
coronary	O
arteries	O
calcium	O
score	O
191	O
.	O
Calcific	O
plaques	O
were	O
seen	O
in	O
the	O
proximal	O
third	O
of	O
the	O
anterior	O
descending	O
and	O
circumflex	O
arteries	O
that	O
did	O
not	O
cause	O
significant	O
stenosis	O
,	O
as	O
well	O
as	O
soft	O
plaque	O
in	O
the	O
middle	O
third	O
of	O
the	O
anterior	O
descending	O
artery	O
that	O
caused	O
50	O
stenosis	O
.	O
EVOLUTION	O
During	O
his	O
stay	O
in	O
the	O
ED	O
,	O
the	O
patient	O
remained	O
asymptomatic	O
and	O
haemodynamically	O
stable	O
at	O
all	O
times	O
.	O
Serial	O
myocardial	O
damage	O
markers	O
were	O
negative	O
.	O
He	O
was	O
assessed	O
by	O
the	O
on	O
call	O
Cardiology	O
team	O
,	O
who	O
performed	O
echocardioscopy	O
where	O
no	O
alterations	O
were	O
observed	O
.	O
In	O
view	O
of	O
the	O
characteristics	O
of	O
the	O
episodes	O
,	O
the	O
possibility	O
of	O
coronary	O
vasospasm	O
was	O
raised	O
,	O
so	O
nitrates	O
were	O
added	O
to	O
his	O
treatment	O
and	O
it	O
was	O
decided	O
to	O
complete	O
the	O
study	O
on	O
an	O
outpatient	O
basis	O
.	O
Admission	O
was	O
not	O
considered	O
necessary	O
because	O
the	O
episodes	O
of	O
pain	O
had	O
not	O
increased	O
in	O
intensity	O
or	O
duration	O
and	O
were	O
not	O
accompanied	O
by	O
palpitations	O
,	O
dizziness	O
or	O
syncope	O
.	O
The	O
Holter	O
recording	O
of	O
long	O
term	O
events	O
two	O
weeks	O
later	O
showed	O
transient	O
ST	O
segment	O
elevation	O
coinciding	O
with	O
a	O
new	O
episode	O
of	O
chest	O
pain	O
,	O
identical	O
to	O
the	O
previous	O
ones	O
,	O
confirming	O
the	O
diagnosis	O
of	O
coronary	O
vasospasm	O
.	O
Bisoprolol	B-FARMACO
was	O
discontinued	O
the	O
patient	O
had	O
already	O
discontinued	O
nitrates	O
due	O
to	O
headache	O
and	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
due	O
to	O
dyspepsia	O
and	O
diltiazem	B-FARMACO
was	O
started	O
at	O
a	O
dose	O
of	O
120	O
mg	O
every	O
12	O
hours	O
.	O
Given	O
that	O
he	O
did	O
not	O
perform	O
strenuous	O
physical	O
exertion	O
,	O
ergometry	O
was	O
requested	O
,	O
which	O
was	O
clinically	O
and	O
electrically	O
negative	O
for	O
ischaemia	O
.	O
Despite	O
this	O
result	O
,	O
in	O
order	O
to	O
rule	O
out	O
underlying	O
obstructive	O
coronary	O
lesions	O
with	O
greater	O
certainty	O
,	O
a	O
CT	O
scan	O
of	O
the	O
coronary	O
arteries	O
was	O
performed	O
,	O
which	O
showed	O
non	O
significant	O
stenosis	O
in	O
the	O
anterior	O
descending	O
and	O
circumflex	O
arteries	O
,	O
and	O
simvastatin	B-FARMACO
was	O
added	O
to	O
his	O
treatment	O
at	O
a	O
dose	O
of	O
20	O
mg	O
daily	O
.	O
The	O
patient	O
has	O
progressed	O
well	O
,	O
with	O
no	O
recurrence	O
of	O
symptoms	O
to	O
date	O
.	O
It	O
is	O
explained	O
to	O
him	O
that	O
in	O
order	O
to	O
avoid	O
new	O
episodes	O
as	O
far	O
as	O
possible	O
,	O
it	O
is	O
essential	O
that	O
he	O
abstains	O
from	O
smoking	O
and	O
adheres	O
to	O
the	O
pharmacological	O
treatment	O
.	O
DIAGNOSIS	O
Vasospastic	O
angina	O
.	O
Coronary	O
arteries	O
without	O
significant	O
lesions	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
60	O
year	O
old	O
patient	O
who	O
attended	O
the	O
Emergency	O
Department	O
on	O
26	O
08	O
2016	O
due	O
to	O
pain	O
in	O
the	O
right	O
lower	O
limb	O
Personal	O
history	O
Intolerance	O
to	O
amoxicillin	B-FARMACO
clavulanic	I-FARMACO
acid	I-FARMACO
.	O
Arterial	O
hypertension	O
under	O
pharmacological	O
treatment	O
with	O
poor	O
control	O
.	O
Dyslipidaemia	O
under	O
pharmacological	O
treatment	O
.	O
Anxiety	O
syndrome	O
.	O
Cardiological	O
history	O
paroxysmal	O
atrial	O
fibrillation	O
diagnosed	O
on	O
01	O
08	O
2016	O
with	O
CHA2DS2	O
VASc	O
2	O
and	O
HAS	O
BLED	O
1	O
.	O
Treatment	O
was	O
started	O
with	O
beta	O
blockers	O
and	O
acenocoumarol	B-FARMACO
.	O
Echocardiogram	O
LVEF	O
60	O
.	O
LA	O
dilatation	O
.	O
Mild	O
mitral	O
stenosis	O
.	O
Episode	O
of	O
mild	O
heart	O
failure	O
in	O
the	O
context	O
of	O
AF	O
with	O
rapid	O
ventricular	O
response	O
on	O
13	O
08	O
2016	O
which	O
was	O
treated	O
in	O
the	O
emergency	O
department	O
with	O
diuretics	O
and	O
digoxin	B-FARMACO
.	O
Current	O
illness	O
The	O
patient	O
came	O
to	O
the	O
ED	O
with	O
pain	O
,	O
coldness	O
and	O
functional	O
impotence	O
of	O
the	O
right	O
lower	O
limb	O
.	O
Physical	O
examination	O
BP	O
178	O
99	O
mmHg	O
,	O
HR	O
109	O
bpm	O
,	O
SatO2	O
99	O
.	O
Cardiac	O
auscultation	O
arrhythmic	O
sounds	O
at	O
110	O
bpm	O
with	O
systolic	O
murmur	O
II	O
VI	O
with	O
preserved	O
2R	O
.	O
Pulmonary	O
auscultation	O
minimal	O
bibasal	O
crackles	O
.	O
Right	O
lower	O
extremity	O
decreased	O
pulse	O
and	O
coldness	O
in	O
MID	O
with	O
intense	O
pain	O
on	O
palpation	O
.	O
COMPLEMENTARY	O
TESTS	O
Blood	O
tests	O
urea	O
24	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
89	O
mg	O
dl	O
,	O
Na	O
139	O
mmol	O
L	O
,	O
K	O
3	O
.	O
9	O
mmol	O
L	O
,	O
Hb	O
15	O
.	O
8	O
g	O
dL	O
,	O
Ht	O
45	O
.	O
8	O
,	O
platelets	O
396	O
,	O
000	O
,	O
INR	O
1	O
.	O
47	O
.	O
D	O
dimer	O
5000	O
ug	O
L	O
.	O
ECG	O
atrial	O
fibrillation	O
with	O
rapid	O
ventricular	O
response	O
at	O
120	O
bpm	O
.	O
ST	O
segment	O
rectification	O
with	O
data	O
of	O
LV	O
overload	O
and	O
negative	O
T	O
wave	O
in	O
DIII	O
and	O
aVF	O
.	O
Chest	O
X	O
ray	O
cardiomegaly	O
.	O
Congestive	O
hilae	O
.	O
Vascular	O
redistribution	O
.	O
No	O
condensation	O
or	O
pinching	O
of	O
costophrenic	O
sinuses	O
.	O
MID	O
Doppler	O
ultrasound	O
decreased	O
monophasic	O
blood	O
flow	O
in	O
the	O
superficial	O
femoral	O
artery	O
with	O
echogenic	O
material	O
partially	O
filling	O
the	O
lumen	O
of	O
the	O
artery	O
.	O
The	O
flow	O
decreases	O
even	O
more	O
in	O
intensity	O
in	O
the	O
distal	O
arteries	O
without	O
being	O
detected	O
in	O
the	O
distal	O
posterior	O
tibial	O
and	O
anterior	O
pedial	O
arteries	O
.	O
Conclusion	O
MID	O
arterial	O
ischaemia	O
due	O
to	O
thrombosis	O
.	O
Ultrasound	O
Doppler	O
MII	O
occupation	O
of	O
the	O
left	O
popliteal	O
a	O
.	O
Popliteal	O
left	O
by	O
echogenic	O
material	O
not	O
in	O
its	O
entirety	O
without	O
flow	O
in	O
Doppler	O
study	O
and	O
with	O
post	O
stenotic	O
morphology	O
at	O
the	O
level	O
of	O
posterior	O
tibial	O
artery	O
.	O
Conclusion	O
arterial	O
ischaemia	O
in	O
popliteal	O
artery	O
.	O
Cranial	O
perfusion	O
computed	O
tomography	O
acute	O
ischaemic	O
stroke	O
in	O
the	O
left	O
MCA	O
territory	O
secondary	O
to	O
carotid	O
occlusion	O
of	O
the	O
ICA	O
,	O
ICA	O
,	O
IMCA	O
M1	O
and	O
ACA	O
A1	O
of	O
cardioembolic	O
profile	O
with	O
mismatch	O
30	O
.	O
Angio	O
CT	O
floating	O
thrombus	O
at	O
the	O
level	O
of	O
the	O
aortic	O
arch	O
distal	O
to	O
the	O
ICA	O
exit	O
occluding	O
the	O
origin	O
of	O
the	O
left	O
subclavian	O
artery	O
.	O
Echocardiography	O
moderate	O
mitral	O
stenosis	O
of	O
rheumatic	O
aspect	O
.	O
Severe	O
dilatation	O
of	O
the	O
left	O
atrium	O
.	O
LVEF	O
60	O
.	O
Aortic	O
sclerosis	O
.	O
EVOLUTION	O
Given	O
that	O
the	O
patient	O
presented	O
pain	O
and	O
coldness	O
in	O
the	O
right	O
lower	O
limb	O
MID	O
,	O
a	O
Doppler	O
ultrasound	O
of	O
the	O
lower	O
limbs	O
was	O
performed	O
which	O
confirmed	O
acute	O
arterial	O
ischaemia	O
due	O
to	O
thrombotic	O
occlusion	O
at	O
the	O
level	O
of	O
the	O
right	O
superficial	O
femoral	O
artery	O
.	O
Treatment	O
was	O
started	O
with	O
intravenous	O
sodium	B-FARMACO
heparin	I-FARMACO
and	O
contact	O
was	O
made	O
with	O
Cardiovascular	O
Surgery	O
at	O
the	O
referral	O
hospital	O
and	O
the	O
patient	O
was	O
referred	O
for	O
evaluation	O
.	O
On	O
arrival	O
,	O
given	O
that	O
the	O
patient	O
showed	O
signs	O
of	O
acute	O
ischaemia	O
of	O
the	O
entire	O
limb	O
despite	O
perfusion	O
,	O
mechanical	O
embolectomy	O
was	O
performed	O
with	O
dissection	O
of	O
the	O
right	O
femoral	O
tripod	O
and	O
MID	O
embolectomy	O
with	O
Fogarty	O
catheter	O
associated	O
with	O
heparin	B-FARMACO
lavage	O
,	O
haemostasis	O
and	O
closure	O
.	O
At	O
24	O
hours	O
,	O
the	O
patient	O
remained	O
haemodynamically	O
stable	O
and	O
a	O
repeat	O
Doppler	O
ultrasound	O
scan	O
was	O
performed	O
with	O
recovery	O
of	O
biphasic	O
flow	O
at	O
femoral	O
level	O
.	O
A	O
review	O
of	O
the	O
patient	O
's	O
INR	O
since	O
the	O
start	O
of	O
anticoagulation	O
had	O
presented	O
INR	O
2	O
with	O
time	O
in	O
therapeutic	O
range	O
of	O
0	O
.	O
Despite	O
having	O
suffered	O
an	O
embolic	O
event	O
with	O
a	O
SAMe	O
TT2R2	O
2	O
which	O
already	O
predicts	O
that	O
the	O
patient	O
will	O
have	O
poor	O
quality	O
anticoagulation	O
with	O
antivitamin	O
K	O
,	O
CHA2DS2	O
VASc	O
4	O
and	O
HAS	O
BLED	O
2	O
,	O
it	O
was	O
decided	O
to	O
maintain	O
treatment	O
at	O
discharge	O
with	O
acenocoumarol	B-FARMACO
.	O
On	O
19	O
02	O
2017	O
the	O
patient	O
returned	O
to	O
the	O
emergency	O
department	O
for	O
pain	O
,	O
coldness	O
and	O
functional	O
impotence	O
in	O
the	O
left	O
lower	O
limb	O
,	O
this	O
time	O
with	O
absence	O
of	O
distal	O
pulse	O
.	O
An	O
echo	O
Doppler	O
of	O
the	O
MII	O
was	O
performed	O
and	O
showed	O
arterial	O
ischaemia	O
in	O
the	O
popliteal	O
artery	O
.	O
Given	O
that	O
the	O
occlusion	O
was	O
at	O
a	O
more	O
distal	O
level	O
and	O
the	O
echogenic	O
material	O
did	O
not	O
occlude	O
the	O
lumen	O
completely	O
,	O
intravenous	O
sodium	B-FARMACO
heparin	I-FARMACO
perfusion	O
was	O
started	O
.	O
On	O
the	O
5th	O
day	O
of	O
admission	O
24	O
02	O
0217	O
the	O
patient	O
suddenly	O
presented	O
pain	O
and	O
coldness	O
in	O
the	O
left	O
upper	O
limb	O
and	O
1	O
hour	O
later	O
presented	O
dysarthria	O
with	O
haemiplegia	O
of	O
the	O
right	O
limbs	O
.	O
On	O
suspicion	O
of	O
intracranial	O
bleeding	O
in	O
the	O
context	O
of	O
intravenous	O
sodium	B-FARMACO
heparin	I-FARMACO
perfusion	O
,	O
a	O
cranial	O
CT	O
scan	O
was	O
performed	O
which	O
ruled	O
out	O
intracranial	O
bleeding	O
.	O
In	O
the	O
following	O
hours	O
,	O
the	O
patient	O
presented	O
a	O
sudden	O
deterioration	O
in	O
the	O
level	O
of	O
consciousness	O
with	O
aphasia	O
and	O
left	O
gaze	O
deviation	O
.	O
With	O
suspicion	O
of	O
stroke	O
in	O
the	O
left	O
middle	O
cerebral	O
artery	O
MCA	O
territory	O
,	O
the	O
Stroke	O
Code	O
was	O
activated	O
NIHSS	O
22	O
and	O
the	O
patient	O
was	O
referred	O
to	O
the	O
reference	O
hospital	O
.	O
On	O
arrival	O
,	O
a	O
brain	O
CT	O
scan	O
was	O
performed	O
which	O
confirmed	O
acute	O
ischaemic	O
stroke	O
in	O
the	O
left	O
MCA	O
territory	O
secondary	O
to	O
carotid	O
occlusion	O
of	O
the	O
ICA	O
MCA	O
.	O
However	O
,	O
the	O
angio	O
CT	O
scan	O
also	O
showed	O
a	O
floating	O
thrombus	O
at	O
the	O
level	O
of	O
the	O
aortic	O
arch	O
distal	O
to	O
the	O
exit	O
of	O
the	O
LMCA	O
left	O
common	O
carotid	O
artery	O
occluding	O
the	O
subclavian	O
artery	O
.	O
Given	O
the	O
seriousness	O
of	O
the	O
patient	O
and	O
the	O
fact	O
that	O
she	O
was	O
being	O
treated	O
with	O
sodium	B-FARMACO
heparin	I-FARMACO
,	O
it	O
was	O
decided	O
to	O
perform	O
a	O
primary	O
mechanical	O
intra	O
arterial	O
thrombectomy	O
with	O
aspiration	O
of	O
the	O
cervical	O
thrombus	O
and	O
fragments	O
at	O
the	O
level	O
of	O
the	O
LMCA	O
ICCA	O
.	O
A	O
control	O
CT	O
scan	O
showed	O
extensive	O
infarction	O
with	O
mass	O
effect	O
that	O
improved	O
progressively	O
over	O
the	O
following	O
days	O
in	O
the	O
ICU	O
,	O
with	O
improvement	O
in	O
aphasia	O
but	O
with	O
right	O
hemiplegia	O
remaining	O
as	O
a	O
sequela	O
on	O
discharge	O
.	O
At	O
the	O
MSI	O
level	O
,	O
there	O
was	O
an	O
improvement	O
in	O
arterial	O
ischaemia	O
and	O
pulse	O
recovery	O
,	O
so	O
conservative	O
management	O
was	O
decided	O
.	O
However	O
,	O
there	O
was	O
no	O
improvement	O
in	O
the	O
MII	O
,	O
presenting	O
a	O
very	O
weak	O
femoral	O
and	O
popliteal	O
pulse	O
with	O
absence	O
at	O
distal	O
level	O
,	O
so	O
it	O
was	O
decided	O
to	O
perform	O
arterial	O
thrombectomy	O
with	O
dissection	O
of	O
the	O
left	O
femoral	O
tripod	O
and	O
extraction	O
of	O
thrombotic	O
material	O
at	O
the	O
left	O
femoro	O
popliteal	O
level	O
with	O
a	O
Fogarty	O
catheter	O
.	O
Cardiologically	O
,	O
the	O
patient	O
initially	O
showed	O
signs	O
of	O
decompensated	O
heart	O
failure	O
due	O
to	O
rapid	O
AF	O
that	O
improved	O
with	O
diuretics	O
and	O
beta	O
blockade	O
.	O
Echocardiography	O
was	O
performed	O
and	O
showed	O
moderate	O
rheumatic	O
mitral	O
stenosis	O
with	O
severe	O
dilatation	O
of	O
the	O
left	O
atrium	O
and	O
normal	O
LVEF	O
.	O
All	O
INRs	O
were	O
reviewed	O
since	O
discharge	O
in	O
August	O
2016	O
and	O
only	O
2	O
of	O
them	O
were	O
in	O
therapeutic	O
range	O
with	O
a	O
TRT	O
of	O
0	O
.	O
DIAGNOSIS	O
Ischaemic	O
stroke	O
in	O
the	O
middle	O
cerebral	O
artery	O
territory	O
secondary	O
to	O
tandem	O
ICA	O
MCA	O
occlusion	O
with	O
a	O
cardioembolic	O
profile	O
.	O
Floating	O
thrombus	O
at	O
the	O
level	O
of	O
the	O
arch	O
with	O
occlusion	O
of	O
origin	O
of	O
the	O
left	O
subclavian	O
artery	O
.	O
Acute	O
arterial	O
ischaemia	O
of	O
MSI	O
with	O
spontaneous	O
resolution	O
.	O
Acute	O
arterial	O
ischaemia	O
of	O
IIM	O
resolved	O
with	O
mechanical	O
thrombectomy	O
with	O
Fogarty	O
catheter	O
.	O
Acute	O
arterial	O
ischaemia	O
of	O
MID	O
resolved	O
with	O
mechanical	O
thrombectomy	O
with	O
Fogarty	O
catheter	O
.	O
Moderate	O
rheumatic	O
mitral	O
stenosis	O
with	O
normal	O
LVEF	O
.	O
Permanent	O
atrial	O
fibrillation	O
CHA2DS2	O
VASc	O
4	O
,	O
HAS	O
BLED	O
3	O
,	O
SAMe	O
TT2R2	O
2	O
.	O
Poor	O
quality	O
of	O
anticoagulation	O
with	O
antivitamin	O
K	O
.	O
Hypertension	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Personal	O
history	O
74	O
year	O
old	O
woman	O
.	O
Cardiovascular	O
risk	O
factors	O
hypertension	O
.	O
Dyslipidaemia	O
.	O
Cardiological	O
history	O
paroxysmal	O
atrial	O
fibrillation	O
since	O
2002	O
,	O
on	O
treatment	O
with	O
sintrom	B-FARMACO
.	O
She	O
continued	O
treatment	O
with	O
amiodarone	B-FARMACO
until	O
2010	O
,	O
withdrawing	O
due	O
to	O
interstitial	O
pneumopathy	O
.	O
In	O
relation	O
to	O
an	O
episode	O
of	O
rapid	O
atrial	O
fibrillation	O
,	O
he	O
required	O
admission	O
for	O
acute	O
pulmonary	O
oedema	O
and	O
electrical	O
cardioversion	O
in	O
2002	O
.	O
The	O
echocardiogram	O
prior	O
to	O
admission	O
showed	O
moderate	O
rheumatic	O
mitral	O
regurgitation	O
,	O
normal	O
LVEF	O
and	O
severe	O
dilatation	O
of	O
the	O
left	O
atrium	O
.	O
Other	O
antecedents	O
episode	O
of	O
DVT	O
and	O
PTE	O
in	O
2002	O
in	O
the	O
same	O
admission	O
in	O
which	O
atrial	O
fibrillation	O
was	O
diagnosed	O
.	O
Breast	O
carcinoma	O
surgery	O
and	O
radiotherapy	O
in	O
2006	O
.	O
Interstitial	O
pneumopathy	O
probably	O
related	O
to	O
amiodarone	B-FARMACO
.	O
Baseline	O
situation	O
IABVD	O
.	O
NYHA	O
CF	O
II	O
.	O
Usual	O
treatment	O
enalapril	B-FARMACO
5	O
mg	O
12h	O
,	O
torasemide	B-FARMACO
5	O
mg	O
d	O
,	O
acenocoumarol	B-FARMACO
according	O
to	O
guideline	O
10	O
.	O
5	O
mg	O
week	O
,	O
atorvastatin	B-FARMACO
20	O
mg	O
d	O
.	O
Current	O
illness	O
The	O
patient	O
was	O
admitted	O
for	O
an	O
episode	O
of	O
atrial	O
fibrillation	O
at	O
200	O
bpm	O
,	O
treated	O
with	O
beta	O
blockers	O
producing	O
spontaneous	O
cardioversion	O
.	O
A	O
transesophageal	O
echocardiogram	O
was	O
performed	O
,	O
showing	O
a	O
thrombus	O
in	O
the	O
left	O
atrial	O
appendage	O
.	O
On	O
admission	O
she	O
had	O
an	O
INR	O
of	O
3	O
.	O
5	O
,	O
but	O
with	O
great	O
variability	O
in	O
previous	O
controls	O
,	O
several	O
below	O
2	O
.	O
On	O
discharge	O
,	O
treatment	O
with	O
atenolol	B-FARMACO
and	O
enoxaparin	B-FARMACO
was	O
prescribed	O
.	O
Two	O
months	O
later	O
,	O
the	O
patient	O
returned	O
to	O
the	O
ED	O
for	O
common	O
atrial	O
flutter	O
,	O
with	O
resolution	O
of	O
the	O
atrial	O
appendage	O
thrombus	O
.	O
It	O
was	O
then	O
decided	O
to	O
ablate	O
the	O
tricuspid	O
cavus	O
isthmus	O
.	O
On	O
a	O
subsequent	O
admission	O
he	O
developed	O
left	O
atrial	O
flutter	O
and	O
treatment	O
was	O
started	O
with	O
atenolol	B-FARMACO
,	O
digoxin	B-FARMACO
and	O
acenocoumarol	B-FARMACO
was	O
reintroduced	O
at	O
this	O
time	O
.	O
She	O
again	O
came	O
to	O
the	O
emergency	O
department	O
for	O
abdominal	O
pain	O
,	O
with	O
an	O
INR	O
of	O
4	O
.	O
4	O
and	O
a	O
CT	O
scan	O
showed	O
an	O
abdominal	O
wall	O
haematoma	O
with	O
active	O
bleeding	O
from	O
the	O
epigastric	O
artery	O
.	O
Physical	O
examination	O
General	O
condition	O
,	O
skin	O
pallor	O
,	O
sweating	O
,	O
tachypnoea	O
.	O
BP	O
135	O
75	O
,	O
HR	O
132	O
,	O
Sat	O
94	O
.	O
Afebrile	O
.	O
No	O
jugular	O
ingurgitation	O
.	O
Cardiopulmonary	O
auscultation	O
normal	O
.	O
Painful	O
abdomen	O
on	O
palpation	O
in	O
the	O
left	O
flank	O
,	O
with	O
haematoma	O
in	O
the	O
wall	O
at	O
the	O
level	O
of	O
the	O
lower	O
abdomen	O
.	O
No	O
peritoneal	O
irritation	O
.	O
Extremities	O
with	O
signs	O
of	O
chronic	O
venous	O
insufficiency	O
,	O
minimal	O
malleolar	O
oedema	O
,	O
symmetrical	O
pulses	O
COMPLEMENTARY	O
TESTS	O
During	O
admission	O
for	O
rapid	O
atrial	O
fibrillation	O
CBC	O
Hb	O
14	O
.	O
5	O
,	O
leukocytes	O
7200	O
,	O
platelets	O
283	O
,	O
000	O
,	O
INR	O
3	O
.	O
5	O
,	O
Cr	O
0	O
.	O
8	O
,	O
Na	O
141	O
,	O
K	O
4	O
.	O
9	O
,	O
PCR	O
negative	O
.	O
We	O
reviewed	O
previous	O
INR	O
with	O
very	O
fluctuating	O
values	O
.	O
ECG	O
atrial	O
fibrillation	O
at	O
170	O
bpm	O
,	O
narrow	O
QRS	O
,	O
normal	O
axis	O
,	O
no	O
evidence	O
of	O
enlargement	O
or	O
overload	O
.	O
Transesophageal	O
echocardiogram	O
mobile	O
thrombus	O
in	O
the	O
left	O
atrial	O
appendage	O
measuring	O
2	O
.	O
0	O
x	O
1	O
.	O
3	O
cm	O
.	O
Mitral	O
valve	O
without	O
stenosis	O
and	O
with	O
moderate	O
insufficiency	O
.	O
Aneurysmal	O
dilatation	O
of	O
the	O
left	O
atrium	O
.	O
Sclerocalcified	O
aortic	O
valve	O
with	O
mild	O
insufficiency	O
.	O
Mild	O
TR	O
allowing	O
an	O
estimated	O
PSAP	O
of	O
50	O
mmHg	O
.	O
Preserved	O
biventricular	O
systolic	O
function	O
,	O
without	O
dilatation	O
of	O
cavities	O
.	O
During	O
admission	O
for	O
atrial	O
flutter	O
Transesophageal	O
echocardiogram	O
no	O
thrombus	O
in	O
the	O
left	O
atrial	O
appendage	O
except	O
for	O
spontaneous	O
contrast	O
.	O
Degenerative	O
organic	O
mitral	O
lesion	O
causing	O
moderate	O
insufficiency	O
.	O
Moderate	O
tricuspid	O
insufficiency	O
.	O
Dilatation	O
of	O
the	O
left	O
atrium	O
.	O
MR	O
Vmax	O
583	O
.	O
3	O
cm	O
s	O
,	O
MR	O
GP	O
max	O
136	O
.	O
1	O
mmHg	O
,	O
MR	O
ERO	O
0	O
.	O
22	O
cm2	O
.	O
MRI	O
PISA	O
radius	O
0	O
.	O
74	O
cm	O
.	O
During	O
admission	O
for	O
haematoma	O
of	O
the	O
abdominal	O
wall	O
Emergency	O
ECG	O
atrial	O
fibrillation	O
alternating	O
with	O
left	O
atrial	O
flutter	O
with	O
cycle	O
length	O
of	O
380	O
msec	O
and	O
variable	O
conduction	O
2	O
1	O
1	O
1	O
.	O
Emergency	O
laboratory	O
tests	O
Hb	O
10	O
;	O
Ht	O
32	O
;	O
leucocytes	O
6	O
,	O
600	O
;	O
neutrophils	O
80	O
;	O
platelets	O
192	O
,	O
000	O
;	O
INR	O
1	O
.	O
2	O
;	O
sodium	O
140	O
;	O
potassium	O
5	O
.	O
7	O
;	O
glycaemia	O
396	O
;	O
creatinine	O
0	O
.	O
9	O
;	O
urea	O
42	O
.	O
Abdominal	O
CT	O
scan	O
anterior	O
abdominal	O
wall	O
haematoma	O
,	O
located	O
in	O
the	O
left	O
anterior	O
rectus	O
muscle	O
,	O
with	O
heterogeneous	O
attenuation	O
,	O
measuring	O
6	O
x	O
8	O
x	O
16	O
cm	O
.	O
Intravenous	O
contrast	O
extravasation	O
is	O
identified	O
in	O
the	O
arterial	O
phase	O
,	O
which	O
increases	O
in	O
the	O
venous	O
phase	O
,	O
compatible	O
with	O
active	O
arterial	O
bleeding	O
dependent	O
on	O
the	O
left	O
inferior	O
epigastric	O
artery	O
.	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
ICU	O
.	O
Anticoagulation	O
was	O
reversed	O
with	O
vitamin	B-FARMACO
K	I-FARMACO
and	O
prothrombin	O
complex	O
Octaplex	O
,	O
the	O
bleeding	O
point	O
was	O
embolised	O
by	O
the	O
Interventional	O
Radiology	O
Service	O
,	O
and	O
2	O
red	O
blood	O
cell	O
concentrates	O
were	O
transfused	O
,	O
with	O
clinical	O
and	O
haemodynamic	O
stabilisation	O
.	O
During	O
admission	O
,	O
atrial	O
fibrillation	O
alternated	O
with	O
atypical	O
flutter	O
and	O
,	O
given	O
the	O
impossibility	O
of	O
frequency	O
control	O
,	O
Cardiology	O
was	O
notified	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
Coronary	O
Unit	O
and	O
intravenous	O
atenolol	B-FARMACO
and	O
digoxin	B-FARMACO
were	O
prescribed	O
,	O
but	O
the	O
patient	O
presented	O
new	O
bouts	O
of	O
200	O
bpm	O
and	O
symptomatic	O
bradycardia	O
.	O
Anticoagulation	O
was	O
not	O
given	O
for	O
the	O
first	O
two	O
episodes	O
.	O
Subsequently	O
,	O
given	O
the	O
history	O
of	O
bleeding	O
and	O
the	O
high	O
thrombotic	O
risk	O
,	O
a	O
continuous	O
infusion	O
of	O
sodium	B-FARMACO
heparin	I-FARMACO
was	O
started	O
.	O
Once	O
on	O
the	O
ward	O
,	O
apixaban	B-FARMACO
was	O
substituted	O
,	O
initially	O
2	O
.	O
5	O
mg	O
every	O
12	O
hours	O
,	O
and	O
then	O
the	O
dose	O
was	O
increased	O
to	O
5	O
mg	O
every	O
12	O
hours	O
.	O
The	O
transesophageal	O
echocardiogram	O
was	O
repeated	O
,	O
again	O
confirming	O
the	O
absence	O
of	O
a	O
thrombus	O
in	O
the	O
atrial	O
appendage	O
.	O
As	O
for	O
the	O
management	O
of	O
atrial	O
fibrillation	O
and	O
atrial	O
flutter	O
,	O
considering	O
the	O
poor	O
control	O
with	O
medical	O
treatment	O
,	O
AV	O
node	O
ablation	O
and	O
DDDR	O
pacemaker	O
implantation	O
were	O
chosen	O
,	O
which	O
was	O
performed	O
without	O
complications	O
.	O
The	O
patient	O
evolved	O
favourably	O
and	O
was	O
discharged	O
on	O
treatment	O
with	O
apixaban	B-FARMACO
5	O
mg	O
12h	O
,	O
atenolol	B-FARMACO
50	O
mg	O
12h	O
as	O
an	O
antihypertensive	O
,	O
atorvastatin	B-FARMACO
20	O
mg	O
day	O
,	O
pantoprazole	B-FARMACO
40	O
mg	O
day	O
and	O
furosemide	B-FARMACO
40	O
mg	O
day	O
.	O
One	O
year	O
later	O
,	O
he	O
presented	O
severe	O
mitral	O
insufficiency	O
with	O
worsening	O
functional	O
class	O
and	O
it	O
was	O
decided	O
to	O
perform	O
surgery	O
to	O
replace	O
the	O
mitral	O
valve	O
with	O
a	O
27	O
mm	O
Epic	O
Mitral	O
bioprosthesis	O
,	O
with	O
surgical	O
ligation	O
of	O
the	O
left	O
atrial	O
appendage	O
at	O
the	O
same	O
time	O
.	O
DIAGNOSIS	O
Paroxysmal	O
atrial	O
fibrillation	O
.	O
Common	O
atrial	O
flutter	O
with	O
ablation	O
of	O
the	O
tricuspid	O
caval	O
isthmus	O
.	O
Left	O
atrial	O
flutter	O
.	O
Bradycardia	O
tachycardia	O
syndrome	O
.	O
CHADS	O
VASc	O
3	O
points	O
.	O
HAS	O
BLED	O
4	O
.	O
Moderate	O
rheumatic	O
mitral	O
insufficiency	O
.	O
Valve	O
replacement	O
with	O
biological	O
mitral	O
prosthesis	O
.	O
Thrombus	O
in	O
left	O
atrial	O
appendage	O
,	O
resolved	O
.	O
Surgical	O
ligation	O
of	O
the	O
left	O
atrial	O
appendage	O
.	O
Spontaneous	O
haematoma	O
of	O
the	O
rectum	O
due	O
to	O
bleeding	O
from	O
the	O
left	O
epigastric	O
artery	O
,	O
in	O
relation	O
to	O
anticoagulation	O
with	O
acenocoumarol	B-FARMACO
,	O
with	O
significant	O
anaemia	O
.	O
Embolisation	O
of	O
the	O
left	O
epigastric	O
artery	O
.	O
AV	O
node	O
ablation	O
.	O
Implantation	O
of	O
DDDR	O
pacemaker	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Reason	O
for	O
consultation	O
chest	O
pain	O
and	O
syncope	O
.	O
Personal	O
history	O
37	O
year	O
old	O
woman	O
with	O
adverse	O
drug	O
reaction	O
to	O
enantyum	B-FARMACO
and	O
paracetamol	B-FARMACO
skin	O
rash	O
.	O
Ex	O
smoker	O
for	O
4	O
years	O
AOD	O
25	O
p	O
a	O
.	O
Surgical	O
interventions	O
cervical	O
disc	O
herniation	O
operated	O
on	O
in	O
private	O
clinic	O
at	O
the	O
end	O
of	O
2012	O
,	O
appendectomy	O
.	O
Family	O
history	O
father	O
AMI	O
at	O
38	O
years	O
of	O
age	O
,	O
subsequent	O
reinfarction	O
,	O
mother	O
AMI	O
at	O
57	O
years	O
of	O
age	O
.	O
Cardiological	O
history	O
according	O
to	O
the	O
private	O
clinic	O
report	O
provided	O
October	O
2010	O
onset	O
of	O
chest	O
pain	O
and	O
cardiac	O
catheterisation	O
in	O
which	O
there	O
was	O
no	O
evidence	O
of	O
coronary	O
lesions	O
.	O
Patient	O
was	O
asymptomatic	O
after	O
the	O
episode	O
until	O
January	O
2013	O
,	O
a	O
few	O
months	O
after	O
the	O
cervical	O
hernia	O
operations	O
.	O
Cardiac	O
catheterisation	O
was	O
performed	O
in	O
February	O
2013	O
LMCA	O
without	O
lesions	O
,	O
proximal	O
LAD	O
lesion	O
52	O
,	O
Cx	O
and	O
CD	O
without	O
lesions	O
.	O
MIBI	O
was	O
performed	O
and	O
small	O
septal	O
ischaemia	O
was	O
reported	O
,	O
so	O
a	O
Biomatrix	O
11	O
mm	O
drug	O
eluting	O
stent	O
was	O
implanted	O
in	O
the	O
LAD	O
.	O
After	O
stent	O
placement	O
,	O
symptoms	O
persisted	O
and	O
catheterisation	O
was	O
repeated	O
in	O
April	O
2013	O
,	O
with	O
no	O
evidence	O
of	O
new	O
lesions	O
or	O
intra	O
stent	O
restenosis	O
.	O
LV	O
size	O
and	O
contractility	O
normal	O
Since	O
April	O
,	O
symptoms	O
worsened	O
with	O
fatigue	O
and	O
progressively	O
disabling	O
chest	O
pain	O
on	O
minimal	O
exertion	O
,	O
with	O
lack	O
of	O
response	O
to	O
multiple	O
treatments	O
,	O
at	O
some	O
point	O
sinus	O
tachycardia	O
at	O
130	O
bpm	O
and	O
transient	O
LBBB	O
were	O
observed	O
.	O
There	O
is	O
a	O
suspicion	O
of	O
microvascular	O
angina	O
and	O
painful	O
LBBB	O
.	O
EPS	O
was	O
performed	O
with	O
no	O
arrhythmic	O
inducibility	O
and	O
later	O
CMR	O
showed	O
mild	O
ischaemia	O
at	O
the	O
septoapical	O
level	O
.	O
Baseline	O
since	O
1	O
month	O
ago	O
dyspnoea	O
on	O
minimal	O
exertion	O
,	O
unable	O
to	O
lead	O
an	O
active	O
life	O
.	O
Previously	O
active	O
in	O
sporting	O
activities	O
,	O
although	O
he	O
reported	O
long	O
standing	O
chest	O
discomfort	O
related	O
to	O
exercise	O
without	O
warm	O
up	O
.	O
Usual	O
treatment	O
ASA	B-FARMACO
100	O
mg	O
0	O
1	O
0	O
,	O
sumial	B-FARMACO
20	O
mg	O
1	O
1	O
2	O
1	O
2	O
,	O
simvastatin	B-FARMACO
10	O
mg	O
0	O
0	O
1	O
.	O
Present	O
illness	O
A	O
37	O
year	O
old	O
female	O
patient	O
came	O
to	O
the	O
emergency	O
department	O
with	O
syncope	O
in	O
the	O
context	O
of	O
chest	O
pain	O
.	O
On	O
climbing	O
stairs	O
she	O
presented	O
with	O
oppressive	O
central	O
thoracic	O
pain	O
radiating	O
to	O
the	O
jaw	O
and	O
left	O
hemithorax	O
together	O
with	O
dyspnoea	O
with	O
subsequent	O
loss	O
of	O
consciousness	O
lasting	O
seconds	O
.	O
The	O
pain	O
lasted	O
for	O
a	O
total	O
of	O
5	O
minutes	O
,	O
subsiding	O
on	O
sitting	O
and	O
at	O
rest	O
.	O
No	O
sphincter	O
relaxation	O
,	O
no	O
tonic	O
clonic	O
movements	O
and	O
no	O
post	O
syncopal	O
confusion	O
.	O
For	O
the	O
last	O
month	O
the	O
patient	O
has	O
been	O
experiencing	O
daily	O
chest	O
pain	O
on	O
increasingly	O
less	O
exertion	O
,	O
in	O
the	O
last	O
few	O
days	O
on	O
minimal	O
exertion	O
.	O
Physical	O
examination	O
Afebrile	O
,	O
HR	O
55	O
bpm	O
,	O
BP	O
119	O
56	O
mmHg	O
,	O
Sat	O
aa	O
98	O
.	O
C	O
and	O
O	O
in	O
all	O
three	O
spheres	O
,	O
quiet	O
cooperative	O
.	O
BEG	O
;	O
NC	O
and	O
NH	O
.	O
Eupneic	O
.	O
ACV	O
RCR	O
,	O
no	O
murmurs	O
or	O
extratonos	O
,	O
no	O
IY	O
.	O
Palpable	O
and	O
symmetrical	O
pedial	O
pulses	O
,	O
palpable	O
and	O
symmetrical	O
femoral	O
pulses	O
.	O
AR	O
VCM	O
without	O
superimposed	O
sounds	O
.	O
ABD	O
soft	O
and	O
depressible	O
,	O
no	O
megaliths	O
,	O
no	O
signs	O
of	O
peritoneal	O
irritation	O
.	O
No	O
murmurs	O
,	O
preserved	O
peristalsis	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
Rs	O
at	O
60	O
bpm	O
,	O
normal	O
PR	O
,	O
narrow	O
QRS	O
,	O
isolated	O
negative	O
T	O
in	O
V1	O
.	O
Chest	O
X	O
ray	O
CTI	O
within	O
normal	O
limits	O
,	O
Mediastinum	O
not	O
widened	O
,	O
SCF	O
free	O
,	O
no	O
condensation	O
in	O
lung	O
parenchyma	O
.	O
CBC	O
05	O
05	O
leukocytes	O
6	O
,	O
180	O
3	O
uL	O
76	O
,	O
Hb	O
12	O
.	O
6	O
g	O
dl	O
,	O
Hto	O
35	O
.	O
8	O
,	O
platelets	O
213	O
.	O
00	O
10	O
3	O
uL	O
,	O
INR	O
0	O
.	O
99	O
,	O
D	O
dimer	O
149	O
ng	O
ml	O
,	O
glucose	O
88	O
mg	O
dl	O
,	O
urea	O
27	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
69	O
mg	O
dl	O
,	O
Na	O
141	O
mEq	O
l	O
,	O
K	O
3	O
.	O
8	O
mEq	O
l	O
.	O
Biomarker	O
curve	O
negative	O
.	O
Admission	O
blood	O
test	O
06	O
06	O
Quick	O
81	O
,	O
INR	O
1	O
.	O
16	O
.	O
Glucose	O
91	O
mg	O
dl	O
,	O
U	O
22	O
mg	O
dl	O
,	O
Cr	O
0	O
.	O
67	O
mg	O
dl	O
,	O
urate	O
5	O
mg	O
dl	O
,	O
TG	O
65	O
mg	O
dl	O
,	O
CT	O
162	O
mg	O
dl	O
HDL	O
54	O
,	O
LDL	O
95	O
,	O
total	O
bili	O
0	O
.	O
7	O
mg	O
dl	O
,	O
GOT	O
GPT	O
16	O
14	O
u	O
l	O
,	O
GGT	O
FAL	O
15	O
63	O
u	O
l	O
,	O
total	O
prot	O
63	O
.	O
5	O
g	O
l	O
,	O
albumin	O
38	O
.	O
7	O
g	O
l	O
,	O
Na	O
141	O
mEq	O
l	O
,	O
K	O
3	O
.	O
8	O
mEq	O
l	O
,	O
Cl	O
108	O
mmol	O
l	O
,	O
HbA1c	O
4	O
.	O
9	O
.	O
Transthoracic	O
echocardiogram	O
June	O
2014	O
overall	O
normal	O
systolic	O
function	O
.	O
Normal	O
sized	O
left	O
ventricle	O
.	O
Normal	O
LV	O
global	O
systolic	O
function	O
.	O
EF	O
59	O
.	O
No	O
abnormalities	O
of	O
segmental	O
contraction	O
or	O
longitudinal	O
strain	O
involvement	O
.	O
Diastolic	O
function	O
not	O
assessable	O
due	O
to	O
associated	O
lesions	O
.	O
No	O
LV	O
hypertrophy	O
.	O
Left	O
atrium	O
of	O
normal	O
size	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
.	O
Left	O
catheterisation	O
June	O
2014	O
stent	O
in	O
the	O
proximal	O
descending	O
anterior	O
descending	O
artery	O
permeable	O
without	O
hyperplasia	O
or	O
restenosis	O
.	O
Rest	O
of	O
artery	O
without	O
lesions	O
.	O
Circumflex	O
artery	O
and	O
right	O
coronary	O
artery	O
without	O
significant	O
lesions	O
.	O
The	O
ergonovine	O
test	O
was	O
performed	O
.	O
She	O
started	O
at	O
maximum	O
dose	O
with	O
precordial	O
pain	O
without	O
angiographic	O
alterations	O
but	O
electrocardiographically	O
she	O
presented	O
complete	O
AVB	O
with	O
escape	O
rhythm	O
that	O
responded	O
spontaneously	O
to	O
sinus	O
rhythm	O
.	O
Ergometry	O
09	O
06	O
14	O
Bruce	O
03	O
05	O
,	O
maximum	O
HR	O
171	O
bpm	O
,	O
maximum	O
BP	O
150	O
90	O
,	O
maximum	O
load	O
4	O
.	O
8	O
METS	O
.	O
Normal	O
resting	O
ECG	O
,	O
very	O
limited	O
functional	O
capacity	O
.	O
Conclusions	O
stress	O
test	O
terminated	O
by	O
fatigue	O
and	O
chest	O
pain	O
,	O
at	O
the	O
end	O
of	O
the	O
first	O
stage	O
without	O
electrical	O
changes	O
.	O
Abnormal	O
tachycardia	O
with	O
standing	O
,	O
at	O
the	O
start	O
of	O
the	O
test	O
HR	O
130	O
bpm	O
.	O
Hormones	O
TSH	O
0	O
.	O
43	O
UI	O
mL	O
,	O
FT4	O
1	O
.	O
04	O
ng	O
dl	O
,	O
NT	O
ProBNP	O
41	O
pg	O
mL	O
.	O
Autoimmunity	O
study	O
LDH	O
178	O
u	O
l	O
,	O
CK	O
63	O
U	O
l	O
,	O
aldolase	O
3	O
.	O
7	O
U	O
l	O
,	O
CRP	O
0	O
.	O
36	O
mg	O
dl	O
,	O
ANA	O
negative	O
,	O
RF	O
20	O
IU	O
mL	O
,	O
haemolytic	O
capacity	O
CD	O
78	O
U	O
mL	O
.	O
Metanephrines	O
in	O
24	O
hour	O
urine	O
24	O
hour	O
acid	O
diuresis	O
,	O
80	O
ml	O
.	O
Metanephrine	O
,	O
normetanephrine	O
,	O
methoxytyramine	O
pending	O
.	O
Right	O
heart	O
catheterisation	O
June	O
2014	O
right	O
heart	O
catheterisation	O
via	O
the	O
right	O
jugular	O
vein	O
without	O
immediate	O
complications	O
.	O
PVC	O
5	O
mmHg	O
,	O
VD	O
26	O
0	O
mmHg	O
,	O
PAPs	O
18	O
19	O
mmHg	O
,	O
PAPd	O
4	O
5	O
mmHg	O
,	O
PAPm	O
10	O
mmHg	O
,	O
PCP	O
5	O
mmHg	O
,	O
GTP	O
5	O
mmHg	O
,	O
GC	O
6	O
.	O
2	O
L	O
min	O
,	O
IC	O
3	O
.	O
5	O
L	O
min	O
m2	O
.	O
Systemic	O
vascular	O
resistances	O
1100	O
dyncm5	O
.	O
Pulmonary	O
vascular	O
resistance	O
less	O
than	O
1	O
Wood	O
Unit	O
.	O
Conclusions	O
pulmonary	O
pressures	O
,	O
cardiac	O
output	O
,	O
PCP	O
,	O
PVC	O
,	O
systemic	O
resistances	O
and	O
pulmonary	O
resistances	O
within	O
normality	O
.	O
There	O
is	O
no	O
RV	O
PA	O
gradient	O
,	O
ruling	O
out	O
pulmonary	O
stenosis	O
.	O
PFR	O
June	O
2014	O
normal	O
,	O
SatO2	O
unchanged	O
on	O
standing	O
upright	O
.	O
Slight	O
alteration	O
of	O
the	O
MEF	O
.	O
TLM	O
events	O
RS	O
with	O
intermittent	O
LBBB	O
at	O
any	O
rate	O
,	O
bouts	O
of	O
sinus	O
tachycardia	O
often	O
detected	O
at	O
130	O
140	O
bpm	O
with	O
standing	O
and	O
from	O
150	O
bpm	O
with	O
LBBB	O
conduction	O
.	O
Standing	O
test	O
with	O
reproducible	O
standing	O
,	O
a	O
disproportionate	O
tachycardia	O
30	O
bpm	O
of	O
baseline	O
HR	O
,	O
150	O
bpm	O
,	O
sinus	O
tachycardia	O
with	O
or	O
without	O
LBBB	O
without	O
hypotension	O
,	O
which	O
reproduces	O
his	O
symptoms	O
of	O
weakness	O
,	O
malaise	O
,	O
nausea	O
,	O
pallor	O
,	O
chest	O
discomfort	O
,	O
distal	O
cyanosis	O
with	O
intense	O
asthenia	O
even	O
exacerbated	O
by	O
speech	O
,	O
these	O
symptoms	O
disappear	O
along	O
with	O
the	O
sinus	O
tachycardia	O
rapidly	O
with	O
decubitus	O
.	O
EVOLUTION	O
The	O
patient	O
is	O
a	O
37	O
year	O
old	O
female	O
smoker	O
with	O
a	O
history	O
of	O
moderate	O
disease	O
of	O
a	O
stented	O
vessel	O
in	O
the	O
LAD	O
,	O
the	O
defect	O
observed	O
at	O
rest	O
after	O
the	O
drug	O
is	O
not	O
very	O
suggestive	O
of	O
ischaemia	O
and	O
is	O
more	O
related	O
to	O
her	O
LBBB	O
.	O
No	O
structural	O
heart	O
disease	O
,	O
ventricular	O
function	O
,	O
filling	O
pressures	O
and	O
normal	O
cardiac	O
output	O
.	O
Patent	O
stent	O
.	O
His	O
clinical	O
manifestations	O
and	O
the	O
standing	O
test	O
were	O
diagnostic	O
of	O
postural	O
orthostatic	O
tachycardia	O
syndrome	O
,	O
with	O
very	O
advanced	O
and	O
disabling	O
symptoms	O
.	O
Three	O
lines	O
of	O
pharmacological	O
treatment	O
and	O
progressive	O
desensitisation	O
through	O
exercise	O
were	O
started	O
.	O
Thus	O
,	O
treatment	O
at	O
discharge	O
consists	O
of	O
Postural	O
measures	O
,	O
frequent	O
drinking	O
of	O
water	O
,	O
diet	O
with	O
salt	O
.	O
Acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
mg	O
,	O
1	O
tablet	O
,	O
oral	O
,	O
Co	O
.	O
Fludrocortisone	B-FARMACO
0	O
.	O
1	O
mg	O
,	O
1	O
tablet	O
,	O
Oral	O
,	O
De	O
.	O
Methyldopa	B-FARMACO
125	O
mg	O
,	O
0	O
.	O
5	O
tab	O
,	O
oral	O
,	O
Ce	O
.	O
Propranolol	B-FARMACO
10	O
mg	O
,	O
1	O
tablet	O
,	O
oral	O
,	O
DeCe	O
.	O
Simvastatin	B-FARMACO
10	O
mg	O
,	O
1	O
tablet	O
,	O
Oral	O
,	O
Ce	O
DIAGNOSIS	O
Postural	O
orthostatic	O
tachycardia	O
syndrome	O
.	O
Intermittent	O
frequency	O
dependent	O
left	O
bundle	O
branch	O
block	O
LBBB	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
The	O
patient	O
is	O
a	O
68	O
year	O
old	O
male	O
with	O
hypertension	O
,	O
dyslipidaemia	O
and	O
World	O
Health	O
Organisation	O
WHO	O
grade	O
1	O
obesity	O
.	O
The	O
patient	O
also	O
suffers	O
from	O
type	O
2	O
diabetes	O
mellitus	O
,	O
being	O
treated	O
with	O
insulin	B-FARMACO
on	O
a	O
bolus	O
basal	O
regimen	O
lantus	B-FARMACO
60	O
IU	O
daily	O
,	O
but	O
with	O
suboptimal	O
control	O
HbA1C	O
8	O
.	O
6	O
.	O
He	O
had	O
been	O
an	O
ex	O
smoker	O
for	O
3	O
years	O
with	O
a	O
P	O
A	O
index	O
of	O
40	O
.	O
His	O
past	O
history	O
included	O
chronic	O
ischaemic	O
heart	O
disease	O
with	O
three	O
vessel	O
coronary	O
artery	O
disease	O
revascularised	O
on	O
multiple	O
occasions	O
.	O
He	O
had	O
made	O
his	O
debut	O
in	O
1998	O
with	O
an	O
inferior	O
infarction	O
revascularised	O
with	O
primary	O
angioplasty	O
to	O
the	O
right	O
coronary	O
artery	O
,	O
and	O
after	O
a	O
non	O
ST	O
segment	O
elevation	O
acute	O
myocardial	O
infarction	O
NSTEMI	O
in	O
March	O
2009	O
,	O
percutaneous	O
revascularisation	O
was	O
performed	O
with	O
drug	O
eluting	O
stents	O
in	O
the	O
anterior	O
descending	O
DA	O
,	O
native	O
right	O
coronary	O
CD	O
and	O
circumflex	O
Cx	O
arteries	O
.	O
He	O
had	O
previously	O
been	O
rejected	O
for	O
revascularisation	O
surgery	O
due	O
to	O
poor	O
distal	O
vascular	O
beds	O
.	O
He	O
presented	O
new	O
acute	O
episodes	O
in	O
August	O
2011	O
,	O
July	O
2012	O
and	O
January	O
2013	O
,	O
with	O
stent	O
implantation	O
in	O
de	O
novo	O
lesions	O
and	O
on	O
one	O
occasion	O
on	O
a	O
restenosis	O
of	O
the	O
stent	O
previously	O
implanted	O
in	O
the	O
proximal	O
Cx	O
.	O
In	O
the	O
intercurrent	O
period	O
,	O
the	O
patient	O
had	O
stable	O
exertional	O
angina	O
,	O
whose	O
threshold	O
had	O
been	O
slowly	O
and	O
progressively	O
shortening	O
despite	O
antianginal	O
treatment	O
until	O
reaching	O
CCS	O
functional	O
class	O
III	O
IV	O
.	O
In	O
addition	O
,	O
his	O
micro	O
and	O
macrovascular	O
metadiabetic	O
involvement	O
included	O
polyneuropathy	O
,	O
stage	O
IIIb	O
chronic	O
kidney	O
disease	O
,	O
and	O
chronic	O
lower	O
limb	O
ischaemia	O
with	O
bilateral	O
femoropopliteal	O
occlusion	O
treated	O
percutaneously	O
on	O
several	O
occasions	O
.	O
Finally	O
,	O
in	O
relation	O
to	O
moderate	O
COPD	O
with	O
an	O
exacerbating	O
phenotype	O
and	O
severe	O
SAHS	O
,	O
he	O
was	O
being	O
treated	O
with	O
inhalers	O
,	O
home	O
oxygen	B-FARMACO
16	O
hours	O
a	O
day	O
and	O
nocturnal	O
CPAP	O
.	O
He	O
was	O
admitted	O
to	O
Cardiology	O
after	O
surgery	O
for	O
amputation	O
of	O
the	O
4th	O
and	O
5th	O
left	O
metatarsophalangeal	O
joints	O
in	O
the	O
context	O
of	O
comprehensive	O
treatment	O
of	O
diabetic	O
foot	O
.	O
Despite	O
the	O
favourable	O
postoperative	O
evolution	O
,	O
the	O
patient	O
presented	O
daily	O
episodes	O
of	O
rest	O
angina	O
triggered	O
by	O
foot	O
pain	O
,	O
poorly	O
controlled	O
despite	O
the	O
use	O
of	O
opioids	O
.	O
Physical	O
examination	O
revealed	O
a	O
good	O
general	O
condition	O
,	O
and	O
the	O
patient	O
was	O
eupneic	O
.	O
Vital	O
signs	O
were	O
BP	O
120	O
60	O
mmHg	O
,	O
HR	O
70	O
bpm	O
,	O
SatO2	O
with	O
GN	O
at	O
2	O
bpm	O
92	O
.	O
Cardiopulmonary	O
auscultation	O
was	O
unremarkable	O
,	O
there	O
was	O
no	O
oedema	O
in	O
the	O
lower	O
limbs	O
and	O
the	O
left	O
1st	O
and	O
2nd	O
fingers	O
had	O
established	O
erythrocyanosis	O
,	O
together	O
with	O
necrotic	O
lesions	O
at	O
the	O
apex	O
.	O
The	O
3rd	O
finger	O
also	O
had	O
a	O
necrotic	O
lesion	O
of	O
0	O
.	O
5	O
cm	O
diameter	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
sinus	O
rhythm	O
at	O
60	O
bpm	O
,	O
1st	O
degree	O
BAV	O
,	O
QRS	O
110	O
ms	O
with	O
HBAI	O
,	O
ST	O
rectification	O
in	O
I	O
,	O
aVL	O
,	O
V5	O
V6	O
,	O
similar	O
to	O
previous	O
ones	O
.	O
No	O
changes	O
with	O
and	O
without	O
pain	O
.	O
Blood	O
tests	O
Hb	O
10	O
g	O
dl	O
,	O
leucocytes	O
16	O
,	O
900	O
,	O
platelets	O
and	O
coagulation	O
normal	O
,	O
creatinine	O
1	O
.	O
65	O
mg	O
dl	O
,	O
ions	O
normal	O
,	O
troponin	O
T	O
serum	O
US	O
26	O
25	O
normal	O
10	O
ng	O
l	O
,	O
CK	O
and	O
CK	O
MB	O
normal	O
.	O
Echocardiogram	O
left	O
ventricle	O
not	O
dilated	O
,	O
with	O
slightly	O
increased	O
wall	O
thickness	O
.	O
Inferior	O
basal	O
akinesia	O
and	O
basal	O
and	O
medial	O
segments	O
of	O
inferior	O
lateral	O
face	O
.	O
Hypokinesia	O
of	O
the	O
inferior	O
septum	O
.	O
Ejection	O
fraction	O
at	O
the	O
lower	O
limit	O
of	O
normal	O
52	O
.	O
Pseudonormalised	O
transmitral	O
filling	O
pattern	O
.	O
Non	O
dilated	O
right	O
ventricle	O
,	O
with	O
normal	O
global	O
systolic	O
function	O
.	O
No	O
significant	O
valvular	O
heart	O
disease	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
with	O
physiological	O
inspiratory	O
collapse	O
.	O
No	O
pericardial	O
effusion	O
.	O
Aortic	O
root	O
not	O
dilated	O
.	O
Coronary	O
angiography	O
previously	O
implanted	O
patent	O
stents	O
.	O
Multivessel	O
coronary	O
artery	O
disease	O
with	O
poor	O
distal	O
beds	O
,	O
thin	O
calibre	O
and	O
diffuse	O
disease	O
,	O
not	O
subsidiary	O
of	O
new	O
revascularisation	O
.	O
EVOLUTION	O
Local	O
treatment	O
of	O
the	O
diabetic	O
foot	O
was	O
carried	O
out	O
,	O
the	O
antibiotic	O
cycle	O
was	O
completed	O
and	O
antianginal	O
medication	O
was	O
titrated	O
,	O
and	O
the	O
patient	O
tolerated	O
bisoprolol	B-FARMACO
10	O
mg	O
day	O
,	O
amlodipine	B-FARMACO
10	O
mg	O
day	O
,	O
Uniket	B-FARMACO
retard	I-FARMACO
50	O
mg	O
day	O
,	O
ranolazine	B-FARMACO
750	O
mg	O
12	O
h	O
and	O
ivabradine	B-FARMACO
5	O
mg	O
12	O
h	O
.	O
From	O
the	O
analgesic	O
point	O
of	O
view	O
,	O
he	O
is	O
tolerating	O
paracetamol	B-FARMACO
c	O
8	O
h	O
,	O
metamizole	B-FARMACO
1c	O
8	O
h	O
,	O
fentanyl	B-FARMACO
patches	O
75	O
mcg	O
72	O
h	O
,	O
and	O
rescue	O
morphine	B-FARMACO
and	O
sublingual	O
NTG	B-FARMACO
.	O
Despite	O
some	O
symptomatic	O
improvement	O
,	O
he	O
continued	O
to	O
present	O
very	O
limiting	O
mild	O
exertional	O
angina	O
,	O
with	O
peaks	O
of	O
pain	O
in	O
the	O
lower	O
extremities	O
that	O
were	O
difficult	O
to	O
control	O
,	O
requiring	O
constant	O
use	O
of	O
rescue	O
medication	O
.	O
Having	O
ruled	O
out	O
the	O
possibility	O
of	O
further	O
revascularisation	O
,	O
spinal	O
cord	O
stimulation	O
therapy	O
was	O
chosen	O
with	O
two	O
posterior	O
epidural	O
electrodes	O
at	O
cervicothoracic	O
C7	O
T4	O
and	O
lumbar	O
T9	O
L2	O
levels	O
for	O
angina	O
and	O
diabetic	O
foot	O
with	O
chronic	O
ischaemia	O
,	O
respectively	O
.	O
With	O
these	O
devices	O
,	O
a	O
generator	O
was	O
placed	O
in	O
a	O
subcutaneous	O
pocket	O
at	O
left	O
flank	O
level	O
.	O
Subsequent	O
evolution	O
after	O
implantation	O
was	O
favourable	O
,	O
allowing	O
angina	O
free	O
daily	O
activity	O
at	O
discharge	O
,	O
avoiding	O
intense	O
physical	O
activity	O
and	O
overexertion	O
.	O
DIAGNOSIS	O
Chronic	O
ischaemic	O
heart	O
disease	O
with	O
mixed	O
percutaneous	O
and	O
surgical	O
revascularisation	O
of	O
three	O
vessel	O
disease	O
.	O
Diffuse	O
tertiary	O
vessel	O
disease	O
.	O
Refractory	O
angina	O
.	O
Chronic	O
lower	O
limb	O
ischaemia	O
.	O
Diabetic	O
foot	O
.	O
Chronic	O
renal	O
disease	O
.	O
COPD	O
with	O
chronic	O
home	O
oxygen	O
.	O
SAHS	O
with	O
CPAP	O
.	O
Type	O
2	O
insulin	O
dependent	O
diabetes	O
.	O
HYPERTENSION	O
.	O
Dyslipidaemia	O
.	O
Obesity	O
.	O
In	O
the	O
long	O
term	O
evolution	O
he	O
had	O
stable	O
angina	O
in	O
CF	O
II	O
III	O
IV	O
of	O
the	O
CCS	O
and	O
the	O
need	O
for	O
left	O
infrapopliteal	O
amputation	O
one	O
year	O
later	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
72	O
year	O
old	O
woman	O
with	O
a	O
history	O
of	O
permanent	O
atrial	O
fibrillation	O
,	O
anticoagulated	O
with	O
acenocoumarol	B-FARMACO
,	O
without	O
structural	O
heart	O
disease	O
in	O
previous	O
echocardiograms	O
.	O
She	O
consulted	O
for	O
months	O
of	O
chest	O
pain	O
on	O
exertion	O
compatible	O
with	O
typical	O
angina	O
on	O
usual	O
exertion	O
.	O
Acetylsalicylic	B-FARMACO
acid	I-FARMACO
was	O
started	O
and	O
ambulatory	O
exercise	O
testing	O
was	O
requested	O
.	O
No	O
findings	O
on	O
initial	O
physical	O
examination	O
.	O
Admitted	O
for	O
coronary	O
angiography	O
due	O
to	O
ergometry	O
findings	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
sinus	O
rhythm	O
,	O
narrow	O
QRS	O
with	O
normal	O
axis	O
,	O
normal	O
repolarisation	O
.	O
Blood	O
tests	O
biochemistry	O
and	O
haemogram	O
parameters	O
in	O
range	O
.	O
Myocardial	O
damage	O
markers	O
not	O
elevated	O
.	O
Chest	O
X	O
ray	O
normal	O
cardiothoracic	O
index	O
.	O
No	O
mediastinal	O
widening	O
.	O
No	O
acute	O
pleuroparenchymal	O
pathology	O
.	O
Transthoracic	O
echocardiogram	O
TTE	O
left	O
ventricle	O
neither	O
dilated	O
nor	O
hypertrophic	O
.	O
Normal	O
segmental	O
contractility	O
and	O
systolic	O
function	O
.	O
Mitral	O
filling	O
with	O
normal	O
pattern	O
for	O
his	O
age	O
.	O
Normal	O
right	O
ventricle	O
and	O
atria	O
.	O
Aneurysm	O
of	O
the	O
interatrial	O
septum	O
without	O
evidence	O
of	O
shunt	O
by	O
Doppler	O
.	O
No	O
significant	O
valvulopathies	O
.	O
Estimated	O
PSP	O
of	O
21	O
mmHg	O
.	O
No	O
pericardial	O
effusion	O
.	O
Ergometry	O
stopped	O
at	O
minute	O
3	O
of	O
the	O
Bruce	O
protocol	O
due	O
to	O
limiting	O
angina	O
.	O
Clinically	O
positive	O
anginal	O
chest	O
pain	O
and	O
dyspnoea	O
from	O
minute	O
1	O
30	O
,	O
which	O
becomes	O
limiting	O
at	O
minute	O
3	O
and	O
persists	O
on	O
recovery	O
for	O
3	O
minutes	O
.	O
Electrically	O
negative	O
to	O
charges	O
reached	O
.	O
No	O
arrhythmias	O
.	O
Normal	O
blood	O
pressure	O
response	O
.	O
Severely	O
limited	O
functional	O
class	O
4	O
METS	O
.	O
Coronary	O
angiography	O
common	O
trunk	O
no	O
lesions	O
.	O
Anterior	O
descending	O
artery	O
vessel	O
of	O
good	O
calibre	O
and	O
development	O
,	O
with	O
calcium	O
,	O
without	O
significant	O
stenosis	O
.	O
Bordering	O
the	O
tip	O
.	O
Circumflex	O
artery	O
.	O
Non	O
dominant	O
,	O
without	O
significant	O
lesions	O
.	O
Right	O
coronary	O
artery	O
severely	O
calcified	O
from	O
the	O
ostium	O
to	O
the	O
distal	O
segment	O
,	O
with	O
subtotal	O
stenosis	O
at	O
the	O
beginning	O
of	O
the	O
middle	O
segment	O
and	O
distal	O
TIMI	O
2	O
flow	O
.	O
The	O
distal	O
vessel	O
receives	O
heterocoronary	O
collateral	O
circulation	O
.	O
EVOLUTION	O
After	O
performing	O
diagnostic	O
coronary	O
angiography	O
,	O
in	O
the	O
presence	O
of	O
critical	O
stenosis	O
of	O
the	O
right	O
coronary	O
artery	O
with	O
reduced	O
flow	O
,	O
ad	O
hoc	O
angioplasty	O
was	O
decided	O
,	O
administering	O
clopidogrel	B-FARMACO
in	O
the	O
haemodynamics	O
room	O
.	O
An	O
attempt	O
was	O
made	O
to	O
cross	O
the	O
lesion	O
with	O
guidewires	O
with	O
increasing	O
crossing	O
and	O
penetration	O
capacity	O
,	O
given	O
that	O
the	O
lesion	O
behaved	O
like	O
a	O
chronic	O
occlusion	O
BMW	O
,	O
Miracle	O
3	O
,	O
Pilot	O
150	O
and	O
Confianza	O
Pro	O
.	O
Support	O
is	O
increased	O
with	O
a	O
1	O
.	O
5F	O
coaxial	O
balloon	O
catheter	O
,	O
but	O
only	O
a	O
false	O
lumen	O
is	O
achieved	O
,	O
causing	O
dissection	O
with	O
an	O
image	O
of	O
contrast	O
retention	O
in	O
the	O
arterial	O
wall	O
,	O
without	O
images	O
suggestive	O
of	O
leakage	O
and	O
with	O
complete	O
occlusion	O
of	O
the	O
artery	O
at	O
the	O
level	O
of	O
the	O
lesion	O
.	O
The	O
patient	O
noted	O
slight	O
precordial	O
pressure	O
which	O
subsided	O
with	O
2	O
mg	O
of	O
Cl	B-FARMACO
morphine	B-FARMACO
.	O
No	O
changes	O
were	O
observed	O
in	O
the	O
12	O
lead	O
ECG	O
at	O
the	O
end	O
of	O
the	O
procedure	O
.	O
She	O
also	O
presented	O
generalised	O
rash	O
,	O
suggesting	O
allergy	O
to	O
iodinated	O
contrast	O
agent	O
,	O
which	O
appeared	O
to	O
be	O
controlled	O
after	O
administration	O
of	O
intravenous	O
corticosteroid	O
and	O
antihistamine	O
.	O
He	O
was	O
transferred	O
to	O
the	O
Coronary	O
Care	O
Unit	O
for	O
close	O
monitoring	O
,	O
and	O
an	O
urgent	O
transthoracic	O
echocardiogram	O
was	O
performed	O
,	O
showing	O
normal	O
biventricular	O
systolic	O
function	O
with	O
no	O
significant	O
findings	O
highlighting	O
the	O
absence	O
of	O
pericardial	O
effusion	O
.	O
The	O
evolution	O
was	O
favourable	O
,	O
with	O
no	O
recurrence	O
of	O
chest	O
pain	O
,	O
with	O
progressive	O
resolution	O
of	O
the	O
allergic	O
symptoms	O
and	O
with	O
discrete	O
elevation	O
of	O
biomarkers	O
without	O
changes	O
in	O
serum	O
levels	O
,	O
and	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
conventional	O
hospital	O
ward	O
the	O
following	O
day	O
.	O
Neither	O
double	O
antiplatelet	O
therapy	O
nor	O
anticoagulation	O
was	O
suspended	O
,	O
given	O
that	O
the	O
information	O
transmitted	O
was	O
of	O
occlusive	O
coronary	O
dissection	O
and	O
not	O
perforation	O
.	O
Forty	O
eight	O
hours	O
after	O
the	O
procedure	O
,	O
the	O
patient	O
reported	O
chest	O
pain	O
that	O
initially	O
appeared	O
to	O
have	O
an	O
angina	O
profile	O
,	O
with	O
constants	O
in	O
range	O
,	O
so	O
an	O
ECG	O
was	O
performed	O
with	O
no	O
signs	O
of	O
ischaemia	O
and	O
intravenous	O
NTG	B-FARMACO
perfusion	O
was	O
started	O
,	O
with	O
subsequent	O
arterial	O
hypotension	O
,	O
general	O
malaise	O
and	O
signs	O
of	O
hypoperfusion	O
,	O
which	O
persisted	O
despite	O
withdrawal	O
of	O
NTG	O
.	O
Urgent	O
TTE	O
was	O
performed	O
,	O
showing	O
pericardial	O
effusion	O
with	O
echocardiographic	O
signs	O
of	O
tamponade	O
,	O
an	O
image	O
suggestive	O
of	O
fibrin	O
deposition	O
at	O
the	O
level	O
of	O
the	O
right	O
AV	O
groove	O
and	O
dyskinesia	O
of	O
the	O
basal	O
portion	O
of	O
the	O
right	O
ventricular	O
free	O
wall	O
.	O
Serum	O
therapy	O
was	O
started	O
,	O
the	O
patient	O
was	O
transferred	O
back	O
to	O
the	O
Coronary	O
Unit	O
and	O
urgent	O
pericardiocentesis	O
was	O
performed	O
with	O
extraction	O
of	O
fluid	O
with	O
a	O
haematic	O
appearance	O
until	O
stabilisation	O
,	O
with	O
subsequent	O
drainage	O
and	O
suspension	O
of	O
antithrombotic	O
treatment	O
.	O
New	O
instability	O
a	O
few	O
hours	O
after	O
placing	O
the	O
pericardial	O
drain	O
,	O
with	O
electromechanical	O
dissociation	O
,	O
with	O
echocardiographic	O
evidence	O
of	O
retapositioning	O
that	O
persisted	O
despite	O
repositioning	O
the	O
drain	O
,	O
with	O
the	O
need	O
for	O
orotracheal	O
intubation	O
due	O
to	O
a	O
low	O
level	O
of	O
consciousness	O
.	O
Cardiac	O
surgery	O
was	O
contacted	O
for	O
urgent	O
surgical	O
pericardial	O
drainage	O
and	O
the	O
time	O
interval	O
was	O
used	O
to	O
perform	O
a	O
transesophageal	O
echocardiogram	O
with	O
the	O
same	O
findings	O
in	O
the	O
right	O
AV	O
groove	O
and	O
basal	O
portion	O
of	O
the	O
RV	O
,	O
without	O
loss	O
of	O
continuity	O
or	O
evidence	O
of	O
flow	O
through	O
the	O
RV	O
myocardium	O
.	O
After	O
pericardial	O
drainage	O
and	O
evacuation	O
of	O
abundant	O
haematic	O
fluid	O
by	O
median	O
sternotomy	O
,	O
a	O
large	O
thrombus	O
was	O
observed	O
adhered	O
to	O
the	O
right	O
AV	O
groove	O
with	O
no	O
active	O
bleeding	O
and	O
haematoma	O
in	O
the	O
basal	O
region	O
of	O
the	O
RV	O
free	O
wall	O
and	O
in	O
the	O
RA	O
,	O
suggestive	O
of	O
dissection	O
of	O
the	O
right	O
AV	O
groove	O
.	O
On	O
leaving	O
the	O
operating	O
theatre	O
,	O
the	O
patient	O
persisted	O
with	O
great	O
haemodynamic	O
instability	O
,	O
so	O
TTE	O
was	O
repeated	O
,	O
ruling	O
out	O
cardiac	O
tamponade	O
but	O
showing	O
severe	O
RV	O
dysfunction	O
with	O
extension	O
of	O
dyskinesia	O
and	O
hyper	O
refringence	O
to	O
mid	O
basal	O
portions	O
of	O
the	O
RV	O
free	O
wall	O
,	O
leading	O
to	O
severe	O
systolic	O
dysfunction	O
of	O
the	O
same	O
.	O
Finally	O
,	O
the	O
indication	O
for	O
circulatory	O
assistance	O
was	O
ruled	O
out	O
and	O
it	O
was	O
decided	O
to	O
limit	O
therapeutic	O
effort	O
,	O
and	O
the	O
patient	O
died	O
within	O
a	O
short	O
period	O
of	O
time	O
.	O
DIAGNOSIS	O
Coronary	O
dissection	O
versus	O
iatrogenic	O
perforation	O
by	O
angioplasty	O
guidewire	O
of	O
the	O
right	O
AV	O
groove	O
.	O
Acute	O
cardiac	O
tamponade	O
.	O
RV	O
free	O
wall	O
haematoma	O
with	O
acute	O
severe	O
dysfunction	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
We	O
present	O
a	O
49	O
year	O
old	O
male	O
,	O
with	O
no	O
previous	O
allergies	O
,	O
who	O
consulted	O
the	O
emergency	O
department	O
for	O
a	O
condition	O
compatible	O
with	O
an	O
allergic	O
reaction	O
.	O
History	O
Cardiovascular	O
risk	O
factors	O
smoker	O
of	O
15	O
cigarettes	O
a	O
day	O
.	O
No	O
hypertension	O
,	O
diabetes	O
or	O
dyslipidaemia	O
.	O
No	O
known	O
cardiological	O
history	O
.	O
As	O
other	O
history	O
,	O
he	O
is	O
diagnosed	O
with	O
moderate	O
COPD	O
spirometry	O
FVC	O
3	O
.	O
27	O
L	O
68	O
FEV1	O
1	O
.	O
90	O
l	O
51	O
,	O
FEV1	O
58	O
moderate	O
obstructive	O
disorder	O
.	O
Volumes	O
TGV	O
5	O
.	O
51	O
L	O
147	O
,	O
TLC	O
8	O
.	O
44	O
L	O
116	O
,	O
RV	O
4	O
.	O
76	O
L	O
204	O
RV	O
TLC	O
56	O
.	O
Hyperinflation	O
with	O
air	O
trapping	O
.	O
DLCO	O
27	O
88	O
91	O
.	O
Chronic	O
treatment	O
with	O
inhalers	O
tiotropium	B-FARMACO
1	O
inhalation	O
every	O
24	O
hours	O
,	O
budesonide	B-FARMACO
formoterol	I-FARMACO
1	O
inhalation	O
every	O
12	O
hours	O
and	O
salbutamol	B-FARMACO
on	O
demand	O
.	O
Present	O
illness	O
Patient	O
suffers	O
a	O
casual	O
fall	O
,	O
hitting	O
his	O
side	O
and	O
right	O
arm	O
,	O
and	O
decides	O
to	O
take	O
the	O
usual	O
analgesia	O
Nolotil	B-FARMACO
.	O
He	O
then	O
began	O
to	O
experience	O
pruritus	O
,	O
generalised	O
rash	O
and	O
very	O
intense	O
dyspnoea	O
.	O
He	O
was	O
taken	O
by	O
ambulance	O
to	O
the	O
hospital	O
emergency	O
room	O
.	O
The	O
patient	O
arrived	O
at	O
the	O
ED	O
with	O
great	O
difficulty	O
in	O
breathing	O
,	O
so	O
immediate	O
treatment	O
with	O
corticosteroids	O
,	O
salbutamol	B-FARMACO
and	O
antihistamines	O
was	O
started	O
,	O
with	O
significant	O
improvement	O
in	O
clinical	O
symptoms	O
and	O
oxygen	O
saturation	O
.	O
When	O
the	O
patient	O
was	O
able	O
to	O
speak	O
after	O
improvement	O
of	O
his	O
dyspnoea	O
,	O
he	O
reported	O
having	O
started	O
with	O
chest	O
pain	O
of	O
intensity	O
10	O
10	O
and	O
an	O
ECG	O
was	O
performed	O
.	O
Physical	O
examination	O
Afebrile	O
36	O
.	O
8	O
C	O
.	O
BP	O
135	O
90	O
,	O
HR	O
80	O
,	O
eupneic	O
after	O
treatment	O
,	O
rash	O
on	O
face	O
and	O
trunk	O
.	O
AC	O
RsCsRs	O
without	O
murmurs	O
AP	O
VCM	O
,	O
some	O
isolated	O
expiratory	O
wheezing	O
after	O
treatment	O
.	O
Abdomen	O
soft	O
,	O
non	O
painful	O
,	O
without	O
masses	O
or	O
megaliths	O
.	O
EEEII	O
without	O
oedema	O
and	O
with	O
positive	O
paedial	O
pulses	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
tests	O
on	O
admission	O
biochemistry	O
glucose	O
202	O
mg	O
dl	O
,	O
urea	O
25	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
87	O
mg	O
dl	O
,	O
sodium	O
ion	O
140	O
mmol	O
l	O
136	O
145	O
,	O
alanine	O
aminotransferase	O
8	O
U	O
l	O
,	O
total	O
bilirubin	O
1	O
.	O
0	O
mg	O
dl	O
.	O
CBC	O
red	O
blood	O
cells	O
4	O
.	O
78	O
x10	O
6	O
L	O
,	O
haemoglobin	O
16	O
.	O
7	O
g	O
dl	O
,	O
haematocrit	O
47	O
.	O
5	O
,	O
V	O
.	O
C	O
.	O
M	O
99	O
.	O
4	O
fl	O
,	O
H	O
.	O
C	O
.	O
M	O
34	O
.	O
9	O
pg	O
,	O
C	O
.	O
H	O
.	O
C	O
.	O
M	O
.	O
35	O
.	O
2	O
g	O
dl	O
,	O
R	O
.	O
D	O
.	O
W	O
.	O
C	O
.	O
V	O
.	O
15	O
.	O
9	O
,	O
leucocytes	O
12	O
.	O
07	O
x10	O
3	O
ul	O
,	O
neutrophils	O
7	O
.	O
01	O
x10	O
3	O
L	O
,	O
neutrophils	O
58	O
.	O
1	O
,	O
lymphocytes	O
4	O
.	O
35	O
x10	O
3	O
L	O
,	O
lymphocytes	O
36	O
.	O
0	O
,	O
monocytes	O
0	O
.	O
60	O
x	O
10	O
3	O
L	O
,	O
monocytes	O
5	O
.	O
0	O
,	O
eosinophils	O
0	O
.	O
08	O
x10	O
3	O
L	O
,	O
eosinophils	O
0	O
.	O
7	O
,	O
basophils	O
0	O
.	O
03	O
x10	O
3	O
L	O
,	O
basophils	O
0	O
.	O
2	O
,	O
immature	O
granulocytes	O
0	O
.	O
04	O
x10	O
3	O
L	O
,	O
immature	O
granulocytes	O
0	O
.	O
30	O
,	O
platelets	O
241	O
x10	O
3	O
L	O
.	O
V	O
.	O
P	O
.	O
M	O
.	O
11	O
,	O
6	O
fl	O
.	O
Coagulation	O
Prothrombin	O
T	O
.	O
10	O
,	O
70	O
sec	O
.	O
Prothrombin	O
T	O
.	O
101	O
,	O
0	O
Prothrombin	O
T	O
.	O
ratio	O
0	O
,	O
99	O
.	O
Partial	O
prothrombin	O
T	O
.	O
28	O
.	O
50	O
sec	O
.	O
Derived	O
fibrinogen	O
447	O
mg	O
dl	O
.	O
I	O
.	O
N	O
.	O
R	O
.	O
0	O
.	O
99	O
.	O
Emergency	O
ECG	O
ST	O
segment	O
elevation	O
of	O
V3	O
V6	O
and	O
inferior	O
face	O
.	O
Chest	O
X	O
ray	O
no	O
signs	O
of	O
HF	O
.	O
No	O
pneumothorax	O
line	O
.	O
Fracture	O
in	O
the	O
8th	O
right	O
costal	O
arch	O
.	O
Coronary	O
angiography	O
anterior	O
descending	O
stenosis	O
of	O
75	O
in	O
proximal	O
third	O
with	O
TIMI	O
3	O
flow	O
and	O
good	O
distal	O
bed	O
.	O
Stenosis	O
of	O
90	O
in	O
distal	O
third	O
with	O
TIMI	O
flow	O
During	O
admission	O
,	O
the	O
patient	O
remains	O
asymptomatic	O
for	O
angina	O
and	O
dyspnoea	O
,	O
with	O
mechanical	O
rib	O
pain	O
related	O
to	O
a	O
fracture	O
of	O
the	O
8th	O
costal	O
arch	O
.	O
The	O
patient	O
was	O
discharged	O
home	O
and	O
consultation	O
with	O
Allergology	O
was	O
requested	O
to	O
complete	O
studies	O
.	O
A	O
skin	O
test	O
was	O
performed	O
which	O
was	O
positive	O
,	O
leading	O
to	O
a	O
diagnosis	O
of	O
type	O
I	O
hypersensitivity	O
immediate	O
,	O
IgE	O
mediated	O
to	O
metamizole	B-FARMACO
NSAID	O
derived	O
from	O
pyrazolone	O
.	O
Furthermore	O
,	O
this	O
mechanism	O
was	O
reaffirmed	O
in	O
vitro	O
,	O
with	O
the	O
induction	O
of	O
basophil	O
activation	O
in	O
response	O
to	O
metamizole	B-FARMACO
stimulation	O
.	O
DIAGNOSIS	O
Acute	O
coronary	O
syndrome	O
ACS	O
with	O
ST	O
elevation	O
STEACS	O
in	O
the	O
context	O
of	O
anaphylactic	O
reaction	O
in	O
a	O
patient	O
with	O
1	O
vessel	O
coronary	O
artery	O
disease	O
Kounis	O
syndrome	O
type	O
II	O
.	O
Allergy	O
to	O
metamizole	B-FARMACO
Nolotil	I-FARMACO
.	O
PTCA	O
2	O
PHARMACOACTIVE	O
STENTS	O
in	O
pAD	O
.	O
LVEF	O
45	O
.	O
Fracture	O
8	O
right	O
costal	O
arch	O
.	O

HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
The	O
patient	O
is	O
a	O
61	O
year	O
old	O
woman	O
,	O
a	O
former	O
smoker	O
,	O
recently	O
diagnosed	O
with	O
LADA	O
type	O
1	O
autoimmune	O
diabetes	O
mellitus	O
,	O
dyslipidaemic	O
,	O
with	O
a	O
history	O
of	O
spinocerebellar	O
ataxia	O
,	O
who	O
consulted	O
the	O
emergency	O
department	O
due	O
to	O
a	O
non	O
productive	O
cough	O
and	O
a	O
feeling	O
of	O
dystrophy	O
that	O
had	O
been	O
evolving	O
for	O
days	O
.	O
She	O
was	O
haemodynamically	O
stable	O
,	O
hypertensive	O
BP	O
189	O
114	O
mmHg	O
,	O
sinus	O
tachycardia	O
at	O
130	O
bpm	O
,	O
tachypneic	O
with	O
a	O
respiratory	O
rate	O
of	O
30	O
rpm	O
at	O
rest	O
,	O
without	O
tugging	O
,	O
and	O
oxygen	O
saturation	O
of	O
94	O
with	O
Ventimask	O
40	O
,	O
flapping	O
and	O
afebrile	O
.	O
ECG	O
with	O
sinus	O
rhythm	O
without	O
repolarisation	O
alterations	O
.	O
The	O
physical	O
examination	O
showed	O
evidence	O
of	O
severe	O
bronchospasm	O
on	O
respiratory	O
auscultation	O
and	O
cardiac	O
auscultation	O
with	O
rhythmic	O
twists	O
without	O
murmurs	O
.	O
The	O
rest	O
of	O
the	O
patient	O
had	O
no	O
pathological	O
findings	O
.	O
COMPLEMENTARY	O
TESTS	O
Emergency	O
ECG	O
sinus	O
rhythm	O
at	O
70	O
bpm	O
,	O
PR	O
140	O
ms	O
,	O
narrow	O
QRS	O
QTc	O
448	O
ms	O
without	O
repolarisation	O
alterations	O
.	O
ICU	O
ECG	O
sinus	O
rhythm	O
at	O
78	O
bpm	O
,	O
PR	O
140	O
ms	O
,	O
narrow	O
QRS	O
,	O
QTc	O
579	O
ms	O
diffuse	O
symmetrical	O
negative	O
T	O
waves	O
.	O
ED	O
ABG	O
pH	O
7	O
.	O
18	O
;	O
PCO2	O
79	O
.	O
9	O
mmHg	O
;	O
PO2	O
142	O
.	O
3	O
mmHg	O
;	O
bicarbonate	O
29	O
.	O
6	O
mmol	O
l	O
;	O
BS	O
1	O
.	O
4	O
;	O
SaO2	O
98	O
.	O
Serial	O
troponin	O
I	O
0	O
.	O
12	O
1	O
.	O
45	O
2	O
.	O
51	O
3	O
.	O
4	O
2	O
.	O
8	O
ng	O
ml	O
.	O
Emergency	O
blood	O
tests	O
creatinine	O
0	O
.	O
73	O
mg	O
dl	O
;	O
urea	O
54	O
mg	O
dl	O
;	O
haemoglobin	O
13	O
.	O
2	O
g	O
dl	O
;	O
haematocrit	O
42	O
.	O
3	O
;	O
leucocytes	O
23	O
,	O
000	O
l	O
;	O
CRP	O
2	O
.	O
4	O
mg	O
dl	O
.	O
Blood	O
tests	O
during	O
admission	O
to	O
Cardiology	O
highlights	O
HbA1C	O
7	O
.	O
1	O
mg	O
dl	O
,	O
total	O
cholesterol	O
172	O
mg	O
dl	O
,	O
HDL	O
49mg	O
dl	O
,	O
LDL	O
91	O
.	O
58	O
mg	O
dl	O
.	O
Normal	O
thyroid	O
profile	O
;	O
D	O
Dimer	O
571	O
ng	O
Ml	O
.	O
Chest	O
X	O
ray	O
in	O
ICU	O
hilar	O
thickening	O
.	O
Apical	O
redistribution	O
.	O
Transthoracic	O
echocardiography	O
LV	O
appears	O
normal	O
in	O
size	O
,	O
slightly	O
increased	O
wall	O
thickness	O
,	O
hyperdynamic	O
symmetrical	O
contractility	O
.	O
Normal	O
LVEF	O
.	O
LA	O
of	O
normal	O
size	O
.	O
RV	O
of	O
normal	O
size	O
and	O
function	O
.	O
RA	O
of	O
normal	O
size	O
.	O
IVC	O
of	O
normal	O
size	O
with	O
inspiratory	O
collapse	O
greater	O
than	O
50	O
.	O
No	O
pericardial	O
effusion	O
.	O
Aortic	O
root	O
of	O
normal	O
size	O
.	O
VAo	O
trivalva	O
,	O
appears	O
to	O
open	O
correctly	O
.	O
MV	O
with	O
thin	O
leaflets	O
,	O
correct	O
kinetics	O
.	O
Competent	O
.	O
No	O
IT	O
detected	O
.	O
PV	O
visualised	O
subcostal	O
,	O
appears	O
to	O
have	O
normal	O
echostructure	O
and	O
flow	O
.	O
LV	O
findings	O
of	O
normal	O
size	O
and	O
function	O
.	O
LA	O
normal	O
.	O
RV	O
of	O
normal	O
size	O
and	O
function	O
.	O
RA	O
of	O
normal	O
size	O
and	O
function	O
.	O
No	O
significant	O
valvulopathies	O
are	O
appreciated	O
by	O
this	O
study	O
route	O
.	O
Signs	O
of	O
normal	O
PVC	O
.	O
No	O
pericardial	O
effusion	O
.	O
Cardiac	O
magnetic	O
resonance	O
LV	O
of	O
normal	O
size	O
,	O
normal	O
walls	O
,	O
symmetrical	O
contractility	O
.	O
Normal	O
LVEF	O
.	O
LA	O
normal	O
size	O
.	O
RV	O
of	O
normal	O
size	O
and	O
function	O
.	O
RA	O
of	O
normal	O
size	O
.	O
No	O
significant	O
valvulopathies	O
.	O
Mild	O
pericardial	O
effusion	O
.	O
No	O
evidence	O
of	O
oedema	O
or	O
abnormalities	O
in	O
gadolinium	O
uptake	O
.	O
Catheterisation	O
right	O
dominance	O
.	O
Coronary	O
arteries	O
without	O
angiographic	O
lesions	O
with	O
normal	O
flow	O
.	O
EVOLUTION	O
He	O
progressed	O
with	O
progressive	O
respiratory	O
failure	O
and	O
hypertensive	O
crisis	O
,	O
starting	O
intravenous	O
diuretic	O
treatment	O
,	O
non	O
invasive	O
mechanical	O
ventilation	O
,	O
antibiotic	O
treatment	O
,	O
bronchodilators	O
and	O
intravenous	O
corticoids	O
,	O
and	O
was	O
admitted	O
to	O
the	O
Intensive	O
Care	O
Unit	O
,	O
with	O
early	O
improvement	O
and	O
early	O
withdrawal	O
of	O
ventilatory	O
support	O
.	O
During	O
his	O
stay	O
with	O
early	O
improvement	O
and	O
withdrawal	O
of	O
ventilatory	O
support	O
,	O
an	O
ECG	O
with	O
diffuse	O
symmetrical	O
T	O
negatives	O
with	O
elongated	O
QTc	O
and	O
peak	O
troponin	O
3	O
.	O
4	O
ng	O
ml	O
was	O
observed	O
in	O
this	O
context	O
.	O
An	O
echocardiogram	O
was	O
performed	O
showing	O
a	O
slightly	O
hypertrophic	O
LV	O
with	O
preserved	O
EF	O
without	O
clear	O
segmentarism	O
,	O
and	O
the	O
patient	O
was	O
initially	O
referred	O
to	O
STEMI	O
Killip	O
II	O
and	O
started	O
on	O
double	O
antiplatelet	O
therapy	O
and	O
anticoagulation	O
.	O
Cardiology	O
was	O
consulted	O
,	O
and	O
given	O
the	O
possibility	O
of	O
type	O
2	O
AMI	O
secondary	O
to	O
hypertensive	O
crisis	O
and	O
bronchospasm	O
in	O
a	O
patient	O
with	O
cardiovascular	O
risk	O
factors	O
as	O
opposed	O
to	O
type	O
1	O
AMI	O
without	O
clear	O
alterations	O
in	O
the	O
echocardiogram	O
,	O
the	O
patient	O
was	O
referred	O
to	O
Cardiology	O
and	O
it	O
was	O
decided	O
to	O
perform	O
coronary	O
angiography	O
,	O
which	O
showed	O
no	O
coronary	O
lesions	O
.	O
In	O
order	O
to	O
rule	O
out	O
other	O
causes	O
of	O
myocardial	O
necrosis	O
without	O
coronary	O
lesions	O
,	O
cardiac	O
magnetic	O
resonance	O
imaging	O
was	O
requested	O
,	O
which	O
was	O
compatible	O
with	O
normality	O
.	O
Since	O
no	O
evidence	O
was	O
found	O
of	O
transient	O
global	O
or	O
segmental	O
ventricular	O
function	O
impairment	O
,	O
it	O
was	O
decided	O
to	O
withdraw	O
double	O
antiplatelet	O
therapy	O
and	O
the	O
most	O
likely	O
diagnosis	O
was	O
type	O
2	O
myocardial	O
infarction	O
in	O
the	O
context	O
of	O
respiratory	O
infection	O
with	O
severe	O
bronchospasm	O
.	O
After	O
several	O
days	O
of	O
hospitalisation	O
,	O
she	O
was	O
discharged	O
home	O
without	O
incident	O
.	O
DIAGNOSIS	O
Respiratory	O
infection	O
with	O
severe	O
bronchospasm	O
.	O
Type	O
2	O
myocardial	O
infarction	O
.	O
Absence	O
of	O
coronary	O
lesions	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Personal	O
history	O
18	O
year	O
old	O
woman	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
No	O
toxic	O
habits	O
.	O
Cardiological	O
history	O
under	O
follow	O
up	O
in	O
general	O
cardiology	O
consultations	O
for	O
mild	O
mitral	O
insufficiency	O
secondary	O
to	O
mitral	O
prolapse	O
;	O
asymptomatic	O
with	O
preserved	O
biventricular	O
systolic	O
function	O
.	O
G1P1A0	O
.	O
Instrumented	O
delivery	O
vacuum	O
extraction	O
with	O
epidural	O
anaesthesia	O
on	O
23	O
January	O
due	O
to	O
premature	O
rupture	O
of	O
membranes	O
at	O
40	O
.	O
3	O
weeks	O
'	O
gestation	O
.	O
Present	O
illness	O
The	O
18	O
year	O
old	O
patient	O
consulted	O
for	O
two	O
days	O
presenting	O
with	O
erratic	O
episodes	O
of	O
oppressive	O
,	O
non	O
radiating	O
,	O
central	O
thoracic	O
pain	O
lasting	O
15	O
20	O
minutes	O
.	O
No	O
catarrhal	O
or	O
diarrhoeal	O
symptoms	O
in	O
previous	O
days	O
.	O
Under	O
treatment	O
with	O
bromocriptine	B-FARMACO
since	O
27	O
January	O
.	O
Physical	O
examination	O
BP	O
123	O
71	O
.	O
HR	O
77	O
beats	O
per	O
minute	O
.	O
Ta	O
36	O
C	O
.	O
Conscious	O
,	O
oriented	O
,	O
good	O
distal	O
perfusion	O
.	O
Good	O
general	O
condition	O
.	O
Eupneic	O
on	O
room	O
air	O
without	O
supplementary	O
oxygen	O
.	O
Tolerating	O
decubitus	O
.	O
Head	O
and	O
neck	O
No	O
IVY	O
,	O
no	O
negative	O
hepatojugular	O
reflux	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
with	O
a	O
mesosystolic	O
murmur	O
II	O
IV	O
predominantly	O
in	O
the	O
apex	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
,	O
without	O
added	O
phenomena	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
.	O
Extremities	O
no	O
oedema	O
,	O
no	O
evidence	O
of	O
deep	O
vein	O
thrombosis	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
sinus	O
rhythm	O
at	O
82	O
beats	O
per	O
minute	O
.	O
ST	O
elevation	O
in	O
DII	O
,	O
DIII	O
and	O
avF	O
.	O
Specular	O
decrease	O
in	O
V2	O
v3	O
and	O
aVL	O
.	O
Control	O
ECG	O
correction	O
of	O
previously	O
described	O
changes	O
.	O
Blood	O
tests	O
Leukocytes	O
13200	O
N	O
69	O
.	O
4	O
,	O
L	O
22	O
,	O
Hb	O
14	O
.	O
1	O
,	O
platelets	O
349	O
,	O
000	O
.	O
D	O
Dimer	O
106	O
.	O
Urea	O
21	O
.	O
Crreat	O
0	O
.	O
6	O
.	O
Na	O
136	O
.	O
K	O
3	O
.	O
9	O
.	O
Coagulation	O
normal	O
.	O
Markers	O
of	O
myocardial	O
damage	O
1st	O
determination	O
of	O
TnI	O
4	O
.	O
95	O
ng	O
ml	O
.	O
2nd	O
determination	O
12	O
.	O
5	O
ng	O
ml	O
peak	O
normal	O
values	O
less	O
than	O
0	O
.	O
017	O
ng	O
ml	O
Chest	O
X	O
ray	O
no	O
evidence	O
of	O
acute	O
pleuropulmonary	O
pathology	O
.	O
Cardiopericardial	O
silhouette	O
at	O
the	O
limit	O
of	O
normality	O
.	O
TTE	O
non	O
dilated	O
,	O
non	O
hypertrophic	O
left	O
ventricle	O
with	O
preserved	O
global	O
and	O
segmental	O
LVEF	O
.	O
Normal	O
diastolic	O
pattern	O
.	O
Mitral	O
insufficiency	O
due	O
to	O
mild	O
posterior	O
leaflet	O
prolapse	O
.	O
Trivalve	O
aortic	O
valve	O
,	O
without	O
transvalvular	O
gradient	O
or	O
significant	O
insufficiency	O
.	O
Normal	O
right	O
chambers	O
.	O
No	O
tricuspid	O
insufficiency	O
.	O
No	O
pericardial	O
effusion	O
.	O
Inspiratory	O
collapse	O
of	O
superior	O
vena	O
cava	O
50	O
with	O
respiration	O
.	O
Coronary	O
angiography	O
left	O
coronary	O
tree	O
LMCA	O
without	O
angiographically	O
significant	O
lesions	O
.	O
Anterior	O
descending	O
artery	O
without	O
significant	O
lesions	O
.	O
Circumflex	O
without	O
angiographically	O
significant	O
lesions	O
.	O
Right	O
dominance	O
.	O
Right	O
coronary	O
artery	O
without	O
angiographically	O
significant	O
lesions	O
.	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
Coronary	O
Unit	O
with	O
a	O
diagnosis	O
of	O
acute	O
coronary	O
syndrome	O
with	O
transient	O
ST	O
segment	O
elevation	O
suprathreshold	O
is	O
documented	O
in	O
the	O
ECG	O
at	O
the	O
health	O
centre	O
,	O
with	O
correction	O
of	O
changes	O
in	O
the	O
ECG	O
on	O
arrival	O
at	O
our	O
regional	O
hospital	O
and	O
treatment	O
with	O
bromocriptine	B-FARMACO
was	O
suspended	O
.	O
A	O
transthoracic	O
echocardiogram	O
was	O
performed	O
,	O
showing	O
preserved	O
global	O
and	O
segmental	O
left	O
ventricular	O
systolic	O
function	O
,	O
with	O
mitral	O
insufficiency	O
due	O
to	O
mitral	O
prolapse	O
already	O
known	O
.	O
Coronary	O
angiography	O
was	O
performed	O
in	O
the	O
first	O
24	O
hours	O
,	O
according	O
to	O
ESC	O
guidelines	O
recommendations	O
,	O
in	O
which	O
angiographically	O
significant	O
coronary	O
lesions	O
were	O
ruled	O
out	O
.	O
The	O
patient	O
's	O
evolution	O
was	O
favourable	O
,	O
remaining	O
haemodynamically	O
stable	O
,	O
with	O
no	O
arrhythmic	O
or	O
mechanical	O
complications	O
,	O
and	O
asymptomatic	O
from	O
the	O
cardiovascular	O
point	O
of	O
view	O
.	O
DIAGNOSIS	O
Acute	O
coronary	O
syndrome	O
with	O
transient	O
ST	O
segment	O
elevation	O
.	O
Killip	O
1	O
.	O
Coronary	O
vasospasm	O
secondary	O
to	O
bromocriptine	B-FARMACO
.	O
Preserved	O
left	O
ventricular	O
systolic	O
function	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
A	O
52	O
year	O
old	O
female	O
smoker	O
,	O
with	O
no	O
history	O
of	O
hypertension	O
,	O
diabetes	O
mellitus	O
or	O
dyslipidaemia	O
.	O
She	O
was	O
admitted	O
in	O
February	O
2016	O
for	O
a	O
syncopal	O
episode	O
without	O
prodrome	O
with	O
cranioencephalic	O
trauma	O
associated	O
with	O
a	O
baseline	O
ECG	O
without	O
alterations	O
and	O
cranial	O
CT	O
scan	O
showing	O
a	O
small	O
focus	O
of	O
subarachnoid	O
haemorrhage	O
in	O
the	O
left	O
parietal	O
and	O
temporal	O
lobes	O
.	O
In	O
November	O
2016	O
,	O
he	O
was	O
readmitted	O
for	O
sudden	O
recurrent	O
syncope	O
with	O
fracture	O
of	O
the	O
bones	O
of	O
the	O
nose	O
,	O
and	O
an	O
echocardiogram	O
was	O
performed	O
with	O
no	O
abnormalities	O
,	O
an	O
orthostatic	O
test	O
and	O
carotid	O
massage	O
were	O
negative	O
,	O
and	O
a	O
tilt	O
test	O
with	O
mixed	O
response	O
after	O
NTG	B-FARMACO
sl	O
,	O
with	O
dizziness	O
and	O
hypotension	O
with	O
HR	O
40	O
bpm	O
,	O
but	O
without	O
loss	O
of	O
consciousness	O
.	O
It	O
was	O
therefore	O
decided	O
to	O
implant	O
a	O
subcutaneous	O
Holter	O
Reveal	O
LINQ	O
.	O
She	O
came	O
for	O
a	O
Reveal	O
review	O
,	O
after	O
activating	O
it	O
due	O
to	O
an	O
episode	O
of	O
loss	O
of	O
consciousness	O
,	O
while	O
in	O
the	O
washroom	O
preparing	O
to	O
go	O
to	O
work	O
,	O
preceded	O
by	O
a	O
strange	O
,	O
undefined	O
sensation	O
,	O
with	O
a	O
subsequent	O
fall	O
to	O
the	O
floor	O
,	O
with	O
rapid	O
recovery	O
,	O
without	O
sphincter	O
release	O
or	O
tongue	O
biting	O
.	O
Reveal	O
monitoring	O
detected	O
a	O
15	O
second	O
pause	O
with	O
a	O
single	O
wide	O
QRS	O
escape	O
,	O
with	O
no	O
previous	O
tachycardia	O
.	O
The	O
patient	O
was	O
admitted	O
for	O
further	O
investigation	O
.	O
Physical	O
examination	O
showed	O
a	O
good	O
general	O
condition	O
.	O
BP	O
125	O
73	O
mmHg	O
HR	O
65	O
bpm	O
.	O
Sat	O
02	O
96	O
.	O
AC	O
rhythmic	O
heart	O
tones	O
without	O
murmurs	O
.	O
AR	O
MVC	O
,	O
without	O
added	O
aggregates	O
.	O
EEII	O
no	O
oedema	O
.	O
COMPLEMENTARY	O
TESTS	O
CBC	O
urea	O
38	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
63	O
mg	O
dl	O
,	O
Na	O
142	O
mEq	O
L	O
,	O
K	O
3	O
.	O
7	O
mEq	O
l	O
,	O
Hb	O
12	O
.	O
1	O
g	O
dl	O
,	O
leukocytes	O
8	O
,	O
050	O
,	O
platelets	O
309	O
,	O
000	O
,	O
coagulation	O
within	O
normal	O
limits	O
.	O
Electrocardiogram	O
RS	O
at	O
60lpm	O
PR	O
164	O
ms	O
narrow	O
QRS	O
,	O
J	O
point	O
elevation	O
0	O
.	O
5	O
mm	O
V3	O
V6	O
.	O
24	O
hour	O
Holter	O
sinus	O
rhythm	O
throughout	O
the	O
recording	O
at	O
a	O
mean	O
HR	O
of	O
60	O
bpm	O
;	O
maximum	O
of	O
104	O
bpm	O
and	O
minimum	O
of	O
49	O
bpm	O
.	O
Rare	O
isolated	O
supraventricular	O
extrasystoles	O
.	O
No	O
significant	O
pauses	O
,	O
maximum	O
RR	O
1	O
.	O
33	O
seconds	O
.	O
Transthoracic	O
echocardiogram	O
normal	O
.	O
Electrocardiogram	O
after	O
pacemaker	O
implantation	O
atrial	O
and	O
ventricular	O
pacing	O
rhythm	O
.	O
EVOLUTION	O
On	O
the	O
cardiology	O
ward	O
,	O
he	O
was	O
kept	O
under	O
continuous	O
monitoring	O
,	O
24	O
hour	O
Holter	O
with	O
no	O
evidence	O
of	O
new	O
arrhythmic	O
episodes	O
and	O
an	O
echocardiogram	O
within	O
normal	O
limits	O
.	O
The	O
patient	O
was	O
diagnosed	O
with	O
malignant	O
vasovagal	O
syncope	O
and	O
it	O
was	O
decided	O
to	O
implant	O
a	O
DDD	O
pacemaker	O
,	O
without	O
incident	O
,	O
with	O
correct	O
pacing	O
and	O
sensing	O
thresholds	O
.	O
After	O
an	O
adequate	O
evolution	O
,	O
she	O
was	O
discharged	O
home	O
.	O
DIAGNOSIS	O
Malignant	O
vasovagal	O
syncope	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
The	O
patient	O
is	O
a	O
42	O
year	O
old	O
woman	O
with	O
hypertension	O
on	O
treatment	O
with	O
enalapril	B-FARMACO
hydrochlorothiazide	I-FARMACO
20	O
12	O
.	O
5	O
mg	O
day	O
,	O
dyslipidaemia	O
on	O
treatment	O
with	O
atorvastatin	B-FARMACO
20	O
mg	O
day	O
and	O
a	O
former	O
smoker	O
of	O
10	O
packs	O
year	O
.	O
History	O
of	O
systemic	O
lupus	O
erythematosus	O
SLE	O
diagnosed	O
at	O
the	O
age	O
of	O
27	O
following	O
skin	O
and	O
renal	O
involvement	O
,	O
on	O
chronic	O
treatment	O
with	O
low	O
dose	O
prednisone	B-FARMACO
5	O
mg	O
day	O
.	O
Class	O
IIIB	O
lupus	O
nephropathy	O
,	O
with	O
biopsy	O
compatible	O
with	O
segmental	O
and	O
focal	O
glomerulonephritis	O
.	O
Positive	O
antiphospholipid	O
antibodies	O
anti	O
cardiolipin	O
IgG	O
,	O
anti	O
cardiolipin	O
IgM	O
,	O
anti	O
beta	O
2	O
glycoprotein	O
I	O
and	O
lupus	O
anticoagulant	O
positive	O
.	O
No	O
history	O
of	O
thrombosis	O
or	O
obstetric	O
and	O
gynaecological	O
problems	O
.	O
She	O
consulted	O
the	O
emergency	O
department	O
for	O
two	O
days	O
of	O
symptoms	O
consisting	O
of	O
paraesthesia	O
,	O
pain	O
and	O
coldness	O
in	O
the	O
right	O
foot	O
that	O
worsened	O
with	O
supine	O
decubitus	O
and	O
claudication	O
of	O
gait	O
after	O
50	O
m	O
.	O
She	O
also	O
had	O
an	O
episode	O
of	O
dizziness	O
and	O
lightheadedness	O
.	O
In	O
addition	O
,	O
episode	O
of	O
dizziness	O
and	O
sweating	O
without	O
clear	O
chest	O
pain	O
or	O
other	O
symptoms	O
.	O
On	O
examination	O
she	O
was	O
in	O
good	O
general	O
condition	O
.	O
Eupneic	O
.	O
BP	O
115	O
75	O
mmHg	O
,	O
HR	O
75	O
bpm	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
without	O
murmurs	O
or	O
extratonos	O
.	O
Pulmonary	O
auscultation	O
with	O
preserved	O
vesicular	O
murmur	O
.	O
Right	O
lower	O
limb	O
with	O
grade	O
3	O
femoral	O
pulse	O
,	O
grade	O
3	O
popliteal	O
pulse	O
,	O
without	O
distal	O
pulses	O
.	O
Pallor	O
and	O
coldness	O
of	O
the	O
right	O
foot	O
,	O
venocapillary	O
filling	O
very	O
slow	O
compared	O
to	O
the	O
contralateral	O
one	O
.	O
Mobility	O
and	O
sensitivity	O
preserved	O
.	O
Absence	O
of	O
trophic	O
lesions	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
sinus	O
rhythm	O
at	O
91	O
bpm	O
.	O
Normal	O
PR	O
.	O
Narrow	O
QRS	O
,	O
normal	O
axis	O
.	O
Q	O
wave	O
in	O
V1	O
V5	O
with	O
negative	O
T	O
wave	O
in	O
V1	O
V2	O
,	O
flattened	O
in	O
V3	O
V6	O
.	O
Echo	O
Doppler	O
right	O
lower	O
limb	O
occlusion	O
of	O
2nd	O
portion	O
of	O
popliteal	O
artery	O
with	O
recanalisation	O
in	O
posterior	O
tibial	O
.	O
Transthoracic	O
echocardiogram	O
non	O
dilated	O
left	O
ventricle	O
,	O
with	O
normal	O
wall	O
thickness	O
.	O
Apical	O
dyskinesia	O
and	O
akinesia	O
of	O
the	O
distal	O
thirds	O
of	O
all	O
faces	O
;	O
hypokinesia	O
of	O
the	O
middle	O
third	O
of	O
the	O
anterior	O
septum	O
and	O
anterior	O
face	O
.	O
Preserved	O
LVEF	O
Simpson	O
biplane	O
55	O
.	O
Occupation	O
of	O
the	O
apex	O
by	O
a	O
sessile	O
,	O
crescentic	O
mass	O
;	O
first	O
diagnostic	O
possibility	O
intraventricular	O
thrombus	O
.	O
Mitral	O
valve	O
with	O
a	O
rounded	O
mass	O
of	O
approximately	O
1	O
x	O
1	O
cm	O
attached	O
to	O
the	O
atrial	O
side	O
of	O
the	O
posterior	O
annulus	O
and	O
the	O
base	O
of	O
the	O
posterior	O
leaflet	O
,	O
causing	O
a	O
very	O
eccentric	O
insufficiency	O
directed	O
towards	O
the	O
interatrial	O
septum	O
.	O
The	O
right	O
ventricle	O
is	O
not	O
dilated	O
,	O
with	O
normal	O
global	O
systolic	O
function	O
.	O
No	O
other	O
valvular	O
heart	O
disease	O
.	O
No	O
pericardial	O
effusion	O
.	O
Transesophageal	O
echocardiogram	O
mitral	O
valve	O
with	O
thin	O
leaflets	O
,	O
normal	O
opening	O
.	O
A	O
rounded	O
image	O
of	O
homogeneous	O
echogenicity	O
and	O
well	O
defined	O
borders	O
is	O
observed	O
,	O
adhering	O
to	O
the	O
atrial	O
side	O
of	O
the	O
posterior	O
portion	O
of	O
the	O
annulus	O
and	O
the	O
base	O
of	O
the	O
posterior	O
leaflet	O
,	O
at	O
the	O
level	O
of	O
the	O
junction	O
of	O
the	O
P2	O
and	O
P3	O
festoons	O
,	O
with	O
a	O
maximum	O
diameter	O
of	O
1	O
.	O
12	O
cm	O
,	O
indicating	O
II	O
IV	O
insufficiency	O
.	O
Coronary	O
CT	O
scan	O
thrombosed	O
dissection	O
of	O
the	O
middle	O
segment	O
of	O
the	O
anterior	O
descending	O
artery	O
,	O
with	O
involvement	O
of	O
the	O
origin	O
of	O
the	O
second	O
diagonal	O
branch	O
.	O
Left	O
intraventricular	O
thrombus	O
.	O
Coronary	O
angiography	O
right	O
dominance	O
.	O
Disease	O
of	O
a	O
vessel	O
with	O
a	O
long	O
lesion	O
in	O
the	O
middle	O
third	O
of	O
the	O
anterior	O
descending	O
artery	O
compatible	O
with	O
dissection	O
,	O
distal	O
vessel	O
with	O
TIMI	O
3	O
flow	O
.	O
EVOLUTION	O
An	O
initial	O
diagnosis	O
was	O
made	O
of	O
subacute	O
ischaemia	O
of	O
the	O
right	O
lower	O
limb	O
secondary	O
to	O
infrapopliteal	O
thrombosis	O
,	O
which	O
was	O
related	O
to	O
antiphospholipid	O
syndrome	O
.	O
Medical	O
treatment	O
with	O
anticoagulation	O
and	O
prostaglandins	O
was	O
started	O
with	O
a	O
good	O
response	O
.	O
However	O
,	O
the	O
ECG	O
showed	O
anteroseptal	O
QS	O
,	O
which	O
led	O
to	O
a	O
transthoracic	O
echocardiogram	O
with	O
findings	O
of	O
contractility	O
alterations	O
compatible	O
with	O
anterior	O
infarction	O
,	O
apical	O
intraventricular	O
thrombus	O
,	O
and	O
a	O
rounded	O
mass	O
adhered	O
to	O
the	O
mitral	O
valve	O
.	O
A	O
transesophageal	O
echocardiogram	O
with	O
negative	O
blood	O
cultures	O
confirmed	O
the	O
diagnosis	O
of	O
emboligenic	O
Libman	O
Sacks	O
endocarditis	O
.	O
In	O
addition	O
,	O
coronary	O
CT	O
and	O
coronary	O
angiography	O
showed	O
a	O
long	O
lesion	O
in	O
the	O
middle	O
LAD	O
compatible	O
with	O
spontaneous	O
thrombosed	O
coronary	O
artery	O
dissection	O
.	O
The	O
study	O
was	O
completed	O
with	O
a	O
cerebral	O
MRI	O
which	O
showed	O
small	O
ischaemic	O
lacunar	O
lesions	O
in	O
both	O
cerebral	O
hemispheres	O
and	O
an	O
aneurysm	O
located	O
at	O
the	O
left	O
sided	O
internal	O
carotid	O
bifurcation	O
.	O
Aggressive	O
treatment	O
of	O
the	O
SLE	O
flare	O
with	O
methylprednisolone	B-FARMACO
pulses	O
,	O
rituximab	B-FARMACO
,	O
mycophenolate	B-FARMACO
mofetil	I-FARMACO
and	O
hydroxychloroquine	B-FARMACO
sulphate	I-FARMACO
and	O
medical	O
treatment	O
of	O
the	O
thromboses	O
with	O
anticoagulation	O
was	O
performed	O
.	O
Asymptomatic	O
at	O
discharge	O
,	O
treatment	O
was	O
started	O
with	O
low	O
doses	O
of	O
beta	O
blockers	O
.	O
Subsequent	O
follow	O
up	O
showed	O
good	O
evolution	O
LV	O
with	O
preserved	O
systolic	O
function	O
,	O
no	O
new	O
episodes	O
of	O
ischaemia	O
,	O
and	O
resolution	O
of	O
the	O
Libman	O
Sacks	O
endocarditis	O
with	O
disappearance	O
of	O
the	O
mass	O
.	O
DIAGNOSIS	O
Acute	O
flare	O
of	O
systemic	O
lupus	O
erythematosus	O
Emboligenic	O
Libman	O
Sacks	O
endocarditis	O
.	O
Left	O
ventricular	O
thrombus	O
.	O
Subacute	O
infrapopliteal	O
ischaemia	O
of	O
the	O
right	O
lower	O
limb	O
.	O
Spontaneous	O
coronary	O
artery	O
dissection	O
of	O
the	O
anterior	O
descending	O
coronary	O
artery	O
.	O
Evolved	O
anterior	O
myocardial	O
infarction	O
with	O
preserved	O
global	O
ventricular	O
function	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
An	O
8	O
month	O
old	O
infant	O
with	O
no	O
history	O
of	O
interest	O
was	O
referred	O
to	O
the	O
outpatient	O
cardiology	O
department	O
of	O
our	O
centre	O
by	O
her	O
paediatrician	O
after	O
a	O
murmur	O
was	O
found	O
during	O
a	O
check	O
up	O
.	O
No	O
medical	O
treatment	O
,	O
except	O
for	O
the	O
vitamin	B-FARMACO
D	I-FARMACO
supplement	O
indicated	O
by	O
protocol	O
.	O
The	O
mother	O
reported	O
that	O
the	O
patient	O
presented	O
fatigue	O
during	O
feedings	O
.	O
The	O
patient	O
's	O
staturo	O
ponderal	O
development	O
was	O
normal	O
and	O
the	O
examination	O
revealed	O
no	O
cyanosis	O
or	O
respiratory	O
tugging	O
;	O
peripheral	O
pulses	O
were	O
preserved	O
and	O
the	O
presence	O
of	O
a	O
systolic	O
murmur	O
in	O
mitral	O
focus	O
II	O
VI	O
was	O
confirmed	O
.	O
COMPLEMENTARY	O
TESTS	O
The	O
electrocardiogram	O
showed	O
sinus	O
tachycardia	O
at	O
150	O
beats	O
per	O
minute	O
with	O
signs	O
of	O
left	O
chamber	O
enlargement	O
and	O
the	O
consultation	O
echocardiogram	O
showed	O
significant	O
mitral	O
regurgitation	O
MR	O
,	O
and	O
a	O
regular	O
transthoracic	O
echocardiogram	O
TTE	O
was	O
requested	O
.	O
The	O
TTE	O
showed	O
situs	O
solitus	O
,	O
levocardia	O
,	O
atrioventricular	O
and	O
ventricular	O
arterial	O
concordance	O
,	O
with	O
a	O
dilated	O
left	O
ventricle	O
after	O
adjusting	O
for	O
weight	O
and	O
height	O
,	O
with	O
preserved	O
left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
despite	O
mild	O
inferior	O
hypokinesia	O
diastolic	O
diameter	O
DD	O
42	O
mm	O
;	O
systolic	O
diameter	O
SD	O
28	O
mm	O
;	O
LVEF	O
62	O
.	O
The	O
left	O
atrium	O
was	O
very	O
dilated	O
,	O
with	O
bulging	O
of	O
the	O
interatrial	O
septum	O
towards	O
the	O
right	O
atrium	O
and	O
left	O
right	O
shunt	O
through	O
the	O
foramen	O
ovale	O
.	O
We	O
observed	O
massive	O
MR	O
due	O
to	O
lack	O
of	O
mitral	O
leaflet	O
coaptation	O
secondary	O
to	O
posterior	O
leaflet	O
retraction	O
with	O
a	O
significant	O
gap	O
between	O
the	O
two	O
leaflets	O
.	O
In	O
addition	O
,	O
both	O
papillary	O
muscles	O
and	O
the	O
chordae	O
tendineae	O
showed	O
increased	O
echogenicity	O
,	O
suggestive	O
of	O
fibroelastosis	O
.	O
During	O
the	O
study	O
of	O
the	O
pulmonary	O
artery	O
PA	O
we	O
observed	O
a	O
diastolic	O
flow	O
with	O
colour	O
Doppler	O
at	O
this	O
level	O
,	O
together	O
with	O
the	O
presence	O
of	O
multiple	O
intramyocardial	O
diastolic	O
flows	O
both	O
in	O
the	O
right	O
ventricle	O
and	O
at	O
the	O
septal	O
level	O
.	O
Pulmonary	O
systolic	O
pressure	O
was	O
30	O
mmHg	O
.	O
All	O
these	O
findings	O
in	O
the	O
TTE	O
led	O
us	O
to	O
suspect	O
a	O
possible	O
anomalous	O
coronary	O
origin	O
from	O
the	O
PA	O
,	O
and	O
we	O
requested	O
a	O
coronary	O
CT	O
scan	O
.	O
The	O
coronary	O
CT	O
confirmed	O
the	O
suspicion	O
,	O
visualising	O
the	O
left	O
main	O
coronary	O
artery	O
emerging	O
from	O
the	O
PA	O
.	O
EVOLUTION	O
After	O
the	O
diagnosis	O
of	O
ALCAPA	O
Anomalous	O
Left	O
Coronary	O
Artery	O
from	O
the	O
Pulmonary	O
Artery	O
,	O
also	O
called	O
Bland	O
White	O
Garland	O
syndrome	O
,	O
the	O
case	O
was	O
presented	O
at	O
a	O
medical	O
surgical	O
session	O
,	O
and	O
it	O
was	O
decided	O
to	O
intervene	O
by	O
means	O
of	O
coronary	O
reimplantation	O
and	O
repair	O
surgery	O
on	O
the	O
mitral	O
valve	O
,	O
due	O
to	O
the	O
fact	O
that	O
the	O
lesions	O
present	O
in	O
the	O
mitral	O
valve	O
apparatus	O
visualised	O
with	O
TTE	O
suggested	O
little	O
expectation	O
of	O
improvement	O
after	O
isolated	O
coronary	O
reimplantation	O
.	O
The	O
intervention	O
was	O
performed	O
via	O
sternotomy	O
,	O
confirming	O
the	O
exit	O
of	O
the	O
left	O
main	O
coronary	O
artery	O
from	O
the	O
PA	O
.	O
Resection	O
of	O
the	O
left	O
coronary	O
button	O
with	O
anastomosis	O
to	O
the	O
posterior	O
wall	O
of	O
the	O
ascending	O
aorta	O
and	O
closure	O
of	O
the	O
PA	O
was	O
performed	O
.	O
This	O
was	O
followed	O
by	O
mitral	O
plasty	O
with	O
suturing	O
of	O
the	O
anterior	O
commissure	O
to	O
one	O
third	O
of	O
the	O
mitral	O
valve	O
and	O
suturing	O
of	O
the	O
posterior	O
leaflet	O
pseudo	O
cleft	O
,	O
the	O
latter	O
probably	O
because	O
the	O
dilatation	O
of	O
the	O
mitral	O
annulus	O
caused	O
excessive	O
separation	O
of	O
the	O
indentations	O
dividing	O
the	O
different	O
scallops	O
of	O
the	O
posterior	O
leaflet	O
.	O
Postoperative	O
TTE	O
showed	O
a	O
significant	O
reduction	O
in	O
MR	O
,	O
from	O
massive	O
to	O
moderate	O
,	O
and	O
in	O
ventricular	O
diameters	O
Our	O
patient	O
evolved	O
favourably	O
during	O
her	O
admission	O
and	O
was	O
discharged	O
1	O
week	O
later	O
,	O
remaining	O
asymptomatic	O
during	O
follow	O
up	O
.	O
The	O
6	O
month	O
follow	O
up	O
TTE	O
showed	O
a	O
marked	O
improvement	O
from	O
baseline	O
,	O
with	O
a	O
significant	O
reduction	O
in	O
ventricular	O
diameters	O
DD	O
31	O
mm	O
;	O
SD	O
21	O
mm	O
,	O
persistence	O
of	O
a	O
normal	O
LVEF	O
61	O
and	O
reduction	O
in	O
left	O
atrial	O
volume	O
.	O
MR	O
was	O
classified	O
as	O
mild	O
and	O
no	O
significant	O
stenosis	O
was	O
observed	O
after	O
mitral	O
plication	O
mean	O
transmitral	O
gradient	O
of	O
4	O
mmHg	O
.	O
Both	O
PA	O
diastolic	O
flow	O
and	O
intramyocardial	O
flows	O
disappeared	O
,	O
and	O
we	O
found	O
no	O
significant	O
PA	O
gradient	O
.	O
DIAGNOSIS	O
ALCAPA	O
Anomalous	O
Left	O
Coronary	O
Artery	O
from	O
the	O
Pulmonary	O
Artery	O
or	O
Bland	O
White	O
Garland	O
Syndrome	O
.	O
Secondary	O
severe	O
mitral	O
insufficiency	O
.	O
Coronary	O
reimplantation	O
surgery	O
and	O
mitral	O
plasty	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
59	O
year	O
old	O
woman	O
with	O
no	O
cardiovascular	O
risk	O
factors	O
with	O
iatrogenic	O
hypothyroidism	O
following	O
thyroidectomy	O
for	O
thyroid	O
cancer	O
on	O
regular	O
treatment	O
with	O
levothyroxine	B-FARMACO
75	O
mcg	O
per	O
day	O
.	O
She	O
had	O
no	O
notable	O
family	O
history	O
.	O
The	O
patient	O
came	O
to	O
the	O
Emergency	O
Department	O
because	O
she	O
suffered	O
loss	O
of	O
consciousness	O
while	O
talking	O
on	O
the	O
phone	O
with	O
her	O
sister	O
while	O
they	O
were	O
arguing	O
,	O
without	O
prodromes	O
and	O
with	O
spontaneous	O
recovery	O
in	O
a	O
few	O
seconds	O
.	O
She	O
did	O
not	O
report	O
a	O
vegetative	O
cortex	O
and	O
had	O
a	O
similar	O
episode	O
when	O
descending	O
stairs	O
months	O
earlier	O
.	O
She	O
had	O
no	O
dyspnoea	O
,	O
palpitations	O
or	O
chest	O
pain	O
.	O
On	O
physical	O
examination	O
the	O
patient	O
was	O
conscious	O
,	O
oriented	O
,	O
normal	O
colour	O
,	O
eupneic	O
,	O
without	O
jugular	O
engorgement	O
,	O
BP	O
120	O
70	O
mmHg	O
,	O
60	O
beats	O
minute	O
,	O
peripheral	O
O2	O
saturation	O
96	O
at	O
baseline	O
,	O
afebrile	O
.	O
Cardiopulmonary	O
auscultation	O
showed	O
preserved	O
vesicular	O
murmur	O
with	O
rhythmic	O
tones	O
and	O
no	O
murmurs	O
.	O
In	O
the	O
abdomen	O
there	O
were	O
no	O
megaliths	O
or	O
signs	O
of	O
ascitesis	O
and	O
in	O
the	O
lower	O
limbs	O
there	O
was	O
no	O
oedema	O
with	O
preserved	O
distal	O
pulses	O
and	O
no	O
signs	O
of	O
deep	O
thrombosis	O
.	O
The	O
neurological	O
examination	O
was	O
normal	O
.	O
A	O
blood	O
test	O
was	O
performed	O
in	O
the	O
emergency	O
department	O
,	O
which	O
detected	O
mild	O
anaemia	O
with	O
no	O
other	O
notable	O
findings	O
,	O
a	O
portable	O
chest	O
X	O
ray	O
and	O
an	O
electrocardiogram	O
.	O
Based	O
on	O
these	O
data	O
,	O
Cardiology	O
was	O
consulted	O
,	O
and	O
an	O
urgent	O
trathoracic	O
echocardiogram	O
was	O
performed	O
,	O
in	O
which	O
no	O
notable	O
anomalies	O
were	O
observed	O
,	O
and	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
hospital	O
ward	O
with	O
monitoring	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
tests	O
leukocytes	O
11	O
,	O
500	O
mm3	O
,	O
haemoglobin	O
10	O
.	O
57	O
g	O
dl	O
,	O
MCV	O
87	O
mm3	O
,	O
MCH	O
24	O
cell	O
,	O
platelets	O
210	O
,	O
000	O
mm3	O
,	O
normal	O
coagulation	O
,	O
creatinine	O
0	O
.	O
57	O
mg	O
dl	O
,	O
urea	O
34	O
mg	O
dl	O
,	O
glomerular	O
filtration	O
rate	O
98	O
ml	O
min	O
1	O
.	O
73	O
m2	O
,	O
Na	O
138	O
mEq	O
L	O
,	O
K	O
4	O
.	O
1	O
mEq	O
L	O
,	O
Mg	O
2	O
.	O
6	O
,	O
CPK	O
140	O
IU	O
L	O
,	O
troponin	O
I	O
0	O
.	O
04	O
ng	O
ml	O
.	O
Urine	O
toxins	O
were	O
negative	O
and	O
thyroid	O
profile	O
was	O
normal	O
.	O
Portable	O
chest	O
X	O
ray	O
cardiothoracic	O
index	O
not	O
very	O
valuable	O
,	O
without	O
pleural	O
effusion	O
or	O
infiltrates	O
.	O
ECG	O
sinus	O
rhythm	O
at	O
72	O
beats	O
minute	O
,	O
normal	O
axis	O
,	O
normal	O
PR	O
interval	O
and	O
QRS	O
complex	O
and	O
normal	O
QTc	O
interval	O
QRS	O
complex	O
and	O
QTc	O
interval	O
of	O
approximately	O
650	O
ms	O
.	O
Urgent	O
transthoracic	O
echocardiogram	O
non	O
dilated	O
left	O
ventricle	O
with	O
DDVI	O
of	O
40	O
mm	O
without	O
significant	O
hypertrophy	O
,	O
preserved	O
LVEF	O
without	O
segmental	O
alterations	O
of	O
contractility	O
and	O
normal	O
diastolic	O
function	O
with	O
normal	O
diastolic	O
pattern	O
and	O
average	O
E	O
E	O
"	O
of	O
6	O
.	O
5	O
.	O
Mitral	O
valve	O
with	O
preserved	O
structure	O
and	O
function	O
.	O
Absence	O
of	O
atrial	O
dilatation	O
.	O
Non	O
dilated	O
aortic	O
root	O
,	O
normofunctioning	O
trivalve	O
aortic	O
valve	O
.	O
Non	O
dilated	O
right	O
chambers	O
,	O
normal	O
right	O
ventricular	O
systolic	O
function	O
by	O
TAPSE	O
of	O
18	O
,	O
absence	O
of	O
tricuspid	O
insufficiency	O
,	O
non	O
dilated	O
inferior	O
vena	O
cava	O
with	O
inspiratory	O
collapse	O
without	O
pericardial	O
effusion	O
.	O
ECG	O
sinus	O
rhythm	O
with	O
very	O
prolonged	O
QT	O
interval	O
and	O
polymorphic	O
ventricular	O
triplets	O
initiated	O
with	O
"	O
R	O
over	O
T	O
"	O
phenomenon	O
.	O
Telemetry	O
tracing	O
with	O
torsades	O
de	O
pointes	O
and	O
cardioversion	O
at	O
100	O
joules	O
.	O
Chest	O
X	O
ray	O
with	O
bicameral	O
implantable	O
cardioverter	O
defibrillator	O
with	O
normal	O
electrode	O
placement	O
.	O
ECG	O
atrial	O
paced	O
rhythm	O
at	O
70	O
beats	O
minute	O
.	O
There	O
was	O
a	O
reduction	O
in	O
the	O
QT	O
interval	O
with	O
respect	O
to	O
the	O
initial	O
ECG	O
after	O
optimising	O
treatment	O
with	O
beta	O
blockers	O
.	O
EVOLUTION	O
On	O
the	O
Cardiology	O
hospital	O
ward	O
,	O
the	O
patient	O
presented	O
with	O
polymorphic	O
ventricular	O
extrasystoles	O
and	O
non	O
sustained	O
polymorphic	O
ventricular	O
tachycardias	O
PSVT	O
.	O
Given	O
these	O
findings	O
,	O
with	O
a	O
baseline	O
sinus	O
rhythm	O
rate	O
of	O
65	O
bpm	O
,	O
intravenous	O
magnesium	B-FARMACO
was	O
administered	O
and	O
,	O
in	O
the	O
absence	O
of	O
improvement	O
,	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
Coronary	O
Care	O
Unit	O
.	O
Despite	O
the	O
initial	O
measures	O
,	O
the	O
patient	O
developed	O
sustained	O
ventricular	O
tachycardia	O
of	O
the	O
torsades	O
de	O
pointes	O
type	O
,	O
with	O
loss	O
of	O
consciousness	O
,	O
and	O
cardioversion	O
at	O
100	O
joules	O
was	O
performed	O
,	O
which	O
was	O
effective	O
.	O
However	O
,	O
she	O
presented	O
again	O
with	O
non	O
sustained	O
DVT	O
,	O
so	O
it	O
was	O
decided	O
to	O
perform	O
sedation	O
.	O
The	O
patient	O
showed	O
signs	O
of	O
respiratory	O
distress	O
,	O
arterial	O
hypertension	O
and	O
finally	O
required	O
deep	O
sedoanalgesia	O
and	O
orotracheal	O
intubation	O
.	O
Beta	O
blockers	O
were	O
started	O
and	O
haemodynamic	O
and	O
arrhythmic	O
stabilisation	O
was	O
achieved	O
,	O
although	O
these	O
drugs	O
were	O
titrated	O
to	O
low	O
doses	O
as	O
the	O
patient	O
presented	O
sinus	O
bradycardia	O
.	O
An	O
analytical	O
study	O
was	O
completed	O
with	O
detection	O
of	O
toxins	O
in	O
urine	O
,	O
which	O
was	O
negative	O
,	O
and	O
a	O
thyroid	O
profile	O
showed	O
no	O
alterations	O
,	O
and	O
the	O
use	O
of	O
drugs	O
that	O
could	O
prolong	O
the	O
QT	O
interval	O
was	O
ruled	O
out	O
.	O
Given	O
the	O
presence	O
of	O
probable	O
congenital	O
long	O
QT	O
syndrome	O
and	O
cardiorespiratory	O
arrest	O
resuscitated	O
by	O
sustained	O
DVT	O
,	O
it	O
was	O
decided	O
to	O
implant	O
a	O
bicameral	O
endovascular	O
automatic	O
defibrillator	O
,	O
which	O
was	O
carried	O
out	O
without	O
incident	O
,	O
and	O
the	O
patient	O
was	O
subsequently	O
transferred	O
to	O
the	O
cardiology	O
ward	O
where	O
the	O
dose	O
of	O
beta	O
blocker	O
was	O
increased	O
to	O
bisoprolol	B-FARMACO
5	O
mg	O
every	O
8	O
hours	O
and	O
blood	O
tests	O
were	O
taken	O
for	O
genetic	O
study	O
.	O
This	O
detected	O
a	O
mutation	O
in	O
the	O
KCNQ1	O
gene	O
in	O
heterozygosis	O
associated	O
with	O
the	O
development	O
of	O
long	O
QT	O
syndrome	O
type	O
1	O
with	O
an	O
autosomal	O
dominant	O
pattern	O
of	O
inheritance	O
,	O
and	O
a	O
family	O
study	O
was	O
performed	O
.	O
DIAGNOSIS	O
Long	O
QT	O
syndrome	O
type	O
1	O
.	O
Pathogenic	O
mutation	O
in	O
the	O
KCNQ1	O
gene	O
.	O
Recurrent	O
syncope	O
.	O
Cardiac	O
arrest	O
resuscitated	O
by	O
PSVT	O
.	O
Absence	O
of	O
significant	O
structural	O
heart	O
disease	O
.	O
Implantation	O
of	O
DR	O
ICD	O
in	O
secondary	O
prevention	O
.	O

HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
A	O
55	O
year	O
old	O
woman	O
,	O
asymptomatic	O
from	O
the	O
cardiovascular	O
point	O
of	O
view	O
to	O
date	O
,	O
suddenly	O
started	O
with	O
oppressive	O
chest	O
pain	O
radiating	O
to	O
the	O
left	O
upper	O
limb	O
.	O
The	O
medical	O
history	O
of	O
interest	O
included	O
the	O
presence	O
of	O
arterial	O
hypertension	O
,	O
hypercholesterolemia	O
and	O
type	O
2	O
diabetes	O
mellitus	O
,	O
all	O
of	O
them	O
under	O
medical	O
treatment	O
with	O
telmisartan	B-FARMACO
80	O
mg	O
24	O
h	O
,	O
atorvastatin	B-FARMACO
20	O
mg	O
24	O
h	O
and	O
metformin	B-FARMACO
850	O
mg	O
24	O
h	O
,	O
respectively	O
.	O
One	O
year	O
earlier	O
,	O
during	O
a	O
periodic	O
company	O
check	O
up	O
,	O
an	O
incidental	O
LBBB	O
of	O
the	O
His	O
bundle	O
had	O
been	O
observed	O
,	O
and	O
for	O
this	O
reason	O
a	O
transthoracic	O
cardiac	O
ultrasound	O
had	O
been	O
performed	O
,	O
with	O
no	O
pathological	O
findings	O
.	O
The	O
patient	O
was	O
a	O
non	O
smoker	O
,	O
had	O
no	O
family	O
history	O
of	O
early	O
ischaemic	O
heart	O
disease	O
and	O
had	O
never	O
undergone	O
surgery	O
or	O
any	O
other	O
medical	O
condition	O
under	O
treatment	O
.	O
Within	O
30	O
minutes	O
of	O
the	O
onset	O
of	O
the	O
symptoms	O
,	O
which	O
had	O
been	O
preceded	O
by	O
a	O
heated	O
discussion	O
,	O
the	O
Emergency	O
Services	O
were	O
notified	O
and	O
,	O
after	O
observing	O
the	O
presence	O
of	O
an	O
LBBB	O
in	O
the	O
ECG	O
,	O
they	O
activated	O
the	O
Infarction	O
Code	O
.	O
He	O
was	O
transferred	O
urgently	O
to	O
our	O
hospital	O
tertiary	O
level	O
for	O
primary	O
angioplasty	O
.	O
On	O
arrival	O
,	O
the	O
chest	O
pain	O
had	O
disappeared	O
,	O
the	O
blood	O
pressure	O
was	O
133	O
70	O
mmHg	O
and	O
the	O
heart	O
rate	O
was	O
70	O
beats	O
per	O
minute	O
,	O
with	O
no	O
evidence	O
of	O
heart	O
failure	O
on	O
physical	O
examination	O
.	O
COMPLEMENTARY	O
TESTS	O
At	O
the	O
urgent	O
coronary	O
angiography	O
,	O
it	O
was	O
decided	O
to	O
first	O
catheterise	O
the	O
right	O
coronary	O
artery	O
with	O
a	O
JR4	O
diagnostic	O
catheter	O
,	O
with	O
no	O
evidence	O
of	O
atheromatous	O
lesions	O
.	O
The	O
left	O
coronary	O
artery	O
was	O
then	O
catheterised	O
with	O
an	O
EBU3	O
.	O
5	O
guide	O
catheter	O
,	O
revealing	O
an	O
anterior	O
descending	O
artery	O
without	O
lesions	O
,	O
as	O
well	O
as	O
a	O
fine	O
,	O
diffuse	O
and	O
progressive	O
narrowing	O
of	O
the	O
first	O
obtuse	O
marginal	O
branch	O
OM1	O
;	O
the	O
only	O
branch	O
of	O
the	O
circumflex	O
territory	O
;	O
involving	O
the	O
two	O
branches	O
into	O
which	O
the	O
artery	O
subsequently	O
bifurcated	O
.	O
Despite	O
the	O
lesion	O
being	O
practically	O
subocclusive	O
at	O
the	O
distal	O
level	O
of	O
the	O
first	O
branch	O
,	O
flow	O
was	O
preserved	O
in	O
both	O
branches	O
TIMI	O
III	O
.	O
To	O
further	O
diagnose	O
the	O
pathology	O
underlying	O
the	O
coronary	O
finding	O
,	O
it	O
was	O
decided	O
to	O
analyse	O
the	O
vessel	O
with	O
an	O
intracoronary	O
imaging	O
technique	O
,	O
the	O
interventional	O
cardiologist	O
opting	O
for	O
optical	O
coherence	O
tomography	O
OCT	O
given	O
its	O
higher	O
spatial	O
resolution	O
.	O
After	O
probing	O
OM1	O
with	O
two	O
angioplasty	O
guides	O
,	O
progressing	O
the	O
OCT	O
monorail	O
,	O
and	O
analysing	O
the	O
withdrawn	O
artery	O
together	O
with	O
the	O
administration	O
of	O
16	O
cc	O
of	O
iodinated	O
contrast	O
,	O
a	O
clear	O
progression	O
of	O
the	O
lumen	O
involvement	O
was	O
evidenced	O
,	O
reaching	O
the	O
circumflex	O
ostium	O
.	O
Despite	O
this	O
,	O
the	O
patient	O
remained	O
asymptomatic	O
,	O
with	O
distal	O
TIMI	O
III	O
flow	O
in	O
all	O
branches	O
,	O
and	O
with	O
the	O
coronary	O
trunk	O
intact	O
.	O
During	O
her	O
hospital	O
admission	O
,	O
a	O
clear	O
ultrasensitive	O
troponin	O
T	O
curve	O
was	O
observed	O
242	O
ng	O
ml	O
to	O
1	O
,	O
860	O
ng	O
ml	O
to	O
1	O
,	O
691	O
ng	O
ml	O
to	O
800	O
ng	O
ml	O
,	O
as	O
well	O
as	O
a	O
reasonably	O
controlled	O
lipid	O
profile	O
triglycerides	O
213	O
mg	O
dl	O
,	O
total	O
cholesterol	O
217	O
mg	O
dl	O
,	O
HDL	O
34	O
mg	O
dl	O
,	O
LDL	O
140	O
mg	O
dl	O
.	O
Hba1C	O
6	O
.	O
7	O
.	O
The	O
rest	O
of	O
the	O
blood	O
tests	O
and	O
chest	O
X	O
ray	O
were	O
unremarkable	O
.	O
Transthoracic	O
echocardiography	O
showed	O
significant	O
akinesia	O
of	O
the	O
OM1	O
dependent	O
territory	O
,	O
with	O
a	O
left	O
ventricular	O
ejection	O
fraction	O
of	O
40	O
,	O
without	O
other	O
pathological	O
findings	O
.	O
In	O
this	O
sense	O
,	O
the	O
study	O
of	O
myocardial	O
function	O
and	O
its	O
possible	O
sequelae	O
was	O
extended	O
with	O
cardiac	O
magnetic	O
resonance	O
imaging	O
,	O
which	O
corroborated	O
the	O
presence	O
of	O
mild	O
ventricular	O
dysfunction	O
,	O
as	O
well	O
as	O
the	O
presence	O
of	O
late	O
gadolinium	O
enhancement	O
of	O
50	O
of	O
the	O
myocardial	O
thickness	O
in	O
lateral	O
and	O
lateral	O
inferior	O
aspect	O
.	O
EVOLUTION	O
Given	O
the	O
angiographic	O
and	O
OCT	O
features	O
of	O
the	O
coronary	O
artery	O
disease	O
,	O
and	O
the	O
fact	O
that	O
the	O
patient	O
was	O
haemodynamically	O
stable	O
and	O
pain	O
free	O
,	O
it	O
was	O
decided	O
to	O
opt	O
for	O
strictly	O
conservative	O
medical	O
management	O
.	O
Since	O
the	O
patient	O
did	O
not	O
develop	O
new	O
symptoms	O
of	O
ischaemia	O
,	O
and	O
after	O
having	O
tolerated	O
starting	O
carvedilol	B-FARMACO
6	O
.	O
25	O
mg	O
12	O
h	O
together	O
with	O
dual	O
antiplatelet	O
therapy	O
ASA	B-FARMACO
and	O
clopidogrel	B-FARMACO
and	O
the	O
previous	O
dose	O
of	O
ARA	O
II	O
,	O
the	O
patient	O
was	O
discharged	O
5	O
days	O
after	O
admission	O
.	O
Subsequent	O
outpatient	O
follow	O
up	O
1	O
year	O
showed	O
no	O
new	O
coronary	O
events	O
,	O
and	O
the	O
patient	O
is	O
in	O
NYHA	O
functional	O
class	O
I	O
IV	O
and	O
without	O
exertional	O
angina	O
.	O
DIAGNOSIS	O
Acute	O
coronary	O
syndrome	O
in	O
the	O
presence	O
of	O
left	O
bundle	O
branch	O
block	O
.	O
HYPERTENSION	O
.	O
Dyslipidaemia	O
.	O
Type	O
2	O
diabetes	O
mellitus	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Patient	O
aged	O
22	O
years	O
,	O
with	O
no	O
known	O
pharmacological	O
allergies	O
and	O
no	O
medical	O
or	O
surgical	O
history	O
.	O
No	O
family	O
history	O
of	O
heart	O
disease	O
or	O
history	O
of	O
sudden	O
death	O
in	O
the	O
family	O
.	O
Habitual	O
sportsman	O
.	O
No	O
toxic	O
habits	O
.	O
Current	O
illness	O
The	O
patient	O
came	O
to	O
the	O
hospital	O
to	O
have	O
his	O
teeth	O
extracted	O
by	O
means	O
of	O
a	O
scheduled	O
operation	O
in	O
the	O
maxillofacial	O
operating	O
theatre	O
for	O
outpatient	O
surgery	O
.	O
He	O
had	O
been	O
previously	O
assessed	O
by	O
anaesthesia	O
preoperatively	O
,	O
with	O
normal	O
physical	O
examination	O
,	O
blood	O
tests	O
without	O
alterations	O
and	O
ASA	O
I	O
evaluation	O
.	O
No	O
baseline	O
electrocardiogram	O
ECG	O
was	O
performed	O
due	O
to	O
his	O
age	O
,	O
in	O
accordance	O
with	O
hospital	O
protocol	O
.	O
During	O
this	O
procedure	O
,	O
the	O
patient	O
presented	O
with	O
a	O
heart	O
rate	O
of	O
around	O
45	O
50	O
beats	O
per	O
minute	O
,	O
and	O
given	O
that	O
this	O
was	O
interpreted	O
as	O
bradycardia	O
,	O
prior	O
to	O
anaesthetic	O
induction	O
,	O
0	O
.	O
5	O
mg	O
of	O
atropine	B-FARMACO
was	O
administered	O
as	O
an	O
intravenous	O
bolus	O
.	O
The	O
patient	O
then	O
presented	O
with	O
symptoms	O
of	O
precordial	O
pressure	O
,	O
palpitations	O
and	O
profuse	O
diaphoresis	O
,	O
and	O
the	O
monitor	O
recorded	O
a	O
rhythmic	O
tachycardia	O
with	O
wide	O
QRS	O
at	O
150	O
160	O
beats	O
per	O
minute	O
,	O
compatible	O
with	O
sustained	O
ventricular	O
tachycardia	O
lasting	O
one	O
minute	O
,	O
with	O
spontaneous	O
transition	O
to	O
sinus	O
rhythm	O
.	O
A	O
bolus	O
of	O
200	O
mg	O
amiodarone	B-FARMACO
was	O
administered	O
without	O
further	O
episodes	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
110	O
50	O
mmHg	O
.	O
Heart	O
rate	O
75	O
bpm	O
.	O
O2	O
saturation	O
100	O
FiO2	O
0	O
.	O
21	O
.	O
Conscious	O
,	O
oriented	O
,	O
normal	O
colour	O
,	O
normohydrated	O
,	O
good	O
distal	O
perfusion	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
without	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
normal	O
vesicular	O
murmur	O
.	O
Abdomen	O
was	O
nondescript	O
.	O
Extremities	O
without	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
operating	O
room	O
sinus	O
rhythm	O
at	O
80	O
bpm	O
.	O
PR	O
0	O
.	O
180	O
msec	O
.	O
Narrow	O
QRS	O
.	O
ST	O
segment	O
depression	O
in	O
V3	O
V5	O
and	O
in	O
III	O
and	O
avF	O
with	O
negative	O
T	O
waves	O
in	O
these	O
same	O
leads	O
.	O
ECG	O
Emergency	O
sinus	O
rhythm	O
at	O
74	O
bpm	O
,	O
variable	O
PR	O
between	O
0	O
.	O
08	O
0	O
.	O
10	O
and	O
occasionally	O
retroconducted	O
P	O
wave	O
,	O
some	O
nodal	O
beats	O
.	O
Blood	O
tests	O
troponin	O
I	O
0	O
.	O
22	O
mg	O
ml	O
.	O
Myoglobin	O
66	O
.	O
Serialisation	O
troponin	O
I	O
2	O
.	O
56	O
.	O
Myoglobin	O
22	O
.	O
Haemogram	O
without	O
alterations	O
Hb	O
15	O
.	O
8	O
g	O
dl	O
.	O
Renal	O
function	O
and	O
ions	O
normal	O
.	O
Hepatic	O
profile	O
without	O
alterations	O
.	O
Cholesterol	O
182	O
mg	O
dl	O
.	O
Transthoracic	O
echocardiogram	O
LV	O
of	O
normal	O
size	O
and	O
wall	O
thickness	O
,	O
with	O
hypertrophy	O
of	O
both	O
papillary	O
muscles	O
.	O
Global	O
LV	O
systolic	O
function	O
normal	O
,	O
without	O
segmental	O
asymmetries	O
of	O
contractility	O
.	O
Diastolic	O
pattern	O
normal	O
.	O
Left	O
atrium	O
of	O
normal	O
dimensions	O
.	O
Right	O
chambers	O
of	O
normal	O
dimensions	O
;	O
RV	O
normocontractile	O
.	O
Aortic	O
root	O
and	O
visualized	O
portion	O
of	O
proximal	O
ascending	O
aorta	O
of	O
normal	O
dimensions	O
.	O
MV	O
thin	O
leaflets	O
,	O
not	O
limited	O
in	O
its	O
opening	O
,	O
competent	O
.	O
VAo	O
trivalve	O
,	O
normal	O
sigmoids	O
,	O
not	O
limited	O
in	O
its	O
opening	O
,	O
competent	O
.	O
IT	O
minimal	O
.	O
IVC	O
not	O
dilated	O
with	O
normal	O
inspiratory	O
collapse	O
.	O
Estimated	O
normal	O
PAPs	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
and	O
intracavitary	O
masses	O
through	O
this	O
access	O
route	O
.	O
Cardiac	O
MRI	O
left	O
ventricle	O
at	O
the	O
high	O
limit	O
of	O
normality	O
DTD	O
56	O
mm	O
,	O
with	O
normal	O
systolic	O
function	O
.	O
No	O
hypertrophy	O
or	O
focal	O
areas	O
of	O
late	O
enhancement	O
indicating	O
fibrosis	O
.	O
Mild	O
RV	O
dilatation	O
with	O
normal	O
EF	O
.	O
Non	O
dilated	O
atria	O
.	O
Minimal	O
MI	O
.	O
Mild	O
TR	O
.	O
Coronary	O
angioCT	O
coronary	O
arteries	O
with	O
normal	O
anatomical	O
origin	O
.	O
No	O
lesions	O
in	O
epicardial	O
coronary	O
arteries	O
.	O
EVOLUTION	O
After	O
the	O
episode	O
of	O
self	O
limited	O
ventricular	O
tachycardia	O
,	O
a	O
12	O
lead	O
ECG	O
was	O
performed	O
showing	O
repolarisation	O
alterations	O
suggestive	O
of	O
myocardial	O
ischaemia	O
on	O
the	O
anteroseptal	O
side	O
with	O
subsequent	O
normalisation	O
,	O
although	O
showing	O
competition	O
between	O
sinus	O
rhythm	O
and	O
nodal	O
rhythm	O
.	O
Since	O
the	O
patient	O
had	O
presented	O
with	O
clinical	O
signs	O
of	O
precordial	O
tightness	O
together	O
with	O
the	O
ECG	O
findings	O
described	O
,	O
it	O
was	O
initially	O
treated	O
as	O
an	O
acute	O
coronary	O
syndrome	O
and	O
enzyme	O
serology	O
was	O
performed	O
with	O
peak	O
troponin	O
I	O
of	O
2	O
.	O
56	O
ng	O
dl	O
.	O
Beta	O
blockers	O
bisoprolol	B-FARMACO
were	O
started	O
at	O
low	O
doses	O
.	O
Subsequently	O
,	O
the	O
patient	O
remained	O
asymptomatic	O
with	O
no	O
new	O
episodes	O
of	O
angina	O
,	O
arrhythmias	O
or	O
electrical	O
changes	O
in	O
the	O
electrocardiogram	O
.	O
Given	O
the	O
patient	O
's	O
clinical	O
manifestations	O
compatible	O
with	O
ventricular	O
arrhythmia	O
secondary	O
to	O
a	O
probable	O
acute	O
coronary	O
event	O
,	O
it	O
was	O
decided	O
to	O
admit	O
the	O
patient	O
for	O
further	O
study	O
.	O
Echocardiography	O
and	O
cardiac	O
MRI	O
were	O
requested	O
to	O
rule	O
out	O
underlying	O
cardiomyopathy	O
,	O
as	O
well	O
as	O
coronary	O
angioCT	O
to	O
rule	O
out	O
coronary	O
artery	O
disease	O
.	O
These	O
tests	O
ruled	O
out	O
structural	O
heart	O
disease	O
.	O
The	O
case	O
was	O
discussed	O
with	O
the	O
arrhythmia	O
unit	O
,	O
which	O
performed	O
an	O
electrophysiological	O
study	O
that	O
was	O
negative	O
for	O
induction	O
of	O
ventricular	O
arrhythmias	O
or	O
reentrant	O
arrhythmias	O
and	O
no	O
evidence	O
of	O
accessory	O
pathways	O
.	O
After	O
ruling	O
out	O
structural	O
heart	O
disease	O
and	O
induction	O
of	O
arrhythmias	O
in	O
the	O
electrophysiological	O
study	O
,	O
it	O
was	O
concluded	O
that	O
the	O
ventricular	O
tachycardia	O
presented	O
was	O
secondary	O
to	O
a	O
probable	O
coronary	O
ischaemic	O
event	O
the	O
patient	O
presented	O
chest	O
tightness	O
with	O
associated	O
vegetative	O
symptoms	O
,	O
clear	O
alterations	O
in	O
the	O
ECG	O
and	O
increased	O
markers	O
of	O
myocardial	O
damage	O
.	O
The	O
ECG	O
alterations	O
described	O
and	O
the	O
elevation	O
of	O
markers	O
of	O
myocardial	O
damage	O
would	O
not	O
be	O
secondary	O
to	O
the	O
ventricular	O
tachycardia	O
as	O
it	O
was	O
of	O
very	O
short	O
duration	O
.	O
Therefore	O
,	O
we	O
believe	O
that	O
the	O
ventricular	O
tachycardia	O
was	O
the	O
secondary	O
event	O
to	O
myocardial	O
ischaemia	O
.	O
Given	O
that	O
the	O
angioCT	O
findings	O
ruled	O
out	O
any	O
structural	O
abnormality	O
that	O
could	O
cause	O
ischaemia	O
,	O
the	O
presence	O
of	O
coronary	O
vasospasm	O
triggered	O
by	O
a	O
sudden	O
change	O
in	O
heart	O
rate	O
in	O
the	O
context	O
of	O
intravenous	O
administration	O
of	O
atropine	B-FARMACO
was	O
proposed	O
as	O
the	O
first	O
diagnostic	O
probability	O
.	O
Since	O
the	O
patient	O
had	O
no	O
cardiovascular	O
risk	O
factors	O
and	O
no	O
clinical	O
history	O
of	O
angina	O
,	O
it	O
was	O
not	O
considered	O
necessary	O
to	O
perform	O
coronary	O
vasospasm	O
provocation	O
studies	O
.	O
Medical	O
treatment	O
with	O
calcium	O
antagonists	O
was	O
not	O
initiated	O
as	O
a	O
clear	O
trigger	O
for	O
the	O
episode	O
was	O
identified	O
.	O
The	O
beta	O
blockers	O
that	O
had	O
been	O
started	O
were	O
withdrawn	O
as	O
they	O
have	O
been	O
described	O
as	O
a	O
possible	O
trigger	O
for	O
coronary	O
vasospasm	O
.	O
With	O
the	O
results	O
of	O
the	O
complementary	O
tests	O
and	O
the	O
good	O
prognosis	O
of	O
the	O
same	O
,	O
and	O
with	O
a	O
diagnosis	O
of	O
ventricular	O
tachycardia	O
in	O
the	O
context	O
of	O
probable	O
coronary	O
vasospasm	O
secondary	O
to	O
the	O
administration	O
of	O
intravenous	O
atropine	B-FARMACO
,	O
hospital	O
discharge	O
was	O
decided	O
for	O
outpatient	O
monitoring	O
without	O
initiating	O
any	O
pharmacological	O
treatment	O
for	O
the	O
time	O
being	O
.	O
DIAGNOSIS	O
Ventricular	O
tachycardia	O
secondary	O
to	O
vasospasm	O
due	O
to	O
atropine	B-FARMACO
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
No	O
known	O
drug	O
allergies	O
.	O
Marfan	O
's	O
syndrome	O
.	O
Subluxation	O
of	O
the	O
crystalline	O
lens	O
.	O
Dural	O
ectasia	O
.	O
Family	O
history	O
of	O
Marfan	O
syndrome	O
in	O
father	O
and	O
paternal	O
grandfather	O
.	O
In	O
2006	O
,	O
she	O
underwent	O
surgery	O
for	O
dilatation	O
of	O
the	O
ascending	O
aorta	O
with	O
involvement	O
of	O
the	O
sinuses	O
of	O
Valsalva	O
using	O
the	O
David	O
technique	O
,	O
with	O
preservation	O
of	O
the	O
native	O
aortic	O
valve	O
.	O
Hyperparathyroidism	O
secondary	O
to	O
vitamin	O
D	O
deficiency	O
.	O
Hypercalciuria	O
.	O
Osteopenia	O
.	O
One	O
term	O
delivery	O
vaginal	O
delivery	O
with	O
vacuum	O
extraction	O
in	O
2011	O
.	O
Usual	O
treatment	O
currently	O
on	O
treatment	O
with	O
ASA	B-FARMACO
100	O
mg	O
and	O
labetalol	B-FARMACO
atenolol	I-FARMACO
had	O
been	O
substituted	O
for	O
labetalol	B-FARMACO
during	O
the	O
previous	O
pregnancy	O
.	O
Present	O
illness	O
Patient	O
aged	O
36	O
years	O
,	O
10	O
weeks	O
pregnant	O
and	O
operated	O
10	O
years	O
ago	O
for	O
aortic	O
root	O
aneurysm	O
,	O
referred	O
to	O
an	O
outpatient	O
cardiologist	O
for	O
advice	O
and	O
risk	O
assessment	O
.	O
Physical	O
examination	O
BP	O
109	O
73	O
mmHg	O
;	O
HR	O
90	O
bpm	O
.	O
Conscious	O
and	O
oriented	O
.	O
Well	O
hydrated	O
and	O
perfused	O
,	O
with	O
good	O
skin	O
and	O
mucous	O
membrane	O
colouring	O
.	O
Eupneic	O
.	O
Marfanoid	O
habitus	O
.	O
Head	O
and	O
neck	O
no	O
jugular	O
ingurgitation	O
.	O
No	O
nuchal	O
rigidity	O
or	O
meningeal	O
signs	O
.	O
No	O
carotid	O
murmurs	O
.	O
Chest	O
mid	O
thoracotomy	O
scar	O
.	O
Rhythmic	O
cardiac	O
auscultation	O
with	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
.	O
Abdomen	O
globular	O
,	O
soft	O
and	O
depressible	O
,	O
without	O
pain	O
on	O
palpation	O
or	O
peritonism	O
.	O
No	O
masses	O
or	O
visceromegaly	O
were	O
palpable	O
.	O
No	O
murmurs	O
were	O
heard	O
Lower	O
extremities	O
no	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
Peripheral	O
pulses	O
were	O
preserved	O
.	O
COMPLEMENTARY	O
TESTS	O
Echocardiogram	O
native	O
aortic	O
valve	O
with	O
three	O
thin	O
leaflets	O
with	O
normal	O
opening	O
and	O
no	O
functional	O
alteration	O
.	O
A	O
rigid	O
structure	O
is	O
identified	O
above	O
the	O
valvular	O
plane	O
with	O
a	O
2D	O
internal	O
diameter	O
of	O
35	O
mm	O
.	O
Aortic	O
sagging	O
visualised	O
in	O
the	O
suprasternal	O
recess	O
,	O
30	O
mm	O
.	O
Discrete	O
image	O
of	O
mild	O
anterior	O
leaflet	O
prolapse	O
without	O
fulfilling	O
strict	O
criteria	O
,	O
with	O
trivial	O
MR	O
.	O
Left	O
ventricle	O
neither	O
dilated	O
nor	O
hypertrophic	O
,	O
with	O
good	O
global	O
systolic	O
function	O
and	O
no	O
alterations	O
in	O
segmental	O
contractility	O
.	O
Type	O
I	O
diastolic	O
pattern	O
.	O
Non	O
dilated	O
right	O
chambers	O
with	O
mild	O
TR	O
and	O
systolic	O
gradient	O
of	O
12	O
mmHg	O
.	O
Pulmonary	O
normotension	O
.	O
MRI	O
mild	O
dilatation	O
of	O
descending	O
thoracic	O
aorta	O
and	O
right	O
common	O
iliac	O
aorta	O
,	O
in	O
a	O
stable	O
situation	O
.	O
EVOLUTION	O
The	O
patient	O
was	O
referred	O
to	O
the	O
Genetics	O
Department	O
,	O
where	O
she	O
was	O
informed	O
of	O
a	O
50	O
probability	O
of	O
transmission	O
,	O
as	O
well	O
as	O
the	O
phenotypic	O
variability	O
and	O
the	O
availability	O
of	O
a	O
prenatal	O
diagnostic	O
test	O
.	O
A	O
molecular	O
study	O
was	O
performed	O
,	O
which	O
was	O
found	O
to	O
be	O
normal	O
,	O
so	O
prenatal	O
diagnosis	O
was	O
not	O
possible	O
in	O
her	O
case	O
.	O
In	O
conjunction	O
with	O
cardiac	O
surgery	O
,	O
discontinuation	O
of	O
ASA	B-FARMACO
and	O
treatment	O
with	O
labetalol	B-FARMACO
50	O
mg	O
was	O
recommended	O
.	O
The	O
patient	O
is	O
being	O
monitored	O
by	O
a	O
High	O
Risk	O
Pregnancy	O
Unit	O
.	O
DIAGNOSIS	O
Pregnant	O
woman	O
with	O
Marfan	O
syndrome	O
with	O
dilatation	O
of	O
the	O
ascending	O
aorta	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Personal	O
history	O
52	O
year	O
old	O
patient	O
with	O
the	O
following	O
personal	O
pathological	O
history	O
smoker	O
of	O
1	O
2	O
pack	O
of	O
cigarettes	O
day	O
,	O
dyslipidaemia	O
under	O
treatment	O
with	O
statins	O
,	O
no	O
diabetes	O
mellitus	O
or	O
arterial	O
hypertension	O
.	O
Current	O
illness	O
The	O
patient	O
consults	O
for	O
approximately	O
1	O
2	O
months	O
for	O
episodes	O
of	O
chest	O
pain	O
that	O
usually	O
appear	O
at	O
rest	O
and	O
at	O
night	O
,	O
but	O
sometimes	O
appear	O
after	O
heavy	O
physical	O
exertion	O
.	O
He	O
refers	O
to	O
the	O
pain	O
as	O
oppressive	O
,	O
radiating	O
to	O
the	O
left	O
arm	O
and	O
jaw	O
,	O
with	O
no	O
accompanying	O
vegetative	O
cortex	O
;	O
the	O
duration	O
of	O
the	O
episodes	O
is	O
usually	O
a	O
maximum	O
of	O
10	O
15	O
minutes	O
and	O
they	O
subside	O
spontaneously	O
.	O
In	O
the	O
last	O
week	O
he	O
presented	O
4	O
episodes	O
of	O
chest	O
pain	O
and	O
consulted	O
his	O
primary	O
care	O
physician	O
,	O
who	O
referred	O
him	O
to	O
Cardiology	O
for	O
assessment	O
.	O
Physical	O
examination	O
Vital	O
signs	O
BP	O
130	O
70	O
,	O
HR	O
70	O
bpm	O
,	O
O2	O
saturation	O
97	O
on	O
room	O
air	O
.	O
Patient	O
conscious	O
and	O
oriented	O
,	O
normal	O
neurological	O
examination	O
.	O
Pulmonary	O
auscultation	O
with	O
preserved	O
vesicular	O
murmur	O
.	O
Auscultation	O
of	O
heart	O
sounds	O
normal	O
,	O
no	O
murmurs	O
or	O
extratonos	O
,	O
no	O
pericardial	O
friction	O
rub	O
.	O
Neck	O
without	O
jugular	O
ingurgitation	O
.	O
Abdomen	O
without	O
pathological	O
findings	O
.	O
Lower	O
extremities	O
without	O
oedema	O
or	O
signs	O
of	O
thrombosis	O
.	O
COMPLEMENTARY	O
TESTS	O
Blood	O
tests	O
glucose	O
120	O
mg	O
dl	O
,	O
urea	O
30	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
85	O
mg	O
dl	O
,	O
sodium	O
142	O
mEq	O
l	O
,	O
potassium	O
4	O
mEq	O
l	O
,	O
chlorine	O
104	O
mEq	O
l	O
.	O
Leukocytes	O
7	O
,	O
500	O
with	O
60	O
neutrophils	O
,	O
haemoglobin	O
13	O
.	O
2	O
g	O
dl	O
,	O
haematocrit	O
40	O
,	O
platelets	O
250	O
,	O
000	O
.	O
Baseline	O
electrocardiogram	O
ECG	O
sinus	O
rhythm	O
at	O
80	O
bpm	O
,	O
little	O
R	O
wave	O
growth	O
in	O
right	O
precordial	O
leads	O
.	O
No	O
other	O
repolarisation	O
abnormalities	O
.	O
Chest	O
X	O
ray	O
normal	O
cardiac	O
silhouette	O
,	O
no	O
acute	O
pleuroparenchymal	O
findings	O
.	O
Transthoracic	O
echocardiogram	O
left	O
ventricle	O
of	O
normal	O
dimensions	O
,	O
normal	O
wall	O
thickness	O
.	O
Preserved	O
systolic	O
function	O
without	O
segmental	O
alterations	O
of	O
contractility	O
.	O
Normal	O
diastolic	O
pattern	O
.	O
Normal	O
left	O
atrium	O
.	O
Mild	O
mitral	O
insufficiency	O
.	O
Aortic	O
root	O
and	O
aortic	O
valve	O
normal	O
.	O
Normal	O
right	O
chambers	O
.	O
No	O
pericardial	O
effusion	O
.	O
Coronary	O
angiography	O
right	O
radial	O
access	O
5F	O
.	O
Cardiac	O
catheterisation	O
right	O
dominance	O
.	O
Left	O
common	O
trunk	O
LMCA	O
without	O
lesions	O
.	O
Anterior	O
descending	O
artery	O
AD	O
without	O
lesions	O
.	O
Bisector	O
branch	O
slight	O
proximal	O
lesion	O
.	O
Circumflex	O
artery	O
Cx	O
with	O
slight	O
mid	O
level	O
lesion	O
.	O
Right	O
coronary	O
artery	O
RCA	O
with	O
severe	O
pseudostenosis	O
due	O
to	O
coronary	O
spasm	O
at	O
midlevel	O
that	O
improves	O
completely	O
after	O
administration	O
of	O
intracoronary	O
nitroglycerin	B-FARMACO
.	O
Diagnosis	O
epicardial	O
coronary	O
arteries	O
without	O
significant	O
hagiographic	O
lesions	O
.	O
Coronary	O
vasospasm	O
of	O
the	O
right	O
coronary	O
artery	O
.	O
EVOLUTION	O
The	O
patient	O
was	O
assessed	O
in	O
the	O
outpatient	O
cardiology	O
department	O
.	O
At	O
that	O
time	O
he	O
was	O
asymptomatic	O
,	O
the	O
physical	O
examination	O
was	O
normal	O
and	O
the	O
ECG	O
showed	O
no	O
changes	O
in	O
repolarisation	O
.	O
A	O
baseline	O
transthoracic	O
echocardiogram	O
TTE	O
was	O
performed	O
,	O
which	O
was	O
normal	O
,	O
with	O
preserved	O
global	O
left	O
ventricular	O
function	O
and	O
no	O
segmental	O
asymmetries	O
of	O
contractility	O
.	O
Since	O
the	O
patient	O
had	O
cardiovascular	O
risk	O
factors	O
dyslipidaemia	O
and	O
smoking	O
and	O
presented	O
a	O
typical	O
clinical	O
picture	O
of	O
exertional	O
angina	O
,	O
it	O
was	O
decided	O
to	O
request	O
coronary	O
angiography	O
to	O
rule	O
out	O
coronary	O
artery	O
disease	O
.	O
At	O
the	O
time	O
of	O
cardiac	O
catheterisation	O
,	O
the	O
patient	O
was	O
asymptomatic	O
and	O
had	O
no	O
symptoms	O
of	O
angina	O
.	O
The	O
ECG	O
on	O
arrival	O
showed	O
no	O
changes	O
with	O
respect	O
to	O
the	O
previous	O
ones	O
.	O
Blood	O
test	O
parameters	O
were	O
normal	O
.	O
Cardiac	O
catheterisation	O
was	O
performed	O
via	O
the	O
right	O
radial	O
artery	O
.	O
First	O
,	O
LMCA	O
was	O
cannulated	O
with	O
evidence	O
of	O
slight	O
lesions	O
in	O
the	O
bisector	O
branch	O
and	O
proximal	O
Cx	O
.	O
Subsequently	O
,	O
the	O
LMCA	O
was	O
cannulated	O
without	O
complications	O
.	O
After	O
the	O
first	O
contrast	O
injection	O
,	O
a	O
pseudo	O
lesion	O
with	O
the	O
appearance	O
of	O
a	O
severe	O
plaque	O
was	O
detected	O
at	O
the	O
level	O
of	O
the	O
middle	O
LMCA	O
.	O
At	O
that	O
time	O
,	O
the	O
patient	O
reported	O
chest	O
pain	O
similar	O
to	O
the	O
episodes	O
described	O
above	O
and	O
ST	O
segment	O
elevation	O
in	O
lead	O
II	O
of	O
the	O
monitoring	O
.	O
Initially	O
it	O
was	O
thought	O
that	O
the	O
patient	O
had	O
a	O
fixed	O
lesion	O
over	O
which	O
there	O
had	O
been	O
added	O
vasospasm	O
,	O
so	O
it	O
was	O
decided	O
to	O
administer	O
intracoronary	O
nitroglycerine	B-FARMACO
,	O
which	O
progressively	O
improved	O
the	O
angina	O
and	O
the	O
repolarisation	O
alterations	O
on	O
the	O
monitor	O
.	O
After	O
a	O
new	O
contrast	O
injection	O
,	O
complete	O
resolution	O
of	O
the	O
previously	O
observed	O
lesion	O
was	O
observed	O
.	O
In	O
view	O
of	O
the	O
typical	O
angina	O
symptoms	O
and	O
the	O
coronary	O
angiographic	O
findings	O
,	O
the	O
case	O
was	O
labelled	O
as	O
vasospastic	O
angina	O
with	O
severe	O
vasospasm	O
during	O
cardiac	O
catheterisation	O
.	O
Medical	O
treatment	O
with	O
calcium	O
antagonists	O
and	O
long	O
acting	O
oral	O
nitrates	O
was	O
started	O
,	O
with	O
excellent	O
clinical	O
evolution	O
during	O
follow	O
up	O
.	O
DIAGNOSIS	O
Vasospastic	O
angina	O
.	O
Right	O
coronary	O
artery	O
spasm	O
triggered	O
by	O
catheter	O
manipulation	O
.	O

HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
We	O
present	O
the	O
case	O
of	O
a	O
73	O
year	O
old	O
male	O
patient	O
with	O
a	O
DDDR	O
pacemaker	O
since	O
2002	O
due	O
to	O
complete	O
atrioventricular	O
block	O
AVB	O
.	O
In	O
November	O
2014	O
,	O
he	O
was	O
admitted	O
for	O
facial	O
and	O
upper	O
limb	O
oedema	O
with	O
intoxication	O
on	O
decubitus	O
.	O
COMPLEMENTARY	O
TESTS	O
As	O
part	O
of	O
the	O
study	O
,	O
venous	O
Doppler	O
ultrasound	O
was	O
performed	O
,	O
showing	O
complete	O
thrombosis	O
of	O
the	O
brachiocephalic	O
venous	O
trunk	O
with	O
extension	O
to	O
the	O
right	O
axillary	O
and	O
jugular	O
veins	O
.	O
The	O
diagnosis	O
was	O
confirmed	O
by	O
venography	O
which	O
reported	O
thrombosis	O
of	O
the	O
superior	O
vena	O
cava	O
and	O
both	O
brachiocephalic	O
venous	O
axes	O
up	O
to	O
the	O
subclavian	O
veins	O
and	O
collateral	O
drainage	O
through	O
intercostal	O
veins	O
to	O
the	O
azygos	O
vein	O
.	O
EVOLUTION	O
With	O
a	O
diagnosis	O
of	O
SVCS	O
in	O
relation	O
to	O
pacemaker	O
electrodes	O
MP	O
,	O
the	O
patient	O
consulted	O
vascular	O
surgery	O
,	O
which	O
dismissed	O
the	O
case	O
due	O
to	O
the	O
impossibility	O
of	O
access	O
for	O
stent	O
implantation	O
in	O
the	O
venous	O
territory	O
.	O
The	O
patient	O
was	O
discharged	O
with	O
diuretic	O
treatment	O
and	O
anticoagulation	O
.	O
He	O
consulted	O
the	O
emergency	O
department	O
on	O
two	O
other	O
occasions	O
due	O
to	O
severe	O
headache	O
and	O
intolerance	O
to	O
decubitus	O
;	O
the	O
family	O
also	O
told	O
us	O
that	O
he	O
had	O
suicidal	O
ideas	O
in	O
relation	O
to	O
his	O
symptoms	O
.	O
The	O
procedure	O
was	O
performed	O
in	O
the	O
operating	O
theatre	O
,	O
under	O
general	O
anaesthesia	O
with	O
invasive	O
monitoring	O
,	O
echocardiographic	O
control	O
and	O
available	O
ECC	O
equipment	O
.	O
Prior	O
to	O
the	O
procedure	O
,	O
the	O
right	O
femoral	O
vein	O
was	O
cannulated	O
leaving	O
a	O
7F	O
introducer	O
and	O
an	O
epicardial	O
electrode	O
was	O
implanted	O
through	O
a	O
left	O
thoracotomy	O
.	O
This	O
electrode	O
was	O
tunneled	O
to	O
a	O
right	O
suprapectoral	O
neobolla	O
and	O
connected	O
to	O
external	O
stimulation	O
,	O
as	O
the	O
patient	O
was	O
dependent	O
on	O
cardiac	O
stimulation	O
.	O
Subsequently	O
,	O
after	O
careful	O
dissection	O
,	O
the	O
old	O
generator	O
was	O
removed	O
,	O
and	O
using	O
Cook	O
radiofrequency	O
sheaths	O
and	O
Spectranetic	O
mechanical	O
sheaths	O
,	O
the	O
electrodes	O
were	O
extracted	O
in	O
their	O
entirety	O
.	O
Once	O
the	O
extraction	O
was	O
completed	O
and	O
prior	O
to	O
the	O
removal	O
of	O
the	O
sheath	O
,	O
a	O
guidewire	O
was	O
introduced	O
through	O
the	O
sheath	O
and	O
advanced	O
to	O
the	O
right	O
femoral	O
vein	O
.	O
Using	O
the	O
femoral	O
access	O
,	O
balloon	O
angioplasty	O
and	O
implantation	O
of	O
two	O
self	O
expanding	O
stents	O
in	O
the	O
superior	O
vena	O
cava	O
Sinus	O
XL	O
14	O
x	O
40	O
mm	O
,	O
Protg	O
GPS	O
9	O
x	O
40	O
mm	O
and	O
another	O
Gore	O
Tex	O
stent	O
Gore	O
Viabahn	O
54	O
mm	O
in	O
the	O
innominate	O
vein	O
were	O
performed	O
.	O
Once	O
the	O
stent	O
implantation	O
was	O
completed	O
,	O
an	O
SSI	O
generator	O
was	O
connected	O
to	O
the	O
right	O
suprapectoral	O
neobag	O
.	O
After	O
24	O
hours	O
,	O
the	O
patient	O
was	O
discharged	O
to	O
the	O
ward	O
with	O
a	O
notable	O
decrease	O
in	O
the	O
oedema	O
in	O
the	O
sella	O
,	O
and	O
was	O
able	O
to	O
sleep	O
all	O
night	O
in	O
the	O
supine	O
position	O
,	O
which	O
he	O
had	O
not	O
been	O
able	O
to	O
do	O
in	O
recent	O
months	O
.	O
The	O
patient	O
was	O
discharged	O
without	O
complications	O
under	O
anticoagulant	O
treatment	O
.	O
At	O
the	O
three	O
month	O
follow	O
up	O
CT	O
scan	O
,	O
the	O
stents	O
were	O
found	O
to	O
be	O
permeable	O
.	O
At	O
the	O
6	O
month	O
check	O
up	O
,	O
he	O
reported	O
complete	O
recovery	O
of	O
his	O
symptoms	O
and	O
was	O
able	O
to	O
lead	O
a	O
normal	O
life	O
.	O
DIAGNOSIS	O
Superior	O
vena	O
cava	O
syndrome	O
after	O
MP	O
implantation	O
.	O
Hybrid	O
approach	O
electrode	O
extraction	O
and	O
venous	O
stent	O
implantation	O
.	O
Epicardial	O
electrode	O
implantation	O
.	O

HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
The	O
patient	O
is	O
a	O
73	O
year	O
old	O
male	O
with	O
no	O
allergies	O
,	O
ex	O
smoker	O
,	O
hypertensive	O
,	O
dyslipidaemic	O
,	O
with	O
stage	O
V	O
chronic	O
kidney	O
disease	O
CKD	O
secondary	O
to	O
obstructive	O
uropathy	O
due	O
to	O
benign	O
prostatic	O
hypertrophy	O
had	O
refused	O
renal	O
transplant	O
,	O
started	O
peritoneal	O
dialysis	O
PD	O
in	O
August	O
2008	O
with	O
several	O
infectious	O
complications	O
,	O
discontinuing	O
PD	O
in	O
June	O
2012	O
due	O
to	O
partial	O
recovery	O
of	O
renal	O
function	O
creatinine	O
4	O
"	O
2	O
mg	O
dl	O
and	O
GFR	O
15	O
ml	O
min	O
,	O
and	O
again	O
presenting	O
criteria	O
for	O
restarting	O
renal	O
replacement	O
therapy	O
RRT	O
since	O
November	O
2014	O
creatinine	O
7	O
"	O
61	O
mg	O
dl	O
and	O
GFR	O
7	O
"	O
7	O
ml	O
min	O
,	O
which	O
he	O
had	O
refused	O
as	O
he	O
was	O
asymptomatic	O
.	O
Hyperparathyroidism	O
and	O
anaemia	O
secondary	O
to	O
CKD	O
.	O
No	O
cardiac	O
history	O
.	O
He	O
reported	O
poor	O
compliance	O
with	O
pharmacological	O
treatment	O
.	O
Admitted	O
to	O
nephrology	O
in	O
November	O
2016	O
with	O
end	O
stage	O
renal	O
failure	O
and	O
anasarca	O
,	O
requiring	O
placement	O
of	O
a	O
right	O
femoral	O
catheter	O
for	O
urgent	O
haemodialysis	O
and	O
transfusion	O
of	O
red	O
blood	O
cell	O
concentrates	O
due	O
to	O
severe	O
anaemia	O
.	O
Examination	O
on	O
admission	O
BP	O
224	O
92	O
mmHg	O
,	O
HR	O
90	O
bpm	O
.	O
Conscious	O
and	O
oriented	O
.	O
Rhythmic	O
heart	O
tones	O
without	O
murmurs	O
,	O
friction	O
rubs	O
or	O
extratones	O
.	O
Jugular	O
ingurgitation	O
and	O
oedema	O
with	O
fovea	O
up	O
to	O
the	O
genital	O
region	O
,	O
with	O
distal	O
pulses	O
not	O
palpable	O
due	O
to	O
oedema	O
.	O
Tachypnoea	O
with	O
bibasal	O
hypophonesis	O
and	O
decreased	O
vocal	O
transmissions	O
of	O
left	O
predominance	O
.	O
Hepatomegaly	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
sinus	O
rhythm	O
at	O
90	O
bpm	O
,	O
normal	O
PR	O
,	O
narrow	O
QRS	O
,	O
0o	O
axis	O
,	O
with	O
electrical	O
alternation	O
,	O
without	O
repolarisation	O
alterations	O
.	O
Blood	O
tests	O
glucose	O
92	O
mg	O
dl	O
,	O
urea	O
291	O
mg	O
dl	O
,	O
creatinine	O
13	O
.	O
1	O
mg	O
dl	O
FG	O
CKD	O
EPI	O
3	O
.	O
3	O
ml	O
min	O
1	O
.	O
73	O
m2	O
,	O
total	O
Ca	O
8	O
.	O
69	O
mg	O
dl	O
,	O
total	O
proteins	O
7	O
.	O
17	O
g	O
dl	O
,	O
Na	O
141	O
.	O
3	O
mmol	O
l	O
,	O
Cl	O
114	O
mmol	O
l	O
.	O
Venous	O
blood	O
gases	O
pH	O
7	O
.	O
15	O
,	O
pCO2	O
25	O
mmHg	O
,	O
bicarbonate	O
8	O
.	O
7	O
mmol	O
l	O
,	O
EB	O
18	O
.	O
6	O
mmol	O
l	O
.	O
Haemogram	O
leucocytes	O
6	O
.	O
46	O
x109	O
l	O
77	O
.	O
9	O
neutrophils	O
,	O
11	O
.	O
1	O
lymphocytes	O
,	O
Hb	O
4	O
.	O
5	O
g	O
dl	O
,	O
HtO	O
14	O
.	O
9	O
,	O
MCV	O
90	O
.	O
3	O
fl	O
,	O
MCH	O
27	O
.	O
4	O
pg	O
,	O
platelets	O
148	O
,	O
000	O
x109	O
l	O
.	O
INR	O
ratio	O
1	O
.	O
07	O
.	O
Serology	O
negative	O
for	O
HCV	O
,	O
HBV	O
and	O
HIV	O
.	O
HBV	O
DNA	O
undetectable	O
.	O
Chest	O
X	O
ray	O
cardiomegaly	O
suggestive	O
of	O
pericardial	O
effusion	O
.	O
Lung	O
parenchyma	O
without	O
congestive	O
signs	O
.	O
Left	O
pleural	O
effusion	O
.	O
Echocardiogram	O
severely	O
hypertrophied	O
LV	O
with	O
good	O
systolic	O
function	O
and	O
diastolic	O
dysfunction	O
due	O
to	O
poor	O
relaxation	O
.	O
LA	O
severely	O
dilated	O
.	O
Normal	O
right	O
chambers	O
.	O
No	O
significant	O
valvulopathies	O
.	O
Severe	O
global	O
pericardial	O
effusion	O
with	O
echocardiographic	O
signs	O
of	O
haemodynamic	O
involvement	O
partial	O
collapse	O
of	O
the	O
free	O
wall	O
of	O
the	O
RA	O
,	O
RV	O
and	O
LA	O
,	O
respiratory	O
variation	O
of	O
mitral	O
filling	O
flow	O
of	O
41	O
,	O
dilatation	O
of	O
inferior	O
cava	O
24	O
mm	O
and	O
suprahepatic	O
veins	O
without	O
inspiratory	O
collapse	O
of	O
the	O
former	O
and	O
inspiratory	O
inversion	O
of	O
the	O
diastolic	O
component	O
of	O
the	O
suprahepatic	O
vein	O
Doppler	O
.	O
Bilateral	O
pleural	O
effusion	O
.	O
Pleural	O
fluid	O
exudate	O
.	O
Proteins	O
3	O
.	O
9	O
g	O
dl	O
5	O
.	O
84	O
g	O
dl	O
in	O
serum	O
,	O
LDH	O
242	O
U	O
l	O
431	O
U	O
l	O
in	O
serum	O
with	O
normal	O
values	O
208	O
378	O
.	O
Clear	O
appearance	O
.	O
Red	O
cells	O
300	O
cells	O
mm3	O
,	O
leukocytes	O
391	O
cells	O
mm3	O
7	O
polymorphonuclear	O
,	O
93	O
mononuclear	O
,	O
glucose	O
94	O
mg	O
dl	O
,	O
ADA	O
9	O
.	O
2	O
U	O
l	O
,	O
CRP	O
10	O
.	O
7	O
mg	O
l	O
,	O
pH	O
7	O
.	O
45	O
.	O
Negative	O
for	O
malignant	O
cells	O
.	O
Negative	O
cultures	O
.	O
Pericardial	O
fluid	O
exudate	O
.	O
Proteins	O
4	O
.	O
1	O
g	O
dl	O
6	O
.	O
78	O
g	O
dl	O
in	O
serum	O
,	O
LDH	O
2313	O
U	O
l	O
456	O
U	O
l	O
in	O
serum	O
with	O
normal	O
values	O
208	O
378	O
.	O
Haemorrhagic	O
appearance	O
.	O
Red	O
cells	O
945	O
,	O
100	O
cells	O
mm3	O
,	O
leukocytes	O
44	O
,	O
965	O
cells	O
mm3	O
2	O
mononuclear	O
,	O
98	O
polymorphonuclear	O
,	O
glucose	O
79	O
.	O
7	O
mg	O
dl	O
,	O
ADA	O
16	O
.	O
2	O
U	O
l	O
.	O
Negative	O
for	O
malignant	O
cells	O
.	O
Thoracic	O
abdominal	O
CT	O
sheet	O
of	O
pericardial	O
effusion	O
.	O
Left	O
pleural	O
effusion	O
with	O
underlying	O
compressive	O
condensation	O
atelectasis	O
.	O
Bilateral	O
renal	O
atrophy	O
and	O
hydronephrosis	O
and	O
right	O
renal	O
tumours	O
under	O
study	O
.	O
Bilateral	O
renal	O
cortical	O
micronodules	O
,	O
non	O
specific	O
.	O
EVOLUTION	O
Given	O
the	O
suspicion	O
of	O
pericardial	O
effusion	O
on	O
radiological	O
imaging	O
,	O
transthoracic	O
echocardiography	O
was	O
performed	O
,	O
which	O
showed	O
severe	O
pericardial	O
effusion	O
with	O
evidence	O
of	O
haemodynamic	O
compromise	O
but	O
without	O
clinical	O
evidence	O
of	O
tamponade	O
.	O
Initially	O
oriented	O
as	O
probable	O
uremic	O
pericardial	O
effusion	O
,	O
a	O
tunnelled	O
right	O
jugular	O
catheter	O
was	O
placed	O
and	O
haemodialysis	O
was	O
intensified	O
,	O
achieving	O
adequate	O
volume	O
depletion	O
,	O
but	O
without	O
improvement	O
of	O
the	O
pericardial	O
effusion	O
after	O
12	O
days	O
.	O
Thoracentesis	O
of	O
the	O
pleural	O
effusion	O
was	O
performed	O
with	O
exudate	O
results	O
,	O
and	O
given	O
the	O
persistence	O
of	O
pericardial	O
effusion	O
despite	O
adequate	O
haemodialysis	O
,	O
it	O
was	O
decided	O
to	O
perform	O
a	O
diagnostic	O
and	O
therapeutic	O
pericardiocentesis	O
.	O
A	O
total	O
drainage	O
of	O
1400	O
ml	O
of	O
haematic	O
fluid	O
was	O
obtained	O
,	O
exudate	O
,	O
with	O
abundant	O
leukocytes	O
with	O
a	O
predominance	O
of	O
polymorphonuclear	O
cells	O
,	O
no	O
glucose	O
consumption	O
or	O
increase	O
in	O
proteins	O
,	O
elevated	O
LDH	O
and	O
negative	O
cytology	O
for	O
malignant	O
cells	O
.	O
In	O
view	O
of	O
these	O
findings	O
,	O
it	O
was	O
decided	O
to	O
perform	O
a	O
whole	O
body	O
CT	O
scan	O
to	O
screen	O
for	O
occult	O
neoplasia	O
,	O
and	O
two	O
solid	O
tumour	O
like	O
masses	O
were	O
observed	O
in	O
the	O
right	O
kidney	O
.	O
With	O
regard	O
to	O
the	O
anaemia	O
,	O
gastrointestinal	O
losses	O
,	O
haemolysis	O
or	O
metabolic	O
deficits	O
were	O
ruled	O
out	O
and	O
attributed	O
to	O
CKD	O
,	O
and	O
treatment	O
with	O
darbepoetin	B-FARMACO
was	O
started	O
.	O
DIAGNOSIS	O
Stage	O
V	O
chronic	O
renal	O
failure	O
due	O
to	O
obstructive	O
uropathy	O
.	O
Malignant	O
pericardial	O
effusion	O
.	O
Severe	O
anaemia	O
secondary	O
to	O
chronic	O
renal	O
disease	O
.	O
Renal	O
neoplasia	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
54	O
year	O
old	O
man	O
with	O
no	O
toxic	O
habits	O
and	O
a	O
history	O
of	O
hypertension	O
and	O
dyslipidaemia	O
.	O
No	O
diabetes	O
mellitus	O
.	O
Fracture	O
of	O
5th	O
metacarpal	O
.	O
Reactive	O
depressive	O
syndrome	O
.	O
Admitted	O
in	O
March	O
2017	O
for	O
NSTEACS	O
without	O
coronary	O
lesions	O
in	O
coronary	O
angiography	O
,	O
being	O
documented	O
atrial	O
fibrillation	O
with	O
subsequent	O
transition	O
to	O
RS	O
.	O
Preserved	O
systolic	O
function	O
.	O
On	O
treatment	O
on	O
admission	O
with	O
atorvastatin	B-FARMACO
40	O
mg	O
,	O
lorazepam	B-FARMACO
1	O
mg	O
,	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
,	O
pantoprazole	B-FARMACO
40	O
mg	O
,	O
adiro	B-FARMACO
100	O
mg	O
,	O
orfidal	B-FARMACO
1	O
mg	O
,	O
escitalopram	B-FARMACO
10	O
mg	O
.	O
Present	O
illness	O
On	O
the	O
day	O
of	O
his	O
admission	O
,	O
he	O
came	O
to	O
the	O
emergency	O
department	O
for	O
an	O
episode	O
of	O
oppressive	O
chest	O
pain	O
and	O
rapid	O
palpitations	O
of	O
sudden	O
onset	O
with	O
irradiation	O
to	O
the	O
neck	O
.	O
The	O
symptoms	O
were	O
precipitated	O
by	O
an	O
argument	O
.	O
On	O
arrival	O
,	O
a	O
wide	O
QRS	O
rhythmic	O
tachycardia	O
at	O
237	O
bpm	O
was	O
observed	O
.	O
He	O
was	O
assessed	O
in	O
the	O
emergency	O
department	O
and	O
underwent	O
electrical	O
cardioversion	O
to	O
stable	O
sinus	O
rhythm	O
.	O
He	O
was	O
admitted	O
for	O
further	O
investigation	O
and	O
treatment	O
.	O
Physical	O
examination	O
On	O
arrival	O
at	O
the	O
ED	O
blood	O
pressure	O
101	O
65	O
,	O
heart	O
rate	O
190	O
bpm	O
,	O
oxygen	O
saturation	O
100	O
.	O
Conscious	O
,	O
oriented	O
,	O
normal	O
colour	O
and	O
normohydrated	O
.	O
Eupneic	O
.	O
No	O
jugular	O
ingurgitation	O
.	O
Pulmonary	O
auscultation	O
normoventilation	O
,	O
no	O
extra	O
sounds	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
tones	O
,	O
tachycardic	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
,	O
without	O
signs	O
of	O
peritoneal	O
irritation	O
.	O
Peristalsis	O
preserved	O
.	O
Lower	O
extremities	O
no	O
oedema	O
or	O
signs	O
of	O
DVT	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
on	O
admission	O
wide	O
QRS	O
tachycardia	O
.	O
QRS	O
0	O
.	O
24	O
.	O
QS	O
in	O
I	O
.	O
BRD	O
morphology	O
.	O
R	O
in	O
V1	O
to	O
V4	O
.	O
R	O
R	O
"	O
aVR	O
QRS	O
in	O
V6	O
with	O
rS	O
morphology	O
.	O
Visualisation	O
of	O
p	O
"	O
without	O
dissociation	O
at	O
80	O
ms	O
of	O
preceding	O
QRS	O
.	O
Discharge	O
ECG	O
sinus	O
rhythm	O
at	O
55	O
bpm	O
,	O
narrow	O
QRS	O
,	O
no	O
repolarisation	O
abnormalities	O
.	O
Chest	O
X	O
ray	O
preserved	O
silhouette	O
.	O
No	O
congestive	O
signs	O
.	O
Chest	O
X	O
ray	O
at	O
discharge	O
automatic	O
defibrillator	O
with	O
distal	O
end	O
of	O
subcutaneous	O
electrode	O
in	O
chest	O
wall	O
.	O
Surgical	O
staples	O
.	O
CBC	O
Biochemistry	O
glucose	O
107	O
mg	O
dl	O
,	O
urea	O
37	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
04	O
mg	O
dl	O
,	O
uric	O
acid	O
5	O
.	O
00	O
mg	O
dl	O
,	O
triglycerides	O
135	O
mg	O
dl	O
,	O
total	O
cholesterol	O
105	O
mg	O
dl	O
,	O
HDL	O
40	O
mg	O
dl	O
,	O
LDL	O
38	O
mg	O
dl	O
,	O
sodium	O
137	O
mEq	O
l	O
,	O
potassium	O
5	O
.	O
0	O
mEq	O
l	O
,	O
CK	O
56	O
U	O
L	O
,	O
FA	O
125	O
U	O
L	O
,	O
GGT	O
101	O
U	O
L	O
,	O
AST	O
29	O
U	O
L	O
,	O
ALT	O
54	O
U	O
L	O
.	O
Cardiac	O
markers	O
peak	O
numbers	O
troponin	O
I	O
0	O
.	O
23	O
ng	O
ml	O
.	O
Thyroid	O
function	O
TSH	O
3	O
.	O
65	O
mIU	O
l	O
,	O
T4	O
0	O
.	O
65	O
ng	O
dl	O
.	O
CBC	O
red	O
blood	O
cells	O
4	O
.	O
67	O
mill	O
mm3	O
,	O
haemoglobin	O
14	O
.	O
8	O
g	O
dl	O
,	O
haematocrit	O
43	O
,	O
MCV	O
92	O
fl	O
,	O
leukocytes	O
6	O
.	O
6	O
mm3	O
59	O
N	O
,	O
28	O
L	O
,	O
platelets	O
150	O
mm3	O
.	O
Echocardiogram	O
LV	O
dimensions	O
at	O
the	O
upper	O
limit	O
of	O
normality	O
taking	O
into	O
account	O
body	O
surface	O
area	O
.	O
Parietal	O
thickness	O
preserved	O
.	O
Global	O
systolic	O
function	O
preserved	O
57	O
by	O
Simpson	O
s	O
biplanar	O
and	O
GLS	O
19	O
.	O
No	O
clear	O
contractile	O
asymmetries	O
.	O
No	O
conclusive	O
data	O
suggesting	O
LVOT	O
elevation	O
.	O
LA	O
slightly	O
dilated	O
biplanar	O
volume	O
36	O
ml	O
m2	O
.	O
Normal	O
right	O
chambers	O
.	O
Aortic	O
root	O
of	O
normal	O
size	O
.	O
MV	O
and	O
VAo	O
without	O
alterations	O
.	O
I	O
do	O
not	O
detect	O
IT	O
adequately	O
to	O
estimate	O
PAPs	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
or	O
intracavitary	O
masses	O
by	O
this	O
access	O
route	O
.	O
Cardiac	O
magnetic	O
resonance	O
CMR	O
acute	O
myocarditis	O
LV	O
with	O
oedema	O
subepicardial	O
linear	O
hypersignal	O
in	O
middle	O
and	O
apical	O
inferior	O
segments	O
and	O
middle	O
lateral	O
segments	O
and	O
fibrosis	O
subepicardial	O
linear	O
late	O
enhancement	O
in	O
basal	O
and	O
middle	O
anterior	O
segments	O
,	O
basal	O
and	O
middle	O
lateral	O
segments	O
,	O
middle	O
and	O
apical	O
inferior	O
segments	O
and	O
middle	O
inferoseptal	O
segment	O
.	O
Moderately	O
dilated	O
left	O
ventricle	O
DTD	O
60	O
mm	O
;	O
with	O
normal	O
systolic	O
function	O
EF	O
52	O
.	O
Normal	O
RV	O
function	O
.	O
Atria	O
not	O
dilated	O
.	O
Mild	O
AI	O
.	O
Electrophysiological	O
study	O
no	O
significant	O
findings	O
.	O
No	O
evidence	O
of	O
accessory	O
pathway	O
or	O
double	O
nodal	O
pathway	O
.	O
Programmed	O
stimulation	O
does	O
not	O
induce	O
ventricular	O
arrhythmias	O
.	O
EVOLUTION	O
Since	O
admission	O
,	O
the	O
patient	O
had	O
a	O
favourable	O
evolution	O
with	O
no	O
new	O
episodes	O
of	O
arrhythmias	O
.	O
CMR	O
was	O
performed	O
which	O
showed	O
the	O
existence	O
of	O
myocardial	O
oedema	O
and	O
findings	O
suggestive	O
of	O
acute	O
myocarditis	O
.	O
The	O
case	O
was	O
discussed	O
with	O
the	O
Arrhythmia	O
Unit	O
,	O
which	O
decided	O
to	O
implant	O
a	O
subcutaneous	O
ICD	O
.	O
The	O
EMBLEM	O
MRI	O
model	O
subcutaneous	O
ICD	O
was	O
implanted	O
without	O
complications	O
or	O
incidents	O
.	O
The	O
implanted	O
system	O
was	O
checked	O
for	O
proper	O
functioning	O
.	O
Tolerates	O
ambulation	O
without	O
limitations	O
.	O
Tension	O
levels	O
tended	O
to	O
be	O
on	O
the	O
low	O
limit	O
,	O
so	O
beta	O
blocker	O
and	O
ARAII	O
treatment	O
was	O
adjusted	O
,	O
with	O
good	O
tolerance	O
,	O
asymptomatic	O
.	O
In	O
a	O
situation	O
of	O
clinical	O
stability	O
it	O
was	O
decided	O
to	O
discharge	O
him	O
from	O
hospital	O
.	O
DIAGNOSIS	O
Sustained	O
ventricular	O
tachycardia	O
in	O
the	O
context	O
of	O
acute	O
myocarditis	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
63	O
year	O
old	O
independent	O
woman	O
with	O
no	O
cognitive	O
impairment	O
.	O
Cardiovascular	O
risk	O
factors	O
smoker	O
,	O
hypertension	O
and	O
hypercholesterolemia	O
under	O
pharmacological	O
treatment	O
with	O
good	O
control	O
.	O
No	O
previous	O
cardiological	O
history	O
or	O
other	O
history	O
of	O
interest	O
.	O
She	O
consulted	O
because	O
,	O
after	O
receiving	O
the	O
news	O
of	O
the	O
death	O
of	O
a	O
relative	O
,	O
she	O
began	O
with	O
generalised	O
malaise	O
associated	O
with	O
abnormal	O
facial	O
movements	O
and	O
slurred	O
speech	O
with	O
difficulty	O
in	O
producing	O
long	O
sentences	O
,	O
the	O
episode	O
lasting	O
about	O
30	O
minutes	O
.	O
Hours	O
later	O
,	O
the	O
same	O
symptoms	O
reappeared	O
and	O
she	O
was	O
assessed	O
by	O
the	O
emergency	O
services	O
who	O
referred	O
her	O
to	O
our	O
centre	O
.	O
Physical	O
examination	O
showed	O
a	O
good	O
level	O
of	O
consciousness	O
,	O
oriented	O
in	O
the	O
three	O
spheres	O
,	O
no	O
meningeal	O
signs	O
.	O
Language	O
not	O
very	O
fluent	O
due	O
to	O
nominative	O
difficulties	O
.	O
She	O
understands	O
and	O
repeats	O
correctly	O
.	O
Normal	O
cranial	O
nerves	O
.	O
Normal	O
campimetry	O
.	O
Facial	O
centred	O
with	O
the	O
rest	O
of	O
the	O
lower	O
pairs	O
normal	O
.	O
Normal	O
long	O
motor	O
,	O
sensory	O
and	O
cerebellar	O
pathways	O
.	O
Skin	O
plantar	O
reflexes	O
ambiguous	O
.	O
CYC	O
PVY	O
normal	O
,	O
carotid	O
pulses	O
normal	O
AP	O
MVC	O
AC	O
normal	O
.	O
Abdomen	O
normal	O
.	O
Extremities	O
Normal	O
pulses	O
,	O
no	O
oedema	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
tests	O
on	O
admission	O
biochemistry	O
glucose	O
87mg	O
dl	O
,	O
urea	O
46	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
86	O
mg	O
dl	O
,	O
sodium	O
143	O
mmol	O
l	O
,	O
potassium	O
3	O
.	O
8	O
mmol	O
l	O
,	O
CRP	O
1	O
.	O
2mg	O
dl	O
.	O
Coagulation	O
PT	O
87	O
,	O
aPTT	O
1	O
.	O
23	O
FBN	O
580mg	O
dl	O
,	O
INR	O
1	O
.	O
09	O
.	O
Haemogram	O
leucocytes	O
6	O
.	O
99	O
103	O
normal	O
formula	O
,	O
HB	O
14	O
.	O
2g	O
dl	O
,	O
252	O
,	O
000	O
platelets	O
.	O
ECG	O
sinus	O
rhythm	O
at	O
56	O
bpm	O
,	O
without	O
repolarisation	O
alterations	O
.	O
Cranial	O
CT	O
scan	O
without	O
contrast	O
,	O
urgent	O
left	O
fronto	O
opercular	O
hypodense	O
lesion	O
also	O
affecting	O
the	O
anterior	O
region	O
of	O
the	O
insular	O
cortex	O
,	O
with	O
loss	O
of	O
corticosubcortical	O
differentiation	O
compatible	O
with	O
subacute	O
ischaemic	O
lesion	O
.	O
There	O
is	O
no	O
significant	O
mass	O
effect	O
on	O
adjacent	O
structures	O
.	O
In	O
the	O
rest	O
of	O
the	O
parenchyma	O
,	O
no	O
intra	O
or	O
extra	O
axial	O
haemorrhages	O
or	O
other	O
ischaemic	O
lesions	O
are	O
identified	O
.	O
Morphology	O
of	O
sulci	O
and	O
ventricles	O
normal	O
for	O
the	O
patient	O
's	O
age	O
.	O
Centred	O
midline	O
.	O
Posterior	O
cranial	O
fossa	O
structures	O
without	O
apparent	O
alterations	O
.	O
No	O
bony	O
lesions	O
were	O
observed	O
.	O
Findings	O
subacute	O
ischaemic	O
lesion	O
in	O
the	O
anterior	O
superficial	O
territory	O
of	O
the	O
left	O
MCA	O
.	O
Control	O
cranial	O
CT	O
scan	O
at	O
72	O
h	O
appearance	O
of	O
a	O
focus	O
of	O
confluent	O
petechial	O
microhaemorrhage	O
,	O
of	O
nodular	O
morphology	O
and	O
approximately	O
9	O
mm	O
in	O
diameter	O
,	O
inside	O
the	O
known	O
ischaemic	O
or	O
subacute	O
frontal	O
and	O
left	O
insular	O
lesion	O
.	O
The	O
latter	O
has	O
slightly	O
increased	O
in	O
size	O
with	O
respect	O
to	O
the	O
previous	O
study	O
,	O
with	O
greater	O
involvement	O
of	O
the	O
left	O
frontal	O
subcortical	O
white	O
matter	O
at	O
the	O
level	O
of	O
the	O
corona	O
radiata	O
.	O
There	O
is	O
no	O
significant	O
mass	O
effect	O
on	O
the	O
surrounding	O
parenchyma	O
,	O
the	O
midline	O
ventricular	O
system	O
.	O
Pineal	O
cystic	O
lesion	O
approximately	O
9	O
mm	O
in	O
diameter	O
and	O
with	O
peripheral	O
gross	O
calcification	O
,	O
non	O
specific	O
and	O
unchanged	O
.	O
The	O
rest	O
of	O
the	O
study	O
showed	O
no	O
significant	O
alterations	O
or	O
changes	O
with	O
respect	O
to	O
the	O
previous	O
one	O
.	O
Conclusions	O
appearance	O
of	O
a	O
focus	O
of	O
confluent	O
petechial	O
microhaemorrhage	O
,	O
without	O
mass	O
effect	O
,	O
within	O
the	O
lesion	O
of	O
subacute	O
ischaemic	O
profile	O
of	O
the	O
known	O
left	O
MCA	O
territory	O
.	O
Transthoracic	O
echocardiogram	O
4	O
days	O
after	O
admission	O
Video	O
1	O
and	O
2	O
Normal	O
sized	O
LV	O
with	O
mild	O
concentric	O
hypertrophy	O
.	O
Preserved	O
LVEF	O
.	O
Prolonged	O
relaxation	O
.	O
RV	O
of	O
normal	O
size	O
and	O
function	O
.	O
Left	O
atrium	O
slightly	O
dilated	O
.	O
Mass	O
in	O
the	O
left	O
atrium	O
dependent	O
on	O
the	O
interatrial	O
septum	O
,	O
heterogeneous	O
echogenic	O
density	O
,	O
deflected	O
limits	O
,	O
which	O
prolapses	O
into	O
the	O
ventricle	O
through	O
the	O
mitral	O
valve	O
not	O
generating	O
significant	O
gradient	O
but	O
mild	O
moderate	O
mitral	O
insufficiency	O
.	O
Impression	O
of	O
myxoma	O
.	O
Normofunctioning	O
aortic	O
valve	O
.	O
Mitral	O
valve	O
with	O
insufficiency	O
generated	O
by	O
prolapse	O
of	O
the	O
atrial	O
mass	O
.	O
Non	O
dilated	O
IVC	O
.	O
No	O
pericardial	O
effusion	O
.	O
EVOLUTION	O
A	O
63	O
year	O
old	O
woman	O
attended	O
the	O
emergency	O
department	O
with	O
clinical	O
neurological	O
deficit	O
.	O
An	O
urgent	O
cranial	O
CT	O
scan	O
was	O
performed	O
,	O
showing	O
a	O
subacute	O
ischaemic	O
lesion	O
in	O
the	O
anterior	O
superficial	O
territory	O
of	O
the	O
left	O
MCA	O
.	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
Stroke	O
Unit	O
for	O
routine	O
management	O
.	O
She	O
progressed	O
favourably	O
with	O
complete	O
recovery	O
of	O
the	O
neurological	O
deficit	O
.	O
After	O
72	O
hours	O
,	O
a	O
repeat	O
CT	O
scan	O
showed	O
a	O
focus	O
of	O
confluent	O
petechial	O
microhaemorrhage	O
,	O
without	O
mass	O
effect	O
,	O
within	O
the	O
lesion	O
with	O
a	O
known	O
subacute	O
ischaemic	O
profile	O
of	O
the	O
left	O
MCA	O
territory	O
.	O
The	O
echocardiogram	O
showed	O
a	O
mass	O
in	O
the	O
left	O
atrium	O
,	O
dependent	O
on	O
the	O
interatrial	O
septum	O
,	O
with	O
deflected	O
limits	O
,	O
which	O
prolapses	O
through	O
the	O
mitral	O
valve	O
into	O
the	O
left	O
ventricle	O
,	O
causing	O
mild	O
moderate	O
mitral	O
insufficiency	O
.	O
Given	O
these	O
findings	O
,	O
the	O
case	O
was	O
re	O
evaluated	O
jointly	O
with	O
the	O
Cardiology	O
,	O
Neurology	O
and	O
Cardiac	O
Surgery	O
Departments	O
;	O
the	O
patient	O
presented	O
a	O
significant	O
surgical	O
risk	O
as	O
a	O
result	O
of	O
the	O
recent	O
stroke	O
with	O
minor	O
haemorrhagic	O
transformation	O
;	O
however	O
,	O
given	O
the	O
characteristics	O
and	O
behaviour	O
of	O
the	O
tumour	O
,	O
with	O
repeated	O
embolisms	O
and	O
given	O
the	O
risk	O
of	O
other	O
complications	O
,	O
it	O
was	O
decided	O
to	O
perform	O
urgent	O
surgery	O
that	O
same	O
day	O
.	O
The	O
atrial	O
mass	O
was	O
excised	O
with	O
resection	O
of	O
the	O
fossa	O
ovalis	O
and	O
reconstruction	O
with	O
a	O
pericardial	O
patch	O
.	O
The	O
patient	O
had	O
an	O
uncomplicated	O
postoperative	O
period	O
and	O
was	O
discharged	O
from	O
hospital	O
.	O
The	O
pathological	O
anatomy	O
of	O
the	O
specimen	O
confirmed	O
the	O
diagnosis	O
of	O
myxoma	O
.	O
DIAGNOSIS	O
Left	O
frontal	O
ischaemic	O
stroke	O
.	O
Confluent	O
petechial	O
microhaemorrhage	O
inside	O
the	O
ischaemic	O
profile	O
lesion	O
.	O
Left	O
atrial	O
myxoma	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Personal	O
history	O
Allergy	O
to	O
mites	O
and	O
pollen	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
Toxic	O
habits	O
smoker	O
of	O
1	O
pack	O
a	O
day	O
.	O
Mild	O
alcoholic	O
habit	O
.	O
No	O
other	O
intoxicants	O
reported	O
.	O
No	O
hypertension	O
,	O
no	O
dyslipidaemia	O
,	O
no	O
diabetes	O
mellitus	O
.	O
No	O
known	O
heart	O
disease	O
.	O
Bronchial	O
asthma	O
treated	O
with	O
inhalers	O
,	O
with	O
10	O
flare	O
ups	O
related	O
to	O
mites	O
and	O
pollen	O
in	O
the	O
last	O
year	O
treated	O
with	O
bronchodilators	O
and	O
auto	O
injectable	O
adrenaline	B-FARMACO
.	O
Surgical	O
interventions	O
right	O
knee	O
meniscus	O
2	O
years	O
ago	O
.	O
Usual	O
treatment	O
poor	O
compliance	O
terbutaline	B-FARMACO
1	O
inhalation	O
in	O
the	O
mornings	O
.	O
Fluticasone	B-FARMACO
furoate	I-FARMACO
vilanterol	I-FARMACO
184	O
22	O
every	O
24	O
hours	O
.	O
Family	O
history	O
father	O
with	O
acute	O
myocardial	O
infarction	O
AMI	O
at	O
the	O
age	O
of	O
52	O
.	O
Present	O
illness	O
A	O
21	O
year	O
old	O
man	O
,	O
with	O
the	O
history	O
described	O
above	O
,	O
presented	O
to	O
his	O
health	O
centre	O
with	O
a	O
sensation	O
of	O
chest	O
tightness	O
and	O
sudden	O
onset	O
of	O
dyspnoea	O
.	O
The	O
report	O
highlights	O
inspiratory	O
stridor	O
and	O
BP	O
80	O
55	O
.	O
Intravenous	O
methylprednisolone	B-FARMACO
80	O
mg	O
and	O
an	O
ampoule	O
of	O
adrenaline	B-FARMACO
1	O
mg	O
ml	O
intramuscular	O
were	O
administered	O
,	O
with	O
improvement	O
of	O
the	O
respiratory	O
symptoms	O
,	O
but	O
he	O
presented	O
with	O
precordial	O
pressure	O
radiating	O
to	O
the	O
neck	O
.	O
An	O
ECG	O
was	O
performed	O
showing	O
an	O
inferoposterolateral	O
subepicardial	O
lesion	O
.	O
Sublingual	O
nitroglycerine	B-FARMACO
was	O
administered	O
without	O
clinical	O
or	O
electrocardiographic	O
improvement	O
,	O
so	O
the	O
Emergency	O
Services	O
were	O
notified	O
and	O
he	O
was	O
transferred	O
to	O
our	O
hospital	O
.	O
On	O
arrival	O
30	O
minutes	O
after	O
the	O
onset	O
of	O
pain	O
,	O
he	O
reported	O
a	O
slight	O
improvement	O
in	O
pain	O
,	O
although	O
ST	O
segment	O
elevation	O
persisted	O
,	O
so	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
haemodynamics	O
room	O
for	O
urgent	O
catheterisation	O
,	O
and	O
coronary	O
arteries	O
were	O
found	O
to	O
have	O
no	O
significant	O
lesions	O
.	O
He	O
was	O
admitted	O
to	O
the	O
Coronary	O
Care	O
Unit	O
without	O
pain	O
,	O
haemodynamically	O
stable	O
and	O
with	O
normalisation	O
of	O
the	O
ECG	O
.	O
Physical	O
examination	O
BP	O
98	O
60	O
,	O
HR	O
95	O
bpm	O
.	O
SatO2	O
97	O
.	O
Well	O
perfused	O
and	O
hydrated	O
.	O
Eupneic	O
.	O
Head	O
and	O
neck	O
no	O
jugular	O
ingurgitation	O
,	O
no	O
palpable	O
adenopathies	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
no	O
murmurs	O
or	O
extratonos	O
.	O
Pulmonary	O
auscultation	O
mild	O
global	O
hypoventilation	O
and	O
scattered	O
expiratory	O
wheezing	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
.	O
Renal	O
fist	O
percussion	O
negative	O
.	O
Lower	O
extremities	O
no	O
oedema	O
,	O
no	O
evidence	O
of	O
DVT	O
,	O
symmetrical	O
palpable	O
pulses	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
health	O
centre	O
with	O
pain	O
sinus	O
rhythm	O
at	O
60	O
bpm	O
,	O
normal	O
axis	O
,	O
subepicardial	O
lesion	O
up	O
to	O
2	O
3	O
mm	O
inferoposterolateral	O
.	O
Chest	O
X	O
ray	O
cardiomediastinal	O
silhouette	O
,	O
costophrenic	O
sinuses	O
,	O
lung	O
fields	O
and	O
bone	O
skeleton	O
studied	O
without	O
alterations	O
.	O
Analysis	O
Glucose	O
127	O
.	O
Urea	O
27	O
.	O
Creatinine	O
0	O
.	O
78	O
.	O
Sodium	O
138	O
.	O
Potassium	O
4	O
.	O
4	O
.	O
Chlorine	O
106	O
.	O
Osmolality	O
calculated	O
296	O
.	O
PCR	O
0	O
,	O
04	O
.	O
Haemoglobin	O
14	O
.	O
4	O
.	O
Platelets	O
172	O
.	O
Leucocytes	O
11	O
.	O
Eosinophils	O
8	O
.	O
Cholesterol	O
158	O
.	O
Triglycerides	O
32	O
.	O
HDL	O
cholesterol	O
76	O
.	O
AST	O
GOT	O
23	O
.	O
ALT	O
GPT	O
11	O
.	O
Alkaline	O
phosphatase	O
102	O
.	O
Initial	O
tryptase	O
32	O
.	O
7	O
ug	O
L	O
,	O
at	O
2	O
hours	O
27	O
.	O
5	O
ug	O
L	O
and	O
7	O
ug	O
L	O
at	O
24	O
hours	O
.	O
Total	O
IgE	O
635	O
kU	O
L	O
and	O
normal	O
complement	O
.	O
Enzymes	O
on	O
arrival	O
CPK	O
205	O
,	O
CK	O
MB	O
mass	O
8	O
.	O
7	O
.	O
Troponin	O
I	O
2520	O
.	O
Peak	O
CK	O
225	O
.	O
CK	O
MB	O
mass	O
8	O
.	O
7	O
.	O
Troponin	O
I	O
3407	O
.	O
Catheterisation	O
trunk	O
no	O
significant	O
stenosis	O
.	O
Anterior	O
descending	O
no	O
significant	O
stenosis	O
.	O
Circumflex	O
no	O
significant	O
stenosis	O
.	O
Right	O
coronary	O
dominant	O
.	O
No	O
significant	O
stenosis	O
.	O
ECG	O
at	O
discharge	O
sinus	O
rhythm	O
at	O
60	O
bpm	O
,	O
axis	O
at	O
60o	O
,	O
R	O
S	O
in	O
V3	O
without	O
repolarisation	O
alterations	O
.	O
Transthoracic	O
echocardiogram	O
at	O
discharge	O
left	O
ventricle	O
of	O
normal	O
size	O
.	O
The	O
left	O
ventricular	O
wall	O
shows	O
normal	O
thickness	O
.	O
Left	O
ventricular	O
systolic	O
function	O
is	O
normal	O
EF	O
65	O
.	O
Left	O
ventricular	O
wall	O
motion	O
is	O
normal	O
.	O
The	O
right	O
ventricle	O
is	O
normal	O
with	O
respect	O
to	O
size	O
and	O
function	O
.	O
Left	O
atrial	O
size	O
is	O
normal	O
.	O
The	O
size	O
of	O
the	O
right	O
atrium	O
is	O
normal	O
.	O
The	O
mitral	O
valve	O
is	O
normal	O
in	O
structure	O
and	O
function	O
.	O
Anterograde	O
mitral	O
inflow	O
with	O
normal	O
filling	O
pattern	O
.	O
Tricuspid	O
valve	O
appears	O
normal	O
.	O
Minimal	O
tricuspid	O
valve	O
insufficiency	O
is	O
detected	O
.	O
Aortic	O
valve	O
normal	O
in	O
structure	O
and	O
function	O
.	O
Conclusion	O
normal	O
echocardiogram	O
.	O
EVOLUTION	O
This	O
is	O
a	O
21	O
year	O
old	O
male	O
,	O
allergic	O
to	O
mites	O
and	O
grasses	O
,	O
smoker	O
,	O
asthmatic	O
with	O
several	O
annual	O
crises	O
requiring	O
emergency	O
department	O
visits	O
and	O
administration	O
of	O
intravenous	O
corticosteroids	O
and	O
intramuscular	O
adrenaline	B-FARMACO
,	O
who	O
was	O
admitted	O
to	O
the	O
Coronary	O
Care	O
Unit	O
of	O
our	O
hospital	O
due	O
to	O
infero	O
posterior	O
STEACS	O
in	O
relation	O
to	O
an	O
anaphylactic	O
reaction	O
with	O
severe	O
bronchospasm	O
and	O
hypotension	O
,	O
with	O
no	O
clear	O
trigger	O
probably	O
environmental	O
factor	O
.	O
The	O
patient	O
required	O
administration	O
of	O
intravenous	O
methylprednisolone	B-FARMACO
and	O
intramuscular	O
adrenaline	B-FARMACO
,	O
improving	O
the	O
respiratory	O
symptoms	O
,	O
but	O
subepicardial	O
lesion	O
persisted	O
despite	O
sublingual	O
nitroglycerine	B-FARMACO
.	O
An	O
urgent	O
coronary	O
angiography	O
was	O
therefore	O
performed	O
without	O
significant	O
lesions	O
.	O
The	O
picture	O
was	O
interpreted	O
as	O
a	O
possible	O
Kounis	O
Syndrome	O
.	O
The	O
Allergy	O
Department	O
assessed	O
the	O
patient	O
with	O
altered	O
tryptase	O
serology	O
and	O
elevated	O
immunoglobulins	O
and	O
eosinophilia	O
,	O
and	O
concluded	O
that	O
the	O
symptoms	O
were	O
due	O
to	O
an	O
immunoallergic	O
mechanism	O
,	O
all	O
of	O
which	O
was	O
compatible	O
with	O
Kounis	O
syndrome	O
.	O
Allergic	O
tests	O
were	O
positive	O
for	O
environmental	O
factors	O
,	O
mites	O
and	O
pollen	O
,	O
as	O
possible	O
triggers	O
.	O
He	O
presented	O
an	O
enzymatic	O
peak	O
of	O
250	O
CK	O
with	O
troponin	O
3	O
,	O
500	O
with	O
an	O
initial	O
TTE	O
with	O
a	O
subsequent	O
basal	O
and	O
mean	O
hypokinesia	O
that	O
resolved	O
on	O
discharge	O
.	O
The	O
patient	O
was	O
treated	O
with	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
,	O
amlodipine	B-FARMACO
,	O
corticotherapy	O
in	O
a	O
descending	O
pattern	O
and	O
antihistamines	O
with	O
good	O
clinical	O
evolution	O
,	O
with	O
no	O
new	O
episodes	O
of	O
chest	O
pain	O
.	O
Cardiac	O
MRI	O
was	O
requested	O
,	O
which	O
showed	O
good	O
contractility	O
,	O
preserved	O
fraction	O
and	O
absence	O
of	O
late	O
enhancement	O
in	O
viability	O
sequences	O
.	O
Given	O
the	O
good	O
evolution	O
,	O
the	O
patient	O
was	O
discharged	O
on	O
the	O
seventh	O
day	O
after	O
admission	O
.	O
DIAGNOSIS	O
Kounis	O
syndrome	O
allergic	O
vasospastic	O
angina	O
.	O
Anaphylactic	O
reaction	O
with	O
severe	O
bronchospasm	O
and	O
hypotension	O
.	O
Allergy	O
to	O
mites	O
and	O
pollen	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
A	O
70	O
year	O
old	O
man	O
,	O
hypertensive	O
with	O
no	O
other	O
personal	O
or	O
family	O
history	O
of	O
interest	O
,	O
was	O
transferred	O
by	O
helicopter	O
by	O
the	O
Emergency	O
Department	O
with	O
suspected	O
acute	O
coronary	O
syndrome	O
.	O
The	O
patient	O
was	O
in	O
an	O
area	O
difficult	O
to	O
access	O
by	O
road	O
and	O
called	O
the	O
Emergency	O
Services	O
referring	O
intense	O
chest	O
pain	O
and	O
nausea	O
.	O
At	O
the	O
time	O
of	O
assessment	O
by	O
Cardiology	O
,	O
the	O
patient	O
was	O
cloudy	O
,	O
haemodynamically	O
unstable	O
BP	O
70	O
40	O
,	O
poorly	O
perfused	O
and	O
with	O
severe	O
chest	O
pain	O
.	O
On	O
cardiac	O
auscultation	O
,	O
no	O
murmurs	O
were	O
heard	O
and	O
the	O
tones	O
were	O
muffled	O
.	O
Pulmonary	O
auscultation	O
revealed	O
no	O
extra	O
sounds	O
.	O
No	O
peripheral	O
pulses	O
are	O
palpable	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
sinus	O
rhythm	O
with	O
ST	O
segment	O
elevation	O
of	O
5	O
mm	O
V2	O
V6	O
,	O
I	O
,	O
aVL	O
,	O
II	O
,	O
III	O
and	O
aVF	O
with	O
ST	O
segment	O
elevation	O
in	O
V1	O
and	O
aVR	O
.	O
Transthoracic	O
echocardiogram	O
LV	O
without	O
apparent	O
contractility	O
alterations	O
.	O
A	O
flap	O
from	O
the	O
aorta	O
is	O
observed	O
in	O
the	O
ventricular	O
cavity	O
,	O
with	O
moderate	O
aortic	O
insufficiency	O
,	O
without	O
adequate	O
visualisation	O
of	O
the	O
ascending	O
aorta	O
.	O
The	O
right	O
cavities	O
are	O
normal	O
and	O
there	O
is	O
no	O
pericardial	O
effusion	O
.	O
Angio	O
CT	O
scan	O
in	O
the	O
non	O
contrast	O
phase	O
,	O
linear	O
calcification	O
is	O
identified	O
in	O
the	O
lumen	O
of	O
the	O
aortic	O
arch	O
,	O
as	O
well	O
as	O
calcifications	O
in	O
the	O
lumen	O
of	O
the	O
abdominal	O
aorta	O
cranial	O
to	O
the	O
renal	O
vessels	O
and	O
both	O
common	O
iliac	O
arteries	O
,	O
compatible	O
with	O
atheroma	O
plaques	O
with	O
displacement	O
of	O
the	O
intima	O
and	O
therefore	O
compatible	O
with	O
the	O
suspicion	O
of	O
dissection	O
.	O
Aneurysm	O
of	O
the	O
ascending	O
aorta	O
measuring	O
5	O
cm	O
.	O
The	O
lung	O
parenchyma	O
showed	O
interstitial	O
thickening	O
,	O
bilateral	O
infiltrates	O
predominantly	O
in	O
posterior	O
regions	O
and	O
small	O
pleural	O
effusions	O
,	O
suggestive	O
of	O
oedema	O
.	O
EVOLUTION	O
Given	O
the	O
echocardiographic	O
findings	O
,	O
emergent	O
CT	O
angiography	O
was	O
requested	O
and	O
Cardiac	O
Surgery	O
was	O
notified	O
for	O
possible	O
intervention	O
.	O
Norepinephrine	B-FARMACO
perfusion	O
was	O
started	O
and	O
the	O
patient	O
was	O
immediately	O
transferred	O
to	O
radiology	O
.	O
There	O
he	O
presented	O
with	O
desaturation	O
requiring	O
OTI	O
and	O
then	O
extreme	O
bradycardia	O
which	O
prevented	O
a	O
valid	O
CT	O
angiography	O
.	O
Only	O
non	O
contrast	O
images	O
were	O
acquired	O
in	O
the	O
arterial	O
phase	O
,	O
which	O
were	O
compatible	O
with	O
the	O
suspicion	O
of	O
dissection	O
of	O
a	O
5	O
cm	O
ascending	O
aortic	O
aneurysm	O
,	O
together	O
with	O
pulmonary	O
oedema	O
.	O
The	O
patient	O
rapidly	O
evolves	O
unfavourably	O
,	O
with	O
extreme	O
bradycardia	O
persisting	O
despite	O
advanced	O
resuscitation	O
manoeuvres	O
,	O
which	O
degenerates	O
into	O
asystole	O
and	O
death	O
.	O
DIAGNOSIS	O
Ascending	O
aortic	O
aneurysm	O
.	O
Acute	O
aortic	O
syndrome	O
with	O
suspected	O
coronary	O
and	O
aortic	O
valve	O
involvement	O
.	O
Evolution	O
to	O
cardiogenic	O
shock	O
and	O
exitus	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Male	O
,	O
38	O
years	O
old	O
,	O
from	O
Morocco	O
.	O
No	O
drug	O
allergies	O
.	O
No	O
medical	O
or	O
surgical	O
history	O
of	O
interest	O
.	O
No	O
toxic	O
habits	O
.	O
No	O
treatment	O
at	O
present	O
.	O
Active	O
baseline	O
life	O
.	O
Works	O
in	O
the	O
countryside	O
.	O
He	O
has	O
been	O
living	O
in	O
Spain	O
for	O
7	O
years	O
.	O
The	O
patient	O
comes	O
to	O
the	O
Cardiology	O
Department	O
with	O
very	O
unspecific	O
symptoms	O
.	O
He	O
reported	O
a	O
sensation	O
of	O
"	O
noises	O
in	O
the	O
heart	O
"	O
that	O
appeared	O
at	O
rest	O
.	O
He	O
denies	O
dyspnoea	O
on	O
exertion	O
.	O
He	O
also	O
had	O
no	O
history	O
of	O
chest	O
pain	O
or	O
syncope	O
.	O
Physical	O
examination	O
showed	O
BP	O
125	O
60	O
mmHg	O
,	O
HR	O
90	O
bpm	O
,	O
good	O
general	O
condition	O
,	O
afebrile	O
,	O
eupneic	O
at	O
rest	O
with	O
baseline	O
O2	O
saturation	O
98	O
.	O
Cardiac	O
auscultation	O
with	O
rhythmic	O
heart	O
sounds	O
,	O
reinforcement	O
of	O
the	O
first	O
sound	O
,	O
mitral	O
opening	O
click	O
and	O
audible	O
diastolic	O
rumble	O
in	O
the	O
apex	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
without	O
rales	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
,	O
no	O
masses	O
or	O
organomegaly	O
.	O
Lower	O
limbs	O
symmetrical	O
paedial	O
pulses	O
present	O
.	O
No	O
oedema	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
sinus	O
rhythm	O
at	O
62	O
bpm	O
,	O
PR	O
0	O
.	O
19	O
sec	O
,	O
nicked	O
P	O
wave	O
in	O
II	O
,	O
III	O
and	O
aVF	O
and	O
in	O
left	O
precordial	O
leads	O
,	O
non	O
pathological	O
q	O
wave	O
in	O
aVL	O
,	O
normal	O
ventriculogram	O
.	O
Blood	O
tests	O
glucose	O
90	O
mg	O
dl	O
.	O
Urea	O
25	O
mg	O
dl	O
.	O
Creatinine	O
0	O
.	O
88	O
mg	O
dl	O
.	O
GOT	O
23	O
.	O
0	O
.	O
GPT	O
13	O
.	O
0	O
g	O
dl	O
.	O
Total	O
cholesterol	O
126	O
mg	O
dl	O
.	O
Triglycerides	O
57	O
mg	O
dl	O
.	O
HDL	O
cholesterol	O
45	O
mg	O
dl	O
.	O
LDL	O
cholesterol	O
70	O
mg	O
dl	O
.	O
Haemoglobin	O
16	O
,	O
0	O
g	O
dl	O
.	O
Haematocrit	O
48	O
,	O
3	O
.	O
MCV	O
87	O
.	O
8	O
fl	O
.	O
Platelets	O
194	O
.	O
0	O
10e3	O
uL	O
.	O
Leukocytes	O
7	O
.	O
96	O
10e3	O
uL	O
;	O
TSH	O
1	O
.	O
55	O
IU	O
ml	O
.	O
Chest	O
X	O
ray	O
slightly	O
increased	O
cardiothoracic	O
index	O
.	O
Left	O
atrial	O
enlargement	O
.	O
Slight	O
vascular	O
redistribution	O
.	O
Free	O
costophrenic	O
sinuses	O
.	O
No	O
infiltrates	O
or	O
condensation	O
.	O
Echocardiography	O
severely	O
dilated	O
left	O
atrium	O
34	O
cm2	O
.	O
Normal	O
right	O
atrium	O
.	O
Normal	O
aortic	O
root	O
,	O
ascending	O
aorta	O
and	O
arch	O
.	O
Rheumatic	O
mitral	O
valve	O
with	O
stenosis	O
morphology	O
and	O
low	O
score	O
for	O
valvuloplasty	O
4	O
,	O
without	O
commissural	O
calcium	O
.	O
Aortic	O
sigmoid	O
aortic	O
valve	O
trivalves	O
,	O
thickened	O
,	O
rheumatic	O
,	O
with	O
slightly	O
reduced	O
opening	O
.	O
Left	O
ventricle	O
slightly	O
dilated	O
59	O
mm	O
,	O
144	O
ml	O
,	O
normal	O
thickness	O
.	O
Preserved	O
global	O
and	O
segmental	O
LVSF	O
EF	O
65	O
.	O
Normal	O
right	O
ventricle	O
.	O
AIS	O
intact	O
.	O
Pericardium	O
and	O
cava	O
system	O
normal	O
.	O
Doppler	O
severe	O
mitral	O
stenosis	O
AVE	O
0	O
.	O
85	O
cm2	O
by	O
THP	O
,	O
by	O
planimetry	O
1	O
.	O
1	O
cm2	O
,	O
mean	O
gradient	O
12	O
14	O
mmHg	O
.	O
Trivial	O
mitral	O
insufficiency	O
.	O
Mild	O
aortic	O
stenosis	O
peak	O
gradient	O
21	O
mmHg	O
.	O
Aortic	O
insufficiency	O
II	O
IV	O
central	O
jet	O
not	O
crossing	O
papillary	O
muscle	O
plane	O
,	O
no	O
diastolic	O
reversal	O
in	O
descending	O
thoracic	O
or	O
abdominal	O
aorta	O
.	O
Trivial	O
tricuspid	O
regurgitation	O
allowing	O
estimation	O
of	O
mild	O
PH	O
42	O
mmHg	O
.	O
EVOLUTION	O
This	O
is	O
a	O
patient	O
with	O
rheumatic	O
valve	O
disease	O
mainly	O
severe	O
mitral	O
stenosis	O
with	O
minimal	O
PH	O
.	O
However	O
,	O
he	O
presents	O
with	O
dubious	O
symptoms	O
or	O
symptoms	O
discordant	O
with	O
the	O
severity	O
of	O
MS	O
.	O
Given	O
the	O
characteristics	O
of	O
the	O
valve	O
disease	O
,	O
percutaneous	O
mitral	O
commissurotomy	O
PMC	O
would	O
be	O
indicated	O
valve	O
area	O
0	O
.	O
85	O
cm2	O
,	O
favourable	O
anatomical	O
characteristics	O
,	O
ultrasound	O
score	O
8	O
,	O
absence	O
of	O
significant	O
calcification	O
or	O
other	O
valve	O
diseases	O
of	O
greater	O
than	O
mild	O
degree	O
.	O
Age	O
is	O
also	O
a	O
factor	O
in	O
favour	O
of	O
PMC	O
,	O
thus	O
postponing	O
valve	O
replacement	O
surgery	O
.	O
We	O
decided	O
to	O
request	O
an	O
exercise	O
ultrasound	O
to	O
evaluate	O
changes	O
in	O
the	O
mitral	O
gradient	O
and	O
pulmonary	O
pressures	O
,	O
which	O
was	O
positive	O
due	O
to	O
the	O
appearance	O
of	O
clinical	O
symptoms	O
and	O
an	O
increase	O
in	O
the	O
mean	O
transmitral	O
gradient	O
to	O
20	O
mmHg	O
and	O
pulmonary	O
pressure	O
60	O
mmHg	O
.	O
With	O
these	O
results	O
,	O
the	O
case	O
was	O
presented	O
at	O
a	O
medical	O
surgical	O
session	O
and	O
was	O
accepted	O
for	O
percutaneous	O
mitral	O
commissurotomy	O
.	O
The	O
commissurotomy	O
was	O
performed	O
using	O
an	O
Inoue	O
balloon	O
.	O
By	O
transseptal	O
puncture	O
,	O
the	O
guide	O
wire	O
was	O
advanced	O
from	O
the	O
right	O
atrium	O
to	O
the	O
left	O
ventricle	O
,	O
crossing	O
the	O
mitral	O
valve	O
.	O
The	O
balloon	O
is	O
progressively	O
inflated	O
from	O
distal	O
to	O
proximal	O
,	O
thus	O
adopting	O
an	O
hourglass	O
shape	O
that	O
will	O
serve	O
to	O
anchor	O
the	O
balloon	O
to	O
the	O
valve	O
upon	O
removal	O
.	O
The	O
procedure	O
proceeds	O
without	O
immediate	O
complications	O
.	O
Postoperative	O
echocardiography	O
shows	O
an	O
optimal	O
result	O
with	O
mitral	O
valve	O
area	O
1	O
.	O
5	O
cm2	O
,	O
with	O
no	O
increase	O
in	O
mitral	O
regurgitation	O
.	O
The	O
patient	O
evolved	O
favourably	O
during	O
hospitalisation	O
and	O
was	O
discharged	O
pending	O
review	O
in	O
the	O
outpatient	O
cardiology	O
department	O
to	O
assess	O
progress	O
and	O
tolerance	O
to	O
effort	O
.	O
DIAGNOSIS	O
Rheumatic	O
polyvalvulopathy	O
severe	O
mitral	O
stenosis	O
,	O
mild	O
double	O
aortic	O
lesion	O
.	O
Preserved	O
left	O
ventricular	O
systolic	O
function	O
.	O
mild	O
pulmonary	O
hypertension	O
at	O
rest	O
,	O
severe	O
on	O
exertion	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
46	O
year	O
old	O
male	O
patient	O
.	O
No	O
cardiovascular	O
risk	O
factors	O
.	O
No	O
known	O
personal	O
cardiological	O
history	O
.	O
No	O
marfanoid	O
habit	O
.	O
Diagnosed	O
with	O
discoid	O
lupus	O
under	O
treatment	O
.	O
Father	O
died	O
of	O
aortic	O
dissection	O
in	O
2010	O
at	O
the	O
age	O
of	O
61	O
,	O
with	O
no	O
history	O
of	O
hypertension	O
or	O
marfanoid	O
habit	O
.	O
Trivalve	O
aortic	O
valve	O
.	O
Two	O
healthy	O
children	O
.	O
Current	O
disease	O
In	O
view	O
of	O
the	O
father	O
's	O
history	O
,	O
our	O
patient	O
and	O
his	O
sister	O
were	O
referred	O
for	O
a	O
study	O
in	O
2010	O
.	O
At	O
that	O
time	O
the	O
patient	O
had	O
an	O
aortic	O
root	O
at	O
the	O
level	O
of	O
the	O
sinuses	O
of	O
Valsalva	O
of	O
39	O
mm	O
,	O
dilated	O
for	O
his	O
body	O
surface	O
,	O
a	O
trivalve	O
aortic	O
valve	O
and	O
no	O
stigma	O
of	O
Marfan	O
or	O
other	O
syndromic	O
entities	O
,	O
so	O
it	O
was	O
decided	O
to	O
follow	O
up	O
.	O
During	O
the	O
follow	O
up	O
,	O
a	O
progressive	O
growth	O
of	O
the	O
aortic	O
root	O
was	O
observed	O
.	O
In	O
March	O
2017	O
,	O
an	O
angio	O
CT	O
scan	O
was	O
completed	O
,	O
confirming	O
a	O
46	O
mm	O
aorta	O
.	O
Physical	O
examination	O
Height	O
1	O
.	O
80	O
m	O
,	O
weight	O
72	O
kg	O
,	O
BP	O
105	O
59	O
mmHg	O
symmetrical	O
in	O
both	O
upper	O
limbs	O
,	O
HR	O
80	O
bpm	O
,	O
SatO2	O
98	O
on	O
room	O
air	O
.	O
Normal	O
phenotype	O
.	O
CBC	O
no	O
jugular	O
ingurgitation	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
no	O
audible	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
no	O
superimposed	O
sounds	O
.	O
Abdomen	O
nondescript	O
.	O
EIA	O
no	O
malleolar	O
oedema	O
.	O
COMPLEMENTARY	O
TESTS	O
Echocardiogram	O
in	O
September	O
2014	O
LV	O
not	O
dilated	O
or	O
hypertrophic	O
with	O
normal	O
systolic	O
function	O
.	O
Diastolic	O
pattern	O
of	O
prolonged	O
relaxation	O
.	O
Dilatation	O
of	O
the	O
aortic	O
root	O
with	O
effacement	O
of	O
the	O
sino	O
tubular	O
junction	O
.	O
Maximum	O
diameter	O
of	O
43	O
mm	O
.	O
Aortic	O
root	O
dilatation	O
with	O
normal	O
systolic	O
function	O
.	O
Normofunctioning	O
MV	O
.	O
Normal	O
right	O
chambers	O
.	O
Echocardiogram	O
in	O
September	O
2016	O
LA	O
of	O
normal	O
size	O
.	O
LV	O
of	O
normal	O
dimensions	O
,	O
without	O
alterations	O
in	O
segmental	O
contractility	O
and	O
with	O
normal	O
systolic	O
function	O
.	O
Normal	O
filling	O
pressures	O
.	O
Normofunctioning	O
MV	O
.	O
AoV	O
trivalva	O
normofunctioning	O
.	O
RV	O
of	O
normal	O
size	O
and	O
function	O
,	O
without	O
adequate	O
signal	O
for	O
PSAP	O
calculation	O
.	O
Dilated	O
aortic	O
root	O
of	O
46	O
mm	O
.	O
No	O
pericardial	O
effusion	O
.	O
Normal	O
vena	O
cava	O
.	O
Analysis	O
biochemistry	O
Glc	O
92	O
mg	O
dl	O
.	O
Urea	O
36	O
mg	O
dl	O
.	O
Creatinine	O
0	O
.	O
95	O
mg	O
dl	O
.	O
Na	O
144	O
mmol	O
l	O
.	O
K	O
4	O
.	O
5	O
mmol	O
L	O
,	O
FA	O
68	O
U	O
l	O
.	O
AST	O
16	O
U	O
l	O
.	O
ALT	O
18	O
U	O
l	O
.	O
GGT	O
22	O
U	O
.	O
Haemogram	O
Hb	O
14	O
.	O
2	O
g	O
dl	O
.	O
Haematocrit	O
44	O
.	O
Leukocytes	O
6	O
,	O
520	O
uL	O
with	O
57	O
neutrophils	O
.	O
Platelets	O
245	O
.	O
000	O
uL	O
.	O
PT	O
coagulation	O
86	O
.	O
INR	O
1	O
.	O
11	O
.	O
Fibrinogen	O
397	O
.	O
Angio	O
CT	O
of	O
aorta	O
and	O
coronary	O
arteries	O
trivalve	O
aortic	O
valve	O
.	O
No	O
alterations	O
are	O
observed	O
in	O
the	O
origin	O
of	O
the	O
coronary	O
arteries	O
.	O
The	O
aortic	O
root	O
measures	O
29	O
.	O
5	O
x	O
23	O
.	O
5	O
mm	O
at	O
the	O
valve	O
annulus	O
,	O
46	O
x	O
42	O
mm	O
at	O
the	O
sinuses	O
of	O
Valsalva	O
and	O
40	O
x	O
37	O
mm	O
at	O
the	O
sinotubular	O
junction	O
.	O
The	O
ascending	O
aorta	O
measures	O
41	O
x	O
37	O
.	O
5	O
mm	O
.	O
The	O
proximal	O
portion	O
of	O
the	O
aortic	O
arch	O
measures	O
30	O
.	O
5	O
x	O
30	O
mm	O
,	O
the	O
medial	O
portion	O
28	O
.	O
5	O
x	O
25	O
.	O
5	O
mm	O
and	O
the	O
isthmus	O
25	O
.	O
5	O
x	O
23	O
.	O
5	O
mm	O
.	O
The	O
descending	O
aorta	O
at	O
the	O
level	O
of	O
the	O
diaphragmatic	O
pillars	O
measures	O
22	O
x	O
20	O
.	O
5	O
mm	O
.	O
Normal	O
origin	O
of	O
coronary	O
arteries	O
.	O
Coronary	O
arteries	O
without	O
lesions	O
.	O
EVOLUTION	O
Given	O
the	O
angio	O
CT	O
findings	O
and	O
measurements	O
together	O
with	O
the	O
family	O
history	O
,	O
once	O
syndromic	O
entities	O
had	O
been	O
ruled	O
out	O
,	O
the	O
patient	O
was	O
framed	O
in	O
the	O
context	O
of	O
aneurysm	O
syndrome	O
and	O
family	O
dissections	O
,	O
and	O
was	O
referred	O
to	O
Cardiac	O
Surgery	O
for	O
surgery	O
.	O
The	O
patient	O
was	O
admitted	O
on	O
a	O
scheduled	O
basis	O
for	O
aortic	O
root	O
and	O
ascending	O
aorta	O
replacement	O
with	O
a	O
34	O
mm	O
tube	O
with	O
aortic	O
valve	O
reimplantation	O
according	O
to	O
David	O
's	O
technique	O
.	O
Immediate	O
postoperative	O
evolution	O
was	O
favourable	O
,	O
with	O
no	O
notable	O
incidents	O
or	O
complications	O
.	O
The	O
post	O
surgery	O
echocardiogram	O
showed	O
a	O
33	O
mm	O
aortic	O
root	O
with	O
correct	O
valve	O
function	O
.	O
The	O
anatomopathological	O
study	O
of	O
the	O
aortic	O
fragment	O
analysed	O
showed	O
a	O
thinned	O
elastic	O
lamina	O
with	O
myxoid	O
degeneration	O
of	O
the	O
media	O
.	O
Finally	O
,	O
the	O
patient	O
was	O
discharged	O
home	O
,	O
pending	O
the	O
results	O
of	O
the	O
genetic	O
study	O
requested	O
.	O
DIAGNOSIS	O
Ascending	O
aortic	O
aneurysm	O
in	O
an	O
asymptomatic	O
patient	O
with	O
a	O
history	O
of	O
aortic	O
dissection	O
in	O
a	O
first	O
degree	O
relative	O
.	O
Surgery	O
for	O
aortic	O
root	O
replacement	O
and	O
ascending	O
aorta	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Personal	O
history	O
HBP	O
.	O
Dyslipidaemia	O
.	O
Paroxysmal	O
atrial	O
fibrillation	O
on	O
OAC	O
treatment	O
.	O
Diagnosed	O
with	O
bladder	O
tumour	O
,	O
TUR	O
performed	O
by	O
the	O
Urology	O
Department	O
.	O
Under	O
outpatient	O
follow	O
up	O
.	O
She	O
has	O
had	O
a	O
DDDR	O
permanent	O
pacemaker	O
for	O
2	O
months	O
due	O
to	O
sinus	O
node	O
disease	O
diagnosed	O
following	O
a	O
syncopal	O
episode	O
.	O
Active	O
fixation	O
electrode	O
.	O
Current	O
illness	O
Initially	O
admitted	O
to	O
the	O
Pneumology	O
Department	O
due	O
to	O
exertional	O
dyspnoea	O
,	O
asthenia	O
and	O
pleuritic	O
chest	O
pain	O
.	O
Physical	O
examination	O
BP	O
110	O
60	O
mmHg	O
.	O
HR	O
90	O
bpm	O
.	O
SatO2	O
98	O
with	O
nasal	O
goggles	O
at	O
2	O
l	O
min	O
.	O
Cardiac	O
auscultation	O
R1	O
and	O
R2	O
rhythmic	O
and	O
regular	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
hypoventilation	O
in	O
the	O
middle	O
and	O
lower	O
left	O
hemithorax	O
.	O
Abdomen	O
non	O
painful	O
,	O
with	O
no	O
signs	O
of	O
peritoneal	O
irritation	O
.	O
Lower	O
extremities	O
no	O
oedema	O
.	O
Neurological	O
examination	O
functions	O
preserved	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
sinus	O
rhythm	O
at	O
75	O
bpm	O
,	O
BRDHH	O
,	O
HBAS	O
.	O
T	O
negative	O
lower	O
and	O
lateral	O
face	O
.	O
CBC	O
leukocytes	O
6	O
,	O
800	O
uL	O
with	O
63	O
.	O
7	O
neutrophils	O
,	O
Hb	O
11	O
.	O
5	O
g	O
dL	O
,	O
Ht	O
33	O
.	O
8	O
,	O
platelets	O
255	O
,	O
000	O
uL	O
,	O
urea	O
23	O
mg	O
dL	O
,	O
creatinine	O
0	O
.	O
91	O
mg	O
dL	O
,	O
Na	O
142	O
mEq	O
L	O
,	O
K	O
4	O
.	O
3	O
mEq	O
L	O
.	O
Chest	O
X	O
ray	O
bicameral	O
pacemaker	O
.	O
Significant	O
left	O
pleural	O
effusion	O
.	O
Echocardioscopy	O
LV	O
of	O
normal	O
dimensions	O
.	O
Preserved	O
LVEF	O
.	O
No	O
apparent	O
segmental	O
alterations	O
of	O
contractility	O
.	O
Normal	O
right	O
cavities	O
with	O
preserved	O
visual	O
contractility	O
.	O
No	O
significant	O
valvulopathies	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
.	O
Computed	O
tomography	O
CT	O
of	O
the	O
chest	O
bicameral	O
pacemaker	O
with	O
leads	O
in	O
the	O
right	O
atrium	O
and	O
ventricle	O
.	O
Perforation	O
of	O
the	O
apex	O
of	O
the	O
right	O
ventricle	O
by	O
the	O
ventricular	O
electrode	O
,	O
the	O
end	O
of	O
which	O
is	O
located	O
about	O
4	O
cm	O
outside	O
the	O
cardiac	O
contour	O
,	O
is	O
confirmed	O
.	O
There	O
is	O
a	O
small	O
haematoma	O
in	O
the	O
sinus	O
of	O
the	O
cardiophrenic	O
fat	O
.	O
There	O
is	O
no	O
pericardial	O
effusion	O
.	O
There	O
is	O
abundant	O
left	O
pleural	O
effusion	O
,	O
of	O
high	O
density	O
,	O
compatible	O
with	O
haemothorax	O
.	O
No	O
pneumothorax	O
was	O
identified	O
.	O
Partial	O
passive	O
atelectasis	O
of	O
LSI	O
and	O
complete	O
atelectasis	O
of	O
LII	O
.	O
EVOLUTION	O
Twenty	O
four	O
hours	O
after	O
admission	O
,	O
he	O
presented	O
dizziness	O
and	O
postural	O
instability	O
without	O
loss	O
of	O
consciousness	O
and	O
chest	O
pain	O
with	O
pleuritic	O
characteristics	O
,	O
for	O
which	O
we	O
requested	O
an	O
assessment	O
.	O
The	O
pacemaker	O
device	O
was	O
checked	O
and	O
failed	O
to	O
sense	O
and	O
stimulate	O
the	O
ventricular	O
electrode	O
.	O
Echocardioscopy	O
without	O
pericardial	O
effusion	O
.	O
Despite	O
the	O
absence	O
of	O
pericardial	O
effusion	O
,	O
due	O
to	O
suspicion	O
of	O
myocardial	O
perforation	O
by	O
the	O
ventricular	O
electrode	O
,	O
an	O
urgent	O
thoracic	O
CT	O
scan	O
was	O
requested	O
and	O
the	O
diagnosis	O
was	O
confirmed	O
.	O
The	O
patient	O
underwent	O
emergency	O
surgery	O
in	O
the	O
operating	O
theatre	O
,	O
and	O
the	O
ventricular	O
electrode	O
was	O
removed	O
percutaneously	O
with	O
repositioning	O
in	O
the	O
RVOT	O
,	O
verifying	O
correct	O
thresholds	O
,	O
sensing	O
and	O
impedance	O
,	O
and	O
the	O
respective	O
chest	O
drain	O
was	O
implanted	O
in	O
the	O
same	O
procedure	O
.	O
The	O
evolution	O
was	O
favourable	O
,	O
with	O
resolution	O
of	O
the	O
haemothorax	O
,	O
correct	O
functioning	O
of	O
the	O
pacing	O
device	O
and	O
asymptomatic	O
at	O
discharge	O
.	O
DIAGNOSIS	O
Late	O
myocardial	O
perforation	O
of	O
RV	O
apex	O
by	O
pacemaker	O
lead	O
.	O
Reimplantation	O
of	O
ventricular	O
lead	O
in	O
RVOT	O
.	O
Secondary	O
haemothorax	O
resolved	O
on	O
discharge	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
46	O
year	O
old	O
woman	O
diagnosed	O
by	O
chance	O
with	O
hepatic	O
angiomas	O
,	O
with	O
no	O
other	O
medical	O
or	O
surgical	O
history	O
of	O
interest	O
.	O
She	O
consulted	O
the	O
cardiology	O
department	O
for	O
self	O
limited	O
episodes	O
of	O
rapid	O
and	O
regular	O
palpitations	O
,	O
with	O
abrupt	O
onset	O
and	O
end	O
,	O
with	O
no	O
other	O
accompanying	O
symptoms	O
.	O
Physical	O
examination	O
revealed	O
elevated	O
jugular	O
venous	O
pressure	O
up	O
to	O
the	O
mandibular	O
angle	O
,	O
with	O
no	O
oedema	O
in	O
the	O
lower	O
limbs	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
no	O
murmurs	O
.	O
No	O
other	O
data	O
of	O
interest	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
tests	O
blood	O
count	O
and	O
biochemistry	O
normal	O
.	O
Normal	O
thyroid	O
hormones	O
.	O
Electrocardiogram	O
sinus	O
rhythm	O
at	O
65	O
bpm	O
,	O
narrow	O
QRS	O
,	O
normal	O
repolarisation	O
.	O
Chest	O
X	O
ray	O
increased	O
cardiothoracic	O
index	O
.	O
Normal	O
lung	O
fields	O
.	O
Transthoracic	O
echocardiogram	O
left	O
ventricle	O
of	O
normal	O
size	O
and	O
function	O
.	O
Normal	O
left	O
atrium	O
.	O
Right	O
atrium	O
occupied	O
by	O
a	O
large	O
intracavitary	O
mass	O
.	O
Morphologically	O
normal	O
valves	O
,	O
without	O
dysfunction	O
.	O
Moderate	O
pericardial	O
effusion	O
with	O
dilated	O
inferior	O
vena	O
cava	O
.	O
After	O
administration	O
of	O
a	O
sulphur	B-FARMACO
hexafluoride	I-FARMACO
ecopotentiator	O
,	O
no	O
uptake	O
by	O
the	O
mass	O
was	O
observed	O
.	O
Transesophageal	O
echocardiogram	O
large	O
intracavitary	O
mass	O
at	O
the	O
level	O
of	O
the	O
right	O
atrium	O
,	O
occupying	O
and	O
filling	O
practically	O
the	O
entire	O
cavity	O
,	O
without	O
reaching	O
the	O
tricuspid	O
valve	O
plane	O
or	O
the	O
atrioventricular	O
groove	O
,	O
with	O
a	O
broad	O
base	O
of	O
implantation	O
at	O
the	O
level	O
of	O
the	O
atrial	O
roof	O
and	O
the	O
interatrial	O
septum	O
,	O
well	O
defined	O
,	O
measuring	O
8	O
cm	O
x	O
6	O
cm	O
,	O
with	O
very	O
heterogeneous	O
echographic	O
characteristics	O
inside	O
,	O
with	O
large	O
anechoic	O
areas	O
and	O
other	O
dense	O
areas	O
,	O
with	O
an	O
irregular	O
interior	O
appearance	O
.	O
This	O
mass	O
crosses	O
the	O
fossa	O
ovalis	O
towards	O
the	O
left	O
atrium	O
,	O
resting	O
superiorly	O
against	O
the	O
aorta	O
without	O
infiltrating	O
it	O
.	O
Cardiac	O
magnetic	O
resonance	O
CMR	O
large	O
mass	O
in	O
the	O
RA	O
9	O
x	O
7	O
cm	O
,	O
well	O
defined	O
borders	O
,	O
does	O
not	O
appear	O
to	O
infiltrate	O
the	O
wall	O
or	O
pericardium	O
,	O
relatively	O
homogeneous	O
,	O
appearing	O
isointense	O
on	O
T1	O
sequences	O
,	O
while	O
on	O
T2	O
weighted	O
sequences	O
it	O
appears	O
hyperintense	O
.	O
After	O
gadolinium	O
administration	O
,	O
there	O
is	O
an	O
absence	O
of	O
perfusion	O
in	O
the	O
first	O
step	O
and	O
only	O
very	O
slight	O
heterogeneous	O
enhancement	O
in	O
the	O
late	O
phases	O
.	O
Cranio	O
thorax	O
abdomen	O
CT	O
scan	O
well	O
defined	O
84	O
x	O
99	O
mm	O
lesion	O
occupying	O
practically	O
the	O
entire	O
right	O
atrium	O
,	O
contacting	O
the	O
uppermost	O
part	O
of	O
the	O
atrium	O
and	O
the	O
interatrial	O
septum	O
,	O
with	O
minimal	O
introduction	O
through	O
the	O
interatrial	O
septum	O
into	O
the	O
left	O
atrium	O
.	O
It	O
contacts	O
the	O
anterior	O
zone	O
of	O
the	O
right	O
pulmonary	O
artery	O
and	O
the	O
right	O
ascending	O
aorta	O
.	O
Persistently	O
hypodense	O
with	O
IV	O
contrast	O
.	O
Large	O
hepatomegaly	O
with	O
areas	O
of	O
uptake	O
,	O
in	O
relation	O
to	O
his	O
known	O
angiomatosis	O
.	O
CT	O
scan	O
of	O
coronary	O
arteries	O
coronary	O
arteries	O
without	O
lesions	O
.	O
Pathological	O
anatomy	O
of	O
the	O
tumour	O
intramyocardial	O
cavernous	O
cavernous	O
haemangioma	O
with	O
papillary	O
endothelial	O
hyperplasia	O
.	O
No	O
signs	O
of	O
malignancy	O
were	O
observed	O
in	O
the	O
material	O
studied	O
.	O
Inguinal	O
adenopathies	O
reactive	O
lymphadenitis	O
.	O
EVOLUTION	O
Following	O
the	O
clinical	O
manifestations	O
described	O
and	O
the	O
findings	O
on	O
examination	O
,	O
a	O
transthoracic	O
echocardiogram	O
was	O
requested	O
with	O
the	O
results	O
described	O
.	O
After	O
finding	O
evidence	O
of	O
a	O
large	O
tumour	O
in	O
the	O
right	O
atrium	O
,	O
various	O
imaging	O
tests	O
were	O
performed	O
.	O
Without	O
a	O
definitive	O
diagnosis	O
,	O
and	O
with	O
the	O
differential	O
diagnosis	O
of	O
myxoma	O
versus	O
sarcoma	O
,	O
the	O
patient	O
underwent	O
surgery	O
.	O
Resection	O
of	O
the	O
tumour	O
in	O
the	O
right	O
atrium	O
was	O
performed	O
with	O
intraoperative	O
biopsy	O
.	O
The	O
right	O
atrium	O
and	O
interatrial	O
septum	O
were	O
reconstructed	O
with	O
two	O
patches	O
of	O
bovine	O
pericardium	O
.	O
Surgical	O
findings	O
atrial	O
tumour	O
with	O
a	O
spongy	O
appearance	O
,	O
highly	O
vascularised	O
,	O
with	O
a	O
wide	O
base	O
of	O
implantation	O
in	O
the	O
roof	O
of	O
both	O
atria	O
and	O
the	O
interatrial	O
septum	O
.	O
Small	O
atrial	O
septal	O
defect	O
with	O
respected	O
fossa	O
ovalis	O
.	O
Infiltration	O
only	O
of	O
the	O
interatrial	O
septum	O
,	O
with	O
absence	O
of	O
epicardial	O
infiltration	O
of	O
other	O
structures	O
.	O
An	O
intraoperative	O
biopsy	O
was	O
performed	O
,	O
which	O
showed	O
a	O
tumour	O
formed	O
by	O
inter	O
anastomosed	O
vascular	O
channels	O
,	O
without	O
cytological	O
atypia	O
with	O
lymphoid	O
aggregates	O
.	O
Vascular	O
tumour	O
of	O
low	O
malignant	O
potential	O
.	O
Postoperative	O
evolution	O
was	O
uneventful	O
,	O
remaining	O
haemodynamically	O
stable	O
and	O
cardiovascular	O
asymptomatic	O
.	O
In	O
subsequent	O
follow	O
ups	O
,	O
the	O
patient	O
presented	O
paroxysmal	O
atrial	O
fibrillation	O
,	O
the	O
rhythm	O
being	O
controlled	O
with	O
flecainide	B-FARMACO
.	O
She	O
remained	O
stable	O
,	O
with	O
no	O
evidence	O
of	O
recurrence	O
in	O
subsequent	O
echocardiograms	O
.	O
DIAGNOSIS	O
Intramyocardial	O
cavernous	O
haemangioma	O
with	O
papillary	O
endothelial	O
hyperplasia	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
64	O
year	O
old	O
male	O
,	O
ex	O
smoker	O
,	O
with	O
a	O
history	O
of	O
long	O
standing	O
arterial	O
hypertension	O
and	O
suboptimal	O
control	O
,	O
treated	O
with	O
ACE	O
inhibitors	O
and	O
diuretics	O
.	O
He	O
had	O
a	O
heart	O
murmur	O
since	O
childhood	O
,	O
"	O
functional	O
"	O
.	O
The	O
first	O
non	O
invasive	O
imaging	O
study	O
was	O
performed	O
in	O
2007	O
,	O
due	O
to	O
a	O
radiological	O
finding	O
of	O
cardiomegaly	O
on	O
chest	O
X	O
ray	O
,	O
in	O
the	O
context	O
of	O
a	O
study	O
of	O
hypertensive	O
crisis	O
in	O
the	O
emergency	O
department	O
.	O
A	O
transthoracic	O
echocardiogram	O
was	O
performed	O
showing	O
severe	O
concentric	O
left	O
ventricular	O
hypertrophy	O
without	O
dilatation	O
of	O
the	O
cavity	O
and	O
with	O
good	O
systolic	O
function	O
ejection	O
fraction	O
72	O
.	O
The	O
mitral	O
valve	O
is	O
congenitally	O
defective	O
,	O
with	O
a	O
"	O
parachute	O
"	O
arrangement	O
,	O
anterior	O
leaflet	O
prolapse	O
and	O
single	O
posteromedial	O
papillary	O
muscle	O
.	O
All	O
this	O
leads	O
to	O
a	O
double	O
functional	O
alteration	O
with	O
mild	O
stenosis	O
effective	O
area	O
2	O
.	O
5	O
cm2	O
;	O
mean	O
gradient	O
4	O
mmHg	O
and	O
moderate	O
III	O
IV	O
eccentric	O
insufficiency	O
.	O
The	O
aortic	O
valve	O
is	O
bicuspid	O
,	O
with	O
a	O
slightly	O
restricted	O
antero	O
posterior	O
opening	O
intercoronary	O
fusion	O
systolic	O
doming	O
;	O
maximum	O
transvalvular	O
gradient	O
of	O
35	O
mm	O
Hg	O
and	O
effective	O
area	O
by	O
continuity	O
equation	O
of	O
1	O
.	O
9	O
cm2	O
.	O
No	O
diastolic	O
prolapse	O
or	O
regurgitation	O
was	O
observed	O
.	O
The	O
aortic	O
root	O
and	O
ascending	O
aorta	O
are	O
of	O
normal	O
diameters	O
.	O
The	O
right	O
chambers	O
are	O
structurally	O
and	O
functionally	O
normal	O
,	O
with	O
no	O
evidence	O
of	O
pulmonary	O
arterial	O
hypertension	O
.	O
Flow	O
analysis	O
of	O
the	O
abdominal	O
and	O
descending	O
thoracic	O
aorta	O
showed	O
data	O
suggestive	O
of	O
aortic	O
coarctation	O
diastolic	O
prolongation	O
and	O
gradient	O
in	O
the	O
descending	O
aorta	O
reaching	O
a	O
systolic	O
peak	O
of	O
107	O
mmHg	O
.	O
In	O
view	O
of	O
these	O
findings	O
,	O
MRI	O
was	O
requested	O
to	O
assess	O
the	O
suspected	O
aortic	O
alterations	O
.	O
This	O
study	O
confirmed	O
the	O
presence	O
of	O
coarctation	O
of	O
the	O
aorta	O
with	O
stenosis	O
distal	O
to	O
the	O
exit	O
of	O
the	O
left	O
subclavian	O
artery	O
with	O
a	O
minimum	O
diameter	O
of	O
7	O
mm	O
pre	O
stenosis	O
,	O
18	O
mm	O
;	O
post	O
stenosis	O
,	O
27	O
mm	O
.	O
In	O
addition	O
,	O
an	O
aberrant	O
right	O
subclavian	O
artery	O
is	O
observed	O
leaving	O
the	O
area	O
of	O
the	O
coarctation	O
with	O
a	O
retroesophageal	O
course	O
.	O
With	O
a	O
confirmed	O
diagnosis	O
of	O
incomplete	O
Shone	O
's	O
syndrome	O
parachute	O
mitral	O
valve	O
,	O
bicuspid	O
aortic	O
valve	O
,	O
aortic	O
coarctation	O
,	O
the	O
surgical	O
option	O
was	O
considered	O
2008	O
,	O
which	O
the	O
patient	O
initially	O
rejected	O
due	O
to	O
his	O
good	O
functional	O
status	O
and	O
absence	O
of	O
symptoms	O
.	O
He	O
maintained	O
regular	O
outpatient	O
check	O
ups	O
for	O
the	O
next	O
four	O
years	O
.	O
However	O
,	O
the	O
progression	O
of	O
the	O
functional	O
grade	O
grade	O
II	O
and	O
the	O
appearance	O
of	O
angina	O
made	O
it	O
necessary	O
to	O
go	O
to	O
the	O
emergency	O
department	O
,	O
from	O
where	O
he	O
was	O
admitted	O
to	O
our	O
department	O
08	O
2012	O
.	O
Physical	O
examination	O
Good	O
general	O
condition	O
.	O
Not	O
hydrated	O
,	O
normal	O
colour	O
.	O
Height	O
within	O
normal	O
limits	O
1	O
.	O
75	O
cm	O
,	O
with	O
adequate	O
development	O
of	O
limbs	O
and	O
secondary	O
sexual	O
characteristics	O
.	O
Skin	O
without	O
lesions	O
,	O
fragility	O
or	O
bruising	O
.	O
No	O
visual	O
defects	O
or	O
other	O
syndromic	O
stigmata	O
.	O
Blood	O
pressure	O
figures	O
in	O
right	O
upper	O
limb	O
160	O
140	O
,	O
similar	O
to	O
lower	O
limbs	O
,	O
left	O
upper	O
limb	O
200	O
105	O
,	O
heart	O
rate	O
90	O
bpm	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
,	O
with	O
pansystolic	O
murmur	O
III	O
VI	O
aortic	O
with	O
preserved	O
S2	O
;	O
systolic	O
murmur	O
II	O
III	O
VI	O
mitral	O
and	O
systodiastolic	O
murmur	O
in	O
the	O
left	O
dorsal	O
region	O
.	O
Abdomen	O
nondescript	O
,	O
no	O
abdominal	O
murmur	O
.	O
Lower	O
extremities	O
symmetrical	O
femoral	O
pulses	O
,	O
but	O
less	O
intense	O
than	O
the	O
humeral	O
and	O
radial	O
pulses	O
,	O
pedial	O
pulses	O
present	O
,	O
no	O
oedema	O
.	O
COMPLEMENTARY	O
TESTS	O
Blood	O
count	O
,	O
biochemistry	O
and	O
coagulation	O
normal	O
.	O
Electrocardiogram	O
.	O
Chest	O
X	O
ray	O
.	O
Transthoracic	O
and	O
transesophageal	O
echocardiogram	O
14	O
8	O
2012	O
slight	O
dilatation	O
25	O
cm2	O
of	O
the	O
left	O
atrium	O
.	O
Bicuspid	O
aortic	O
valve	O
,	O
with	O
thickening	O
of	O
both	O
leaflets	O
and	O
slight	O
calcification	O
mainly	O
at	O
the	O
level	O
of	O
the	O
raphe	O
that	O
homogeneously	O
restricts	O
mobility	O
and	O
causes	O
a	O
moderate	O
reduction	O
in	O
systolic	O
opening	O
,	O
without	O
significant	O
aortic	O
insufficiency	O
.	O
Severe	O
concentric	O
hypertrophy	O
of	O
the	O
left	O
ventricle	O
without	O
dilatation	O
of	O
the	O
cavity	O
and	O
with	O
good	O
systolic	O
function	O
.	O
In	O
the	O
left	O
ventricular	O
outflow	O
tract	O
there	O
is	O
a	O
fibrous	O
bundle	O
with	O
a	O
maximum	O
thickness	O
of	O
9	O
mm	O
.	O
As	O
a	O
whole	O
aortic	O
valve	O
and	O
subaortic	O
bundle	O
,	O
there	O
is	O
a	O
severe	O
obstruction	O
to	O
the	O
left	O
ventricular	O
outflow	O
tract	O
maximum	O
velocity	O
4	O
.	O
12	O
m	O
s	O
,	O
mean	O
gradient	O
41	O
mmhg	O
.	O
Parachute	O
mitral	O
valve	O
with	O
diffuse	O
thickening	O
of	O
both	O
leaflets	O
and	O
prolapse	O
of	O
the	O
anterior	O
leaflet	O
,	O
leading	O
to	O
severe	O
mitral	O
insufficiency	O
IV	O
IV	O
directed	O
eccentrically	O
and	O
with	O
Coanda	O
effect	O
towards	O
the	O
posterior	O
and	O
lateral	O
wall	O
of	O
the	O
left	O
atrium	O
;	O
the	O
regurgitant	O
jet	O
enters	O
the	O
pulmonary	O
veins	O
and	O
reverses	O
the	O
systolic	O
component	O
of	O
the	O
antegrade	O
flow	O
.	O
Descending	O
thoracic	O
aorta	O
with	O
post	O
stromal	O
narrowing	O
and	O
acceleration	O
of	O
systolic	O
flow	O
as	O
evidenced	O
by	O
colour	O
Doppler	O
.	O
Doppler	O
analysis	O
shows	O
a	O
pattern	O
of	O
systolic	O
acceleration	O
with	O
a	O
peak	O
gradient	O
of	O
80	O
mmHg	O
,	O
without	O
diastolic	O
prolongation	O
.	O
Coronary	O
angiography	O
performed	O
via	O
the	O
right	O
femoral	O
artery	O
due	O
to	O
the	O
impossibility	O
of	O
progression	O
to	O
the	O
radial	O
access	O
left	O
coronary	O
tree	O
without	O
lesions	O
.	O
Severe	O
proximal	O
stenosis	O
of	O
the	O
right	O
coronary	O
artery	O
.	O
Aberrant	O
right	O
subclavian	O
artery	O
with	O
retroesophageal	O
trajectory	O
from	O
descending	O
aorta	O
distal	O
to	O
coarctation	O
.	O
Pressures	O
in	O
ascending	O
aorta	O
166	O
73	O
and	O
descending	O
aorta	O
104	O
64	O
.	O
Angio	O
CT	O
scan	O
of	O
thoracic	O
aorta	O
aortic	O
coarctation	O
immediately	O
distal	O
to	O
the	O
origin	O
of	O
the	O
left	O
subclavian	O
artery	O
,	O
with	O
a	O
diameter	O
of	O
9	O
.	O
5	O
x	O
12	O
mm	O
at	O
the	O
narrowest	O
point	O
.	O
Anatomical	O
variant	O
of	O
aberrant	O
right	O
subclavian	O
artery	O
originating	O
distal	O
to	O
the	O
coarctation	O
,	O
with	O
a	O
clearly	O
smaller	O
calibre	O
than	O
the	O
left	O
subclavian	O
artery	O
.	O
There	O
is	O
no	O
visualisation	O
of	O
intercostal	O
artery	O
hypertrophy	O
.	O
There	O
is	O
some	O
hypertrophy	O
of	O
the	O
left	O
mammary	O
artery	O
.	O
Renal	O
artery	O
aneurysms	O
,	O
the	O
largest	O
of	O
which	O
is	O
10	O
mm	O
in	O
diameter	O
,	O
with	O
calcium	O
and	O
mural	O
thrombus	O
.	O
Bilateral	O
simple	O
renal	O
cysts	O
.	O
Calcifications	O
in	O
the	O
aortic	O
valve	O
.	O
EVOLUTION	O
Given	O
that	O
the	O
hypertension	O
was	O
severe	O
,	O
treatment	O
was	O
started	O
with	O
calcium	O
antagonists	O
,	O
ARAII	O
,	O
beta	O
blockers	O
,	O
diuretics	O
,	O
doxazosin	B-FARMACO
,	O
nitrates	O
and	O
antilipemiant	O
drugs	O
.	O
The	O
case	O
was	O
presented	O
at	O
a	O
medical	O
surgical	O
session	O
and	O
was	O
accepted	O
for	O
surgery	O
.	O
After	O
evaluating	O
the	O
different	O
surgical	O
options	O
,	O
it	O
was	O
finally	O
decided	O
to	O
replace	O
the	O
valve	O
at	O
first	O
,	O
and	O
then	O
to	O
treat	O
the	O
coarctation	O
of	O
the	O
aorta	O
by	O
means	O
of	O
endovascular	O
therapy	O
or	O
surgery	O
.	O
During	O
the	O
entire	O
hospital	O
stay	O
,	O
the	O
patient	O
remained	O
without	O
new	O
episodes	O
of	O
chest	O
pain	O
,	O
with	O
good	O
control	O
of	O
blood	O
pressure	O
,	O
and	O
was	O
discharged	O
with	O
a	O
good	O
functional	O
level	O
.	O
Once	O
the	O
diagnosis	O
and	O
comorbidities	O
had	O
been	O
established	O
,	O
treatment	O
was	O
started	O
,	O
addressing	O
different	O
objectives	O
which	O
,	O
in	O
the	O
present	O
patient	O
,	O
merited	O
adequate	O
control	O
.	O
Severe	O
arterial	O
hypertension	O
is	O
controlled	O
by	O
means	O
of	O
a	O
pharmacological	O
combination	O
that	O
includes	O
calcium	O
antagonists	O
,	O
ARAII	O
,	O
beta	O
blockers	O
,	O
diuretics	O
and	O
doxazosin	B-FARMACO
.	O
Statins	O
are	O
added	O
as	O
secondary	O
prevention	O
of	O
ischaemic	O
heart	O
disease	O
and	O
nitrates	O
for	O
symptomatic	O
relief	O
of	O
angina	O
.	O
It	O
was	O
decided	O
to	O
surgically	O
intervene	O
the	O
different	O
elements	O
that	O
make	O
up	O
this	O
complex	O
congenital	O
heart	O
disease	O
.	O
The	O
approach	O
included	O
initially	O
treating	O
the	O
left	O
ventricular	O
outflow	O
tract	O
obstruction	O
valve	O
replacement	O
and	O
impeller	O
resection	O
and	O
deferring	O
the	O
approach	O
to	O
the	O
coarctation	O
to	O
a	O
later	O
stage	O
,	O
either	O
by	O
surgery	O
or	O
by	O
percutaneous	O
intervention	O
.	O
On	O
15	O
3	O
2013	O
he	O
underwent	O
surgery	O
using	O
extracorporeal	O
circulation	O
total	O
CPB	O
time	O
171	O
minutes	O
;	O
ischaemia	O
time	O
137	O
minutes	O
and	O
antegrade	O
and	O
retrograde	O
perfusion	O
.	O
Double	O
valve	O
replacement	O
was	O
performed	O
metal	O
prosthesis	O
No	O
23	O
in	O
supra	O
annular	O
aortic	O
position	O
and	O
metal	O
prosthesis	O
No	O
27	O
in	O
mitral	O
position	O
,	O
without	O
preservation	O
of	O
mitral	O
leaflets	O
and	O
resection	O
of	O
the	O
subaortic	O
leaflet	O
.	O
In	O
the	O
immediate	O
postoperative	O
period	O
he	O
remained	O
dependent	O
on	O
amines	O
and	O
with	O
complete	O
AV	O
block	O
.	O
He	O
subsequently	O
developed	O
atrial	O
fibrillation	O
associated	O
with	O
right	O
bundle	O
branch	O
block	O
and	O
enzyme	O
peak	O
in	O
the	O
necrosis	O
range	O
3967	O
ngr	O
l	O
,	O
which	O
was	O
interpreted	O
as	O
perioperative	O
infarction	O
,	O
without	O
haemodynamic	O
repercussions	O
.	O
He	O
required	O
blood	O
pressure	O
control	O
with	O
ACE	O
inhibitors	O
and	O
doxazosin	B-FARMACO
to	O
maintain	O
cerebral	O
and	O
splanchnic	O
blood	O
pressure	O
at	O
therapeutic	O
targets	O
110	O
70	O
and	O
170	O
80	O
mmHg	O
,	O
respectively	O
.	O
The	O
control	O
echocardiogram	O
in	O
sinus	O
rhythm	O
shows	O
prosthetic	O
normofunction	O
and	O
preserved	O
ejection	O
fraction	O
,	O
so	O
it	O
is	O
possible	O
to	O
be	O
discharged	O
on	O
the	O
tenth	O
postoperative	O
day	O
,	O
with	O
the	O
aforementioned	O
antihypertensive	O
treatment	O
and	O
statins	O
,	O
as	O
well	O
as	O
permanent	O
oral	O
anticoagulation	O
acenocoumarol	B-FARMACO
.	O
At	O
present	O
,	O
her	O
blood	O
pressure	O
control	O
remains	O
suboptimal	O
and	O
her	O
functional	O
grade	O
II	O
limits	O
her	O
daily	O
activities	O
to	O
some	O
extent	O
.	O
He	O
is	O
awaiting	O
percutaneous	O
repair	O
of	O
the	O
coarctation	O
angioplasty	O
and	O
stent	O
implantation	O
,	O
which	O
was	O
accepted	O
by	O
the	O
medical	O
surgical	O
team	O
and	O
by	O
the	O
patient	O
at	O
his	O
last	O
outpatient	O
check	O
up	O
09	O
01	O
2014	O
DIAGNOSIS	O
Complex	O
congenital	O
heart	O
disease	O
with	O
serial	O
stenosis	O
of	O
the	O
left	O
ventricle	O
flow	O
incomplete	O
Shone	O
's	O
syndrome	O
.	O
Single	O
posteromedial	O
papillary	O
muscle	O
.	O
Parachute	O
mitral	O
valve	O
with	O
anterior	O
leaflet	O
prolapse	O
and	O
double	O
lesion	O
mild	O
stenosis	O
and	O
severe	O
insufficiency	O
.	O
Subaortic	O
stenosis	O
moderate	O
subvalvular	O
aortic	O
stenosis	O
.	O
Schaeffer	O
's	O
type	O
1	O
bicuspid	O
aortic	O
valve	O
moderate	O
aortic	O
stenosis	O
.	O
Yuxtaductal	O
aortic	O
coarctation	O
adult	O
type	O
with	O
severe	O
obstruction	O
to	O
aortic	O
flow	O
.	O
Aberrant	O
right	O
subclavian	O
artery	O
with	O
origin	O
in	O
postductal	O
aorta	O
.	O
Secondary	O
arterial	O
hypertension	O
with	O
suboptimal	O
control	O
.	O
Coronary	O
artery	O
disease	O
with	O
severe	O
stenosis	O
of	O
proximal	O
right	O
coronary	O
artery	O
.	O
Renal	O
artery	O
aneurysms	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Transfer	O
to	O
the	O
emergency	O
department	O
due	O
to	O
deterioration	O
of	O
the	O
level	O
of	O
consciousness	O
and	O
left	O
hemiplegia	O
.	O
Personal	O
history	O
Allergy	O
to	O
adolonta	B-FARMACO
,	O
metamizol	B-FARMACO
and	O
tramadol	B-FARMACO
.	O
Smoker	O
of	O
10	O
20	O
cigarettes	O
a	O
day	O
.	O
Percutaneous	O
mitral	O
valvuloplasty	O
with	O
residual	O
mild	O
rheumatic	O
mitral	O
stenosis	O
.	O
Paroxysmal	O
AF	O
.	O
Depressive	O
syndrome	O
.	O
Usual	O
treatment	O
sintrom	B-FARMACO
.	O
Mother	O
died	O
of	O
aortic	O
aneurysm	O
.	O
Physical	O
examination	O
Patient	O
sedated	O
and	O
connected	O
to	O
mechanical	O
ventilation	O
,	O
well	O
adapted	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
without	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
with	O
preserved	O
vesicular	O
murmur	O
and	O
no	O
added	O
sounds	O
.	O
Left	O
hemiplegia	O
.	O
Positive	O
and	O
symmetrical	O
distal	O
pulses	O
.	O
Present	O
illness	O
Patient	O
admitted	O
to	O
his	O
hospital	O
of	O
reference	O
for	O
sudden	O
loss	O
of	O
consciousness	O
,	O
accompanied	O
by	O
left	O
hemiplegia	O
.	O
Suspicion	O
of	O
stroke	O
with	O
thromboembolic	O
characteristics	O
led	O
to	O
the	O
activation	O
of	O
the	O
Stroke	O
Code	O
.	O
She	O
was	O
transferred	O
to	O
our	O
centre	O
to	O
complete	O
studies	O
and	O
assess	O
treatment	O
.	O
COMPLEMENTARY	O
TESTS	O
Cranial	O
CT	O
scan	O
without	O
intravenous	O
contrast	O
hypodense	O
lesion	O
affecting	O
the	O
right	O
insular	O
and	O
frontal	O
territory	O
,	O
suggestive	O
of	O
subacute	O
infarction	O
.	O
Angio	O
CT	O
of	O
supra	O
aortic	O
trunks	O
and	O
Willis	O
polygon	O
repletion	O
defect	O
in	O
the	O
M2	O
branch	O
of	O
the	O
anterior	O
trunk	O
of	O
the	O
right	O
MCA	O
compatible	O
with	O
thrombus	O
.	O
The	O
rest	O
of	O
the	O
intracranial	O
arteries	O
showed	O
no	O
stenosis	O
or	O
repletion	O
defects	O
.	O
Incidentally	O
,	O
an	O
intramural	O
haematoma	O
was	O
observed	O
at	O
the	O
level	O
of	O
the	O
aortic	O
arch	O
,	O
with	O
passage	O
of	O
contrast	O
into	O
the	O
interior	O
,	O
compatible	O
with	O
an	O
unstable	O
penetrating	O
ulcer	O
,	O
so	O
it	O
was	O
decided	O
to	O
complete	O
the	O
study	O
by	O
means	O
of	O
a	O
CT	O
angiography	O
of	O
the	O
thoraco	O
abdominal	O
aorta	O
.	O
Perfusion	O
CT	O
scan	O
decrease	O
in	O
flow	O
,	O
increase	O
in	O
mean	O
transit	O
time	O
and	O
decrease	O
in	O
volume	O
affecting	O
almost	O
the	O
entire	O
anterior	O
superficial	O
territory	O
of	O
the	O
right	O
MCA	O
,	O
compatible	O
with	O
subacute	O
infarction	O
.	O
Angio	O
CT	O
of	O
the	O
thoracoabdominal	O
aorta	O
intramural	O
haematoma	O
affecting	O
the	O
ascending	O
aorta	O
,	O
aortic	O
arch	O
and	O
descending	O
aorta	O
and	O
extending	O
to	O
the	O
origin	O
of	O
the	O
renal	O
arteries	O
,	O
identifying	O
an	O
aortic	O
ulcer	O
at	O
the	O
level	O
of	O
the	O
arch	O
with	O
active	O
contrast	O
passage	O
,	O
suggestive	O
of	O
unstable	O
haematoma	O
.	O
Bilateral	O
pleural	O
effusion	O
was	O
also	O
observed	O
,	O
more	O
noticeable	O
on	O
the	O
left	O
side	O
.	O
Echocardiogram	O
severe	O
LA	O
enlargement	O
.	O
Mild	O
non	O
dilated	O
LVH	O
with	O
preserved	O
EF	O
.	O
Poor	O
diastolic	O
relaxation	O
.	O
Rheumatic	O
mitral	O
valve	O
with	O
mean	O
gradient	O
of	O
4	O
.	O
7	O
mmHg	O
.	O
Ascending	O
aorta	O
dilatation	O
of	O
45	O
mm	O
.	O
At	O
the	O
level	O
of	O
the	O
sinotubular	O
junction	O
there	O
is	O
an	O
intra	O
aortic	O
linear	O
image	O
separating	O
two	O
spaces	O
,	O
the	O
smaller	O
posterior	O
one	O
with	O
no	O
lumen	O
inside	O
,	O
which	O
looks	O
like	O
a	O
haematoma	O
.	O
Aortic	O
V	O
.	O
without	O
gradient	O
or	O
insufficiency	O
.	O
Right	O
cavities	O
in	O
the	O
high	O
limit	O
with	O
mild	O
TR	O
and	O
PSAP	O
28	O
PVC	O
.	O
EVOLUTION	O
65	O
year	O
old	O
patient	O
admitted	O
for	O
right	O
hemispheric	O
stroke	O
,	O
in	O
the	O
context	O
of	O
unstable	O
mural	O
haematoma	O
.	O
Given	O
the	O
patient	O
's	O
associated	O
pathology	O
and	O
the	O
surgical	O
risk	O
,	O
emergency	O
surgical	O
treatment	O
was	O
rejected	O
.	O
She	O
was	O
admitted	O
to	O
the	O
ICU	O
,	O
requiring	O
intravenous	O
treatment	O
with	O
antihypertensive	O
drugs	O
and	O
sedation	O
for	O
48	O
hours	O
to	O
control	O
her	O
blood	O
pressure	O
.	O
After	O
the	O
sedation	O
period	O
,	O
the	O
patient	O
awoke	O
conscious	O
,	O
with	O
left	O
hemiplegia	O
.	O
The	O
echocardiogram	O
performed	O
after	O
stabilising	O
the	O
patient	O
showed	O
a	O
normofunctioning	O
aortic	O
valve	O
,	O
with	O
the	O
rest	O
of	O
the	O
study	O
similar	O
to	O
that	O
on	O
admission	O
.	O
Haemodynamically	O
,	O
the	O
patient	O
evolved	O
satisfactorily	O
,	O
improving	O
the	O
pulmonary	O
oedema	O
with	O
diuretics	O
and	O
extubation	O
was	O
possible	O
on	O
the	O
tenth	O
day	O
of	O
admission	O
.	O
After	O
the	O
stay	O
in	O
the	O
ICU	O
,	O
the	O
patient	O
was	O
discharged	O
to	O
the	O
hospital	O
ward	O
,	O
where	O
she	O
progressed	O
satisfactorily	O
,	O
without	O
complications	O
.	O
Blood	O
pressure	O
was	O
adequately	O
controlled	O
with	O
beta	O
and	O
alpha	O
blockers	O
.	O
Prior	O
to	O
hospital	O
discharge	O
,	O
a	O
control	O
CT	O
angiography	O
of	O
the	O
thoraco	O
abdominal	O
aorta	O
was	O
performed	O
,	O
which	O
showed	O
a	O
good	O
evolution	O
of	O
the	O
aortic	O
intramural	O
haematoma	O
,	O
with	O
a	O
reduction	O
in	O
the	O
diameters	O
of	O
the	O
aorta	O
and	O
the	O
mural	O
collection	O
.	O
A	O
small	O
myointimal	O
defect	O
remains	O
adjacent	O
to	O
the	O
origin	O
of	O
the	O
supra	O
aortic	O
trunks	O
.	O
No	O
alterations	O
were	O
observed	O
at	O
the	O
level	O
of	O
the	O
celiac	O
,	O
superior	O
mesenteric	O
or	O
renal	O
trunks	O
.	O
DIAGNOSIS	O
Stroke	O
of	O
the	O
right	O
cerebral	O
hemisphere	O
Intramural	O
aortic	O
haematoma	O
in	O
resolution	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
57	O
year	O
old	O
woman	O
,	O
active	O
smoker	O
of	O
10	O
cigarettes	O
a	O
day	O
with	O
a	O
history	O
of	O
overweight	O
,	O
dyslipidaemia	O
under	O
treatment	O
with	O
statins	O
and	O
ezetimibe	B-FARMACO
,	O
hypothyroidism	O
with	O
replacement	O
therapy	O
and	O
generalised	O
anxiety	O
disorder	O
under	O
follow	O
up	O
by	O
the	O
mental	O
health	O
unit	O
.	O
She	O
was	O
referred	O
for	O
stress	O
echocardiography	O
with	O
dobutamine	O
because	O
she	O
presented	O
functional	O
class	O
II	O
IV	O
of	O
the	O
New	O
York	O
Heart	O
Association	O
and	O
moderate	O
effort	O
angina	O
with	O
submaximal	O
ergometry	O
due	O
to	O
weakness	O
in	O
the	O
lower	O
limbs	O
.	O
On	O
physical	O
examination	O
,	O
the	O
patient	O
was	O
in	O
good	O
general	O
condition	O
with	O
auscultation	O
of	O
rhythmic	O
heart	O
tones	O
without	O
murmurs	O
or	O
other	O
findings	O
of	O
interest	O
.	O
The	O
stress	O
test	O
was	O
started	O
.	O
The	O
baseline	O
electrocardiogram	O
showed	O
sinus	O
rhythm	O
,	O
pr	O
200	O
msec	O
,	O
narrow	O
QRS	O
,	O
without	O
repolarisation	O
alterations	O
.	O
The	O
baseline	O
transthoracic	O
echocardiogram	O
showed	O
good	O
global	O
and	O
segmental	O
left	O
ventricular	O
function	O
,	O
with	O
normal	O
wall	O
thickness	O
,	O
no	O
significant	O
valvular	O
heart	O
disease	O
and	O
normal	O
pulmonary	O
artery	O
pressure	O
.	O
During	O
stress	O
echocardiography	O
with	O
maximum	O
dose	O
of	O
dobutamine	O
40	O
mcg	O
kg	O
min	O
,	O
a	O
paradoxically	O
negative	O
chronotropic	O
response	O
was	O
observed	O
,	O
reaching	O
a	O
bradycardia	O
of	O
36	O
bpm	O
.	O
After	O
administration	O
of	O
0	O
.	O
5	O
mg	O
atropine	B-FARMACO
,	O
the	O
patient	O
presented	O
chest	O
pain	O
,	O
with	O
ST	O
segment	O
depression	O
in	O
inferior	O
leads	O
and	O
from	O
V3	O
to	O
V6	O
up	O
to	O
3	O
mm	O
with	O
ST	O
segment	O
elevation	O
in	O
AVR	O
and	O
V1	O
V2	O
,	O
I	O
and	O
aVL	O
,	O
and	O
moderate	O
left	O
ventricular	O
dysfunction	O
with	O
hypokinesia	O
of	O
the	O
basal	O
segments	O
and	O
LV	O
apical	O
hypercontractility	O
.	O
After	O
administering	O
solinitrine	B-FARMACO
and	O
intravenous	O
metoprolol	B-FARMACO
,	O
the	O
persistence	O
of	O
chest	O
pain	O
and	O
electrocardiographic	O
alterations	O
continued	O
,	O
so	O
an	O
urgent	O
coronary	O
angiography	O
was	O
performed	O
,	O
which	O
showed	O
normal	O
epicardial	O
coronary	O
arteries	O
,	O
without	O
lesions	O
susceptible	O
to	O
revascularisation	O
,	O
with	O
no	O
evidence	O
of	O
coronary	O
vasospasm	O
.	O
Ventriculography	O
showed	O
apical	O
hypercontractility	O
with	O
hypokinesia	O
of	O
basal	O
segments	O
.	O
COMPLEMENTARY	O
TESTS	O
Basal	O
electrocardiogram	O
sinus	O
rhythm	O
,	O
normal	O
pr	O
,	O
left	O
inferior	O
axis	O
,	O
narrow	O
QRS	O
,	O
without	O
repolarisation	O
alterations	O
.	O
Baseline	O
transthoracic	O
echocardiogram	O
preserved	O
LVEF	O
with	O
no	O
alterations	O
in	O
segmental	O
contractility	O
,	O
no	O
LV	O
dilatation	O
or	O
hypertrophy	O
,	O
no	O
significant	O
valvular	O
heart	O
disease	O
and	O
normal	O
pulmonary	O
artery	O
pressure	O
.	O
Stress	O
echocardiography	O
Maximum	O
dose	O
of	O
dobutamine	O
is	O
reached	O
with	O
paradoxically	O
negative	O
chronotropic	O
response	O
.	O
After	O
administration	O
of	O
atropine	B-FARMACO
the	O
patient	O
presented	O
chest	O
pain	O
,	O
with	O
electrocardiographic	O
changes	O
.	O
Moderate	O
left	O
ventricular	O
dysfunction	O
with	O
hypokinesia	O
of	O
the	O
basal	O
segments	O
and	O
LV	O
apical	O
hypercontractility	O
.	O
Catheterisation	O
coronary	O
arteries	O
without	O
lesions	O
susceptible	O
to	O
revascularisation	O
.	O
Ventriculography	O
apical	O
hypercontractility	O
,	O
hypokinesia	O
of	O
basal	O
segments	O
.	O
EVOLUTION	O
After	O
cardiac	O
catheterisation	O
,	O
the	O
electrocardiogram	O
evolved	O
to	O
progressive	O
normalisation	O
,	O
the	O
patient	O
remained	O
asymptomatic	O
and	O
a	O
maximum	O
peak	O
troponin	O
level	O
of	O
1	O
.	O
7	O
ng	O
ml	O
normal	O
value	O
0	O
.	O
00	O
0	O
.	O
16	O
ng	O
ml	O
and	O
a	O
creatine	O
kinase	O
MB	O
mass	O
of	O
31	O
.	O
79	O
ng	O
ml	O
normal	O
value	O
0	O
.	O
00	O
5	O
.	O
10	O
ng	O
ml	O
was	O
reached	O
.	O
Once	O
on	O
the	O
ward	O
,	O
the	O
dose	O
of	O
beta	O
blockers	O
was	O
increased	O
with	O
good	O
tolerance	O
and	O
progressive	O
improvement	O
in	O
left	O
ventricular	O
function	O
,	O
and	O
she	O
was	O
discharged	O
one	O
week	O
after	O
admission	O
with	O
a	O
left	O
ventricular	O
ejection	O
fraction	O
of	O
60	O
according	O
to	O
Simpson	O
and	O
no	O
segmental	O
alterations	O
in	O
contractility	O
.	O
DIAGNOSIS	O
Reverse	O
Tako	O
tsubo	O
during	O
dobutamine	O
stress	O
echocardiography	O
.	O

HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
We	O
present	O
a	O
72	O
year	O
old	O
patient	O
from	O
Ukraine	O
in	O
an	O
autonomous	O
functional	O
situation	O
with	O
no	O
known	O
drug	O
allergies	O
,	O
with	O
a	O
personal	O
history	O
of	O
hypertension	O
,	O
dyslipidaemia	O
,	O
type	O
2	O
diabetes	O
mellitus	O
and	O
permanent	O
atrial	O
fibrillation	O
.	O
Under	O
home	O
treatment	O
with	O
ramipril	B-FARMACO
10	O
mg	O
24	O
h	O
,	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
24	O
h	O
,	O
metformin	B-FARMACO
850	O
mg	O
24	O
h	O
,	O
fenofibrate	B-FARMACO
145	O
mg	O
24	O
h	O
and	O
Sintrom	B-FARMACO
4	O
mg	O
according	O
to	O
haematology	O
guidelines	O
.	O
She	O
came	O
to	O
the	O
emergency	O
department	O
for	O
repeated	O
presyncopal	O
and	O
syncopal	O
episodes	O
of	O
sudden	O
onset	O
,	O
lasting	O
seconds	O
and	O
with	O
spontaneous	O
recovery	O
,	O
with	O
no	O
apparent	O
sequelae	O
.	O
She	O
reported	O
no	O
prodromal	O
symptoms	O
,	O
clear	O
triggers	O
,	O
chest	O
pain	O
or	O
palpitations	O
.	O
No	O
dyspnoea	O
or	O
associated	O
trauma	O
.	O
After	O
observing	O
a	O
cervical	O
asymmetry	O
,	O
he	O
describes	O
the	O
recent	O
appearance	O
of	O
a	O
large	O
"	O
lump	O
"	O
,	O
with	O
a	O
progressive	O
increase	O
in	O
size	O
over	O
the	O
last	O
month	O
.	O
Physical	O
examination	O
BP	O
126	O
57	O
mmHg	O
,	O
HR	O
92	O
bpm	O
,	O
T	O
36	O
.	O
4	O
C	O
,	O
baseline	O
SatO2	O
96	O
.	O
Patient	O
conscious	O
and	O
oriented	O
,	O
normohydrated	O
and	O
normal	O
colour	O
.	O
Mild	O
tachypnoea	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
without	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
normoventilation	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
,	O
no	O
masses	O
or	O
megaliths	O
palpable	O
.	O
Peristalsis	O
preserved	O
.	O
Negative	O
jugular	O
ingurgitation	O
,	O
negative	O
hepatojugular	O
reflux	O
.	O
No	O
oedema	O
in	O
the	O
lower	O
extremities	O
or	O
signs	O
of	O
DVT	O
.	O
There	O
was	O
a	O
voluminous	O
,	O
heterogeneous	O
and	O
indurated	O
right	O
laterocervical	O
tumour	O
with	O
marked	O
vascularisation	O
,	O
identifying	O
vessels	O
of	O
increased	O
calibre	O
adhering	O
to	O
deep	O
planes	O
.	O
ENT	O
examination	O
no	O
pharyngolaryngeal	O
alterations	O
,	O
good	O
glottic	O
space	O
,	O
good	O
cord	O
mobility	O
.	O
No	O
oedema	O
in	O
pharyngeal	O
laryngeal	O
mucous	O
membranes	O
,	O
permeable	O
airway	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
atrial	O
fibrillation	O
with	O
mean	O
ventricular	O
response	O
at	O
74	O
bpm	O
,	O
without	O
LVH	O
criteria	O
or	O
repolarisation	O
alterations	O
.	O
Chest	O
X	O
ray	O
normal	O
cardiac	O
silhouette	O
,	O
hilar	O
thickening	O
with	O
vascular	O
appearance	O
.	O
Signs	O
of	O
chronic	O
bronchopathy	O
with	O
pulmonary	O
hyperinflation	O
.	O
No	O
pleuroparenchymal	O
alterations	O
of	O
acute	O
evolution	O
.	O
Blood	O
tests	O
cardiac	O
markers	O
troponin	O
I	O
0	O
.	O
01	O
ng	O
ml	O
,	O
myoglobin	O
74	O
,	O
NT	O
proBNP	O
750	O
pg	O
ml	O
.	O
Biochemistry	O
glycaemia	O
139	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
97	O
mg	O
dl	O
,	O
Na	O
132	O
mEq	O
l	O
,	O
Cl	O
98	O
mEq	O
l	O
,	O
K	O
4	O
.	O
1	O
mEq	O
l	O
,	O
Ca	O
9	O
.	O
2	O
mg	O
dl	O
.	O
Mg	O
2	O
mEq	O
l	O
.	O
Haemogram	O
leucocytes	O
8	O
,	O
800	O
mL	O
with	O
77	O
neutrophils	O
.	O
Hb	O
11	O
.	O
9	O
g	O
dl	O
,	O
Ht	O
38	O
.	O
1	O
,	O
platelets	O
225	O
,	O
000	O
mcL	O
.	O
Coagulation	O
INR	O
1	O
.	O
5	O
,	O
TTP	O
29	O
.	O
9	O
sg	O
,	O
PT	O
16	O
.	O
9	O
sg	O
,	O
AP	O
61	O
.	O
Transthoracic	O
echocardiogram	O
non	O
dilated	O
LV	O
with	O
mild	O
moderate	O
concentric	O
LVH	O
.	O
Preserved	O
LVEF	O
.	O
Slightly	O
dilated	O
atria	O
.	O
Mild	O
calcification	O
of	O
the	O
posterior	O
mitral	O
annulus	O
with	O
mild	O
MR	O
.	O
VAo	O
appears	O
trivalve	O
with	O
sclerosis	O
of	O
sigmoid	O
arteries	O
without	O
generating	O
restriction	O
to	O
its	O
opening	O
.	O
Normal	O
right	O
chambers	O
.	O
No	O
pericardial	O
effusion	O
.	O
Monitoring	O
in	O
ED	O
observation	O
room	O
atrial	O
fibrillation	O
with	O
mean	O
ventricular	O
response	O
70	O
bpm	O
.	O
Significant	O
pauses	O
of	O
up	O
to	O
5	O
.	O
5	O
seconds	O
were	O
observed	O
.	O
Neck	O
thoracic	O
abdomino	O
pelvic	O
CT	O
scan	O
right	O
supraclavicular	O
adenopathy	O
12	O
mm	O
in	O
diameter	O
extending	O
craniocaudally	O
through	O
the	O
right	O
carotid	O
space	O
from	O
the	O
jugular	O
gulf	O
to	O
the	O
jugulosubclavian	O
bifurcation	O
,	O
also	O
affecting	O
the	O
posteroinferior	O
parotid	O
region	O
,	O
the	O
homolateral	O
parapharyngeal	O
and	O
paravertebral	O
space	O
,	O
as	O
well	O
as	O
the	O
sternocleidomastoid	O
muscle	O
and	O
the	O
lateral	O
region	O
of	O
the	O
right	O
thyroid	O
lobe	O
.	O
It	O
protrudes	O
into	O
the	O
right	O
oropharyngeal	O
lateral	O
wall	O
and	O
envelops	O
the	O
jugulocarotid	O
axis	O
there	O
is	O
contrast	O
filling	O
in	O
the	O
carotid	O
and	O
not	O
in	O
the	O
jugular	O
.	O
Small	O
bilateral	O
axillary	O
lymph	O
nodes	O
.	O
Other	O
smaller	O
lymph	O
nodes	O
in	O
the	O
prevascular	O
mediastinum	O
on	O
both	O
sides	O
of	O
the	O
midline	O
.	O
Pacemaker	O
with	O
electrode	O
tip	O
in	O
the	O
right	O
ventricle	O
.	O
Global	O
cardiomegaly	O
.	O
Coronary	O
atheromatosis	O
.	O
Moderate	O
pulmonary	O
hyperinflation	O
with	O
signs	O
of	O
chronic	O
bronchopneumopathy	O
.	O
No	O
involvement	O
of	O
the	O
pleural	O
space	O
.	O
The	O
rest	O
of	O
the	O
examination	O
was	O
unaltered	O
.	O
No	O
retroperitoneal	O
or	O
mesenteric	O
adenopathy	O
was	O
observed	O
,	O
nor	O
in	O
the	O
iliac	O
or	O
inguinal	O
chains	O
.	O
Pathological	O
anatomy	O
of	O
the	O
biopsy	O
of	O
the	O
cervical	O
adenopathic	O
conglomerate	O
high	O
grade	O
,	O
diffuse	O
large	O
cell	O
B	O
lymphoma	O
.	O
Activated	O
immunophenotype	O
ABC	O
CD10	O
BCL6	O
MUM	O
1	O
.	O
Cellularity	O
large	O
blasts	O
,	O
vesicular	O
nuclei	O
,	O
with	O
one	O
or	O
more	O
prominent	O
nucleoli	O
.	O
Diffuse	O
growth	O
pattern	O
.	O
Immunohistochemistry	O
expresses	O
CD79a	O
;	O
CD20	O
irregular	O
;	O
BCL2	O
;	O
Bcl6	O
and	O
MUM1	O
.	O
Negative	O
for	O
CD3	O
;	O
CD5	O
;	O
CD10	O
;	O
CD23	O
;	O
cyclin	O
D1	O
,	O
CD30	O
and	O
EBER	O
.	O
C	O
MYC	O
positivity	O
in	O
40	O
50	O
of	O
the	O
tumour	O
population	O
pending	O
FISH	O
.	O
Proliferative	O
activity	O
,	O
assessed	O
with	O
KI67	O
90	O
100	O
.	O
Bone	O
marrow	O
aspirate	O
cytological	O
diagnosis	O
of	O
DLBCL	O
.	O
Flow	O
cytometry	O
no	O
abnormal	O
immunophenotype	O
lymphocytes	O
with	O
a	O
frequency	O
of	O
more	O
than	O
1	O
8	O
,	O
000	O
cells	O
were	O
detected	O
in	O
this	O
sample	O
.	O
EVOLUTION	O
This	O
is	O
a	O
patient	O
with	O
the	O
aforementioned	O
history	O
who	O
presented	O
with	O
a	O
right	O
cervical	O
mass	O
of	O
three	O
months	O
'	O
evolution	O
with	O
progressive	O
growth	O
causing	O
dysphagia	O
for	O
solids	O
with	O
a	O
weight	O
loss	O
of	O
20	O
kg	O
.	O
She	O
came	O
to	O
the	O
emergency	O
department	O
for	O
repeated	O
abrupt	O
syncopal	O
episodes	O
and	O
atrial	O
fibrillation	O
with	O
significant	O
pauses	O
of	O
up	O
to	O
5	O
6	O
seconds	O
duration	O
was	O
observed	O
on	O
monitoring	O
.	O
Controlled	O
massage	O
of	O
the	O
left	O
carotid	O
sinus	O
reproduced	O
the	O
same	O
symptomatology	O
with	O
a	O
positive	O
cardioinhibitory	O
response	O
with	O
pauses	O
of	O
4	O
sec	O
.	O
After	O
discussing	O
the	O
case	O
with	O
Cardiology	O
and	O
Otorhinolaryngology	O
on	O
duty	O
,	O
beta	O
blocker	O
treatment	O
was	O
suspended	O
and	O
the	O
patient	O
was	O
admitted	O
to	O
the	O
observation	O
room	O
for	O
monitoring	O
and	O
ECG	O
recording	O
,	O
in	O
addition	O
to	O
performing	O
an	O
ultrasound	O
guided	O
FNA	O
with	O
the	O
aim	O
of	O
identifying	O
the	O
cervical	O
mass	O
to	O
allow	O
therapeutic	O
guidance	O
.	O
During	O
monitoring	O
,	O
the	O
patient	O
suffered	O
new	O
syncopal	O
and	O
presyncopal	O
episodes	O
with	O
bradycardia	O
and	O
significant	O
pauses	O
.	O
FNAUS	O
was	O
performed	O
with	O
inconclusive	O
results	O
.	O
In	O
view	O
of	O
the	O
finding	O
of	O
episodes	O
of	O
symptomatic	O
bradycardia	O
with	O
significant	O
pauses	O
,	O
the	O
patient	O
was	O
diagnosed	O
with	O
peripheral	O
neurocardiogenic	O
syncope	O
secondary	O
to	O
carotid	O
compression	O
by	O
a	O
large	O
cervical	O
mass	O
pending	O
filiation	O
,	O
and	O
was	O
admitted	O
to	O
Cardiology	O
for	O
implantation	O
of	O
a	O
VVIR	O
pacemaker	O
to	O
control	O
the	O
cardioinhibitory	O
reflex	O
.	O
This	O
procedure	O
was	O
carried	O
out	O
without	O
complications	O
,	O
and	O
its	O
correct	O
functioning	O
was	O
checked	O
,	O
being	O
programmed	O
in	O
VVIR	O
at	O
70	O
60	O
beats	O
per	O
minute	O
.	O
Subsequently	O
,	O
beta	O
blockers	O
were	O
restarted	O
for	O
AF	O
at	O
around	O
110	O
beats	O
per	O
minute	O
.	O
After	O
a	O
CT	O
scan	O
,	O
biopsy	O
and	O
anatomopathological	O
study	O
of	O
the	O
cervical	O
mass	O
,	O
Otorhinolaryngology	O
concluded	O
that	O
it	O
was	O
a	O
cervical	O
adenopathic	O
conglomerate	O
with	O
a	O
diagnosis	O
of	O
high	O
grade	O
diffuse	O
large	O
cell	O
B	O
lymphoma	O
.	O
The	O
patient	O
was	O
transferred	O
to	O
the	O
haematology	O
department	O
to	O
complete	O
the	O
study	O
and	O
start	O
specific	O
chemotherapy	O
treatment	O
according	O
to	O
the	O
R	O
CHOP	O
scheme	O
rituximab	B-FARMACO
,	O
cyclophosphamide	B-FARMACO
,	O
liposomal	B-FARMACO
doxorubicin	I-FARMACO
due	O
to	O
being	O
a	O
cardiac	O
patient	O
,	O
vincristine	B-FARMACO
and	O
prednisone	B-FARMACO
.	O
During	O
admission	O
to	O
haematology	O
,	O
episodes	O
of	O
dyspnoea	O
and	O
dysphagia	O
with	O
good	O
response	O
to	O
corticoids	O
and	O
cytoreduction	O
with	O
cyclophosphamide	B-FARMACO
.	O
Rapid	O
reduction	O
of	O
the	O
cervical	O
mass	O
with	O
symptomatic	O
improvement	O
and	O
no	O
new	O
syncopal	O
episodes	O
.	O
Given	O
the	O
clinical	O
stability	O
,	O
discharge	O
was	O
decided	O
to	O
continue	O
treatment	O
on	O
an	O
outpatient	O
basis	O
.	O
DIAGNOSIS	O
Cardioinhibitory	O
reflex	O
vasovagal	O
syncope	O
secondary	O
to	O
compression	O
of	O
the	O
carotid	O
sinus	O
by	O
a	O
large	O
cervical	O
mass	O
.	O
Large	O
B	O
cell	O
non	O
Hodgkin	O
's	O
lymphoma	O
,	O
stage	O
II	O
B	O
,	O
triple	O
Hit	O
BCL	O
2	O
,	O
BCL	O
6	O
and	O
C	O
MYC	O
.	O

HISTORY	O
,	O
CURRENT	O
DISEASE	O
AND	O
PHYSICAL	O
EXAMINATION	O
We	O
present	O
the	O
case	O
of	O
a	O
77	O
year	O
old	O
woman	O
,	O
hypertensive	O
and	O
diabetic	O
,	O
with	O
no	O
family	O
history	O
or	O
previous	O
cardiological	O
history	O
.	O
The	O
patient	O
consulted	O
the	O
emergency	O
department	O
of	O
her	O
hospital	O
for	O
an	O
episode	O
of	O
chest	O
pain	O
at	O
rest	O
,	O
of	O
about	O
two	O
hours	O
'	O
duration	O
,	O
accompanied	O
by	O
vegetative	O
crust	O
.	O
She	O
reported	O
symptoms	O
compatible	O
with	O
exertional	O
angina	O
during	O
the	O
previous	O
two	O
weeks	O
,	O
with	O
a	O
progressive	O
drop	O
in	O
the	O
pain	O
threshold	O
.	O
There	O
were	O
no	O
other	O
cardiological	O
symptoms	O
in	O
the	O
anamnesis	O
.	O
An	O
electrocardiogram	O
was	O
performed	O
showing	O
ST	O
segment	O
elevation	O
in	O
the	O
anterior	O
face	O
,	O
and	O
the	O
haemodynamics	O
department	O
was	O
contacted	O
,	O
and	O
the	O
patient	O
was	O
transferred	O
to	O
our	O
hospital	O
for	O
primary	O
angioplasty	O
.	O
Catheterisation	O
revealed	O
95	O
stenosis	O
in	O
the	O
middle	O
LAD	O
see	O
coronary	O
angiography	O
,	O
which	O
was	O
revascularised	O
by	O
thromboaspiration	O
and	O
implantation	O
of	O
two	O
drug	O
eluting	O
stents	O
.	O
Subsequent	O
transfer	O
to	O
ICU	O
to	O
continue	O
immediate	O
evolution	O
.	O
On	O
admission	O
,	O
the	O
patient	O
was	O
haemodynamically	O
stable	O
and	O
in	O
good	O
general	O
condition	O
.	O
BP	O
140	O
70	O
HR	O
90	O
bpm	O
ACP	O
rhythmic	O
tones	O
without	O
murmurs	O
.	O
Bladder	O
murmur	O
preserved	O
without	O
pathological	O
sounds	O
.	O
Lower	O
limbs	O
without	O
oedema	O
.	O
No	O
congestive	O
or	O
low	O
output	O
semiology	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
on	O
admission	O
to	O
Cardiology	O
sinus	O
rhythm	O
at	O
75	O
bpm	O
.	O
Normal	O
axis	O
.	O
Normal	O
PR	O
.	O
Narrow	O
QRS	O
QS	O
from	O
V1	O
V4	O
with	O
significant	O
ST	O
elevation	O
in	O
precordial	O
leads	O
more	O
pronounced	O
in	O
V3	O
V4	O
,	O
"	O
tombstone	O
ST	O
"	O
and	O
in	O
inferior	O
face	O
.	O
CBC	O
blood	O
glucose	O
140	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
90	O
mg	O
dl	O
,	O
urea	O
37	O
mg	O
dl	O
,	O
Na	O
140	O
mEq	O
l	O
,	O
K	O
3	O
mEq	O
l	O
,	O
Hb	O
10	O
g	O
dl	O
.	O
Leukocytosis	O
of	O
14	O
,	O
000	O
on	O
admission	O
predominantly	O
polymorphonuclear	O
which	O
subsequently	O
normalised	O
.	O
Platelets	O
500	O
,	O
000	O
,	O
normal	O
coagulation	O
.	O
Liver	O
,	O
lipid	O
and	O
thyroid	O
profile	O
without	O
alterations	O
.	O
Glycated	O
Hb	O
10	O
.	O
7	O
.	O
Peak	O
TNTUs	O
1327	O
ng	O
L	O
,	O
CPK	O
227	O
mU	O
ml	O
.	O
Coronary	O
angiography	O
normo	O
developed	O
anterior	O
descending	O
artery	O
of	O
good	O
calibre	O
,	O
with	O
acute	O
lesion	O
95	O
in	O
the	O
middle	O
segment	O
,	O
distal	O
vessel	O
TIMI	O
1	O
flow	O
,	O
of	O
regular	O
calibre	O
.	O
Rest	O
without	O
significant	O
lesions	O
.	O
Right	O
dominance	O
.	O
Urgent	O
PCI	O
on	O
middle	O
LAD	O
thromboaspiration	O
with	O
catheter	O
,	O
implanting	O
zotarolimus	O
eluting	O
stent	O
2	O
.	O
25	O
x	O
18	O
mm	O
and	O
another	O
non	O
consecutive	O
stent	O
eluting	O
stent	O
3	O
x	O
15	O
mm	O
.	O
Final	O
TIMI	O
flow	O
2	O
improved	O
with	O
intracoronary	O
nitroprusside	B-FARMACO
.	O
Transthoracic	O
echocardiography	O
left	O
atrium	O
slightly	O
dilated	O
37	O
ml	O
m2	O
.	O
Mitral	O
valve	O
with	O
calcification	O
of	O
the	O
posterior	O
annulus	O
but	O
with	O
thin	O
leaflets	O
and	O
good	O
mobility	O
.	O
Mild	O
central	O
mitral	O
regurgitation	O
.	O
Slightly	O
dilated	O
LV	O
VTDi	O
68	O
.	O
23	O
ml	O
m2	O
with	O
9	O
mm	O
basal	O
septum	O
and	O
6	O
.	O
5	O
mm	O
posterior	O
wall	O
.	O
Mitral	O
filling	O
pattern	O
with	O
E	O
A	O
and	O
E	O
e	O
averaged	O
7	O
.	O
Akinesia	O
of	O
all	O
apical	O
segments	O
with	O
compensatory	O
hypercontractility	O
of	O
the	O
remaining	O
segments	O
and	O
LVEF	O
estimated	O
by	O
Simpson	O
biplane	O
at	O
65	O
.	O
An	O
interventricular	O
septal	O
defect	O
was	O
observed	O
at	O
the	O
apical	O
level	O
compatible	O
with	O
VSD	O
.	O
The	O
largest	O
diameter	O
is	O
recorded	O
in	O
more	O
anterior	O
planes	O
1	O
.	O
3	O
mm	O
.	O
High	O
velocity	O
flow	O
is	O
achieved	O
with	O
Vmax	O
4	O
.	O
5	O
m	O
sec	O
and	O
mean	O
gradient	O
42	O
.	O
5	O
mmHg	O
.	O
Fibrocalcified	O
aortic	O
valve	O
with	O
adequate	O
opening	O
and	O
mild	O
central	O
insufficiency	O
.	O
Non	O
dilated	O
RV	O
with	O
preserved	O
systolic	O
function	O
TAPSE	O
23	O
mm	O
.	O
Mild	O
IT	O
jet	O
that	O
allows	O
estimating	O
a	O
PAPs	O
of	O
56	O
57	O
mmHG	O
.	O
Non	O
dilated	O
IVC	O
with	O
adequate	O
inspiratory	O
collapse	O
.	O
No	O
pericardial	O
effusion	O
Transesophageal	O
echocardiography	O
in	O
the	O
most	O
apical	O
segment	O
of	O
the	O
septum	O
,	O
which	O
is	O
akinetic	O
,	O
there	O
is	O
a	O
solution	O
of	O
continuity	O
compatible	O
with	O
VSD	O
with	O
high	O
velocity	O
flow	O
passage	O
.	O
This	O
VSD	O
is	O
best	O
defined	O
in	O
more	O
anterior	O
planes	O
of	O
the	O
septum	O
,	O
with	O
diameters	O
of	O
1	O
.	O
2	O
cm	O
x	O
1	O
.	O
9	O
cm	O
area	O
2	O
cm2	O
with	O
friable	O
surrounding	O
tissue	O
.	O
The	O
septal	O
myocardium	O
more	O
proximal	O
to	O
the	O
defect	O
,	O
also	O
akinetic	O
,	O
has	O
a	O
rarefied	O
and	O
hollow	O
appearance	O
.	O
The	O
VSD	O
lacks	O
borders	O
in	O
its	O
distal	O
part	O
,	O
continuing	O
with	O
the	O
more	O
apical	O
myocardium	O
which	O
is	O
very	O
thinned	O
.	O
EVOLUTION	O
The	O
patient	O
evolves	O
favourably	O
in	O
the	O
first	O
hours	O
after	O
the	O
intervention	O
.	O
Bedside	O
echocardiography	O
showed	O
akinesia	O
in	O
the	O
apical	O
territory	O
and	O
preserved	O
LVEF	O
.	O
The	O
patient	O
was	O
monitored	O
and	O
treatment	O
for	O
acute	O
coronary	O
syndrome	O
was	O
continued	O
.	O
At	O
12	O
hours	O
,	O
the	O
patient	O
had	O
a	O
loud	O
systolic	O
murmur	O
,	O
more	O
audible	O
in	O
the	O
left	O
parasternal	O
focus	O
,	O
which	O
was	O
not	O
present	O
on	O
arrival	O
.	O
A	O
repeat	O
transthoracic	O
echocardiogram	O
was	O
performed	O
to	O
rule	O
out	O
early	O
post	O
AMI	O
mechanical	O
complications	O
.	O
A	O
solution	O
of	O
continuity	O
was	O
found	O
in	O
the	O
apical	O
interventricular	O
septum	O
with	O
a	O
high	O
velocity	O
left	O
to	O
right	O
flow	O
passage	O
.	O
Echocardiography	O
also	O
showed	O
data	O
compatible	O
with	O
pulmonary	O
hypertension	O
.	O
After	O
a	O
diagnosis	O
of	O
ventricular	O
septal	O
defect	O
VSD	O
,	O
the	O
Cardiac	O
Surgery	O
Department	O
was	O
consulted	O
and	O
,	O
given	O
the	O
clinical	O
context	O
advanced	O
age	O
in	O
a	O
patient	O
with	O
comorbidity	O
,	O
double	O
antiplatelet	O
therapy	O
and	O
relative	O
stability	O
,	O
emergency	O
surgery	O
was	O
ruled	O
out	O
at	O
that	O
time	O
.	O
The	O
patient	O
remained	O
stable	O
for	O
the	O
next	O
72	O
hours	O
and	O
was	O
transferred	O
to	O
the	O
cardiology	O
monitoring	O
unit	O
for	O
further	O
treatment	O
.	O
She	O
initially	O
evolved	O
unfavourably	O
,	O
presenting	O
congestive	O
semiology	O
,	O
so	O
continuous	O
perfusion	O
of	O
furosemide	B-FARMACO
was	O
started	O
.	O
A	O
24	O
hour	O
infusion	O
of	O
levosimendan	B-FARMACO
was	O
prescribed	O
,	O
with	O
subsequent	O
improvement	O
.	O
Repeat	O
transthoracic	O
echocardiography	O
showed	O
a	O
septoapical	O
VSD	O
with	O
a	O
high	O
speed	O
left	O
to	O
right	O
shunt	O
V	O
max	O
4	O
.	O
5	O
m	O
sec	O
mean	O
gradient	O
43	O
mmHg	O
.	O
The	O
RV	O
AD	O
gradient	O
is	O
53	O
mmHg	O
,	O
compatible	O
with	O
at	O
least	O
moderate	O
pulmonary	O
hypertension	O
.	O
Given	O
that	O
there	O
was	O
an	O
indication	O
for	O
VSD	O
closure	O
,	O
and	O
in	O
order	O
to	O
decide	O
on	O
the	O
optimal	O
approach	O
percutaneous	O
versus	O
surgical	O
,	O
transesophageal	O
echocardiography	O
was	O
requested	O
.	O
A	O
3D	O
TEE	O
reconstruction	O
of	O
the	O
septal	O
defect	O
diameter	O
1	O
.	O
2	O
x	O
1	O
.	O
9	O
cm	O
and	O
area	O
2	O
cm2	O
was	O
performed	O
.	O
The	O
VSD	O
lacked	O
borders	O
in	O
its	O
distal	O
part	O
,	O
and	O
the	O
myocardium	O
proximal	O
to	O
it	O
was	O
rarefied	O
friable	O
appearance	O
and	O
with	O
hollows	O
.	O
Given	O
these	O
findings	O
,	O
percutaneous	O
closure	O
was	O
ruled	O
out	O
and	O
the	O
patient	O
was	O
accepted	O
for	O
surgery	O
.	O
Surgery	O
was	O
performed	O
three	O
weeks	O
after	O
the	O
AMI	O
.	O
DIAGNOSIS	O
Anterior	O
STEMI	O
subjected	O
to	O
primary	O
angioplasty	O
with	O
revascularisation	O
of	O
the	O
culprit	O
lesion	O
in	O
the	O
mid	O
LAD	O
using	O
two	O
drug	O
eluting	O
stents	O
.	O
Septoapical	O
VSD	O
as	O
an	O
early	O
post	O
AMI	O
mechanical	O
complication	O
corrected	O
surgically	O
.	O
Akinesia	O
in	O
the	O
apical	O
territory	O
,	O
with	O
preserved	O
LVEF	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
78	O
year	O
old	O
woman	O
,	O
independent	O
for	O
basic	O
activities	O
of	O
daily	O
living	O
and	O
without	O
cognitive	O
impairment	O
.	O
She	O
had	O
previously	O
been	O
diagnosed	O
with	O
arterial	O
hypertension	O
,	O
obesity	O
,	O
hypothyroidism	O
and	O
depression	O
.	O
She	O
was	O
being	O
treated	O
with	O
candesartan	B-FARMACO
8	O
mg	O
,	O
sertraline	B-FARMACO
100	O
mg	O
and	O
levothyroxine	B-FARMACO
150	O
mcg	O
.	O
She	O
came	O
to	O
the	O
emergency	O
department	O
for	O
dyspnoea	O
of	O
2	O
months	O
'	O
duration	O
,	O
with	O
no	O
clear	O
relationship	O
with	O
exertion	O
.	O
She	O
reported	O
no	O
chest	O
pain	O
,	O
palpitations	O
or	O
other	O
cardiac	O
symptoms	O
.	O
Physical	O
examination	O
afebrile	O
,	O
with	O
a	O
heart	O
rate	O
of	O
77	O
bpm	O
,	O
BP	O
140	O
94	O
mmHg	O
and	O
respiratory	O
rate	O
of	O
16	O
rpm	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
and	O
without	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
moderate	O
inspiratory	O
stridor	O
.	O
The	O
neurological	O
,	O
abdominal	O
and	O
extremities	O
examination	O
showed	O
no	O
abnormalities	O
.	O
COMPLEMENTARY	O
TESTS	O
Biochemistry	O
Na	O
141	O
mEq	O
L	O
,	O
K	O
4	O
.	O
2	O
mEq	O
L	O
,	O
Cr	O
0	O
.	O
9	O
mg	O
dl	O
,	O
U	O
43	O
IU	O
L	O
,	O
AST	O
26	O
IU	O
L	O
,	O
ALT	O
31	O
IU	O
L	O
.	O
Blood	O
count	O
and	O
coagulation	O
Hb	O
12	O
.	O
4	O
mg	O
dl	O
,	O
MCV	O
95	O
fL	O
,	O
Htco	O
45	O
,	O
Leukocytes	O
10	O
,	O
203	O
ml	O
,	O
PT	O
97	O
.	O
Baseline	O
arterial	O
blood	O
gases	O
pH	O
7	O
.	O
35	O
,	O
SatO2	O
85	O
,	O
pO2	O
55	O
mmHg	O
,	O
pCO2	O
32	O
mmHg	O
.	O
ECG	O
sinus	O
at	O
90	O
bpm	O
.	O
No	O
evidence	O
of	O
ischaemia	O
,	O
conduction	O
disturbances	O
or	O
repolarisation	O
.	O
Chest	O
X	O
ray	O
normal	O
cardiothoracic	O
index	O
.	O
No	O
condensation	O
.	O
Angio	O
CT	O
of	O
pulmonary	O
arteries	O
absence	O
of	O
acute	O
PTE	O
.	O
No	O
local	O
complications	O
at	O
the	O
level	O
of	O
the	O
thoracic	O
aorta	O
.	O
EVOLUTION	O
Given	O
the	O
absence	O
of	O
signs	O
of	O
decompensation	O
due	O
to	O
heart	O
failure	O
and	O
given	O
that	O
the	O
initial	O
tests	O
were	O
not	O
suggestive	O
of	O
structural	O
heart	O
disease	O
,	O
she	O
was	O
initially	O
evaluated	O
by	O
pulmonology	O
due	O
to	O
inspiratory	O
stridor	O
.	O
Bronchoscopy	O
revealed	O
an	O
intermediate	O
tracheobronchomalacia	O
,	O
for	O
which	O
bronchodilator	O
and	O
corticosteroid	O
treatment	O
was	O
started	O
.	O
The	O
evolution	O
was	O
poor	O
,	O
with	O
the	O
patient	O
presenting	O
numerous	O
episodes	O
of	O
dyspnoea	O
and	O
desaturation	O
,	O
mainly	O
when	O
sitting	O
or	O
standing	O
upright	O
.	O
Cardiology	O
consultation	O
was	O
requested	O
.	O
A	O
transthoracic	O
echocardiogram	O
was	O
performed	O
which	O
showed	O
non	O
dilated	O
left	O
ventricle	O
with	O
preserved	O
systolic	O
function	O
,	O
non	O
dilated	O
and	O
normofunctioning	O
right	O
ventricle	O
,	O
aneurysmal	O
interatrial	O
septum	O
with	O
right	O
left	O
bubble	O
passage	O
after	O
infusion	O
of	O
agitated	O
saline	O
,	O
mitral	O
insufficiency	O
grade	O
II	O
IV	O
,	O
no	O
pericardial	O
effusion	O
or	O
other	O
findings	O
of	O
interest	O
.	O
A	O
catheterisation	O
was	O
requested	O
for	O
a	O
pressure	O
study	O
,	O
with	O
normal	O
pulmonary	O
pressure	O
,	O
interlocking	O
pressure	O
and	O
pressures	O
in	O
the	O
left	O
chambers	O
.	O
During	O
this	O
procedure	O
,	O
an	O
AL2	O
catheter	O
was	O
passed	O
into	O
the	O
left	O
atrium	O
through	O
the	O
foramen	O
ovale	O
,	O
allowing	O
oximetry	O
samples	O
to	O
be	O
obtained	O
at	O
the	O
central	O
venous	O
level	O
,	O
in	O
the	O
right	O
and	O
left	O
chambers	O
,	O
both	O
in	O
the	O
supine	O
and	O
seated	O
positions	O
.	O
A	O
jump	O
in	O
O2	O
saturation	O
and	O
pressure	O
was	O
observed	O
between	O
the	O
pulmonary	O
veins	O
and	O
left	O
chambers	O
.	O
Systemic	O
flow	O
was	O
also	O
26	O
higher	O
than	O
pulmonary	O
flow	O
.	O
The	O
patient	O
was	O
referred	O
back	O
to	O
the	O
haemodynamics	O
laboratory	O
for	O
closure	O
of	O
the	O
foramen	O
ovale	O
in	O
a	O
procedure	O
guided	O
by	O
transesophageal	O
echocardiography	O
.	O
A	O
balloon	O
occlusion	O
test	O
was	O
initially	O
performed	O
,	O
showing	O
an	O
increase	O
in	O
supine	O
arterial	O
saturation	O
from	O
78	O
to	O
93	O
.	O
Subsequently	O
,	O
the	O
patent	O
foramen	O
ovale	O
was	O
closed	O
using	O
an	O
18	O
mm	O
Amplatzer	O
ASD	O
device	O
.	O
Control	O
TEE	O
showed	O
a	O
near	O
total	O
reduction	O
of	O
the	O
shunt	O
with	O
correct	O
positioning	O
of	O
the	O
Amplatzer	O
.	O
DIAGNOSIS	O
Platypnoea	O
orthodeoxia	O
syndrome	O
.	O
Patent	O
foramen	O
ovale	O
with	O
occasional	O
right	O
to	O
left	O
shunt	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Personal	O
history	O
Independent	O
for	O
ADLs	O
.	O
Lives	O
with	O
daughter	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
Denies	O
toxic	O
habits	O
.	O
She	O
has	O
a	O
history	O
of	O
years	O
of	O
arterial	O
hypertension	O
and	O
dyslipidaemia	O
Diabetes	O
mellitus	O
type	O
2	O
in	O
treatment	O
with	O
oral	O
antidiabetics	O
.	O
Hypothyroidism	O
on	O
hormone	O
replacement	O
therapy	O
.	O
Ischaemic	O
stroke	O
2015	O
in	O
the	O
left	O
MCA	O
territory	O
,	O
of	O
atherothrombotic	O
aetiology	O
,	O
the	O
only	O
sequelae	O
being	O
deviation	O
of	O
the	O
oral	O
commissure	O
.	O
The	O
family	O
reports	O
a	O
benign	O
brain	O
tumour	O
possible	O
meningioma	O
.	O
Left	O
optic	O
nerve	O
atrophy	O
with	O
secondary	O
decrease	O
in	O
visual	O
acuity	O
Cardiological	O
history	O
chronic	O
ischaemic	O
heart	O
disease	O
starting	O
with	O
angina	O
in	O
2003	O
,	O
with	O
TC	O
and	O
3	O
vessel	O
disease	O
.	O
In	O
2005	O
,	O
double	O
coronary	O
artery	O
bypass	O
from	O
internal	O
mammary	O
artery	O
IMA	O
to	O
anterior	O
descending	O
AD	O
and	O
from	O
saphenous	O
vein	O
SV	O
to	O
right	O
coronary	O
artery	O
RCA	O
was	O
performed	O
in	O
another	O
centre	O
.	O
Subsequently	O
new	O
episodes	O
of	O
angina	O
,	O
with	O
coronary	O
angiography	O
2008	O
distal	O
coronary	O
trunk	O
TCd	O
75	O
including	O
ostium	O
of	O
DA	O
and	O
circumflex	O
CF	O
90	O
in	O
all	O
these	O
lesions	O
,	O
CDp	O
CTO	O
,	O
AMI	O
DA	O
100	O
and	O
VS	O
DP	O
permeable	O
.	O
PCI	O
was	O
not	O
performed	O
.	O
In	O
2013	O
,	O
she	O
presented	O
an	O
episode	O
of	O
unstable	O
angina	O
and	O
was	O
studied	O
at	O
the	O
centre	O
where	O
she	O
had	O
undergone	O
surgery	O
,	O
and	O
echocardiography	O
was	O
performed	O
with	O
preserved	O
LVEF	O
and	O
infero	O
basal	O
akinesia	O
,	O
and	O
coronary	O
angiography	O
was	O
repeated	O
2013	O
severe	O
lesion	O
in	O
distal	O
TC	O
and	O
DAp	O
,	O
chronic	O
underocclusion	O
in	O
proximal	O
CF	O
,	O
chronic	O
complete	O
occlusion	O
in	O
proximal	O
CD	O
;	O
occluded	O
AMI	O
DA	O
graft	O
and	O
patent	O
VS	O
DP	O
without	O
stenosis	O
.	O
It	O
was	O
considered	O
a	O
bad	O
case	O
for	O
percutaneous	O
revascularisation	O
,	O
opting	O
for	O
medical	O
treatment	O
,	O
as	O
it	O
seems	O
that	O
she	O
has	O
had	O
few	O
symptoms	O
from	O
the	O
cardiological	O
point	O
of	O
view	O
for	O
several	O
years	O
.	O
Usual	O
medication	O
ASA	B-FARMACO
100	O
mg	O
1	O
0	O
0	O
,	O
atenolol	B-FARMACO
25	O
1	O
0	O
0	O
,	O
oral	O
nitrates	O
40	O
mg	O
1	O
1	O
1	O
,	O
metformin	B-FARMACO
850	O
mg	O
0	O
1	O
0	O
,	O
levothyroxine	B-FARMACO
75	O
mcg	O
1	O
0	O
0	O
,	O
atorvastatin	B-FARMACO
80	O
mg	O
0	O
0	O
1	O
,	O
enalapril	B-FARMACO
20	O
mg	O
1	O
0	O
0	O
.	O
CURRENT	O
ILLNESS	O
Since	O
17	O
04	O
17	O
he	O
has	O
had	O
episodes	O
of	O
palpitations	O
,	O
accompanied	O
by	O
oppressive	O
central	O
thoracic	O
pain	O
with	O
irradiation	O
to	O
both	O
upper	O
extremities	O
,	O
without	O
vegetatism	O
,	O
which	O
subside	O
with	O
rest	O
.	O
She	O
has	O
presented	O
daily	O
episodes	O
of	O
chest	O
pain	O
of	O
the	O
same	O
characteristics	O
,	O
some	O
related	O
to	O
small	O
efforts	O
and	O
others	O
at	O
rest	O
,	O
self	O
limited	O
and	O
of	O
variable	O
duration	O
up	O
to	O
2	O
hours	O
,	O
which	O
remind	O
her	O
of	O
the	O
episodes	O
of	O
angina	O
with	O
which	O
her	O
coronary	O
disease	O
debuted	O
in	O
2003	O
.	O
On	O
21	O
04	O
17	O
,	O
when	O
she	O
woke	O
up	O
at	O
9	O
am	O
,	O
she	O
had	O
another	O
episode	O
of	O
similar	O
pain	O
lasting	O
about	O
30	O
minutes	O
,	O
so	O
she	O
consulted	O
the	O
Accident	O
and	O
Emergency	O
department	O
of	O
the	O
corresponding	O
regional	O
hospital	O
.	O
On	O
arrival	O
,	O
the	O
patient	O
was	O
asymptomatic	O
and	O
haemodynamically	O
stable	O
.	O
An	O
ECG	O
was	O
performed	O
with	O
evidence	O
of	O
AF	O
at	O
69	O
bpm	O
not	O
described	O
in	O
previous	O
reports	O
,	O
with	O
unknown	O
LBBB	O
not	O
described	O
in	O
the	O
2015	O
medical	O
report	O
.	O
Troponin	O
I	O
was	O
measured	O
at	O
1	O
.	O
4	O
ng	O
ml	O
limit	O
of	O
significance	O
0	O
.	O
04	O
ng	O
ml	O
.	O
A	O
300	O
mg	O
ASA	B-FARMACO
and	O
300	O
mg	O
clopidogrel	B-FARMACO
and	O
40	O
mg	O
enoxaparin	B-FARMACO
were	O
administered	O
,	O
and	O
the	O
patient	O
was	O
referred	O
to	O
our	O
centre	O
for	O
admission	O
to	O
the	O
Coronary	O
Unit	O
.	O
COMPLEMENTARY	O
TESTS	O
Blood	O
tests	O
at	O
the	O
regional	O
hospital	O
creatinine	O
1	O
.	O
06	O
mg	O
dl	O
.	O
CK	O
110U	O
L	O
.	O
Sodium	O
139	O
mEq	O
L	O
,	O
potassium	O
4	O
.	O
8	O
mEq	O
L	O
.	O
Chlorine	O
108	O
mEq	O
L	O
.	O
Glucose	O
178	O
mg	O
dl	O
.	O
Lactate	O
1	O
.	O
82	O
mmol	O
L	O
.	O
GSV	O
pH	O
7	O
.	O
28	O
,	O
pCO2	O
43	O
mmHg	O
.	O
Bicarbonate	O
25	O
.	O
8	O
mmol	O
L	O
.	O
INR	O
1	O
.	O
18	O
,	O
TTPAr	O
30	O
.	O
2s	O
.	O
Hb	O
11	O
.	O
4	O
g	O
dl	O
,	O
Htc	O
35	O
.	O
6	O
.	O
Leukocytes	O
5	O
,	O
680	O
,	O
platelets	O
163	O
,	O
000	O
.	O
Troponin	O
I	O
1	O
.	O
42	O
1	O
.	O
948	O
peak	O
1	O
.	O
3	O
ng	O
ml	O
.	O
Cardiological	O
profile	O
Gluc	O
88	O
mg	O
dl	O
.	O
Urea	O
43	O
mg	O
dl	O
.	O
Creatinine	O
0	O
,	O
79	O
mg	O
dl	O
.	O
Cholesterol	O
119	O
mg	O
dl	O
.	O
HDL	O
36	O
mg	O
dl	O
.	O
LDL	O
64	O
mg	O
dl	O
.	O
TG	O
89	O
mg	O
dl	O
.	O
GOT	O
209	O
U	O
L	O
.	O
GPT	O
211	O
U	O
L	O
.	O
GGT	O
180	O
U	O
L	O
.	O
FAlc	O
134	O
U	O
l	O
.	O
Na	O
143	O
mEq	O
l	O
.	O
K	O
4	O
.	O
2	O
mEq	O
l	O
.	O
Hb	O
11	O
.	O
3	O
g	O
dl	O
.	O
Ht	O
3	O
7	O
.	O
2	O
,	O
MCV	O
87	O
.	O
Platelets	O
146	O
,	O
000	O
.	O
TSH	O
0	O
m42	O
uU	O
ml	O
,	O
free	O
T4	O
1	O
.	O
26	O
ng	O
dl	O
.	O
HbA1c	O
8	O
.	O
2	O
Control	O
laboratory	O
tests	O
8	O
weeks	O
after	O
discharge	O
HbA1c	O
7	O
.	O
1	O
,	O
GOT	O
112	O
,	O
GPT	O
71	O
,	O
GGT	O
91U	O
L	O
,	O
FAlc	O
96	O
.	O
ECG	O
on	O
admission	O
atrial	O
fibrillation	O
with	O
FVM	O
of	O
72	O
bpm	O
,	O
LBBB	O
.	O
Control	O
ECG	O
sinus	O
rhythm	O
50	O
bpm	O
,	O
LBBB	O
,	O
frequent	O
atrial	O
extrasystoles	O
.	O
ECG	O
at	O
discharge	O
RS	O
at	O
57	O
bpm	O
,	O
LBBB	O
.	O
Chest	O
X	O
ray	O
silhouette	O
at	O
high	O
limit	O
of	O
normality	O
.	O
Sternotomy	O
sutures	O
.	O
Normal	O
lung	O
fields	O
.	O
Coronary	O
angiography	O
severe	O
lesion	O
at	O
the	O
level	O
of	O
the	O
distal	O
common	O
trunk	O
.	O
It	O
is	O
a	O
trifurcated	O
trunk	O
DA	O
Biscitrus	O
CX	O
.	O
LAD	O
with	O
significant	O
lesions	O
in	O
the	O
middle	O
third	O
.	O
Distal	O
vessel	O
of	O
small	O
calibre	O
.	O
Significant	O
lesion	O
at	O
the	O
level	O
of	O
the	O
middle	O
distal	O
third	O
of	O
the	O
bisector	O
branch	O
.	O
Small	O
calibre	O
distal	O
vessel	O
.	O
CX	O
with	O
severe	O
lesion	O
at	O
the	O
level	O
of	O
the	O
proximal	O
third	O
.	O
Critical	O
lesion	O
at	O
the	O
level	O
of	O
the	O
CX	O
1st	O
OM	O
bifurcation	O
.	O
Small	O
calibre	O
distal	O
vessel	O
.	O
Dominant	O
DC	O
with	O
chronic	O
occlusion	O
at	O
the	O
level	O
of	O
the	O
proximal	O
third	O
.	O
Distal	O
vessel	O
visible	O
from	O
saphenous	O
graft	O
to	O
posterior	O
descending	O
artery	O
.	O
Saphenous	O
graft	O
to	O
posterior	O
descending	O
without	O
significant	O
lesions	O
.	O
No	O
cannulation	O
of	O
mammary	O
graft	O
to	O
LAD	O
occluded	O
according	O
to	O
previous	O
reports	O
.	O
Echocardiogram	O
non	O
dilated	O
left	O
ventricle	O
,	O
moderate	O
septal	O
hypertrophy	O
,	O
preserved	O
systolic	O
function	O
EF	O
Simpson	O
4C	O
53	O
with	O
akinesia	O
and	O
thinning	O
of	O
mid	O
and	O
basal	O
segments	O
of	O
inferior	O
and	O
inferoseptal	O
face	O
,	O
without	O
other	O
evident	O
alterations	O
of	O
segmental	O
wall	O
contractility	O
.	O
Pseudonormal	O
diastolic	O
pattern	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
,	O
preserved	O
function	O
.	O
Left	O
atrium	O
slightly	O
dilated	O
.	O
Normal	O
aortic	O
diameters	O
.	O
Trivalve	O
aortic	O
valve	O
,	O
with	O
thickening	O
and	O
calcification	O
of	O
the	O
base	O
of	O
all	O
leaflets	O
,	O
predominantly	O
the	O
non	O
coronary	O
leaflet	O
with	O
preserved	O
opening	O
,	O
mild	O
insufficiency	O
.	O
Mitral	O
valve	O
with	O
slightly	O
thickened	O
leaflets	O
,	O
preserved	O
opening	O
,	O
mild	O
central	O
regurgitation	O
EROA	O
0	O
.	O
04	O
cm2	O
,	O
RV	O
8	O
ml	O
.	O
Tricuspid	O
valve	O
with	O
mild	O
insufficiency	O
allowing	O
estimation	O
of	O
PSAP	O
of	O
at	O
least	O
26	O
mmHg	O
.	O
Non	O
dilated	O
inferior	O
vena	O
cava	O
with	O
inspiratory	O
collapse	O
50	O
.	O
No	O
pericardial	O
effusion	O
.	O
No	O
intracardiac	O
masses	O
are	O
evident	O
.	O
EVOLUTION	O
On	O
arrival	O
,	O
she	O
remained	O
asymptomatic	O
.	O
Echoscopy	O
was	O
performed	O
with	O
preserved	O
LVEF	O
.	O
Akinesia	O
of	O
the	O
basal	O
segments	O
of	O
the	O
inferior	O
and	O
inferolateral	O
face	O
and	O
severe	O
hypokinesia	O
of	O
the	O
middle	O
segments	O
of	O
the	O
inferior	O
and	O
inferolateral	O
face	O
.	O
RV	O
with	O
normal	O
morphology	O
and	O
contractility	O
.	O
No	O
significant	O
valvulopathy	O
or	O
pericardial	O
effusion	O
.	O
ECG	O
on	O
admission	O
in	O
AF	O
with	O
controlled	O
FVM	O
,	O
reverting	O
to	O
RS	O
spontaneously	O
at	O
the	O
time	O
of	O
admission	O
.	O
We	O
maintain	O
double	O
antiplatelet	O
therapy	O
and	O
anticoagulation	O
for	O
NSTEACS	O
and	O
paroxysmal	O
AF	O
in	O
patient	O
with	O
CHA2DS2	O
VASc	O
8	O
.	O
Tendency	O
to	O
bradycardia	O
,	O
so	O
beta	O
blockers	O
were	O
suspended	O
and	O
restarted	O
on	O
24	O
4	O
at	O
low	O
doses	O
.	O
ECG	O
persists	O
with	O
LBBB	O
and	O
supraventricular	O
extrasystoles	O
.	O
Peak	O
troponin	O
I	O
1	O
.	O
9	O
ng	O
ml	O
.	O
Tolerates	O
sitting	O
.	O
After	O
reviewing	O
the	O
last	O
coronary	O
angiography	O
,	O
and	O
given	O
the	O
abruptness	O
of	O
the	O
clinical	O
picture	O
with	O
high	O
suspicion	O
of	O
VS	O
bypass	O
lesion	O
occlusion	O
,	O
it	O
was	O
decided	O
to	O
perform	O
coronary	O
angiography	O
directly	O
without	O
prior	O
ischaemia	O
detection	O
test	O
,	O
which	O
showed	O
similar	O
findings	O
to	O
those	O
found	O
according	O
to	O
the	O
report	O
from	O
the	O
hospital	O
where	O
the	O
revascularisation	O
surgery	O
was	O
performed	O
in	O
the	O
study	O
performed	O
in	O
2013	O
.	O
Haematoma	O
in	O
relation	O
to	O
the	O
radial	O
puncture	O
that	O
is	O
resolved	O
by	O
prolonging	O
the	O
compressive	O
bandage	O
given	O
the	O
clinical	O
stability	O
is	O
discharged	O
to	O
the	O
ward	O
.	O
On	O
the	O
ward	O
it	O
was	O
considered	O
that	O
the	O
infarction	O
could	O
be	O
related	O
to	O
episodes	O
of	O
paroxysmal	O
atrial	O
fibrillation	O
,	O
so	O
amiodarone	B-FARMACO
was	O
added	O
and	O
beta	O
blockers	O
were	O
adjusted	O
.	O
It	O
was	O
decided	O
to	O
optimise	O
medical	O
treatment	O
.	O
An	O
ordinary	O
analysis	O
revealed	O
elevated	O
transaminases	O
,	O
already	O
present	O
in	O
previous	O
analyses	O
,	O
probably	O
related	O
to	O
high	O
doses	O
of	O
statins	O
,	O
so	O
atorvastatin	B-FARMACO
was	O
replaced	O
by	O
pitavastatin	B-FARMACO
.	O
The	O
patient	O
was	O
switched	O
to	O
pitavastatin	B-FARMACO
4	O
mg	O
to	O
assess	O
liver	O
enzyme	O
control	O
on	O
an	O
outpatient	O
basis	O
.	O
HbA1c	O
8	O
.	O
2	O
was	O
also	O
noted	O
,	O
so	O
it	O
was	O
decided	O
to	O
start	O
empaglifazone	O
on	O
discharge	O
.	O
Given	O
the	O
history	O
of	O
a	O
possible	O
meningioma	O
and	O
the	O
haematoma	O
of	O
the	O
right	O
arm	O
,	O
it	O
was	O
decided	O
not	O
to	O
start	O
anticoagulation	O
and	O
to	O
assess	O
its	O
initiation	O
on	O
an	O
outpatient	O
basis	O
.	O
She	O
remained	O
stable	O
,	O
with	O
no	O
new	O
episodes	O
of	O
chest	O
pain	O
.	O
She	O
began	O
to	O
ambulate	O
with	O
good	O
tolerance	O
and	O
was	O
discharged	O
from	O
hospital	O
.	O
The	O
patient	O
was	O
seen	O
8	O
weeks	O
after	O
hospital	O
discharge	O
and	O
presented	O
CF	O
II	O
,	O
with	O
no	O
new	O
episodes	O
of	O
angina	O
since	O
she	O
had	O
been	O
at	O
home	O
and	O
with	O
a	O
glycated	O
haemoglobin	O
of	O
7	O
.	O
1	O
,	O
as	O
well	O
as	O
an	O
improvement	O
in	O
her	O
liver	O
profile	O
.	O
DIAGNOSIS	O
Paroxysmal	O
atrial	O
fibrillation	O
Non	O
ST	O
elevation	O
myocardial	O
infarction	O
,	O
type	O
2	O
.	O
Chronic	O
ischaemic	O
heart	O
disease	O
.	O
Coronary	O
artery	O
disease	O
of	O
LMCA	O
and	O
3	O
vessels	O
.	O
Carrier	O
of	O
double	O
bypass	O
AMI	O
DA	O
occluded	O
and	O
VS	O
DP	O
patent	O
.	O
Ischaemic	O
heart	O
disease	O
with	O
preserved	O
ventricular	O
function	O
.	O
History	O
of	O
ischaemic	O
stroke	O
.	O
Arterial	O
hypertension	O
.	O
Dyslipidaemia	O
.	O
Diabetes	O
mellitus	O
type	O
2	O
Hypothyroidism	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Personal	O
history	O
No	O
known	O
drug	O
allergies	O
.	O
Ex	O
smoker	O
for	O
30	O
years	O
.	O
Ex	O
excessive	O
drinker	O
for	O
3	O
4	O
years	O
.	O
CVRF	O
hypertension	O
,	O
dyslipidaemia	O
.	O
No	O
diabetes	O
mellitus	O
.	O
Studied	O
in	O
May	O
2015	O
by	O
the	O
Chest	O
Pain	O
Unit	O
for	O
recurrent	O
chest	O
pain	O
with	O
negative	O
ischaemia	O
detection	O
tests	O
.	O
Previous	O
surgical	O
interventions	O
appendectomy	O
.	O
Usual	O
treatment	O
simvastatin	B-FARMACO
20	O
mg	O
c	O
24	O
hours	O
;	O
enalapril	B-FARMACO
20	O
mg	O
c	O
24	O
hours	O
.	O
Current	O
disease	O
Patient	O
with	O
the	O
previously	O
described	O
personal	O
history	O
came	O
to	O
the	O
emergency	O
department	O
of	O
our	O
hospital	O
after	O
starting	O
with	O
oppressive	O
central	O
thoracic	O
pain	O
,	O
radiating	O
to	O
the	O
shoulder	O
and	O
left	O
upper	O
limb	O
,	O
without	O
associated	O
vegetative	O
cortex	O
while	O
he	O
was	O
shaving	O
.	O
Given	O
the	O
persistence	O
of	O
the	O
pain	O
,	O
he	O
decided	O
to	O
sit	O
down	O
,	O
subsequently	O
fainting	O
with	O
sudden	O
loss	O
of	O
consciousness	O
,	O
without	O
prodrome	O
and	O
with	O
associated	O
cranioencephalic	O
traumatism	O
after	O
hitting	O
the	O
floor	O
,	O
recovery	O
ad	O
integrum	O
,	O
without	O
remembering	O
anything	O
of	O
what	O
had	O
happened	O
and	O
without	O
being	O
able	O
to	O
specify	O
the	O
duration	O
as	O
it	O
was	O
not	O
witnessed	O
by	O
anyone	O
.	O
The	O
patient	O
reported	O
that	O
he	O
had	O
previously	O
been	O
awakened	O
by	O
a	O
central	O
thoracic	O
pain	O
of	O
similar	O
characteristics	O
,	O
but	O
of	O
shorter	O
duration	O
and	O
self	O
limited	O
.	O
He	O
denied	O
worsening	O
of	O
functional	O
class	O
,	O
no	O
orthopnoea	O
or	O
episodes	O
of	O
paroxysmal	O
nocturnal	O
dyspnoea	O
.	O
She	O
had	O
not	O
had	O
previous	O
syncopal	O
episodes	O
or	O
chest	O
pain	O
related	O
to	O
exertion	O
or	O
at	O
rest	O
.	O
Physical	O
examination	O
The	O
patient	O
was	O
stable	O
,	O
in	O
good	O
general	O
condition	O
.	O
Well	O
hydrated	O
and	O
perfused	O
.	O
Eupneic	O
at	O
rest	O
and	O
tolerating	O
decubitus	O
.	O
Afebrile	O
and	O
haemodynamically	O
stable	O
.	O
BP	O
203	O
96	O
mmHg	O
.	O
HR	O
80	O
bpm	O
.	O
On	O
auscultation	O
,	O
rhythmic	O
tones	O
,	O
no	O
murmurs	O
.	O
Bladder	O
murmur	O
was	O
preserved	O
,	O
with	O
no	O
other	O
superimposed	O
noises	O
.	O
The	O
rest	O
of	O
the	O
examination	O
was	O
unremarkable	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
sinus	O
rhythm	O
at	O
70	O
bpm	O
,	O
normal	O
axis	O
.	O
PR	O
160	O
msec	O
.	O
Narrow	O
QRS	O
,	O
rectified	O
ST	O
segment	O
in	O
V6	O
already	O
described	O
in	O
previous	O
records	O
.	O
Laboratory	O
tests	O
biochemistry	O
with	O
renal	O
function	O
,	O
glycaemia	O
and	O
ions	O
in	O
range	O
.	O
Haemogram	O
with	O
values	O
within	O
normality	O
.	O
Serial	O
cardiac	O
enzymes	O
within	O
normal	O
range	O
.	O
Chest	O
X	O
ray	O
normal	O
cardiothoracic	O
index	O
.	O
No	O
images	O
of	O
parenchymal	O
condensation	O
,	O
free	O
costophrenic	O
sinuses	O
.	O
Transthoracic	O
echocardiography	O
left	O
atrium	O
of	O
normal	O
dimensions	O
.	O
Left	O
ventricle	O
not	O
dilated	O
,	O
normal	O
myocardial	O
thickness	O
.	O
No	O
segmental	O
alterations	O
of	O
contractility	O
are	O
visualised	O
,	O
systolic	O
function	O
by	O
Simpson	O
biplane	O
of	O
60	O
.	O
Trivalve	O
aortic	O
valve	O
with	O
slight	O
fibrosclerosis	O
,	O
opening	O
and	O
mobility	O
of	O
its	O
leaflets	O
preserved	O
.	O
Aortic	O
root	O
not	O
dilated	O
.	O
Mitral	O
valve	O
with	O
thin	O
leaflets	O
and	O
good	O
mobility	O
.	O
Mitral	O
filling	O
pattern	O
with	O
E	O
A	O
wave	O
.	O
Right	O
chambers	O
not	O
dilated	O
,	O
preserved	O
systolic	O
function	O
TAPSE	O
20	O
mm	O
.	O
Mild	O
tricuspid	O
insufficiency	O
allowing	O
an	O
estimated	O
PAP	O
of	O
17	O
mmHg	O
.	O
No	O
pericardial	O
effusion	O
.	O
Cardiac	O
catheterisation	O
left	O
coronary	O
trunk	O
without	O
lesions	O
.	O
Descending	O
artery	O
without	O
lesions	O
with	O
good	O
distal	O
vessel	O
.	O
Circumflex	O
artery	O
without	O
lesions	O
.	O
Very	O
high	O
origin	O
of	O
the	O
right	O
coronary	O
artery	O
with	O
impossibility	O
of	O
selective	O
probing	O
;	O
aortography	O
visualised	O
the	O
proximal	O
,	O
middle	O
and	O
distal	O
segments	O
without	O
disease	O
.	O
Coronary	O
angio	O
CT	O
anomaly	O
in	O
the	O
exit	O
of	O
the	O
right	O
coronary	O
artery	O
which	O
instead	O
of	O
leaving	O
the	O
right	O
coronary	O
sinus	O
leaves	O
the	O
medial	O
portion	O
of	O
the	O
left	O
common	O
coronary	O
trunk	O
,	O
following	O
an	O
interarterial	O
path	O
between	O
the	O
pulmonary	O
artery	O
and	O
the	O
ascending	O
aorta	O
to	O
then	O
reach	O
its	O
usual	O
position	O
malignant	O
coronary	O
anomaly	O
,	O
measuring	O
the	O
maximum	O
calibre	O
at	O
its	O
interarterial	O
passage	O
of	O
2	O
.	O
5	O
3	O
mm	O
to	O
continue	O
with	O
its	O
usual	O
route	O
with	O
a	O
calibre	O
of	O
4	O
mm	O
.	O
The	O
rest	O
of	O
the	O
vessels	O
without	O
anomalies	O
.	O
Doppler	O
ultrasound	O
of	O
supra	O
aortic	O
trunks	O
non	O
significant	O
stenosis	O
of	O
the	O
left	O
internal	O
carotid	O
artery	O
.	O
Non	O
significant	O
stenosis	O
of	O
the	O
right	O
external	O
carotid	O
artery	O
.	O
EVOLUTION	O
Patient	O
with	O
multiple	O
CVRF	O
admitted	O
to	O
our	O
ward	O
for	O
chest	O
pain	O
with	O
a	O
high	O
intermediate	O
pre	O
test	O
probability	O
of	O
ischaemic	O
heart	O
disease	O
,	O
so	O
it	O
was	O
decided	O
to	O
carry	O
out	O
a	O
test	O
to	O
detect	O
intermediate	O
ischaemia	O
.	O
During	O
his	O
admission	O
the	O
day	O
before	O
the	O
stress	O
test	O
was	O
performed	O
,	O
the	O
patient	O
presented	O
a	O
new	O
episode	O
of	O
chest	O
pain	O
coinciding	O
with	O
high	O
blood	O
pressure	O
figures	O
and	O
documenting	O
electrical	O
changes	O
in	O
the	O
ECG	O
performed	O
,	O
which	O
normalised	O
after	O
the	O
pain	O
subsided	O
,	O
so	O
it	O
was	O
decided	O
to	O
request	O
direct	O
coronary	O
angiography	O
,	O
suspending	O
the	O
exercise	O
stress	O
test	O
.	O
The	O
catheterisation	O
was	O
reported	O
as	O
a	O
left	O
coronary	O
artery	O
without	O
lesions	O
and	O
the	O
inability	O
to	O
probe	O
the	O
right	O
coronary	O
artery	O
due	O
to	O
a	O
very	O
high	O
origin	O
which	O
,	O
given	O
the	O
images	O
,	O
was	O
suggestive	O
of	O
an	O
anomaly	O
of	O
the	O
origin	O
of	O
this	O
coronary	O
artery	O
.	O
Given	O
the	O
findings	O
,	O
it	O
was	O
decided	O
to	O
perform	O
a	O
coronary	O
angio	O
CT	O
scan	O
to	O
confirm	O
the	O
suspected	O
diagnosis	O
,	O
which	O
documented	O
the	O
anomalous	O
origin	O
of	O
the	O
right	O
coronary	O
artery	O
which	O
,	O
instead	O
of	O
leaving	O
its	O
usual	O
location	O
in	O
the	O
right	O
coronary	O
sinus	O
,	O
has	O
its	O
origin	O
in	O
the	O
left	O
common	O
coronary	O
trunk	O
and	O
then	O
follows	O
a	O
path	O
between	O
both	O
pulmonary	O
arteries	O
and	O
the	O
aorta	O
and	O
then	O
follows	O
its	O
usual	O
path	O
,	O
this	O
being	O
a	O
malignant	O
coronary	O
anomaly	O
.	O
It	O
was	O
decided	O
to	O
present	O
the	O
case	O
at	O
a	O
medical	O
surgical	O
session	O
to	O
discuss	O
the	O
possibility	O
of	O
surgery	O
for	O
this	O
anomaly	O
,	O
and	O
the	O
patient	O
was	O
accepted	O
.	O
The	O
intervention	O
was	O
carried	O
out	O
during	O
admission	O
,	O
proceeding	O
to	O
dissection	O
and	O
reanostomosis	O
of	O
the	O
right	O
coronary	O
artery	O
to	O
the	O
right	O
coronary	O
sinus	O
with	O
good	O
results	O
and	O
without	O
intraoperative	O
complications	O
.	O
The	O
patient	O
evolved	O
favourably	O
during	O
the	O
postoperative	O
period	O
,	O
without	O
complications	O
related	O
to	O
the	O
intervention	O
and	O
without	O
new	O
episodes	O
of	O
chest	O
pain	O
or	O
other	O
symptoms	O
,	O
and	O
was	O
subsequently	O
discharged	O
home	O
.	O
After	O
hospital	O
discharge	O
and	O
with	O
regular	O
check	O
ups	O
,	O
the	O
patient	O
remains	O
asymptomatic	O
and	O
in	O
good	O
functional	O
class	O
.	O
DIAGNOSIS	O
Typical	O
chest	O
pain	O
in	O
a	O
patient	O
with	O
malignant	O
coronary	O
anomaly	O
with	O
origin	O
of	O
the	O
right	O
coronary	O
artery	O
from	O
the	O
left	O
main	O
coronary	O
artery	O
.	O
Surgical	O
intervention	O
with	O
reanastomosis	O
of	O
the	O
right	O
coronary	O
artery	O
to	O
the	O
aortic	O
coronary	O
sinus	O
on	O
the	O
same	O
side	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
We	O
present	O
the	O
case	O
of	O
an	O
85	O
year	O
old	O
man	O
,	O
in	O
good	O
baseline	O
condition	O
,	O
independent	O
in	O
all	O
activities	O
,	O
with	O
no	O
known	O
medical	O
history	O
,	O
no	O
regular	O
treatment	O
and	O
no	O
recent	O
check	O
ups	O
.	O
He	O
was	O
completely	O
asymptomatic	O
in	O
the	O
early	O
morning	O
and	O
went	O
to	O
the	O
fields	O
to	O
do	O
his	O
work	O
.	O
He	O
begins	O
with	O
oppressive	O
chest	O
pain	O
but	O
decides	O
not	O
to	O
seek	O
urgent	O
medical	O
attention	O
.	O
Some	O
time	O
later	O
he	O
was	O
found	O
by	O
his	O
relatives	O
who	O
,	O
alarmed	O
by	O
the	O
fact	O
that	O
they	O
also	O
observed	O
some	O
difficulty	O
in	O
speaking	O
and	O
walking	O
,	O
took	O
him	O
to	O
the	O
local	O
health	O
centre	O
.	O
The	O
patient	O
is	O
unable	O
to	O
specify	O
the	O
exact	O
time	O
of	O
evolution	O
from	O
the	O
onset	O
of	O
symptoms	O
,	O
although	O
it	O
could	O
correspond	O
to	O
an	O
interval	O
of	O
4	O
5	O
hours	O
until	O
the	O
first	O
medical	O
contact	O
.	O
On	O
arrival	O
he	O
presented	O
BP	O
150	O
60	O
mmHg	O
,	O
HR	O
45	O
bpm	O
.	O
Afebrile	O
.	O
O2	O
sat	O
96	O
at	O
baseline	O
.	O
Cardiopulmonary	O
auscultation	O
arrhythmic	O
with	O
ejection	O
systolic	O
murmur	O
suggestive	O
of	O
aortic	O
sclerosis	O
.	O
Bladder	O
murmur	O
preserved	O
without	O
clear	O
crackles	O
.	O
He	O
continued	O
with	O
residual	O
chest	O
discomfort	O
,	O
of	O
lesser	O
intensity	O
.	O
ECG	O
shows	O
atrial	O
fibrillation	O
at	O
50	O
bpm	O
.	O
Normal	O
axis	O
.	O
Little	O
marked	O
ST	O
segment	O
elevation	O
in	O
II	O
,	O
III	O
and	O
avF	O
,	O
without	O
Q	O
wave	O
.	O
Good	O
R	O
wave	O
growth	O
in	O
precordial	O
leads	O
.	O
During	O
the	O
first	O
assessment	O
,	O
the	O
patient	O
's	O
speech	O
was	O
striking	O
,	O
with	O
difficulty	O
in	O
expressing	O
certain	O
words	O
,	O
and	O
the	O
physical	O
examination	O
revealed	O
haemiparesis	O
of	O
the	O
left	O
limbs	O
.	O
It	O
was	O
decided	O
to	O
transfer	O
the	O
patient	O
to	O
the	O
Emergency	O
Department	O
of	O
the	O
hospital	O
,	O
where	O
the	O
neurologist	O
on	O
duty	O
was	O
notified	O
and	O
an	O
urgent	O
brain	O
CT	O
scan	O
was	O
performed	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
on	O
arrival	O
at	O
the	O
Emergency	O
Department	O
atrial	O
fibrillation	O
at	O
50	O
bpm	O
.	O
Normal	O
axis	O
.	O
Little	O
marked	O
ST	O
segment	O
elevation	O
in	O
II	O
,	O
III	O
and	O
avF	O
,	O
without	O
Q	O
wave	O
.	O
Urgent	O
brain	O
CT	O
scan	O
no	O
signs	O
of	O
intracranial	O
bleeding	O
.	O
There	O
were	O
signs	O
of	O
small	O
vessel	O
encephalopathy	O
,	O
cerebral	O
ageing	O
and	O
lacunar	O
infarcts	O
without	O
evidence	O
of	O
acute	O
extensive	O
ischaemic	O
infarction	O
.	O
Urgent	O
echocardiogram	O
non	O
dilated	O
left	O
ventricle	O
.	O
Mild	O
wall	O
hypertrophy	O
.	O
Global	O
contractility	O
preserved	O
,	O
estimated	O
LVEF	O
60	O
.	O
Inferolateral	O
hypokinesia	O
.	O
No	O
pericardial	O
effusion	O
.	O
No	O
aortic	O
root	O
dilatation	O
.	O
Good	O
suprasternal	O
window	O
and	O
no	O
involvement	O
of	O
supra	O
aortic	O
vessels	O
.	O
CBC	O
haemogram	O
,	O
ions	O
,	O
renal	O
function	O
in	O
range	O
.	O
Elevation	O
of	O
cardiac	O
markers	O
.	O
First	O
determination	O
of	O
troponin	O
I	O
51	O
ng	O
ml	O
.	O
EVOLUTION	O
In	O
the	O
Emergency	O
Department	O
,	O
intravenous	O
nitroglycerine	B-FARMACO
perfusion	O
was	O
started	O
,	O
which	O
almost	O
completely	O
controlled	O
the	O
chest	O
pain	O
.	O
Electrocardiographic	O
findings	O
showed	O
an	O
inferior	O
STEACS	O
in	O
the	O
context	O
of	O
non	O
anticoagulated	O
AF	O
.	O
Neurological	O
examination	O
showed	O
left	O
hemiparesis	O
3	O
5	O
,	O
facial	O
nerve	O
involvement	O
on	O
the	O
same	O
side	O
and	O
ipsilateral	O
positive	O
Babinski	O
.	O
The	O
clinical	O
suspicion	O
was	O
ischaemic	O
stroke	O
of	O
embolic	O
origin	O
.	O
We	O
decided	O
not	O
to	O
administer	O
antiplatelet	O
agents	O
until	O
an	O
imaging	O
test	O
was	O
available	O
.	O
First	O
of	O
all	O
,	O
we	O
transferred	O
the	O
patient	O
for	O
a	O
cranial	O
and	O
thoracic	O
CT	O
scan1	O
.	O
This	O
confirmed	O
the	O
ischaemic	O
nature	O
of	O
the	O
stroke	O
,	O
ruled	O
out	O
intracranial	O
haemorrhage	O
and	O
possible	O
anomalies	O
of	O
the	O
supra	O
aortic	O
trunks	O
dissection	O
type	O
.	O
Intravenous	O
thrombolysis	O
in	O
the	O
Stroke	O
Code	O
is	O
only	O
recommended	O
in	O
patients	O
seen	O
within	O
4	O
.	O
5	O
hours	O
of	O
the	O
onset	O
of	O
symptoms1	O
.	O
At	O
the	O
time	O
of	O
our	O
assessment	O
,	O
the	O
time	O
was	O
longer	O
and	O
did	O
not	O
meet	O
the	O
criteria	O
for	O
mechanical	O
thrombectomy	O
,	O
so	O
no	O
cerebral	O
reperfusion	O
treatment	O
could	O
be	O
carried	O
out	O
.	O
We	O
then	O
performed	O
an	O
urgent	O
echocardiogram	O
where	O
we	O
observed	O
a	O
hypokinesia	O
in	O
the	O
inferolateral	O
face	O
,	O
with	O
no	O
other	O
significant	O
findings	O
.	O
After	O
this	O
,	O
urgent	O
coronary	O
angiography	O
was	O
performed	O
via	O
the	O
femoral	O
artery	O
radial	O
access	O
was	O
not	O
possible	O
.	O
The	O
images	O
showed	O
angiographically	O
normal	O
left	O
main	O
coronary	O
artery	O
,	O
anterior	O
descending	O
,	O
circumflex	O
and	O
right	O
coronary	O
arteries	O
.	O
A	O
stop	O
was	O
observed	O
at	O
the	O
level	O
of	O
the	O
middle	O
circumflex	O
artery	O
with	O
superior	O
convexity	O
,	O
compatible	O
with	O
coronary	O
embolism	O
.	O
Thromboaspiration	O
was	O
performed	O
,	O
recovering	O
TIMI	O
III	O
flow	O
,	O
with	O
a	O
good	O
final	O
result	O
.	O
There	O
was	O
no	O
angiographic	O
stenosis	O
suggestive	O
of	O
underlying	O
atherosclerotic	O
disease	O
.	O
No	O
stent	O
implantation	O
was	O
necessary	O
.	O
The	O
history	O
of	O
non	O
anticoagulated	O
embolic	O
AF	O
,	O
the	O
normal	O
coronary	O
angiography	O
and	O
the	O
angiographic	O
appearance	O
of	O
the	O
culprit	O
lesion	O
suggested	O
coronary	O
embolism	O
as	O
the	O
cause	O
of	O
the	O
acute	O
myocardial	O
infarction	O
.	O
The	O
patient	O
was	O
admitted	O
to	O
hospital	O
and	O
72	O
hours	O
later	O
a	O
repeat	O
CT	O
scan	O
of	O
the	O
brain	O
showed	O
a	O
new	O
cortico	O
subcortical	O
hypodensity	O
in	O
the	O
medial	O
aspect	O
of	O
the	O
right	O
temporal	O
lobe	O
in	O
relation	O
to	O
the	O
acute	O
ischaemic	O
stroke	O
in	O
progress	O
,	O
with	O
an	O
intermediate	O
risk	O
of	O
haemorrhagic	O
transformation	O
.	O
DIAGNOSIS	O
Non	O
anticoagulated	O
atrial	O
fibrillation	O
.	O
Ischaemic	O
stroke	O
of	O
embolic	O
origin	O
,	O
dependent	O
on	O
the	O
right	O
posterior	O
cerebral	O
artery	O
.	O
STEMI	O
.	O
Coronary	O
embolism	O
in	O
the	O
circumflex	O
territory	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Personal	O
history	O
Allergies	O
to	O
metamizole	B-FARMACO
and	O
tonopan	B-FARMACO
dihydroergotamine	I-FARMACO
mesylate	I-FARMACO
caffeine	I-FARMACO
propifenazone	I-FARMACO
.	O
Cardiovascular	O
risk	O
factors	O
hypercholesteronemia	O
.	O
No	O
diabetes	O
mellitus	O
or	O
known	O
hypertension	O
.	O
Smoker	O
.	O
Sedentary	O
life	O
in	O
relation	O
to	O
joint	O
problems	O
in	O
both	O
MMII	O
.	O
Perthes	O
disease	O
right	O
hip	O
cup	O
arthroplasty	O
.	O
Left	O
ankle	O
fracture	O
with	O
prosthesis	O
implant	O
.	O
Tonsillectomy	O
.	O
Usual	O
treatment	O
No	O
previous	O
usual	O
treatment	O
.	O
Present	O
illness	O
Patient	O
aged	O
44	O
years	O
who	O
,	O
while	O
eating	O
at	O
home	O
,	O
began	O
to	O
experience	O
deviation	O
of	O
the	O
corner	O
of	O
her	O
mouth	O
to	O
the	O
left	O
and	O
speech	O
disturbance	O
.	O
The	O
SAMU	O
was	O
notified	O
and	O
in	O
the	O
initial	O
assessment	O
they	O
obtained	O
a	O
score	O
of	O
3	O
on	O
the	O
NIHSS	O
scale	O
and	O
observed	O
ECG	O
alterations	O
with	O
bouts	O
of	O
bigeminy	O
and	O
T	O
wave	O
inversion	O
,	O
especially	O
in	O
the	O
lateral	O
face	O
.	O
The	O
patient	O
denied	O
chest	O
pain	O
,	O
dyspnoea	O
,	O
paraesthesia	O
or	O
neurovegetative	O
symptoms	O
.	O
Physical	O
examination	O
During	O
her	O
stay	O
in	O
the	O
ED	O
,	O
her	O
general	O
condition	O
was	O
acceptable	O
.	O
Well	O
hydrated	O
and	O
perfused	O
.	O
BP	O
107	O
70	O
mmHg	O
,	O
HR	O
111	O
bpm	O
,	O
RR	O
18	O
rpm	O
.	O
Eupneic	O
at	O
rest	O
with	O
basal	O
SatO2	O
98	O
.	O
Carotids	O
without	O
murmurs	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
with	O
mitral	O
murmur	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
,	O
without	O
aggregates	O
.	O
Soft	O
,	O
non	O
painful	O
,	O
depressible	O
abdomen	O
.	O
No	O
oedema	O
in	O
the	O
lower	O
extremities	O
or	O
evidence	O
of	O
DVT	O
painful	O
,	O
reddened	O
area	O
on	O
the	O
left	O
ankle	O
.	O
Neurological	O
examination	O
mild	O
expressive	O
aphasia	O
difficulties	O
in	O
naming	O
some	O
objects	O
with	O
occasional	O
paraphasia	O
,	O
with	O
preserved	O
comprehension	O
.	O
No	O
dysarthria	O
.	O
Right	O
hemianopsia	O
.	O
No	O
ophthalmoparesis	O
.	O
Mild	O
right	O
central	O
facial	O
paresis	O
.	O
No	O
obvious	O
motor	O
or	O
sensory	O
deficits	O
.	O
Normal	O
cerebellum	O
.	O
NIHSS	O
scale	O
6	O
.	O
COMPLEMENTARY	O
TESTS	O
Admission	O
electrocardiogram	O
sinus	O
tachycardia	O
at	O
115	O
bpm	O
.	O
PR	O
segment	O
90	O
ms	O
pre	O
excitation	O
,	O
incomplete	O
right	O
bundle	O
branch	O
block	O
.	O
Alterations	O
in	O
repolarisation	O
characterised	O
by	O
ST	O
underleveling	O
and	O
negative	O
T	O
waves	O
of	O
V3	O
V6	O
and	O
DII	O
,	O
DIII	O
and	O
aVF	O
.	O
QTc	O
500	O
.	O
Chest	O
X	O
ray	O
cardiac	O
silhouette	O
respected	O
.	O
No	O
evidence	O
of	O
pulmonary	O
congestion	O
.	O
Laboratory	O
haemoglobin	O
15	O
.	O
5	O
g	O
dL	O
.	O
Leukocytes	O
11	O
,	O
590	O
N	O
68	O
.	O
4	O
.	O
Platelets	O
249	O
,	O
000	O
.	O
Biochemistry	O
glucose	O
109	O
mg	O
dl	O
,	O
urea	O
11	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
57	O
mg	O
dl	O
,	O
sodium	O
136	O
mmol	O
l	O
,	O
potassium	O
3	O
.	O
7	O
mmol	O
l	O
.	O
Coagulation	O
normal	O
with	O
INR	O
0	O
.	O
97	O
.	O
Biomarkers	O
creatine	O
kinase	O
57	O
U	O
L	O
normal	O
24	O
195	O
.	O
Troponin	O
T	O
36	O
ng	O
L	O
14	O
negative	O
.	O
Homocysteine	O
19	O
.	O
3	O
mol	O
L	O
.	O
Lupus	O
anticoagulant	O
SCT	O
C	O
1	O
.	O
34	O
high	O
.	O
Cardiac	O
monitoring	O
no	O
arrhythmic	O
events	O
of	O
interest	O
,	O
in	O
sinus	O
rhythm	O
at	O
all	O
times	O
.	O
Transthoracic	O
echocardiogram	O
TTE	O
on	O
admission	O
left	O
ventricle	O
neither	O
hypertrophic	O
nor	O
dilated	O
.	O
LVEF	O
slightly	O
affected	O
visu	O
visu	O
with	O
akinesia	O
of	O
all	O
apical	O
segments	O
and	O
compensatory	O
hypercontractility	O
of	O
the	O
basal	O
segments	O
.	O
Intraventricular	O
gradient	O
up	O
to	O
64	O
mmHg	O
.	O
Right	O
chambers	O
of	O
normal	O
size	O
and	O
function	O
.	O
Moderate	O
mitral	O
regurgitation	O
due	O
to	O
SAM	O
.	O
Normofunctioning	O
aortic	O
valve	O
.	O
No	O
pericardial	O
effusion	O
.	O
Vena	O
cava	O
not	O
dilated	O
.	O
Multimodal	O
cranial	O
CT	O
scan	O
on	O
admission	O
no	O
haemorrhages	O
were	O
observed	O
.	O
Slight	O
loss	O
of	O
left	O
hemispheric	O
sulcus	O
of	O
temporal	O
predominance	O
without	O
clear	O
representation	O
of	O
hypodense	O
areas	O
,	O
except	O
in	O
a	O
doubtful	O
way	O
in	O
the	O
deepest	O
region	O
of	O
the	O
left	O
sylvian	O
valley	O
.	O
ASPECTS	O
9	O
10	O
.	O
Perfusion	O
extensive	O
cortical	O
ischaemic	O
lesion	O
of	O
the	O
left	O
temporal	O
lobe	O
and	O
extending	O
towards	O
the	O
parietal	O
lobe	O
with	O
extensive	O
areas	O
of	O
decreased	O
flow	O
and	O
volume	O
,	O
showing	O
little	O
mismatch	O
.	O
Only	O
the	O
highest	O
area	O
at	O
the	O
level	O
of	O
the	O
parietal	O
lobe	O
is	O
spared	O
.	O
Angio	O
CT	O
no	O
alterations	O
in	O
the	O
caudal	O
outflow	O
of	O
the	O
supra	O
aortic	O
trunks	O
.	O
Permeable	O
vertebrae	O
.	O
Carotid	O
territories	O
without	O
significant	O
alterations	O
.	O
Proximal	O
obstruction	O
of	O
the	O
left	O
M2	O
parietal	O
branch	O
,	O
with	O
scarce	O
collaterals	O
.	O
Incidentally	O
,	O
an	O
incipient	O
aneurysmal	O
ectasia	O
is	O
seen	O
in	O
the	O
most	O
distal	O
region	O
of	O
the	O
right	O
middle	O
cerebral	O
artery	O
at	O
the	O
level	O
of	O
its	O
bifurcation	O
.	O
Perfusion	O
angio	O
CT	O
scan	O
extensive	O
cortical	O
ischaemic	O
lesion	O
affecting	O
the	O
left	O
temporal	O
lobe	O
and	O
extending	O
into	O
the	O
parietal	O
lobe	O
with	O
extensive	O
areas	O
of	O
decreased	O
flow	O
and	O
volume	O
,	O
reflecting	O
low	O
mismatch	O
.	O
The	O
anterior	O
two	O
thirds	O
of	O
the	O
infarct	O
is	O
low	O
and	O
only	O
the	O
highest	O
area	O
at	O
the	O
level	O
of	O
the	O
parietal	O
lobe	O
is	O
respected	O
.	O
CT	O
of	O
coronary	O
arteries	O
no	O
abnormalities	O
are	O
observed	O
in	O
the	O
origin	O
of	O
the	O
coronary	O
arteries	O
.	O
TCI	O
normal	O
without	O
lesions	O
DA	O
normal	O
without	O
lesions	O
.	O
Superficial	O
intramyocardial	O
tract	O
of	O
14	O
mm	O
in	O
the	O
middle	O
third	O
.	O
Cx	O
of	O
small	O
calibre	O
and	O
development	O
,	O
without	O
lesions	O
.	O
OM	O
developed	O
,	O
without	O
lesions	O
.	O
Normal	O
DC	O
without	O
lesions	O
.	O
Right	O
dominance	O
.	O
Trivalve	O
aortic	O
valve	O
.	O
Mild	O
pericardial	O
effusion	O
.	O
Calcification	O
of	O
a	O
middle	O
dorsal	O
intervertebral	O
disc	O
.	O
Conclusion	O
coronary	O
arteries	O
without	O
lesions	O
.	O
Echocardiogram	O
in	O
consultation	O
,	O
after	O
discharge	O
normal	O
.	O
EVOLUTION	O
Patient	O
aged	O
44	O
years	O
with	O
smoking	O
and	O
dyslipidaemia	O
as	O
known	O
risk	O
factors	O
,	O
admitted	O
as	O
a	O
Code	O
Ictus	O
,	O
having	O
received	O
treatment	O
with	O
intravenous	O
fibrinolysis	O
within	O
the	O
protocol	O
,	O
and	O
with	O
evidence	O
of	O
occlusion	O
in	O
left	O
parietal	O
M2	O
subsequently	O
recanalised	O
.	O
Control	O
neuroimaging	O
studies	O
showed	O
subacute	O
ischaemia	O
of	O
the	O
infarcted	O
territory	O
,	O
as	O
well	O
as	O
petechial	O
haemorrhagic	O
transformation	O
and	O
oedema	O
.	O
At	O
the	O
same	O
time	O
,	O
the	O
patient	O
presented	O
striking	O
alterations	O
in	O
the	O
ECG	O
,	O
with	O
pathological	O
TTE	O
in	O
the	O
emergency	O
department	O
characterised	O
by	O
akinesia	O
of	O
all	O
the	O
apical	O
segments	O
and	O
compensatory	O
hypercontractility	O
of	O
the	O
basal	O
segments	O
with	O
suspicion	O
of	O
probable	O
stress	O
cardiopathy	O
,	O
for	O
which	O
reason	O
CT	O
angiography	O
of	O
the	O
coronary	O
arteries	O
was	O
performed	O
,	O
which	O
showed	O
no	O
significant	O
lesions	O
.	O
The	O
control	O
TTE	O
showed	O
normalisation	O
of	O
segmental	O
contractility	O
.	O
In	O
the	O
aetiological	O
study	O
there	O
was	O
no	O
evidence	O
of	O
a	O
cardioembolic	O
or	O
vascular	O
source	O
with	O
evanescent	O
occlusion	O
of	O
the	O
vessel	O
.	O
In	O
the	O
analytical	O
study	O
,	O
lupus	O
anticoagulant	O
was	O
detected	O
,	O
coinciding	O
chronologically	O
with	O
an	O
active	O
infection	O
at	O
the	O
level	O
of	O
the	O
left	O
ankle	O
.	O
On	O
discharge	O
,	O
lupus	O
anticoagulant	O
and	O
thrombophilia	O
studies	O
by	O
haematology	O
were	O
pending	O
confirmation	O
;	O
antiplatelet	O
treatment	O
and	O
statins	O
were	O
prescribed	O
.	O
As	O
a	O
sequel	O
,	O
she	O
persists	O
with	O
mild	O
mixed	O
dysphasia	O
undergoing	O
speech	O
therapy	O
.	O
DIAGNOSIS	O
Ischaemic	O
stroke	O
in	O
the	O
left	O
middle	O
cerebral	O
artery	O
territory	O
M2	O
.	O
Stress	O
cardiomyopathy	O
in	O
relation	O
to	O
acute	O
neurological	O
process	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
Male	O
,	O
68	O
years	O
old	O
.	O
History	O
Allergic	O
to	O
penicillin	B-FARMACO
.	O
Ex	O
smoker	O
for	O
20	O
years	O
,	O
no	O
alcohol	O
consumption	O
.	O
Hypertension	O
.	O
No	O
diabetes	O
or	O
dyslipidaemia	O
.	O
No	O
personal	O
or	O
family	O
history	O
of	O
heart	O
disease	O
.	O
Usual	O
treatment	O
amiloride	B-FARMACO
hydrochlorothiazide	I-FARMACO
5	O
50	O
mg	O
per	O
day	O
.	O
Current	O
illness	O
In	O
December	O
2016	O
,	O
he	O
presented	O
with	O
catarrhal	O
symptoms	O
with	O
dry	O
cough	O
,	O
wheezing	O
and	O
dyspnoea	O
on	O
moderate	O
exertion	O
.	O
He	O
was	O
assessed	O
by	O
his	O
primary	O
care	O
doctor	O
,	O
who	O
classified	O
the	O
case	O
as	O
acute	O
bronchitis	O
and	O
started	O
bronchodilators	O
and	O
treatment	O
with	O
levofloxacin	B-FARMACO
in	O
January	O
and	O
February	O
2017	O
.	O
A	O
chest	O
X	O
ray	O
in	O
February	O
2017	O
showed	O
vascular	O
redistribution	O
,	O
although	O
diuretic	O
treatment	O
was	O
not	O
started	O
.	O
ECG	O
in	O
February	O
2017	O
in	O
sinus	O
rhythm	O
with	O
incomplete	O
LBBB	O
.	O
No	O
febrile	O
or	O
infectious	O
symptoms	O
after	O
December	O
2016	O
.	O
Good	O
blood	O
pressure	O
self	O
control	O
.	O
Due	O
to	O
progression	O
of	O
dyspnoea	O
,	O
orthopnoea	O
and	O
oedema	O
,	O
she	O
went	O
to	O
the	O
emergency	O
department	O
.	O
Admitted	O
to	O
the	O
cardiology	O
ward	O
for	O
study	O
and	O
treatment	O
of	O
heart	O
failure	O
.	O
Physical	O
examination	O
Conscious	O
and	O
oriented	O
.	O
Tachypneic	O
and	O
tachycardic	O
.	O
BP	O
147	O
73	O
mmHg	O
,	O
HR	O
90	O
bpm	O
.	O
Sat	O
02	O
95	O
with	O
Ventimask	O
at	O
31	O
.	O
Jugular	O
ingurgitation	O
and	O
hepatojugular	O
reflux	O
.	O
Cardiac	O
auscultation	O
tachycardic	O
with	O
gallop	O
rhythm	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
bibasal	O
crackles	O
.	O
ABD	O
soft	O
and	O
depressible	O
,	O
no	O
masses	O
or	O
megaliths	O
,	O
not	O
painful	O
on	O
palpation	O
,	O
peristalsis	O
present	O
.	O
Lower	O
extremities	O
pretibial	O
oedema	O
in	O
both	O
extremities	O
.	O
No	O
signs	O
of	O
DVT	O
.	O
Peripheral	O
pulses	O
present	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
tests	O
on	O
admission	O
creatinine	O
0	O
.	O
88	O
mg	O
dl	O
,	O
urea	O
53	O
mg	O
dl	O
,	O
K	O
3	O
.	O
5	O
mEq	O
L	O
,	O
Na	O
144	O
mEq	O
L	O
,	O
glucose	O
126	O
mg	O
dl	O
,	O
INR	O
1	O
.	O
16	O
.	O
Haemogram	O
without	O
alterations	O
.	O
Arterial	O
blood	O
gases	O
pH	O
7	O
.	O
54	O
,	O
pCO2	O
24	O
.	O
2	O
mmHg	O
,	O
pO2	O
24	O
.	O
2	O
mmHg	O
,	O
bicarbonate	O
21	O
.	O
3	O
mmol	O
L	O
,	O
lactate	O
2	O
.	O
15	O
mmol	O
L	O
.	O
ECG	O
sinus	O
rhythm	O
at	O
86	O
bpm	O
.	O
Signs	O
of	O
LA	O
growth	O
.	O
Normal	O
PR	O
.	O
Narrow	O
QRS	O
with	O
incomplete	O
LBBB	O
,	O
lateral	O
negative	O
T	O
wave	O
.	O
Chest	O
X	O
ray	O
cardiomegaly	O
.	O
Signs	O
of	O
vascular	O
redistribution	O
to	O
upper	O
fields	O
.	O
No	O
pleural	O
effusion	O
or	O
pneumonic	O
consolidation	O
.	O
Echocardiogram	O
21	O
04	O
17	O
LV	O
dilatation	O
with	O
severely	O
depressed	O
function	O
,	O
hypertrabeculation	O
without	O
echocardiographic	O
criteria	O
of	O
non	O
compaction	O
suboptimal	O
window	O
.	O
Mild	O
functional	O
MR	O
.	O
Grade	O
II	O
diastolic	O
dysfunction	O
with	O
elevated	O
LVEDP	O
criteria	O
.	O
Dilated	O
RV	O
with	O
mild	O
dysfunction	O
.	O
Mild	O
TR	O
.	O
Normal	O
PAPs	O
may	O
be	O
underestimated	O
due	O
to	O
RV	O
dysfunction	O
.	O
Minimally	O
elevated	O
PVC	O
signs	O
.	O
No	O
pericardial	O
effusion	O
.	O
Coronary	O
angiography	O
24	O
04	O
17	O
no	O
angiographic	O
lesions	O
.	O
Cardiac	O
MRI	O
26	O
04	O
17	O
dilated	O
LV	O
,	O
wall	O
thickness	O
at	O
the	O
lower	O
limit	O
of	O
normality	O
,	O
hypertrabeculation	O
with	O
criteria	O
of	O
non	O
compaction	O
in	O
the	O
inferolateral	O
wall	O
ratio	O
non	O
compacted	O
myocardium	O
compacted	O
of	O
4	O
1	O
global	O
hypocontractility	O
with	O
severely	O
depressed	O
EF	O
24	O
.	O
5	O
.	O
Dilated	O
LA	O
.	O
Dilated	O
RV	O
with	O
depressed	O
function	O
.	O
Dilated	O
RA	O
.	O
Subjectively	O
mild	O
MR	O
.	O
Minimal	O
pericardial	O
effusion	O
.	O
Presence	O
of	O
intramyocardial	O
uptake	O
in	O
basal	O
and	O
middle	O
segments	O
of	O
septal	O
wall	O
and	O
RV	O
insertion	O
.	O
Conclusions	O
dilated	O
cardiomyopathy	O
with	O
severe	O
ventricular	O
dysfunction	O
with	O
non	O
compaction	O
criteria	O
.	O
Intramyocardial	O
septal	O
uptake	O
.	O
Cranial	O
CT	O
29	O
04	O
17	O
no	O
established	O
ischaemic	O
brain	O
lesions	O
.	O
No	O
acute	O
haemorrhages	O
.	O
Occlusion	O
of	O
the	O
posterior	O
communicating	O
segment	O
P2	O
of	O
the	O
right	O
posterior	O
cerebral	O
artery	O
.	O
Cranial	O
CT	O
30	O
04	O
17	O
established	O
ischaemic	O
lesions	O
at	O
the	O
level	O
of	O
the	O
right	O
temporo	O
occipital	O
,	O
ipsilateral	O
thalamus	O
and	O
bilateral	O
cerebellar	O
.	O
Small	O
focus	O
of	O
haemorrhagic	O
transformation	O
in	O
the	O
temporo	O
occipital	O
lesion	O
.	O
EVOLUTION	O
During	O
admission	O
to	O
the	O
ward	O
,	O
depletive	O
treatment	O
was	O
started	O
,	O
together	O
with	O
beta	O
blockers	O
,	O
ARAII	O
intolerance	O
to	O
ACE	O
inhibitors	O
due	O
to	O
cough	O
,	O
eplerenone	B-FARMACO
and	O
ivabradine	B-FARMACO
.	O
An	O
echocardiogram	O
was	O
performed	O
showing	O
cardiomyopathy	O
with	O
severe	O
biventricular	O
dysfunction	O
and	O
hypertrabeculation	O
of	O
the	O
left	O
ventricle	O
,	O
without	O
meeting	O
the	O
criteria	O
for	O
non	O
compaction	O
with	O
suboptimal	O
window	O
.	O
Laboratory	O
tests	O
with	O
normal	O
thyroid	O
profile	O
,	O
autoimmunity	O
and	O
proteinogram	O
.	O
Normal	O
renal	O
function	O
.	O
Coronary	O
angiography	O
ruled	O
out	O
coronary	O
lesions	O
.	O
Finally	O
,	O
for	O
the	O
aetiological	O
study	O
,	O
cardiac	O
MRI	O
was	O
performed	O
which	O
showed	O
the	O
presence	O
of	O
dilated	O
cardiomyopathy	O
with	O
severe	O
ventricular	O
dysfunction	O
with	O
criteria	O
of	O
non	O
compaction	O
and	O
intramyocardial	O
septal	O
uptake	O
.	O
Enoxaparin	B-FARMACO
was	O
started	O
at	O
anticoagulant	O
doses	O
1	O
mg	O
kg	O
12	O
h	O
.	O
During	O
the	O
evolution	O
of	O
the	O
patient	O
's	O
clinical	O
deterioration	O
,	O
dobutamine	B-FARMACO
perfusion	O
at	O
inotropic	O
doses	O
was	O
started	O
.	O
After	O
several	O
days	O
of	O
treatment	O
,	O
the	O
patient	O
improved	O
and	O
dobutamine	B-FARMACO
was	O
withdrawn	O
and	O
beta	O
blockers	O
,	O
ARAII	B-FARMACO
and	O
eplerenone	B-FARMACO
were	O
restarted	O
.	O
As	O
a	O
complication	O
during	O
admission	O
,	O
the	O
patient	O
had	O
an	O
ischaemic	O
stroke	O
despite	O
the	O
anticoagulation	O
already	O
started	O
.	O
Fibrinolysis	O
was	O
ruled	O
out	O
as	O
the	O
patient	O
was	O
anticoagulated	O
and	O
thrombectomy	O
was	O
ruled	O
out	O
as	O
the	O
territory	O
was	O
small	O
and	O
with	O
progressive	O
clinical	O
improvement	O
.	O
On	O
discharge	O
the	O
patient	O
was	O
anticoagulated	O
with	O
dabigatran	B-FARMACO
110	O
mg	O
12h	O
for	O
1	O
month	O
,	O
after	O
which	O
it	O
was	O
increased	O
to	O
150	O
mg	O
12h	O
as	O
recommended	O
by	O
haematology	O
.	O
He	O
will	O
continue	O
to	O
be	O
monitored	O
in	O
the	O
heart	O
failure	O
unit	O
and	O
neurology	O
consultation	O
.	O
DIAGNOSIS	O
Debut	O
heart	O
failure	O
.	O
Non	O
compaction	O
cardiomyopathy	O
with	O
biventricular	O
dysfunction	O
.	O
Ischaemic	O
cerebral	O
vascular	O
accident	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
68	O
year	O
old	O
woman	O
,	O
with	O
no	O
known	O
drug	O
allergies	O
,	O
hypertension	O
,	O
with	O
a	O
history	O
of	O
subclinical	O
hypothyroidism	O
,	O
arthritis	O
,	O
osteoporosis	O
,	O
hypermetropia	O
and	O
glaucoma	O
.	O
No	O
family	O
history	O
of	O
interest	O
.	O
For	O
two	O
months	O
she	O
had	O
been	O
experiencing	O
episodes	O
of	O
central	O
thoracic	O
pressure	O
radiating	O
to	O
the	O
left	O
upper	O
extremity	O
ESI	O
on	O
exertion	O
,	O
which	O
self	O
limited	O
spontaneously	O
within	O
a	O
few	O
minutes	O
.	O
On	O
the	O
day	O
of	O
her	O
admission	O
,	O
she	O
went	O
to	O
her	O
health	O
centre	O
for	O
presenting	O
while	O
walking	O
with	O
oppressive	O
precordial	O
pain	O
radiating	O
to	O
the	O
shoulder	O
and	O
LTE	O
,	O
similar	O
to	O
previous	O
episodes	O
but	O
of	O
greater	O
intensity	O
and	O
duration	O
about	O
30	O
minutes	O
.	O
An	O
ECG	O
was	O
performed	O
with	O
pain	O
that	O
showed	O
sinus	O
rhythm	O
with	O
negative	O
T	O
wave	O
in	O
V4	O
6	O
,	O
I	O
and	O
AVL	O
,	O
for	O
which	O
she	O
was	O
transferred	O
to	O
our	O
centre	O
.	O
On	O
arrival	O
at	O
the	O
ED	O
,	O
BP	O
194	O
97	O
mmHg	O
,	O
HR	O
108	O
bpm	O
,	O
O2	O
saturation	O
95	O
baseline	O
,	O
and	O
an	O
ECG	O
was	O
performed	O
even	O
with	O
chest	O
pain	O
,	O
which	O
was	O
similar	O
to	O
that	O
described	O
previously	O
.	O
A	O
few	O
minutes	O
later	O
,	O
after	O
cessation	O
of	O
pain	O
and	O
control	O
of	O
blood	O
pressure	O
,	O
a	O
new	O
ECG	O
was	O
performed	O
in	O
which	O
the	O
described	O
alterations	O
disappeared	O
.	O
In	O
a	O
subsequent	O
control	O
ECG	O
,	O
electrical	O
alterations	O
were	O
again	O
observed	O
,	O
with	O
a	O
negative	O
T	O
wave	O
in	O
V2	O
6	O
,	O
I	O
and	O
AVL	O
,	O
although	O
the	O
patient	O
remained	O
asymptomatic	O
at	O
that	O
time	O
.	O
Physical	O
examination	O
conscious	O
and	O
oriented	O
,	O
normohydrated	O
and	O
well	O
perfused	O
.	O
Eupneic	O
at	O
rest	O
with	O
no	O
signs	O
of	O
respiratory	O
work	O
.	O
No	O
IY	O
or	O
other	O
congestive	O
signs	O
.	O
AC	O
rhythmic	O
around	O
105	O
bpm	O
,	O
no	O
murmurs	O
or	O
audible	O
extratonos	O
.	O
PA	O
normoventilation	O
in	O
all	O
fields	O
.	O
Abdomen	O
was	O
nondescript	O
.	O
LES	O
no	O
oedema	O
or	O
signs	O
of	O
DVT	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
1	O
sinus	O
rhythm	O
at	O
100	O
bpm	O
,	O
normal	O
PR	O
,	O
narrow	O
QRS	O
,	O
negative	O
T	O
wave	O
in	O
V4	O
6	O
,	O
I	O
and	O
AVL	O
.	O
ECG	O
2	O
sinus	O
rhythm	O
at	O
70	O
bpm	O
,	O
normal	O
PR	O
,	O
narrow	O
QRS	O
,	O
no	O
repolarisation	O
abnormalities	O
.	O
ECG	O
3	O
sinus	O
rhythm	O
at	O
75	O
bpm	O
,	O
normal	O
PR	O
,	O
narrow	O
QRS	O
,	O
negative	O
T	O
wave	O
in	O
V4	O
V6	O
,	O
I	O
and	O
AVL	O
.	O
Blood	O
tests	O
troponin	O
I	O
0	O
.	O
01	O
by	O
3	O
determinations	O
.	O
Glucose	O
103	O
mg	O
dl	O
,	O
urea	O
32	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
86	O
mg	O
dl	O
,	O
uric	O
acid	O
5	O
.	O
60	O
mg	O
dl	O
,	O
triglycerides	O
135	O
mg	O
dl	O
,	O
serum	O
cholesterol	O
136	O
mg	O
dl	O
,	O
serum	O
HDL	O
cholesterol	O
36	O
mg	O
dl	O
,	O
serum	O
LDL	O
cholesterol	O
calculated	O
73	O
mg	O
dl	O
,	O
chloride	O
102	O
mEq	O
L	O
,	O
sodium	O
141	O
mEq	O
L	O
,	O
K	O
4	O
.	O
6	O
mEq	O
L	O
,	O
CK	O
60	O
U	O
L	O
,	O
FA	O
64	O
U	O
L	O
,	O
GGT	O
19	O
U	O
L	O
,	O
GOT	O
20	O
U	O
L	O
,	O
GPT	O
26	O
U	O
L	O
.	O
Leukocytes	O
8	O
,	O
300	O
microlitre	O
,	O
Hb	O
16	O
.	O
4	O
g	O
dL	O
,	O
Hto	O
48	O
.	O
2	O
,	O
MCV	O
90	O
fl	O
.	O
Platelets	O
250	O
,	O
000	O
microlitre	O
.	O
Chest	O
X	O
ray	O
normal	O
cardiomediastinal	O
silhouette	O
,	O
without	O
pleuroparenchymal	O
alterations	O
of	O
acute	O
evolution	O
.	O
Transthoracic	O
echocardiogram	O
non	O
dilated	O
LV	O
,	O
with	O
mild	O
concentric	O
left	O
ventricular	O
hypertrophy	O
.	O
Global	O
systolic	O
function	O
preserved	O
,	O
without	O
segmental	O
alterations	O
of	O
contractility	O
.	O
Normal	O
diastolic	O
pattern	O
,	O
with	O
non	O
elevated	O
LVEDP	O
data	O
.	O
Right	O
chambers	O
of	O
normal	O
dimensions	O
,	O
RV	O
normocontractile	O
TAPSE	O
21	O
mm	O
,	O
S	O
"	O
wave	O
11	O
cm	O
sec	O
.	O
MV	O
thin	O
veils	O
,	O
not	O
limited	O
in	O
its	O
opening	O
,	O
minimal	O
central	O
MI	O
.	O
VAo	O
trivalva	O
,	O
preserved	O
opening	O
without	O
generating	O
significant	O
gradient	O
,	O
competent	O
.	O
Mild	O
TR	O
.	O
Estimated	O
normal	O
PAPs	O
.	O
No	O
pericardial	O
effusion	O
or	O
intracavitary	O
masses	O
by	O
this	O
access	O
route	O
.	O
Coronary	O
angiography	O
left	O
common	O
trunk	O
without	O
angiographic	O
disease	O
.	O
Anterior	O
descending	O
intramyocardial	O
bridging	O
in	O
mid	O
distal	O
segment	O
with	O
significant	O
milking	O
.	O
Rest	O
of	O
the	O
vessel	O
very	O
looped	O
without	O
angiographic	O
disease	O
.	O
Circumflex	O
very	O
looped	O
vessel	O
,	O
without	O
angiographic	O
disease	O
.	O
Right	O
coronary	O
dominant	O
.	O
Slight	O
ostial	O
sharpening	O
,	O
which	O
is	O
calcified	O
.	O
Rest	O
of	O
the	O
vessel	O
without	O
angiographic	O
disease	O
.	O
In	O
conclusion	O
very	O
tortuous	O
coronary	O
arteries	O
without	O
significant	O
angiographic	O
disease	O
and	O
mid	O
distal	O
LAD	O
with	O
intramyocardial	O
bridging	O
leading	O
to	O
significant	O
milking	O
.	O
EVOLUTION	O
The	O
physical	O
examination	O
was	O
normal	O
at	O
all	O
times	O
,	O
as	O
were	O
the	O
laboratory	O
tests	O
,	O
and	O
there	O
was	O
no	O
evidence	O
of	O
enzyme	O
elevation	O
compatible	O
with	O
myocardial	O
necrosis	O
.	O
A	O
chest	O
X	O
ray	O
was	O
performed	O
,	O
showing	O
no	O
radiological	O
alterations	O
of	O
acute	O
evolution	O
,	O
and	O
an	O
echocardiogram	O
was	O
performed	O
with	O
no	O
findings	O
of	O
interest	O
.	O
The	O
clinical	O
picture	O
was	O
interpreted	O
as	O
unstable	O
angina	O
with	O
dynamic	O
electrocardiographic	O
changes	O
suggestive	O
of	O
ischaemia	O
,	O
so	O
the	O
case	O
was	O
discussed	O
with	O
the	O
Intensive	O
Care	O
Unit	O
and	O
,	O
given	O
the	O
patient	O
's	O
haemodynamic	O
stability	O
,	O
it	O
was	O
decided	O
to	O
admit	O
her	O
to	O
Cardiology	O
.	O
The	O
patient	O
was	O
admitted	O
to	O
our	O
department	O
,	O
with	O
continuous	O
monitoring	O
.	O
After	O
24	O
hours	O
,	O
coronary	O
angiography	O
showed	O
very	O
tortuous	O
coronary	O
arteries	O
with	O
no	O
significant	O
angiographic	O
disease	O
and	O
mid	O
distal	O
LAD	O
with	O
intramyocardial	O
bridging	O
leading	O
to	O
significant	O
milking	O
.	O
The	O
patient	O
remained	O
asymptomatic	O
throughout	O
admission	O
,	O
with	O
good	O
control	O
of	O
blood	O
pressure	O
and	O
no	O
arrhythmic	O
events	O
during	O
monitoring	O
.	O
She	O
was	O
discharged	O
after	O
48	O
hours	O
with	O
low	O
dose	O
beta	O
blocker	O
treatment	O
emconcor	B-FARMACO
2	O
.	O
5	O
mg	O
every	O
24	O
hours	O
.	O
The	O
patient	O
has	O
recently	O
been	O
assessed	O
in	O
cardiology	O
consultations	O
,	O
remaining	O
asymptomatic	O
with	O
good	O
functional	O
class	O
,	O
so	O
the	O
prescribed	O
treatment	O
has	O
been	O
maintained	O
.	O
DIAGNOSIS	O
Chest	O
pain	O
.	O
Coronary	O
arteries	O
without	O
significant	O
angiographic	O
lesions	O
.	O
Intramyocardial	O
tract	O
of	O
the	O
anterior	O
descending	O
artery	O
at	O
mid	O
distal	O
level	O
with	O
significant	O
milking	O
.	O
Preserved	O
systolic	O
function	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
83	O
year	O
old	O
woman	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
Intolerance	O
to	O
amlodipine	B-FARMACO
due	O
to	O
oedema	O
.	O
Denies	O
toxic	O
habits	O
.	O
Cardiovascular	O
risk	O
factors	O
arterial	O
hypertension	O
AHT	O
.	O
Dyslipidaemia	O
.	O
No	O
diabetes	O
.	O
History	O
Mitral	O
insufficiency	O
diagnosed	O
in	O
2017	O
after	O
an	O
episode	O
of	O
heart	O
failure	O
.	O
Intervention	O
in	O
November	O
2020	O
with	O
placement	O
of	O
St	O
.	O
Jude	O
No	O
25	O
mechanical	O
prosthesis	O
.	O
Paroxysmal	O
atrial	O
fibrillation	O
.	O
Mild	O
moderate	O
pulmonary	O
hypertension	O
.	O
Mild	O
moderate	O
stenosis	O
of	O
the	O
middle	O
anterior	O
descending	O
coronary	O
artery	O
.	O
Moderate	O
chronic	O
obstructive	O
pulmonary	O
disease	O
with	O
small	O
bronchiectasis	O
in	O
the	O
right	O
base	O
.	O
Anxious	O
syndrome	O
.	O
Surgical	O
interventions	O
appendectomy	O
.	O
Intervened	O
caesarean	O
section	O
.	O
Mitral	O
valve	O
replacement	O
.	O
Baseline	O
situation	O
independent	O
for	O
basic	O
activities	O
of	O
daily	O
living	O
,	O
no	O
cognitive	O
impairment	O
.	O
Lives	O
at	O
home	O
with	O
her	O
husband	O
.	O
Two	O
daughters	O
,	O
one	O
under	O
neurological	O
follow	O
up	O
for	O
multiple	O
sclerosis	O
,	O
lives	O
independently	O
,	O
and	O
the	O
other	O
with	O
granted	O
dependency	O
due	O
to	O
mental	O
retardation	O
.	O
No	O
orthopnoea	O
.	O
No	O
usual	O
oedema	O
.	O
Treatment	O
simvastatin	B-FARMACO
10	O
mg	O
1	O
tablet	O
at	O
dinner	O
,	O
enalapril	B-FARMACO
5	O
mg	O
1	O
tablet	O
at	O
breakfast	O
,	O
bisoprolol	B-FARMACO
5	O
mg	O
1	O
tablet	O
at	O
breakfast	O
,	O
amiodarone	B-FARMACO
200	O
mg	O
5	O
days	O
a	O
week	O
,	O
sintrom	B-FARMACO
4	O
mg	O
total	O
weekly	O
dose	O
10	O
mg	O
1	O
tablet	O
at	O
snack	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
1	O
tablet	O
at	O
breakfast	O
,	O
ferrimanitol	B-FARMACO
ovalbumin	I-FARMACO
40	O
mg	O
1	O
tablet	O
at	O
lunch	O
,	O
furosemide	B-FARMACO
40	O
mg	O
1	O
tablet	O
at	O
breakfast	O
,	O
spironolactone	B-FARMACO
25	O
mg	O
1	O
tablet	O
at	O
breakfast	O
,	O
alprazolam	B-FARMACO
0	O
.	O
5	O
mg	O
1	O
tablet	O
at	O
bedtime	O
,	O
budesonide	B-FARMACO
formoterol	I-FARMACO
160	O
4	O
.	O
5	O
mg	O
2	O
puffs	O
at	O
breakfast	O
and	O
dinner	O
,	O
tiotropium	B-FARMACO
bromide	I-FARMACO
2	O
puffs	O
at	O
lunch	O
.	O
Current	O
illness	O
He	O
presented	O
to	O
the	O
emergency	O
department	O
for	O
an	O
episode	O
of	O
self	O
limited	O
aphasia	O
and	O
two	O
partial	O
seizures	O
in	O
the	O
left	O
arm	O
and	O
leg	O
he	O
started	O
with	O
clinical	O
aphasia	O
and	O
later	O
movements	O
in	O
the	O
leg	O
first	O
and	O
then	O
in	O
the	O
arm	O
,	O
accompanied	O
by	O
a	O
sensation	O
of	O
some	O
dysmetry	O
and	O
loss	O
of	O
strength	O
in	O
the	O
right	O
arm	O
.	O
He	O
was	O
admitted	O
to	O
neurology	O
,	O
who	O
,	O
suspecting	O
cardioembolic	O
stroke	O
,	O
requested	O
an	O
echocardiogram	O
to	O
complete	O
the	O
study	O
.	O
Due	O
to	O
an	O
increase	O
in	O
the	O
mean	O
mitral	O
prosthetic	O
gradient	O
after	O
implantation	O
3	O
.	O
5	O
mmHg	O
now	O
7	O
.	O
7	O
mmHg	O
,	O
it	O
was	O
decided	O
to	O
perform	O
a	O
transesophageal	O
echocardiogram	O
TEE	O
in	O
which	O
he	O
presented	O
two	O
mobile	O
images	O
suggestive	O
of	O
thrombus	O
adhered	O
to	O
the	O
mitral	O
prosthesis	O
.	O
There	O
was	O
no	O
evidence	O
of	O
endocarditis	O
and	O
no	O
previous	O
compatible	O
history	O
.	O
She	O
has	O
not	O
presented	O
fever	O
or	O
shivering	O
,	O
previous	O
infectious	O
symptoms	O
or	O
stigmata	O
of	O
endocarditis	O
.	O
Previous	O
INR	O
values	O
checked	O
since	O
October	O
,	O
all	O
values	O
are	O
below	O
2	O
.	O
5	O
and	O
there	O
are	O
even	O
two	O
below	O
2	O
,	O
so	O
she	O
is	O
referred	O
to	O
cardiology	O
for	O
further	O
evolution	O
and	O
treatment	O
.	O
Physical	O
examination	O
Afebrile	O
.	O
Blood	O
pressure	O
136	O
54	O
mmHg	O
,	O
heart	O
rate	O
71	O
bpm	O
,	O
baseline	O
oxygen	O
saturation	O
95	O
.	O
Neck	O
no	O
jugular	O
ingurgitation	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
.	O
Normal	O
prosthetic	O
sounds	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
without	O
crackles	O
.	O
Abdomen	O
no	O
hepatomegaly	O
.	O
Lower	O
limbs	O
no	O
oedema	O
.	O
No	O
Janeway	O
lesions	O
or	O
Osler	O
nodules	O
.	O
COMPLEMENTARY	O
TESTS	O
Emergency	O
laboratory	O
tests	O
glucose	O
119	O
mg	O
dl	O
,	O
urea	O
51	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
65	O
mg	O
dl	O
,	O
sodium	O
136	O
mmol	O
l	O
,	O
potassium	O
4	O
.	O
7	O
mmol	O
l	O
,	O
ultrasensitive	O
troponin	O
T	O
11	O
ng	O
l	O
,	O
Hb	O
12	O
g	O
dl	O
,	O
platelets	O
277	O
x103	O
mm3	O
,	O
leukocytes	O
6	O
.	O
95	O
x103	O
mm3	O
,	O
normal	O
formula	O
.	O
Urinalysis	O
in	O
the	O
emergency	O
department	O
no	O
significant	O
findings	O
.	O
Emergency	O
ECG	O
sinus	O
rhythm	O
at	O
80	O
bpm	O
.	O
Atrioventricular	O
block	O
AVB	O
first	O
degree	O
with	O
PR	O
240	O
ms	O
.	O
Normal	O
voltages	O
.	O
T	O
flattened	O
in	O
III	O
,	O
with	O
no	O
other	O
findings	O
.	O
Postero	O
anterior	O
chest	O
X	O
ray	O
,	O
ED	O
sternotomy	O
surgical	O
clips	O
.	O
Metallic	O
prosthesis	O
in	O
mitral	O
position	O
.	O
Calcified	O
atheromas	O
in	O
the	O
aorta	O
.	O
Small	O
ill	O
defined	O
areas	O
of	O
increased	O
density	O
in	O
the	O
left	O
upper	O
field	O
and	O
right	O
and	O
left	O
midfield	O
,	O
radiologically	O
unspecific	O
,	O
may	O
correspond	O
to	O
inflammatory	O
changes	O
,	O
chronic	O
changes	O
,	O
etc	O
.	O
;	O
in	O
the	O
context	O
of	O
a	O
coronavirus	O
pandemic	O
it	O
is	O
recommended	O
to	O
rule	O
out	O
,	O
with	O
analytical	O
data	O
and	O
PCR	O
,	O
that	O
it	O
is	O
pulmonary	O
involvement	O
by	O
COVID	O
19	O
.	O
Images	O
of	O
calcium	O
density	O
in	O
right	O
hypochondrium	O
compatible	O
with	O
calcified	O
hepatic	O
granulomas	O
Degenerative	O
changes	O
in	O
the	O
spine	O
and	O
calcifying	O
tendinitis	O
in	O
the	O
right	O
shoulder	O
.	O
Serology	O
and	O
PCR	O
of	O
nasopharyngeal	O
aspirate	O
for	O
COVID	O
19	O
negative	O
.	O
Cranial	O
CT	O
no	O
signs	O
of	O
acute	O
intracranial	O
pathology	O
.	O
Magnetic	O
resonance	O
imaging	O
MRI	O
of	O
the	O
brain	O
several	O
lesions	O
were	O
seen	O
.	O
One	O
in	O
the	O
left	O
parietal	O
white	O
matter	O
.	O
Another	O
punctiform	O
on	O
the	O
right	O
side	O
of	O
the	O
pons	O
in	O
the	O
posterior	O
midline	O
.	O
In	O
the	O
superior	O
area	O
of	O
the	O
left	O
cerebellar	O
hemisphere	O
.	O
They	O
show	O
restriction	O
in	O
the	O
diffusion	O
sequence	O
to	O
a	O
greater	O
or	O
lesser	O
degree	O
,	O
do	O
not	O
show	O
oedema	O
or	O
significant	O
mass	O
effect	O
,	O
and	O
show	O
low	O
signal	O
on	O
T1	O
and	O
high	O
signal	O
on	O
T2	O
and	O
FLAIR	O
.	O
They	O
are	O
compatible	O
with	O
acute	O
subacute	O
ischaemic	O
lesions	O
,	O
to	O
be	O
assessed	O
with	O
history	O
heart	O
disease	O
,	O
etc	O
.	O
.	O
There	O
are	O
no	O
signs	O
of	O
haemorrhage	O
in	O
these	O
lesions	O
.	O
In	O
the	O
T2	O
gradient	O
echo	O
sequence	O
,	O
some	O
right	O
medial	O
occipital	O
cortical	O
haemosiderin	O
deposits	O
are	O
observed	O
in	O
the	O
upper	O
area	O
of	O
the	O
left	O
cerebellar	O
hemisphere	O
and	O
the	O
lower	O
area	O
of	O
the	O
right	O
cerebellar	O
hemisphere	O
.	O
Encephalo	O
ventricular	O
pattern	O
with	O
atrophy	O
correlated	O
with	O
the	O
age	O
of	O
the	O
patient	O
.	O
The	O
Willis	O
polygon	O
shows	O
normal	O
calibre	O
and	O
patency	O
of	O
the	O
main	O
arteries	O
,	O
with	O
less	O
flow	O
through	O
the	O
distal	O
branches	O
of	O
the	O
left	O
middle	O
cerebral	O
artery	O
.	O
Conclusion	O
multiple	O
supra	O
and	O
infratentorial	O
ischaemic	O
lesions	O
,	O
acute	O
subacute	O
.	O
To	O
be	O
assessed	O
with	O
history	O
image	O
3	O
.	O
Laboratory	O
tests	O
on	O
admission	O
no	O
significant	O
alterations	O
with	O
respect	O
to	O
the	O
ED	O
in	O
terms	O
of	O
acute	O
phase	O
reactants	O
.	O
Renal	O
,	O
liver	O
and	O
lipid	O
profile	O
within	O
normal	O
limits	O
.	O
Transthoracic	O
echocardiogram	O
TTE	O
18	O
01	O
non	O
dilated	O
left	O
ventricle	O
LV	O
with	O
mild	O
concentric	O
hypertrophy	O
,	O
anomalous	O
movement	O
of	O
the	O
septum	O
due	O
to	O
surgery	O
,	O
normal	O
contractility	O
,	O
LVEF	O
Simpson	O
63	O
.	O
Mild	O
left	O
atrial	O
dilatation	O
,	O
non	O
dilated	O
right	O
chambers	O
with	O
normal	O
function	O
.	O
Pulmonary	O
artery	O
systolic	O
pressure	O
PSAP	O
in	O
high	O
normal	O
range	O
estimated	O
at	O
41	O
mmHg	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
with	O
adequate	O
inspiratory	O
collapse	O
.	O
Non	O
stenotic	O
fibrotic	O
trichomysial	O
fibrosed	O
aortic	O
valve	O
with	O
mild	O
regurgitation	O
.	O
Mechanical	O
mitral	O
prosthesis	O
with	O
normal	O
disc	O
motion	O
,	O
area	O
estimated	O
by	O
hemi	O
pressure	O
time	O
at	O
2	O
.	O
3	O
cm2	O
,	O
mean	O
gradient	O
7	O
.	O
7	O
mmHg	O
.	O
No	O
pericardial	O
effusion	O
.	O
Aortic	O
root	O
not	O
dilated	O
.	O
Conclusions	O
mild	O
left	O
ventricular	O
hypertrophy	O
,	O
normofunctioning	O
prosthesis	O
,	O
mild	O
aortic	O
insufficiency	O
.	O
Transesophageal	O
echocardiogram	O
TEE	O
19	O
01	O
in	O
the	O
presence	O
of	O
a	O
slightly	O
increased	O
mean	O
mitral	O
prosthetic	O
gradient	O
,	O
TEE	O
was	O
performed	O
,	O
showing	O
a	O
non	O
ligated	O
left	O
atrial	O
appendage	O
,	O
free	O
of	O
thrombus	O
.	O
The	O
interatrial	O
septum	O
was	O
intact	O
.	O
Bidisc	O
mechanical	O
mitral	O
prosthesis	O
with	O
good	O
opening	O
.	O
At	O
around	O
9	O
o	O
'	O
clock	O
in	O
the	O
lateral	O
position	O
,	O
seen	O
from	O
the	O
left	O
atrium	O
,	O
a	O
filiform	O
mass	O
of	O
12	O
x	O
4	O
mm	O
,	O
mobile	O
,	O
prolapsing	O
towards	O
the	O
LV	O
in	O
diastole	O
,	O
echogenicity	O
suggestive	O
of	O
thrombus	O
no	O
fever	O
adhered	O
to	O
the	O
atrial	O
side	O
of	O
the	O
prosthetic	O
ring	O
.	O
In	O
the	O
anteromedial	O
portion	O
towards	O
1	O
2	O
h	O
of	O
the	O
clock	O
,	O
a	O
filiform	O
image	O
is	O
visualised	O
adhered	O
to	O
the	O
anteroseptal	O
portion	O
of	O
the	O
ring	O
,	O
measuring	O
2	O
x	O
7	O
mm	O
,	O
more	O
hyperechogenic	O
,	O
contiguous	O
with	O
the	O
ring	O
tissue	O
,	O
with	O
slight	O
movement	O
towards	O
the	O
LV	O
in	O
diastole	O
.	O
Some	O
calcified	O
atheroma	O
plaque	O
in	O
descending	O
thoracic	O
aorta	O
.	O
Conclusions	O
mobile	O
image	O
in	O
the	O
posterolateral	O
area	O
of	O
a	O
recent	O
mechanical	O
mitral	O
prosthesis	O
,	O
without	O
significant	O
obstruction	O
,	O
suggestive	O
as	O
a	O
first	O
possibility	O
of	O
thrombus	O
.	O
Mobile	O
hyperechogenic	O
image	O
in	O
anteromedial	O
position	O
.	O
Three	O
small	O
jets	O
of	O
functional	O
intraprosthetic	O
regurgitation	O
.	O
Blood	O
cultures	O
x3	O
19	O
01	O
only	O
one	O
of	O
them	O
isolated	O
coagulase	O
negative	O
Staphylococcus	O
Penicillin	O
R	O
,	O
Oxacillin	O
R	O
,	O
Gentamicin	O
S	O
,	O
Clindamycin	O
R	O
,	O
Erythromycin	O
R	O
,	O
Vancomycin	O
S	O
,	O
Cotrimoxazole	O
R	O
;	O
R	O
being	O
resistant	O
and	O
S	O
sensitive	O
probable	O
contamination	O
.	O
TEE	O
of	O
control	O
26	O
01	O
mechanical	O
prosthesis	O
that	O
impresses	O
of	O
adequate	O
opening	O
and	O
closing	O
of	O
the	O
discs	O
,	O
3	O
narrow	O
jet	O
of	O
prosthetic	O
washout	O
are	O
observed	O
,	O
with	O
a	O
fourth	O
more	O
eccentric	O
compatible	O
with	O
periprosthetic	O
leak	O
at	O
anterior	O
level	O
of	O
the	O
aortic	O
suture	O
12	O
h	O
of	O
the	O
clock	O
,	O
which	O
is	O
directed	O
to	O
interatrial	O
septum	O
,	O
reaching	O
the	O
left	O
atrial	O
roof	O
,	O
with	O
decrease	O
of	O
the	O
systolic	O
component	O
in	O
left	O
superior	O
pulmonary	O
vein	O
.	O
Contractile	O
vein	O
of	O
2	O
mm	O
and	O
area	O
of	O
the	O
contractile	O
vein	O
in	O
3D	O
4	O
mm2	O
,	O
estimated	O
as	O
moderate	O
grade	O
not	O
visualised	O
in	O
previous	O
study	O
.	O
As	O
for	O
the	O
image	O
visible	O
in	O
the	O
previous	O
study	O
,	O
it	O
is	O
located	O
in	O
the	O
posterolateral	O
part	O
of	O
the	O
annulus	O
,	O
filiform	O
appearance	O
with	O
movement	O
concordant	O
with	O
the	O
posterior	O
disc	O
,	O
14	O
mm	O
long	O
and	O
4	O
5	O
mm	O
wide	O
,	O
which	O
has	O
decreased	O
somewhat	O
with	O
respect	O
to	O
the	O
previous	O
study	O
.	O
Conclusions	O
moderate	O
eccentric	O
mitral	O
insufficiency	O
MI	O
due	O
to	O
periprosthetic	O
leak	O
.	O
Image	O
compatible	O
with	O
thrombus	O
in	O
posterior	O
mitral	O
prosthesis	O
.	O
Blood	O
cultures	O
x3	O
27	O
01	O
only	O
one	O
of	O
them	O
isolated	O
coagulase	O
negative	O
Staphylococcus	O
coagulase	O
,	O
with	O
the	O
same	O
antibiogram	O
as	O
the	O
previous	O
one	O
.	O
Probable	O
contamination	O
.	O
Surgical	O
report	O
31	O
01	O
median	O
re	O
sternotomy	O
.	O
Dissection	O
of	O
pleuropericardial	O
adhesions	O
due	O
to	O
previous	O
surgery	O
.	O
Ascending	O
aorta	O
,	O
single	O
cavoatrial	O
and	O
coronary	O
sinus	O
cannulation	O
.	O
Establishment	O
of	O
extracorporeal	O
circulation	O
ECC	O
.	O
Aortic	O
clamping	O
.	O
Left	O
atriotomy	O
.	O
Administration	O
of	O
cardioplegia	O
.	O
Explanation	O
of	O
the	O
mitral	O
prosthesis	O
,	O
implantation	O
of	O
a	O
25	O
mm	O
Epic	O
mitral	O
prosthesis	O
.	O
Closure	O
of	O
the	O
atriotomy	O
.	O
Administration	O
of	O
enriched	O
warm	O
haematic	O
cardioplegia	O
and	O
aortic	O
declapping	O
.	O
Recovery	O
of	O
spontaneous	O
heartbeat	O
.	O
Warmed	O
to	O
normothermia	O
and	O
disconnected	O
from	O
CPB	O
.	O
Removal	O
of	O
cannulae	O
,	O
haemostasis	O
and	O
neutralisation	O
of	O
heparin	B-FARMACO
.	O
The	O
prosthesis	O
is	O
checked	O
for	O
proper	O
functioning	O
by	O
TEE	O
.	O
No	O
ventricular	O
electrode	O
.	O
Drains	O
anterior	O
mediastinum	O
and	O
pericardial	O
sac	O
pericardium	O
is	O
not	O
closed	O
.	O
Incidents	O
right	O
lung	O
was	O
damaged	O
during	O
dissection	O
,	O
the	O
leak	O
was	O
repaired	O
with	O
tachosil	B-FARMACO
,	O
with	O
good	O
results	O
.	O
Anaesthetic	O
part	O
induction	O
with	O
etomidate	B-FARMACO
,	O
rocuronium	B-FARMACO
,	O
fentanyl	B-FARMACO
and	O
maintenance	O
with	O
sevoflurane	B-FARMACO
,	I-FARMACO
propofol	I-FARMACO
and	O
rocuronium	B-FARMACO
.	O
Cormack	O
Lehane	O
I	O
IV	O
with	O
Burp	O
manoeuvre	O
.	O
Antibiotic	O
prophylaxis	O
with	O
levofloxacin	B-FARMACO
.	O
Need	O
of	O
vasoactive	O
support	O
with	O
noradrenaline	B-FARMACO
and	O
dobutamine	B-FARMACO
at	O
low	O
doses	O
.	O
CPB	O
time	O
70	O
min	O
and	O
ischaemia	O
time	O
52	O
min	O
.	O
Furosemide	B-FARMACO
80	O
mg	O
and	O
continuous	O
insulin	B-FARMACO
perfusion	O
.	O
Tranexamic	B-FARMACO
acid	I-FARMACO
in	O
total	O
1	O
,	O
360	O
mg	O
,	O
coagulation	O
monitoring	O
by	O
thromboelastogram	O
and	O
total	O
transfusion	O
of	O
4	O
red	O
blood	O
cell	O
concentrates	O
,	O
1	O
pool	O
of	O
platelets	O
,	O
1	O
,	O
500	O
IU	O
octaplex	O
,	O
and	O
2	O
g	O
of	O
fibrinogen	B-FARMACO
total	O
of	O
around	O
1	O
,	O
750	O
cc	O
of	O
inflow	O
.	O
Returned	O
from	O
the	O
operating	O
theatre	O
extubated	O
,	O
with	O
clevidipine	B-FARMACO
perfusion	O
and	O
stable	O
from	O
the	O
respiratory	O
and	O
haemodynamic	O
point	O
of	O
view	O
.	O
Prosthesis	O
microbiology	O
no	O
pathogen	O
growth	O
.	O
TTE	O
post	O
surgery	O
09	O
02	O
left	O
ventricle	O
of	O
normal	O
characteristics	O
and	O
function	O
LVEF	O
60	O
.	O
Biological	O
prosthesis	O
in	O
normofunctioning	O
mitral	O
position	O
.	O
Mild	O
tricuspid	O
insufficiency	O
.	O
Estimated	O
PSAP	O
around	O
41	O
mmHg	O
.	O
Mild	O
pericardial	O
effusion	O
without	O
repercussions	O
.	O
CLINICAL	O
EVOLUTION	O
During	O
his	O
admission	O
to	O
the	O
ward	O
he	O
did	O
not	O
present	O
fever	O
and	O
no	O
stigmata	O
of	O
endocarditis	O
were	O
observed	O
.	O
There	O
were	O
no	O
signs	O
of	O
heart	O
failure	O
.	O
In	O
the	O
first	O
days	O
of	O
admission	O
,	O
still	O
in	O
neurology	O
,	O
she	O
presented	O
self	O
limited	O
episodes	O
of	O
focal	O
seizures	O
,	O
which	O
did	O
not	O
generalise	O
,	O
and	O
which	O
were	O
treated	O
with	O
lamotrigine	B-FARMACO
.	O
Subsequently	O
asymptomatic	O
.	O
A	O
brain	O
MRI	O
was	O
performed	O
which	O
confirmed	O
multiple	O
supra	O
and	O
infratentorial	O
ischaemic	O
lesions	O
with	O
no	O
signs	O
of	O
bleeding	O
.	O
Although	O
there	O
was	O
no	O
initial	O
evidence	O
of	O
endocarditis	O
,	O
after	O
extraction	O
of	O
x3	O
blood	O
cultures	O
,	O
empirical	O
antibiotic	O
treatment	O
with	O
vancomycin	B-FARMACO
was	O
started	O
,	O
in	O
addition	O
to	O
anticoagulation	O
with	O
sodium	B-FARMACO
heparin	I-FARMACO
.	O
In	O
the	O
echocardiographic	O
control	O
a	O
week	O
after	O
treatment	O
,	O
one	O
of	O
the	O
possible	O
thrombotic	O
images	O
was	O
significantly	O
reduced	O
in	O
size	O
and	O
the	O
other	O
had	O
practically	O
disappeared	O
.	O
However	O
,	O
a	O
moderate	O
perivalvular	O
leak	O
appeared	O
in	O
the	O
area	O
occupied	O
by	O
the	O
latter	O
.	O
Therefore	O
,	O
despite	O
the	O
absence	O
of	O
inflammation	O
no	O
leukocytosis	O
,	O
normal	O
procalcitonin	O
,	O
etc	O
.	O
or	O
clear	O
infection	O
only	O
growth	O
in	O
one	O
of	O
the	O
blood	O
cultures	O
of	O
a	O
coagulase	O
negative	O
Staphylococcus	O
,	O
which	O
was	O
assumed	O
to	O
be	O
possible	O
contamination	O
,	O
the	O
current	O
clinical	O
suspicion	O
is	O
of	O
probable	O
endocarditis	O
added	O
to	O
the	O
valve	O
thrombosis	O
,	O
and	O
cardiac	O
reintervention	O
is	O
decided	O
.	O
Mitral	O
valve	O
replacement	O
with	O
a	O
25	O
mm	O
Epic	O
bioprosthesis	O
was	O
performed	O
,	O
with	O
no	O
incidents	O
during	O
the	O
procedure	O
,	O
and	O
the	O
patient	O
was	O
extubated	O
before	O
leaving	O
the	O
operating	O
theatre	O
.	O
Postoperatively	O
,	O
she	O
had	O
spells	O
of	O
AF	O
with	O
RVR	O
with	O
haemodynamic	O
repercussions	O
which	O
were	O
controlled	O
with	O
occasional	O
doses	O
of	O
amiodarone	B-FARMACO
.	O
Subsequently	O
,	O
sintrom	B-FARMACO
was	O
replaced	O
by	O
apixaban	B-FARMACO
.	O
Even	O
with	O
the	O
absence	O
of	O
biological	O
growth	O
in	O
prosthetic	O
material	O
,	O
it	O
was	O
decided	O
to	O
complete	O
treatment	O
with	O
vancomycin	B-FARMACO
for	O
4	O
weeks	O
.	O
DIAGNOSIS	O
Cardioembolic	O
stroke	O
with	O
multiple	O
supra	O
and	O
infratentorial	O
ischaemic	O
lesions	O
.	O
Focal	O
motor	O
crises	O
without	O
alteration	O
of	O
the	O
level	O
of	O
consciousness	O
secondary	O
to	O
the	O
above	O
.	O
Prosthetic	O
valve	O
thrombosis	O
.	O
Periprosthetic	O
leak	O
with	O
moderate	O
new	O
onset	O
insufficiency	O
.	O
Replacement	O
of	O
the	O
prosthetic	O
valve	O
with	O
a	O
25	O
mm	O
Epic	O
biological	O
prosthesis	O
.	O
Preserved	O
biventricular	O
function	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
We	O
present	O
the	O
case	O
of	O
a	O
35	O
year	O
old	O
woman	O
with	O
the	O
following	O
personal	O
history	O
Family	O
history	O
grandmother	O
died	O
at	O
the	O
age	O
of	O
86	O
years	O
due	O
to	O
acute	O
myocardial	O
infarction	O
.	O
Two	O
paternal	O
uncles	O
with	O
chronic	O
ischaemic	O
heart	O
disease	O
at	O
62	O
and	O
73	O
years	O
of	O
age	O
respectively	O
.	O
Paternal	O
aunt	O
underwent	O
aortic	O
valve	O
replacement	O
at	O
the	O
age	O
of	O
75	O
.	O
Cousin	O
with	O
congenital	O
heart	O
disease	O
that	O
he	O
cannot	O
specify	O
.	O
Father	O
under	O
follow	O
up	O
for	O
chest	O
pain	O
,	O
with	O
coronary	O
angiography	O
without	O
lesions	O
at	O
64	O
years	O
of	O
age	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
Cardiovascular	O
risk	O
factors	O
smoker	O
of	O
5	O
cigarettes	O
per	O
day	O
3	O
.	O
8	O
packs	O
per	O
year	O
.	O
No	O
hypertension	O
,	O
diabetes	O
or	O
dyslipidaemia	O
.	O
No	O
previous	O
cardiological	O
history	O
.	O
No	O
other	O
medical	O
or	O
surgical	O
illnesses	O
.	O
Baseline	O
sedentary	O
lifestyle	O
,	O
but	O
no	O
symptoms	O
related	O
to	O
physical	O
activity	O
.	O
No	O
chronic	O
home	O
treatment	O
.	O
She	O
consulted	O
the	O
emergency	O
department	O
for	O
having	O
presented	O
that	O
same	O
afternoon	O
,	O
while	O
seated	O
,	O
with	O
syncope	O
lasting	O
about	O
20	O
seconds	O
,	O
with	O
a	O
sensation	O
of	O
palpitations	O
and	O
previous	O
chest	O
discomfort	O
.	O
After	O
regaining	O
consciousness	O
,	O
she	O
reported	O
chest	O
discomfort	O
,	O
nausea	O
,	O
headache	O
and	O
general	O
weakness	O
.	O
No	O
sphincter	O
release	O
and	O
complete	O
spontaneous	O
recovery	O
.	O
In	O
the	O
anamnesis	O
,	O
she	O
reported	O
a	O
very	O
similar	O
episode	O
two	O
or	O
three	O
weeks	O
earlier	O
,	O
with	O
the	O
same	O
characteristics	O
,	O
also	O
at	O
rest	O
,	O
while	O
lying	O
in	O
bed	O
,	O
preceded	O
by	O
a	O
vegetative	O
cortex	O
.	O
Since	O
then	O
,	O
she	O
reports	O
having	O
noticed	O
isolated	O
,	O
self	O
limited	O
episodes	O
of	O
palpitations	O
with	O
sudden	O
onset	O
and	O
end	O
.	O
She	O
denies	O
any	O
other	O
clinical	O
manifestations	O
in	O
recent	O
weeks	O
,	O
or	O
the	O
use	O
of	O
drugs	O
or	O
other	O
substances	O
.	O
On	O
arrival	O
at	O
the	O
hospital	O
,	O
the	O
patient	O
was	O
asymptomatic	O
and	O
without	O
neurological	O
focality	O
.	O
Haemodynamically	O
stable	O
blood	O
pressure	O
120	O
75	O
mmHg	O
,	O
heart	O
rate	O
70	O
bpm	O
,	O
baseline	O
oxygen	O
saturation	O
100	O
.	O
Oriented	O
and	O
cooperative	O
.	O
No	O
jugular	O
ingurgitation	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
without	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
.	O
Abdomen	O
soft	O
,	O
non	O
painful	O
,	O
no	O
masses	O
or	O
megaliths	O
.	O
Lower	O
limbs	O
no	O
oedema	O
,	O
no	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
COMPLEMENTARY	O
TESTS	O
CBC	O
creatinine	O
0	O
.	O
6	O
mg	O
dl	O
,	O
potassium	O
3	O
.	O
7	O
mEq	O
l	O
,	O
sodium	O
136	O
mEq	O
l	O
,	O
haemoglobin	O
11	O
.	O
8	O
g	O
dl	O
,	O
haematocrit	O
36	O
,	O
leucocytes	O
9000	O
ml	O
,	O
platelets	O
159000	O
mm3	O
.	O
Electrocardiogram	O
ECG	O
sinus	O
rhythm	O
at	O
65	O
bpm	O
,	O
normal	O
axis	O
,	O
normal	O
PR	O
,	O
narrow	O
QRS	O
,	O
no	O
repolarisation	O
abnormalities	O
.	O
No	O
serial	O
ECG	O
changes	O
.	O
Chest	O
X	O
ray	O
normal	O
cardiothoracic	O
index	O
.	O
Free	O
costophrenic	O
sinuses	O
.	O
No	O
infiltrates	O
were	O
observed	O
.	O
Normal	O
mediastinum	O
.	O
Transthoracic	O
echocardiography	O
left	O
ventricle	O
LV	O
of	O
normal	O
size	O
,	O
thickness	O
and	O
systolic	O
and	O
diastolic	O
function	O
.	O
Right	O
ventricle	O
RV	O
of	O
normal	O
size	O
and	O
function	O
.	O
Left	O
atrium	O
LA	O
and	O
right	O
atrium	O
RA	O
of	O
normal	O
size	O
.	O
No	O
valvular	O
heart	O
disease	O
.	O
No	O
indirect	O
signs	O
of	O
PAH	O
.	O
Aortic	O
root	O
of	O
normal	O
size	O
.	O
No	O
pericardial	O
effusion	O
.	O
Cardiac	O
MRI	O
ventricles	O
with	O
preserved	O
morphology	O
and	O
systolic	O
function	O
.	O
No	O
oedema	O
or	O
myocardial	O
fibrosis	O
necrosis	O
.	O
Telemetry	O
24	O
h	O
sinus	O
rhythm	O
.	O
Ventricular	O
extrasystoles	O
VE	O
of	O
moderate	O
monotopic	O
density	O
with	O
very	O
short	O
coupling	O
in	O
the	O
ascending	O
branch	O
of	O
the	O
T	O
with	O
episodes	O
of	O
doublets	O
and	O
4	O
episodes	O
of	O
symptomatic	O
polymorphic	O
non	O
sustained	O
ventricular	O
tachycardia	O
PSVT	O
palpitations	O
and	O
new	O
syncopal	O
symptoms	O
.	O
Electrophysiological	O
study	O
EPS	O
and	O
ablation	O
with	O
navigation	O
system	O
baseline	O
with	O
moderate	O
density	O
VS	O
with	O
LBBB	O
morphology	O
and	O
transition	O
in	O
V5	O
,	O
with	O
short	O
coupling	O
period	O
.	O
Three	O
dimensional	O
reconstruction	O
of	O
the	O
RV	O
is	O
performed	O
with	O
echo	O
intracardiac	O
.	O
The	O
presence	O
of	O
a	O
prominent	O
moderator	O
band	O
is	O
noteworthy	O
.	O
Activation	O
mapping	O
was	O
performed	O
with	O
greater	O
precocity	O
at	O
the	O
level	O
of	O
the	O
middle	O
portion	O
of	O
the	O
RV	O
free	O
wall	O
,	O
the	O
anatomical	O
point	O
being	O
located	O
inside	O
the	O
cavity	O
.	O
Correlation	O
mapping	O
is	O
also	O
performed	O
by	O
topo	O
stimulation	O
,	O
with	O
95	O
of	O
the	O
morphology	O
reproduced	O
in	O
the	O
moderator	O
band	O
.	O
Radiofrequency	O
applications	O
are	O
performed	O
at	O
this	O
point	O
40	O
45	O
W	O
,	O
30	O
ml	O
min	O
with	O
an	O
irrigated	O
catheter	O
with	O
a	O
contact	O
sensor	O
,	O
repeatedly	O
inducing	O
intense	O
automatic	O
activity	O
.	O
Subsequently	O
,	O
isoproterenol	B-FARMACO
is	O
administered	O
without	O
the	O
appearance	O
of	O
extrasystoles	O
after	O
30	O
minutes	O
of	O
waiting	O
.	O
Ventricular	O
arrhythmia	O
induction	O
test	O
was	O
performed	O
and	O
was	O
negative	O
.	O
Flecainide	O
test	O
negative	O
.	O
CLINICAL	O
EVOLUTION	O
After	O
evaluation	O
of	O
the	O
patient	O
by	O
cardiology	O
in	O
the	O
emergency	O
department	O
,	O
despite	O
the	O
normality	O
of	O
the	O
complementary	O
tests	O
ECG	O
,	O
chest	O
X	O
ray	O
and	O
laboratory	O
tests	O
,	O
given	O
the	O
characteristics	O
of	O
the	O
syncope	O
that	O
suggest	O
a	O
cardiogenic	O
profile	O
,	O
it	O
was	O
decided	O
to	O
admit	O
the	O
patient	O
for	O
electrocardiographic	O
monitoring	O
and	O
to	O
complete	O
the	O
studies	O
.	O
On	O
admission	O
to	O
the	O
ward	O
,	O
the	O
patient	O
remained	O
stable	O
and	O
with	O
no	O
new	O
syncope	O
.	O
Echocardiography	O
ruled	O
out	O
structural	O
heart	O
disease	O
.	O
During	O
the	O
first	O
hours	O
of	O
monitoring	O
,	O
she	O
had	O
self	O
limited	O
episodes	O
of	O
palpitations	O
and	O
a	O
new	O
syncopal	O
episode	O
,	O
identical	O
to	O
the	O
previous	O
ones	O
that	O
led	O
to	O
her	O
admission	O
.	O
Telemetry	O
showed	O
isolated	O
low	O
density	O
VE	O
and	O
episodes	O
of	O
very	O
rapid	O
NSTEVT	O
symptomatic	O
due	O
to	O
the	O
R	O
over	O
T	O
phenomenon	O
due	O
to	O
a	O
very	O
short	O
coupling	O
period	O
240	O
ms	O
.	O
He	O
was	O
admitted	O
to	O
the	O
intensive	O
care	O
unit	O
ICU	O
and	O
an	O
EPS	O
was	O
programmed	O
with	O
a	O
view	O
to	O
navigation	O
guided	O
ablation	O
of	O
the	O
focus	O
of	O
the	O
VS	O
with	O
possible	O
origin	O
in	O
the	O
RV	O
moderator	O
band	O
LBBB	O
morphology	O
,	O
transition	O
in	O
V5	O
,	O
left	O
superior	O
axis	O
and	O
QRS	O
150	O
ms	O
.	O
Radiofrequency	O
ablation	O
was	O
performed	O
in	O
the	O
moderator	O
band	O
BM	O
guided	O
by	O
the	O
CARTO	O
navigation	O
system	O
,	O
in	O
addition	O
to	O
a	O
flecainide	O
test	O
,	O
which	O
was	O
negative	O
.	O
The	O
morphological	O
study	O
was	O
completed	O
with	O
cardiac	O
magnetic	O
resonance	O
imaging	O
MRI	O
without	O
alterations	O
.	O
Subsequently	O
,	O
he	O
remained	O
on	O
the	O
cardiology	O
ward	O
for	O
telemetric	O
monitoring	O
without	O
any	O
sustained	O
arrhythmias	O
or	O
clinical	O
incidents	O
.	O
A	O
24	O
hour	O
Holter	O
recording	O
5	O
days	O
after	O
ablation	O
showed	O
a	O
single	O
isolated	O
PVC	O
in	O
24	O
hours	O
.	O
Given	O
the	O
success	O
of	O
the	O
procedure	O
and	O
the	O
absence	O
of	O
induction	O
of	O
ventricular	O
arrhythmias	O
,	O
it	O
was	O
decided	O
to	O
implant	O
a	O
subcutaneous	O
Holter	O
prior	O
to	O
discharge	O
.	O
On	O
review	O
8	O
months	O
after	O
ablation	O
,	O
an	O
NSTEVT	O
of	O
14	O
beats	O
associated	O
with	O
palpitations	O
was	O
recorded	O
,	O
and	O
implantation	O
of	O
an	O
implantable	O
cardioverter	O
defibrillator	O
ICD	O
was	O
proposed	O
,	O
which	O
was	O
carried	O
out	O
without	O
complications	O
.	O
In	O
addition	O
,	O
a	O
genetic	O
study	O
was	O
completed	O
which	O
showed	O
no	O
mutations	O
associated	O
with	O
channelopathies	O
or	O
sudden	O
death	O
.	O
The	O
patient	O
was	O
asymptomatic	O
at	O
subsequent	O
check	O
ups	O
and	O
had	O
no	O
new	O
events	O
.	O
DIAGNOSIS	O
Repeated	O
syncope	O
in	O
the	O
context	O
of	O
polymorphic	O
ventricular	O
tachycardia	O
induced	O
by	O
short	O
coupled	O
ventricular	O
extrasystoles	O
originating	O
in	O
the	O
right	O
ventricular	O
moderator	O
band	O
.	O
Ablation	O
of	O
right	O
ventricular	O
moderator	O
band	O
extrasystoles	O
.	O
ICD	O
implantation	O
for	O
secondary	O
prevention	O
.	O
No	O
structural	O
heart	O
disease	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
49	O
year	O
old	O
male	O
.	O
Cardiovascular	O
risk	O
factors	O
hypertension	O
,	O
very	O
difficult	O
to	O
control	O
,	O
treated	O
with	O
4	O
drugs	O
,	O
under	O
follow	O
up	O
by	O
nephrology	O
.	O
No	O
diabetes	O
mellitus	O
or	O
dyslipidaemia	O
.	O
No	O
toxic	O
habits	O
.	O
Chronic	O
kidney	O
disease	O
secondary	O
to	O
interstitial	O
nephropathy	O
due	O
to	O
vesicoureteral	O
reflux	O
with	O
the	O
start	O
of	O
haemodialysis	O
at	O
the	O
age	O
of	O
31	O
in	O
1989	O
,	O
double	O
kidney	O
transplant	O
in	O
1992	O
and	O
2015	O
,	O
both	O
dysfunctional	O
and	O
embolised	O
,	O
currently	O
under	O
study	O
for	O
a	O
new	O
transplant	O
and	O
on	O
haemodialysis	O
.	O
Multiple	O
complications	O
at	O
the	O
level	O
of	O
arteriovenous	O
fistulas	O
AVF	O
stenosis	O
,	O
obstruction	O
,	O
currently	O
presents	O
AVF	O
in	O
right	O
upper	O
limb	O
.	O
Multifactorial	O
anaemia	O
being	O
treated	O
with	O
erythropoietin	B-FARMACO
and	O
transfusions	O
.	O
Resistant	O
secondary	O
hyperparathyroidism	O
with	O
renal	O
osteodystrophy	O
and	O
parathyroid	O
adenoma	O
in	O
the	O
right	O
lower	O
lobe	O
.	O
No	O
significant	O
structural	O
heart	O
disease	O
except	O
moderate	O
ventricular	O
hypertrophy	O
with	O
normal	O
LVEF	O
.	O
Chronic	O
treatment	O
pantoprazole	B-FARMACO
20	O
mg	O
12	O
h	O
,	O
acfol	B-FARMACO
1	O
tablet	O
24	O
h	O
,	O
losartan	B-FARMACO
100	O
mg	O
24	O
h	O
,	O
manidipine	B-FARMACO
10	O
mg	O
24	O
h	O
,	O
metoprolol	B-FARMACO
100	O
mg	O
12	O
h	O
,	O
prednisone	B-FARMACO
2	O
.	O
5	O
24	O
h	O
,	O
carduran	B-FARMACO
4	O
mg	O
12	O
h	O
,	O
resincalcio	B-FARMACO
1	O
sachet	O
24	O
h	O
,	O
septrim	B-FARMACO
1	O
tablet	O
48	O
h	O
.	O
Present	O
illness	O
After	O
a	O
haemodialysis	O
session	O
,	O
the	O
patient	O
presented	O
with	O
general	O
malaise	O
and	O
palpitations	O
,	O
with	O
haemodynamic	O
stability	O
.	O
The	O
monitor	O
showed	O
wide	O
QRS	O
tachycardia	O
at	O
150	O
beats	O
per	O
minute	O
bpm	O
.	O
A	O
12	O
lead	O
electrocardiogram	O
ECG	O
was	O
performed	O
,	O
which	O
was	O
interpreted	O
as	O
sustained	O
monomorphic	O
ventricular	O
tachycardia	O
SMVT	O
,	O
so	O
4	O
boluses	O
of	O
100	O
mg	O
of	O
procainamide	B-FARMACO
were	O
administered	O
,	O
and	O
the	O
patient	O
progressed	O
to	O
an	O
arrhythmic	O
narrow	O
QRS	O
tachycardia	O
that	O
appeared	O
to	O
be	O
atrial	O
tachycardia	O
and	O
then	O
went	O
into	O
sinus	O
rhythm	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
190	O
100	O
,	O
70	O
bpm	O
,	O
saturation	O
98	O
baseline	O
.	O
No	O
jugular	O
ingurgitation	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
without	O
over	O
additions	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
,	O
systolic	O
murmur	O
II	O
VI	O
in	O
the	O
apex	O
.	O
Abdomen	O
soft	O
,	O
non	O
painful	O
,	O
with	O
renal	O
graft	O
in	O
FID	O
.	O
Lower	O
extremities	O
without	O
oedema	O
.	O
Palpable	O
and	O
symmetrical	O
paedial	O
pulses	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
tests	O
on	O
admission	O
Biochemistry	O
creatinine	O
4	O
.	O
74	O
mg	O
dl	O
,	O
estimated	O
glomerular	O
filtration	O
rate	O
13	O
ml	O
min	O
1	O
.	O
73	O
,	O
uric	O
acid	O
5	O
.	O
04	O
mg	O
dl	O
,	O
triglycerides	O
109	O
mg	O
dl	O
,	O
total	O
cholesterol	O
112	O
mg	O
dl	O
,	O
HDL	O
30	O
mg	O
dl	O
,	O
LDL	O
60	O
mg	O
dl	O
,	O
total	O
BR	O
1	O
.	O
20	O
mg	O
dl	O
,	O
AST	O
15	O
U	O
l	O
,	O
ALT	O
13	O
U	O
l	O
,	O
GGT	O
22	O
U	O
l	O
,	O
sodium	O
141	O
mmol	O
l	O
,	O
potassium	O
5	O
.	O
39	O
mmol	O
l	O
,	O
magnesium	O
1	O
.	O
85	O
mg	O
dl	O
,	O
inorganic	O
phosphate	O
6	O
.	O
3	O
mg	O
dl	O
,	O
Hb	O
A1c	O
3	O
,	O
90	O
.	O
Albumin	O
3080	O
mg	O
dl	O
.	O
TSH	O
1	O
.	O
98	O
peak	O
IU	O
ml	O
,	O
free	O
T4	O
1	O
.	O
26	O
ng	O
dl	O
.	O
Haemoglobin	O
9	O
.	O
5	O
g	O
dl	O
,	O
MCV	O
94	O
fl	O
,	O
MCHC	O
30	O
.	O
5	O
g	O
dl	O
,	O
platelets	O
204000	O
,	O
leukocytes	O
5990	O
,	O
neutrophils	O
3960	O
66	O
.	O
2	O
,	O
lymphocytes	O
570	O
21	O
.	O
2	O
.	O
Coagulation	O
PT	O
12s	O
,	O
ATP	O
79	O
,	O
INR	O
1	O
.	O
17	O
,	O
aPTT	O
35	O
.	O
9s	O
.	O
Urgent	O
blood	O
gases	O
after	O
tachycardia	O
pH	O
7	O
.	O
480	O
,	O
pCO2	O
41	O
mmHg	O
,	O
pO2	O
93	O
mmHg	O
,	O
sodium	O
131	O
mmol	O
l	O
,	O
potassium	O
4	O
.	O
7	O
mmol	O
l	O
,	O
bicarbonate	O
40	O
.	O
5	O
mmol	O
l	O
,	O
oxygen	O
saturation	O
97	O
.	O
8	O
.	O
Chest	O
X	O
ray	O
on	O
admission	O
normal	O
cardiothoracic	O
index	O
with	O
no	O
signs	O
of	O
congestion	O
or	O
costophrenic	O
sinus	O
impingement	O
.	O
Calcified	O
aorta	O
with	O
no	O
other	O
findings	O
.	O
Electrocardiogram	O
ECG	O
on	O
admission	O
regular	O
wide	O
QRS	O
tachycardia	O
at	O
153	O
bpm	O
with	O
morphology	O
of	O
right	O
bundle	O
branch	O
block	O
RBBB	O
,	O
superior	O
axis	O
;	O
no	O
fusion	O
beats	O
,	O
AV	O
dissociation	O
or	O
concordance	O
in	O
precordials	O
.	O
Transthoracic	O
echocardiogram	O
on	O
admission	O
non	O
dilated	O
left	O
ventricle	O
with	O
moderate	O
concentric	O
hypertrophy	O
and	O
preserved	O
global	O
systolic	O
function	O
without	O
segmental	O
disorders	O
.	O
Moderately	O
dilated	O
left	O
atrium	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
and	O
preserved	O
contractility	O
.	O
Mitroaortic	O
sclerosis	O
without	O
repercussion	O
mild	O
mitral	O
insufficiency	O
.	O
Filling	O
pattern	O
impaired	O
relaxation	O
.	O
Minimal	O
posterior	O
pericardial	O
effusion	O
without	O
repercussion	O
.	O
Normal	O
aorta	O
.	O
Electrophysiological	O
study	O
EPS	O
poor	O
and	O
decremental	O
ventriculoatrial	O
conduction	O
.	O
Anterograde	O
Wenkebach	O
point	O
360	O
ms	O
,	O
no	O
overt	O
pre	O
excitation	O
with	O
atrial	O
stimulation	O
;	O
with	O
adenosine	O
administration	O
there	O
is	O
evidence	O
of	O
pre	O
excitation	O
at	O
low	O
frequencies	O
but	O
also	O
simultaneous	O
block	O
of	O
the	O
pathway	O
and	O
atrioventricular	O
node	O
AVN	O
blocked	O
P	O
waves	O
.	O
Induction	O
of	O
atrial	O
tachycardia	O
is	O
not	O
achieved	O
even	O
after	O
isoprenaline	B-FARMACO
infusion	O
.	O
Coronary	O
sinus	O
mapping	O
was	O
performed	O
and	O
during	O
bouts	O
of	O
pre	O
excitation	O
an	O
area	O
of	O
greater	O
ventricular	O
precocity	O
was	O
observed	O
at	O
the	O
posterior	O
postero	O
lateral	O
level	O
and	O
a	O
pre	O
excitation	O
pattern	O
consistent	O
12	O
12	O
with	O
clinical	O
tachycardia	O
.	O
Transseptal	O
puncture	O
was	O
performed	O
and	O
the	O
mitral	O
annulus	O
was	O
mapped	O
to	O
identify	O
the	O
area	O
of	O
maximum	O
ventricular	O
pre	O
excitation	O
in	O
the	O
posterior	O
area	O
,	O
requiring	O
several	O
applications	O
to	O
achieve	O
ablation	O
of	O
the	O
pathway	O
,	O
which	O
was	O
finally	O
checked	O
with	O
adenosine	B-FARMACO
.	O
After	O
adenosine	B-FARMACO
,	O
the	O
patient	O
presented	O
atrial	O
fibrillation	O
,	O
and	O
electrical	O
cardioversion	O
was	O
successfully	O
performed	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
cardiac	O
intermediate	O
care	O
unit	O
for	O
monitoring	O
.	O
On	O
arrival	O
,	O
a	O
transthoracic	O
echocardiogram	O
showed	O
concentric	O
hypertrophy	O
with	O
normal	O
global	O
systolic	O
function	O
without	O
segmental	O
disorders	O
.	O
The	O
wide	O
QRS	O
tachycardia	O
tracings	O
were	O
initially	O
interpreted	O
as	O
ventricular	O
tachycardia	O
originating	O
in	O
the	O
posterior	O
papillary	O
muscle	O
QRS	O
with	O
BCRDHH	O
morphology	O
and	O
superior	O
axis	O
,	O
so	O
we	O
started	O
treatment	O
with	O
oral	O
verapamil	B-FARMACO
120	O
mg	O
every	O
12	O
hours	O
,	O
despite	O
which	O
he	O
continued	O
to	O
present	O
episodes	O
of	O
tachycardia	O
with	O
wide	O
QRS	O
on	O
the	O
monitor	O
,	O
self	O
limited	O
.	O
Daily	O
12	O
lead	O
ECG	O
showed	O
sinus	O
rhythm	O
at	O
75	O
bpm	O
,	O
with	O
evidence	O
of	O
ventricular	O
enlargement	O
,	O
early	O
transition	O
and	O
left	O
anterior	O
hemiblock	O
HBAIHH	O
,	O
with	O
a	O
pseudo	O
delta	O
wave	O
in	O
inferior	O
leads	O
and	O
V3	O
V5	O
,	O
which	O
was	O
interpreted	O
as	O
alterations	O
typical	O
of	O
ventricular	O
hypertrophy	O
.	O
Two	O
days	O
later	O
,	O
an	O
ECG	O
was	O
performed	O
in	O
sinus	O
rhythm	O
at	O
82	O
bpm	O
where	O
a	O
clear	O
delta	O
wave	O
was	O
observed	O
;	O
in	O
addition	O
,	O
telemetry	O
showed	O
more	O
obvious	O
pre	O
excitation	O
in	O
supraventricular	O
extrasystoles	O
.	O
Although	O
the	O
wide	O
QRS	O
tachycardia	O
was	O
initially	O
interpreted	O
as	O
SMVT	O
,	O
and	O
the	O
delta	O
wave	O
as	O
a	O
pseudo	O
delta	O
wave	O
in	O
the	O
context	O
of	O
ventricular	O
hypertrophy	O
,	O
what	O
led	O
us	O
to	O
suspect	O
a	O
possible	O
pre	O
excitation	O
was	O
the	O
ECG	O
immediately	O
after	O
the	O
infusion	O
of	O
procainamide	O
,	O
in	O
which	O
a	O
narrow	O
basal	O
QRS	O
without	O
a	O
delta	O
wave	O
was	O
observed	O
,	O
and	O
how	O
in	O
the	O
following	O
days	O
,	O
without	O
the	O
effect	O
of	O
procainamide	O
,	O
an	O
inconspicuous	O
delta	O
wave	O
was	O
observed	O
in	O
the	O
ECGs	O
in	O
sinus	O
rhythm	O
,	O
which	O
became	O
more	O
pronounced	O
with	O
verapamil	B-FARMACO
treatment	O
.	O
Given	O
the	O
suspicion	O
of	O
a	O
left	O
lateral	O
accessory	O
pathway	O
,	O
we	O
performed	O
a	O
test	O
with	O
12	O
mg	O
of	O
i	O
.	O
v	O
.	O
adenosine	B-FARMACO
,	O
which	O
revealed	O
pre	O
excitation	O
.	O
The	O
case	O
was	O
discussed	O
with	O
arrhythmology	O
and	O
an	O
electrophysiological	O
study	O
was	O
performed	O
,	O
where	O
an	O
accessory	O
pathway	O
was	O
found	O
in	O
the	O
posterior	O
portion	O
of	O
the	O
mitral	O
annulus	O
,	O
which	O
was	O
successfully	O
ablated	O
,	O
and	O
the	O
pre	O
excitation	O
disappeared	O
in	O
the	O
control	O
ECGs	O
.	O
DIAGNOSIS	O
Pre	O
excited	O
atrial	O
tachycardia	O
due	O
to	O
an	O
accessory	O
pathway	O
located	O
in	O
the	O
posterior	O
portion	O
of	O
the	O
mitral	O
annulus	O
.	O
Successful	O
ablation	O
of	O
accessory	O
pathway	O
.	O
Hypertensive	O
heart	O
disease	O
with	O
diastolic	O
dysfunction	O
.	O
Stage	O
V	O
chronic	O
kidney	O
disease	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
Cardiovascular	O
risk	O
factors	O
no	O
arterial	O
hypertension	O
,	O
no	O
dyslipidaemia	O
,	O
no	O
diabetes	O
mellitus	O
.	O
Non	O
smoker	O
,	O
no	O
other	O
toxic	O
habits	O
.	O
No	O
known	O
cardiological	O
history	O
.	O
Other	O
history	O
haemorrhoids	O
,	O
anal	O
fissure	O
,	O
tension	O
headache	O
.	O
Usual	O
treatment	O
none	O
.	O
Present	O
illness	O
A	O
55	O
year	O
old	O
woman	O
attended	O
the	O
emergency	O
department	O
for	O
two	O
episodes	O
of	O
central	O
thoracic	O
pain	O
triggered	O
by	O
moderate	O
exertion	O
.	O
She	O
described	O
oppressive	O
,	O
non	O
radiating	O
pain	O
with	O
associated	O
vegetative	O
cramping	O
that	O
persisted	O
at	O
the	O
time	O
of	O
consultation	O
.	O
The	O
patient	O
had	O
no	O
previous	O
angina	O
or	O
infectious	O
symptoms	O
.	O
Physical	O
examination	O
Weight	O
64	O
kg	O
,	O
height	O
1	O
.	O
70	O
m	O
.	O
Body	O
mass	O
index	O
BMI	O
22	O
.	O
14	O
kg	O
m2	O
.	O
Blood	O
pressure	O
BP	O
138	O
82	O
mmHg	O
.	O
Heart	O
rate	O
HR	O
86	O
bpm	O
.	O
Oxygen	O
saturation	O
SatO2	O
95	O
on	O
room	O
air	O
.	O
Eupneic	O
at	O
rest	O
,	O
without	O
orthopnoea	O
or	O
platypnoea	O
.	O
Jugular	O
venous	O
pressure	O
normal	O
.	O
Negative	O
hepatojugular	O
reflex	O
.	O
Cardiac	O
auscultation	O
regular	O
rhythm	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
,	O
without	O
aggregates	O
.	O
Extremities	O
no	O
oedema	O
.	O
Peripheral	O
pulses	O
preserved	O
and	O
symmetrical	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiograms	O
ECG	O
ECG	O
on	O
arrival	O
at	O
the	O
emergency	O
department	O
sinus	O
bradycardia	O
at	O
54	O
bpm	O
.	O
PR	O
140	O
ms	O
.	O
QRS	O
80	O
ms	O
,	O
axis	O
at	O
30o	O
.	O
ST	O
segment	O
elevation	O
in	O
V3	O
V5	O
.	O
Q	O
waves	O
in	O
DIII	O
and	O
aVF	O
.	O
Control	O
ECG	O
24	O
hours	O
after	O
admission	O
negative	O
T	O
waves	O
,	O
deep	O
and	O
symmetrical	O
in	O
V3	O
V6	O
,	O
DII	O
,	O
DIII	O
and	O
aVF	O
.	O
In	O
recurrence	O
of	O
angina	O
during	O
admission	O
loss	O
of	O
R	O
wave	O
in	O
V3	O
V4	O
.	O
ST	O
segment	O
elevation	O
in	O
V3	O
V5	O
with	O
biphasic	O
T	O
wave	O
.	O
Blood	O
tests	O
haemoglobin	O
12	O
.	O
4	O
g	O
dl	O
,	O
haematocrit	O
41	O
,	O
platelets	O
164	O
,	O
000	O
l	O
,	O
leukocytes	O
7	O
,	O
400	O
l	O
.	O
International	O
normalised	O
ratio	O
INR	O
1	O
.	O
05	O
.	O
Basal	O
glycaemia	O
82	O
mg	O
dl	O
.	O
Urea	O
36	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
81	O
mg	O
dl	O
,	O
sodium	O
137	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
1	O
mEq	O
l	O
.	O
Biomarkers	O
of	O
myocardial	O
damage	O
troponin	O
I	O
hsTnI	O
6	O
,	O
514	O
ng	O
l	O
3	O
,	O
343	O
ng	O
l	O
3	O
,	O
810	O
ng	O
l	O
3	O
,	O
046	O
2	O
,	O
343	O
ng	O
l	O
normal	O
range	O
0	O
.	O
0	O
11	O
.	O
6	O
ng	O
l	O
.	O
RT	O
PCR	O
for	O
SARS	O
CoV2	O
negative	O
.	O
Chest	O
X	O
ray	O
centred	O
cardiomediastinal	O
silhouette	O
.	O
Cardiothoracic	O
index	O
CTI	O
less	O
than	O
0	O
.	O
5	O
.	O
Lung	O
fields	O
translucent	O
,	O
without	O
pleural	O
effusion	O
or	O
condensation	O
.	O
Transthoracic	O
echocardiogram	O
Portable	O
echocardiogram	O
on	O
admission	O
to	O
the	O
coronary	O
unit	O
non	O
dilated	O
left	O
ventricle	O
,	O
with	O
extensive	O
septal	O
akinesia	O
,	O
without	O
other	O
alterations	O
of	O
segmental	O
contractility	O
,	O
with	O
preserved	O
global	O
systolic	O
function	O
.	O
Non	O
dilated	O
right	O
ventricle	O
with	O
preserved	O
systolic	O
function	O
.	O
Normal	O
filling	O
pressures	O
.	O
Absence	O
of	O
significant	O
valvular	O
heart	O
disease	O
.	O
Aortic	O
root	O
and	O
left	O
atrium	O
of	O
normal	O
diameters	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
.	O
Echocardiogram	O
prior	O
to	O
discharge	O
similar	O
to	O
previous	O
study	O
.	O
Global	O
systolic	O
function	O
preserved	O
.	O
Haemodynamics	O
Emergent	O
coronary	O
angiography	O
on	O
arrival	O
.	O
Trunk	O
normal	O
.	O
Anterior	O
descending	O
artery	O
image	O
compatible	O
with	O
spontaneous	O
coronary	O
dissection	O
at	O
mid	O
distal	O
level	O
.	O
Distal	O
flow	O
TIMI	O
3	O
.	O
Circumflex	O
artery	O
image	O
compatible	O
with	O
spontaneous	O
coronary	O
artery	O
dissection	O
at	O
first	O
obtuse	O
marginal	O
level	O
.	O
Distal	O
flow	O
TIMI	O
3	O
.	O
Right	O
coronary	O
artery	O
dominant	O
,	O
normal	O
.	O
Control	O
coronary	O
angiography	O
on	O
the	O
third	O
day	O
of	O
admission	O
.	O
Truncus	O
normal	O
.	O
Anterior	O
descending	O
artery	O
image	O
compatible	O
with	O
spontaneous	O
coronary	O
artery	O
dissection	O
at	O
mid	O
level	O
with	O
progression	O
to	O
more	O
distal	O
level	O
compared	O
to	O
previous	O
catheterisation	O
and	O
increased	O
haematoma	O
causing	O
distal	O
flow	O
TIMI	O
1	O
.	O
Circumflex	O
artery	O
image	O
compatible	O
with	O
spontaneous	O
coronary	O
artery	O
dissection	O
at	O
first	O
obtuse	O
marginal	O
level	O
.	O
Distal	O
flow	O
TIMI	O
3	O
.	O
Right	O
coronary	O
artery	O
dominant	O
,	O
normal	O
.	O
Angio	O
CT	O
cardiac	O
cavities	O
of	O
normal	O
size	O
.	O
Ascending	O
and	O
descending	O
thoracic	O
aorta	O
of	O
normal	O
calibre	O
,	O
slightly	O
elongated	O
.	O
Abdominal	O
aorta	O
of	O
high	O
normal	O
calibre	O
28	O
29	O
mm	O
without	O
arteriosclerosis	O
.	O
At	O
the	O
origin	O
of	O
the	O
celiac	O
trunk	O
there	O
is	O
an	O
image	O
compatible	O
with	O
a	O
haematoma	O
with	O
dense	O
contrast	O
in	O
its	O
interior	O
that	O
could	O
correspond	O
to	O
intramural	O
bleeding	O
causing	O
severe	O
stenosis	O
at	O
that	O
level	O
.	O
Hepatic	O
,	O
splenic	O
and	O
mesenteric	O
arteries	O
without	O
alterations	O
.	O
Normal	O
renal	O
arteries	O
.	O
Absence	O
of	O
coronary	O
calcium	O
.	O
Coronary	O
angiography	O
left	O
coronary	O
trunk	O
of	O
normal	O
calibre	O
and	O
origin	O
without	O
arteriosclerosis	O
.	O
Anterior	O
descending	O
artery	O
of	O
normal	O
calibre	O
and	O
origin	O
without	O
arteriosclerosis	O
.	O
Haematoma	O
is	O
visualised	O
in	O
the	O
distal	O
anterior	O
descending	O
AD	O
artery	O
causing	O
significant	O
stenosis	O
.	O
Circumflex	O
artery	O
of	O
normal	O
calibre	O
and	O
origin	O
without	O
arteriosclerosis	O
.	O
Marginal	O
obtuse	O
branch	O
of	O
good	O
calibre	O
,	O
without	O
arteriosclerosis	O
or	O
signs	O
of	O
vascular	O
involvement	O
.	O
Right	O
coronary	O
artery	O
of	O
normal	O
calibre	O
and	O
origin	O
,	O
without	O
arteriosclerosis	O
,	O
the	O
distal	O
segments	O
are	O
not	O
adequately	O
visualised	O
due	O
to	O
movement	O
artefacts	O
.	O
Absence	O
of	O
signs	O
of	O
vascular	O
involvement	O
.	O
In	O
summary	O
an	O
image	O
compatible	O
with	O
focal	O
haematoma	O
small	O
longitudinal	O
extension	O
with	O
signs	O
of	O
intramural	O
bleeding	O
contrast	O
density	O
in	O
the	O
central	O
area	O
located	O
at	O
the	O
origin	O
of	O
the	O
celiac	O
trunk	O
and	O
in	O
the	O
distal	O
portion	O
of	O
the	O
anterior	O
descending	O
artery	O
causing	O
a	O
significant	O
decrease	O
in	O
the	O
calibre	O
of	O
both	O
vessels	O
.	O
No	O
other	O
notable	O
vascular	O
alterations	O
were	O
observed	O
.	O
CLINICAL	O
EVOLUTION	O
On	O
arrival	O
at	O
the	O
emergency	O
department	O
,	O
an	O
electrocardiogram	O
was	O
performed	O
showing	O
ST	O
segment	O
elevation	O
in	O
anterior	O
leads	O
,	O
activating	O
the	O
haemodynamic	O
alert	O
.	O
Diagnostic	O
coronary	O
angiography	O
showed	O
spontaneous	O
coronary	O
dissection	O
in	O
the	O
middle	O
anterior	O
descending	O
artery	O
mAD	O
and	O
the	O
first	O
obtuse	O
marginal	O
branch	O
1st	O
OM	O
with	O
preserved	O
distal	O
flow	O
in	O
both	O
arteries	O
,	O
and	O
conservative	O
treatment	O
was	O
decided	O
with	O
double	O
antiplatelet	O
therapy	O
and	O
anticoagulation	O
and	O
admission	O
to	O
the	O
coronary	O
unit	O
for	O
follow	O
up	O
.	O
The	O
patient	O
remained	O
asymptomatic	O
for	O
the	O
first	O
2	O
days	O
with	O
a	O
progressive	O
decrease	O
in	O
biomarkers	O
of	O
myocardial	O
damage	O
and	O
electrocardiographic	O
evolution	O
characterised	O
by	O
the	O
appearance	O
of	O
deep	O
negative	O
T	O
waves	O
in	O
the	O
anterolateral	O
and	O
inferior	O
face	O
.	O
On	O
the	O
third	O
day	O
of	O
admission	O
to	O
the	O
coronary	O
unit	O
,	O
he	O
presented	O
several	O
episodes	O
of	O
angina	O
like	O
central	O
thoracic	O
pain	O
at	O
rest	O
with	O
ST	O
segment	O
elevation	O
in	O
anterior	O
leads	O
.	O
It	O
was	O
decided	O
to	O
repeat	O
the	O
coronary	O
angiography	O
showing	O
progression	O
of	O
the	O
LAD	O
dissection	O
at	O
distal	O
level	O
with	O
compromise	O
of	O
distal	O
flow	O
TIMI	O
1	O
.	O
In	O
view	O
of	O
the	O
findings	O
described	O
,	O
it	O
was	O
decided	O
to	O
maintain	O
conservative	O
and	O
symptomatic	O
management	O
.	O
Subsequent	O
good	O
evolution	O
without	O
new	O
episodes	O
of	O
chest	O
pain	O
,	O
with	O
progressive	O
decrease	O
in	O
biomarkers	O
of	O
myocardial	O
damage	O
and	O
electrocardiographic	O
evolution	O
of	O
acute	O
myocardial	O
infarction	O
,	O
so	O
it	O
was	O
decided	O
to	O
discharge	O
the	O
patient	O
with	O
double	O
antiplatelet	O
therapy	O
with	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
mg	O
and	O
clopidogrel	B-FARMACO
75	O
mg	O
,	O
atorvastatin	B-FARMACO
40	O
mg	O
,	O
ramipril	B-FARMACO
2	O
.	O
5	O
mg	O
,	O
pantoprazole	B-FARMACO
40	O
mg	O
and	O
nebivolol	B-FARMACO
2	O
.	O
5	O
mg	O
.	O
The	O
patient	O
attended	O
a	O
scheduled	O
outpatient	O
check	O
up	O
with	O
the	O
cardiologist	O
in	O
the	O
area	O
2	O
weeks	O
later	O
,	O
reporting	O
episodes	O
of	O
typical	O
angina	O
with	O
moderate	O
exertion	O
,	O
so	O
it	O
was	O
decided	O
to	O
request	O
an	O
angio	O
CT	O
scan	O
to	O
assess	O
the	O
resolution	O
of	O
the	O
haematoma	O
and	O
rule	O
out	O
fibromuscular	O
dysplasia	O
FMD	O
.	O
The	O
CT	O
scan	O
showed	O
an	O
image	O
compatible	O
with	O
focal	O
haematoma	O
with	O
signs	O
of	O
intramural	O
bleeding	O
located	O
at	O
the	O
origin	O
of	O
the	O
celiac	O
trunk	O
and	O
in	O
the	O
distal	O
portion	O
of	O
the	O
anterior	O
descending	O
artery	O
,	O
causing	O
a	O
significant	O
reduction	O
in	O
the	O
calibre	O
of	O
both	O
vessels	O
.	O
The	O
decision	O
was	O
made	O
to	O
maintain	O
conservative	O
management	O
of	O
both	O
lesions	O
by	O
increasing	O
the	O
dose	O
of	O
oral	O
beta	O
blockers	O
,	O
withdrawing	O
clopidogrel	B-FARMACO
and	O
adding	O
nitrates	O
to	O
relieve	O
symptoms	O
,	O
with	O
good	O
initial	O
clinical	O
response	O
,	O
no	O
recurrence	O
of	O
episodes	O
of	O
chest	O
pain	O
and	O
no	O
associated	O
abdominal	O
symptoms	O
.	O
DIAGNOSIS	O
Anterior	O
STEMI	O
.	O
Killip	O
I	O
.	O
Spontaneous	O
coronary	O
artery	O
dissection	O
of	O
the	O
mid	O
distal	O
anterior	O
descending	O
artery	O
and	O
first	O
obtuse	O
marginal	O
artery	O
.	O
Preserved	O
LV	O
systolic	O
function	O
.	O
Focal	O
haematoma	O
with	O
signs	O
of	O
intramural	O
bleeding	O
located	O
at	O
the	O
origin	O
of	O
the	O
celiac	O
trunk	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
Family	O
history	O
of	O
ischaemic	O
heart	O
disease	O
in	O
his	O
father	O
at	O
47	O
years	O
of	O
age	O
,	O
and	O
in	O
two	O
maternal	O
uncles	O
at	O
42	O
and	O
50	O
years	O
of	O
age	O
respectively	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
Cardiovascular	O
risk	O
factors	O
no	O
hypertension	O
,	O
no	O
diabetes	O
,	O
no	O
dyslipidaemia	O
.	O
Obesity	O
body	O
mass	O
index	O
BMI	O
35	O
.	O
No	O
toxic	O
habits	O
.	O
Cardiological	O
history	O
assessed	O
in	O
2012	O
for	O
progressive	O
exertional	O
angina	O
,	O
antianginal	O
and	O
anti	O
ischaemic	O
treatment	O
was	O
started	O
and	O
an	O
echocardiogram	O
was	O
performed	O
with	O
globally	O
and	O
segmentally	O
preserved	O
systolic	O
function	O
;	O
given	O
clinical	O
persistence	O
despite	O
medical	O
treatment	O
,	O
coronary	O
catheterisation	O
was	O
performed	O
with	O
no	O
significant	O
angiographic	O
lesions	O
.	O
Cardiological	O
treatment	O
was	O
withdrawn	O
,	O
anxiolytics	O
and	O
the	O
usual	O
analgesics	O
were	O
started	O
,	O
and	O
the	O
patient	O
was	O
discharged	O
from	O
cardiology	O
consultations	O
.	O
Referred	O
again	O
in	O
2014	O
for	O
progressive	O
exertional	O
angina	O
,	O
with	O
sporadic	O
episodes	O
at	O
rest	O
,	O
which	O
persisted	O
despite	O
antidepressant	O
treatment	O
combined	O
with	O
the	O
usual	O
analgesics	O
,	O
it	O
was	O
decided	O
to	O
request	O
another	O
coronary	O
catheterisation	O
,	O
again	O
showing	O
no	O
significant	O
angiographic	O
lesions	O
.	O
She	O
was	O
again	O
discharged	O
from	O
cardiology	O
and	O
referred	O
to	O
psychiatry	O
by	O
her	O
primary	O
care	O
physician	O
.	O
Referred	O
again	O
in	O
2019	O
due	O
to	O
functional	O
worsening	O
,	O
with	O
persistent	O
episodes	O
of	O
chest	O
pain	O
on	O
exertion	O
and	O
isolated	O
episodes	O
of	O
greater	O
intensity	O
at	O
rest	O
.	O
In	O
this	O
case	O
,	O
a	O
diagnosis	O
of	O
"	O
syndrome	O
X	O
"	O
was	O
made	O
and	O
only	O
ranolazine	B-FARMACO
375	O
mg	O
12	O
hours	O
was	O
added	O
to	O
her	O
treatment	O
without	O
antiplatelet	O
agents	O
or	O
statins	O
and	O
myocardial	O
perfusion	O
SPECT	O
,	O
a	O
new	O
transthoracic	O
echocardiogram	O
and	O
a	O
review	O
in	O
one	O
year	O
with	O
the	O
results	O
were	O
requested	O
.	O
No	O
other	O
history	O
of	O
interest	O
.	O
Baseline	O
situation	O
sedentary	O
lifestyle	O
.	O
Life	O
limited	O
by	O
episodes	O
of	O
chest	O
pain	O
with	O
significant	O
impairment	O
and	O
secondary	O
emotional	O
lability	O
.	O
Usual	O
treatment	O
ranolazine	B-FARMACO
375	O
mg	O
12	O
hours	O
,	O
sertraline	B-FARMACO
50	O
mg	O
at	O
breakfast	O
,	O
lorazepam	B-FARMACO
2	O
mg	O
1	O
tablet	O
at	O
breakfast	O
and	O
another	O
at	O
dinner	O
,	O
paracetamol	B-FARMACO
650	O
mg	O
tramadol	B-FARMACO
75	O
mg	O
every	O
8	O
hours	O
and	O
ibuprofen	B-FARMACO
400	O
mg	O
on	O
demand	O
.	O
Current	O
illness	O
Consultation	O
at	O
the	O
emergency	O
department	O
for	O
an	O
episode	O
of	O
oppressive	O
central	O
thoracic	O
pain	O
,	O
with	O
significant	O
accompanying	O
neurovegetative	O
symptoms	O
,	O
onset	O
at	O
rest	O
,	O
self	O
limiting	O
,	O
lasting	O
about	O
20	O
minutes	O
and	O
with	O
significant	O
emotional	O
involvement	O
.	O
He	O
says	O
that	O
it	O
reminds	O
him	O
of	O
previous	O
episodes	O
of	O
chest	O
pain	O
and	O
that	O
he	O
has	O
already	O
had	O
several	O
coronary	O
angiographies	O
and	O
that	O
"	O
he	O
has	O
never	O
had	O
to	O
have	O
stents	O
fitted	O
"	O
,	O
but	O
that	O
he	O
has	O
recently	O
undergone	O
a	O
test	O
to	O
study	O
his	O
heart	O
,	O
which	O
he	O
cannot	O
specify	O
and	O
that	O
he	O
is	O
awaiting	O
a	O
review	O
in	O
the	O
outpatient	O
cardiology	O
department	O
with	O
the	O
results	O
next	O
week	O
.	O
After	O
reviewing	O
the	O
patient	O
's	O
history	O
and	O
medical	O
records	O
,	O
it	O
is	O
found	O
that	O
a	O
few	O
weeks	O
ago	O
a	O
myocardial	O
perfusion	O
SPECT	O
was	O
performed	O
showing	O
inducible	O
myocardial	O
ischaemia	O
in	O
the	O
anterior	O
aspect	O
.	O
Serial	O
electrocardiograms	O
performed	O
in	O
the	O
emergency	O
department	O
,	O
carried	O
out	O
when	O
the	O
patient	O
was	O
no	O
longer	O
in	O
pain	O
,	O
showed	O
no	O
changes	O
or	O
dynamic	O
alterations	O
suggestive	O
of	O
ischaemia	O
.	O
The	O
study	O
was	O
completed	O
by	O
enzyme	O
seriation	O
,	O
which	O
was	O
found	O
to	O
be	O
normal	O
.	O
Chest	O
X	O
ray	O
with	O
no	O
findings	O
.	O
However	O
,	O
despite	O
the	O
normality	O
of	O
the	O
complementary	O
tests	O
performed	O
in	O
the	O
emergency	O
department	O
,	O
they	O
decided	O
to	O
contact	O
the	O
on	O
call	O
cardiology	O
team	O
for	O
assessment	O
.	O
Physical	O
examination	O
On	O
arrival	O
,	O
the	O
patient	O
was	O
haemodynamically	O
stable	O
,	O
with	O
a	O
blood	O
pressure	O
of	O
130	O
60	O
mmHg	O
,	O
a	O
heart	O
rate	O
of	O
64	O
beats	O
per	O
minute	O
and	O
an	O
oxygen	O
saturation	O
of	O
98	O
at	O
baseline	O
.	O
She	O
was	O
oriented	O
and	O
cooperative	O
,	O
with	O
marked	O
emotional	O
lability	O
and	O
crying	O
.	O
Physical	O
examination	O
was	O
unremarkable	O
.	O
Echocardioscopy	O
showed	O
preserved	O
systolic	O
function	O
globally	O
and	O
segmentally	O
,	O
without	O
significant	O
valvular	O
heart	O
disease	O
or	O
pericardial	O
effusion	O
.	O
At	O
the	O
insistence	O
of	O
the	O
patient	O
and	O
her	O
history	O
,	O
it	O
was	O
decided	O
to	O
admit	O
her	O
to	O
hospital	O
for	O
readjustment	O
of	O
medical	O
treatment	O
and	O
to	O
assess	O
the	O
possibility	O
of	O
performing	O
a	O
new	O
coronary	O
catheterisation	O
with	O
invasive	O
functional	O
study	O
to	O
rule	O
out	O
coronary	O
vasospasm	O
and	O
or	O
microvascular	O
dysfunction	O
as	O
the	O
aetiology	O
of	O
the	O
chest	O
pain	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
tests	O
glucose	O
83	O
mg	O
dl	O
,	O
glycosylated	O
haemoglobin	O
A1c	O
5	O
.	O
3	O
,	O
creatinine	O
serum	O
0	O
.	O
86	O
mg	O
dl	O
,	O
glomerular	O
filtration	O
rate	O
calculated	O
by	O
CKD	O
EPI	O
formula	O
76	O
ml	O
min	O
1	O
.	O
73	O
m2	O
,	O
urea	O
38	O
mg	O
dl	O
21	O
43	O
,	O
uric	O
acid	O
4	O
.	O
1	O
mg	O
dl	O
,	O
total	O
proteins	O
7	O
.	O
7	O
g	O
dl	O
,	O
total	O
cholesterol	O
147	O
mg	O
dl	O
,	O
hDL	O
cholesterol	O
45	O
mg	O
dl	O
,	O
LDL	O
cholesterol	O
calculated	O
125	O
mg	O
dl	O
,	O
triglycerides	O
98	O
mg	O
dl	O
,	O
total	O
bilirubin	O
0	O
.	O
72	O
mg	O
dl	O
,	O
aspartate	O
transaminase	O
GOT	O
19	O
U	O
l	O
,	O
alanine	O
transaminase	O
GPT	O
22	O
,	O
haemoglobin	O
12	O
.	O
7	O
g	O
dl	O
,	O
leucocytes	O
9745	O
x	O
103l	O
,	O
platelets	O
289	O
x	O
103l	O
.	O
Electrocardiogram	O
ECG	O
sinus	O
rhythm	O
at	O
67	O
beats	O
per	O
minute	O
,	O
PR	O
180	O
ms	O
,	O
normal	O
axis	O
,	O
narrow	O
QRS	O
,	O
QTc	O
410	O
ms	O
,	O
no	O
acute	O
repolarisation	O
abnormalities	O
.	O
Chest	O
X	O
ray	O
cardiothoracic	O
index	O
within	O
the	O
normal	O
range	O
.	O
Free	O
costophrenic	O
sinuses	O
,	O
no	O
evidence	O
of	O
vascular	O
redistribution	O
.	O
No	O
masses	O
or	O
consolidations	O
.	O
Echocardioscopy	O
preserved	O
systolic	O
function	O
without	O
segmentarity	O
.	O
Absence	O
of	O
significant	O
valvulopathies	O
.	O
No	O
pericardial	O
effusion	O
.	O
Transthoracic	O
echocardiogram	O
left	O
ventricle	O
LV	O
of	O
normal	O
size	O
,	O
thickness	O
and	O
systolic	O
and	O
diastolic	O
function	O
.	O
Right	O
ventricle	O
RV	O
of	O
normal	O
size	O
and	O
function	O
.	O
Left	O
atrium	O
LA	O
and	O
right	O
atrium	O
RA	O
of	O
normal	O
size	O
.	O
No	O
valvular	O
heart	O
disease	O
.	O
No	O
indirect	O
signs	O
of	O
pulmonary	O
hypertension	O
PHT	O
.	O
Aortic	O
root	O
of	O
normal	O
size	O
.	O
No	O
pericardial	O
effusion	O
.	O
Myocardial	O
perfusion	O
SPECT	O
Mild	O
precordial	O
pressure	O
without	O
ECG	O
alteration	O
during	O
regadenoson	O
administration	O
Baseline	O
HR	O
90	O
bpm	O
post	O
stress	O
120	O
bpm	O
.	O
Post	O
stress	O
study	O
shows	O
anteroseptal	O
myocardial	O
hypocaptation	O
which	O
normalises	O
at	O
rest	O
.	O
Findings	O
suggestive	O
of	O
myocardial	O
ischaemia	O
induced	O
in	O
the	O
territory	O
of	O
the	O
anterior	O
descending	O
coronary	O
artery	O
AD	O
.	O
Coronary	O
catheterisation	O
with	O
invasive	O
functional	O
study	O
coronary	O
tree	O
of	O
normal	O
distribution	O
and	O
development	O
.	O
Right	O
dominance	O
.	O
Absence	O
of	O
angiographically	O
significant	O
lesions	O
.	O
A	O
study	O
of	O
microvascular	O
dysfunction	O
was	O
performed	O
by	O
thermodilution	O
with	O
saline	O
boluses	O
and	O
an	O
IMR	O
of	O
78	O
and	O
a	O
CFR	O
of	O
0	O
.	O
8	O
were	O
obtained	O
,	O
indicating	O
severe	O
microvascular	O
dysfunction	O
.	O
Positive	O
vasoreactivity	O
test	O
with	O
acetylcholine	O
in	O
the	O
territory	O
of	O
the	O
anterior	O
descending	O
artery	O
at	O
a	O
dose	O
of	O
100	O
m	O
reduction	O
of	O
coronary	O
diameter	O
90	O
,	O
ischaemic	O
changes	O
in	O
the	O
electrocardiogram	O
and	O
clinical	O
signs	O
of	O
angina	O
.	O
Conclusion	O
severe	O
microvascular	O
dysfunction	O
and	O
coronary	O
spasm	O
in	O
the	O
territory	O
of	O
the	O
anterior	O
descending	O
coronary	O
artery	O
.	O
CLINICAL	O
EVOLUTION	O
Once	O
admitted	O
to	O
the	O
cardiology	O
ward	O
,	O
anti	O
ischaemic	O
and	O
anti	O
anginal	O
treatment	O
was	O
reinforced	O
,	O
and	O
a	O
transthoracic	O
echocardiogram	O
and	O
a	O
new	O
coronary	O
catheterisation	O
with	O
invasive	O
functional	O
study	O
were	O
requested	O
.	O
The	O
echocardiographic	O
study	O
showed	O
preserved	O
global	O
and	O
segmental	O
systolic	O
function	O
,	O
without	O
systolic	O
dysfunction	O
or	O
valvular	O
heart	O
disease	O
.	O
However	O
,	O
the	O
coronary	O
catheterisation	O
performed	O
showed	O
no	O
significant	O
angiographic	O
lesions	O
,	O
with	O
no	O
changes	O
with	O
respect	O
to	O
previous	O
studies	O
.	O
It	O
was	O
decided	O
to	O
perform	O
a	O
complete	O
functional	O
study	O
in	O
the	O
haemodynamics	O
room	O
using	O
thermodilution	O
with	O
saline	O
boluses	O
and	O
intravenous	O
adenosine	O
perfusion	O
to	O
obtain	O
the	O
microvascular	O
resistance	O
index	O
MRI	O
and	O
coronary	O
flow	O
reserve	O
CFR	O
.	O
The	O
results	O
obtained	O
were	O
markers	O
of	O
severe	O
microvascular	O
dysfunction	O
MRI	O
78	O
cut	O
off	O
point	O
25	O
and	O
CFR	O
of	O
0	O
.	O
8	O
cut	O
off	O
point	O
2	O
2	O
.	O
5	O
.	O
The	O
study	O
was	O
completed	O
with	O
the	O
coronary	O
vasoreactivity	O
test	O
to	O
rule	O
out	O
coronary	O
vasospasm	O
,	O
which	O
was	O
positive	O
in	O
the	O
territory	O
of	O
the	O
anterior	O
descending	O
coronary	O
artery	O
with	O
an	O
intracoronary	O
dose	O
of	O
100	O
g	O
reduction	O
in	O
coronary	O
diameter	O
greater	O
than	O
90	O
,	O
dynamic	O
alterations	O
in	O
the	O
ECG	O
and	O
clinical	O
symptoms	O
of	O
angina	O
.	O
Given	O
these	O
results	O
,	O
the	O
patient	O
was	O
diagnosed	O
with	O
severe	O
microvascular	O
dysfunction	O
and	O
coronary	O
vasospasm	O
,	O
and	O
it	O
was	O
decided	O
to	O
progressively	O
withdraw	O
anxiolytic	O
and	O
antidepressant	O
treatment	O
,	O
and	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
,	O
atorvastatin	B-FARMACO
,	O
amlodipine	B-FARMACO
and	O
nitroglycerin	B-FARMACO
night	O
patches	O
were	O
added	O
,	O
showing	O
clear	O
symptomatic	O
improvement	O
,	O
as	O
well	O
as	O
a	O
marked	O
decrease	O
in	O
emotional	O
lability	O
on	O
finally	O
learning	O
the	O
aetiology	O
of	O
the	O
chest	O
pain	O
.	O
At	O
the	O
review	O
12	O
months	O
after	O
admission	O
to	O
the	O
cardiology	O
outpatient	O
clinic	O
,	O
the	O
patient	O
is	O
asymptomatic	O
from	O
the	O
cardiovascular	O
point	O
of	O
view	O
,	O
and	O
has	O
managed	O
to	O
discontinue	O
all	O
antidepressant	O
and	O
anxiolytic	O
medication	O
and	O
has	O
progressively	O
begun	O
to	O
engage	O
in	O
physical	O
activity	O
with	O
excellent	O
tolerance	O
.	O
DIAGNOSIS	O
Angina	O
with	O
documented	O
ischaemia	O
in	O
AD	O
territory	O
with	O
coronary	O
arteries	O
without	O
significant	O
lesions	O
INOCA	O
.	O
Severe	O
microvascular	O
dysfunction	O
confirmed	O
by	O
invasive	O
functional	O
study	O
.	O
Coronary	O
vasospasm	O
in	O
the	O
territory	O
of	O
the	O
anterior	O
descending	O
artery	O
induced	O
during	O
acetylcholine	B-FARMACO
test	O
.	O
Preserved	O
global	O
and	O
segmental	O
systolic	O
function	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
58	O
year	O
old	O
male	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
Active	O
smoker	O
of	O
1	O
pack	O
a	O
day	O
.	O
No	O
other	O
cardiovascular	O
risk	O
factors	O
.	O
Recent	O
diagnosis	O
of	O
gastric	O
adenocarcinoma	O
with	O
lymph	O
node	O
involvement	O
,	O
undergoing	O
adjuvant	O
chemotherapy	O
treatment	O
with	O
docetaxel	B-FARMACO
,	O
oxaliplatin	B-FARMACO
,	O
leucovorin	B-FARMACO
,	O
5	O
fluorouracil	B-FARMACO
FLOT	O
scheme	O
.	O
He	O
started	O
the	O
first	O
cycle	O
24	O
hours	O
before	O
admission	O
to	O
the	O
cardiology	O
department	O
.	O
Usual	O
medication	O
metamizole	B-FARMACO
575	O
mg	O
8h	O
,	O
metoclopramide	B-FARMACO
10	O
mg	O
8h	O
,	O
paracetamol	B-FARMACO
1	O
g	O
8h	O
,	O
tramadol	B-FARMACO
50	O
mg	O
8h	O
,	O
dexamethasone	B-FARMACO
8	O
mg	O
24h	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
24h	O
.	O
Present	O
illness	O
Started	O
chemotherapy	O
with	O
5	B-FARMACO
fluorouracil	B-FARMACO
in	O
continuous	O
infusion	O
through	O
a	O
reservoir	O
24	O
hours	O
ago	O
.	O
He	O
came	O
to	O
the	O
emergency	O
department	O
for	O
an	O
episode	O
of	O
oppressive	O
chest	O
pain	O
,	O
radiating	O
to	O
both	O
extremities	O
and	O
associated	O
with	O
vegetative	O
cortex	O
,	O
with	O
abrupt	O
onset	O
and	O
spontaneous	O
disappearance	O
after	O
30	O
minutes	O
,	O
and	O
was	O
subsequently	O
asymptomatic	O
.	O
On	O
arrival	O
at	O
the	O
emergency	O
department	O
,	O
electrocardiogram	O
ECG	O
showed	O
isoelectric	O
ST	O
and	O
the	O
patient	O
was	O
haemodynamically	O
stable	O
.	O
After	O
2	O
hours	O
in	O
the	O
ED	O
,	O
he	O
presented	O
a	O
second	O
episode	O
of	O
typically	O
angina	O
like	O
central	O
thoracic	O
pain	O
with	O
electrical	O
evidence	O
of	O
ST	O
elevation	O
of	O
up	O
to	O
4	O
mm	O
on	O
the	O
inferolateral	O
side	O
associated	O
with	O
hypertensive	O
reaction	O
blood	O
pressure	O
BP	O
198	O
101	O
mmHg	O
.	O
After	O
administration	O
of	O
sublingual	O
nitroglycerin	B-FARMACO
,	O
there	O
was	O
clinical	O
improvement	O
and	O
retrogradation	O
of	O
electrical	O
changes	O
with	O
flattening	O
of	O
repolarisation	O
in	O
V5	O
V6	O
.	O
No	O
dyspnoea	O
or	O
other	O
associated	O
symptoms	O
.	O
During	O
his	O
stay	O
in	O
the	O
emergency	O
department	O
he	O
presented	O
a	O
new	O
recurrence	O
of	O
pain	O
with	O
ST	O
elevation	O
in	O
II	O
III	O
aVF	O
,	O
V1	O
V4	O
.	O
Cardiology	O
was	O
contacted	O
and	O
the	O
AMI	O
code	O
was	O
activated	O
.	O
Initially	O
the	O
perfusion	O
of	O
5	B-FARMACO
fluorouracil	B-FARMACO
was	O
stopped	O
and	O
i	O
.	O
v	O
.	O
nitroglycerin	B-FARMACO
was	O
started	O
.	O
On	O
arrival	O
in	O
haemodynamics	O
the	O
patient	O
was	O
asymptomatic	O
and	O
the	O
ECG	O
changes	O
had	O
regressed	O
.	O
Emergent	O
coronary	O
angiography	O
was	O
performed	O
with	O
ectatic	O
coronary	O
arteries	O
,	O
without	O
significant	O
angiographic	O
lesions	O
.	O
Aortography	O
ruled	O
out	O
signs	O
of	O
dissection	O
at	O
the	O
level	O
of	O
the	O
ascending	O
aorta	O
,	O
aortic	O
arch	O
and	O
thoracic	O
descending	O
aorta	O
.	O
Physical	O
examination	O
Weight	O
85	O
kg	O
,	O
height	O
1	O
.	O
85m	O
.	O
Good	O
general	O
condition	O
,	O
normohydrated	O
,	O
normoperfused	O
.	O
Conscious	O
and	O
oriented	O
.	O
No	O
signs	O
of	O
heart	O
failure	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
tones	O
,	O
no	O
murmurs	O
.	O
Peripheral	O
pulses	O
present	O
and	O
symmetrical	O
.	O
Respiratory	O
auscultation	O
preserved	O
vesicular	O
murmur	O
.	O
Abdomen	O
normal	O
examination	O
,	O
no	O
pathological	O
findings	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiograms	O
ECG	O
with	O
pain	O
sinus	O
rhythm	O
at	O
80	O
bpm	O
,	O
normal	O
PR	O
,	O
narrow	O
QRS	O
axis	O
at	O
30o	O
,	O
ST	O
elevation	O
II	O
,	O
III	O
,	O
aVF	O
,	O
V3	O
,	O
V4	O
,	O
V5	O
,	O
V6	O
maximum	O
4	O
mm	O
in	O
II	O
.	O
ECG	O
without	O
pain	O
and	O
on	O
discharge	O
sinus	O
rhythm	O
at	O
74	O
bpm	O
,	O
normalisation	O
of	O
the	O
previously	O
described	O
changes	O
with	O
isoelectric	O
ST	O
,	O
without	O
other	O
repolarisation	O
alterations	O
.	O
AP	O
portable	O
chest	O
X	O
ray	O
on	O
arrival	O
at	O
the	O
ED	O
no	O
condensation	O
in	O
the	O
lung	O
parenchyma	O
or	O
signs	O
of	O
pulmonary	O
congestion	O
.	O
Laboratory	O
tests	O
Initial	O
blood	O
tests	O
in	O
the	O
ED	O
glucose	O
160	O
mg	O
dl	O
;	O
urea	O
51	O
mmol	O
l	O
;	O
creatinine	O
1	O
mg	O
dl	O
;	O
GFR	O
82	O
ml	O
min	O
;	O
sodium	O
139	O
mEq	O
l	O
;	O
potassium	O
3	O
.	O
85	O
mEq	O
l	O
;	O
leukocytes	O
10	O
.	O
82	O
x109	O
l	O
;	O
haemoglobin	O
15	O
.	O
6	O
g	O
dl	O
;	O
haematocrit	O
44	O
.	O
1	O
;	O
platelets	O
210	O
x109	O
l	O
;	O
INR	O
1	O
.	O
14	O
.	O
Myocardial	O
enzymes	O
peak	O
TnI	O
US	O
29	O
.	O
70	O
pg	O
ml	O
normal	O
2	O
25	O
pg	O
ml	O
and	O
peak	O
CK	O
295	O
U	O
l	O
normal	O
10	O
195	O
U	O
l	O
.	O
SARS	O
CoV	O
2	O
PCR	O
negative	O
.	O
Complete	O
laboratory	O
tests	O
24	O
hours	O
after	O
admission	O
Metabolic	O
profile	O
total	O
cholesterol	O
186	O
mg	O
dl	O
;	O
LDL	O
123	O
mg	O
dl	O
;	O
HDL	O
40	O
mg	O
dl	O
;	O
triglycerides	O
115	O
mg	O
dl	O
;	O
HbA1c	O
5	O
.	O
1	O
.	O
Liver	O
function	O
GOT	O
23	O
U	O
l	O
,	O
GPT	O
14	O
U	O
l	O
,	O
GGT	O
20	O
U	O
l	O
,	O
total	O
bilirubin	O
0	O
.	O
71	O
.	O
Haemogram	O
without	O
alterations	O
.	O
Coronary	O
angiography	O
right	O
dominance	O
.	O
Ectatic	O
coronary	O
arteries	O
,	O
without	O
significant	O
angiographic	O
lesions	O
.	O
Aortography	O
absence	O
of	O
complications	O
of	O
ascending	O
aorta	O
and	O
aortic	O
arch	O
.	O
Transthoracic	O
echocardiogram	O
left	O
ventricle	O
LV	O
neither	O
dilated	O
nor	O
hypertrophied	O
with	O
normal	O
systolic	O
function	O
without	O
regional	O
contractile	O
asymmetries	O
.	O
Right	O
ventricle	O
not	O
dilated	O
and	O
normocontractile	O
.	O
Normal	O
atria	O
.	O
Absence	O
of	O
functionally	O
significant	O
valvular	O
heart	O
disease	O
.	O
Normal	O
pulmonary	O
pressure	O
.	O
No	O
pericardial	O
effusion	O
.	O
No	O
mechanical	O
complications	O
.	O
CLINICAL	O
EVOLUTION	O
Medical	O
treatment	O
was	O
maintained	O
with	O
intravenous	O
nitrates	O
,	O
with	O
subsequent	O
enteral	O
conversion	O
after	O
satisfactory	O
blood	O
pressure	O
control	O
,	O
remaining	O
haemodynamically	O
stable	O
and	O
without	O
angina	O
recurrence	O
.	O
After	O
48	O
hours	O
of	O
monitoring	O
,	O
we	O
contacted	O
our	O
medical	O
oncology	O
colleagues	O
to	O
adjust	O
and	O
control	O
the	O
medication	O
for	O
her	O
oncological	O
process	O
.	O
During	O
the	O
subsequent	O
evolution	O
,	O
given	O
that	O
he	O
did	O
not	O
require	O
treatment	O
with	O
5	B-FARMACO
FU	B-FARMACO
,	O
it	O
was	O
decided	O
to	O
perform	O
a	O
subtotal	O
R2	O
gastrectomy	O
and	O
start	O
treatment	O
with	O
irinotecan	B-FARMACO
.	O
On	O
discharge	O
,	O
from	O
the	O
cardiological	O
point	O
of	O
view	O
,	O
treatment	O
was	O
maintained	O
with	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
100	O
mg	O
0	O
1	O
0	O
,	O
nifedipine	B-FARMACO
20	O
mg	O
1	O
1	O
1	O
,	O
isosorbide	B-FARMACO
mononitrate	I-FARMACO
40	O
mg	O
0	O
1	O
1	O
and	O
fluvastatin	B-FARMACO
40	O
mg	O
0	O
0	O
1	O
1	O
.	O
DIAGNOSIS	O
Coronary	O
vasospasm	O
secondary	O
to	O
5	B-FARMACO
fluoruracil	B-FARMACO
treatment	O
.	O
Non	O
Q	O
acute	O
myocardial	O
infarction	O
AMI	O
.	O
Killip	O
I	O
.	O
Preserved	O
LV	O
systolic	O
function	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
64	O
year	O
old	O
female	O
patient	O
,	O
with	O
the	O
following	O
history	O
No	O
family	O
history	O
of	O
interest	O
for	O
the	O
current	O
picture	O
.	O
No	O
known	O
adverse	O
drug	O
reactions	O
.	O
Cardiovascular	O
risk	O
factors	O
long	O
standing	O
arterial	O
hypertension	O
,	O
dyslipidaemia	O
and	O
long	O
standing	O
type	O
2	O
diabetes	O
mellitus	O
,	O
without	O
target	O
organ	O
damage	O
.	O
Denies	O
toxic	O
habits	O
.	O
Previous	O
surgeries	O
breast	O
reduction	O
,	O
tubal	O
ligation	O
.	O
Previous	O
admissions	O
admission	O
in	O
2019	O
to	O
internal	O
medicine	O
for	O
atypical	O
chest	O
pain	O
,	O
discharged	O
after	O
ergometry	O
,	O
which	O
was	O
inconclusive	O
,	O
and	O
myocardial	O
perfusion	O
SPECT	O
,	O
which	O
was	O
negative	O
.	O
Usual	O
treatment	O
enalapril	B-FARMACO
20	O
mg	O
hydrochlorothiazide	B-FARMACO
12	O
.	O
5	O
mg	O
1	O
tablet	O
every	O
24	O
hours	O
,	O
sitagliptin	B-FARMACO
100	O
mg	O
1	O
tablet	O
every	O
24	O
hours	O
.	O
Present	O
illness	O
She	O
was	O
referred	O
to	O
the	O
emergency	O
department	O
for	O
chest	O
pain	O
of	O
several	O
days	O
'	O
duration	O
.	O
The	O
patient	O
describes	O
the	O
pain	O
as	O
central	O
thoracic	O
,	O
oppressive	O
,	O
intermittent	O
,	O
non	O
radiating	O
,	O
not	O
accompanied	O
by	O
vegetative	O
cortex	O
,	O
which	O
appears	O
with	O
exertion	O
and	O
improves	O
with	O
rest	O
,	O
of	O
5	O
days	O
'	O
evolution	O
.	O
Today	O
's	O
episode	O
was	O
more	O
intense	O
,	O
so	O
she	O
went	O
to	O
her	O
primary	O
care	O
physician	O
,	O
who	O
referred	O
her	O
to	O
the	O
hospital	O
due	O
to	O
pathological	O
findings	O
on	O
the	O
electrocardiogram	O
ECG	O
,	O
suggestive	O
of	O
acute	O
coronary	O
syndrome	O
without	O
ST	O
segment	O
elevation	O
.	O
The	O
main	O
finding	O
of	O
interest	O
in	O
the	O
ED	O
analysis	O
was	O
the	O
presence	O
of	O
mobilisation	O
of	O
markers	O
of	O
myocardial	O
damage	O
in	O
the	O
range	O
of	O
myocardial	O
necrosis	O
TnT	O
hs	O
25	O
47	O
93	O
ng	O
l	O
.	O
A	O
diagnosis	O
of	O
non	O
ST	O
elevation	O
acute	O
coronary	O
syndrome	O
was	O
therefore	O
made	O
,	O
and	O
coronary	O
angiography	O
was	O
requested	O
,	O
which	O
was	O
performed	O
the	O
following	O
day	O
and	O
showed	O
a	O
lesion	O
in	O
the	O
middle	O
circumflex	O
artery	O
,	O
which	O
was	O
revascularised	O
by	O
implanting	O
a	O
drug	O
eluting	O
stent	O
.	O
During	O
her	O
stay	O
on	O
the	O
hospital	O
ward	O
,	O
she	O
progressed	O
well	O
,	O
with	O
no	O
new	O
episodes	O
of	O
chest	O
pain	O
.	O
Echocardiography	O
was	O
performed	O
,	O
which	O
showed	O
preserved	O
biventricular	O
function	O
,	O
without	O
segmental	O
contractility	O
disorders	O
.	O
In	O
hospital	O
laboratory	O
tests	O
showed	O
preserved	O
renal	O
function	O
,	O
an	O
improved	O
lipid	O
profile	O
and	O
high	O
levels	O
of	O
glycosylated	O
haemoglobin	O
.	O
Finally	O
,	O
she	O
was	O
discharged	O
with	O
the	O
following	O
treatment	O
at	O
discharge	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	O
100	O
mg	O
1	O
tablet	O
every	O
24	O
h	O
,	O
ticagrelor	B-FARMACO
90	O
mg	O
1	O
tablet	O
every	O
12	O
h	O
,	O
enalapril	B-FARMACO
hydrochlorothiazide	I-FARMACO
20	O
12	O
.	O
5	O
mg	O
1	O
tablet	O
every	O
24	O
h	O
,	O
bisoprolol	B-FARMACO
5	O
mg	O
1	O
tablet	O
every	O
24	O
h	O
,	O
atorvastatin	B-FARMACO
80	O
mg	O
1	O
tablet	O
in	O
the	O
evening	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
1	O
tablet	O
before	O
breakfast	O
,	O
canaglifozin	B-FARMACO
100	O
mg	O
1	O
tablet	O
every	O
24	O
h	O
,	O
sitagliptin	B-FARMACO
metformin	I-FARMACO
50	O
mg	O
1g	O
1	O
tablet	O
every	O
12	O
h	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
in	O
the	O
emergency	O
department	O
.	O
Coronary	O
angiography	O
right	O
dominance	O
.	O
Right	O
coronary	O
artery	O
without	O
significant	O
lesions	O
suggestive	O
of	O
revascularisation	O
.	O
Left	O
coronary	O
tree	O
with	O
significant	O
lesion	O
in	O
the	O
middle	O
circumflex	O
artery	O
,	O
revascularised	O
by	O
implanting	O
1	O
drug	O
eluting	O
stent	O
.	O
Echocardiography	O
non	O
dilated	O
left	O
ventricle	O
with	O
slight	O
concentric	O
hypertrophy	O
of	O
the	O
walls	O
.	O
No	O
segmental	O
contractility	O
disorders	O
were	O
observed	O
.	O
Right	O
ventricle	O
not	O
dilated	O
.	O
Biventricular	O
function	O
preserved	O
LVEF	O
58	O
.	O
Atria	O
not	O
dilated	O
.	O
Absence	O
of	O
significant	O
valvular	O
heart	O
disease	O
.	O
No	O
pericardial	O
effusion	O
.	O
Regular	O
laboratory	O
tests	O
renal	O
function	O
preserved	O
,	O
with	O
baseline	O
creatinine	O
of	O
0	O
.	O
48	O
mg	O
dl	O
and	O
estimated	O
filtration	O
rate	O
of	O
104	O
ml	O
min	O
1	O
.	O
73	O
m2	O
.	O
Lipid	O
profile	O
total	O
cholesterol	O
174	O
mg	O
dl	O
,	O
with	O
LDL	O
cholesterol	O
98	O
mg	O
dl	O
and	O
HDL	O
46	O
mg	O
dl	O
and	O
triglycerides	O
150	O
mg	O
dl	O
.	O
Glycosylated	O
haemoglobin	O
7	O
.	O
3	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
referred	O
on	O
discharge	O
to	O
cardiac	O
rehabilitation	O
,	O
where	O
she	O
started	O
a	O
structured	O
exercise	O
programme	O
,	O
in	O
addition	O
to	O
a	O
comprehensive	O
approach	O
to	O
cardiovascular	O
risk	O
factors	O
.	O
She	O
was	O
a	O
diabetic	O
patient	O
with	O
poor	O
control	O
,	O
with	O
an	O
HbA1c	O
of	O
7	O
.	O
3	O
,	O
who	O
was	O
on	O
home	O
treatment	O
with	O
sitagliptin	B-FARMACO
and	O
who	O
,	O
on	O
discharge	O
,	O
was	O
upgraded	O
to	O
sitagliptin	B-FARMACO
metformin	I-FARMACO
and	O
it	O
was	O
decided	O
to	O
add	O
canaglifozin	B-FARMACO
for	O
cardiovascular	O
benefit	O
.	O
During	O
follow	O
up	O
,	O
the	O
patient	O
presented	O
gastrointestinal	O
discomfort	O
,	O
which	O
subsided	O
after	O
stopping	O
metformin	B-FARMACO
,	O
so	O
she	O
started	O
to	O
discontinue	O
oral	O
hypoglycaemic	O
treatment	O
and	O
began	O
to	O
have	O
poor	O
daily	O
glycaemic	O
control	O
.	O
Not	O
only	O
that	O
,	O
but	O
practically	O
simultaneously	O
,	O
the	O
patient	O
had	O
several	O
episodes	O
of	O
genitourinary	O
tract	O
infections	O
,	O
all	O
of	O
fungal	O
origin	O
C	O
.	O
albicans	O
,	O
associated	O
with	O
treatment	O
with	O
sodium	B-FARMACO
glucose	I-FARMACO
cotransporter	I-FARMACO
type	I-FARMACO
2	I-FARMACO
iSGLT2	I-FARMACO
inhibitors	O
,	O
which	O
responded	O
to	O
antifungal	O
treatment	O
,	O
but	O
relapsed	O
a	O
few	O
days	O
later	O
.	O
In	O
this	O
situation	O
,	O
it	O
was	O
decided	O
to	O
take	O
general	O
measures	O
to	O
try	O
to	O
prevent	O
new	O
episodes	O
of	O
genitourinary	O
infections	O
,	O
but	O
all	O
these	O
measures	O
were	O
ineffective	O
,	O
so	O
her	O
primary	O
care	O
physician	O
decided	O
to	O
discontinue	O
treatment	O
with	O
iSGLT2	B-FARMACO
and	O
to	O
start	O
treatment	O
directly	O
with	O
slow	O
acting	O
insulin	B-FARMACO
.	O
When	O
she	O
was	O
reviewed	O
again	O
in	O
cardiac	O
rehabilitation	O
consultations	O
,	O
it	O
was	O
decided	O
to	O
try	O
a	O
different	O
course	O
of	O
action	O
,	O
which	O
was	O
to	O
start	O
treatment	O
with	O
a	O
glucagon	O
like	O
peptide	O
type	O
1	O
receptor	O
agonist	O
arGLP1	O
.	O
Therefore	O
,	O
treatment	O
was	O
started	O
with	O
semaglutide	B-FARMACO
0	O
.	O
25	O
mg	O
1	O
injection	O
per	O
week	O
,	O
which	O
was	O
well	O
tolerated	O
.	O
After	O
4	O
weeks	O
,	O
the	O
dose	O
is	O
increased	O
to	O
0	O
.	O
5	O
mg	O
1	O
injection	O
per	O
week	O
.	O
Again	O
it	O
is	O
well	O
tolerated	O
and	O
with	O
good	O
glycaemic	O
control	O
.	O
Finally	O
,	O
after	O
another	O
4	O
weeks	O
,	O
a	O
maximum	O
dose	O
of	O
1	O
g	O
per	O
week	O
is	O
reached	O
,	O
with	O
good	O
clinical	O
tolerance	O
and	O
good	O
glycaemic	O
control	O
,	O
even	O
leading	O
to	O
withdrawal	O
of	O
insulin	B-FARMACO
.	O
After	O
3	O
months	O
of	O
treatment	O
,	O
the	O
regular	O
blood	O
test	O
showed	O
an	O
HbA1c	O
of	O
6	O
.	O
4	O
,	O
reaching	O
the	O
desired	O
target	O
,	O
having	O
lost	O
3	O
kg	O
of	O
weight	O
throughout	O
the	O
process	O
.	O
All	O
this	O
led	O
to	O
the	O
decision	O
to	O
maintain	O
this	O
monotherapy	O
treatment	O
indefinitely	O
.	O
DIAGNOSIS	O
Ischaemic	O
heart	O
disease	O
.	O
Acute	O
coronary	O
syndrome	O
without	O
ST	O
segment	O
elevation	O
,	O
with	O
single	O
vessel	O
involvement	O
of	O
the	O
circumflex	O
artery	O
,	O
revascularised	O
by	O
implanting	O
1	O
stent	O
.	O
Preserved	O
biventricular	O
function	O
.	O
Very	O
high	O
cardiovascular	O
risk	O
hypertension	O
,	O
dyslipidaemia	O
and	O
long	O
standing	O
type	O
2	O
diabetes	O
mellitus	O
with	O
poor	O
metabolic	O
control	O
.	O
Intolerance	O
to	O
metformin	B-FARMACO
.	O
Repeated	O
urinary	O
tract	O
infections	O
with	O
iSGLT2	B-FARMACO
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
No	O
known	O
drug	O
allergies	O
.	O
Ex	O
smoker	O
for	O
3	O
months	O
.	O
Cardiovascular	O
risk	O
factors	O
hypertension	O
HT	O
,	O
dyslipidaemia	O
and	O
DM2	O
.	O
Hyperuricaemia	O
.	O
Significant	O
stenosis	O
of	O
right	O
internal	O
carotid	O
artery	O
with	O
percutaneous	O
revascularisation	O
with	O
stent	O
in	O
2015	O
.	O
Usual	O
treatment	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
100	O
mg	O
every	O
24	O
h	O
,	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
every	O
24	O
h	O
,	O
atorvastatin	B-FARMACO
80	O
mg	O
every	O
24	O
h	O
,	O
ramipril	B-FARMACO
5	O
mg	O
every	O
24	O
h	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
every	O
24	O
h	O
,	O
metformin	B-FARMACO
empaglifozin	I-FARMACO
5	O
mg	O
1	O
,	O
000	O
mg	O
every	O
12	O
h	O
,	O
lormetazepam	B-FARMACO
2	O
mg	O
every	O
24	O
h	O
.	O
Present	O
illness	O
A	O
58	O
year	O
old	O
male	O
patient	O
with	O
the	O
previously	O
described	O
family	O
and	O
personal	O
history	O
and	O
under	O
follow	O
up	O
in	O
outpatient	O
cardiology	O
consultations	O
for	O
progressive	O
angina	O
of	O
2	O
months	O
'	O
evolution	O
and	O
segmental	O
alterations	O
in	O
transthoracic	O
echocardiography	O
,	O
who	O
was	O
admitted	O
to	O
the	O
ward	O
for	O
scheduled	O
coronary	O
angiography	O
.	O
Physical	O
examination	O
Good	O
general	O
condition	O
,	O
well	O
hydrated	O
and	O
perfused	O
.	O
Eupneic	O
at	O
rest	O
,	O
tolerates	O
decubitus	O
.	O
Blood	O
pressure	O
147	O
92	O
mmHg	O
.	O
Heart	O
rate	O
65	O
bpm	O
.	O
Central	O
obesity	O
.	O
Height	O
165	O
cm	O
.	O
Weight	O
97	O
,	O
5	O
kg	O
.	O
Body	O
mass	O
index	O
BMI	O
35	O
,	O
81	O
.	O
Cardiorespiratory	O
auscultation	O
with	O
rhythmic	O
tones	O
,	O
no	O
murmurs	O
.	O
Conservative	O
vesicular	O
murmur	O
with	O
no	O
added	O
noises	O
.	O
Absence	O
of	O
oedema	O
in	O
the	O
lower	O
limbs	O
with	O
pulses	O
present	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
sinus	O
rhythm	O
at	O
65	O
bpm	O
,	O
normal	O
axis	O
.	O
Normal	O
PR	O
.	O
QRS	O
with	O
right	O
bundle	O
branch	O
block	O
image	O
,	O
Q	O
wave	O
in	O
DII	O
,	O
DIII	O
and	O
avF	O
.	O
Laboratory	O
tests	O
on	O
admission	O
glomerular	O
filtration	O
rate	O
78	O
ml	O
min	O
,	O
glucose	O
148	O
mg	O
dl	O
,	O
Hb1Ac	O
8	O
.	O
3	O
.	O
Lipid	O
profile	O
with	O
total	O
cholesterol	O
307	O
mg	O
dl	O
,	O
LDL	O
cholesterol	O
215	O
mg	O
dl	O
,	O
triglycerides	O
513	O
mg	O
dl	O
.	O
GOT	O
20	O
IU	O
l	O
,	O
GPT	O
33	O
IU	O
l	O
.	O
Transthoracic	O
echocardiogram	O
left	O
atrium	O
not	O
dilated	O
.	O
Non	O
dilated	O
left	O
ventricle	O
with	O
moderate	O
concentric	O
hypertrophy	O
.	O
Inferobasal	O
hypokinesia	O
with	O
remaining	O
preserved	O
segmental	O
contractility	O
.	O
LVEF	O
61	O
.	O
Mitral	O
filling	O
flow	O
with	O
impaired	O
relaxation	O
pattern	O
.	O
Trivalve	O
aortic	O
valve	O
without	O
significant	O
valvulopathy	O
.	O
Aortic	O
root	O
and	O
ascending	O
aorta	O
not	O
dilated	O
.	O
Normal	O
appearing	O
mitral	O
valve	O
without	O
significant	O
valvulopathy	O
.	O
Right	O
chambers	O
not	O
dilated	O
,	O
right	O
ventricular	O
function	O
preserved	O
.	O
No	O
tricuspid	O
insufficiency	O
TI	O
to	O
estimate	O
pulmonary	O
artery	O
systolic	O
pressure	O
.	O
No	O
pericardial	O
effusion	O
.	O
Cardiac	O
catheterisation	O
severe	O
stenosis	O
of	O
65	O
of	O
the	O
distal	O
left	O
main	O
coronary	O
artery	O
LMCA	O
,	O
70	O
stenosis	O
of	O
the	O
proximal	O
anterior	O
descending	O
LAD	O
,	O
90	O
stenosis	O
in	O
the	O
middle	O
segment	O
of	O
the	O
circumflex	O
Cx	O
,	O
100	O
occlusion	O
of	O
the	O
proximal	O
segment	O
.	O
Post	O
admission	O
blood	O
tests	O
normal	O
haemogram	O
.	O
Renal	O
function	O
with	O
glomerular	O
filtration	O
rate	O
90	O
ml	O
min	O
,	O
normal	O
ions	O
,	O
urea	O
29	O
mg	O
dl	O
.	O
Lipid	O
profile	O
with	O
total	O
cholesterol	O
115	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
52	O
mg	O
dl	O
,	O
LDL	O
cholesterol	O
33	O
mg	O
dl	O
,	O
triglycerides	O
150	O
mg	O
dl	O
,	O
lipoprotein	O
a	O
4	O
.	O
5	O
mg	O
dl	O
.	O
Glycosylated	O
haemoglobin	O
HbA1c	O
6	O
.	O
4	O
.	O
GPT	O
18	O
IU	O
l	O
,	O
GGT	O
38	O
IU	O
l	O
.	O
CLINICAL	O
EVOLUTION	O
Scheduled	O
coronary	O
angiography	O
was	O
performed	O
,	O
documenting	O
significant	O
LMCA	O
disease	O
and	O
three	O
vessel	O
disease	O
.	O
Given	O
the	O
multivessel	O
coronary	O
involvement	O
,	O
the	O
patient	O
's	O
age	O
and	O
DM2	O
,	O
the	O
option	O
of	O
surgical	O
treatment	O
was	O
recommended	O
.	O
Cardiac	O
surgery	O
was	O
consulted	O
and	O
accepted	O
the	O
case	O
and	O
the	O
patient	O
was	O
scheduled	O
for	O
revascularisation	O
surgery	O
during	O
admission	O
.	O
Myocardial	O
revascularisation	O
surgery	O
was	O
performed	O
with	O
quadruple	O
aortocoronary	O
bypass	O
proximal	O
internal	O
mammary	O
artery	O
proximal	O
LAD	O
,	O
posterior	O
descending	O
saphenous	O
,	O
marginal	O
saphenous	O
obtuse	O
,	O
saphenous	O
1odiagonal	O
without	O
incident	O
and	O
with	O
good	O
evolution	O
during	O
the	O
postoperative	O
period	O
.	O
During	O
admission	O
and	O
on	O
discharge	O
after	O
the	O
operation	O
,	O
the	O
analytical	O
parameters	O
were	O
analysed	O
,	O
highlighting	O
poor	O
metabolic	O
control	O
with	O
HbA1c	O
figures	O
of	O
8	O
.	O
3	O
and	O
a	O
lipid	O
profile	O
outside	O
target	O
figures	O
according	O
to	O
her	O
cardiovascular	O
risk	O
level	O
.	O
Therefore	O
,	O
in	O
accordance	O
with	O
current	O
recommendations	O
on	O
the	O
management	O
of	O
patients	O
at	O
high	O
cardiovascular	O
risk	O
,	O
it	O
was	O
decided	O
to	O
optimise	O
treatment	O
with	O
high	O
potency	O
statins	O
rosuvastatin	B-FARMACO
20	O
mg	O
plus	O
ezetimibe	B-FARMACO
10	O
mg	O
and	O
to	O
add	O
arGLP1	O
to	O
the	O
oral	O
antidiabetic	O
treatment	O
as	O
a	O
weekly	O
injectable	O
semaglutide	B-FARMACO
,	O
given	O
its	O
proven	O
cardiovascular	O
and	O
metabolic	O
benefits	O
.	O
The	O
initial	O
dose	O
of	O
semaglutide	B-FARMACO
0	O
.	O
25	O
mg	O
subcutaneous	O
weekly	O
is	O
started	O
and	O
will	O
be	O
titrated	O
in	O
consultations	O
according	O
to	O
tolerance	O
.	O
On	O
discharge	O
,	O
the	O
patient	O
is	O
reminded	O
of	O
the	O
importance	O
of	O
smoking	O
cessation	O
and	O
lifestyle	O
changes	O
.	O
The	O
patient	O
was	O
reviewed	O
in	O
consultations	O
4	O
months	O
after	O
admission	O
,	O
the	O
clinical	O
evolution	O
was	O
favourable	O
,	O
with	O
no	O
new	O
episodes	O
of	O
chest	O
pain	O
and	O
progressive	O
recovery	O
of	O
his	O
normal	O
life	O
after	O
the	O
operation	O
.	O
The	O
patient	O
reports	O
that	O
he	O
has	O
lost	O
nearly	O
10	O
kg	O
but	O
continues	O
to	O
smoke	O
.	O
The	O
control	O
laboratory	O
tests	O
show	O
LDL	O
cholesterol	O
figures	O
of	O
33	O
mg	O
dl	O
and	O
HbA1c	O
levels	O
of	O
6	O
.	O
4	O
,	O
as	O
well	O
as	O
an	O
improvement	O
in	O
the	O
liver	O
profile	O
and	O
normalisation	O
of	O
uric	O
acid	O
parameters	O
.	O
His	O
primary	O
care	O
physician	O
has	O
titrated	O
subcutaneous	O
doses	O
of	O
semaglutide	B-FARMACO
,	O
and	O
he	O
is	O
currently	O
on	O
a	O
maintenance	O
dose	O
1	O
mg	O
sc	O
per	O
week	O
,	O
and	O
the	O
patient	O
does	O
not	O
report	O
any	O
intolerance	O
to	O
the	O
drug	O
and	O
only	O
highlights	O
the	O
increased	O
feeling	O
of	O
satiety	O
that	O
has	O
helped	O
him	O
to	O
lose	O
weight	O
.	O
It	O
was	O
decided	O
to	O
refer	O
the	O
patient	O
to	O
the	O
smoking	O
cessation	O
centre	O
at	O
his	O
health	O
centre	O
.	O
At	O
subsequent	O
check	O
ups	O
,	O
the	O
patient	O
remained	O
asymptomatic	O
,	O
had	O
stopped	O
smoking	O
after	O
starting	O
treatment	O
with	O
varenicline	B-FARMACO
Champix	I-FARMACO
,	O
continued	O
analytical	O
control	O
with	O
target	O
figures	O
in	O
secondary	O
prevention	O
and	O
no	O
new	O
hospital	O
admissions	O
.	O
DIAGNOSIS	O
Chronic	O
ischaemic	O
heart	O
disease	O
.	O
Progressive	O
angina	O
with	O
multivessel	O
coronary	O
disease	O
.	O
Surgical	O
revascularisation	O
by	O
quadruple	O
coronary	O
artery	O
bypass	O
grafting	O
.	O
Poorly	O
controlled	O
familial	O
combined	O
dyslipidaemia	O
.	O
Poorly	O
controlled	O
type	O
2	O
diabetes	O
mellitus	O
.	O

BACKGROUND	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
29	O
year	O
old	O
woman	O
.	O
History	O
Family	O
history	O
father	O
died	O
of	O
sudden	O
death	O
with	O
suspected	O
ischaemic	O
heart	O
disease	O
at	O
the	O
age	O
of	O
58	O
years	O
,	O
in	O
April	O
2020	O
no	O
autopsy	O
due	O
to	O
COVID	O
19	O
pandemic	O
situation	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
Personal	O
history	O
asthmatic	O
bronchitis	O
,	O
thalassaemia	O
minor	O
.	O
No	O
contact	O
at	O
risk	O
for	O
COVID	O
19	O
infection	O
.	O
No	O
past	O
infection	O
.	O
Not	O
vaccinated	O
.	O
Toxic	O
habits	O
active	O
smoking	O
10	O
packs	O
year	O
,	O
daily	O
use	O
of	O
cannabis	O
.	O
Previous	O
medication	O
levonorgestrel	B-FARMACO
ethinylestradiol	I-FARMACO
as	O
oral	O
contraceptive	O
,	O
inhaled	O
formoterol	B-FARMACO
budesonide	I-FARMACO
on	O
demand	O
,	O
folic	B-FARMACO
acid	I-FARMACO
.	O
Current	O
illness	O
She	O
came	O
to	O
the	O
emergency	O
department	O
for	O
chest	O
pain	O
.	O
The	O
previous	O
day	O
she	O
had	O
presented	O
with	O
oppressive	O
central	O
chest	O
pain	O
at	O
rest	O
one	O
hour	O
after	O
eating	O
,	O
increasing	O
with	O
deep	O
inspiration	O
,	O
non	O
radiating	O
,	O
without	O
vegetative	O
cortex	O
.	O
The	O
patient	O
had	O
consulted	O
her	O
health	O
centre	O
,	O
where	O
she	O
underwent	O
an	O
electrocardiogram	O
that	O
showed	O
no	O
abnormalities	O
.	O
During	O
the	O
night	O
she	O
presented	O
vomiting	O
and	O
diarrhoeic	O
stools	O
,	O
as	O
well	O
as	O
persistent	O
pain	O
,	O
which	O
finally	O
subsided	O
with	O
a	O
600	O
mg	O
ibuprofen	B-FARMACO
tablet	O
,	O
allowing	O
her	O
to	O
rest	O
.	O
The	O
day	O
she	O
went	O
to	O
the	O
emergency	O
department	O
,	O
she	O
started	O
again	O
with	O
more	O
intense	O
,	O
stabbing	O
,	O
non	O
radiating	O
pain	O
,	O
which	O
improved	O
when	O
seated	O
and	O
worsened	O
in	O
the	O
supine	O
decubitus	O
and	O
with	O
inspiration	O
,	O
without	O
vegetative	O
cortex	O
,	O
with	O
a	O
fever	O
of	O
37	O
.	O
5	O
oC	O
,	O
with	O
no	O
other	O
symptoms	O
.	O
The	O
patient	O
denied	O
temperature	O
control	O
in	O
previous	O
days	O
.	O
On	O
our	O
assessment	O
in	O
the	O
emergency	O
department	O
,	O
intravenous	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
was	O
administered	O
,	O
with	O
partial	O
relief	O
of	O
pain	O
,	O
which	O
persisted	O
only	O
on	O
deep	O
inspiration	O
.	O
The	O
patient	O
reported	O
having	O
presented	O
some	O
months	O
earlier	O
with	O
non	O
specific	O
precordial	O
discomfort	O
,	O
always	O
self	O
limited	O
and	O
without	O
other	O
symptoms	O
,	O
which	O
she	O
related	O
to	O
anxiety	O
.	O
There	O
were	O
no	O
previous	O
episodes	O
suggestive	O
of	O
angina	O
and	O
no	O
recent	O
worsening	O
of	O
functional	O
class	O
.	O
Laboratory	O
tests	O
showed	O
an	O
elevation	O
of	O
ultrasensitive	O
troponin	O
,	O
in	O
a	O
downward	O
curve	O
.	O
An	O
electrocardiogram	O
was	O
performed	O
,	O
showing	O
diffuse	O
ST	O
segment	O
elevation	O
in	O
the	O
inferior	O
and	O
anterior	O
face	O
,	O
as	O
well	O
as	O
urgent	O
echocardioscopy	O
at	O
the	O
bedside	O
,	O
which	O
showed	O
a	O
left	O
ventricle	O
that	O
was	O
neither	O
dilated	O
nor	O
hypertrophic	O
,	O
with	O
apical	O
septal	O
akinesia	O
and	O
of	O
the	O
apical	O
segment	O
of	O
the	O
right	O
ventricle	O
,	O
with	O
no	O
other	O
notable	O
pathological	O
findings	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
BP	O
142	O
82	O
mmHg	O
,	O
heart	O
rate	O
HR	O
120	O
bpm	O
,	O
oxygen	O
saturation	O
99	O
with	O
room	O
air	O
.	O
Acceptable	O
general	O
condition	O
,	O
normohydrated	O
,	O
normoperfused	O
,	O
eupneic	O
at	O
rest	O
.	O
No	O
jugular	O
ingurgitation	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
vesicular	O
murmur	O
preserved	O
in	O
all	O
fields	O
,	O
no	O
extra	O
sounds	O
.	O
Lower	O
limbs	O
no	O
oedema	O
,	O
no	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
,	O
good	O
distal	O
perfusion	O
,	O
symmetrical	O
pulses	O
.	O
COMPLEMENTARY	O
TESTS	O
CBC	O
on	O
admission	O
haemoglobin	O
12	O
.	O
9	O
g	O
dl	O
,	O
leukocytes	O
18	O
,	O
040	O
l	O
with	O
14	O
,	O
670	O
neutrophils	O
l	O
,	O
1	O
,	O
880	O
lymphocytes	O
l	O
,	O
platelets	O
412	O
.	O
000	O
l	O
,	O
D	O
dimer	O
310	O
mg	O
ml	O
,	O
creatinine	O
0	O
.	O
67	O
mg	O
dl	O
with	O
estimated	O
glomerular	O
filtration	O
rate	O
90	O
ml	O
min	O
1	O
.	O
73	O
m2	O
,	O
ions	O
in	O
normal	O
range	O
,	O
GOT	O
202	O
,	O
GPT	O
36	O
,	O
LDH	O
555	O
,	O
GGT	O
20	O
IU	O
l	O
,	O
total	O
bilirubin	O
0	O
.	O
82	O
mg	O
dl	O
.	O
CPK	O
1	O
,	O
079	O
IU	O
l	O
,	O
HDL	O
cholesterol	O
36	O
mg	O
dl	O
,	O
LDL	O
135	O
mg	O
dl	O
,	O
CRP	O
18	O
.	O
7	O
mg	O
l	O
,	O
troponin	O
I	O
hs	O
TnI	O
19	O
,	O
141	O
15	O
,	O
540	O
ng	O
l	O
normal	O
53	O
.	O
5	O
ng	O
l	O
,	O
NTproBNP	O
1	O
,	O
982	O
pg	O
ml	O
.	O
CBC	O
3rd	O
day	O
of	O
admission	O
haemogram	O
normal	O
,	O
renal	O
function	O
and	O
ions	O
normal	O
;	O
CRP	O
rising	O
196	O
mg	O
l	O
.	O
Procalcitonin	O
normal	O
.	O
Electrocardiogram	O
on	O
admission	O
sinus	O
rhythm	O
at	O
67	O
bpm	O
,	O
PR	O
200	O
ms	O
,	O
narrow	O
QRS	O
,	O
normal	O
axis	O
.	O
Amputated	O
R	O
wave	O
in	O
V4	O
V5	O
.	O
Diffuse	O
ST	O
elevation	O
in	O
V2	O
V5	O
and	O
inferior	O
aspect	O
.	O
Electrocardiogram	O
after	O
24	O
hours	O
sinus	O
rhythm	O
at	O
75	O
bpm	O
,	O
PR	O
200	O
ms	O
,	O
narrow	O
QRS	O
,	O
normal	O
axis	O
,	O
ST	O
segment	O
elevation	O
in	O
V2	O
5	O
and	O
inferior	O
aspect	O
with	O
negative	O
T	O
wave	O
in	O
the	O
same	O
leads	O
.	O
Chest	O
X	O
ray	O
on	O
admission	O
cardiothoracic	O
index	O
within	O
normal	O
limits	O
,	O
free	O
costophrenic	O
sinuses	O
,	O
no	O
evidence	O
of	O
vascular	O
redistribution	O
,	O
no	O
parenchymal	O
opacities	O
.	O
SARS	O
CoV	O
2	O
PCR	O
on	O
admission	O
and	O
at	O
8	O
days	O
undetectable	O
.	O
SARS	O
CoV	O
2	O
serology	O
IgG	O
negative	O
;	O
IgM	O
positive	O
.	O
Transthoracic	O
echocardiogram	O
2nd	O
day	O
of	O
admission	O
non	O
dilated	O
,	O
non	O
hypertrophic	O
left	O
ventricle	O
,	O
with	O
preserved	O
global	O
systolic	O
function	O
.	O
Akinesia	O
of	O
the	O
apex	O
and	O
apical	O
segments	O
of	O
the	O
inferior	O
septum	O
and	O
inferior	O
face	O
,	O
and	O
of	O
the	O
apical	O
and	O
middle	O
segment	O
of	O
the	O
anterior	O
septum	O
.	O
Apical	O
intracavitary	O
thrombus	O
with	O
a	O
fresh	O
appearance	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
and	O
function	O
.	O
Akinesia	O
of	O
the	O
most	O
apical	O
segment	O
of	O
the	O
right	O
ventricular	O
free	O
wall	O
.	O
Atria	O
of	O
normal	O
size	O
.	O
Mild	O
tricuspid	O
insufficiency	O
without	O
other	O
valvulopathies	O
.	O
Minimal	O
amount	O
of	O
pericardial	O
fluid	O
.	O
CT	O
of	O
coronary	O
arteries	O
2nd	O
day	O
of	O
admission	O
video	O
2	O
calcium	O
score	O
Agatston	O
0	O
.	O
Coronary	O
arteries	O
with	O
normal	O
anatomical	O
origin	O
.	O
Right	O
dominance	O
.	O
Left	O
coronary	O
artery	O
trunk	O
vessel	O
of	O
good	O
development	O
,	O
without	O
lesions	O
.	O
Anterior	O
descending	O
AD	O
well	O
developed	O
vessel	O
.	O
In	O
the	O
middle	O
segment	O
,	O
between	O
the	O
exit	O
of	O
the	O
2nd	O
diagonal	O
and	O
the	O
septal	O
,	O
there	O
is	O
a	O
lesion	O
of	O
about	O
5	O
mm	O
in	O
length	O
that	O
stenoses	O
the	O
lumen	O
by	O
50	O
,	O
which	O
is	O
compatible	O
with	O
soft	O
plaque	O
as	O
a	O
first	O
possibility	O
.	O
Diagonals	O
2	O
of	O
moderate	O
development	O
,	O
without	O
lesions	O
and	O
one	O
septal	O
of	O
good	O
development	O
.	O
Circumflex	O
CX	O
well	O
developed	O
vessel	O
,	O
without	O
lesions	O
.	O
Marginal	O
obtuse	O
4	O
vessels	O
,	O
the	O
first	O
of	O
which	O
is	O
very	O
poorly	O
developed	O
,	O
the	O
rest	O
are	O
well	O
developed	O
,	O
without	O
lesions	O
.	O
Right	O
coronary	O
artery	O
RC	O
dominant	O
vessel	O
of	O
good	O
development	O
,	O
without	O
lesions	O
.	O
Posterior	O
descending	O
pulmonary	O
artery	O
PVI	O
poorly	O
developed	O
,	O
no	O
lesions	O
.	O
Chest	O
visualisation	O
thrombus	O
in	O
the	O
cardiac	O
apex	O
.	O
No	O
pericardial	O
effusion	O
.	O
Catheterisation	O
on	O
the	O
2nd	O
day	O
of	O
admission	O
videos	O
3	O
and	O
4	O
right	O
radial	O
access	O
.	O
Trunk	O
no	O
lesions	O
.	O
LAD	O
normodeveloped	O
,	O
with	O
eccentric	O
focal	O
stenosis	O
in	O
the	O
middle	O
segment	O
,	O
with	O
contrast	O
defect	O
highly	O
suggestive	O
of	O
parietal	O
thrombus	O
.	O
The	O
distal	O
LAD	O
presents	O
abundant	O
contrastation	O
defects	O
that	O
suggest	O
thrombus	O
embolisation	O
as	O
a	O
first	O
possibility	O
.	O
CX	O
no	O
significant	O
lesions	O
.	O
CD	O
dominant	O
,	O
with	O
contrastation	O
defect	O
in	O
proximal	O
segment	O
compatible	O
with	O
intracoronary	O
thrombus	O
.	O
Good	O
distal	O
vessel	O
.	O
Catheterisation	O
on	O
the	O
12th	O
day	O
of	O
admission	O
angiographic	O
review	O
and	O
optical	O
coherence	O
tomography	O
OCT	O
.	O
Left	O
coronary	O
artery	O
LMCA	O
without	O
lesions	O
.	O
The	O
anterior	O
descending	O
artery	O
of	O
good	O
calibre	O
and	O
development	O
with	O
angiographically	O
mild	O
atheromatosis	O
in	O
the	O
middle	O
segment	O
,	O
distal	O
to	O
the	O
exit	O
of	O
the	O
main	O
diagonal	O
branch	O
.	O
The	O
distal	O
vessel	O
showed	O
TIMI	O
3	O
flow	O
,	O
with	O
no	O
angiographic	O
evidence	O
of	O
thrombus	O
.	O
OCT	O
was	O
performed	O
,	O
visualising	O
a	O
completely	O
healthy	O
distal	O
vessel	O
with	O
the	O
presence	O
of	O
a	O
lipid	O
plaque	O
in	O
the	O
middle	O
LAD	O
,	O
with	O
a	O
thin	O
layer	O
fibroatheroma	O
and	O
very	O
focal	O
intimal	O
rupture	O
,	O
immediately	O
distal	O
to	O
the	O
diagonal	O
,	O
with	O
a	O
minimal	O
non	O
pathological	O
luminal	O
area	O
MLA	O
7	O
.	O
5	O
mm2	O
and	O
absence	O
of	O
thrombus	O
.	O
Circumflex	O
of	O
good	O
calibre	O
and	O
development	O
without	O
significant	O
lesions	O
.	O
Dominant	O
right	O
coronary	O
artery	O
of	O
good	O
calibre	O
and	O
development	O
without	O
significant	O
lesions	O
.	O
The	O
thrombus	O
is	O
not	O
visualised	O
in	O
the	O
proximal	O
segment	O
and	O
the	O
vessel	O
has	O
distal	O
TIMI	O
3	O
flow	O
.	O
OCT	O
was	O
not	O
performed	O
in	O
CD	O
due	O
to	O
ostial	O
spasm	O
with	O
the	O
catheter	O
.	O
Conclusion	O
apical	O
infarction	O
secondary	O
to	O
thrombotic	O
lesion	O
in	O
the	O
middle	O
LAD	O
with	O
embolisation	O
of	O
thrombus	O
to	O
the	O
distal	O
vessel	O
which	O
is	O
healthy	O
on	O
OCT	O
.	O
Probable	O
coronary	O
embolism	O
from	O
thrombus	O
in	O
LV	O
apex	O
to	O
DC	O
,	O
resolved	O
after	O
antithrombotic	O
treatment	O
.	O
Transthoracic	O
echocardiogram	O
at	O
discharge	O
non	O
dilated	O
,	O
non	O
hypertrophic	O
left	O
ventricle	O
,	O
with	O
preserved	O
global	O
systolic	O
function	O
.	O
Akinesia	O
of	O
the	O
apical	O
segments	O
and	O
strict	O
apex	O
with	O
mobile	O
intracavitary	O
thrombus	O
of	O
smaller	O
size	O
and	O
echogenicity	O
than	O
in	O
the	O
previous	O
echocardiogram	O
1	O
.	O
5	O
x	O
1	O
.	O
2	O
cm	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
and	O
function	O
.	O
Atria	O
of	O
normal	O
size	O
.	O
Minimal	O
tricuspid	O
insufficiency	O
without	O
other	O
valvulopathies	O
.	O
No	O
indirect	O
evidence	O
of	O
pulmonary	O
hypertension	O
.	O
Minimal	O
amount	O
of	O
pericardial	O
fluid	O
as	O
previously	O
described	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
coronary	O
unit	O
in	O
respiratory	O
and	O
contact	O
isolation	O
due	O
to	O
the	O
positive	O
result	O
of	O
the	O
Sars	O
Cov	O
2	O
PCR	O
,	O
with	O
the	O
initial	O
diagnostic	O
suspicion	O
of	O
viral	O
myopericarditis	O
for	O
observation	O
and	O
completion	O
of	O
the	O
study	O
.	O
A	O
regular	O
echocardiogram	O
was	O
performed	O
with	O
an	O
image	O
of	O
intracavitary	O
thrombus	O
that	O
was	O
not	O
present	O
the	O
previous	O
day	O
,	O
so	O
anticoagulant	O
treatment	O
was	O
started	O
with	O
i	O
.	O
v	O
.	O
unfractionated	B-FARMACO
heparin	I-FARMACO
.	O
Given	O
the	O
echocardiogram	O
findings	O
and	O
taking	O
into	O
account	O
the	O
patient	O
's	O
low	O
cardiovascular	O
risk	O
,	O
a	O
CT	O
scan	O
of	O
the	O
coronary	O
arteries	O
was	O
performed	O
showing	O
at	O
least	O
a	O
moderate	O
lesion	O
in	O
the	O
LAD	O
artery	O
.	O
Coronary	O
angiography	O
showed	O
intracoronary	O
thrombosis	O
without	O
underlying	O
atherosclerotic	O
lesions	O
in	O
the	O
middle	O
and	O
distal	O
LAD	O
and	O
proximal	O
RCA	O
,	O
with	O
preserved	O
flow	O
.	O
Given	O
the	O
suspicion	O
of	O
an	O
underlying	O
prothrombotic	O
state	O
patient	O
smoker	O
,	O
in	O
treatment	O
with	O
oral	O
contraceptives	O
and	O
active	O
SARS	O
CoV2	O
infection	O
and	O
given	O
that	O
the	O
patient	O
was	O
asymptomatic	O
at	O
that	O
time	O
and	O
haemodynamically	O
stable	O
,	O
initial	O
pharmacological	O
management	O
was	O
decided	O
with	O
infusion	O
of	O
a	O
glycoprotein	B-FARMACO
IIb	I-FARMACO
IIIa	I-FARMACO
inhibitor	I-FARMACO
,	O
followed	O
by	O
treatment	O
with	O
anticoagulation	O
and	O
double	O
antiplatelet	O
therapy	O
with	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
and	O
clopidogrel	B-FARMACO
.	O
During	O
her	O
stay	O
in	O
the	O
coronary	O
unit	O
,	O
the	O
patient	O
presented	O
chest	O
discomfort	O
with	O
an	O
inflammatory	O
profile	O
,	O
with	O
an	O
increase	O
in	O
acute	O
phase	O
reactants	O
CRP	O
rising	O
to	O
149	O
mg	O
l	O
,	O
without	O
pericardial	O
effusion	O
.	O
Bacterial	O
superinfection	O
was	O
ruled	O
out	O
and	O
treatment	O
with	O
colchicine	B-FARMACO
was	O
started	O
,	O
with	O
good	O
clinical	O
evolution	O
and	O
improvement	O
in	O
the	O
analytical	O
parameters	O
of	O
inflammation	O
in	O
the	O
following	O
days	O
.	O
He	O
was	O
transferred	O
to	O
the	O
cardiology	O
ward	O
where	O
he	O
remained	O
clinically	O
stable	O
.	O
A	O
new	O
control	O
coronary	O
angiography	O
was	O
performed	O
ten	O
days	O
after	O
the	O
first	O
one	O
,	O
where	O
the	O
previous	O
thrombi	O
in	O
the	O
LAD	O
and	O
DC	O
were	O
not	O
visualised	O
.	O
OCT	O
showed	O
a	O
lipid	O
plaque	O
in	O
the	O
middle	O
LAD	O
,	O
with	O
thin	O
layer	O
fibroatheroma	O
and	O
very	O
focal	O
intimal	O
rupture	O
.	O
Given	O
the	O
angiographic	O
evolution	O
,	O
the	O
patient	O
's	O
clinical	O
profile	O
and	O
the	O
findings	O
on	O
intracoronary	O
imaging	O
techniques	O
,	O
conservative	O
management	O
of	O
the	O
lesion	O
in	O
the	O
middle	O
LAD	O
was	O
decided	O
.	O
A	O
control	O
echocardiogram	O
prior	O
to	O
discharge	O
showed	O
persistent	O
thrombus	O
in	O
the	O
apex	O
,	O
although	O
smaller	O
than	O
in	O
previous	O
studies	O
.	O
During	O
the	O
following	O
days	O
,	O
treatment	O
was	O
maintained	O
with	O
acenocoumarol	B-FARMACO
and	O
clopidogrel	B-FARMACO
.	O
The	O
patient	O
was	O
discharged	O
with	O
the	O
following	O
treatment	O
clopidogrel	B-FARMACO
,	O
acenocoumarol	B-FARMACO
,	O
pantoprazole	B-FARMACO
,	O
bisoprolol	B-FARMACO
,	O
atorvastatin	B-FARMACO
and	O
colchicine	B-FARMACO
.	O
She	O
was	O
assessed	O
by	O
haematology	O
and	O
a	O
thrombophilia	O
study	O
was	O
decided	O
once	O
the	O
acute	O
phase	O
had	O
passed	O
,	O
on	O
an	O
outpatient	O
basis	O
.	O
Smoking	O
cessation	O
was	O
recommended	O
and	O
hormonal	O
contraception	O
was	O
discontinued	O
.	O
The	O
patient	O
progressed	O
favourably	O
,	O
the	O
SARS	O
CoV2	O
infection	O
resolved	O
,	O
and	O
she	O
was	O
discharged	O
to	O
continue	O
outpatient	O
follow	O
up	O
.	O
DIAGNOSIS	O
Acute	O
pericarditis	O
due	O
to	O
SARS	O
CoV	O
2	O
.	O
Acute	O
coronary	O
syndrome	O
of	O
the	O
anterior	O
STEMI	O
type	O
thrombosis	O
in	O
the	O
middle	O
anterior	O
descending	O
artery	O
due	O
to	O
atheroma	O
plaque	O
instability	O
with	O
distal	O
embolisation	O
.	O
Embolic	O
infarction	O
in	O
proximal	O
right	O
coronary	O
artery	O
with	O
preserved	O
distal	O
flow	O
,	O
without	O
angiographically	O
significant	O
atheromatous	O
stenosis	O
.	O
Apical	O
akinesia	O
with	O
apical	O
thrombus	O
.	O
Preserved	O
global	O
left	O
ventricular	O
systolic	O
function	O
.	O
Suspected	O
thrombophilia	O
,	O
pending	O
completion	O
of	O
the	O
study	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
Cardiovascular	O
risk	O
factors	O
arterial	O
hypertension	O
without	O
medical	O
treatment	O
and	O
grade	O
II	O
obesity	O
weight	O
90	O
kg	O
,	O
height	O
1	O
.	O
6	O
m	O
,	O
body	O
mass	O
index	O
BMI	O
35	O
.	O
15	O
kg	O
m2	O
.	O
Other	O
history	O
low	O
back	O
pain	O
due	O
to	O
L4	O
L5	O
and	O
L5	O
S1	O
facet	O
overload	O
and	O
L4	O
L5	O
disc	O
degeneration	O
,	O
cervical	O
pain	O
due	O
to	O
cervical	O
spondylosis	O
with	O
slight	O
posterior	O
protrusion	O
C3	O
C4	O
,	O
C5	O
C6	O
and	O
C6	O
C7	O
without	O
spinal	O
cord	O
involvement	O
.	O
Anxiety	O
syndrome	O
,	O
claustrophobia	O
.	O
Peripheral	O
vertigo	O
.	O
Surgical	O
right	O
carpal	O
tunnel	O
syndrome	O
,	O
caesarean	O
section	O
,	O
curettage	O
for	O
abortion	O
.	O
Toxic	O
denied	O
.	O
Family	O
history	O
paternal	O
grandfather	O
died	O
of	O
acute	O
myocardial	O
infarction	O
AMI	O
at	O
the	O
age	O
of	O
64	O
.	O
Usual	O
medication	O
diazepam	B-FARMACO
5	O
mg	O
orally	O
if	O
required	O
,	O
dexketoprofen	B-FARMACO
25	O
mg	O
orally	O
if	O
required	O
.	O
Present	O
illness	O
A	O
44	O
year	O
old	O
woman	O
presented	O
with	O
a	O
clinical	O
picture	O
of	O
48	O
hours	O
'	O
evolution	O
,	O
characterised	O
by	O
a	O
first	O
episode	O
of	O
oppressive	O
,	O
retrosternal	O
chest	O
pain	O
of	O
moderate	O
intensity	O
,	O
while	O
at	O
rest	O
,	O
self	O
limited	O
for	O
30	O
minutes	O
,	O
not	O
radiating	O
,	O
not	O
accompanied	O
by	O
vegetative	O
cortex	O
and	O
without	O
modification	O
with	O
postural	O
changes	O
,	O
which	O
she	O
relieved	O
spontaneously	O
.	O
In	O
the	O
following	O
24	O
hours	O
,	O
he	O
presented	O
two	O
new	O
episodes	O
of	O
similar	O
characteristics	O
one	O
in	O
the	O
early	O
morning	O
,	O
self	O
limited	O
,	O
and	O
the	O
other	O
in	O
the	O
afternoon	O
for	O
which	O
he	O
consulted	O
a	O
private	O
centre	O
.	O
The	O
electrocardiogram	O
ECG	O
showed	O
an	O
inframillimetric	O
suprathreshold	O
level	O
in	O
DI	O
AVL	O
and	O
a	O
tendency	O
to	O
ST	O
segment	O
sublevel	O
in	O
DIII	O
and	O
AVF	O
.	O
Anti	O
inflammatory	O
treatment	O
was	O
administered	O
with	O
clinical	O
improvement	O
,	O
and	O
she	O
was	O
referred	O
to	O
the	O
emergency	O
department	O
of	O
the	O
referral	O
hospital	O
.	O
On	O
arrival	O
at	O
the	O
emergency	O
department	O
,	O
the	O
patient	O
remained	O
asymptomatic	O
,	O
but	O
during	O
her	O
stay	O
she	O
presented	O
a	O
febrile	O
peak	O
,	O
without	O
associated	O
infectious	O
focus	O
,	O
with	O
the	O
same	O
electrocardiographic	O
findings	O
and	O
echocardiogram	O
with	O
preserved	O
left	O
ventricular	O
LV	O
systolic	O
function	O
,	O
without	O
segmental	O
alterations	O
of	O
contractility	O
,	O
without	O
significant	O
valvular	O
heart	O
disease	O
and	O
without	O
pericardial	O
effusion	O
.	O
In	O
view	O
of	O
the	O
patient	O
's	O
clinical	O
condition	O
,	O
it	O
was	O
decided	O
to	O
admit	O
her	O
to	O
the	O
coronary	O
care	O
unit	O
,	O
with	O
suspicion	O
of	O
acute	O
myocarditis	O
versus	O
acute	O
coronary	O
syndrome	O
,	O
for	O
continuous	O
cardiovascular	O
monitoring	O
and	O
extension	O
studies	O
,	O
such	O
as	O
cardiac	O
catheterisation	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
BP	O
155	O
87	O
mmHg	O
,	O
heart	O
rate	O
HR	O
75	O
bpm	O
,	O
respiratory	O
rate	O
RR	O
14	O
rpm	O
,	O
temperature	O
36	O
.	O
3	O
oC	O
,	O
basal	O
oxygen	O
saturation	O
97	O
.	O
General	O
condition	O
stable	O
,	O
hydrated	O
,	O
eupneic	O
.	O
Neck	O
jugular	O
ingurgitation	O
could	O
not	O
be	O
assessed	O
due	O
to	O
obesity	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
,	O
muffled	O
tones	O
without	O
murmurs	O
or	O
friction	O
rubs	O
.	O
Pulmonary	O
auscultation	O
clear	O
audible	O
vesicular	O
murmur	O
,	O
no	O
extra	O
sounds	O
.	O
Lower	O
extremities	O
no	O
oedema	O
or	O
signs	O
of	O
venous	O
thrombosis	O
.	O
Neurological	O
vigil	O
,	O
conscious	O
,	O
oriented	O
,	O
without	O
focality	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiograms	O
Initial	O
ECG	O
with	O
chest	O
pain	O
RS	O
70	O
bpm	O
,	O
PR	O
160	O
msec	O
,	O
QRS	O
90	O
msec	O
with	O
60o	O
axis	O
,	O
suprathreshold	O
0	O
.	O
5	O
mm	O
in	O
DI	O
AVL	O
and	O
tendency	O
to	O
ST	O
segment	O
sublevel	O
in	O
DIII	O
and	O
AVF	O
.	O
No	O
significant	O
changes	O
in	O
subsequent	O
electrocardiograms	O
without	O
chest	O
pain	O
.	O
ECG	O
ED	O
,	O
without	O
chest	O
pain	O
,	O
with	O
fever	O
RS	O
70	O
bpm	O
,	O
PR	O
160	O
,	O
QRS	O
90	O
msec	O
,	O
axis	O
60	O
,	O
ST	O
elevation	O
of	O
1mm	O
in	O
DI	O
,	O
aVL	O
,	O
DII	O
with	O
negative	O
T	O
in	O
III	O
and	O
aVF	O
and	O
ST	O
rectification	O
in	O
V4	O
V5	O
.	O
ECG	O
at	O
discharge	O
RS	O
at	O
66	O
bpm	O
.	O
PR	O
160	O
msec	O
.	O
Narrow	O
QRS	O
.	O
Normal	O
electrical	O
axis	O
.	O
ST	O
elevation	O
of	O
0	O
.	O
5	O
mm	O
in	O
I	O
,	O
aVL	O
with	O
inferior	O
rectification	O
.	O
Q	O
wave	O
in	O
aVL	O
.	O
Blood	O
tests	O
On	O
admission	O
ED	O
glucose	O
144	O
mg	O
dl	O
,	O
urea	O
27	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
74	O
mg	O
dl	O
,	O
Na	O
139	O
.	O
3	O
mmol	O
l	O
,	O
K	O
3	O
.	O
84	O
mmol	O
l	O
,	O
CRP	O
8	O
.	O
9	O
mg	O
dl	O
.	O
Venous	O
gases	O
pH	O
7	O
.	O
41	O
,	O
pCO2	O
40	O
,	O
HCO3	O
35	O
.	O
7	O
,	O
EB	O
0	O
.	O
7	O
.	O
Leukocytes	O
8990	O
,	O
N	O
77	O
.	O
7	O
,	O
haemoglobin	O
13	O
g	O
dl	O
,	O
haematocrit	O
39	O
.	O
5	O
,	O
platelets	O
354	O
,	O
000	O
,	O
INR	O
1	O
.	O
Urine	O
toxins	O
positive	O
for	O
benzodiazepines	O
,	O
rest	O
negative	O
.	O
Control	O
total	O
cholesterol	O
182mg	O
dl	O
,	O
HDL	O
42cmg	O
dl	O
,	O
LDL	O
124	O
mg	O
dl	O
,	O
TGC	O
79	O
mg	O
dl	O
,	O
liver	O
profile	O
normal	O
.	O
CRP	O
6	O
.	O
7	O
mg	O
l	O
,	O
TSH	O
1	O
.	O
35	O
mU	O
l	O
,	O
Hb	O
1AC	O
5	O
.	O
6	O
.	O
Evolution	O
of	O
myocardial	O
necrosis	O
markers	O
ultrasensitive	O
troponin	O
I	O
22	O
,	O
973	O
pg	O
ml	O
on	O
admission	O
15	O
,	O
255	O
pg	O
ml	O
on	O
discharge	O
.	O
CK	O
589	O
U	O
l	O
on	O
admission	O
85U	O
l	O
on	O
discharge	O
.	O
Chest	O
X	O
ray	O
normal	O
cardiothoracic	O
index	O
,	O
without	O
alterations	O
of	O
the	O
pulmonary	O
parenchyma	O
,	O
free	O
costophrenic	O
and	O
cardiophrenic	O
sinuses	O
.	O
Admission	O
portable	O
echocardiogram	O
LV	O
neither	O
dilated	O
nor	O
hypertrophied	O
with	O
preserved	O
global	O
contractility	O
and	O
altered	O
relaxation	O
.	O
Left	O
atrium	O
LA	O
slightly	O
dilated	O
.	O
No	O
structural	O
or	O
functional	O
valvular	O
alterations	O
of	O
note	O
.	O
Non	O
dilated	O
right	O
chambers	O
with	O
preserved	O
ventricular	O
contractility	O
.	O
Absence	O
of	O
indirect	O
data	O
indicative	O
of	O
significant	O
pulmonary	O
hypertension	O
PH	O
.	O
Control	O
echocardiogram	O
before	O
discharge	O
unchanged	O
with	O
respect	O
to	O
previous	O
study	O
.	O
Coronary	O
angiography	O
right	O
radial	O
.	O
Right	O
dominance	O
.	O
Coronary	O
arteries	O
without	O
significant	O
angiographic	O
lesions	O
.	O
CMR	O
15	O
days	O
after	O
discharge	O
study	O
in	O
the	O
late	O
phase	O
after	O
contrast	O
administration	O
shows	O
subepicardial	O
gadolinium	O
uptake	O
in	O
inferomedial	O
,	O
inferolateromedial	O
,	O
anterolateral	O
basal	O
and	O
anterior	O
basal	O
and	O
middle	O
and	O
intramyocardial	O
anterolateral	O
middle	O
and	O
apical	O
segments	O
.	O
Normal	O
systolic	O
function	O
.	O
Conclusion	O
myocarditis	O
with	O
fibrosis	O
in	O
the	O
described	O
segments	O
.	O
CLINICAL	O
EVOLUTION	O
During	O
her	O
admission	O
to	O
the	O
coronary	O
unit	O
,	O
she	O
remained	O
asymptomatic	O
,	O
coronary	O
angiography	O
performed	O
12	O
hours	O
after	O
admission	O
ruled	O
out	O
obstructive	O
coronary	O
artery	O
disease	O
.	O
A	O
repeat	O
transthoracic	O
echocardiogram	O
TTE	O
was	O
performed	O
24	O
hours	O
later	O
,	O
with	O
normal	O
biventricular	O
function	O
persisting	O
,	O
without	O
segmental	O
contractility	O
defects	O
or	O
pericardial	O
effusion	O
.	O
Myocardial	O
injury	O
markers	O
remained	O
elevated	O
in	O
plateau	O
for	O
the	O
next	O
48	O
hours	O
.	O
Platelet	O
antiplatelet	O
therapy	O
was	O
maintained	O
with	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
,	O
due	O
to	O
suspicion	O
of	O
NOCA	O
PT	O
,	O
and	O
ACE	O
inhibitors	O
were	O
started	O
due	O
to	O
a	O
tendency	O
to	O
hypertension	O
HT	O
with	O
good	O
tolerance	O
,	O
as	O
well	O
as	O
a	O
high	O
potency	O
statin	O
.	O
The	O
clinical	O
evolution	O
was	O
satisfactory	O
,	O
remaining	O
haemodynamically	O
stable	O
without	O
signs	O
of	O
heart	O
failure	O
,	O
afebrile	O
,	O
without	O
anginal	O
recurrence	O
and	O
without	O
ventricular	O
arrhythmias	O
on	O
continuous	O
cardiac	O
monitoring	O
.	O
Since	O
CMR	O
was	O
not	O
possible	O
during	O
admission	O
,	O
he	O
was	O
scheduled	O
for	O
outpatient	O
surgery	O
15	O
days	O
later	O
.	O
CMR	O
showed	O
anterolateral	O
and	O
inferior	O
subepicardial	O
fibrosis	O
compatible	O
with	O
clinical	O
suspicion	O
of	O
myocarditis	O
,	O
so	O
antiplatelet	O
treatment	O
and	O
statin	O
was	O
withdrawn	O
.	O
During	O
follow	O
up	O
,	O
the	O
patient	O
suffered	O
some	O
epigastric	O
discomfort	O
with	O
a	O
non	O
coronary	O
profile	O
and	O
palpitations	O
,	O
with	O
no	O
evidence	O
of	O
ventricular	O
arrhythmias	O
on	O
Holter	O
and	O
normal	O
residual	O
ventricular	O
function	O
.	O
DIAGNOSIS	O
Acute	O
myocarditis	O
.	O
Preserved	O
left	O
ventricular	O
systolic	O
function	O
without	O
segmental	O
alterations	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
44	O
year	O
old	O
woman	O
.	O
History	O
No	O
cardiovascular	O
risk	O
factors	O
CVRF	O
or	O
toxic	O
habits	O
.	O
Obstetric	O
history	O
two	O
miscarriages	O
,	O
several	O
assisted	O
reproduction	O
processes	O
and	O
one	O
spontaneous	O
delivery	O
.	O
Hysterectomy	O
and	O
double	O
adnexectomy	O
for	O
endocervical	O
adenocarcinoma	O
.	O
She	O
does	O
not	O
undergo	O
treatment	O
on	O
a	O
regular	O
basis	O
.	O
Current	O
illness	O
No	O
previous	O
cardiological	O
symptoms	O
.	O
On	O
the	O
day	O
of	O
admission	O
,	O
she	O
consulted	O
the	O
emergency	O
department	O
for	O
an	O
episode	O
of	O
intense	O
and	O
prolonged	O
chest	O
tightness	O
1	O
hour	O
,	O
radiating	O
to	O
the	O
neck	O
and	O
upper	O
limbs	O
,	O
while	O
walking	O
,	O
without	O
associated	O
vegetative	O
cortex	O
.	O
An	O
electrocardiogram	O
ECG	O
was	O
performed	O
showing	O
an	O
inferolateral	O
subendocardial	O
lesion	O
and	O
serum	O
markers	O
of	O
myocardial	O
damage	O
were	O
found	O
to	O
be	O
elevated	O
.	O
Admission	O
to	O
cardiology	O
for	O
acute	O
myocardial	O
infarction	O
AMI	O
without	O
ST	O
elevation	O
.	O
Physical	O
examination	O
On	O
arrival	O
,	O
haemodynamically	O
stable	O
with	O
blood	O
pressure	O
120	O
60	O
mmHg	O
,	O
heart	O
rate	O
65	O
bpm	O
.	O
No	O
jugular	O
venous	O
engorgement	O
.	O
Normal	O
cardiorespiratory	O
auscultation	O
,	O
no	O
murmurs	O
.	O
Lower	O
limbs	O
without	O
oedema	O
.	O
Radial	O
and	O
femoral	O
pulses	O
present	O
and	O
symmetrical	O
.	O
COMPLEMENTARY	O
TESTS	O
CBC	O
haemoglobin	O
12	O
.	O
6	O
g	O
dl	O
,	O
platelets	O
199	O
,	O
000	O
x	O
10	O
3	O
l	O
,	O
leukocytes	O
6	O
,	O
220	O
x	O
10	O
3	O
l	O
with	O
normal	O
formula	O
.	O
Coagulation	O
TTPa	O
Ratio	O
1	O
,	O
08	O
,	O
INR	O
1	O
,	O
03	O
.	O
Biochemistry	O
glucose	O
104	O
mg	O
dl	O
;	O
urea	O
24	O
.	O
6	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
61	O
mg	O
dl	O
,	O
sodium	O
145	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
33	O
mEq	O
l	O
,	O
initial	O
TnT	O
54	O
ng	O
l	O
,	O
peak	O
134	O
ng	O
l	O
normal	O
15	O
ng	O
l	O
,	O
glycosylated	O
haemoglobin	O
5	O
.	O
9	O
,	O
total	O
cholesterol	O
203	O
mg	O
dl	O
,	O
HDL	O
59	O
mg	O
dl	O
,	O
LDL	O
124	O
mg	O
dl	O
,	O
TG	O
98	O
mg	O
dl	O
,	O
non	O
HDL	O
143	O
mg	O
dl	O
.	O
SARS	O
CoV	O
2	O
RNA	O
detection	O
nasopharyngeal	O
exudate	O
negative	O
.	O
Emergency	O
ECG	O
sinus	O
rhythm	O
at	O
65	O
bpm	O
.	O
Normal	O
and	O
constant	O
PR	O
.	O
Narrow	O
QRS	O
,	O
normal	O
axis	O
.	O
Scarce	O
R	O
wave	O
progression	O
in	O
precordial	O
leads	O
,	O
inferolateral	O
subendocardial	O
lesion	O
with	O
subepicardial	O
ischaemia	O
.	O
Chest	O
X	O
ray	O
in	O
the	O
emergency	O
department	O
normal	O
cardiothoracic	O
index	O
,	O
free	O
costophrenic	O
sinuses	O
,	O
no	O
parenchymal	O
infiltrates	O
,	O
no	O
bone	O
or	O
pleural	O
alterations	O
.	O
ECG	O
on	O
the	O
cardiology	O
ward	O
,	O
first	O
admission	O
sinus	O
rhythm	O
at	O
70	O
bpm	O
.	O
Normal	O
and	O
constant	O
PR	O
.	O
Narrow	O
QRS	O
.	O
Subepicardial	O
lesion	O
of	O
up	O
to	O
4	O
mm	O
in	O
the	O
anterior	O
face	O
.	O
First	O
emergency	O
catheterisation	O
left	O
main	O
coronary	O
artery	O
LMCA	O
without	O
lesions	O
.	O
Anterior	O
descending	O
artery	O
ADA	O
with	O
diffuse	O
lumen	O
involvement	O
and	O
occlusion	O
at	O
the	O
beginning	O
of	O
the	O
distal	O
segment	O
with	O
TIMI	O
0	O
distal	O
flow	O
,	O
suggesting	O
spontaneous	O
haematoma	O
dissection	O
.	O
Circumflex	O
artery	O
Cx	O
with	O
diffuse	O
involvement	O
of	O
the	O
lumen	O
also	O
,	O
somewhat	O
more	O
marked	O
in	O
the	O
middle	O
third	O
.	O
Right	O
coronary	O
artery	O
RCA	O
dominant	O
,	O
with	O
no	O
lesions	O
and	O
smooth	O
contours	O
.	O
Angioplasty	O
on	O
RCA	O
the	O
guidewire	O
progresses	O
but	O
appears	O
to	O
be	O
in	O
false	O
lumen	O
.	O
Intravascular	O
ultrasound	O
IVUS	O
was	O
performed	O
,	O
which	O
confirmed	O
that	O
it	O
was	O
a	O
coronary	O
dissection	O
with	O
haematoma	O
from	O
the	O
origin	O
of	O
the	O
artery	O
,	O
and	O
that	O
the	O
guidewire	O
was	O
in	O
false	O
lumen	O
,	O
with	O
collapsed	O
true	O
lumen	O
.	O
An	O
attempt	O
was	O
made	O
to	O
pass	O
the	O
guidewire	O
to	O
the	O
true	O
lumen	O
with	O
a	O
Sasuke	O
double	O
lumen	O
catheter	O
,	O
but	O
without	O
success	O
.	O
IVUS	O
was	O
repeated	O
and	O
the	O
patient	O
recovered	O
distal	O
TIMI	O
3	O
flow	O
,	O
with	O
spiroid	O
dissection	O
of	O
the	O
ADA	O
in	O
the	O
mid	O
distal	O
third	O
.	O
As	O
the	O
patient	O
had	O
no	O
chest	O
pain	O
and	O
isoelectric	O
ST	O
,	O
it	O
was	O
decided	O
not	O
to	O
continue	O
with	O
the	O
intervention	O
.	O
Angio	O
CT	O
of	O
the	O
supra	O
aortic	O
trunks	O
and	O
aorta	O
study	O
within	O
the	O
normal	O
range	O
.	O
The	O
ascending	O
aorta	O
,	O
aortic	O
arch	O
and	O
descending	O
aorta	O
and	O
their	O
visceral	O
branches	O
showed	O
no	O
abnormalities	O
.	O
Emergency	O
ECG	O
,	O
readmission	O
sinus	O
rhythm	O
60	O
bpm	O
.	O
Normal	O
and	O
constant	O
PR	O
.	O
Narrow	O
QRS	O
,	O
axis	O
at	O
0o	O
.	O
Subepicardial	O
lesion	O
in	O
high	O
lateral	O
face	O
with	O
associated	O
subepicardial	O
ischaemia	O
,	O
specular	O
descent	O
in	O
inferior	O
face	O
,	O
subendocardial	O
lesion	O
in	O
anterior	O
face	O
with	O
subepicardial	O
ischaemia	O
up	O
to	O
V4	O
.	O
Second	O
emergency	O
catheterisation	O
small	O
calibre	O
LMCA	O
due	O
to	O
intramural	O
haematoma	O
verified	O
by	O
IVUS	O
extending	O
towards	O
LAD	O
and	O
Cx	O
with	O
involvement	O
of	O
proximal	O
segments	O
of	O
both	O
.	O
LAD	O
with	O
intramural	O
haematoma	O
up	O
to	O
the	O
beginning	O
of	O
the	O
middle	O
segment	O
where	O
a	O
double	O
lumen	O
is	O
seen	O
,	O
similar	O
to	O
the	O
final	O
result	O
of	O
previous	O
PCI	O
,	O
with	O
TIMI	O
3	O
flow	O
and	O
proven	O
by	O
IVUS	O
.	O
Cx	O
with	O
intramural	O
haematoma	O
compressing	O
its	O
lumen	O
and	O
causing	O
a	O
pseudo	O
occlusion	O
of	O
the	O
marginal	O
branch	O
previously	O
not	O
present	O
with	O
TIMI	O
1	O
flow	O
lesion	O
responsible	O
.	O
Dominant	O
ACD	O
,	O
intramural	O
haematoma	O
type	O
guidewire	O
progresses	O
to	O
ADA	O
,	O
Cx	O
and	O
OM	O
.	O
PCI	O
is	O
performed	O
with	O
simple	O
balloon	O
in	O
OM	O
Pantera	O
pro	O
2	O
x	O
20	O
mm	O
at	O
8	O
atm	O
and	O
in	O
Cx	O
,	O
then	O
by	O
cutting	O
balloon	O
Wolverine	O
2	O
x	O
10	O
mm	O
at	O
12	O
atm	O
with	O
kissing	O
,	O
and	O
ends	O
with	O
simple	O
balloon	O
in	O
Cx	O
somewhat	O
more	O
distal	O
due	O
to	O
displacement	O
of	O
the	O
haematoma	O
Mozec	O
1	O
.	O
5	O
x	O
15	O
mm	O
at	O
8	O
atm	O
.	O
Coronary	O
CT	O
angiography	O
images	O
4	O
A	O
and	O
B	O
Coronary	O
CT	O
angiography	O
after	O
second	O
admission	O
Thrombosis	O
of	O
the	O
false	O
lumen	O
is	O
observed	O
in	O
the	O
IVC	O
,	O
which	O
conditions	O
the	O
filiform	O
calibre	O
of	O
the	O
true	O
lumen	O
.	O
DA	O
proximal	O
proximal	O
third	O
filiform	O
lumen	O
due	O
to	O
thrombosis	O
of	O
the	O
false	O
lumen	O
.	O
Cx	O
thrombosis	O
of	O
the	O
false	O
lumen	O
and	O
the	O
proximal	O
proximal	O
proximal	O
lumen	O
.	O
Control	O
coronary	O
CT	O
angiography	O
at	O
3	O
weeks	O
TCI	O
short	O
with	O
normalisation	O
of	O
the	O
luminal	O
diameter	O
.	O
ADA	O
notable	O
improvement	O
in	O
vessel	O
calibre	O
with	O
persistence	O
only	O
at	O
the	O
ostial	O
level	O
of	O
thrombosis	O
of	O
the	O
false	O
lumen	O
.	O
Intimal	O
flap	O
still	O
present	O
from	O
the	O
middle	O
1	O
3	O
with	O
good	O
filling	O
of	O
the	O
distal	O
vessel	O
.	O
Cx	O
normalisation	O
of	O
the	O
vessel	O
lumen	O
with	O
no	O
evident	O
signs	O
of	O
dissection	O
at	O
present	O
.	O
ACD	O
no	O
evidence	O
of	O
lesions	O
or	O
images	O
of	O
dissection	O
.	O
DP	O
and	O
PL	O
branches	O
without	O
lesions	O
.	O
CLINICAL	O
EVOLUTION	O
During	O
his	O
stay	O
on	O
the	O
cardiology	O
ward	O
he	O
presented	O
with	O
angina	O
at	O
rest	O
with	O
vegetative	O
cortex	O
and	O
in	O
the	O
ECG	O
an	O
anterior	O
subepicardial	O
lesion	O
of	O
up	O
to	O
4	O
mm	O
in	O
V2	O
,	O
for	O
which	O
urgent	O
coronary	O
angiography	O
was	O
performed	O
where	O
,	O
with	O
the	O
aid	O
of	O
IVUS	O
,	O
an	O
image	O
of	O
spontaneous	O
coronary	O
artery	O
dissection	O
SCD	O
with	O
mural	O
haematoma	O
was	O
observed	O
extending	O
from	O
LMCA	O
towards	O
Cx	O
with	O
TIMI	O
3	O
flow	O
and	O
towards	O
the	O
LAD	O
with	O
distal	O
occlusion	O
.	O
Final	O
TIMI	O
3	O
flow	O
was	O
achieved	O
after	O
passing	O
the	O
angioplasty	O
guidewire	O
without	O
stent	O
implantation	O
,	O
but	O
spiroid	O
dissection	O
persisted	O
in	O
the	O
mid	O
distal	O
segment	O
.	O
Angio	O
CT	O
of	O
the	O
supra	O
aortic	O
and	O
aortic	O
trunks	O
was	O
performed	O
without	O
detecting	O
extracoronary	O
vascular	O
lesions	O
,	O
at	O
discharge	O
echocardiography	O
without	O
segmentarism	O
and	O
with	O
preserved	O
ejection	O
fraction	O
.	O
The	O
possibility	O
of	O
an	O
underlying	O
antiphospholipid	O
syndrome	O
was	O
not	O
ruled	O
out	O
,	O
so	O
after	O
completing	O
1	O
week	O
of	O
double	O
antiplatelet	O
therapy	O
and	O
anticoagulation	O
,	O
he	O
was	O
discharged	O
with	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
and	O
low	B-FARMACO
molecular	I-FARMACO
weight	I-FARMACO
heparin	I-FARMACO
until	O
the	O
hypercoagulability	O
study	O
was	O
completed	O
.	O
However	O
,	O
two	O
days	O
after	O
discharge	O
from	O
hospital	O
,	O
she	O
went	O
to	O
the	O
emergency	O
department	O
for	O
oppressive	O
chest	O
pain	O
radiating	O
to	O
the	O
upper	O
limbs	O
with	O
vegetative	O
cortex	O
,	O
in	O
ECG	O
lateral	O
subepicardial	O
lesion	O
,	O
activating	O
AMI	O
code	O
.	O
Coronary	O
angiography	O
with	O
progression	O
of	O
dissection	O
to	O
LMCA	O
verified	O
by	O
IVUS	O
,	O
intramural	O
haematoma	O
in	O
circumflex	O
artery	O
causing	O
pseudo	O
occlusion	O
of	O
marginal	O
branch	O
culprit	O
lesion	O
;	O
angioplasty	O
with	O
simple	O
balloon	O
and	O
cutting	O
balloon	O
was	O
performed	O
with	O
resolution	O
of	O
the	O
occlusion	O
.	O
A	O
coronary	O
angio	O
CT	O
scan	O
was	O
performed	O
3	O
weeks	O
apart	O
,	O
the	O
first	O
during	O
the	O
last	O
admission	O
,	O
and	O
after	O
discharge	O
home	O
,	O
showing	O
an	O
improvement	O
in	O
the	O
intramural	O
haematoma	O
,	O
with	O
persistent	O
intimal	O
flap	O
from	O
the	O
middle	O
third	O
of	O
the	O
anterior	O
descending	O
artery	O
and	O
thrombosis	O
of	O
the	O
false	O
lumen	O
at	O
the	O
proximal	O
anterior	O
descending	O
artery	O
.	O
On	O
discharge	O
,	O
double	O
antiplatelet	O
therapy	O
was	O
maintained	O
for	O
3	O
months	O
until	O
a	O
subsequent	O
review	O
,	O
and	O
treatment	O
was	O
prescribed	O
with	O
statins	O
,	O
beta	O
blockers	O
and	O
nitrates	O
.	O
DIAGNOSIS	O
Spontaneous	O
coronary	O
artery	O
dissection	O
in	O
the	O
left	O
coronary	O
tree	O
due	O
to	O
intramural	O
haematoma	O
Acute	O
myocardial	O
infarction	O
with	O
anterior	O
ST	O
elevation	O
.	O
Spontaneous	O
coronary	O
artery	O
dissection	O
with	O
occlusion	O
of	O
distal	O
anterior	O
descending	O
artery	O
,	O
recovery	O
of	O
TIMI	O
3	O
flow	O
by	O
low	O
pressure	O
balloon	O
angioplasty	O
and	O
coronary	O
guidewire	O
without	O
stent	O
implantation	O
.	O
90	O
minutes	O
of	O
ischaemia	O
.	O
Recurrence	O
of	O
acute	O
myocardial	O
infarction	O
with	O
lateral	O
ST	O
elevation	O
.	O
Successful	O
primary	O
balloon	O
angioplasty	O
in	O
obtuse	O
marginal	O
circumflex	O
bifurcation	O
.	O
Preserved	O
biventricular	O
ejection	O
fraction	O
.	O
Angio	O
CT	O
without	O
extracoronary	O
arterial	O
anomalies	O
.	O
Prediabetes	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
Allergy	O
to	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
.	O
Cardiovascular	O
risk	O
factors	O
hypertension	O
.	O
Ex	O
smoker	O
for	O
7	O
years	O
,	O
previously	O
smoked	O
10	O
cigarettes	O
a	O
day	O
.	O
No	O
cardiological	O
history	O
.	O
Other	O
history	O
intraocular	O
hypertension	O
.	O
Seasonal	O
allergic	O
rhinitis	O
.	O
Usual	O
treatment	O
enalapril	B-FARMACO
10	O
mg	O
1	O
tablet	O
per	O
day	O
,	O
rupatadine	B-FARMACO
fumarate	I-FARMACO
10	O
mg	O
1	O
tablet	O
per	O
day	O
,	O
latanoprost	B-FARMACO
50	O
mcg	O
ml	O
1	O
ophthalmic	O
single	O
dose	O
pack	O
per	O
day	O
Baseline	O
independent	O
for	O
activities	O
of	O
daily	O
living	O
.	O
Active	O
life	O
.	O
No	O
cognitive	O
impairment	O
.	O
Present	O
illness	O
A	O
71	O
year	O
old	O
man	O
came	O
to	O
the	O
emergency	O
department	O
with	O
clinical	O
manifestations	O
of	O
weakness	O
and	O
clumsiness	O
in	O
the	O
right	O
upper	O
limb	O
on	O
waking	O
up	O
in	O
the	O
morning	O
,	O
perceived	O
as	O
being	O
unable	O
to	O
turn	O
off	O
the	O
alarm	O
clock	O
.	O
When	O
trying	O
to	O
get	O
out	O
of	O
bed	O
,	O
he	O
fell	O
to	O
the	O
floor	O
due	O
to	O
weakness	O
in	O
the	O
right	O
lower	O
limb	O
.	O
In	O
addition	O
,	O
there	O
was	O
a	O
deviation	O
of	O
the	O
corner	O
of	O
the	O
mouth	O
to	O
the	O
right	O
.	O
He	O
reported	O
very	O
slight	O
improvement	O
in	O
these	O
symptoms	O
during	O
his	O
stay	O
in	O
the	O
emergency	O
room	O
.	O
Asymptomatic	O
when	O
he	O
began	O
to	O
rest	O
at	O
night	O
the	O
previous	O
night	O
.	O
No	O
thermometric	O
fever	O
or	O
dysthermic	O
sensation	O
.	O
No	O
chest	O
pain	O
,	O
dyspnoea	O
or	O
palpitations	O
.	O
Physical	O
examination	O
Good	O
general	O
condition	O
.	O
Normal	O
colour	O
of	O
skin	O
and	O
mucous	O
membranes	O
.	O
Adequate	O
nutrition	O
and	O
hydration	O
.	O
No	O
rash	O
or	O
petechiae	O
.	O
No	O
lymphadenopathies	O
.	O
Eupneic	O
at	O
rest	O
.	O
Blood	O
pressure	O
BP	O
159	O
94	O
mmHg	O
;	O
heart	O
rate	O
HR	O
79	O
bpm	O
;	O
oxygen	O
saturation	O
97	O
aa	O
;	O
blood	O
glucose	O
118	O
mg	O
dl	O
;	O
temperature	O
36	O
.	O
6	O
oC	O
.	O
Cardiac	O
auscultation	O
regular	O
sounds	O
without	O
murmurs	O
.	O
Respiratory	O
auscultation	O
preserved	O
vesicular	O
murmur	O
,	O
no	O
pathological	O
sounds	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
,	O
non	O
painful	O
,	O
with	O
no	O
signs	O
of	O
peritoneal	O
irritation	O
and	O
no	O
evidence	O
of	O
visceromegaly	O
or	O
masses	O
.	O
Lower	O
extremities	O
without	O
oedema	O
and	O
with	O
present	O
and	O
symmetrical	O
pulses	O
.	O
Neurological	O
examination	O
NIHSS	O
2	O
.	O
Conscious	O
and	O
oriented	O
with	O
preserved	O
language	O
.	O
Discrete	O
dysarthria	O
.	O
Pupils	O
isochoric	O
and	O
normoreactive	O
.	O
Normal	O
confrontational	O
campimetry	O
.	O
Normal	O
extrinsic	O
ocular	O
motility	O
.	O
Deviation	O
of	O
the	O
oral	O
commissure	O
to	O
the	O
right	O
with	O
disappearance	O
of	O
the	O
left	O
nasolabial	O
fold	O
.	O
No	O
signs	O
of	O
meningeal	O
irritation	O
.	O
No	O
carotid	O
murmurs	O
were	O
heard	O
.	O
Strength	O
in	O
MSD	O
4	O
5	O
,	O
MID	O
4	O
5	O
,	O
MSI	O
5	O
5	O
,	O
MII	O
5	O
5	O
.	O
Sensibility	O
and	O
reflexes	O
normal	O
.	O
Plantar	O
cutaneous	O
reflexes	O
in	O
flexion	O
.	O
No	O
dysmetria	O
or	O
adiodokinesia	O
.	O
Romberg	O
negative	O
,	O
with	O
no	O
alterations	O
in	O
gait	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
sinus	O
rhythm	O
at	O
58	O
bpm	O
,	O
PR	O
200	O
ms	O
,	O
left	O
bundle	O
branch	O
block	O
type	O
ventricular	O
conduction	O
disorder	O
.	O
Blood	O
tests	O
haemoglobin	O
15	O
.	O
5	O
g	O
dl	O
,	O
haematocrit	O
45	O
.	O
4	O
,	O
mean	O
corpuscular	O
volume	O
90	O
.	O
7	O
fl	O
,	O
mean	O
corpuscular	O
haemoglobin	O
30	O
.	O
9	O
pg	O
,	O
leukocytes	O
6300	O
ml	O
,	O
neutrophils	O
3500	O
ml	O
,	O
lymphocytes	O
1700	O
ml	O
,	O
monocytes	O
600	O
ml	O
,	O
platelets	O
240000	O
ml	O
.	O
Coagulation	O
partial	O
thromboplastin	O
time	O
PTT	O
29	O
.	O
8	O
s	O
,	O
thromboplastin	O
time	O
ratio	O
1	O
.	O
02	O
,	O
fibrinogen	O
248	O
mg	O
dl	O
,	O
INR	O
1	O
.	O
0	O
.	O
Biochemistry	O
glucose	O
135	O
mg	O
dl	O
,	O
urea	O
31	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
11	O
mg	O
dl	O
,	O
glomerular	O
filtration	O
rate	O
60	O
ml	O
min	O
m2	O
,	O
sodium	O
140	O
mmol	O
l	O
,	O
potassium	O
3	O
.	O
8	O
mmol	O
l	O
,	O
total	O
bilirubin	O
0	O
.	O
6	O
mg	O
dl	O
,	O
ALT	O
26	O
U	O
l	O
,	O
CK	O
70	O
U	O
l	O
,	O
amylase	O
71	O
U	O
l	O
,	O
C	O
reactive	O
protein	O
1	O
mg	O
l	O
.	O
Posteroanterior	O
and	O
lateral	O
chest	O
X	O
ray	O
normal	O
cardiothoracic	O
index	O
.	O
Elongation	O
of	O
the	O
aorta	O
.	O
Thickening	O
of	O
the	O
peribronchovascular	O
interstitium	O
,	O
without	O
identifying	O
areas	O
of	O
consolidation	O
or	O
pleural	O
effusion	O
.	O
No	O
other	O
significant	O
findings	O
in	O
lung	O
parenchyma	O
or	O
cardiomediastinal	O
silhouette	O
.	O
CT	O
scan	O
of	O
the	O
skull	O
without	O
contrast	O
and	O
cerebral	O
angio	O
CT	O
in	O
the	O
emergency	O
department	O
empty	O
cranial	O
CT	O
scan	O
hypoattenuation	O
of	O
periventricular	O
white	O
matter	O
in	O
relation	O
to	O
changes	O
due	O
to	O
chronic	O
hypoxic	O
ischaemic	O
encephalopathy	O
.	O
Rest	O
of	O
brain	O
and	O
cerebellar	O
parenchyma	O
unaltered	O
.	O
No	O
areas	O
of	O
intra	O
or	O
extra	O
axial	O
cerebral	O
haemorrhage	O
,	O
oedema	O
,	O
midline	O
deviation	O
or	O
hydrocephalus	O
.	O
No	O
lesions	O
in	O
the	O
calvarium	O
.	O
Signs	O
of	O
sinusopathy	O
with	O
mucosal	O
debris	O
occupying	O
bilateral	O
ethmoidal	O
cells	O
.	O
Cerebral	O
CT	O
angiography	O
of	O
the	O
supra	O
aortic	O
trunks	O
and	O
the	O
polygon	O
of	O
Willis	O
the	O
large	O
vessels	O
forming	O
the	O
supra	O
aortic	O
trunks	O
and	O
the	O
polygon	O
of	O
Willis	O
were	O
patent	O
and	O
of	O
normal	O
calibre	O
,	O
with	O
no	O
occlusions	O
,	O
images	O
of	O
stenosis	O
or	O
aneurysms	O
.	O
Lipoma	O
measuring	O
10	O
x	O
5	O
mm	O
on	O
the	O
inferior	O
aspect	O
of	O
the	O
right	O
sternocleidomastoid	O
muscle	O
.	O
Cervical	O
degenerative	O
changes	O
.	O
Other	O
structures	O
included	O
in	O
the	O
study	O
,	O
with	O
no	O
other	O
significant	O
findings	O
.	O
Brain	O
magnetic	O
resonance	O
imaging	O
MRI	O
and	O
angio	O
MRI	O
images	O
2	O
,	O
3	O
and	O
4	O
scan	O
performed	O
without	O
and	O
after	O
administration	O
of	O
IVC	O
there	O
are	O
multiple	O
foci	O
of	O
diffusion	O
restriction	O
due	O
to	O
acute	O
ischaemia	O
distributed	O
dispersed	O
throughout	O
the	O
right	O
midbrain	O
territory	O
with	O
both	O
cortical	O
and	O
deep	O
involvement	O
.	O
Although	O
smaller	O
in	O
number	O
and	O
volume	O
,	O
there	O
were	O
also	O
multiple	O
foci	O
of	O
acute	O
ischaemia	O
in	O
the	O
posterior	O
border	O
territory	O
of	O
the	O
left	O
hemisphere	O
.	O
No	O
signs	O
of	O
haemorrhagic	O
complications	O
.	O
Vascular	O
examination	O
showed	O
no	O
significant	O
stenotic	O
pathology	O
in	O
supra	O
aortic	O
trunks	O
or	O
structures	O
of	O
the	O
polygon	O
of	O
Willis	O
.	O
Holter	O
sinus	O
rhythm	O
throughout	O
the	O
recording	O
.	O
Mean	O
heart	O
rate	O
75	O
bpm	O
,	O
minimum	O
heart	O
rate	O
of	O
44	O
bpm	O
and	O
maximum	O
of	O
110	O
bpm	O
.	O
There	O
was	O
a	O
ventricular	O
conduction	O
disorder	O
such	O
as	O
left	O
bundle	O
branch	O
block	O
and	O
PR	O
at	O
the	O
limit	O
.	O
No	O
signs	O
of	O
high	O
grade	O
atrioventricular	O
block	O
.	O
Maximum	O
RR	O
1	O
.	O
15	O
s	O
.	O
Conclusion	O
intraventricular	O
disorder	O
without	O
arrhythmias	O
with	O
cardioembolic	O
potential	O
.	O
Transthoracic	O
echocardiography	O
mild	O
concentric	O
hypertrophy	O
of	O
the	O
left	O
ventricle	O
with	O
preserved	O
global	O
systolic	O
function	O
.	O
Abnormal	O
septobasal	O
movement	O
,	O
without	O
other	O
alterations	O
of	O
segmental	O
contractility	O
at	O
rest	O
.	O
Absence	O
of	O
significant	O
valvular	O
heart	O
disease	O
.	O
Transmitral	O
filling	O
pattern	O
of	O
impaired	O
relaxation	O
without	O
signs	O
of	O
increased	O
left	O
ventricular	O
filling	O
pressures	O
.	O
Normal	O
right	O
ventricle	O
.	O
Mild	O
tricuspid	O
insufficiency	O
allowing	O
estimation	O
of	O
pulmonary	O
systolic	O
pressure	O
of	O
approximately	O
35	O
mmHg	O
.	O
Transesophageal	O
echocardiography	O
transesophageal	O
exploration	O
carried	O
out	O
after	O
sedation	O
with	O
midazolam	B-FARMACO
i	O
.	O
v	O
.	O
6	O
mg	O
,	O
without	O
complications	O
.	O
Vibrating	O
,	O
filamentous	O
mass	O
of	O
intermediate	O
echorefringence	O
,	O
approximately	O
6	O
x	O
2	O
.	O
5	O
mm	O
in	O
size	O
on	O
the	O
ventricular	O
side	O
of	O
the	O
aortic	O
valve	O
,	O
suggestive	O
of	O
papillary	O
fibroelastoma	O
.	O
Normal	O
transvalvular	O
aortic	O
flow	O
.	O
Left	O
aortic	O
valve	O
free	O
of	O
thrombus	O
.	O
No	O
shunt	O
through	O
the	O
interatrial	O
septum	O
after	O
administration	O
of	O
agitated	O
saline	O
.	O
The	O
rest	O
of	O
the	O
study	O
is	O
superimposable	O
to	O
the	O
transthoracic	O
examination	O
.	O
CLINICAL	O
EVOLUTION	O
In	O
summary	O
,	O
this	O
is	O
a	O
71	O
year	O
old	O
man	O
who	O
was	O
admitted	O
to	O
the	O
neurology	O
department	O
for	O
a	O
picture	O
of	O
neurological	O
focality	O
of	O
sudden	O
onset	O
consisting	O
of	O
weakness	O
of	O
the	O
right	O
lower	O
and	O
upper	O
limbs	O
and	O
facial	O
asymmetry	O
,	O
with	O
progressive	O
resolution	O
during	O
hospitalisation	O
.	O
As	O
for	O
the	O
aetiological	O
study	O
,	O
cerebral	O
magnetic	O
resonance	O
imaging	O
revealed	O
multiple	O
cortical	O
and	O
deep	O
ischaemic	O
lesions	O
in	O
the	O
territory	O
of	O
both	O
middle	O
cerebral	O
arteries	O
.	O
In	O
view	O
of	O
the	O
suspected	O
cardioembolic	O
aetiology	O
,	O
the	O
cardiology	O
department	O
was	O
contacted	O
to	O
complete	O
the	O
study	O
.	O
During	O
her	O
hospital	O
stay	O
,	O
electrocardiographic	O
monitoring	O
by	O
Holter	O
,	O
which	O
showed	O
no	O
arrhythmias	O
suggestive	O
of	O
causing	O
the	O
current	O
clinical	O
picture	O
,	O
and	O
transthoracic	O
and	O
transesophageal	O
echocardiography	O
,	O
the	O
latter	O
showing	O
a	O
lesion	O
in	O
the	O
aortic	O
valve	O
compatible	O
with	O
papillary	O
fibroelastoma	O
.	O
After	O
finding	O
evidence	O
of	O
this	O
lesion	O
,	O
the	O
cardiac	O
surgery	O
department	O
was	O
contacted	O
to	O
assess	O
the	O
case	O
.	O
Given	O
the	O
symptoms	O
of	O
embolic	O
origin	O
consisting	O
of	O
ischaemic	O
involvement	O
of	O
the	O
right	O
and	O
left	O
middle	O
cerebral	O
arteries	O
,	O
surgery	O
was	O
performed	O
consisting	O
of	O
resection	O
of	O
the	O
tumour	O
,	O
without	O
the	O
need	O
for	O
valve	O
repair	O
.	O
In	O
successive	O
outpatient	O
check	O
ups	O
,	O
the	O
patient	O
was	O
asymptomatic	O
,	O
with	O
no	O
evidence	O
of	O
new	O
embolic	O
phenomena	O
.	O
DIAGNOSIS	O
Biterritorial	O
ischaemic	O
stroke	O
both	O
middle	O
cerebral	O
arteries	O
of	O
cardioembolic	O
aetiology	O
secondary	O
to	O
aortic	O
fibroelastoma	O
.	O

77	O
year	O
old	O
male	O
seen	O
in	O
cardiology	O
outpatient	O
clinic	O
,	O
visit	O
1	O
after	O
admission	O
for	O
acute	O
myocardial	O
infarction	O
without	O
ST	O
segment	O
elevation	O
Killip	O
I	O
;	O
attention	O
is	O
drawn	O
to	O
poorly	O
controlled	O
insulin	O
dependent	O
diabetes	O
mellitus	O
.	O
HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
No	O
drug	O
allergies	O
.	O
Independent	O
for	O
basic	O
activities	O
of	O
daily	O
living	O
.	O
Smoker	O
15	O
cigarettes	O
a	O
day	O
until	O
the	O
date	O
of	O
the	O
infarction	O
he	O
reports	O
that	O
after	O
admission	O
he	O
started	O
smoking	O
again	O
but	O
now	O
only	O
smokes	O
5	O
cigarettes	O
a	O
day	O
.	O
Diabetes	O
mellitus	O
type	O
2	O
for	O
22	O
years	O
,	O
insulin	O
dependent	O
,	O
dyslipidaemia	O
,	O
hypertension	O
.	O
Chronic	O
kidney	O
disease	O
with	O
usual	O
glomerular	O
filtration	O
rate	O
GFR	O
47	O
ml	O
min	O
1	O
.	O
7m2	O
.	O
History	O
of	O
lumbar	O
malignant	O
melanoma	O
resected	O
10	O
years	O
ago	O
without	O
relapse	O
.	O
Benign	O
prostatic	O
hypertrophy	O
prostatectomy	O
10	O
years	O
ago	O
.	O
Usual	O
treatment	O
on	O
admission	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
100	O
mg	O
24	O
h	O
,	O
bisoprolol	B-FARMACO
5	O
mg	O
12	O
h	O
,	O
insulin	B-FARMACO
glargine	I-FARMACO
52	O
IU	O
24	O
h	O
,	O
metformin	B-FARMACO
sitagliptin	I-FARMACO
1000	O
50	O
mg	O
24	O
12	O
h	O
,	O
gembifrozil	B-FARMACO
900	O
mg	O
24	O
h	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
24	O
h	O
.	O
Patient	O
admitted	O
for	O
acute	O
myocardial	O
infarction	O
on	O
08	O
09	O
2020	O
,	O
with	O
symptoms	O
of	O
typical	O
chest	O
pain	O
without	O
dyspnoea	O
or	O
signs	O
of	O
heart	O
failure	O
.	O
The	O
electrocardiogram	O
ECG	O
,	O
in	O
sinus	O
rhythm	O
at	O
60	O
bpm	O
,	O
showed	O
negative	O
T	O
in	O
V3	O
V4	O
,	O
which	O
was	O
positive	O
on	O
discharge	O
,	O
with	O
a	O
peak	O
Tn	O
of	O
11051	O
.	O
The	O
admission	O
blood	O
test	O
showed	O
basal	O
glucose	O
133	O
,	O
creatinine	O
1	O
.	O
20	O
,	O
cholesterol	O
185	O
mg	O
dl	O
,	O
HDL	O
34	O
mg	O
dl	O
,	O
LDL	O
107	O
mg	O
dl	O
,	O
triglycerides	O
219	O
mg	O
dl	O
,	O
Hb	O
glycated	O
7	O
.	O
1	O
.	O
Coronary	O
catheterisation	O
showed	O
anterior	O
descending	O
artery	O
AD	O
of	O
good	O
calibre	O
and	O
extension	O
with	O
critical	O
lesion	O
in	O
proximal	O
middle	O
third	O
and	O
long	O
plaque	O
with	O
significant	O
stenosis	O
in	O
middle	O
third	O
that	O
conditions	O
TIMI	O
1	O
distal	O
flow	O
;	O
non	O
dominant	O
circumflex	O
artery	O
Cx	O
with	O
minimal	O
non	O
significant	O
plaque	O
in	O
middle	O
third	O
and	O
very	O
distal	O
borderline	O
plaque	O
with	O
scarce	O
distal	O
field	O
at	O
that	O
level	O
and	O
normal	O
distal	O
flow	O
;	O
dominant	O
right	O
coronary	O
artery	O
RCA	O
with	O
minimal	O
proximal	O
non	O
significant	O
plaque	O
and	O
distal	O
irregularity	O
.	O
Primary	O
angioplasty	O
with	O
implantation	O
of	O
two	O
drug	O
eluting	O
stents	O
in	O
the	O
proximomedial	O
LAD	O
and	O
mid	O
LAD	O
.	O
Echocardiography	O
was	O
performed	O
compatible	O
with	O
ischaemic	O
heart	O
disease	O
and	O
normal	O
LVEF	O
report	O
attached	O
.	O
Examination	O
revealed	O
a	O
systolic	O
murmur	O
II	O
VI	O
in	O
the	O
aortic	O
focus	O
and	O
grade	O
I	O
obesity	O
weight	O
103	O
kg	O
,	O
height	O
183	O
cm	O
,	O
body	O
mass	O
index	O
BMI	O
30	O
.	O
75	O
with	O
abdominal	O
circumference	O
112	O
cm	O
.	O
Treatment	O
at	O
hospital	O
discharge	O
omeprazole	B-FARMACO
20	O
g	O
24	O
h	O
,	O
ASA	B-FARMACO
100	O
mg	O
24	O
h	O
,	O
ticagrelor	B-FARMACO
90	O
mg	O
24	O
h	O
,	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
24	O
h	O
,	O
rosuvastatin	B-FARMACO
ezetimibe	I-FARMACO
20	O
10	O
mg	O
24	O
h	O
,	O
insulin	B-FARMACO
glargine	I-FARMACO
52	O
IU	O
24	O
h	O
and	O
metformin	B-FARMACO
sitagliptin	I-FARMACO
1000	O
50	O
mg	O
12	O
h	O
.	O
COMPLEMENTARY	O
TESTS	O
Admission	O
blood	O
tests	O
creatinine	O
1	O
.	O
25	O
GFR	O
58	O
ml	O
min	O
1	O
.	O
73	O
m2	O
,	O
cholesterol	O
185	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
34	O
mg	O
dl	O
,	O
LDL	O
cholesterol	O
107	O
mg	O
dl	O
,	O
triglycerides	O
219	O
mg	O
dl	O
,	O
glycated	O
haemoglobin	O
7	O
.	O
1	O
.	O
Coronary	O
catheterisation	O
coronary	O
catheterisation	O
showed	O
a	O
good	O
calibre	O
and	O
extension	O
LAD	O
with	O
critical	O
lesion	O
in	O
the	O
proximal	O
middle	O
third	O
and	O
long	O
plaque	O
with	O
significant	O
stenosis	O
in	O
the	O
middle	O
third	O
that	O
conditions	O
distal	O
flow	O
TIMI	O
1	O
;	O
non	O
dominant	O
Cx	O
with	O
minimal	O
non	O
significant	O
plaque	O
in	O
the	O
middle	O
third	O
and	O
very	O
distal	O
borderline	O
plaque	O
with	O
scant	O
distal	O
field	O
at	O
that	O
level	O
and	O
normal	O
distal	O
flow	O
;	O
dominant	O
DC	O
with	O
minimal	O
proximal	O
non	O
significant	O
plaque	O
and	O
distal	O
irregularity	O
.	O
Transthoracic	O
echocardiogram	O
TTE	O
moderate	O
left	O
ventricular	O
hypertrophy	O
LVH	O
septal	O
sigmoid	O
septum	O
,	O
strict	O
apical	O
and	O
apical	O
septal	O
akinesia	O
and	O
mid	O
septal	O
anterior	O
segment	O
hypokinesia	O
.	O
Normal	O
global	O
LVEF	O
.	O
Normal	O
aortic	O
valve	O
AoV	O
and	O
mitral	O
valve	O
MV	O
.	O
Grade	O
I	O
diastolic	O
dysfunction	O
.	O
Normal	O
left	O
atrium	O
LA	O
.	O
Right	O
ventricle	O
RV	O
of	O
normal	O
size	O
and	O
function	O
.	O
No	O
tricuspid	O
insufficiency	O
TI	O
.	O
Signs	O
of	O
normal	O
central	O
venous	O
pressure	O
CVP	O
.	O
No	O
pericardial	O
effusion	O
.	O
Aortic	O
root	O
of	O
normal	O
size	O
.	O
No	O
intracardiac	O
masses	O
.	O
Laboratory	O
tests	O
glycated	O
haemoglobin	O
8	O
.	O
2	O
,	O
haemoglobin	O
11	O
.	O
8	O
g	O
dl	O
,	O
total	O
cholesterol	O
92	O
mg	O
dl	O
,	O
HDL	O
36	O
mg	O
dl	O
,	O
LDL	O
cholesterol	O
17	O
.	O
13	O
mg	O
dl	O
.	O
CLINICAL	O
EVOLUTION	O
On	O
being	O
seen	O
at	O
our	O
clinic	O
,	O
the	O
patient	O
reported	O
no	O
new	O
chest	O
pains	O
,	O
gradual	O
return	O
to	O
normal	O
physical	O
activity	O
with	O
slight	O
dyspnoea	O
on	O
moderate	O
exertion	O
,	O
which	O
he	O
attributed	O
to	O
physical	O
deconditioning	O
.	O
She	O
has	O
gained	O
3	O
kg	O
current	O
weight	O
106	O
kg	O
,	O
BMI	O
31	O
.	O
7	O
.	O
In	O
control	O
laboratory	O
tests	O
,	O
glycated	O
haemoglobin	O
8	O
.	O
2	O
,	O
haemoglobin	O
11	O
.	O
8	O
g	O
dl	O
,	O
total	O
cholesterol	O
92	O
mg	O
dl	O
,	O
HDL	O
36	O
mg	O
dl	O
,	O
LDL	O
cholesterol	O
17	O
.	O
13	O
mg	O
dl	O
.	O
Dulaglutide	B-FARMACO
0	O
.	O
75	O
mg	O
subcutaneous	O
every	O
7	O
days	O
was	O
started	O
and	O
increased	O
to	O
1	O
.	O
5	O
mg	O
7	O
days	O
if	O
well	O
tolerated	O
.	O
Contact	O
was	O
made	O
with	O
primary	O
care	O
and	O
clinical	O
control	O
was	O
scheduled	O
with	O
daily	O
glycaemic	O
self	O
monitoring	O
for	O
possible	O
adjustment	O
of	O
the	O
insulin	B-FARMACO
regimen	O
and	O
to	O
check	O
tolerance	O
to	O
the	O
drug	O
.	O
Control	O
with	O
blood	O
tests	O
and	O
iron	O
studies	O
in	O
6	O
months	O
.	O
DIAGNOSIS	O
Acute	O
myocardial	O
infarction	O
without	O
ST	O
Killip	O
I	O
elevation	O
preserved	O
LVEF	O
.	O
Significant	O
coronary	O
artery	O
disease	O
of	O
a	O
main	O
vessel	O
.	O
Type	O
II	O
insulin	O
dependent	O
diabetes	O
mellitus	O
with	O
poor	O
metabolic	O
control	O
.	O
Obesity	O
grade	O
I	O
.	O
Smoking	O
.	O
Dyslipidaemia	O
.	O
Chronic	O
kidney	O
disease	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
39	O
year	O
old	O
woman	O
,	O
primigravida	O
at	O
9	O
weeks	O
,	O
with	O
a	O
personal	O
history	O
of	O
grade	O
II	O
obesity	O
and	O
severe	O
aortic	O
insufficiency	O
,	O
who	O
underwent	O
surgery	O
at	O
the	O
age	O
of	O
24	O
using	O
the	O
Tyrone	O
David	O
technique	O
replacement	O
of	O
ascending	O
aorta	O
with	O
valve	O
repair	O
.	O
At	O
the	O
age	O
of	O
29	O
,	O
a	O
new	O
operation	O
with	O
implantation	O
of	O
a	O
metallic	O
aortic	O
prosthesis	O
.	O
Usually	O
anticoagulated	O
with	O
acenocoumarol	B-FARMACO
,	O
at	O
the	O
beginning	O
of	O
pregnancy	O
she	O
started	O
treatment	O
with	O
low	B-FARMACO
molecular	I-FARMACO
weight	I-FARMACO
heparin	I-FARMACO
LMWH	I-FARMACO
with	O
a	O
regimen	O
of	O
enoxaparin	B-FARMACO
12	O
,	O
000	O
IU	O
120	O
mg	O
0	O
.	O
8	O
ml	O
once	O
a	O
day	O
.	O
In	O
addition	O
,	O
he	O
suffers	O
from	O
hypothyroidism	O
and	O
is	O
treated	O
with	O
levothyroxine	B-FARMACO
150	O
mcg	O
per	O
day	O
.	O
After	O
waking	O
up	O
in	O
the	O
morning	O
,	O
she	O
began	O
to	O
feel	O
pain	O
in	O
the	O
left	O
cervical	O
region	O
and	O
a	O
significant	O
sensation	O
of	O
corkiness	O
in	O
the	O
homolateral	O
side	O
of	O
the	O
face	O
,	O
associated	O
with	O
moderate	O
precordial	O
pain	O
radiating	O
to	O
the	O
left	O
shoulder	O
,	O
together	O
with	O
vomiting	O
.	O
Due	O
to	O
a	O
feeling	O
of	O
general	O
malaise	O
,	O
2	O
hours	O
after	O
the	O
onset	O
of	O
symptoms	O
,	O
she	O
decided	O
to	O
return	O
to	O
bed	O
and	O
after	O
sleeping	O
for	O
approximately	O
30	O
minutes	O
she	O
awoke	O
without	O
facial	O
paresthesia	O
,	O
however	O
,	O
given	O
that	O
she	O
continued	O
with	O
central	O
thoracic	O
discomfort	O
,	O
she	O
decided	O
to	O
consult	O
the	O
emergency	O
services	O
.	O
There	O
,	O
haemodynamic	O
stability	O
was	O
observed	O
with	O
blood	O
pressure	O
of	O
117	O
63	O
,	O
heart	O
rate	O
of	O
70	O
bpm	O
,	O
afebrile	O
state	O
and	O
baseline	O
oxygen	O
saturation	O
of	O
92	O
.	O
The	O
neurological	O
examination	O
ruled	O
out	O
focality	O
at	O
that	O
time	O
.	O
Cranial	O
nerves	O
were	O
preserved	O
and	O
pupils	O
were	O
isochoric	O
and	O
normoreactive	O
.	O
There	O
was	O
rhythmic	O
cardiac	O
auscultation	O
with	O
metallic	O
click	O
,	O
without	O
murmurs	O
and	O
respiratory	O
auscultation	O
with	O
preserved	O
vesicular	O
murmur	O
without	O
added	O
noises	O
.	O
The	O
abdomen	O
is	O
soft	O
,	O
depressible	O
and	O
painless	O
and	O
the	O
lower	O
limbs	O
show	O
no	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
On	O
arrival	O
,	O
an	O
electrocardiogram	O
ECG	O
was	O
performed	O
,	O
showing	O
ST	O
segment	O
rectification	O
in	O
the	O
inferior	O
face	O
of	O
approximately	O
0	O
.	O
5	O
mm	O
,	O
and	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
monitored	O
observation	O
room	O
.	O
Following	O
the	O
results	O
of	O
the	O
first	O
analysis	O
,	O
which	O
showed	O
elevated	O
markers	O
of	O
myocardial	O
damage	O
,	O
the	O
on	O
call	O
cardiologist	O
was	O
consulted	O
.	O
On	O
evaluation	O
,	O
a	O
new	O
ECG	O
was	O
performed	O
with	O
negative	O
T	O
waves	O
in	O
leads	O
V5	O
V6	O
and	O
in	O
II	O
,	O
III	O
and	O
aVF	O
.	O
A	O
transthoracic	O
echocardiogram	O
was	O
performed	O
showing	O
inferoapical	O
and	O
apical	O
segmental	O
contractility	O
defects	O
.	O
An	O
attempt	O
was	O
made	O
to	O
perform	O
a	O
transesophageal	O
echocardiogram	O
to	O
assess	O
the	O
mechanical	O
aortic	O
prosthesis	O
,	O
ruling	O
out	O
thrombosis	O
.	O
Due	O
to	O
the	O
analytical	O
,	O
echo	O
and	O
electrocardiographic	O
findings	O
,	O
a	O
diagnosis	O
of	O
high	O
risk	O
non	O
ST	O
segment	O
elevation	O
acute	O
coronary	O
syndrome	O
NSTEACS	O
was	O
made	O
and	O
early	O
coronary	O
angiography	O
was	O
requested	O
,	O
and	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
intensive	O
care	O
unit	O
ICU	O
for	O
continuous	O
monitoring	O
.	O
COMPLEMENTARY	O
TESTS	O
Initial	O
ECG	O
sinus	O
rhythm	O
at	O
74	O
bpm	O
,	O
normal	O
axis	O
,	O
isoelectric	O
ST	O
,	O
flattened	O
T	O
waves	O
in	O
III	O
and	O
aVF	O
but	O
positive	O
.	O
ECG	O
on	O
admission	O
to	O
ICU	O
sinus	O
rhythm	O
at	O
80	O
bpm	O
,	O
normal	O
axis	O
,	O
development	O
of	O
negative	O
T	O
waves	O
in	O
II	O
,	O
III	O
,	O
aVF	O
and	O
from	O
V3	O
to	O
V6	O
.	O
ST	O
elevation	O
1	O
mm	O
in	O
III	O
and	O
rectification	O
in	O
aVF	O
.	O
CBC	O
haemogram	O
leukocytes	O
7	O
.	O
7	O
thousands	O
l	O
,	O
segmented	O
74	O
5	O
.	O
7	O
thousands	O
l	O
,	O
lymphocytes	O
18	O
.	O
5	O
1	O
.	O
4	O
thousands	O
l	O
,	O
red	O
cells	O
4	O
.	O
23	O
million	O
l	O
,	O
haemoglobin	O
13	O
g	O
dl	O
,	O
haematocrit	O
38	O
.	O
5	O
,	O
MCV	O
91	O
.	O
1	O
fl	O
,	O
platelets	O
180	O
thousands	O
l	O
.	O
Coagulation	O
prothrombin	O
time	O
12	O
.	O
9	O
seconds	O
,	O
prothrombin	O
activity	O
80	O
.	O
0	O
,	O
aTTP	O
37	O
.	O
2	O
seconds	O
,	O
fibrinogen	O
638	O
mg	O
dl	O
,	O
INR	O
1	O
.	O
17	O
INR	O
.	O
Biochemistry	O
glucose	O
87	O
mg	O
dl	O
,	O
urea	O
10	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
51	O
mg	O
dl	O
,	O
estimated	O
glomerular	O
filtration	O
rate	O
MDRD	O
4	O
IDMS	O
60	O
ml	O
min	O
1	O
.	O
73	O
,	O
sodium	O
136	O
mmol	O
l	O
,	O
potassium	O
3	O
.	O
5	O
mmol	O
l	O
,	O
chlorine	O
107	O
mmol	O
l	O
,	O
magnesium	O
1	O
.	O
96	O
mg	O
dl	O
.	O
Peak	O
myocardial	O
damage	O
markers	O
CPK	O
783	O
IU	O
l	O
,	O
TnIhs	O
6953	O
.	O
3	O
ng	O
l	O
.	O
Anti	O
Xa	O
levels	O
1st	O
determination	O
0	O
.	O
71	O
IU	O
mL	O
;	O
2nd	O
determination	O
0	O
.	O
8	O
IU	O
mL	O
.	O
Transthoracic	O
echocardiogram	O
non	O
dilated	O
left	O
ventricle	O
without	O
significant	O
hypertrophy	O
,	O
subjectively	O
preserved	O
left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
with	O
dyskinesia	O
in	O
the	O
apex	O
,	O
distal	O
inferior	O
and	O
distal	O
septal	O
,	O
with	O
normal	O
diastolic	O
pattern	O
.	O
No	O
mitral	O
valvulopathy	O
.	O
Left	O
atrium	O
not	O
dilated	O
.	O
Mechanical	O
aortic	O
prosthesis	O
with	O
very	O
discrete	O
lavage	O
jets	O
and	O
with	O
parameters	O
of	O
GPAo	O
26	O
mmHg	O
,	O
GMAo	O
12	O
mmHg	O
,	O
LVOT	O
LVOT	O
Ao	O
ratio	O
of	O
0	O
.	O
6	O
no	O
stenosis	O
.	O
Right	O
ventricle	O
RV	O
not	O
dilated	O
with	O
normal	O
systolic	O
function	O
,	O
no	O
tricuspid	O
insufficiency	O
TI	O
to	O
estimate	O
pulmonary	O
arterial	O
systolic	O
pressure	O
PSAP	O
,	O
no	O
pericardial	O
effusion	O
.	O
Transesophageal	O
echocardiogram	O
TEE	O
videos	O
1	O
and	O
2	O
no	O
thrombosis	O
of	O
aortic	O
mechanical	O
prosthesis	O
.	O
Left	O
aortic	O
valve	O
without	O
thrombus	O
inside	O
.	O
Non	O
dilated	O
LV	O
with	O
no	O
thrombus	O
inside	O
.	O
Preferential	O
coronary	O
angiography	O
left	O
dominance	O
.	O
Left	O
main	O
coronary	O
artery	O
without	O
significant	O
stenosis	O
.	O
Anterior	O
descending	O
artery	O
of	O
good	O
calibre	O
and	O
development	O
,	O
with	O
an	O
image	O
compatible	O
with	O
an	O
embolus	O
in	O
the	O
very	O
distal	O
section	O
,	O
in	O
the	O
apex	O
and	O
when	O
the	O
vessel	O
is	O
already	O
of	O
fine	O
calibre	O
.	O
Circumflex	O
artery	O
of	O
good	O
calibre	O
and	O
development	O
,	O
dominant	O
,	O
angiographically	O
normal	O
.	O
Right	O
coronary	O
artery	O
of	O
small	O
calibre	O
and	O
development	O
,	O
non	O
dominant	O
,	O
without	O
lesions	O
.	O
Absence	O
of	O
significant	O
atherosclerotic	O
lesions	O
.	O
CT	O
scan	O
of	O
the	O
aorta	O
the	O
metallic	O
aortic	O
valve	O
prosthesis	O
and	O
the	O
post	O
surgical	O
changes	O
of	O
the	O
aortic	O
root	O
in	O
the	O
first	O
40	O
mm	O
are	O
observed	O
.	O
Along	O
the	O
entire	O
length	O
of	O
the	O
ascending	O
aorta	O
there	O
is	O
a	O
constant	O
diameter	O
of	O
30	O
mm	O
.	O
Although	O
optimal	O
aortic	O
lumen	O
density	O
has	O
not	O
been	O
reached	O
in	O
the	O
images	O
obtained	O
,	O
there	O
are	O
no	O
radiological	O
findings	O
suggestive	O
of	O
dissection	O
along	O
the	O
aorta	O
or	O
its	O
TSA	O
.	O
No	O
other	O
radiologically	O
significant	O
findings	O
were	O
found	O
with	O
this	O
imaging	O
technique	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
admitted	O
to	O
the	O
ICU	O
for	O
monitoring	O
.	O
Prior	O
to	O
coronary	O
angiography	O
,	O
the	O
on	O
call	O
gynaecology	O
team	O
was	O
contacted	O
and	O
the	O
patient	O
was	O
informed	O
of	O
the	O
benefits	O
risks	O
of	O
the	O
procedure	O
and	O
warned	O
that	O
due	O
to	O
the	O
average	O
radiation	O
dose	O
received	O
per	O
patient	O
less	O
than	O
500	O
mGy	O
,	O
it	O
was	O
not	O
advisable	O
to	O
legally	O
terminate	O
the	O
pregnancy	O
.	O
The	O
haemodynamics	O
department	O
was	O
then	O
contacted	O
to	O
perform	O
a	O
preferential	O
catheterisation	O
,	O
which	O
identified	O
an	O
angiographic	O
image	O
suggestive	O
of	O
embolism	O
in	O
the	O
very	O
distal	O
anterior	O
descending	O
coronary	O
artery	O
.	O
Subsequently	O
,	O
obstetric	O
ultrasound	O
was	O
performed	O
,	O
which	O
confirmed	O
foetal	O
viability	O
.	O
On	O
admission	O
,	O
aortic	O
CT	O
angiography	O
was	O
requested	O
to	O
detect	O
aortic	O
dissection	O
and	O
or	O
brachiocephalic	O
and	O
carotid	O
trunk	O
dissection	O
,	O
which	O
was	O
finally	O
ruled	O
out	O
.	O
His	O
stay	O
in	O
the	O
ICU	O
was	O
uneventful	O
.	O
The	O
haematology	O
department	O
was	O
consulted	O
to	O
adjust	O
the	O
anticoagulation	O
dose	O
which	O
,	O
prior	O
to	O
admission	O
,	O
was	O
maintained	O
at	O
12	O
,	O
000	O
IU	O
120	O
mg	O
0	O
.	O
8	O
ml	O
once	O
a	O
day	O
.	O
The	O
anticoagulant	O
treatment	O
was	O
adjusted	O
to	O
10	O
,	O
000	O
IU	O
100	O
mg	O
1	O
ml	O
every	O
12	O
hours	O
and	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
cardiology	O
ward	O
,	O
where	O
antiXa	O
levels	O
were	O
requested	O
and	O
showed	O
borderline	O
levels	O
between	O
prophylactic	O
and	O
therapeutic	O
doses	O
.	O
The	O
most	O
likely	O
aetiology	O
of	O
NSTEACS	O
was	O
assumed	O
to	O
be	O
coronary	O
embolism	O
in	O
relation	O
to	O
the	O
undercoagulated	O
mechanical	O
prosthesis	O
,	O
which	O
in	O
addition	O
to	O
releasing	O
a	O
small	O
embolus	O
into	O
the	O
coronary	O
circulation	O
,	O
could	O
possibly	O
have	O
released	O
one	O
into	O
the	O
cerebral	O
circulation	O
,	O
causing	O
the	O
facial	O
paresthesia	O
and	O
cervical	O
pain	O
.	O
After	O
a	O
multidisciplinary	O
approach	O
between	O
the	O
gynaecology	O
,	O
cardiology	O
and	O
haematology	O
teams	O
,	O
it	O
was	O
decided	O
that	O
since	O
the	O
patient	O
was	O
still	O
in	O
the	O
first	O
trimester	O
of	O
pregnancy	O
,	O
treatment	O
with	O
LMWH	O
should	O
continue	O
until	O
week	O
13	O
adjusted	O
according	O
to	O
anti	O
Xa	O
levels	O
and	O
then	O
reintroduce	O
vitamin	O
K	O
antagonists	O
VKA	O
until	O
delivery	O
.	O
Her	O
stay	O
in	O
the	O
cardiology	O
ward	O
was	O
uneventful	O
and	O
she	O
was	O
discharged	O
after	O
5	O
days	O
of	O
hospitalisation	O
.	O
DIAGNOSIS	O
Acute	O
myocardial	O
infarction	O
without	O
septal	O
and	O
apical	O
ST	O
elevation	O
in	O
relation	O
to	O
embolism	O
at	O
the	O
level	O
of	O
the	O
very	O
distal	O
anterior	O
descending	O
coronary	O
artery	O
.	O
Possible	O
transient	O
ischaemic	O
attack	O
.	O
Undertherapeutic	O
anticoagulation	O
levels	O
in	O
a	O
patient	O
with	O
a	O
mechanical	O
aortic	O
prosthesis	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
49	O
year	O
old	O
woman	O
,	O
with	O
no	O
known	O
allergies	O
or	O
toxic	O
habits	O
.	O
Lives	O
at	O
home	O
with	O
her	O
parents	O
,	O
under	O
guardianship	O
,	O
independent	O
for	O
basic	O
activities	O
of	O
daily	O
living	O
BADLL	O
.	O
No	O
cardiovascular	O
risk	O
factors	O
or	O
family	O
history	O
of	O
heart	O
disease	O
.	O
Cardiological	O
history	O
of	O
mitral	O
prolapse	O
with	O
moderate	O
mitral	O
insufficiency	O
under	O
follow	O
up	O
in	O
cardiology	O
consultations	O
.	O
Other	O
history	O
of	O
cognitive	O
deficit	O
secondary	O
to	O
intrauterine	O
infection	O
,	O
micrognathia	O
and	O
psoriasis	O
without	O
associated	O
osteoarthritis	O
.	O
No	O
treatment	O
as	O
usual	O
.	O
Current	O
illness	O
Admission	O
to	O
cardiology	O
,	O
after	O
detecting	O
in	O
outpatient	O
clinic	O
,	O
where	O
he	O
went	O
for	O
review	O
of	O
his	O
valvulopathy	O
,	O
ECG	O
compatible	O
with	O
evolved	O
AMI	O
with	O
anteroseptal	O
Q	O
wave	O
,	O
paucisymptomatic	O
.	O
Anamnesis	O
was	O
difficult	O
due	O
to	O
the	O
patient	O
's	O
baseline	O
condition	O
;	O
we	O
spoke	O
to	O
her	O
parents	O
,	O
who	O
reported	O
that	O
she	O
had	O
presented	O
at	O
home	O
in	O
the	O
previous	O
days	O
with	O
episodes	O
of	O
epigastric	O
pain	O
and	O
diffuse	O
abdominal	O
pain	O
,	O
which	O
subsided	O
with	O
paracetamol	B-FARMACO
1g	O
8h	O
,	O
and	O
for	O
which	O
they	O
did	O
not	O
consult	O
,	O
without	O
associated	O
vegetative	O
cortex	O
.	O
They	O
denied	O
objective	O
dyspnoea	O
,	O
chest	O
pain	O
or	O
syncope	O
.	O
There	O
was	O
no	O
fever	O
or	O
associated	O
infectious	O
semiology	O
at	O
any	O
level	O
.	O
Likewise	O
,	O
for	O
approximately	O
two	O
weeks	O
,	O
the	O
patient	O
has	O
had	O
clinical	O
symptoms	O
of	O
instability	O
with	O
behavioural	O
alterations	O
,	O
pending	O
an	O
appointment	O
for	O
neurological	O
assessment	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
120	O
75	O
mmHg	O
,	O
heart	O
rate	O
98	O
bpm	O
.	O
Baseline	O
O2	O
saturation	O
98	O
.	O
Afebrile	O
.	O
Conscious	O
,	O
oriented	O
,	O
normohydrated	O
and	O
perfused	O
,	O
eupneic	O
at	O
rest	O
.	O
Cachexia	O
body	O
mass	O
index	O
15	O
.	O
No	O
jugular	O
ingurgitation	O
at	O
45o	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
,	O
known	O
mitral	O
II	O
VI	O
systolic	O
murmur	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
preserved	O
peristalsis	O
,	O
painful	O
on	O
general	O
palpation	O
,	O
no	O
signs	O
of	O
peritoneal	O
irritation	O
,	O
no	O
murmurs	O
.	O
Lower	O
extremities	O
no	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
No	O
loss	O
of	O
skin	O
continuity	O
.	O
COMPLEMENTARY	O
TESTS	O
ECG	O
on	O
admission	O
sinus	O
tachycardia	O
at	O
127	O
bpm	O
.	O
ST	O
elevation	O
V1	O
V4	O
Q	O
in	O
V1	O
V2	O
.	O
ECG	O
on	O
discharge	O
sinus	O
rhythm	O
at	O
90	O
bpm	O
,	O
with	O
negative	O
T	O
waves	O
from	O
V1	O
to	O
V4	O
.	O
Myocardial	O
necrosis	O
markers	O
ultrasensitive	O
troponin	O
T	O
1050	O
968	O
.	O
8	O
ng	O
l	O
.	O
Blood	O
tests	O
biochemistry	O
glucose	O
120	O
mg	O
dl	O
,	O
HbA1c	O
5	O
.	O
5	O
,	O
urea	O
0	O
.	O
5	O
g	O
l	O
,	O
creatinine	O
1	O
mg	O
dl	O
,	O
glomerular	O
filtration	O
rate	O
90	O
ml	O
min	O
.	O
Total	O
cholesterol	O
112	O
mg	O
dl	O
,	O
LDL	O
cholesterol	O
54	O
mg	O
dl	O
,	O
HDL	O
cholesterol	O
45	O
mg	O
dl	O
,	O
triglycerides	O
83	O
mg	O
dl	O
,	O
sodium140	O
mEq	O
l	O
,	O
potassium	O
4	O
mEq	O
l	O
.	O
TSH	O
0	O
.	O
6	O
mcU	O
ml	O
.	O
Blood	O
count	O
haemoglobin	O
14	O
.	O
2	O
g	O
dl	O
,	O
haematocrit	O
40	O
,	O
leucocytes	O
6400	O
mm3	O
,	O
platelets	O
305000	O
mm3	O
.	O
Coagulation	O
AP	O
75	O
,	O
INR	O
1	O
,	O
fibrinogen	O
465	O
mg	O
dl	O
.	O
Chest	O
X	O
ray	O
normal	O
cardiomediastinal	O
silhouette	O
.	O
Hiatal	O
hernia	O
.	O
Bilateral	O
apical	O
fibrocystic	O
fibrocystic	O
tracts	O
.	O
No	O
acute	O
pleuroparenchymal	O
alterations	O
.	O
Myocardial	O
perfusion	O
scan	O
at	O
rest	O
non	O
viability	O
.	O
Myocardial	O
necrosis	O
in	O
the	O
apex	O
and	O
anteroapical	O
and	O
anteroseptal	O
segments	O
infarct	O
area	O
between	O
16	O
and	O
22	O
of	O
the	O
left	O
ventricular	O
area	O
;	O
LVEF	O
53	O
.	O
Coronary	O
computed	O
tomography	O
CT	O
occlusion	O
of	O
the	O
middle	O
anterior	O
descending	O
artery	O
AD	O
with	O
permeable	O
and	O
filiform	O
apical	O
bed	O
.	O
AMI	O
in	O
the	O
anterior	O
and	O
apical	O
septum	O
thinning	O
and	O
hypoperfusion	O
in	O
the	O
apex	O
and	O
anterior	O
septum	O
.	O
No	O
perivalvular	O
abscesses	O
are	O
observed	O
.	O
Transthoracic	O
echocardiogram	O
TTE	O
on	O
admission	O
apical	O
akinesia	O
with	O
preserved	O
systolic	O
function	O
LVEF	O
55	O
.	O
Mass	O
visualised	O
on	O
the	O
atrial	O
side	O
of	O
the	O
anterior	O
leaflet	O
in	O
the	O
mitral	O
valve	O
suggestive	O
of	O
vegetations	O
,	O
hypermobile	O
,	O
1	O
.	O
17	O
0	O
.	O
5	O
cm	O
in	O
size	O
,	O
filiform	O
with	O
a	O
wide	O
base	O
of	O
implantation	O
that	O
conditions	O
moderate	O
severe	O
mitral	O
insufficiency	O
A2	O
P3	O
with	O
posterior	O
eccentric	O
jet	O
and	O
Coanda	O
effect	O
,	O
without	O
systolic	O
inversion	O
in	O
the	O
pulmonary	O
veins	O
.	O
No	O
perforation	O
of	O
the	O
leaflet	O
or	O
mitroaortic	O
fibrosis	O
was	O
observed	O
.	O
There	O
is	O
no	O
mitral	O
valve	O
stenosis	O
.	O
Dilated	O
left	O
atrium	O
.	O
Thin	O
layer	O
of	O
pericardial	O
effusion	O
.	O
Echocardiogram	O
at	O
6	O
weeks	O
left	O
ventricle	O
of	O
normal	O
size	O
and	O
thickness	O
,	O
with	O
borderline	O
systolic	O
function	O
LVEF	O
50	O
.	O
Akinesia	O
and	O
apical	O
thinning	O
.	O
Moderate	O
left	O
atrial	O
dilatation	O
.	O
Normal	O
right	O
chambers	O
.	O
Remarkable	O
decrease	O
in	O
the	O
size	O
of	O
the	O
vegetation	O
in	O
the	O
anterior	O
mitral	O
leaflet	O
almost	O
complete	O
disappearance	O
.	O
Mitral	O
valve	O
prolapse	O
of	O
the	O
anterior	O
leaflet	O
causing	O
moderate	O
regurgitation	O
with	O
eccentric	O
jet	O
similar	O
to	O
studies	O
prior	O
to	O
admission	O
.	O
No	O
perforation	O
of	O
the	O
leaflet	O
or	O
involvement	O
of	O
the	O
mitroaortic	O
fibrosa	O
was	O
observed	O
.	O
The	O
rest	O
of	O
the	O
patient	O
had	O
no	O
significant	O
valvular	O
alterations	O
.	O
Pulmonary	O
arterial	O
systolic	O
pressure	O
cannot	O
be	O
calculated	O
due	O
to	O
the	O
absence	O
of	O
tricuspid	O
insufficiency	O
.	O
Aortic	O
root	O
of	O
normal	O
size	O
.	O
No	O
pericardial	O
effusion	O
.	O
Microbiology	O
Blood	O
cultures	O
25	O
01	O
2020	O
Streptococcus	O
anginosus	O
.	O
Urine	O
culture	O
25	O
01	O
2020	O
negative	O
.	O
PCR	O
influenza	O
and	O
respiratory	O
syncytial	O
virus	O
RSV	O
07	O
02	O
2020	O
negative	O
.	O
Urine	O
culture	O
07	O
02	O
2020	O
Escherichia	O
coli	O
.	O
Blood	O
cultures	O
on	O
28	O
01	O
,	O
05	O
02	O
,	O
07	O
02	O
and	O
11	O
02	O
2020	O
negative	O
.	O
Abdominal	O
CT	O
scan	O
hiatus	O
hernia	O
.	O
Uterine	O
myoma	O
of	O
14	O
mm	O
.	O
Rest	O
without	O
alterations	O
.	O
Craniocerebral	O
CT	O
scan	O
hyperdense	O
area	O
compatible	O
with	O
haemorrhagic	O
focus	O
of	O
10	O
x	O
7	O
mm	O
in	O
left	O
fronto	O
parietal	O
lobe	O
,	O
which	O
does	O
not	O
rule	O
out	O
the	O
existence	O
of	O
underlying	O
pathology	O
.	O
Rest	O
of	O
the	O
brain	O
parenchyma	O
without	O
significant	O
alterations	O
.	O
Magnetic	O
resonance	O
imaging	O
MRI	O
of	O
the	O
brain	O
left	O
occipital	O
annular	O
uptake	O
that	O
could	O
be	O
related	O
to	O
septic	O
embolism	O
,	O
as	O
well	O
as	O
left	O
occipital	O
temporal	O
temporal	O
corticojuxtacortical	O
signal	O
alteration	O
suggesting	O
acute	O
subacute	O
ischaemic	O
lesion	O
and	O
left	O
frontal	O
subacute	O
haemorrhagic	O
focus	O
.	O
In	O
context	O
,	O
the	O
findings	O
could	O
all	O
be	O
related	O
to	O
septic	O
embolism	O
.	O
CLINICAL	O
EVOLUTION	O
Admitted	O
with	O
a	O
diagnosis	O
of	O
acute	O
myocardial	O
infarction	O
,	O
paucisymptomatic	O
.	O
In	O
the	O
first	O
hours	O
of	O
hospitalisation	O
he	O
presented	O
febrile	O
peaks	O
of	O
up	O
to	O
38oC	O
,	O
with	O
no	O
associated	O
infectious	O
semiology	O
,	O
so	O
blood	O
and	O
urine	O
cultures	O
were	O
requested	O
,	O
PCR	O
for	O
respiratory	O
viruses	O
and	O
empirical	O
antibiotic	O
therapy	O
was	O
started	O
,	O
which	O
was	O
modified	O
after	O
growth	O
of	O
S	O
.	O
anginosus	O
in	O
the	O
first	O
24	O
hours	O
in	O
both	O
blood	O
cultures	O
,	O
to	O
intravenous	O
penicillin	B-FARMACO
G	I-FARMACO
sodium	I-FARMACO
and	O
intravenous	O
gentamicin	B-FARMACO
.	O
TTE	O
showed	O
apical	O
akinesia	O
with	O
preserved	O
LVEF	O
and	O
an	O
image	O
suggestive	O
of	O
vegetation	O
in	O
the	O
anterior	O
mitral	O
leaflet	O
atrial	O
side	O
of	O
11	O
mm	O
,	O
which	O
led	O
to	O
moderate	O
regurgitation	O
with	O
eccentric	O
jet	O
.	O
Of	O
note	O
,	O
it	O
was	O
impossible	O
to	O
perform	O
a	O
transesophageal	O
echocardiogram	O
due	O
to	O
the	O
patient	O
's	O
facial	O
anatomy	O
.	O
On	O
the	O
one	O
hand	O
,	O
in	O
the	O
case	O
of	O
a	O
recently	O
diagnosed	O
advanced	O
acute	O
myocardial	O
infarction	O
,	O
a	O
viability	O
study	O
was	O
performed	O
with	O
myocardial	O
perfusion	O
scintigraphy	O
at	O
rest	O
,	O
showing	O
an	O
absence	O
of	O
viability	O
in	O
the	O
segments	O
compatible	O
with	O
the	O
LAD	O
territory	O
.	O
A	O
coronary	O
CT	O
scan	O
was	O
also	O
performed	O
,	O
confirming	O
occlusion	O
in	O
the	O
mid	O
LAD	O
with	O
a	O
permeable	O
and	O
filiform	O
apical	O
bed	O
.	O
It	O
was	O
decided	O
not	O
to	O
revascularise	O
due	O
to	O
the	O
absence	O
of	O
clinical	O
benefit	O
,	O
and	O
the	O
patient	O
remained	O
stable	O
without	O
new	O
episodes	O
of	O
chest	O
pain	O
.	O
Residual	O
LV	O
systolic	O
function	O
was	O
preserved	O
with	O
apical	O
akinesia	O
at	O
discharge	O
.	O
On	O
the	O
other	O
hand	O
,	O
with	O
the	O
diagnosis	O
of	O
subacute	O
endocarditis	O
in	O
native	O
mitral	O
valve	O
,	O
together	O
with	O
the	O
initial	O
clinical	O
manifestations	O
of	O
instability	O
and	O
behavioural	O
alteration	O
,	O
as	O
well	O
as	O
diffuse	O
abdominal	O
pain	O
,	O
an	O
extension	O
study	O
was	O
performed	O
with	O
Cranioencephalic	O
CT	O
and	O
cerebral	O
MRI	O
which	O
confirmed	O
the	O
existence	O
of	O
images	O
suggestive	O
of	O
septic	O
embolisms	O
and	O
abdominal	O
CT	O
where	O
no	O
significant	O
alterations	O
were	O
found	O
.	O
Both	O
ruled	O
out	O
the	O
presence	O
of	O
abscesses	O
.	O
A	O
gynaecological	O
examination	O
was	O
also	O
performed	O
,	O
which	O
ruled	O
out	O
abscess	O
or	O
complications	O
at	O
this	O
level	O
.	O
Subsequent	O
clinical	O
and	O
haemodynamic	O
evolution	O
was	O
favourable	O
,	O
with	O
negative	O
blood	O
cultures	O
at	O
72	O
hours	O
,	O
presenting	O
as	O
a	O
complication	O
urinary	O
tract	O
infection	O
by	O
E	O
coli	O
and	O
Enterococcus	O
faecium	O
2	O
weeks	O
after	O
starting	O
antibiotherapy	O
,	O
for	O
which	O
treatment	O
was	O
escalated	O
,	O
replacing	O
penicillin	B-FARMACO
with	O
ceftriaxone	B-FARMACO
,	O
completing	O
6	O
weeks	O
of	O
antibiotic	O
treatment	O
,	O
with	O
no	O
other	O
complications	O
.	O
After	O
completing	O
the	O
6	O
weeks	O
,	O
a	O
new	O
control	O
TTE	O
was	O
repeated	O
,	O
where	O
the	O
vegetation	O
practically	O
disappeared	O
,	O
with	O
prolapse	O
of	O
the	O
anterior	O
mitral	O
leaflet	O
leading	O
to	O
moderate	O
residual	O
mitral	O
insufficiency	O
similar	O
to	O
previous	O
studies	O
and	O
preserved	O
left	O
ventricular	O
systolic	O
function	O
.	O
Given	O
the	O
absence	O
of	O
progression	O
of	O
mitral	O
regurgitation	O
MR	O
and	O
the	O
disappearance	O
of	O
valvular	O
vegetations	O
in	O
a	O
frail	O
patient	O
FRAIL	O
5	O
;	O
CFS	O
7	O
,	O
conservative	O
treatment	O
was	O
chosen	O
.	O
Finally	O
,	O
after	O
completion	O
of	O
the	O
physiotherapy	O
programme	O
by	O
the	O
rehabilitation	O
service	O
,	O
with	O
progressive	O
recovery	O
of	O
motor	O
function	O
,	O
she	O
was	O
discharged	O
home	O
with	O
outpatient	O
follow	O
up	O
,	O
with	O
no	O
episodes	O
of	O
decompensation	O
to	O
date	O
and	O
in	O
NYHA	O
functional	O
class	O
I	O
at	O
the	O
last	O
review	O
.	O
DIAGNOSIS	O
Subacute	O
endocarditis	O
on	O
native	O
mitral	O
valve	O
anterior	O
leaflet	O
due	O
to	O
Streptococcus	O
anginosus	O
viridans	O
resolved	O
with	O
prolonged	O
antibiotic	O
therapy	O
and	O
complicated	O
with	O
septic	O
embolism	O
Acute	O
embolic	O
apical	O
myocardial	O
infarction	O
with	O
occlusion	O
in	O
middle	O
LAD	O
not	O
revascularised	O
due	O
to	O
lack	O
of	O
viability	O
.	O
Left	O
occipital	O
and	O
left	O
frontotemporal	O
ischaemic	O
cerebrovascular	O
accident	O
CVA	O
with	O
subsequent	O
haemorrhagic	O
transformation	O
due	O
to	O
septic	O
embolisms	O
.	O
Borderline	O
residual	O
LV	O
systolic	O
function	O
LVEF	O
50	O
with	O
apical	O
akinesia	O
.	O
Urinary	O
tract	O
infections	O
due	O
to	O
E	O
coli	O
and	O
Enterococcus	O
faecium	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
49	O
year	O
old	O
male	O
patient	O
with	O
the	O
following	O
personal	O
history	O
No	O
known	O
adverse	O
drug	O
reactions	O
.	O
Cardiovascular	O
risk	O
factors	O
arterial	O
hypertension	O
of	O
13	O
years	O
of	O
evolution	O
,	O
initially	O
untreated	O
and	O
which	O
,	O
in	O
recent	O
years	O
,	O
has	O
had	O
treatment	O
with	O
irregular	O
adherence	O
to	O
it	O
;	O
dyslipidaemia	O
of	O
8	O
years	O
of	O
evolution	O
,	O
in	O
treatment	O
with	O
oral	O
lipid	O
lowering	O
drugs	O
,	O
but	O
also	O
with	O
irregular	O
adherence	O
to	O
it	O
.	O
Toxic	O
habits	O
active	O
smoker	O
of	O
more	O
than	O
15	O
cigarettes	O
a	O
day	O
IPA	O
of	O
35	O
packs	O
year	O
,	O
alcoholism	O
with	O
a	O
regular	O
consumption	O
of	O
around	O
1	O
litre	O
of	O
beer	O
a	O
day	O
since	O
adolescence	O
,	O
occasional	O
cocaine	O
user	O
.	O
Cardiological	O
history	O
Chronic	O
coronary	O
syndrome	O
,	O
with	O
debut	O
in	O
2012	O
in	O
the	O
form	O
of	O
acute	O
myocardial	O
infarction	O
without	O
ST	O
segment	O
elevation	O
NSTEMI	O
.	O
During	O
this	O
admission	O
,	O
monovalvular	O
coronary	O
artery	O
disease	O
of	O
the	O
proximal	O
anterior	O
descending	O
artery	O
was	O
detected	O
,	O
which	O
was	O
revascularised	O
with	O
the	O
implantation	O
of	O
1	O
drug	O
eluting	O
stent	O
.	O
Left	O
ventricular	O
ejection	O
fraction	O
LVEF	O
was	O
preserved	O
at	O
discharge	O
.	O
New	O
admission	O
in	O
2017	O
for	O
NSTEMI	O
,	O
caused	O
by	O
thrombosis	O
at	O
the	O
level	O
of	O
the	O
proximal	O
ostial	O
circumflex	O
artery	O
without	O
total	O
obstruction	O
and	O
treated	O
with	O
abciximab	B-FARMACO
perfusion	O
initially	O
and	O
subsequently	O
with	O
balloon	O
PCI	O
.	O
Left	O
ventricular	O
systolic	O
function	O
preserved	O
.	O
Abandoned	O
follow	O
up	O
in	O
cardiology	O
outpatient	O
clinic	O
.	O
Usual	O
treatment	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
ASA	I-FARMACO
100	O
mg	O
1	O
tablet	O
every	O
24	O
h	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
1	O
tablet	O
every	O
24	O
h	O
,	O
telmisartan	B-FARMACO
40	O
mg	O
1	O
tablet	O
every	O
24	O
h	O
,	O
lorazepam	B-FARMACO
1	O
mg	O
1	O
tablet	O
every	O
12	O
h	O
,	O
bisoprolol	B-FARMACO
2	O
.	O
5	O
mg	O
1	O
tablet	O
every	O
24	O
h	O
,	O
atorvastatin	B-FARMACO
80	O
mg	O
1	O
tablet	O
every	O
24	O
h	O
,	O
fenofibrate	B-FARMACO
145	O
mg	O
1	O
tablet	O
every	O
24	O
h	O
.	O
Present	O
illness	O
The	O
patient	O
,	O
with	O
the	O
history	O
described	O
above	O
,	O
presents	O
with	O
chest	O
pain	O
at	O
home	O
,	O
unrelated	O
to	O
exertion	O
.	O
He	O
describes	O
the	O
pain	O
as	O
central	O
thoracic	O
,	O
oppressive	O
,	O
radiating	O
to	O
the	O
neck	O
and	O
left	O
upper	O
limb	O
,	O
similar	O
to	O
the	O
two	O
previous	O
heart	O
attacks	O
and	O
accompanied	O
by	O
vegetative	O
symptoms	O
in	O
the	O
form	O
of	O
profuse	O
sweating	O
and	O
nausea	O
.	O
Initially	O
,	O
he	O
decided	O
to	O
take	O
one	O
tablet	O
of	O
lorazepam	B-FARMACO
and	O
,	O
as	O
his	O
symptoms	O
worsened	O
,	O
he	O
decided	O
to	O
take	O
two	O
tablets	O
of	O
sublingual	O
caffeine	B-FARMACO
,	O
which	O
he	O
vomited	O
immediately	O
.	O
The	O
family	O
then	O
called	O
the	O
emergency	O
services	O
.	O
On	O
arrival	O
of	O
the	O
emergency	O
team	O
,	O
the	O
patient	O
was	O
symptomatic	O
,	O
with	O
chest	O
pain	O
and	O
significant	O
impairment	O
of	O
the	O
general	O
condition	O
,	O
conscious	O
,	O
oriented	O
and	O
cooperative	O
,	O
with	O
the	O
following	O
physical	O
examination	O
Vitals	O
systolic	O
blood	O
pressure	O
of	O
95	O
54	O
mmHg	O
;	O
heart	O
rate	O
of	O
around	O
100	O
bpm	O
,	O
saturating	O
at	O
96	O
without	O
oxygen	B-FARMACO
supply	O
.	O
Skin	O
pallor	O
,	O
acral	O
coldness	O
,	O
weak	O
peripheral	O
pulses	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
tones	O
,	O
tachycardic	O
,	O
no	O
audible	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
bilateral	O
vesicular	O
murmur	O
preserved	O
,	O
with	O
crackles	O
in	O
the	O
bases	O
.	O
Lower	O
limbs	O
no	O
oedema	O
.	O
An	O
electrocardiogram	O
ECG	O
was	O
then	O
performed	O
,	O
showing	O
ST	O
segment	O
elevation	O
images	O
1	O
and	O
2	O
,	O
so	O
it	O
was	O
decided	O
to	O
administer	O
a	O
loading	O
dose	O
of	O
ASA	B-FARMACO
300	O
mg	O
,	O
ticagrelor	B-FARMACO
180	O
mg	O
,	O
and	O
emergency	O
cardiology	O
was	O
contacted	O
pre	O
hospital	O
for	O
transfer	O
to	O
our	O
hospital	O
.	O
COMPLEMENTARY	O
TESTS	O
Emergency	O
ECG	O
sinus	O
rhythm	O
at	O
90	O
bpm	O
,	O
normal	O
PR	O
,	O
ST	O
segment	O
elevation	O
in	O
DII	O
,	O
DIII	O
,	O
AVF	O
up	O
to	O
7	O
mm	O
and	O
in	O
V4	O
6	O
,	O
with	O
specular	O
decrease	O
in	O
V1	O
2	O
,	O
aVL	O
.	O
Initial	O
coronary	O
angiography	O
video	O
1	O
Left	O
main	O
coronary	O
artery	O
No	O
stenosis	O
.	O
Recurrence	O
of	O
very	O
late	O
thrombosis	O
of	O
the	O
stent	O
implanted	O
in	O
the	O
ostial	O
anterior	O
descending	O
artery	O
,	O
a	O
phenomenon	O
that	O
in	O
this	O
case	O
affects	O
the	O
distal	O
left	O
main	O
coronary	O
artery	O
both	O
anterior	O
descending	O
and	O
circumflex	O
,	O
but	O
maintaining	O
TIMI	O
3	O
epicardial	O
flow	O
in	O
both	O
branches	O
.	O
Anterior	O
descending	O
permeable	O
ostial	O
proximal	O
ostial	O
stent	O
,	O
not	O
restenotic	O
,	O
with	O
presence	O
of	O
ostial	O
thrombus	O
.	O
Rest	O
of	O
the	O
vessel	O
without	O
de	O
novo	O
lesions	O
.	O
Occlusion	O
by	O
embolisation	O
of	O
the	O
anterior	O
descending	O
artery	O
at	O
the	O
terminal	O
apical	O
level	O
.	O
Circumflex	O
co	O
dominant	O
,	O
without	O
lesions	O
,	O
with	O
presence	O
of	O
ostial	O
proximal	O
thrombus	O
,	O
as	O
previously	O
detailed	O
.	O
Occlusion	O
by	O
embolus	O
of	O
the	O
distal	O
posterior	O
descending	O
artery	O
of	O
the	O
circumflex	O
.	O
Right	O
coronary	O
artery	O
codominant	O
,	O
without	O
lesions	O
.	O
Post	O
catheterisation	O
ECG	O
on	O
admission	O
to	O
the	O
coronary	O
unit	O
image	O
3	O
sinus	O
rhythm	O
with	O
narrow	O
QRS	O
,	O
normalisation	O
of	O
the	O
ST	O
segment	O
,	O
Q	O
wave	O
of	O
1	O
mm	O
in	O
DII	O
,	O
DIII	O
,	O
aVF	O
,	O
V5	O
6	O
.	O
Admission	O
blood	O
tests	O
haemogram	O
red	O
series	O
with	O
Hb	O
15	O
.	O
7	O
g	O
dl	O
and	O
haematocrit	O
45	O
.	O
8	O
.	O
White	O
series	O
with	O
leukocytosis	O
of	O
17	O
,	O
760	O
cells	O
mm3	O
and	O
neutrophilia	O
of	O
15	O
,	O
590	O
cells	O
mm3	O
.	O
Platelets	O
261	O
,	O
000	O
cells	O
mm3	O
.	O
Blood	O
glucose	O
74	O
mg	O
dl	O
.	O
Renal	O
function	O
creatinine	O
1	O
.	O
04	O
mg	O
dl	O
and	O
urea	O
33	O
mg	O
dl	O
.	O
Ions	O
within	O
normal	O
range	O
.	O
CRP	O
0	O
.	O
6	O
mg	O
l	O
.	O
Myocardial	O
damage	O
markers	O
CPK	O
365	O
1283	O
2487	O
731	O
203	O
142	O
83	O
87	O
U	O
l	O
.	O
Ultra	O
sensitive	O
troponin	O
T	O
11	O
904	O
2166	O
871	O
1484	O
1069	O
1429	O
10	O
5	O
ng	O
l	O
.	O
GSV	O
pH	O
7	O
.	O
25	O
;	O
pCO2	O
40	O
.	O
4	O
mmHg	O
;	O
lactic	O
acid	O
7	O
.	O
4	O
mmol	O
l	O
;	O
HCO3	O
17	O
.	O
7	O
mmol	O
l	O
.	O
HbA1c	O
5	O
.	O
6	O
.	O
Lipid	O
profile	O
total	O
cholesterol	O
103	O
mg	O
dl	O
;	O
triglycerides	O
92	O
mg	O
dl	O
;	O
HDL	O
cholesterol	O
60	O
mg	O
dl	O
;	O
LDL	O
cholesterol	O
25	O
mg	O
dl	O
.	O
Urinalysis	O
with	O
toxins	O
positive	O
for	O
cocaine	O
and	O
benzodiazepines	O
.	O
Echocardiography	O
in	O
the	O
ED	O
left	O
ventricle	O
of	O
globular	O
appearance	O
,	O
with	O
preserved	O
LVEF	O
,	O
no	O
segmental	O
contractility	O
disorders	O
can	O
be	O
seen	O
due	O
to	O
poor	O
endocardial	O
visualisation	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
and	O
preserved	O
systolic	O
function	O
.	O
No	O
significant	O
valvulopathies	O
.	O
No	O
pericardial	O
effusion	O
.	O
Vena	O
cava	O
of	O
normal	O
size	O
and	O
with	O
adequate	O
inspiratory	O
collapse	O
.	O
Control	O
coronary	O
angiography	O
at	O
7	O
days	O
resolution	O
of	O
the	O
stent	O
thrombosis	O
generated	O
in	O
the	O
ostial	O
anterior	O
descending	O
artery	O
,	O
described	O
in	O
the	O
previous	O
angiography	O
,	O
was	O
confirmed	O
.	O
Doppler	O
ultrasound	O
of	O
the	O
left	O
groin	O
hypoechogenic	O
image	O
is	O
seen	O
in	O
the	O
perivascular	O
soft	O
tissues	O
,	O
adjacent	O
to	O
the	O
superficial	O
femoral	O
artery	O
,	O
with	O
no	O
flow	O
inside	O
,	O
compatible	O
with	O
changes	O
secondary	O
to	O
puncture	O
,	O
probably	O
haematic	O
infiltration	O
.	O
No	O
significant	O
post	O
puncture	O
haematoma	O
is	O
evident	O
.	O
All	O
the	O
vessels	O
studied	O
appear	O
permeable	O
and	O
with	O
normal	O
flow	O
morphology	O
.	O
There	O
were	O
no	O
images	O
suggesting	O
additional	O
complications	O
arteriovenous	O
fistula	O
or	O
pseudoaneurysm	O
.	O
ECG	O
at	O
hospital	O
discharge	O
sinus	O
rhythm	O
at	O
65	O
bpm	O
.	O
Constant	O
PR	O
of	O
100	O
ms	O
.	O
Narrow	O
QRS	O
of	O
80	O
ms	O
.	O
Negative	O
T	O
waves	O
in	O
II	O
,	O
III	O
,	O
aVF	O
and	O
V4	O
6	O
.	O
Transthoracic	O
echocardiography	O
TTE	O
at	O
discharge	O
non	O
dilated	O
left	O
ventricle	O
,	O
with	O
slight	O
concentric	O
hypertrophy	O
of	O
walls	O
13	O
mm	O
of	O
septum	O
and	O
13	O
mm	O
of	O
posterior	O
wall	O
,	O
with	O
preserved	O
left	O
ventricular	O
systolic	O
function	O
57	O
,	O
without	O
segmental	O
contractility	O
disorders	O
.	O
Right	O
ventricle	O
not	O
dilated	O
and	O
normofunctioning	O
.	O
Atria	O
of	O
normal	O
dimensions	O
.	O
Normal	O
aortic	O
root	O
.	O
Absence	O
of	O
organic	O
valvular	O
pathology	O
.	O
No	O
pericardial	O
effusion	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
with	O
adequate	O
inspiratory	O
collapse	O
.	O
The	O
Doppler	O
study	O
showed	O
normal	O
anterograde	O
valvular	O
flows	O
,	O
with	O
no	O
significant	O
valvular	O
insufficiencies	O
.	O
Blood	O
tests	O
at	O
discharge	O
Normal	O
haemogram	O
of	O
the	O
3	O
series	O
.	O
Coagulation	O
normal	O
.	O
Biochemistry	O
glycaemia	O
,	O
renal	O
function	O
and	O
ions	O
normal	O
.	O
Markers	O
of	O
myocardial	O
damage	O
CPK	O
87	O
U	O
l	O
and	O
TnT	O
5	O
ng	O
l	O
.	O
CRP	O
1	O
.	O
2	O
mg	O
l	O
.	O
GSV	O
pH	O
7	O
.	O
37	O
;	O
pCO2	O
50	O
.	O
5	O
mmHg	O
;	O
HCO3	O
28	O
.	O
6	O
mmol	O
l	O
;	O
lactic	O
2	O
.	O
1	O
mmol	O
l	O
.	O
CLINICAL	O
EVOLUTION	O
On	O
arrival	O
at	O
the	O
hospital	O
emergency	O
department	O
,	O
the	O
patient	O
was	O
found	O
to	O
be	O
in	O
a	O
very	O
poor	O
general	O
state	O
,	O
hypotensive	O
and	O
with	O
a	O
low	O
level	O
of	O
consciousness	O
,	O
which	O
made	O
it	O
necessary	O
to	O
initiate	O
aminergic	O
support	O
noradrenaline	B-FARMACO
with	O
a	O
view	O
to	O
performing	O
primary	O
angioplasty	O
in	O
which	O
thrombosis	O
was	O
observed	O
in	O
the	O
area	O
of	O
the	O
ostium	O
of	O
the	O
anterior	O
descending	O
trunk	O
and	O
trunk	O
circumflex	O
.	O
As	O
in	O
the	O
NSTEACS	O
of	O
2017	O
,	O
initial	O
pharmacological	O
management	O
was	O
chosen	O
in	O
order	O
to	O
reduce	O
the	O
thrombotic	O
burden	O
prior	O
to	O
any	O
interventional	O
procedure	O
.	O
Thus	O
,	O
an	O
intracoronary	O
bolus	O
of	O
abciximab	B-FARMACO
was	O
administered	O
and	O
intravenous	O
perfusion	O
was	O
left	O
in	O
place	O
.	O
After	O
starting	O
this	O
treatment	O
,	O
haemodynamic	O
improvement	O
and	O
recovery	O
of	O
the	O
level	O
of	O
consciousness	O
was	O
observed	O
,	O
and	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
coronary	O
unit	O
for	O
continued	O
monitoring	O
and	O
follow	O
up	O
.	O
The	O
case	O
was	O
presented	O
at	O
a	O
medical	O
surgical	O
session	O
and	O
it	O
was	O
decided	O
to	O
repeat	O
the	O
coronary	O
angiography	O
after	O
7	O
days	O
,	O
depending	O
on	O
the	O
results	O
of	O
the	O
coronary	O
angiography	O
,	O
medical	O
treatment	O
,	O
percutaneous	O
revascularisation	O
or	O
surgery	O
could	O
be	O
considered	O
depending	O
on	O
the	O
findings	O
.	O
During	O
his	O
stay	O
,	O
initially	O
in	O
the	O
coronary	O
unit	O
and	O
subsequently	O
in	O
the	O
cardiology	O
ward	O
,	O
the	O
patient	O
evolved	O
favourably	O
in	O
clinical	O
and	O
haemodynamic	O
terms	O
,	O
with	O
no	O
congestive	O
signs	O
,	O
no	O
arrhythmic	O
events	O
,	O
no	O
recurrence	O
of	O
chest	O
pain	O
and	O
with	O
preserved	O
LVEF	O
without	O
complications	O
in	O
the	O
control	O
TTE	O
.	O
On	O
re	O
history	O
,	O
the	O
patient	O
reported	O
that	O
in	O
the	O
previous	O
weeks	O
he	O
had	O
increased	O
his	O
alcohol	O
and	O
tobacco	O
consumption	O
,	O
and	O
that	O
he	O
had	O
used	O
cocaine	O
again	O
on	O
several	O
occasions	O
,	O
the	O
last	O
dose	O
the	O
day	O
before	O
the	O
event	O
.	O
A	O
repeat	O
coronary	O
angiography	O
was	O
performed	O
7	O
days	O
later	O
,	O
in	O
this	O
case	O
via	O
the	O
femoral	O
artery	O
,	O
and	O
resolution	O
of	O
the	O
thrombus	O
was	O
observed	O
.	O
In	O
view	O
of	O
this	O
situation	O
,	O
it	O
was	O
decided	O
not	O
to	O
perform	O
any	O
more	O
invasive	O
procedures	O
on	O
this	O
patient	O
and	O
,	O
after	O
an	O
adequate	O
evolution	O
on	O
the	O
hospital	O
ward	O
,	O
it	O
was	O
decided	O
to	O
discharge	O
the	O
patient	O
with	O
recommendations	O
,	O
leaving	O
him	O
on	O
a	O
double	O
anti	O
aggregation	O
treatment	O
with	O
ASA	B-FARMACO
and	O
ticagrelor	B-FARMACO
.	O
Prior	O
to	O
discharge	O
,	O
the	O
patient	O
presented	O
a	O
painful	O
tumour	O
in	O
the	O
inguinal	O
region	O
,	O
coinciding	O
with	O
the	O
puncture	O
site	O
for	O
coronary	O
angiography	O
via	O
the	O
femoral	O
artery	O
,	O
which	O
made	O
it	O
necessary	O
to	O
perform	O
a	O
Doppler	O
ultrasound	O
to	O
rule	O
out	O
complications	O
of	O
the	O
procedure	O
.	O
After	O
performing	O
the	O
ultrasound	O
and	O
ruling	O
out	O
these	O
complications	O
,	O
the	O
patient	O
was	O
discharged	O
from	O
the	O
hospital	O
.	O
Emphasis	O
was	O
placed	O
on	O
the	O
importance	O
of	O
abandoning	O
the	O
consumption	O
of	O
toxic	O
substances	O
and	O
the	O
importance	O
of	O
therapeutic	O
compliance	O
.	O
He	O
was	O
transferred	O
to	O
the	O
cardiac	O
rehabilitation	O
unit	O
on	O
discharge	O
,	O
where	O
these	O
recommendations	O
were	O
insisted	O
on	O
,	O
as	O
well	O
as	O
diet	O
and	O
physical	O
exercise	O
.	O
After	O
follow	O
up	O
,	O
he	O
was	O
discharged	O
with	O
subsequent	O
review	O
in	O
outpatient	O
cardiology	O
consultations	O
.	O
At	O
the	O
present	O
time	O
,	O
and	O
more	O
than	O
1	O
year	O
after	O
the	O
acute	O
event	O
,	O
the	O
patient	O
has	O
completely	O
abandoned	O
the	O
consumption	O
of	O
toxic	O
substances	O
and	O
has	O
not	O
presented	O
any	O
further	O
coronary	O
events	O
.	O
Given	O
his	O
history	O
,	O
it	O
was	O
also	O
decided	O
to	O
prolong	O
the	O
double	O
antiplatelet	O
therapy	O
,	O
and	O
the	O
patient	O
is	O
currently	O
on	O
ticagrelor	B-FARMACO
60	O
mg	O
every	O
12	O
hours	O
.	O
DIAGNOSIS	O
Inferolateral	O
KK	O
IV	O
STEACS	O
.	O
Late	O
stent	O
thrombosis	O
in	O
ostial	O
anterior	O
descending	O
artery	O
affecting	O
the	O
left	O
common	O
trunk	O
and	O
the	O
ostium	O
of	O
the	O
circumflex	O
artery	O
with	O
TIMI	O
3	O
flow	O
but	O
with	O
distal	O
embolisation	O
with	O
occlusion	O
of	O
distal	O
anterior	O
descending	O
and	O
distal	O
posterior	O
descending	O
arteries	O
.	O
Pharmacological	O
treatment	O
with	O
intracoronary	O
abciximab	B-FARMACO
and	O
later	O
triple	O
antiplatelet	O
therapy	O
with	O
intravenous	O
abciximab	B-FARMACO
and	O
ASA	B-FARMACO
ticagrelor	I-FARMACO
orally	O
.	O
Global	O
preserved	O
LVEF	O
with	O
no	O
mechanical	O
complications	O
or	O
valvular	O
heart	O
disease	O
.	O
Cocaine	O
use	O
as	O
a	O
precipitating	O
factor	O
.	O
Active	O
smoking	O
and	O
alcoholism	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
26	O
year	O
old	O
male	O
,	O
high	O
intensity	O
sportsman	O
,	O
firefighter	O
by	O
profession	O
.	O
No	O
family	O
history	O
of	O
heart	O
disease	O
or	O
sudden	O
death	O
SD	O
at	O
an	O
early	O
age	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
No	O
smoker	O
or	O
drinker	O
.	O
No	O
consumption	O
of	O
other	O
toxic	O
substances	O
.	O
No	O
known	O
cardiovascular	O
risk	O
factors	O
.	O
No	O
medical	O
illnesses	O
or	O
surgical	O
interventions	O
of	O
interest	O
.	O
No	O
chronic	O
treatment	O
.	O
Current	O
illness	O
Patient	O
attended	O
the	O
emergency	O
department	O
in	O
March	O
2020	O
for	O
an	O
episode	O
of	O
dizziness	O
associated	O
with	O
loss	O
of	O
vision	O
and	O
a	O
fall	O
to	O
the	O
floor	O
while	O
at	O
rest	O
,	O
while	O
making	O
a	O
sudden	O
neck	O
twisting	O
movement	O
,	O
without	O
knowing	O
whether	O
she	O
lost	O
consciousness	O
.	O
Immediate	O
recovery	O
with	O
no	O
post	O
critical	O
period	O
,	O
no	O
sphincter	O
relaxation	O
or	O
tonic	O
clonic	O
movements	O
.	O
She	O
reported	O
that	O
this	O
was	O
the	O
first	O
time	O
this	O
symptomatology	O
had	O
occurred	O
,	O
denying	O
previous	O
syncopal	O
episodes	O
or	O
palpitations	O
.	O
Physical	O
examination	O
General	O
state	O
of	O
health	O
.	O
Well	O
hydrated	O
and	O
perfused	O
.	O
Athletic	O
build	O
.	O
Eupneic	O
at	O
rest	O
.	O
Oxygen	O
saturation	O
99	O
without	O
oxygen	O
therapy	O
.	O
Blood	O
pressure	O
BP	O
125	O
65	O
mmHg	O
,	O
heart	O
rate	O
HR	O
55	O
bpm	O
.	O
No	O
jugular	O
ingurgitation	O
.	O
No	O
adenopathies	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
,	O
at	O
a	O
good	O
frequency	O
.	O
No	O
murmurs	O
or	O
audible	O
extratonos	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
.	O
Abdomen	O
soft	O
,	O
non	O
painful	O
,	O
no	O
masses	O
or	O
megaliths	O
.	O
Lower	O
limbs	O
no	O
oedema	O
or	O
signs	O
of	O
venous	O
insufficiency	O
or	O
deep	O
vein	O
thrombosis	O
.	O
Distal	O
pulses	O
present	O
and	O
symmetrical	O
COMPLEMENTARY	O
TESTS	O
ECG	O
sinus	O
bradycardia	O
at	O
55	O
bpm	O
,	O
normal	O
axis	O
,	O
short	O
PR	O
with	O
marked	O
pre	O
excitation	O
positive	O
delta	O
wave	O
in	O
I	O
,	O
inferior	O
face	O
and	O
from	O
V1	O
V6	O
,	O
negative	O
in	O
avL	O
,	O
wide	O
QRS	O
due	O
to	O
initial	O
filling	O
with	O
RsR	O
'	O
morphology	O
in	O
V1	O
with	O
marked	O
repolarisation	O
alterations	O
with	O
ST	O
underleveling	O
and	O
negative	O
T	O
waves	O
in	O
II	O
,	O
III	O
,	O
aVF	O
and	O
V1	O
V6	O
.	O
Chest	O
X	O
ray	O
normal	O
cardiothoracic	O
index	O
.	O
No	O
images	O
suggestive	O
of	O
condensation	O
.	O
Free	O
costophrenic	O
sinuses	O
.	O
Normal	O
lung	O
parenchyma	O
.	O
CBC	O
haemoglobin	O
14	O
.	O
6	O
g	O
dl	O
,	O
leucocytes	O
7200	O
microl	O
67	O
PMN	O
,	O
platelets	O
365	O
,	O
000	O
microl	O
.	O
Coagulation	O
PT	O
80	O
.	O
Biochemistry	O
creatinine	O
0	O
.	O
67	O
mg	O
dl	O
,	O
urea	O
28	O
mg	O
dl	O
,	O
ions	O
normal	O
.	O
Hepatobiliary	O
profile	O
and	O
thyroid	O
hormones	O
normal	O
.	O
Echocardiogram	O
videos	O
1	O
and	O
2	O
left	O
ventricle	O
not	O
dilated	O
,	O
without	O
ventricular	O
hypertrophy	O
but	O
showing	O
marked	O
hypertrabeculation	O
especially	O
at	O
the	O
apical	O
,	O
lower	O
apical	O
,	O
middle	O
and	O
lateral	O
apical	O
levels	O
,	O
with	O
numerous	O
intraventricular	O
recesses	O
which	O
are	O
checked	O
by	O
colour	O
Doppler	O
for	O
communication	O
with	O
the	O
ventricular	O
cavity	O
.	O
LVEF	O
at	O
the	O
limit	O
of	O
normality	O
LVEFbp	O
55	O
.	O
No	O
segmental	O
contractility	O
disorders	O
.	O
Left	O
ventricular	O
LV	O
diastolic	O
function	O
normal	O
transmitral	O
pattern	O
with	O
E	O
A	O
ratio	O
1	O
.	O
4	O
and	O
TDE	O
296	O
ms	O
.	O
Normal	O
filling	O
pressures	O
average	O
E	O
E	O
8	O
,	O
lateral	O
E	O
16	O
cm	O
s	O
,	O
medial	O
E	O
8	O
.	O
5	O
cm	O
s	O
,	O
LA	O
34	O
ml	O
m2	O
,	O
IT	O
2	O
.	O
8	O
m	O
s	O
.	O
Right	O
ventricle	O
of	O
normal	O
size	O
with	O
normal	O
systolic	O
function	O
TAPSE	O
23	O
mm	O
.	O
Normal	O
left	O
atrium	O
.	O
Normal	O
right	O
atrium	O
.	O
Normal	O
size	O
thoracic	O
aorta	O
.	O
No	O
valvulopathies	O
.	O
Pericardium	O
without	O
relevant	O
findings	O
.	O
No	O
intracavitary	O
masses	O
or	O
thrombi	O
.	O
Inferior	O
vena	O
cava	O
of	O
adequate	O
calibre	O
and	O
respiratory	O
dynamics	O
.	O
Ergometry	O
Bruce	O
MET	O
protocol	O
24	O
.	O
Excellent	O
functional	O
capacity	O
.	O
The	O
test	O
was	O
stopped	O
when	O
the	O
target	O
heart	O
rate	O
HR	O
was	O
reached	O
.	O
No	O
chest	O
pain	O
or	O
dyspnoea	O
during	O
exercise	O
.	O
No	O
dynamic	O
changes	O
suggestive	O
of	O
ischaemia	O
.	O
During	O
the	O
entire	O
tracing	O
,	O
there	O
was	O
overt	O
pre	O
excitation	O
with	O
secondary	O
repolarisation	O
alterations	O
,	O
which	O
disappeared	O
when	O
the	O
heart	O
rate	O
reached	O
170	O
bpm	O
and	O
the	O
repolarisation	O
alterations	O
disappeared	O
.	O
Subsequently	O
,	O
during	O
recovery	O
,	O
the	O
patient	O
remained	O
without	O
pre	O
excitation	O
and	O
without	O
repolarisation	O
alterations	O
due	O
to	O
probable	O
exhaustion	O
of	O
the	O
accessory	O
pathway	O
.	O
There	O
were	O
no	O
arrhythmic	O
events	O
of	O
interest	O
.	O
Adequate	O
tension	O
and	O
chronotropic	O
response	O
.	O
Conclusions	O
clinically	O
and	O
electrically	O
negative	O
for	O
ischaemia	O
.	O
Pre	O
excitation	O
that	O
disappears	O
at	O
170	O
bpm	O
.	O
Holter	O
RS	O
study	O
with	O
HR	O
between	O
24	O
43	O
95	O
bpm	O
.	O
Maximum	O
pause	O
of	O
3	O
.	O
7	O
seconds	O
,	O
intermittent	O
pre	O
excitation	O
.	O
Occasional	O
nodal	O
rhythm	O
.	O
Cardiac	O
magnetic	O
resonance	O
CMR	O
left	O
ventricle	O
LV	O
slightly	O
dilated	O
with	O
marked	O
trabeculation	O
of	O
the	O
myocardium	O
,	O
on	O
all	O
sides	O
except	O
the	O
septum	O
and	O
basal	O
segments	O
that	O
show	O
less	O
trabeculae	O
.	O
The	O
ratio	O
of	O
non	O
compacted	O
myocardium	O
to	O
compacted	O
myocardium	O
NCM	O
CM	O
is	O
greater	O
than	O
2	O
.	O
3	O
with	O
a	O
maximum	O
value	O
of	O
4	O
.	O
3	O
in	O
several	O
segments	O
.	O
Global	O
and	O
segmental	O
mobility	O
are	O
preserved	O
.	O
The	O
EF	O
measured	O
with	O
the	O
Simpson	O
method	O
is	O
62	O
.	O
VTDVI	O
of	O
243	O
ml	O
,	O
indexed	O
by	O
body	O
surface	O
area	O
of	O
124	O
ml	O
m2	O
,	O
VTSVI	O
of	O
91	O
.	O
6	O
ml	O
,	O
indexed	O
by	O
body	O
surface	O
area	O
of	O
47	O
ml	O
m2	O
.	O
Cardiac	O
output	O
of	O
10	O
l	O
min	O
.	O
There	O
were	O
deep	O
crypts	O
located	O
at	O
the	O
inferior	O
junction	O
of	O
both	O
ventricles	O
,	O
another	O
in	O
the	O
middle	O
anteroseptal	O
segment	O
and	O
the	O
third	O
at	O
the	O
level	O
of	O
the	O
apical	O
inferior	O
segment	O
.	O
The	O
right	O
ventricle	O
is	O
neither	O
dilated	O
nor	O
hypertrophic	O
,	O
with	O
marked	O
hypertrabeculation	O
.	O
Global	O
and	O
segmental	O
mobility	O
preserved	O
.	O
The	O
EF	O
measured	O
with	O
the	O
Simpson	O
method	O
is	O
66	O
.	O
Both	O
atria	O
are	O
of	O
normal	O
size	O
.	O
The	O
first	O
pass	O
perfusion	O
sequence	O
shows	O
no	O
perfusion	O
defect	O
at	O
rest	O
.	O
Late	O
enhancement	O
viability	O
sequence	O
does	O
not	O
show	O
gadolinium	O
retention	O
suggesting	O
necrosis	O
and	O
or	O
fibrosis	O
.	O
Conclusion	O
non	O
compaction	O
cardiomyopathy	O
with	O
involvement	O
of	O
both	O
ventricles	O
.	O
Preserved	O
biventricular	O
function	O
.	O
Slight	O
LV	O
dilatation	O
.	O
Absence	O
of	O
fibrosis	O
.	O
ECG	O
after	O
ablation	O
sinus	O
tachycardia	O
at	O
105	O
bpm	O
,	O
normal	O
axis	O
,	O
PR	O
146	O
ms	O
,	O
narrow	O
QRS	O
,	O
non	O
pathological	O
q	O
wave	O
in	O
inferior	O
face	O
,	O
ST	O
rectification	O
in	O
inferior	O
face	O
and	O
V5	O
V6	O
with	O
negative	O
T	O
in	O
inferior	O
face	O
,	O
normal	O
QTc	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
assessed	O
in	O
the	O
emergency	O
department	O
by	O
the	O
cardiology	O
service	O
in	O
the	O
event	O
of	O
a	O
syncopal	O
episode	O
,	O
and	O
an	O
electrocardiogram	O
was	O
performed	O
in	O
sinus	O
rhythm	O
with	O
short	O
PR	O
and	O
a	O
marked	O
positive	O
delta	O
wave	O
in	O
inferior	O
aspect	O
and	O
V1	O
V6	O
and	O
negative	O
in	O
aVL	O
,	O
thus	O
giving	O
the	O
impression	O
of	O
a	O
left	O
lateral	O
accessory	O
pathway	O
.	O
Laboratory	O
tests	O
and	O
chest	O
X	O
ray	O
were	O
performed	O
,	O
compatible	O
with	O
normality	O
,	O
as	O
well	O
as	O
echocardiography	O
showing	O
a	O
non	O
dilated	O
left	O
ventricle	O
but	O
with	O
marked	O
hypertrabeculation	O
at	O
the	O
apical	O
,	O
apical	O
lateral	O
and	O
lower	O
middle	O
and	O
apical	O
levels	O
,	O
with	O
numerous	O
recesses	O
communicating	O
with	O
the	O
ventricular	O
cavity	O
,	O
with	O
preserved	O
LVEF	O
,	O
right	O
ventricle	O
of	O
normal	O
morphology	O
and	O
function	O
and	O
no	O
significant	O
valvulopathies	O
videos	O
1	O
and	O
2	O
.	O
Given	O
the	O
suspicion	O
of	O
non	O
compaction	O
cardiomyopathy	O
with	O
left	O
lateral	O
accessory	O
pathway	O
,	O
studies	O
were	O
completed	O
with	O
genetic	O
study	O
and	O
screening	O
of	O
first	O
degree	O
relatives	O
and	O
CMR	O
images	O
2	O
,	O
3	O
and	O
4	O
which	O
confirmed	O
the	O
presence	O
of	O
non	O
compaction	O
cardiomyopathy	O
with	O
biventricular	O
involvement	O
,	O
more	O
marked	O
in	O
the	O
left	O
ventricle	O
,	O
which	O
was	O
slightly	O
dilated	O
and	O
affected	O
in	O
all	O
segments	O
except	O
the	O
septum	O
and	O
basal	O
segments	O
,	O
with	O
a	O
maximum	O
ratio	O
between	O
non	O
compacted	O
and	O
compacted	O
myocardium	O
of	O
4	O
.	O
3	O
.	O
There	O
are	O
deep	O
crypts	O
located	O
at	O
the	O
inferior	O
junction	O
of	O
both	O
ventricles	O
,	O
another	O
in	O
the	O
mid	O
anteroseptal	O
segment	O
and	O
the	O
third	O
at	O
the	O
level	O
of	O
the	O
apical	O
inferior	O
segment	O
.	O
The	O
rest	O
of	O
the	O
study	O
was	O
compatible	O
with	O
normality	O
,	O
with	O
preserved	O
biventricular	O
systolic	O
function	O
and	O
no	O
fibrosis	O
in	O
the	O
late	O
enhancement	O
sequence	O
.	O
The	O
patient	O
was	O
referred	O
to	O
the	O
arrhythmia	O
and	O
electrophysiology	O
unit	O
and	O
underwent	O
ergometry	O
,	O
reaching	O
24	O
METs	O
,	O
without	O
arrhythmic	O
events	O
during	O
the	O
test	O
and	O
with	O
marked	O
pre	O
excitation	O
during	O
the	O
start	O
of	O
the	O
test	O
,	O
which	O
disappeared	O
when	O
170	O
bpm	O
was	O
reached	O
,	O
and	O
remained	O
without	O
pre	O
excitation	O
during	O
recovery	O
.	O
A	O
24	O
hour	O
Holter	O
monitor	O
was	O
also	O
performed	O
,	O
which	O
showed	O
the	O
presence	O
of	O
intermittent	O
pre	O
excitation	O
but	O
no	O
arrhythmic	O
events	O
of	O
interest	O
.	O
Based	O
on	O
the	O
above	O
,	O
it	O
was	O
decided	O
to	O
perform	O
an	O
electrophysiological	O
study	O
EPS	O
in	O
May	O
2020	O
,	O
and	O
programmed	O
stimulation	O
was	O
performed	O
with	O
the	O
finding	O
of	O
concentric	O
decremental	O
anterograde	O
conduction	O
at	O
baseline	O
and	O
,	O
therefore	O
,	O
through	O
the	O
specific	O
conduction	O
system	O
which	O
became	O
eccentric	O
and	O
with	O
an	O
earlier	O
ventriculogram	O
at	O
the	O
left	O
lateral	O
level	O
after	O
infusion	O
of	O
isoproterenol	B-FARMACO
via	O
the	O
accessory	O
pathway	O
.	O
Similarly	O
,	O
atrioventricular	O
dissociation	O
is	O
observed	O
at	O
600	O
ms	O
in	O
programmed	O
retrograde	O
pacing	O
from	O
the	O
right	O
ventricular	O
apex	O
,	O
which	O
changes	O
to	O
concentric	O
decremental	O
retrograde	O
conduction	O
after	O
isoproterenol	B-FARMACO
infusion	O
.	O
The	O
anterograde	O
refractory	O
period	O
of	O
the	O
pathway	O
is	O
measured	O
and	O
is	O
240	O
ms	O
after	O
isoproterenol	B-FARMACO
infusion	O
.	O
No	O
tachycardias	O
are	O
induced	O
after	O
baseline	O
programmed	O
atrial	O
and	O
ventricular	O
pacing	O
and	O
after	O
isoproterenol	B-FARMACO
.	O
Mitral	O
annulus	O
mapping	O
was	O
performed	O
by	O
retroaortic	O
access	O
,	O
with	O
radiofrequency	O
ablation	O
at	O
the	O
left	O
anterolateral	O
level	O
,	O
and	O
ablation	O
was	O
effective	O
with	O
disappearance	O
of	O
pre	O
excitation	O
in	O
2	O
.	O
5	O
seconds	O
.	O
After	O
ablation	O
,	O
the	O
patient	O
continued	O
subsequent	O
follow	O
up	O
in	O
the	O
arrhythmia	O
and	O
electrophysiology	O
unit	O
,	O
remaining	O
asymptomatic	O
in	O
NYHA	O
functional	O
class	O
I	O
and	O
without	O
events	O
in	O
serial	O
Holter	O
monitoring	O
,	O
in	O
sinus	O
rhythm	O
without	O
pre	O
excitation	O
in	O
the	O
baseline	O
ECG	O
although	O
maintaining	O
marked	O
alterations	O
in	O
ventricular	O
repolarisation	O
.	O
In	O
October	O
2020	O
,	O
the	O
results	O
of	O
the	O
genetic	O
study	O
were	O
obtained	O
,	O
identifying	O
a	O
previously	O
undescribed	O
variant	O
in	O
the	O
ACTC1	O
gene	O
p	O
.	O
Pro260Leu	O
,	O
which	O
could	O
be	O
associated	O
with	O
the	O
patient	O
's	O
phenotype	O
non	O
compaction	O
cardiomyopathy	O
,	O
although	O
more	O
information	O
is	O
needed	O
to	O
confirm	O
this	O
,	O
and	O
screening	O
of	O
first	O
degree	O
relatives	O
has	O
yet	O
to	O
be	O
completed	O
.	O
DIAGNOSIS	O
Non	O
compaction	O
cardiomyopathy	O
with	O
biventricular	O
involvement	O
and	O
preserved	O
systolic	O
function	O
.	O
Slight	O
dilatation	O
of	O
the	O
left	O
ventricle	O
.	O
Left	O
anterolateral	O
accessory	O
pathway	O
with	O
intermittent	O
pre	O
excitation	O
.	O
Successful	O
ablation	O
of	O
the	O
pathway	O
by	O
radiofrequency	O
.	O
Variant	O
of	O
uncertain	O
significance	O
in	O
the	O
ACTC1	O
gene	O
p	O
.	O
Pro260Leu	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
80	O
year	O
old	O
woman	O
.	O
No	O
known	O
adverse	O
drug	O
reactions	O
.	O
Cardiovascular	O
risk	O
factors	O
hypertension	O
with	O
good	O
ambulatory	O
control	O
.	O
Non	O
insulin	O
dependent	O
type	O
2	O
diabetes	O
mellitus	O
with	O
good	O
outpatient	O
control	O
.	O
Mixed	O
dyslipidaemia	O
with	O
good	O
outpatient	O
control	O
.	O
Denies	O
toxic	O
habits	O
.	O
Cardiological	O
history	O
paroxysmal	O
atrial	O
fibrillation	O
with	O
two	O
electrical	O
cardioversions	O
2016	O
and	O
2018	O
.	O
Other	O
medical	O
and	O
surgical	O
history	O
depressive	O
disorder	O
,	O
essential	O
thrombocythemia	O
,	O
severe	O
neurotrophic	O
corneal	O
ulcer	O
operated	O
on	O
.	O
Usual	O
treatment	O
fluoxetine	B-FARMACO
20	O
mg	O
1	O
tablet	O
every	O
day	O
,	O
started	O
one	O
month	O
ago	O
,	O
lorazepam	B-FARMACO
1	O
mg	O
every	O
day	O
,	O
acenocoumarol	B-FARMACO
1	O
mg	O
1	O
tablet	O
every	O
day	O
and	O
adjust	O
according	O
to	O
controls	O
,	O
amiodarone	B-FARMACO
200	O
mg	O
1	O
tablet	O
every	O
other	O
day	O
,	O
chlorthalidone	B-FARMACO
50	O
mg	O
1	O
tablet	O
every	O
day	O
,	O
irbesartan	B-FARMACO
300	O
mg	O
1	O
tablet	O
every	O
day	O
,	O
felodipine	B-FARMACO
5	O
mg	O
1	O
tablet	O
every	O
day	O
,	O
atorvastatin	B-FARMACO
20	O
mg	O
1	O
tablet	O
every	O
day	O
,	O
glimepiride	B-FARMACO
20	O
mg	O
1	O
tablet	O
daily	O
,	O
linagliptin	B-FARMACO
5	O
mg	O
1	O
tablet	O
daily	O
,	O
doxycycline	B-FARMACO
200	O
mg	O
1	O
capsule	O
daily	O
and	O
1	O
tablet	O
100	O
mg	O
daily	O
,	O
moxifloxacin	B-FARMACO
ophthalmic	I-FARMACO
,	O
paracetamol	B-FARMACO
tramadol	I-FARMACO
75	O
650	O
mg	O
1	O
tablet	O
every	O
12	O
hours	O
,	O
famotidine	B-FARMACO
20	O
mg	O
1	O
tablet	O
daily	O
,	O
pantoprazole	B-FARMACO
20	O
mg	O
1	O
tablet	O
daily	O
,	O
anagrelide	B-FARMACO
0	O
.	O
5	O
mg	O
2	O
tablets	O
every	O
7	O
days	O
.	O
Present	O
illness	O
The	O
patient	O
is	O
an	O
80	O
year	O
old	O
woman	O
who	O
comes	O
to	O
the	O
point	O
of	O
continuous	O
care	O
PAC	O
for	O
symptoms	O
of	O
loss	O
of	O
consciousness	O
the	O
day	O
before	O
the	O
consultation	O
and	O
on	O
three	O
occasions	O
during	O
the	O
same	O
,	O
lasting	O
approximately	O
30	O
seconds	O
and	O
complete	O
spontaneous	O
recovery	O
.	O
She	O
also	O
had	O
a	O
feeling	O
of	O
dizziness	O
of	O
the	O
unsteadiness	O
type	O
and	O
previous	O
tinnitus	O
,	O
with	O
no	O
associated	O
vegetative	O
cortex	O
.	O
No	O
palpitations	O
.	O
No	O
semiology	O
of	O
heart	O
failure	O
.	O
No	O
chest	O
pain	O
.	O
No	O
infectious	O
clinical	O
manifestations	O
due	O
to	O
equipment	O
.	O
During	O
her	O
stay	O
in	O
the	O
PAC	O
,	O
she	O
presented	O
a	O
new	O
episode	O
witnessed	O
by	O
the	O
doctor	O
,	O
who	O
defibrillated	O
on	O
evidence	O
of	O
pulseless	O
ventricular	O
fibrillation	O
PSVF	O
on	O
the	O
electrocardiogram	O
which	O
we	O
do	O
not	O
have	O
and	O
performed	O
cardiopulmonary	O
resuscitation	O
CPR	O
manoeuvres	O
for	O
less	O
than	O
5	O
minutes	O
.	O
After	O
recovery	O
of	O
sinus	O
rhythm	O
,	O
the	O
patient	O
was	O
referred	O
to	O
the	O
hospital	O
emergency	O
department	O
.	O
Once	O
there	O
,	O
the	O
critical	O
box	O
monitor	O
showed	O
a	O
torsade	O
de	O
Pointes	O
TdP	O
rhythm	O
,	O
initiated	O
by	O
the	O
phenomenon	O
of	O
R	O
over	O
T	O
,	O
self	O
limited	O
for	O
seconds	O
,	O
with	O
presyncopal	O
symptoms	O
,	O
so	O
isoproterenol	B-FARMACO
and	O
magnesium	B-FARMACO
sulphate	I-FARMACO
perfusion	O
was	O
started	O
.	O
It	O
was	O
decided	O
not	O
to	O
implant	O
a	O
temporary	O
pacemaker	O
due	O
to	O
the	O
non	O
relapse	O
of	O
the	O
arrhythmia	O
with	O
isoproterenol	B-FARMACO
perfusion	O
the	O
patient	O
remained	O
in	O
sinus	O
rhythm	O
at	O
95	O
bpm	O
and	O
was	O
admitted	O
to	O
the	O
coronary	O
care	O
unit	O
CCU	O
for	O
monitoring	O
and	O
correction	O
of	O
triggering	O
factors	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
BP	O
125	O
84	O
mmHg	O
,	O
heart	O
rate	O
HR	O
95	O
bpm	O
,	O
oxygen	O
saturation	O
98	O
with	O
FiO2	O
21	O
.	O
Digital	O
blood	O
glucose	O
238	O
mg	O
dl	O
.	O
Good	O
general	O
condition	O
.	O
Conscious	O
and	O
oriented	O
.	O
No	O
signs	O
of	O
respiratory	O
distress	O
.	O
Cardiopulmonary	O
auscultation	O
regular	O
,	O
no	O
audible	O
murmurs	O
.	O
Vesicular	O
murmur	O
preserved	O
,	O
without	O
added	O
noises	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
,	O
no	O
palpable	O
masses	O
or	O
organomegaly	O
,	O
not	O
painful	O
on	O
palpation	O
.	O
No	O
signs	O
of	O
peritoneal	O
irritation	O
.	O
Lower	O
limbs	O
no	O
oedema	O
.	O
No	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
.	O
Neurological	O
conscious	O
and	O
oriented	O
.	O
Glasgow	O
15	O
.	O
Mild	O
bradypsychia	O
.	O
Language	O
correct	O
in	O
form	O
and	O
content	O
.	O
Cranial	O
nerves	O
without	O
alterations	O
.	O
Normal	O
eye	O
movements	O
.	O
Pupils	O
isochoric	O
,	O
normoreactive	O
.	O
Strength	O
and	O
sensitivity	O
of	O
limbs	O
preserved	O
and	O
symmetrical	O
5	O
5	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiograms	O
ECG	O
Health	O
Centre	O
sinus	O
rhythm	O
at	O
80	O
bpm	O
,	O
PR	O
160	O
ms	O
,	O
QRS	O
120	O
ms	O
with	O
morphology	O
of	O
complete	O
right	O
bundle	O
branch	O
block	O
CRBBB	O
and	O
electrical	O
axis	O
at	O
60o	O
,	O
asymmetrical	O
negative	O
T	O
waves	O
in	O
V3	O
V6	O
,	O
flattened	O
T	O
waves	O
in	O
I	O
,	O
II	O
,	O
III	O
and	O
aVL	O
.	O
QT	O
600	O
ms	O
,	O
QTc	O
Bazett	O
639	O
ms	O
.	O
In	O
the	O
critical	O
care	O
unit	O
polymorphic	O
ventricular	O
tachycardia	O
of	O
the	O
TdP	O
type	O
.	O
On	O
discharge	O
from	O
the	O
cardiology	O
ward	O
sinus	O
rhythm	O
at	O
65	O
bpm	O
,	O
PR	O
160	O
ms	O
,	O
QRS	O
160	O
ms	O
with	O
BCRDHH	O
morphology	O
and	O
electrical	O
axis	O
at	O
60o	O
,	O
asymmetrical	O
negative	O
T	O
waves	O
in	O
V1	O
and	O
III	O
.	O
QT	O
480	O
ms	O
,	O
QTc	O
492	O
ms	O
.	O
Blood	O
tests	O
haemoglobin	O
10	O
.	O
9	O
g	O
dl	O
,	O
MCV	O
81	O
.	O
6	O
fl	O
,	O
MCH	O
25	O
.	O
3	O
pg	O
,	O
MCHC	O
31	O
g	O
dl	O
,	O
leukocytes	O
10	O
10	O
9	O
l	O
,	O
neutrophils	O
8	O
10	O
9	O
l	O
,	O
lymphocytes	O
1	O
10	O
9	O
l	O
,	O
platelets	O
190	O
10	O
9	O
l	O
.	O
Coagulation	O
prothrombin	O
time	O
PT	O
16	O
.	O
3	O
sec	O
.	O
Quick	O
's	O
index	O
59	O
,	O
INR	O
1	O
.	O
39	O
.	O
APTT	O
28	O
s	O
.	O
Biochemistry	O
glucose	O
137	O
mg	O
dl	O
,	O
sodium	O
136	O
mEq	O
l	O
,	O
potassium	O
2	O
.	O
9	O
mEq	O
l	O
,	O
magnesium	O
1	O
.	O
6	O
mg	O
dl	O
,	O
calcium	O
corrected	O
to	O
albumin	O
8	O
.	O
1	O
mg	O
dl	O
,	O
chlorine	O
94	O
mEq	O
l	O
total	O
bilirubin	O
3	O
.	O
99	O
mg	O
dl	O
,	O
direct	O
bilirubin	O
2	O
.	O
07	O
mg	O
dl	O
,	O
indirect	O
bilirubin	O
1	O
.	O
92	O
mg	O
dl	O
,	O
alanine	O
aminotransferase	O
GPT	O
34	O
U	O
l	O
,	O
urea	O
91	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
08	O
mg	O
dl	O
,	O
estimated	O
glomerular	O
filtration	O
rate	O
GFR	O
CKDEPI	O
48	O
.	O
6	O
ml	O
min	O
1	O
.	O
73	O
m2	O
,	O
C	O
reactive	O
protein	O
7	O
.	O
1	O
mg	O
dl	O
,	O
ferritin	O
109	O
ng	O
dl	O
,	O
iron	O
47	O
g	O
dl	O
,	O
transferrin	O
saturation	O
index	O
15	O
.	O
2	O
,	O
uric	O
acid	O
10	O
.	O
2	O
mg	O
dl	O
,	O
protein	O
6	O
.	O
6	O
g	O
dl	O
,	O
TSH	O
2	O
.	O
3	O
mIU	O
l	O
.	O
HF	O
markers	O
Carbohydrate	O
Ag	O
.	O
125	O
CA125	O
154	O
IU	O
ml	O
,	O
NT	O
proBNP	O
35	O
,	O
000	O
pg	O
ml	O
.	O
Arterial	O
blood	O
gases	O
pH	O
7	O
.	O
52	O
pCO2	O
40	O
mmHg	O
,	O
pO2	O
75	O
mmHg	O
,	O
HCO3a	O
32	O
.	O
7	O
mmol	O
l	O
,	O
O2SAT	O
95	O
.	O
7	O
,	O
lactate	O
2	O
.	O
3	O
mmol	O
l	O
.	O
Transthoracic	O
echocardiogram	O
concentric	O
left	O
ventricular	O
hypertrophy	O
.	O
Increased	O
left	O
ventricular	O
volumes	O
with	O
global	O
hypokinesia	O
,	O
more	O
severe	O
in	O
lower	O
segments	O
,	O
and	O
severe	O
depression	O
of	O
global	O
systolic	O
function	O
LVEF	O
32	O
.	O
Moderate	O
mitral	O
regurgitation	O
.	O
Mitral	O
filling	O
pattern	O
suggestive	O
of	O
increased	O
end	O
diastolic	O
pressure	O
.	O
Severe	O
left	O
atrial	O
dilatation	O
.	O
Right	O
ventricle	O
with	O
normal	O
diameters	O
and	O
mild	O
depression	O
of	O
global	O
systolic	O
function	O
,	O
mild	O
tricuspid	O
insufficiency	O
TI	O
with	O
GP	O
31	O
mmHg	O
.	O
Inferior	O
vena	O
cava	O
IVC	O
not	O
dilated	O
.	O
Estimated	O
systolic	O
pulmonary	O
artery	O
pressure	O
SPAP	O
35	O
mmHg	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
.	O
Chest	O
X	O
ray	O
very	O
poorly	O
inspired	O
study	O
.	O
Increased	O
bilateral	O
perihilar	O
alveolar	O
raster	O
,	O
which	O
could	O
correspond	O
to	O
discrete	O
oedema	O
.	O
There	O
were	O
no	O
images	O
suggestive	O
of	O
pulmonary	O
consolidation	O
.	O
Free	O
costophrenic	O
sinuses	O
.	O
Cardiomegaly	O
.	O
Calcification	O
of	O
the	O
aortic	O
button	O
.	O
Degenerative	O
changes	O
in	O
the	O
dorsal	O
spine	O
.	O
Coronary	O
angiography	O
epicardial	O
coronary	O
arteries	O
without	O
lesions	O
.	O
CLINICAL	O
EVOLUTION	O
During	O
her	O
stay	O
in	O
the	O
OCU	O
,	O
the	O
patient	O
remained	O
asymptomatic	O
and	O
electrocardiograms	O
showed	O
prolonged	O
QT	O
interval	O
QTc	O
639	O
ms	O
,	O
of	O
probable	O
iatrogenic	O
acquired	O
aetiology	O
,	O
as	O
she	O
was	O
taking	O
up	O
to	O
3	O
drugs	O
with	O
known	O
risk	O
of	O
TdP	O
moxifloxacin	B-FARMACO
,	O
anagrelide	B-FARMACO
,	O
amiodarone	B-FARMACO
and	O
4	O
that	O
could	O
be	O
arrhythmogenic	O
in	O
specific	O
conditions	O
fluoxetine	B-FARMACO
,	O
pantoprazole	B-FARMACO
,	O
famotidine	B-FARMACO
and	O
tramadol	B-FARMACO
.	O
In	O
addition	O
,	O
blood	O
tests	O
showed	O
mild	O
hypokalaemia	O
,	O
hypomagnesaemia	O
and	O
hypocalcaemia	O
,	O
electrolyte	O
disorders	O
that	O
predispose	O
to	O
prolongation	O
of	O
the	O
QT	O
interval	O
.	O
For	O
all	O
these	O
reasons	O
,	O
it	O
was	O
decided	O
to	O
discontinue	O
the	O
predisposing	O
medication	O
and	O
to	O
supplement	O
magnesium	B-FARMACO
,	O
calcium	B-FARMACO
and	O
potassium	B-FARMACO
to	O
correct	O
their	O
plasma	O
levels	O
.	O
After	O
48	O
hours	O
of	O
monitoring	O
without	O
new	O
episodes	O
and	O
correction	O
of	O
the	O
QTc	O
to	O
540	O
ms	O
,	O
it	O
was	O
decided	O
to	O
transfer	O
him	O
to	O
the	O
cardiology	O
ward	O
to	O
complete	O
treatment	O
and	O
study	O
HF	O
with	O
severe	O
ventricular	O
dysfunction	O
with	O
moderate	O
mitral	O
insufficiency	O
MI	O
on	O
regular	O
echocardiography	O
.	O
During	O
her	O
stay	O
in	O
the	O
cardiology	O
ward	O
,	O
coronary	O
angiography	O
was	O
performed	O
to	O
complete	O
the	O
study	O
of	O
dilated	O
cardiomyopathy	O
without	O
any	O
pathological	O
findings	O
.	O
The	O
patient	O
progressed	O
favourably	O
and	O
due	O
to	O
clinical	O
and	O
haemodynamic	O
stability	O
and	O
correction	O
of	O
the	O
electrocardiographic	O
alteration	O
,	O
after	O
19	O
days	O
in	O
hospital	O
it	O
was	O
decided	O
to	O
discharge	O
her	O
home	O
with	O
subsequent	O
monitoring	O
and	O
follow	O
up	O
by	O
the	O
heart	O
failure	O
unit	O
.	O
Pharmacological	O
treatment	O
was	O
started	O
for	O
HF	O
with	O
reduced	O
LVEF	O
sacubitril	B-FARMACO
valsartan	I-FARMACO
24	O
26	O
mg	O
1	O
tablet	O
every	O
12	O
h	O
,	O
eplerenone	B-FARMACO
25	O
mg	O
1	O
tablet	O
every	O
24	O
h	O
,	O
nebivolol	B-FARMACO
2	O
.	O
5	O
mg	O
0	O
.	O
5	O
tablet	O
every	O
24	O
h	O
,	O
dapagliflozin	B-FARMACO
10	O
mg	O
1	O
tablet	O
every	O
24	O
h	O
,	O
furosemide	B-FARMACO
40	O
mg	O
1	O
tablet	O
every	O
24	O
h	O
together	O
with	O
magnesium	B-FARMACO
53	O
mg	O
2	O
tablets	O
every	O
12	O
h	O
and	O
edoxaban	B-FARMACO
30	O
mg	O
1	O
tablet	O
every	O
24	O
h	O
.	O
Similarly	O
,	O
it	O
was	O
decided	O
to	O
discontinue	O
drugs	O
precipitating	O
QT	O
interval	O
prolongation	O
fluoxetine	B-FARMACO
,	O
moxifloxacin	B-FARMACO
,	O
amiodarone	B-FARMACO
,	O
pantoprazole	B-FARMACO
and	O
famotidine	B-FARMACO
.	O
In	O
the	O
cardiology	O
outpatient	O
follow	O
up	O
,	O
one	O
month	O
after	O
discharge	O
home	O
,	O
and	O
after	O
optimal	O
medical	O
treatment	O
of	O
HF	O
,	O
the	O
patient	O
showed	O
clinical	O
stability	O
with	O
no	O
recurrence	O
of	O
HF	O
,	O
partial	O
recovery	O
of	O
LVEF	O
current	O
LVEF	O
40	O
and	O
QT	O
interval	O
within	O
normal	O
limits	O
.	O
Therefore	O
,	O
the	O
patient	O
is	O
labelled	O
as	O
non	O
ischaemic	O
dilated	O
cardiomyopathy	O
with	O
a	O
tachycardiomyopathy	O
component	O
and	O
treatment	O
is	O
maintained	O
at	O
the	O
appropriate	O
doses	O
.	O
DIAGNOSIS	O
Iatrogenic	O
acquired	O
prolonged	O
QT	O
interval	O
pharmacological	O
and	O
hydroelectrolytic	O
with	O
arrhythmic	O
events	O
in	O
the	O
form	O
of	O
polymorphic	O
ventricular	O
tachycardia	O
torsade	O
de	O
Pointes	O
and	O
recovered	O
cardiorespiratory	O
arrest	O
.	O
Heart	O
failure	O
with	O
reduced	O
LVEF	O
in	O
the	O
context	O
of	O
non	O
ischemic	O
dilated	O
cardiomyopathy	O
with	O
some	O
component	O
of	O
tachycardiomyopathy	O
.	O
Coronary	O
arteries	O
without	O
lesions	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
Male	O
,	O
45	O
years	O
old	O
.	O
No	O
drug	O
allergies	O
.	O
No	O
arterial	O
hypertension	O
,	O
no	O
diabetes	O
mellitus	O
,	O
no	O
dyslipidaemia	O
.	O
No	O
known	O
heart	O
disease	O
or	O
bronchopathy	O
.	O
Advanced	O
chronic	O
kidney	O
disease	O
on	O
haemodialysis	O
programme	O
,	O
secondary	O
to	O
autosomal	O
dominant	O
polycystic	O
kidney	O
disease	O
.	O
Renal	O
transplant	O
in	O
May	O
2018	O
with	O
acute	O
rejection	O
on	O
the	O
10th	O
day	O
with	O
good	O
subsequent	O
response	O
.	O
Proximal	O
deep	O
vein	O
thrombosis	O
at	O
the	O
level	O
of	O
superficial	O
femoral	O
,	O
popliteal	O
vein	O
and	O
deep	O
and	O
twin	O
branches	O
of	O
left	O
lower	O
limb	O
in	O
November	O
2018	O
in	O
current	O
treatment	O
with	O
acenocoumarol	B-FARMACO
.	O
Pyelonephritis	O
of	O
the	O
renal	O
graft	O
in	O
March	O
2019	O
with	O
good	O
response	O
to	O
antibiotic	O
treatment	O
.	O
Current	O
treatment	O
prednisone	B-FARMACO
20	O
mg	O
24	O
hours	O
,	O
tacrolimus	B-FARMACO
4	O
mg	O
24	O
hours	O
,	O
omeprazole	B-FARMACO
20	O
mg	O
24	O
hours	O
,	O
enoxaparin	B-FARMACO
60	O
mg	O
24	O
hours	O
and	O
furosemide	B-FARMACO
40	O
mg	O
24	O
hours	O
.	O
Present	O
illness	O
He	O
was	O
admitted	O
from	O
the	O
nephrology	O
department	O
for	O
clinical	O
manifestations	O
of	O
fever	O
,	O
predominantly	O
nocturnal	O
,	O
up	O
to	O
38	O
.	O
3oC	O
,	O
of	O
2	O
weeks	O
of	O
evolution	O
,	O
together	O
with	O
exertional	O
dyspnoea	O
NYHA	O
III	O
,	O
orthopnoea	O
,	O
oedematisation	O
of	O
the	O
lower	O
limbs	O
and	O
cough	O
with	O
whitish	O
expectoration	O
.	O
He	O
had	O
been	O
admitted	O
2	O
months	O
previously	O
for	O
the	O
same	O
reason	O
with	O
partial	O
improvement	O
and	O
without	O
identification	O
of	O
the	O
aetiology	O
,	O
but	O
the	O
symptoms	O
recurred	O
after	O
discontinuation	O
of	O
antibiotic	O
therapy	O
.	O
No	O
micturition	O
symptoms	O
,	O
no	O
alterations	O
in	O
bowel	O
habits	O
.	O
On	O
previous	O
admission	O
,	O
a	O
study	O
was	O
performed	O
for	O
a	O
similar	O
clinical	O
picture	O
and	O
fever	O
of	O
unknown	O
origin	O
.	O
Chest	O
CT	O
scan	O
on	O
admission	O
showed	O
mild	O
pericardial	O
effusion	O
and	O
a	O
micronodular	O
interstitial	O
pattern	O
with	O
well	O
defined	O
nodules	O
,	O
bilaterally	O
and	O
symmetrically	O
distributed	O
.	O
In	O
this	O
context	O
,	O
blood	O
cultures	O
,	O
urine	O
cultures	O
and	O
serology	O
were	O
negative	O
and	O
there	O
was	O
no	O
PCR	O
detection	O
of	O
cytomegalovirus	O
,	O
Pneumocystis	O
jirovecii	O
in	O
bronchoalveolar	O
lavage	O
and	O
respiratory	O
viruses	O
.	O
Negative	O
smear	O
microscopy	O
,	O
PCR	O
for	O
tuberculosis	O
in	O
bronchoalveolar	O
lavage	O
and	O
bronchoaspirate	O
and	O
negative	O
mycobacterial	O
culture	O
.	O
Galactomannan	O
for	O
aspergillus	O
in	O
bronchoalveolar	O
lavage	O
negative	O
.	O
Negative	O
PCR	O
for	O
Leishmania	O
in	O
bone	O
marrow	O
.	O
Given	O
the	O
lack	O
of	O
detection	O
of	O
an	O
aetiological	O
agent	O
during	O
admission	O
and	O
the	O
improvement	O
with	O
antibiotic	O
treatment	O
,	O
it	O
was	O
decided	O
to	O
discharge	O
the	O
patient	O
on	O
a	O
course	O
of	O
ciprofloxacin	B-FARMACO
and	O
follow	O
up	O
in	O
consultations	O
.	O
Physical	O
examination	O
Good	O
general	O
condition	O
.	O
Eupneic	O
at	O
rest	O
.	O
Blood	O
pressure	O
136	O
80	O
mmHg	O
,	O
heart	O
rate	O
100	O
bpm	O
,	O
oxygen	O
saturation	O
96	O
FiO2	O
0	O
.	O
21	O
.	O
Central	O
venous	O
pressure	O
absence	O
of	O
jugular	O
ingurgitation	O
.	O
Cardiac	O
and	O
respiratory	O
auscultation	O
rhythmic	O
tones	O
without	O
audible	O
murmurs	O
.	O
Vesicular	O
murmur	O
with	O
no	O
added	O
sounds	O
.	O
Abdomen	O
soft	O
,	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
.	O
Palpable	O
hepatomegaly	O
and	O
splenomegaly	O
.	O
Murphy	O
and	O
Blumberg	O
negative	O
.	O
Lower	O
limbs	O
left	O
lower	O
limb	O
with	O
signs	O
of	O
deep	O
venous	O
thrombosis	O
already	O
known	O
with	O
increased	O
diameter	O
compared	O
to	O
the	O
right	O
.	O
Right	O
lower	O
limb	O
with	O
oedema	O
in	O
the	O
distal	O
third	O
with	O
fovea	O
.	O
COMPLEMENTARY	O
TESTS	O
Blood	O
tests	O
on	O
admission	O
haemoglobin	O
11	O
.	O
6	O
g	O
dl	O
,	O
MCV	O
77	O
fl	O
,	O
MCH	O
23	O
.	O
4	O
pg	O
,	O
leukocytes	O
3	O
,	O
350	O
l	O
,	O
neutrophils	O
2	O
,	O
540	O
l	O
,	O
lymphocytes	O
470	O
l	O
and	O
platelets	O
99	O
,	O
000	O
	O
.	O
Biochemistry	O
glucose	O
86	O
mg	O
dl	O
,	O
urea	O
119	O
mg	O
dl	O
,	O
creatinine	O
3	O
.	O
34	O
mg	O
dl	O
,	O
sodium	O
140	O
mEq	O
l	O
,	O
potassium	O
3	O
.	O
7	O
mEq	O
l	O
,	O
chlorine	O
97	O
mEq	O
l	O
,	O
magnesium	O
1	O
.	O
4	O
mg	O
dl	O
.	O
AST	O
11	O
U	O
l	O
,	O
ALT	O
10	O
U	O
l	O
,	O
GGT	O
104	O
U	O
l	O
,	O
alkaline	O
phosphatase	O
114	O
U	O
l	O
,	O
LDH	O
209	O
U	O
l	O
,	O
protein	O
5	O
.	O
5	O
g	O
dl	O
,	O
albumin	O
2	O
.	O
90	O
g	O
dl	O
,	O
iron	O
34	O
g	O
dl	O
,	O
ferritin	O
293	O
g	O
ml	O
,	O
transferrin	O
145	O
mg	O
dl	O
,	O
transferrin	O
saturation	O
index	O
18	O
.	O
46	O
.	O
Urine	O
system	O
glucose	O
,	O
protein	O
,	O
bilirubin	O
,	O
haemoglobin	O
,	O
leukocyte	O
esterase	O
and	O
nitrites	O
negative	O
.	O
Sediment	O
normal	O
.	O
Tacrolimus	B-FARMACO
levels	O
4	O
.	O
3	O
ng	O
ml	O
therapeutic	O
range	O
5	O
10	O
ng	O
ml	O
.	O
Electrocardiogram	O
sinus	O
rhythm	O
at	O
100	O
bpm	O
,	O
normal	O
PR	O
,	O
narrow	O
QRS	O
with	O
normal	O
axis	O
,	O
no	O
low	O
voltages	O
.	O
No	O
electrical	O
alternans	O
.	O
No	O
repolarisation	O
alterations	O
.	O
Chest	O
CT	O
bilateral	O
and	O
diffuse	O
micronodular	O
lung	O
pattern	O
.	O
Mild	O
bilateral	O
pleural	O
effusion	O
.	O
Severe	O
pericardial	O
effusion	O
.	O
Blood	O
cultures	O
,	O
urine	O
culture	O
and	O
sputum	O
culture	O
negative	O
.	O
Mantoux	O
test	O
negative	O
.	O
Echocardiogram	O
on	O
admission	O
left	O
atrium	O
of	O
normal	O
size	O
area	O
15	O
cm2	O
and	O
volume	O
29	O
ml	O
15	O
ml	O
m2	O
.	O
Left	O
ventricle	O
of	O
normal	O
size	O
,	O
mild	O
parietal	O
hypertrophy	O
,	O
preserved	O
global	O
systolic	O
function	O
IVS	O
14mm	O
,	O
Dd	O
56	O
mm	O
,	O
Ds	O
31	O
mm	O
,	O
LVEF	O
by	O
Teicholtz	O
76	O
.	O
Biphasic	O
filling	O
pattern	O
with	O
E	O
A	O
ratio	O
at	O
1	O
.	O
5	O
,	O
E	O
E	O
'	O
at	O
6	O
.	O
4	O
lateral	O
.	O
No	O
valvulopathies	O
.	O
Normal	O
aortic	O
root	O
.	O
Normal	O
right	O
chambers	O
.	O
Right	O
ventricle	O
with	O
good	O
function	O
TAPSE	O
of	O
22	O
mm	O
,	O
lateral	O
S	O
'	O
peak	O
at	O
18	O
cm	O
sec	O
.	O
Minimal	O
TR	O
allowing	O
estimation	O
of	O
normal	O
PSAP	O
.	O
Normal	O
right	O
atrium	O
with	O
area	O
15	O
cm2	O
and	O
volume	O
33	O
ml	O
16	O
ml	O
m2	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
with	O
adequate	O
inspiratory	O
collapse	O
.	O
Non	O
dilated	O
suprahepatic	O
veins	O
.	O
Severe	O
circumferential	O
pericardial	O
effusion	O
with	O
an	O
M	O
mode	O
measurement	O
in	O
the	O
parasternal	O
long	O
axis	O
19	O
18	O
mm	O
.	O
Respiratory	O
variation	O
of	O
mitral	O
filling	O
flow	O
less	O
than	O
25	O
.	O
Conclusion	O
severe	O
pericardial	O
effusion	O
,	O
without	O
haemodynamic	O
repercussion	O
by	O
echocardiography	O
.	O
Chest	O
X	O
ray	O
after	O
pericardiocentesis	O
normal	O
cardiothoracic	O
index	O
,	O
not	O
suggestive	O
of	O
pericardial	O
effusion	O
.	O
Increased	O
perihilar	O
vascular	O
network	O
,	O
without	O
condensation	O
or	O
occupation	O
of	O
costophrenic	O
sinuses	O
.	O
Pericardial	O
fluid	O
analysis	O
Cells	O
erythrocytes	O
265	O
,	O
200	O
l	O
and	O
leukocytes	O
1	O
,	O
432	O
l	O
10	O
neutrophils	O
and	O
90	O
monocytes	O
.	O
Glucose	O
77	O
mg	O
dl	O
VN	O
70	O
110	O
mg	O
dl	O
,	O
protein	O
3	O
.	O
9	O
g	O
dl	O
,	O
amylase	O
33	O
U	O
l	O
VN	O
0	O
100	O
U	O
l	O
,	O
LDH	O
1	O
,	O
085	O
U	O
l	O
.	O
Pathology	O
of	O
pericardial	O
fluid	O
pericardial	O
fluid	O
cytology	O
negative	O
for	O
malignancy	O
.	O
Cytological	O
smear	O
very	O
haematic	O
with	O
abundant	O
mixed	O
lymphocytic	O
and	O
polymorphonuclear	O
inflammatory	O
cellularity	O
.	O
With	O
fewer	O
histiocytes	O
;	O
no	O
giant	O
cells	O
,	O
no	O
granulomas	O
,	O
no	O
evidence	O
of	O
BAAR	O
with	O
Zhiel	O
technique	O
.	O
Microbiology	O
Sputum	O
culture	O
and	O
antibiogram	O
negative	O
.	O
Urine	O
culture	O
and	O
antibiogram	O
negative	O
.	O
Pericardial	O
fluid	O
bacilloscopy	O
negative	O
.	O
Pericardial	O
fluid	O
culture	O
and	O
antibiogram	O
negative	O
.	O
PCR	O
of	O
extrapulmonary	O
tuberculosis	O
in	O
pericardial	O
fluid	O
PCR	O
of	O
the	O
tuberculous	O
complex	O
positive	O
.	O
Mycobacterium	O
tuberculosis	O
mutations	O
in	O
pericardial	O
fluid	O
no	O
mutations	O
in	O
RPO	O
B	O
gene	O
associated	O
with	O
rifampicin	B-FARMACO
resistance	O
were	O
detected	O
.	O
Mycobacterial	O
culture	O
in	O
pericardial	O
fluid	O
positive	O
for	O
Mycobacterium	O
tuberculosis	O
result	O
obtained	O
after	O
discharge	O
.	O
Blood	O
tests	O
prior	O
to	O
discharge	O
haemoglobin	O
12	O
.	O
4	O
g	O
dl	O
,	O
MCV	O
81	O
.	O
3	O
fl	O
,	O
MCH	O
24	O
.	O
9	O
pg	O
,	O
leukocytes	O
2	O
,	O
910	O
l	O
,	O
neutrophils	O
1990	O
l	O
,	O
lymphocytes	O
540	O
l	O
and	O
platelets	O
125	O
,	O
000	O
l	O
.	O
Biochemistry	O
glucose	O
73	O
mg	O
dl	O
,	O
urea	O
96	O
mg	O
dl	O
,	O
creatinine	O
3	O
.	O
39	O
mg	O
dl	O
,	O
sodium	O
142	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
5	O
mEq	O
l	O
,	O
chlorine	O
109	O
mEq	O
l	O
,	O
magnesium	O
1	O
.	O
5	O
mg	O
dl	O
.	O
AST	O
14	O
U	O
l	O
,	O
ALT	O
15	O
U	O
l	O
,	O
GGT	O
96	O
U	O
l	O
,	O
alkaline	O
phosphatase	O
128	O
U	O
l	O
,	O
LDH	O
209	O
U	O
l	O
,	O
protein	O
5	O
.	O
4	O
g	O
dl	O
,	O
albumin	O
2	O
.	O
90	O
g	O
dl	O
,	O
iron	O
61	O
g	O
dl	O
,	O
ferritin	O
271	O
.	O
9	O
g	O
ml	O
,	O
transferrin	O
142	O
mg	O
dl	O
,	O
transferrin	O
saturation	O
index	O
33	O
.	O
82	O
.	O
CLINICAL	O
EVOLUTION	O
During	O
admission	O
,	O
he	O
had	O
a	O
good	O
evolution	O
with	O
no	O
fever	O
peaks	O
and	O
improvement	O
of	O
dyspnoea	O
after	O
diuretic	O
and	O
antibiotic	O
treatment	O
.	O
Blood	O
cultures	O
,	O
urine	O
culture	O
,	O
sputum	O
culture	O
and	O
Mantoux	O
were	O
negative	O
.	O
The	O
transthoracic	O
echocardiogram	O
on	O
admission	O
showed	O
preserved	O
biventricular	O
function	O
with	O
severe	O
circumferential	O
pericardial	O
effusion	O
without	O
signs	O
of	O
haemodynamic	O
compromise	O
.	O
As	O
this	O
was	O
a	O
patient	O
with	O
immunosuppressive	O
treatment	O
,	O
fever	O
of	O
unknown	O
origin	O
and	O
these	O
findings	O
in	O
the	O
chest	O
CT	O
scan	O
,	O
tuberculosis	O
was	O
suspected	O
despite	O
Mantoux	O
and	O
negative	O
tests	O
from	O
the	O
previous	O
admission	O
,	O
so	O
treatment	O
was	O
extended	O
for	O
coverage	O
.	O
In	O
addition	O
,	O
it	O
was	O
decided	O
to	O
perform	O
diagnostic	O
pericardiocentesis	O
,	O
previously	O
explaining	O
the	O
risks	O
to	O
the	O
patient	O
due	O
to	O
the	O
presence	O
of	O
liver	O
cysts	O
associated	O
with	O
polycystic	O
kidney	O
disease	O
.	O
It	O
was	O
performed	O
without	O
complications	O
,	O
obtaining	O
800	O
ml	O
of	O
serohaematic	O
content	O
and	O
sending	O
the	O
extracted	O
fluid	O
for	O
biochemical	O
and	O
microbiological	O
analysis	O
.	O
Biochemical	O
analysis	O
of	O
the	O
pericardial	O
fluid	O
was	O
compatible	O
with	O
exudate	O
.	O
Cytology	O
showed	O
a	O
very	O
haematic	O
content	O
with	O
abundant	O
mixed	O
lymphocytic	O
and	O
polymorphonuclear	O
inflammatory	O
cellularity	O
.	O
In	O
the	O
microbiological	O
analysis	O
,	O
the	O
culture	O
of	O
the	O
first	O
days	O
was	O
negative	O
,	O
but	O
with	O
positive	O
PCR	O
for	O
tuberculous	O
complex	O
without	O
the	O
presence	O
of	O
mutations	O
in	O
the	O
RPO	O
B	O
gene	O
associated	O
with	O
resistance	O
to	O
rifampicin	B-FARMACO
.	O
Thus	O
,	O
the	O
diagnosis	O
of	O
tuberculosis	O
was	O
confirmed	O
despite	O
the	O
other	O
negative	O
tests	O
and	O
the	O
corresponding	O
treatment	O
was	O
completed	O
.	O
The	O
patient	O
remained	O
afebrile	O
and	O
improved	O
in	O
analytical	O
and	O
radiographic	O
controls	O
,	O
so	O
it	O
was	O
decided	O
to	O
discharge	O
him	O
from	O
hospital	O
with	O
his	O
immunosuppressive	O
treatment	O
tacrolimus	B-FARMACO
and	O
prednisone	B-FARMACO
and	O
with	O
a	O
specific	O
regimen	O
for	O
tuberculosis	O
with	O
isoniazid	B-FARMACO
pyridoxine	I-FARMACO
,	O
rifabutin	B-FARMACO
,	O
ethambutol	B-FARMACO
and	O
pyrazinamide	B-FARMACO
for	O
2	O
months	O
and	O
,	O
subsequently	O
,	O
with	O
isoniazid	B-FARMACO
pyridoxine	I-FARMACO
and	O
rifabutin	B-FARMACO
for	O
7	O
more	O
months	O
.	O
On	O
follow	O
up	O
,	O
pericardial	O
fluid	O
culture	O
was	O
finally	O
found	O
to	O
be	O
positive	O
for	O
mycobacterium	O
,	O
further	O
supporting	O
the	O
diagnosis	O
.	O
A	O
transthoracic	O
echocardiogram	O
was	O
performed	O
at	O
6	O
months	O
,	O
with	O
the	O
pericardial	O
effusion	O
resolved	O
and	O
no	O
pericardial	O
constriction	O
.	O
The	O
patient	O
has	O
now	O
completed	O
treatment	O
for	O
tuberculosis	O
without	O
complications	O
and	O
is	O
afebrile	O
and	O
clinically	O
well	O
.	O
DIAGNOSIS	O
Pericardial	O
effusion	O
due	O
to	O
Mycobacterium	O
tuberculosis	O
in	O
a	O
patient	O
immunocompromised	O
by	O
renal	O
transplantation	O
.	O
Absence	O
of	O
signs	O
of	O
pericardial	O
constriction	O
at	O
follow	O
up	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
Smoker	O
of	O
3	O
cigarettes	O
a	O
day	O
.	O
Severe	O
mitral	O
regurgitation	O
secondary	O
to	O
chordal	O
rupture	O
pending	O
surgery	O
.	O
Pre	O
anaesthetic	O
assessment	O
performed	O
,	O
with	O
last	O
transthoracic	O
echocardiography	O
TTE	O
,	O
transesophageal	O
echocardiography	O
TTE	O
and	O
pre	O
surgical	O
coronary	O
angiography	O
without	O
epicardial	O
lesions	O
the	O
month	O
prior	O
to	O
the	O
episode	O
.	O
Inguinal	O
hernia	O
surgery	O
.	O
No	O
chronic	O
treatment	O
.	O
Present	O
illness	O
50	O
year	O
old	O
male	O
brought	O
to	O
hospital	O
emergency	O
department	O
by	O
SAMU	O
after	O
recovered	O
cardiorespiratory	O
arrest	O
.	O
The	O
patient	O
presented	O
at	O
rest	O
while	O
watching	O
television	O
with	O
an	O
episode	O
of	O
loss	O
of	O
consciousness	O
without	O
previous	O
symptoms	O
,	O
at	O
which	O
point	O
his	O
relative	O
called	O
112	O
and	O
started	O
basic	O
cardiopulmonary	O
resuscitation	O
CPR	O
.	O
On	O
arrival	O
of	O
the	O
SAMU	O
,	O
they	O
observed	O
cardiorespiratory	O
arrest	O
and	O
began	O
advanced	O
CPR	O
manoeuvres	O
laryngeal	O
mask	O
mechanical	O
ventilation	O
,	O
observing	O
as	O
the	O
first	O
rhythm	O
ventricular	O
fibrillation	O
VF	O
,	O
for	O
which	O
5	O
shocks	O
were	O
administered	O
,	O
450	O
mg	O
of	O
amiodarone	B-FARMACO
and	O
3	O
mg	O
of	O
adrenaline	B-FARMACO
,	O
recovering	O
sinus	O
rhythm	O
.	O
On	O
arrival	O
at	O
the	O
emergency	O
department	O
,	O
a	O
laryngeal	O
mask	O
was	O
replaced	O
by	O
an	O
endotracheal	O
tube	O
.	O
The	O
patient	O
was	O
sedoanalgesiated	O
and	O
well	O
adapted	O
to	O
mechanical	O
ventilation	O
,	O
haemodynamically	O
stable	O
without	O
vasopressor	O
or	O
inotropic	O
drugs	O
.	O
Physical	O
examination	O
Blood	O
pressure	O
BP	O
127	O
91	O
mmHg	O
,	O
heart	O
rate	O
HR	O
93	O
bpm	O
,	O
oxygen	O
saturation	O
96	O
IMV	O
with	O
FIO2	O
100	O
.	O
Cardiac	O
auscultation	O
regular	O
heart	O
sounds	O
,	O
predominant	O
systolic	O
murmur	O
in	O
EIB	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
,	O
crackles	O
in	O
the	O
bases	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
,	O
no	O
pain	O
on	O
palpation	O
.	O
No	O
masses	O
or	O
megaliths	O
.	O
No	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
in	O
the	O
lower	O
limbs	O
.	O
Pulses	O
present	O
,	O
bilateral	O
and	O
symmetrical	O
.	O
Neurological	O
no	O
sounds	O
,	O
no	O
response	O
to	O
pain	O
,	O
medium	O
photoreactive	O
pupils	O
.	O
COMPLEMENTARY	O
TESTS	O
Electrocardiogram	O
ECG	O
on	O
arrival	O
at	O
the	O
critical	O
care	O
unit	O
sinus	O
rhythm	O
at	O
100	O
bpm	O
,	O
isolated	O
ventricular	O
extrasystoles	O
,	O
PR	O
160ms	O
.	O
Narrow	O
QRS	O
with	O
normal	O
axis	O
,	O
without	O
repolarisation	O
alterations	O
.	O
ECG	O
during	O
monitoring	O
sinus	O
rhythm	O
at	O
100	O
bpm	O
,	O
normal	O
PR	O
,	O
frequent	O
polytopic	O
ventricular	O
extrasystoles	O
,	O
narrow	O
QRS	O
with	O
normal	O
axis	O
,	O
signs	O
of	O
LVH	O
,	O
no	O
significant	O
repolarisation	O
abnormalities	O
.	O
Blood	O
tests	O
on	O
arrival	O
at	O
the	O
critical	O
care	O
unit	O
haemoglobin	O
17	O
g	O
dl	O
,	O
MCV	O
96	O
.	O
3	O
fl	O
.	O
Leukocytes	O
18100	O
Ne	O
13300	O
,	O
Li	O
3800	O
.	O
PLT	O
235	O
,	O
000	O
.	O
D	O
dimer	O
11538	O
g	O
ml	O
.	O
IQ	O
100	O
.	O
Na	O
137mmEq	O
l	O
,	O
K	O
4mmEq	O
l	O
,	O
Ur	O
36	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
15	O
mg	O
dl	O
,	O
calcium	O
8	O
.	O
8	O
mg	O
dl	O
,	O
protein	O
6	O
.	O
6	O
g	O
dl	O
,	O
CRP	O
0	O
.	O
1	O
mg	O
dl	O
,	O
GPT	O
186	O
U	O
l	O
,	O
amylase	O
173	O
U	O
l	O
.	O
Arterial	O
blood	O
gases	O
on	O
arrival	O
FiO2	O
50	O
pH	O
7	O
.	O
16	O
,	O
pCO2	O
58	O
mmHg	O
,	O
pO2	O
113	O
mmHg	O
,	O
HCO3	O
20	O
.	O
7	O
mEq	O
l	O
,	O
Sat	O
O2	O
98	O
.	O
8	O
,	O
lactate	O
5	O
.	O
6	O
mmol	O
l	O
.	O
Arterial	O
blood	O
gas	O
one	O
hour	O
after	O
arrival	O
pH	O
7	O
.	O
24	O
,	O
pCO2	O
50	O
mmHg	O
,	O
pO2	O
131	O
mmHg	O
,	O
HCO3	O
21	O
.	O
4	O
mEq	O
l	O
,	O
Sat	O
O2	O
99	O
.	O
3	O
,	O
lactate	O
3	O
mmol	O
l	O
.	O
PCR	O
SARS	O
VOC	O
2	O
on	O
arrival	O
negative	O
.	O
Computed	O
tomography	O
CT	O
scan	O
of	O
the	O
brain	O
size	O
of	O
the	O
ventricular	O
system	O
within	O
the	O
normal	O
range	O
,	O
without	O
significant	O
dilatation	O
of	O
sulci	O
,	O
identifying	O
no	O
intracranial	O
haematic	O
collections	O
,	O
space	O
occupying	O
lesions	O
,	O
fracture	O
traces	O
or	O
alterations	O
suggesting	O
the	O
presence	O
of	O
areas	O
of	O
acute	O
ischaemia	O
.	O
Midline	O
elements	O
are	O
centred	O
.	O
Pulmonary	O
CT	O
bibasal	O
condensation	O
due	O
to	O
probable	O
aspiration	O
during	O
orotracheal	O
intubation	O
OTI	O
.	O
Minimal	O
undisplaced	O
fractures	O
of	O
the	O
4th	O
and	O
5th	O
right	O
anterior	O
costal	O
arches	O
.	O
Distended	O
stomach	O
.	O
Chest	O
X	O
ray	O
portable	O
study	O
with	O
little	O
inspiration	O
,	O
signs	O
of	O
vascular	O
redistribution	O
without	O
showing	O
infiltrates	O
or	O
pleural	O
effusion	O
.	O
TTE	O
and	O
TEE	O
mitral	O
valve	O
with	O
eversion	O
of	O
the	O
posterior	O
leaflet	O
at	O
P2	O
flail	O
due	O
to	O
chordal	O
rupture	O
.	O
Two	O
divergent	O
regurgitant	O
jets	O
of	O
globally	O
severe	O
regurgitation	O
ORE	O
by	O
PISA	O
0	O
.	O
5	O
cm2	O
,	O
vena	O
contracta	O
6	O
7	O
mm	O
,	O
regurgitant	O
volume	O
96	O
ml	O
.	O
Left	O
ventricle	O
LV	O
of	O
greatly	O
increased	O
diameters	O
and	O
volumes	O
with	O
mildly	O
depressed	O
systolic	O
function	O
LVEF	O
45	O
50	O
.	O
Absence	O
of	O
other	O
significant	O
valvulopathies	O
.	O
Very	O
dilated	O
left	O
atrium	O
.	O
Right	O
ventricle	O
with	O
normal	O
diameters	O
and	O
systolic	O
function	O
preserved	O
in	O
limits	O
.	O
No	O
signs	O
of	O
pulmonary	O
hypertension	O
PAPS	O
30	O
35	O
mmHg	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
.	O
CLINICAL	O
EVOLUTION	O
The	O
patient	O
was	O
transferred	O
to	O
the	O
coronary	O
unit	O
UCO	O
.	O
Cerebral	O
and	O
pulmonary	O
CT	O
was	O
performed	O
to	O
rule	O
out	O
cerebrovascular	O
accident	O
CVA	O
,	O
pulmonary	O
thromboembolism	O
PTE	O
or	O
acute	O
aortic	O
syndrome	O
.	O
Given	O
the	O
CT	O
findings	O
,	O
empirical	O
antibiotic	O
therapy	O
was	O
started	O
.	O
A	O
few	O
hours	O
later	O
,	O
he	O
was	O
extubated	O
,	O
with	O
good	O
clinical	O
evolution	O
and	O
remained	O
stable	O
in	O
haemodynamic	O
and	O
respiratory	O
terms	O
.	O
No	O
neurological	O
involvement	O
was	O
identified	O
as	O
a	O
sequelae	O
of	O
the	O
arrest	O
.	O
The	O
control	O
chest	O
X	O
ray	O
showed	O
disappearance	O
of	O
the	O
alveolar	O
infiltrates	O
.	O
Ten	O
days	O
later	O
,	O
the	O
cardiac	O
surgery	O
team	O
operated	O
to	O
repair	O
the	O
mitral	O
valve	O
,	O
placing	O
a	O
mitral	O
ring	O
and	O
4	O
neo	O
strings	O
.	O
During	O
surgery	O
,	O
extensive	O
prolapse	O
of	O
P2	O
,	O
chordal	O
rupture	O
and	O
cleft	O
between	O
P1	O
P2	O
were	O
observed	O
.	O
Postoperative	O
TEE	O
was	O
performed	O
and	O
showed	O
no	O
residual	O
mitral	O
regurgitation	O
MR	O
after	O
repair	O
.	O
After	O
the	O
operation	O
,	O
he	O
remained	O
in	O
the	O
OCU	O
,	O
presenting	O
several	O
episodes	O
of	O
atrial	O
fibrillation	O
AF	O
that	O
led	O
to	O
haemodynamic	O
instability	O
and	O
were	O
controlled	O
by	O
electrical	O
cardioversion	O
ECV	O
and	O
intravenous	O
amiodarone	B-FARMACO
perfusion	O
.	O
After	O
reaching	O
stability	O
,	O
a	O
single	O
chamber	O
implantable	O
cardioverter	O
defibrillator	O
ICD	O
was	O
implanted	O
for	O
secondary	O
prevention	O
.	O
The	O
patient	O
was	O
subsequently	O
discharged	O
.	O
He	O
has	O
continued	O
to	O
undergo	O
check	O
ups	O
at	O
the	O
clinic	O
,	O
remaining	O
in	O
NYHA	O
functional	O
class	O
I	O
and	O
with	O
no	O
new	O
arrhythmic	O
events	O
.	O
DIAGNOSIS	O
Malignant	O
mitral	O
valve	O
prolapse	O
complicated	O
with	O
recovered	O
CRP	O
.	O
Severe	O
mitral	O
insufficiency	O
due	O
to	O
P2	O
prolapse	O
due	O
to	O
chordal	O
rupture	O
,	O
surgically	O
repaired	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
No	O
known	O
drug	O
allergies	O
.	O
Lives	O
with	O
her	O
husband	O
.	O
Never	O
smoker	O
.	O
Occasional	O
drinker	O
.	O
No	O
cardiovascular	O
risk	O
factors	O
or	O
previous	O
cardiological	O
history	O
.	O
Other	O
antecedents	O
varicose	O
veins	O
in	O
lower	O
limbs	O
.	O
No	O
previous	O
surgical	O
intervention	O
.	O
Chronic	O
treatment	O
oral	O
contraceptive	O
levonorgestrel	B-FARMACO
0	O
.	O
1	O
mg	O
etinylestradiol	B-FARMACO
0	O
.	O
02	O
mg	O
1	O
tablet	O
per	O
day	O
.	O
Present	O
illness	O
The	O
patient	O
presents	O
with	O
a	O
self	O
limiting	O
episode	O
of	O
precordial	O
pain	O
at	O
rest	O
.	O
It	O
is	O
attributed	O
to	O
musculoskeletal	O
origin	O
and	O
treated	O
with	O
anti	O
inflammatory	O
drugs	O
.	O
At	O
22	O
15	O
hours	O
the	O
following	O
day	O
,	O
she	O
presented	O
with	O
a	O
new	O
episode	O
of	O
precordial	O
pain	O
,	O
which	O
did	O
not	O
subside	O
with	O
rest	O
,	O
together	O
with	O
general	O
malaise	O
.	O
Her	O
husband	O
called	O
the	O
emergency	O
services	O
.	O
At	O
that	O
moment	O
,	O
the	O
patient	O
suffered	O
cardiorespiratory	O
arrest	O
CRA	O
and	O
her	O
husband	O
started	O
basic	O
cardiopulmonary	O
resuscitation	O
CPR	O
.	O
On	O
arrival	O
of	O
the	O
emergency	O
services	O
,	O
a	O
shockable	O
rhythm	O
was	O
detected	O
,	O
which	O
changed	O
to	O
sinus	O
rhythm	O
after	O
3	O
shocks	O
at	O
200	O
joules	O
.	O
Fifteen	O
minutes	O
of	O
advanced	O
CPR	O
were	O
recorded	O
,	O
with	O
orotracheal	O
intubation	O
and	O
invasive	O
mechanical	O
ventilation	O
.	O
The	O
outgoing	O
electrocardiogram	O
ECG	O
showed	O
right	O
bundle	O
branch	O
block	O
without	O
clear	O
ST	O
segment	O
elevation	O
,	O
so	O
the	O
Infarction	O
Code	O
was	O
not	O
activated	O
.	O
The	O
patient	O
was	O
transferred	O
to	O
the	O
emergency	O
department	O
of	O
our	O
centre	O
.	O
Physical	O
examination	O
On	O
arrival	O
at	O
the	O
ED	O
temperature	O
36	O
.	O
7	O
C	O
,	O
blood	O
pressure	O
90	O
73	O
mmHg	O
,	O
heart	O
rate	O
92	O
bpm	O
,	O
respiratory	O
rate	O
16	O
rpm	O
,	O
oxygen	O
saturation	O
94	O
.	O
Sedoanalgesia	O
,	O
connected	O
to	O
invasive	O
mechanical	O
ventilation	O
.	O
Good	O
distal	O
perfusion	O
.	O
Jugular	O
venous	O
pressure	O
normal	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
,	O
tachycardic	O
,	O
no	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
.	O
Lower	O
extremities	O
without	O
oedema	O
.	O
Carotid	O
,	O
radial	O
and	O
femoral	O
pulses	O
present	O
.	O
COMPLEMENTARY	O
TESTS	O
CBC	O
haemoglobin	O
12	O
.	O
5	O
g	O
dl	O
,	O
MCV	O
95	O
.	O
9	O
fl	O
,	O
MCH	O
30	O
.	O
3	O
pg	O
C	O
,	O
leukocytes	O
13	O
,	O
920	O
l	O
,	O
platelets	O
398	O
,	O
000	O
l	O
.	O
Biochemistry	O
glucose	O
385	O
mg	O
dl	O
,	O
urea	O
27	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
25	O
mg	O
dl	O
,	O
sodium	O
139	O
mmol	O
l	O
,	O
potassium	O
2	O
.	O
6	O
mmol	O
l	O
,	O
C	O
reactive	O
protein	O
0	O
.	O
3	O
mg	O
dl	O
.	O
Lipid	O
profile	O
total	O
cholesterol	O
165	O
mg	O
dl	O
,	O
LDL	O
94	O
mg	O
dl	O
,	O
HDL	O
33	O
mg	O
dl	O
,	O
triglycerides	O
194	O
mg	O
dl	O
,	O
HbA1C	O
5	O
.	O
4	O
.	O
TSH	O
1	O
.	O
22	O
IU	O
ml	O
.	O
Ultrasensitive	O
troponin	O
T	O
normal	O
14	O
ng	O
l	O
serial	O
on	O
admission	O
on	O
arrival	O
,	O
at	O
3	O
hours	O
,	O
at	O
24	O
hours	O
,	O
at	O
36	O
hours	O
and	O
at	O
discharge	O
204	O
6	O
,	O
032	O
1	O
,	O
954	O
2	O
,	O
003	O
1	O
,	O
704	O
ng	O
l	O
.	O
Coagulation	O
INR	O
0	O
.	O
92	O
.	O
Prothrombin	O
rate	O
115	O
.	O
Partial	O
thromboplastin	O
time	O
28	O
.	O
6	O
sec	O
.	O
Partial	O
thromboplastin	O
time	O
ratio	O
0	O
.	O
92	O
.	O
D	O
dimer	O
3	O
,	O
349	O
ng	O
ml	O
.	O
Arterial	O
blood	O
gas	O
pH	O
7	O
.	O
28	O
.	O
pO2	O
282	O
mmHg	O
.	O
pCO2	O
35	O
mmHg	O
.	O
Bicarbonate	O
16	O
.	O
9	O
mmol	O
l	O
.	O
ECG	O
post	O
arrest	O
sinus	O
rhythm	O
,	O
negative	O
T	O
wave	O
in	O
V3	O
V5	O
.	O
On	O
admission	O
to	O
ICU	O
sinus	O
rhythm	O
,	O
ST	O
segment	O
elevation	O
from	O
V2	O
to	O
V4	O
.	O
Angio	O
CT	O
of	O
pulmonary	O
arteries	O
no	O
evidence	O
of	O
pulmonary	O
thromboembolism	O
or	O
deep	O
vein	O
thrombosis	O
.	O
Cranial	O
CT	O
scan	O
without	O
contrast	O
no	O
signs	O
of	O
acute	O
intracranial	O
pathology	O
.	O
Echocardiogram	O
in	O
ICU	O
moderately	O
affected	O
LVEF	O
39	O
with	O
septoapical	O
and	O
apex	O
akinesia	O
,	O
mid	O
septal	O
and	O
lateroapical	O
hypokinesia	O
.	O
Doubtful	O
image	O
at	O
apical	O
level	O
two	O
chambers	O
,	O
which	O
could	O
correspond	O
to	O
thrombus	O
.	O
Mild	O
mitral	O
insufficiency	O
.	O
Coronary	O
angiography	O
right	O
coronary	O
artery	O
without	O
stenosis	O
.	O
Left	O
main	O
coronary	O
artery	O
without	O
stenosis	O
.	O
Anterior	O
descending	O
artery	O
AD	O
with	O
spiroid	O
dissection	O
from	O
the	O
proximal	O
portion	O
and	O
occlusion	O
in	O
the	O
middle	O
segment	O
,	O
TIMI	O
0	O
flow	O
.	O
Percutaneous	O
coronary	O
intervention	O
to	O
the	O
LAD	O
intra	O
aortic	O
balloon	O
counterpulsation	O
is	O
implanted	O
.	O
After	O
verifying	O
by	O
IVUS	O
the	O
presence	O
of	O
coronary	O
dissection	O
with	O
guidewire	O
in	O
the	O
true	O
lumen	O
,	O
three	O
drug	O
eluting	O
stents	O
were	O
implanted	O
from	O
the	O
distal	O
LAD	O
to	O
the	O
ostial	O
LAD	O
with	O
final	O
TIMI	O
3	O
flow	O
and	O
without	O
complications	O
.	O
Echocardiogram	O
with	O
contrast	O
13	O
x	O
8	O
mm	O
mural	O
thrombus	O
in	O
the	O
apex	O
of	O
the	O
left	O
ventricle	O
LV	O
.	O
CLINICAL	O
EVOLUTION	O
A	O
46	O
year	O
old	O
woman	O
was	O
admitted	O
after	O
an	O
out	O
of	O
hospital	O
CRA	O
resuscitated	O
by	O
a	O
relative	O
.	O
At	O
the	O
time	O
no	O
infarction	O
code	O
was	O
activated	O
by	O
ECG	O
without	O
clear	O
ST	O
segment	O
elevation	O
.	O
On	O
arrival	O
at	O
the	O
ED	O
,	O
other	O
possible	O
causes	O
of	O
CRA	O
were	O
ruled	O
out	O
normal	O
pulmonary	O
CT	O
angiography	O
and	O
cranial	O
CT	O
.	O
Initial	O
emergency	O
echocardioscopy	O
showed	O
no	O
segmental	O
contractility	O
alterations	O
.	O
She	O
was	O
transferred	O
to	O
the	O
ICU	O
,	O
where	O
she	O
was	O
sedated	O
,	O
perfused	O
with	O
low	O
doses	O
of	O
noradrenaline	B-FARMACO
,	O
in	O
sinus	O
rhythm	O
and	O
without	O
respiratory	O
compromise	O
;	O
reactive	O
to	O
verbal	O
stimuli	O
,	O
making	O
coordinated	O
movements	O
with	O
the	O
upper	O
limbs	O
and	O
with	O
reactive	O
pupils	O
.	O
An	O
echocardiogram	O
was	O
performed	O
on	O
admission	O
to	O
the	O
ICU	O
which	O
showed	O
ventricular	O
dysfunction	O
and	O
segmental	O
alterations	O
in	O
contractility	O
in	O
the	O
territory	O
of	O
the	O
LAD	O
artery	O
,	O
so	O
a	O
repeat	O
ECG	O
was	O
performed	O
which	O
showed	O
an	O
elevation	O
of	O
the	O
anterior	O
ST	O
segment	O
.	O
Emergent	O
coronary	O
angiography	O
was	O
performed	O
,	O
showing	O
a	O
spirodial	O
dissection	O
of	O
the	O
proximal	O
LAD	O
with	O
occlusion	O
at	O
the	O
level	O
of	O
the	O
middle	O
LAD	O
and	O
distal	O
TIMI	O
0	O
flow	O
,	O
and	O
three	O
drug	O
eluting	O
stents	O
were	O
implanted	O
with	O
good	O
angiographic	O
results	O
,	O
as	O
well	O
as	O
intra	O
aortic	O
balloon	O
counterpulsation	O
IABP	O
.	O
In	O
the	O
ICU	O
,	O
she	O
had	O
a	O
favourable	O
evolution	O
that	O
allowed	O
the	O
amine	B-FARMACO
support	O
and	O
IABP	O
to	O
be	O
withdrawn	O
.	O
She	O
was	O
discharged	O
to	O
the	O
hospital	O
ward	O
.	O
She	O
remained	O
in	O
stable	O
condition	O
with	O
amnesia	O
of	O
recent	O
episodes	O
as	O
an	O
identifiable	O
immediate	O
neurological	O
sequela	O
.	O
She	O
remained	O
with	O
a	O
tendency	O
to	O
arterial	O
hypotension	O
and	O
sinus	O
tachycardia	O
during	O
admission	O
without	O
clinical	O
repercussions	O
,	O
which	O
allowed	O
the	O
initiation	O
of	O
neurohormonal	O
treatment	O
with	O
angiotensin	O
converting	O
enzyme	O
inhibitors	O
ACE	O
inhibitors	O
and	O
beta	O
blockers	O
.	O
Incidentally	O
,	O
in	O
the	O
initial	O
echocardiogram	O
with	O
moderate	O
LV	O
dysfunction	O
,	O
an	O
image	O
suggestive	O
of	O
apical	O
thrombus	O
was	O
observed	O
,	O
which	O
was	O
later	O
confirmed	O
with	O
contrast	O
echocardiography	O
.	O
Electrocardiographically	O
,	O
the	O
patient	O
progressed	O
to	O
established	O
myocardial	O
necrosis	O
with	O
Q	O
wave	O
from	O
V1	O
to	O
V3	O
.	O
At	O
discharge	O
,	O
triple	O
antithrombotic	O
therapy	O
was	O
maintained	O
with	O
double	O
antiplatelet	O
therapy	O
with	O
acetylsalicylic	B-FARMACO
acid	I-FARMACO
,	O
clopidogrel	B-FARMACO
and	O
acenocoumarol	B-FARMACO
.	O
Acenocoumarol	B-FARMACO
was	O
withdrawn	O
after	O
3	O
months	O
of	O
outpatient	O
follow	O
up	O
,	O
after	O
resolution	O
of	O
the	O
thrombus	O
.	O
DIAGNOSIS	O
Out	O
of	O
hospital	O
cardiorespiratory	O
arrest	O
in	O
defibrillable	O
rhythm	O
,	O
resuscitated	O
.	O
Ischaemic	O
heart	O
disease	O
,	O
ST	O
segment	O
elevation	O
acute	O
coronary	O
syndrome	O
STEMI	O
,	O
Q	O
wave	O
infarction	O
secondary	O
to	O
spiroid	O
dissection	O
of	O
the	O
LAD	O
with	O
mid	O
segment	O
occlusion	O
.	O
Percutaneous	O
treatment	O
with	O
implantation	O
of	O
three	O
drug	O
eluting	O
overlapping	O
stents	O
from	O
distal	O
LAD	O
to	O
ostial	O
LAD	O
.	O
Moderately	O
affected	O
LVEF	O
in	O
acute	O
phase	O
with	O
mural	O
thrombus	O
in	O
LV	O
apex	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
No	O
drug	O
allergies	O
.	O
Tuberous	O
sclerosis	O
and	O
epilepsy	O
under	O
follow	O
up	O
by	O
neurology	O
and	O
medical	O
oncology	O
required	O
treatment	O
with	O
everolimus	B-FARMACO
which	O
was	O
suspended	O
due	O
to	O
reduction	O
of	O
brain	O
lesions	O
,	O
after	O
which	O
they	O
remain	O
stable	O
in	O
control	O
brain	O
MRI	O
scans	O
,	O
the	O
last	O
one	O
a	O
month	O
ago	O
.	O
Rhabdomyoma	O
with	O
remission	O
in	O
2006	O
.	O
Bilateral	O
renal	O
angiomyolipomas	O
.	O
Facial	O
angiofibromas	O
.	O
Giant	O
subependymal	O
astrocytomas	O
and	O
numerous	O
cerebral	O
cortical	O
tuberosities	O
.	O
Toxic	O
habits	O
not	O
reported	O
.	O
Current	O
treatment	O
lacosamide	B-FARMACO
150	O
mg	O
12	O
hours	O
and	O
topical	O
sirolimus	B-FARMACO
.	O
Present	O
illness	O
A	O
20	O
year	O
old	O
male	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
recurrent	O
vomiting	O
of	O
about	O
3	O
months	O
'	O
duration	O
,	O
initially	O
postprandial	O
and	O
,	O
subsequently	O
,	O
not	O
clearly	O
related	O
to	O
ingestion	O
,	O
together	O
with	O
diarrhoeal	O
stools	O
and	O
pruritus	O
.	O
No	O
chest	O
pain	O
,	O
no	O
dyspnoea	O
,	O
no	O
abdominal	O
pain	O
,	O
no	O
fever	O
or	O
other	O
associated	O
symptoms	O
.	O
Physical	O
examination	O
Acceptable	O
general	O
condition	O
.	O
Eupneic	O
at	O
rest	O
.	O
Skin	O
pallor	O
.	O
Cardiorespiratory	O
auscultation	O
rhythmic	O
tones	O
at	O
a	O
good	O
frequency	O
,	O
without	O
murmurs	O
or	O
extratones	O
.	O
Bladder	O
murmur	O
preserved	O
with	O
no	O
extra	O
sounds	O
.	O
Abdomen	O
soft	O
and	O
depressible	O
,	O
not	O
painful	O
on	O
palpation	O
,	O
with	O
no	O
signs	O
of	O
peritoneal	O
irritation	O
.	O
No	O
masses	O
or	O
visceromegaly	O
were	O
palpable	O
.	O
Lower	O
extremities	O
no	O
oedema	O
or	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
.	O
COMPLEMENTARY	O
TESTS	O
Emergency	O
venous	O
blood	O
gases	O
pH	O
7	O
.	O
44	O
,	O
sodium	O
135	O
mmol	O
l	O
,	O
potassium	O
3	O
.	O
4	O
mmol	O
l	O
,	O
haemoglobin	O
14	O
.	O
2	O
g	O
dl	O
,	O
lactic	O
acid	O
2	O
.	O
3	O
mmol	O
l	O
and	O
bicarbonate	O
25	O
.	O
8	O
mmol	O
l	O
.	O
Blood	O
tests	O
on	O
admission	O
haemoglobin	O
13	O
.	O
6	O
g	O
dl	O
,	O
MCV	O
82	O
.	O
1	O
fl	O
,	O
leukocytes	O
4580	O
l	O
,	O
neutrophils	O
2740	O
l	O
,	O
lymphocytes	O
1330	O
l	O
and	O
platelets	O
139000	O
	O
Coagulation	O
INR	O
1	O
.	O
6	O
and	O
TPAct	O
45	O
.	O
Biochemistry	O
glucose	O
88	O
mg	O
d	O
,	O
urea	O
45	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
94	O
mg	O
dl	O
,	O
glomerular	O
filtration	O
rate	O
107	O
ml	O
min	O
,	O
sodium	O
138	O
mEq	O
l	O
,	O
potassium	O
3	O
.	O
5	O
mEq	O
l	O
,	O
chlorine	O
98	O
mEq	O
l	O
,	O
AST	O
76	O
U	O
l	O
,	O
ALT	O
122	O
U	O
l	O
,	O
GGT	O
44	O
U	O
l	O
,	O
alkaline	O
phosphatase	O
58	O
U	O
l	O
,	O
TSH	O
3	O
.	O
78	O
mU	O
l	O
.	O
Iron	O
23	O
g	O
dl	O
,	O
ferritin	O
25	O
.	O
4	O
ng	O
ml	O
,	O
transferrin	O
241	O
mg	O
dl	O
,	O
TSI	O
7	O
.	O
51	O
.	O
Copper	O
1	O
.	O
70	O
mg	O
l	O
VN	O
0	O
.	O
65	O
1	O
.	O
65	O
,	O
ceruloplasmin	O
32	O
mg	O
dl	O
VN	O
20	O
60	O
,	O
1	O
antitrypsin	O
177	O
mg	O
dl	O
VN	O
90	O
200	O
.	O
Anti	O
mitochondrial	O
,	O
anti	O
smooth	O
muscle	O
,	O
anti	O
LKM	O
and	O
anti	O
parietal	O
cell	O
antibodies	O
negative	O
.	O
Anti	O
transglutaminase	O
antibodies	O
IgA	O
0	O
.	O
60	O
VN	O
7	O
and	O
IgA	O
282	O
mg	O
dl	O
VN	O
90	O
450	O
.	O
Upper	O
gastrointestinal	O
endoscopy	O
EDA	O
normal	O
oesophagus	O
up	O
to	O
the	O
cardia	O
with	O
small	O
longitudinal	O
fibrinous	O
erosion	O
of	O
about	O
5	O
mm	O
in	O
length	O
.	O
Otherwise	O
normal	O
cardia	O
.	O
Stomach	O
with	O
good	O
motility	O
and	O
distensibility	O
with	O
normal	O
mucosa	O
and	O
without	O
lesions	O
except	O
for	O
slight	O
petechiae	O
in	O
the	O
fornix	O
suggestive	O
of	O
secondary	O
to	O
nausea	O
.	O
A	O
sample	O
was	O
taken	O
for	O
urease	O
.	O
Centric	O
and	O
permeable	O
pylorus	O
.	O
Bulb	O
and	O
second	O
duodenal	O
portion	O
without	O
lesions	O
.	O
Diagnosis	O
Los	O
Angeles	O
grade	O
A	O
erosive	O
oesophagitis	O
.	O
Slight	O
petechiae	O
in	O
the	O
fornix	O
.	O
Urease	O
.	O
Control	O
laboratory	O
tests	O
haemoglobin	O
12	O
.	O
5	O
g	O
dl	O
,	O
MCV	O
81	O
.	O
3	O
fl	O
,	O
leukocytes	O
4920	O
l	O
,	O
neutrophils	O
3090	O
l	O
,	O
lymphocytes	O
1380	O
l	O
and	O
platelets	O
203000	O
	O
Coagulation	O
INR	O
1	O
.	O
8	O
and	O
TPAct	O
39	O
.	O
Biochemistry	O
glucose	O
85	O
mg	O
dl	O
,	O
urea	O
45	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
84	O
mg	O
dl	O
,	O
glomerular	O
filtration	O
rate	O
122	O
ml	O
min	O
,	O
sodium	O
137	O
mEq	O
l	O
,	O
potassium	O
3	O
.	O
6	O
mEq	O
l	O
,	O
chlorine	O
99	O
mEq	O
l	O
,	O
AST	O
79	O
U	O
l	O
,	O
ALT	O
111	O
U	O
l	O
,	O
GGT	O
39	O
U	O
l	O
,	O
alkaline	O
phosphatase	O
58	O
U	O
l	O
,	O
total	O
bilirubin	O
2	O
.	O
6	O
mg	O
dl	O
.	O
Total	O
cholesterol	O
91	O
mg	O
dl	O
,	O
HDL	O
15	O
mg	O
dl	O
,	O
LDL	O
62	O
mg	O
dl	O
and	O
triglycerides	O
70	O
mg	O
dl	O
.	O
Total	O
protein	O
5	O
.	O
6	O
g	O
dl	O
,	O
albumin	O
3	O
.	O
40	O
g	O
dl	O
,	O
prealbumin	O
7	O
mg	O
dl	O
VN	O
20	O
40	O
,	O
C	O
reactive	O
protein	O
13	O
.	O
48	O
mg	O
l	O
.	O
Cortisol	O
28	O
.	O
90	O
g	O
dl	O
VN	O
4	O
.	O
30	O
22	O
.	O
40	O
.	O
Serology	O
IgG	O
positive	O
for	O
HSV	O
and	O
varicella	O
zoster	O
and	O
negative	O
for	O
cytomegalovirus	O
and	O
Epstein	O
Baar	O
virus	O
.	O
Negative	O
IgM	O
for	O
HSV	O
,	O
varicella	O
zoster	O
,	O
cytomegalovirus	O
,	O
Epstein	O
Baar	O
and	O
hepatitis	O
A	O
.	O
Stool	O
normal	O
calprotectin	O
.	O
Abdominal	O
ultrasound	O
liver	O
of	O
normal	O
size	O
,	O
borders	O
and	O
echogenicity	O
,	O
without	O
focal	O
lesions	O
.	O
Gallbladder	O
with	O
double	O
wall	O
ingested	O
without	O
lithiasis	O
.	O
Normal	O
biliary	O
tract	O
.	O
Cava	O
and	O
suprahepatic	O
ducts	O
not	O
dilated	O
.	O
Patent	O
portal	O
of	O
normal	O
calibre	O
8	O
.	O
3	O
mm	O
.	O
No	O
by	O
pass	O
circulation	O
.	O
Central	O
area	O
hidden	O
by	O
gas	O
.	O
Normal	O
spleen	O
size	O
.	O
Small	O
renal	O
cysts	O
.	O
Free	O
fluid	O
in	O
pelvis	O
.	O
Left	O
pleural	O
effusion	O
.	O
Diagnosis	O
small	O
amount	O
of	O
fluid	O
in	O
the	O
pelvis	O
with	O
no	O
ultrasound	O
evidence	O
of	O
chronic	O
liver	O
disease	O
.	O
Left	O
pleural	O
effusion	O
.	O
Renal	O
cysts	O
Thoracic	O
abdominal	O
CT	O
with	O
contrast	O
Chest	O
thickening	O
of	O
the	O
interlobular	O
septa	O
and	O
bronchial	O
walls	O
associated	O
with	O
a	O
faint	O
ground	O
glass	O
pattern	O
in	O
declined	O
areas	O
.	O
There	O
is	O
also	O
cardiomegaly	O
at	O
the	O
expense	O
of	O
the	O
ventricles	O
and	O
rectification	O
of	O
the	O
interventricular	O
septum	O
.	O
The	O
trunk	O
of	O
the	O
pulmonary	O
artery	O
is	O
enlarged	O
up	O
to	O
34	O
mm	O
and	O
there	O
is	O
reflux	O
of	O
intravenous	O
contrast	O
into	O
the	O
superior	O
venae	O
cavae	O
and	O
suprahepatic	O
veins	O
.	O
Pericardial	O
effusion	O
sheet	O
.	O
Edema	O
of	O
the	O
subcutaneous	O
cellular	O
tissue	O
.	O
No	O
pleural	O
effusion	O
.	O
Abdomen	O
free	O
fluid	O
in	O
pelvis	O
,	O
between	O
loops	O
,	O
perihepatic	O
and	O
in	O
both	O
droplets	O
.	O
Bilateral	O
renal	O
cysts	O
.	O
Increased	O
calibre	O
of	O
suprahepatic	O
veins	O
,	O
suggestive	O
of	O
stasis	O
.	O
Pancreas	O
,	O
spleen	O
,	O
adrenal	O
glands	O
and	O
kidneys	O
without	O
appreciable	O
findings	O
.	O
Discrete	O
edematous	O
mural	O
thickening	O
in	O
the	O
cecum	O
and	O
right	O
colon	O
of	O
non	O
specific	O
appearance	O
.	O
No	O
pneumoperitoneum	O
was	O
observed	O
.	O
Conclusion	O
signs	O
of	O
cardiac	O
overload	O
.	O
Intra	O
abdominal	O
free	O
fluid	O
in	O
moderate	O
quantity	O
.	O
Discrete	O
oedematous	O
thickening	O
in	O
the	O
right	O
cecum	O
colon	O
,	O
of	O
non	O
specific	O
appearance	O
.	O
Blood	O
tests	O
on	O
the	O
cardiology	O
ward	O
haemoglobin	O
14	O
.	O
6	O
g	O
dl	O
,	O
MCV	O
79	O
.	O
9	O
fl	O
,	O
leukocytes	O
4580	O
l	O
,	O
neutrophils	O
6870	O
l	O
,	O
lymphocytes	O
1520	O
l	O
and	O
platelets	O
208000	O
	O
Coagulation	O
INR	O
1	O
.	O
6	O
and	O
TPAct	O
46	O
.	O
Biochemistry	O
glucose	O
82	O
mg	O
dl	O
,	O
urea	O
44	O
mg	O
dl	O
,	O
creatinine	O
0	O
.	O
86	O
mg	O
dl	O
,	O
glomerular	O
filtration	O
rate	O
119	O
ml	O
min	O
,	O
sodium	O
142	O
mEq	O
l	O
,	O
potassium	O
3	O
.	O
3	O
mEq	O
l	O
,	O
chlorine	O
95	O
mEq	O
l	O
,	O
AST	O
70U	O
l	O
,	O
ALT	O
112	O
U	O
l	O
,	O
GGT	O
49	O
U	O
l	O
,	O
LDH	O
407	O
U	O
l	O
,	O
total	O
bilirubin	O
2	O
.	O
8	O
mg	O
dl	O
,	O
direct	O
B	O
.	O
1	O
.	O
5	O
mg	O
dl	O
.	O
Total	O
cholesterol	O
115	O
mg	O
dl	O
,	O
HDL	O
17	O
mg	O
dl	O
,	O
LDL	O
81	O
mg	O
dl	O
and	O
triglycerides	O
82	O
mg	O
dl	O
.	O
Total	O
protein	O
6	O
.	O
6	O
g	O
dl	O
,	O
albumin	O
3	O
.	O
80	O
g	O
dl	O
,	O
iron	O
27	O
g	O
dl	O
,	O
ferritin	O
35	O
.	O
5	O
ng	O
ml	O
,	O
transferrin	O
262	O
mg	O
dl	O
,	O
TSI	O
8	O
.	O
11	O
,	O
folate	O
9	O
.	O
9	O
ng	O
ml	O
and	O
vitamin	O
B12	O
717	O
pg	O
ml	O
.	O
HbA1c	O
6	O
.	O
NT	O
proBNP	O
10200	O
pg	O
ml	O
.	O
Electrocardiogram	O
sinus	O
rhythm	O
at	O
about	O
65	O
bpm	O
,	O
signs	O
of	O
biauricular	O
enlargement	O
,	O
long	O
PR	O
BAV	O
1st	O
degree	O
,	O
left	O
axis	O
,	O
wide	O
QRS	O
with	O
intraventricular	O
conduction	O
disturbances	O
.	O
PA	O
chest	O
X	O
ray	O
increased	O
cardiothoracic	O
index	O
,	O
capillary	O
redistribution	O
pattern	O
,	O
signs	O
of	O
left	O
atrial	O
dilatation	O
.	O
No	O
alveolar	O
infiltrates	O
or	O
images	O
of	O
pleural	O
effusion	O
.	O
Echocardiogram	O
on	O
admission	O
non	O
hypertrophic	O
left	O
ventricle	O
LV	O
,	O
severely	O
dilated	O
with	O
severely	O
depressed	O
global	O
systolic	O
function	O
due	O
to	O
global	O
hypokinesia	O
and	O
asynchrony	O
IVS	O
8	O
mm	O
,	O
Dd	O
77	O
mm	O
,	O
TVD	O
218	O
ml	O
,	O
STV	O
149	O
ml	O
,	O
LVEF	O
31	O
by	O
Simpson	O
4C	O
,	O
subjective	O
LVEF	O
25	O
.	O
Lateral	O
and	O
inferior	O
trabeculation	O
.	O
Dilated	O
left	O
atrium	O
52	O
ml	O
m2	O
.	O
Biphasic	O
left	O
ventricular	O
filling	O
with	O
diastolic	O
dysfunction	O
III	O
and	O
high	O
filling	O
pressures	O
E	O
A	O
2	O
.	O
5	O
,	O
E	O
e	O
'	O
19	O
.	O
Normal	O
aortic	O
root	O
.	O
No	O
signs	O
of	O
coarctation	O
.	O
Dilated	O
right	O
chambers	O
with	O
mild	O
RV	O
dysfunction	O
TAPSE	O
15	O
mm	O
.	O
Mild	O
tricuspid	O
insufficiency	O
TI	O
allowing	O
estimation	O
of	O
PSAP	O
at	O
49	O
PVC	O
mmHg	O
.	O
Dilated	O
suprahepatic	O
vessels	O
.	O
Mild	O
mitral	O
insufficiency	O
MI	O
.	O
Mild	O
circumferential	O
pericardial	O
effusion	O
.	O
Rest	O
without	O
findings	O
.	O
Conclusion	O
dilated	O
cardiomyopathy	O
DCM	O
with	O
biventricular	O
dysfunction	O
.	O
Severe	O
LV	O
dysfunction	O
.	O
Diastolic	O
dysfunction	O
III	O
.	O
High	O
filling	O
pressures	O
.	O
Pulmonary	O
hypertension	O
PHT	O
.	O
Mild	O
pericardial	O
effusion	O
.	O
Coronary	O
angio	O
CT	O
Dominance	O
right	O
.	O
No	O
anomalies	O
are	O
visualised	O
in	O
coronary	O
artery	O
outflow	O
.	O
Left	O
coronary	O
left	O
coronary	O
trunk	O
LMCA	O
without	O
lesions	O
.	O
Normal	O
LAD	O
,	O
without	O
stenosis	O
or	O
lesions	O
.	O
Two	O
normal	O
diagonal	O
branches	O
.	O
Marginal	O
obtuse	O
circumflex	O
artery	O
Cx	O
OM	O
without	O
lesions	O
or	O
calcium	O
plaques	O
,	O
very	O
thin	O
.	O
Right	O
coronary	O
artery	O
own	O
CD	O
without	O
calcium	O
or	O
significant	O
stenosis	O
.	O
Normal	O
DP	O
and	O
TPL	O
branches	O
.	O
Left	O
ventricle	O
very	O
dilated	O
along	O
with	O
the	O
rest	O
of	O
the	O
cavities	O
with	O
slow	O
flow	O
in	O
the	O
appendage	O
does	O
not	O
appear	O
to	O
be	O
thrombus	O
.	O
Moderate	O
pericardial	O
effusion	O
.	O
Enlarged	O
pulmonary	O
trunk	O
32	O
mm	O
without	O
central	O
pulmonary	O
thromboembolism	O
PTE	O
.	O
Persistent	O
signs	O
of	O
pulmonary	O
oedema	O
septal	O
thickening	O
,	O
patchy	O
ground	O
glass	O
,	O
etc	O
.	O
.	O
No	O
pleural	O
effusion	O
.	O
Conclusion	O
study	O
without	O
significant	O
coronary	O
lesions	O
.	O
Cardiac	O
magnetic	O
resonance	O
imaging	O
MRI	O
without	O
and	O
with	O
contrast	O
video	O
2	O
Left	O
ventricle	O
markedly	O
dilated	O
with	O
severe	O
dysfunction	O
.	O
DDFV	O
295	O
ml	O
;	O
indexed	O
DDFV	O
164	O
ml	O
m2	O
.	O
ESR	O
244	O
ml	O
;	O
indexed	O
ESR	O
136	O
ml	O
mV	O
.	O
LVEF	O
17	O
.	O
Right	O
ventricle	O
equally	O
dilated	O
with	O
severe	O
dysfunction	O
end	O
diastolic	O
diameter	O
53	O
mm	O
.	O
RSV	O
216	O
ml	O
;	O
indexed	O
RSV	O
121	O
ml	O
m2	O
.	O
ESR	O
172	O
ml	O
;	O
indexed	O
ESR	O
96	O
ml	O
m2	O
.	O
RVEF	O
20	O
.	O
Generalised	O
hypokinesia	O
.	O
Enlargement	O
of	O
both	O
atria	O
,	O
more	O
accentuated	O
left	O
atrium	O
34	O
cm2	O
,	O
moderately	O
dilated	O
.	O
Enlarged	O
inferior	O
vena	O
cava	O
24	O
mm	O
.	O
Moderate	O
pericardial	O
effusion	O
.	O
No	O
areas	O
of	O
myocardial	O
oedema	O
on	O
T2	O
sequence	O
.	O
Ratio	O
of	O
non	O
compacted	O
myocardium	O
to	O
compacted	O
myocardium	O
in	O
the	O
lateral	O
aspect	O
of	O
the	O
LV	O
,	O
fulfilling	O
MRI	O
criteria	O
for	O
non	O
compacted	O
cardiomyopathy	O
.	O
No	O
myocardial	O
perfusion	O
defects	O
are	O
seen	O
after	O
contrast	O
administration	O
.	O
In	O
late	O
enhancement	O
,	O
a	O
subendocardial	O
area	O
of	O
late	O
enhancement	O
is	O
seen	O
at	O
the	O
septal	O
level	O
and	O
to	O
a	O
lesser	O
degree	O
in	O
the	O
anterior	O
aspect	O
.	O
Conclusion	O
severe	O
dilated	O
cardiomyopathy	O
with	O
severe	O
biventricular	O
dysfunction	O
.	O
No	O
compaction	O
in	O
the	O
lateral	O
aspect	O
CNM	O
criteria	O
.	O
PA	O
and	O
lateral	O
radiography	O
after	O
ICD	O
CRT	O
implantation	O
increased	O
cardiothoracic	O
index	O
,	O
capillary	O
redistribution	O
pattern	O
,	O
signs	O
of	O
left	O
atrial	O
dilatation	O
.	O
No	O
alveolar	O
infiltrates	O
or	O
images	O
of	O
pleural	O
effusion	O
.	O
ICD	O
CRT	O
in	O
left	O
upper	O
hemithorax	O
with	O
3	O
normally	O
positioned	O
leads	O
.	O
Blood	O
tests	O
prior	O
to	O
discharge	O
haemoglobin	O
12	O
.	O
5	O
g	O
dl	O
,	O
MCV	O
82	O
.	O
1	O
fl	O
,	O
leukocytes	O
6310	O
l	O
,	O
neutrophils	O
3090	O
l	O
,	O
lymphocytes	O
2550	O
l	O
and	O
platelets	O
188000	O
	O
Coagulation	O
INR	O
1	O
.	O
1	O
and	O
TPAct	O
79	O
.	O
Biochemistry	O
glucose	O
85	O
mg	O
dl	O
,	O
urea	O
56	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
02	O
mg	O
dl	O
,	O
glomerular	O
filtration	O
rate	O
97	O
ml	O
min	O
,	O
sodium	O
136	O
mEq	O
l	O
,	O
potassium	O
4	O
.	O
9	O
mEq	O
l	O
,	O
chlorine	O
97	O
mEq	O
l	O
,	O
AST	O
56	O
U	O
l	O
,	O
ALT	O
74	O
U	O
l	O
,	O
GGT	O
91	O
U	O
l	O
,	O
LDH	O
341	O
U	O
l	O
,	O
total	O
bilirubin	O
1	O
.	O
5	O
mg	O
dl	O
,	O
direct	O
B	O
.	O
1	O
mg	O
dl	O
.	O
Total	O
cholesterol	O
133	O
mg	O
dl	O
,	O
HDL	O
27	O
mg	O
dl	O
,	O
LDL	O
81	O
mg	O
dl	O
and	O
triglycerides	O
122	O
mg	O
dl	O
.	O
Total	O
protein	O
6	O
g	O
dl	O
,	O
albumin	O
3	O
.	O
60	O
g	O
dl	O
,	O
iron	O
40	O
g	O
dl	O
,	O
ferritin	O
58	O
.	O
9	O
ng	O
ml	O
,	O
transferrin	O
262	O
mg	O
dl	O
,	O
TSI	O
12	O
.	O
02	O
.	O
NTproBNP	O
8088	O
pg	O
ml	O
.	O
Genetic	O
study	O
after	O
study	O
of	O
genes	O
related	O
to	O
dilated	O
cardiomyopathy	O
,	O
a	O
variant	O
of	O
uncertain	O
significance	O
c	O
.	O
5009G	O
A	O
;	O
p	O
.	O
Arg1670His	O
,	O
in	O
probable	O
heterozygosis	O
,	O
has	O
been	O
observed	O
in	O
the	O
LAMA4	O
gene	O
.	O
Variants	O
in	O
this	O
gene	O
have	O
been	O
associated	O
with	O
dilated	O
cardiomyopathy	O
,	O
a	O
pathology	O
with	O
an	O
autosomal	O
dominant	O
pattern	O
of	O
inheritance	O
.	O
Echocardiogram	O
at	O
one	O
year	O
follow	O
up	O
video	O
3	O
Severely	O
dilated	O
and	O
dysfunctional	O
left	O
ventricle	O
,	O
due	O
to	O
very	O
marked	O
general	O
hypokinesia	O
and	O
slight	O
asynchrony	O
;	O
Dd	O
71	O
mm	O
2D	O
,	O
x	O
Simpson	O
calculations	O
VTD	O
246	O
ml	O
,	O
VTS	O
163	O
ml	O
,	O
EF	O
34	O
.	O
Biphasic	O
left	O
ventricular	O
filling	O
with	O
E	O
A	O
of	O
2	O
.	O
5	O
,	O
average	O
E	O
e	O
'	O
9	O
.	O
5	O
.	O
Dilated	O
left	O
atrium	O
34	O
ml	O
m2	O
.	O
Normal	O
aortic	O
root	O
.	O
Coil	O
catheter	O
in	O
right	O
chambers	O
,	O
right	O
ventricle	O
RV	O
non	O
functioning	O
with	O
TAPSE	O
of	O
19	O
mm	O
and	O
S	O
'	O
at	O
12	O
cm	O
s	O
.	O
Very	O
mild	O
TR	O
allowing	O
estimation	O
of	O
PSAP	O
at	O
35	O
mmHg	O
PVC	O
.	O
Suprahepatic	O
vessels	O
not	O
dilated	O
.	O
No	O
pericardial	O
effusion	O
.	O
Conclusion	O
DCM	O
with	O
biventricular	O
dysfunction	O
.	O
Severe	O
LV	O
dysfunction	O
with	O
asynchrony	O
unchanged	O
with	O
respect	O
to	O
previous	O
ultrasound	O
.	O
CLINICAL	O
EVOLUTION	O
During	O
his	O
evolution	O
,	O
the	O
patient	O
showed	O
improvement	O
in	O
dyspnoea	O
and	O
oedematisation	O
of	O
the	O
lower	O
limbs	O
,	O
maintaining	O
a	O
good	O
diuresis	O
rate	O
after	O
adjustment	O
of	O
treatment	O
.	O
Cardiac	O
magnetic	O
resonance	O
imaging	O
was	O
requested	O
,	O
showing	O
dilated	O
cardiomyopathy	O
with	O
severe	O
biventricular	O
dysfunction	O
,	O
non	O
compaction	O
on	O
the	O
lateral	O
side	O
and	O
late	O
anteroseptal	O
subendocardial	O
enhancement	O
,	O
which	O
ruled	O
out	O
myocarditis	O
as	O
the	O
cause	O
.	O
However	O
,	O
in	O
view	O
of	O
the	O
finding	O
of	O
subendocardial	O
late	O
enhancement	O
,	O
angio	O
CT	O
of	O
the	O
coronary	O
arteries	O
was	O
requested	O
to	O
rule	O
out	O
ischaemic	O
origin	O
of	O
the	O
dysfunction	O
in	O
view	O
of	O
the	O
possibility	O
of	O
a	O
congenital	O
coronary	O
anomaly	O
,	O
but	O
the	O
study	O
was	O
normal	O
.	O
Finally	O
,	O
a	O
genetic	O
study	O
was	O
requested	O
to	O
determine	O
the	O
aetiology	O
,	O
which	O
was	O
positive	O
for	O
DCM	O
with	O
variant	O
of	O
uncertain	O
significance	O
c	O
.	O
5009G	O
A	O
;	O
p	O
.	O
Arg1670His	O
in	O
probable	O
heterozygosis	O
in	O
the	O
LAMA4	O
gene	O
.	O
During	O
follow	O
up	O
,	O
the	O
patient	O
showed	O
good	O
evolution	O
without	O
clinical	O
signs	O
of	O
heart	O
failure	O
,	O
but	O
because	O
the	O
ejection	O
fraction	O
did	O
not	O
improve	O
despite	O
medical	O
treatment	O
,	O
an	O
implantable	O
cardioverter	O
defibrillator	O
ICD	O
was	O
implanted	O
for	O
primary	O
prevention	O
together	O
with	O
resynchronisation	O
therapy	O
CRT	O
due	O
to	O
the	O
presence	O
of	O
a	O
wide	O
QRS	O
of	O
140	O
msec	O
and	O
asynchrony	O
.	O
The	O
ICD	O
was	O
implanted	O
without	O
incident	O
,	O
but	O
a	O
resynchronisation	O
lead	O
could	O
not	O
be	O
implanted	O
due	O
to	O
the	O
impossibility	O
of	O
cannulating	O
the	O
coronary	O
sinus	O
.	O
The	O
case	O
was	O
presented	O
to	O
the	O
Heart	O
Team	O
to	O
determine	O
the	O
best	O
therapeutic	O
option	O
for	O
failed	O
CRT	O
implantation	O
,	O
and	O
the	O
decision	O
was	O
made	O
to	O
implant	O
a	O
pacemaker	O
with	O
Hisian	O
pacing	O
.	O
The	O
procedure	O
was	O
performed	O
6	O
months	O
after	O
diagnosis	O
,	O
in	O
which	O
the	O
His	O
zone	O
was	O
located	O
with	O
selective	O
capture	O
,	O
but	O
without	O
QRS	O
shortening	O
,	O
so	O
the	O
left	O
branch	O
was	O
located	O
,	O
obtaining	O
a	O
narrower	O
QRS	O
144	O
msec	O
but	O
with	O
R	O
morphology	O
in	O
V1	O
.	O
Currently	O
,	O
the	O
patient	O
is	O
asymptomatic	O
from	O
the	O
cardiac	O
point	O
of	O
view	O
,	O
although	O
with	O
persistent	O
left	O
ventricular	O
dysfunction	O
and	O
asynchrony	O
in	O
the	O
echocardiographic	O
control	O
one	O
year	O
after	O
diagnosis	O
and	O
after	O
implantation	O
of	O
the	O
pacemaker	O
with	O
physiological	O
stimulation	O
in	O
the	O
His	O
bundle	O
.	O
Therefore	O
,	O
this	O
is	O
a	O
clinical	O
case	O
of	O
a	O
patient	O
with	O
diagnosed	O
tuberous	O
sclerosis	O
associated	O
with	O
dilated	O
cardiomyopathy	O
whose	O
aetiology	O
has	O
not	O
been	O
identified	O
since	O
the	O
genetic	O
study	O
shows	O
an	O
inconclusive	O
mutation	O
.	O
The	O
association	O
between	O
both	O
entities	O
is	O
rare	O
.	O
DIAGNOSIS	O
Dilated	O
cardiomyopathy	O
in	O
a	O
patient	O
with	O
tuberous	O
sclerosis	O
.	O
Hisian	O
physiological	O
pacing	O
pacemaker	O
implantation	O
in	O
a	O
patient	O
with	O
left	O
ventricular	O
dysfunction	O
with	O
asynchrony	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
51	O
year	O
old	O
male	O
with	O
the	O
following	O
personal	O
history	O
No	O
relevant	O
family	O
history	O
of	O
cardiological	O
problems	O
.	O
No	O
known	O
drug	O
allergies	O
.	O
Cardiovascular	O
risk	O
factors	O
no	O
arterial	O
hypertension	O
,	O
diabetes	O
or	O
dyslipidaemia	O
.	O
No	O
toxic	O
habits	O
.	O
No	O
previous	O
cardiological	O
history	O
.	O
Baseline	O
situation	O
sportsman	O
.	O
Asymptomatic	O
when	O
performing	O
physical	O
exertion	O
.	O
No	O
chronic	O
home	O
treatment	O
.	O
Current	O
illness	O
Consultation	O
at	O
the	O
emergency	O
department	O
due	O
to	O
palpitations	O
of	O
several	O
hours	O
'	O
duration	O
,	O
associated	O
with	O
a	O
feeling	O
of	O
dizziness	O
.	O
According	O
to	O
the	O
patient	O
,	O
he	O
had	O
had	O
palpitations	O
on	O
previous	O
occasions	O
,	O
although	O
they	O
subsided	O
in	O
a	O
self	O
limited	O
manner	O
with	O
rest	O
.	O
Given	O
the	O
persistence	O
of	O
the	O
symptoms	O
,	O
she	O
decided	O
to	O
go	O
to	O
hospital	O
.	O
She	O
had	O
no	O
other	O
accompanying	O
symptoms	O
no	O
chest	O
pain	O
or	O
dyspnoea	O
.	O
No	O
history	O
of	O
syncope	O
.	O
Physical	O
examination	O
On	O
physical	O
examination	O
he	O
was	O
haemodynamically	O
stable	O
,	O
with	O
a	O
blood	O
pressure	O
of	O
110	O
55	O
mmHg	O
and	O
a	O
heart	O
rate	O
of	O
217	O
bpm	O
.	O
Baseline	O
oxygen	O
saturation	O
was	O
98	O
.	O
No	O
jugular	O
venous	O
engorgement	O
.	O
Cardiac	O
auscultation	O
rhythmic	O
heart	O
sounds	O
without	O
murmurs	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
.	O
Abdomen	O
soft	O
,	O
non	O
painful	O
,	O
no	O
masses	O
or	O
megaliths	O
.	O
Lower	O
extremities	O
no	O
oedema	O
,	O
no	O
signs	O
of	O
deep	O
vein	O
thrombosis	O
DVT	O
with	O
present	O
and	O
symmetrical	O
pulses	O
.	O
The	O
electrocardiogram	O
showed	O
a	O
regular	O
wide	O
QRS	O
tachycardia	O
at	O
217	O
bpm	O
with	O
atrioventricular	O
dissociation	O
and	O
absence	O
of	O
Q	O
wave	O
in	O
aVR	O
,	O
suggestive	O
of	O
ventricular	O
tachycardia	O
.	O
In	O
view	O
of	O
the	O
findings	O
,	O
the	O
patient	O
was	O
transferred	O
to	O
the	O
intensive	O
care	O
unit	O
ICU	O
for	O
continuous	O
monitoring	O
and	O
surveillance	O
.	O
COMPLEMENTARY	O
TESTS	O
Laboratory	O
tests	O
blood	O
count	O
and	O
coagulation	O
within	O
normal	O
range	O
.	O
Renal	O
function	O
and	O
ions	O
within	O
normal	O
parameters	O
.	O
NT	O
proBNP	O
1890	O
pg	O
ml	O
.	O
Electrocardiogram	O
in	O
tachycardia	O
regular	O
tachycardia	O
with	O
wide	O
QRS	O
LC	O
275	O
ms	O
with	O
atrioventricular	O
dissociation	O
and	O
absence	O
of	O
Q	O
in	O
aVR	O
,	O
suggestive	O
of	O
monomorphic	O
VT	O
.	O
Ventricular	O
complex	O
with	O
superior	O
electrical	O
axis	O
,	O
positive	O
in	O
V1	O
BRD	O
morphology	O
and	O
negative	O
in	O
I	O
.	O
Basal	O
electrocardiogram	O
sinus	O
rhythm	O
at	O
70	O
bpm	O
.	O
Narrow	O
QRS	O
,	O
with	O
fractionated	O
complexes	O
.	O
Electrical	O
axis	O
of	O
120o	O
.	O
Negative	O
T	O
waves	O
in	O
inferior	O
face	O
and	O
lateral	O
precordial	O
.	O
Echocardiogram	O
left	O
ventricle	O
neither	O
dilated	O
nor	O
hypertrophic	O
with	O
mild	O
systolic	O
dysfunction	O
LVEF	O
47	O
.	O
There	O
was	O
akinesia	O
in	O
the	O
basal	O
and	O
middle	O
segments	O
of	O
the	O
inferolateral	O
and	O
lateral	O
face	O
.	O
The	O
right	O
ventricle	O
shows	O
preserved	O
systolic	O
function	O
,	O
with	O
normal	O
structure	O
.	O
Absence	O
of	O
valvulopathies	O
of	O
interest	O
,	O
with	O
normal	O
morphology	O
in	O
the	O
4	O
valves	O
.	O
Absence	O
of	O
pericardial	O
effusion	O
.	O
Inferior	O
vena	O
cava	O
not	O
dilated	O
with	O
respiratory	O
phasic	O
changes	O
.	O
Coronary	O
catheterisation	O
coronary	O
tree	O
with	O
normal	O
distribution	O
and	O
development	O
.	O
Right	O
dominance	O
.	O
Absence	O
of	O
angiographically	O
significant	O
lesions	O
.	O
Cardiac	O
magnetic	O
resonance	O
CMR	O
dilated	O
left	O
ventricle	O
with	O
eccentric	O
remodelling	O
and	O
moderate	O
systolic	O
dysfunction	O
.	O
Left	O
ventricular	O
fatty	O
infiltration	O
and	O
segmental	O
contractility	O
abnormalities	O
.	O
Late	O
subepicardial	O
inferior	O
and	O
inferior	O
subepicardial	O
gadolinium	O
enhancement	O
at	O
basal	O
and	O
midventricular	O
levels	O
.	O
Based	O
on	O
the	O
enhancement	O
observed	O
,	O
the	O
findings	O
are	O
suggestive	O
of	O
arrhythmogenic	O
cardiomyopathy	O
,	O
and	O
chronic	O
myopericarditis	O
cannot	O
be	O
ruled	O
out	O
.	O
CLINICAL	O
EVOLUTION	O
After	O
admission	O
to	O
the	O
ICU	O
,	O
the	O
patient	O
remained	O
haemodynamically	O
stable	O
despite	O
persistent	O
tachycardia	O
.	O
Echocardiography	O
was	O
performed	O
,	O
showing	O
left	O
ventricular	O
dysfunction	O
and	O
akinesia	O
in	O
the	O
basal	O
and	O
middle	O
segments	O
at	O
the	O
inferolateral	O
and	O
lateral	O
levels	O
.	O
The	O
right	O
ventricle	O
maintained	O
normal	O
structure	O
and	O
preserved	O
systolic	O
function	O
.	O
Treatment	O
with	O
amiodarone	B-FARMACO
intravenous	O
infusion	O
was	O
administered	O
to	O
control	O
the	O
ventricular	O
tachycardia	O
,	O
achieving	O
pharmacological	O
cardioversion	O
and	O
recovering	O
sinus	O
rhythm	O
a	O
few	O
hours	O
after	O
starting	O
the	O
infusion	O
.	O
He	O
remained	O
in	O
sinus	O
rhythm	O
for	O
the	O
next	O
48	O
hours	O
,	O
asymptomatic	O
,	O
and	O
was	O
transferred	O
to	O
the	O
cardiology	O
hospital	O
ward	O
to	O
complete	O
the	O
aetiological	O
study	O
of	O
the	O
tachycardia	O
.	O
Once	O
on	O
the	O
hospital	O
ward	O
,	O
a	O
regular	O
echocardiography	O
was	O
performed	O
in	O
sinus	O
rhythm	O
,	O
which	O
confirmed	O
mild	O
systolic	O
dysfunction	O
and	O
segmental	O
disorders	O
of	O
left	O
ventricular	O
contractility	O
.	O
In	O
view	O
of	O
the	O
findings	O
,	O
it	O
was	O
subsequently	O
decided	O
to	O
perform	O
a	O
preferential	O
coronary	O
angiography	O
to	O
rule	O
out	O
coronary	O
ischaemia	O
as	O
the	O
cause	O
of	O
the	O
symptoms	O
,	O
and	O
a	O
coronary	O
tree	O
with	O
a	O
normal	O
distribution	O
and	O
no	O
significant	O
angiographic	O
lesions	O
was	O
observed	O
.	O
The	O
patient	O
remained	O
in	O
hospital	O
for	O
several	O
days	O
,	O
remaining	O
asymptomatic	O
and	O
in	O
sinus	O
rhythm	O
.	O
Finally	O
,	O
cardiac	O
magnetic	O
resonance	O
CMR	O
was	O
performed	O
,	O
showing	O
a	O
striking	O
subepicardial	O
fatty	O
infiltration	O
in	O
the	O
left	O
ventricle	O
and	O
late	O
gadolinium	O
enhancement	O
LGE	O
with	O
subepicardial	O
distribution	O
.	O
These	O
findings	O
are	O
suggestive	O
of	O
arrhythmogenic	O
cardiomyopathy	O
of	O
the	O
left	O
ventricle	O
.	O
Subsequent	O
genetic	O
study	O
confirmed	O
the	O
diagnosis	O
,	O
resulting	O
in	O
a	O
pathogenic	O
mutation	O
for	O
ACM	O
in	O
the	O
FLNC	O
gene	O
filamin	O
C	O
.	O
Once	O
the	O
case	O
was	O
presented	O
and	O
discussed	O
in	O
a	O
clinical	O
session	O
,	O
it	O
was	O
decided	O
to	O
implant	O
an	O
implantable	O
cardioverter	O
defibrillator	O
ICD	O
for	O
primary	O
prevention	O
of	O
sudden	O
death	O
and	O
to	O
start	O
treatment	O
with	O
beta	O
blockers	O
.	O
Ablation	O
of	O
the	O
arrhythmic	O
substrate	O
will	O
be	O
assessed	O
in	O
the	O
follow	O
up	O
in	O
the	O
event	O
of	O
persistent	O
tachycardia	O
or	O
appropriate	O
ICD	O
discharges	O
.	O
DIAGNOSIS	O
Arrhythmogenic	O
cardiomyopathy	O
of	O
the	O
left	O
ventricle	O
in	O
structural	O
phase	O
.	O
Sustained	O
monomorphic	O
ventricular	O
tachycardia	O
.	O
Mild	O
left	O
ventricular	O
systolic	O
dysfunction	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
No	O
drug	O
allergies	O
.	O
No	O
cardiovascular	O
risk	O
factors	O
.	O
Cardiovascular	O
history	O
none	O
.	O
Other	O
not	O
of	O
interest	O
.	O
Usual	O
treatment	O
denied	O
.	O
Family	O
history	O
not	O
of	O
interest	O
.	O
Two	O
healthy	O
children	O
.	O
Present	O
illness	O
She	O
presented	O
after	O
a	O
fall	O
with	O
rib	O
trauma	O
and	O
fracture	O
of	O
several	O
ribs	O
.	O
Chest	O
X	O
ray	O
showed	O
cardiomegaly	O
and	O
alteration	O
of	O
the	O
aortic	O
arch	O
,	O
so	O
on	O
call	O
cardiology	O
was	O
notified	O
.	O
On	O
questioning	O
,	O
the	O
patient	O
reported	O
a	O
previous	O
episode	O
of	O
dizziness	O
on	O
exertion	O
without	O
loss	O
of	O
consciousness	O
.	O
She	O
denied	O
dyspnoea	O
,	O
chest	O
pain	O
,	O
haemoptysis	O
or	O
other	O
associated	O
symptoms	O
.	O
She	O
has	O
two	O
children	O
born	O
vaginally	O
without	O
complications	O
.	O
Physical	O
examination	O
Heart	O
rate	O
83	O
bpm	O
,	O
oxygen	O
saturation	O
98	O
at	O
baseline	O
and	O
95	O
when	O
walking	O
300	O
metres	O
.	O
Cardiac	O
auscultation	O
systolic	O
murmur	O
at	O
the	O
left	O
sternal	O
border	O
.	O
Pulmonary	O
auscultation	O
preserved	O
vesicular	O
murmur	O
without	O
added	O
noise	O
.	O
Lower	O
extremities	O
no	O
oedema	O
.	O
Minimal	O
acropacities	O
.	O
COMPLEMENTARY	O
TESTS	O
Blood	O
tests	O
haemoglobin	O
13	O
.	O
8	O
g	O
dl	O
,	O
platelets	O
21	O
x1000	O
l	O
;	O
NT	O
proBNP	O
230	O
pg	O
ml	O
,	O
troponin	O
T	O
hs	O
5	O
.	O
5	O
ng	O
l	O
.	O
Rest	O
without	O
relevant	O
findings	O
.	O
Chest	O
X	O
ray	O
fracture	O
of	O
the	O
right	O
posterior	O
eighth	O
arch	O
and	O
probable	O
fracture	O
of	O
the	O
seventh	O
and	O
ninth	O
arch	O
associated	O
with	O
right	O
effusion	O
,	O
probable	O
haemothorax	O
given	O
the	O
rib	O
fractures	O
.	O
Cardiomegaly	O
,	O
alteration	O
in	O
the	O
morphology	O
of	O
the	O
superior	O
mediastinum	O
suggesting	O
alteration	O
in	O
the	O
arrangement	O
of	O
the	O
aortic	O
arch	O
.	O
Likewise	O
,	O
given	O
the	O
cardiac	O
morphology	O
,	O
pericardial	O
effusion	O
should	O
be	O
ruled	O
out	O
if	O
there	O
is	O
no	O
history	O
of	O
congenital	O
heart	O
disease	O
.	O
No	O
previous	O
studies	O
are	O
available	O
for	O
comparison	O
.	O
Electrocardiogram	O
ECG	O
sinus	O
rhythm	O
at	O
70	O
bpm	O
.	O
Normal	O
PR	O
.	O
Wide	O
QRS	O
left	O
axis	O
.	O
Complete	O
right	O
bundle	O
branch	O
block	O
and	O
evidence	O
of	O
right	O
ventricular	O
hypertrophy	O
.	O
Anterior	O
left	O
bundle	O
branch	O
hemiblock	O
.	O
Portable	O
transthoracic	O
echocardiogram	O
left	O
ventricle	O
of	O
normal	O
size	O
,	O
thickness	O
and	O
function	O
.	O
Severely	O
dilated	O
right	O
ventricle	O
64	O
mm	O
basal	O
diameter	O
,	O
hypertrophic	O
,	O
with	O
preserved	O
function	O
.	O
Biauricular	O
dilatation	O
,	O
greater	O
right	O
atrial	O
dilatation	O
.	O
There	O
is	O
a	O
large	O
ostium	O
primum	O
type	O
atrial	O
septal	O
defect	O
with	O
bidirectional	O
flow	O
.	O
Mitral	O
valve	O
with	O
cleft	O
and	O
moderate	O
mitral	O
insufficiency	O
grade	O
III	O
.	O
Dysplastic	O
tricuspid	O
valve	O
with	O
moderate	O
severe	O
tricuspid	O
regurgitation	O
grade	O
III	O
.	O
Estimated	O
pulmonary	O
artery	O
systolic	O
pressure	O
of	O
62	O
5	O
mmHg	O
.	O
Mild	O
pulmonary	O
insufficiency	O
.	O
Pulmonary	O
acceleration	O
time	O
of	O
81	O
msec	O
without	O
mesosystolic	O
notch	O
.	O
Trivalve	O
aortic	O
valve	O
without	O
stenosis	O
or	O
insufficiency	O
.	O
Mild	O
circumferential	O
pericardial	O
effusion	O
.	O
CLINICAL	O
EVOLUTION	O
It	O
was	O
proposed	O
that	O
the	O
patient	O
be	O
admitted	O
to	O
hospital	O
to	O
complete	O
the	O
study	O
right	O
heart	O
catheterisation	O
and	O
cardiopulmonary	O
exercise	O
test	O
and	O
to	O
consider	O
starting	O
pulmonary	O
vasodilator	O
treatment	O
,	O
but	O
for	O
personal	O
reasons	O
the	O
patient	O
refused	O
,	O
preferring	O
to	O
opt	O
for	O
outpatient	O
management	O
.	O
Unfortunately	O
,	O
the	O
patient	O
never	O
attends	O
the	O
outpatient	O
appointments	O
and	O
the	O
study	O
is	O
never	O
completed	O
.	O
DIAGNOSIS	O
Incomplete	O
atrioventricular	O
canal	O
of	O
new	O
diagnosis	O
.	O
Suspicion	O
of	O
pulmonary	O
arterial	O
hypertension	O
associated	O
with	O
uncorrected	O
congenital	O
heart	O
disease	O
.	O

HISTORY	O
,	O
CURRENT	O
ILLNESS	O
AND	O
PHYSICAL	O
EXAMINATION	O
History	O
No	O
known	O
drug	O
allergies	O
.	O
Ex	O
smoker	O
for	O
15	O
years	O
.	O
Obesity	O
.	O
Arterial	O
hypertension	O
under	O
pharmacological	O
treatment	O
,	O
with	O
recent	O
modification	O
of	O
treatment	O
.	O
Recently	O
diagnosed	O
type	O
2	O
diabetes	O
mellitus	O
10	O
months	O
,	O
on	O
treatment	O
with	O
oral	O
antidiabetics	O
.	O
No	O
other	O
medical	O
or	O
surgical	O
history	O
of	O
interest	O
.	O
Family	O
history	O
father	O
died	O
of	O
lung	O
cancer	O
60	O
years	O
,	O
mother	O
with	O
acute	O
myocardial	O
infarction	O
AMI	O
60	O
years	O
.	O
Brother	O
died	O
at	O
25	O
years	O
of	O
age	O
of	O
unknown	O
cause	O
.	O
Home	O
treatment	O
amlodipine	B-FARMACO
10	O
mg	O
0	O
1	O
0	O
,	O
olmesartan	B-FARMACO
medoxomil	I-FARMACO
20	O
mg	O
1	O
0	O
0	O
,	O
metformin	B-FARMACO
1000	O
mg	O
empagliflozin	B-FARMACO
5	O
mg	O
1	O
0	O
1	O
.	O
Current	O
disease	O
A	O
45	O
year	O
old	O
male	O
patient	O
,	O
with	O
no	O
history	O
of	O
heart	O
disease	O
,	O
attended	O
the	O
emergency	O
department	O
in	O
the	O
early	O
hours	O
of	O
the	O
morning	O
due	O
to	O
deterioration	O
of	O
his	O
functional	O
class	O
with	O
progressive	O
dyspnoea	O
on	O
minimal	O
exertion	O
,	O
associated	O
with	O
episodes	O
of	O
paroxysmal	O
nocturnal	O
dyspnoea	O
in	O
the	O
previous	O
two	O
days	O
,	O
as	O
well	O
as	O
oedematisation	O
of	O
the	O
lower	O
limbs	O
.	O
In	O
addition	O
,	O
he	O
reported	O
an	O
episode	O
of	O
epigastralgia	O
two	O
weeks	O
earlier	O
for	O
which	O
he	O
had	O
been	O
seen	O
in	O
the	O
emergency	O
department	O
and	O
was	O
discharged	O
home	O
with	O
a	O
diagnosis	O
of	O
suspected	O
biliary	O
colic	O
.	O
No	O
infectious	O
symptoms	O
in	O
the	O
previous	O
days	O
or	O
other	O
associated	O
symptoms	O
,	O
afebrile	O
.	O
After	O
initial	O
assessment	O
in	O
the	O
emergency	O
department	O
,	O
the	O
patient	O
was	O
found	O
to	O
be	O
stable	O
although	O
tending	O
towards	O
hypertension	O
,	O
oligosymptomatic	O
and	O
unable	O
to	O
tolerate	O
decubitus	O
,	O
and	O
an	O
electrocardiogram	O
was	O
performed	O
showing	O
sinus	O
tachycardia	O
and	O
electrical	O
alternation	O
.	O
A	O
chest	O
X	O
ray	O
was	O
requested	O
,	O
showing	O
a	O
large	O
cardiomegaly	O
,	O
with	O
no	O
other	O
relevant	O
pathological	O
findings	O
.	O
Given	O
the	O
suspicion	O
of	O
pericardial	O
effusion	O
,	O
portable	O
echocardiocopy	O
was	O
performed	O
video	O
1	O
,	O
confirming	O
the	O
diagnosis	O
of	O
severe	O
circumferential	O
pericardial	O
effusion	O
20	O
mm	O
,	O
with	O
collapse	O
of	O
the	O
right	O
chambers	O
.	O
Given	O
the	O
initial	O
haemodynamic	O
stability	O
of	O
the	O
patient	O
,	O
it	O
was	O
decided	O
to	O
admit	O
him	O
to	O
cardiology	O
with	O
close	O
monitoring	O
and	O
serum	O
therapy	O
,	O
with	O
a	O
view	O
to	O
performing	O
a	O
fluoroscopy	O
guided	O
pericardiocentesis	O
first	O
thing	O
the	O
following	O
morning	O
.	O
However	O
,	O
2	O
hours	O
later	O
,	O
the	O
patient	O
was	O
again	O
notified	O
due	O
to	O
clinical	O
and	O
haemodynamic	O
deterioration	O
,	O
with	O
arterial	O
hypotension	O
and	O
tachypnoea	O
,	O
so	O
we	O
proceeded	O
to	O
perform	O
emergent	O
pericardiocentesis	O
guided	O
by	O
echocardiography	O
using	O
a	O
subxiphoid	O
approach	O
,	O
achieving	O
drainage	O
of	O
1	O
,	O
500	O
ml	O
of	O
haematic	O
pericardial	O
fluid	O
,	O
collecting	O
samples	O
for	O
aetiological	O
diagnosis	O
,	O
with	O
immediate	O
haemodynamic	O
recovery	O
of	O
the	O
patient	O
.	O
After	O
ultrasound	O
verification	O
of	O
the	O
practical	O
resolution	O
of	O
the	O
effusion	O
,	O
continuous	O
drainage	O
is	O
left	O
in	O
the	O
bag	O
and	O
the	O
patient	O
is	O
continuously	O
monitored	O
.	O
Physical	O
examination	O
Good	O
general	O
condition	O
,	O
conscious	O
,	O
oriented	O
in	O
the	O
three	O
spheres	O
,	O
normal	O
colour	O
and	O
normal	O
depth	O
,	O
no	O
jugular	O
venous	O
engorgement	O
.	O
Hypertension	O
150	O
90	O
mmHg	O
,	O
normocardic	O
,	O
eupneic	O
on	O
room	O
air	O
with	O
no	O
increase	O
in	O
work	O
of	O
breathing	O
,	O
but	O
not	O
tolerating	O
decubitus	O
,	O
maintaining	O
basal	O
oxygen	O
saturation	O
of	O
98	O
,	O
afebrile	O
.	O
Cardiopulmonary	O
auscultation	O
low	O
pitched	O
rhythmic	O
heart	O
sounds	O
,	O
no	O
murmurs	O
.	O
Bladder	O
murmur	O
was	O
preserved	O
,	O
with	O
no	O
additional	O
pathological	O
sounds	O
.	O
Abdomen	O
globular	O
,	O
soft	O
and	O
depressible	O
,	O
not	O
painful	O
on	O
superficial	O
or	O
deep	O
palpation	O
.	O
Lower	O
extremities	O
with	O
oedema	O
and	O
fovea	O
up	O
to	O
the	O
knees	O
.	O
COMPLEMENTARY	O
TESTS	O
CBC	O
haemoglobin	O
11	O
g	O
dl	O
,	O
MCV	O
81	O
fl	O
,	O
MCH	O
27	O
pg	O
,	O
leukocytes	O
13	O
,	O
8000	O
l	O
,	O
neutrophils	O
79	O
,	O
lymphocytes	O
11	O
,	O
platelets	O
428	O
.	O
000	O
l	O
,	O
glucose	O
221	O
mg	O
dl	O
,	O
creatinine	O
1	O
.	O
56	O
mg	O
dl	O
,	O
GFR	O
CKD	O
EPI	O
53	O
ml	O
min	O
1	O
.	O
73	O
m2	O
,	O
CRP	O
4	O
.	O
25	O
mg	O
dl	O
,	O
procalcitonin	O
0	O
.	O
21	O
ng	O
ml	O
,	O
ultrasensitive	O
troponin	O
I	O
3	O
.	O
1	O
pg	O
ml	O
,	O
CK	O
MB	O
1	O
.	O
20	O
ng	O
ml	O
,	O
NT	O
proBNP	O
231	O
pg	O
ml	O
,	O
glycosylated	O
haemoglobin	O
9	O
,	O
TSH	O
1	O
.	O
870	O
mIU	O
l	O
.	O
Electrocardiogram	O
sinus	O
tachycardia	O
at	O
100	O
bpm	O
,	O
normal	O
PR	O
,	O
normal	O
axis	O
,	O
narrow	O
QRS	O
,	O
little	O
R	O
progression	O
in	O
precordials	O
,	O
generalised	O
negative	O
T	O
waves	O
,	O
electrical	O
alternans	O
.	O
Chest	O
X	O
ray	O
significant	O
cardiomegaly	O
,	O
without	O
alterations	O
of	O
the	O
lung	O
parenchyma	O
.	O
Portable	O
echocardioscopy	O
left	O
ventricle	O
LV	O
with	O
moderate	O
severe	O
concentric	O
hypertrophy	O
,	O
preserved	O
LV	O
function	O
,	O
severe	O
pericardial	O
effusion	O
20	O
mm	O
circumferential	O
,	O
with	O
swinging	O
heart	O
.	O
Collapsed	O
right	O
chambers	O
.	O
Transthoracic	O
echocardiogram	O
after	O
pericardiocentesis	O
moderate	O
concentric	O
LV	O
hypertrophy	O
with	O
septal	O
predominance	O
,	O
without	O
LV	O
outflow	O
tract	O
obstruction	O
.	O
LVEF	O
65	O
.	O
Moderate	O
pericardial	O
effusion	O
15	O
mm	O
in	O
posterior	O
face	O
in	O
PEEL	O
and	O
5	O
mm	O
in	O
anterior	O
face	O
,	O
no	O
respiratory	O
variation	O
of	O
mitral	O
flow	O
,	O
no	O
echographic	O
data	O
of	O
tamponade	O
.	O
No	O
valvulopathies	O
.	O
Analysis	O
of	O
the	O
fluid	O
haematic	O
aspect	O
,	O
cellularity	O
not	O
assessable	O
due	O
to	O
the	O
presence	O
of	O
clots	O
,	O
glucose	O
187	O
mg	O
dl	O
,	O
protein	O
5	O
.	O
3	O
g	O
dl	O
,	O
pH	O
7	O
.	O
25	O
,	O
Gram	O
stain	O
with	O
no	O
microorganisms	O
observed	O
,	O
negative	O
bacteriological	O
culture	O
.	O
Samples	O
could	O
not	O
be	O
sent	O
for	O
mycobacteria	O
or	O
cytology	O
.	O
Tumour	O
markers	O
,	O
autoimmunity	O
,	O
serology	O
CA	O
125	O
451	O
U	O
ml	O
,	O
rest	O
negative	O
.	O
Autoimmunity	O
negative	O
,	O
non	O
specific	O
elevation	O
of	O
complement	O
C3	O
and	O
C4	O
.	O
Serology	O
hepatotropic	O
viruses	O
,	O
CMV	O
,	O
Treponema	O
pallidum	O
and	O
Coxiella	O
burnetii	O
negative	O
.	O
EBV	O
IgG	O
positive	O
.	O
Chest	O
abdomen	O
pelvis	O
CT	O
scan	O
no	O
radiological	O
signs	O
suggestive	O
of	O
neoproliferative	O
process	O
.	O
Severe	O
pericardial	O
effusion	O
and	O
mild	O
left	O
pleural	O
effusion	O
,	O
slightly	O
heterogeneous	O
nodule	O
in	O
the	O
right	O
thyroid	O
lobe	O
16	O
mm	O
maximum	O
diameter	O
with	O
fine	O
calcifications	O
inside	O
,	O
left	O
renal	O
angiomyolipoma	O
,	O
enlarged	O
prostate	O
with	O
stigmata	O
of	O
chronic	O
prostatitis	O
.	O
Echocardiogram	O
at	O
discharge	O
moderate	O
concentric	O
LV	O
hypertrophy	O
.	O
LVEF	O
68	O
.	O
Mild	O
pericardial	O
effusion	O
,	O
mostly	O
posterior	O
,	O
10	O
mm	O
,	O
minimal	O
in	O
the	O
left	O
ventricle	O
LV	O
.	O
Visceral	O
pericardial	O
thickening	O
in	O
the	O
apex	O
.	O
No	O
cavity	O
involvement	O
.	O
No	O
valvular	O
heart	O
disease	O
.	O
CLINICAL	O
EVOLUTION	O
During	O
his	O
admission	O
to	O
the	O
ward	O
the	O
patient	O
presented	O
very	O
good	O
clinical	O
evolution	O
,	O
with	O
better	O
control	O
of	O
blood	O
pressure	O
after	O
pharmacological	O
adjustment	O
,	O
with	O
sinus	O
tachycardia	O
as	O
the	O
only	O
event	O
recorded	O
on	O
telemetry	O
,	O
asymptomatic	O
from	O
the	O
cardiorespiratory	O
point	O
of	O
view	O
,	O
minimal	O
pericardial	O
friction	O
on	O
auscultation	O
.	O
A	O
regulated	O
transthoracic	O
echocardiogram	O
was	O
performed	O
,	O
showing	O
moderate	O
concentric	O
LV	O
hypertrophy	O
,	O
preserved	O
left	O
ventricular	O
function	O
and	O
moderate	O
pericardial	O
effusion	O
15	O
mm	O
in	O
the	O
posterior	O
face	O
in	O
PEEL	O
,	O
and	O
5	O
mm	O
in	O
the	O
anterior	O
face	O
,	O
with	O
no	O
evidence	O
of	O
tamponade	O
.	O
After	O
more	O
than	O
30	O
hours	O
without	O
debit	O
,	O
drainage	O
was	O
removed	O
.	O
Empirical	O
treatment	O
was	O
started	O
with	O
non	O
steroidal	O
anti	O
inflammatory	O
drugs	O
NSAIDs	O
and	O
colchicine	B-FARMACO
,	O
and	O
a	O
referral	O
was	O
made	O
to	O
internal	O
medicine	O
for	O
an	O
overall	O
assessment	O
of	O
the	O
case	O
in	O
order	O
to	O
search	O
for	O
the	O
underlying	O
aetiology	O
,	O
with	O
the	O
initial	O
objective	O
of	O
ruling	O
out	O
paraneoplastic	O
pathology	O
.	O
The	O
characteristics	O
of	O
the	O
pericardial	O
fluid	O
were	O
very	O
unspecific	O
haematic	O
with	O
abundant	O
clots	O
that	O
did	O
not	O
allow	O
cellularity	O
,	O
proteins	O
and	O
glucose	O
within	O
normal	O
limits	O
and	O
negative	O
bacteriological	O
culture	O
,	O
although	O
it	O
was	O
not	O
possible	O
to	O
send	O
a	O
new	O
valid	O
sample	O
for	O
mycobacterial	O
studies	O
.	O
With	O
regard	O
to	O
the	O
analytical	O
study	O
with	O
determination	O
of	O
tumour	O
markers	O
and	O
autoimmunity	O
,	O
he	O
only	O
presented	O
non	O
specific	O
elevation	O
of	O
CA	O
125	O
and	O
complement	O
fractions	O
C3	O
and	O
C4	O
.	O
Serology	O
for	O
hepatotropic	O
viruses	O
,	O
HIV	O
,	O
CMV	O
,	O
Treponema	O
pallidum	O
and	O
Coxiella	O
burnetii	O
was	O
negative	O
,	O
IgG	O
positive	O
for	O
EBV	O
.	O
As	O
part	O
of	O
the	O
extension	O
study	O
,	O
a	O
CT	O
scan	O
of	O
the	O
thorax	O
abdomen	O
pelvis	O
was	O
performed	O
which	O
ruled	O
out	O
a	O
neoproliferative	O
process	O
,	O
highlighting	O
a	O
nodule	O
in	O
the	O
right	O
lower	O
thyroid	O
lobe	O
and	O
an	O
enlarged	O
prostate	O
with	O
stigmata	O
of	O
chronic	O
prostatitis	O
.	O
Serial	O
echocardiographic	O
controls	O
were	O
performed	O
,	O
presenting	O
progressive	O
reduction	O
of	O
the	O
effusion	O
,	O
leaving	O
only	O
a	O
slight	O
pericardial	O
effusion	O
of	O
10	O
mm	O
on	O
the	O
posterior	O
and	O
lateral	O
wall	O
of	O
the	O
LV	O
at	O
discharge	O
.	O
Finally	O
,	O
given	O
the	O
favourable	O
clinical	O
and	O
effusion	O
evolution	O
,	O
and	O
despite	O
the	O
absence	O
of	O
a	O
definitive	O
aetiological	O
diagnosis	O
,	O
it	O
was	O
decided	O
to	O
discharge	O
the	O
patient	O
home	O
and	O
continue	O
close	O
outpatient	O
follow	O
up	O
and	O
study	O
.	O
After	O
8	O
months	O
of	O
follow	O
up	O
,	O
the	O
patient	O
was	O
asymptomatic	O
,	O
with	O
better	O
control	O
of	O
blood	O
pressure	O
and	O
glycaemia	O
,	O
better	O
exercise	O
tolerance	O
,	O
reporting	O
only	O
an	O
episode	O
of	O
self	O
limited	O
stabbing	O
pain	O
6	O
months	O
after	O
the	O
index	O
event	O
,	O
with	O
complete	O
recovery	O
of	O
renal	O
function	O
,	O
reduction	O
of	O
inflammatory	O
markers	O
,	O
as	O
well	O
as	O
CA	O
125	O
and	O
glycosylated	O
haemoglobin	O
.	O
Radiological	O
improvement	O
with	O
disappearance	O
of	O
cardiomegaly	O
,	O
leaving	O
minimal	O
residual	O
pericardial	O
effusion	O
of	O
3	O
4	O
mm	O
on	O
the	O
free	O
wall	O
of	O
the	O
RV	O
.	O
The	O
patient	O
is	O
currently	O
undergoing	O
an	O
aetiological	O
study	O
by	O
internal	O
medicine	O
.	O
DIAGNOSIS	O
Severe	O
pericardial	O
effusion	O
with	O
progression	O
to	O
cardiac	O
tamponade	O
.	O
Urgent	O
pericardiocentesis	O
haematic	O
pericardial	O
fluid	O
.	O
Etiology	O
unknown	O
,	O
so	O
far	O
idiopathic	O
.	O
Preserved	O
left	O
ventricular	O
function	O
.	O

